<SEC-DOCUMENT>0001104659-26-034911.txt : 20260326
<SEC-HEADER>0001104659-26-034911.hdr.sgml : 20260326
<ACCEPTANCE-DATETIME>20260326084545
ACCESSION NUMBER:		0001104659-26-034911
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260326
DATE AS OF CHANGE:		20260326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MetaVia Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		26794502

	BUSINESS ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeuroBo Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20191231

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mtva-20251231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.2.0.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/25/2026 3:11:38 PM -->
<!-- iXBRL Library version: 1.0.9448.42501 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:mtva="http://metaviatx.com/20251231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>METAVIA INC._December 31, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_HBfbrzIvdUOSNDYPtKcU7g">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" xs:nil="true" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_aWhQFe3VK069qYthur7e-g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" xs:nil="true" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_4XOCELpTlEyvjOWvQEVjUw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityCentralIndexKey" id="Tc_zo3KCIwdHEOxd3-lRA6tVA_2_1">0001638287</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentFiscalYearFocus" id="Tc_4iDaqXM7d0uce58WrbZh5A_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentFiscalPeriodFocus" id="Tc_VPWvT72f0Uuv2C12rS5RcQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_8cMI9dmksEq4qT-BG4yhLw">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_1PX6G9rlREaqOUwCT5gBiw">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg" name="us-gaap:OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" id="Hidden_04y-e2dfO0KSrs6lCUbLtw">http://metaviatx.com/20251231#DongStMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" name="us-gaap:OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" id="Hidden_OlrKa7URCkCtFvuhgd859A">http://metaviatx.com/20251231#DongStMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" name="us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" id="Hidden_f_SITYnZr0yzCRs8SPB4uw">http://fasb.org/us-gaap/2025#RelatedPartyMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" xs:nil="true" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" name="us-gaap:PreferredStockValue" id="Hidden_RZkET5TQh0W_DYzsRn-H1A"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" xs:nil="true" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" name="us-gaap:PreferredStockValue" id="Hidden_yacnpFgWGE-wqPKYDVGxSQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_8EGw4Ym3A0uwPDR1wgoCVw">0.091</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_CVpJmymx606CfdrAoZpgUA" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_o4iplQlu0UKYhhkCeUIVBg">0.2</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_tJe91g6JuUaYMezRgMatVw" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_3jKcbu2it0anJWRaB5fFmg">0.033</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_vz1AO0nR9UenRLqd0V7ORw" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_zDOjGvv570SVRG19o1qIjg">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_VOralR6i3ki9t2Jyaw8bcA">http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_W8CSMwv8-EWiuCXptape3A">http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" name="us-gaap:GainContingencyUnrecordedAmount" id="Hidden_wKCHieRLFUC2maYfjLnuGQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zi6cmK3ti0qodROqObmB_g" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Hidden_oXMhiHp3dkGLoMt6wJhXIA">3.10</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:AmendmentFlag" id="Narr_Ic-eC7KoQ0SOUNPVkGXKag">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="mtva-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_n93HbMQVrkW0-qSzZp9fag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_NtxswooMrke0riRhyc4qoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_ynvr0hrecE6I1UL40A9GOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_VMMqp0PeAkmV1Ye9POrQ7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_hUpyIKRg90qXsba8GqK17A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_N6OYhzZRwkyDYwrDvyw5kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_DzLxM32I3UiH0dZZsCbJ1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_m2f7pvSnI0u6Km1eo2IeDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PipeCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_CVpJmymx606CfdrAoZpgUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_tJe91g6JuUaYMezRgMatVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d9qFrE2vD06_O6u11oBBfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1wHJTMoMnEqOTRvvG6b7qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fdw-5IVX0Ee-7JYOFozQCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yB5rb2fUc0ucbha081KM0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4prxmkqkS0ulQgJCLHuryg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wS0yOhGUekml-8634yMsxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_UbXNPFwR4km-FBdk7rEUxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_g-nMTDkmr0qcUvmTTdeMng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ExKQGNyc2UCDlqt3ydfMgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_BY79CPAZZk27J-wqZYzO7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_hGYstxKTzU2ZqyDcJ15G0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_v7UzME_8uUKyZkD-egDxIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_TwoThousandTwentyOnePlanMember_MH43z9s-vEmoE1YjdETXcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:TwoThousandTwentyOnePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_w5EWKu_kcUSEno9r_g_0ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_fPHz9pePvU-5r9-YvskzmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentContingentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2019Member_gmTdCJ8ork6VP-4xURIA1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_BxRCSzAuXEimnCRFgvNQ_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_3128W61YJ0eOKZC5tMQTAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_0R6iYR8SXEKx11Ao953ZHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2026_To_3_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingMember_RAxNUZYdMUeN8hu5p8owPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_uNAveP-XZ06GyWkwukd-jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_Hor3BE5nO0Ky5ynGuPLNiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_vz1AO0nR9UenRLqd0V7ORw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_NRfJ8T4b6Eu_-IBdIjogkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_vvalEg-TrUejRp41VE8WPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_GG-OyGYbHUevmT63tYsdDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-11-01</xbrli:startDate><xbrli:endDate>2026-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_us-gaap_TypeOfArrangementAxis_mtva_SecuritiesPurchaseAgreementMember_xy3ONbSXnUiU4ZOJJSQw7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RjEAz-8aH0qGHIsQmJ0Vyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_J_K81PseZUeD9UJGSY4LKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_m9XJ7gRPJEitR8u7ybUG-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_qToyrodAZ0ObK7Ly10LSHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_pFCcYjunlUeQQZkwtqzvuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_NeLyzkBTRESkMVZRZnvj7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_DBzDIMGO0UWZ5viFB9H-Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-eIdE4X3kkqQfEoPjdgKQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Vqqqe4ArJ0WMHcE3iolyIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_eujJ4gdQVEqiI8yThjB2Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_hyOQooLLv0aTYxqxsTi_Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_Mc6s5k_bG0SSAZ7j_mIrwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan20192022AndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_aNE-h6VMsU2pzK3AIQny9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan20192022AndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WuZ-wtRHAUqZiprK61-caA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rT0WgaTgaUCjX8WYjbJJTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_e1wxSJsny0iiOB1sr8mCHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_mylIA7H1dEi-aM6e5VbgCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice9900.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_YGrezCPF50-XvUz2iIIe3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice33000.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_PtYIpmGNVk2Lhpzik7xP3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice15919.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_Bv82ps5MOk6lD4sKnKRyPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_KNYPj3hEekKCq6iIEa5aJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesBWarrantExercisePrice43.23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_0TANxl4zWU2M4iUW_Dzy7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesaWarrantExercisePrice43.23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_UBBH_Z1Tz0S_4XGQiyGdpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_6202WPiPKkSw1AqR8WV3jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PlacementAgentWarrantExercisePrice54.0375Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_5R_W5kJG9k-0RfAK0QNCRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesBWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_A7Fo-RQiLkOdMLTRGG3G9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_RrvMS22yxkOjSxk0GAVqjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesDWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zi6cmK3ti0qodROqObmB_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesCWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_ZkP_xSv4vUWma066ndav7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_CldTLXRU7EGJY2I47LLydQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice9900.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_h23ZVALXkUePo8zvVv2roQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice33000.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_wyVIcQ8InUKuk3VoxOQDHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice15919.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_5XNmuoAqREGcG2s4IaMjeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesBWarrantExercisePrice43.23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_mJd36VtBzkuAj1i6nsWyDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesaWarrantExercisePrice43.23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_5H7GHDBMaE2UtxHkUd3cCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_lJphVo6Jl0qN7JwUudMRRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PlacementAgentWarrantExercisePrice54.0375Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SlAYXsZ0v0Ojj_aGP7CPdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Pj0_bY8RoEiWwD-LtiPp0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentContingentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_orxQwUg110-1269nNhDK5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_waCAFY3cfEuZyDAJOyUoHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0d43O4ut1Eiyd57Bcg_7ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_viTtU6jhrEuruIoP1QHhgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_eTjUAZIRBk2CMl0mq0_sdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kgPNiqIU3EqTQ0FXBCZBtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ZPTKidCK6ECs_qqex1EGQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qjUNJ2DdcESFldGXnzeBGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_yZobbedVRk2iue_r9d0-Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U6f5XE8pkEWgllVziJrf-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_7qHL6fLtgESMlXNDqOZJ2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9AAALrlJp0yWgwl3bBqvvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1hYaSL2Lxk-1ulrcFV5TrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_oBKoosGoG0GmD3xTsVOS-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentContingentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K_oHMLsqlUWlbv8jTh14Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7SMIbo51mEy0336DbR5j1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ieg6WHdrokO31k0M--imaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_QGD8FaaTKk-VCqeDRjoO0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesBWarrantExercisePrice43.23Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ffXAC5ncsEmnTRq2WxB_jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PipeCommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Owwpee6TWESXOEjeyqvrAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_H5aw50Xy8UOPMQzuBjjNEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongStMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9ad2NPEyvEeMZjvJ8Yr8bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mtva:DongStMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongSocioHoldingCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__CXlbv6yq0CPsUFeeflmGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mtva:DongSocioHoldingCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesDWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesDWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_OjEPyphxgUe99Gl8la9gVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesCWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_HGwlAKHDTEqwMSPqX6zFpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesCWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_I_-uWg1Oy0Oe1RoSXLv9bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PwnDqJ_0xkebhJ_3_12wnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_GxJU8xTtk064vc3Bitk13A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_88E3SsucMk6CjnvOW7ejPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_WmjFk2Gzpk-vzxZey8nlRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1726Member_F0QfeopiT0211MFhaQu96A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:Da1726Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1241Member_SxJHN2alKEOYThrSrZEvCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:Da1241Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_2dC3y_eK3ki1KsOJenFcjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_31_2019_srt_RangeAxis_srt_MaximumMember_AaM2dzgtbUGUiNDeiHy-eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mtva:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mtva:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PCbVTPdsR0KR7b1czjWLjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_nrhpLK0mj0K9W2Dt9Ye5iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2025_To_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EuG_rsEk0UOcbgfii4_NdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_KFhU-S1q0U2O8QEiJ_Qd2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_lI9JRhh7LEyE3NLlrMdSug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2026_MZ61IcNrt0a4XydPVofg3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_Vote_shares_ETjCJisZMkuUls7w3gpdKA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>mtva:Vote</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_location_PUM6ABDH9EqMpz0Yzt6Sgw"><xbrli:measure>mtva:location</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_i1i903DmOka3fCx6uRjRsw"><xbrli:measure>mtva:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_security_7HQ_97jGkEaCEOxlJP1q6A"><xbrli:measure>mtva:security</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g"><xbrli:measure>mtva:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:41pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;line-height:1.19;padding-top:1pt;text-align:center;border-top:1.5pt solid #000000;margin:0pt;">f</p><a id="_fb9216e6_f981_4d4a_a0ff_90a716342458"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:12.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:12.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Form </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentType" id="Narr_Z2FmQsFLBECuIphEOWt1OQ"><b style="font-size:9pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b>&#160;</p><a id="_ff3a5d31_e90d_4b5a_80a1_4a523cc7db63"></a><a id="Tc_e3i-2VHNokqY6NmTSfr6gA_1_1"></a><a id="Tc_TmWoDPJhZkWiKYUjqbMihA_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:fixed-true" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentAnnualReport" id="Tc__HlMuhIRp0KfFUm79fr4eA_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentPeriodEndDate" id="Narr_y6rEmewz4k2x6yn3QSUqWw"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:CurrentFiscalYearEndDate" id="Narr_llupbxOVTUK5GDP2P6CRMw"><b style="font-size:9pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, 2025</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:4pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_64b835f1_e536_49e7_884d_bfc588c2b08f"></a><a id="Tc_FSTS_h8gokqZWyP0aZzeWA_1_1"></a><a id="Tc_1sS1PP_ObUmAWdi9o3RFvA_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentTransitionReport" id="Tc_fvy0NhjE102ifT_gKAEuWw_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;to&#160;</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:4pt 0pt 0pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityFileNumber" id="Narr_bMOe8mZ-a0eFHboSOweTyg"><b style="font-size:9pt;font-weight:bold;">001-37809</b></ix:nonNumeric><span style="font-size:9pt;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><img src="mtva-20251231x10k001.jpg" alt="Graphic" style="display:inline-block;height:41pt;width:214.55pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;min-height:0.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityRegistrantName" id="Narr_dv7hl5S7J0u2NhO1qDF3-A"><b style="font-weight:bold;">METAVIA INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:0.0pt;text-align:center;margin:0pt 0pt 4pt 0pt;">(Exact name of Registrant as specified in its charter)</p><a id="_5ecc298a_9c5a_4b93_ac0c_8d5d50754fd5"></a><a id="Tc_OJx0jSyqNEK5j8WoW3SL0A_0_0"></a><a id="Tc_nK6adreT80O4byOr6u5p8Q_2_0"></a><a id="Tc_tZJGygzj2EqbtrHisKregw_2_2"></a><a id="Tc_0epOfK1SI0uLOfiNt9pocw_3_0"></a><a id="Tc_CwiYctupv0Kj9Efecf9rUw_4_0"></a><a id="Tc_xcmkjUnddE-fN2Mls6Ekbw_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">the </p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityIncorporationStateCountryCode" id="Tc_KDsEIKc9TEegZaP2K9siMA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:6.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityTaxIdentificationNumber" id="Tc_kC7pxyEbJUW0Ce95miui7A_1_2"><b style="font-size:9pt;font-weight:bold;">47-2389984</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityAddressAddressLine1" id="Narr_Vg7UR7dd5UybT5h-Y97Y-A"><b style="font-size:9pt;font-weight:bold;">545 Concord Avenue, Suite 210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityAddressCityOrTown" id="Narr_mQaL4c7dD06fLhp8G1c_6Q"><b style="font-size:9pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityAddressStateOrProvince" id="Narr_4o1TfxwxT0eaK4LdlV6wVQ"><b style="font-size:9pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityAddressPostalZipCode" id="Tc_aIuu6PvB8keNFtDxk2RTvQ_3_2"><b style="font-size:9pt;font-weight:bold;">02138</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:3pt 0pt 0pt 0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:CityAreaCode" id="Narr_UW5dq6b5D0yEORxFKVTi5w"><b style="font-size:9pt;font-weight:bold;">857</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:LocalPhoneNumber" id="Narr_rQ6mdfobbUWHBohVFj5HhA"><b style="font-size:9pt;font-weight:bold;">702-9600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:4pt 0pt 4pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Securities&#160;registered&#160;pursuant&#160;to&#160;Section&#160;12(b)&#160;of the Act:</span></p><a id="_db101494_73f9_470a_898f_8004be2c6bce"></a><a id="Tc_nJ8vmwlfJUqnjfD0pWhdmg_1_0"></a><a id="Tc_ytpkP0TYjUKvkF0aUOmhRg_1_2"></a><a id="Tc_mSIWt98M_0Cc0tDtkoutXQ_1_4"></a><a id="Tc_EyI_26pS9UyxQvMPTUDgeg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;">&#160;</p></div></div></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><span style="font-size:9pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:40.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:38.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</span></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:top;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:40.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of Exchange on Which Registered</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:38.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:Security12bTitle" id="Tc_dwBFcYNJyUKBwXeEP_W-qw_2_0"><span style="font-size:9pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:9pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:TradingSymbol" id="Tc_dEtpjhcVjkyMYv5qUgrtdA_2_2"><span style="font-size:9pt;">MTVA</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;margin:0pt 0pt 3pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:40.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:9pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:SecurityExchangeName" id="Narr_u2D8s_5vekOHEWZ9JBxGzg"><span style="font-size:9pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:9pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:4pt 0pt 4pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Securities&#160;registered&#160;pursuant&#160;to&#160;Section&#160;12(g)&#160;of&#160;the&#160;Act:&#160;None</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;Yes </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_5GmRfF2T4UuacdVTHTXe4w"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityVoluntaryFilers" id="Narr_QTalRdA-OEyVeFIOuDuuPg"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:justify;margin:0pt 3.8pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityCurrentReportingStatus" id="Narr_By85bIV8-E6KFt7iSQofkg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:justify;margin:0pt 3.8pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityInteractiveDataCurrent" id="Narr_rtDdaDJqG0-s-gOzKng_bA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:justify;margin:0pt 3.8pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.4pt;text-align:center;margin:0pt;">Large accelerated filer<span style="display:inline-block;width:27.07pt;"></span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.4pt;margin:0pt;">Accelerated filer<span style="display:inline-block;width:11.79pt;"></span><span style="display:inline-block;width:36pt;"></span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.4pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityFilerCategory" id="Narr_9U7CxDhuqUq1ZDWUMGKVPA"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric><span style="display:inline-block;width:31.8pt;"></span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.4pt;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company</span><span style="display:inline-block;width:9.53pt;"></span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntitySmallBusiness" id="Narr_waZ5dt-BlkmWmiuU7tTDuA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.4pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging growth company</span><span style="display:inline-block;width:9.52pt;"></span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityEmergingGrowthCompany" id="Narr_uSTykthic06c6_rfMo3uFQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.4pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:4pt 0pt 4pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:IcfrAuditorAttestationFlag" id="Narr_RBv3KIinC0axcv6szOWvbg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_Bua0hKR0y0mczvI_mqD19w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:EntityShellCompany" id="Narr_ukZtz0-S-E2SoaRtMCveYw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">As of June 30, 2025, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" format="ixt:num-dot-decimal" scale="6" contextRef="As_Of_6_30_2025_lI9JRhh7LEyE3NLlrMdSug" decimals="-5" name="dei:EntityPublicFloat" id="Narr_466U2PL9Bkei-qjS36xL3A">3.0</ix:nonFraction> </span><span style="font-size:9pt;">million, based on the closing price on the Nasdaq Capital Market on the last business day of the registrant&#8217;s most recently completed second fiscal quarter.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><span style="font-size:9pt;">As of March 20, 2026, the registrant had </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_20_2026_MZ61IcNrt0a4XydPVofg3Q" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_iOQBqJrVu06vT_38AapCeA">5,090,936</ix:nonFraction></span><span style="font-size:9pt;"> shares of common stock, $0.001 par value per share, outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1.5pt solid #000000;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fce7ed04_578f_451f_ac45_dbaa29af3f4e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">METAVIA INC</b>.</p><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;width:97.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ForwardLookingStatements"><span style="font-style:normal;font-weight:normal;">Special Note Regarding Forward-Looking Statements</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-align:right;text-indent:-4.05pt;margin:0pt;">2</p></td></tr><tr style=""><td colspan="2" style="vertical-align:bottom;width:97.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#SummaryRiskFactors"><span style="font-style:normal;font-weight:normal;">Summary Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">3</p></td></tr><tr style=""><td colspan="3" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#PartI_629645"><span style="font-style:normal;font-weight:normal;">Part I</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM1BUSINESS_687476"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM1BUSINESS_687476"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_215230"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_215230"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">38</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">69</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Item 1C</span></a>.</p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#Item1C"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">69</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM2PROPERTIES_644950"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM2PROPERTIES_644950"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">70</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_754217"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_754217"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">70</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_848551"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_848551"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 4.05pt;">70</p></td></tr><tr style=""><td colspan="3" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:4.05pt;text-indent:-4.05pt;margin:0pt;"><a href="#PARTII_387386"><span style="font-style:normal;font-weight:normal;">Part II</span></a></p></td></tr><tr style=""><td style="vertical-align:top;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item5"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:top;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item5"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">70</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_394630"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_394630"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">71</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#item7"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#item7"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">71</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item8_FinancialStatements"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item8_FinancialStatements"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#item9"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#item9"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item9A"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item9A"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a> </p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">80</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_848698"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_848698"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">81</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevents Inspections</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">81</p></td></tr><tr style=""><td colspan="3" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTIII_373562"><span style="font-style:normal;font-weight:normal;">Part III</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.95pt;text-indent:-3.95pt;margin:0pt;"><a href="#Item10"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.95pt;text-indent:-3.95pt;margin:0pt;"><a href="#Item10"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 3.95pt;">81</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_607490"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_607490"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">85</p></td></tr><tr style=""><td style="vertical-align:top;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.95pt;text-indent:-3.95pt;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAIN_50405"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a> </p></td><td style="vertical-align:top;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAIN_50405"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder&#160;Matters</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 3.95pt;">89</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#item13"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#item13"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">91</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.95pt;text-indent:-3.95pt;margin:0pt;"><a href="#item14"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.95pt;text-indent:-3.95pt;margin:0pt;"><a href="#item14"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 3.95pt;">93</p></td></tr><tr style=""><td colspan="3" style="vertical-align:bottom;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PartIV_36663"><span style="font-style:normal;font-weight:normal;">Part IV</span></a></p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.8pt;text-indent:-3.8pt;margin:0pt;"><a href="#ITEM15_562720"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.8pt;text-indent:-3.8pt;margin:0pt;"><a href="#ITEM15_562720"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 3.8pt;">94</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM16_822338"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:88.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM16_822338"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">96</p></td></tr><tr style=""><td style="vertical-align:bottom;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.8pt;text-indent:-3.8pt;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:88.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:3.8pt;text-indent:-3.8pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 0pt 3.6pt;">97</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">1</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9bd3a1ac_7f69_49f7_af89_18731cc5f2b4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Unless the context requires otherwise, references in this Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (this &#8220;Annual Report&#8221; or &#8220;Report&#8221;) to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;the Company,&#8221; &#8220;MetaVia&#8221; and &#8220;our&#8221; refer to MetaVia Inc. (the &#8220;Company&#8221;) and its subsidiaries.</i></p><a id="ForwardLookingStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Special Note Regarding Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">This Annual Report contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). <span style="background:#ffffff;">All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, our expectations regarding our ability to execute our commercial strategy; our expectations regarding the sufficiency of our existing cash and cash equivalents on hand to fund our operations; the timeline for regulatory submissions, regulatory steps and potential regulatory approval of our current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co., Ltd., a related party (&#8220;Dong-A ST&#8221;), including the impact on our future financial and operating results; the ability to integrate the product candidates into our business in a timely and cost-efficient manner; the cooperation of our contract manufacturers, clinical study partners and others involved in the development of our current and future product candidates; our ability to initiate clinical trials on a timely basis; our planned clinical trials and our ability to recruit subjects for our clinical trials; the costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the changes in applicable laws or regulations; and the effects of changes to our stock price on the terms of the license agreement and any future fundraising and other risks and uncertainties described in our filings with the </span>Securities and Exchange Commission (&#8220;SEC&#8221;)<span style="background:#ffffff;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Forward-looking statements are based on management&#8217;s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. These statements may be identified by words such as <span style="background:#ffffff;">&#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. In addition, statements that &#8220;we believe,&#8221; &#8220;we expect,&#8221; &#8220;we anticipate&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report and management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.</span> <span style="background:#ffffff;">We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results or expectations, except as required by law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Forward-looking statements are subject to a number of risks and uncertainties, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements<span style="background:#ffffff;">, including without limitation, the possibility that regulatory authorities do not accept our applications or approve the marketing of our products, the possibility we may be unable to raise the funds necessary for the development and commercialization of our products, and those described in this Annual Report and in our other filings with the SEC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="background:#ffffff;">We operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. </span>We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">2</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SummaryRiskFactors"></a><a id="_88b430f7_56da_4df0_8e6f_9570ed95ce0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Summary Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">Our business is subject to a number of risks, as fully described&#160;in Part I, Item 1A. Risk Factors in this Annual Report. The principal factors and uncertainties include, among others:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred net losses since inception, and we anticipate that we will continue to incur net losses for the foreseeable future. We require additional capital to accomplish our business plan and the failure to obtain necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As we do not generate any revenue, we are dependent on working capital to fund our business plan, and raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights to our technologies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Future sales, or the perception of future sales, by us or our securityholders could cause the market price of our common stock to decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Adverse global economic conditions could have a material adverse effect on our business, results of operations and financial condition and liquidity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Public opinion and scrutiny of treatments for obesity, overweight patients, MASH and MASH patients may impact public perception of our Company, DA-1726, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vanoglipel (DA-1241), </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or may adversely affect our ability to conduct our business and our business plans.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be required to make significant payments under the 2022 License Agreement (as defined below).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we obtain favorable clinical results, we may not be able to obtain regulatory approval for, or successfully commercialize vanoglipel (DA-1241) and DA-1726.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preliminary, interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our efforts to discover drug candidates beyond our current drug candidates may not succeed, and any drug candidates we recommend for clinical development may not actually begin clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Delays in our clinical trials may lead to a delay in the submission of marketing approval applications and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may develop vanoglipel (DA-1241) and DA-1726, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential future drug candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with MASH or obesity and significant competition for recruiting such patients in clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">3</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we or our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely and will continue to rely on collaborative partners regarding the development of our research programs and product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are subject to United States (&#8220;U.S.&#8221;) and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have relied and will rely on third-party clinical research organizations (&#8220;CROs&#8221;) to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to manufacture our product candidates and preclinical and clinical drug supplies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may engage in future acquisitions, mergers, in-licenses and out-licenses of technology that could disrupt our business, cause dilution to the organization&#8217;s stockholders and harm our financial condition and operating results. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain sufficient intellectual property rights, our competitive position could be harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to protect or practice our intellectual property rights throughout the world. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently have a small number of employees and consultants, and our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our two largest stockholders may use their significant interest to take actions not supported by our other stockholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business and operations may suffer in the event of system failures or other unplanned events.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">4</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4ad38d51_86d7_49b2_b828_a8d7a059e04f"></a><a id="PartI_629645"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Part I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9ed260c9_9892_48be_8b6a_a06d21bf0d42"></a><a id="ITEM1BUSINESS_687476"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1.</b></span><b style="font-weight:bold;">Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Overview </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;) and obesity. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) is a novel GPR119 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">(&#8220;GPR119&#8221;) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agonist with development optionality as a standalone or combination therapy for both MASH and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">Type 2 Diabetes Mellitus&#160;(&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">T2DM&#8221;). Agonism of GPR119 in the gut promotes the release of key gut peptides, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">glucagon-like peptide-1&#160;(&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">GLP-1&#8221;), glucagon-dependent insulinotropic polypeptide receptor (&#8220;GIP&#8221;), and peptide YY </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">(&#8220;PYY&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel (DA-1241) has demonstrated beneficial effects on glucose, lipid profile and liver inflammation, as demonstrated during in-vivo preclinical studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In Phase&#160;1a and 1b human clinical trials, vanoglipel (DA-1241) was well tolerated in both healthy volunteers and those with T2DM. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We initiated a Phase&#160;2a clinical trial in 2023 with the goal of establishing the mechanism of action and efficacy of vanoglipel (DA-1241) in the treatment of MASH and to evaluate trends for T2DM. This is the first-in-human MASH clinical trial for vanoglipel (DA-1241). In November 2024, we completed the last patient last visit for the Phase 2a clinical trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">In December 2024, we an</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nounced positive topline 16-week results from the two-part Phase 2a clinical trial in patients with presumed MASH. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In May 2025, we presented the topline 16-week results from the two-part Phase 2a clinical trial at the European Association for the Study of the Liver (&#8220;EASL&#8221;) 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">In November 2025, we presented sub-group analysis on glucose control in prediabetes and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">diabetes subjects and additional data on inflammation and lipidomic profiles at the American</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">Association for the Study of Liver Diseases (&#8220;AASLD&#8221;) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Liver Meeting</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are expecting to finalize the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical Study Report (&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CSR&#8221;) of the Phase 2a clinical trial in the first half of 2026.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 is a novel oxyntomodulin (&#8220;OXM&#8221;) analog functioning as a GLP-1 receptor (&#8220;GLP1R&#8221;) and glucagon receptor (&#8220;GCGR&#8221;) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With the activation of the dual agonist, weight loss may be achieved by GLP1R reducing appetite while GCGR increases energy expenditure.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide and tirzepatide. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We initiated a Phase&#160;1 clinical trial in 2024 with the goal of establishing the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety and tolerability of DA-1726 while exploring the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">mechanism of action and efficacy of DA-1726 in the treatment of obesity.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This is the first-in-human clinical trial for DA-1726.</span><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In September 2024, we announced positive topline data from the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single ascending dose </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">SAD</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Part 1 of our Phase 1 clinical trial evaluating DA-1726 while an additional SAD study and a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple-ascending dose </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(&#8220;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MAD&#8221;) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">study were ongoing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">Overall safety and tolerability in Part 1 of the Phase 1 clinical trial was clean and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">allowed us to continue the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">MAD Part 2 of the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 clinical trial</span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">In April 2025, we announced positive topline data from our up to 32 mg, MAD cohort Part 2 of the Phase 1 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical </span><span style="color:#231f20;font-family:'Times NR MT Pro';font-size:10pt;font-style:normal;font-weight:normal;">trial. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In June 2025, we began enrollment for a higher-dose MAD cohort to assess the maximum tolerated dose and fully realize DA-1726&#8217;s potential, as higher doses may also show a similar profile, while potentially demonstrating increased weight reduction. We dosed the first patient in the non-titrated 48 mg, MAD cohort of our Phase 1 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial in July 2025, and we extended the clinical trial for this 48 mg, MAD cohort to eight weeks from four weeks to further explore the non-titrated maximum tolerated dose, explore safety and </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">5</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy. Also, in August 2025, we administered the fifth dose for the first patient in the 48 mg, MAD cohort of our Phase 1 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In November 2025, we presented new Phase 1 and pre-clinical data in two poster presentations at ObesityWeek</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2025. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 5, 2026, we announced positive topline data from our non-titrated 48 mg, MAD cohort 5 Part 2 of the Phase 1 clinical trial. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are planning to start Part 3a and Part 3b of the Phase 1 clinical trial in April 2026. Part 3a will be a one-step titration with 16 mg for four weeks and 48 mg for 12 weeks. Part 3b will be a two-step titration with 16 mg for four weeks, 32 mg for four weeks and 64 mg for eight weeks. These titration studies are to see if it can remove any moderate adverse effects from the 48 mg dose level and to seek DA-1726 at a higher dose level of 64 mg. We expect dose-dependent exploratory weight loss and other early signals in the exploratory endpoints with potential for best-in-class safety and tolerability. The data readout for both Part 3a and Part 3b is planned for the fourth quarter of 2026. </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">While we focus our financial resources and management&#8217;s attention on the development of vanoglipel (DA-1241) and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases, which we are not planning to advance development on and have, or continue to consider for, out-licensing and divestiture opportunities:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19.</span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NB-01 for the treatment for painful diabetic neuropathy (&#8220;PDN&#8221;). </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">In July 2024, we entered into an exclusive out-license agreement with MThera Pharma Co., LTD. (&#8220;MThera&#8221;) to provide MThera with the rights to NB-01 for the treatment of painful diabetic neuropathy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NB-02 for the treatment of cognitive impairment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gemcabene for the treatment of dyslipidemia.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our operations have consisted principally of performing research and development (&#8220;R&amp;D&#8221;) activities, preclinical developments, clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved and other risks listed<b style="font-weight:bold;"> </b>in Part I, Item 1A. Risk Factors in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our goal is to discover and develop novel therapeutics designed to impact a range of indications primarily in cardiometabolic diseases. The key elements of our business strategy to achieve this goal include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance vanoglipel (DA-1241) through the FDA regulatory process to obtain approval for the treatment of MASH.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Successful completion of the Phase&#160;2a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial is designed to establish the mechanism of action and an early signal of efficacy in MASH and T2DM, which will allow us to seek initiation of a Phase 2b </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trial </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as monotherapy or in combination with GLP1R or other therapeutic candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Pursue vanoglipel (DA-1241) combination therapy</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Phase 2a Part 2 clinical trial </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">showed vanoglipel&#8217;s (DA-1241) strong potential for monotherapy as well as the potential for combination therapy with its strong safety signals</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. With the successful proof of concept demonstrated in the Phase 2a clinical trial, we plan to explore other combination therapies that can benefit from the mechanism of action of vanoglipel (DA-1241) and to expand the target efficacy of vanoglipel (DA-1241) for the treatment of MASH.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advance DA-1726 through the FDA regulatory process to obtain approval for the treatment of obesity. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Explore various avenues to advance DA-1726 through the FDA approval process, including seeking ways to expedite clinical trials and conducting non-clinical studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Pursue additional pipelines and/or other business opportunities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. With both vanoglipel (DA-1241) and DA-1726 in clinical trials, we plan to explore adding (i) clinical stage product candidates to diversify and enrich our pipeline and/or (ii) other technologies.</span></td></tr></table><div style="margin-top:8pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">6</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:180pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Our Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our focus is on two cardiometabolic assets. Our first asset, vanoglipel (DA-1241), is a GPR119 agonist, in a Phase 2a clinical trial for treatment of MASH. Our second asset is DA-1726, a GLP-1 receptor and glucagon receptor dual agonist, in a Phase 1 clinical trial for treatment of obesity. The following illustrates the current status of our assets as of the filing date of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 8pt 36pt;"><img src="mtva-20251231x10k002.jpg" alt="Graphic" style="display:inline-block;height:180pt;width:445.68pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 8pt 36pt;"><img src="mtva-20251231x10k003.jpg" alt="Graphic" style="display:inline-block;height:90.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:295pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Vanoglipel (DA-1241)</b><b style="font-weight:bold;"> Treatment of MASH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Vanoglipel (DA-1241) is a potential first-in-class GPR119 agonist with therapeutic potential for MASH and T2DM that is designed to be orally administered once a day. Two Phase 1 clinical trials for the treatment of T2DM have been completed and a Phase 2a clinical trial for the treatment of MASH is ongoing in the U.S. In November 2024, we completed the last patient last visit for Phase 2a clinical trial. In December 2024, we announced positive topline 16-week results from the two-part Phase 2a clinical trial in patients with presumed MASH. In May 2025, we presented the topline 16-week results from the two-part Phase 2a clinical trial at EASL 2025. In November 2025, we presented sub-group analysis on glucose control in prediabetes and diabetes subjects and additional data on inflammation and lipidomic profiles at the AASLD The Liver Meeting<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 2025. The data highlights vanoglipel&#8217;s differentiated dual activity across both hepatic and metabolic pathways, demonstrating clinically meaningful improvements in glucose control, liver health, and plasma lipidomic profiles following 16 weeks of treatment. Currently, we are expecting to finalize the CSR of the Phase 2a clinical trial in the first half of 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Vanoglipel (DA-1241) is a novel chemical drug candidate selectively activating GPR119 which has shown consistent target-related mechanisms and glucose-lowering effects from nonclinical studies in Phase&#160;1b exploratory clinical trials in patients with T2DM in the U.S. GPR119 is known to be a regulator of both blood glucose and lipid levels. Non-clinical studies suggest vanoglipel (DA-1241) selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as GLP-1, and thereby reduces plasma glucose levels without hypoglycemia risk and lowers plasma lipids levels of both triglycerides and cholesterol. Moreover, impaired insulin action and lipid metabolism which are frequently observed in T2DM patients are highly associated with the pathogenesis of steatosis and inflammation in MASH. Extensive non-clinical studies have shown vanoglipel (DA-1241) has therapeutic potential for the reduction in hepatic steatosis, inflammation, fibrosis, and improved glucose control regardless of body weight reduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">MASH Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (&#8220;MASLD&#8221;) characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma and death. MASLD was formerly known as nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;) and was changed by the AASLD and its European and Latin American </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">7</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">counterparts. Patients with MASH are at increased risk of liver damage and other complications. Fibrosis is generally reversible in its early-to-mid stages. However, late-stage fibrosis can be irreversible in the absence of therapy and prevents the liver from performing its natural functions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The prevalence of MASLD, which affects approximately 30% of the global population, and MASH, which develops in approximately 12% to 14% of MASLD patients, is growing and is driven primarily by the worldwide obesity epidemic. Over the past three decades, the global prevalence of MASLD has grown substantially from 17.6% (1990) to over 30% (2024), with an average increase of about 0.7% to 0.8% annually. The critical pathophysiologic mechanisms underlying the development and progression of MASH include reduced ability to handle lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. Patients with MASH frequently have other significant metabolic co-morbidities such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute to the risk of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Vanoglipel (DA-1241) Preclinical Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Extensive preclinical pharmacology, Absorption, Distribution, Metabolism and Excretion (&#8220;ADME&#8221;), safety and toxicology studies have been completed for vanoglipel (DA-1241). The pharmacokinetic (&#8220;PK&#8221;) characteristics of vanoglipel (DA-1241) were identified through the full set of preclinical ADME studies. The safety and toxicology studies completed were: (i)&#160;central nervous system, cardiovascular, and respiratory safety in rats and dogs; (ii)&#160;a single-dose, 4-week, 13-week and 26-week oral toxicity studies in rats; (iii)&#160;4-week, 13-week and 39-week oral toxicity studies in dogs; (iv)&#160;pre-natal development studies in rats and rabbits; and (v)&#160;genotoxicity tests of in vitro bacterial reverse mutation, chromosome aberration, and in-vivo micronucleus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Comprehensive non-clinical studies demonstrated vanoglipel (DA-1241) distinctively activates GPR119 across species, stimulates the secretion of insulin and GLP-1, a gut peptide hormone with various metabolic benefits, from the pancreas and intestine, respectively, and thereby reduces postprandial glucose and lipid levels after single administration to mice. The postprandial hypoglycemic response by vanoglipel (DA-1241) observed in wild type mice disappeared in GPR119-deficient mice, demonstrating target engagement. Notably, vanoglipel (DA-1241) treatment did not cause hypoglycemia &lt; 50 mg/dl in overnight fasted mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In diabetic mice with hypertriglyceridemia, chronic treatment with vanoglipel (DA-1241) lowered fasting and non-fasting blood glucose levels, in which vanoglipel (DA-1241) prevented pancreatic beta cell loss and preserved pancreatic function. Moreover, vanoglipel (DA-1241) treatment decreased hepatic lipid accumulation in addition to plasma triglycerides levels at the same dose levels. When a DPP4 inhibitor was cotreated with vanoglipel (DA-1241) to prolong the biological half-life of plasma GLP-1, plasma concentrations of active GLP-1 increased more than those due to degradation blockade with DPP4 inhibitors, and thereby potentiation of GLP-1 action further improved glucose and lipid metabolism compared to each treatment alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In a non-diabetic mouse model with pre-established dyslipidemia, vanoglipel (DA-1241) completely reduced plasma and hepatic triglycerides to normal control levels and also decreased plasma LDL-cholesterol, independent of glycemic control. Comprehensive mechanism studies have shown that the lipid-lowering effects of vanoglipel (DA-1241) are due in part to inhibiting lipid synthesis in the liver and interfering with dietary lipid transport in the intestine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">With regard to the MASH indication, vanoglipel (DA-1241) has been shown to improve fatty liver in various types of mouse models with metabolic diseases. Thereafter, therapeutic potential for treating MASH has been evaluated in several MASH mice models with different pathophysiology. Among them, the STAM-MASH mouse model exhibits mild fatty liver and moderate liver inflammation/fibrosis and is rapidly chemically induced. Vanoglipel (DA-1241) improved hepatic inflammation and fibrosis, showing a decrease in MASLD activity score and relative fibrotic area of the liver compared to the vehicle-treated control. Diet-induced obesity (&#8220;DIO&#8221;)-MASH mice are chronically induced through a Western diet and are characterized by marked fatty liver and mild to moderate hepatic inflammation/fibrosis. In DIO-MASH mice, vanoglipel (DA-1241) improved hepatic steatosis, inflammation, and fibrosis assessed by histological and biochemical methods regardless of body weight reduction. Of note, vanoglipel (DA-1241) improved systemic inflammatory status with reduced plasma inflammatory cytokines (TNF&#945;, IL6) and chemokines (CCL2, CXCL1, CXCL2, CXCL10) contributing to tissue damage. Therefore, vanoglipel (DA-1241) treatment reduced the levels of plasma liver enzymes (ALT, AST), which were increased due to liver tissue damage in DIO-MASH mice. In mice with metabolic diseases, the effects of vanoglipel (DA-1241) on the MASH phenotypes (steatosis, inflammation, and fibrosis in the liver) are enhanced by the co-treatment with a DPP4 inhibitor compared to each treatment alone due to potentiated GLP-1 actions.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">8</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:167.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Result of Phase&#160;1 U.S. Clinical Trial for Vanoglipel (DA-1241)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Completed Phase&#160;1a and 1b clinical trials in the U.S. healthy subjects.</span><b style="font-weight:bold;"> </b>The first-in-humans Phase&#160;1a study was a double-blind, placebo controlled, SAD, single-center study in 60 healthy male volunteers to evaluate the safety, tolerability, PK, pharmacodynamics (&#8220;PD&#8221;), and interaction effect with metformin. Each cohort was given a single oral dose of 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg of vanoglipel (DA-1241) or placebo tablets. The dose level of vanoglipel (DA-1241) for the interaction effect (&#8220;IE&#8221;) assessment of metformin on the PK of vanoglipel (DA-1241) was 100 mg. Therefore, the IE cohort had two separate treatment periods. Subjects in the IE cohort received vanoglipel (DA-1241) 100 mg or placebo alone in Treatment Period 1, and vanoglipel (DA-1241) 100 mg or placebo with 500 mg metformin (IR formulation) in Treatment Period 2. Vanoglipel (DA-1241) was well tolerated over a dose range of 12.5 mg to 400 mg. There was no effect of concomitant administration of metformin on vanoglipel (DA-1241) PK parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Phase&#160;1b, Part&#160;1 was a double-blind placebo-controlled, MAD, single-center study of vanoglipel (DA-1241) in healthy subjects. Overall, 24 male subjects were blinded and randomized to receive vanoglipel (DA-1241): 50 mg, 100 mg or 200 mg or placebo, as single daily oral doses for 28&#160;days. Safety data reviews and dose escalation decisions between cohorts took place after all subjects of an ongoing cohort had completed procedures through Day 14. All doses tested were well tolerated. There were no serious adverse events (&#8220;SAEs&#8221;) and no discontinuations due to adverse events (&#8220;AEs&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">Completed Phase&#160;1b clinical trial in the U.S. T2DM patients. </span><span style="font-size:10pt;">The Phase&#160;1b study was designed as a placebo and active comparator (sitagliptin 100 mg) controlled, double-blind, randomized, multi-center study with an objective of evaluating whether vanoglipel (DA-1241) delivers improved glucose-lowering efficacy in 83 diabetic patients. Patients were treated with placebo, sitagliptin 100 mg or vanoglipel (DA-1241) 25 mg, 50 mg and 100 mg once daily for eight weeks, in combination with stable doses of metformin (13-19 patients/group). In the mixed meal tolerance test to evaluate the ability to reduce postprandial glucose through GPR119 activation, the incremental AUE</span><span style="font-size:7.5pt;">0-4h</span><span style="font-size:10pt;">&#160;of plasma glucose (&#8220;iAUE&#8221;) upon nutrient ingestion was measured and compared. Eight-week treatment of vanoglipel (DA-1241) 25 mg, 50 mg and 100 mg showed the changes of +6.3%,&#160;-2.0%&#160;and&#160;-13.8%&#160;in iAUE levels from the baseline and vanoglipel (DA-1241) 100 mg showed similar blood glucose improvement with that of sitagliptin 100 mg (-9.0%), and it outperformed placebo (+10.5%).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><span style="font-style:italic;font-weight:bold;">Exploratory P1b Study in the U.S.: Glucose-Lowering Effects</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><img src="mtva-20251231x10k004.jpg" alt="Graphic" style="display:inline-block;height:167.04pt;width:227.52pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 72pt;"><span style="font-style:italic;font-weight:bold;">Mean Change in Postprandial Glucose Excursion at Week 8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt;">In the parameters of glycemic variability measured with a Continuous Glucose Monitoring system and fasting plasma glucose, the glucose-lowering efficacy by vanoglipel (DA-1241) was similar to that of sitagliptin. Moreover, the time-in-range, the&#160;percentage of how long blood glucose value is within 70-180 mg/dL, was increased by mitigating the hypoglycemia risk and duration of hyperglycemia whereas such time-in-range was reduced in the placebo group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Single administration or 8-week repeated administration of vanoglipel (DA-1241) increased secretion of gut peptide hormones such as GLP-1, GIP and PYY in gastrointestinal tracts after taking meals. The amount of secretion of such hormones increased in proportion to the extent of exposure to vanoglipel (DA-1241).</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">9</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177.84pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 72pt;"><span style="font-style:italic;font-weight:bold;">Exploratory P1b Study in the U.S.: Target-related Biomarker Change</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><img src="mtva-20251231x10k005.jpg" alt="Graphic" style="display:inline-block;height:177.84pt;width:288.72pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 72pt;">* &amp; ** P&lt;0.05 &amp; P&lt;0.01 versus corresponding baseline values; DA, vanoglipel (DA-1241); Sita, Sitagliptin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 4pt 90pt;"><span style="font-style:italic;font-weight:bold;">Total GLP-1 Secretion during Mixed Meal Tolerance Test </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In terms of safety, no clinically significant AEs were observed following the 8-week treatment, confirming the tolerability of vanoglipel (DA-1241), and the bodyweight showed a tendency to decrease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Vanoglipel (DA-1241) Phase&#160;2a Clinical Trial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are currently finalizing the CSR on a Phase&#160;2a clinical trial in the U.S.</span><b style="font-weight:bold;"> </b>MASH Phase&#160;2a is a&#160;16-week, multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical trial to establish safety and an early signal of efficacy in MASH as a next-generation competitive oral agent while we follow the trend for T2DM. The clinical trial completed the last patient last visit in November 2024 and topline results were disclosed in December 2024. A total of 109 patients were randomized, while 95 patients completed the dosing. These patients were randomized into four treatment groups and dosed with: vanoglipel (DA-1241) 50 mg, vanoglipel (DA-1241) 100 mg, vanoglipel (DA-1241) 100 mg/Sitagliptin 100 mg, or Placebo in a 1:2:2:2 ratio. The primary efficacy endpoint for the study is the change from baseline in the alanine transaminase (&#8220;ALT&#8221;) levels at Week 16. The secondary efficacy endpoints evaluate changes in the following at Week 16 including: proportion of subjects with normalization of ALT level of &lt; 30 IU/L; relative percent change in liver fat fraction from baseline; absolute change in liver fat from baseline; proportion of subjects with a 30% or more reduction in liver fat from baseline; change in aspartate transaminase (&#8220;AST&#8221;), gamma glutamyl transpeptidase, and alkaline phosphatase from baseline; change in hemoglobin A1c (&#8220;HbA1c&#8221;) (%); change in NAFLD Fibrosis Score from baseline; liver stiffness measurement assessed by FibroScan<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> from baseline; and change in FAST (FibroScan - AST) from baseline. Safety will be evaluated by monitoring AEs including determination of SAEs and AEs leading to discontinuation and laboratory abnormalities as characterized by type, frequency, timing, severity (mild, moderate, severe), seriousness and relationship to vanoglipel (DA-1241), vital signs measurements, clinical laboratory tests and electrocardiogram assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Topline results from the Phase 2a Study.</span> We have reported positive topline 16-week results from the two-part Phase 2a clinical trial in patients with presumed MASH in December 2024. Part 1 of this Phase 2a clinical trial is exploring vanoglipel (DA-1241), a novel GPR119 agonist compared to placebo, while Part 2 is investigating the efficacy of vanoglipel (DA-1241) in combination with sitagliptin, a DPP-4 inhibitor. An overview of the topline 16-week results from the two-part Phase 2a clinical trial is included below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;">Overview of the Topline Results</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Achieved primary efficacy endpoint.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) 100 mg showed statistically significant reductions in ALT levels at Weeks 4 and 8 (p = 0.0159 and p = 0.0342, respectively) and a near statistically significant reduction (p = 0.0506) at Week 16 compared to placebo.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Normalized ALT levels in 16 weeks.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) 50 mg showed a statistically significant improvement in the normalization of ALT levels compared to placebo, with an odds ratio of 10.500 (p = 0.0487). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Direct hepatic effect shown by significant improvements in CAP score and FAST score.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) 100 mg and vanoglipel (DA-1241) 100 mg + Sitagliptin 100 mg showed significant improvements in the CAP score compared to </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">10</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:259.92pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">placebo (p=0.0308 and p=0.0452, respectively).</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) 100 mg in combination with Sitagliptin 100 mg showed a statistically significant reduction in the FAST score compared to placebo (p = 0.0416).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:2.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Additional glycemic control with significant reduction of HbA1c in 16 weeks.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) 100 mg and vanoglipel (DA-1241) 100 mg in combination with Sitagliptin 100 mg showed significant reductions in HbA1c from baseline at Week 16 compared to the placebo group (p = 0.0179 and p = 0.0050, respectively).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:2.15pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Strong safety signal compared to competition.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Vanoglipel (DA-1241) was shown to be </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">very</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> well tolerated with mostly mild AEs and no drug-related SAEs in the treatment groups</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> with no </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment emergent adverse events (&#8220;TEAEs&#8221;)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> leading to study drug discontinuation. </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;">Primary Efficacy Endpoint</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 8pt 0pt;">LS Mean ALT Changes from Baseline (U/L)</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:12.53%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:13.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ffffff;visibility:hidden;background:#00ffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ffffff;visibility:hidden;background:#00ffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.91%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:14.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ffffff;visibility:hidden;background:#00ffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ffffff;visibility:hidden;background:#00ffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:15.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ffffff;visibility:hidden;background:#00ffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="color:#ffffff;visibility:hidden;background:#00ffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.6%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=23)</p></td><td style="vertical-align:middle;width:17.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241) 100 mg + Sitagliptin 100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=34)</p></td><td style="vertical-align:middle;width:8.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td><td style="vertical-align:middle;width:14.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">50 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=12)</p></td><td style="vertical-align:middle;width:8.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td><td style="vertical-align:middle;width:15.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=22)</p></td><td style="vertical-align:middle;width:8.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td></tr><tr style=""><td style="vertical-align:middle;width:12.53%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Baseline Mean</p></td><td style="vertical-align:middle;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">68.4</p></td><td style="vertical-align:middle;width:17.88%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">63.2</p></td><td style="vertical-align:middle;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">65.8</p></td><td style="vertical-align:middle;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">57.2</p></td><td style="vertical-align:middle;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 4 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:13.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-1.51</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-8.23, 5.21)</p></td><td style="vertical-align:middle;width:17.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-8.38</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-13.89, -2.87)*</p></td><td style="vertical-align:middle;width:8.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.1195</p></td><td style="vertical-align:middle;width:14.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-9.63</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-18.90, -0.35)*</p></td><td style="vertical-align:middle;width:8.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.1622</p></td><td style="vertical-align:middle;width:15.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-13.44</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-20.32, -6.57)*</p></td><td style="vertical-align:middle;width:8.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0159&#8224;</p></td></tr><tr style=""><td style="vertical-align:middle;width:12.53%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 8 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.13</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-7.83, 8.09)</p></td><td style="vertical-align:middle;width:17.88%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-10.27</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-16.80, -3.73)*</p></td><td style="vertical-align:middle;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0479&#8224;</p></td><td style="vertical-align:middle;width:14.9%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-11.05</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-22.04, -0.05)*</p></td><td style="vertical-align:middle;width:8.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.1050</p></td><td style="vertical-align:middle;width:15.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-12.25</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-20.40, -4.10)*</p></td><td style="vertical-align:middle;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0342&#8224;</p></td></tr><tr style=""><td style="vertical-align:middle;width:12.53%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 16 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:13.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-4.70</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-14.05, 4.65)</p></td><td style="vertical-align:middle;width:17.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-8.24</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-15.91, -0.57)*</p></td><td style="vertical-align:middle;width:8.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.5624</p></td><td style="vertical-align:middle;width:14.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-16.81</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-29.72, -3.89)*</p></td><td style="vertical-align:middle;width:8.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.1345</p></td><td style="vertical-align:middle;width:15.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-18.09</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-27.67, -8.52)*</p></td><td style="vertical-align:middle;width:8.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0506</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:4pt 0pt 8pt 18pt;">* Confidence interval excludes 0, suggesting a statistically meaningful difference.<br/>&#8224; p &lt; 0.05 vs. placebo. LS Mean ALT Changes from Baseline (U/L)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:4pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k006.jpg" alt="Graphic" style="display:inline-block;height:259.92pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:475.2pt;"/></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">11</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;">Notable Secondary Endpoints</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 8pt 0pt;">Proportion of Subjects with Normalized ALT &lt;30 IU/L at Week 16</p><div style="padding-left:18.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.63%;"><tr style="height:1pt;"><td style="vertical-align:top;width:21.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.41%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:21.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Number of Subjects, n</p></td><td style="vertical-align:middle;width:19.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=23)</p></td><td style="vertical-align:middle;width:19.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241) 100 mg + Sitagliptin 100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=34)</p></td><td style="vertical-align:middle;width:19.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">50 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=12)</p></td><td style="vertical-align:middle;width:19.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=22)</p></td></tr><tr style=""><td style="vertical-align:middle;width:21.96%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&lt; 30, n (%)</p></td><td style="vertical-align:middle;width:19.38%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">1 (4.3%)</p></td><td style="vertical-align:middle;width:19.61%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">3 (8.8%)</p></td><td style="vertical-align:middle;width:19.61%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">4 (33.3%)</p></td><td style="vertical-align:middle;width:19.41%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">4 (18.2%)</p></td></tr><tr style=""><td style="vertical-align:middle;width:21.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Odds Ratio </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(p value)</p></td><td style="vertical-align:middle;width:19.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2.423</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(0.4576)</p></td><td style="vertical-align:middle;width:19.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">10.500&#8224;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(0.0487)&#8224;</p></td><td style="vertical-align:middle;width:19.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">5.600</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(0.1402)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:4pt 0pt 0pt 36pt;">&#8224; p &lt; 0.05 vs. placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:8pt 0pt 8pt 0pt;">LS Mean CAP, VCTE, FAST score Changes from Baseline at Week 16</p><div style="margin-left:-13.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:105.4%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:16.52%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:13.46%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:13.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:14.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:7.93%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=23)</p></td><td style="vertical-align:middle;width:17.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241) 100 mg + Sitagliptin 100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=34)</p></td><td style="vertical-align:middle;width:8.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td><td style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">50 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=12)</p></td><td style="vertical-align:middle;width:8.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td><td style="vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=22)</p></td><td style="vertical-align:middle;width:7.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Baseline Mean (dB/m)</p></td><td style="vertical-align:middle;width:13.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">347.4</p></td><td style="vertical-align:middle;width:17.05%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">344.1</p></td><td style="vertical-align:middle;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">347.3</p></td><td style="vertical-align:middle;width:8.07%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">336.0</p></td><td style="vertical-align:middle;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 16 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">CAP Score (dB/m)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:13.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-2.32</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-16.17, 11.52)</p></td><td style="vertical-align:middle;width:17.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-20.62</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-31.99, -9.26)*</p></td><td style="vertical-align:middle;width:8.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0452&#8224;</p></td><td style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-8.94</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-28.08, 10.20)</p></td><td style="vertical-align:middle;width:8.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.5787</p></td><td style="vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-24.32</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-38.54, -10.10)*</p></td><td style="vertical-align:middle;width:7.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0308&#8224;</p></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Baseline Mean (kPa)</p></td><td style="vertical-align:middle;width:13.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">10.00</p></td><td style="vertical-align:middle;width:17.05%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">9.89</p></td><td style="vertical-align:middle;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">10.71</p></td><td style="vertical-align:middle;width:8.07%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">10.32</p></td><td style="vertical-align:middle;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 16 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">VCTE Score (kPa)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:13.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.29</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-1.31, 1.89)</p></td><td style="vertical-align:middle;width:17.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-1.45</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-2.77, -0.13)*</p></td><td style="vertical-align:middle;width:8.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0997</p></td><td style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-1.40</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-3.62, 0.83)</p></td><td style="vertical-align:middle;width:8.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.2257</p></td><td style="vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.00</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-1.64, 1.64)</p></td><td style="vertical-align:middle;width:7.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.8051</p></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Baseline Mean</p></td><td style="vertical-align:middle;width:13.46%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.555</p></td><td style="vertical-align:middle;width:17.05%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.564</p></td><td style="vertical-align:middle;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.35%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.604</p></td><td style="vertical-align:middle;width:8.07%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.538</p></td><td style="vertical-align:middle;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:16.52%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 16 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">FAST score</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:13.46%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.09</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.17, -0.01)*</p></td><td style="vertical-align:middle;width:17.05%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.26, -0.13)*</p></td><td style="vertical-align:middle;width:8.62%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0416&#8224;</p></td><td style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.17</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.28, -0.06)*</p></td><td style="vertical-align:middle;width:8.07%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.2429</p></td><td style="vertical-align:middle;width:14.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.27, -0.11)*</p></td><td style="vertical-align:middle;width:7.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0704</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:4pt 0pt 0pt 18pt;">* Confidence interval excludes 0, suggesting a statistically meaningful difference.<br/>&#8224; p &lt; 0.05 vs. placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:8pt 0pt 8pt 0pt;">LS Mean HbA1c Changes from Baseline at Week 16 (%)</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.31%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:15.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.16%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.96%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:13.11%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:10.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:14.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:8.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:15.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=23)</p></td><td style="vertical-align:middle;width:16.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241) 100 mg + Sitagliptin 100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=34)</p></td><td style="vertical-align:middle;width:8.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td><td style="vertical-align:middle;width:13.11%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">50 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=12)</p></td><td style="vertical-align:middle;width:10.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td><td style="vertical-align:middle;width:14.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=22)</p></td><td style="vertical-align:middle;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">P value vs. PBO</p></td></tr><tr style=""><td style="vertical-align:middle;width:15.61%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Baseline Mean</p></td><td style="vertical-align:middle;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">6.78</p></td><td style="vertical-align:middle;width:16.32%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">6.51</p></td><td style="vertical-align:middle;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.11%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">6.58</p></td><td style="vertical-align:middle;width:10.23%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.92%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">7.01</p></td><td style="vertical-align:middle;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:15.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Week 16 LS Mean</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(95% CI)</p></td><td style="vertical-align:middle;width:12.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.10</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.23, 0.44)</p></td><td style="vertical-align:middle;width:16.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.52</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.80, -0.25)*</p></td><td style="vertical-align:middle;width:8.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0050&#8224;</p></td><td style="vertical-align:middle;width:13.11%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.24</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.70, 0.22)</p></td><td style="vertical-align:middle;width:10.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.2357</p></td><td style="vertical-align:middle;width:14.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">-0.48</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(-0.82, -0.13) *</p></td><td style="vertical-align:middle;width:8.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">0.0179&#8224;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:4pt 0pt 0pt 18pt;">* Confidence interval excludes 0, suggesting a statistically meaningful difference.<br/>&#8224; p &lt; 0.05 vs. placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">12</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:169.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0pt 72pt;"><img src="mtva-20251231x10k007.jpg" alt="Graphic" style="display:inline-block;height:169.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:303.84pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12.45pt;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">In subjects with 40 &#8804; ALT &lt; 200 U/L at baseline: Placebo (n=21); </span><span style="color:#010302;">van</span>oglipel<span style="color:#010302;"> (DA-1241)</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;"> 50 mg (n=9); </span><span style="color:#010302;">van</span>oglipel<span style="color:#010302;"> (DA-1241)</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">100 mg (n=17) &#8224;95% CI not crossing 0</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 72pt;"><img src="mtva-20251231x10k008.jpg" alt="Graphic" style="display:inline-block;height:169.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:304.56pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12.45pt;text-align:justify;margin:0pt;"><span style="color:#010302;">In subjects with 40 &#8804; ALT &lt; 200 U/L at baseline: Placebo (n=21); van</span>oglipel<span style="color:#010302;"> (DA-1241) 50 mg (n=9); van</span>oglipel<span style="color:#010302;"> (DA-1241) 100 mg (n=17) &#8224;95% CI not crossing 0.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:12.45pt;text-align:justify;margin:0pt 144pt 0pt 72pt;"><span style="color:#010302;font-size:12.45pt;line-height:1.19;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 72pt;"><img src="mtva-20251231x10k009.jpg" alt="Graphic" style="display:inline-block;height:167.04pt;width:259.92pt;"/></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">13</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:205.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;">LS Mean CAP, FAST, NIS-4 score Changes from Baseline at Week 16</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k010.jpg" alt="Graphic" style="display:inline-block;height:168.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:410.4pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">In subjects with 40 &#8804; ALT &lt; 200 U/L at baseline: Placebo (n=21); </span><span style="color:#010302;">van</span>oglipel<span style="color:#010302;"> (DA-1241)</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;"> 50 mg (n=9); </span><span style="color:#010302;">van</span>oglipel<span style="color:#010302;"> (DA-1241)</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">100 mg (n=17) &#8224;95% CI not crossing 0.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k011.jpg" alt="Graphic" style="display:inline-block;height:205.21pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:416.04pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">Reduced circulating biomarkers of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">cell death (CK18F/M30), in</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.05pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">lammation (hs-CRP, CCL2), and</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">ibrosis (TIMP1).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k012.jpg" alt="Graphic" style="display:inline-block;height:155.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:429.84pt;"/></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">14</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:202.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Overall TEAE Summary</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:89.15%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:26.52%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:middle;width:11.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:middle;width:13.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:middle;width:11.52%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:middle;width:12.6%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td colspan="1" style="margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:bottom;width:35.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">N (%)</p></td><td colspan="2" style="vertical-align:middle;width:13.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placebo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=32)</p></td><td colspan="2" style="vertical-align:middle;width:13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241) 100 mg + Sitagliptin 100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=36)</p></td><td colspan="2" style="vertical-align:middle;width:12.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">50 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=14)</p></td><td style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vanoglipel (DA-1241)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">100 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(N=26)</p></td></tr><tr style=""><td colspan="1" style="margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:top;width:35.16%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subjects with any Treatment Related AE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Mild</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Moderate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Severe</span></p></td><td colspan="2" style="vertical-align:middle;width:13.31%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">9 ( 28.1%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">8 ( 25.0%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1 ( 3.1%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td colspan="2" style="vertical-align:middle;width:13%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">10 ( 27.8%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">9 ( 25.0%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1 ( 2.8%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td colspan="2" style="vertical-align:middle;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4 ( 28.6%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4 ( 28.6%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td style="vertical-align:middle;width:12.29%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">9 ( 34.6%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">8 ( 30.8%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1 ( 3.8%)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td></tr><tr style="height:13.9pt;"><td colspan="1" style="margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:middle;width:35.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subjects with any Treatment related SAE</p></td><td colspan="2" style="vertical-align:middle;width:13.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td colspan="2" style="vertical-align:middle;width:13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td colspan="2" style="vertical-align:middle;width:12.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td></tr><tr style=""><td colspan="1" style="margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:middle;width:35.16%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subjects with any TEAE leading to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">study discontinuation</p></td><td colspan="2" style="vertical-align:middle;width:13.31%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td colspan="2" style="vertical-align:middle;width:13%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1 ( 3.1%)</p></td><td colspan="2" style="vertical-align:middle;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td style="vertical-align:middle;width:12.29%;background:#cceeff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td></tr><tr style=""><td colspan="1" style="margin:0pt;padding:0pt;"/><td colspan="3" style="vertical-align:middle;width:35.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Subjects with any TEAE leading to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">study drug discontinuation</p></td><td colspan="2" style="vertical-align:middle;width:13.31%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1 ( 3.1%)</p></td><td colspan="2" style="vertical-align:middle;width:13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td colspan="2" style="vertical-align:middle;width:12.3%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td><td style="vertical-align:middle;width:12.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">0</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">DA-1726 Treatment of Obesity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">DA-1726 is a novel OXM analog functioning as a GLP1R and GCGR dual agonist. It is a long-acting, novel peptide drug candidate, with a Phase 1 investigational new drug (&#8220;IND&#8221;) approved by the FDA with therapeutic potential for obesity. Activation of GLP1R contributes to central anorexic effect (appetite suppression) and activation of GCGR peripherally enhances basal metabolic rate. Accordingly, non-clinical studies have shown that DA-1726 not only reduces food intake but also increases energy expenditure even at the basal resting state, leading to persistent weight loss in DIO mice and rats. DA-1726 directly lowers blood glucose and lipid levels in addition to the accompanying metabolic improvement by weight loss. Weight reduction is closely related to the alleviation of fatty liver. Having stabilized the fragile peptide through several unique modifications, DA-1726 is predicted to be available as a once-weekly regimen to humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 54pt;"><img src="mtva-20251231x10k013.jpg" alt="Graphic" style="display:inline-block;height:202.32pt;left:0%;padding-bottom:0.2pt;position:relative;top:0pt;width:391.68pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 162pt;"><span style="font-style:italic;font-weight:bold;">Physiological effects of oxyntomodulin</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Background</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Obesity is a disease caused by abnormal or excessive fat accumulation due to an imbalance in energy intake and consumption over a long period of time. According to the World Health Organization (&#8220;WHO&#8221;), in 2022, there were 2.5 billion adults (18 years and older), and approximately 43% of all adults were overweight and 890 million, or approximately 16%, were obese. In 2024, the NCD Risk Factor Collaboration published findings that estimate that more than one billion people in the world are now obese and nearly three billion people are either overweight or obese. The comorbidities of obesity include T2DM, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">15</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:146.16pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">cardiovascular disease, hypertension and MASH, and the risk of these diseases is higher in obese people than in non-obese people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The treatment of obesity can be divided into three mechanisms: (i)&#160;appetite control, (ii)&#160;absorption inhibition, and (iii)&#160;increase of energy expenditure. Currently, there are a total of eight approved anti-obesity medications on the market, of which the most notable are Novo Nordisk semaglutide (WEGOVY<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) and Eli Lilly tirzepatide (Zepbound<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>). However, there is still an unmet need in the market as there are no agents with a mechanism to reduce body weight by increasing energy expenditure in peripheral tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Oxyntomodulin is a gut hormone released from intestinal L-cells after meal ingestion and represents dual agonism of the GLP-1 receptor and glucagon receptor. It increases energy expenditure through glucagon receptors and increases appetite suppression and insulin secretion through GLP-1 receptor activation, ultimately inducing weight loss and glycemic control. The furthest stage of development of any oxyntomodulin analog are survudutide and mazdutide in Phase 3 clinical trials in the U.S., mazdutide which is approved in China, and in Phase 2 clinical trial in the U.S. for the treatment of obesity and MASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:20pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">DA-1726 Preclinical Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Animal toxicity studies of DA-1726 for the Phase&#160;1 clinical trial have been completed. The toxicity studies included safety pharmacology studies and general toxicity studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The mode of action and pharmacological effects of DA-1726 were evaluated in various disease models. In high-fat diet-induced obese (&#8220;HF-DIO&#8221;) mice, DA-1726 showed more body weight loss and increasing energy expenditure than a pair-fed group. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k014.jpg" alt="Graphic" style="display:inline-block;height:146.16pt;width:478.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:11.5pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 216pt;">Mean energy expenditure:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 0pt 324pt;">DA-1726*<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">#</sup> 16.6 kcal/kg/hr</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:11.5pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 0pt 324pt;">Pair-Fed 12.4 kcal/kg/hr</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 8pt 324pt;">HF Control 12.6 kcal/kg/hr</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mechanism of Action</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In comparison with GLP-1 analog, DA-1726 represented superior body weight loss compared to semaglutide in HF-DIO mice. At the end of the study, DA-1726 significantly increased the expression of thermogenic genes (<i style="font-style:italic;">Ucp-1</i>&#160;and&#160;<i style="font-style:italic;">Ppargc1a</i>) in epididymal fat and increased white adipose tissue browning was histologically confirmed. In addition, DA-1726 inhibited adipocyte differentiation&#160;<i style="font-style:italic;">in vitro</i>. Taken together, it suggests the GCGR action of DA-1726 contributes to reduced adiposity by enhancing fat burning and inhibiting adipogenesis. DA-1726 effectively reduced postprandial glucose excursion in acute oral glucose tolerance test in normal mice. Notably, DA-1726 showed similar glycemic control and excellent weight loss to semaglutide in obese mice with hyperglycemia. Simultaneously, DA-1726 enhanced insulin sensitivity by significantly reducing fasting plasma insulin and glucose levels. Meanwhile, DA-1726 showed no hypoglycemia risk in overnight fasted normal mice, unlike semaglutide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In comparison with GLP-1 receptor and GIP dual agonist tirzepatide in HF-DIO MASH mice, DA-1726 showed similar body weight while consuming significantly more food. In addition, DA-1726 reduced plasma clinical chemistry parameters (ALT, AST, ALP, T-BIL, glucose, and cholesterol) and hepatic fat accumulation. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">16</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:163.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><img src="mtva-20251231x10k015.jpg" alt="Graphic" style="display:inline-block;height:162.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:504pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 144pt;">Notes: HF-DIO; BWL (Body Weight Loss)</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:180pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Dong-A ST Study Report 105497. All treatments given as twice weekly injections.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:180pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">Jung I-H et al. 83rd Meeting of the American Diabetes Association. 2023; Abstract 1668-P.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;text-indent:20.15pt;margin:8pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Weight Loss and Plasma Biochemistry Analysis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:20pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">DA-1726 Phase&#160;1 Clinical Trial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are currently conducting a Phase 1 clinical trial in the U.S.</span><b style="font-weight:bold;"> </b>The Phase&#160;1 clinical trial, a first-in-human clinical trial, is a randomized, placebo-controlled, double-blind, two-part study to investigate the safety, tolerability, PK, and PD of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. The primary endpoint for SAD Part 1 and MAD Part 2 of our Phase 1 clinical trial is to assess the safety and tolerability of DA-1726 by monitoring AEs, SAEs, TEAEs and AEs leading to treatment discontinuation. Secondary endpoints include the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726. Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index, among others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In September 2024, we announced positive topline data from the single ascending dose Part 1 of our Phase 1 clinical trial. Overall safety and tolerability in Part 1 of our Phase 1 clinical trial was clean and allowed us to initiate MAD Part 2 of Phase 1 clinical trial. In April 2025, we announced positive topline data from the MAD Part 2 study of our Phase 1 clinical trial up to a 32 mg dose. For this study of up to 32 mg dose level, gastrointestinal AEs were mild with no treatment-related discontinuations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In June 2025, we began enrollment for a higher-dose MAD cohort to assess the maximum tolerated dose and fully realize DA-1726&#8217;s potential, as higher doses may also show a similar profile, while potentially demonstrating increased weight reduction. We dosed the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial in July 2025, and we extended the clinical trial for this 48 mg, MAD cohort to eight weeks from four weeks to further explore the non-titrated maximum tolerated dose, explore safety and other primary, secondary and exploratory endpoints over a longer treatment duration, and evaluate longer-term early efficacy. Also, in August 2025, we administered the fifth dose for the first patient in the 48 mg, MAD cohort of our Phase 1 clinical trial. On January 5, 2026, we announced positive topline data of non-titrated 48 mg, MAD cohort of our Phase 1 clinical trial, and the results show robust early weight loss, statistically significant reductions in waist circumference, strong improvements in glucose control, and meaningful reductions in liver stiffness, alongside a favorable safety and tolerability profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In November 2025, we presented new Phase 1 and pre-clinical data on DA-1726 in two poster presentations at ObesityWeek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> 2025. The Phase 1 data demonstrated favorable safety and tolerability, a newly characterized 32 mg PK profile supporting once-weekly dosing, and meaningful reductions in body weight and waist circumference following four weeks of treatment. Additionally, in a DIO mouse model, DA-1726 achieved comparable weight loss to pemvidutide with superior lipid-lowering efficacy.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are planning to start Part 3a and Part 3b of Phase 1 clinical trial in April 2026. Part 3a of Phase 1 will be a one-step titration with 16 mg for four weeks and 48 mg for 12 weeks. Part 3b of Phase 1 will be two-step titration with 16 mg for four weeks, 32 mg for four weeks and 64 mg for eight weeks. These titration studies are to remove any moderate adverse effects from the 48 mg dose level and to push DA-1726 to its maximum potential with 64 mg. We expect dose-dependent exploratory weight loss and other early signals with potential for best- in-class safety and tolerability. The data readout for both Part 3a and Part 3b is planned for the fourth quarter of 2026. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">17</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Topline results from the Phase 1 MAD Part 1 Study.</span><span style="display:inline-block;width:0.42pt;"></span>We have reported positive topline up to eight week results from the MAD Part 2 of our Phase 1 clinical trial in obese, otherwise healthy patients on January 5, 2026. An overview of the topline results from Phase 1 MAD Part 2 clinical trial is included below: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;">Overview of the Topline Results</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:8pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Primary safety and tolerability. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 showed no treatment-related discontinuation up to a non-titrated 48 mg dose level with mild to moderate gastrointestinal AEs. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:8pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Exploratory weight change. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 showed dose-dependent weight loss from 8 mg up to 48 mg, with 48 mg showing statistically significant reduction of 6.1% (14.6 lbs.) mean weight loss at Day 26 compared to placebo (p = 0.003). Cohort 5 48 mg showed 9.1% (21.2 lbs.) weight reduction by Day 56. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:8pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Exploratory waist circumferences change. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 48 mg showed statistically significant waist circumference reduction of 5.8 cm (2.3 inches) on Day 26 compared to placebo (p = 0.006) and statistically significant reduction of 9.8 cm (3.8 inch) on Day 56 compared to placebo (p = 0.022). </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:8pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Exploratory glucose control in eight weeks. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 48 mg showed fasted glucose control with 12.3 mg/dL reduction from a baseline of 105.3 mg/dL in eight weeks, with one prediabetic subject with baseline HbA1c of 6.0%, normalized to 5.5% in eight weeks. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:2.25pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Exploratory VCTE in eight weeks.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> DA-1726 48 mg showed a significant reduction in liver stiffness with 23.7% reduction in eight weeks, from a baseline of 5.9 kPa reduced to 4.5 kPa.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;">Subject Disposition and Baseline Characteristics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k016.jpg" alt="Graphic" style="display:inline-block;height:178.5pt;width:498.24pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k017.jpg" alt="Graphic" style="display:inline-block;height:192pt;width:500.15pt;"/></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">18</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:264pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;">Primary safety and tolerability of Phase 1 MAD Part 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt -22.5pt;"><img src="mtva-20251231x10k018.jpg" alt="Graphic" style="display:inline-block;height:264pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:543.95pt;"/></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">19</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:249pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">Exploratory weight change in Phase&#160;1 MAD Part&#160;2 Day 26</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k019.jpg" alt="Graphic" style="display:inline-block;height:248.6pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:419.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">Exploratory weight change in Phase&#160;1 MAD Part&#160;2 Cohort 5 48 mg up to Day 54</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k020.jpg" alt="Graphic" style="display:inline-block;height:152.39pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:412.5pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">Exploratory waist circumference changes in Phase&#160;1 MAD Part&#160;2 Cohort 5 48 mg</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k021.jpg" alt="Graphic" style="display:inline-block;height:165.1pt;width:411.25pt;"/></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">20</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:228pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;">Exploratory fasted glucose and HbA1c change in Phase 1 MAD Part 2 Cohort 5 48 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k022.jpg" alt="Graphic" style="display:inline-block;height:47pt;width:467.08pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Potentially best-in-class glucose control with mean HbA1c change by&#160;-0.22%&#160;point in non-diabetic subjects after eight weeks of 48 mg. Pre-diabetic subjects with mean HbA1c of 6% at baseline was reduced to 5.5% by Day 54.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.2pt;">Exploratory VCTE change in Phase&#160;1 MAD Part&#160;2 Cohort 5 48 mg</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="mtva-20251231x10k023.jpg" alt="Graphic" style="display:inline-block;height:49.5pt;width:283.77pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10.55pt 0pt;">PK in Phase 1 MAD Part 2 up to 32 mg</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10.55pt 0pt;"><img src="mtva-20251231x10k024.jpg" alt="Graphic" style="display:inline-block;height:227.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:432.15pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10.55pt 0pt;"><b style="font-weight:bold;">Other Product Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We are focusing our financial resources and management&#8217;s attention on the development of vanoglipel (DA-1241) for MASH and DA-1726 for obesity. We also have four legacy therapeutic programs, ANA001, NB-01, NB-02 and Gemcabene, that we are not planning to advance development on. We have or continue to consider out-licensing and divestiture opportunities with respect to the following legacy programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;"><b style="font-weight:bold;">ANA001 Treatment of COVID-19 Symptoms</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="background:#ffffff;">ANA001 is a proprietary oral niclosamide formulation that was developed as a treatment for patients with moderate COVID-19&#160;</span>(patients not requiring ventilators)<span style="background:#ffffff;">. Niclosamide is a potential oral antiviral and anti-inflammatory agent </span>with<span style="background:#ffffff;"> a long history of use and documented safety in humans. </span>Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. In preclinical research by <span style="background:#ffffff;">an independent academic group published in&#160;</span><i style="font-style:italic;background:#ffffff;">Antimicrobial Agents and Chemotherapy</i><span style="background:#ffffff;">, niclosamide inhibited viral replication&#160;in vitro&#160;and was more potent than remdesivir and chloroquine in the same assay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 36pt;">We believe ANA001 has the potential to reduce the viral load and inflammation associated with cytokine dysregulation, acute respiratory distress syndrome, and coagulation abnormalities and thus improve time to clinical improvement as defined as hospital discharge recorded using the WHO Ordinal Scale for Clinical Improvement.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">21</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;"><b style="font-weight:bold;">NB-01</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;">NB-01 addresses a range of mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. These include a decrease in key inflammatory markers, restoration of nerve growth factor (&#8220;NGF&#8221;) to normal levels, and reduction of advanced glycation end products (&#8220;AGEs&#8221;). Inflammation is a central factor in pain generation and other peripheral neurodegenerative diseases. NB-01 reduces levels of TNF-<span style="font-family:'Symbol';background:#ffffff;">a</span><span style="background:#ffffff;">&#160;</span>and IL-6, both of which are markers of inflammation. NB-01 also reduces AGEs, which are implicated in diabetes-related complications. AGE inhibitors have been clinically tested as potential treatments for these complications. NB-01 also restores the neurotrophin NGF, which is involved in nerve growth, maintenance and repair. NB-01 has been shown in animal models to alleviate symptoms of PDN. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;"><span style="background:#ffffff;">In July 2024, we entered into an exclusive out-license agreement with MThera to provide MThera with the rights to NB-01 for the treatment of painful diabetic neuropathy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;"><b style="font-weight:bold;">NB-02</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;">NB-02 was being developed for the symptomatic and disease modifying treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease and tauopathies. In preclinical studies, we have observed the mechanisms of action of NB-02 to include inhibition of tau phosphorylation, acetylcholinesterase (&#8220;AChE&#8221;) inhibition, inhibition of Ab toxicity and amyloid plaque formation, and anti-inflammatory effects. Specifically, in both in-vitro and in-vivo models, NB-02 has demonstrated inhibition of AChE, as is the case with three of the current products on the market to treat the symptoms of Alzheimer&#8217;s disease. It has also demonstrated inhibition of tau phosphorylation and of amyloid plaque formation, both mechanisms believed to contribute to the progression of neurodegenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;"><b style="font-weight:bold;">Gemcabene</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 36pt;">Gemcabene is a novel, once-daily, oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C, hsCRP and triglycerides. Gemcabene shares many of the attributes of statin therapy, including broad therapeutic applications, convenient route of administration and cost-effective manufacturing process, but does not appear to increase the reporting of myalgia when added to statin therapy. Gemcabene has also shown additive LDL-C lowering in combination with stable low, moderate or high-intensity statin therapy. As described below, we licensed global rights to Gemcabene from Pfizer in April 2011. Under the terms of the amended and restated license agreement with Pfizer, Pfizer may currently terminate the license at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">License Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">License Agreement with Dong-A ST for Vanoglipel (DA-1241) and DA-1726</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In September 2022, we entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) and a Securities Purchase Agreement with Dong-A ST (the &#8220;Securities Purchase Agreement&#8221;). Pursuant to the 2022 License Agreement and subject to the conditions set forth therein, we received an exclusive global license (excluding the Republic of Korea) to two proprietary compounds. The 2022 License Agreement covers the rights to a compound referred to as vanoglipel (DA-1241) and a compound referred to as DA-1726. The 2022 License Agreement became effective in November 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">Under the terms of the 2022 License Agreement, Dong-A ST (i) received an upfront payment which was settled in 2,200 shares of preferred stock of MetaVia designated as &#8220;Series A Convertible Preferred Stock,&#8221; par value $0.001 per share (which was subsequently converted into shares of our common stock), under the terms of the Securities Purchase Agreement; (ii) is eligible to receive single digit royalties on net sales received by us from the commercial sale of products covering vanoglipel (DA-1241) or DA-1726; (iii) is eligible to receive commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iv) is eligible to receive regulatory milestone payments of up to $178.0 million for DA-1726 and $138.0 million for vanoglipel (DA-1241), dependent upon the achievement of specific regulatory developments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our obligation to pay royalties to Dong-A ST under the 2022 License Agreement continues on a product-by-product and country-by-country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Either we or Dong-A ST may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60&#160;days of notice of such breach; provided that if the breach cannot be cured within the 60-day period and the breaching party started to remedy the breach, if such breach is not cured within 90&#160;days of receipt of written notice or (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a 30-day cure period in the case of a petition for bankruptcy).</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">22</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">License Agreement with Dong-A ST for NB-01</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In January 2018, we entered into an exclusive license agreement with Dong-A ST (the &#8220;2018 License Agreement&#8221;), which was amended in April 2018 and July 2019. Under the terms of the 2018 License Agreement, we obtained an exclusive, royalty-bearing, worldwide (except for the Republic of Korea) license to make, use, offer to sell, sell and import products covered by certain Dong-A ST intellectual property rights in its proprietary compound designated as DA-9801 (NB-01). Our license rights cover any and all applications and markets for the therapeutic, health, nutrition or well-being of humans. We may grant sublicenses to any affiliate or third party. We are responsible for all future patent prosecution costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are obligated to use commercially reasonable efforts to develop products for use in each of the U.S., the European Union, Japan and the People&#8217;s Republic of China. If we terminate, discontinue or suspend, for longer than 12 months, the development of any product listed as a product under development in any development plan provided to Dong-A ST (other than for reasons of force majeure or requirements of applicable law), then we are deemed in breach of this development obligation, and Dong-A ST may terminate the 2018 License Agreement for cause after a 60-day cure period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The term of the 2018 License Agreement continues on a country-by country and product-by-product basis until the later of the 12th anniversary of the first commercial sale of such product in such country or expiration or termination of the last valid claim within the patent rights covering the product. Either Dong-A ST or we may terminate the 2018 License Agreement if the other party is in material breach of the 2018 License Agreement and has not cured or started to cure the breach within 60 days of notice of such breach, or is subject to a bankruptcy or insolvency event. We may terminate the 2018 License Agreement at any time upon 90 days&#8217; written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Pfizer License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In August 2018, an Amended and Restated License Agreement with Pfizer (the &#8220;Pfizer Agreement&#8221;) for the research, development, manufacture and commercialization of Gemcabene went into effect. The Pfizer Agreement amended and restated the prior license agreement with Pfizer dated April 16, 2011. The Pfizer Agreement includes milestone payments to Pfizer and tiered royalties on a country-by-country basis based upon the annual amount of net sales as specified in the Pfizer Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party&#8217;s material breach following a cure period or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate the Pfizer Agreement in the event that (i) we or any of our affiliates or sublicenses contests or challenges, or supports or assists any third party to contest or challenge, Pfizer&#8217;s ownership of or rights in, or the validity, enforceability or scope of any of the patents licensed under the Pfizer Agreement or (ii) we or any of our affiliates or sublicensees fails to achieve the first commercial sale in at least one country by April 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">License Agreement with Beijing SL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms and conditions of a License and Collaboration Agreement dated July 23, 2019 (the &#8220;Beijing SL License Agreement&#8221;), Beijing SL has an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, Gemcabene in the territory comprised of mainland China, Hong Kong, Macau and Taiwan. We retain all rights to Gemcabene outside of the territory. The parties have agreed to collaborate with respect to development and commercialization activities under the Beijing SL License Agreement through a joint steering committee composed of an equal number of representatives of Beijing SL and us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Pursuant to the Beijing SL License Agreement, Beijing SL made an upfront gross payment of $2.5 million. Additionally, with respect to each licensed product, Beijing SL will make payments for specified developmental and regulatory milestones and payments for specified global net sales milestones. Beijing SL will also be obligated to pay tiered royalties ranging from the mid-teens to twenty percent on the net sales of all licensed products in the territory until the latest of (a) the date on which any applicable regulatory exclusivity with respect to such Licensed Product expires in such region, (b) the expiration or abandonment of the last valid patent claim or joint patent claim covering such Licensed Product in each region and (c) the fifth anniversary of the first commercial sale of such Licensed Product in such region. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Either party may terminate the Beijing SL License Agreement (x) with written notice for the other party&#8217;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In addition, we may terminate the Beijing SL License Agreement in its entirety if Beijing SL or its affiliates or sublicensees commence a proceeding challenging the validity, enforceability or scope of any of our patents. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">23</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Dong-A ST manufactures clinical quantities of vanoglipel (DA-1241) and DA-1726 in accordance with the 2022 License Agreement and the Shared Services Agreement. As MetaVia advances the product candidates through clinical development, our current plans are to continue to use third parties including Dong-A ST to manufacture drug products for our clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Among the conditions for FDA approval of a pharmaceutical product is the requirement that the manufacturer&#8217;s quality control and manufacturing procedures conform to current good manufacturing practices (&#8220;cGMP&#8221;). The FDA typically inspects manufacturing facilities every two&#160;years. In complying with cGMP regulations, pharmaceutical manufacturers must expend resources and time to ensure compliance with product specifications as well as production, record keeping, quality control, reporting and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Some of our competitors may have significantly greater financial resources and expertise in R&amp;D, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Other firms may also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for our programs. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors with us, particularly through collaborative arrangements with large established companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize therapeutics that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain marketing approvals for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected because in some cases insurers or other third-party payors, including government programs, seek to encourage the use of generic products. This may have the effect of making branded products less attractive from a cost perspective to buyers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Vanoglipel (DA-1241) and DA-1726 - MASH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">There is only one approved treatment of MASH, Madrigal Pharmaceuticals&#8217; thyroid hormone receptor beta agonist. However, various therapeutics are used off-label for the treatment of MASH, including vitamin E (an antioxidant), insulin sensitizers (e.g.,&#160;metformin, pioglitazone), antihyperlipidemic agents (e.g., gemfibrozil), pentoxifylline and ursodeoxycholic acid. There are several product candidates in Phase&#160;3 or earlier clinical or preclinical development for the treatment of MASH, including Novo Nordisk&#8217;s GLP1R agonist semaglutide, Eli Lilly&#8217;s GLP1R and GIP dual agonist tirzepatide, Akero Therapeutics&#8217; FGF21 analog efruxifermin, 89 Bio&#8217;s FGF21 analog pegaozafermin, Inventiva&#8217;s pan-peroxisome proliferator-activated receptor agonist, Boston Pharmaceuticals and Roche&#8217;s fibroblast growth factor 21 analogs, and farnesoid X receptor agonists from Intercept Pharmaceuticals Inc., among others. Additional pharmaceutical and biotechnology companies with product candidates in development for the treatment of MASH include AstraZeneca plc, Altimmune Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Durect Corporation, Galectin Therapeutics Inc., Galmed Pharmaceuticals Ltd., Immuron Ltd., Ionis Pharmaceuticals, Inc., Islet Sciences, Inc., MediciNova, Inc., NGM Biopharmaceuticals, Inc., NuSirt Sciences Inc., Pfizer Inc., Viking Therapeutics, Inc. and Zydus Pharmaceuticals (USA) Inc. MASH is a complex disease and we believe that it is unlikely that any one therapeutic option will be optimal for every MASH patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">DA-1726-Obesity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Due to the growing overweight and obesity epidemic and consumer demand, there are many competitors in the field of obesity treatment. Obesity treatments range from behavioral modification to drugs, medical devices and surgery, generally as a last resort. If DA-1726 were approved for obesity, our primary competition in the obesity treatment market would currently be from approved and marketed products, including semaglutide (WEGOVY<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) and tirzepatide (Zepbound<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>). Further competition could arise from products currently in development, including among others, with GLP1R/GCGR dual agonists, Boehringer Ingelheim, Merck/Hanmi Pharmaceutical, AstraZeneca, Altimmune, Innovent Biologics/Eli Lilly, Carmot and D&amp;D Pharma; with GLP1R/GCGR/GIP triple agonists, Hanmi Pharmaceutical and Eli Lilly; Amgen with its GLP-1R agonist/GIP antagonist </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">24</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">antibody; and Novo Nordisk with Amylin and Amylin-GLP-1 combination. To the extent our product candidate is approved for obesity, the commercial success of our product will also depend on our ability to demonstrate benefits over the then-prevailing standard of care. Finally, morbidly obese patients sometimes undergo a gastric bypass procedure, with salutary effects on the many co-morbid conditions of obesity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Vanoglipel (DA-1241) and DA-1726 - </b><b style="font-weight:bold;">T2DM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for T2DM. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Intellectual </b><b style="font-weight:bold;">Property</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries, including the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application or a Patent Cooperation Treaty application to which a U.S. application claims priority. In the U.S., a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a U.S. patent that covers a drug or biological product may also be eligible for patent term extension when approval from the FDA is granted, provided statutory and regulatory requirements are met. In the future, if our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and/or other factors. There can be no assurance that any of our pending patent applications will be issued or that we will benefit from any patent term extension or other favorable adjustment to the term of any patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates, preclinical compounds, and core technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, patent applications that we may file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, prior to March 16, 2013, in the U.S., patent applications were subject to a &#8220;first to invent&#8221; rule of law. Applications effectively filed on or after March 16, 2013, are subject to a &#8220;first to file&#8221; rule of law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Discoveries reported in the scientific literature often lag the actual discoveries, and patent applications in the U.S. and other jurisdictions and are typically not published until 18 months after filing, or in some cases not at all. We cannot be certain that any existing application will be subject to the &#8220;first to file&#8221; or &#8220;first to invent&#8221; rule of law, that we or our licensor were the first to make the inventions claimed in our existing patent portfolio subject to the prior laws, or that we or our licensor were the first to file for patent protection of such inventions subject to the new laws. If third parties prepare and file patent applications in the U.S. that also claim technology we have claimed in our patents or patent applications, we may have to participate in interference or derivation proceedings and/or invalidation proceedings in the USPTO, which could result in substantial costs to us, even if the eventual outcome is favorable. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition to patents, we rely upon unpatented trade secrets, know-how, and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. Confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed under those agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our ability to commercialize product candidates depends in large part on our ability to obtain and maintain intellectual property protection for our product candidates. Our policy is to seek to protect our intellectual property position by, among other methods, filing U.S. and foreign patent applications related to the technology, inventions and improvements that are important to the development and implementation of our business strategy. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">25</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Vanoglipel (DA-1241)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, our exclusively licensed intellectual property portfolio for vanoglipel (DA-1241) consists of multiple patent families covering composition of matter, pharmaceutical compositions, and methods of use, including the treatment of NAFLD, nonalcoholic steatohepatitis, diabetes, and related metabolic disorders. Our intellectual property estate comprised of 69 granted and pending patents in the U.S. and internationally, providing protection through 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the U.S., the DA-1241 portfolio includes issued patents and pending non-provisional patent applications directed to composition of matter and/or methods of use. Based on the earliest priority dates reflected in the licensed patent families, the issued U.S. patents are expected to expire in or around 2035, excluding any patent term adjustments or patent term extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Outside the U.S., the DA-1241 portfolio includes numerous issued patents and pending patent applications across multiple jurisdictions. The issued non-U.S. patents are expected to expire between approximately 2035 and 2041, excluding any patent term adjustments or patent term extensions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The non-U.S. jurisdictions covered by the DA-1241 portfolio include Australia, Brazil, Canada, China, the European Patent Convention, Hong Kong, India, Israel, Japan, Mexico, New Zealand, the Philippines, the Republic of Korea, Russia, Saudi Arabia, and Singapore.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">DA-1726</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, our exclusively licensed intellectual property portfolio for DA-1726 consists of multiple patent families covering composition of matter and methods of use, including acylated oxyntomodulin peptide analogs and GLP-1/glucagon dual agonists. Our intellectual property estate comprised of 39 granted and pending patents in the U.S. and internationally, providing protection through 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the U.S., the DA-1726 portfolio includes issued patents and pending non-provisional patent applications directed to composition of matter and/or methods of use. Based on the earliest priority dates reflected in the licensed patent families, the issued U.S. patents are expected to expire between approximately 2038 and 2041, excluding any patent term adjustments or patent term extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Outside the U.S., the DA-1726 portfolio includes numerous issued patents and pending patent applications. The issued non-U.S. patents are expected to expire between approximately 2038 and 2041, excluding any patent term adjustments or patent term extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The non-U.S. jurisdictions covered by the DA-1726 portfolio include Australia, Brazil, Canada, China, the European Patent Convention, Hong Kong, India, Israel, Japan, Mexico, New Zealand, the Philippines, the Republic of Korea, Russia, Saudi Arabia, and Singapore.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">NB-01 and NB-02</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, our intellectual property portfolio for NB-01 included four issued U.S. patents, comprised of one patent directed to composition of matter and three patents directed to use, and 65 granted foreign patents, all related to our NB-01 programs in peripheral neuropathy and neurological conditions. The issued patents have expiration dates ranging between October 2026 and July 2038. The jurisdictions for the foreign patents and application include: Brazil, China, the European Patent Convention (including Austria, Belgium, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Switzerland, Turkey, and the United Kingdom), India, Japan, the Republic of Korea, and Russia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, our intellectual property portfolio for NB-02 included three issued U.S. patents, 80 foreign granted patents, and one foreign patent application. The issued patents have an expiration date between December 2034 and March 2040. The jurisdictions for the foreign patents and applications include: Brazil, Canada, China, the European Patent Convention (including Austria, Belgium, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Switzerland, Turkey, and the United Kingdom), India, Japan, Mexico, the Republic of Korea, and Russia. All of the above patents and patent applications for NB-02 were assigned to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Gemcabene</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, our intellectual property portfolio relating to Gemcabene included seven issued U.S. patents, one pending U.S. patent application, and two foreign-granted patents directed to formulations, compositions, methods of use and methods of manufacturing. The Gemcabene intellectual property are Company owned for the issued and pending patents in the U.S. and foreign jurisdictions. The issued patents in the U.S. and foreign countries have expiration dates between December 2031 and October 2040. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">26</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Government Regulation</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Government authorities at the federal, state and local level in the U.S. and in other countries extensively regulate, among other things, the research, development, testing, manufacture (including any manufacturing changes), packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of pharmaceutical products, such as those we are developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">U.S. FDA Regulation</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the U.S., pharmaceutical products are subject to regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as imposition of clinical holds, refusal by the FDA to approve pending new drug applications (&#8220;NDAs&#8221;), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, civil penalties and criminal prosecution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Pharmaceutical product development in the U.S. typically involves preclinical or other nonclinical laboratory and animal tests and the submission to the FDA of an IND application, which must become effective before clinical testing may commence. For commercial approval, the sponsor must submit adequate tests by all methods reasonably applicable to show that the drug is safe for use under the conditions prescribed, recommended or suggested in the proposed labeling. The sponsor must also submit substantial evidence, generally consisting of adequate, well-controlled clinical trials to establish that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended or suggested in the proposed labeling. Satisfaction of the FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Nonclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal requirements, including the FDA&#8217;s good laboratory practice regulations and the regulations of the U.S. Department of Agriculture implementing the Animal Welfare Act. The results of nonclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term nonclinical tests, such as animal studies of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Clinical trials involve the administration of the IND to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with good clinical practice (&#8220;GCP&#8221;), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors (some of which have been codified into U.S. federal regulations), and (iii) under protocols detailing the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with the FDA requirements or presents an unacceptable risk to the clinical trial patients. The clinical trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (&#8220;IRB&#8221;) at each site where a clinical trial will be conducted for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or may impose other conditions. Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general, in Phase 1, the initial introduction of the drug into healthy human volunteers or, in some cases, patients, the drug is tested to assess metabolism, PK, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence of effectiveness. Phase 2 usually involves clinical trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">27</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. The FDA may, however, determine that a drug is effective based on one clinical trial plus confirmatory evidence. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval to gather additional information on the drug&#8217;s effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">After completion of the required clinical testing, a NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting a NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The FDA has 60 days from its receipt of a NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the date of filing to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement between the FDA and the applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established pursuant to the Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA&#8217;s current performance goals call for the FDA to complete review of 90% of standard (non-priority) NDAs within 10 months of receipt and within six months for priority NDAs, but two additional months are added to standard and priority NDAs for a new molecular entity (&#8220;NME&#8221;) such that the 10-month and 6-month action goals for NME applications begin to run from the 60-day filing date rather than from receipt of the original NDA submission. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with cGMP regulations is satisfactory, and the NDA contains data that provides substantial evidence that the drug is safe and effective in the indication studied. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter (&#8220;CRL&#8221;) generally outlines the deficiencies in the submission and may require substantial additional testing or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing 90% of NDA resubmissions within two to six months depending on the type of information included in response to the deficiencies identified in the CRL. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and/or elements to assure safe use (&#8220;ETASU&#8221;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, or problems are identified following initial marketing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Fast Track Designation and Accelerated Approval</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The FDA is authorized to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment, and which demonstrate the potential to address unmet medical needs for the condition. These programs include Fast Track designation, breakthrough therapy designation, priority review designation and other accelerated approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Under the Fast Track Program, the sponsor of a new drug candidate that is intended to treat a serious condition may request that the FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60 </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">28</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">days of receipt of the sponsor&#8217;s request (possibly in some cases within 30 days). In addition to other benefits such as the ability to engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act. This law established a new regulatory program for products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to designated breakthrough therapies, including: holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The FDA may also designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case- by-case basis, whether the proposed drug represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The accelerated approval regulations are codified within Title 21 of the Code of Federal Regulations, as Subpart H under Part 314, the part of the FDA regulations covering applications for FDA approval to market a new drug, and as such the accelerated approval pathway is sometimes referred to as approval under &#8220;Subpart H.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved under Subpart H is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. Unless otherwise informed by the FDA, for an accelerated approval product an applicant must submit to the FDA for consideration during the pre-approval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the FDA, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Orphan Drugs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition generally a disease or condition that affects fewer than 200,000 individuals. The U.S. Orphan Drug Designation must be requested before submitting a NDA. After the FDA grants orphan drug designation, the generic identity and trade name, if any, of the drug and its designated use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">29</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Pediatric Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers for submission of data, as well as deferrals for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;) provides NDA holders a six-month extension of any exclusivity-patent or non-patent-for a drug if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and report on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Special Protocol Assessment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">A company may reach an agreement with the FDA under the Special Protocol Assessment (&#8220;SPA&#8221;) process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim for a new drug product. According to its performance goals, the FDA seeks to evaluate the protocol within 45 days of the request to assess whether the proposed clinical trial is adequate, and that evaluation may result in discussions and a request for additional information. An SPA request must be made before the proposed clinical trial begins, and all open issues must be resolved before the clinical trial begins. If a written agreement is reached, it will be documented and made part of the administrative record. Under the FDCA and FDA guidance implementing the statutory requirement, an SPA is generally binding on the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and the FDA agree to the change in writing, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Disclosure of Clinical Trial Information</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Sponsors of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical trial information on a public website maintained by the U.S. National Institutes of Health (&#8220;NIH&#8221;). Information related to the product, patient population, phase of investigation, study sites and investigator, and other aspects of the clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these clinical trials after completion. Disclosure of the results of these clinical trials can be delayed for up to two years if the sponsor certifies that it is seeking approval of an unapproved product or that it will file an application for approval of a new indication for an approved product within one year. Competitors may use this publicly available information to gain knowledge regarding the design and progress of the development programs. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. Since the NIH&#8217;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, both NIH and FDA have signaled the government&#8217;s willingness to begin enforcing those requirements against clinical trial sponsors who fail to meet those legal obligations, with the FDA releasing a guidance document in August 2020 for certain procedural steps it intends to take when determining whether and how to assess civil monetary penalties against a non-compliant party. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Post-Approval Requirements</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Drugs manufactured, marketed or distributed pursuant to FDA approval decisions are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">30</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">approval before they can be implemented. There also are continuing, annual user fee requirements for any marketed products and related manufacturing facilities, as well as new application fees for supplemental applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, drug manufacturers and other entities involved in the manufacture of approved drugs are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA for compliance with cGMP requirements. Prescription drug distribution facilities are also subject to state licensure, including inspections, by the relevant local regulatory authority. Changes to the manufacturing process, specifications or container closure system for an approved drug are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and others involved in the drug manufacturing process. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance and ensure ongoing compliance with other statutory requirements of the FDCA, such as the requirements for making manufacturing changes to an approved NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Thus, even after new drug approval is granted, regulatory authorities may withdraw that approval or request product recalls if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of regulatory non-compliance include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of products; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As described below, the FDA strictly regulates marketing, labeling, advertising and promotion of prescription drug products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">The Hatch-Waxman Amendments</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Orange Book Listing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. As part of the marketing application process when seeking approval for a new drug through a NDA, applicants are required to list with the FDA every patent of which claims cover the applicant&#8217;s product or an approved method of using the product. Upon approval of a drug, approval information about the drug along with each of the applicant&#8217;s listed patents is then published in the FDA&#8217;s <i style="font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</i>, commonly known as the &#8220;Orange Book.&#8221; Pursuant to the Hatch-Waxman Amendments, drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application (&#8220;ANDA&#8221;). An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the reference license drug (&#8220;RLD&#8221;) and has been shown through bioequivalence testing to be bioequivalent to the RLD. The FDA is responsible for determining that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug, although under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are most often considered to be therapeutically equivalent to the RLD, are commonly referred to as &#8220;generic equivalents&#8221; to the RLD, and can often be substituted by pharmacists under prescriptions written for the original RLD in accordance with state law. Specifically, upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in the Orange Book. By operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">31</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">equivalence in the Orange Book often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or the patient.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Hatch-Waxman Amendments also amended the FDCA to enact Section 505(b)(2) of the FDCA, which permits the filing of a NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. A Section 505(b)(2) applicant may eliminate the need to conduct certain preclinical or clinical studies, if it can establish that reliance on studies conducted for a previously approved product is scientifically appropriate. The FDA may also require companies to perform additional clinical trials or measurements to support the change from the approved product. The FDA may then approve the new product for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. With respect to listed patents, patent certification requirements, and the blocking of follow-on marketing applications for the drug product previously approved under a NDA and listed in the Orange Book known as the RLD-505(b)(2) NDA applications and ANDAs are required under the statute and FDA&#8217;s implementing regulations to follow similar procedures and are subject to similar conditions. However, only in some cases is a 505(b)(2) NDA-approved drug product determined by the FDA to be therapeutically equivalent to the original innovator RLD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As part of our own marketing application process, the ANDA/505(b)(2) applicant is required to certify to the FDA concerning any patents listed for the relevant RLD in the FDA&#8217;s Orange Book. Specifically, the applicant must certify either that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the generic product. The ANDA applicant may also elect to submit a Section VIII statement, certifying that the proposed ANDA or 505(b)(2) labeling does not contain (or carves out) any language regarding the patented method-of-use, rather than certify to a listed method-of-use patent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If the ANDA/505(b)(2) applicant does not challenge the innovator&#8217;s listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA/505(b)(2) application will not be approved by the FDA until all the listed patents claiming the referenced product have expired. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA/505(b)(2) applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of that Paragraph IV certification to the NDA sponsor and patent holders once the FDA accepts the ANDA/505(b)(2) application for filing. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification, as provided for in the statute. The filing of a patent infringement lawsuit within 45 days of receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA/505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA/505(b)(2) applicant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Non-Patent Exclusivity</i><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the Hatch-Waxman Amendments, the FDA also may not approve an ANDA or 505(b)(2) NDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity (&#8220;NCE&#8221;) which is a drug that contains no active moiety that has been approved by the FDA in any other NDA. During these five years of marketing exclusivity, the FDA cannot receive any ANDA or 505(b)(2) application seeking approval of a drug that references a version of the NCE drug. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or the addition of a new indication. During this three-year period of exclusivity, the FDA cannot approve an ANDA or 505(b)(2) application that includes the change. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">An ANDA or 505(b)(2) application may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification requirement, and in such situations, no ANDA or 505(b)(2) application may be filed before the expiration of the exclusivity period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Patent Term Extension</i><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#8217;s testing phase&#8212;the time between IND submission and NDA submission&#8212;and all of the review phase&#8212;the time between NDA submission and approval up to a maximum of five years. The time can be </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">32</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years from market approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the U.S. Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which a NDA has not been submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Prescription Drug Marketing Act</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (&#8220;PDMA&#8221;) imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">New Legislation and Regulations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA and relevant regulatory authorities outside the U.S. In addition to new legislation, regulations and policies are often revised or interpreted by regulatory authorities in ways that may significantly affect our business and our product candidates. It is impossible to predict whether further legislative changes will be enacted or whether regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Other U.S. Healthcare Laws and Compliance Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If we obtain regulatory approval of our product candidates and launch them commercially in the U.S., we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. Some of the laws that may affect our future ability to operate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the Physician Payments Sunshine Act, which require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Moreover, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act.</span></td></tr></table><div style="margin-top:8pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">33</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Europe/Rest of World Government Regulation </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition to regulations in the U.S., we are and will be subject, either directly or through our potential partners, to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencement of clinical trials or marketing of the product in those countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the European Union, medicinal products are subject to extensive pre- and post-marketing regulation by regulatory authorities at both the European Union and national levels. Additional rules also apply at the national level to the manufacture, import, export, storage, distribution and sale of controlled substances. In many European Union member states, the regulatory authority responsible for medicinal products is also responsible for controlled substances. Responsibility is, however, split in some member states. Generally, any company manufacturing or distributing a medicinal product containing a controlled substance in the European Union will need to hold a controlled substances license from the competent national authority and will be subject to specific record-keeping and security obligations. Separate import or export certificates are required for each shipment into or out of the member state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Clinical Trials and Marketing Approval</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Certain countries outside of the U.S. have a process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application (&#8220;CTA&#8221;) must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements and a company has received favorable ethics committee approval, clinical trial development may proceed in that country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, even though there is some degree of legal harmonization in the European Union member states resulting from the national implementation of the underlying European Union legislation. In all cases, the clinical trials must be conducted in accordance with the International Conference on Harmonization guidelines on GCP and other applicable regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">To obtain regulatory approval to place a drug on the market in the European Union, we must submit a marketing authorization application. This application is similar to the NDA in the U.S., with the exception of, among other things, country-specific document requirements. All application procedures require an application in the common technical document format, which includes the submission of detailed information about the manufacturing and quality of the product, and non-clinical and clinical trial information. Drugs can be authorized in the European Union by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralized procedure or (iv) national authorization procedures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The European Commission created the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the European Union and, by extension (after national implementing decisions) in Iceland, Liechtenstein and Norway, which, together with European Union member states, comprise the European Economic Area. Applicants file marketing authorization applications with the European Medicines Agency (&#8220;EMA&#8221;), where a relevant scientific committee reviews them, in most cases the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;). The EMA forwards CHMP opinions to the European Commission, which uses them as the basis for deciding whether to grant a marketing authorization. This procedure results in a single marketing authorization granted by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that: (i) are derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) are officially designated &#8220;orphan drugs&#8221; (drugs used for rare human diseases) and (iv) are advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may, at the voluntary request of the applicant, also be used for human drugs which do not fall within the above-mentioned categories if the CHMP agrees that (a) the human drug contains a new active substance not yet approved as of November 20, 2005; (b) it constitutes a significant therapeutic, scientific or technical innovation or (c) authorization under the centralized procedure is in the interests of patients at the European Union level.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">34</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application by the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP), with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: (i) the seriousness of the disease to be treated, (ii) the absence of an appropriate alternative therapeutic approach, and (iii) anticipation of exceptional high therapeutic benefit. In this circumstance, the EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion is issued thereafter. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">For those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications to the national medicines regulators through one of three procedures: (i) the mutual recognition procedure (which must be used if the product has already been authorized in at least one other European Union member state, and in which the European Union member states are required to grant an authorization recognizing the existing authorization in the other European Union member state, unless they identify a serious risk to public health), (ii) the decentralized procedure (in which applications are submitted simultaneously in two or more European Union member states) or (iii) national authorization procedures (which results in a marketing authorization in a single European Union member state).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Mutual Recognition Procedure </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The mutual recognition procedure (&#8220;MRP&#8221;) for the approval of human drugs is an alternative approach to facilitate individual national marketing authorizations within the European Union. Basically, the MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products and must be used if the product has already been authorized in one or more member states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The characteristic of the MRP is that the procedure builds on a pre-existing marketing authorization in a member state of the European Union that is used as a reference in order to obtain marketing authorizations in other European Union member states. In the MRP, a marketing authorization for a drug already exists in one or more member states of the European Union and subsequently marketing authorization applications are made in other European Union member states by referring to the initial marketing authorization. The member state in which the marketing authorization was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently applied for act as concerned member states. The concerned member states are required to grant an authorization recognizing the existing authorization in the reference member state unless they identify a serious risk to public health. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The MRP is based on the principle of mutual recognition by the European Union member states of their respective national marketing authorizations. Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member states. In such cases, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days of acknowledgement of the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If any European Union member state refuses to recognize the marketing authorization by the reference member state, on the grounds of potential serious risk to public health, the issue will be referred to a coordination group. Within a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The opinion of this EMA Committee is then forwarded to the European Commission for the start of the decision-making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human Medicinal Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Data and Market Exclusivity in the European Union </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the European Union, NCEs qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a NCE and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full marketing authorization application (&#8220;MAA&#8221;) with a complete database of pharmaceutical test, preclinical studies and clinical trials and obtain marketing approval of its product.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">35</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Sales of pharmaceutical products approved for marketing in the U.S. by the FDA will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, such as government health programs, and commercial insurance and managed health care organizations. These third-party payors are increasingly challenging the prices charged for medical products and services. Additionally, the containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, utilization management and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our operating results. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&#8220;MMA&#8221;) imposed requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Part D is available through both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval in the U.S. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), was enacted with the goal of expanding coverage for the uninsured while at the same time containing overall health care costs. With regard to pharmaceutical products, among other things, the ACA expanded and increased industry rebates for drugs covered under Medicaid programs and made changes to the coverage requirements under the Medicare Part D program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Individual states in the U.S. have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the U.S., Medicare covers certain drug purchases by the elderly and eligible disabled people and introduced a reimbursement methodology based on average sales prices for physician-administered drugs. In addition, Medicare may limit the number of drugs that will be covered in any therapeutic class. Ongoing cost reduction initiatives and future laws could decrease the coverage and price that we will receive for any approved products. While Medicare beneficiaries are limited to most elderly and certain disabled individuals, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Among the provisions of the ACA of importance or potential importance to our product candidates are the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">36</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of manufacturers&#8217; Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service Act&#8217;s pharmaceutical pricing program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new requirements to report financial arrangements with physicians and teaching hospitals (i.e., the Federal Physician Payment Sunshine Act, which has since been expanded to cover additional specified healthcare providers);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we will receive for any approved product. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">There remain judicial and political challenges to certain aspects of the ACA. In June 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 2021 to August 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to health care, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, with the exception of a temporary suspension from May 2020 through March 2022, unless additional Congressional action is taken. In addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. The likelihood of success of these and other measures is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, some European Union jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. Such differences in national pricing regimes may create price differentials between European Union member states. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the U.S. In the European Union, the downward pressure on healthcare costs in general, particularly prescription medicines, has become intense. As a result, barriers to entry of new products are becoming increasingly high and patients are unlikely to use a drug product that is not reimbursed by their government. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">37</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Human Capital </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, we had eight full-time (and total) employees, of which four were engaged in R&amp;D functions, three were engaged in general and administrative (&#8220;G&amp;A&#8221;) functions, and one was engaged in both R&amp;D and G&amp;A functions. We have no collective bargaining agreements with our employees and have not experienced any work stoppages. We consider our relationships with our employees to be good. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our&#160;human capital&#160;resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new full-time employees. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our Company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Corporate Information </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">MetaVia was incorporated under the laws of the State of Delaware in October 2014. Our principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138. Our website address is www.metaviatx.com. The information contained on or that can be accessed through our website is not a part of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Additional Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">On our website, we make available, free of charge, our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding us and other companies that file materials with the SEC electronically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Also available on our website is information relating to our corporate governance and our Board of Directors, including our corporate governance guidelines; our code of business conduct; and our board committee charters. We will provide any of the foregoing information without charge upon written request to MetaVia Inc., 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f73ef9ab_0afe_4d4e_aa3e_421118f2f43c"></a><a id="ITEM1ARISKFACTORS_215230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1A.</b></span><b style="font-weight:bold;">Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks described below, together with the other information contained in this Annual Report, including in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in our consolidated financial statements and the related notes included elsewhere in this Annual Report. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks related to our financial position and need for capital</b></p><a id="_cp_text_1_2"></a><a id="_cp_text_1_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred net losses since inception</span><span style="font-style:italic;font-weight:bold;">, and we </span><span style="font-style:italic;font-weight:bold;">anticipate that we will continue to incur net losses for the foreseeable future</span><span style="font-style:italic;font-weight:bold;">. We require additional capital to accomplish our business plan and the failure to obtain necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></p><a id="_cp_text_1_6"></a><a id="_cp_text_1_8"></a><a id="_cp_text_1_15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;text-align:justify;margin:8pt 0pt 0pt 0pt;">We have experienced net losses and negative cash flows from operating activities since our inception, and we have a net loss of $13.0 million and an accumulated deficit of $148.8 million as of December 31, 2025.&#160;<span style="color:#231f20;font-family:'Times NR MT Pro';">We have concluded that there is substantial doubt about our ability to continue as a going</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">concern within twelve months from the date the consolidated </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">inancial statements were issued. Our</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">independent registered public accounting </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">i</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">r</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">m has issued an opinion on our consolidated </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">inancial statements</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">included in this Annual Report that also states that there is substantial doubt about our ability to</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">continue</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">as</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">a</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">going</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">concern.</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">Our</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">consolidated</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">inancial</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">statements</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.25pt;">have</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">been</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">prepared</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">using</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">accounting</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">principles generally accepted in the U.S. applicable for a going concern, which assume that we will reali</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.1pt;">z</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.25pt;">e our</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">assets and satisfy our liabilities in the no</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">r</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">mal course of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">business. Our consolidated </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">inancial statements do</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">not include any adjustments to the amounts and classi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">ication of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">assets and liabilities that may be necessary</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">should we be unable to continue as a going concern.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">We expect to incur increasing levels of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">losses from operating activities for the foreseeable future,</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">particularly as we advance our product candidates through clinical development. Our prior losses, combined</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217;</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">equity and working capital. We expect our R&amp;D expenses to increase in</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">connection with our additional planned clinical trials for our product candidates and the development of</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">other future product candidates we may choose to pursue. In addition, if</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">we obtain marketing approval for</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">any</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:2.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">our</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">product</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">candidates,</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">we</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">will</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">38</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;text-align:justify;margin:0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';">incur</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">signi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">icant</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">sales,</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">marketing</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">and</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">outsourced</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:1.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">manufacturing</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">expenses in connection with the commercialization of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">our product candidates. As a result, we expect to</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">continue to incur signi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">icant and increasing losses from operating activities for the foreseeable future. To-date,</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">we have not generated any revenue and we do not know when, or if, we will generate any revenue. Even if</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">we do become pro</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">itable, we may not be able to sustain or increase our pro</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">itability on a quarterly or annual</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">basis. We do not expect to generate signi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">icant revenue unless and until we obtain marketing approval for,</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">and begin to sell, one or more of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.35pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">our product candidates. It is possible we will never generate revenue or pro</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">it.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">Although we are exploring </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">inancing opportunities and carefully monitoring the capital markets, we do</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">not</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">yet</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.25pt;">have</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">any</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">commitments</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">for</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">additional</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">inancing</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">and</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">may</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">not</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">be</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">successful</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">in</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">our</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">efforts</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">to</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.25pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">raise</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">additional funds. There can be no assurances that additional </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">inancing will be available to us on satisfactory</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">te</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">r</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">ms, or at all. If</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">we are unable to raise suf</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">icient additional capital (which is not assured at this time),</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">our business plan may not be accomplished, and we may be forced to delay, limit, reduce or te</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">r</span><span style="color:#231f20;font-family:'Times NR MT Pro';">minate our</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">operations.</span> For more information about our liquidity and capital resources, see &#8220;Liquidity and Capital Resources&#8221; in Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">As we do not generate any revenue, we are dependent on working capital to fund our business plan, and raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights to our technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We believe that our existing cash, together with the proceeds from the underwritten public offering in January 2026, will be sufficient to fund our operations into the fourth quarter of 2026. Until such time, if ever, as we can generate revenue, we expect to finance our cash needs through a combination of equity offerings, debt financing, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds from our current or future expected business plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of current stockholders may be materially diluted, and the terms of such securities could include liquidation preferences or other preferences that adversely affect the rights of our current stockholders. The terms of debt and/or equity financings, if available, may provide rights senior to those of our common stock and could contain covenants or protective rights that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financing or other arrangements when needed, we may be required to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses, out-licenses or acquisitions. If we need to secure additional financing, such additional fundraising efforts may divert our management and research efforts from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales, or the perception of future sales, by us or our securityholders could cause the market price of our common stock to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The sale of shares of our common stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">For example, in January 2023, we filed a registration statement on Form S-3 relating to the reoffer and resale from time to time of up to 2,057,262 shares of our common stock by the selling stockholders named therein, and such registration statement was declared effective on January 31, 2023. Additionally, in July 2024, we filed a registration statement on Form S-1 relating to the reoffer and resale from time to time of up to 1,561,414 shares of our common stock by the selling securityholders named therein, and such registration statement was declared effective on July 24, 2024. Furthermore, in July 2025, we filed a registration statement on Form S-3 relating to the reoffer and resale from time to time of up to 1,280,409 shares of our common stock by the selling stockholders named therein, and such registration statement was declared effective on July 10, 2025. Most recently, in January 2026, we filed a registration statement on Form S-1 which also covered the offer and sale of up to 3,678,723 shares of our common stock upon exercise of certain pre-funded warrants, Series C Common Warrants and Series D Common Warrants. By exercising their registration rights and selling a large number of shares of our common stock in reliance on these and other existing registration statements, these securityholders could cause the prevailing market price of our common stock to decline. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">As of December 31, 2025, we had outstanding warrants to purchase an aggregate of 722,644 shares of our common stock. Each warrant entitles the holder thereof to purchase one share of our common stock. To the extent such warrants are exercised, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">39</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">additional shares of our common stock will be issued, which will result in dilution to the then existing holders of shares our common stock and increase the number of shares eligible for resale in the public market. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, the shares of our common stock reserved for future issuance under our equity incentive plans will become eligible for sale in the public market once those shares are issued, subject to provisions relating to various vesting agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144, as applicable. We have filed registration statements on Form S-8 to register shares of our common stock or securities convertible into or exchangeable for shares of our common stock issued pursuant to our equity incentive plans. We expect to file additional registration statements on Form S-8 in the future to register additional shares reserved for future issuance under our equity incentive plans, and Form S-8 registration statements automatically become effective upon filing. Accordingly, shares registered under such registration statements will be available for sale in the open market. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the future, we may also issue our securities in connection with investments or acquisitions. The number of shares of our common stock issued in connection with an investment or acquisition could constitute a material portion of our then-outstanding shares of common stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to our stockholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse global economic conditions could have a material adverse effect on our business, results of operations and financial condition and liquidity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our business, financial condition, results of operations and prospects could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, service providers or other partners and there is a risk that one or more would not survive or be able to meet their commitments to us under such circumstances. As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years due to the impacts of health pandemics, and, more recently, the ongoing conflicts in Ukraine and in the Middle East, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflation, rising interest rates, increases in unemployment rates and uncertainty about tariffs and economic stability. There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in and uncertainty surrounding U.S. trade policy could have a material adverse impact on our business, financial condition and results of operations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.85pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">As a result of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">changes in tariffs that have been announced and/or implemented, and the underlying</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">uncertainty currently surrounding international trade, we could experience a negative impact to our costs of</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">materials and production processes, and supply chain disruptions and delays as a result of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">any new tariff</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">policies or trade restrictions. If</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">we are unable to obtain necessary raw materials or product components in</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.15pt;">suf</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';">icient</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">quantity</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">and</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">in</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">a</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">timely</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">manner</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">due</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">to</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">disruptions</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">in</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">the</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">global</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">supply</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">chain</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">caused</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">by</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">macroeconomic events and conditions, the development, testing and clinical trials of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.85pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">our product candidates</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">may be delayed or infeasible, and regulatory approval or commercial launch of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">any resulting product may</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">be delayed or not obtained, which could signi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">icantly ha</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">r</span><span style="color:#231f20;font-family:'Times NR MT Pro';">m our business. We cannot yet predict the effect of</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">the recently imposed U.S. tariffs on imports, or the extent to which other countries will impose quotas,</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">future trade policy or the te</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.2pt;">r</span><span style="color:#231f20;font-family:'Times NR MT Pro';">ms of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">any renegotiated trade agreements and their impact on our business.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. If, for example, banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened. While it is not possible at this time to predict the extent of the impact that the failure of these financial institutions or the high market volatility and instability of the banking sector could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">40</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks related to our operations and to the development, marketing, commercialization and regulation of our product candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future R&amp;D programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Additionally, our R&amp;D efforts are focused, in part, on developing <span style="color:#231f20;font-family:'Times NR MT Pro';">vanoglipel</span> (DA-1241) for the treatment of MASH, an indication for which there is only one approved product. The regulatory approval process for novel product candidates, such as <span style="color:#231f20;font-family:'Times NR MT Pro';">vanoglipel</span> (DA-1241) for MASH, can be more expensive and take longer than for other, better known or extensively studied product candidates. In addition to <span style="letter-spacing:0.2pt;">Madrigal Pharmaceuticals</span>&#8217; approved product, other companies are in later stages of clinical trials for their potential MASH therapies, and we expect that the path for regulatory approval for MASH therapies may continue to evolve in the near term as these other companies refine their regulatory approval strategies and interact with regulatory authorities. Such evolution may impact our future clinical trial designs, including clinical trial size and endpoints, in ways that we cannot predict today. Our anticipated development costs would likely increase if the development of vanoglipel (DA-1241) or any future product candidate is delayed because the FDA requires us to perform studies or clinical trials in addition to, or different from, those that we currently anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of any increase in our anticipated development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Public opinion and scrutiny of treatments for obesity, overweight patients, MASH and MASH patients may impact public perception of our Company, DA-1726, vanoglipel (DA-1241), or may adversely affect our ability to conduct our business and our business plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Public perception may be influenced by claims, such as claims that DA-1726 and vanoglipel (DA-1241) are unsafe, unethical or immoral and, consequently, our approach may not gain the acceptance of the public or the medical community. Negative public reaction to treatments for obesity, overweight patients, MASH and MASH patients in general could result in greater government regulation and stricter labeling requirements of products to treat these chronic conditions, including DA-1726 and vanoglipel (DA-1241), if approved, and could cause a decrease in the demand for DA-1726, vanoglipel (DA-1241) or any product candidates we may develop. For example, severe AEs observed with&#160;GLP-1&#160;receptor agonists include, but are not limited to, acute pancreatitis, acute gallbladder disease, acute kidney injury and worsening of diabetic retinopathy. Such side effects associated with&#160;GLP-1&#160;receptor or&#160;GLP-1/GIP&#160;receptor targeting treatments may negatively impact public perception of us, DA-1726 or any product candidates we develop. Adverse public attitudes may also adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians and their patients being willing to receive treatments that involve the use of DA-1726, vanoglipel (DA-1241) or any product candidates we develop, in lieu of or in addition to, existing treatments that such physicians and their patients are already familiar with and for which greater clinical data may be available. AEs in our clinical trials, even if not ultimately attributable to DA-1726, vanoglipel (DA-1241) or any product candidates we develop, and the resulting publicity could result in withdrawal of clinical trial participants, increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of DA-1726, vanoglipel (DA-1241) or any product candidates we develop, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. More restrictive government regulations or negative public opinion could have a material and adverse impact on our business, financial condition, results of operations and prospects, and may delay or impair the development, commercialization (if approved) or demand for DA-1726, vanoglipel (DA-1241) or any product candidates we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be required to make significant payments under the 2022 License Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We have exclusive rights (other than in the Republic of Korea) to vanoglipel (DA-1241) and DA-1726 for the specific indications provided in the 2022 License Agreement. Under the 2022 License Agreement, in consideration for the license, we made an upfront payment of 2,200 shares of our Series A Convertible Preferred Stock. As additional consideration for the license, we are required to pay Dong-A ST milestone payments upon the achievement of specified regulatory milestones and milestone payments upon the achievement of specified commercial milestones. Commencing on the first commercial sale of </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">41</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">licensed products, we are obligated to pay royalties of single-digit percentages on annual net sales of the products covered by the license. If the milestone is reached or the other non-royalty obligations become due, we may not have sufficient funds available to meet our obligations, which may materially adversely affect our business operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain favorable clinical results, we may not be able to obtain regulatory approval for, or successfully commercialize vanoglipel (DA-1241) and DA-1726.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Of the large number of drugs in development in the U.S., only a small percentage receive FDA regulatory approval and are commercialized in the U.S. We are not permitted to market vanoglipel (DA-1241) or DA-1726 in the U.S. until we receive approval of a NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries or jurisdictions, such as the EMA in the European Union. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As a condition to submitting a NDA to the FDA for vanoglipel (DA-1241) or DA-1726, we must successfully complete several clinical trials demonstrating efficacy and safety. For example, we must successfully meet a number of critical developmental milestones, including: (i) developing dosages that will be well-tolerated, safe and effective; (ii) completing the development and scale-up to permit manufacture of our product candidates in commercial quantities and at acceptable costs; (iii) demonstrating through pivotal clinical trials that the product candidate is safe and effective in patients for the intended indication; (iv) establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; and (v) obtaining and maintaining exclusive rights, including patent and trade secret protection and non-patent exclusivity for our product candidates. The time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for any product candidates that we may develop. We are continuing to test and develop our product candidates and may explore possible design or formulation changes to address safety, dosage, efficacy, manufacturing efficiency and performance issues to the extent any arise. The design of a clinical trial may be able to determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. There is no assurance that we will be able to design and complete a clinical trial to support marketing approval. Moreover, nonclinical and clinical data are often susceptible to multiple interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have experienced significant setbacks in advanced clinical trials, even after achieving promising results in earlier clinical trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Successfully completing clinical trials and obtaining approval of a NDA is a complex, lengthy, expensive and uncertain process, and the FDA, or a comparable foreign regulatory authority, may delay, limit or deny approval of a NDA for many reasons, including, among others: (i) disagreement with the design or implementation of our clinical trials; (ii) disagreement with the sufficiency of our clinical trials; (iii) failure to demonstrate the safety and efficacy of the product candidate for the proposed indications; (iv) failure to demonstrate that any clinical and other benefits of the product candidate outweigh their safety risks; (v) a negative interpretation of the data from our nonclinical studies or clinical trials; (vi) insufficient data collected from clinical trials or changes in the approval requirements that render our nonclinical and clinical data insufficient to support the filing of a NDA or to obtain regulatory approval; or (vii) changes in clinical practice in our approved products available for the treatment of the target patient population that could have an impact on the indications that we are pursuing for our product candidates. Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market vanoglipel (DA-1241) and DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Vanoglipel (DA-1241) and DA-1726 may not be successful in clinical trials or receive regulatory approval. Further, vanoglipel (DA-1241) and DA-1726 may not receive regulatory approval even if they are successful in clinical trials, or these product candidates may be approved for fewer or more limited indications than we request, such approval may be contingent on the performance of costly post-marketing clinical trials or we may not be allowed to include the labeling claims necessary or desirable for the successful commercialization of such product candidate. In addition, the policies or regulations, or the type and amount of clinical data necessary to gain approval, may change during a product candidate&#8217;s clinical development and may vary among jurisdictions. Our development activities could be harmed or delayed by a partial shutdown of the U.S. government, including the FDA. We have not obtained regulatory approval for any product candidate, and it is possible that vanoglipel (DA-1241) and DA-1726 will never obtain regulatory approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not as broad as we intend or desire or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional, unanticipated clinical trials to obtain approval or be subject to additional post marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product, or the FDA may require a REMS for a product, which could impose restrictions on our distribution. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">42</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preliminary, interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or clinical trial. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Therefore, positive interim results in any ongoing clinical trial may not be predictive of similarly positive results in the completed study or clinical trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Adverse changes between preliminary or interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our shares of common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our Company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material, or otherwise appropriate, information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize any product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding promising results in earlier studies. Similarly, our future clinical trial results may not be successful for these or other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">This drug candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early to late-stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late-stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve these intended objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Any of these changes could make the results of our planned clinical trials or other future clinical trials we may initiate less predictable and could cause our product candidates to perform differently, including causing toxicities, which could delay the completion of our clinical trials, delay the approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Undesirable side effects caused by any of our product candidates that we may develop or acquire could cause us or the FDA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in more restrictive labels or the delay or denial of marketing approval by the FDA or other regulatory authorities of such product candidates. Results of our clinical trials could reveal high and unacceptable severity and prevalence of these or other side effects. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">43</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">further development of or deny approval of our product candidates for any or all targeted indications. In addition, any drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw or limit their approval of such product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall the product, change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require a REMS plan to mitigate risks, which could include medication guides to be distributed to patients, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to regulatory investigations and government enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may decide to remove such product candidates from the marketplace after they are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may be rendered less competitive, and sales may decrease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our efforts to discover drug candidates beyond our current drug candidates may not succeed, and any drug candidates we recommend for clinical development may not actually begin clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We intend to continue to use our technology, including our licensed technology, knowledge and expertise to develop novel drugs to address some of the world&#8217;s most widespread and costly chronic diseases. We intend to expand our existing pipeline of core assets by advancing drug compounds from current ongoing discovery programs into clinical development. However, the process of researching and discovering drug compounds is expensive, time-consuming and unpredictable. Data from our current preclinical programs may not support the clinical development of our lead compounds or other compounds from these programs, and we may not identify any additional drug compounds suitable for recommendation for clinical development. Moreover, any drug compounds we recommend for clinical development may not demonstrate, through preclinical studies, indications of safety and potential efficacy that would support advancement into clinical trials. Such findings would potentially impede our ability to maintain or expand our clinical development pipeline. Our ability to identify new drug compounds and advance them into clinical development also depends upon our ability to fund our R&amp;D operations, and we cannot be certain that additional funding will be available on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in our clinical trials may lead to a delay in the submission of marketing approval applications and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may experience delays in ongoing and planned clinical trials. We do not know whether planned clinical trials will begin or enroll subjects on time, need to be redesigned or be completed on schedule, if at all. Clinical trials may be delayed, suspended or terminated for a variety of reasons, such as: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in reaching an agreement with the FDA or a comparable foreign regulatory authority on a clinical trial design that we are able to execute;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">44</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in obtaining authorization to commence a clinical trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability, delay or failure in identifying and maintaining a sufficient number of clinical trial sites, many of which may already be engaged in competing clinical trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issues with the manufacture of drug substance for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in recruiting and enrolling suitable subjects to participate in a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in having subjects complete a clinical trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites and investigators deviating from clinical trial protocol, failing to conduct the clinical trial in accordance with regulatory requirements, or dropping out of a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in obtaining IRB approval to conduct a clinical trial at each site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays resulting from negative or equivocal findings of the Data Safety Monitoring Board (&#8220;DSMB&#8221;), if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ambiguous or negative results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decision by the FDA, a comparable foreign regulatory authority, or recommendation by a DSMB to suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conflicts affecting clinical trial sites and regions where clinical trials are being completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the product development program; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in governmental regulations or requirements.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may develop vanoglipel (DA-1241) and DA-1726, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may develop vanoglipel (DA-1241) and DA-1726 and future product candidates in combination with one or more currently approved therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the U.S. could revoke approval of the therapy used in combination with our product candidate or that safety, dosage, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may also evaluate vanoglipel (DA-1241) and DA-1726 or any other future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the U.S. We will not be able to market and sell vanoglipel (DA-1241) and DA-1726 or any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. If the FDA or similar regulatory authorities outside of the U.S. do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with the drugs we choose to evaluate in combination with vanoglipel (DA-1241) and DA-1726 or any other product candidate we develop, we may be unable to obtain approval of or market vanoglipel (DA-1241) and DA-1726 or any other product candidate we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential future drug candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We may seek collaboration arrangements with biopharmaceutical companies for the development or commercialization of our current and potential future drug candidates. To the extent that we decide to enter into collaboration agreements, we will face </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">45</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, execute and implement. We may not be successful in our efforts to establish and implement collaborations, or other alternative arrangements should we choose to enter into such arrangements, and the terms of the arrangements may not be favorable to us. If, and when we collaborate with a third party for development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Disagreements between parties to a collaboration arrangement can lead to delays in developing or commercializing the applicable drug candidate and can be difficult to resolve in a mutually beneficial manner. In some cases, collaborations with biopharmaceutical companies and other third parties are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with MASH or obesity and significant competition for recruiting such patients in clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our clinical trials. In particular, as a result of the inherent difficulties in diagnosing MASH or obesity and the significant competition for recruiting patients with MASH or obesity in clinical trials, there may be delays in enrolling the patients we need to complete clinical trials on a timely basis, or at all. This risk may be more significant for us than other companies conducting clinical trials for the treatment of patients with MASH because we are enrolling only patients with a biopsy-confirmed diagnosis of MASH in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Factors that may generally affect patient enrollment include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and location of clinical sites we enroll;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition with other companies for clinical sites or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility and exclusion criteria for the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain and maintain patient consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that enrolled participants will drop out before completion; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, if any significant AEs or other side effects are observed in any of our future clinical trials, it may make it more difficult for us to recruit patients to our clinical trials and patients may drop out of our clinical trials, or we may be required to abandon the clinical trials or our development efforts of one or more product candidates altogether. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, which would increase our costs and have an adverse effect on our Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The development and commercialization of new products is highly competitive. Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of our product candidates. Our objective is to develop and commercialize new products with superior efficacy, convenience, tolerability and safety. In many cases, the products that we commercialize will compete with existing, market-leading products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Many of our potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. In particular, these companies </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">46</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">have greater experience and expertise in securing government contracts and grants to support their R&amp;D efforts, conducting testing and clinical trials, obtaining regulatory approvals to market products, manufacturing such products on a broad scale and marketing approved products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development and have collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products before, or more effectively than, we do. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. If we are not able to compete effectively against potential competitors, our business will not grow, and our financial condition and operations will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;letter-spacing:0.2pt;">MASH</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">There is only one approved treatment of MASH, Madrigal Pharmaceuticals&#8217; thyroid hormone receptor beta agonist. However, various therapeutics are used off-label for the treatment of MASH, including vitamin E (an antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), antihyperlipidemic agents (e.g., gemfibrozil), pentoxifylline and ursodeoxycholic acid. There are several product candidates in Phase 3 or earlier clinical or preclinical development for the treatment of MASH, including Novo Nordisk&#8217;s GLP1 agonist semaglutide, Eli Lilly&#8217;s GLP1R and GIP dual agonist tirzepatide, Akero Therapeutics&#8217; FGF21 analog efruxifermin, 89 Bio&#8217;s FGF21 analog pegaozafermin, Inventiva&#8217;s pan-peroxisome proliferator-activated receptor agonist, Boston Pharmaceuticals and Roche&#8217;s fibroblast growth factor 21 analogs, and farnesoid X receptor agonists from Intercept Pharmaceuticals Inc., among others. Additional pharmaceutical and biotechnology companies with product candidates in development for the treatment of MASH include AstraZeneca plc, Altimmune Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Durect Corporation, Galectin Therapeutics Inc., Galmed Pharmaceuticals Ltd., Immuron Ltd., Ionis Pharmaceuticals, Inc., Islet Sciences, Inc., MediciNova, Inc., NGM Biopharmaceuticals, Inc., NuSirt Sciences Inc., Pfizer Inc., Viking Therapeutics, Inc. and Zydus Pharmaceuticals (USA) Inc. MASH is a complex disease and we believe that it is unlikely that any one therapeutic option will be optimal for every MASH patient.</span><span style="display:inline-block;width:9.18pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;letter-spacing:0.2pt;">Obesity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">Due to the growing overweight and obesity epidemic and consumer demand, there are many competitors in the field of obesity treatment. Obesity treatments range from behavioral modification to drugs and medical devices, and surgery, generally as a last resort. If DA-1726 were approved for obesity, our primary competition in the obesity treatment market would currently be from approved and marketed products, including semaglutide (WEGOVY</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="letter-spacing:0.2pt;">) and tirzepatide (Zepbound</span><sup style="font-size:7.5pt;letter-spacing:0.2pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="letter-spacing:0.2pt;">). Further competition could arise from products currently in development, including among others, with GLP1R/GCGR dual agonists, from Boehringer Ingelheim, Merck/Hanmi Pharmaceutical, AstraZeneca, Altimmune, Innovent Biologics/Eli Lilly, Carmot and D&amp;D Pharma; with GLP1R/GCGR/GIP triple agonists, from Hanmi Pharmaceutical and Eli Lilly; Amgen with its GLP-1R agonist/GIP antagonist antibody; and Novo Nordisk with Amylin and Amylin-GLP-1 combination. To the extent any of our product candidates are approved for obesity, the commercial success of our product will also depend on our ability to demonstrate benefits over the then-prevailing standard of care. Finally, morbidly obese patients sometimes undergo a gastric bypass procedure, with salutary effects on the many co-morbid conditions of obesity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">T2DM</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for T2DM. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among hospitals, physicians, health care payors, patients, and the medical community. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">47</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Market acceptance of any of our product candidates for which we receive regulatory approval depends on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product candidate is approved; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by major operators of hospitals, physicians and patients of the product candidate as a safe and effective treatment, particularly the ability of our product candidates to establish themselves as a new standard of care in the treatment paradigm for the indications that we are pursuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of our product candidates over alternative treatments as compared to the relative costs of the product candidates and alternative treatments; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to prescribe, and patients to take, a product candidate that is based on a botanical source;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects with respect to our product candidates, and any elements that may be imposed by the FDA under a REMS program that could discourage market uptake of the products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of adequate reimbursement and pricing for any approved products by third party payors and government authorities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability of certain types of patients to take our product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrated ability to treat patients and, if required by any applicable regulatory authority in connection with the approval for target indications, to provide patients with incremental cardiovascular disease benefits, as compared with other available therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative convenience and ease of administration of our product candidates, including as compared with other treatments available for approved indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the labeling approved by the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of alternative treatments already approved or expected to be commercially launched in the near future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">guidelines and recommendations of organizations involved in research, treatment and prevention of various diseases that may advocate for alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians or patients may be reluctant to switch from existing therapies even if potentially more effective, safe or convenient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy, safety, and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our product for sale at competitive prices; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our product together with other medications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interactions of our product with other medicines patients are taking; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our products as well as competitive products.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">There may be delays in getting our product candidates, if approved, on hospital or insurance formularies or limitations on coverages that may be available in the early stages of commercialization for newly approved drugs. If any of our product candidates are approved but fail to achieve market acceptance among hospitals, physicians, patients or health care payors, we will not be able to generate significant revenues, which would have a material adverse effect on our business, prospects, financial condition and results of operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">48</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize a future pharmaceutical drug candidate, the profitability of such product candidate will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our ability to commercialize a drug successfully will depend in part on the extent to which coverage and adequate reimbursement will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, whether the level of reimbursement will be adequate. Assuming we obtain coverage for our product candidates, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use a product candidate, if approved, unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement are critical to new product acceptance. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which a product candidate is approved by the FDA or similar regulatory authorities outside the U.S. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for a new product, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases, in-licensing and out-licensing of products, drug candidates or technologies. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial condition and results of operations. For example, these transactions may entail numerous operational and financial risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exposure to unknown liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, drug candidates</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">technologies</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or businesses</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incurrence of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">higher-than-expected transaction and integration costs;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">49</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">write-downs of assets or goodwill or impairment charges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased amortization expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty and cost in combining the operations and personnel of any acquired businesses or product lines with our operations and personnel;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to retain key employees of any acquired business.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we complete may be subject to the foregoing risk or other risks and could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any product that we may develop. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with any of our products or future product candidates during product testing, manufacturing, marketing or sale. For example, we may be sued on allegations that a product candidate caused injury or that the product is otherwise unsuitable. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If we cannot successfully defend ourselves against claims that our product caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidate that we are developing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased FDA warnings on product labels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to clinical trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidate that we may develop; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the removal of a product from the market; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased insurance costs. </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our R&amp;D activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by us and our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the U.S. and abroad governing laboratory procedures and the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur costs due to injuries to our employees resulting from the use of </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">50</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">hazardous materials, and this insurance may not provide adequate coverage against potential liabilities. Compliance with applicable environmental, health and safety laws and regulations are expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely and will continue to rely on collaborative partners regarding the development of our research programs and product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are and expect to continue to be dependent on collaborations with partners relating to the development and commercialization of our existing and future research programs and product candidates. In particular, we rely on Dong-A ST to provide services with respect to our development of vanoglipel (DA-1241) and DA-1726. In addition, we have had, have and will continue to have discussions on potential partnering opportunities with various pharmaceutical companies. If we fail to enter into or maintain collaborative agreements on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our products could change, and our costs of development and commercialization could increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our dependence on collaborative partners subjects us to a number of risks, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to control the amount or timing of resources that collaborative partners devote to our research programs and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to relinquish significant rights, including intellectual property, marketing and distribution rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we rely on the information and data received from third parties regarding our research programs and product candidates and will not have control of the process conducted by the third party in gathering and composing such data and information. We may not have formal or appropriate guarantees from our contract parties with respect to the quality and the completeness of such data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborative partner may develop a competing product either by itself or in collaboration with others, including one or more of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborative partners&#8217; willingness or ability to complete their obligations under our collaboration arrangements may be adversely affected by business combinations or significant changes in a collaborative partner&#8217;s business strategy; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in, or increases in the costs of, the development of our research programs and product candidates due to the termination or expiration of collaborative R&amp;D arrangements.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We do not have sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell some of our product candidates if and when they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future pharmaceutical products; and</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">51</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenues may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Any pharmaceutical product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and recordkeeping. Even if the marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing and/or promotion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such products, manufacturers or manufacturing processes; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling, marketing, distribution or use of a product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-approval clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning or untitled letters; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals for the drug products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We or any potential collaborator may never receive regulatory approval to market our product candidates outside of the U.S.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The activities associated with the development and commercialization of pharmaceutical drugs are subject to comprehensive regulation by the FDA, other regulatory agencies in the U.S. and by comparable authorities in other countries. Failure to obtain regulatory approval for our product candidates will prevent us or any potential collaborator from commercializing our product candidates as pharmaceutical drugs. We have not received regulatory approval to market any of our product candidates in any jurisdiction, and we do not expect to obtain FDA or any other regulatory approvals to market any of our product candidates for the foreseeable future, if at all. The process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">52</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek to avail ourselves of mechanisms to expedite and/or reduce the cost for development or approval of any of our product candidates or product candidates we may pursue in the future, such as Fast Track designation or orphan drug designation, but such mechanisms may not actually lead to a faster or less expensive development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may seek Fast Track designation, priority review, orphan drug designation, or accelerated approval for any product candidate we may pursue in the future. For example, if a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast Track designation. However, the FDA has broad discretion with regard to these mechanisms, and even if we believe a particular product candidate is eligible for any such mechanism, we cannot assure you that the FDA would decide to grant it. Even if we obtain Fast Track or priority review designation or pursue an accelerated approval pathway, we may not experience a faster and/or less costly development process, review or approval compared to conventional FDA procedures. The FDA may withdraw a particular designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current and future legislation may increase the difficulty and cost of obtaining marketing approval and commercialization of our product candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. See the section titled &#8220;Government Regulation&#8221; in above Item 1. Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our product candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with healthcare providers and third-party payors will be subject to applicable </span><span style="font-style:italic;font-weight:bold;">anti-kickback, fraud and abuse and other healthcare laws and regulations</span><span style="font-style:italic;font-weight:bold;">, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties and consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidate for which we obtain marketing approval. Restrictions and obligations under applicable federal and state healthcare laws and regulations are noted in &#8220;Government Regulation&#8221; in above Item 1. Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">53</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations which can harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the U.S. to sell our products abroad and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Our violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our </span><b style="font-weight:bold;">net operating losses (&#8220;</b><span style="font-style:italic;font-weight:bold;">NOLs&#8221;) to offset future taxable income may be subject to certain limitations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In general, under Section 382 of Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change in the ownership of our equity by certain stockholders over a rolling three year period, is subject to limitations on its ability to utilize carryforwards to offset future taxable income. Similar provisions of state tax law may also apply. Our existing NOL carryforwards were subject to limitation arising from an ownership change related to the Dong-A ST Financing and the underwritten public offering we closed on in November 2022. Future changes in our stock ownership, some of which are outside of our control, could result in further ownership changes under Section 382 of the Code. There is also a risk that due to regulatory changes, such as suspensions on the use of NOL carryforwards, or other unforeseen reasons, our existing and any future NOL carryforwards could expire or otherwise be unavailable to offset future income tax liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Tax matters, including the changes in corporate tax rates, disagreements with taxing authorities and imposition of new taxes could impact the results of our operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are subject to income and other taxes in the U.S. and our operations, plans and results are affected by tax and other initiatives. In 2017, comprehensive changes to the Code were signed into law, informally titled the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;). The Tax Act included significant changes that could materially impact the taxation of corporations, like us, including among other things, changes to the corporate income tax rate, revisions to the calculation of tax deductions for interest expense and business interest income, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the orphan drug tax credit and limitations on the deductibility of research and experimental expenditures). The Tax Act also included a limitation of the deduction for NOLs generated in tax years beginning after 2017 to 80% of current year taxable income and the general elimination of carrybacks of NOLs generated in taxable years ending after 2017. The Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;) signed into law in 2020, subsequently provided that NOLs generated in a taxable year beginning in 2018, 2019 or 2020, may now be carried back five years. The Cares Act also temporarily removed the 80% taxable income limitation, allowing NOLs to fully offset net taxable income for the relevant years. In July&#160;2025, Congress enacted the One Big Beautiful Bill Act (&#8220;OBBBA&#8221;). The OBBBA included, among other changes, amendments to various Code provisions that had been enacted or amended by the Tax Act. The OBBBA amendments included further changes to the limitation on tax deductions for interest expense, immediate deductions for certain new investments, and immediate expensing of research and experimental expenditures. The overall impact of these tax acts and any future tax reform is uncertain and our business and financial condition could be adversely affected. The impact of these tax acts and any future tax reform on holders of our common stock is likewise uncertain and could be adverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are also subject to regular reviews, examinations, and audits by the IRS and other taxing authorities with respect to our taxes. Although we believe our tax estimates are reasonable, if a taxing authority disagrees with the positions we have taken, we could face additional tax liability, including interest and penalties. There can be no assurance that payment of such additional amounts upon final adjudication of any disputes will not have a material impact on our results of operations and financial position. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">54</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We also need to comply with new, evolving or revised tax laws and regulations. The enactment of or increases in tariffs, or other changes in the application or interpretation of the Code, or on specific products that we may ultimately sell or with which our products compete, may have an adverse effect on our business or on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inadequate funding of the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which the combined organization&#8217;s operations may rely, including those that fund R&amp;D activities is subject to the political process, which is inherently fluid and unpredictable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the U.S., including foreign countries where the drugs are sold at lower prices than in the U.S., which could adversely affect our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may face competition for our product candidates, if approved, from cheaper alternatives sourced from foreign countries that have placed price controls on pharmaceutical products. For example, in October 2020, the FDA published a final rule that would allow for the importation of certain prescription drugs from Canada, where there are government price controls. In January 2024, the FDA approved Florida&#8217;s request to import certain lower-priced medications from Canada. While the full implications of the final rule are currently unknown, legislation or regulations allowing the reimportation of drugs could decrease the price we receive for any products we may develop and adversely affect our future revenues and potential profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks related to dependence on third parties</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have relied and will rely on </span><span style="font-style:italic;font-weight:bold;">CROs </span><span style="font-style:italic;font-weight:bold;">to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We have relied upon and plan to continue to rely upon CROs and clinical data management organizations to monitor and manage data for our ongoing preclinical and clinical programs. Although we control only certain aspects of their activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to conduct our preclinical studies in accordance with Good Laboratory Practice (&#8220;GLP&#8221;) requirements and the Laboratory Animal Welfare Act of 1966 requirements. We, our CROs and our clinical trial sites are required to comply with regulations and current GCP, and comparable foreign requirements to ensure that the health, safety and rights of patients are protected in clinical trials, and that data integrity is assured. Regulatory authorities ensure compliance with GCP requirements through periodic inspections of clinical trial sponsors and clinical trial sites. If we, any of our CROs or our clinical trial sites fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials, or a specific site may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical programs. If CROs do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">55</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to manufacture our product candidates and preclinical and clinical drug supplies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We have no experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently work exclusively with Dong-A ST as the sole manufacturer for the production of vanoglipel (DA-1241) and DA-1726. To meet our projected needs for clinical supplies to support our activities for vanoglipel (DA-1241) and DA-1726 through regulatory approval and commercial manufacturing, Dong-A ST will need to provide sufficient scale of production for these projected needs. If any issues arise in the manufacturing and we are unable to arrange for alternative third-party manufacturing sources, we are unable to find an alternative third party capable of reproducing the existing manufacturing method or we are unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete the development of our product candidates, or market or distribute them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates and preclinical and clinical drug supplies, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliance on the third party for regulatory compliance and quality assurance; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates or any products that we may eventually commercialize in accordance with our specifications); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of termination or nonrenewal of the agreement by the third party, based on our own business priorities, at a time that is costly or damaging to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay in, or failure to obtain, regulatory approval of any of our product candidates because of the failure by our third-party manufacturer to comply with cGMP or failure to scale up manufacturing processes; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current manufacturers and any future manufacturers may not be able to manufacture our product candidates at a cost or in quantities or in a timely manner necessary to make commercially successful products.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If third-party manufacturers do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may engage in future acquisitions, mergers, in-licenses and out-licenses of technology that could disrupt our business, cause dilution to the organization&#8217;s stockholders and harm our financial condition and operating results. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may, in the future, make acquisitions or licenses of, or investments in, companies, products or technologies that we believe are a strategic or commercial fit with our current product candidates and business or otherwise offer opportunities for us. In connection with these acquisitions, mergers or investments, the organization may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue stock that would dilute our stockholders&#8217; percentage of ownership; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expend cash; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur debt and assume liabilities; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We also may be unable to find suitable acquisition, merger or license candidates and we may not be able to complete acquisitions, mergers or licenses on favorable terms, if at all. If we do complete an acquisition, merger or license, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed negatively by customers, financial markets or investors. Further, future acquisitions, mergers or licenses could also pose numerous additional risks to our operations, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">problems integrating the purchased or licensed business, products or technologies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increases to our expenses; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to have discovered undisclosed liabilities of the acquired or licensed asset or company; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management&#8217;s attention from their day-to-day responsibilities; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">56</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">harm to our operating results or financial condition; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entrance into markets in which we have limited or no prior experience; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential loss of key employees, particularly those of the acquired entity.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may not be able to complete one or more acquisitions or mergers or effectively integrate the operations, products or personnel gained through any such acquisition without a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our products and any future product candidates that we may develop. Any strategic alliance or collaboration may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. Our likely collaborators include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our products or any future product candidate. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Collaborations involving our product candidates, or any future product candidate pose the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of any such product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">57</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may learn about our discoveries and use this knowledge to compete with us in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of collaborators&#8217; preclinical or clinical studies could harm or impair other development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be conflicts between different collaborators that could negatively affect those collaborations and potentially others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may not lead to the development or commercialization of our product candidate in the most efficient manner or at all. If our present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may be unable to obtain the necessary marketing approvals.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If future collaboration partners fail to develop or effectively commercialize our product candidates or any future product candidate for any of these reasons, such candidate may not be approved for sale and our sales of such product candidate, if approved, may be limited, which would have an adverse effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity, such as employee training, may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending such action or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks related to intellectual property</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient intellectual property rights, our competitive position could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We depend on our ability to protect our proprietary technology. We rely on trade secrets, patents, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary technology and products. Where we have the right to do so under our license agreements, we seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel technologies and products that are important to our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The patent positions of pharmaceutical and biotechnology companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">58</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The steps we have taken to police and protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the U.S. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages that we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">With respect to patent rights, we do not know whether any of our pending patent applications for any of our product candidates will result in the issuance of patents that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent is issued from such applications. Further, the examination process may require us or our licensors to narrow the claims, which may limit the scope of patent protection that may be obtained. Although our license agreement with Dong-A ST includes a number of issued patents that are exclusively licensed to us, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may, in some cases, not be possible. In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect or practice </span><span style="font-style:italic;font-weight:bold;">our</span><span style="font-style:italic;font-weight:bold;"> intellectual property rights throughout the world. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In jurisdictions where we have not obtained patent protection, competitors may use our intellectual property to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor products may compete with our product candidates, if approved, or any future product candidate in jurisdictions where we do not have issued or granted patents or where the issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we, or our licensors, encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we, or any of our licensors, are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition to the possibility of litigation relating to infringement claims asserted against us, we may become a party to other patent litigation and other proceedings, including <i style="font-style:italic;">inter partes</i> review proceedings, post-grant review proceedings, derivation proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future technologies or product candidates or products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">59</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Competitors may infringe or otherwise violate our intellectual property, including patents that may be issued to or be licensed by us. As a result, we may be required to file claims in an effort to stop third-party infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. This can be prohibitively expensive, particularly for a company of our size, and time-consuming, and even if we are successful, any award of monetary damages or other remedy we may receive may not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our intellectual property does not cover our technology. An adverse determination in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not being issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third parties to commercialize our technology or products or result in our inability to commercialize our technology and products without infringing third-party intellectual property rights. Further, third parties may be dissuaded from collaborating with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Interference or derivation proceedings brought by the USPTO or its foreign counterparts may be necessary to determine the priority of inventions with respect to our patent applications, and we may also become involved in other proceedings, such as re-examination proceedings, before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability of any future patents that we may obtain. In addition, any such litigation, submission or proceeding may be resolved adversely to us and, even if successful, may result in substantial costs and distraction to our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, intellectual property law relating to the fields in which we operate is still evolving and, consequently, patent and other intellectual property positions in our industry are subject to change and are often uncertain. We may not prevail in any of these suits or other efforts to protect our technology, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of this type of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price for the combined organization&#8217;s common stock could be significantly harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates, and to use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference and various post grant proceedings before the USPTO or non-U.S. opposition proceedings. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As a result of any such infringement claims, or to avoid potential claims, we may choose or be compelled to seek intellectual property licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us likely would be nonexclusive, which would mean that our competitors also could obtain licenses to the same intellectual property. Ultimately, we could be prevented from commercializing a product candidate or technology or be forced to cease some aspects of our business operations if, as a result of actual or threatened infringement claims, we are unable to enter into licenses of the relevant intellectual property on acceptable terms. Further, if we attempt to modify a product candidate or technology or to develop alternative methods or products in response to infringement claims or to avoid potential claims, we could incur substantial costs, encounter delays in product introductions or interruptions in sales. Ultimately, such efforts could be unsuccessful. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">60</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">these results to be negative, it could have a substantial adverse effect on the price of our common stock and negatively impact our ability to raise additional funds. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our employees and consultants have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we are not aware of any claims currently pending against us, we may be subject to claims that these employees, or we have, inadvertently or otherwise used or disclosed trade secrets or other proprietary information or intellectual property of the former employers of our employees. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which would adversely affect our commercial development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition to seeking patents for some of our technologies and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality, non-competition, non-solicitation, and invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions developed in the course of their work for us. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to seek patent protection on technology relating to our product candidates or obtain adequate remedies for such breaches. As a result, we may be forced to bring claims against third parties, or defend claims that they bring against us, to determine ownership of what we regard as our intellectual property. Monitoring unauthorized disclosures is difficult and we do not know whether the procedures that we have followed to prevent such disclosure are or will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. may be less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Furthermore, if any of the technology or information that we protect as trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to obtain and maintain our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">61</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make product candidates that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our future licensors or collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or our future licensors or collaborators might not have been the first to file patent applications covering certain of our inventions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct R&amp;D activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks related to operations, employee matters and managing growth</b><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have a small number of employees and consultants, and our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Because of the specialized scientific nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. We are highly dependent upon current members of our management and scientific team. We intend to increase our technical and management staff as needs arise and supporting resources become available, but the loss of one or more of our senior executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the pharmaceutical field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to increase the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We are a clinical-stage biopharmaceutical company with a small number of employees, and our management systems currently in place are not likely to be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees and to implement and improve our operational, financial and management systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to expand and enhance our operational, financial and management systems in conjunction with our potential future growth, it could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, we had eight full-time (and total) employees. As our development and commercialization plans and strategies develop, or as a result of any future acquisitions, we may need additional managerial, operational, development, sales, marketing, financial and other resources. Our management, personnel and systems currently in place may not be adequate to support our future growth. Future growth would impose significant added responsibilities on our employees, including:</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">62</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our clinical trials effectively; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, maintaining, motivating and integrating additional employees; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, contractors and other third parties; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our managerial, development, operational and finance systems.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As our operations expand, we will need to manage additional relationships with various CROs, strategic partners, and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative, R&amp;D, and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing MetaVia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We intend to market our product candidates outside of the U.S., and if we do, we will be subject to the risks of doing business outside of the U.S. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Because we intend to market our product candidates, if approved, outside of the U.S., our business is subject to risks associated with doing business outside of the U.S. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to develop an international sales, marketing and distribution system for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition, including as a result of military conflicts or war (including the ongoing conflicts in Ukraine and in the Middle East), inflation, increases in interest rates, health epidemics, the imposition of tariffs by the U.S. or other countries or trade wars;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in foreign laws and regulatory requirements; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty of effective enforcement of contractual provisions in local jurisdictions; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inadequate intellectual property protection in foreign countries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inadequate data protection against unfair commercial use; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade-protection measures, import or export licensing requirements such as Export Administration Regulations promulgated by the U.S. Department of Commerce and fines, penalties or suspension or revocation of export privileges; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of applicable foreign tax structures and potentially adverse tax consequences; and </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant adverse changes in foreign currency exchange rates.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render certain of our products obsolete or uncompetitive. This is particularly true in the development of therapeutics for indications where new products and combinations of products are rapidly being developed that change the treatment paradigm for patients. There is no assurance that our product candidates will be the most effective, have the best safety profile, be the first to market, or be the most economical to make or use. The introduction of competitive therapies as alternatives to our product candidates could dramatically reduce the value of those development projects or chances of successfully commercializing those product candidates, which could have a material adverse effect on our long-term financial success. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We will compete with companies in the U.S. and internationally, including major pharmaceutical and chemical companies, specialized CROs, R&amp;D firms, universities and other research institutions. Many of our competitors have greater financial resources and selling and marketing capabilities, greater experience in clinical testing and human clinical trials of pharmaceutical products and greater experience in obtaining FDA and other regulatory approvals than we do. In addition, some of our competitors may have lower development and manufacturing costs.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">63</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Risks related to our common stock </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The trading price of our common stock has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in preclinical studies, clinical trials, regulatory decisions or the development status of our product candidates or any product candidates we may pursue in the future; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise sufficient additional funds on satisfactory terms, or at all, necessary for the continued development of our product candidates whether through potential collaborative, partnering or other strategic arrangements or otherwise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any future collaborative, licensing or other strategic arrangements that we may establish; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to comply with the minimum listing requirements of Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of achievement of, or failure to achieve, our, or any potential collaborator&#8217;s clinical, regulatory and other milestones, such as the commencement of clinical development, the completion of a clinical trial or the receipt of regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decisions to initiate a clinical trial, not initiate a clinical trial, or terminate an existing clinical trial; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval for our product candidates or regulatory actions requiring or leading to a delay or stoppage of any clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercial success of any product approved by the FDA or its foreign counterparts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws, rules or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse developments concerning our manufacturers, suppliers, collaborators and other third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of health epidemics or contagious diseases, and potential effects on our business, clinical trial sites, supply chain and manufacturing facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to commercialize our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if our patents covering our product candidates expire or are invalidated or are found to be unenforceable, or if some or all of our patent applications do not result in issued patents or result in patents with narrow, overbroad, or unenforceable claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated safety concerns related to the use of any product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our announcements or our competitor&#8217;s announcements regarding new products, enhancements, significant contracts, acquisitions or strategic partnerships and investments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our target markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our, or companies perceived to be similar to us, failure to meet external expectations, or management guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about us or our industry, recommendations, earning results or estimates or withdrawal of research coverage by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">64</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general economic, industry, political and market conditions due to military conflicts or war (including the ongoing conflicts in Ukraine and in the Middle East), inflation, increases in interest rates, health epidemics, the imposition of tariffs by the U.S. or other countries or trade wars; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure or dividend policy, future issuances of securities, sales of common stock by officers, directors and significant stockholders or our incurrence of debt;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting practices and ineffectiveness of our internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes, litigation or developments relating to proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of milestones and royalty payments; and</span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, the stock market in general, Nasdaq, and the stock of biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our two largest stockholders may use their significant interest to take actions not supported by our other stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#231f20;font-family:'Times NR MT Pro';">As of March 20, 2026, our two largest stockholders, Dong-A ST and Dong-A Socio Holdings Co., Ltd.</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">(&#8220;Dong-A Holdings&#8221;), an affiliate company of Dong-A ST, benefi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">cially owned 18% and 17%, respectively, of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.9pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';">our voting rights. As a result, Dong-A ST</span> <span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">and Dong-A Holdings are able to exert a signi</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.15pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">icant in</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.05pt;">f</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.05pt;">luence on the outcome of</span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:0.7pt;"> </span><span style="color:#231f20;font-family:'Times NR MT Pro';letter-spacing:-0.1pt;">corporate actions requiring</span> <span style="color:#231f20;font-family:'Times NR MT Pro';">stockholder approval, including mergers, share capital increases and other extraordinary items.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, pursuant to the Investor Rights Agreement between Dong-A ST and us, Dong-A ST has the right to appoint a number of our directors commensurate with its percentage holding of our common stock, which may result in Dong-A ST controlling both the determinations of the board of directors (&#8220;Board&#8221;) and the vote of all matters submitted to a vote of our stockholders, which enables them to control all corporate decisions. This concentration of ownership may delay, deter or prevent acts that would be favored by our other stockholders. The interests of Dong-A ST may not always coincide with our interests or the interests of our other stockholders. For as long as Dong-A ST owns shares of our common stock and the Investor Rights Agreement is effective, Dong-A ST will have significant influence on our management, business plans and policies, including the appointment and removal of members of our Board, decisions on whether to raise future capital and amending our certificate of incorporation and bylaws, which govern the rights attached to our common stock. In particular, with a significant ownership percentage of our stock, Dong-A ST will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of ownership could deprive you of an opportunity to receive a premium for your shares of common stock as part of a sale of MetaVia and ultimately might affect the market price of our common stock. In addition, this concentration of ownership may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Dong-A ST, Dong-A Holdings and their affiliates engage in a broad spectrum of activities, including investments in the healthcare industry generally. In the ordinary course of its business activities, Dong-A ST, Dong-A Holdings and their affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or are suppliers or customers of ours. Nothing in our certificate of incorporation provides that Dong-A ST or any of their affiliates or any director who is not employed by us (including any non-employee director who serves as one of our officers in both her or his director and officer capacities) or its affiliates have any duty to refrain from engaging, directly or indirectly, in the same business activities or similar business activities or lines of business in which we operate. Dong-A ST and Dong-A Holdings also may pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us. In addition, Dong-A ST or Dong-A Holdings may have an interest in pursuing acquisitions, divestitures and other transactions that, in their judgment, could enhance their investments, even though such transactions might involve risks to our stockholders.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">65</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law may make an acquisition of MetaVia, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Provisions in our certificate of incorporation and the bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by stockholders to replace or remove the current management by making it more difficult for stockholders to replace members of our Board. Among other things, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified Board such that not all members of the Board are elected at one time; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of our directors to be changed only by resolution of our Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which our stockholders can remove directors from the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit our stockholders from calling special meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our Board to issue preferred stock without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock, and which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board; and </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended (the &#8220;DGCL&#8221;), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with it for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nasdaq has proposed enhanced listing standards, which could adversely affect our ability to maintain our Nasdaq listing and access to capital markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our common stock is listed for trading on Nasdaq. We must satisfy Nasdaq&#8217;s continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for thirty consecutive business days. On January 13, 2026, Nasdaq filed a rule proposal with the SEC to adopt a new continued listing requirement that would require all companies listed on Nasdaq to maintain a&#160;minimum market value of listed securities&#160;of $5 million. Under the proposed rule, if a company&#8217;s market value of listed securities falls below this threshold for 30 consecutive trading days, Nasdaq may immediately suspend trading and initiate delisting proceedings without affording the company a compliance cure period. This proposed rule, if adopted, would be in addition to Nasdaq&#8217;s existing continued listing requirements. If the proposed rule is adopted and the market value of our common stock were to fall below the proposed $5 million threshold or we otherwise fail to satisfy Nasdaq&#8217;s continued listing standards, we could face delisting proceedings on an accelerated basis. The delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to such companies could make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We are a &#8220;smaller reporting company,&#8221; as defined in the Exchange Act. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley Act&#8221;), only being </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">66</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">required to provide two years of audited financial statements in our annual reports and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">General risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations may suffer in the event of system failures or other unplanned events. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we are not aware of any such material system failure, accident or security breach to-date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, and the further development and commercialization of our product candidates could be delayed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Furthermore, any unplanned event, such as flood, fire, explosion, tornadoes, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize the facilities, may have an adverse effect on our ability to operate the business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, may compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the ordinary course of our business, our CROs and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information, including R&amp;D information and business and financial information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks, and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare company financial information, manage various G&amp;A aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, and our research, development and commercialization efforts could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for our common stock may not be maintained.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our common stock is currently traded on Nasdaq, but we can provide no assurance that we will be able to maintain an active trading market for our shares on Nasdaq or any other exchange in the future. If there is no active market for our common stock, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">67</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our business, the price of our stock could decline. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If one or more analysts cover our business and downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur increased costs as a result of operating as a public company and our management is required to devote substantial time to compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the stock exchange upon which our common stock is listed, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, only being required to provide two years of audited financial statements in our annual reports and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. If we no longer qualify as a &#8220;smaller reporting company,&#8221; we will need to comply with additional reporting requirements that are applicable to other public companies that may be costly and require management to devote substantial time to compliance with such requirements, such as providing an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">To achieve compliance with Section 404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we must dedicate internal resources, hire additional finance and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">During the course of our review and testing, we may identify deficiencies or material weaknesses and be unable to remediate them before we must provide the required reports. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, as a public company we are required to timely file accurate quarterly and annual reports with the SEC under the Exchange Act. In order to report the results of our operations and financial position on an accurate and timely basis, we will depend on CROs to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from Nasdaq or other adverse consequences that would materially harm our business. </p><a id="_cp_text_2_1"></a><a id="_cp_text_2_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate declaring or paying, in the foreseeable future, any cash dividends and, consequently, the ability of our stockholders to achieve a return on their investment will depend on appreciation in the price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We have never declared or paid any cash dividend on our capital stock and do not currently intend to do so in the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchased them.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">68</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will generally be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation or the bylaws or any other action asserting a claim governed by the internal affairs doctrine. This provision does not apply to claims arising under the Securities Act and the Exchange Act or any claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of the bylaws described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find this provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-indent:-72pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_266cef99_22af_4dec_b115_ac552457d491"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1B.</b></span><b style="font-weight:bold;">Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item1C"></a><a id="_201f10a6_5f43_4b1c_91f0_826bc3000c0f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1C.</b></span><b style="font-weight:bold;">Cybersecurity</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_hjPP7Rv1zkWBsTxptJb0gA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risk management</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_cjncE07pGUGDv_HrlyALjg" escape="true">We recognize the importance of assessing, identifying, and managing risks associated with cybersecurity threats. These risks include, among other things, operational risks; intellectual property theft; fraud; extortion; harm to employees, violation of privacy or security laws and other litigation and legal risk; and reputational risks. We are <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_67r1kivvkEa5OM4mg5Vf_w">committed</ix:nonNumeric> to maintaining robust governance and oversight of these risks and to implementing mechanisms, controls, technologies, and processes designed to help us assess, identify, and manage these risks.</ix:nonNumeric> While <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_n_4TA8NdgUOHlw2CcRXwMQ">we have not, as of the date of this Annual Report, experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations</ix:nonNumeric>, there can be no guarantee that we will not experience such an incident in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We aim to incorporate industry best practices throughout our cybersecurity program. Our cybersecurity strategy focuses on implementing effective and efficient controls, technologies, and other processes to assess, identify, and manage material cybersecurity risks. Our cybersecurity program is designed to be aligned with applicable industry standards. We work with a <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_Nf00S4jlcEub_ZplXeIvJQ">third-party</ix:nonNumeric> provider to monitor threats and potential cybersecurity breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We have processes in place to assess, identify, manage, and address material cybersecurity threats and incidents. These include, among other things: ongoing security awareness training for employees; mechanisms to detect and monitor unusual network activity; and containment and incident response tools. We monitor issues that are internally discovered or reported by our third-party monitoring service that may affect our information services and have processes to assess those issues for potential cybersecurity impact or risk. We impose security requirements upon our <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_56Ofq76ZCUqZwX6TP-4itw">suppliers and CROs</ix:nonNumeric>, including maintaining an effective security management program; abiding by information handling and asset management requirements; and notifying us in the event of any known or suspected cyber incident.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_-xFRZbhKsk6F5_ikMGeuCg" continuedAt="Tb_-xFRZbhKsk6F5_ikMGeuCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Governance</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_qgyXAbr950mC1hOCTl7UIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Our Board has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to Company priorities, resource allocations, and oversight structures. The Board is assisted by the audit committee, which reviews our cybersecurity program with management and reports to the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_At2LzhHgw0muDG3xjgmCyw" escape="true">The audit committee</ix:nonNumeric> is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The audit committee is composed of Board members with diverse expertise including risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_RHwe12homk2v3lruVoxG8Q" continuedAt="Tb_RHwe12homk2v3lruVoxG8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_437FtPUV_kmu3Q5Km_4PAw" escape="true">Our <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_m-_6x3psmkyasVVJ9PB_FA" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_lMKqAi0Ho068139nJ5RsdQ">Chief Executive Officer, Chief Financial Officer and corporate controller</ix:nonNumeric></ix:nonNumeric> have operational experience in assessing and managing cybersecurity risk.</ix:nonNumeric> Our Chief Executive Officer plays a pivotal role in informing the audit committee on </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">69</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-xFRZbhKsk6F5_ikMGeuCg_cont1"><ix:continuation id="Tb_RHwe12homk2v3lruVoxG8Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">cybersecurity risks. They provide comprehensive briefings to the audit committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current cybersecurity landscape and emerging threats;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Status of ongoing cybersecurity initiatives and strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Incident reports and learnings from any cybersecurity events; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with regulatory requirements and industry standards.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In addition to our scheduled meetings, the audit committee and Chief Executive Officer maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#8217;s oversight is proactive and responsive. The audit committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into the broader strategic objectives of MetaVia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_dqU5NYcWRkumfJ6kOa7gtA" escape="true">Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary.</ix:nonNumeric> Furthermore, <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_oitQHDQz802lEB3Qkfsk9w">significant cybersecurity matters, and strategic risk management decisions are escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</ix:nonNumeric></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ee528800_0b22_49e2_a706_e1089afd56ae"></a><a id="ITEM2PROPERTIES_644950"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-weight:bold;">Item 2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-weight:bold;">Properties</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We currently lease 2,441 square feet of office space in Cambridge, Massachusetts, as our corporate headquarters. The initial lease term is for&#160;three years&#160;with an option, which was exercised in November 2025, to renew for an additional&#160;two-year&#160;term. The lease commenced in September 2023 and expires in August 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We believe that our leased properties are adequate for our purposes and to pursue our strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4334f92f_b29e_4dfb_97aa_d8963fa51a4b"></a><a id="ITEM3LEGALPROCEEDINGS_754217"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-weight:bold;">Item 3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-weight:bold;">Legal Proceedings</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">From time to time, we may be involved in various claims and legal proceedings arising out of our ordinary course of business. We are not currently a party to any claims or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business and consolidated financial statements. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45pt;text-indent:-45pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_aa8f773c_b5a8_4a7e_8ea9_6029c5c09f54"></a><a id="ITEM4MINESAFETYDISCLOSURES_848551"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-weight:bold;">Item 4</b><b style="font-weight:bold;">.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;"><b style="font-weight:bold;">Mine Safety Disclosures</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_6bbf3a9a_6f36_4e18_bdcc_cb012afa2383"></a><a id="PARTII_387386"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Part II</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_8d265fe1_c682_4963_8f8f_f18b0fe358b6"></a><a id="Item5"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;text-align:justify;"><b style="font-weight:bold;">Item 5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;text-align:justify;"><b style="font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Market information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 8pt 0pt;">Our common stock is listed on Nasdaq under the symbol &#8220;MTVA.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">On March 20, 2026, we had 5,090,936 shares of common stock outstanding and 26 holders of record of our common stock. The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Dividend policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">We have never declared or paid any dividends on our common stock, and we do not currently intend to pay any dividends on our common stock for the foreseeable future. Any future determination to pay dividends on our common stock will be, subject to applicable law, at the discretion of our Board and will depend upon, among other factors, our results of operations, financial condition, capital requirements, and contractual restrictions in loan or other agreements. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">70</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Recent sales of unregistered securities; use of proceeds from registered offerings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">During the year ended December 31, 2025, we did not issue or sell any unregistered securities not previously disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Purchases of equity securities by the issuer and affiliated purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-indent:-45.35pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_5403a07f_44b1_4f8c_976f_ef371b30f411"></a><a id="ITEM6SELECTEDFINANCIALDATA_394630"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Item 6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">[Reserved]</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-indent:-45.35pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_357510d5_f849_40ec_8341_4f10e1db2336"></a><a id="item7"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;text-align:justify;"><b style="font-weight:bold;">Item 7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;text-align:justify;"><b style="font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the information set forth under our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Our actual results may differ materially from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties described under &#8220;Risk Factors&#8221; elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Certain amounts in the following discussion and analysis may not add due to rounding, and all percentages have been calculated using unrounded amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-align:justify;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">We are a clinical-stage biotechnology company focused primarily on </span>developing novel pharmaceuticals to treat <span style="letter-spacing:0.2pt;">cardiometabolic diseases. </span><span style="letter-spacing:0.2pt;">We have two programs focused primarily on the treatment of MASH and obesity. </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Vanoglipel (DA-1241) is a novel GPR119 agonist with development optionality as a standalone or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, GLP-1, GIP and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel (DA-1241) has demonstrated beneficial effects on glucose, lipid profile and liver inflammation, as demonstrated during in-vivo preclinical studies. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DA-1726 is a novel oxyntomodulin analog functioning as a GLP1R and GCGR dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously. With the activation of the dual agonist, weight loss may be achieved by GLP1R reducing appetite while GCGR increases energy expenditure.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;letter-spacing:0.2pt;">While we focus our financial resources and management&#8217;s attention on the development of vanoglipel (DA-1241) and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases, which we are not planning to advance development on and have, or continue to consider for, out-licensing and divestiture opportunities. In 2024, we entered into an exclusive out-license agreement with MThera to provide MThera with the rights to one of our legacy therapeutic program, NB-01, for the treatment of painful diabetic neuropathy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">Our operations consisted principally of performing R&amp;D activities, which include preclinical development and clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, such as failing to secure additional funding before sustainable revenues and profit from operations are achieved. </span>For more information on our business and product candidates, see Part I, Item 1. Business of this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Recent developments</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">November 2025: Presented new Phase 1 and pre-clinical data on DA-1726 in two poster presentations at ObesityWeek</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2025. The Phase 1 data demonstrated favorable safety and tolerability, a newly characterized 32 mg PK profile supporting once-weekly dosing, and meaningful reductions in body weight and waist circumference following four weeks of treatment. Additionally, in a DIO mouse model, DA-1726 achieved comparable weight loss to pemvidutide with superior lipid-lowering efficacy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">November 2025: Presented positive new data from our Phase 2a clinical trial evaluating vanoglipel (DA-1241), and the data highlights vanoglipel&#8217;s differentiated dual activity across both hepatic and metabolic pathways, demonstrating clinically meaningful improvements in glucose control, liver health, and plasma lipidomic profiles following 16 weeks of treatment.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">71</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">January </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">202</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Announced positive statistically significant results from the 8-week (extended from four weeks) non-titrated 48 mg, MAD cohort of our Phase 1 clinical trial of DA-1726, and the results show robust early weight loss, statistically significant reductions in waist circumference, strong improvements in glucose control, and meaningful reductions in liver stiffness, alongside a favorable safety and tolerability profile.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">January 2026: Closed an underwritten public offering of shares of common stock, pre-funded warrants, Series C Common Warrants and Series D Common Warrants for gross proceeds of approximately $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">February 2026: Announced positive AI-modeling results from the ongoing collaboration with Syntekabio, Inc., an AI-driven drug discovery company, leveraging their proprietary DeepMatcher&#174; platform. The results confirmed vanoglipel&#8217;s strong inflammatory and cardiometabolic target engagement, supporting development in MASH and, potentially, type 2 diabetes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">February 2026: Strengthened global intellectual property position for DA-1726 with 39 granted and pending patents in the U.S. and internationally, providing protection at least through 2041, unless extended further. Exclusively licensed from Dong-A ST Co., Ltd., the portfolio broadly covers DA-1726&#8217;s novel peptide structure, its long-acting dual-incretin design, and therapeutic use across obesity, metabolic disease, and related cardiometabolic conditions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">March 2026: Announced a comprehensive global intellectual property portfolio supporting vanoglipel with 48 granted and pending patents across three patent families in the U.S., Europe, Japan, China and other countries, providing protection into 2035, unless extended further. Exclusively licensed from Dong-A ST Co., Ltd., the patent portfolio provides broad protection for vanoglipel itself, how it is manufactured, and its potential use across a range of serious metabolic and liver conditions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">March 2026: Received IRB approval from Clinical Pharmacology of Miami for the Phase 1 Part 3 16-week titration study of DA-1726, enabling higher-dose evaluation in obese, otherwise healthy adults.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Common stock reverse stock split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In December 2025, we completed a one-for-eleven reverse stock split of our common stock (the &#8220;Reverse Stock Split&#8221;). As a result, every eleven shares of our issued and outstanding common stock were combined, converted and changed into one share of our common stock. Any fraction of a share of our common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of our common stock as reported on Nasdaq on the last trading day before the Reverse Stock Split. The Reverse Stock Split was approved by our stockholders at the annual meeting of stockholders in June 2025. At the annual meeting, the stockholders approved a proposal to amend our certificate of incorporation to affect a reverse split of our outstanding common stock at a ratio in the range of one-for-five to one-for-thirty to be determined at the discretion of our Board. In November 2025, our Board approved the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Reverse Stock Split did not impact the number of authorized shares of common stock, which remains at 100,000,000 shares. For the Reverse Stock Split, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of our common stock, the number of shares issuable upon vesting of restricted stock units (&#8220;RSUs&#8221;) and the number of shares reserved for issuance pursuant to our equity incentive compensation plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In this Annual Report, including the accompanying consolidated financial statements and the notes to the consolidated financial statements, the number of shares of common stock and per share data have been adjusted to give effect to the Reverse Stock Split for all periods presented. Additionally, since the common stock par value was unchanged, the amounts for common stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">K</b><b style="font-weight:bold;">ey operating information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">R&amp;D expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">R&amp;D expenses consist primarily of costs incurred in connection with the development of our product candidates. These expenses include:</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">72</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 36pt 8pt 0pt;"><i style="font-style:italic;">Direct costs</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with the clinical development of our product candidates, including under agreements with third parties, such as CROs and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing and storing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants and Clinical Manufacturing Organizations (&#8220;CMOs&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to compliance with regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments made under third-party licensing agreements including the Shared Services Agreement with Dong-A ST (related party).</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Indirect costs</i></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits and stock-based compensation, for employees engaged in R&amp;D functions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consulting and other expenses not directly tied to a product candidate.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">We recognize external development costs based on an evaluation of the progress toward completion of specific tasks using information provided to us by our service providers. This process involves reviewing contracts and purchase orders, communicating with our clinical research staff to identify services that have been performed on our behalf, and estimating the level of service provided and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Nonrefundable advance payments for goods or services to be received in the future for use in R&amp;D activities are recorded as prepaid expenses. Such amounts are recognized as an expense when the goods have been delivered or the services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our direct R&amp;D expenses consist primarily of external costs, such as fees paid to CROs, CMOs, research laboratories and outside consultants in connection with our clinical development, quality assurance and quality control processes, manufacturing, and clinical development activities. Our direct R&amp;D expenses also include fees incurred under third-party license agreements, including the <span style="color:#212529;background:#ffffff;">Shared Services Agreement with Dong-A ST (related party)</span>. We utilize our employee and infrastructure resources across multiple R&amp;D projects. We do not allocate employee costs and costs associated with our facilities, including depreciation or other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We utilize internal resources to manage CRO and CMO activities. These employees work across multiple programs. Our direct R&amp;D expenses consist of (i) expenses attributable to our product candidates and (ii) certain other R&amp;D expenses, including clinical, non-clinical and preclinical services or other R&amp;D expenses that are not attributable to a single product candidate. Our indirect R&amp;D expenses consist of (i) employment-related expenses for compensation and benefits, which are internal costs and (ii) consulting expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">Clinical development activities are central to our business model. We do not believe that our historical costs are indicative of the future costs associated with these programs, nor do they represent the costs of future programs we may initiate. Product candidates in later stages of clinical development generally have higher development costs than those in </span>preclinical development or in <span style="background:#ffffff;">earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We have some control over the timing of these expenses, but costs may be difficult to control once clinical trials have commenced.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The successful development and commercialization of our product candidates are highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates. Additionally, because of the risks inherent in novel treatment discovery and development, we cannot reasonably estimate or know:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the timing and progress of preclinical and clinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the number and scope of preclinical and clinical programs that we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">our ability to maintain our current development programs and to establish new ones;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">establishing an appropriate safety profile with IND-enabling studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">successful patient enrollment in, and the initiation and completion of, clinical trials;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">73</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the receipt of regulatory approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">our ability to establish new licensing or collaboration arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">maintaining a continued acceptable safety profile of the product candidates following commercialization; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">the effect of competing technological and market developments.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">G&amp;A expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">G&amp;A expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. G&amp;A expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We anticipate that our G&amp;A expenses will increase in the future as a result of accounting, audit, legal, regulatory, compliance, and director and officer insurance costs as we pursue the development of our product pipeline, as well as investor and public relations expenses associated with being a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">We have had significant pre-tax losses since our inception, and we have not yet generated revenues and face significant challenges to becoming profitable. Accordingly, we recorded a valuation allowance on the deferred tax assets attributable to the NOL we have incurred in each year or for our earned R&amp;D credits. We will continue to monitor all positive and negative evidence until we believe it is more likely than not that the valuation allowance is no longer necessary, resulting in an income tax benefit in the period such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">We have U.S. federal NOL carryforwards, and these carryforwards will not expire. We also have state NOL carryforwards, and these carryforwards will begin to expire in 2042, if not utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Net loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">We have incurred significant operating losses since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. To date, we have not generated any revenue from product sales, collaborations with other companies, government grants or any other source, and do not expect to generate any revenue in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">Accumulated deficit </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We have an accumulated deficit, and we expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue clinical development for our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate preclinical studies and clinical trials with respect to our current product candidates and indications and any future product candidates or indications that we may pursue;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">74</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and/or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure and/or enter into partnership arrangements to commercialize any products for which we may obtain regulatory approval; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add administrative, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, and to support being a public reporting company.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-weight:bold;">2025 compared to 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">The following table summarizes our results of operations for 2025 and 2024 (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,802</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,553</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,906</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,256</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,708</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,809</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,708)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28,809)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">     Gain from change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 225</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 297</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">     Interest income, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 510</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 920</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 735</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,217</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,973)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,592)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,973)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (27,592)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss per share of common stock, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7.35)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39.13)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average shares of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,766,026</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 705,193</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Operating expenses and loss from operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">Our total operating expenses and loss from operations for 2025 were $13.7 million, a decrease of $15.1 million, or 52.4%, compared to 2024. This decrease was attributable to lower R&amp;D and G&amp;A expenses for 2025. <span style="background:#ffffff;">Our R&amp;D expenses were $6.8 million for 2025, a decrease of $14.8 million, or 68.4%, compared to 2024.&#160;</span><span style="color:#212529;background:#ffffff;">Our&#160;</span><span style="background:#ffffff;">G&amp;A</span><span style="color:#212529;background:#ffffff;">&#160;expenses were $6.9 million for 2025, a decrease of $0.4 million, or 4.8%, compared to 2024. </span><span style="background:#ffffff;">The following table summarizes our R&amp;D expenses for 2025 and 2024 (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Change</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Vanoglipel (DA-1241) (credits) costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (845)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,959</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,804)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">DA-1726 costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,468</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,397</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,929)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Other R&amp;D costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 107</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 303</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (196)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Indirect costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,653</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,606</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 419</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 288</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 131</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,802</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,553</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,751)</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">75</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The $14.8 million decrease in R&amp;D expenses&#160;reflects decreased R&amp;D activities related to the Phase 2a clinical trial for vanoglipel (DA-1241) and decreased activities related to the Phase 1 clinical trial for DA-1726 as compared to 2024.&#160;Specifically, the decrease in R&amp;D expenses was primarily attributable to (i) $10.8 million in lower direct R&amp;D expenses related to vanoglipel (DA-1241) product development, (ii) $3.9 million in lower direct R&amp;D expenses related to DA-1726 product development, and (iii) $0.2 million in lower direct other R&amp;D costs. These decreases were partially offset by $0.1 million in higher indirect consulting expenses and a slight increase in indirect employee compensation and benefits. The credit amount for direct vanoglipel (DA-1241) costs in 2025 includes a credit of $1.2 million in connection with the close-out of the clinical trial with the CRO. Included in direct R&amp;D costs were expenses totaling $3.4 million and $4.9 million for 2025 and 2024, respectively, related to investigational drug manufacturing, non-clinical and preclinical costs incurred under the Shared Services Agreement with Dong-A ST (related party).</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our G&amp;A expenses were $6.9 million for 2025, a decrease of $0.4 million, or 4.8%, compared to 2024. This decrease in G&amp;A expenses was primarily attributable to $0.7 million in lower consulting expenditures, $0.1 million in lower insurance, and $0.2 million in lower other G&amp;A expenses. These decreases were partially offset by $0.5 million in higher legal and professional fees and $0.1 million in higher employee compensation and benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Total other income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">Our total other income for 2025 was $0.7 million, a decrease of $0.5 million, or 39.6%, compared to 2024. This decrease was attributable to $0.4 million <span style="background:#ffffff;">in lower interest income, net, due to lower balances of cash and cash equivalents and lower interest rates, and </span>$0.1 million in lower gain from the change in fair value of warrant liabilities due to the impact of our common stock&#8217;s volatile stock price during the last few years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Provision for income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">Our effective tax rate for 2025 and 2024 was zero percent as we have recorded a full valuation allowance for the income tax benefits attributable to our pre-tax losses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Net loss</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">For 2025, <span style="background:#ffffff;">we had a net </span>loss of $13.0 million, or <span style="background:#ffffff;">$7.35 per share of basic and diluted common stock, compared to a net loss of $27.6 million, or $39.13 per share of basic and diluted common stock for 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">As reflected in the consolidated financial statements, we had&#160;$10.3&#160;million in cash and cash equivalents as of December 31, 2025. We have experienced net losses and negative cash flows from operating activities since our inception and had an accumulated deficit of&#160;$148.8&#160;million as of December 31, 2025. We have incurred a net loss of&#160;$13.0&#160;million and net cash used in operating activities of $15.7&#160;million for 2025. Due in large part to ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of our consolidated financial statements in Part II, Item 8. Financial Statements and Supplementary Data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We believe that our existing cash and cash equivalents, together with the proceeds from the underwritten public offering in January 2026, will be sufficient to fund our operations into the fourth quarter of 2026. <span style="color:#212529;background:#ffffff;">We plan to continue to fund our operations through equity offerings, debt financing, the exercise of existing warrants, or other sources, potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all, or that the warrants issued in previously consummated offerings will be exercised. To the extent that we can raise additional funds by issuing equity securities or in the event our existing warrants are exercised, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, we may slow down or stop our ongoing and planned clinical trials until such time as additional capital is raised and this may have a material adverse effect on the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The determination as to whether we can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;</span>Our consolidated financial statements&#160;<span style="background:#ffffff;">have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of our liabilities in the normal course of business.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">76</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Liquidity and capital resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Our primary use of cash is to fund our R&amp;D activities. We have funded our operations primarily through public offerings of our common stock and private placements of equity and convertible securities. As of December 31, 2025, we had cash totaling $10.3 million. </span>We maintain cash at financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In May 2025, we closed on a private placement offering with Dong-A ST, a related party, and Dong-A Holdings, an affiliate company of Dong-A ST, and received net proceeds of $9.1&#160;million, net of placement agent cash fees of $0.4&#160;million and related offering expenses of $0.5&#160;million. The private placement offering was comprised of (i)&#160;861,758 shares of our common stock for a purchase price of $7.81 per share and (ii)&#160;418,651 pre-funded warrants to purchase up to an equivalent number of shares of our common stock for a purchase price of $7.799 per pre-funded warrant. Each pre-funded warrant had an exercise price of $0.011&#160;per share and were fully exercised as of June 30, 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">At the market offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">In November 2025, we entered into an At The Market Offering Agreement (the &#8220;ATM Sales Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as sales agent and/or principal (&#8220;Ladenburg&#8221;), pursuant to which we may offer and sell, from time to time through or to Ladenburg, shares of our common stock having an aggregate offering price of up to $2.3 million (the &#8220;ATM Program&#8221;). The offer and sale of the shares of common stock pursuant to the ATM Program is made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-278646) filed with the SEC on April 12, 2024, and declared effective by the SEC on April 23, 2024, as supplemented by a prospectus supplement to be filed with the SEC on November 6, 2025 pursuant to Rule 424(b) under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the ATM Sales Agreement, Ladenburg may sell the shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act. We are not obligated to make any sales of the shares under the ATM Sales Agreement. The offering of shares pursuant to the ATM Sales Agreement will terminate upon the termination of the ATM Sales Agreement by Ladenburg or us, as permitted therein. We are obligated to pay Ladenburg an aggregate sales agent commission of 3.0% of the gross sales price of the shares sold pursuant to the ATM Sales Agreement. We will also reimburse Ladenburg for certain specified expenses in connection with entering into the ATM Sales Agreement, which contains customary representations and warranties and conditions to the placements of the shares pursuant thereto. In November 2025, we sold 106,788 shares of common stock under the ATM Program and received net proceeds of $0.9 million, net of sales agent commission and related offering expenses. As of December 31, 2025, we have $1.1 million remaining under the ATM Program in which we may offer and sell shares of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">For additional information, see &#8220;Note 7. Stockholders&#8217; equity&#8221; to the consolidated financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">January 2026 Public Offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In January 2026, we closed on an underwritten public offering, pursuant to which we issued and sold, (i)&#160;1,006,870 Class&#160;A Units, with each Class&#160;A Unit consisting of (A)&#160;one share of common stock, (B)&#160;1.5 Series&#160;C Common Warrants to purchase 1.5 shares of common stock, and (C)&#160;1.5 Series&#160;D Common Warrants to purchase 1.5 shares of common stock, at a price of $3.10 per Class&#160;A Unit, and (ii)&#160;1,998,704 Class&#160;B Units, with each Class&#160;B Unit consisting of (A)&#160;one pre-funded warrant to purchase one share of common stock, (B)&#160;1.5 Series&#160;C Common Warrants to purchase 1.5 shares of common stock, and (C)&#160;1.5 Series&#160;D Common Warrants to purchase 1.5 shares of common stock, at a purchase price of $3.099 per Class&#160;B Unit. Each pre-funded warrant has an exercise price of $0.001 per share and is immediately exercisable and will expire when exercised in full. Each Series&#160;C Common Warrant and Series D Common Warrant has an exercise price of $3.10 per whole share of common stock, subject to certain adjustments, are immediately exercisable, and will expire on January&#160;16, 2031 and January 16, 2028, respectively. Under the Series&#160;C Common Warrant and the Series D Common Warrant, we&#160;may not affect the exercise of any such warrants, and a holder will not be entitled to exercise any portion of any such warrants, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) to exceed the beneficial ownership limitation contained therein. We received gross proceeds of $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">77</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The principal use of cash in operating activities is to fund our current expenditures in support of our </span>R&amp;D activities and clinical development activities. <span style="background:#ffffff;">Financing activities currently represent the principal source of our cash flow.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The following table reflects the major&#160;categories of cash flows&#160;for each of the periods presented (in thousands).</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,701)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,710)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,964</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,300</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:57.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net decrease in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,739)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,418)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:8pt 0pt 0pt 0pt;">Net cash used in operating activities was $15.7 million for 2025 and consisted of net loss of $13.0 million and net cash used by change in operating assets and liabilities of $2.9 million, partially offset by adjustments for non-cash charges totaling $0.2 million, which was primarily attributable to $0.4 million of stock-based compensation costs and $0.2 million gain from change in fair value of warrant liabilities. Net cash used in operating activities was $24.7 million for 2024 and consisted of net loss of $27.6 million, partially offset by net cash provided by change in operating assets and liabilities of $2.6 million and non-cash charges totaling $0.3 million, which was primarily attributable to $0.5 million of stock-based compensation and $0.2 million gain from change in fair value of warrant liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Net cash used in investing activities, related to the purchases of property equipment, was less than $0.1 million for 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Net cash provided by financing activities was $10.0 million for 2025, which primarily consisted of proceeds of $10.0 million from the 2025 private placement offering and $1.2 million from the ATM Program. Partially offsetting these cash inflows were cash outflows for the payment of $0.9 million of issuance costs in connection with the 2025 private placement offering and $0.4 million of issuance costs in connection with the at the market offering. Net cash provided by financing activities was $18.3 million for 2024, which primarily consisted of proceeds of $20.0 million from the 2024 private placement offering, partially offset by the payment of $1.7 million of issuance costs in connection with the 2024 private placement offering. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">For additional details, see the consolidated statements of cash flows in the consolidated financial statements included elsewhere in this Annual Report.</p><a id="ds47101_contractual_obligations_and_comm"></a><a id="toc_ds47101_2"></a><a id="ds47101_critical_accounting_policies_a__"></a><a id="toc_ds47101_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Contractual obligations, purchase commitments and employment agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Contractual obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">We entered into a non-cancelable operating lease for our corporate headquarters in Cambridge, Massachusetts. For additional i<span style="background:#ffffff;">nformation, see &#8220;Note 6. Commitments and contingencies&#8221; to the consolidated financial statements included in this Annual Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our products or product candidates, use of such products or product candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is sometimes unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of December 31, 2025 and 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In the normal course of business, we may be confronted with issues or events that may result in contingent liability. These generally relate to lawsuits, claims, environmental actions, or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">We are party to license agreements with respect to certain of our product candidates that would obligate us to pay royalties with respect to revenue from such product candidates and milestone payments upon achievement of certain development milestones. As of the date hereof, we do not expect to achieve such milestones in the near term, but we would have to obtain additional capital to pay such milestone payments.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">78</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">Additional information regarding contingent payments and license agreements is in &#8220;Note 5. Related party&#8221; and &#8220;Note 6. Commitments and contingencies&#8221; to the consolidated financial statements included in this Annual Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-size:10pt;font-weight:bold;background:#ffffff;">Purchase commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Information regarding purchase commitments is in &#8220;Note 6. Commitments and contingencies&#8221; to the consolidated financial statements included in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><b style="font-size:10pt;font-weight:bold;">Employment agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Information regarding employment agreements is in &#8220;Note 6. Commitments and contingencies&#8221; to the consolidated financial statements included in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Critical Accounting Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">Our consolidated financial statements included in this Annual Report have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our critical accounting estimates and judgments relate to the following items: (i) cash forecast for conclusion about MetaVia&#8217;s ability to continue as a going concern, (ii) conclusion on the classification of warrants based on the underlying warrant and transaction agreements, and (iii) clinical trial costs and accruals. Our cash forecast for the 12-month period from the filing date of this Annual Report utilizes current cash balance less estimated payments for future clinical trials and G&amp;A costs plus forecasted cash inflows. Our estimates and judgments used in clinical trial costs and accruals are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Accrual for R&amp;D costs related to clinical trial activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to record an accrual for R&amp;D costs related to clinical trial activities. This process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed on our behalf and estimating the level of service provided and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Certain of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some service providers require advance payments. We make estimates of our accrued and prepaid expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued R&amp;D expenses include fees paid to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with preclinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs and investigative sites in connection with preclinical studies and clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CMOs in connection with the production of preclinical and clinical trial materials.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">We base the expense recorded related to external R&amp;D on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">79</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;">Information regarding (i) adoption of new accounting standards during 2025 and (ii) accounting standards issued but not yet adopted is included in &#8220;Note 1. Business, basis of presentation, new accounting standards and summary of significant accounting policies&#8221; to the consolidated financial statements included in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3ec92a44_193e_43bb_993d_cf6f504f1f1b"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;"><b style="font-weight:bold;">Item 7A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;"><b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#242424;">We are exposed to market risks in the ordinary course of business. Some potential market risks are discussed below:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="color:#242424;font-weight:bold;">Market risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#242424;">Strategic and operational risks arise if we fail to carry out business operations and/or raise sufficient equity and/or debt financing. These strategic opportunities or risks arise from a range of factors that might include changing economic and political circumstances and regulatory approvals and competitor actions. The risk is mitigated by consideration of other potential development opportunities and challenges which management may undertake.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="color:#242424;font-weight:bold;">Currency risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#242424;">Our operating results and financial position are reported in U.S. dollars.&#160;S</span>ome of our <span style="color:#242424;">financial transactions are denominated in currencies other than the U.S. dollar. Accordingly, our results of operations are subject to currency transaction risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#242424;">We have no hedging agreements in place with respect to foreign exchange rates. We have not entered into any agreements or purchased any instruments to hedge possible currency risks at this time.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="color:#242424;font-weight:bold;">Interest rate risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#242424;">Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate as a result of changes in market interest rates. Cash bears interest at market rates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="color:#242424;font-weight:bold;">Inflation risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#242424;">If our costs become subject to significant inflationary pressures, it could harm our business, financial condition, and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_e45ec8a0_4b29_45d2_ae8f_eb5df0d23a5e"></a><a id="Item8_FinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 8.</b></span><b style="font-weight:bold;background:#ffffff;">Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="background:#ffffff;">Reference is made to the financial statements, the notes thereto, and the report thereon, commencing on page F-1 of this Annual Report, which financial statements, notes and report are incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_be369de3_562f_403f_8dbd_eee557bd078d"></a><a id="item9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.</b></span><b style="font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosur</b><b style="font-weight:bold;">e</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7940cf53_bd67_46e2_8051_647091c128f2"></a><a id="Item9A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9A.</b></span><b style="font-weight:bold;">Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Evaluation of disclosure controls and procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="color:#242424;">As required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act, our management, with the participation of our principal executive officer (&#8220;PEO&#8221;) and principal financial officer (&#8220;PFO&#8221;), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report. Based upon that evaluation, our PEO and PFO concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Management&#8217;s annual report on internal control over financial reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and Board; and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">80</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 3.8pt 8pt 0pt;">Management has assessed the effectiveness of our internal control over financial reporting as of the end of the period covered by this Annual Report. The scope of management&#8217;s assessment regarding the Company&#8217;s internal control over financial reporting includes the criteria set forth by the Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon that assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. The management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the SEC that permit us to provide only the management&#8217;s report in this Annual Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Inherent limitations of disclosure controls and procedures and internal control over financial reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our management, including our PEO and PFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Changes in internal control over financial reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3e6e4bf3_b87d_4655_a44b_fe9c7d778b7a"></a><a id="ITEM9BOTHERINFORMATION_848698"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9B.</b></span><b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">Trading Plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">During the three months ended December 31, 2025, <ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_SGH1Z6y0_keDCHtA4fFzqw">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_1w2Me-CPfEqZduWeDeVKSQ">o</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_x3YHVWX9-EibiJnLorv3Gw">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_xr1Oy9dcxkaMTl0kGurgPQ">e</ix:nonNumeric> of our directors or Section 16 officers&#160;adopted&#160;or&#160;terminated&#160;any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of&#160;Rule 10b5-1(c)&#160;of the Exchange Act or any &#8220;non-Rule&#160;10b5-1&#160;trading arrangement.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d5931e47_5bea_49b3_9d85_4a944794223a"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9C.</b></span><b style="font-weight:bold;">Disclosure Regarding Foreign Jurisdictions that Prevents Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b87c9b45_656e_4f5e_9497_2f8774d7f91f"></a><a id="PARTIII_373562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Part II</b><b style="font-weight:bold;">I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_45172380_fdad_48fb_9dd5_54cf0b68fa74"></a><a id="Item10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 10.</b></span><b style="font-weight:bold;background:#ffffff;">Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Directors and executive officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Board is divided into three classes. Members of each class serve staggered three-year term. The terms of directors in Class I, Class II and Class III expire at the annual meetings of stockholders to be held in 2026, 2027 and 2028, respectively. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">81</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table provides information as to each person who is, as of the filing hereof, a director and/or executive officer of MetaVia.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:61.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;">Name</p></td><td style="vertical-align:top;width:61.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;">Position(s)</p></td><td style="vertical-align:top;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;">Age</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">D. Gordon Strickland</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Class I Director</p></td><td style="vertical-align:top;width:10.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">79</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">James P. Tursi</p></td><td style="vertical-align:top;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Class I Director</p></td><td style="vertical-align:top;width:10.2%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">61</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Jason L. Groves</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Class II Director</p></td><td style="vertical-align:top;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">55</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Chief Executive Officer, President and Class II Director</p></td><td style="vertical-align:top;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">50</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Andrew I. Koven</p></td><td style="vertical-align:top;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Class II Director and Chair of the Board</p></td><td style="vertical-align:top;width:10.2%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">68</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Mark A. Glickman</p></td><td style="vertical-align:top;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Class III Director</p></td><td style="vertical-align:top;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">60</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Michael Salsbury</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">Class III Director</p></td><td style="vertical-align:top;width:10.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#cceeff;margin:0pt;">76</p></td></tr><tr style=""><td style="vertical-align:top;width:28.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Marshall H. Woodworth</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:10.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;background:#ffffff;margin:0pt;">68</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Business experience and background of directors and executive officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;D. Gordon Strickland&#160;</span>has served as a member of the Board since January 2022. He served as Chair&#160;of Ampex Corporation (&#8220;Ampex&#8221;), a technology company that was previously listed on Nasdaq, from March 2012 until June 2019. He also served as&#160;Ampex&#8217;s Chief Executive Officer from February 2007 to March 2012. Prior to Ampex, he served as President and Chief Executive Officer of Cardiff Holdings, a privately held producer of credit, debit, loyalty and other cards by Brookside Equity Partners from March 2012 to August 2013. Prior to Cardiff Holdings, Mr.&#160;Strickland was the Chair of Medical Resources, a public operator of diagnostic imaging centers. Mr.&#160;Strickland was also president and CEO of MCSi, Inc., a technical integrator of audio-visual products, from March 2003 until March 2004. Prior to MCSi, Inc., Mr.&#160;Strickland was the president and CEO of Capitol Wire, Inc, an internet-based news and information service provider from September 1999 until August 2002 and had leadership roles with Kerr Group, a manufacturer of glass containers and plastic packaging, from June 1986 until August 1997, including serving as the president and CEO, and as Senior Vice President, Finance and Chief Financial Officer. Mr.&#160;Strickland has over 35&#160;years of experience as a senior executive and board member with public and private companies. Mr.&#160;Strickland received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A from Yale University. The Board believes that Mr.&#160;Strickland&#8217;s experience serving as Chair and Chief Executive Officer of a publicly-traded company, Ampex, qualifies him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr. James P. Tursi</span> has served as a member of the Board since November 2023. Dr. Tursi is currently serving as the Chief Scientific Officer of Contraline, Inc. Prior to this, he served as Executive Vice President &#8211; Global R&amp;D for Endo Pharmaceuticals from January 2022 until its acquisition in October 2025. From April 2020 until January 2022, Dr. Tursi served as Chief Scientific Officer U.S. for Ferring Pharmaceuticals. From August 2018 until April 2020, Dr. Tursi served as Executive Vice President, R&amp;D for Antares Pharma Inc. (Nasdaq: ATRS). Prior to August 2018, Dr. Tursi served as Chief Medical Officer at Aralez, Chief Medical Officer and Vice President of Clinical R&amp;D for Auxilium Pharmaceuticals Inc. and held positions of increasing responsibility at GlaxoSmithKline (NYSE: GSK) and Procter &amp; Gamble Pharmaceuticals. Dr. Tursi practiced medicine and surgery for over 10 years and created a medical education company, I Will Pass<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, which assisted physicians in the process of board certification. He holds a Bachelor of Science degree in Chemistry and Biology from Ursinus College; a Doctor of Medicine from Medical College of Pennsylvania and performed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital. The Board believes Dr. Tursi&#8217;s pharmaceutical industry and senior leadership experience qualifies him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Jason L. Groves, Esq.</span> has served as a member of the Board since December 2019. Since July 2022, Mr. Groves has served as the Chief Legal Officer and Corporate Secretary of Medifast, Inc. (&#8220;Medifast&#8221;) (NYSE: MED), a publicly-held leading manufacturer and distributor of clinically-proven, healthy-living products and programs. After joining Medifast in 2009, Mr. Groves has held several executive management positions, most recently serving as Executive Vice President and General Counsel of Medifast from 2011 to July 2022. Mr. Groves was a Medifast director from 2009 to 2015, serving on the audit committee from 2009 to 2011. Prior to joining Medifast, Mr. Groves was Assistant Vice President of Government Affairs for Verizon Maryland, a telecommunications company, where he was responsible for the company&#8217;s legislative policy and government affairs. A U.S. Army veteran, Mr. Groves was a direct-commissioned Judge Advocate in the U.S. Army Judge Advocate General&#8217;s (JAG) Corps. As a JAG officer, he practiced law and had the distinction of prosecuting criminal cases in the District Court of Maryland as a Special Assistant U.S. Attorney. Over the course of three years, he received two Army Achievement Medals and one Army Commendation Medal. Mr. Groves completed nine years with the Anne Arundel Medical Center Board of Trustees, chairing their international captive insurance company board for eight years. Mr. Groves received his Bachelor of Science degree, cum laude, in Hospitality Management from Bethune-Cookman University, and obtained his Juris Doctor from North Carolina Central University School of Law. The Board believes that Mr. Grove&#8217;s experience serving as an independent director, audit committee member, and chief legal officer of a large public corporation while assisting with the initial international introduction of such corporation&#8217;s products qualifies him to serve as a director.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">82</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Hyung Heon Kim</span> has served as a member of the Board since July 2021 and was appointed as our President and Chief Executive Officer in August 2023. Previously, Mr. Kim was the General Counsel and a Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APis. Mr. Kim served as General Counsel of Dong-A ST from January 2018 until August 2023 and as a Vice President of Dong-A ST from December 2020 until August 2023. Mr. Kim previously served as Executive Director of Dong-A ST from January 2018 through December 2020. Prior to his roles with Dong-A ST, Mr. Kim was Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. From April 2021 to December 2025, Mr. Kim served as a director of AnaPath Services GmbH, a private Swiss-based provider of scientific R&amp;D services, and STP America Research Corp, a private New Jersey-based R&amp;D company. Prior to joining Dong-A Socio Group, Mr. Kim served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. from 2008 to 2011. Mr. Kim received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law. The Board believes that Mr. Kim&#8217;s experiences gained as General Counsel and Head of International Legal Affairs to an established pharmaceutical group of companies qualify him to serve as a director. In addition, his day-to-day leadership of MetaVia gives him critical insights into our operations, strategy and competition, and he facilitates the Board&#8217;s ability to perform its oversight function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Andrew I. Koven</span> has served as a member of the Board since July 2021, and Chair of the Board since January 2022. Mr. Koven previously served as Lead Independent Director of Kala Bio, Inc. (&#8220;Kala&#8221;) (Nasdaq: KALA), a public biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, from December 2018 to January 2026. He was also a member of Kala&#8217;s board of directors from September 2017 to January 2026, during which time he served as Chair of Kala&#8217;s compensation committee and as a member of its audit committee. Mr. Koven was, until his retirement in January 2019, the President and Chief Business Officer of Aralez and served in that role with the company&#8217;s predecessor, Pozen Inc. (&#8220;Pozen&#8221;), commencing in June 2015. Prior to joining Pozen, Mr. Koven served as Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals Inc., a public specialty biopharmaceutical company, from February 2012 until January 2015, when it was acquired by Endo. Mr. Koven served as President and Chief Administrative Officer and a member of the board of directors of Neurologix, Inc. (&#8220;Neurologix&#8221;), a company focused on the development of multiple innovative gene therapy development programs, from September 2011 to November 2011. Before Neurologix, Mr. Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals, Inc., a public specialty pharmaceutical company, from July 2010 until May 2011 when it was acquired by Merck &amp; Co., Inc. (NYSE: MRK). Previously, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor Inc. (now Sunovion), a public specialty pharmaceutical company, from March 2007 until February 2010 when it was acquired by Dainippon Sumitomo Pharma Co., Ltd. Prior to joining Sepracor, Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals, Inc., a public specialty pharmaceutical company, from August 2003 until its acquisition by Abbott Laboratories (now AbbVie) in December 2006. Mr. Koven began his career in the pharmaceutical industry first as an Assistant General Counsel and then as Associate General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992, he was a corporate associate at Cahill, Gordon &amp; Reindel in New York. From 1992 to 1993, he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S. Mr. Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and B.A. Degree in Political Science from Dalhousie University. The Board believes that Mr. Koven&#8217;s extensive experience in the pharmaceutical industry qualifies him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Mark A. Glickman </span>has served as a member of the Board since May 2023. Mr. Glickman has also served as a member of the board of Otsuka Precision Health since March 2024. Since December 2023, Mr. Glickman has served as President and Chief Executive Officer of BioFlorida, Inc., an association representing life sciences and research organizations based in Florida. Previously, Mr. Glickman served as the Co-Chief Executive Officer for TherapeuticsMD, Inc. (&#8220;TXMD&#8221;) (Nasdaq: TXMD), a women&#8217;s healthcare product company, from September 2022 through the sale of the assets of TXMD, Inc. to Mayne Therapeutics (now Mayne Pharma Group Ltd) in January 2023. Mr. Glickman also served as Chief Business Officer, Commercial of TXMD, since June 2021 through the sale of assets of TXMD. Previously, Mr. Glickman served as the Chief Commercial Officer for Esperion Therapeutics, Inc. (Nasdaq: ESPR) from 2018 until December 2020, where he developed and led the commercial division in the launch of the company&#8217;s first cardiovascular prescription therapy. From June 2015 to March 2018, Mr. Glickman served as the Chief Commercial Officer for Aralez Pharmaceuticals, Inc. (&#8220;Aralez&#8221;), a public specialty pharmaceutical company, where he built out and led the first commercial effort for a previously clinical organization. Prior to June 2015, Mr. Glickman was Executive Vice President of Sales and Marketing for Auxilium Pharmaceuticals Inc., which was acquired by Endo International plc (&#8220;Endo&#8221;) in January 2015, where he led all commercial efforts for a portfolio of thirteen pharmaceutical products. Mr. Glickman&#8217;s previous positions include Senior Vice President of Sales and Marketing and Vice President of Medical Devices for Otsuka America Pharmaceuticals Inc. and Marketing Head, Regional Sales Director and Vice President of Sales and Operations at Kos Pharmaceuticals (Abbott Laboratories, now AbbVie Inc. (NYSE: ABBV)), where he </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">83</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">expanded his skills in the commercial products area. Mr. Glickman received a Bachelor of Arts degree in Political Science from S.U.N.Y Oswego, and a Master of Business Administration in Finance and International Management from the N.Y.U. Stern School of Business. The Board believes that Mr. Glickman&#8217;s 30 years of experience in the pharmaceutical and medical device industry qualifies him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Michael Salsbury</span> has served as a member of the Board since December 2019. Since June 2025, Mr. Salsbury has served as Secretary and General Counsel of Current Health, Inc. (&#8220;Current Health&#8221;), a provider of remote care management services and products. Prior to his current role at Current Health, Mr. Salsbury served as Counsel to the company from May 2021 to August 2024. Current Health was acquired by Best Buy Co., Inc. (NYSE: BBY) in November 2021. From September 2017 to May 2022, Mr. Salsbury served as Counsel to Verisma Systems, Inc., a provider of cloud-based automated disclosure management systems; and from February 2013 to July 2017, he served as Secretary and General Counsel to Best Doctors, Inc., a provider of expert medical opinions. Best Doctors was acquired by Teladoc Health, Inc. (NYSE: TDOC) in July 2017. Mr. Salsbury has more than 25 years&#8217; experience as a senior executive with public and private companies and at a private law practice. Mr. Salsbury received a J.D. and M.B.A. from the University of Virginia and a B.A. from Dartmouth College. The Board believes that Mr. Salsbury&#8217;s legal expertise and his experience serving as general counsel and secretary of a Fortune 100 corporation qualifies him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Marshall Woodworth </span>served as our Acting Chief Financial Officer from October 25, 2023 until his appointment as our Chief Financial Officer on March 1, 2024. Previously, Mr. Woodworth served as the Chief Financial Officer of Nevakar Inc. and its respective subsidiaries (Nevakar Injectables Inc. and Vyluma Inc.) from May 2017 through May 2023, where Mr. Woodworth was responsible for the accounting, financing, legal and human resources functions. From October 2015 through October 2016, Mr. Woodworth served as the Chief Financial Officer of Braeburn Pharmaceuticals Inc., where Mr. Woodworth led and coordinated the accounting, finance and treasury functions. From May 2014 to July 2015, Mr. Woodworth served as the Chief Financial Officer of Aerocrine AB, where Mr. Woodworth had responsibility for directing and coordinating the accounting and finance, FRS (Swedish SEC) reporting, investor relations, human resources and legal aspects of the company. From January 2010 through February 2014, Mr. Woodworth served as Chief Financial Officer of Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), where Mr. Woodworth led a multi-disciplinary team and managed accounting, finance, SEC reporting, financial planning, analysis and reporting, and treasury functions. Mr. Woodworth received a Bachelor of Science degree from the University of Maryland and a Master of Business Administration degree in Finance from Indiana University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Family relationships</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">None of our directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Involvement in certain previous legal proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Mr.&#160;Glickman served as Chief Commercial Officer at Aralez from June 2016 to March 2018, Mr. Koven served as President and Chief Business Officer of Aralez&#8217;s predecessor, Pozen, and then at Aralez from June 2015 to January 2019, and Dr. Tursi served as Chief Medical Officer of Pozen and then Aralez from 2015 until August 2018, and has served as Executive Vice President &#8211; Global R&amp;D for Endo since January 2022.&#160;Each of Aralez and Endo and certain of their respective affiliates filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code on August 10, 2018 and August 16, 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Code of business conduct and ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our Board has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive officers, as applicable. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of these provisions, on our website. The full text of our code of conduct is posted on the investor relations section of our website at http://metaviatx.com under &#8220;Investors &amp; News-Corporate Governance-Highlights.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_7lsHq2GGZUKiIkAYP6Q-9g"><b style="font-weight:bold;">Insider Trading Policy</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our Board has adopted an Insider Trading Compliance Policy (&#8220;Insider Trading Policy&#8221;) governing the purchase, sale, and/or other dispositions of our securities by directors, officers, employees and other specified persons. Our Insider Trading Policy is designed to promote compliance with insider trading laws by informing, educating and creating reasonable processes to prevent our directors, officers, employees and other specified persons from insider trading violations and the appearance of any related improper conduct. The policy prohibits the trading of our securities on the basis on material nonpublic information, establishes regular blackout periods when directors, executive officers and other specified persons are prohibited from trading in our securities, and requires legal compliance for any insider trading plans intended to rely on the affirmative defense against insider trading liability in accordance with Rule&#160;10b5-1 under the Exchange Act. Additionally, the policy specifically prohibits all </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">84</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">directors, officers, employees and other specified persons from speculative trading and hedging transactions involving our common stock, including short sales, transactions in put or call options, and other speculative transactions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-align:justify;text-indent:-10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Audit committee </b></p><a id="page_de15601_1_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our Board has established an audit committee, which is comprised of Mr.&#160;Strickland, Mr.&#160;Koven and Mr. Glickman, with Mr. Strickland serving as chair of the committee. Each member of our audit committee meets the requirements for independence under the current Nasdaq and SEC rules and regulations and is financially literate. In addition, our Board has determined that Messrs. Glickman and Strickland each qualifies as an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii) of Regulation&#160;S-K promulgated under the Securities Act based on his serving as chief executive officer of multiple companies as described above. This designation does not impose on either of them any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_4f4bd4f0_5821_42b0_bc8c_dbe93292c8e2"></a><a id="ITEM11EXECUTIVECOMPENSATION_607490"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 11.</b></span><b style="font-weight:bold;background:#ffffff;">Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Executive officer compensation </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Summary compensation table for 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table presents summary information regarding the total compensation for services rendered in all capacities that were earned by our named executive officers for 2025 and 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Salary</p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Bonus</p></td><td style="vertical-align:bottom;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock Awards </p></td><td style="vertical-align:bottom;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">All Other Compensation<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (1)</sup></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name and Principal Position</p></td><td style="vertical-align:middle;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year</p></td><td style="vertical-align:middle;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Hyung Heon Kim, President and</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 479,723</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 239,862</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,743</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 756,328</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:36.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 460,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 220,163</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,116</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 716,404</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Marshall H. Woodworth, Chief</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 393,300</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 157,320</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,365</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 562,985</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 316,667</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120,663</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 209,015</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 128,254</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 774,599</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:27pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:27pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.27%;"><tr style=""><td style="vertical-align:top;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:-0.1pt;margin:0pt;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;text-indent:-0.1pt;margin:0pt;">All Other Compensation for 2025 was related to health and welfare benefits paid by MetaVia.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.9pt;margin:8pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Narrative disclosure to summary compensation table for 2025 and 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Agreements with our named executive officers </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We entered into an employment agreement with Mr. Kim in connection with his appointment as our President and Chief Executive Officer in August 2023. In October 2023, Mr. Woodworth was appointed as the Acting Chief Financial Officer of MetaVia, pursuant to an engagement agreement with WhiteCap Search Holdings, LLC (&#8220;WhiteCap&#8221;). In March 2024, we entered into an employment agreement with Mr. Woodworth in connection with his appointment as Chief Financial Officer of MetaVia (the &#8220;Woodworth Employment Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Hyung Heon Kim</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We entered into an employment agreement with Mr. Kim in connection with his appointment as our Chief Executive Officer and President in August 2023 (the &#8220;Kim Employment Agreement&#8221;). Under the terms of Kim Employment Agreement, we agreed to provide Mr. Kim: (i) an annual base salary of $450,000, reviewed annually; (ii) an annual discretionary bonus targeted at 50% of his base salary, as determined in the sole discretion of the Board or committee thereof; (iii) the right to participate in the benefit programs and arrangements that we make available to our employees, including paid vacation and sick leave, contributory and non-contributory welfare and benefit plans, disability plans, and medical, death benefit and life insurance plans for which Mr. Kim is eligible under the terms of those plans; and (iv) a RSU award for 7,103 shares of our common stock pursuant to the terms of a RSU grant notice and form award agreement (the&#160;&#8220;Kim RSU Award&#8221;) under our Amended and Restated 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;). The Kim RSU Award vested as to 50% of the shares underlying the Kim RSU Award on the first anniversary of Mr. Kim&#8217;s employment with MetaVia and, the remaining shares subject to the Kim RSU Award, vested and become exercisable in equal monthly installments on the last day of each full month over the twelve (12) months following the first anniversary of Mr. Kim&#8217;s employment with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">In the event of Mr. Kim&#8217;s death during the employment period or a termination due to disability, Mr. Kim or his beneficiaries or legal representatives shall be entitled to receive (i) any annual base salary earned, but unpaid, for services rendered to MetaVia on or prior to the date on which the employment period ends, (ii) unreimbursed expenses and (iii) certain other benefits provided for in the employment agreement (the &#8220;Kim Unconditional Entitlements&#8221;). In the event of termination for cause by </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">85</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">MetaVia or the termination of employment as a result of resignation without good reason, Mr. Kim shall be provided the Kim Unconditional Entitlements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the event of a resignation by Mr. Kim for good reason or the exercise by MetaVia of its right to terminate Mr. Kim other than for cause, death or disability, Mr. Kim will receive the Kim Unconditional Entitlements and, subject to Mr. Kim signing and delivering to us and not revoking a general release of claims in favor of MetaVia and certain related parties, we shall pay a severance amount to Mr. Kim equal to fifty percent (50%) of Mr. Kim&#8217;s then-current base salary (the &#8220;Severance Amount&#8221;) and pay for Mr. Kim&#8217;s continued health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;) for a period of six (6) months following Mr. Kim&#8217;s termination (the&#160;&#8220;Kim Conditional Benefits&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the event of a resignation by Mr. Kim for good reason, the exercise by MetaVia of its right to terminate Mr. Kim other than for cause, death or disability, in each case, within twelve (12) months following or three (3) months prior to the effective date of a change in control, Mr. Kim will receive the following: (i) the Kim Unconditional Entitlements and the Kim Conditional Benefits less the Severance Amount; (ii) an amount equal to the product of 1.0 times the sum of Mr. Kim&#8217;s annual base salary and target annual cash bonus, less the Non-Compete Amount (as defined in the Kim Employment Agreement), if applicable; and (iii) accelerated vesting of all equity awards that were assumed, continued or substituted by the surviving or acquiring corporation in the change in control and remain subject to time-based vesting conditions, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In addition, Mr. Kim entered into an Employee Proprietary Information and Invention Assignment Agreement that applies during the term of Mr. Kim&#8217;s employment and thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Marshall H. Woodworth</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In October 2023, Mr. Woodworth was appointed as the Acting Chief Financial Officer of MetaVia, pursuant to an engagement agreement with WhiteCap, dated February 3, 2023. Mr. Woodworth received his compensation and benefits from WhiteCap. In connection with the appointment of Mr. Woodworth as our Acting Chief Financial Officer, we paid WhiteCap approximately $375.00 per hour under the engagement agreement for services rendered to MetaVia by Mr. Woodworth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In March 2024, we entered into the Woodworth Employment Agreement with Mr. Woodworth in connection with his appointment as Chief Financial Officer of MetaVia. The Woodworth Employment Agreement has an initial term of two (2) years beginning on March 1, 2024 (&#8220;Initial Term&#8221;) and automatically renews for an additional one-year period at the end of the Initial Term and each anniversary thereafter (&#8220;Renewal Term&#8221;) provided that at least 60 days prior to the expiration of the Initial Term or any Renewal Term the Board does not notify Mr. Woodworth of its intention not to renew. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the terms of Woodworth Employment Agreement, we agreed to provide Mr. Woodworth: (i) an annual base salary of $380,000, reviewed annually; (ii) an annual discretionary bonus targeted at 40% of his base salary, as determined in the sole discretion of the Board or committee thereof; (iii) the right to participate in the benefit programs and arrangements that we make available to our employees, including paid vacation and sick leave, contributory and non-contributory welfare and benefit plans, disability plans, and medical, death benefit and life insurance plans for which Mr. Woodworth is eligible under the terms of those plans; and (iv) a RSU award for 3,045 shares of our common stock pursuant to the terms of a RSU grant notice and form award agreement (the &#8220;Woodworth RSU Award&#8221;) under our 2022 Plan. The Woodworth RSU Award vests as follows: (i) 30% of the shares underlying the Woodworth RSU Award on the first anniversary of the grant; (ii) 30% of the shares underlying the Woodworth RSU Award on the second anniversary of the grant date; and (iii) the remaining shares subject to the Woodworth RSU Award, shall vest and become exercisable in equal monthly installments on the last day of each full month over the twelve (12) months following the first anniversary of grant date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">If during the period Mr. Woodworth is employed by MetaVia, we consummate a Change in Control (as defined in the Woodworth Employment Agreement) and the Woodworth RSU Award is not assumed, continued or substituted by the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) in such Change in Control in the manner contemplated by the 2022 Plan, then 100% of the unvested portion of the Woodworth RSU Award shall fully vest immediately prior to the effectiveness of such Change in Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the event of Mr. Woodworth&#8217;s death during the employment period or a termination due to disability, Mr. Woodworth or his beneficiaries or legal representatives shall be entitled to receive any annual base salary earned, but unpaid, for services rendered to MetaVia on or prior to the date on which the employment period ends, unreimbursed expenses and certain other benefits provided for in the Woodworth Employment Agreement (the &#8220;Unconditional Entitlements&#8221;). In the event of termination for cause by MetaVia or the termination of employment as a result of resignation without good reason, Mr. Woodworth shall be provided the Unconditional Entitlements.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">86</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the event of a resignation by Mr. Woodworth for good reason or the exercise by MetaVia of its right to terminate Mr. Woodworth other than for cause, death or disability, Mr. Woodworth will receive the Unconditional Entitlements and, subject to Mr. Woodworth signing and delivering to MetaVia and not revoking a general release of claims in favor of the MetaVia and certain related parties, we shall pay a severance amount to Mr. Woodworth equal to twenty-five percent (25%) of Mr. Woodworth&#8217;s then-current annual base salary and pay for Mr. Woodworth&#8217;s continued health insurance coverage under &#160;COBRA for a period of three (3) months (the &#8220;Conditional Benefits&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the event of a resignation by Mr. Woodworth for good reason or the exercise by MetaVia of its right to terminate Mr. Woodworth other than for cause, death or disability, in each case, within twelve (12) months following or three (3) months prior to the effective date of a Change in Control, Mr. Woodworth will receive the following: (i) the Unconditional Entitlements and the Conditional Benefits less the Severance Amount; (ii) an amount equal to the product of 0.50 times the sum of Mr. Woodworth&#8217;s annual base salary and target annual cash bonus, less the Non-Compete Amount (as defined in the Woodworth Employment Agreement), if applicable; and (iii) accelerated vesting of all equity awards that were assumed, continued or substituted by the surviving or acquiring corporation in the Change in Control and remain subject to time-based vesting conditions, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at Fiscal Year-End 2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table sets forth information regarding outstanding stock option and RSU awards held by our named executive officers as of December 31, 2025: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Option Awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock Awards</p></td></tr><tr style=""><td style="vertical-align:bottom;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Number of</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Market</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Number of</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value of</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Underlying</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Share of</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Share of</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Unexercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Option</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock That</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock That</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Options</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Option</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Have</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Have</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:21.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Exercisable)</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Expiration</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Not Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Not Vested <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:21.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Grant Date</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(#)</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Date</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(#)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:21.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">June 9, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,274.40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 9, 2032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:21.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Marshall Woodworth</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,132</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,951</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:22.5pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:13.5pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">This column shows the market value of the unvested RSUs held by our named executive officers based on $8.42 per share, the closing price of our Common Stock on December&#160;31, 2025 (the last trading day of 2025).</span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:13.5pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">913 shares vested on March&#160;1, 2026 and the remaining 1,219 shares will vest in twelve equal installments on the last day of each full month following March&#160;1, 2026, subject to continuing service.</span></td><td style="width:36pt;"/></tr></table><div style="margin-top:5pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Policy on Timing of Option Grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">During 2025, we did not grant stock options to our executive officers, directors or employees. Our compensation committee has not established policies and practices regarding the timing of stock option grants in relation to the release of material nonpublic information and does not take material non-public information into account when determining the timing and terms of stock option awards to executive officers. We do not time the disclosure of material non-public information for the purpose of affecting the value of executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Non-employee director compensation </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our non-employee directors receive a mix of cash and share-based compensation intended to encourage non-employee directors to continue to serve on the Board, further align the interests of the directors and stockholders, and attract new non-employee directors with outstanding qualifications. Directors who are employees or officers of MetaVia do not receive any additional compensation for Board service. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">87</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table provides compensation information for 2025 for each non-employee member of the Board. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fees Earned </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">or Paid</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">in Cash<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;white-space:pre-wrap;">  (1)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Awards <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total </p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">D. Gordon Strickland</p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,099</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 82,099</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">James P. Tursi</p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,099</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63,099</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jason L. Groves</p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,099</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 63,099</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Andrew I. Koven</p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 94,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,099</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 112,099</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Mark A. Glickman</p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,099</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 73,099</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Michael Salsbury</p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 52,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,099</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70,099</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:35.95pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:84.86%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;">The amounts in this column represent the value of annual cash earned from retainers by directors serving on the Board and committees of the Board in 2025.</p></td></tr><tr style=""><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:5pt;line-height:1.19;vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><span style="font-size:5pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:3.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(2) </sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:96.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;">Amounts reported reflect the aggregate grant date fair value of 2,558 RSUs granted to each of our directors for service in 2025, whose grant date fair value was determined based on <span style="background:#ffffff;">the closing sales price of our common stock as reported on Nasdaq on the date of grant.</span> The amounts shown exclude the impact of estimated forfeitures related to service-based&#160;vesting conditions.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Non-employee director compensation policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">In May 2024, the compensation committee recommended, and the Board approved our Amended and Restated Non-Employee Director Compensation Policy (as further amended in November 2024, the &#8220;Amended Non-Employee Director Compensation Policy&#8221;). Under the Amended Non-Employee Director Compensation Policy, all of our non-employee directors receive an annual cash retainer of $40,000 for Board service except for the Non-Executive Chair of the Board who receives an annual cash retainer of $75,000. Additionally, directors receive an additional cash retainer for serving as a committee chair or member as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:70%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Nominating</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">and Corporate</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Audit</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Governance</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Committee</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Committee</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Committee</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Committee chair</p></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,000</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:49.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Committee member (other than the chair)</p></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial grant: </span>For each non-employee director who is first elected or appointed to the Board on or following the effective date of the Amended Non-Employee Director Compensation Policy, at the close of business on the date of such non-employee director&#8217;s initial election or appointment to the Board, such non-employee director will be automatically, and without further action by the Board or the compensation committee, granted an RSU award covering a number of RSUs equal to (a)&#160;$40,000 divided by (b)&#160;the average fair market value of a share of our common stock for the 30 consecutive market trading days ending on and including the last market trading day prior to the grant date of such RSU award, rounded down to the nearest whole unit (each, an &#8220;Initial Grant&#8221;). 50% of each Initial Grant will vest as of the date of grant and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to the non-employee director&#8217;s continuous service on each vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Annual grant and prorated annual grant:</span> At the close of business after the first annual meeting of our stockholders following the effective date of the Amended Non-Employee Director Compensation Policy and on the date of each subsequent annual meeting of our stockholders held following the initial annual meeting of stockholders (each, a &#8220;Company Annual Meeting&#8221;), each person who is then a non-employee director will be automatically, and without further action by the Board or the compensation committee, granted an RSU award covering a number of RSUs equal to (i) $20,000 divided by (ii) the average fair market value of a share of common stock for the 30 consecutive market trading days ending on and including the last market trading day prior to the grant date of such RSU award, rounded down to the nearest whole unit (each, an &#8220;Annual Grant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">In addition, for each non-employee director who is first elected or appointed to the Board after the first Company Annual Meeting following the effective date on a date other than the date of our Annual Meeting, at the close of business on the thirtieth (30th) day following such non-employee director&#8217;s initial election or appointment to the Board, such non-employee director will be automatically, and without further action by the Board or the compensation committee, granted an RSU award covering </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">88</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">a number of RSUs equal to (i)&#160;$20,000 divided by (ii)&#160;the average fair market value of a share of common stock for the 30&#160;consecutive market trading days ending on and including the last market trading day prior to the grant date of such RSU award, multiplied by a fraction, the numerator of which equals 365 minus the total number of days, as of the grant date of such RSU award, that have occurred since the last Company Annual Meeting and the denominator of which equals 365, rounded down to the nearest whole unit (each, a &#8220;Prorated Annual Grant&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Each Annual Grant and Prorated Annual Grant will vest in full on the earlier of the (i)&#160;one-year anniversary of the grant date of the Annual Grant or Prorated Annual Grant, as applicable, and (ii)&#160;date immediately prior to the date of the Company Annual Meeting following the grant date of such Annual Grant or Prorated Annual Grant, as applicable, subject to the non-employee director&#8217;s continuous service on the vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Retainer grant:</span>&#160;Each non-employee director may elect to forego receiving payment of all (but not less than all) of the annual cash retainers described above that he is otherwise eligible to receive for the period during our fiscal year that the election applies commencing on the first day of such fiscal year (or if the non-employee director makes the election in our fiscal year that the election applies, on the first day of our fiscal quarter next following our fiscal quarter in which the election is made) and ending on the last day of such fiscal year and instead receive an RSU award (the &#8220;Retainer Grant&#8221;), provided such election is timely made and complies with certain other requirements specified in the Amended Non-Employee Director Compensation Policy. If a non-employee director timely makes the election described above in accordance with the Amended Non-Employee Director Compensation Policy, on the first day of our fiscal year that the election applies (or if the non-employee director makes the election in our fiscal year that the election applies, on the first day of fiscal quarter following our fiscal quarter in which the election is made), the non-employee director will be automatically granted a Retainer Grant covering a number of RSUs equal to the (i) aggregate amount of the annual cash retainers that the non-employee director is eligible to receive under the Amended Non-Employee Director Compensation Policy for the applicable period to which the election applies divided by (ii) average fair market value of a share of our common stock for the 30 consecutive market trading days ending on and including the last market trading day prior to the grant date of such Retainer Grant, rounded down to the nearest whole unit. Each Retainer Grant will vest in equal quarterly installments over the period commencing on the grant date of the Retainer Grant and ending on the last day of the fiscal year in which the Retainer Grant is granted, subject to the non-employee director&#8217;s continued service on each vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferral of settlement of RSU awards:</span><b style="font-weight:bold;">&#160;</b>Each non-employee director may elect to defer the delivery of shares in settlement of any RSU award granted under the Amended Non-Employee Director Compensation Policy that would otherwise be delivered to such non-employee director on or following the date such award vests pursuant to the terms of a deferral election such non-employee director makes in accordance with the Amended Non-Employee Director Compensation Policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Change of Control; Death; Disability</span><b style="font-weight:bold;">:&#160;</b>Each RSU award held by a non-employee director that is granted under the Non-Employee Director Compensation Policy, including the awards described above, will fully vest upon such non-employee director&#8217;s death or disability (as defined in the 2022 Plan), or immediately prior to the consummation of a Change in Control (as defined in the 2022 Plan), in each case to extent such award is outstanding immediately prior to the occurrence of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Non-employee director compensation limit:</span><b style="font-weight:bold;">&#160;</b>The aggregate value of all compensation granted or paid, to any non-employee director with respect to any of our fiscal year, including awards granted and cash fees paid by us to such non-employee director, will not exceed the limits set forth in the 2022 Plan, currently, (1) $750,000 in total value or (2) if such non-employee director first joins the Board during such fiscal year, $1,000,000 in total value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">All RSU awards shall be issued pursuant to the terms of our 2022 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7d629db9_8cf4_4e8e_978d_4c000c76d601"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAIN_50405"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;text-align:justify;"><b style="font-weight:bold;">Item 12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:8pt;text-align:justify;"><b style="font-weight:bold;background:#ffffff;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder&#160;Matters</b><b style="font-weight:bold;background:#ffffff;"> </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">The following table sets forth certain information regarding beneficial ownership of our common stock, as of March 20, 2026 by: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, who we know to beneficially own more than 5% of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our named executive officers and directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of our executive officers and directors as a group.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The percentage ownership information shown in the table is based on an aggregate of 5,090,936 shares of common stock outstanding as of March 20, 2026. In addition, the rules provide for the inclusion of shares of our common stock issuable pursuant to the vesting and settlement of RSUs and the exercise of stock options and warrants that are either immediately </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">89</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">exercisable or exercisable within 60&#160;days of March 20, 2026. These shares of common stock are deemed to be outstanding and beneficially owned by the person holding those RSUs, options or warrants for the purpose of computing the&#160;percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Except as otherwise noted below, the address for each person or entity listed in the table is c/o&#160;MetaVia Inc., 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, 02138. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Beneficially</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Owned <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Percent <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name of Beneficial Owner</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(#)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(%)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Greater than 5% stockholders</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Dong-A ST Co., Ltd. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 908,698</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">17.8%</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Dong-A Socio Holdings Co., Ltd. <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 857,874</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">16.9%</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Directors and Named Executive Officers</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Mark A. Glickman</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 885</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Jason Groves <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,623</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Andrew I. Koven<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (6)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,624</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Hyung Heon Kim<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (7)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,552</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Michael Salsbury<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (5)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,623</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">D. Gordon Strickland <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,617</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">James P. Tursi, Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 824</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marshall H. Woodworth <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,617</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:68.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">All current executive officers and directors as a group (8 persons)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:13.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,365</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">*</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;background:#ffffff;">*&#160;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;background:#ffffff;">Represents beneficial ownership of less than one percent.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Includes shares underlying (i) options that are exercisable and (ii) RSUs that are vested or will become vested, in each case, within 60 days of March 20, 2026.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Applicable percentage of ownership is based on 5,090,936 shares of common stock outstanding as of March 20, 2026, as adjusted for each stockholder.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Represents shares of common stock owned by Dong-A ST, a South Korean corporation, and its address is 64 Cheonho-daero, Dongdaemun-gu, Seoul, Republic of Korea.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Represents shares of common stock owned by Dong-A Holdings, a South Korean corporation, and its address is 64 Cheonho-daero, Dongdaemun-gu, Seoul, Republic of Korea.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Includes (i) 29</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-size:9pt;">shares of common stock issuable upon exercise of outstanding options within 60 days of March 20, 2026, and (ii) 1,595 vested RSUs whose common stock issuance was deferred under the terms of the RSU award.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Includes (i) 29</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-size:9pt;">shares of common stock issuable upon exercise of outstanding options within 60 days of March 20, 2026, and (ii) 707 vested RSUs whose common stock issuance was deferred under the terms of the RSU award.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Includes 7</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-size:9pt;">shares of common stock issuable upon exercise of outstanding options within 60 days of March 20, 2026.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(8)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:5pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Includes 22</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="font-size:9pt;">shares of common stock issuable upon exercise of outstanding options within 60 days of March 20, 2026.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:53.8pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:13.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:5pt;margin-top:0pt;text-align:justify;background:#ffffff;"><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">(9)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:5pt;margin-top:0pt;text-align:justify;background:#ffffff;"><span style="font-size:9pt;">Includes 101</span><span style="font-size:9pt;"> RSUs that will vest within 60 days </span><span style="font-size:9pt;">of March 20, 2026.</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">90</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Securities authorized for issuance under equity compensation plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:8pt 0pt 8pt 0pt;">The following table presents information as of December&#160;31, 2025 with respect to compensation plans under which shares of our common stock may be issued. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:86.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:55.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(a) </p></td><td style="vertical-align:bottom;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(b) </p></td><td style="vertical-align:bottom;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(c) </p></td><td style="vertical-align:bottom;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:55.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Number of securities to be issued upon exercise of outstanding options, warrants and rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted average exercise price of outstanding options, warrants and rights</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:55.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Plan Category </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(#)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">($)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(#)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:55.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Equity compensation plans approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">35,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,240.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">167,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:55.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">378</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:55.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">35,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,240.22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">167,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">The number of shares of common stock remaining available for future issuance represents shares available for issuance under the 2022 Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:5pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">The 2022 Plan provides that the number of shares that may be issued under the 2022 Plan shall be increased on the first day of each fiscal year by an amount equal to the lesser of (i) 10% of the Fully Diluted Shares (as defined in the 2022 Plan) on such date and (ii) such lesser amount as set by our Board prior to January 1</span><sup style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">st</sup><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> of the applicable year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Our only equity compensation plan not approved by our security holders is our 2021 Inducement Plan. A total of 378 shares of our common stock has been reserved for issuance under the Inducement Plan, subject to adjustment for stock dividends, stock splits, or other changes in our common stock or capital structure. The Inducement Plan was approved by the compensation committee without stockholder approval pursuant to Nasdaq Stock Market Listing Rule 5635(c)(4), and is to be utilized exclusively for the grant of stock awards to individuals who were not previously an employee or non-employee director of MetaVia (or following a bona fide period of non-employment with MetaVia) as an inducement material to such individual&#8217;s entry into employment with MetaVia, within the meaning of Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is administered by the Board. Stock awards under the Inducement Plan may only be granted by: (i) the compensation committee or (ii) another committee of the Board composed solely of at least two members of the Board who meet the requirements for independence under the Nasdaq Stock Market Listing Rules (the foregoing subsections (i) and (ii) are collectively referred to as the &#8220;Committee&#8221;). Under the 2021 Inducement Plan, the Committee may choose to grant (i) non-statutory stock options, (ii) stock appreciation rights, (iii) restricted stock awards, (iv) RSU awards, (v) performance stock awards, (vi) performance cash awards, and (vii) other stock awards to eligible recipients, with each grant to be evidenced by an award agreement setting forth the terms and conditions of the grant as determined by the compensation committee in accordance with the terms of the Inducement Plan.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_a5143459_4f55_4c9a_98d6_63bd7640b755"></a><a id="item13"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Item 13. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;background:#ffffff;">Certain Relationships and Related Transactions, and Director Independence</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following includes a summary of transactions since January 1, 2024 to which we have been a party, in which the amount involved in the transaction exceeded the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, nominees for director, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">2024 private placement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">In June 2024, we entered into a Securities Purchase Agreement (the &#8220;2024 Securities Purchase Agreement&#8221;) with Dong-A and another institutional investor (the &#8220;2024 Private Placement&#8221;). Pursuant to the 2024 Securities Purchase Agreement, we issued to Dong-A 231,320 shares of our common stock, Series&#160;A Warrants to purchase up to 231,320 shares of our common stock (the &#8220;Series&#160;A Warrants&#8221;), and Series&#160;B Warrants to purchase up to 693,962 shares of our common stock (the &#8220;2024 Series&#160;B Warrants&#8221;) in a private placement pursuant to Section&#160;4(a)(2) and Regulation&#160;D promulgated under the Securities Act. The Series&#160;A Warrants and the 2024 Series&#160;B Warrants have an exercise price of $43.23 per share and became exercisable as of </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">91</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">September&#160;18, 2024, which is the effective date of stockholder approval received at the Company&#8217;s special meeting of stockholders for the issuance of the shares of common stock upon exercise of the Series&#160;A Warrants and the 2024 Series&#160;B Warrants. In connection with the 2024 Securities Purchase Agreement, Dong-A entered into a voting agreement, whereby it agreed to vote all shares of common stock that it or its affiliate beneficially owned with respect to any proposals presented to stockholders for approval on September&#160;18, 2024. The Series&#160;A Warrants expired in June&#160;2025, and the 2024 Series&#160;B Warrants will expire on the earlier of the five&#160;years anniversary of September&#160;18, 2024 and within six&#160;months following the public announcement of MetaVia receiving positive Phase&#160;1 Part&#160;3 data readout for DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In connection with the 2024 Private Placement, on June&#160;23, 2024, we entered into a registration rights agreement with Dong-A and another institutional investor, pursuant to which, among other things, we were required to prepare and file with the SEC one or more registration statements to register for resale the shares of common stock sold in the 2024 Private Placement to Dong-A, as well as the shares issued to the other institutional investor in the 2024 Private Placement and in the registered direct offering (including the shares of common stock issuable upon exercise of the warrants issued in such offerings). On July&#160;18, 2024, we filed a registration statement on Form S-1 to register such securities (the &#8220;Resale Registration Statement&#8221;). The Resale Registration Statement was declared effective by the SEC on July&#160;24, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">2025 private placement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In May&#160;2025, we entered into the Securities Purchase Agreement with Dong-A ST and Dong-A Holdings (the &#8220;2025 Private Placement&#8221;). Pursuant to the Securities Purchase Agreement, we issued (i)&#160;861,758 shares of common stock for a price of $7.81 per share (the &#8220;Shares&#8221;), and (ii)&#160;418,651 pre-funded common stock purchase warrants to purchase up to 418,651 shares of common stock for a purchase price of $7.799 per pre-funded warrant (the &#8220;Private Placement Pre-Funded Warrants&#8221;), in a private placement pursuant to Section&#160;4(a)(2) and Regulation&#160;D promulgated under the Securities Act. Each Private Placement Pre-Funded Warrant has an exercise price of $0.011 per share, and will be exercisable beginning on the effective date of receiving stockholder approval for the shares of common stock underlying the Private Placement Pre-Funded Warrants. Under the terms of the Private Placement Pre-Funded Warrants, we may not affect the exercise of any such Private Placement Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Private Placement Pre-Funded Warrant, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates for purposes of Section&#160;13(d) or Section&#160;16 of the Exchange Act) would exceed 19.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise (the &#8220;Beneficial Ownership Limitation&#8221;), as such&#160;percentage ownership is calculated in accordance with Section&#160;13(d) of the Exchange Act and the applicable regulations of the SEC. A holder may increase or decrease the Beneficial Ownership Limitation to a higher or lower&#160;percentage (not to exceed 19.99%), effective 61&#160;days after written notice to us. Any such increase or decrease will apply only to that holder and not to any other holder of the Private Placement Pre-Funded Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In connection with the 2025 Private Placement, in May&#160;2025, we entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with Dong-A ST and Dong-A Holdings, pursuant to which, among other things, we were required to prepare and file with the SEC one or more registration statements to register for resale the shares of common stock issued and underlying the Private Placement Pre-Funded Warrants that were sold in the 2025 Private Placement. The Registration Rights Agreement provides Dong-A ST and Dong-A Holdings with demand and piggyback registration rights, including the right to two long-form registration statements. In addition, we agreed to file, within 30&#160;days following the receipt of stockholder approval, a registration statement to (i)&#160;register the Shares and Private Placement Pre-Funded Warrants sold in the 2025 Private Placement (the &#8220;Registrable Securities&#8221;); and (ii)&#160;to use commercially reasonable efforts to cause each registration statement to be declared effective under the Securities Act, as promptly as possible after the filing thereof, but in any event no later than the 60th&#160;day after the receipt of stockholder approval (or in case the SEC reviews the registration statement, the 90th&#160;date after receiving stockholder approval); provided that if were are notified that the registration statement is not being reviewed or is no longer subject to comment, we are required to make the registration statement effective by the fourth trading day after such date. We have agreed to use commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule&#160;144. In July&#160;2025, we filed a registration statement on Form&#160;S-3 to register such securities (the &#8220;July Resale Registration Statement&#8221;). The July Resale Registration Statement was declared effective by the SEC on July&#160;10, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Director independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our common stock is listed on Nasdaq. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">92</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board of directors committee: (i) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (ii) be an affiliated person of the listed company or any of its subsidiaries.</p><a id="ny20009150x2_def14a_105-corporate_pg2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Board has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, the Board affirmatively determined that Mark A. Glickman, Jason Groves, Andrew I. Koven, Michael Salsbury, D. Gordon Strickland, and James P. Tursi, M.D., are &#8220;independent directors&#8221; as defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq. The Board determined that Hyung Heon Kim, our Chief Executive Officer and President, who serves as a director, is not an &#8220;independent director&#8221; as defined under the applicable regulations of the SEC and the listing requirements and rules of Nasdaq. In making this determination, the Board considered the current and prior relationships that each non-employee director has with us and all other facts and circumstances that the Board deemed relevant in determining each non-employee director&#8217;s independence, including the participation by our non-employee directors, or their affiliates, in certain financing transactions by us and the beneficial ownership of the common stock by each non-employee director. See &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Additionally, all of our committees are comprised solely of independent directors under the current Nasdaq and SEC rules and regulations, with Messrs. Glickman, Koven and Strickland serving on our audit committee, Messrs. Glickman, Salsbury and Strickland serving on our compensation committee, and Messrs. Groves, Koven and Tursi serving on our nominating and corporate governance committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_c880e899_476c_4bfc_9b4b_9dd2b5a93311"></a><a id="item14"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Item 14. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Principal Accountant Fees and Services</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Service fees paid to the independent registered public accounting firms </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The audit committee has considered the scope and fee arrangements for all services provided by BDO USA,&#160;P.C. (&#8220;BDO&#8221;), taking into account whether the provision of non-audit-related services is compatible with maintaining BDO independence. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table presents fees for professional audit services rendered by BDO for the audit of the annual financial statements for 2025 and 2024 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:50.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:50.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Audit fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 704</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 570</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:50.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Audit-related fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:50.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:50.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">All other fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:50.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 704</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 570</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">Audit fees consist of fees billed for services relating to the audit of our annual financial statement and review of our quarterly financial statements, and services that are normally provided in connection with statutory and regulatory filings or engagements, comfort letters, reports on an issuer&#8217;s internal controls, and review of documents to be filed with the SEC (e.g.,&#160;periodic filings, registration statements, and company responses to SEC comment letters).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Policy on audit committee pre-approval of audit and permissible non-audit services of independent registered public accounting firm </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our audit committee generally pre-approves all audit and permitted non-audit and tax services provided by the independent registered public accounting firm. Pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered public accounting firm and management are required to periodically report to the audit committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to date. Our audit committee may also pre-approve particular services on a case-by-case basis. All of the services relating to the fees described in the table above were approved by our audit committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">93</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_be5d99f9_aa22_4ed1_99ec_eb4fbfd0527b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt;"><b style="font-weight:bold;">Part IV</b></p><a id="PartIV_36663"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_13daf604_2218_4552_816c_9b4e56ee2283"></a><a id="ITEM15_562720"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:45.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:7pt;text-align:justify;"><b style="font-weight:bold;">Item 15.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:7pt;text-align:justify;"><b style="font-weight:bold;background:#ffffff;">Exhibits and Financial Statement Schedules</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></span><b style="font-weight:bold;">Financial statements and financial statements schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Financial Statements are listed in the Index to Financial Statements on page F-1 of this Annual Report.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;background:#ffffff;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;background:#ffffff;">No financial statement schedules are included because such schedules are not applicable, are not required, or because required information is included in the consolidated financial statements or notes thereto.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></span><b style="font-weight:bold;">Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.91%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.19;margin:0pt;">HIDDEN_ROW</p></div></div></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">Exhibit<br/>Number</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Description of Document</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">2.1+++</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000051/tmb-20201231xex2d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of December 31, 2020, by and among the Registrant, Shelby Merger Sub 1, Inc., Shelby Merger Sub 2, LLC, ANA Therapeutics, Inc. and Akash Bakshi (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 6, 2021).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.1 </p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465916138639/a16-16524_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed with the SEC on August&#160;10, 2016).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.2 </p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 31, 2019).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.3 </p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 31, 2019).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.4</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022014321/nrbo-20220912xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">(Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 12, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.5</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837023019894/nrbo-20231219xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on December 19, 2023).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">3.6</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837024015839/nrbo-20241115xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 18, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.7</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465925117540/mtva-20251202xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 2, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.8</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837024015839/nrbo-20241115xex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 18, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">3.9</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations, filed with the Delaware Secretary of State on November 4, 2022, with respect to the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 8, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">3.10</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations, filed with the Delaware Secretary of State on November 4, 2022, with respect to the Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 8, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.1 </p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746916013774/a2228362zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Amendment No.&#160;1 to Registration Statement on Form&#160;S-1, filed with the SEC on June&#160;13, 2016).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.2</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000329/tmb-20210118xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 21, 2021).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.3</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series B Warrant to purchase shares of common stock (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 8, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.4</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agency Agreement, dated as of November 8, 2022, by and between the Registrant and American Stock Transfer and Trust Company LLC (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on November 8, 2022).</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">94</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.91%;"><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.5</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465924074565/tm2418076d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 25, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.6</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465924074565/tm2418076d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 25, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.7*</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities.</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.8</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/tm263364d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Agency Agreement, by and between the Registrant and Equiniti Trust Company, LLC. (incorporated by reference to Exhibit&#160;4.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 16, 2026).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.9</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/tm263364d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 16, 2026).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.10</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/tm263364d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series C Common Warrant (incorporated by reference to Exhibit&#160;4.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 16, 2026).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">4.11</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465926004532/tm263364d1_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series D Common Warrant (incorporated by reference to Exhibit&#160;4.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on January 16, 2026).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.1#</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025003386/mtva-20241231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.2</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837023018842/nrbo-20230930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated as of August 23, 2023, by and between Alewife Properties LLC and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2023)</span></a>.</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.3*</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Extension to Lease, dated as of November 26, 2025, by and between Alewife Properties LLC and the Registrant.</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.4#</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837023014716/nrbo-20230810xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement entered into on August 11, 2023 by and between the Registrant and Hyung Heon Kim (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 14, 2023).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.5#</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837024002312/nrbo-20240304xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement entered into on March 1, 2024 by and between the Registrant and Marshall H. Woodworth (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 4, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.6#</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025003386/mtva-20241231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2021 Inducement Plan of the Registrant and form of award agreements (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.7#</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025003386/mtva-20241231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2022 Equity Incentive Plan of the Registrant and form of award agreements (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.8#</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025003386/mtva-20241231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Non-Employee Director Compensation Policy, dated May 7, 2024, as amended November 29, 2024 (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.9</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated September 14, 2022, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 14, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.10</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shared Services Agreement, dated September 14, 2022, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 14, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.11</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated September 14, 2022, by and among Dong-A ST Co., Ltd., The E&amp;Healthcare Investment Fund II, The E&amp;Healthcare Investment Fund No. 6, The E&amp;Healthcare Investment Fund No. 7 and the Registrant (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 14, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.12</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investor Rights Agreement, dated September 14, 2022, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 14, 2022).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.13+</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837018006442/gemp-20180802ex1012c91f0.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated License Agreement, effective as of August&#160;2, 2018, by and between the Registrant and Pfizer&#160;Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed with the SEC on August&#160;6, 2018).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.14+++</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837019006287/ex-10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License and Collaboration Agreement, dated as of July&#160;23, 2019, by and between the Registrant and Beijing SL Pharmaceutical&#160;Co.,&#160;Ltd. (incorporated by reference to Exhibit&#160;10.6 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed with the SEC on July&#160;25, 2019).</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">95</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.91%;"><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.15++</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Contingent Value Rights Agreement, dated as of December&#160;30, 2019, by and among the Registrant, Grand Rapids Holders Representative, LLC, Computershare Inc. and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on December 31, 2019).</span></a>&#160;</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.16</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021003397/tmb-20210323xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Contingent Value Rights Agreement, dated as of December&#160;30, 2019, by and among the Registrant, Grand Rapids Holders Representative, LLC, Computershare Inc. and Computershare Trust Company, N.A., dated as of March 23, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on March 24, 2021).</span></a>&#160;</p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.17</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465924074565/tm2418076d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Registration Rights Agreement, dated as of June 23, 2024, by and among the Registrant and the Purchasers identified in the signature pages thereto (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on June 25, 2024).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.18</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465925048210/tm259573d4_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated as of May 8, 2025, by and among the Registrant and the Purchasers identified on the signature pages thereto (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 14, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">10.19</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465925107726/mtva-20250930xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At The Market Offering Agreement, dated as of November 6, 2025, by and between the Registrant and Ladenburg Thalmann &amp; Co. Inc. (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 6, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">19.1</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025003386/mtva-20241231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Compliance Policy (incorporated by reference to Exhibit 19.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">21.1</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837025003386/mtva-20241231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">23.1*</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm (</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">BDO USA, P.C.).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">24.1*</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a href="#POA"><span style="font-style:normal;font-weight:normal;">Power of Attorney (reference is made to the signature page hereto).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">31.1*</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">31.2*</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a).</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">32.1**</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">32.2**</p></td><td colspan="2" style="vertical-align:top;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20251231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr style=""><td colspan="2" style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">97.1</p></td><td colspan="2" style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001638287/000155837025003386/mtva-20241231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy for the Recovery of Erroneously Awarded Compensation, dated November 3, 2023, as amended on November 29, 2024 (incorporated by reference to Exhibit 97.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 20, 2025).</span></a></p></td></tr><tr style=""><td style="vertical-align:middle;width:8.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0.65pt 0pt 0pt;">101.INS*</p></td><td colspan="2" style="vertical-align:middle;width:83.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0.65pt 0pt 0pt;">Inline XBRL Instance Document.</p></td><td colspan="1" style="margin:0pt;padding:0pt;"/></tr><tr style=""><td colspan="2" style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">101.SCH*</p></td><td colspan="2" style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr style=""><td colspan="2" style="vertical-align:middle;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">101.CAL*</p></td><td colspan="2" style="vertical-align:middle;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr style=""><td colspan="2" style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">101.DEF*</p></td><td colspan="2" style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr style=""><td colspan="2" style="vertical-align:middle;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">101.LAB*</p></td><td colspan="2" style="vertical-align:middle;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr><tr style=""><td colspan="2" style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">101.PRE*</p></td><td colspan="2" style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr><tr style=""><td colspan="2" style="vertical-align:middle;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">104*</p></td><td colspan="2" style="vertical-align:middle;width:90.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:92.91%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:9.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">#</p></td><td style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Indicates management contract or compensatory plan.</p></td></tr><tr style=""><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">*</p></td><td style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Filed herewith.</p></td></tr><tr style=""><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">**</p></td><td style="vertical-align:middle;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Furnished herewith.</p></td></tr><tr style=""><td style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">+</p></td><td style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule&#160;406 promulgated under the Securities Act.</p></td></tr><tr style=""><td style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">++</p></td><td style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Certain schedules and exhibits have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</p></td></tr><tr style=""><td style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;"><span style="font-size:5pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0.65pt 0pt 0pt;">+++</p></td><td style="vertical-align:top;width:90.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0.65pt 0pt 0pt;">Certain schedules and exhibits have been omitted pursuant to Item&#160;601(a)(5) of Regulation&#160;S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain portions of the exhibits that are not material and would be competitively harmful if publicly disclosed have been redacted pursuant to Item&#160;601(b)(10)(iv) of Regulation&#160;S-K. Copies of the unredacted exhibits will be furnished to the SEC upon request.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cea6eafc_2a64_4192_a695_3cbc6baba215"></a><a id="ITEM16_822338"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:45pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 16.</b></span><b style="font-weight:bold;">Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">None.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">96</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1063dcfc_ad11_48f3_bdbb_cad71bc27229"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Signatures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 26, 2026.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Hyung Heon Kim</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Marshall H. Woodworth</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Marshall H. Woodworth</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="POA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Power of Attorney</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hyung Heon Kim and Marshall H. Woodworth, and each of them, as his true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report and to file the same, with any exhibits thereto and other documents in connection therewith, with the SEC, granting unto such attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons in the capacities indicated on March 26, 2026.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;text-align:center;margin:0pt;">Signature</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Title</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Hyung Heon Kim</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">President, Chief Executive Officer and Director</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Marshall H. Woodworth</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Chief Financial Officer (Principal Financial Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Marshall H. Woodworth</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">and Principal Accounting Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Mark A. Glickman</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Mark A. Glickman</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Jason L. Groves</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Jason L. Groves</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Andrew I. Koven</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Chair of the Board</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Andrew I. Koven</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="font-style:italic;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ Michael Salsbury</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Michael Salsbury</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ D. Gordon Strickland</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">D. Gordon Strickland</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">/s/ James P. Tursi</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Director</p></td></tr><tr style=""><td style="vertical-align:top;width:47.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">James P. Tursi</p></td><td style="vertical-align:top;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;margin-bottom:4.7pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:0pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;line-height:1.19;margin-bottom:4.7pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;">97</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;margin-bottom:4.7pt;visibility:hidden;">&#8203;</span></p><a id="_26ffc578_1731_4992_ba25_73ba008f6181"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Index to Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.09%;"><tr style="height:6.85pt;"><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Opinion"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (<ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:AuditorName" id="Narr_IwwTOihZrUGl_SchNjxHvA">BDO USA, P.C.</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:AuditorLocation" id="Narr_5rwyb3PM7k6u8vYIrfirxA">Boston Massachusetts</ix:nonNumeric>, PCAOB ID#<ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="dei:AuditorFirmId" id="Narr__9vPvvMBhUi8Wjw2uRYxIQ">243</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-2 </p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#BalanceSheets_736952"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-4</p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ComprehensiveLoss_782761"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Operations</span></a></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#EquityDeficit_89715"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity </span></a></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#StatementsofCashFlows_804215"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-7</p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:94.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Notes"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:3.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-8</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 4.69pt 63pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:4.7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>1</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_11e61060_3eed_4be7_83fc_efb4b60fe253"></a><a id="Opinion"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Shareholders and Board of Directors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">MetaVia Inc.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Cambridge, Massachusetts</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Opinion on the Consolidated Financial Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have audited the accompanying </span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> balance sheets of </span><span style="font-family:'Times New Roman','Times','serif';">MetaVia Inc.</span><span style="font-family:'Times New Roman','Times','serif';"> (the &#8220;Company&#8221;) as of December 31, </span><span style="font-family:'Times New Roman','Times','serif';">2025</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">2024</span><span style="font-family:'Times New Roman','Times','serif';">, the related </span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> statements of </span><span style="font-family:'Times New Roman','Times','serif';">operations</span><span style="font-family:'Times New Roman','Times','serif';">, stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, </span><span style="font-family:'Times New Roman','Times','serif';">2025</span><span style="font-family:'Times New Roman','Times','serif';">, and the related notes (collectively referred to as the &#8220;</span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> financial statements&#8221;). In our opinion, the </span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> financial statements present fairly, in all material respects, the financial position of the Company at December 31, </span><span style="font-family:'Times New Roman','Times','serif';">2025</span><span style="font-family:'Times New Roman','Times','serif';"> and </span><span style="font-family:'Times New Roman','Times','serif';">2024</span><span style="font-family:'Times New Roman','Times','serif';">, and the results of its operations and its cash flows for each of the two years in the period ended December 31, </span><span style="font-family:'Times New Roman','Times','serif';">2025</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,</b><span style="font-family:'Times New Roman','Times','serif';"> in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 4.69pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Going Concern Uncertainty</b></p><a id="_Hlk339650"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The accompanying </span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note </span><span style="font-family:'Times New Roman','Times','serif';">1</span><span style="font-family:'Times New Roman','Times','serif';"> to the </span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> financial statements, </span><span style="font-family:'Times New Roman','Times','serif';">the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern</span><span style="font-family:'Times New Roman','Times','serif';">. Management&#8217;s plans in regard to these matters are also described in Note 1. The </span><span style="font-family:'Times New Roman','Times','serif';">consolidated</span><span style="font-family:'Times New Roman','Times','serif';"> financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. </span><span style="font-family:'Times New Roman','Times','serif';">We believe that our audit provide a reasonable basis for our opinion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Clinical Trial Accrued Liabilities</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As seen in the balance sheet and as described in Note 1 to the consolidated financial statements, the Company&#8217;s clinical trial accrued liabilities balances were approximately $0.1 million at December 31, 2025. This accrual includes liabilities for </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations. Expenses incurred for certain research and development activities are recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to the Company by its vendors on actual activities completed or costs incurred.</span></p><a id="_Hlk192709729"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We identified the determination of the </span><span style="font-family:'Times New Roman','Times','serif';">clinical trial accrued liabilities </span><span style="font-family:'Times New Roman','Times','serif';">as a critical audit matter. When estimating clinical trial accrued liabilities, the Company considered several factors including clinical trial budgets, contract amendments, the progress toward completion and payments made to vendors. Auditing these elements involved especially challenging auditor judgment due to the nature and extent of audit effort required to address this matter.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The primary procedures we performed to address the critical audit matter included:</span></p><div style="margin-top:12pt;"><a id="_Hlk161861671"></a></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For certain contract research organizations, inspecting, on a sample basis, invoices received from and payments made to such organizations in the development of the clinical trial accruals. </span></td></tr></table><a id="_Hlk161861687"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For certain clinical trial studies, assessing the Company's estimates of the activities completed to date through (i) inspection of original contract terms, change orders and the expected timeline for the related study, (ii) discussion of the current status of the clinical trials with certain members of management and project teams (iii) confirmation of patient enrollment information and cost incurred with vendors (iv) evaluation of the payments made and the invoices received after December 31, 2025 for proper application in the determination of the accruals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Testing the completeness of the Company&#8217;s clinical trial accruals by reviewing i) the Company&#8217;s press releases and public databases that track clinical trials and ii) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board of directors&#8217; materials regarding the status of clinical trials.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ BDO USA, P.C.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have served as the Company&#8217;s auditor since 2019.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 4.69pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</span><span style="font-family:'Times New Roman','Times','serif';"><br/></span><span style="font-family:'Times New Roman','Times','serif';">March 26, 2026</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_51c417a9_288a_4652_aefb_7196ef897a45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><a id="BalanceSheets_736952"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_bf3af7da_f034_46bc_8c39_6851e81451f0"></a><a id="Tc_S6EslUIiGECEF5AXcJYBJg_1_2"></a><a id="Tc_2OVejgO3oUWITimLZhvcsw_2_2"></a><a id="Tc_u-sbK57Hl0KYpcQiq9Hyqg_2_5"></a><a id="Tc_XfsrYKvRwEGNi3QLVfJr1Q_3_0"></a><a id="Tc_x92dhe-5hEaUQgKTIErL7A_4_0"></a><a id="Tc_mJIQrE2Ub0CjtdNBRjn8QA_5_0"></a><a id="Tc_KIx8Qc7un0mmxunAPZxJWw_5_2"></a><a id="Tc_a9YEVk0ODEO6ejt3wZqZ1w_5_5"></a><a id="Tc_p_qZuLs8TESM3vvQskuUJw_6_0"></a><a id="Tc_x_JK1aZFPEeFPCWflNWTRQ_7_0"></a><a id="Tc_gA4Aoq3G7kSnnL2mnRvC8Q_8_0"></a><a id="Tc__8iPu0362kmI8E1zrY79zg_9_0"></a><a id="Tc_GEmWY_cK4ECkf0Ul27GTGg_10_0"></a><a id="Tc_M180LoNzCE2nQzk4bTOWjg_11_0"></a><a id="Tc_W9QZxX0sl0-sHO0GN2z19A_11_2"></a><a id="Tc_Pa6S6f7DDEaX5jdU5iSVuw_11_5"></a><a id="Tc_-YvjULbGf02Vq_OMxFB37g_12_0"></a><a id="Tc_tEm2SKY0wE-IJuWzDs1-hA_13_0"></a><a id="Tc_fHW0HuGLbEyffQnmAfnGKQ_14_0"></a><a id="Tc_P_nHmHGEy0O8zCLu5oQrkg_14_2"></a><a id="Tc_GkIjoUpHS0iEbKU6oESV2A_14_5"></a><a id="Tc_Mj-oYX8VHk2GCZNBWmFuHw_15_0"></a><a id="Tc_EIjvVVx9PU2vWLnJQNGTlg_16_0"></a><a id="Tc_Bl2W-KQswEevLBYIlMiAWw_17_0"></a><a id="Tc_umdQwGDA70uijoTD9962QQ_19_0"></a><a id="Tc_LZqaT1ryzkKTJIavcs6ZtQ_20_0"></a><a id="Tc_YqMszXnHcUGKJNyEtfFY2w_21_0"></a><a id="Tc_X-h0XPaiu02VwjWJQsFmoQ_22_0"></a><a id="Tc_X_Jjp_lgjkiXrsCJSVhRrg_23_0"></a><a id="Tc_DMil2rCz-0WePA7-jkIAVg_24_0"></a><a id="Tc_Z7y1c1w7dkukp5GgmqrLtg_25_0"></a><a id="Tc_gP2N7o7p8k2OSLmreEVy5A_26_0"></a><a id="Tc_VlXjFGjZZk6EzQ7AeKS1qQ_27_0"></a><a id="Tc_o5wKXXrqP0izEuWDhZ5o1g_28_0"></a><a id="Tc_wvrNZwuQ_0ikZXd4DN0Trw_29_0"></a><a id="Tc_LhuX9xDRE0CK_Ru8RJMicA_30_0"></a><a id="Tc_jK-ArzqaA0W3THKlLBGykQ_30_2"></a><a id="Tc_-UTq-9MAFkeIdodyTue26w_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"> Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_nwKMfHdgnkCM59Umdf7scA_5_3">10,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_NxBBAjRuvk6dfSYngfodEg_5_6">16,017</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"> Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Mav3pGXxl0miZgHhe8zwBA_6_3">597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_dF1A5BsqJU231E22SoGMDg_6_6">55</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_wXyKYb54xkOKWGPI3WKunw_7_3">10,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_2Qr7vSJESUq_R2XHGPQf6A_7_6">16,072</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_jLgJMnBSVEmczfb2cFfl1w_8_3">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qCijoPXF4EiY_hqHwULMvA_8_6">34</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_EXuynwVihkipo8zzefhBUg_9_3">210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_K7Yl__PlUU2qS0d7BnB-Zw_9_6">133</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Ajy6tW_Mk0Gq1k4Ts4G7iw_10_3">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_yLPXPfiPtkWtSGAAvuqO2g_10_6">21</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_uA-Jk3TC6kKwpaobs_YGfA_11_3">11,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_gC2cLLXlkUG97-TeeJUQhw_11_6">16,260</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_mGQMEytW-EiY-wLH_ehvug_14_3">1,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_k5-BGuMugUCBDV4Zr8kZOw_14_6">3,879</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Clinical trial accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:AccruedLiabilitiesClinicalTrialCurrent" scale="3" id="Tc_HzvEG_LOtUaDMLnQKJt0bQ_15_3">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:AccruedLiabilitiesClinicalTrialCurrent" scale="3" id="Tc_1WK4sCsJiUWhmaThUrb_uw_15_6">1,696</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_Qab1VdD0PUCmxZX1ABqrSA_16_3">993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_gX5pPXK_YUCdxlrE0bBuGg_16_6">785</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" scale="3" id="Tc_z2frcdPUQkWMjKU-fm-cPg_17_3">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" scale="3" id="Tc_F6gRQrMxV0aQV6QJJrdEgw_17_6">361</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="-sec-ix-hidden:Hidden_f_SITYnZr0yzCRs8SPB4uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Related party payable</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_bVIHllOxP0WVRbL9pfcLyw_18_3">3,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_ivUuDOUsE0Cn0O83fC8LeA_18_6">1,472</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Lease liability, short-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_1Fsyxd3UOk6of4xpY7NgWA_19_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_AFMhy9_yjUuW9VYtPjQkNQ_19_6">78</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ZcWqKjTB3024zYsrPwmFbA_20_3">5,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_D9MxSonDE0620Cl0h95Bzg_20_6">8,271</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_RVHaO-4VtkuA2mtK-fv4SA_21_3">142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_LuFy0zyz7EG2IXErt9b6mQ_21_6">58</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_qxiNZJhH7EONgwWQE3TMLg_22_3">5,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_RLHqvw2OZkSIosMWIUjA8Q_22_6">8,329</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Commitments and contingencies (Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_l4Pp8gyCMUmtkCN6VI3zRQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_dz_6CcFZVkCb0LeDUD01Mg">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Lv7-QfvbK0uPvEypHDZQBA"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_dUgm6wkH3Eyjj66KkbqG4w">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_JXs2yaO0F0mg6uYszBlsKQ"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_0iIYdtnw10mGBFOoPhj9IQ"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_dThWxl5FFUiLPUU1-3VCaA"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Zlv8r10yW0OxgSjyhvmmGw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of December 31, 2025 and 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_RZkET5TQh0W_DYzsRn-H1A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_yacnpFgWGE-wqPKYDVGxSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_M9AibZJMZkGNnPEsv78MTA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YfwL9zkV3EeP_jregAuZXg">0.001</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_MvR6JN8d5ky4ZrHRWuEQEA"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Rpf77MeP8U2fF-WaZt4_EA">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December 31, 2025 and 2024; <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_dLuT3i2icU-NryId3ZgZWw"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_9XoDNMvBzEeGOl27KsUoBw">2,308,294</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_ZFx55uqcBECeeFbl1v3vfg"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_kebsGtkiMEKMHMKy-kJLjQ">785,194</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2025 and 2024, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_EJIMDje4n0e6Ta_3voK3Lw_26_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_MUFrnPN-D06GG9QcXdeVBQ_26_6">1</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional paid&#8211;in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_IDH_Rd1p20y1g8IpgsGQ6w_27_3">154,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc__dZZT6QFQ0WgG7_ujxcRuA_27_6">143,787</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_CF9z_H3zo0G3LBneTcnx_Q_28_3">148,830</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_URM2BDXs60ewne9haTvG0Q_28_6">135,857</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XtffdNRSqEOZajza1t6y9w_29_3">5,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XvaBUNBZt0ScDNCiATFmGQ_29_6">7,931</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:69.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities and stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_8r5HgWhJjEaR2GGlrk5VEg_30_3">11,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_1WucLgu3FUeLZs_uicAjOg_30_6">16,260</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="background:#ffffff;">The accompanying notes are an integral part of these consolidated financial statements</span>.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aff7a069_2834_4bdd_8d51_a2471eed97b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><a id="ComprehensiveLoss_782761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_a564c470_3719_4f3b_9f2b_d85b5edf1eba"></a><a id="_55231cb2_f0bd_4611_ba96_2d6d883aa3fd"></a><a id="Tc_cwyKmCrsXkeUtRVFb0flsg_1_2"></a><a id="Tc_kkZZr7CG8kSilzh5sEPMJA_2_2"></a><a id="Tc_RXheuXJli0-rMYj4hsU-3Q_2_5"></a><a id="Tc_ET360n0_NUC4FX8uUlIBIg_3_0"></a><a id="Tc_z8WURD7fR0Wj5Gs2US4Pvw_4_0"></a><a id="Tc_4wrTw5_BqU6_Rev6I7KMvQ_4_2"></a><a id="Tc_-ZGc0mCDZ02JWJ3HMGlmAw_4_5"></a><a id="Tc_d8xS-QavUUCPTiTs6uzR6g_5_0"></a><a id="Tc_W-JCyOGy6UmOOdK1fD_YJA_6_0"></a><a id="Tc_jXKPKwMMUE-UTmT9liZRuQ_7_0"></a><a id="Tc_1zhjWe0pHUayZfN84kMW5A_8_0"></a><a id="Tc_Xu43Ou86A0GklL8ClQ4Adw_9_0"></a><a id="Tc_saM-Eqfp2EaHI6m2QCyvpQ_10_0"></a><a id="Tc_eva98XntK0CZsC48xwh3HQ_11_0"></a><a id="Tc_qsTOYLNVx0KDlixAg8z1gg_12_0"></a><a id="Tc_ENxE5tC_LEqvgiaAXVeI8g_13_0"></a><a id="Tc_DRsv6V5H-EKMe8mIQrqnaA_14_0"></a><a id="Tc_B7E_XoqJ4UeRefZza0_FTA_15_0"></a><a id="Tc_GvcQJxytjESJPzrlMVmtHA_15_2"></a><a id="Tc_4AwA4XU7oECibxBoQWyvgA_15_5"></a><a id="Tc_Un3pHV5JpUyhUiEUj4huuQ_16_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_RSaqH1g-uEuDFMcM6iRH9A_4_3">6,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_77ZwWVQsC0Wc6rwGRHwyuQ_4_6">21,553</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_DwhKxR3SMU-NT0VINzeMoA_5_3">6,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_iGT4XQH8pkSMrzjCXCX_Sg_5_6">7,256</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_ZQGziAuQa0GB7y1SyTFF-A_6_3">13,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_DZlw6zMHpEGi7zLBYt04XQ_6_6">28,809</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_sl3ZoRr--0mdrzq8pVU7uQ_7_3">13,708</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_pfPMp-YKMUmJIPHRZpI_qg_7_6">28,809</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Gain from change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_1XTF-qmDbk61JLH427br1g_9_3">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_gmWFABmkd0WvChpbNWzFAA_9_6">297</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="Tc_hTO1cFBou0-7sXt7IhRfgQ_10_3">510</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="Tc_rMn3Zxu0jkG5z5PFpQxBkQ_10_6">920</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_uYKdX3Vxl0KmBzQL_70AZA_11_3">735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_8vhnBu0O5EWnyy6rpDYCnA_11_6">1,217</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_RqRbPKN-cUSiZ-85DeRJ1g_12_3">12,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_w86cJyIbVEqBJXui19MKjw_12_6">27,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_CZ1hfqqHT0eaucBxhAykcA_13_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_LpphFcyFKUm9t3Y2nnCUKw_13_6">&#8212;</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oLnfJueySU-JUV5bd8DK3g_14_3">12,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2KmeyEYbYUyZO31WxAzL2w_14_6">27,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss per share of common stock, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_sqIRN93zqUuCY2RvW2iZFA_15_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_sqIRN93zqUuCY2RvW2iZFA_15_3_2">7.35</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_qhZCwEMbr0mRRlftle-WsQ_15_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_qhZCwEMbr0mRRlftle-WsQ_15_6_2">39.13</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average shares of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_vXHOx7K29EKF7xai2KgnmQ_16_3"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_vXHOx7K29EKF7xai2KgnmQ_16_3_2">1,766,026</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_MG6adgwKFEmFu55csFLtAg_16_6"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_MG6adgwKFEmFu55csFLtAg_16_6_2">705,193</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="background:#ffffff;">The accompanying notes are an integral part of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_37338b0c_3cdf_4e1c_987e_c04872d73f1f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><a id="EquityDeficit_89715"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">(In thousands, except share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_edf2d1b7_0117_4310_b5ca_1a5bf7856f76"></a><a id="Tc_nJC_bJr33EaBd1mHy6_CyA_1_6"></a><a id="Tc_3jSDt7kEuE6XILIAIeLTSQ_2_1"></a><a id="Tc_I-HXmNgkKUGHflpiYTpmQQ_2_6"></a><a id="Tc_XLcSLzCpQkux4fb_atURsw_2_9"></a><a id="Tc_2wvv4s1vCkScAgMa-WwabA_2_12"></a><a id="Tc_49-K0pdrKUimTr_u0prSMQ_3_1"></a><a id="Tc_qlmICEiRtEiHHia2frBpsA_3_3"></a><a id="Tc_rCKdX1f4W0mY0hUxyqh5dQ_3_6"></a><a id="Tc_qyPDPFvSvEeqK6tWsEK0BA_3_9"></a><a id="Tc_F3MtA5kxo0mM6tB06Un2Fg_3_12"></a><a id="Tc_olYQtNatkEmSExTZKVMN0w_4_0"></a><a id="Tc_YRKj-OHXdUSPH-EI5rZM5A_4_3"></a><a id="Tc_x9YTINurvUe-DftelMouag_4_6"></a><a id="Tc_ECuEFeu4Ik-vC-j0UhR9WA_4_9"></a><a id="Tc_BvrKojOf-kuG_3udM9wsLw_4_12"></a><a id="Tc_iSFHFytenkKTv8Sw40gLyg_5_0"></a><a id="Tc_oQ01ETdecEqO8aE1iwCyJg_5_4"></a><a id="Tc_YKOGsZkdW0WugihZEZ_ojQ_5_10"></a><a id="Tc_ran_L-xi20-DU3P44UKD4g_6_0"></a><a id="Tc_UEx_ZhUg-kWnvAM6n5gXQQ_6_1"></a><a id="Tc_hCUyZJ0jBkqmaRIRQI_Gkg_6_4"></a><a id="Tc_DdogxYP8yUmfEOZm4bhmQw_6_10"></a><a id="Tc_1mcQhsDcc0SYdgZ53SEw1g_7_0"></a><a id="Tc_8m3z_WzkGUqCyQrHSFycFQ_7_4"></a><a id="Tc_afv_O4ke-EmQo415Pw58jA_7_10"></a><a id="Tc_Ar7DLJxVIkORRm1kuPKE-w_8_0"></a><a id="Tc_99ffzbivrE-3at9E7oGJzA_8_4"></a><a id="Tc_aEWnqVT1JUy9cSyMQ8uzvw_8_10"></a><a id="Tc_H57vAv-FuE2EsrHZQwJWsQ_9_0"></a><a id="Tc_de1YrUYr0USjVny3uykkOA_9_1"></a><a id="Tc_GozI3_COB02RcZe8g51Tcg_9_4"></a><a id="Tc_V8PMlgc57EG5x2QWek83Cw_9_10"></a><a id="Tc_5Mrm3Wyy8U--FEVipJJfng_10_0"></a><a id="Tc_OaQiQ-Yqv0KeqdArKnC-lA_10_1"></a><a id="Tc_1qc_mLzSHEWr114lNGfb9A_10_4"></a><a id="Tc_SPDJShtUREiLtA-qTgZavA_10_7"></a><a id="Tc_5_HQpRWLG0ubecUPns9eNA_11_0"></a><a id="Tc_bmD7pIYaok-Nz6Q-8pLPsg_11_3"></a><a id="Tc_c0ysx1CaU0GAe75zF4OBRQ_11_6"></a><a id="Tc_8Zmd6U5-T0qvMUA-HQafUw_11_9"></a><a id="Tc_6lxKIDQgiE6ew-_cCINmqw_11_12"></a><a id="Tc_MgrOAfn5iUmc3GdGJ8mW9A_12_0"></a><a id="Tc_1jkam6Y510W6j3dLRB76DQ_12_10"></a><a id="Tc_isawX5olGU-k5hBm-gor-w_13_0"></a><a id="Tc_MV4g7O0eC0ChBKVxF9BHJA_13_4"></a><a id="Tc_dUvPr7BavESJ1ZpYzgRDyg_13_10"></a><a id="Tc_MW9l1aIz-0-M-MnnIOUMog_14_0"></a><a id="Tc_T-r6relx506J4HEQ8PNqiw_14_4"></a><a id="Tc_wOrrv5Bivka0pvQqkw6TYA_14_10"></a><a id="Tc_7F9BFyxR7k-y8rfOY5NWgw_15_0"></a><a id="Tc_FBja-j9f90mhwaaCGbIkJQ_15_4"></a><a id="Tc_KWyNKe1Yv0WYOrDZT9GiRQ_15_10"></a><a id="Tc_t2GwLp6tmUmfuc3nM2vhSw_16_0"></a><a id="Tc_hywRKCPaYkCaWqf-BL7Hzw_16_1"></a><a id="Tc_XVgtP9mNVEi8DfadXJ83Bw_16_4"></a><a id="Tc_5WTHz-E7B0W9PISMASSZlw_16_10"></a><a id="Tc_MPvwg8gS8UeviTTcCudOrA_17_0"></a><a id="Tc_y6OEdtdxGE6Aq9YRGTZsrA_17_1"></a><a id="Tc_6fAPXQb09UG4ExX7pBty5w_17_4"></a><a id="Tc_PIHbmv7UNU6zI0P5G4Xo3w_17_7"></a><a id="Tc_dGi3cEMO1EC5uAHS5LVkXw_18_0"></a><a id="Tc_uiVW293BIEywdZLoelfp9A_18_3"></a><a id="Tc_X0CWE36-eE6s5O7HtFH1Ig_18_6"></a><a id="Tc_e2rN7txchUOjbwItAMSVIw_18_9"></a><a id="Tc_CL7XScQe702em7mTN05-aw_18_12"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.030910492%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Additional</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common&#160;Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Paid-In</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Accumulated</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Equity</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Tc_ngsj666n7Uq56dR3Pl4n0Q_4_1">446,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_D1XDa5iZSkaUl23ClFAkNA_4_4">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wS0yOhGUekml-8634yMsxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_p-pPooLQV0eavrjdX7YqHw_4_7">124,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4prxmkqkS0ulQgJCLHuryg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_C6q5EoUx6Ui1HSzLI8ztkQ_4_10">108,265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LRmdGexm3US-hQTSxxzf7g_4_13">16,685</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock and warrants under the securities purchase agreements, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockAndWarrantsIssuanceCosts" scale="3" id="Narr_9q4SyGdp9EmDxDjzBGDpNg">1,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodSharesCommonStockAndWarrants" scale="3" id="Tc_7VjtZqE05kCJWjiUeeKYDQ_5_1">300,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_dxkQlnauAE6ZJWQeNdMWdQ_5_7">18,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_XLMEUmGSdUS-DBvdaEsm3g_5_13">18,038</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of placement agent warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_XIdy2AkBjk6-aGeD7bR94A_6_7">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_EFBtSxt45UeReZB9JA-xYA_6_13">309</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of stock from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_jW4X7hRVyUO4Ocp5ENIEOw_7_1">31,925</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_hJD2G8yJGUKwm1icXZNCiw_7_7">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_e28yap288E2fFOSZHwcEJA_7_13">1</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" scale="3" id="Tc_WKOTzhQSD0eNdVi2fLPqtA_8_1">6,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_dkhlGFYbAky00Wg5Mx3lnA_8_7">48</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" sign="-" scale="3" id="Tc_ras103tzok2o0AuwuL-GkA_8_13">48</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_vZV7KC_4g0e6Lc-TUrwcsA_9_7">538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_YQXMTxXpc0Kq59UGnzGNjA_9_13">538</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Vqqqe4ArJ0WMHcE3iolyIw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__n_xs-ZDBEaXsNVdWFvqWg_10_10">27,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JJBwLDSPWkaytTgfR0fZBQ_10_13">27,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rT0WgaTgaUCjX8WYjbJJTw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Tc_GCISPq3QpkOP_G0StyPHHA_11_1">785,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rT0WgaTgaUCjX8WYjbJJTw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_otNcr_MQr0qTBUDGw4_5EA_11_4">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yB5rb2fUc0ucbha081KM0w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TtdmAvx_zU2MFqNA3szTgA_11_7">143,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fdw-5IVX0Ee-7JYOFozQCA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_hhQZP74YekGpTueAfH1sMg_11_10">135,857</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xAyPVOSZjU-UMuuMNImnFg_11_13">7,931</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockAndWarrantsIssuanceCosts" scale="3" id="Narr_2udofOYuwEeJz2hkCY2DXA">887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodSharesCommonStockAndWarrants" scale="3" id="Tc_Jr2d3xKB1E67GeDQXaAWnA_12_1">861,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_UJfr0xKwMUuhBVThiw3aRw_12_4">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_tO-C7Y-aw0KQdQx2O4MjvA_12_7">9,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants" scale="3" id="Tc_t2tL4XyJ_UGEHFoCfDf0sw_12_13">9,109</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of stock for exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_4bQRBqlS2kapfXsjG4MinA_13_1">548,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_AXrTqqMUfECyT7aTwWJn1Q_13_7">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_l96_DME7DU-IpeMg9w1vjg_13_13">6</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock under an at the market offering agreement, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="mtva:StockIssuanceCostAtMarketOfferingAgreement" scale="3" id="Narr_Tt7yqV6yMkq54kw-m_JQuw">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_nZqOrKlcuEWafwizqj0QwQ_14_1">106,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_UjXTAyc-V0ORGQuw26DUAg_14_7">861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__AVHSq4G7EqAdHSxaMbq-g_14_13">861</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of stock for vested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_Abj3aaW540eWCSbB0mDpUw_15_1">5,902</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" sign="-" scale="3" id="Tc_0ZIc6ryZF0GDKaAGgf4FSg_15_7">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" sign="-" scale="3" id="Tc_W6uApr-Wx0egQ1Q9Y8jgNA_15_13">12</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_TCiX7L6qR0G1KnAkBFfrxQ_16_7">411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_O5c6m47DIkeLD0NpCRvJqA_16_13">411</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-eIdE4X3kkqQfEoPjdgKQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_P8_AqpiXWkejjEpfYNd32A_17_10">12,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_KM7XUpMNrUiDNQjN7SzdkA_17_13">12,973</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:41.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WuZ-wtRHAUqZiprK61-caA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="Tc_WMMNth4xGEuAHbkV_J87jg_18_1">2,308,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WuZ-wtRHAUqZiprK61-caA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4SU1byqoVUelpjnLQnG2ew_18_4">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1wHJTMoMnEqOTRvvG6b7qw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_b-cNY6wWak-n0Jpq92y9-Q_18_7">154,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d9qFrE2vD06_O6u11oBBfg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LiG2OHktOUydmTZpWi9uwA_18_10">148,830</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E-776yTjlEucwnW4GAg8ZA_18_13">5,333</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="background:#ffffff;">The accompanying notes are an integral part of these consolidated financial statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e7a3cd68_b8ae_4edf_ae27_4473bea318b5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><a id="StatementsofCashFlows_804215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">(In thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_05d98cad_97de_4cbb_bf77_626e53e4ba86"></a><a id="Tc_6-y1Kay3wUuNYgnv1Ty-mw_1_1"></a><a id="Tc_e56lxFiGyUqMggHhTES2Rg_2_1"></a><a id="Tc_wz6lmiQjB06Lz0IY815ulA_2_4"></a><a id="Tc_3ACp7ijt6kmleiTOPAqsNg_3_0"></a><a id="Tc_pSjtUYh5_kiKLdPN8tZrHg_4_0"></a><a id="Tc_w5a_4wOMm0uS0fos5a7L7A_4_1"></a><a id="Tc_6-1eFtFFSk-j9uDVt1oamw_4_4"></a><a id="Tc_MNuCwD43QEuJhlT8cCwJKg_5_0"></a><a id="Tc_VYXAFs7m7UKl3ZhMFHW7Ug_6_0"></a><a id="Tc_JBVobTbcakaWfRfttOLPHA_7_0"></a><a id="Tc_hEtOwLtgyUa832rF_lXwFg_8_0"></a><a id="Tc_Y5Ey67TydUqX74JWz9OCjQ_9_0"></a><a id="Tc_80JXoYMtW0-EddFacJzazw_10_0"></a><a id="Tc_Oqxu11Ue_EGijKgQLlhp9Q_11_0"></a><a id="Tc_wjVzBx2us0mUXu90-2AnMA_12_0"></a><a id="Tc_rYw0hKlcHEuRynxxgMDDcA_13_0"></a><a id="Tc_qleyS5UXxE6DuKyvmqwahw_14_0"></a><a id="Tc_XCpphti94025ZJP_7YHXJQ_15_0"></a><a id="Tc_ItH7rfYSWU6x5qIKVHHVBw_16_0"></a><a id="Tc_c38qxPiRlEWG1tsW_rk9Yg_17_0"></a><a id="Tc_qvDVUWgx0kqZgRCYfrJmqw_18_0"></a><a id="Tc_eECE5DetFk6onpzxGcjReg_19_0"></a><a id="Tc_pCTCBNV2KUiDT8l37lNFow_20_0"></a><a id="Tc_yQt3E4fomU6seq6idSnZ8g_21_0"></a><a id="Tc_8D0NGw1KY0OXF_5i4xyX1w_21_5"></a><a id="Tc_5QHrx87lGEijwBeqMhB1Hw_22_0"></a><a id="Tc_iADV-oz5cUabz9FhWjhUTA_22_5"></a><a id="Tc_lahHEQRvVU6C8FrJCrkvOw_23_0"></a><a id="Tc_QCn_HQxiYk2Fa4gmtVOF9w_24_0"></a><a id="Tc_Dly87m_b_k2OM0oYoixzDQ_25_0"></a><a id="Tc_RMP6HrxP5USiToqZAZ8sfQ_26_0"></a><a id="Tc_XKf5DF9xTku-0e1HmOdRhA_27_0"></a><a id="Tc_PR9R5J4BmUiACwZJg9jVVw_28_0"></a><a id="Tc_lvfhOiDEikKZ-yjuRI0XSg_28_1"></a><a id="Tc_baWfTgLmT0ySiaHIh71B9w_28_4"></a><a id="Tc_iv0bE4KPhECEn-kYBZdQKQ_30_0"></a><a id="Tc_O0MPzG73RUS1mXCXGzkOyA_31_0"></a><a id="Tc_3p1uYuPAoUSBWe7DefmH6g_31_1"></a><a id="Tc_dgKW4--3vUy1hlAVRAftsw_31_2"></a><a id="Tc_5UU32DQWlkqXJtPWrjVbtw_31_4"></a><a id="Tc_UJE0VtBVqkO35jbedS0FNA_32_0"></a><a id="Tc_DqbFzx1CBkG89Mv1M5PGIA_32_1"></a><a id="Tc_BiNx2exXUUWBCiT5ZCbF8A_32_4"></a><a id="Tc_Lk2sAleyIke_g8JGcXaDPA_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ybB3BGIJf06tpZyLk0vjyA_4_2">12,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4-SpmduImk2iv41rwgrbfg_4_5">27,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_JgSv5zgAgkOFW4E8xxDH7A_6_2">411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_QrOQ5ixe60eJTdMvK3K5hQ_6_5">538</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Non-cash lease (credit) charge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="mtva:NonCashLeaseCreditCharge" sign="-" scale="3" id="Tc_vlTP3sgYO0izqr8rrpkMLQ_7_2">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:NonCashLeaseCreditCharge" scale="3" id="Tc_ASKp-MwllUOGnhp8WYAh6A_7_5">4</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_h1zBqECJXEqp-fq1s4uedQ_8_2">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_VsUS7Bqq9kydZHNAsGf5zw_8_5">20</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Gain from change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_JUd4VwMnMkODogB9eG2BRQ_9_2">225</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_TwPHqIqngEiNYs1AVl2Yaw_9_5">297</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Change in operating assets and liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_WjUZS1SgGEenR8ZJ7-z6Yg_11_2">542</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_iapRxwDbV0mJ5dzVghhOUg_11_5">20</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_3oZN9WKQZECg0Um_DX3utw_12_2">2,819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_P6TGv8V-n0aWiScj_rGIiA_12_5">3,058</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_fBL8PZQNPEOtjPuKYWURAQ_13_2">431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_vV-olSnR-UiFAEq8sntgfA_13_5">461</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_HS4UrSrf6ke8gm_v7JY1eg_14_2">15,701</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_K2mtE7nSbUeG2heJ08cb2g_14_5">24,710</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_cE7Db4uLxESK10LOaUpkuA_16_2">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_5hnAelWY7Ui4Ct9M66BJyg_16_5">8</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_yXR0jJ7ASUWTUtrqR7Emeg_17_2">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_xek2EgKbl0WIO9HICir7QA_17_5">8</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" id="Tc_h-pEcIfcHkmFa9D7IkICLQ_19_2">9,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="3" id="Tc_hRhTNABM1UqRfD8nPxNCSg_19_5">19,998</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payment of issuance costs in connection with the sale of common stock and warrants under the securities purchase agreements from a private placement offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RjEAz-8aH0qGHIsQmJ0Vyw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_Mygo1PcH9ke4ij4C8k30YA_20_2">887</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_m9XJ7gRPJEitR8u7ybUG-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_m6pnIIJ8REOxcYl3jRmuhw_20_5">1,651</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from the issuance of common stock under an at the market offering agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_J_K81PseZUeD9UJGSY4LKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_OWWX__4qUEOK1qyUj7JvCg_21_2">1,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payment of issuance costs in connection with the sale of common stock under an at the market offering agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_J_K81PseZUeD9UJGSY4LKg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_Y1e6Lg3UNUKVyOmleo8ZJw_22_2">351</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_UZaegN36Gkm6N2UPwFHWLw_23_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_MfbTCvCj7EeOcEU3R1nOLQ_23_5">1</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_vZmcxe7SWEuvkRSrjNlgwA_24_2">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_ksv80UEnXk6ZZ0_htrTinw_24_5">48</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_LWPR3NESlk62InYd9kYI7w_25_2">9,964</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_T8KgUj0w1k27yhWPuy7xxg_25_5">18,300</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_-LOf-oFrMUeYPegjsAqRrw_26_2">5,739</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_awNBlM1yBEyfsdsPSF7xGw_26_5">6,418</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_mth9HEhN2kaOr_HtF7hMQQ_27_2">16,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_p6BGbHzMikGjugACnlLEcQ_27_5">22,435</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash and cash equivalents at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_CX-3zot4EkWQAUTu1qvi9g_28_2">10,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_rFThqKngD0mnYqExeahaBA_28_5">16,017</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Supplemental non-cash investing and financing transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Fair value of warrants issued to placement agent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:FairValueOfWarrantsIssuedToPlacementAgent" scale="3" id="Tc_qN-brSMSikKwMRku6a0HmQ_31_5">309</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:74.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_gNlwzEdjek2jbEi0Y_3zSQ_32_2">152</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="background:#ffffff;">The accompanying notes are an integral part of these consolidated financial statements</span>.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="Notes"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_Wp5OK9utLEeaYTcs8OZzLQ" continuedAt="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1. </b></span><b style="font-weight:bold;">Business, basis of presentation, new accounting standards and summary of significant accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">MetaVia&#160;Inc. (the &#8220;Company&#8221;), a Delaware corporation, and its subsidiaries are referred to collectively in these notes to the financial statements of the Company as &#8220;MetaVia,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us.&#8221; <span style="letter-spacing:0.2pt;">We are a clinical-stage biotechnology company focused primarily on </span>developing novel pharmaceuticals to treat <span style="letter-spacing:0.2pt;">cardiometabolic diseases. </span><span style="letter-spacing:0.2pt;">We have two programs, vanoglipel (DA-1241) and DA-1726, focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;) and obesity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;letter-spacing:0.2pt;">While we focus our financial resources and management&#8217;s attention on the development of vanoglipel (DA-1241) and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases which we are not planning to advance development on and have, or continue to consider for, out-licensing and divestiture opportunities. In July 2024, we entered into an exclusive out-license agreement with MThera Pharma Co., LTD. (&#8220;MThera&#8221;) to provide MThera with the rights to one of our legacy therapeutic program, NB-01, for the treatment of painful diabetic neuropathy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">Our operations consisted principally of performing research and development (&#8220;R&amp;D&#8221;) activities, which include preclinical development and clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Common stock reverse stock split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In December 2025, we completed a <span style="-sec-ix-hidden:Hidden_8EGw4Ym3A0uwPDR1wgoCVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-eleven reverse stock split of our common stock (the &#8220;Reverse Stock Split&#8221;). As a result, every eleven shares of our issued and outstanding common stock were combined, converted and changed into one share of our common stock. Any fraction of a share of our common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of our common stock as reported on Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;) on the last trading day before the Reverse Stock Split. The Reverse Stock Split was approved by our stockholders at the annual meeting of stockholders in June 2025. At the annual meeting, the stockholders approved a proposal to amend our certificate of incorporation to affect a reverse split of our outstanding common stock at a ratio in the range of <span style="-sec-ix-hidden:Hidden_o4iplQlu0UKYhhkCeUIVBg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-five to <span style="-sec-ix-hidden:Hidden_3jKcbu2it0anJWRaB5fFmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-thirty to be determined at the discretion of our Board of Directors (&#8220;Board&#8221;). In November 2025, our Board approved the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Reverse Stock Split did not impact the number of authorized shares of common stock, which remains at <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_sjacPYcP-k2E-s0nbbmITw">100,000,000</ix:nonFraction> shares. For the Reverse Stock Split, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of our common stock, the number of shares issuable upon vesting of restricted stock units (&#8220;RSUs&#8221;) and the number of shares reserved for issuance pursuant to our equity incentive compensation plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the accompanying consolidated financial statements and these notes to the consolidated financial statements, the number of shares of common stock and per share data have been adjusted to give effect to the Reverse Stock Split for all periods presented. Additionally, since the common stock par value was unchanged, the amounts for common stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">As reflected in the consolidated financial statements, we had&#160;</span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_-GUtkhYWIEmDI9TL5bnnfg">10.3</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million in cash as of December 31, 2025. We have experienced net losses and negative cash flows from operating activities since our inception and had an accumulated deficit of&#160;</span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_SKFBRUjHnEiO2onhs71iLw">148.8</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million as of December 31, 2025. We have incurred a net loss of&#160;</span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_0JBcK2osK0aGULmsAELjVg">13.0</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million and net cash used in operating activities of </span><span style="color:#212529;background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="6" id="Narr_0DS6G7R5y0G4keuXPzQytQ">15.7</ix:nonFraction></span><span style="color:#212529;background:#ffffff;">&#160;million for 2025. Due in large part to ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="color:#212529;background:#ffffff;">We plan to continue to fund our operations through equity offerings, debt financing, the exercise of existing warrants, or other sources, potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all, or that the warrants issued in previously consummated offerings will be exercised. To the extent that we can raise additional funds by issuing equity securities or in the event our existing warrants are exercised, our stockholders may experience significant dilution. Any debt financing, if available, </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont1" continuedAt="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, we may slow down or stop our ongoing and planned clinical trials until such time as additional capital is raised and this may have a material adverse effect on the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The determination as to whether we can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;</span>Our consolidated financial statements&#160;<span style="background:#ffffff;">have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of our liabilities in the normal course of business.</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_yIhAM8zTQkW1ITfLVcs5Dw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).<span style="background:#ffffff;"> Our fiscal year-end is December 31st for each year presented. </span>All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_XHhuEbM02k6OaEgzMz8DQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">New accounting standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;background:#ffffff;">Adoption of new accounting standards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">In December 2023, the</span>&#160;<span style="background:#ffffff;">Financial Accounting Standards Board</span>&#160;(&#8220;FASB&#8221;)<span style="color:#212529;background:#ffffff;"> issued</span><span style="color:#212529;">&#160;</span>Accounting Standards Update (&#8220;ASU&#8221;) <span style="color:#212529;">2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve the transparency of income tax disclosures by amending the required rate reconciliation disclosures as well as requiring disclosure of income taxes paid disaggregated by jurisdiction. As amended, the rate reconciliation disclosure will be required to be presented in both percentages and reporting currency amounts, with consistent categories and greater disaggregation of information. This ASU also includes amendments intended to improve the effectiveness of income tax disclosures and eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. This ASU is&#160;</span><span style="color:#212529;background:#ffffff;">effective for annual periods beginning after December 15, 2024. We adopted ASU 2023-09 in 2025, </span>and applied the new disclosure requirements retrospectively. Accordingly, prior period disclosures have been adjusted to reflect the new disclosure requirements, <span style="color:#212529;background:#ffffff;">see Note 9. Income taxes for additional information. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;background:#ffffff;">Accounting standards issued but not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">In November 2024, the FASB issued&#160;ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the consolidated financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to the consolidated financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting period beginning after December 15, 2027. Early adoption is permitted. We continue to evaluate the impact of adopting this ASU to our notes to the consolidated financial statements and processes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:UseOfEstimates" id="Tb_Z36PNNdx_0qNEcfQEIIWNQ" continuedAt="Tb_Z36PNNdx_0qNEcfQEIIWNQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont2" continuedAt="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont3"><ix:continuation id="Tb_Z36PNNdx_0qNEcfQEIIWNQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_7iD2znEzCUixNxL-At-GRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">D.</b></span><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We maintain cash and cash equivalents at a financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_33zJL9LY2EWyH92xpFadjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Property&#160;and equipment, net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Property and equipment are recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from <span style="-sec-ix-hidden:Hidden_zDOjGvv570SVRG19o1qIjg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to <ix:nonNumeric contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_NRfJ8T4b6Eu_-IBdIjogkw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_lDPj4xnuuUi_dlzdhF7aKA">five years</ix:nonNumeric>. Tangible assets acquired for R&amp;D activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_4xCuHQD2-EKJ6cv2uHU8cg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">F.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We assess our contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. We have recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to our&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, we recognize lease payments as an expense on a straight-line basis over the remaining lease term.&#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="mtva:WarrantLiabilitiesPolicyPolicyTextBlock" id="Tb_vzc-xHh_WEu5_2OlBOw3Xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">G.</b></span><b style="font-weight:bold;">Warrant liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Warrants are accounted for as liabilities at their fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities is recognized as a fair value change in warrant liabilities in the consolidated statements of operations and as an operating item in the statement of cash flows. Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_H4h8RU8w306TyliZ2LClwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">H.</b></span><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. <span style="background:#ffffff;">The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.</span><span style="background:#ffffff;"> </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_c2RfVQQ3MkuMcghw3H_Mdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">I.</b></span><b style="font-weight:bold;">Segment reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We manage and operate as <ix:nonFraction unitRef="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_91M_AP6Q2kOZTIYpj49-fQ">one</ix:nonFraction> reportable segment, which is principally the business of development of pharmaceutical products, with <ix:nonFraction unitRef="Unit_Standard_location_PUM6ABDH9EqMpz0Yzt6Sgw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt-sec:numwordsen" name="mtva:NumberOfGeographicLocation" scale="0" id="Narr_AbS5ZoXJAU2AkMSQRXRyCg">one</ix:nonFraction> geographic location in the U.S. We do not operate separate lines of business with respect to each pharmaceutical product being studied. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our chief executive officer. The CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. The measure of performance used by the CODM to assess segment performance is reported on the consolidated statements of operations as loss from operations and net loss. Since the Company only has&#160;<ix:nonFraction unitRef="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_pwm5DyNCfkWPrEDEuoO6tg">one</ix:nonFraction>&#160;reportable segment, our CODM does not need to decide on how to allocate resources between segments. The measure of segment assets is reported on the consolidated balance sheets as total assets. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_vCtNhG5yAUOBQVEpy0EdKg" continuedAt="Tb_vCtNhG5yAUOBQVEpy0EdKg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">J.</b></span><b style="font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">R&amp;D expenditures for pre-clinical and clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the United States Food and Drug Administration, are charged to R&amp;D expense as incurred. These expenses consist of costs incurred in performing development activities, including salaries and benefits, equity-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Expenses incurred for certain R&amp;D activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont3" continuedAt="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont4"><ix:continuation id="Tb_vCtNhG5yAUOBQVEpy0EdKg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for R&amp;D activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected as clinical trial accrued liabilities in the accompanying consolidated financial statements. Advance payments, if any, for goods or services to be received in the future for R&amp;D activities are deferred and capitalized as prepaid expenses and other current assets in the accompanying consolidated balance sheets. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Tb_6-lE8_YPkUmTpLSUFD3LqQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">K.</b></span><b style="font-weight:bold;">General and administrative expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with R&amp;D activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="mtva:PatentCostPolicyPolicyTextBlock" id="Tb_AkxpN7TfzUmGr3ue6dj3oQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">L.</b></span><b style="font-weight:bold;">Patent costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_SfcWxPiWEkWvZB5r7iRjPQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">M.</b></span><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Compensation costs related to equity instruments granted are recognized at the grant date fair value, which is amortized as compensation expense on a straight-line basis over the requisite service period (generally, the vesting period) for both graded and cliff vesting awards. We have elected to account for forfeitures as they occur.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_SpMm6ZENU06fJ-sUVOY_Sw" continuedAt="Tb_SpMm6ZENU06fJ-sUVOY_Sw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">N.</b></span><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for under the asset and liability method.&#160;Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Regular assessments are made on the likelihood that our deferred tax assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of available positive and negative evidence, giving weight based on the evidence&#8217;s relative objectivity. Sources of positive evidence include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years, and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected in future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that, if unfavorably resolved, would adversely affect future profit levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The remaining carrying value of our deferred tax assets, after recording the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably. To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our policy is to recognize both interest and penalties related to uncertain tax positions as part of the income tax provision.&#160;A significant judgment is required in evaluating our tax positions, and in determining our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions are likely to be challenged and we may ultimately not prevail in defending those positions.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Wp5OK9utLEeaYTcs8OZzLQ_cont4"><ix:continuation id="Tb_SpMm6ZENU06fJ-sUVOY_Sw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_1-1M_hCKpkGRjvniwmVRlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">O.</b></span><b style="font-weight:bold;">Foreign currency translation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Certain transactions are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_8ldNbMYmXkOTt15J74_J5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">P.</b></span><b style="font-weight:bold;">Loss per share of common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Basic earnings or loss per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the weighted average number of shares of common stock. Diluted earnings per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the sum of the weighted average number of shares of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive securities had been issued. Potentially dilutive securities include convertible preferred stock, outstanding stock options, non-vested RSUs and outstanding warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share of common stock by application of the treasury stock method, except if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities. For additional information, see Note 10. Loss per share of common stock.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_-TmJv0wwakCMY3O4rnMWbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q.</b></span><b style="font-weight:bold;">Concentrations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Financial instruments that potentially subject us to concentration of credit risk consist of cash. As of December 31, 2025, our cash is held by one financial institution in the U.S., and we believe that the financial institution is financially sound. Accordingly, minimal credit risk exists with the financial institution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Supplier Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In 2022, we entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A ST&#8221;), a related party, which requires Dong-A ST to be the sole manufacturer for the production of vanoglipel (DA-1241) and DA-1726. If any issues arise in the manufacturing and we are unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete the development of vanoglipel (DA-1241) or DA-1726.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="Tb_yXbvhNye0UmuvmCJnePt8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">R.</b></span><b style="font-weight:bold;">Loss contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In determining whether an accrual for a loss contingency is required, we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range, that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely), no accrual is recognized. </p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_30f6db70_9722_43b1_8670_195fe29a05ab"></a><a id="Tc_DFmAsVm4qEmISYmANER5sw_1_2"></a><a id="Tc_sfvaQVeeu0Ch5NRYNuRFEA_2_2"></a><a id="Tc_LGjUD_NeiECVldc4Vsj4ZQ_2_6"></a><a id="Tc_f5FeH6enCEmu9QYjfHbHfQ_3_0"></a><a id="Tc_dKN2ubsG_keTN4fKdYUgHQ_3_2"></a><a id="Tc_m-AOZW-mRUGveUVSQ3dskQ_3_5"></a><a id="Tc_EH6IZaxZxEG81ikQSB8t4w_4_0"></a><a id="Tc_d-uc9GAsVkG8pA1zANyvag_5_0"></a><a id="Tc_XXf-KlnKIkyN4tlcpPT40Q_5_6"></a><a id="Tc_u3WPjiHdSEaVtwT7ffkXWA_6_0"></a><a id="Tc_yQq3GM9QP0yRof9-gmTbgw_7_0"></a><a id="Tc_DlmuKdA0lkSAEZcOayYPrQ_7_2"></a><a id="Tc_kRKwJDoxaUOo8KWnyWZNPQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock" id="Tb_ARfeCe10nU6oWtA2FVes6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2. </b></span><b style="font-weight:bold;">Prepaid expenses and other current assets</b>&#160;</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_gNUgKDKZtk-FxxQXDhriXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Prepaid expenses and other current assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_HdwC_WcjQE-8Fvl4e-_bRg_3_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_GJWuP7wiRkCARgMPq4B0bA_3_6">5</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" id="Tc_Za741FJ_HkiQzDgMVV8scg_4_3">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" id="Tc_n-2cQcx200OBrAka5yw6wA_4_6">16</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Deferred equity offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" id="Tc_ogP4mvZapU25213hbxfrBQ_5_3">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_JMH0td9A2UKdAPaR5nxj0A_6_3">47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="Tc_mJj0mKxdnkqwZJuhN71f_Q_6_6">34</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_SCpDBp9EvkOMPamWXcw16Q_7_3">597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_5KtX7F-gVEGCRaOwN5qoqw_7_6">55</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e815b213_0a52_4bb6_864f_2b5678e5de76"></a><a id="Tc_czio0Lx2vE6RnLNXgDaxBQ_1_2"></a><a id="Tc_W3d1oSLM0kiAd0DpKnNKdA_2_2"></a><a id="Tc_5Ai7sEl25UORX8-_RlYuaA_2_6"></a><a id="Tc_fSQ80uMO0UibME3Mp9jgqg_3_0"></a><a id="Tc_ZboI1_gEfkS5HCjbqHh8fg_3_2"></a><a id="Tc_hOHnQ_l4-kKON_7L9-ixvg_3_5"></a><a id="Tc_3PS7ErYfVE-WT3R4YUGvew_4_0"></a><a id="Tc_AAn09Dx1YEKQr13ERct8Uw_5_0"></a><a id="Tc_7A8GMnO5S06PCJdpL4eigw_5_2"></a><a id="Tc_vCE78MgoqkS6nIEwAp3B6A_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_PWRKFS7yxU6hUiptMUYdvw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3. </b></span><b style="font-weight:bold;">Property and equipment, net </b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_OiLptOCobkykxunUpgewZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Property and equipment, net consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sz9glBx46kKXETTsz5EoAg_3_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_85dZqCPnjEaYZ4xVvfqvFw_3_6">88</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_IwamY-sDG0uNnqA8yURd5g_4_3">73</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_iDdQ_xcG50G_tDBiPXiw-Q_4_6">54</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_lGQuEuBIiUWE7AALxq6fUQ_5_3">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_xHvHu0-tTUiRFr7u-F8tGw_5_6">34</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">We recorded depreciation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Narr_PpeMgF1hqkSux_UwdpP6jQ">19</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Narr__yoKruYtD0uDXvpaZYASpQ">20</ix:nonFraction> thousand for 2025 and 2024, respectively, which was included in general and administrative operating expenses in the accompanying consolidated statements of operations.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d2737aff_39ba_4570_ae49_1f5a5d1f288e"></a><a id="Tc_Y1V68RHzxE-SifAUPrDk-A_1_2"></a><a id="Tc_-jugkjpW906r_HqAAWFanA_2_2"></a><a id="Tc_GAU566nACUCQeDZVmkIlmQ_2_6"></a><a id="Tc_bCdQW_TX0Ui9twKQ52KzJQ_3_0"></a><a id="Tc_YbxL7POPC0G6W7oeB0cEeA_3_2"></a><a id="Tc_3bLR8TCm50ybSx5vSkgdew_3_5"></a><a id="Tc_7fBgsmDunEWfPdaG1PzHGA_4_0"></a><a id="Tc_EsLES_WcIUmSkyVvfsE9xQ_5_0"></a><a id="Tc_iRTvOzD1Pka84WM6u1g9Xw_6_0"></a><a id="Tc_Nky7rjmX10qu48NdrjeDoA_6_2"></a><a id="Tc_vd_ukLD9DUWZggRijYTLnQ_6_5"></a><a id="_28f3df3c_6fc2_4ef1_bcda_596b6b443333"></a><a id="Tc_2hgHrseP10iF_9b602JmkA_1_2"></a><a id="Tc_8Tm6MEGwPkCtilZz2YXMvQ_2_0"></a><a id="Tc_YQe6yhxsdkmXdRfhhemfqQ_2_2"></a><a id="Tc_czx2SOdIDEGu3Dr2SjCUAQ_4_0"></a><a id="Tc_QuyaclhTFE2WTeMCPtzAAQ_6_0"></a><a id="Tc_JEO7ibdlnUKMUtQOVcd2UQ_6_2"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="mtva:CurrentLiabilitiesTextBlock" id="Tb_Jr9Wu_FhJ0mrakawNh1R3w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4. </b></span><b style="font-weight:bold;">Current liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Accrued expenses and other current liabilities</i></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_yH6mRNl1NEOQGeHHcMHo2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Employee related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_AT8nD7X950G8BzEACFZh0g_3_3">829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_z1c8__TxCEKIrox3B08E8g_3_6">713</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_gLTT5uTR1EioesULEjcYpg_4_3">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_ImxB0ATupk2Fiz7ILoCNMg_4_6">17</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_pWKWh3cxYUKJ9KZjq83wUQ_5_3">149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_CU9v3LXKYkeIEyRgaRuY3g_5_6">55</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_f-8hLSb0z0qERliY4HFi3w_6_3">993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_bfSJ4_R1xUugoBIDE4Hx5g_6_6">785</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><i style="font-style:italic;">Warrant liabilities</i></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock" id="Tb_N74r6oCNt0utbjek1ZHqXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">Changes to our warrant liabilities are summarized as follows (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" scale="3" id="Tc_oZ2bPylSU0moVYW2zamVgA_2_3">658</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_VOralR6i3ki9t2Jyaw8bcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gain from change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_AB9deOn6Gkitl1khKYTroA_3_3">297</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" scale="3" id="Tc_nnGAXZ-nU0-hsSIqw411lA_4_3">361</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_W8CSMwv8-EWiuCXptape3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gain from change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_oXhh9QoGJ06KoqLsMacv5g_5_3">225</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" scale="3" id="Tc_RfUehSAMhE-yfb0J-NG-xw_6_3">136</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">Our warrant liabilities relate to the 2022 Series B warrants issued in November 2022. These warrants are considered to be derivative instruments; accordingly, we recorded their estimated fair value as warrant liabilities. We estimated the fair value of these warrants using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_5JUPmWBTaUaA1SH0VbF-BA">eight</ix:nonFraction> warrants can be exercised for one share of common stock for <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_GG-OyGYbHUevmT63tYsdDg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_CPue0qjI9EyKCGeZkw5ndA">no</ix:nonFraction> additional consideration, which results in the warrant exercise price to be <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Pm8jpU390US1n5cJZv4yWw">zero</ix:nonFraction>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_m5Kr-gwjxUac9XKlSyRUUw" continuedAt="Tb_m5Kr-gwjxUac9XKlSyRUUw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b></span><b style="font-weight:bold;">Related party</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">License agreement with Dong-A ST for </b><b style="font-weight:bold;">vanoglipel</b><b style="font-weight:bold;letter-spacing:-0.2pt;background:#ffffff;"> (DA-1241) and DA-1726</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We entered into a license agreement with Dong-A ST pursuant to which we received an exclusive global license (except for the territory of the Republic of Korea) for two proprietary compounds for specified indications (the &#8220;2022 License Agreement&#8221;) upon meeting certain financing milestones. The 2022 License Agreement covers the rights to vanoglipel (DA-1241) for treatment of MASH and DA-1726 for treatment of obesity and MASH. The 2022 License Agreement also provides that we may develop vanoglipel (DA-1241) for the treatment of&#160;<span style="letter-spacing:0.2pt;">type 2 diabetes mellitus</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">In connection with the 2022 License Agreement, we entered into a shared services agreement with Dong-A ST (the &#8220;Shared Services Agreement&#8221;), relating to vanoglipel (DA-1241) and DA-1726, pursuant to which Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel (DA-1241) and DA-1726 under the terms provided in the Shared Services Agreement.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ebcf3173_e4c2_43d4_ae8a_142feed3de9d"></a><a id="_ebcf3173_e4c2_43d4_ae8a_142feed3de9d_2"></a><a id="_ebcf3173_e4c2_43d4_ae8a_142feed3de9d_3"></a><a id="_444b5ebc_0762_4b68_8bbc_aaf38a813ebb"></a><a id="_444b5ebc_0762_4b68_8bbc_aaf38a813ebb_2"></a><a id="_444b5ebc_0762_4b68_8bbc_aaf38a813ebb_3"></a><ix:continuation id="Tb_m5Kr-gwjxUac9XKlSyRUUw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the terms of the 2022 License Agreement, Dong-A ST will be eligible to receive (i) regulatory milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1726Member_F0QfeopiT0211MFhaQu96A" decimals="-5" format="ixt:num-dot-decimal" name="mtva:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" scale="6" id="Narr_fnK2zV0ErUauXnf1Kpfqlw">178.0</ix:nonFraction> million for DA-1726 and $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1241Member_SxJHN2alKEOYThrSrZEvCw" decimals="-5" format="ixt:num-dot-decimal" name="mtva:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" scale="6" id="Narr_UE--tdxS9Eqw5T-lMeRyMw">138.0</ix:nonFraction> million for vanoglipel (DA-1241), dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by us from the commercial sale of products covering vanoglipel (DA-1241) or DA-1726. The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A ST or MetaVia may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within <ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A" format="ixt-sec:durwordsen" name="mtva:PeriodForFailToCureBreachMayTerminateAgreement" id="Narr_qYrbDbAGZkKSLdoGYsLbIw">60 days</ix:nonNumeric> of notice of such breach; provided that if the breach cannot be cured within the <ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A" format="ixt-sec:durwordsen" name="mtva:CurePeriodForBreachingParty" id="Narr_M4apPvEAwUSL5goiTfKKlg">60-day</ix:nonNumeric> period and the breaching party started to remedy the breach, if such breach is not cured within <ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A" format="ixt-sec:durwordsen" name="mtva:PeriodForTerminationNotice" id="Narr_X5UH0W3_0UO0YfKIkvIW6g">90 days</ix:nonNumeric> of receipt of written notice, or (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a <ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A" format="ixt-sec:durwordsen" name="mtva:CurePeriodForPetitionForBankruptcy" id="Narr_GWzlaVha3ESmuYwfUBWTpA">30-day</ix:nonNumeric> cure period in the case of a petition for bankruptcy).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, there were no potential milestones under the 2022 License Agreement<span style="background:#ffffff;"> that were </span>yet considered probable; therefore, <span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_88E3SsucMk6CjnvOW7ejPA" decimals="-5" format="ixt-sec:numwordsen" name="mtva:MilestonesAccrued" scale="6" id="Narr_yR0T9WMyj0ONFCzsx8iApg">no</ix:nonFraction></span><span style="background:#ffffff;">&#160;liabilities were recorded.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">As of December 31, 2025, Dong-A ST and Dong-A Socio Holdings Co. Ltd. (&#8220;Dong-A Holdings&#8221;),&#160;an affiliate company of Dong-A ST, owns approximately </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongStMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9ad2NPEyvEeMZjvJ8Yr8bg" decimals="2" format="ixt:num-dot-decimal" name="mtva:PercentageOfCommonStockOutstanding" scale="-2" id="Narr_4czs7M2IZkmQD3P6kaOVXA">39</ix:nonFraction>%</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongSocioHoldingCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__CXlbv6yq0CPsUFeeflmGA" decimals="2" format="ixt:num-dot-decimal" name="mtva:PercentageOfCommonStockOutstanding" scale="-2" id="Narr_GW0gkcFozU-01TesEtzs5w">37</ix:nonFraction>%</span><span style="background:#ffffff;">, respectively, of our outstanding common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Shared services agreement with Dong-A ST</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In conjunction with the 2022 License Agreement, we entered into the Shared Services Agreement with Dong-A ST, relating to vanoglipel (DA-1241) and DA-1726. The Shared Services Agreement provides that Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel (DA-1241) and DA-1726 under the terms provided in the Shared Services Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="font-size:10pt;">Either party may terminate the Shared Services Agreement for the other party&#8217;s material breach that is not cured within&#160;</span><ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_H5aw50Xy8UOPMQzuBjjNEw" format="ixt-sec:durwordsen" name="mtva:PeriodForFailToCureBreachMayTerminateAgreement" id="Narr_PoTz9ArO70qnokzUOCVjfg"><span style="font-size:10pt;">30 days</span></ix:nonNumeric><span style="font-size:10pt;">&#160;of notice. Dong-A ST may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by us which is not cured within&#160;</span><ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_H5aw50Xy8UOPMQzuBjjNEw" format="ixt-sec:durwordsen" name="mtva:PeriodForFailToCureBreachMayTerminateAgreement" id="Narr_We8xgnFaL0y8rzK1ZRAVrg"><span style="font-size:10pt;">30 days</span></ix:nonNumeric><span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="background:#ffffff;">We incurred R&amp;D expenses of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_Hor3BE5nO0Ky5ynGuPLNiA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_O7kEMHJJzUqQVmw-eCCNEg">3.4</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_uNAveP-XZ06GyWkwukd-jg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="Narr_IfpMelcF-U6V2q-xOe8Thg">4.9</ix:nonFraction></span><span style="background:#ffffff;"> million for 2025 and 2024, respectively, under the Shared Services Agreement, which are included in operating expenses: research and development in the accompanying consolidated statement of operations</span>. The aggregate payable to <span style="background:#ffffff;">Dong-A ST</span><span style="background:#ffffff;"> was </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_ijSpHdvY9EeDuNgww9C1Jg">3.3</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="Narr_LoTBTmyOiUmq8mWhqf-jlw">1.5</ix:nonFraction></span><span style="background:#ffffff;"> million as of December 31, 2025 and 2024, respectively, under the Shared Services Agreement, which is included in </span><span style="color:#212529;background:#ffffff;">related party payable</span><span style="background:#ffffff;"> in the accompanying consolidated balance sheets. Of the total amount payable to Dong-A ST as of December 31, 2025, (i)&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" decimals="-5" format="ixt:num-dot-decimal" name="mtva:RelatedPartyExtendedPaymentLiability" scale="6" id="Narr_TX3vj0vg4Ueu8-rRRQAZzQ">2.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million is payable in accordance with an invoice with extended terms in which&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" decimals="-3" format="ixt:num-dot-decimal" name="mtva:RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" scale="3" id="Narr_q4Cd07Unr0aBvdGvk_4Tdw">650</ix:nonFraction></span><span style="background:#ffffff;">&#160;thousand will be paid on March 31, 2026 and June 30, 2026 and&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" decimals="-3" format="ixt:num-dot-decimal" name="mtva:RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" scale="3" id="Narr_14WD4Zo0qk665cS260xa4Q">716</ix:nonFraction></span><span style="background:#ffffff;">&#160;thousand will be paid on September 30, 2026, (ii)&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" decimals="-3" format="ixt:num-dot-decimal" name="mtva:RelatedPartyAccruedInterestPayable" scale="3" id="Narr_cdKjiBh3k0KHtPNA740ZwA">29</ix:nonFraction></span><span style="background:#ffffff;">&#160;thousand is payable in accrued interest based on a fixed interest rate of&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_Hor3BE5nO0Ky5ynGuPLNiA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionRate" scale="-2" id="Narr_NGhUw8KhfkuDEzO0Oxo7Ng">4.6</ix:nonFraction>%</span><span style="background:#ffffff;">&#160;per annum, and (iii)&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A" decimals="-5" format="ixt:num-dot-decimal" name="mtva:RelatedPartyClinicalTrialAccruedLiability" scale="6" id="Narr_j7-OnoSMT0iWDPGeTZzWxw">1.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million is payable in clinical trial accrued liabilities.&#160;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_iYe_778hB0yP7kBd-QUUpg" continuedAt="Tb_iYe_778hB0yP7kBd-QUUpg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">. </b></span><b style="font-weight:bold;">Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Operating lease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="font-size:10pt;">In August 2023, we entered into a non-cancelable operating lease for our corporate headquarters in Cambridge, Massachusetts. The initial lease term is for&#160;</span><ix:nonNumeric contextRef="As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_5m5x1hDwJUSw-MwbZwWdpQ"><span style="font-size:10pt;">three years</span></ix:nonNumeric><span style="font-size:10pt;">&#160;with an option, which was exercised in November 2025, to renew for an additional&#160;</span><ix:nonNumeric contextRef="As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_C7AFsxAbE0SrylNm15swdQ"><span style="font-size:10pt;">two-year</span></ix:nonNumeric><span style="font-size:10pt;">&#160;term. The lease commenced in September 2023 and expires in August 2028. We recorded lease rental expenses and made lease cash payments of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_DBzDIMGO0UWZ5viFB9H-Hw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_jFGU-5v3YEeeT3vucLpaAg"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_NeLyzkBTRESkMVZRZnvj7g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_9yYh_Kzodkm9nyVpO3xhsA"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_DBzDIMGO0UWZ5viFB9H-Hw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_IfIYlR2W5U-sf8IaQshrgg"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_NeLyzkBTRESkMVZRZnvj7g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_IdmyvdE91E6F8tz2OudfTA">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;"> million for 2025 and 2024. </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f281824c_6952_47cd_aeaf_2de041cf2d82"></a><a id="Tc_I22QibGDCkOvAfoVEFEG6Q_1_2"></a><a id="Tc_McC7rTJD3kSuNEeMazee4Q_2_2"></a><a id="Tc_76cIEtTx5ESw7_PiFIM8gQ_3_0"></a><a id="Tc_FR1W8vzOKE6qXgR2Kd9c3A_3_2"></a><a id="Tc_8qKZvmYPB0auKyi5c4JQZw_4_0"></a><a id="Tc_Z6_CTmOojU6tO_el8zxR7g_5_0"></a><a id="Tc_4kRh08Z2JEyK2KU7XEfn5Q_6_0"></a><a id="Tc_Q0AggiEXCEmRMH59dW03wA_7_0"></a><a id="Tc_fUyMEv8Kq0aCESSjKzN2ew_8_0"></a><a id="Tc_VxpiHSUswkqXKC_syE3alg_9_0"></a><a id="Tc_9LIxWHddTk22sMuXRXPINA_10_0"></a><a id="Tc_VNGrwt-yMEGRImZSUnNvyA_10_2"></a><ix:continuation id="Tb_iYe_778hB0yP7kBd-QUUpg_cont1" continuedAt="Tb_iYe_778hB0yP7kBd-QUUpg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_YFmtnYE-wkevLFfUSqTrhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Operating</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Lease</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_R171cp4eMEGf2yZ0hHCjpQ_3_3">92</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_tdVFkw6gn0yYQRZlT_scfQ_4_3">94</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_NRFCOdpgpUKaaXaYKR09NQ_5_3">64</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_-9sfFGkEfkS3IGcoZqGS7Q_6_3">250</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less effect of discounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_RFlLrxyka0WtFAK1FjQtwg_7_3">40</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">  Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_4k4qEeftZEu_YHA3cUDscg_8_3">210</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_3Btod2l5pkCD1rWosBw_ww_9_3">68</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_PiSJTs1myEm91dghVECZeA_10_3">142</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">As of December 31, 2025 and 2024, our lease liability, which represents the net present value of future lease payments, was calculated utilizing a discount rate of <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_hyOQooLLv0aTYxqxsTi_Fw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_dp8--xAWSUeIYbLwqy9New"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_eujJ4gdQVEqiI8yThjB2Ww" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_eRwWylDNmkmI_ZWw_yoQdw">11</ix:nonFraction></ix:nonFraction>%, which corresponds to our estimated incremental borrowing rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Contingent payments and license agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">We have certain contractual contingent payments under various merger or license agreements executed between 2019 and 2020 for our </span><span style="letter-spacing:0.2pt;">legacy therapeutic programs. </span>Since we have discontinued the clinical development of our legacy therapeutic programs, we believe any <span style="letter-spacing:0.2pt;">contractual payments to be paid by us or to be received by us under these agreements are</span> remote. Therefore, a<span style="background:#ffffff;">s of December 31, 2025, </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractualObligation" scale="3" id="Narr_cfAO8Huhjk-YSdm0XDZuLw">no</ix:nonFraction></span><span style="background:#ffffff;">&#160;liabilities or </span><span style="-sec-ix-hidden:Hidden_wKCHieRLFUC2maYfjLnuGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">assets</span></span><span style="background:#ffffff;"> were recorded in the accompanying consolidated financial statements for our legacy therapeutic programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Legal proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">From time to time, we may be involved in various claims and legal proceedings arising out of our ordinary course of business. We are not currently a party to any claims or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business and consolidated financial statements. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Purchase commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies, and testing, manufacturing, and other services and products for operating purposes. These contracts provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. There are no minimum purchase requirements under these contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Employment agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Employee benefit plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;background:#ffffff;">We adopted a 401(k) defined contribution plan in November 2018, which became effective in January 2019, for all employees over age&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg" format="ixt-sec:duryear" name="mtva:DefinedContributionPlanEmployeeEligibilityAge" id="Narr_RVNqvAhtL0m4gW8BW2vJsw"><span style="font-size:10pt;background:#ffffff;">21</span></ix:nonNumeric><span style="font-size:10pt;background:#ffffff;">. Employees can defer up to </span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2019_To_1_31_2019_srt_RangeAxis_srt_MaximumMember_AaM2dzgtbUGUiNDeiHy-eQ" decimals="2" format="ixt:num-dot-decimal" name="mtva:DefinedContributionPlanEmployeeContributionDeferredPercentage" scale="-2" id="Narr_rzQe7El220y5923fOMP43Q">90</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;"> of their compensation through payroll withholdings into the plan subject to federal law limits. Discretionary employer matches vest over a </span><ix:nonNumeric contextRef="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg" format="ixt-sec:durwordsen" name="mtva:DefinedContributionPlanEmployerMatchingContributionVestingPercentage" id="Narr_UOBlGVkcTU-gOtnRHgyv7w"><span style="font-size:10pt;background:#ffffff;">six-year</span></ix:nonNumeric><span style="font-size:10pt;background:#ffffff;"> period beginning on the second anniversary of an employee&#8217;s date of hire. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are </span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg" decimals="2" format="ixt:num-dot-decimal" name="mtva:EmployeeCompensationVestingPercentageOnContribution" scale="-2" id="Narr_2L07GgwzsUGNo_yOu3ilkA">100</ix:nonFraction>%</span><span style="font-size:10pt;background:#ffffff;"> vested upon contribution. </span><span style="font-size:10pt;background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_YXaYJtstS0aQEh4kulVFvQ"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_8EDgZHAkuEyLPMg5GzTEtg">No</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;background:#ffffff;"> matching contributions were made for 2025 and 2024.</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_iYe_778hB0yP7kBd-QUUpg_cont2"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_yOfJwkFjAkGdTvreyU--iA" continuedAt="Tb_yOfJwkFjAkGdTvreyU--iA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">S</b><b style="font-weight:bold;">tockholders&#8217; equity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock when outstanding. The holders of the common stock are entitled to <ix:nonFraction unitRef="Unit_Divide_Vote_shares_ETjCJisZMkuUls7w3gpdKA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt-sec:numwordsen" name="mtva:CommonStockVotingRightsPerShare" scale="0" id="Narr_9OEbb1sco0C72jPi_U1aYg">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders. Common stockholders are entitled to receive dividends at the sole discretion of our Board. There have been <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DividendsCommonStockCash" scale="0" id="Narr_e8ZsuSa-kES7swEDjIHSGg">no</ix:nonFraction> dividends declared on common stock to date as of December 31, 2025. In the event of any liquidation, dissolution, or winding-up of MetaVia, the holders of common stock shall be entitled to share in the remaining assets of MetaVia available for distribution post preferential distributions made to any holders of our preferred stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="color:#212529;font-weight:bold;">2025 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Private placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In May 2025, we closed on a private placement offering with Dong-A ST and Dong-A Holdings, and received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q" decimals="-5" format="ixt:num-dot-decimal" name="mtva:ProceedsFromIssuanceOfStockAndPrefundedWarrants" scale="6" id="Narr_9gAgdbjBFE-0BXwnhRi7dw">9.1</ix:nonFraction>&#160;million, net of placement agent cash fees of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q" decimals="-5" format="ixt:num-dot-decimal" name="mtva:PaymentsForPlacementAgentFees" scale="6" id="Narr_4ASI11rtKEOLUFMxseQoTA">0.4</ix:nonFraction>&#160;million and related offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr__Gk0X5xUFES_xM1KEpShZw">0.5</ix:nonFraction>&#160;million. The private placement offering was comprised of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wnYn01gZwkuVXR2tkTICZw">861,758</ix:nonFraction>&#160;shares of our common stock for a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_g-nMTDkmr0qcUvmTTdeMng" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_YFtyoxW15E6CFBG4MBwE5g">7.81</ix:nonFraction>&#160;per share, and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EuG_rsEk0UOcbgfii4_NdQ" decimals="INF" format="ixt:num-dot-decimal" name="mtva:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr__C0Rbf1yLEiPCLXrbls5Sw">418,651</ix:nonFraction>&#160;pre-funded warrants to purchase up to an equivalent number of shares of our common stock for a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_UbXNPFwR4km-FBdk7rEUxg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_tkFyyJdJokm6FoE15EPDqg">7.799</ix:nonFraction>&#160;per pre-funded warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Each pre-funded warrant had an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SlAYXsZ0v0Ojj_aGP7CPdQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_3qx26sz80EiDmRUJk8EM6Q">0.011</ix:nonFraction>&#160;per share, and was exercisable beginning on June 30, 2025, which was the effective date of receiving stockholder approval for the issuance of the shares of common stock underlying the pre-funded warrants. Thereafter, on the same date, all pre-funded warrants were exercised for an equivalent number of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">At the market offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">In November 2025, we entered into an At The Market Offering Agreement (the &#8220;ATM Sales Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as sales agent and/or principal (&#8220;Ladenburg&#8221;), pursuant to which we may offer and sell, from time to time through or to Ladenburg, shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_11_30_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_WmjFk2Gzpk-vzxZey8nlRQ" decimals="-5" format="ixt:num-dot-decimal" name="mtva:MaximumAggregateOfferingPrice" scale="6" id="Narr_IVxqrKrtRUqSc8lmc9QHVg">2.3</ix:nonFraction> million (the &#8220;ATM Program&#8221;). The offer and sale of the shares of common stock pursuant to the ATM Program is made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-278646) filed with the SEC on April 12, 2024, and declared effective by the SEC on April 23, 2024, as supplemented by a prospectus supplement to be filed with the SEC on November 6, 2025 pursuant to Rule 424(b) under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the ATM Sales Agreement, Ladenburg may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act. We are not obligated to make any sales of the Shares under the ATM Sales Agreement. The offering of Shares pursuant to the ATM Sales Agreement will terminate upon the termination of the ATM Sales Agreement by Ladenburg or us, as permitted therein. We are obligated to pay Ladenburg an aggregate sales agent commission of <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_11_30_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_WmjFk2Gzpk-vzxZey8nlRQ" decimals="3" format="ixt:num-dot-decimal" name="mtva:PercentageOfSalesAgentCommission" scale="-2" id="Narr_UElZ-0GONUSDC3tVE3u1uw">3.0</ix:nonFraction>% of the gross sales price of the Shares sold pursuant to the ATM Sales Agreement. We will also reimburse Ladenburg for certain specified expenses in connection with entering into the ATM Sales Agreement, which contains customary representations and warranties and conditions to the placements of the Shares pursuant thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;">In November 2025, we sold <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tsRUNXWZPEGfDNhRZemC5w">106,788</ix:nonFraction> shares of common stock under the ATM Program and received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_aqF2nNXCCkaYBcbWg_ubGw">0.9</ix:nonFraction> million, net of sales agent commission and related offering expenses. As of December 31, 2025, we have $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_KFhU-S1q0U2O8QEiJ_Qd2Q" decimals="-5" format="ixt:num-dot-decimal" name="mtva:AggregateOfferingPrice" scale="6" id="Narr_vdFmDrj_QkSaANYa380Jyw">1.1</ix:nonFraction> million remaining under the ATM Program in which we may offer and sell shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;padding-top:8pt;background:#ffffff;margin:0pt;"><b style="color:#212529;font-weight:bold;">2024 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Securities purchase agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">In June 2024, we entered into and closed on&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_security_7HQ_97jGkEaCEOxlJP1q6A" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="INF" format="ixt-sec:numwordsen" name="mtva:NumberOfSecuritiesPurchaseAgreementsEntered" scale="0" id="Narr_QKLtXQEm10qRFzjIdgXSoA">two</ix:nonFraction></span><span style="color:#212529;">&#160;securities purchase agreements (the &#8220;Offering&#8221;)&#160;</span><span style="color:#212529;">with an institutional investor and Dong-A ST, and&#160;</span><span style="color:#212529;">received aggregate gross proceeds of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_XGG-TXLTCE6irySFyVooBA">20.0</ix:nonFraction></span><span style="color:#212529;">&#160;million, of which </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_us-gaap_TypeOfArrangementAxis_mtva_SecuritiesPurchaseAgreementMember_xy3ONbSXnUiU4ZOJJSQw7Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_JSQ5p1Au2kemQROv4ydxHg">10.0</ix:nonFraction></span><span style="color:#212529;">&#160;million was received from Dong-A ST. The </span>net proceeds received was $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_nWm-0apYuUqLdzwLg9iW4w">18.3</ix:nonFraction>&#160;million, net of placement agent cash fees of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="-5" format="ixt:num-dot-decimal" name="mtva:PaymentsForPlacementAgentFees" scale="6" id="Narr_XVE00dMkekeo_rxDG30HwA">0.7</ix:nonFraction>&#160;million and related offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_TYx9uSrGb0OzgDAw8wi68w">1.0</ix:nonFraction>&#160;million. <span style="color:#212529;">The Offering was comprised of (i)&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_LI4XOpgH4UWr_CcK618ewQ">300,707</ix:nonFraction></span><span style="color:#212529;">&#160;shares of common stock at a purchase price of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ExKQGNyc2UCDlqt3ydfMgA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_YwNBgD7n8EiXK_KbEVwNXg">43.23</ix:nonFraction></span><span style="color:#212529;">&#160;per share, (ii) pre-funded warrants to purchase up to&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_XsQA2v8F9EmA-rSv4Z8zuw">161,924</ix:nonFraction></span><span style="color:#212529;">&#160;shares of common&#160;stock at a purchase price of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_B4d24TGsU06ooiONIt817g">43.219</ix:nonFraction></span><span style="color:#212529;">&#160;per warrant, (iii) Series A warrants to purchase&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_5R_W5kJG9k-0RfAK0QNCRg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Z4CCYnDiU0OUR6aVHbhaDg">462,640</ix:nonFraction></span><span style="color:#212529;">&#160;shares of common stock, and (iv) Series B warrants to purchase up to&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesBWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_A7Fo-RQiLkOdMLTRGG3G9A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_oQWiYiEp_U-3QG1HPRrFMw">693,962</ix:nonFraction></span><span style="color:#212529;">&#160;shares of </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yOfJwkFjAkGdTvreyU--iA_cont1" continuedAt="Tb_yOfJwkFjAkGdTvreyU--iA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">common stock. Collec</span><span style="color:#212529;">tively, the Series A and Series B warrants are referred to as &#8220;PIPE Common Warrants.&#8221; Of the total shares of common stock issued in the Offering,&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_m2f7pvSnI0u6Km1eo2IeDA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wN9-AbGwB0a-NxnVcvE-7A">69,396</ix:nonFraction></span><span style="color:#212529;">&#160;shares were sold to an institutional investor. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">The pre-funded warrants have an exercise price of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Apz5-CsLqE66VJhI9Exrlw">0.011</ix:nonFraction></span><span style="color:#212529;">&#160;per share and are immediately exercisable and </span>are considered to be perpetual warrants without any expiration date.&#160;In the second quarter of 2025,&#160;all of the&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.<span style="color:#212529;"> The PIPE Common Warrants have an exercise price of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ffXAC5ncsEmnTRq2WxB_jQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_6DY12ZzxH0eowCRt91rOxQ">43.23</ix:nonFraction></span><span style="color:#212529;">&#160;per share and are exercisable as of September 18, 2024, which is the effective date of the stockholder approval received at the Special Meeting of Stockholders for the issuance of the shares upon exercise of the warrants. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Series A warrants </span>were exercisable at any time from September 18, 2024 and expired unexercised in June 2025. The <span style="color:#212529;">Series B warrants </span>were exercisable at any time from September 18, 2024<span style="color:#212529;"> and </span>expire on the earlier of September 18, 2029 and the&#160;six month&#160;anniversary following the date on which we publicly announce receiving positive Phase 1, Part 3 data for DA-1726.<span style="color:#212529;"> Based on the terms of the PIPE Common Warrants, we have concluded that the accounting classification of the PIPE Common Warrants is to be stockholders&#8217; equity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-size:10pt;">Under the terms of the pre-funded warrants and the PIPE Common Warrants issued to the institutional investor, we may not affect the exercise of any such pre-funded warrants or PIPE Common Warrants, and the holder will not be entitled to exercise any portion of any pre-funded warrants or PIPE Common Warrants, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates) would exceed&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg" decimals="4" format="ixt:num-dot-decimal" name="mtva:ThresholdPercentageForBeneficialOwnership" scale="-2" id="Narr_iKRzkA49RkGt1ayJ8-R3ug">9.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;"> (in the case of the pre-funded warrants) or&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ffXAC5ncsEmnTRq2WxB_jQ" decimals="4" format="ixt:num-dot-decimal" name="mtva:ThresholdPercentageForBeneficialOwnership" scale="-2" id="Narr_5WvCWznwck-al7ysHcMblg">4.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;"> (in the case of the PIPE Common Warrants) of the number of shares of our outstanding common stock immediately after giving effect to the exercise (the &#8220;Beneficial Ownership Limitation&#8221;), as such percentage ownership is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the SEC. A holder of the pre-funded warrants or PIPE Common Warrants that were issued to the institutional investor may increase or decrease the Beneficial Ownership Limitation to a higher or lower percentage (not to exceed&#160;</span><span style="color:#212529;font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg" decimals="4" format="ixt:num-dot-decimal" name="mtva:ThresholdPercentageForBeneficialOwnership" scale="-2" id="Narr_l2MUpM4nR0W44LKu4o0pyw">9.99</ix:nonFraction>%</span><span style="color:#212529;font-size:10pt;">), effective&#160;</span><ix:nonNumeric contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_2dC3y_eK3ki1KsOJenFcjg" format="ixt-sec:durwordsen" name="mtva:EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" id="Narr_24JHYo2fjU2S2tN8OV0GSw"><span style="color:#212529;font-size:10pt;">61&#160;days</span></ix:nonNumeric><span style="color:#212529;font-size:10pt;"> after written notice to us. Any such increase or decrease will apply only to that holder and not to any other holder of the pre-funded Warrants or PIPE Common Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Placement agent</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">We paid the placement agent a cash fee equal to&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="3" format="ixt:num-dot-decimal" name="mtva:PercentageOfPlacementAgentFee" scale="-2" id="Narr_Y1aOzlZnvkGf04TXh_7sIQ">7.0</ix:nonFraction>%</span><span style="color:#212529;">&#160;of the gross proceeds of the Offering received from a certain institutional investor and&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="-5" format="ixt:num-dot-decimal" name="mtva:PlacementAgentFeesNonAccountableExpensesAndClearingCosts" scale="6" id="Narr_ZOkuYIoBeEqmXx2GGCG6iw">0.1</ix:nonFraction></span><span style="color:#212529;">&#160;million for non-accountable expenses and clearing costs. In addition, we issued warrants to the placement agent&#8217;s designees (&#8220;Placement Agent Warrants&#8221;) to purchase up to&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_UWwXt0LFQUGszw5aFILSWg">11,564</ix:nonFraction></span><span style="color:#212529;">&#160;shares of common stock (which represents&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="2" format="ixt:num-dot-decimal" name="mtva:PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" scale="-2" id="Narr_M22hAD_um0S12rslnJ8nVg">5</ix:nonFraction>%</span><span style="color:#212529;">&#160;of the sum of the shares of common stock and pre-funded&#160;Warrants sold to the institutional investor in the Offering) at an exercise price of&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_pVBUh4UCvUWaR2wRlPETNg">54.0375</ix:nonFraction></span><span style="color:#212529;">&#160;per share (which represents a premium of&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Owwpee6TWESXOEjeyqvrAw" decimals="2" format="ixt:num-dot-decimal" name="mtva:PremiumOfOfferingPriceForExercisePricePercentage" scale="-2" id="Narr_GajzAu84AU-tovqERLFEZg">125</ix:nonFraction>%</span><span style="color:#212529;">&#160;of the offering price per share of common stock in the Offering). The Placement Agent Warrants are exercisable at any time from September 18, 2024 and expire in July 2026. The grant date fair value of the Placement Agent Warrants was&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_JRbtNwgbMkubIffCED4uRg">0.3</ix:nonFraction></span><span style="color:#212529;">&#160;million, which represents a non-cash issuance cost. The weighted average grant date fair value per share of these Placement Agent Warrants was&#160;</span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Owwpee6TWESXOEjeyqvrAw" decimals="2" format="ixt:num-dot-decimal" name="mtva:WeightedAverageFairValuePerShareOfWarrants" scale="0" id="Narr_QqTPNEmZa02wL-cGnEIGpg">30.03</ix:nonFraction></span><span style="color:#212529;">, which was determined using the Black-Scholes option pricing model. Based on the terms of the Placement Agreement Warrants, we have concluded that the accounting classification of the Placement Agent Warrants is stockholders&#8217; equity in the accompanying consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">Upon the exercise for cash of any PIPE Common Warrants issued to a certain institutional investor, we shall pay the placement agent (i) a cash fee of&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="3" format="ixt:num-dot-decimal" name="mtva:PercentageOfPlacementAgentFee" scale="-2" id="Narr_jJ8RaZLtM0CWIu6zUipbwA">7.0</ix:nonFraction>%</span><span style="color:#212529;"> of the aggregate gross exercise price paid in cash with respect thereto and (ii) a non-cash fee in the form of additional warrants to purchase the number of shares of common stock equal to&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA" decimals="3" format="ixt:num-dot-decimal" name="mtva:PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" scale="-2" id="Narr__ZnZFbInY0u7wYMi4dbJOQ">5.0</ix:nonFraction>%</span><span style="color:#212529;"> of the aggregate number of such shares of common stock underlying such warrants. The cash fee payable to the placement agent for any PIPE Common Warrants exercised by the institutional investor is accounted for as a contingent commitment and will be recorded as an offset to any gross proceeds received from any future exercises of PIPE Common Warrants by the institutional investor. The non-cash fee payable to the placement agent for any PIPE Common Warrants exercised by the institutional investor is accounted for as contingent warrants (&#8220;Placement Agent Contingent Warrants&#8221;) to purchase up to&#160;</span><span style="color:#212529;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Pj0_bY8RoEiWwD-LtiPp0A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_7Uggju1H3kqx0kLuyWd1_Q">28,915</ix:nonFraction></span><span style="color:#212529;">&#160;shares of common stock, which is subject to performance criteria of the institutional investor regarding any exercise for cash of any PIPE Common Warrants with an assumed grant date of the Offering closing date, and an exercise price of </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Pj0_bY8RoEiWwD-LtiPp0A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8p1cC49bg0GxFAQqldtBNg">54.0375</ix:nonFraction></span><span style="color:#212529;">&#160;per share. The weighted average grant date fair value per share of these Placement Agent Contingent Warrants was </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_oBKoosGoG0GmD3xTsVOS-w" decimals="2" format="ixt:num-dot-decimal" name="mtva:WeightedAverageFairValuePerShareOfWarrants" scale="0" id="Narr_nRw4ituWC02RUKMe-7YtJA">37.73</ix:nonFraction></span><span style="color:#212529;">, which was determined using the Black-Scholes option pricing model. Based on the terms of the placement agent engagement letter, we have concluded that the accounting classification of the Placement Agent Contingent Warrants is to be stockholders&#8217; equity. On each balance sheet reporting date, we will need to assess whether it is probable for us to issue warrants to the placement agent based on whether it is probable for any PIPE Common Warrants to be exercised by the institutional investor. As of December 31, 2025 and 2024, </span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ab4e30b6_f6cc_44dc_ad0a_fc5f0e84942a"></a><a id="Tc_x8dt9ND07EKb-MJzQLuhsg_1_1"></a><a id="Tc_siI-MssMIk6rNz7QJ3LoFg_2_1"></a><a id="Tc_EOtXEnK73USUJcLsst1Fyg_3_1"></a><a id="Tc_mYTlqqU0C0WwsPkNLOWRnw_3_5"></a><a id="Tc_HkipINKqeEiDtFCwMa8zXg_3_8"></a><a id="Tc_ewVLMKcwpEyR5r4LSViaWg_4_0"></a><a id="Tc_Wco8LkhAikiFtI1L_jGgug_4_1"></a><a id="Tc_Y1V66xg9oE6xWRlQIxWuhQ_4_3"></a><a id="Tc__fwDRVOFb0KJK37XvXHphA_4_5"></a><a id="Tc_eWae42zL0kKIE17MMhfhzQ_4_8"></a><a id="Tc_Kc9Qs5BpzESPnRNzzwqKyQ_5_0"></a><a id="Tc_TXxg6Dj8kEmmHu9Ad3Pdyg_5_1"></a><a id="Tc_WDazFICnKkSV-hFrdPc2KQ_5_5"></a><a id="Tc_WAHGTIa07EGwWxkMBtaEzA_5_8"></a><a id="Tc_lmv9H2t_O0aRzsWg0Enw1A_6_0"></a><a id="Tc_lG-qV8fyo0alLMdeSZXIhw_6_5"></a><a id="Tc_DjGm5uj2-0y5_f0_aH5abg_6_8"></a><a id="Tc_LjX5H5Uh2Eyh5LmohfeXmg_7_0"></a><a id="Tc_A9s3HRecC0S7zljonI_VQA_7_1"></a><a id="Tc_o1RsDeyYaEWOces-UBVkHA_7_5"></a><a id="Tc_qbGOW4g7eEiU-uXetx0p7w_7_8"></a><a id="Tc_LG2kJ8EzY06kedXXzu3h3w_8_0"></a><a id="Tc_ZwCUpy03zEOGxROC0PsqSw_8_5"></a><a id="Tc_qb1mR4RgPEiX_8N9TvZF8g_8_8"></a><a id="Tc_tkHclftd9UaPv61aW7-MYQ_9_0"></a><a id="Tc_D92fHbUpqEiabEm5tdCH9Q_9_5"></a><a id="Tc_8-vDX2N8vkKsdJtOVrUyNA_9_8"></a><a id="Tc_ZVVtV-xM2U-Pah0IxaeEsQ_10_0"></a><a id="Tc_D0H4stYdaEqqeOobde-2jg_10_1"></a><a id="Tc_3a30sef-X0ONsScUdFTwNA_10_5"></a><a id="Tc_-2nTb--woUOQ2LBZN29fKA_10_8"></a><a id="Tc_56id06OVvUOLG9UUNlE29g_11_0"></a><a id="Tc_Bi-piahbhEGwokoEpughvA_11_1"></a><a id="Tc_gWrNztVvu0WDKC5zk_Blmw_11_5"></a><a id="Tc_8FyB2gEGMkiml-nx7Q6yOw_11_8"></a><a id="Tc_vHgAKmkS0kO8_O6hwHY8YQ_12_0"></a><a id="Tc_IwLNp6xEUEi4YQfds3FRPQ_12_5"></a><a id="Tc_aK9q7eX7KUOFslNG4UOD7A_12_8"></a><a id="Tc_0d0JRyVPIUycvLzPV9sa8g_13_0"></a><a id="_ae953b24_0d08_4369_8b87_04e2ef823289"></a><a id="Tc_c4WYWhHdOEK3hmxkbKY__A_1_3"></a><a id="Tc_xCrz03tnZUGIK9YAV62MNQ_2_3"></a><a id="Tc_ifKE6VAOB0mFqSv5sLFC_g_2_6"></a><a id="Tc_cLPkdeRHr0GA63w-1d9vhQ_3_0"></a><a id="Tc_NmCB0aS96kSLHLlW39H5MQ_3_3"></a><a id="Tc_WAz4j3bD6UePTQmSC_wVqA_3_6"></a><a id="Tc_GvFRsrhwbE-2s1fltcm1XQ_4_0"></a><a id="Tc_qjYBvgivTEWmLmNIGWn8sg_5_0"></a><a id="Tc_LCIthB3rpU2TsQvoTaicIg_5_3"></a><a id="Tc_FLrXN_bGYE-Czoii04cVVw_5_6"></a><ix:continuation id="Tb_yOfJwkFjAkGdTvreyU--iA_cont2" continuedAt="Tb_yOfJwkFjAkGdTvreyU--iA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">we determined that the issuance of additional warrants to the placement agent is not yet probable; accordingly, the Placement Agent Contingent Warrants had no impact on the consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following warrants were outstanding as of December 31, 2025 and 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_iRwSIDeWIU6-jO8KxYZk5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of Common Stock Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Outstanding Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Expiration</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrant Issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Date</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 2020 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_YGrezCPF50-XvUz2iIIe3A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__6UCso7Hs0upP_kAGJfCAQ_5_3">14</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_h23ZVALXkUePo8zvVv2roQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_2RGdiUMyCk6UxMDRTUAI0w_5_6">33,000.00</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_wyVIcQ8InUKuk3VoxOQDHg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_oiJjbR7yTk2PYZ8NOoXi9g_6_1">942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_PtYIpmGNVk2Lhpzik7xP3g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__jYwjMVEhUuLzPIV4dwVXw_6_3">942</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_wyVIcQ8InUKuk3VoxOQDHg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_8eVQMufNtEGsF5utXYocPA_6_6">15,919.20</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 2021 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_mylIA7H1dEi-aM6e5VbgCg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_dXtbXuqAZE2qRFr3evCzAQ_7_3">1,399</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_CldTLXRU7EGJY2I47LLydQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_U6tSg15Sr0SEHr1zkchmew_7_6">9,900.00</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 2022 Series B <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_P2PYXQtICka2t-8vSHUfrA_8_1">16,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_Bv82ps5MOk6lD4sKnKRyPA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_J7IsQ8CKVUSriKTluwUA6g_8_3">16,176</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Z-hHgsnYS0GGw_lNgdOT-Q_8_6">0.00</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2027</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Placement Agent<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_lJphVo6Jl0qN7JwUudMRRg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_HPjcDq5xw0K5qk4As0Uz4Q_9_1">11,564</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_6202WPiPKkSw1AqR8WV3jw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_gWtJ1XNPwkaNl-kdl0MICQ_9_3">11,564</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_lJphVo6Jl0qN7JwUudMRRg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_1Sur5rg8ZEGlddaXU6nZWw_9_6">54.0375</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Pre-Funded <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_UBBH_Z1Tz0S_4XGQiyGdpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_sS0UDqGWzEmVLl_a-fi4rw_10_3">130,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_5H7GHDBMaE2UtxHkUd3cCQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_eBU5bwuqWUy4C90sskSSHQ_10_6">0.011</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">No expiration date</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Series A <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_0TANxl4zWU2M4iUW_Dzy7g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_i0LyqIFn1E2nETOQFp_PjQ_11_3">462,641</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_mJd36VtBzkuAj1i6nsWyDQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Q2rUUolfyUGl808Ez8VKtA_11_6">43.23</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Series B <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_5XNmuoAqREGcG2s4IaMjeQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_hBDZssLNYUyNkyd5U38Zug_12_1">693,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_KNYPj3hEekKCq6iIEa5aJA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_bGRAZtnpaUumefeT4KPrMg_12_3">693,962</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_5XNmuoAqREGcG2s4IaMjeQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_EYWsAHago0mgEEW4Mm-I9A_12_6">43.23</ix:nonFraction> </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">September 2029 (latest date)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Mlp1gj5kJE2pVxl-jy10Ig_13_1">722,644</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_NDHlvQzLFUqvB2yVL-YJ5w_13_3">1,316,698</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="margin-top:4pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants expired unexercised in April 2025.</span><span style="display:inline-block;width:4.57pt;"></span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">T</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hese warrants have a cashless exercise provision whereby&#160;the warrants can be exercised for common stock for&#160;</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_vvalEg-TrUejRp41VE8WPw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_aW1gUfZAlEyY8jtoEtbsSw">no</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;additional consideration, which renders the </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_waCAFY3cfEuZyDAJOyUoHA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_c86q4lSMZUWMgLqbPbMYjw">264</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;per warrant exercise price to be&#160;</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_orxQwUg110-1269nNhDK5w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_I6xw34AGg0miQteYY0BFVg">zero</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expire in July 2026. </span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable immediately and are considered to be perpetual warrants without any expiration date. In the second quarter of 2025,&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_e1wxSJsny0iiOB1sr8mCHA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_m5OO97UkAEmJ-Po4o9Vo7w">130,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock. Additionally, in the third quarter of 2024, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_nrhpLK0mj0K9W2Dt9Ye5iQ" decimals="INF" format="ixt:num-dot-decimal" name="mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_yrZcbrrVkUqJUJkpO5rLtw">31,924</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.</span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expired unexercised in June 2025.</span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expire on the earlier of September 18, 2029 and the </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_QGD8FaaTKk-VCqeDRjoO0w" format="ixt-sec:durwordsen" name="mtva:ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" id="Narr_CIWpvX1rNEmBAQO0Yu8N4w"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary following the date on which we publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.</span></td><td style="width:36pt;"/></tr></table><div style="margin-top:8pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_zOf13awCrUSmwnJ5izt-ww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense was included in general and administrative <span style="color:#212529;">and research and development as follows&#160;</span><span style="color:#212529;background:#ffffff;">(in thousands)</span><span style="color:#212529;">:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_7qHL6fLtgESMlXNDqOZJ2w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_BNJgHxVouUySqp7vpGnm4A_3_4">305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1hYaSL2Lxk-1ulrcFV5TrA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2-u-Ut5rd0mLaMS4STG1qg_3_7">366</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U6f5XE8pkEWgllVziJrf-Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yft7mZUF0UuHGorGLZDieA_4_4">106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9AAALrlJp0yWgwl3bBqvvA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_m0L3j3TMH0yXJWWychBT_w_4_7">172</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_V8n0HcPbhEW4EysAB-8qUQ_5_4">411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YO2lcn88Tku2dqnR9QVUrg_5_7">538</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Stock-based award plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In December 2019, in connection with a merger, we adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;). Additionally, we adopted the 2021 Inducement Plan in November 2021 and the Amended and Restated 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;) in December 2022. The 2019 Plan, 2021 Inducement Plan and 2022 Plan provide for the grant of stock options, restricted stock, RSUs and other equity awards of our common stock to employees, officers, consultants, and directors. Stock options granted under any of these plans expire within a period of not more than </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2019Member_gmTdCJ8ork6VP-4xURIA1A" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_LS5zrXslwEu58p-lLRWN5Q"><span style="font-size:10pt;">ten years</span></ix:nonNumeric><span style="font-size:10pt;"> from the date of grant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">With the adoption of the 2022 Plan, <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_WheZv6ekHUqp74VTHk60Zw">no</ix:nonFraction> additional shares may be added to or granted from the 2019 Plan, and any shares related to forfeited awards are carryover to the 2022 Plan. In June 2024, in connection with the 2024 Annual Meeting of Stockholders, </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_QtUsom2I0kGWjIZFpWqeBQ_1_6"></a><a id="Tc_5u8eiPqwuUaIyebtkt37oQ_2_2"></a><a id="Tc_iLSb48EE4UyZybdszg01ZQ_2_6"></a><a id="Tc_HaplBjUsjkCmB0sVIzXhQA_3_0"></a><a id="Tc_EZ_EHNGt-UeL21wln1at_w_3_2"></a><a id="Tc_vPio5uEDs0WG_WUnUEqLhw_3_4"></a><a id="Tc_5zfFDFhJmU6ZY03laBpqug_3_6"></a><a id="Tc_rZcovSxeUEiaRIWG4gqYWw_4_0"></a><a id="Tc_BMBNDnxRc0eb180vxFkn-g_4_2"></a><a id="Tc_Huh4JaDNNEGTvbWt3wr3sQ_4_4"></a><a id="Tc_Gj_CoXf2DUqSbw2x2icOlA_4_6"></a><a id="Tc_S74vfNCcLUugs5qDr1XlVg_5_0"></a><a id="Tc_nrTZFJus0USBIRfO3Z28fg_6_0"></a><a id="Tc_GlUyJt08zUyTfHw1dE05Lg_6_2"></a><a id="Tc_dhBGqSDTr0qLzjhFfmeE2A_6_4"></a><a id="Tc_-TIrG0aEV0yoJRyCRNvXiw_7_0"></a><a id="_f19e6f2a_9eed_4156_b50f_ca960c26eea0"></a><a id="Tc_0hx0vJM7mUOiZN97aSU7OQ_1_2"></a><a id="Tc__twAP1fsK0aCQ7x5a8mdpA_1_10"></a><a id="Tc_OncQ1v1VbUeSN-9RSLYb1A_2_2"></a><a id="Tc_X_OrVMBnVUqxc1TiMmEK7g_2_4"></a><a id="Tc_0YOWLfkZwECmAcpqn51o5A_2_10"></a><a id="Tc_7axwOVYFJ0yBDkqI83OPtA_2_12"></a><a id="Tc_bf-j4xsM4UqX7tNzxQCeLw_3_2"></a><a id="Tc_7JzY52HpCk2jqI7pz4x0sA_3_4"></a><a id="Tc_Z69VRxKo0USpwYqCktfMHQ_3_7"></a><a id="Tc_66dZaudIy02h4M5dO1rx3A_3_10"></a><a id="Tc_UftGvBDxZU-Hzrhp5nDbbw_3_12"></a><a id="Tc_oVrdk8A4m02g4wOnNGeU7w_3_15"></a><a id="Tc_gM7EeWNtukmFKS72SELnaQ_4_2"></a><a id="Tc_FyKHGATe9ky_JAzXQ0x7Rg_4_4"></a><a id="Tc_617PoCuPiUORTl7Kswxx6A_4_7"></a><a id="Tc_xBDzBViHdE2h40SVY0P1uA_4_10"></a><a id="Tc_n7pYf8Ya5Eelq3euLLv0VQ_4_12"></a><a id="Tc_paDuKgEWz0mW-FBpcOy55A_4_15"></a><a id="Tc_WhlXm1_UgEqJs3BtyYHgTw_5_2"></a><a id="Tc__VwA5XofSEez4iWuoH7UJA_5_4"></a><a id="Tc_Fq478i_gs02GbCQxkMUwbA_5_7"></a><a id="Tc_zOS9LK35dk2Bx-6dqACxCg_5_10"></a><a id="Tc_hSwx6stLT0KfFpZPWvgY1w_5_12"></a><a id="Tc_JmNaHHOwekST2L5xB3kATg_5_15"></a><a id="Tc_tH2gGl90DUuK5kl7fvUIHw_6_0"></a><a id="Tc_sKtSWNxzYUikzmVaHMP4og_6_4"></a><a id="Tc_OyAQNwnCx0WOmU1r5-pQXA_6_7"></a><a id="Tc_Ui6hOAFINUO9FITW4j7OtA_6_12"></a><a id="Tc_rO85tA3oZkGetoftoLBE9A_6_15"></a><a id="Tc_XJ0IShnldEm3VdZvmI3Cbw_7_0"></a><a id="Tc_MyK8MdUUP0yluevQYOZTPg_8_0"></a><a id="Tc_YI3iDOk_Dk6065bIs84pEw_9_0"></a><a id="Tc_qd9JvHPWNk6ThLevIm2z7w_10_0"></a><a id="Tc_srVE1dy4jk-ZXGShwvUo2g_11_0"></a><a id="Tc_e9w_OOszW0q_YKE7qDha-A_12_0"></a><a id="Tc_2XeVjls-OkWUOfHEbGgJdQ_13_0"></a><a id="Tc_L540BI9de0iE0R4cRe0Jcw_13_4"></a><a id="Tc_cQle9117OUqbDIIz7Q4e5w_13_7"></a><a id="Tc_bjzfQSKLCkareuJqCDrzBQ_13_12"></a><a id="Tc_C7EWhAFmZU2PaB7n2jS2DQ_13_15"></a><ix:continuation id="Tb_yOfJwkFjAkGdTvreyU--iA_cont3" continuedAt="Tb_yOfJwkFjAkGdTvreyU--iA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">our stockholders approved an amendment (the &#8220;Amendment&#8221;) to our 2022 Plan. Pursuant to the terms and conditions of the Amendment, the 2022 Plan was amended to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">automatically increase on January 1st of each year for a period of </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg" format="ixt-sec:durwordsen" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" id="Narr_GxzALvtxdE6pw1KT1yY2Ww"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> commencing on January 1, 2025 and ending on (and including) January 1, 2032, the aggregate number of shares of common stock that may be issued pursuant to Awards (as defined i</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">n the 2022 Plan) to an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_bptj8j1ggkOdOwqHXocPhg">10</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Fully Diluted Shares (as defined in the 2022 Plan) as of the last day of the preceding calendar year, provided, however that the Board may act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of shares of common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of Incentive Stock Options (as defined in the 2022 Plan) to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_fPHz9pePvU-5r9-YvskzmQ" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="Narr_8CKtGuiCo0SaxePZkq7XkQ">1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million shares of the common stock plus the amount of any increase in the number of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares that may be available for issuance pursuant to the annual increase described above, but in no event more than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_w5EWKu_kcUSEno9r_g_0ww" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="Narr_IkDwlSgFqUaEcbVYUdlDRw">15</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million shares of the common stock issued as incentive stock options.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table summarizes the outstanding awards issued pursuant to our stock-based award plans and inducement grants as of December 31, 2025 and the remaining shares of common stock available for future issuance:</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="Tb_8iyLJOgDFke_CEF7ztzlOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining shares of</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">common stock available</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Plan Name</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for future issuance</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2022 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_hGYstxKTzU2ZqyDcJ15G0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_dLlqkJl6SEis4mruaNoyyQ_5_2">6,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_BxRCSzAuXEimnCRFgvNQ_w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_f4WDwKEAiE-CiTjOR18sbQ_5_4">29,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_fPHz9pePvU-5r9-YvskzmQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_9UbFIe_2_EaFl3MogUHDMg_5_6">167,471</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2021 Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_TwoThousandTwentyOnePlanMember_MH43z9s-vEmoE1YjdETXcg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_pYp_sNYIok2pU99-aLBpvA_6_6">378</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_v7UzME_8uUKyZkD-egDxIQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_sPqL5jhMOEeL228TriQckA_7_2">6,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_3128W61YJ0eOKZC5tMQTAQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_N2aJCpxHJEOo_0UKG5nWQg_7_4">29,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_V8H3B9tvJUatjjXtAV7WOA_7_6">167,849</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;">For outstanding awards granted under the 2019 Plan and 2022 Plan as of December 31, 2025, unrecognized stock-based compensation costs totaled $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_aNE-h6VMsU2pzK3AIQny9g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_pz8zhF8N2UKRKdZWGi0DEw">0.2</ix:nonFraction> million. The unrecognized stock-based costs are expected to be recognized as an expense over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_Mc6s5k_bG0SSAZ7j_mIrwQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_keCO0FiOSUOM0Tx352MKVw">1.1</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><i style="font-size:10pt;font-style:italic;">RSUs</i></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_K1o6QGN74EOPZ_qiHweoZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table summarizes the status of our RSUs and related transactions for the period presented (in thousands, except share and per share amounts)</span>: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vested and Deferred Release</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Grant Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Aggregate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Grant Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Aggregate</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Intrinsic</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_ZDQqGsRISUiWCgfaDh1AhA_6_2">12,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_GVUq89SD1kib4cfH-1Dd5w_6_5">50.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" scale="3" id="Tc_7xNasLXYgkmsX3IjHdD3GA_6_8">523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="INF" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" scale="0" id="Tc_q9H0Uy0NsUatst6JYUSWbQ_6_10">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="2" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_FiZKrSJNZkSBLBgu-iZ46Q_6_13">44.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_0Bn4uHW-f0CCpGP_h0qurQ_6_16">20</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc___GKh__XtUeY958Eir7CkA_7_2">10,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_1swAPaflPEmznJOoy052fw_7_5">50.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_8OikCtoockqubBzR4HJshQ_8_2">7,855</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_Gq6bMFhxCEmWEL1EOBYHFg_8_5">47.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" scale="3" id="Tc_KNw91BHQVkmVTBRJj-_ScQ_8_8">284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc__Hd_FnGicUan5ExvhckZ9Q_9_2">15,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_F2xdH_5YBkiRNrIvAEyf5w_9_5">51.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" scale="3" id="Tc_Y5X50EvtXkGa17_KVbjzvw_9_8">355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" scale="0" id="Tc_IsBoRJeiS0-drroSgKZYfg_9_10">1,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="2" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_c69EfIQbV0e3_RnufL2mRg_9_13">46.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_iwXQwTZof0mNMbO5qiqZpQ_9_16">26</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_i96CxDU7AkufaDkrQpFcvA_10_2">22,218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_szkIGhNijkm4YngiYjUDmg_10_5">7.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_wqDmuMMHekmuh5-0OfDkkg_11_2">6,693</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_IDqqhFo8vEyDnk6gjr5fIA_11_5">53.58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" scale="3" id="Tc_wmxlTRIyxUe3d2-GxnPTIw_11_8">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_PZ_60SYQvE2heVE8GTcAaQ_12_2">2,142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_nhIWyJUxGUykIrPB3NTsuw_12_5">30.04</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_h1EpaziwJ0uJ91CIPMO8QA_13_2">29,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_MICUTEgWdEuukWQSBELGDg_13_5">18.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" scale="3" id="Tc_5UFgjPPzXEiz9Tvcdqj7Kw_13_8">247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" scale="0" id="Tc_-swsZmxzBEmYAa5dlbr3kw_13_10">3,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="2" format="ixt:num-dot-decimal" name="mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_AngwFLSrHEC8RMVMHgM5Ag_13_13">43.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="Tc_phdDK7r47EO4S5ChPFgNlw_13_16">26</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c54fa43a_07ab_4a38_a8bc_dfd70c7e0bea"></a><a id="Tc_3wTkLQrBw0q3s7z8VqnKxw_1_2"></a><a id="Tc_3BosH2hi0EGnJk-nSgC2Iw_1_9"></a><a id="Tc_xWeRcZYlF0yviHhhljDqAg_2_2"></a><a id="Tc_-8dLsUiXw02Rg2thxwcvwQ_2_7"></a><a id="Tc_XpUoBYfi40elfcW6VzO9MQ_2_9"></a><a id="Tc_flKi8af8O0SHNgkql2Nisw_2_14"></a><a id="Tc_dn4pxQ2Do0-21S-OwxwWgA_3_2"></a><a id="Tc_iAowjMS3D0-QfFjZte7XXg_3_4"></a><a id="Tc_j-bJVi-kyEKLXCPdxTvLFQ_3_7"></a><a id="Tc_FsgCWLfjvUe2gZyy7h1KyA_3_9"></a><a id="Tc_T9DE_xB7LEGocVd2QzP-3g_3_11"></a><a id="Tc_HOqL3osgvkCHr1wgjjVlIA_3_14"></a><a id="Tc_7_Z5gJt7w0ets-wLKGU4hA_4_2"></a><a id="Tc_kGpVyYsVdUK23OtkYWFSDw_4_4"></a><a id="Tc_V_fWSvX0hEaPAQ8IdBFFCg_4_7"></a><a id="Tc_fouakyJG6EqbZbgWxRyaQg_4_9"></a><a id="Tc_OXbHTCb5ekah58H90JXQ5g_4_11"></a><a id="Tc_FBHGrkJIkUuBk7ndQ4CfIg_4_14"></a><a id="Tc_8vldslrSlEG3eAZwBOfKtw_5_2"></a><a id="Tc_k_YkknDnnUesYqrlzquEWA_5_4"></a><a id="Tc_QCuGVm7SiEuN5uaOH6pv0Q_5_7"></a><a id="Tc_PSPxyxdBOk6WeDcG5I6Lpg_5_9"></a><a id="Tc_CuGssx-hMkOqxnpkcKgQLg_5_11"></a><a id="Tc_vlMKFqcP4k206pWtHZW77w_5_14"></a><a id="Tc_CC7Waa6bqUCny7ZIR2rNsg_6_2"></a><a id="Tc_OWGrKVrdpE2I5qKKYfAcHw_6_4"></a><a id="Tc_52IDz27X0EWymIjR6kVEag_6_7"></a><a id="Tc_KJ2wvB0fg0e-c4NBzQWHzg_6_9"></a><a id="Tc_sBUoy9SwDkiItYUG_arclg_6_11"></a><a id="Tc_EADxICAYQEKYGFt71rQ3yA_6_14"></a><a id="Tc_bSu7Fgd950CW0h3nXd5a2g_7_0"></a><a id="Tc_UQ66XTNVL06MKxeD_Asl8A_7_4"></a><a id="Tc_rLF3HM-eE0mfRWq_8_yGmg_7_11"></a><a id="Tc_QVLpH7CxBESl-ElgEvl3yA_8_0"></a><a id="Tc_nZYqU_7p-E6WcW-pYbdxMg_9_0"></a><a id="Tc_LeH1a1sSCEe10cS5RR8ZcQ_9_4"></a><a id="Tc__yhqxQ5mrEyEJwSbeqRxAA_9_11"></a><a id="Tc_pMwHPysfy02l5Wi7spq4NQ_1_2"></a><a id="Tc_SYlWhPEnbUizeeosrP7fkw_2_6"></a><a id="Tc_wqeh9Z8EpUGENvHUxuYn4g_3_2"></a><a id="Tc_npaNntTgl0aySZ0UKEmdwA_3_6"></a><a id="Tc_abS5LWX8p0KKGPKzw06Y4A_4_2"></a><a id="Tc_4AFsXKb_iku7Dvm5Q2DHtw_4_6"></a><a id="Tc_SxyDptZaCUOW4JyyUeQ0dw_5_2"></a><a id="Tc_oGeCnrzu-EutK0oGRAQ8fw_5_6"></a><a id="Tc_6JoTbHT7IEOD3GTC4P9Z5g_6_0"></a><a id="Tc_lot4iQLh50KJS_4cph0iKg_6_2"></a><a id="Tc_ZBKYmE2ms0KiI46OJNVG4g_6_6"></a><a id="Tc_gnk8VadHNkShiFiInadk8w_7_0"></a><a id="Tc_Oj63XDw_y0iUiJc93kW-jQ_7_4"></a><a id="Tc_Hkc_N-DEAUeJkTNJv9yfDg_7_8"></a><a id="Tc_IiXcvcAIkEGmmZFXGAzZWg_8_0"></a><a id="Tc_M4ehIqZ4mEKxu-HuXb0Q5A_9_0"></a><a id="Tc_5pDsI6_nzUCg7AibdJFqEw_9_3"></a><a id="Tc_7f-2BxKypUGjF6KTfsyGhg_9_4"></a><a id="Tc_Rd-gAAt2q0G42KOrYQWMiA_9_7"></a><a id="Tc_hpV03YapYEii65KsEjqrFw_9_8"></a><a id="Tc_Z2JYC1e5PUa1XFKguqWkkg_10_0"></a><a id="Tc_Xa60GqlEOUKsgEjX09EMDQ_10_4"></a><a id="Tc_epTY5gX_FUS01IdsheRf-A_10_8"></a><ix:continuation id="Tb_yOfJwkFjAkGdTvreyU--iA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Stock options</i></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_TKKr_QJSoE6qLqwss4l1Gw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The following table summarizes the status of our outstanding and exercisable options and related transactions for the period presented (</span><span style="color:#212529;background:#ffffff;">in thousands, except share and per share amounts):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:37.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercisable</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contractual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contractual</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Term (years)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_QcL6GkLVHk2fdLfeiuukqQ_7_2">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0M6nQgA_8k-JvXKOgZ2c5Q_7_5">4,240.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_BY79CPAZZk27J-wqZYzO7w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Gtr4BHY3s0Oq5nbp6pLjig_7_7"> 8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_JmRV3DykD0Sxs89dNMN1tA_7_9">408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_MN6aKowe8U-ulWSIUZLKqA_7_12">4,149.85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_BY79CPAZZk27J-wqZYzO7w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_o_45NMxpn0adTYb4mmHYRg_7_14"> 8.6</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_B2Nodj2iTUeVHcOKJLkRVA_8_2">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_inEC2bTgY0OnvwZ93CRLgg_8_5">4,240.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_EosatiHxTUuZnUiddyeAtA_8_7"> 7.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_DsFkQOeZ6EKH15jNgKXuSw_8_9">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_rLqnmzcNHEGItFGM26tPqw_8_12">4,240.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_o2swNSt0TkGu4EbXmdrufA_8_14"> 7.5</ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_y3vBSDGTQky6T8eXKLJZ6Q_9_2">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Gu8t0kSGq0qRFLlqCL-VqA_9_5">4,240.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_zylc2RUf5k6UjEeWDzA9AQ_9_7"> 6.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_93T3V8SWX0mNDFPcU1UFjA_9_9">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_2Xx3JLIYSECv-uIZ4EZJMg_9_12">4,240.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Y24k1hsq3E-m-QIGOkkGeg_9_14"> 6.6</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The aggregate intrinsic value of our outstanding and exercisable options was <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_TjTu3Xn8X0qsgpAwd6wrCg"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_U0o2I5rEZkSNSAg4JADT9A"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Narr_J9xMbPiMYEqA3FhGkkspug">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction> as of December 31, 2025 and 2024, and January 1, 2024.<i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="color:#212529;font-style:italic;">Grant date fair value of RSUs, stock options and warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">We estimated the grant date fair value of RSUs granted to employees, consultants, and directors based on <span style="background:#ffffff;">the closing sales price of our common stock as reported on Nasdaq on the date of grant. </span>We estimated the grant date fair value of stock options and warrants granted to employees, consultants, and directors using the Black-Scholes option pricing model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The following table sets forth the fair value per share of Placement Agent Warrants granted in 2024 and the assumptions used in the Black-Scholes option-pricing model:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_tHjxjNsdXUaG4r6cDZoeEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placement Agent</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contingent</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Warrants</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Granted in</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Granted in</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2024</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average fair value </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_PWleMhOS-E6wShqBoEtk3g_6_3">30.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_sKC-hDcUvUeiFx_EjLBkDw_6_7">37.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected stock price volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_wRjWTWaxxUKRmmRAeOHdeQ_7_3">140.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_lXg2UpTO9kuGXJYkc8pMGA_7_7">127.0</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_twQWHWCZgECIDvgIX1Wlow_8_3">2.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_SsPDtUbBIEqkU9gmgPUBYw_8_7">5.7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_8mH0RPsrKkW_GEITdkVicg_10_3">4.63</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_I0lXVXCg-0O29KFap2IkRQ_10_7">4.31</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5ec99f19_2ccc_48f4_bf35_2db0a04aa7a1"></a><a id="Tc_icuSDzHmGEyzGC_fP7saTA_1_2"></a><a id="Tc_FNdk4LtqJ0yH8JDPmL4B4g_2_2"></a><a id="Tc_3YW9_pnHkUqUX8stbvklQw_2_5"></a><a id="Tc_XcdnZ6kcGkS50Fujfl8mOg_3_0"></a><a id="Tc_Fd4HifeIIUuzImmWBWwwTg_4_0"></a><a id="Tc_ZhfuJIzLm0Ocmkf37h6enw_5_0"></a><a id="Tc_j_6sryk1yEKn_wHIcopQZw_6_0"></a><a id="Tc_y5qp6dnCnEuSazva6fZMmw_6_2"></a><a id="Tc_swq5YhgVeUaPoRlK0KQ6AA_6_5"></a><a id="Tc_QSoKQDlLt0CWxRKK3quOzg_7_0"></a><a id="Tc_iA4ztWCZyEOml4uB1prUTA_8_0"></a><a id="Tc_W0ANhcidjE2Zl_x68I6L9g_9_0"></a><a id="Tc_7XOWMqWIEkCTHw7Rg4cFNA_10_0"></a><a id="Tc_I9RKaL2Uok6Hr-2jAcwVqw_11_0"></a><a id="Tc_BYAn0u8jfE61nYmZWKZsoQ_12_0"></a><a id="Tc_ZsLUENy0R0eo1jyTA1cKcw_13_0"></a><a id="Tc_kfq_duZm70-lMApSimqt8g_14_0"></a><a id="Tc_GWGnFPGmzUa2rmeUADSiCA_15_0"></a><a id="Tc_0IrQ-4uXHkSZjdRkUqECcQ_16_0"></a><a id="Tc_8Wf2nDGySk6uDV-1HzEkKQ_17_0"></a><a id="Tc_kOW8_3DBbU-7DkibgP04OQ_18_0"></a><a id="Tc_s4hT0X3y3kKpnw3-XkoaRA_19_0"></a><a id="Tc_qPZhhnfCw0WtS8jD21ZnAw_20_0"></a><a id="Tc_SA5sq-Spyk6--09h3tPP_w_21_0"></a><a id="Tc_piz04WMtb0u8Idty7yr7_A_22_0"></a><a id="Tc_ochdwVnzckGtq4Q10M0rCQ_22_2"></a><a id="Tc_90QY8qeY-UCXLv-oMqKjPA_22_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_A32EAp2B9U-k0SKeovmiww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span><b style="font-weight:bold;">Significant segment expenses and loss before income taxes</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_F71nPkZs7UmZVp4rREt5HA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;letter-spacing:0.2pt;">The following table sets forth the significant segment expenses for our </span><span style="color:#212529;letter-spacing:0.2pt;"><ix:nonFraction unitRef="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="Narr_vnRde_-5UU2hJ00RaXK1ow">one</ix:nonFraction></span><span style="color:#212529;letter-spacing:0.2pt;"> reportable segment (in thousands) that are regularly provided to our CODM: </span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Direct expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Vanoglipel (DA-1241) credits (costs) <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" sign="-" scale="3" id="Tc_6aObyGwtFkyxT-nJscdKlw_6_3">845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" scale="3" id="Tc_7K_iHL1iQUSJR8yJe0YpvQ_6_6">9,959</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">DA-1726 costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" scale="3" id="Tc_j1_1EtSiR0qpfyKwPDSbQg_7_3">5,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" scale="3" id="Tc_NKaCycz4bEWsoAmg80ZZAQ_7_6">9,397</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other R&amp;D costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_iUSdVORlq0OroDLZD6Y2Og_8_3">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="Tc_NTMBTxBPE0CpyQSJZS0Drw_8_6">303</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Indirect expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:LaborAndRelatedExpenseResearchAndDevelopment" scale="3" id="Tc_49XcaDWLaEGieUu6AmajVg_10_3">1,653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:LaborAndRelatedExpenseResearchAndDevelopment" scale="3" id="Tc_f44ZE5MnrUGBB3OLoCIFog_10_6">1,606</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ConsultingFeeResearchAndDevelopment" scale="3" id="Tc_YvgmapzFHEWpoSQWZ-O2KA_11_3">419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ConsultingFeeResearchAndDevelopment" scale="3" id="Tc_Wkr7HAkrw0GbtZ-_gxoDyg_11_6">288</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_go6lX10Uh0yDtxXfHXEoyw_12_3">6,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_KEPMvSzX1EmM_kSArEha3Q_12_6">21,553</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Legal and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:LegalAndProfessionalFees" scale="3" id="Tc_TxK3A9Ydw0OeNpCXoA1vew_14_3">3,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:LegalAndProfessionalFees" scale="3" id="Tc_AnaZGDHNuEqiCJVtbMkQiw_14_6">2,864</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ConsultingFeeGeneralAndAdministrative" scale="3" id="Tc_UnaASSrCkU-jDRiXFCthFw_15_3">823</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:ConsultingFeeGeneralAndAdministrative" scale="3" id="Tc_yG_eFnxHgEeABC3q5nJG8Q_15_6">1,512</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:LaborAndRelatedExpenseGeneralAndAdministrative" scale="3" id="Tc_4bVcrab82UWL-lgX8ZFOFQ_16_3">1,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:LaborAndRelatedExpenseGeneralAndAdministrative" scale="3" id="Tc_aBLnnMxT5kmLrmxXo88NAA_16_6">1,659</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_cpxKrsVL00qoVefKeCYPdA_17_3">948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="Tc_5Wqasac64E2wd8-LjHMQCw_17_6">1,221</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_SO948mnW-EyoCe1D64tnCw_18_3">6,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_aKIMjiAMJEqVbrlwEOdPiw_18_6">7,256</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_MMA83WEPN0iqAA4dvStEWA_19_3">13,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_sLbohdsnd0ys-YuAOdpXhg_19_6">28,809</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_NJIZ_oanREKGwkgMspcTDA_20_3">13,708</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_gnpvGiT0tE6d5X17-H9j0w_20_6">28,809</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_dP-97CvVC06gXuPtMEJqKw_21_3">735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_60ZjPLmW0E-zyRpO3zBXyw_21_6">1,217</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_I6i9CIa4T02amMIfMWZpdw_22_3">12,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_JesIar9_DkaSTsnnmmBXCw_22_6">27,592</ix:nonFraction>)</p></td></tr></table><div style="margin-top:4pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes a credit of </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ" decimals="-5" format="ixt:num-dot-decimal" name="mtva:ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" scale="6" id="Narr_kikZxq7Am0WVRHAFcHg5ag">1.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> million recorded in 2025 </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">in connection with the close-out of the clinical trial with the</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">clinical research organization.</span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes clinical, non-clinical and preclinical services or other R&amp;D expenses that are not attributable to a single product candidate.</span></td><td style="width:36pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.35pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes all other general and administrative expenses, such as insurance, software license fees, non-income state taxes, lease rental expenses, etc.</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> </span></td><td style="width:36pt;"/></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f8c48883_0cea_454c_a95e_6ca8c99437c3"></a><a id="Tc_A3eyfgcqfki_931LdsgG-g_1_2"></a><a id="Tc_rqH6JVC97keYBXP9_aWCJw_2_2"></a><a id="Tc_fsckzwG8-UWWqUAT8x5uNw_2_5"></a><a id="Tc_4j208nBYJUOFea3tvJ6mug_3_0"></a><a id="Tc_N10kZNZYpUGRvYENjrqx4w_3_2"></a><a id="Tc_y35xriPsHk2_RGE-xmW2Dw_3_5"></a><a id="Tc_RlUXAegZrkyEVcADIXO_sg_4_0"></a><a id="Tc_AR4yGWW9UEm1xOV1egomEQ_4_2"></a><a id="Tc_BSMWLgrq8U2Z1Fl5bN0qcQ_4_5"></a><a id="_fe46b29c_f499_474a_9b8a_3109d82889c9"></a><a id="Tc_0-QquqKxkECaYNMpO0WWUg_1_2"></a><a id="Tc_k8gCVO4tv06B6luLMIiAJA_2_2"></a><a id="Tc_xObK1Hbq_kWPwxuk3oheHg_2_5"></a><a id="Tc_N2h0WNXKR0ezBQv2zptFQQ_3_0"></a><a id="Tc_CCATML5a8ECp5I8p0TzWRg_4_0"></a><a id="Tc_AHX0IcNLe0ezURJEWpC5rg_5_0"></a><a id="Tc_zIy_LxzRGEeUueI-MKMwoQ_5_2"></a><a id="Tc_1quVUYxL-keyVdmSxfqA_A_5_5"></a><a id="Tc_ldVfrj10TkycsLzprM86jw_6_0"></a><a id="Tc_6yWQygKTLEGj00q2JgEzFA_7_0"></a><a id="Tc_SxBI_DTnIUuUhNYM9GK4jA_8_0"></a><a id="Tc_RA2zTU5QLUS34Kf4q6vCsA_9_0"></a><a id="Tc_Q8KQNIsCIka1W1lvxBSFvQ_10_0"></a><a id="Tc_qm6-cipZek2jbOMEEY11pw_10_2"></a><a id="Tc_ty8hxxK9ZUWXnbV3MdMK4g_10_3"></a><a id="Tc_uzaQzvXnAk2rIwld_EY75g_10_5"></a><a id="Tc_oce6PIeAF0WkuoTwSIYQ1g_10_6"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_FNvYXOoovUKnjlpyjThDnw" continuedAt="Tb_FNvYXOoovUKnjlpyjThDnw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span><b style="font-weight:bold;">Income taxes</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_PTWyi32skkWIsztGZzv31A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our loss before income taxes is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_c_W3aazixUmlg7-_0r5uOg_3_3">12,973</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_vAxJWgdUekyOd3Z_eq5CGA_3_6">27,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_8d-Nos0RmkOz0_Pneei5lA_4_3">12,973</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_9zfkzIZiTUCvGpZGQVTEjg_4_6">27,592</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_AoQCvxSUp0mjE_KLfdQz4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The components of our income tax provision are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income tax (benefit) expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_pZP8RRDVCkCsr97JMKPTYw_5_3">2,683</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ZTZ4MIaKiE-e2S5rZRkSmw_5_6">5,809</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="Tc_MXthECkjtUSAkfWIuFXBlg_6_3">270</ix:nonFraction></p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_J0Yjs1AhWEysYdX_kun0yQ_6_6">2,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred income tax (benefit) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_G8UlVcjzG0-ZAFklXwKsrQ_7_3">2,413</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_9qYvAJi-F0CMAOxuz77qOQ_7_6">8,401</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_NtxswooMrke0riRhyc4qoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Tc_mxtWnn8-20mFVVZzLHPT6Q_8_3">2,683</ix:nonFraction></p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_VMMqp0PeAkmV1Ye9POrQ7Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Tc_OFBPMUjyn0KuUFOfs-1KHw_8_6">5,809</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_n93HbMQVrkW0-qSzZp9fag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="Tc_mGDtGStZa0eZVZTY-vGzMA_9_3">270</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_ynvr0hrecE6I1UL40A9GOA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Tc_Rgb_JVVw9kiYt-KRr1OY9g_9_6">2,592</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_13c4dc7f_4b6f_4cb9_a56b_57cad70e55bf"></a><a id="Tc_Blnm9Aax3UeKvR4DQ-KoGA_1_2"></a><a id="Tc_Az-gSLfoGUeJx9ysGl-teg_2_2"></a><a id="Tc_DDgZ0nBzgEqxwxjLlBMHOA_2_8"></a><a id="Tc_6m95fl6q3kuI00DzMyTnZw_3_0"></a><a id="Tc_933fiXqX-UW3XjiJNjHHLQ_3_2"></a><a id="Tc_XEL8GgT84k6EkUPZ9j_75g_3_6"></a><a id="Tc_7zYr9ms-n02NfRmZV3MEsg_3_8"></a><a id="Tc_-9RbIJTyT02BKov-VpaljQ_3_12"></a><a id="Tc_P8JH1bshjUCxujCdh9z-gA_4_0"></a><a id="Tc_bKwy1tCA2kqCRRPrKXHq1w_4_3"></a><a id="Tc_xafF5rLhZki5fNgEpgP0Gg_4_5"></a><a id="Tc_0FldGMbD8k6yJT9-4af2bQ_4_9"></a><a id="Tc_50E3mbGgoE6TMLk3Tkv7lw_4_11"></a><a id="Tc_3TbP-t1LFEyrWc_dLDxU0g_5_0"></a><a id="Tc_qQa4N0hLaE-Gt7lplGW77w_6_0"></a><a id="Tc_EHerWAZcDkuQ3uSYP-8yNA_7_0"></a><a id="Tc_XDHnTSr6pUWoRL4rZ4PnyA_8_0"></a><a id="Tc_nbMC5eQI30ipbUVESuYiCA_9_0"></a><a id="Tc_JZ1WrDy8zkeimZW8XhqB9A_9_6"></a><a id="Tc_p2aInY9l9Um-M9iVDEHL_Q_9_8"></a><a id="Tc_qZR_V3G_uE2FncqDcInfig_9_12"></a><a id="_2a0b19d1_a8f7_4eae_a85e_6e14a9ce7a1c"></a><a id="Tc_EqukjeOHTEuFGBZ-sVt3vQ_1_2"></a><a id="Tc_uEAkSVgyv0KqT5amtgsscg_2_2"></a><a id="Tc_lbO5AU0dzEeKTPQar9PUsQ_2_5"></a><a id="Tc_nShiN01hhkGZa7pQ47Q5pw_3_0"></a><a id="Tc_TweyzMkFG0-ojGltmtRDng_4_0"></a><a id="Tc_I5PbLAeePkKWI26qDKUoKg_4_2"></a><a id="Tc_F_l7jSVzGkafwqIxAkKQgA_4_5"></a><a id="Tc_1BxUdoOyQUa8FCNAULPhhw_5_0"></a><a id="Tc_zaiBvO7dUE2w-1hr-0bKnw_6_0"></a><a id="Tc_8GPAMtoRQEm8SPscHF7l6A_6_6"></a><a id="Tc_Jmu7C2OlR02OCfKFepQyig_7_0"></a><a id="Tc_Yj-vnUx6Tkq-HTHYaPlA8Q_8_0"></a><a id="Tc_N08T74jZlESn3L2kkmb8Rw_9_0"></a><a id="Tc_GgdDYvKS60G_aubaxYYpVw_10_0"></a><a id="Tc_IESLT7d5j0WU8bXX-5C-VA_11_0"></a><a id="Tc_dpHlKBQBwkeMe7FgJPx4jQ_12_0"></a><a id="Tc_nZb7yKGBwUaBApR7zrnmQw_13_0"></a><a id="Tc_zP5BpBSe_0-cqA1muOTlcg_14_0"></a><a id="Tc_dujVPpIQCUyQa5vLa_RqVw_15_0"></a><a id="Tc__Q3VUxKf_0CyXfBOpjVq7Q_16_0"></a><a id="Tc_bkirSinVmU6qm4FuymayJg_17_0"></a><a id="Tc_18l3SlpyUUunq3X9PRXbIw_17_3"></a><a id="Tc_y5_H1-X-TkuKO3RCGBkAPw_18_0"></a><a id="Tc_cU99t9FSt0e9EOj8ThUIcQ_19_0"></a><a id="Tc_XzFNkoxnvEW6Zr1CnDOrIw_19_2"></a><a id="Tc_2b_iGG6WdUeya44EN6_59w_19_5"></a><ix:continuation id="Tb_FNvYXOoovUKnjlpyjThDnw_cont1" continuedAt="Tb_FNvYXOoovUKnjlpyjThDnw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our effective tax rate for 2025 and 2024 was <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_ldzweiKsa0KEdZwYy3DlVg"><ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_L7uZQiLrXEu461KEql7Pqw">zero</ix:nonFraction></ix:nonFraction> percent. <ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Group_LOYe-rtx3kmRNl-a719d9w" continuedAt="Group_LOYe-rtx3kmRNl-a719d9w_2" escape="true">A reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate is as follows (in thousands, except for percentages):</ix:nonNumeric></p><ix:continuation id="Group_LOYe-rtx3kmRNl-a719d9w_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income taxes at U.S. federal statutory rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_2fM26tOJHUe7loakmvbLyA_3_3">2,724</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_p1JYKbGITk23K2fCOv38GQ_3_5">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_kcFwIpc3Z0a4FuYI2l0VAQ_3_9">5,794</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_1rBOR_hOK0654DwgK6PrMQ_3_11">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">State income tax, net of federal benefit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Changes in valuation allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_jqpOH4xOV0WDkfWopWzrhA_5_3">2,683</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_ITiRH1HLU0mR2BJ6mXTS-w_5_5">20.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="Tc_TwTBSV5BZ0me13s-Ynttdw_5_9">5,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_Ru8jaJ5ApkaLWA10HQ-Egw_5_11">21.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nontaxable and nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" sign="-" scale="3" id="Tc_Zgyo82RNIUa1AdL0lcOofw_7_3">47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="3" format="ixt:num-dot-decimal" name="mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" scale="-2" id="Tc_4h-nL5T88U-4lPuFmsZpfw_7_5">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" sign="-" scale="3" id="Tc_8xoLvRDHDEuYDKFexpHD9Q_7_9">62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="3" format="ixt:num-dot-decimal" name="mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" scale="-2" id="Tc_SDepet6-GUGlHUSBs17_Ig_7_11">0.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="Tc_YouGkKkjbkmojPyj7P6M2w_8_3">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" sign="-" scale="-2" id="Tc_u769VhVCVUC8kfJLcVjpTA_8_5">0.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="Tc_enWbz3qk6Uy9UJ3PPmrQNQ_8_9">47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" sign="-" scale="-2" id="Tc_HOtPq9UrkUWhMj09LeJoGw_8_11">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective tax rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_C-dzxIpl1U6oT6YRgjgRPg_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_thLnp91ClU6QvDoPrlqUSw_9_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_L0MQBt6QIUOwFg4D4e0TJg_9_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="3" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_xkRhnLO7cECGXfyeWzw7zg_9_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_q-Vf_KJd70qWPPlnqnUfag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The significant components of our deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. federal and state net operating loss ("NOL") carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_egh37u_4eUifzkx588TWFQ_4_3">7,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_XtCD4DWNA0uN1xaH-cF81A_4_6">4,959</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired intangibles </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_7rkP82L9v02Yr8wHvh9QoQ_5_3">2,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_75_LVwMoDkmF7iZ-9ww0gw_5_6">3,000</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net unrealized built-in loss (NUBIL) - 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxAssetsUnrealizedBuiltInLoss" scale="3" id="Tc_-pVVPW6CvEaG1ZzZrQ_enQ_6_3">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_p4RKVbE7pUemdaI2X1Us4g_7_3">515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_UvcZrD8uBEuAr8xVGb43qw_7_6">458</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_HveKb5HEcE2igZDI3FIF2w_8_3">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_B86TV_uSzUej3aEHf-AB8A_8_6">37</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_Z2zRv-GXME2Nib8y12rgvw_9_3">7,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_uxKwb6VdH0OcWKXaG1_wBw_9_6">7,516</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_Bmi23W-vcUCjWOtmyXR0wg_10_3">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_8fR710u1lky19kxzpswoQQ_10_6">118</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">R&amp;D credit carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_rDhBq8TFFEaU2WFTqwDNtQ_11_3">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_JZFDuEqrZEGdSiB6n9Oyzg_11_6">26</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_Iq4NVegL8k29yO_GNKq8yQ_12_3">18,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_Iyr4QzlJEEOQQrvIto0l-w_12_6">16,114</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_eZXSJVpZDUarHRGnbxZkhw_13_3">18,491</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_0M5IQgeqPE-fPfN41faQmw_13_6">16,077</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_dEWpS_I49EqsyBLRnLq0MA_14_3">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_B4nkngU6Hk2DHeRGgjhGJA_14_6">37</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxLiabilitiesRouAsset" scale="3" id="Tc_c1szzZDbbUyVa0s87pk6MQ_16_3">58</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="mtva:DeferredTaxLiabilitiesRouAsset" scale="3" id="Tc_D88Bepx39kWTe_EmD6htBw_16_6">36</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="Tc_5Bkw0c0Lx0ubWpBaeMR9Tg_17_6">1</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_M3Or_95ajESs0BEWcpXoFg_18_3">58</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_METVlHSD8Uaoz4i3bC8KQg_18_6">37</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred income tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_f-qh88iWOEisYOygHUVjHg_19_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_KtWEnKkwUkK6M1PoYnhvKg_19_6">&#8212;</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The realization of our deferred income tax assets is primarily dependent upon future taxable income, if any, and such income is uncertain in both amount and timing. We have had significant pre-tax losses since our inception, and we have not yet generated revenues and face significant challenges to becoming profitable. Accordingly, we have recorded a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_bvBiOj9W-USks05lHjonjQ">18.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_lVZqyJkq1UqonGQyaJzx-Q">16.1</ix:nonFraction> million as of December 31, 2025 and 2024, respectively. U.S. federal deferred income tax assets will continue to require a valuation allowance until we can demonstrate their realizability through sustained profitability or another source of income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025 and 2024, our U.S. federal NOL carryforwards were $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_6zn-kRdrl02p1w4xtZXVzQ">33.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_pFCcYjunlUeQQZkwtqzvuw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_D6qw5Gv9WU-JAug3EdZO-A">18.5</ix:nonFraction> million, respectively. We had less than $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_hUpyIKRg90qXsba8GqK17A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_9OohKjOchUaE1r7n4RFWhg"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_NRfJ8T4b6Eu_-IBdIjogkw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_vWTBRbYCy0amSR-mQntGpg">0.1</ix:nonFraction></ix:nonFraction> million of U.S. federal R&amp;D credit carryforwards as of December 31, 2025 and 2024. Our U.S. federal NOL were incurred after December 31, 2017 and therefore, will not expire. As of December 31, 2025 and 2024, we had state NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_GxJU8xTtk064vc3Bitk13A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_arbQikBCskqNJ9gzHjk_FA">12.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_qToyrodAZ0ObK7Ly10LSHA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_BGVwPBX1e0a-wShQRq8LZw">17.4</ix:nonFraction> million, respectively. The state NOL carryforwards will begin to expire in 2042, if not utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our ability to utilize our NOL and R&amp;D credit carryforwards have been and may be substantially limited due to the ownership changes that have occurred or that could occur in the future, as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change,&#8221; as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. We completed a Section 382 study for 2025 and it was determined that we experienced <ix:nonFraction unitRef="Unit_Standard_item_i1i903DmOka3fCx6uRjRsw" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="INF" format="ixt-sec:numwordsen" name="mtva:NumberOfOwnershipChangesOfOver50" scale="0" id="Narr_z1I_7mbF8U6gEItbtP7_hA">one</ix:nonFraction> ownership change of over 50% since 2022, which was the year of the last 50% or greater ownership change. The 2025 ownership change occurred on May 8, 2025, and going forward, the utilization of loss carryforwards and tax credits generated before May 8, 2025 will be </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FNvYXOoovUKnjlpyjThDnw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">subject to an annual limitation. As a result of the ownership changes and limitations, $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g" decimals="-5" format="ixt:num-dot-decimal" name="mtva:NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" scale="6" id="Narr_fy9zgEndYEykq3qOOSDyvg">100.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_GxJU8xTtk064vc3Bitk13A" decimals="-5" format="ixt:num-dot-decimal" name="mtva:NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" scale="6" id="Narr_sHsya9BFK0Ob0NPZWDDFfw">68.6</ix:nonFraction> million of federal and state NOL carryforwards, respectively, will expire unutilized and have been written off. Additionally, $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g" decimals="-5" format="ixt:num-dot-decimal" name="mtva:ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" scale="6" id="Narr__GPnGwF1hEu-ZedmuwVjow">1.2</ix:nonFraction> million of federal R&amp;D credit carryforwards will expire unutilized and have been written off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We recognize interest and/or penalties related to uncertain tax positions in income tax expense. There were <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_TeP_S8C42ECfFpy8ABxVew"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_LAfa9QcDzEWHSxsdhMTnJw">no</ix:nonFraction></ix:nonFraction> uncertain tax positions as of December 31, 2025 and 2024, and as such, <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_vfwXbosRjEykFz9OPU34og"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_xnvMYT0z7kmD2qMIpYfccQ">no</ix:nonFraction></ix:nonFraction> interest or penalties were recorded to income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:IncomeTaxExaminationDescription" id="Narr_EQrAfed_i0-QAr25Y8iQug">We have analyzed our filing positions in all significant U.S. federal, state, and local jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, we are no longer subject to U.S. federal, state, and local tax examinations by tax authorities for years before 2022, although carryforward attributes that were generated prior to 2022 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">For 2025 and 2024, we had <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Narr_fweFx9qQGkS03qDtlC9DEQ"><ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Narr_f1l6paO0ukO7XfSSPjfFwQ">no</ix:nonFraction></ix:nonFraction> cash payments for income taxes, net of refunds received, in any U.S. federal, state, or foreign jurisdiction.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5b3ee00b_af84_48fb_bcd6_7a0ceb3f53b5"></a><a id="_f28d62fe_94b4_451c_8bc4_b0f4008e36ab"></a><a id="Tc_nRNbK-pDX0WEP6haAh4mwg_1_2"></a><a id="Tc_6KVWBGIsoUK3BdDxjPDNXw_2_2"></a><a id="Tc_BVKDjUqBake5vnhn4j_3wg_2_5"></a><a id="Tc_4_q8VSQTtECHYikSvUXwtg_3_0"></a><a id="Tc_jJpYB_NG6kSuhPepp37sqg_4_0"></a><a id="Tc_GeyEoAJgdkeqQS0onSIXxQ_4_2"></a><a id="Tc_JQ_jhToufkuZ9K0Je746tA_4_5"></a><a id="Tc_4lVI6qUt5k-K8PJaMgyxYQ_5_0"></a><a id="Tc_Bxd_GH4jxU6RC77oIhrDaw_6_0"></a><a id="Tc_hW-q8UCkD0CECd89ZhktbQ_7_0"></a><a id="Tc_pSWefe7WQkGxLyvXBOhydg_7_3"></a><a id="Tc_COFEvPQEb0u2im3d6GYjpg_7_6"></a><a id="Tc_TPIjlgFgAke7hOCd8OQcnA_8_0"></a><a id="Tc_0zWgKjLIAEWns3WUtIS5UQ_9_0"></a><a id="Tc_7Bmn4iDZhEW-kdaEG1in5w_9_2"></a><a id="Tc_UtAPicGloka0VQFyL1aZoQ_9_5"></a><a id="Tc_3CGoqwplgUW01XzzfZrIYA_1_2"></a><a id="Tc_R00cW67J3UKKOJ9qdSAEGw_2_2"></a><a id="Tc_USp61k6idUW2nW2kdZVpFQ_2_4"></a><a id="Tc_wqKDmVukvE6Y8xEkvgQbRQ_3_0"></a><a id="Tc_8mIKFuz-IkeEJFgG68QOjw_4_0"></a><a id="Tc_cyUZYCrekUmhEdKcbmaQzQ_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_63d1yx7-okKhhofz6n16Vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Loss per share of common stock</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_x0Bc7-R_nUepOo75fQdcrQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table sets forth the computation of basic and diluted loss per share of common stock <span style="color:#212529;background:#ffffff;">(in thousands, except share and per share amounts):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:60.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:middle;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_e1R2--Jf2kq7f6csw1INyw_4_3">12,973</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_xc0uN8Sfv0ersAGDQg2bcA_4_6">27,592</ix:nonFraction>)</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Weighted average shares of common stock, basic</p></td><td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ptIPYegB8EegXPtcbI-Z8Q_6_3">1,766,026</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Gv5BeH3bNUK7FrqBp6JQDg_6_6">705,193</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Effect of dilutive securities</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Weighted average shares of common stock, diluted</p></td><td style="vertical-align:middle;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_IVqvihXhy0qhHhaX9UAeRQ_8_3">1,766,026</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_iNF5JB0TwE-tiyTY_GVbFQ_8_6">705,193</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Loss per share of common stock, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_HwY-3oPY_Uyl3k6L0wd0cQ_9_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_HwY-3oPY_Uyl3k6L0wd0cQ_9_3_2">7.35</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WQUvIiOpVkmvMKsx-dcOeQ_9_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_WQUvIiOpVkmvMKsx-dcOeQ_9_6_2">39.13</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:8pt 0pt 0pt 0pt;"><span style="color:#212529;">For each of the periods presented in the above table, our basic weighted average shares of common stock include any outstanding (i) November 2022 Series B warrants, (ii) June 2024 Pre-Funded Warrants and (iii) vested RSUs in which their release was deferred in accordance with the respective award agreement during the respective period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">Since we reported a net loss for 2025 and 2024, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per share of common stock and our basic and diluted weighted average shares of common stock are the same for 2025 and 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">The following table sets forth the outstanding securities as of the periods presented which were not included in the calculation of diluted earnings per share of common stock for 2025 and 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_e9iNl9JpHkW9A4FcSUzBPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kgPNiqIU3EqTQ0FXBCZBtQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_vaKwFS-L4ECYpW7wBw_jdQ_3_2">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_yZobbedVRk2iue_r9d0-Tw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GZmUSBR0N0qIOhrLqnCH8A_3_4">420</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_eTjUAZIRBk2CMl0mq0_sdg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TCI-jNz0MEiu69M9OkXMXw_4_2">26,213</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qjUNJ2DdcESFldGXnzeBGw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6grSF64dLk-oekTHUXMgkw_4_4">14,728</ix:nonFraction></p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_viTtU6jhrEuruIoP1QHhgg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Vhc40kNMgkSISIKC42DnRg_5_2">706,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ZPTKidCK6ECs_qqex1EGQA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_D2gfjVWHvkWME93Axq1sjg_5_4">1,170,522</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_pL56Wug0OkODVVQvdSP8KQ" continuedAt="Tb_pL56Wug0OkODVVQvdSP8KQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;">Fair value measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Fair value is a market-based measurement, not an entity specific measurement and is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three-level hierarchy:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Level&#160;1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Unadjusted quoted prices for identical assets or liabilities in active markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Level&#160;2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability; and </p></td></tr></table></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:82.35%;border:0;margin:30pt 8.82% 30pt 8.82%;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">MetaVia Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; Continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_26f264af_cb5b_4331_9281_95967275f392"></a><a id="Tc_YNMof6B7jESN_wbzm1FKtQ_1_2"></a><a id="Tc_i8xJqY_53UCOZEPifuNOjQ_1_14"></a><a id="Tc_Ncm0ODUYykmqil0OuCIrgw_2_0"></a><a id="Tc_gU5DoXoOWE6nPJrHQPwdSQ_2_2"></a><a id="Tc_bQvu-c6Rc0ekK1EPj5yIgg_2_5"></a><a id="Tc_wp_PeNCJc0-KgD6ORLBxwQ_2_8"></a><a id="Tc_2MpiltGml0OH9SS1O8ghew_2_11"></a><a id="Tc_OCoui8JcpUGZ_gHTQZF6SQ_2_14"></a><a id="Tc_UVB_VT-xbEO5-nsvNQhjOg_2_17"></a><a id="Tc_uz0p2jzzkkOb6Kj0nsZT2A_2_20"></a><a id="Tc_ZVpHDrLPS0O1K5dYv05SYQ_2_23"></a><a id="Tc_94YaRhLsGEeVkVvPHtmmQw_3_0"></a><a id="Tc_2eXRudcatkCJGoUr71WXGQ_4_0"></a><a id="Tc_k-AeVDw3kE2nO9YbppLlgw_4_2"></a><a id="Tc_vwcNDBtATUmYYROWOqYCsg_4_5"></a><a id="Tc_TxY_Y6Caa0WK0czY32PFmA_4_8"></a><a id="Tc_TPQPceW7q0eeEV_4YQXExg_4_9"></a><a id="Tc_6xCfxib0S0-qehyI_WSiEA_4_11"></a><a id="Tc_--nLN8ABxUy5Bm8dvFrCDw_4_12"></a><a id="Tc_ugSu2WE-O0Ww1liiUBpyHA_4_14"></a><a id="Tc_TO-ffac-HUWeV84RiO4STQ_4_15"></a><a id="Tc_ipH9NBLpF0SrpoyzlvbwtQ_4_17"></a><a id="Tc_jcUHmYt_LkaxTZJ7atDF4Q_4_18"></a><a id="Tc_QMgOi8YrG0W7bmZy2nB_Vg_4_20"></a><a id="Tc_vU-tPn3NBUGTgkF-WRPz_A_4_21"></a><a id="Tc_C5p23JKZsU-UQ6R8KLyAqA_4_23"></a><a id="Tc_6TqMvOj2tUekRw5SMLwVnA_4_24"></a><a id="Tc_1NQjoY_Mh0SSFZPjKBUZTg_5_0"></a><a id="Tc_GsKhKmW4dUO0Eo01kPWmAg_5_2"></a><a id="Tc_DY13zG11AkSyBZNCSVHUqA_5_5"></a><a id="Tc_YRQLTtF1QkmEMyOwL6NvmA_5_8"></a><a id="Tc_c9tNzqLeBkuWsGbuNzGoPg_5_9"></a><a id="Tc_Z44kJDHFs0aoLDCasSKhMQ_5_11"></a><a id="Tc_GFAmnllJw0m5ToXTk2s-KA_5_12"></a><a id="Tc_Q5jsMIW0Yk2jxu83_z1Hqg_5_14"></a><a id="Tc_mHUfUNlVh0SZ6P3vVAvmUw_5_15"></a><a id="Tc_aRhmD4RPg02GtpM-sBa44g_5_17"></a><a id="Tc_e_lShvUakEaRv0sBI5Z4ZA_5_18"></a><a id="Tc_Odu1O6ARc0qjOHZC1spfkA_5_20"></a><a id="Tc_mM8mcdOgBkmiQK0LkOQsrg_5_21"></a><a id="Tc_O61j4DnOekqKpi073uk70g_5_23"></a><a id="Tc_xB0Tv3mk60y7ermBecYHiw_5_24"></a><a id="Tc_WDjPZavli0WEHgPmdXIsig_7_0"></a><a id="Tc_UatOJIRioUOTXJvwWVVJ_Q_8_0"></a><a id="Tc_0YCxbQOt4UKmkXfA_W3HQw_8_2"></a><a id="Tc_DHDBSG581UqihgTfcSOUoQ_8_5"></a><a id="Tc_2ObCpickEkes3ZnZJDpi2Q_8_6"></a><a id="Tc_k4p64iMqOUqlUzWHLtnPiQ_8_8"></a><a id="Tc_KfBu0Y3720ivfkHzJtJfgQ_8_11"></a><a id="Tc_EiXgN_P-Yke0HwlDl6wOuw_8_12"></a><a id="Tc_5jdiJnCmnUKwyqSq3KAVnw_8_14"></a><a id="Tc_TpxmC_nNE0yfZqvs7gmMuQ_8_17"></a><a id="Tc_ev5Jvd4CH0OG1uUK-H6G1A_8_18"></a><a id="Tc_YMNvMcuBaESzLtax6x6ySw_8_20"></a><a id="Tc_He4flPvTT022J5ZMJdELFQ_8_23"></a><a id="Tc_L2Kvc61GWU6Pbtkkq_hnHQ_8_24"></a><a id="Tc_8Fk4o_I1xUqWbW5xHgKVEQ_9_0"></a><a id="Tc_dHnufuAZ4UKMVHZSEULifA_9_2"></a><a id="Tc_nunQHEbmwk6TH37xS3-0tg_9_5"></a><a id="Tc_xO1VllYctUCj46JQB7HiMA_9_6"></a><a id="Tc_nzvaQuCIYUK6bqiq36uVMg_9_8"></a><a id="Tc_x6_Jco_E2UO-ET8_QS-xkw_9_11"></a><a id="Tc_Xed_YBRdR0WZ7mMWtST0Jg_9_12"></a><a id="Tc_rQazHO7wTUq8w9X_owPUFg_9_14"></a><a id="Tc_KHrvyXNMSEKbMsdBV1b2TQ_9_17"></a><a id="Tc_8YseaGTHYEa1JIyXJSTsng_9_18"></a><a id="Tc_vSghR9MhWkG9KMhbn_pyRA_9_20"></a><a id="Tc_LMIhHX7vjkCF_wn_FYl0tw_9_23"></a><a id="Tc_v1ah7fNgLkKIsxZ6GaYpMw_9_24"></a><ix:continuation id="Tb_pL56Wug0OkODVVQvdSP8KQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt -0.7pt 8pt 36pt;">Level&#160;3: Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. </p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="Tb_QTaT0oTJrE-26dplpaoowA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table sets forth our financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy&#160;</span><span style="color:#212529;background:#ffffff;">(in thousands)</span><span style="color:#212529;">:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:35.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:33.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December&#160;31,&#160;2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;3</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Bank money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_CirOSrYFhUubOMQ7x_Dp4Q_4_3">8,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0d43O4ut1Eiyd57Bcg_7ZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_dGfhCCUXFkuro5Wlha99uw_4_6">8,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_tJR0T3GFu0C0YDbDOHivig_5_3">8,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0d43O4ut1Eiyd57Bcg_7ZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_yYIOEevoaUurGzhDcTL8Jg_5_6">8,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA" decimals="-3" format="ixt:num-dot-decimal" name="mtva:WarrantLiabilitiesFairValueDisclosure" scale="3" id="Tc_MzXMo9aWpU2SRiV560iUsw_8_3">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K_oHMLsqlUWlbv8jTh14Aw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:WarrantLiabilitiesFairValueDisclosure" scale="3" id="Tc_Y6byeNasmUOzMfMEbpSSkw_8_9">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ieg6WHdrokO31k0M--imaw" decimals="-3" format="ixt:num-dot-decimal" name="mtva:WarrantLiabilitiesFairValueDisclosure" scale="3" id="Tc_EISOEQuIE0eMeGh4BEWJHQ_8_15">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7SMIbo51mEy0336DbR5j1Q" decimals="-3" format="ixt:num-dot-decimal" name="mtva:WarrantLiabilitiesFairValueDisclosure" scale="3" id="Tc_ioJ3hTy5-ESfEv9POgXrFg_8_21">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_G9O-_3h84UisTHnavln19A_9_3">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K_oHMLsqlUWlbv8jTh14Aw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_wW2zRVt1IEuKlD5f43GeEw_9_9">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ieg6WHdrokO31k0M--imaw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_VsZflq0S406xuslEiY3aQQ_9_15">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7SMIbo51mEy0336DbR5j1Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="Tc_d7erSAkTKE-AluHZixbk-g_9_21">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The bank money market funds </span>are carried at cost, which approximates market fair value. We estimated the fair value of our warrant liabilities using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA" decimals="INF" format="ixt-sec:numwordsen" name="mtva:ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" scale="0" id="Narr_eTXy3A1EskigG3Ta4GynWw">eight</ix:nonFraction> warrants can be exercised for one share of common stock for <ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_vvalEg-TrUejRp41VE8WPw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Narr_XT2YDoFUZECYTxtv--Kc7g">no</ix:nonFraction> additional consideration, which results in the warrant exercise price to be <ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_r7s6Ae3Eokm5iTwCgZDr7A">zero</ix:nonFraction>. Accordingly, our warrant liabilities were considered to be Level 2 of the fair value hierarchy.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_sNOY7TXMtEy22U6CdzIZ4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12. </b></span><b style="font-weight:bold;">Subsequent events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><i style="font-style:italic;">2026 public offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">In January 2026, we closed on an underwritten public offering, pursuant to which we issued and sold, (i) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_N6OYhzZRwkyDYwrDvyw5kg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_O8X6Cae_3UKfSvn85M2I_g">1,006,870</ix:nonFraction> Class A Units, with each Class A Unit consisting of (A) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PwnDqJ_0xkebhJ_3_12wnw" decimals="INF" format="ixt-sec:numwordsen" name="mtva:NumberOfCommonStockIssuedPerUnit" scale="0" id="Narr_rgUca9Pbu0ymJqTLQxHTcQ">one</ix:nonFraction> share of common stock, (B) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_OjEPyphxgUe99Gl8la9gVA" decimals="INF" format="ixt:num-dot-decimal" name="mtva:NumberOfWarrantsIssuedPerUnit" scale="0" id="Narr_IAVylbQrykOYDcpoAPt0Ww">1.5</ix:nonFraction> Series C Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_OjEPyphxgUe99Gl8la9gVA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_9EPugOhc6Ua3UCAq6NYWSw">1.5</ix:nonFraction> shares of common stock, and (C) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg" decimals="INF" format="ixt:num-dot-decimal" name="mtva:NumberOfWarrantsIssuedPerUnit" scale="0" id="Narr_dgtOcprWaEyEASffHjyseA">1.5</ix:nonFraction> Series D Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Ey1n12vDl0Wm_4-qgoW7Lw">1.5</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Rsuf-J-0jkyFxSc8o3L7-A">3.10</ix:nonFraction> per Class A Unit, and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_DzLxM32I3UiH0dZZsCbJ1g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ermnyb4GPkGAw5sFbVmUCw">1,998,704</ix:nonFraction> Class B Units, with each Class B Unit consisting of (A) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_I_-uWg1Oy0Oe1RoSXLv9bw" decimals="INF" format="ixt-sec:numwordsen" name="mtva:NumberOfWarrantsIssuedPerUnit" scale="0" id="Narr__HgBFtqEiEuyTNMNuAXCBw">one</ix:nonFraction> pre-funded warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_I_-uWg1Oy0Oe1RoSXLv9bw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_eDxD06NVgEuGyn2Cl7DdEQ">one</ix:nonFraction> share of common stock, (B) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_HGwlAKHDTEqwMSPqX6zFpA" decimals="INF" format="ixt:num-dot-decimal" name="mtva:NumberOfWarrantsIssuedPerUnit" scale="0" id="Narr_AgJJrbd6W06C7gjBCQPJQQ">1.5</ix:nonFraction> Series C Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_HGwlAKHDTEqwMSPqX6zFpA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Kq06cEGL00OLp0lTXNe8PA">1.5</ix:nonFraction> shares of common stock, and (C) <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg" decimals="INF" format="ixt:num-dot-decimal" name="mtva:NumberOfWarrantsIssuedPerUnit" scale="0" id="Narr_XYdGUc6sgEKTJeSPRGDy3A">1.5</ix:nonFraction> Series D Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_-Vgc2U6spU2Vhgu7WfYJRw">1.5</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_WKNaLAIU7EmX_VSqVOloNg">3.099</ix:nonFraction> per Class B Unit. Each pre-funded warrant has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_ZkP_xSv4vUWma066ndav7Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_jnHbOR9QJE-c8NnWfFgduw">0.001</ix:nonFraction> per share and is immediately exercisable and will expire when exercised in full. Each Series&#160;C Common Warrant and Series D Common Warrant has an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw" contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_RrvMS22yxkOjSxk0GAVqjw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_9Tbi0Vxp50Wmi1d001597A">3.10</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_oXMhiHp3dkGLoMt6wJhXIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per</span></span> whole share of common stock, subject to certain adjustments, are immediately exercisable, and will expire on January&#160;16, 2031 and January 16, 2028, respectively. Under the Series&#160;C Common Warrant and the Series D Common Warrant, we&#160;may not affect the exercise of any such warrants, and a holder will not be entitled to exercise any portion of any such warrants, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) to exceed the beneficial ownership limitation contained therein. We received gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_0R6iYR8SXEKx11Ao953ZHw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" id="Narr__e6qOIOR80-WGWL6-l9w2Q">9.3</ix:nonFraction> million, prior to deducting underwriting discounts and commissions and offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;">The Series&#160;D Common Warrants are callable at our option following the release of a positive data readout for our Phase 1b Part&#160;III clinical trial for DA-1726 via a widely disseminated press release, subject to satisfaction of certain conditions. The Series&#160;C and Series&#160;D Common Warrants are fixed priced and do not contain any variable pricing features or alternative exercise provisions. Subsequently, <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_3_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PCbVTPdsR0KR7b1czjWLjw" decimals="INF" format="ixt:num-dot-decimal" name="mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_C053n7MSyUKKnn63pFGP_g">1,630,964</ix:nonFraction> pre-funded warrants have been exercised for an equivalent number of shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><i style="color:#212529;font-style:italic;">At the market offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">In March 2026, we sold <ix:nonFraction unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g" contextRef="Duration_3_1_2026_To_3_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingMember_RAxNUZYdMUeN8hu5p8owPg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_W1EPLv4yGE6ZgXJIVY5h5g">216,625</ix:nonFraction> shares of common stock under the ATM Program and received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg" contextRef="Duration_3_1_2026_To_3_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingMember_RAxNUZYdMUeN8hu5p8owPg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_D6z8NaGvfkevLTwSuIE-Fg">0.3</ix:nonFraction> million, net of sales agent commission and related offering expenses.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:26.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F<span style="font-size:10pt;">-</span>24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>2
<FILENAME>mtva-20251231xex4d7.htm
<DESCRIPTION>EX-4.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 03:11:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.71%;padding-right:4.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:right;margin:12pt 0pt 0pt 0pt;"><a name="_Hlk222314160"></a><a name="_Toc167790904"></a><a name="_Hlk168068781"></a>Exhibit 4.7</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following summary describes the securities of MetaVia, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221;), certain provisions of the Company&#8217;s Third Amended and Restated Certificate of Incorporation, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Certificate of Incorporation</font>&#8221;), Fourth Amended and Restated Bylaws (the &#8220;<font style="font-style:italic;font-weight:bold;">Bylaws</font>&#8221;), and certain provisions of Delaware law. This summary does not purport to be complete and is qualified in its entirety by reference to the full text of our Certificate of Incorporation and our Bylaws, copies of which have been filed with the Securities and Exchange Commission, and the applicable provisions of Delaware law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has one class of securities registered under Section 12 of the Exchange Act, the Company&#8217;s common stock, par value $0.001 per share (&#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s authorized capital stock consists of 100,000,000 shares of Common Stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share (&#8220;<font style="font-style:italic;font-weight:bold;">Preferred Stock</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Voting Rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of our Common Stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66-2/3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending certain provisions of our Certificate of Incorporation, such as the provisions relating to amending our Bylaws, procedures for our stockholder meetings, the classified <font style="font-size:12pt;"><a name="_9kMHG5YVt466679LGmqu"></a></font>board, director liability, and amendments requirements of our Certificate of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Dividend Rights</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to preferences that may be applicable to any then-outstanding Preferred Stock, the holders of Common Stock are entitled to receive ratably dividends, if any, as may be declared by the Board of Directors (&#8220;<font style="font-size:12pt;"><a name="_9kR3WTr244457JEkos"></a></font><font style="font-style:italic;font-weight:bold;">Board</font>&#8221;) out of legally available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Liquidation, Dissolution or Winding Up</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of our liquidation, dissolution, or winding up, the holders of Common Stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any Preferred Stock then-outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Other Rights and Preferences</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of Common Stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences, and privileges of holders of Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of Preferred Stock that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investor Rights Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">On September&#160;14, 2022, we entered into the Investor Rights Agreement (the &#8220;<font style="font-style:italic;font-weight:bold;">Investor Rights Agreement</font>&#8221;) with <font style="font-size:12pt;"><a name="_9kR3WTr266459NGxqEvF0Mcc1"></a></font>Dong-A ST Co. Ltd. (&#8220;<font style="font-style:italic;font-weight:bold;">Dong-A</font>&#8221;) &#160;pursuant to which, Dong-A has the right, subject to the terms thereof, to designate for appointment to the Board that number of directors commensurate with Dong-A&#8217;s and its affiliates&#8217; beneficial ownership of our Common Stock, with the number of directors that Dong-A is entitled to designate rounded up to the nearest whole<font style="letter-spacing:0.2pt;"> </font>number (&#8220;<font style="font-style:italic;font-weight:bold;">DA Designees</font>&#8221;). To the extent necessary to permit the designation of the DA Designees, the size of the Board shall be increased to that number of directors that would permit Dong-A to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><a name="_iDocIDFieldabd642b0-1eb3-49e7-965f-8c11"></a>63909224</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.71%;margin-right:4.71%;margin-top:30pt;page-break-after:always;width:90.59%;border-width:0;"><div style="max-width:100%;padding-left:4.71%;padding-right:4.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">designate a number of directors to fill the vacancies created thereby that is commensurate with Dong-A&#8217;s and its affiliates&#8217; collective beneficial ownership of the Common Stock outstanding at such time (taking into account any DA Designees already serving on the Board at such time). For so long as Dong-A has the right to designate any DA Designee to the Board, Dong-A will vote their shares of our Common Stock in favor of any Company Director (as defined in the Investor Rights Agreement) or any nominee designated by the <font style="font-size:12pt;"><a name="_9kR3WTr26645BZQwrtmt2xwkswMSEGEH47CafRI"></a></font>Nominating and Corporate Governance Committee of the Board and against the removal of any Company Director, in each case, at any meeting of the stockholders of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Registration Rights&#8201;&#8212;&#8201;2022 Registration Rights Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;14, 2022, we entered into the 2022 Registration Rights Agreement <font style="letter-spacing:0.2pt;">(the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;">2022 Registration Rights Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) </font>with Dong-A and the other parties thereto. The 2022 Registration Rights Agreement provides Dong-A with demand and piggyback registration rights, including the right to two long-form registration statements. In addition, we agreed to file a registration statement to register the shares of Common Stock issuable upon any Common Stock held by the parties to the 2022 Registration Rights Agreement and to use commercially reasonable efforts to cause each registration statement to be declared effective under the Securities Act of 1933, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Securities Act</font>&#8221;) as promptly as possible after the filing thereof. We also agreed to use our commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date that all securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule&#160;144.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Registration Rights&#8201;&#8212;&#8201;2024 Registration Rights Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 23, 2024, we entered into the <font style="font-size:12pt;"><a name="_9kR3WTr26645CeKglyAAsv406kawwAMeNBAy78A"></a></font>Registration Rights Agreement with Dong-A and Armistice Capital Master Fund&#160;Ltd <font style="letter-spacing:0.2pt;">(the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;">2024 Registration Rights Agreement</font><font style="letter-spacing:0.2pt;">&#8221;)</font>. The 2024 Registration Rights Agreement provides Dong-A and Armistice Capital Master Fund Ltd., among other things, with registration rights for the shares of Common Stock, as well as the shares of Common Stock underlying warrants, in each case issued in June 2024. &#160;We also agreed to use our commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date that all securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule&#160;144.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Registration Rights&#8201;&#8212;&#8201;2025 Registration Rights Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="letter-spacing:0.2pt;">On May 8, 2025, we entered into the </font><font style="font-size:12pt;"><a name="_9kMHG5YVt48867EgMin0CCux628mcyyCOgPDC09"></a></font><font style="letter-spacing:0.2pt;">Registration Rights Agreement</font><font style="letter-spacing:0.2pt;"> (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;">2025 Registration Rights Agreement</font><font style="letter-spacing:0.2pt;">&#8221;) with Dong-A and Dong-A Socio Holdings Co., Ltd. (&#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;">Dong-A Holdings</font><font style="letter-spacing:0.2pt;">&#8221;). The 2025 Registration Rights Agreement provides Dong-A and Dong-A Holdings, among other things, with demand and piggyback registration rights, including the right to two long-form registration statements. In addition, we agreed to file a registration statement to (i) register the shares of Common Stock underlying the pre-funded warrants sold in the private placement (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;">2025 Registrable Securities</font><font style="letter-spacing:0.2pt;">&#8221;); and (ii) to use commercially reasonable efforts to cause each registration statement to be declared effective under the Securities Act, as promptly as possible after the filing thereof. We also agreed to use our commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date that all 2025 Registrable Securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule 144.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of Preferred Stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series, any or all of which may be greater than the rights of our Common Stock. The issuance of our Preferred Stock could adversely affect the voting power of holders of our Common Stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of Preferred Stock could have the effect of decreasing the market price of our Common Stock and could also have the effect of delaying, deferring or preventing a change of control or other corporate action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2021, in connection with a securities purchase agreement, we issued to certain institutional investors in a private placement pursuant to Section 4(a)(2) of the Securities Act, a warrant to purchase up to 942 shares of our Common Stock, at an exercise price of $15,919.20 per share (the &#8220;<font style="font-style:italic;font-weight:bold;">January 2021 Warrant</font>&#8221;). As of December 31, 2025, the January 2021 Warrant was exercisable for 942 shares of our Common Stock at an exercise price of $15,919.20 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="letter-spacing:0.2pt;">In November 2022, in connection with an underwritten public offering, we issued 65,340 </font><font style="font-size:12pt;"><a name="_9kR3WTr26645DgLrwkvT2SuCwtDJ"></a></font><font style="letter-spacing:0.2pt;">Series B Warrants</font><font style="letter-spacing:0.2pt;"> to purchase up to 65,340 shares of Common Stock at an exercise price of $264.00 per share (the &#8220;</font><font style="font-style:italic;font-weight:bold;letter-spacing:0.2pt;">2022 Series B Warrants</font><font style="letter-spacing:0.2pt;">&#8221;). As of December 31, 2025, the 2022 Series B Warrants were exercisable for 16,176 shares of our Common Stock at an exercise price of $264.00 per share. </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><a name="_iDocIDFieldabd642b0-1eb3-49e7-965f-8c11"></a>63909224</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.71%;margin-right:4.71%;margin-top:30pt;page-break-after:always;width:90.59%;border-width:0;"><div style="max-width:100%;padding-left:4.71%;padding-right:4.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="letter-spacing:0.2pt;">The 2022 Series B Warrants have a cashless exercise provision whereby one warrant can be exercised for one share of Common Stock for no additional consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2024, we issued&#160;to Armistice Capital Master Fund&#160;Ltd and Dong-A in a private placement pursuant to Section 4(a)(2) of the Securities Act, Series B warrants to purchase up to 693,962 shares of Common Stock at an exercise price of&#160;$43.23 per share (the &#8220;<font style="font-style:italic;font-weight:bold;">2024 Series B Warrants</font>&#8221;). As of December 31, 2025, our 2024 Series B Warrants were exercisable for 693,962 shares of our Common Stock at an exercise price of $43.23 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2024, we issued&#160;to H.C. Wainwright &amp; Co., LLC and certain of its designees in a private placement pursuant to Section 4(a)(2) of the Securities Act, a warrant to purchase up to&#160;11,564&#160;shares of Common Stock at an exercise price of&#160;$54.0375&#160;per share (the &#8220;<font style="font-style:italic;font-weight:bold;">Placement Agent Warrants</font>&#8221;). As of December 31, 2025, the Placement Agent Warrants were exercisable for 11,564 shares of our Common Stock at an exercise price of $54.0375 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2026, in connection with an underwritten public offering, we issued 1,998,704 pre-funded warrants to purchase up to 1,998,704 shares of our Common Stock, 4,508,361 Series C warrants to purchase 4,508,361 shares of our Common Stock and 4,508,361 Series D warrants to purchase 4,508,361 shares of our Common Stock, with an exercise price of $0.001, $3.10 and $3.10, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation and Bylaws contain provisions that could make it more difficult to complete an acquisition of us by means of a tender offer, a proxy contest or otherwise or the removal and replacement of our incumbent officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Removal of Directors; Board Vacancies; Board Size</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote of at least 66 2/3% of the voting power of the then outstanding voting stock. In addition, our Certificate of Incorporation provides that any vacancy occurring on our Board may be filled by a majority of directors then in office, even if less than a quorum,&#160;unless the Board determines that such vacancy shall be filled by the stockholders. Finally, the authorized number of directors may be changed only by a resolution of the Board. This system of removing directors, filling vacancies and fixing the size of the Board makes it more difficult for stockholders to replace a majority of the directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Classes</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation and Bylaws provide that the Board be divided into three classes of directors, as nearly equal in number as possible, with each class serving a staggered three-year term. The classification system of electing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us since the classification of the Board generally increases the difficulty of replacing a majority of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Special Stockholder Meetings</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Certificate of Incorporation and Bylaws provide that a special meeting of stockholders may be called only by a resolution adopted by a majority of our Board or by the chair of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Stockholder Advance Notice Procedure&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Bylaws establish an advance notice procedure for stockholders to make nominations of candidates for election as directors or to bring other business before an annual meeting of our stockholders. The Bylaws provide that any stockholder wishing to nominate persons for election as directors at, or bring other business before, an annual meeting must deliver to our secretary a written notice of the stockholder&#8217;s intention to do so. To be timely, the stockholder&#8217;s notice must be delivered to or mailed and received by us not more than 120 days, and not less than 90 days before the anniversary date of the preceding annual meeting, except that if the annual meeting is set for a date that is not within 30 days before or 30 days after such anniversary date, we must receive the notice not earlier than the close of business on the 120<sup style="font-size:7.5pt;vertical-align:top;">th</sup> day prior to the annual meeting and not later than the close of business on the later of (i) the 90<sup style="font-size:7.5pt;vertical-align:top;">th</sup> day prior to the annual meeting or (ii) the 10<sup style="font-size:7.5pt;vertical-align:top;">th</sup> day following the day on which we first made public announcement of the date of meeting. The notice must include the following information:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as to director nominations all information relating to each director nominee that is required by the rules of the SEC to be disclosed in solicitations of proxies, or is otherwise required by Section 14 of the Exchange Act, including Regulation 14A and Rule 14a-19, and a description of all </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_9kR3WTr1AB458M6rw1ut252bjxuD1m6D9FK"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Derivative Transactions</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> (as defined in the Bylaws) by each nominee during the previous twelve-month period;</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><a name="_iDocIDFieldabd642b0-1eb3-49e7-965f-8c11"></a>63909224</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.71%;margin-right:4.71%;margin-top:30pt;page-break-after:always;width:90.59%;border-width:0;"><div style="max-width:100%;padding-left:4.71%;padding-right:4.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as to any other business that the stockholder proposes to bring before the meeting, a reasonably brief description of the business to be proposed, the text of the proposal, the reasons for conducting such business at the meeting and, if any, and the stockholder&#8217;s material interest in the proposed business; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as to the stockholder who intends to make the nomination (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Notifying Stockholder</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (i) the name and address of the Notifying Stockholder, (ii) the class, series and number of our securities that Notifying Stockholder beneficially owns of record and (iii) a description of any participants, associates, family members living in the same household and any person or entity who is a member of a group with the Notifying Stockholder.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Undesignated Preferred Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ability to authorize undesignated Preferred Stock makes it possible for our Board to issue Preferred Stock with voting or other rights or preferences that could have the effect of delaying, deferring, preventing or otherwise impeding any attempt to change control of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Delaware Anti-Takeover Statute</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to Section 203 (&#8220;<font style="font-style:italic;font-weight:bold;">Section 203</font>&#8221;) of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation such as us from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that the stockholder became an interested stockholder, unless:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prior to the time the stockholder became an interested stockholder, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_9kMIH5YVt466679LGmqu"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_9kMJI5YVt466679LGmqu"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Section 203 defines a business combination to include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation involving the corporation and the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority-owned subsidiary);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transfer agent and registrar for our Common Stock is Equiniti Trust Company, LLC.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><a name="_iDocIDFieldabd642b0-1eb3-49e7-965f-8c11"></a>63909224</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.71%;margin-right:4.71%;margin-top:30pt;page-break-after:always;width:90.59%;border-width:0;"><div style="max-width:100%;padding-left:4.71%;padding-right:4.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Listing on the Nasdaq Capital Market</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Common Stock is listed on the <font style="font-size:12pt;"><a name="_9kR3WTr26645AYCosbpS7r05yreO0Bz9"></a></font>Nasdaq Capital Market under the symbol &#8220;MTVA.&#8221;<font style="font-size:12pt;"><a name="nt10019324x1_s3_206-description_pg5"></a><a name="tDDS"></a></font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><a name="_iDocIDFieldabd642b0-1eb3-49e7-965f-8c11"></a>63909224</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.71%;margin-right:4.71%;margin-top:30pt;page-break-after:avoid;width:90.59%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>mtva-20251231xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head></head><body link=blue lang="EN-US"><div><div align="center"><div align="center"><div style="position:absolute; top:17px; right:64px; font-family:'Times New Roman'; font-size:10pt; font-weight:bold;">Exhibit 10.3</div><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td style="padding:0in 5.4pt 0in 5.4pt;valign:middle;width:7.7%"></td><td width="84.4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="mtva-20251231xex10d3g001.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td style="padding:0in 5.4pt 0in 5.4pt;valign:middle;width:7.7%"></td><td width="84.4%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="mtva-20251231xex10d3g002.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:avoid;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>mtva-20251231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 03:11:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;background:#ffffff;margin:0pt;">Exhibit&#160;23.1</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Trebuchet MS';font-size:10.5pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-269365, 333-255418, 333-252412, 333-278646 and 333-288486), Form S-1 (No. 333-280865, 333-267482, 333-292581 and 333-292743) and Form S-8 (No. 333-271292, 333-237535, 333-260765 and 333-286184) of MetaVia Inc. (the Company) of our report dated March 26, 2026, relating to the consolidated financial statements which appear in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:4.7pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ BDO USA, P.C.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">March 26, 2026</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>mtva-20251231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 03:11:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">Exhibit 31.1 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">pursuant to Rule 13a-14(a) or Rule 15d-14(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">I, Hyung Heon Kim, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.4pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of MetaVia Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.4pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">present</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">respects</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">condition, results</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cash</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">flows</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">responsible</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.75pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.55pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">my</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supervision,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reasonable</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assurance regarding</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliability</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">report)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">affected,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reasonably</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">likely</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to materially</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">affect,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">control over financial reporting;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0.5pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on my most recent evaluation of internal</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">control</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">over</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">auditors</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">committee</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board of directors (or persons performing the equivalent</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.45pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal control</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.45pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a significant role in the registrant&#8217;s internal control over financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.76%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt -5.45pt;">Date: March 26, 2026</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">/s/ Hyung Heon Kim</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="1" style="margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>mtva-20251231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 03:11:42 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:21.6pt;min-height:32.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">Exhibit 31.2 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">pursuant to Rule 13a-14(a) or Rule 15d-14(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">I, Marshall H. Woodworth, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.4pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this annual report on Form 10-K of MetaVia Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.4pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">present</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">material</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">respects</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">condition, results</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operations</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cash</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">flows</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.4pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">responsible</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.55pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">my</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supervision,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reasonable</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assurance regarding</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reliability</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.55pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">report)</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">has</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">materially</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">affected,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reasonably</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">likely</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to materially</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">affect,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">control over financial reporting;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0.5pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on my most recent evaluation of internal</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">control</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">over</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">auditors</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">audit</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">committee</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">registrant&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">board of directors (or persons performing the equivalent</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.45pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal control</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.45pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a significant role in the registrant&#8217;s internal control over financial</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.76%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt -5.45pt;">Date: March 26, 2026</p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">/s/ Marshall H. Woodworth</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Chief Financial Officer</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">(Principal Financial Officer)</p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="1" style="margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>mtva-20251231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 03:11:43 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;min-height:18pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit 32.1</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification of Chief Executive Officer</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">under Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(18 U.S.C. &#167; 1350)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin:0pt 18.1pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;margin:0pt 18.1pt 0pt 0pt;">In connection with the Annual Report of MetaVia Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Hyung Heon Kim, President and Chief Executive Officer, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;text-indent:21pt;margin:0pt 18.1pt 0pt 15pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td><td style="width:18.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;margin:0pt 18.1pt 0pt 36pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td><td style="width:18.1pt;"></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.76%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt -5.45pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March 26, 2026</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Hyung Heon Kim</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">President and Chief Executive Officer</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(Principal Executive Officer)</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="1" style="margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>mtva-20251231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 3/25/2026 03:11:43 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:8.82%;padding-right:8.82%;position:relative;"><div style="margin-top:30pt;min-height:18pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Exhibit 32.2</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification of Chief Financial Officer</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">under Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">(18 U.S.C. &#167; 1350)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;margin:0pt 18.1pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;margin:0pt 18.1pt 0pt 0pt;">In connection with the Annual Report of MetaVia Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Marshall H. Woodworth, Chief Financial Officer, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;text-indent:21pt;margin:0pt 18.1pt 0pt 15pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td><td style="width:18.1pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:justify;margin:0pt 18.1pt 0pt 36pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td><td style="width:18.1pt;"></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:92.76%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt -5.45pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March 26, 2026</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ Marshall H. Woodworth</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Financial Officer</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(Principal Financial Officer)</font></p></td></tr><tr style=""><td style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="1" style="margin:0pt;padding:0pt;"></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:8.82%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:82.35%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>mtva-20251231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !2 :X# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7]MC916T=/\ /\3[/@# ?4LDISDO>JMS?H]%^"3^84445\\?HX4444 %%%%
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MX3B[/_(Z>SU2&[P =DG]UJN5QG2M&SUJ6WPLG[U/?J*ZU+N><X]CNM-F\VV
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MS4=SYUQ%$0/P<_E7YQ_\$N_#Z:U^UEI5TR[O[*TN]O!D9P3'Y'_M8T%K8O\
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M6(/^"4OP0NH(YH=0\4RPR*'21-3A*LI&00?)Y%/_ .'3WP4_Y_/%?_@QB_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>mtva-20251231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %H WP# 2(  A$! Q$!_\0
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M .A;'_@?=?\ QVC_ (9<^&?_ $+8_P# ^Z_^.UZO10!Y0?V7/AF 3_PC8_\
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MA;Q9I.M:%9EA=7]M<KY=L5&YO-+8,>%Y^;''/2@#$_X9H^&__0MC_P #[O\
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M/AO_ -"V/_ ^[_\ CU>GT4 >:V_[,GPVEE"GPV,8_P"?^[_^/59_X9<^&?\
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MA;'_ ('W7_QVO5Z* /*/^&7/AG_T+8_\#[K_ ..T?\,N?#/_ *%L?^!]U_\
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MG);/6NE^%C_#K]H_]L'PCX_\+/X9\$^ ? :RZ9H,%O-;6=_XCO&RFY+92KK
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MS-L!/;<S''J347_#._PN_P"$&'@P^ ?#K>%5N#>+H[6"-;K.>L@4]&XQD<T
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M /H(7G_@3)_C1_J]/_GZO_ $']OP_P"?3_\  V?I=_PK3XA?]%FU7_P1Z?\
M_&Z/^%8^/S][XS:OGVT73Q_[2K\T?[7O_P#H(7G_ ($R?XT?VO?_ /00O/\
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M/-K_ -#YX]_\*&3_  H_X9WL?^AW\=_^%%-7K%%'MZG</8T^QY/_ ,,[V/\
MT._CO_PHIJ/^&=['OXV\=D>G_"135ZQ11[>IW%[&GV/)_P#AG;3?^AR\=?\
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M+\3'!XF%>2NE?\FC@QV'EB\/*C%V;M^:9^3I&:" >H!^M?HDW[(OA4L2-+M
M/3RJ3_AD3PM_T#+3_OU7VG^LU#_GV_P/C_\ 5NM_S\7XGYV[5QC:,?2EVCT'
MY5^B/_#(GA;_ *!EI_WZH_X9$\+?] RT_P"_5'^LU#_GV_P#_5NM_P _%^)^
M=NT>@_*EVCT'Y5^B/_#(GA;_ *!EI_WZH_X9$\+?] RT_P"_5'^LU#_GV_P#
M_5NM_P _%^)^=P '0 4!0.@ ^@K]$?\ AD3PM_T#+3_OU1_PR)X6_P"@9:?]
M^J/]9J'_ #[?X!_JW6_Y^+\3\[2H/4 _A2X'H*_1'_AD3PK_ - RT_[]T?\
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M9(\+0L)!IEIE?F'[ON*Y#Q!^U9X>^#'B;5?",WA_4[VXTN40R3PR1!')16R
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M1N$"3,I+<9R,&@#NJ*3K2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<=*Q=/\ @'\/]+EN);;PO9(\YC+LV]N$N1=(@RQVHLZB0(,*#GCDT <=X?\
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M%/(B/YB*Q4/C&X ]<5H>)KS4]2UFXN=8#_;Y=K/YB;3C&!@=A@<5ET %%%%
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MHTW*$F]=-?*VWWH6K/-J4=:]%U+X1YG\2/I>HO<6FE/<"-I[9X_-$*!Y!NZ
M@'\3Z9%>=#J*]"G5A55X,EJQ^@?[&?\ R)6E_P#7LM<%XP_Y&[7/^O\ G_\
M1C5WO[&?_(E:7_U[+7!>,/\ D;M<_P"O^?\ ]&-7X?C/]YJ_XG^;/16R,BBB
MNFATW3[0Z+;S6<UY)J,:2-/'*5V;W*A4&,$KCG/?BN09S-*.M=7J'A&'9!#:
MW4;7B6UQ(T>UL2B*>52V[H"548'M23^ 9;:^2UDOH%<M)&V0<AT )"C^+.<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ;)]QOH:_+/\ :>_Y+_XX_P"OY?\ T3'7ZF2?<;Z&ORS_
M &GO^2_^./\ K^7_ -$QU]EPM_O<_P##^J,*WPGE]7K_ $6\TP6AN8&C%W;)
M>0\@[HGSM;CIG:?RJD.#7J&E_%Z'1]/TN&U2Z@EMTT>&=T5?WD=J\S3)R>0X
ME4 =#@YK]'JSJ0LX1N<JMU./LI]?BOWU6WNG%Q?$+/>&1&5C,S?+*3E1N*,2
M&],TZ'Q!XGUC7;*6*^O;S54N9)+9U.]_.? <KQ@EMHSV(%=II?Q9TVS32(2-
M0M[2P;3Y'MH44QSF"YGD=6&X#!29,$YYC (Q@U9TOXNZ)HUGHJVL6IQS6=];
M7+],HJF?SMAWX^;S5P HX7#$\&N.4ZFO[J[V0].YYW8^(-<T&&2.QU&6VCO
M9W2W93RP923@$HV,CC!P?2L41L$SM.WIG'%>E:9\1M-M(H(#=ZI:RQ1VBOJE
MM"C3S^5-<.Z,&;[KB9#U/*8((JOK7Q0@U/0Y]+AMI;6QEL+R$62JOE1SRWYN
M(W'^XAV9ZCH.*V52HI:4]WOY=]OZ\A:=SSNNY^"G_)3-'^LG_H!KAJ[GX*?\
ME,T?ZR?^@&L\R_W*M_AE^3''XD?IYX:_Y UM_N"M.LSPU_R!K;_<%:=?B!Z
M4444 %%%% !1110 4444 %%%% !1110 5\Z_MV?\D5MO^PS:_P#H$M?15?.O
M[=G_ "16V_[#-K_Z!+7K93_O]'_$B)_"SX!KH_#5QXAU77KZ;3+QQJ,\$UQ=
MSRRHH>(8>5I"_P I&<$Y[XKG*Z'P1XH'A'4K^]V%I9=-N;2']VKA9)% 4LK<
M%>.0<U^RU4W!\JN_,X$3Z[J'BG0]?1M0O;D:E;NU]'-O609G4,TJL,JPD!!)
MY!K.TSQ/K6BP3Q6%_<6D5TQ=UBP-S$%21QP2"1E<<'%>FCXUZ9))JEP]G/\
M:KN877[R$.C9MA%]E*JZ#R48'8""-K'Y<C-5_P#A:?AZ"RT2WM[;4 ;%B%FD
M17DM0UD8-T99B"RR$2  */E'\7-<"J5.6TJ/3Y=_S*T[G$V6L>)/!=C9QV-_
M+96^H1C4(XX0K<AY(@^"IVL#&PR,'&*J6WBK7OLDVGPZC=-!>&19(LAC+YI
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M3CI70?!/_D:U^@H ^JE^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#+D^^WU--J"2VG\QO]+8<G_EFM-^S3_P#/X_\ W[6@"S15;[-/
M_P _C_\ ?M:/LT__ #^/_P!^UH LT56^S3_\_C_]^UH^S3_\_C_]^UH LT56
M^S3_ //X_P#W[6C[-/\ \_C_ /?M: +-%5OLT_\ S^/_ -^UH^S3_P#/X_\
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M O451^Q7/_/Z_P#W[6C[%<_\_K_]^UH O451^Q7/_/Z__?M:/L5S_P _K_\
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M,,J@&K]5A:S@8%XW_?I:/LT__/X__?M:\$T+-%5OLT__ #^/_P!^UH^S3_\
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M0S$X_6OH.SL9EEPETR\'I$M6VTV9NMV3]8EKP)SE4DYRW>IJ?)G_  K37O\
MGT:C_A6FO?\ /HU?67]ER_\ /S_Y"6C^RY?^?G_R$M0!\F_\*TU[_GT:C_A6
MFO?\^9KZR_LN7_GY_P#(2T?V7+_S\_\ D): /DW_ (5IKW_/HU'_  K37O\
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M_P!^UH O451^Q7/_ #^O_P!^UH^Q7/\ S^O_ -^UH AD^^WU--ITGWV^IIM
M!1110 4444 %%%% !1110 4444 %%%% !6A:?ZA?QK/K0M/]0OXT 34444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 C?=/TK*'2M5ONGZ5E#I0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !1110 4444 %%%% "-]T_2LH=*U6^Z?I64.E !1110 4444 %%%%
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M:_B$D9FV 8VL(\=><@G/3'UJ>/P7;07OER7)GM#Y/[Y(^2&G6,[.??OT],T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!G7EQ?ZC;6MM-&5A29CYK9Q)*Y 9V)[_ "@?A3)8-4M8TEDDGC#+'+$2Y!<
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MI64.E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_A1_PT#IO_0I>,__  0S_P"%>I[V_O-^=&]O[S?G1S4_Y?Q#EJ?S?@>6?\-
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M_AHG3O\ H4?&7_@@N/\ XFC_ (:)T[_H4?&7_@@N/_B:]8P*,"CFI_R_C_P
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M^)KUC HP*.:G_+^/_ #EJ?S?@>3_ /#1.G?]"CXR_P#!!<?_ !-'_#1.G?\
M0H^,O_!!<?\ Q->L8%&!1S4_Y?Q_X <M3^;\#R?_ (:)T[_H4?&7_@@N/_B:
M/^&B=._Z%'QE_P"""X_^)KUC HP*.:G_ "_C_P  .6I_-^!Y/_PT3IW_ $*/
MC+_P07'_ ,31_P -$Z=_T*/C+_P07'_Q->L8%&!1S4_Y?Q_X <M3^;\#R?\
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MZH3E.4;;WU^[_+N<7>@?\/"_$IP,_P#"MFY_X"M?*?ASPY\,I?V M2\07%W
MWQ,L[Y8;-S='[5;,)U\N.),_*AC+,<#J2<U^INJ_#'P]<>(-2\4V^CVP\5W.
MER:6-2Y$AA*$+&><8SCM7@O[+?[&^@^"_A1X8M_B-X.T:^\:Z5/<.+EL3%5:
M4M'E@<-@>N<5S8?,Z-.DIMM./LU96N^52O\ +N:U,-.4[::\WRO;\3YX^,,7
MBCXA_'KX9:!XBOM$A!\!V-U!#XR$G]GRWCQYG)52,RD^OH:D\>_#F^^&7[#G
MQ<TRX\5Z)XCM'\06DT%MH,SR6VGDO'OA7=]T9P0N:^_/B#\(?!GQ6MK>#Q=X
M;L->CM\^2;J/+1YZA6&"![9Q5"/X"?#R'P'=>"X_"6G1>%KJ19I],1"L<KJ0
M0S8.21M'.>U8QSB"C2CRM*+BVDE;1WNGW_JY;P<FY.^]]?56.B\"?\B-X;_[
M!EK_ .B4K<J*TM8K&UAMK>,100HL4<:]%50  /H *EKY>3O)L]1*R2"M"T_U
M"_C6?6A:?ZA?QJ1DU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 87CO_D2M?_[!]Q_Z*:OYV8O]
M3%_N+_(5_1-X[_Y$K7_^P?<?^BFK^=F+_4Q?[B_R%?HO"7PUO^W?U/F<Y^Q\
MQ]%%%?H!\T%%%% !5_0= U'Q3K-II.D64VHZE=R"*WM;==TDKGLH[GBJ%>D?
MLX>.-*^&OQU\$^*-;EDATG2M12YN9(D+LJ ,"0HY/6LJTI0IRE!7:3LNYI!*
M4TI.R.9M_AWXGN[2*Z@T*_FMY=1;28Y(X"P:\4;F@&/XP.2*KZAX+U[2O%3^
M&;O2+N#Q LRV[::\1\\2, 53;UR01Q[U]'^,_P!JK2[WX:Z=;^%HH?"7B:Q\
M>76MQ_V/;O&K6<D'E^>S.3^];<P(],<"N+^+'Q(\,_$3]KG5?&5GKNH:-X6O
M]7AN!K%K"RW5O"(HU9T3[VX;6 ^M>?2Q&(DWST[*S[[IJWWIG5.E12]V5W='
M 3?!'Q];^*H/#4GA'5DUZ: W,>GFV;S7B'5P/[H]:9I7P8\=:Y<:O!8>$]6N
MYM(<QW\<5JQ:V8#)5QV.!G'I7U=KG[27PZE\4:CI-AXQU.'PG>>#Y_"^G:G#
M93F\TG]]'*)96;YY6E(;<5Z8%6=*_:@^'=U\6_B!\0!XNU;0-2N)HH_#MG-9
MS2VBLEG';M?SQ1\/(P#X4],\UQ_7L9RW]ET[/>Z_X/I:^NAO]7P]_CZ]U_7^
M9\5GPEK(\,'Q$=,N1H7VG[']O*$1&;&?+![MCG%9-?7'BG]H#X;ZQ^S!%X+1
M&FU"WT:*UM-';3RK0:M]H+SZB+GIB13]SKVKY'(YKU<-6J5E)U(<MFTO-=SB
MK4X0:Y)7N@HHHKL.<**** "O=OV*?^3@-'_Z];G_ - %>$U[M^Q3_P G :/_
M ->MS_Z *\K-?]PK?X7^1VX+_>:?JC]I=!_Y!-M_N"K]4-!_Y!-M_N"K]?AY
M]\%%%% !1110 4444 %%%% !1110 4444 3V?^O'T-7ZH6?^O'T-7Z "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,F=UB\QW8(BY9F8X  ZDUP'A3X\>"/&/@=_&%EKD,'AM;
MR2P&H7W^CQO*C;2%+=1GH1UP:S/VK/$UUX/_ &=/B1JUDQCNX-&N$C=>J%\1
M[A[C?G\*^./VAO#4'A;_ ()E?"VQA10DDVEWC@=&:>.:9B?^^Z]K!8&&)C%R
M=N::BONN_P!#BKUW2;LME<^]?#?Q*\*>,+AK?1/$>F:K.HR8K2Z21L?0'-:/
MB+Q/I'A'36U#6M2M=*L0ZH;B[E$:;CT&3W-?$7[9'P<\+?!WX+>'?B?X$TV'
MPCXNT6\T]X[K3,Q"=9 -RNH.&YY_,5K_ +5OB#2/C3\4OA!\+M=U*UTG0;FS
M?Q/KSSS"-$S 1 F3WW%L#W]JUAEU.JX3IR?(^:^FJY5=^M[JWF2\3*/-%K56
MMYW/M'3M1M=8L+>^L;B.[L[A!+#/"P9)%/1@1U%6&8*I9B H&23T KY!_8,^
M,6G:5^SUKFB^)]8MK;_A7E_/I]W>R2 QK:;R8I-P_ASO4'V%>UW>L>"_VH_
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MMS.MS,L[[@\BH45C[A25'8 X%4]2U2[UBY%Q>W$EU.(TB\R4Y;8BA$&?0*H
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MK5;[I^E90Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>mtva-20251231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "X E(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]'?BG\6M%
M^$6DV>H:VMRT%U<?9X_LT>\[MA;GD<84UYI_PVSX _YY:K_X##_XJL7]N_\
MY$'PW_V%C_Z(DKXGKZW+LLP^)PZJ5+WUZGY-Q#Q-C\LS"6&H<O*DMU?=>I]Y
M?\-L^ /^>6J_^ P_^*H_X;9\ ?\ /+5?_ 8?_%5\&T5Z7]B83S^\^:_UUS7^
M[]W_  3[R_X;9\ ?\\M5_P# 8?\ Q5'_  VSX _YY:K_ . P_P#BJ^#:*/[$
MPGG]X?ZZYK_=^[_@GWE_PVSX _YY:K_X##_XJC_AMGP!_P \M5_\!A_\57P;
M11_8F$\_O#_77-?[OW?\$^\O^&V? '_/+5?_  &'_P 51_PVSX _YY:K_P"
MP_\ BJ^#:*/[$PGG]X?ZZYK_ '?N_P""?>7_  VSX _YY:K_ . P_P#BJ/\
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M?XU\2T4?V-@_Y7][#_7+-_YU_P" H^VO^&Z_"_\ T -4_-/\:/\ ANOPO_T
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M\N[6-$C640^5$)%,Q0'[V>V,#GVJ?JN6/77\31YIQ,G9\OW1[7_KY]F>N?\
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M)\4^+-3\::LVIZO.MU?.H5YA$D9?'=MH&3ZD\FM:<<0IWJ-6UV^5OU.3$U,
MZ/+AX24O=U?SYNOI;3[C(HHHKK/'"BBB@#L_@O\ \E@\$?\ 8:M/_1JUZ?\
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MF7:2.A(]:>O[2ELJ*@T_4 JH8PHN%P%/5?H>XKP6BNKZI1[&7]B8)?9?WO\
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M^VSH6I:]X&\/Q:;87-_+'JA=DMHFD*KY$@R0 >,D5\=?\*Y\5?\ 0MZM_P"
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M_J#1_P"@A_<O\S\K_P#A7/BK_H6]6_\  *3_ .)H_P"%<^*O^A;U;_P"D_\
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M1_Z"']R_S/RO_P"%<^*O^A;U;_P"D_\ B:/^%<^*O^A;U;_P"D_^)K]4,"C
MH_M^?_/M?>'^H-'_ *"']R_S/RO_ .%<^*O^A;U;_P  I/\ XFC_ (5SXJ_Z
M%O5O_ *3_P")K]4,"C H_M^?_/M?>'^H-'_H(?W+_,_*_P#X5SXJ_P"A;U;_
M , I/_B:/^%<^*O^A;U;_P  I/\ XFOU0P*,"C^WY_\ /M?>'^H-'_H(?W+_
M #/RO_X5SXJ_Z%O5O_ *3_XFC_A7/BK_ *%O5O\ P"D_^)K]4,"C H_M^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_@N?_XY3_M+"?S_ (/_ ",7E..?_+O\5_F?&"KFI56OLT?\$U=8'_,\V/\
MX+G_ /CE.'_!-C6!_P SQ8_^"Y__ (Y36983^?\ !_Y&+R?'_P#/K\5_F?&J
MK4BK7V2/^";>L#_F>+'_ ,%[_P#QRG#_ ()O:P/^9WL?_!<__P <I_VGA/Y_
MP?\ D8O)<P?_ "Z_%?YGQPJYJ55K[%'_  3AU@?\SO8_^"]__CE.'_!./5Q_
MS.UE_P""]_\ XY1_:>$_G_!_Y&+R/,7_ ,NOQ7^9\>*M2*M?8(_X)S:N/^9V
MLO\ P7O_ /'*>/\ @G3JX_YG6R_\%[__ !RJ_M/!_P _X/\ R,7D.9O_ )=?
MBO\ ,^0%6I%6OKT?\$[-6'_,Z67_ ( /_P#%T\?\$[]6'_,Z67_@ _\ \71_
M:F#_ .?GX/\ R,'D&:/_ )<_C'_,^1%6I%6OKD?\$\]6'_,YV7_@ _\ \73E
M_P"">NK#_F<[+_P ?_XNG_:F#_Y^?@_\C)\/9H_^7/XQ_P SY)5<5(JXKZU'
M_!/C51_S.5G_ . #_P#Q=.'_  3[U4?\SE9_^ #_ /Q=/^U,'_S\_!_Y&+X=
MS9_\N7]\?\SY,5:E5<5]8C_@G]JH_P"9QL__  !?_P"+IP_8!U0?\SA9_P#@
M"_\ \71_:F#_ .?GX/\ R,'PWF__ #X?WQ_S/E!5J55KZL'[ FJC_F<+/_P!
M?_XNGC]@?5!_S-]G_P" +_\ Q=5_:N#_ .?GX/\ R,7PSG#_ .7#^^/^9\J*
MOI3P,5]5#]@G5!_S-]G_ . +_P#Q=+_PP5JG_0WV?_@"_P#\71_:N#_Y^?@_
M\C%\+YR_^7#^^/\ F?*M%?57_#!6J?\ 0WV?_@"__P 71_PP5JG_ $-]G_X
MO_\ %T?VK@_^?GX/_(G_ %6SC_GP_OC_ )GRK17U5_PP5JG_ $-]G_X O_\
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MXAENK.!^OE+;V\!?'8/)#(X]0P/>N^HH **** "BBB@ HHHH **** "BBB@
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M_I5BB@"O]E;_ )[O^E'V5O\ GN_Z58HH K_96_Y[O^E'V5O^>[_I5BB@"O\
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M_GK)_P!]FC^P/^GOX?\ !-%QLW_S#_\ DW_VI^P_VJ'_ )ZI_P!]"D^UP_\
M/5/^^A7XYM=S?\]I/^^S4+WDO_/:3_OLT?V#_P!/?P_X)JN,F_\ F'_\F_\
MM3]DOM</_/6/_OH4?:X?^>L?_?0K\9VO)O\ GM)_WV:A:\F_Y[2?]]FE_8/_
M $\_#_@FJXO;_P"7'_DW_P!J?L]]KA_YZQ_]]"C[7#_SUC_[Z%?BXUY-_P ]
MI/\ OL_XU"]Y-_SVD_[[/^-+^PO^GGX?\$U7%;?_ "X_\F_X!^U/VN#_ )[1
M_P#?8H^V0?\ /:/_ +[%?B@]Y-_SVD_[[-0O>3?\]I/^^S_C1_87_3S\/^";
M+BAO_ES_ .3?\ _;7[9!_P ]H_\ OL4?;(/^>T?_ 'V*_$1[V;_GM)_WV?\
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M+O'-SH-I%X-\+V0N-2U1[A3+?7$<KR6UOY.<E4?:=Q&"&8=A7V".!0 M%%%
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M43>"O$?_ $ -3_\  .3_  I<\>YU1I2[&([5"[UMOX)\1_\ 0 U/_P  Y/\
M"HF\$>(_^@!JG_@')_A2YX]SKC3EV,-FIM:=]X7UG2[9KB\TF^M(%(!EGMG1
M1GIR1BLRE>^QK:V@5]'?L.6'Q+G^+$%QX#<PZ:C*NM278)LF@SRL@'5\9*X^
M8'VSGG?V:_V7/$/[0NO*8_,TKPO;2 7NKLF0!WCB!X:0_D.I]#^KOPY^&_A[
MX4^%;3P]X:T^/3]-MEP%7EY&[N[=68]237B9CC84HNDE>3_ ]K 8.=62JMV2
M_$Z>BBBOC3ZX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MML<#F\GAGE'3LT" >V:** +.G? C3M)\0IK-MJM]'=1:Q_;$42E1"CF*:*1
MF, .MQ)N(Y)P<Y&:Z;X9>#9/ 7@VSTB>Y6\NEEN+JXG1=JO-//)/*5'8;Y&P
M/3%%% '4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mtva-20251231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %/ <@# 2(  A$! Q$!_\0
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M1110 4444 %%%% !1110 4444 %%%% 'QS\6/@CXPO?"OQW\0>%])N#XLO\
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M:)2,G&,9.,GO:** "BBB@ HHHH \M\4>$;J;]H?P!X@L],S8V^D:U#?W\<8
M620V A#MU)(B<#/9#7.>#O"\VG_$;17\/^%-1\)""\U&;Q')=2R36]Y%)YAB
M"2LV)6>9HYE(!\M5=#M) KW6B@ HHHH **** "BBB@#R6V\':G9?M!^+-9TV
MQ2PL[WPC96MOJ!A!@:]%W?N^X @L1YL;-R"0PYK%^"'PW\5^ /B9XE_M;^SY
M]*FT:PC%_:6\L;7ET)KIY9"SR-EB969\]3(N.AS[I10 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_P#V-_\
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MNHHHK, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHQV IJKB:?+%NVZ>OR;['7ALRPN,G[.A.[M?9K\T=-1117CGIA1110 4444
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MF[2NT %,@X.?'/V-_P#D7?BG_P!E-\4?^G&2OH"@#YPV?M<_\]O@K_WZU?\
M^*I=G[7.?];\%?\ OUJ__P 57T=10!\@_$+X7_M4?$B*Q34+[X/VXLRY0VR:
MJ,[MN<YS_=%<9_PRY^TK_P!!CX4_EJ?^%?>-%.X'P=_PRY^TK_T&/A3^6I_X
M4?\ #+G[2O\ T&/A3^6I_P"%?>-%%V!\'?\ #+G[2O\ T&/A3^6I_P"%;_@G
MX'?M0>!-=75;'4OA'-.L;1A+A=4*X;KTP:^TJ*+L#YQV?M<_\]?@K_WZU?\
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M (EWPJ_[\ZE_\=H_X:S_ &E>?^)=\*O^_.I?_':PJ*_2_P#57+/Y7][/A/\
M6#'_ ,R^Y&[_ ,-9_M*9_P"0;\*O^_.I?_':/^&L_P!I3_H&_"K_ +\ZE_\
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MIMG[77_/;X*_]^M7_P#BJ]^\._\ (OZ9_P!>T7_H(K1K,#QWX8+^T /%4?\
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M5(T4<!54  #H!7T;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\I?M;?\CUI/\ V#5_]&R5]6U\I?M;?\CUI/\
MV#5_]&R5]?PK_P C./H_R/F^(/\ <)>J_,\.HHHK]L/RL**** /I7]D#_CS\
M4_\ 72V_E)7T37SM^R!_QY^*?^NEM_*2OHFOPGB3_D:UOE_Z2C];R/\ Y%]+
MY_FPKXZ/P2\;Y_Y ,O\ W]C_ /BJ^Q:*^;3L>Z?'/_"DO&__ $ )O^_L?_Q5
M'_"DO&__ $ )O^_L?_Q5?8U%/F8'QS_PI+QO_P! ";_O['_\51_PI+QO_P!
M";_O['_\57V-11S,"EHL$EKHUA#*NR6."-&7T(4 BKM%%2 4444 %%%% !11
M10 4444 %>6?M.ZWIGA[X*:[?:QX>M/$^GI+9J]AJ$ABME9KJ)4GFD"L8XX6
M*S,X!*B,GM7J=?+G[;VK^/\ POI_A[6_"?Q?\.?#?2(?.BU/2_$$UI:G5<@%
M1!/<6UP Z[3\@C.X,<]* ,;]B;X@>&_'?C3QG?:3X5T"RUJ\M_MFJZ[X:OI+
MJUDF_M&^B,.'R(BWE_:0%/SBXW$#C/UY7R9^PGXVU[QM9ZU=:E)XY-DL,9B_
MX2'0M/LM,F<\F6RN+6V@:X!'&YE Q@X%?6= !1110 4444 ?/_[&_P#R+OQ3
M_P"RF^*/_3C)7T!7S_\ L;_\B[\4_P#LIOBC_P!.,E?0% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RE^UM_R/
M6D_]@U?_ $;)7U;7RE^UM_R/6D_]@U?_ $;)7U_"O_(SCZ/\CYOB#_<)>J_,
M\.HHHK]L/RL**** /I7]D#_CS\4_]=+;^4E?1-?.W[('_'GXI_ZZ6W\I*^B:
M_">)/^1K6^7_ *2C];R/_D7TOG^;"BBBOFCW0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *\M^+_ .S)\-_CQK.AZMXVT&?5-3T-94TZ[MM5O+&2W$FW
M?M-O-'G.T<G/MU->I44 >>_#+X"^#?A!?7MWX8M]6@GO(UBF.HZ_J&HJ5!R-
MJW,\@4Y[J :]"HHH **** "BBB@#Y_\ V-_^1=^*?_93?%'_ *<9*^@*^?\
M]C?_ )%WXI_]E-\4?^G&2OH"@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KY^_:'^%?B?QWXKTZ]T/31>VT5D(7?
M[1%'A_,<XP[ ]"*^@:*]'+\?5RZNL112;5UKMKZ-'%C,)3QU)T:C:7E_3/BK
M_AG3X@_] $?^!MO_ /'*/^&=/B#_ - $?^!MO_\ '*^U:*^I_P!<,?\ R0^Z
M7_R1\_\ ZM8/^:7WK_(^*O\ AG3X@_\ 0!'_ (&V_P#\<H_X9T^(/_0!'_@;
M;_\ QROM6BC_ %PQ_P#)#[I?_)!_JU@_YI?>O\CQG]G#X>Z_X!MM>37;#["U
MT\)A'G1R;@H?/W&./O#K7LU%%?)XW&5,?B)8FJDI2MMMHK>?8^BPN&A@Z,:%
M-NR[^MPHHHKA.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***\=_:!^*4_A?PEXOT6Q@U#1]2;PY>W=MXJNK.7^Q]/D\F0(\]Q&&92I
M8@*3C% 'L5%?G9X6\730QZ#\.-9\:F#0U\8VMAKGB[0_%%W+!J:/H\UVD0NI
MY&> ^8B;UC=02HQMR5KZ'_9^^+/BY_V=OAYJDWA+Q1\2[Z^LI/-U/3+C34D9
M$E*122FZNK?<9$VL"@;."3C(R 7/V-_^1=^*?_93?%'_ *<9*^@*\4_93\'>
M(_"'A'QD_B?0KCPY>ZWXSUO7H-/N[BWFFCMKJ[::+>T$DD8;:PR YP0>:]KH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#?!?_P &VK__ "-1]M_:U_Z WP7_ /!MJ_\ \C4 ?1=%?.GVW]K7_H#?!?\
M\&VK_P#R-1]M_:U_Z WP7_\ !MJ__P C4 ?1=%?'_P 3OC-^T]\*/^$3_M?P
M]\)+C_A)?$%IX<M/L6IZHWEW-QO\MY-T"XC&PY(R>F%-=K]M_:U_Z WP7_\
M!MJ__P C4 ?1=%?.GVW]K7_H#?!?_P &VK__ "-1]M_:U_Z WP7_ /!MJ_\
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MR,@@;.U8'@S]D/QSX/TRZUK1KKPSX7\067BQ/$F@>%=/:XET*RB^R-:SVWS
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MNP.JL%W[L!E4XQD \5N4 %%%% 'FWQS\=>)/ ?AJVN_#FARZK-)?V4$DJ2Q
M1K)=11LI5V!)978 CIU.,5QO[1MAJ&L:+\-=9N;O4]#:V\9Z#YNB0W*>3*SZ
ME O[\IGS H)(7=MSAL$JI'O=4M5T33]=A@BU&RM[Z*"XBNXDN(PX2:-P\<@!
MZ,K*&!Z@@$4 ?-_Q'MPNL^*/%8@C/C'2/&^A:7H]YNS<16<TVGI+;H<DK'*L
M]QN08#9+$9 ([GX__#D_%76_!&C//X1EMK*YNM6?2O%=F=02Z9(# K+9[T\Y
M4%RY+%P$9HS@G KTFZ\$^'[WQ#!KUQHEA-K< Q%J$ENAG3@@8?&1P2/QJ/5_
M /AK7[(6FIZ%I]_;"=[H17-LKJ)7)+N 1]XDDD]\T ?/]_X=O?&6@^ _'FD6
M.D^'8=+BMK:VL;61E-C+!>8,-AM0*8KO:+=C\G[IE.&^Y7I'P4^)>E>)+W5?
M#5O!?KJ5@K7\UY>[2+X/=W,#SKM8[09[6<!&P54(  , >E+HNGQPV$2V5ND5
M@0UI&L0"VY"%!L&/EPK,O'8D55T;PEHGAR]U&[TK2++3KK49?.O)K6!8WN'R
M3N<@98Y9CSW8GN: ->BBB@ KR7Q)\2/%VF?'GPUX6M/#,]QX>O=+U"YFN1/
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mtva-20251231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %D CT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL70/%^G>)=5\2:=9/(U
MSX?U!-,O@Z%0LS6MO= *?XAY5U$<^I([4 ;5%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?/?C']L+1?!_Q,L?"5UHFK)>$W,=S:&S9KEW7;]G\@+E)%ER
M_P VX;=OS8KZ$KS'6?V</ .O>)+76;K0H&EB6[$UMY2&*[:XV[WFRI9F&WY2
M&&,FN7$*NXKV#2?GV/H,EJ953K3>;0E*'*[<KL^:SM^/XVULG?9\>_%.Q^'/
MA&U\2:QINI+IC[#=-! )FL59<[Y54D[0>"4#8Z]*Y;]GO]H.V^.V@Q75OI-Y
M:SQ6X>\N!$1:)-N(,,;M@NP&"2!CGK7?:UX!\/>(],T_3M3TJVO[&P96MH+A
M-Z1E5*J<'@X![YK%^&/P6\*_"33K6WT&QVW,-JMF^H3!?M%Q&&+#S&15#$$G
MG%)JO[9--<G7O<TIU<H66583IR^LN2Y7]E1UO=7].O;1V=^ZHHHKK/FPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZK1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6%S?7]U#965M&TT]S<2"..)%&69F. J@ DD\"N*_X7]\,/\ HH_A'_P>VO\
M\<H [VBN7\-?%+P9XSU!K#P_XNT+7;Y8S*;;3=3AN)0@(!8JC$X!(&?<5U%
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M:CX3\7:5'K7AW4/+^U6,KNBR^7(LJ9*$,,.B'@]J\/\ ^';W[-W_ $2S3_\
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MC']XUYSJ/[(WAF;XQ^(OB-I>MZ[X<U;7-*:PGATB\,4<-P9[:8WD0.0LA-G
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M5W=_$7QCXS2>'RA:^)+BTDBB.0=Z"&WB.[C')(P3Q0!Z#1110 4444 %%%%
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MA//Z***_3C^9CF?B?_R33Q;_ -@B[_\ 1+U^S8Z"OQD^)_\ R33Q;_V"+O\
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M;QK\*_B#\1=&CTGQ'\</%.IZ?'=07JP26&GJ!-#(LL3Y6 'Y753CIQSFM_\
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M6J/\*/HC^3<9_O-7_$_S"N__ &%?^3\M6_[)M-_Z=+>N KO_ -A7_D_+5O\
MLFTW_ITMZ\?._P#='ZH^PX+_ .1M'_#(_3>OS)_;K_Y/QT?_ +)M%_Z=+BOT
MVK\R?VZ_^3\='_[)M%_Z=+BOC\M_WNGZGZ]Q'_R*<1_A//Z***_3C^9CF?B?
M_P DT\6_]@B[_P#1+U^S8Z"OQD^)_P#R33Q;_P!@B[_]$O7[-CH*^)S_ /BT
M_0_:N ?]VK_XE^1Y7^UA_P FM?&/_L3-9_\ 2&:OYK*_I3_:P_Y-:^,?_8F:
MS_Z0S5_-97RI^IA1110!^J?_  0QZ_&S_N"?^W]?JK7Y5?\ !#'K\;/^X)_[
M?U^JM !117F7C6T^,,OB.Y;PEJ/@RWT(A/(CUBTNI+D':-^YHW"_>SC Z8H
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M\1_^V]?55?*O[ O_ #<;_P!EF\1_^V] 'U51110!\J_M#_\ )]G[(W_<W?\
MIKCKZJKY5_:'_P"3[/V1O^YN_P#37'7U50!\J_M]?\VY?]EF\.?^W%?55?*O
M[?7_ #;E_P!EF\.?^W%?55 !1110!\J_\$N/^3$_AE_W$_\ TZ7=?55?*O\
MP2X_Y,3^&7_<3_\ 3I=U]54 %%%?#'[77PH\8? ']G3QEX^\/_'OXIWNL:-#
M!);P:EJEH]NY>XBB.\):HQ^60GAAR!]* /N>BO$_AW^SKJ?@WQ+I>O7'QF^)
M?B>.V!=M)US4K26RN-R%<2*EJC$#=N&&'*CZ5[90 5\>_M;?\GE?LH_]S9_Z
M;H:^PJ^/?VMO^3ROV4?^YL_]-T-;4?XD?5&=7X)>C/8J***^G/ "K?[)W_)K
M/P;_ .Q,T;_TAAJI5O\ 9._Y-9^#?_8F:-_Z0PUY./\ L_/]#T<']KY'JM?F
M/^PG_P FK>"?^W[_ -+KBOTXK\Q_V$_^35O!/_;]_P"EUQ7=D'^]2_PO\T<N
M;_P(^OZ,]ZHHHK[X^0.,^!/_ "D>N_\ LE#_ /IXCK[QKX.^!/\ RD>N_P#L
ME#_^GB.OO&OR_,O]\J>I][@?]VAZ'Q+^W'_R=3^RY_W-/_I#!6Y6'^W'_P G
M4_LN?]S3_P"D,%;E?5Y!_NLO\3_)'SV;_P >/I^K"N"^/_\ R0?XD?\ 8M:E
M_P"DLE=[7!?'_P#Y(/\ $C_L6M2_])9*]^M_"EZ,\BE_$CZH^I?V3?\ DUCX
M-_\ 8F:-_P"D,-+^UA_R:S\9/^Q,UG_TAFI/V3?^36/@W_V)FC?^D,-+^UA_
MR:S\9/\ L3-9_P#2&:OR(_1C\N/A?_R33PE_V"+3_P!$I735S/PO_P"2:>$O
M^P1:?^B4KIJ_6J/\*/HC^3<9_O-7_$_S"N__ &%?^3\M6_[)M-_Z=+>N KO_
M -A7_D_+5O\ LFTW_ITMZ\?._P#='ZH^PX+_ .1M'_#(_3>OS)_;K_Y/QT?_
M +)M%_Z=+BOTVK\R?VZ_^3\='_[)M%_Z=+BOC\M_WNGZGZ]Q'_R*<1_A//Z*
M**_3C^9CF?B?_P DT\6_]@B[_P#1+U^S8Z"OQD^)_P#R33Q;_P!@B[_]$O7[
M-CH*^)S_ /BT_0_:N ?]VK_XE^1Y7^UA_P FM?&/_L3-9_\ 2&:OYK*_I3_:
MP_Y-:^,?_8F:S_Z0S5_-97RI^IA1110!^J?_  0QZ_&S_N"?^W]?JK7Y5?\
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M^JJ /DI/C=^T+XIU7Q#<^%- ^&7_  CMGKVJZ39-K-_J,=VZ6=]/:;I%CB9
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M6W_)Y7[*/_<V?^FZ&O#H_P 2/JCUJOP2]&>Q4445].> %6_V3O\ DUGX-_\
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M  (^OZ,]ZHHHK[X^0.,^!/\ RD>N_P#LE#_^GB.OO&O@[X$_\I'KO_LE#_\
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M^B4KIJ_6J/\ "CZ(_DW&?[S5_P 3_,*[_P#85_Y/RU;_ +)M-_Z=+>N KO\
M]A7_ )/RU;_LFTW_ *=+>O'SO_='ZH^PX+_Y&T?\,C]-Z_,G]NO_ )/QT?\
M[)M%_P"G2XK]-J_,G]NO_D_'1_\ LFT7_ITN*^/RW_>Z?J?KW$?_ "*<1_A/
M/Z***_3C^9CF?B?_ ,DT\6_]@B[_ /1+U^S8Z"OQD^)__)-/%O\ V"+O_P!$
MO7[-CH*^)S_^+3]#]JX!_P!VK_XE^1Y7^UA_R:U\8_\ L3-9_P#2&:OYK*_I
M3_:P_P"36OC'_P!B9K/_ *0S5_-97RI^IA1110!^J?\ P0QZ_&S_ +@G_M_7
MZJU^57_!#'K\;/\ N"?^W]?JK0!^*W_!:O\ Y.E\*_\ 8F6O_I=?5\ 5]_\
M_!:O_DZ7PK_V)EK_ .EU]7P!0 4444 ?U3K]T?2EI%^Z/I2T %%%% !1110
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MP)_Y2/7?_9*'_P#3Q'7WC7Y?F7^^5/4^]P/^[0]#XE_;C_Y.I_9<_P"YI_\
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M2:>+?^P1=_\ HEZ_9L=!7Q.?_P 6GZ'[5P#_ +M7_P 2_(\K_:P_Y-:^,?\
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M0M(C.^&4!UR4)&1R""."*]WKRKX-_P#)1?CM_P!CG;?^H]HU 'JM?*O[ O\
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M-7\UE?TI_M8?\FM?&/\ [$S6?_2&:OYK*^5/U,**** /U3_X(8]?C9_W!/\
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ME^9IA_XJ_KH?;5?'O[6W_)Y7[*/_ '-G_INAK["KX]_:V_Y/*_91_P"YL_\
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M_8(N_P#T2]?LV.@K\9/B?_R33Q;_ -@B[_\ 1+U^S8Z"OB<__BT_0_:N ?\
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MM_"6Q$_X1?1MJ8VC^SXN,=/X:7_A77A3?O\ ^$8T?=C&?L$6<?\ ?- 'G/\
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M !R*]+U;X%^$M0^"5S\*+:Q;2O!LVE'1UM;)RKQ6Y7:0K-D[L<[CDDDDY)H
MVOA?JMUKWPT\):G?2F>]O-(M+B>4C!>1X49F_$DFNGK.\.:%;>%_#VEZ-9ES
M::=:Q6D)D.6V1H$7)[G %:- !7RO=Q^-OBO^U5\4?"-I\2_$'@W0O#6E:-<V
M=MHL=L0TERDYD+F6)R>8E(QCJ:^J*\2\:_LK:1XM^(^N>-K/QEXQ\)ZUK5K;
MV=\?#FK?9$FC@5EBR I.0';G/\1H XSX&_M/0^'_  IXSL/C%XQT:WU#PEXP
MO/"B>(9=MK'J@CCCFC<QCA)-DFUE&1E#R:SOCU\7_BKX=^/OPAT_3(]*T7X9
M:WXHMM,^V0W1GOM962U\YB4V!885.],;BS% W .*]V^%?P2\)?!WP@/#OA_3
MBUM)<R7]W=:@YN;J^NY,>;<W$KY:25\#+GG  X  #_B'\(-"^)>L^"]3U8W*
M7'A+5EUG3Q;R!%\]49 '&#E<.>.* .XHHHH *^*OAW8_%;XH_"SQOX[T_P",
MNMZ+K>G:SKEOI^GS6EI-IJ+:74T<22*8MY4K& 3NXZX.,'[5KYPD_8;\*RV6
MLZ5_PFOCR'PSK%]<WU_X>M=>>"QN#<2-)/$R(H/EN68,N>0Q!ZT >1_M'_M/
M_%^#]A/PW\6/!EKHVASWVBZ?J6N:LTK&2VDFE@A\JS@*L"6DESND8A4!'S,0
M1]Q:;*T^G6LCG<[Q*S'U) KS[XG_ +/OA#XI_!&Y^%%_:2:9X.FM[6T2UTMA
M"8(K>6.2)(S@A0#"@Z=*]&MX%MK>.%,[(U"#/7 &* )**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\9^(/B[XYZ7XOO[;P=\._"FN^&T\
MO[+J&I>)I+.XES&I?=$+9PN'+J/F.0 >,X'LU% 'SQ_PGO[37_1)/ W_ (64
MW_R'1_PGO[37_1)/ W_A93?_ "'7T/7F/[3WB34_!W[./Q/UW1;R33M7TWPW
MJ%W9W<)P\,R6[LCK[@@'\* .&_X3W]IK_HDG@;_PLIO_ )#H_P"$]_::_P"B
M2>!O_"RF_P#D.L>^\12QV.B2?#?Q)XRU_P 5RZEIBR66K+=R6;6;7< O3)Y\
M810+<S$,"&! Q7#Z9\0=;NOAE\0/$4VH?$N[\2:=K/B.*RNM)BEFL(Q;:A=1
M6RA,&-E1(XU(*G[IX)H ]0_X3W]IK_HDG@;_ ,+*;_Y#H_X3W]IK_HDG@;_P
MLIO_ )#J[X8\<:A\:_'3^';;Q&]IH.E^%='URYU'P^_E'5IM0-QL:*0@M'"B
MVA8;<,QF ) 3#;^@Z[JO@GXXVG@&ZU:ZU[1M9\/W&LZ?+?X>YLGM)K>&>-Y0
M 9$D%W"ZEOF5DD&XAE"@')_\)[^TU_T23P-_X64W_P AT?\ ">_M-?\ 1)/
MW_A93?\ R'7T/10!G>'+C4[OP]I<^MVD&GZS+:Q/?6EK,9HH)R@,B)(0I=5;
M(#8&0 <#I6C110!X3XCT[]IA_$.J-H.O?"N'0S=2FPCU'1]2>Y2WWGRA*R7(
M5G";=Q4 $YP *SO[,_:N_P"AB^#W_@CU3_Y+I_[/W@Y/'_P'T?5[_6=9AUZ^
M6[W:M#J,OG1N+F95=06*_* , C''2N.D^/&H?$OX,? G3K^_FT;7_B#9VNK:
MW=Z8)$DMM/MXTFNY(]@+*)9#! .F!<D@_+0!UW]F?M7?]#%\'O\ P1ZI_P#)
M=']F?M7?]#%\'O\ P1ZI_P#)==/^R_\ $2;QM\/;C2=3OI+_ ,2>$KZ7P_J=
MS,I62Y:'!@NF! (\^W:";IP9".<9KT[Q+I5QKOA_4=.M-3N=%N;NW>&/4;((
M9K9F! D3>"NX9R,@C/:@#PK^S/VKO^AB^#W_ ((]4_\ DNC^S/VKO^AB^#W_
M ((]4_\ DNM+PO?.WQN2R\$W>IZQX:T?2[VW\1SSWS3VCZB'@^SPHSYW7"XN
M/,*, @(#@D@+D_#&[UOX:V'PZ_X61H=W!XBUMX]/N-6BUIKN--3E@DD=)8<A
M4C9ED2,J7 ^0':: )/[,_:N_Z&+X/?\ @CU3_P"2Z/[,_:N_Z&+X/?\ @CU3
M_P"2Z[OXQ_$G7? NM_#G2= TVPU&[\5^(#H\C:A.\26T0L[FY>8;5)9E%OPG
M&[IN7.X>;>(_VD/&OA7PI\6==O-#T*:V^&-[Y&I"&>8/JL8MH+IC"I&+=A#<
M)@,907##Y0-Q +W]F?M7?]#%\'O_  1ZI_\ )=?0]?/_ ,0_CWXOTKP3\6_%
MWA;1-%NM)\ +>1F#5+F5)=1DM;99KAE9 1$J;F55(8R%",Q@AJ]QT'4'U?0M
M.OI$"/=6T<[*O0%E!('YT 7Z\)\1^-OVA[3Q#JD&B?"_P;J&C174J6-W=>+)
M899X Y$;O&+5@C,N"5R<$D9/6O=J^8/V?O#?B/X@?LP>#?&C_$'Q/!XRU3P[
M'?\ V^XO3<6ZW31$AVMF&QUW<E.,]B.M &Q_PGO[37_1)/ W_A93?_(='_">
M_M-?]$D\#?\ A93?_(=<]XT_:,C\:?"GX+1-XEM/AQJGQ)M+75[W4GU".W.E
MV,=NES<F*27 9FD:&W7H<3EOX37JG[,WQ9'QA^$FFZK<7]CJ&NZ?)+H^M2Z;
M,LL!O[=O+F>-E)'ER$"5/5)4/>@#C/\ A/?VFO\ HDG@;_PLIO\ Y#H_X3W]
MIK_HDG@;_P +*;_Y#KUOXMZGKVB_"WQ??>%K&74_$UOI-U)I=G",M-=B)O)4
M?5]M>*3_ !)C^!FB>(+[7D\:?V]8^%=4UBSM_$FHI=6VI+8Q)+,T?ERNB2'*
MD(Q5MI? P#@ T/\ A/?VFO\ HDG@;_PLIO\ Y#H_X3W]IK_HDG@;_P +*;_Y
M#HAU+Q+\-=6^"^H7GBK4O$3^,]031M<M[XJT#RR:9=7:W%O& /(*RVH&U3MV
M2,""0K#T'XJ?%34/ /B;P#H&EZ!%KNH>+M1N=.A\^_\ LD=NT5E/=;V/EN2I
M\C:<#(#$@,0%(!Y]_P )[^TU_P!$D\#?^%E-_P#(='_">_M-?]$D\#?^%E-_
M\ATU_P!J/Q%9Z+XGU:]^']M!9>#]=70?$ACU[>\<K?9F$MD/LX^T(([N)SYA
M@;J K$5:^(/[3>M>&_!7Q#\9^&_ ]OXF\*^"FOK>\GFUO['<W-Q:9%P(8O(=
M3'&ZNC.SJV8WVH_R[@#W^BH;2?[5:PS;=OF(K[<YQD9Q7E/[1NI:E9Z7X&LM
M.U6]TA=6\6:?IUU/I\QAF:"3S-Z!QR,X'(]* *WQ!\7?'/2_%]_;>#OAWX4U
MWPVGE_9=0U+Q-)9W$N8U+[HA;.%PY=1\QR #QG YW_A/?VFO^B2>!O\ PLIO
M_D.MOQ3=ZC\%O&_PTAL]>U;6M'\4Z])H%]9:Q<FZ9&>QN;F*>.1OF4JUIM*Y
MVE96.,@&O)/'_P"U#;:-\7-:\41_$33;'PCX.URS\-WWA5[VW62_1@\>H7GE
MEO,/DRW-MC SBPN  ?,S0!Z!_P )[^TU_P!$D\#?^%E-_P#(='_">_M-?]$D
M\#?^%E-_\AU]"HZR(K*0RL,@@Y!%>/\ [6/B'QSX4^!?C/6_ U_INCWFE:)J
M&ISZE>QM-+"L%L\JK!$,*7<KMWNV$^]M?[M '-?\)[^TU_T23P-_X64W_P A
MT?\ ">_M-?\ 1)/ W_A93?\ R'6_XQ\4ZQJ-]\(?"EMJ=QIP\4B:;5+^V.VX
M:""Q:0I&_P# S2M"2P&=JN!@D&N$UOXE^)_#7BN[^&0UR\=KKQKI>B:?KKA9
M+N+3[C3GOID=R #+_HEU$LF"0LL9.6&: -S_ (3W]IK_ *))X&_\+*;_ .0Z
M/^$]_::_Z))X&_\ "RF_^0ZZ?X=:SJGASXX^+_AW<ZM?:WI%KH.F>(+"XU.3
MSKF W$][!-"TN 73-HCKNRP+N,D;0L?BCXX>([+X@^./"WAWP99ZW)X4T>PU
MFXN;S6C9B>.X-UF)%%O)^\'V0[<D*VXY9,#< <Y_PGO[37_1)/ W_A93?_(=
M>[>'+C4[OP]I<^MV<&GZS+:Q/?6EK,9HH)R@,B)(0I=5;(#8&0 <#I7A,/[7
M4>G:#X>\5^(O"QT;P/XB\-7/BC3-1AU#[3>+;P6B7;I<VPB58W,3DKY<LH)7
M!VDBMN'XZ>+]-\>?#;0/$?P^M=)M?'%U=06UY:Z]]J>Q6*QFNU%Q']G0>:PA
M*E(W=!\Q\QL , >V5QGQ5U?QUHOAZWG^'_AW2O$VLM=*DMIK&IM81)!L<LXD
M6.0E@P0;<#AB<\8/9U\D:Q\0-:\/Z/K4_P 0M>\:_#SQ7;/>^7XABL&O/#ML
MF^0P3>7$#&\*1F/(EVL=IW,#\U '8?\ ">_M-?\ 1)/ W_A93?\ R'1_PGO[
M37_1)/ W_A93?_(=<W\>?CYXJ\+/XULO!D%M<:MI'_"'-)J5WJ;):S0:EJ,M
MNWDPB&4(3Y80MN/RS;P=T*K)WGC_ /:%U3P+>7.GOX>T:35-,TV#4=2MKGQ
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M$'P2(Y5.=XS0!N_\)[^TU_T23P-_X64W_P AT?\ ">_M-?\ 1)/ W_A93?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
.*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mtva-20251231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (( [<# 2(  A$! Q$!_\0
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M_P#]:C[;K7_0.@_[_P#_ -:@#9HK&^VZU_T#H/\ O_\ _6H^VZU_T#H/^_\
M_P#6H V:*QOMNM?] Z#_ +__ /UJ/MNM?] Z#_O_ /\ UJ -FBL;[;K7_0.@
M_P"__P#]:C[;K7_0.@_[_P#_ -:@#9HK&^VZU_T#H/\ O_\ _6H^VZU_T#H/
M^_\ _P#6H V:*QOMNM?] Z#_ +__ /UJ/MNM?] Z#_O_ /\ UJ -FBL;[;K7
M_0.@_P"__P#]:C[;K7_0.@_[_P#_ -:@#9HK&^VZU_T#H/\ O_\ _6H^VZU_
MT#H/^_\ _P#6H V:*QOMNM?] Z#_ +__ /UJ/MNM?] Z#_O_ /\ UJ -FBL;
M[;K7_0.@_P"__P#]:C[;K7_0.@_[_P#_ -:@#9HK&^VZU_T#H/\ O_\ _6H^
MVZU_T#H/^_\ _P#6H V:*QOMNM?] Z#_ +__ /UJ#>:U_P! Z#_O_P#_ %J
M-FF2R+"C.[!$499B< "LW2M4N+N[NK:ZMU@E@"DA'W [JFUW_D"W_P#UP?\
MD: '#6; C_C[A_[[%']LV/\ S]P_]]BG:3_R"[/_ *XI_P"@BK= %+^V;'_G
M[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q1_;-C_P _</\ WV*NT4 4
MO[9L?^?N'_OL4?VS8_\ /W#_ -]BKM% %+^V;'_G[A_[[%']LV/_ #]P_P#?
M8J[10!2_MFQ_Y^X?^^Q1_;-C_P _</\ WV*NT4 4O[9L?^?N'_OL4?VS8_\
M/W#_ -]BKM% %+^V;'_G[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q1
M_;-C_P _</\ WV*NT4 4O[9L?^?N'_OL4?VS8_\ /W#_ -]BKM% %+^V;'_G
M[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q1_;-C_P _</\ WV*NT4 4
MO[9L?^?N'_OL4?VS8_\ /W#_ -]BKM% %+^V;'_G[A_[[%']LV/_ #]P_P#?
M8J[10!2_MFQ_Y^X?^^Q1_;-C_P _</\ WV*NT4 4O[9L?^?N'_OL4?VS8_\
M/W#_ -]BKM% %+^V;'_G[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q1
M_;-C_P _</\ WV*NT4 4O[9L?^?N'_OL4?VS8_\ /W#_ -]BKM% %+^V;'_G
M[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q1_;-C_P _</\ WV*NT4 4
MO[9L?^?N'_OL4?VS8_\ /W#_ -]BKM% %+^V;'_G[A_[[%']LV/_ #]P_P#?
M8J[10!2_MFQ_Y^X?^^Q1_;-C_P _</\ WV*NT4 4O[9L?^?N'_OL4?VS8_\
M/W#_ -]BKM% %+^V;'_G[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q1
M_;-C_P _</\ WV*NT4 4O[9L?^?N'_OL4?VS8_\ /W#_ -]BKM% %+^V;'_G
M[A_[[%']LV/_ #]P_P#?8J[10!2_MFQ_Y^X?^^Q4D&I6MU+Y<-Q'))C.U6!.
M*LUC3?\ (VV__7HW_H5 &S1110 5C:/_ ,AG6?\ KHG_ *#6S6-H_P#R&=9_
MZZ)_Z#0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%<+\3_B[H_PJ
MF\.QZMN/]LWZV:LIX@0X#3/_ +"LT8/NXH [JBN5^)OC"]\ ^#-2\06>E1ZP
M-/B:XFMGNOLY,:@EBK;&R?; ^M-^&?B_4/'GA*QUV^TB+1DOHUG@@CO/M#&,
MC(+'8F#[#/UH ZRBO)/B#\8_$G@*RN]2E\&6\VDQZ@FGP32ZL8I9R[A5D\OR
M& 4D_P!XFNR\)>(O$&K:C?VFN>'8]&$$4,T-S;7QNH9PY<%0QC0AEV#(Q_$*
M .IHK@_&?Q4B\.^)K#PMI.FR^(?%-Y"URNGPRK$L, .#++(00BYX'!)/04U/
M'GB6#5X-(OO!P@U"YBE>WFAU 2V;%%W;&E\L,I/NGYT =]17CWA'XQ^,?&WA
MN_UG3/ =B\=G<SVKVSZ\1,\D3;6"C[,0<GIR,TRY^-WB:+XA:7X13P1;+?ZE
M8-J-O)<ZR8U$:G#*X%N2K ]N1[T >R45Y[X ^+)\6^+-=\*:IHLV@>)='CCG
MGM6F6>*2)_NR1R #(^H!Y^N.D\8^+[3P7I'VVYCEN99'6&WL[<;IKF5CA8T'
M<D_EU- &]17E&H>.?%6G2+_:FL^"?#%S*IDBTG4[AGG9?>3S4 /J0A ]Z[3P
M;XJD\26MQ'=VJV.IVK!+B".021G*AE>-_P")&!!!Q0!T=%>8>*?BYJGAGXN>
M&_!C^&8I+/7B_P!EUB34O+3$:!I08_*/S@9PN[YOEY&>$\$?%O6?%'Q(\0>$
M-0\+0:-<Z-$DTD_]J>=YR/G8T:^4N5.,$DC'I0!ZA17#>"?'FM>*H]=EN_#2
M64.G7#VL+6VH"X-VZ]=N40*.<9)ZY':K'PM^(<?Q,\*'6TL'TQ1<S6Q@ED#L
M#&Y4DD#':@#L:*\[T#XKW'C;Q ]OX7T%]4T&WN#;W.O370@M]RG#^2NUFEQT
MSP">,UV'B;Q'8>$M OM9U*806-G$TTKD]@.@]2>@'<F@#4HKQSQW\:?$O@&#
MPU+<^#[>]77[E+:!!J1@>VD<95)08FR0!RP/7C'&3UWQ!\:ZYX-T6QOK+P[;
MZQ)-+'#/ =1\CRG<@#:3$VX GKQQV[4 =K17)>(?$VL:<VAV=CIMK/K5^7>2
MUEN&$21HF7_>A<_>:-<[3]XG%<_\%?BWJ?Q<LM0OYO#<6AZ=:7,MGYG]H_:)
M'FC8!AL\I0%Y/S9[=.] 'IM%<OXG\8?\(CJ^E_V@B+HU_,MH+L<&"=CA-^3C
M:QPH/8XSG/'44 %%%% !1110 4444 %%%% !1110 4444 %%%% &-I__ ",N
MK?[D/_H)JUKO_(%OO^N#_P C573_ /D9=6_W(?\ T$U:UW_D"WW_ %P?^1H
MDTG_ )!=G_UQ3_T$5;JII/\ R"[/_KBG_H(JW0 4444 %%%% !1110 4444
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M:CH7P@T6PU.VEM[F"2Y56N8_+GN(_M$ACN)5_ADE4K(X_O.>!TKTN@ HHHH
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MKD\;^(O"?AZ30]<LM DO#>W]X^FRODPR[8X?D#;=[ -N.!M&: /=J*3KS2T
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MT,?AN3^SW\MK]-1"7C3L 56$PQQLK2$*5+,OS "@#ZQI:04M !1110 4444
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MG_\ (RZM_N0_^@FK6N_\@6^_ZX/_ "-5=/\ ^1EU;_<A_P#035K7?^0+??\
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MJ:O_ - 3_P FTK9HH QO[4U?_H"?^3:4G]IZO_T!/_)M/\*VJ* ,;^U-7_Z
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MW_H25]D5^;Y__OGR7ZGZ%D?^Z?-_H?#G[1__ "6?Q%];?_TGCKS2O2_VC_\
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M%OO^N#_R-5=/_P"1EU;_ '(?_035K7?^0+??]<'_ )&@"32?^079_P#7%/\
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M[[3^?Y,^IZ*QO[1UC_H#I_X%+_A1_:.L?] =/_ I?\*_+C]+-FBL;^T=8_Z
MZ?\ @4O^%']HZQ_T!T_\"E_PH V:*QO[1UC_ * Z?^!2_P"%']HZQ_T!U_\
M I?\* -FBHK5Y9($::(0RD?-&&W8/UJ6@ HHHH **** ,;3_ /D9=6_W(?\
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M+_X3]?T1Y>*^->AO>!/^1NTO_KK_ $-5/VEO^1GTK_KS/_H;5;\"?\C=I?\
MUU_H:J?M+?\ (SZ5_P!>9_\ 0VKLI?[]#T9A+_=Y>IX\.E>M_LV?\CAJ7_7@
MW_HQ*\D'2O6_V;/^1PU+_KP;_P!&)7J8_P#W6?H<F%_C1/SG^+'_ "5/QE_V
M&;S_ -'O7*UU7Q8_Y*GXR_[#-Y_Z/>N5KZ.E_#CZ(\B?Q,_4_P#81_Y-H\.?
M]?%Y_P"E$E?0-?/W["/_ ";1X<_Z^+S_ -*)*^@:_*L?_O=7_$_S/M,-_ AZ
M+\BK-IZ37]O=EF$D*LJJ.ASZU:HHKA.DS_$/_( U/_KUE_\ 0#7SI7T7XA_Y
M &I_]>LO_H!KYTKW,N^&1YN*W05Z-\9/^206_P#V[?R%><UZ-\9/^206_P#V
M[?R%=E3^/1]3"'\.IZ'S97<?!+_DIVB?6;_T2]</7<?!+_DIVB?6;_T2]>]B
MOX%3_"_R//H_Q(^J_,\*_P""C_\ R731_P#L7H/_ $HN:^5*^J_^"C__ "73
M1_\ L7H/_2BYKY4KORS_ '.EZ')C/]XGZGZ#_P#!-#_D0O&/_83B_P#15?9-
M?&W_  30_P"1"\8_]A.+_P!%5]DU\#FW^^U/7]$?38+_ '>!5U+3X]4LI+:1
MF5'QDKUX(/\ 2K-+17D'<%8TW_(VV_\ UZ-_Z%6S6--_R-MO_P!>C?\ H5 &
MS1110 5C:/\ \AG6?^NB?^@ULUC:/_R&=9_ZZ)_Z#0!LTE+10!Y)XS^#7B;Q
M/X['B2R^(=UHQAB,-I:1:='*ELI^\5+-RS=VQG''2NN^'W@[5O"5K>_VUXHN
M_%5]<R!OM-S"L(C0# 147@=22>IS[5UM% !1110 4444 %%%% !1110!X%^V
M%_R)>B?]A#_VFU?)U?6/[87_ ")>B?\ 80_]IM7R=7Z7D?\ N4?5_F?G.=?[
MY+T7Y!1117T!X04444 >S?LG_P#)4W_[!\W_ *$E?8^*^./V3_\ DJ;_ /8/
MF_\ 0DK[(K\WS_\ WSY+]3]"R/\ W3YO]#X;_:._Y+/XB^MO_P"D\=>:UZ7^
MT?\ \EG\1?6W_P#2>.O-*^ZP/^ZTO\,?R1\5C?\ >JO^)_F%%%%=QQ!1110!
M]F_LJ_\ )*(O^OV;_P!EKT/Q]_R(GB/_ +!MS_Z*:O//V5?^241_]?LW]*]"
M\??\B+XD_P"P;<_^BFK\JQG_ ",)_P"+]3]/PG^XP_P_H?GA1117ZJ?F 444
M4 %367_'Y!_UT7^=0U-9?\?D'_71?YTGL-;GZ45\]?MB_P#(N^'?^ON3_P!
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M //M>?\ ?@U\T_\ !0/6XM0^ \,20W$9_MBW.98BH^Y+WKTLM_WREZHY,7_
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M:;_D;;?_ *]&_P#0J -FBBB@ K&T?_D,ZS_UT3_T&MFL;1_^0SK/_71/_0:
M-FBBO.?&7QAN?".OSZ9'X \8Z^L2JWV[1[".6W?<H.%9I5)(S@\=10!U'C7Q
M;;^"O#UQJ4T3W,H(CM[2'F2YF8X2-!W)/Y#)/ -87P.^(-W\5/A9H/BJ^MH;
M.YU%97:"WSL3;,Z #))Z*/QS7F_B7XAZG%\1M5O=6^'/C/5;72 ]KHQTW3TD
MMAE<2W19I%R[?='&%0<<NU._8F\3/J?P0T'26T;4[)-/ADVZA=0JMM=;IY#^
MY8,2V,X.0.10!] T444 %%8Q_P"$@R<'3<>_F4?\5!ZZ9_Y$H V:*QO^*@]=
M,_\ (E'_ !4'KIG_ )$H V:*QO\ BH/73/\ R)1_Q4'KIG_D2@#QO]L+_D2]
M$_["'_M-J^3J^H_VLO[3_P"$0T;[=]D\O[=\OV?=G/EMUS7RY7Z7D?\ N4?5
M_F?G.=?[Y+T7Y!1117T!X04444 >S?LG_P#)4W_[!\W_ *$E?8^:^+_V7OM?
M_"S&^Q>3YWV&7_7YVXRGI7UO_P 5!SSIOY25^;Y__OGR7ZGZ%D?^Z?-_H?&W
M[1__ "6?Q%];?_TGCKS2O1/V@_M'_"WM?^U>5Y^8-WDYV_ZB/&,\],5YW7W6
M!_W6E_AC^2/BL;_O-7_$_P PHHHKN.(**** /LW]E7_DE$?_ %^S?TKT+Q]_
MR(OB3_L&W/\ Z*:O+/V8_P"UO^%7Q_8_L7D?;)O]?OW9X].*[WQS_;O_  A/
MB#S/[.\O^S[C=L\S./+;./>ORO&?\C"?^+]3]/PG^X0_P_H? U%%%?JA^8!1
M110 5-9?\?D'_71?YU#4UIG[7#CKO7K]:3V&MS]**^>OVQ?^1=\._P#7U)_Z
M *]L_P"*@]=,_P#(E>"_M:?VE_PC^@?;OLNS[5)M^S[LYV#KFORS*/\ ?J?S
M_)GZ9FO^Y5/ZZH^9****_5#\R"BBB@ KZ4_8U_X^/%O^[:_SEKYLKZ&_9%_M
M#[1XI^P_9L[;;?\ :-WK+C&/QKQ<Y_W"I\OS1[&4?[[3^?Y,^IZ*QO\ BH/7
M3/\ R)1_Q4'KIG_D2ORX_2S9HK&_XJ#UTS_R)1_Q4'KIG_D2@#9HK&_XJ#UT
MS_R)0?\ A(/73?\ R)0!LT5%:^?Y"?:?+\['S>5G;GVSS4M !1110 4444 8
MVG_\C+JW^Y#_ .@FK6N_\@6^_P"N#_R-5=/_ .1EU;_<A_\ 035K7?\ D"WW
M_7!_Y&@"32?^079_]<4_]!%6ZJ:3_P @NS_ZXI_Z"*MT %<F?A1X..O?VV?#
M.EG5_M'VO[;]F7S?.W;O,W8SNW<Y]:ZRDH \ZN_^%F:A/K>GRV7AN+3IWDCL
MM0CN9C+'"20#)"4(9L>C@9KJ/ GA"U\!>$-*\/V3%[>PA$2NPP6.26./<DG\
M:W:6@ I,4M% !1110 4444 %%%% !7S!_P %$?\ D@,/_89MO_0):^GZ^8/^
M"B!S\ 8/^PS;?^@2UZ66_P"^4O5')B_X$_0_,ZO1OV</^2^?#[_L-VG_ *,6
MO.:]&_9P_P"2^?#[_L-VG_HQ:_3L1_!GZ/\ (^/I?Q(^J/V*HHHK\?/NPHHH
MH \L^,__ !]:7_N2?S6O-Z](^,__ !]:5_N2?S6O-Z^GPG\"/]=3QZ_\1G;?
M"/\ Y&E_^O9_YK7C?Q!_Y'SQ#_V$)_\ T8:]D^$?_(TO_P!>S_S6O'/B%_R/
M?B'_ +"$_P#Z,-=F#_WJ?HC"M_!7J<_7OOPX_P"2!^(_^N%[_P"BJ\"KWWX<
M?\D#\1_]<+W_ -%5KFG\&/\ B1&#_B/T9^35%%%?8'@G[H4445^+GZ %%%%
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M_P!*+FOE2OJO_@H__P ETT?_ +%Z#_THN:^5*[\L_P!SI>AR8S_>)^I^@_\
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M/_Y&75O]R'_T$U:UW_D"WW_7!_Y&@"32?^079_\ 7%/_ $$5;JII/_(+L_\
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M:7_Z]G_FM>.?$+_D>_$/_80G_P#1AKV/X1_\C2__ %[/_-:\<^(7_(]^(?\
ML(3_ /HPUV8/_>I^B,*W\%>IS]>^_#C_ )('XC_ZX7O_ **KP*O??AQ_R0/Q
M'_UPO?\ T56N:?P8_P")$8/^(_1GY-4445]@>"?NA1117XN?H 4444 <O\3/
M^1*U#ZQ_^C%KPRO<_B9_R)6H?6/_ -&+7AE?09?_  GZ_HCR\5\:]#>\"?\
M(W:7_P!=?Z&JG[2W_(SZ5_UYG_T-JM^!/^1NTO\ ZZ_T-5/VEO\ D9]*_P"O
M,_\ H;5V4O\ ?H>C,)?[O+U/'ATKUO\ 9L_Y'#4O^O!O_1B5Y(.E>M_LV?\
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M_P"B7KAZ[CX)?\E.T3ZS?^B7KWL5_ J?X7^1Y]'^)'U7YGA7_!1__DNFC_\
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M\"I_A?Y'GT?XD?5?F>%?\%'_ /DNFC_]B]!_Z47-?*E?5?\ P4?_ .2Z:/\
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M[CB"BBB@#[-_95_Y)1'_ -?LW_LM>A>/O^1%\1_]@VY_]%-7GO[*O_)*(_\
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MO[\O_?EO\*/^$MT[^_+_ -^6_P *V:* ,;_A+=._OR_]^6_PH_X2W3O[\O\
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M!ZW:V7P-\0V\K.)6@O,!4)',7J!7B->^_#C_ )('XC_ZX7O_ **K7-/X,?\
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MU#4UGS=P8.#O7^=)[#6Y^E%?/7[8W_(N>'?^ON3_ - %>V?V=K'_ $&$_P#
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M_N0_^@FK6N_\@6^_ZX/_ "- $FD_\@NS_P"N*?\ H(JW532?^079_P#7%/\
MT$5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M+/C/_P ?6E?[DG\UKS>OHZ_T:PU0H;RSANBF0IE0-C/7&:J_\(AHG_0)L_\
MORO^%>O0QL:5-0:V.&IAW.3DF>8_"/\ Y&E_^O9_YK7CGQ"_Y'OQ#_V$)_\
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M>*6XG=I))"[@LQ.2>&]:]7+\7#"3E*:;OV./$T95XI19\A5[[\./^2!^(_\
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M;7R6\7VR;Y&A#<\=Z[WQS8ZLO@GQ 7U.-T&GW&Y1;@9'EMQG-?E>,_Y&$_\
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M0!L45C_\)=I'_/X/^^&_PH_X2[2/^?P?]\-_A0!L45C_ /"7:1_S^#_OAO\
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M>?#".1+^YMA]LF&R)@!VYKO?'.AS1^"?$#G5;QPNGW!VLPP?W;<'BORO&?\
M(PG_ (OU/T["?[A#_#^A\#4445^J'YB%%%% !4UE_P ?D'_71?YU#4UF,W<
MZ?.O\Z3V&MS]***QO[ G_P"@O>_]]#_"C^P)_P#H+WO_ 'T/\*_%3]B-FBL;
M^P)_^@O>_P#?0_PH_L"?_H+WO_?0_P * -FBL;^P)_\ H+WO_?0_PH_L"?\
MZ"][_P!]#_"@#9HK&_L"?_H+WO\ WT/\*/[ G_Z"][_WT/\ "@#9HK&_L"?_
M *"][_WT/\*/[ G_ .@O>_\ ?0_PH V:*QO[ G_Z"][_ -]#_"C^P)_^@O>_
M]]#_  H V:*QO[ G_P"@O>_]]#_"C^P)_P#H+WO_ 'T/\* -FBHK6$V]ND;2
MO,5&#(_WC]:EH **** "BBB@#&T__D9=6_W(?_035K7?^0+??]<'_D:JZ?\
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MO1O_ $*MFL:;_D;;?_KT;_T*@#9HHHH *QM'_P"0SK/_ %T3_P!!K9K&T?\
MY#.L_P#71/\ T&@#9KE-*^%/@S0M975].\*:/8:JA++>V]C&DP)!!.\#/()'
MXUU=% ''ZQ\'O OB'4Y]1U3P=H>HW\YS+=76GQ222''\3%<FMGPUX1T/P;9/
M9Z#I%CHUH[F1H+"W6%&8@#<0H S@#GVK7HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#X<_:/_P"2S^(OK;_^D\=>:5Z7^T?_ ,EG\1?6W_\
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MC573_P#D9=6_W(?_ $$U:UW_ ) M]_UP?^1H DTG_D%V?_7%/_015NJFD_\
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MA_[YH_X1O3/^?*'_ +YH M_;K;_GXB_[[%'VZV_Y^(O^^Q53_A&],_Y\H?\
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M -\T 6_MUM_S\1?]]BC[=;?\_$7_ 'V*J?\ "-Z9_P ^4/\ WS2?\(WIF?\
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MS0!;^W6W_/Q%_P!]BC[=;?\ /Q%_WV*J?\(WIG_/E#_WS1_PC>F?\^4/_?-
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M5ZMXVM/&WBWPEX]\-Z59CPY="R%OH>NF]5_M3M%\S%5&Z+#?+D\\Y'2O3**
M/ /!OP\U*\^*_A3Q3;^!)/A]_9FGRV>KE[RW>._0Q;(HHUAD?>J/M</($.%Q
MCFKAT?Q3)^U+%XC_ .$0U%/#2:0=+_M1KFTV;R^[?L\[S-G;[N[_ &:]SHH
M**** "BBB@ HHHH *\-_:*B:W\:_!V[BGN(Y)?%UM;2(DS"-XS%*Q!3.T\JO
M.,\5VWCWX%^ ?BAJT&I^*O"]CK=_! +>.>Y#%EC#,P48(XRS'\:YWXV^ /&7
MCGQ)X'NO#T>ABQ\.ZM%K$AU*\FBEFD173RP$A< 8?.XG.>W>@#G?VG[M?#^J
M^%==UG1Y/%/@VW::&_T*W;=,\C+\DRP_\M0@!RO8'/:NK_9M$,WPX2^LM4AU
M#2;ZZEN;"&"8RK90,WRP;CSE>X['BD^)_A[6K;Q=X<\::1>:8+S3;>>SETO5
MIY(K>=90"2LB(Q5P5P"4.03TK"^&'A[6=%\)ZH?"MYH-IK^JZN-2N[&2.3['
M:1NP\R.(+ABV <,0 2<D"N5XJ@JRP[FN=ZVOJ:>SFX<]M.YB:;H]I\=_C'\3
M]/\ $/FS6/AX0:7I<*R%1:.T99[A,'B0L1ANH"@5YMX0^*TGC_PQ\$]3^)MP
MH\#ZE8ZA!?WMXVVTGU*&=H8?M3?= *QLPW8!9B>W'NNM?"SQ5H7C?Q1X@\$7
M>DP-XHM(XKZ/4GE3[+<HI5;F+8K;SM/*$KD@'=5K3?AQXH^&_P -_#O@CX?7
M&D6MI8VIMYM7U9I6F1R26D2!5VNS,S-S(H!.,$5U&9SW[,'B5+[5_B/X?TR^
M?4O"VAZM&FCSLQ8+%+$'>)2>2B-D#V/'%>\UR'PP^&FF_"SPR-)T]Y;N>:9[
MN^U"Y.9KVY<YDF<^I/;L,"NOH **** "BBB@ HHHH **** "BBB@ HHHH *Q
MIO\ D;;?_KT;_P!"K9K&F_Y&VW_Z]&_]"H V:*** "L;1_\ D,:S_P!=$_\
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MI&BQHHP%48 _"G4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"_YH_X1:U_Y[W?_?\ - &S16-_PBUK_P ][O\ [_FC_A%K7_GO=_\ ?\T
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M@ 8^1A3PN <"O0_VG-/O;WX8--9>3<K97]M=W&ESS&)=3B1_FM<CJ7)&!W(
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M?_?\U^='Z ;-%8W_  BUK_SWN_\ O^:/^$6M?^>]W_W_ #0!LT5C?\(M:_\
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M6HH R?\ A$M)_P"?-?\ OMO\:/\ A$M)_P"?-?\ OMO\:UJ* ,G_ (1+2?\
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M]% &7#X8TRWF26.U59$8,K;FX(Z=ZU*** "L:;_D;;?_ *]&_P#0JV:QIO\
MD;;?_KT;_P!"H V:*** "L;1_P#D,ZS_ -=$_P#0:V:QM'_Y#.L_]=$_]!H
MV:H0:!IEK<K<0:;:0SJ21+' JL">O(&:O9I!(K' 8$^@- $%[IMIJ2*EW:PW
M2J<A9XPX'YBI88([:)8XHUBC485$& !["G,X098A1[FE!!&1R* %HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:YKQW'X
MPDTR(>#)]$M]1\S]XVNPS2P^7CL(G4[LX[XH K_%CQ;?^ OAQXC\2:=907]Q
MI%A/?F"XE**R11M(W(!).%Z<=>M<]XF^+L_AKX%V/CN6RADNKG3[.Y,!8K#'
M).$Y8\D(I?)/7 K'^-^N7GAW]F+QL?'&IZ-;ZS=Z%?V0>PWPV\]Q)!*L4<2R
M,6+-P,9))SVK&NO&"2?LB:-J&@Q6_B* :-8V=TL*"Z6./;''<DH =S1KO)4@
M\K@B@#LO!'Q!\07OCR7PSK::3J&[3EU*+4M##B%%+ !'#,W)SD$'D \5;^*/
MQ)NO"6I^'/#^BVT%YXD\07#06B79/DPHB[GED"D$@#' (R3UKR3X"P:)X!^(
M&I:;X!\0CQ+\.)M.:^N64_:1IEPN,()@.=RY/E=5P>*N_$7Q!INL^.?A7\6+
M*X>7P=:O<6EW>R0O$+99 0LL@8 JFX8)( '!- &W=?M(3>&-$\6VGB#3;<^+
M_#]]:Z=]DM'98+N2Z(%LZELE$;=DYSC:W6NAT/XE^(-&^)VF>"?&5KIWVG6K
M&6]TJ_TE9$B=H<&:%U=F.Y0RL&!P1V%>3V_AKPE\1-:^,_C3Q9>QZ=\/]??3
MK.RU6:?[.':TCP+F"0@?\M#\A&=Q7 R#SK?"?P?JOQ ^,>F^.I]5US5/"/A>
MQFT_1+_Q"B17.HSS +-.D:1Q[8@BA0S*&<C.2.@!]+4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8VG_\C+JW^Y#_ .@FK6N_\@6^
M_P"N#_R-5=/_ .1EU;_<A_\ 035K7?\ D"WW_7!_Y&@"32?^079_]<4_]!%6
MZJ:3_P @NS_ZXI_Z"*MT %%%% !1110 4444 %%%% $%\+EK.86;Q)=%3Y33
MJ60-VW $$CZ$5X'X*^+7Q/\ &EUXWM+73O#/V[PQ>O9-:^7./M;*,_*_F?+G
MMD&OH.OE?X4:)XHU[Q]\;K7P[XCL_#@E\0RQR7$VFM=3(2/O1,)D"G'JK4 :
MFM_M0ZU?_ =/B9X8T[33!9W"V>IZ;J2R,\<QD2/]VZ, 0#(IY'(;MBNI\<?$
MSQ]\-_!T7BW4;+0=:T2*..:\AL4FM[B.-L9*EW<-C/M7#?'+X5:7\'/V.-?\
M-Z5)+/&D]I-/=38WSS->0;G(Z#H  .@ Z]:E^.OPS\27'P835?\ A-;_ %G3
M=+M(KZYT+588([>[C158QL]ND38P.,DT >J^-?CEI'A3P=H6L002:C>:_P"6
MFEZ<AVR3NX! )[ 9Y-5M=\4?$GPIX?DU^]TK0M2M;6,SW>EV)E2Y2,#+;)&8
MJ[ 9.-HSBO$O$_BF/Q!XQ_9Z\;/8'2_#TRF#R,?N[:4Y51GTXP/;%?6.NWEK
MI^AZA=7V/L4-O)+/N.!Y84EN?H#0!0\#^--+^(?A73O$.C3&?3[Z/?&S##*<
MX92.Q!!!]Q6]7S]^Q!I-]IGP1CEO$:."]U"XNK1'[0EL _0D,1]:^@: "BBB
M@ HHHH 2O(_''Q-\5W'C:7PSX B\,W^H642O?)K=Z\;JS<JJ*F2>.3QQ7KE>
M-_&#]GGPAXNTW5==MK--"\411O=1:WIY,,RRHN0SE2 W3G- &UXR^)NJ?#WP
M;H;:M96=YXQU>>.PMK"R=A;M<N>?F;YMB]2>OYTGASXE:K9?$A/ _BVWL8=4
MO+$ZAI]WIP=8;A5.)(]K$D.O7K@CGBO&_%.L:OKQ_9QUS75*W#7TBW<I&%:1
MXE"$CMN(.*ZOXIV4FK_M:?">WMY)%,&G:E-<M"2&2%HG3.1R,D[01R"<CF@#
MZ$S1FOCSPM\.-(\1_"KXP76HO?W,FD^)-733P]]+BV,038ZC=RP 4;FR< >^
M6^)/#L5I\%/AU\1!=W\GC!KW3HFU*2[D9FC>0(R;<[=NWL![T ?8N:*^>_B[
M<647QST*/QZT*_#Z72YA;_;6Q9_;,C)ER<;MIX+<=.]3?LD^!;/PYH_BK4[;
M3Q'97NM7(TB]GBQ/+IXVB/+$;BI8,1GZT >_4M(*6@ HHHH K:C-<6]E-):0
M)<W"KE(I)/+5C[M@X_*N'^"7Q(O?BCX,FUK4;"'3+F.^GM&MXG+*OEMMY)ZG
MKZ5WTG^K;Z&O$_V8XWD^%.O(@+.VMZF% ]?-.* )Y/C-XBU^U\3ZWX6TJQO/
M#GA^9X)#=%_/O6C_ -=Y14[5"\]0<UIZ_P#':T_X1GPC=>'+=-3U;Q9(L>EV
MLK;5'R[G>3'(5!G..:X/]G.5+#]G3Q9#<N(9K6ZU1+E7."C8.=U>9?"73KO2
M=<_9^N[]'BM)TOQ#+*,*2P=E'U*D8H ^E_"'Q)U"3XAZAX&\3P6EOKL-FNI6
MEQ8AE@N[8MM8JK$E65N",GUKT:OGOQCIQUW]LCPM!$TIAMO"UPUYY#LC)&\D
MBKEE(*Y9EZ'->5>&? >G:[^RYXU\0WLU_/JNC7>IW&GSF]E_T9XFW*5&[&20
M,D@D],XQ0!]M4F:^3/&OAJW\.:)\)/&]I<WQ\4ZA=6 N]1FNY':=98E+(P)V
M[>>@ _G73?$N723\?6M_B/) O@J;1_\ B6#4'VVGG_\ +7/.!)Z$\^E 'T;2
MUX1^R%X(_P"$4^'U[=/I_P!E_M"^FDM9YHMMQ-:!SY)<D;B,$E<]C7N] !11
M10!'//':P233.L44:EW=C@*H&22:\G\)?$_Q/\6OM.H^#K'3K#PO%,\$&J:R
MDDC7I4D,\<:,N$R,9)['BNH^,UA>ZG\)O%]KIP<WLNEW"QK&2&8[#E1CN1D?
MC7)?LD7UE>_L^^$5LF4^1;M!,@/*2J[!PP['.3^- '2>$/%_B:\\::CX?\1:
M/:V/V>S2Z@O;.1GCNLN5; /*X^7*G/7K7>9KSOX\^-[GP+\+O$NIZ7(G]L6U
MB\L(!!>,9"F3'7"D@UXY\2/"&G^$O@7HGQ \-2R6_BNTBM;XZK',3-?,^TR)
M*Q/SAB2,'I[4 ?4]%?,L_AZ#QI^TM8VNJ27HM-0\+"[N[-+R54=R5RG#<+S]
MT$#BL3X>?"[1/$=I\6_#>I&^NM#\/ZI<Q:79->RA+7]WNRN&Y((&-V<<^IR
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MJ"OIACQD CU2B@#RG3OV</#-E\-HO \M]J]_HMM.+FS:XN5$UHX8L#&Z(O\
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M6[P;"V[S-\>!QMPW44 >S2_&[P#"\BOXOT@,D3SD"[4_(IPQ&#S@\'%3Z_\
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MZ"2-\$;E(R#@\]*^!7\#>)QX3T'PE>^#=4O[J+P5'HGBK3++4=.-U!;M/(5
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M62WFVEXV" %3M)&0?0D4 :U%%% !1110 4444 %%%% !1110 4444 8VG_\
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M:UW_ ) M]_UP?^1H DTG_D%V?_7%/_015NJFD_\ (+L_^N*?^@BK= !1110
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M'/'?.* /1O%UE;ZAX7U6"Z@BN86M9,QS('4_*>H/%>'^#?&5S\/?V-+#7;!
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MK_XT?\(AI/\ SZG_ +^O_C6S10!C?\(AI/\ SZG_ +^O_C1_PB&D_P#/J?\
MOZ_^-;-% &-_PB&D_P#/J?\ OZ_^-'_"(:3_ ,^I_P"_K_XULT4 8W_"(:3_
M ,^I_P"_K_XT?\(AI/\ SZG_ +^O_C6S10!C?\(AI/\ SZG_ +^O_C1_PB&D
M_P#/J?\ OZ_^-;-% &-_PB&D_P#/J?\ OZ_^-'_"(:3_ ,^I_P"_K_XULT4
M8W_"(:3_ ,^I_P"_K_XT?\(AI/\ SZG_ +^O_C6S10!C?\(AI/\ SZG_ +^O
M_C1_PB&D_P#/J?\ OZ_^-;-% &-_PB&D_P#/J?\ OZ_^-'_"(:3_ ,^I_P"_
MK_XULT4 8W_"(:3_ ,^I_P"_K_XT?\(AI/\ SZG_ +^O_C6S10!C?\(AI/\
MSZG_ +^O_C1_PB&D_P#/J?\ OZ_^-;-% &-_PB&D_P#/J?\ OZ_^-'_"(:3_
M ,^I_P"_K_XULT4 8W_"(:3_ ,^I_P"_K_XT?\(AI/\ SZG_ +^O_C6S10!C
M?\(AI/\ SZG_ +^O_C1_PB&D_P#/J?\ OZ_^-;-% &-_PB&D_P#/J?\ OZ_^
M-'_"(:3_ ,^I_P"_K_XULT4 8W_"(:3_ ,^I_P"_K_XT?\(AI/\ SZG_ +^O
M_C6S10!C?\(AI/\ SZG_ +^O_C1_PB&D_P#/J?\ OZ_^-;-% &-_PB&D_P#/
MJ?\ OZ_^-'_"(:3_ ,^I_P"_K_XULT4 8W_"(:3_ ,^I_P"_K_XT?\(AI/\
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MC_A&O^HKJ?\ X$?_ %JV:* ,;_A&O^HKJ?\ X$?_ %J/^$:_ZBNI_P#@1_\
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MMFB@#&_X1K_J*ZG_ .!'_P!:C_A&O^HKJ?\ X$?_ %JV:* ,;_A&O^HKJ?\
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M1_\ 6H_X1K_J*ZG_ .!'_P!:MFB@#&_X1K_J*ZG_ .!'_P!:C_A&O^HKJ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !14<]Q';)OED6-<XRQQSZ5B^#?'.A?$'0K;6?#VI1:GIMR&,4T8*[@&*GY
M6 (^92.1VH WJ*\S^,7QH/PDU#PG;?\ ".WFO'Q#J(TV+['*BM'*5++PW7./
M:LSX/?M 2?$?QKXG\&:]X4O/!?B[05BGETZZN$N$GMI,^7-'*@ (."",9% '
MK]%>=^-/C-I_A;Q9:^%+:RFOO$=Y&'MX;AQ9VSYS@">3 <\<K$)&'=16[X7L
M_%1OI;WQ#J%D(GCVQ:7I\&(XB2#N:1LL[#!'&U3G[N<4 =-2U\R^++F+XQ_M
M>W?PSUWSI?"_A[PK'K;V"2,B7-Q/,8E9]I!.P*2/<YK<_8X\;:EXF\$^)=&U
M2ZEOY/#&OW>CP74[;I)($?\ =ACU)"G&3Z4 >^T5\:V4(_:#U+]HK7-8N[R"
M[\&:I=Z!X>:WG:,Z8]K:K)]HBVD?.TC%B3U  Z5!XJU'XF?M+?LI?"C7M(\/
MZ?XFM-0L8M1\3Z4^J2Z=<7S)'@+ \8X)E!DP2!E5'3- 'VB*6O&OV2[_ ,(Z
ME\%M-E\&Z;?Z+IZ7$\5UI>ISO-=6=VK;9HI&8DEE88^F*;H?Q\U>^^,GB[P%
MJ?A*WT7^PM._M.'4I]7W+?0G.UT3R1@9!#'<2OH: /9Z*\%3]I#Q%,OAG3T\
M PQ^*=;LY]2BTFYUQ(4-O&^T>7*T/[R5A@^7M& PRU>R>$]:G\1^%])U6ZT^
M;2;F]M8[B2PN.9+9F4,8VX'*DX/':@#6J*XN(K2!YIY4AB0;GDD8*JCU)/2O
M._C1\9A\'8O#,CZ!>:ZFMZO;Z0HLY%5XI)6VJ<'[W/;CZUYM>?'MOB)I7Q4^
M'_B?P=>>#O$^E^'KF_2SN[E+F.[M6B<+,DB #(8<KU!H ^B[*]M]2M8KJTN(
MKJVE&Z.:%PZ./4$<$5/7RO\ !3XJZIX!_9G^$%II7AF37[J]T 3R75U=_8;"
MTCC4%C/<E'"$[@%!'//(Q7:^&_VJ--\8_#OP/KVC:)/=ZWXQNIK'2]$-R@W2
MPK(TS/, 5$2")B9 #U7 ).* /<ZJZAJ=II-JUS?7<%E;J0#+<2"-!GIR2!7B
M=_\ M2P>$_"&I:AXU\-R>#-8M-;70(K35+Y(K*[N'0.DD-Y(J*T.PEC)MXV.
M,$C%>,?%[]I#0?CS\ _BCI:6EDFN^%GM7F32]3CU.UD5Y%*207$84/T(((!!
MH ^W%8.H92"",@CO2UX#X=_:=?2?'5MX0\:^#;_P5!<Z9)J&E:O=74<\%[#"
M@:7<$YB<+SM.>.]1-^UD=/T_POXFU?P;=:;\//$M[#8Z?XB%ZLDB-,=L#W%N
M$'E1N<#=O;&1D"@#Z#HI <@$<@TM !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+KMIX^;QMX:>TWFV9OD(AF3'R*0'3 SU!KN/B)\)OB-\=_A-J&G>*Y-#\/\
MB!9;:[TZPLF:[LTG@D$@,K. 7#$ 8P,#/6@#D_B/^T7H'Q>^&7Q;\%W-@--U
M_3/#D^H+#%J$5W%-$8VVNDL+$9!'*GD5T'PK_:3@T:?X<>"]>\):UH=IKVGP
MVVC^(+M5^RWLZP[C%@'<C$*2-W6K^F_"'QCXQ^&_BK2O$FA>$O!NK:GI,^F1
M+X<BWQR/(A7S9'VJ<>B=O6J^A?![QQXSN?AC:^-K'2=&TOP'.MZATZ\:YDU&
MY2%H8VY1?*0!V8K\Q)QS0!?UG]KS2])\/3>,E\,ZG=_#."]:QF\6P.C1*5F,
M#3"'.\PB0$>8..,]*][@GCNH(YH762*10Z.IR&!&017R1H7[-OQ#T'X(ZW\!
MU&D7?@2[FN+:S\3/=,+NVTZ>9I7B:WV?/*H=U5]X'0D<5]8:3IL.C:79Z?;
MK;VD*01 G)"JH4?H* +=%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mtva-20251231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 ET# 2(  A$! Q$!_\0
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MLO\ P'7_  H_X1;1_P#H%67_ (#K_A6I10!E_P#"+:/_ - JR_\  =?\*/\
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M JR_\!U_PH_X1;1_^@59?^ Z_P"%:E% S+_X1;1_^@59?^ Z_P"%'_"+:/\
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M!VC\:S/@O^VWI'QI^,-SX%T[PW=V:1K=/'J<ETK)*L+8!V!<C=UZ\4 ?0O\
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MMGXS6GB[3O[5L-/VW$5L97C7S6,:ASL8$X&>O')K[]AA2WA2.-0D: *JJ,
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M_P"0%IW_ %[1_P#H(K0K/T'_ ) 6G?\ 7M'_ .@BM"F(**** "BBB@ HHHH
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M)XKU*OB:QN8)?V*O FCP2(?$+>(K.QAM5(\];Y-5W2+CJ' #L1UP<]#7VS0
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M\)>,+-?#=[H%K;>)M1>)+E8UC >X<F!0C'#1;0K#  )&": /HVBBB@ HHHH
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MTW2[NZPEI:7-U'#)-S@"-"06], 5HMIUH[W+-;0EKD;9R8P?-&,8;^\,<<T
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MS$]R37(V?P!\.:?X1\-^&XY]0.GZ!K2Z]:,TRF0W"SR3 .=N"FZ1N  <8&:
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M_P J (-&_P"018_]<$_]!%7*IZ/_ ,@BR_ZX)_Z"*N4 9\W_ "'K3_KWF_\
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MM'_Z"*T*S]!_Y 6G?]>T?_H(K0IB"BBB@ HHHH **** "BBB@ HHHH ****
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M<6SK)NC95P<(2.@]17EAQUKM?@U_R4/3?]R7_P! -#$F[GTM11169TA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%=?\>LW^X?Y
M5+45U_QZS?[A_E0!!H__ ""++_K@G_H(JY5/1_\ D$67_7!/_015R@#/F_Y#
MUI_U[S?^A1UH5GS?\AZU_P"O>7_T*.M"@1YY\?\ Q!?^%O@GXWU?29GM]2M=
M*G>">,X:)]I&\>ZYR/I7FO@7PEIGPL^-7@O2O"ZR6VG^(/#%S-JD/GM(MQ+
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M>*E3NT6DH,?3?*:YSX#P>)$TV_M_"UX-(\9^'919ZWX4OF_T:YV\+-'D_+N
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MU[G10%K'A?\ PTIK_P#T1/X@_P#@'!_\=H_X:4U__HB?Q!_\ X/_ ([7NE%
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M!_\  .#_ ..U[G10!X9_PTIK_P#T1/X@_P#@'!_\=I/^&E-?_P"B)_$'_P
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M_$59TS]DOQ#HU\EW9?&7Q-;W* A9%L;3(!&#UCHYD-0=SZ2HKPK_ (4'X_\
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M=H-LT6?[K=5(.01ZCFNXN+>*Z@>&9%DA=2CHXR&!&"".XKYK\#S2_LT?%YO
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M%^1^'U_XT_5_F%%%%:F04444 ?H;^P7_ ,D,?_L+77\DKZ.KYQ_8,_Y(8_\
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MW73?^VG_ ++7=5POQ.ZZ;_VT_P#9:3V&MSJM!_Y 6G?]>T?_ *"*T*S]!_Y
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M'=/T=M(T+3(]B7=[;,Z,;F=!RD8V((XV^;!+';D @'T/7+^!O]5KG_87NO\
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M -]?_6H ?13-TG]Q?^^O_K4;I/[B_P#?7_UJ 'T4S=)_<7_OK_ZU&Z3^XO\
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MK<ZK0?\ D!:=_P!>T?\ Z"*T*S]!_P"0%IW_ %[1_P#H(K0IB"BBB@ HHHH
M**** "BBB@ HHHH *X?XT?\ )*?%'_7D]=Q7#_&C_DE/BC_KR>NG#?QZ?JOS
M.;$_P9^C_(^"A]T4E*OW5I*_7S\E"BBB@ IPZCZTVG?Q#\*!H_2'3/\ D&6O
M_7%/_015NJFF?\@RU_ZXI_Z"*MU^,/XF?L$=D%%%%(H_)+XP?\E:\:_]A>[_
M /1C5R-=;\7_ /DJ_C3_ +#%W_Z,:N1ZBOW.C_!AZ+\C\0K_ ,:?J_S8M%%%
M:F(4444 ?H;^P7_R0Q_^PM=?R2OHZOG']@S_ )(8_P#V%KK_ -DKZ.K\;S7_
M 'ZM_B9^PY7_ +C1_P *_(*BNO\ CUF_W#_*I:ANO^/:;_</\J\L]0AT?_D$
M67_7!/\ T$5<JGH__((LO^N"?^@BKE &?-_R'K7_ *]Y?_0HZT*SYO\ D/6G
M_7O-_P"A1US'C_XO>%OAI/:V^NW\T-S<QO.MO:6LMS*L*8\R9UB5BL:Y&7(
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MMSJM!_Y 6G?]>T?_ *"*T*S]!_Y 6G?]>T?_ *"*T*8@HHHH **** "BBB@
MHHHH **** "N'^-'_)*?%'_7D]=Q7#_&C_DE/BC_ *\GKIPW\>GZK\SFQ/\
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M^_9_^*HVW'_/2+_OV?\ XJIZ* L0;;C_ )Z1?]^S_P#%4;;C_GI%_P!^S_\
M%5/10%C"USQ)8>&38+JNK6&G&_NH[&T%VPC\^X?.R),M\SM@X4<G%0^(?$6E
M:,^GV.M:KIMDVK7 L;2&]94^US,"1$BLWSL0"<#/3I7R;^WQ\//%.N^*_A#J
M.G_$;4]"T^\\<:/IMKI5O96\D5E=LTY6^5G4LTBYP$;Y?:LS]IW]D_XP>/\
MQ/X6OO"GC76M0?0=.@U":ZO-92U2_P!3@Q"H@A6/;9RO#)<.;A=PW,!M&,T
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M'XG*<(8B4JD;J[_,^K?CMJ>H^)O OQ/@UD&X30?&,%IH8>  P1E2IBCP/N[
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MHOC#Q9IVDKI>HZEJ=]<S1PZRUQ#=);_9I7"80QO(V0!R%3J.O>_"?XDZI=?
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MD%177_'K-_N'^52U#=?\>TW^X?Y4AD.C_P#((LO^N"?^@BKE4]'_ .019?\
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M2.Z5HU"0GRODB/F@E2&)V_>&3CZ@FT/3I]$?1I+*!M*>W-HUEY8$1A*[3'M
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M2BB@!*&_K110 4444 %%%%  >E*?NFBB@; ?=%)110(**** #^+\*!U%%%
+O]:BN/X:** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mtva-20251231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 ET# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#],M&\.:3+
MH]B[Z9:.[0(Q9H%))VCGI5W_ (1;1_\ H%67_@.O^%2:#_R M._Z]H__ $$5
MH4",O_A%M'_Z!5E_X#K_ (4?\(MH_P#T"K+_ ,!U_P *U**!F7_PBVC_ /0*
MLO\ P'7_  H_X1;1_P#H%67_ (#K_A6I10!E_P#"+:/_ - JR_\  =?\*/\
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M&VG:)JGP3\6^%+&ZW^9J^I(P@@VHS#<?+'4@+UZD4 >V_P#"+:/_ - JR_\
M =?\*/\ A%M'_P"@59?^ Z_X5\IZ!^WKK7B\Z@_ASX)^*/$5I8W+VTUSILHF
M1'7L2L9P<8./>O:O@!^T'H7[0GAN\U'2;6[TN^TZ?[+?Z9>@"6WDQD9(X((S
M@^H((&* /0O^$6T?_H%67_@.O^%'_"+:/_T"K+_P'7_"M2B@9E_\(MH__0*L
MO_ =?\*/^$6T?_H%67_@.O\ A6I10!E_\(MH_P#T"K+_ ,!U_P */^$6T?\
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M1;1_^@59?^ Z_P"%:E% S+_X1;1_^@59?^ Z_P"%'_"+:/\ ] JR_P# =?\
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M @3*J!B=K8'=2IR 02..: /:_P#A%M'_ .@59?\ @.O^%'_"+:/_ - JR_\
M =?\*\-_9C_; TK]I/5M:TVWT"X\/WFFV\=R$N+E9O.C9BK$848VG:/^!5F?
M!C]MK2/C3\8;GP+IWAJ[M%C%T\>J272NDJPM@'8%R PYZ\4 ?0O_  BVC_\
M0*LO_ =?\*/^$6T?_H%67_@.O^%:E)G- S,_X1;1_P#H%67_ (#K_A1_PBVC
M_P#0*LO_  '7_"O#_B#^U5=>&_C0WPU\,?#_ %7QKK%K;Q75_):7"0K;1OM^
M;!4[@ ZDDE>N*]H\7^+=*\$>&M1U[6[Q-/TNPA:>XN9.B*/U)/0 <D]*!%C_
M (1;1_\ H%67_@.O^%'_  BVC_\ 0*LO_ =?\*^59?V_Y_[.;Q-;_"+Q7/\
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MBVC_ /0*LO\ P'7_  H_X1;1_P#H%67_ (#K_A6I10!E_P#"+:/_ - JR_\
M =?\*/\ A%M'_P"@59?^ Z_X5J44",O_ (1;1_\ H%67_@.O^%'_  BVC_\
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MM[X,?!S0_@5X*3PMX?GOKC3TN)+@/J,PEEW.1D;@JC'''% COJ***!A1110
M4444 %%%% !1110 5POQ.ZZ;_P!M/_9:[JN%^)W73?\ MI_[+2>PUN=5H/\
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M[X'>O,O'G@W5/V=- _9[^*US;R17GA^VM]%\11*N)!;RJ2%8=<JKRH<]]HH
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MNIR.37D'QG_9CO/&7QC^$<^D:#ILO@#PW;O97]E-(JHD&<!!&WWQMXKZGHH
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M4(+J0O&[*.@8HR[P.V[/2O3** *&DZ19:!IMMIVG6L-C86L:Q06]N@2.- ,
M*HZ#Z5?HHH **** "H;K_CVF_P!P_P JFJ*Z_P"/6;_</\J (-'_ .019?\
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M73?^VG_LM=U7"_$[KIO_ &T_]EI/8:W.JT'_ ) 6G?\ 7M'_ .@BM"L_0?\
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M6.L6H.TS:?<I.@/IN0D9I\6O:;<:Q/I$6H6KZK!&L\M@LRF>.,G =DSN"D\
MD8- &G115)=2M&U-]/%U";Y(A.UL)!Y@C)*A]N<A258 XQD&@"[16%;^-_#M
MUX@ET&#7M-FUN+)?38[R-KE,#G,8;<,>XJ_J.L6.D?9OMMY!9FYF6W@$\JIY
MLK9VQIDC<QP<*.30(O451U'4[/28EFOKJ&TB:18EDGD"*7=@JJ"3U8D #N35
MZ@84444 %%%% !1110 5%=?\>LW^X?Y5+45U_P >LW^X?Y4 0:/_ ,@BR_ZX
M)_Z"*N53T?\ Y!%E_P!<$_\ 015R@"A-_P ARU_Z]Y?_ $*.K]4)O^0Y:_\
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M4#"N7\"_ZK7/^PO=?^ABNHKE_ W^IUS_ +"]U_Z'0)G44444#"BBB@ HHHH
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MTUBSEL[^UAO+24;9(+B,.CCT*D8(HTW3+/1K*.SL+6&RM(AB."WC$:(/0*H
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M$6E6O^OU.SB_WYU'\S67<_$OPQ:DB37+0$?W'W?RS7A,7[(WB^$Y'Q>N&/\
MM^'+1OYFM*V_9I\=6>##\7MI'_4I:>?YBM-#;4]2G^,_A2(D)?R7!](8'/\
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M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%177_'K-_N'^52U%=?\ 'K-_N'^5 $&C_P#((LO^N"?^@BKE4]'_ .019?\
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MTK_PG1_\=KZLHIW9/*NQ\I_\,I_$W_HJ.E?^$Z/_ ([1_P ,I_$W_HJ6E?\
MA.#_ ..U]64478<J['RQ:?LN_%&QNH;F'XIZ2)8G$B$^'%/S Y'_ "UKLO\
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MU3\F85Z,,1!PG_P4^C7FCSWX-_%[2_C!X035K-?LM] ?(U#3G_UEI./O(P_
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M% #?,'O^1H\P>_Y&G44 -\P>_P"1KAOB6X/]G8S_ ,M.Q_V*[NN%^)W73?\
MMI_[+2>PUN=5H/\ R M._P"O:/\ ]!%:%9^@_P#("T[_ *]H_P#T$5H4Q!11
M10 4444 %%%% !1110!\4?M.?\E@U+_KWM__ $"O*Z]5_:>_Y+#J?_7M;_\
MH%>55^LX#_=*7^%?D?E6._WJK_B?YA1117><(5]8_L?_ /(C:Q_V$/\ VFE?
M)U?6/['_ /R(VL?]A#_VFE>!GG^Y2]5^9[V2?[XO1GO5%%%?FQ^BGB_[7_\
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MV%[K_P!#%=17+^!O]5KG_87NO_0Q0)G44444#"BBB@ HHHH **** &N@=2K
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MYOQ&[8N/^%?FQU-Y]Z=17UY\D-KN?@7_ ,EM\"_]ABU_]#KB*[;X$_\ );/
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M@ HHHH **** "BBB@#EOB%X#TCXF^$[_ ,/:Y;"YL+I<=MT;#[KH>S \@_\
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ML=L9QEK%W)****@L*@N+>.ZADBE4/&XVLIZ$=ZIWGB#3-/O(+2\U&TM;N?\
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M?]A#_P!II7@9Y_N4O5?F>]DG^^+T9[U1117YL?HIXO\ M?\ _)NOBW_=A_\
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M_P"VG_LM)[ MSJM!_P"0%IW_ %[1_P#H(K0K/T'_ ) 6G?\ 7M'_ .@BM"F
M4444 %%%% !1110 4444 ?%'[3G_ "6#4O\ KWM__0*\KKU3]IS_ )+!J7_7
MO;_^@5Y77ZS@/]TI?X5^1^58[_>JO^)_F%%%%=YPA7UC^Q__ ,B-K'_80_\
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M1?BF_A5M:>Z3_A&]<M?$%D+64)FY@W>6'R#N3YCD<9]:[>BB@ HHHH ****
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MOG?;_@;^1^K=%%%?AY^TA7SQ\2?^1VU;_KHO_H"U]#U\\?$G_D=M6_ZZ+_Z
MM>%G'\&/J>?C?X:]3FZ***^4/'"BBB@#W'X._P#(GK_U\R_TKM;K_CUF_P!P
M_P JXKX._P#(GK_U\R_TKM;K_CUF_P!P_P J^\P?^[P]$?0X?^'$@T?_ )!%
ME_UP3_T$5<JGH_\ R"++_K@G_H(JY78;E";_ )#EK_UPE_\ 0HZOUS/BWQ1I
M7@L'6M;OHM-TJTM9&GNISA8P7B )_$@5XO<ZMIG[17Q9?2].\4W[^$++PVM_
M:2Z%?R6OF7DES+%YQ>,J6,8A^56RH)/!H$CZ.HKY_P!)^+>N1?L;MX\FF\[Q
M%;>'Y9OM)0'=-&&02D=#DJ'(Z'I6+\"Y;WP]\1-*L=8C\4:1<ZYHCW4$>L:Q
M_:4.KNC1L]PX))MKA0XS&N4*OV*T#/IJN7\"_P"JUS_L+W7_ *&*W-2U!-+M
M&GDCGF52!MMX6E<_\!4$_I7,_#_4([FSUB58YXP^K7)"R0.K#Y^ZD9!H$=E1
M4'VR/^[+_P!^7_PH^V1_W9?^_+_X4!<GHJ#[9'_=E_[\O_A1]LC_ +LO_?E_
M\* N3T5!]LC_ +LO_?E_\*/MD?\ =E_[\O\ X4!<GHJ#[9'_ '9?^_+_ .%'
MVR/^[+_WY?\ PH"Y/14'VR/^[+_WY?\ PH^V1_W9?^_+_P"% 7)Z*@^V1_W9
M?^_+_P"%'VR/^[+_ -^7_P * N3T5!]LC_NR_P#?E_\ "C[9'_=E_P"_+_X4
M!<GHJ#[9'_=E_P"_+_X4?;(_[LO_ 'Y?_"@+D]%0?;(_[LO_ 'Y?_"C[9'_=
ME_[\O_A0%R>BH/MD?]V7_OR_^%'VR/\ NR_]^7_PH"Y/14'VR/\ NR_]^7_P
MH^V1_P!V7_OR_P#A0%R>BH/MD?\ =E_[\O\ X4?;(_[LO_?E_P#"@+D]%0?;
M(_[LO_?E_P#"C[9'_=E_[\O_ (4!<YWQMX8/B"SCN+-_(U6T/FVLPZAA_#GT
M-2^#/% \2:<WG+Y&HVQ\JZMSQL?Z>G%;OVR/^[+_ -^7_P *X7Q=93Z)JJ>)
MM(B<SQC;?0"-@)XO7IU'^>E<-5.C+VT-NJ\N_JOQ1A).#YU\_P#,\A_;K^'V
MI^,/ FBZII5M]HDT>\9YT'7RG7!.?0$"OEO]GCX;:[XG^,/A1HK":&UL-1AO
MKJ5P!M2)@QZ'N0.>.?K7Z6Z;KEGKFFQ75N6F@F3IY;$>X/%.L+/3M+5Q9V*6
MN[EA!:E-WUPO-?88/.Y8?!/#1C>][/U/&Q.4PQ6*CB^;:VGH?)7_  4?U;XD
M:1X%\-R>%GT.W\.-KVE)/-<75S%??;#>*(D'E_+Y!X#Y.[!.!7*_M@']HN]T
MKP!;Z;8:?JNIVP&OZKI?AVPN7LX9["5IBR71D1G\U&CC6V89D(;!'&?J+X[_
M  AT_P".G@ZR\.WNHWFE0VNK66K":WMB[,UM,)0A##HQ7&:]*^V1_P!V7_OR
M_P#A7SI] <M\*9=?NOAQX=F\47PU'7I[-)KNY^P&P+,XW -;EF,3 $ J2<$&
MJOQ.ZZ;_ -M/_9:[/[9'_=E_[\O_ (5Q/Q)G20Z=P_'F=48?W/:D]AK<ZW0?
M^0%IW_7M'_Z"*T*S]!_Y 6G?]>T?_H(K0I@%%%% !1110 4444 %%%% 'Q7^
MTO"UQ\:+V*,9DEAMHU&>I*<5<\,>$-3^&'A7QGKVI:=;)KEE:VQL1<>5<HB2
M3%'; +#/&*H?M.?\E@U+_KWM_P#T"N'\)>-=2\%75Q+I_P!GECNHO*GMKR$2
MP2C.1N0\'!YK]-HTZE7 THP:M:-UWV=K]+K39GYM5J4Z6-JRFG>\K/M>ZO;K
MKKNC?^-NE6FG_$.=+*"*RCN[:WN3;PKA8Y)(P6 ';GM[UZ'\0%TW7_"NKV7A
MF]TM[72H[1;VV_L8PW4:?(OF+,0&8[AR-HXXY[^0ZCX^UG5YM;FO)H;B?5S&
M;B9H5WCRSE?+./W8& /E[5IZ]\7_ !-XCTHV-W<P*)?+-Q<V\"QW%SY?W/-<
M<MMX/UIO#5FJ2TO"W7T[KR:6OF*.*H)U7TG?IZ]GYI[>1Z/\5#8:_P"%->;P
MO=:7-INC26ZWEL-)^S7,*G 5A*V"V6'/ KM_V/\ _D1M8_["'_M-*^?O$_Q8
M\0^+M*;3[Z6V6*9D>Z>VMDBDNBOW3*PY8BOH']C_ /Y$;6/^PA_[32O*QU"=
M#+I0GW7Z;NR_+8]3!5X8C,8SAV?Z[:O\]SWJBBBOAC[8\7_:_P#^3=?%O^[#
M_P"CXZ_/[P5HGA2]LI[W7O%?]D7EM.#!IITZ287:C!QYBG:F?N\U^@G[7,4D
M_P"SYXK2)&D<K#A5&2?W\?85^:O]EWO_ #XW7_@/)_A7Z1PXN;!3CS6]Y[6[
M+O<_/.('R8V$N5/W5O>V[[-'UU\:;+5+30_CG?:H)FT/6)M(&@2R',5P_P N
M/(/0X4?P^E<9\$M(\4>!O#WCC1Y_A]?:]J3W.GQ7VG6VHO:7D$?+I\L?SE3N
MSD''K7@=R=;NK.WM9UU2XMK;_CWMW$ICA_W%Z+^%26MUXCL[U[N";6+>[<;6
MN8_.65AZ%QR1TXKU88"4:#HN:=[=&OA44MG?[-WYL\V6.C*NJR@TU?JG\3DW
MNK?:T\D?6O@#PKX1^'WQNU;^S?%^GS^*)-<@L+>WUJ:2:YAMF6-IT1\-OF8D
MPAF(P >:\=T_38=)_; L8(;^VU-?^$K1_M%KG:I:;<8^0/F7)5N.HXR*\ACL
MM3BG$\=I>K.#N$@CD#;O7.,Y]Z[;X)6%\WQK\$SS6MW_ ,AFV9I)$D_YZ<DD
MBE]4="-2K*IS-PMK;HOR\@^MJO*G2C3Y;3OI?J_S_K0_56BBBOR,_50KYX^)
M/_([:M_UT7_T!:^AZ^>/B3_R.VK?]=%_] 6O"SC^#'U//QO\->IS=%%%?*'C
MA1110![C\'?^1/7_ *^9?Z5VEU_Q[3?[A_E7%_!W_D3E_P"OF3^E=K=?\>LW
M^X?Y5]Y@_P#=X>B/H</_  XD&C_\@BR_ZX)_Z"*N53T?_D$67_7!/_015RNP
MW,VZB2;6+9)$#H;>7*L,@_-'VKB?'GP7L/&>M6NKVFL:KX5U2*TDTV6\T.6.
M)Y[1VW-"P9&& W(8 %220>:[F;_D.6O_ %PE_P#0HZOT"1PMO\(=#M](@T-&
MN_\ A%X=&;0SH)FS9R0M@;V&-QDV@KOW=">_-9G@+X'V'@C7K?5Y=>UKQ)>6
M5D=,TYM9G246-L2I9$VHN6.Q07;+$*!GKGTVB@9%/,+>!Y6#,J*6(49) '8>
MM>-Z?\6K71-*ULP6%X]W->SSP^;#MC&YN-[9X/M7M-<?X6L+?5-.\0VEU$LU
MO+JMTKQL.&&[I3$_(\X\*?'#4X]4VZR@O;-P<"TA_>(<<8 ZCZ\U)\:/B;%K
M7P0^(3Z0-4TR]M-$N)DN&0P,AVX!5@<AJ](\-_#;0O"MZUY8VK_:2"JR2R%R
M@/4#/2K/CSP99?$'P;K'AK49)HK#4[9[69[=@L@1A@[200#]0:'8E)]3YG\'
M6-W_ ,)7X/N/ ^D_$/284WR^(+GQ*]VMA-:?9WR MP[;I#(8RACZ98GCI!HG
M[0OB#P%\'O @CN_#\ERWAR/49)O$6H2R7=_)EP8HX8@T@.%_UK_+EL#.#CZU
MBTR*'2DT]2WDK"( 2?FVA<?GBO';;]E7PS8VD5KI^N>)-+@.DQ:+>)9WJ)]O
MMHMX02GR\@@.PRA3@TBRE9_'#QA\0;F.+P#X:TN=[30K#6]0CUJ]>,LUW$TL
M5K"47&[:IS(WR@D<=:Y/Q-^V#J6E>)=7ALM MI+/0[I+&]TMUNI=0N90J&<0
M-%$T(V%RHW/\^PGY01GT2[_9F\/S6-C:VFM^(-(2'2(="NI--O%B;4;.)2L:
M3_NR"0I8!U"MAB,U+<_LT^&S>W T_5=?T/1KQH9+W0M*U PV5TT:H@+#!=2R
MQHK;'7>%&<T >;V7Q4\;>!+KXI^(UL++6/!6C>*9#=F\O)1?"%H;8,MLFTJJ
MQAM^UB-Q+ 8/)Z+4_P!H3Q+:V>K^,XM!TV3X<Z5K+:1.S74@U*54G%N]RB[=
MFT2'B,G<0I.1P*Z/4OV9_#VK:[K%Y<ZSX@;3M:U%=4U+0Q>JMA=S*$VAXPF[
M;^[3(##=@;LCBIK_ /9O\-ZAKEW<OJ.M)HMYJ(U:[\-I> :;<708/YC)MW8+
MJ'*!PI;G;1H!ZW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !2$!@01D&EHI-7 \Y.?AIXBSS_PC>HR?46LI_DI_P ]*[33M=T_5]XLKV"Y
M*?>$4@./RKF/BS9W=]X4*VJF41S+)*BC)*#/;ZXKSSX66-Y-XMM9K=6$,6[S
MI,';MQ]TGUSCBO%=>6&Q"H1C>+_"_;R.#G=*HJ:6C/?****]L[PKA?B=UTW_
M +:?^RUW5<+\3NNF_P#;3_V6D]AK<ZK0?^0%IW_7M'_Z"*T*S]!_Y 6G?]>T
M?_H(K0IB"BBB@ HHHH **** "BBB@#B_$/PC\(^*]5DU+5]%AOKZ155IG=P<
M#@# ;%9W_#/_ ,/?^A8M_P#O[+_\57HM%=4<5B()1C4:2\V<TL+0D[R@F_1'
MG?\ PS]\/O\ H6;?_O[+_P#%4G_#/WP]_P"A9M_^_LO_ ,77HM%/ZYB?^?LO
MO?\ F3]3PW_/N/W(\Z_X9^^'W_0LV_\ W]E_^+KI?"7@S1/!5G-:Z)8K86TT
MGFNBECEL8S\Q/H*Z"BHGB*U1<M2;:\VRX8>C3?-""3\D@HHHKG.@*3:/2EHH
M$)BC%+10%A,48I:* L%%%% PKYW^)/\ R.VK?]=%_P#0%KZ(KYZ\?1I+X^U&
M.67R(FE0-*1G8-J\X[UX>;J]*/J>?C?@7J86GZ5>:M*8[*UENI%&2(ESCW/I
M5:2-X9&1U,<B'!4C!'^%=YI.GB/PWJ]KH=Z=3N3<VTA:VC:-MN[G@\X&,U6\
M4VR3?$&\O!$6TZ&\@6YF ^13\H(/XUX$L-RTU*^OX=?RMKZGG.E:*?\ 77_(
MY>\T6_T^WBN+JSGMX9?]7)+&0#QG^5%[HM_ID44EW9SVT4O^K:6,@'C./K7J
M&NVT)U&:YN%O+*WCU6W+?:92T-V">JCH H].U9'Q!M6;3M3N&2]LO+U$#9<R
M[DNB<_.@_AP/3C%;5,'&$9-/;_@^7E_P_726'44VNAUOP=_Y$]?^OF7^E=K=
M?\>LW^X?Y5Q7P=_Y$]?^OF7^E=K=?\>LW^X?Y5]3@_\ =X>B/6P_\.)!H_\
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MPJN[ 9"GKMR<#)'&:\9^'_B3XG^+]'^*.GR7^CV/C"QU=+.P.PR6>GHT$#D
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M@K5+?PUXHU$V&DZY)/#LF&V1O,>($O&&$9*!A\PYXZ5[E7QKX&\(>++SQ?\
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MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M%KA?B=UTW_MI_P"RUW.:X;XFGG3>?^>G_LM)[#6YY,OW1]!_*BBBF(*4=311
M3$ ZFDHHH8QW<_C3:**0#C]XT#H?I113 04E%%(!?\:5>E%%  ?O&ANE%%
M?O&FT44 %.]:** &T[UHHH !]X4VBB@!3T%*.A^E%%,!M%%%( HHHH =ZT#H
M?I113 4]#3)/N-]#110!]"Z-_P @:P_ZX)_Z"*O444A(\V^,732?K+_[+7FW
M\-%%/H E**** #^&DHHI#'-TI?XZ** &4444 %+_  T44 )1110 4444 .[C
M\*0=#110 E%%% !3EZ444 -I?X:** $I3T%%% "^M-HHH **** %_AI*** "
7BBB@ HHHH 4]_K2444 %,GZ+110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mtva-20251231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %. @8# 2(  A$! Q$!_\0
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M7>)_$4&D0:O<VDES)Y5O=7UF\-O,Q.  Y'&3_>Q1=A9'K7_"&:#_ - 73_\
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MM+&1Y[UHLB1HDQED&#\W2E=A8] _X0O0/^@+8?\ @.G^%'_"&:#_ - 73_\
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M'X&\4W'C/4/ 7A:;1M,?4=LNIA"EOJ4@W'?$I/R@9Z8&-PX]/(/C/X,?Q_\
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MNGA4RH/9L9%7Z*!%7^S[3[;]L^S0_:]NS[1Y8WX]-W7%1+H6FIJ3:B-/M5U
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MXK'XXN?#7CN+P7\,OB5J/Q&F\2^#M4NX)-0U9=2:UU*&(/;3)+C$1ERP\HG
MPIP!7T;XN\,>*_$H\1V5GXJBT#3+W35@TV>QM,WMC=Y):=G8E9$(P-FT=&YK
MB_A=\$-8T'QS!XK\53^&A?:?8S6&FZ=X2TLV%G&9F0W%U(&)+SR>6B]E4# S
MG-)IMZ MCQ;3/&VM>%O#>N>'IM4\3>&M#UU;(1:EXJDF6]TNWAMP=;NQYN9
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M5L ^2G?;SQBMC?>_\\8/^_K?_$U3TG_D(ZQ_U]C_ -$QUK4V"*N^]_YXP?\
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M:O\ 2+_V:O6Z^FP565:A&I/=_P"9ZM";J4U*6Y5WWO\ SQ@_[^M_\31OO?\
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MVOPK_P!>$O\ Z')7F8Z+7XQG=:>!Q+IT797DON>A]Z\34]C3GUDDW]R/7_\
MA>EK_P! F?\ [^+6EX;^*4?B?58["WT]X975F#2RC' ]A7AM=K\(_P#D>+?_
M *Y2?RKQ</F%>I5A"3T;705/$U)346SW'?>_\\8/^_K?_$T;[W_GC!_W];_X
MFK5%?6'KV*N^]_YXP?\ ?UO_ (FC?>_\\8/^_K?_ !-6J* L5=][_P \8/\
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MGUL_C?J:7AO_ )&'2_\ KZB_]#%?3U?,/AO_ )&'2_\ KZB_]#%?3U?19/\
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M]A7A?C/XLV7Q'USP;X6\"^-(!!K6I3P:EJNASQ2S6\4-L\YC4D,$=]JC.,@
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M^WG^AY7$7^_?]NK\V%?>'_!/7_DF?B+_ +"Y_P#125\'U]X_\$]_^2:>(O\
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M_L+G_P!%)6G$'^X2]5^9'#_^_P ?1FMXV_Y'#6O^OJ3^=8E;?C;_ )'#6O\
MKZD_G6)7\SU?XDO5GUL_C?J:7AO_ )&'2_\ KZB_]#%?3U?,/AO_ )&'2_\
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MATR)TMK6WC+,%7>2S,S,6)/X5Z.RAQA@"/0TZB@!JJJ#"@*/0"G444 %%%%
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MCWZ<URG[7&H7?PS\=1^)=-0[O%?AN[\,,$')N"P,)^OSD#_=I?VBO!<_P_\
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M'R,HY7&X'UKVH?L]>$GTF]L[Q=1U*ZO)XKJ76+N^D>_$T0(A=9\AE,8)"[<
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ME;# LFQL$#[QJW^T'X?U#Q7\*]4T+3'LX[O5)(+5?M]QY,3*TR%EW8.25!&
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MVG@JCRR$+TX]JT+C7=;^'GB7Q9X<\$7-MH]G/XVTNQMT>W66"V%W:AYU5.
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M#_P]!)')'I5NLB$,I /!'3O7F8JA6K2BZ4[);ZLY*U.<VG%V/,O'^F6WB_\
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M.7@'^CP@$DMEV\QB?^>?7)H V_BY_P BY;?]?:_^@/12?%[_ )%NV_Z^U_\
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MZW__ '[3_P"+H"YWM%<%_P +DT7_ )];_P#[]I_\71_PN31?^?6__P"_:?\
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:KFC100PWD;)<JQ+HHZ*P[-[T5:1C)JY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mtva-20251231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 S4# 2(  A$! Q$!_\0
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M(RB,XBD9>">?TH ^@/!_[0OPM\;?"WQ%X]L;%8]$T%F6\6>R595(56&%[YW
M#WKK/@UXX\$_''P?_P ))X=TF,:?]H>V_P!*LUC?>N">/3YA7YT>%;34=*TO
MP[\.;1"FG?%&TT2]9QT3RII%G/X[,GZ5]E?\$_42W^"6I1QKB-/$5^J@=  R
M@4 ?0DGAS0HV57TZP1F^Z&A0$_2O,OC!\6O GP:U30M+U+09=4U;6BXM+#2[
M!9I6"8W,1V R/UKYGUW[!\1_$?QKU;QWXPO] UWPS)(NB6<6H&V%NB1EHW1
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M]7U"Y,MY-&5*[=YZ  \ "MW5OC%I]I9Z-]ATZ]U74]60R6VG01@3;1]XMG&
M/Z54E^/6CP>$M1UJ:RO(IM-NTLKW3G4":&1B ,C.,>X]*Y5@,5))J#U=OQM^
M>E]KG?+-<%!M2J)65_E:^^U[:VWMJ=EX&\'6'P^\'Z5X;TLR&PTV 6\'FON?
M:/4]Z\K\??L=_#[X@>);O6YX+_2[N^_X_ETN\>WCN_\ KHH.#GUK>F^.,<=C
M9M_PCFJ_VC?3,EGIK*JRS(!GS.3@+SWKK/ GCJR\>:5+=VL<MK+#,T%Q:W P
M\,@ZJ:BI@\11A[2<;+^OZN:4<QPN(J*E2G>7;7UZ];6=M[:G)ZO^S;X+U73?
M!&G16<NFV'@^[6]TRWLWV*)!@_-_>R>3W)-=IX^\%V'Q$\'ZKX9U/S1I^I0&
M"?R6VOM/H>QKQ_XJ_M:1?#/Q%K-FO@G7=7TK0Q'_ &GK$$:I;PEQG"EB"^ >
M<5S$W[47B/4OVE/#7AG2=!OKOPEJ&E)>J(;=?-G$JAEG+$\1IG!QSG-<9Z)J
MZ?\ L%_#JV:TCO+O7]4T^V=733KW4W>W.WD ITQ[5]'6L*6L*0QJL<4:A45>
M  . *^?_ -J7QKXB^&_B7X7:]INK75EH,NNQZ?K%LA'E2Q2X"[@1V^;\J\>\
M*_M'^+I_VK+Z[OM9F/PSO]3U#0-/MR1]G$]M AW#CNQ4YS_$:!GW/D>M&X>H
MKXT^'/Q<^*U]^S_J?BS2[2Y\5:SKVJ7K6<EY(J0:59H&*R=!D#! '<@54@_:
M-\7^%/V)='\82ZH+WQ;J=]_9\>I7RJPB9Y&'F$8P=JJ>O% 'VMD>M+7R]^R5
MXXUGQ'XB\16,OQ2L_B1HD%O%*AGM_L]_:W!.'^7:,PGG!R>@QC)KZ?7O0 ZB
MBB@ HHHH H:Y_P @:^_ZY-_*KD7^J3Z"J>N?\@:^_P"N3?RJY%_JD^@H ?11
M10 5FG_D8?\ MV'_ *$:TJS3_P C#_V[#_T(T"-*BBB@84444 %(648R0,^]
M!Z5YA^T:\J?"75S%*T3[H@'1BI'SCN*Z,/2^L5H4;VYFE]YR8S$?5,/4Q%K\
MB;MWLKGI^X>HHW#U%?*.L>--0N/"6@>&-9E>#Q%HNOV4$N'(-Q =VR0'N".#
M[_6NE>#6=5\3?%ZST:[>&_985@)E*XRHR%)X4GU%>S+)Y05YS2_*W-%)W[-2
MN?-QXBA4:5.DV^U];\LI.-NZ<7'U/H<LK<9!]LUY_P"+/@#\//'.NSZSK_A/
M3-5U2<*LEU<0AG8* JY/L !7C7@%=#T/QCX>C,>O>"M>#^5<1WQ>:#4&(QM+
M%L D\@U[SK/Q/\,Z';:@\NL6CRV,;-+;QR@R KU&WUSQ7)BLOG0J*%.\K^7G
M;HVGZIGH8'-Z>*HRJUK0L_YK]+]5%I]TTOFC./P)^'[>$3X7;PIIAT RF<6!
M@&P2'JP'8\#FI?"WP2\">"='O]+T3PSI^G65_&8KM(H0/.0@@JYZD8)KS3X5
M>(=7U;XSWEUK5\%_M#2Q<06*S92W1F^1,9QOQR?J:ZK]H+2-9U?2-(&G0W-_
MI\-UYFH:=93&.:XC X (Y..>!3GE_L\3##SFES)._3T_3HB*>;^VP53&4Z3?
M*VK=79I7T3:[[-I=+Z'2VGP?\%6UWH-W;^'M/6?0HC!IDBPC-JASE4]!R?SK
M9\*>#-$\#:;)8:#IMOI=G),]PT%LFU3(YRS8]37BGPFU[PYX=UKQ%<:;=:OI
M-O!IYN9_#6J(Q,>SEI49F.>X_&NN\&?$+QKXA_LG5[GP[9CPYJ>YD>VG+3V\
M?.'D!P"..U.OEM2E*7*]%;?W=U>UF]7Z-KS##9S1KQAS+WI7TC>2232NVEHK
MM;I-=5HS;\6_ KP!X\UR+6->\+:;J>I1D8N9X06;'0'U_&MV[\ >';[7-&UB
M;2+234M'C:/3[DQC=;*PPP3T!'%>7WGQK\33Z9JGB;3="LI_"FF7#12-).1<
MRJK89U&,#Z&KE_\ %OQ'JOCK_A'_  KH]G>QMI]OJ0N;N4IMB?&<CN>1@?6I
M_LO$];:7OJM+6NGV>J*_MS!NUFW=I+W9:WO9K35.SU/7[NU@OK>2"XB2>"12
MKQR*&5@>H(-<=X:^"G@3P=K+ZMHGA32=,U)B<W-O;*CC/7! XKSF[_:*OTU"
M[O;>STV30;2^^QO$]P1>R -M:14Z8SV->M>+?$5UH?@G4=:TNQ&IW4-JUQ!:
M-*(A*V,@%CPH]ZYL3@ZV$4755KG;@\QPV/<E0E?E\O75=UHR30O!&@>&M8U?
M5=+TRVL=1UB19;^XA0![EESAF/<_,?SK*\<?!SP5\2;ZVN_$_AS3]:N;=#'%
M)=Q!V52<D"OG#P-^U=X\U_XC?\(3?6/A*_U;4]&N[RP?0[YI4M+F*-W6&X;)
M&?EP2OKFND_8,\6>-/&/PPO]0\4W":C;2ZA,;>_EN&EN)'W?O X/ 4<!<=JX
MCTCW/P5\*_"/PX$X\,>']/T0SX$K6< 0OCU(Y-=:",=:_._XE>*;OX2:_P#'
MGP/;SS)<^)+BS?28MYW$W+;7V_@#T]:YJUO=53X8:;\ [F_FEUZ+XAQZ<[B0
M@M9X\W=US@L<T#/TUW#U'-!('>OB;]H>P\=V'QQ^&L^LZO;V_A/_ (2**UT?
M1;#<"(U0?O9FS\S=0!V%<E^T_P"+D\9_M#:]X;\00^*M2\/Z%I2RVFG>&6(:
M*4C+7+C(!"]>?I0(_0;(]:6O-/V=M6M-:^"_A6\L-?N_$]JUH%34[^/9/+M)
M7$@R?F7!4\G[M>ET#"BBB@ HHHH X3XH?\PS_MK_ .R44?%#_F&?]M?_ &2B
MLWN7'8ZO0/\ D!:;_P!>\?\ Z"*T*S] _P"0%IO_ %[Q_P#H(K0K0@**** "
MD;H<=:6B@#S/Q]\.M8O?%6G>*_"]Y#9ZW:1&W>.Y7,4\1/W3Z=:RH_ 'CF?2
MO$E[>ZS#+KFJ0?9X+:)BMK;+T) ]<9KV&BO2ACZL(1A9.W5I7LG>U^USQJF5
M8>I4E4O)<UVTI-*[5KV[V_SW/"-3_9?TQ_!!L[.XN4UZ.$-#.UPQA6<<[MG0
M<Y_.MZP^&&JW_P 1-*\2:['972Q:,MC<QD;]TX)RP!&,=_QKUFBKEFF*G%QG
M*][ZO?7>QC'(\#3DI4X<MN71;/EO9M=7JRK:V<5C"L5O!';Q#@)&H4?D*^7K
M+P7':_M%?%_P;J9:&Q^(.AI=6ES_ 'B$:*4+ZE3)G'M7U4>E5I=.MIKN&ZDM
MXY+F$,(Y64%D!ZX/;->5>[NSWDK:(^+V_9E^,6I^!?!O@?4+S0#X?\(ZI#<6
MMQ$[>==Q([;2W'R[58\=^*WKKX&_&#PG\7O'7B?PC#X8N[#Q%<+(%U?+LBA0
M!QCBOKI%VYIU SY%^'W[)/BCPY8>&[?5M0L+E)/%G_"3ZU#;@I$ICC/DQQ+W
M&_D_A747W[/?B2X^(OQLUQ);,6?C+2(['3P7.Y76$(=_H,BOI*B@#Y6T[]FO
MQ386/P,CEN+$'P27;4CYAPP.[[G'/6MO]EZPDU[XB_%WQZBE=.UO6!:V3D8\
MR.W!4N/8L2/PKZ+= X((R",$5#8Z?;Z;;+;VL$=O"N=L<2A5'X"@#Y3^/O[,
MWC?XE_%_4-<M3I6M^';[34LX+76)Y%72Y ,-+'&IPY)&>?7VK,T[]F'XB>%M
M#^#]SI1TBYUSP7+.D\%Q.PBECD8G<& ZX)XK['%+0!QGQ4\#M\2OA7XB\,3A
M!-JFG26ZY/RK*5^4_0/@_A7S7X/_ &,]<TO]ECQ1X&U*XLY/&&K7OV];Q7+(
MKQ[!"-W7@(?^^C7V/10!Y3^S9\)KOX-_!_2_#5_)'-JBF2:\EB;<K2NQ)(/?
MM7G/@7]EC4X_@#X\^'OB*[@AF\07]S<PW-L=XBW.'C8^X91D5].44 ?*/PD_
M9X^(<7Q'\$ZWXYET2UL/!.G/I^G+HX.^[!0(&DXXX ./7/K7U=110 4444 %
M%%% !6=I7_'SJ'_7<_\ H(K1K.TK_CYU'_KN?_010)FC1110,*SM3_X_-,_Z
M[G_T!JT:SM3_ ./S3/\ KN?_ $!J -&BBB@ HHHH *8R\YQ3Z* /+?A9\-;G
MPW>^+9M:LK6?^T=6DN[8E1(1&W3J./I61/\ !C4/%_CS6]<UR]N=,A*K;:>N
MFW&QA"!SGCC/I7M-%>G_ &C752=5.TI*WIMMZVU/$_L?"NC3H23<8-NW=N^_
M>UW8\+T+X3>+_">B>)M#T/4_LEJUREWI5T[AF/\ >CD&.A]:CMOA[XL\6>-?
M#NJZOHFE>'DTF83S7-B^Z6Z8=N .#[^M>\45M_:E9N4FES/K;756?W^=]=3G
M_L+#)1@I2Y(V]V^FDN9;K2S[6TT=SSKQAX+U/6OB3X1UJV5/L6F&7[06;##<
M.,#O7;ZG9S7VG75O#.UM-+&R).O6,D$!A]*O45YTZ\YJ"?V59?>W^I[%/#4Z
M4JDH_;=W]R6GR1\Z:_\ #GX@>+- 3PWJVDZ/=S+( ?$CN/.*AL[L 9W8XKI+
MOP1XN\%^,;O6?#5M;:PE_816DHNI?+:-XQ@/[CC.*]GHKT99K5DN7DCRZW5G
M9WM?KY+:R/&CD5"+Y_:2Y]+2NKKENETUTD]7=N^YXWK'@;QE;:UX<\5P&SU?
M7K*U>VO+4MY4<BL<_(>V*P=4^#/B;6?"OBFXN5M5U[Q!J5O>/:H_[N!(CPN[
MN<9KZ"HI0S2O3MRI75M;=$^9+M:Y57(L-6YE.4FG?2_5QY7+O=QTWMUM<\?^
M*GPSU/7=5\/ZWIEG#J,VG1M!-833&$2(P'*L.A&*Z/X4>$+KPKHMP;[3K/3K
MN[F,SP63,P4=!N9C\S8[UWM%<\\=5GAUAY;+_.]NV_D==/+*%+%2Q<?B?I:]
MDK[7V7>WD?#'QL_9E^*7Q#\>^/C-:P:_IFJGS=$O;K57BBTZ,#B,0#@MP!D_
M6NUT7X.?$+P?\6?AGXJLM&L[ZWL/#L6A:G$]UM-N0,,XX^;BOK*BO//7/(_V
MI/A9?_&+X,ZQX?TI4_MD/%=6/F-M431N".>W&ZO!/$W['WBB?]D_PQX5TU;=
M?'VFZDVK33>=@--*SB4;_P#<9?KL%?:]% 'F?@+X:3^"/@'8>"X50WEOHS6C
M!3\IF:,[N?3>QYKP]OV4_$FN_L?Z;\/;PVMKXHTZ[^WP*S[X6D61B$8^A5C7
MUY10!\Q_ ;X0>-4^-&I?$?QAHNE>%&_L:/1H-*T=PRS;6#-*^ !VX'T]*^FU
MSWI:* "BBB@ HHHH H:Y_P @:^_ZY-_*KD7^J3Z"J>N?\@:^_P"N3?RJY%_J
MD^@H ?1110 5FG_D8/\ MW'_ *$:TJS3_P C!_V[C_T(T"-*BBB@84444 (:
MY3XE^#)/'_@^\T1+@6C3E")BN[;M8'I^%=916E*I*C.-2&Z=T8UJ,,13E1J*
M\9)I^C/*?B%\#K?QOKGA_6(KH6%_IK1B5PF1<(I5@#[@@X/O4MW\%5O]0\93
MSZE(B:^8V3R,J]NR#@Y[\BO4:*[5F&)C",%/1:+;NG^:1YDLHP4JDJKIZR=W
MOJ^5Q_)M?CN>.P?!KQ#JVIZ*WB;Q,FJZ?I$JSP0Q6_EN[K]TLWX5VFJ?"WPM
MK'VDW6A6;O<MNFD$8#.<[LDCGKC\JZZBHJ8[$5&GS6MVT\^ENIK2RS"4HRCR
M<U]^;WGM;>5^FAY;H/P'T?P[\0AXBLHHX;:. )#: 'Y),\OG//':MKXB_#^Z
M\8G3KS3M4ETC5M/D,D%POS(<]0R]Q7<44/&XB52-64KRBK*^NGSW".682%&=
M"$+1D[M+37>ZMMMI;8\IT3X-WL_B#4=<\4ZP-9U"[L'TU1!$(DCA;[W'<_XF
MF>%?A+XAT*32K&X\4O/X?TMB8+2*+9)(O.$D;N!FO6:*T>88B2:;5GY+2RMI
MIIH^AE'*,)!J23NFW?FE=W:;N[ZZI;WV/%[OX$ZJ+/4="L?$7V7PKJ-P9I[,
MPYE 9MS(K]@375:%\,4\/_$"Z\0P3@VTNEQ:9':;>4$9!!S^%=]12GF&(J1<
M92T>^BUO;?ST6NXZ64X.C)3A#5--:MVM>R6NBU>FVIXU!\"]1TS5;E=,UN&T
MT6YO#>/"UFCSJ2<LJN1P#76_%OX<'XH?"_7?" OI=._M&V\A;J/JA!!'3MQ@
MCT-=Q16-?%5<3;VKO;R7X]SIPN!H8*ZH*U_-O[K[+R1\J_##]CW7/!/Q"\(>
M*;_Q%I<[Z#9W&G&TT_3A;I)"\10-D<F3YB2Q]!7H/[-GP1UWX%:+JN@WFO6^
ML:(]T]Q81QVYCDBWL2V]L\]NGI7M-%<AWGS[\5OV4[?XE_'?PG\0FU)+:+2#
M&US9&/)N3&Q9#GM@X_*DN/V4K:?]J>#XN?VA$MM'$&;2_*Y-P(3$)<].F#]1
M7T'10!Y/\9O@K/\ %3Q)X&U2+4DL5\.:F+]XWC+><,8VCTKD?B[^S7X@\3_$
M2Y\:>"/%<?A;5]1T\Z9J(GMO.2>'&,@=FQ7T-10!PWP:^&%K\'?AOHWA*RF>
MZBT^-@T\@PTKLQ=VQVRS&NYHHH **** "BBB@#A/BA_S#/\ MK_[)11\4/\
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M (^=0_Z[G_T$4"9HT444#"L[4_\ C\TS_KN?_0&K1K.U/_C\TS_KN?\ T!J
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MT,Q487D'CCTKYGT:W/QHT3QOXF\53W,FLZ#X<TF?2I4N'A^PS2Z<MS)/&JL
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M^/\ QUXLUCQ+JVEZWH>AZ%X>U1=..FZE;DBZ4%?,=Y]V8R=QVX4CIG.: /H
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ME\Z%9"1L?&-P([X-=-10!Y[9_!#P)H?A_5-)AT"R@T[4U5;T..9U4Y578\D
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M<PXRSJ!_"1NP,UZ)_P -G_!;_H?K'_OQ/_\ &Z:?VS?@L<_\5_8_]^)__C=
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MSJ'_ %W/_H(J^CAP".AZ50TK_CYU#_KN?_010(T:***!A6=J?_'YIG_7<_\
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M!/AUH_P[TR>STI9F-Q*9[BYNI3+-/(>K.YZGC%9Y^#OALV LQ;2" :W_ ,)
M!YAS]L\SS-_TW'.*[>B@#QSXK?!@:OINJW'A[3;6\U/5+^"^O4N[AXB[1H$4
MQ2KS$X &"*D_9[^$VH_#>T\17>JK'!>ZU>BZ:V2X:X,2J@4!I6Y=CC)->NE<
MTH&!0  8%+110 4QXQ(K*>A&#3Z* .$N?@OX8NO EOX1-K*FD6TAF@,<I6:&
M0R&3>C]58,Q.:H+^S]X2'A2;06ANY(YKL7[WSW+&\-P.DOF]=P'&?3BO2J*
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MQ'?ZJ=5: W3[_+$>=O ']* /FO[/#_SQC_[X%+]GA_YXQ_\ ? KWS_AF5?\
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MC^'?^P?;_P#HM:Z"OPJI\<O5G[C3^!>@@7%9^E?\?.H?]=S_ .@BM&L[2O\
MCYU'_KN?_01699HT444#"L[4_P#C\TS_ *[G_P! :M&L[4_^/S3/^NY_] :@
M#0*[NM(%(Z'%.HH$8'CL$>"]<.>?L<O_ *":^,0QP.37V?X\_P"1*US_ *\Y
M?_037Q>.E,!=Q]31N/J:2BD,7<?4T;CZFDHH ];_ &;LMXRO@3_RYG_T(5](
M@''7'X5\W?LV_P#(YWW_ %YG_P!"%?20Z"@0F#Z_I1@^OZ4ZB@9\G?M@DCQG
MH(!P/L#' _ZZ&O \U[Y^V%_R.F@?]@]O_1AKP*OU/*O]RI^GZL_,<T_WRIZ_
MHA<T9I**]4\H7-&>*2@]* /O3X(@M\)_"[9Y^QK_ #-=Q@^OZ5Q'P._Y)+X7
M_P"O-?YFNYK\@Q7^\5/\3_,_6<+_  *?HOR&X/K^E4M;!_LB]R>D+]O]DU?J
MCK?_ "![W_KB_P#Z":PC\2.B6S/QUNOFNI\\XD;KSW/K46P>@_[Y'^%37'_'
MU<?]=6_F:CK]XYFC\*<4QNP>@_[Y'^%'EJ>JJ?\ @(IU%',Q<D>PW8HZ*H_X
M"*]T_8K&/V@M$ X'V:ZX[?ZH]J\-KW/]BO\ Y.#T3_KVNO\ T4:\[,6W@ZW^
M%_D>EEL4L92M_,OS/TF"D=#1LYR33J*_%C]F*&MC&C7O_7)OY5<B_P!4GT%4
M]<_Y U]_UR;^57(O]4GT% #Z*** "LT_\C!_V[C_ -"-:59I_P"1@_[=Q_Z$
M:!&E1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#A/BA_P PS_MK_P"R44?%#_F&?]M?_9**S>Y<
M=CJ] _Y 6F_]>\?_ *"*T*S] _Y 6F_]>\?_ *"*T*T("DI:* &EB!VKQ?P]
M^TI'XA_:0U'X3KX3U?36LM,FU$:SJ*>3#=B.9(CY"]73+'Y\@<=*[7QU\,E\
M<:GI%Z?%'B703ITGFBWT/4C;17/(.V90IWKQC''!KB=1^&&OR_M::9X_B@A?
MP[;>#9]&=VE'F&Y:[64+MZX*C[U C6_:/_:$T3]F[X<7'BK5[>349!(L%IIM
MNVV6ZE;^%>#@!06)QP%)KT'PUK8\2>'M+U5(C"E]:Q70C)R4#H& SWQFODKX
M\_LT_$K]H?PK<>*;C51X3\8-H%SI$7@\BWO[.,R.VYDN7 V/*@C#.HR!\N>N
M?I_X7>']2\*?#SPWH^L7G]H:G86$-O<7.Q4WNJ 'A>..G'7% '54444#"BBB
M@#S?]H?_ ))%K_\ US7_ -#%?#-?<W[0_P#R2+7_ /KFO_H8KX:/%?H'#W^[
M2_Q?HCX+/_\ >8_X?U8E%%%?4'S(4444 ?2G['',WBC_ '8/_9Z^F1TKYE_8
MX_UWB?\ W8/_ &>OIH=*_,LZ_P!^G\OR1^DY/_N4/G^;%HHHKQ#VC\Z_VZO^
M2W+_ -@^+^;5\\'K7T/^W5_R6Y?^P?%_-J^>#UK]ERO_ '&CZ(_'<S_WZMZA
M1117IGF!0!\P^HHH'4?44UN)['Z]^ ?^1'\._P#8/M__ $6M=!7/^ ?^1'\.
M_P#8/M__ $6M=!7X55^.7JS]RI_ O0*SM*_X^=0_Z[G_ -!%:-9VE?\ 'SJ'
M_7<_^@BLRV:-%%% PK.U/_C\TS_KN?\ T!JT:SM3_P"/S3/^NY_] :@#1HHH
MH P?'G_(E:Y_UYR_^@FOB\=*^T/'G_(E:Y_UYR_^@FOB\=* "BBB@ HHHH ]
M;_9M_P"1SOO^O,_^A"OI(=!7S;^S;_R.=]_UYG_T(5])#H*!"T444#/D[]L+
M_D=-!_[![?\ HPUX%7OO[87_ ".F@_\ 8/?_ -&&O J_4\J_W*GZ?JS\QS3_
M 'RIZ_H@HHHKU3R@H/2B@]*!GWK\#O\ DDOA?_KS7^9KN:X;X'?\DE\+_P#7
MFO\ ,UW-?D&*_P!XJ?XG^9^L87^!3]%^051UO_D#WO\ UQ?_ -!-7JHZW_R!
M[W_KB_\ Z":PC\2.B6S/QVN/^/JX_P"NK?S-1U)<?\?5Q_UU;^9J.OW8_# H
MHHH *]S_ &+/^3@M$/\ T[77_HHUX8:]R_8K.?V@=%_Z][K_ -%&O/S'_<ZW
M^%_D>CEW^^4O\2_,_2FBBBOQ<_9"AKO&C7W_ %Q;^57(O]4GT%4]=YT:^_ZX
MM_*KD7^J3Z"@!]%%% !6:?\ D8/^W<?^A&M*LT_\C!_V[C_T(T"-*BBB@851
MUG6K'P[I-WJFJ7D&GZ=9Q--<75RX2.)%&69F/   ZU=/(-?/_P"WCH>J^(OV
M4_'EEH]M->W7D02O;VZEI)(4GC>90!US&K\=Z /2OA?\:O!'QHTNZU'P3XDL
M?$5G:R^3.]HQS$^,@,I (R.0<8/:J6G?M"?#K5OB1/X M/%^EW'C&'=OTE)?
MWN0,LH/W2P')4'(':OE_X&_$WPM#\=OB'\1-.>73O &IZ?I&A6=RMG(L<]_C
M 4(%S\H*J3C QC->0>%H[Z;6O 7@C2M$N9_B?X>^(&JZYJ%N\+0G[/B1E=YB
M,!)040-GO[4Q'Z0Q_$'P[+XZ?P8FL6K>*4L?[3?2@^9UMM^SS2O9=V!715^?
M_P"SEX=^(_AS]N1M4\<^$KJ'Q'X@\'W5QK6I?VA#-;KF]3RO+V,0(T6..%8\
M[L?.>IK[_I#%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** ,'QY_R)6N?]><O_H)KXO'2OM#Q[_R)6N?]><O_H)KXO'2@ HHHH ****
M/6_V;?\ D<[[_KS/_H0KZ2'05\V_LV_\CG??]>9_]"%?20Z"@0M%%% SY-_;
M"_Y'/0O^P>W_ *,->!U[[^V%_P CIH/_ &#V_P#1AKP*OU/*O]RI>GZL_,<T
M_P!]J>OZ(****]4\H*#THH/2@9]Z_ [_ ))+X7_Z\U_F:[FN&^!W_))?"_\
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M@**** "BBB@ HHHH **** "BBB@#S?\ :'_Y)%K_ /US7_T,5\,U]S?M#_\
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M_P#("T[_ *]H_P#T$5H5GZ#_ ,@+3O\ KVC_ /016A5D!1110 4444 %%%%
M!1110 4444 >;_M#_P#)(M?_ .N:_P#H8KX9K[F_:'_Y)%K_ /US7_T,5\-5
M^@</?[M+_%^B/@L__P!YC_A_5B448HZ\U]0?,A1110!])_L<?Z[Q/_NP?^SU
M]-#I7S+^QO\ Z_Q-_NP?S>OINOS+.?\ ?I_+\D?I.3_[E#Y_FPHHHKQ#VC\Z
M_P!NG_DMR_\ 8/B_FU?/!ZU]#?MU?\EN'_8/B_FU?/)ZU^RY7_N-'T1^.YG_
M +]6]0HHHKTSS H'4?444#J/J*:W$]C]>_ /_(C^'?\ L'V__HM:Z"N?\ _\
MB/X=_P"P?;_^BUKH*_"JGQR]6?N5/X%Z!6=I7_'SJ'_7<_\ H(K1K.TK_CYU
M#_KN?_0169;-&BBB@85G:G_Q^:9_UW/_ * U:-9VI_\ 'YIG_7<_^@-0!HT4
M44 8/CS_ )$K7/\ KSE_]!-?&"]*^X]2L(=5L;BRN%+03QF-P#C((P>:X0?
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MUW-<-\#O^22^%_\ KS7^9KN:_(,5_O%3_$_S/UC"_P "GZ+\@JCK?_('O?\
MKB__ *":O51UO_D#WO\ UQ?_ -!-81^)'1+9GX[7'_'U<?\ 75OYFHZ?<_\
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M "#/^VO_ +)11\4/^89_VU_]DHJ&:QV.KT#_ ) 6F_\ 7O'_ .@BM"L_0?\
MD!:;_P!>\?\ Z *T*LS"BBB@ HHHH **** "BBB@ HHHH \W_:'_ .21:_\
M]<U_]#%?#7I7W+^T/_R2+7_^N:_^ABOAFOT#A[_=I?XOT1\%G_\ O,?\/ZL*
M***^H/F0HHHH ^D_V-_]?XF_W8/YO7TW7S)^QO\ Z_Q-_NP?S>OINOS+.?\
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M_P!>UU_Z*->?F/\ N=;_  O\CT<N_P!\I?XE^9^E%%%%?BY^R%#7?^0+??\
M7%OY5<B_U2?053UW_D"WW_7%OY5<B_U2?04 /HHHH *S3_R,'_;N/_0C6E6:
M?^1@_P"W<?\ H1H$:5%%% PHHHH **** "BBB@ HHHH *0TM(>E 'P-\9_\
MDJOBG_K_ )/Z5Q==I\9_^2K>*?\ K_?^E<77Z_AOX%/T7Y'Y+B?X\_5_F%%%
M%=)S!72?#?\ Y*!X;_["$/\ Z$*YNNC^''_)0/#?_80A_P#0A6-;^%+T?Y&U
M'^+'U7YGZ%#I2T@Z4M?CI^NA7SW^W3_R02Y_["-K_P"A&OH2OGO]NG_D@ES_
M -A&U_\ 0C7J97_OU'_$CS,S_P!RK?X7^1^=%%%%?LA^.!1110,#TK[W_P""
M?7_)+-<_["S?^BTKX(/2OO?_ ()]?\DLUS_L+-_Z+2OG.(?]PEZH^CX?_P!_
M7HSZDHHHK\J/U(X3XH?\PS_MK_[)12?%'KIG_;7_ -DHJ6:1V.LT#_D!:;_U
M[Q_^@BM"L_0/^0%IO_7O'_Z"*T*HS"BBB@ HHHH **** "BBB@ HHHH \W_:
M'_Y)%K__ %S7_P!#%?#1ZU]R_M#_ /)(M?\ ^N:_^ABOAFOT#A[_ ':7^+]$
M?!9__O,?\/ZL****^H/F0HHHH ^D_P!CC_7>)_\ =@_]GKZ:'2OF7]CC_7>)
M_P#=@_\ 9Z^FATK\RSK_ 'Z?R_)'Z3D_^Y0^?YL6BBBO$/:/SJ_;J_Y+</\
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M/^0%IO\ U[Q_^@BM"M" HHHH **** "BBB@ HHHH **** /-_P!H?_DD6O\
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MQ\ZC_P!=S_Z"*S+9HT444#"L[4_^/S3/^NY_] :M&L[4_P#C\TS_ *[G_P!
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M=%8****S- HHHH **** "BBB@ HHHH H:Y_R!K[_ *Y-_*KD7^J3Z"J>N?\
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MI[PVEU'.ZI(VXA2"<?+7U012%,]Z4L[QDHN+:U\AQR7"1DI)/3S%4Y I:0#
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MG:G_ ,?FF?\ 7<_^@-6C6;JK!+K368@ 3GD_[C4 :5%1^?'_ ,]%_.CSX_\
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/<L?^!_\ LM%%%64MC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mtva-20251231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &< T0# 2(  A$! Q$!_\0
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M)S);L%D!*#!Y_P!KVK3KG_#O_(9UW_KLO_LU &M]KF_Y\IO^^D_^*H^US?\
M/E-_WTG_ ,55JB@"K]KF_P"?*;_OI/\ XJC[7-_SY3?]])_\55JB@"K]KF_Y
M\IO^^D_^*H^US?\ /E-_WTG_ ,55JB@"K]KF_P"?*;_OI/\ XJC[7-_SY3?]
M])_\55JJ&KZ]IGA^W6?5-1M--@9MBRWDZQ*6] 6(&: )?M<W_/E-_P!])_\
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M_%4?:YO^?*;_ +Z3_P"*JU10!5^US?\ /E-_WTG_ ,53K&\34+.*XC#*D@W
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M444 %<_X=_Y#.N_]=E_]FKH*Y_P[_P AG7?^NR_^S4 =!1110 4444 %%%%
M!1110 45PGQRUS4O#7PLUW5-(O7T_4+98GCGC16(_>H",,".02.G?CFN.\*>
M/-<O_BX\5Q?R2Z;>ZEJ>EIII51';I:)&4D7C=N8ER22<AUXX% 'ME%%% !11
M10 445XA\0O&^OZ;XFU_1[35)[>*\U+0]-MYHTCW6"74C+,Z$K]XA3@MG#,/
MI0![?17A%[J.O?$'X!Z'KZ>+-8\-:JBE/.T80![V?S3;Q!_,B<;7?:V% ^]U
MKMO >KZK/\1O'>D7^I27]IIJZ=]E61$7R]]N3)@J 3N8;N<]?3B@#T&BBB@
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M HHHH **** "BN ^(WQ/E\$:OIUE;Z>E^'@>^O7>;RS#:K+%$608.Y]TP('
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MUYT?]]?SK\L/V>OB]XT\1_&[P7IFJ>)M2OM/NM2BBGMIYRR2(3R".XK]0?\
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MVL2Q0H(XUZ*HP!4E &$O_(ZM_P!>7_LXK=K"7_D=6_Z\O_9Q6[0 4444 %>
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M*=KW_!7,*]7V%-U&KV/HCX0?#NS^%6I^*V'BR\UJRU2X@EMEU745N'@5(@I
M.!CG/KP%KTK^VM._Y_[7_O\ +_C7XJ_\)KXB_P"@]J?_ (&2?_%5^DO[!D\F
ML_ *&YU"1[ZX.I7*^=<L9'P-N!ELFO4QV42P-+VKG?6VQQ8;'+$3Y%&Q]"_V
MUIW_ #_VO_?Y?\:/[:T[_G_M?^_R_P"-3?8+;_GWB_[X%5;;1XH;R\E:*)DF
M92B[!\N% /ZU\^>H>/>#O"FM>#;ZY=)/#^H00Q7%A;++?%?-MFEN)U9QM(#;
MGAC*\C&]L]!6+=?"[5KO3--M+2ZT+0[M)]2OUU*UO SZ>UR+@?98EV@-'F6(
MDY'*L=O2OH7[!;?\^\7_ 'P*_+O]L_Q)J^D_M*^,;6QU6]L[6/['L@M[AXT7
M-G 3A0<#))/XUZ6 P3QU5TE*UE?\O\SDQ.(6&@IM7UL??7P+\,P_#7P5)I%S
M/IEA&UY+<6^FV5UYD-E&VW]VC-@D%@[]!S(1VKT3^VM._P"?^U_[_+_C7XJ_
M\)KXB_Z#VI_^!DG_ ,57[%_#2VAN/AQX4EEB265])M&=W4%F)A0DD]S71F&6
M2P$8R<KW\C+"XQ8EM*-K&_\ VUIW_/\ VO\ W^7_ !K!\>VFG^,_ ^OZ -4M
M(&U.PGLQ*TJD(70J"1GMFND^P6W_ #[Q?]\"JFE:-%8Z?#!+'%+(@P7V#GFO
M%/0/(3I'B&;P]XCAN]/\+7UQX@=KBYM9]2+10RLB1  E#N 5 ^< YX]ZXF[_
M &;9-0DO[9?%<&DI'9LMOJUA- UU>SLEJ +A98W0HKVN>A/[S(*D<_3_ -@M
MO^?>+_O@5^*MWXT\0BZF U[4P [<?;)/7ZU[&7Y<\PYK2MRVZ=[_ .1P8K%K
M"\MU>Y^QG@UK?P[X1T32KS6H+Z[LK*&VEN7EC#2NB!2Q"A5Y([ #V%;']M:=
M_P _]K_W^7_&OR7_ &>?%>MWWQT\!V]SK&H7%O+K-JDD4MT[(ZF09!!."*_6
M[[!;?\^\7_? J,PP#P$XP<KW5RL+B5B8N25K$2:Q82.JK>VS,QP%$JDD_G5R
MLW5=&BOK&2&&.*&1BI#[ ,88'M]*TJ\H[1#TK-\,_P#(!LO^N=:1Z5F^&?\
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M:TZ* ,S^P(/^?B\_\"7_ ,:/[ @_Y^+S_P "7_QK3HH S/[ @_Y^+S_P)?\
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M][&NTX+%22,]UQWJ;PKIVK:/XT\;^/9_#^H2?VY<6%E9Z7&$%RL$2!&G<%@
M-S,<9R GO7L%% 'SKXH^&OB"3PU\1? 5II<\T/BO6/MUKK"E3;P0S>3YIDYR
M&C\IN,?-E<=ZZ_Q#K][)XCM=,E\%>(K[0]'DC:V:V@C9+J=,;)"S2+A$P"..
M3R<!1GUNB@ J.>".YA>*50\;C#*>XJ2B@#*_X1?2O^?*/]?\:\0_;5T'3[+]
MF7QE-!:I'*OV/##.1F]@%?0E>%_MO_\ )KWC3_MR_P#2V"NW _[U2_Q1_-'/
MB/X,_1_D?E'7V)_P3<TVVU'QEXS6YA695L(2 W;]X:^.Z^S?^"9__(Z>-?\
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M*GZ?JSXW'?[Q/^NA]W_\$V+2:Y\/>.C%>26H%U:Y$:J<_))Z@U]F_P!E7?\
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MQ-^Z3Y0<Y/2@#?HK+_LN]_Z"T_\ WZC_ ,*CNK&^M[::4:K,2B%@#$G.!]*
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MC[%F1@ 3_H4'8<5]/P]_O4O\+_-'CYI_!7K^C/$*_:GX7?\ ),_"/_8(L_\
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M_G_XFCS]7_Y]+7_O^?\ XFM2B@#+\_5_^?2U_P"_Y_\ B://U?\ Y]+7_O\
MG_XFM2B@#+\_5_\ GTM?^_Y_^)K\>_CJ7/QN^()D 60^(=0W!3D _:9,X-?L
MQ7XU?'O_ )+G\1/^QBU'_P!*9*^MX=_BU/3]3P\U^"/J<)7Z\?LZS:FOP(\
MB*UMVC&BVNUFF()'ECJ-M?D/7[$?LW_\D"^'W_8$M?\ T6*[^(OX,/7]#FRK
M^)+T.T\_5_\ GTM?^_Y_^)H\_5_^?2U_[_G_ .)K4HKX,^E,OS]7_P"?2U_[
M_G_XFCS]7_Y]+7_O^?\ XFM2B@#+\_5_^?2U_P"_Y_\ B://U?\ Y]+7_O\
MG_XFM2B@#+\_5_\ GTM?^_Y_^)H\_5_^?2U_[_G_ .)K4HH R_/U?_GTM?\
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MX;-9_P">UC_WZ?\ ^*HV:S_SVL?^_3__ !5:=%?EQ]D9FS6?^>UC_P!^G_\
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M?P5Z_HSPNOV7^&*:M_PK;PGLEL@G]DVF T;YQY*=?FK\:*_:GX7?\DS\(_\
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MOX\/3]3LRK^'+U"BBBOE#V@KG_#O_(9UW_KLO_LU=!7/^'?^0SKO_79?_9J
M.@JAKFNZ?X:TFYU/5;N*QL+9=\MQ,V%4?YXQWIGB/Q'IWA+1+K5]6N19Z=:J
M&FG*LP0$@#A02>2.@KQ'XH_$+1/B-%\.)?#^HC4M'D\96UK=L(W12R1/*JD.
M!GYO+/ITH ]F\,^,-(\7PW$FE7?GFW?RYXI(GAEA8C(#QN%9<@@C(&1R*V))
M$AC:21E2-069F.  .I)KQ32[FXMOVP=:M;;(LKKPG%/=JIPIE2X"QL1W.UF
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M95_$EZ'K%%9G]KW'_0*NOS3_ .*H_M>X_P"@5=?FG_Q5?!GTIIT5F?VO<?\
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MDGC_ +3N?G:?8<_+VP:^KS__ '3YK]3Q<L_C_(^HJ*R_MNJ?] R+_P "A_\
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M/_T2E>CQ%\%/U?Z')E7Q3.GHHHKX<^C"OPTO/^/N?_?;^=?N77X:7G_'W/\
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M ,*U** ,O_A([/TN/_ =_P#"C_A([/TN/_ =_P#"M2B@#+_X2.S]+C_P'?\
MPH_X2.S]+C_P'?\ PK4HH _/#_@I%?Q7_CCP>T0<!=.E!WH5_P"6ON*^/J^R
MO^"E_P#R/7@S_L&R_P#HVOC6OU'*?]RI^GZL^-QW^\3_ *Z'W=_P38U.&P\/
M>.A*)"6NK4C9&S_P2>@K[._X2.S]+C_P'?\ PKX\_P""9?\ R+OCS_KZM/\
MT"2OM>OALW_WZI\OR1]'@?\ =X?UU,O_ (2.S]+C_P !W_PH_P"$CL_2X_\
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MR-G_ )"JG_"1V?I<?^ [_P"%:E% &7_PD=GZ7'_@._\ A1_PD=GZ7'_@._\
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M!9G8X"@=237E'Q:^(L%QHN@V'AK789&UG7K+2+B]TNY222WBE?Y]K*3M8J"
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MT %%<3\5O'=QX'TG2DT^*&;5]9U.VTFR%QGRTDE?!D<#DJJY.!UP!WJO\/\
MQU?ZMXN\5^$]9-O+JV@O;O\ :K2,QQW$$T>]&V$L58$,I&3V/>@#OJ*XG7?%
MVJ:5\5/"N@(MJVE:O:WLLC%6\Y7A6,C!SC!\ST[5B>/_ !5XX\)W=OJUO%I<
MNAMJ5O9?V6T3M=S1R2*GF+('VAOFR%VG@<F@#U&BBF2RI!&TDCJB*,EF. *
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M^X>_W>?^+]$?,YI_%CZ?J>H?LO\ _)PG@'_L+0_SK]@*_'_]E_\ Y.$\ _\
M86A_G7[ 5YG$7\>'I^IV95_#EZA1117RA[05S_AW_D,Z[_UV7_V:N@KG_#O_
M "&==_Z[+_[-0!?\0^'K#Q5HUUI6IPM/87*A98TE>(L 01\R$,.0.AKSKQ)\
M"M-MO#>FVWA.$:?>:5K$6MVJ7=U-,DDR *RLSLS ,F5XZ9SCK7JU% 'E^C^
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M5O/$8RJ;"/E\O^]SGM537K?Q]>>,?M<6@Z+>Z39M_H"7&J/&0QX,SJ(3E\<
M9P 3U)R/3:* "D90X(8 @]0:6B@"+[+!_P \8_\ OD4?98/^>,?_ 'R*EHH
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M?%K>,O[6B\=2P>'UE20Z"NDP."@4;D\['F?,03D<C.!7GUY\4XO$7BQ;K5/
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MG^-'_".67_3?_P ")/\ &M2B@#+_ .$<LO\ IO\ ^!$G^-'_  CEE_TW_P#
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M,ZK#\"M:\-:5%JOBS5+NT>SADGDC>XD9\G=(YV+@=,@>G% 'I]LQ>VB8G)*
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M=6#'&PYP..*Y3XA_!WQG=SI<:3XRN9TN=?MK][;^S+8FW42##[VY81J!A3U
MZ4 >[T4R%'CAC61_-=5 9\8W'N<=J2>%;B%XV+!6&#M)!_,4 245F?\ "/6O
M]^Y_\"'_ ,:/^$>M?[]S_P"!#_XT :=%9G_"/6O]^Y_\"'_QH_X1ZU_OW/\
MX$/_ (T :=%9G_"/6O\ ?N?_  (?_&C_ (1ZU_OW/_@0_P#C0!IU\+_\%._^
M::_]Q/\ ]M:^U?\ A'K7^_<_^!#_ .-?$'_!2[3HK#_A7'E&0[_[2SYDC/T^
MR],GCK7M9-_OU/Y_DSS\?_NTOE^:/B&OT[_X)\_\F\P?]A2Z_FM?F)7Z7?L"
M:1!>?L_022-,&_M.Y'R3,H_A[ U]7G_^Z?-?J>+EG\?Y'U%169_PCUK_ '[G
M_P "'_QH_P"$>M?[]S_X$/\ XU^='U1IU^4?[;__ "=#XT_[<O\ TB@K]2?^
M$>M?[]S_ .!#_P"-?EC^VM;I:?M->,HD+%5^Q8+L6/\ QY0'J:^GX>_WJ7^%
M_FCQ\T_@KU_1GB%?M3\+O^29^$?^P19_^B4K\5J_9?X8Z#;2?#;PFQ>XRVDV
MA.+AP/\ 4I[UZ/$7P4_5_H<F5?%,[FBLS_A'K7^_<_\ @0_^-'_"/6O]^Y_\
M"'_QKX<^C-.OPTO/^/N?_?;^=?MQ_P (]:_W[G_P(?\ QK\1[L8NYO\ ?;^=
M?9\.;U?^W?U/G\V^Q\_T/0OV;_\ DOGP^_[#=K_Z,%?L37XY_LZQ+/\ '?P#
M&V0K:U:@[20?]8.XK]>?^$>M?[]S_P"!#_XUAQ%_&I^GZFN5?PY>IIT5G1:%
M;0RI(KW!92&&Z=R./;-:-?)GMB'I6;X9_P"0#9?]<ZTCTK-\,_\ (!LO^N=
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M /X$M6I17P9]*9?]@I_S^W__ ($M1_8*?\_M_P#^!+5J44 9?]@I_P _M_\
M^!+4?V"G_/[?_P#@2U:E% &7_8*?\_M__P"!+4?V"G_/[?\ _@2U:E% &7_8
M*?\ /[?_ /@2U5]1T%!I]S_IM]_JF_Y>6]#6Y5;4?^0?=?\ 7)OY&FMP/PXH
MHHK]G/S\_;S^P4_Y_;__ ,"6H_L%/^?V_P#_  ):M2BOQ<_0"*V@%M"L8=Y
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MK_H*W/\ WRG_ ,37Y9?MK1/!^TUXR1Y6G8?8LR. "?\ 0H/2OUAK\H_VW_\
MDZ'QI_VY?^D4%?3\/?[U+_"_S1X^:?P5Z_HSPNOV7^&.EW+_  V\)L-3N$!T
MFT(4*F!^Y3CI7XT5^U/PN_Y)GX1_[!%G_P"B4KT>(O@I^K_0Y,J^*9I_V3=?
M]!6Y_P"^4_\ B:/[)NO^@K<_]\I_\36I17PY]&9?]DW7_05N?^^4_P#B:_$B
M[_X^YO\ ?;^=?N77X:7G_'W/_OM_.OL^'-ZO_;OZGS^;?8^?Z'?_ +.J-+\=
M_ **YC9M:M0'7&1^\'/-?KQ_9-U_T%;G_OE/_B:_(K]F_P#Y+Y\/O^PW:_\
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M).1G<R@D<9Z \XK-\-ZCKMKHMS=>,DTC39XI"0VGW+O (L##,TBK@YW>V,4
M4_A'XXG^)/PZT7Q+<V:Z?/J$;2-;(VX1D.RXSW^[6WXE\00>&-&GU"=7EV86
M."+[\TAX2-1W9C@"O,/V:O$FEVG[.VA:C+?P+96-O.]S,'R(0LLC'=CD?*0<
M=>:M:_%XN\7^(M&\3^%!X>UOPVMFL^G+J-U/$/-D',^U(V!.PA5)^Z&;C)H
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M+!5)RJWU70\S'8>>(C%0Z'YY5^Q'[-__ "0+X??]@2U_]%BO&O\ AW'\./\
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M=Y>7%O*%BL9;E2,[T=0 ?3DU<HH S/[4O/\ H$S_ /?R/_XJC^U+S_H$S_\
M?R/_ .*K3HH S/[4O/\ H$S_ /?R/_XJC^U+S_H$S_\ ?R/_ .*K3HH S/[4
MO/\ H$S_ /?R/_XJC^U+S_H$S_\ ?R/_ .*K3HH S/[4O/\ H$S_ /?R/_XJ
MC^U+S_H$S_\ ?R/_ .*K3HH S/[4O/\ H$S_ /?R/_XJC^U+S_H$S_\ ?R/_
M .*K3HH S/[4O/\ H$S_ /?R/_XJC^U+S_H$S_\ ?R/_ .*K3HH S/[4O/\
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M-/\ ^^'_ ,:U:* ,K;K?_/33_P#OA_\ &C;K?_/33_\ OA_\:U:* ,K;K?\
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M<Q21[UW(RY5CR&!4CKD$50\;3W6EZ%\/?'4=U8Z4GANT9I!J]RJ6US!+ BN
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MIG:N/AAXCU.PU_PQ/I%O%8:GXI;6QK1N498H/M"3C;']_P WY-F, ?,3N[$
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M9M66+<0Q&>,D#<V!]*Y/QAX)\9ZS9?%.*U\+S"3Q'J%C-8.;ZV&$ACA1F?\
M>?+_ *@D 9/S+[XV?$'@GQ/>WWCN&'0(;J#Q=IUK:K<SW<:BT98#%)YR\EL9
M+#9NSC'&<T >CZ?K]OJ'CB_L(->@N1!8PR-I"0?-$69B)O-SR&&%"]MI.>:Z
M6O+/!?@_6= ^*UQ=2:=)_8</ARST>'49)XR9I())&+; Q8 B7 R/X3[5ZG0
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M 4444 82_P#(ZM_UY?\ LXK=K"7_ )'5O^O+_P!G%;M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4R:&.YA>*6-98G!5D< JP/4$'J*?10!C>'_!GA
M_P )M.=#T+3-&,YS,=/LXX/,/JVP#/XULT44 %%%% !1110!ACP+X;&O?VX/
M#VE#6LY_M+[%']I_[^;=WZUN444 %%%% !1110 4444 (>E9OAG_ ) -E_US
MK2/2LWPS_P @&R_ZYT :=%%% &7XA_X\HO\ KXB_]#%:E9?B'_CRB_Z^(O\
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ME_\ /PW_ 'Y?_"@#7HK(_P"$KTO_ )^&_P"_+_X4?\)7I?\ S\-_WY?_  H
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M (1[3/\ GQ@_[XH_X1[3/^?&#_OBM&B@#._X1[3/^?&#_OBC_A'M,_Y\8/\
MOBM&B@#._P"$>TS_ )\8/^^*/^$>TS_GQ@_[XK1HH SO^$>TS_GQ@_[XH_X1
M[3/^?&#_ +XK1HH SO\ A'M,_P"?&#_OBC_A'M,_Y\8/^^*T:* ,[_A'M,_Y
M\8/^^*MVMG!91F.WB6%"<[4&!FIJ* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M K7>FVM^5-Q;QS%>A=<XJO\ \(]IG_/C!_WQ6C10!G?\(]IG_/C!_P!\4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQKJ^IP0Z=?>*]>FUM]+MI!)'9AD2,*6  :1O+WN1QN<@$XW'U"BB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mtva-20251231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $V U@# 2(  A$! Q$!_\0
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M!A_\(5X>_P"@%IG_ ("1_P#Q-'_"%>'O^@%IG_@)'_\ $UN44 8?_"%>'O\
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M>FSO9HXZ?$&%J^S4$WSMI?"MN7O)+[2T5WNFKIH]M_X0KP]_T M,_P# 2/\
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M-:QYM?/:&%<56A*+=W9\NR:7\VNZMR\S?J?0W_"%>'O^@%IG_@)'_P#$T?\
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M_P#;B@#5_P"$*\/?] +3/_ 2/_XFC_A"O#W_ $ M,_\  2/_ .)K<HH P_\
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MK3K*$N224VE%M*SNFTUKM9;.SVT.I_X0KP]_T M,_P# 2/\ ^)H_X0KP]_T
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M9_X"1_\ Q-'_  A7A[_H!:9_X"1__$UN44 8?_"%>'O^@%IG_@)'_P#$T?\
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M>KT4 ?'GB_X/_$_Q7>7"ZEI6H:OJ,'B6/4(M1E\1JFF_8DNUD1+>S5@%D$8
M/F+U#-N)(KVSX.^&_$'A'Q5\1[;5-*\G3-3\02ZSI^I1W,;I<)-'&I0Q@[T9
M3'SN&#D8S7J]% '@\_P<UN3]I^/Q4OE'P6T2ZM*AD&3JJ0-:)\G7_4MNW>HI
M/@%\&-7^'/CCQI?ZK'$FG+*;#PYLE#,FGM/-=,"!]T^9<;<'_GF.V*]YHH \
M,UKX,:KXKUGXY6UUY=GIWC'3;*ST^[\P,=Z6LD;,RCD!79>O4=*R/AW\//%=
MYX[^'^H:MX/LO!5IX-TJXL)IK2\BF_M-Y(TC"1B/E804,G[S!R1QP37T510
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MPQR*]6HH ^<_ /[/>HVOC3XF)X@6-/"U_:W6E:"D4@;;:7LLEQ<_+_#B215
M/]W-=3^S%\.?$/P^\!70\7^4WBG4+LS7;1R"3Y(HTMX!O'7]U"C8[;C7L=%
M'S/J_P  O$&M?"CQ)I,UA93ZJOC:X\46%C=S V][$+OS4B=AG:)$W+ST)Y[U
MV?PJ\(^()OB?XH\;ZQX=C\%V^H:=::;#I$=S%/),T+.QN)6BRF?W@C4 D[5Y
MQP*]EHH **** "BBB@ HHHH R_$__(M:M_UZ2_\ H!HH\3_\BWJ__7I+_P"@
M&BI946'AC_D6](_Z](O_ $ 5J5E^&/\ D6](_P"O2+_T 5J51(4444 %%%%
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M5S;_ !*\,Q>!(?&;:O#_ ,(Q+#'.E^JL59'8*A"@;LEF48QG)QC- '5T444
M%%%% !1110 4444 %%%% !7'?\R%_P!MO_;BNQKCO^9"_P"VW_MQ0!V-%%%
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M%V7[16N06NE^,-5T[3$^'NLWM[8V7V<R'4(3 L[)++GY&$GV:3Y5 V[DY/-
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MZ'I]GXC^)_Q7\*>);[PO>^$-#\+PW;(NJRPM<WES/&(MJI$[A8T7<=Q.6)7
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MUWXAV/B&]\(0:/H%UXI353H,SP2"TBCTV2#[1(B$IODE*$A<D$ DYK+_ .%
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MHT6I:9-X<@O(GNK339YUEMUCE8JDLL0C56^8;@V 21SZ+\.M#\0>(?BGKOQ
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M]G#*00V <@C-;W_#3?PF_P"BC>&__!C'_P#%4?\ #3?PF_Z*-X;_ /!C'_\
M%4#-7X4?#R;X>:'?QW^H_P!K:WJVH2ZKJ=ZL?EQR7$F 0B9.U%5$5023A17=
M5YC_ ,--_"?_ **-X;_\&,?_ ,52?\--_";_ **-X;_\&,?_ ,50(W_B#H_B
M?4[/3Y_"FIV6GZG8W0G,&I0>9;7<>UE:)V WQ_>R'3D%1D$&O+].^ _B[PQ?
M6GBO2-7T67QLVHZA?7T-U#*FG2+>"(/$FTEUV&"(ACRQ#9QNX[,?M,?"@]/B
M+X;/_<2B_P#BJ7_AICX3_P#11?#?_@RB_P :!F;)\$+F/]GJ]^',6J1RWUW9
MSQRZE+$0C3S2M+(^P'(7>[8&>!BJWCWX&7_BZ/XDK#JEM;_\)5IVG64!>)CY
M#6S2%BV.H;>, >E;G_#3'PG_ .BB>&__  91?XTG_#3'PG_Z*+X;_P#!E%_C
M0(\0\1:7XB3Q]-X,T2.\.EW7CFVUZ:UN]$G$HC%S'//*MV"8#;;D+*?]9N^3
M;WKZ[KS/_AICX3_]%%\-_P#@RB_QIO\ PTS\)_\ HHWAK_P91?\ Q5 &OXG\
M"3Z]\2/!7B2.ZCA@T!;X2P,I+R^?$J#:>@QMR<UYK8_LYZQ+%IOA35=5T^?X
M>:/>WE]8PV\3K?RF=9U2.5B=@6/[3)AE'S87('.>T'[3'PH;I\1?#9_[B47_
M ,53O^&F/A/_ -%$\-_^#*+_ !I#,/X;_"/Q-HGB+PY>^*=6TR^M?"NE2:1H
MZZ=#)&\ROY:M//N) ?9"B[5R,ECGH >-O@9?^*I/B2T6J6\ \5MI30[XV/D?
M92N[=Z[MO&.E;?\ PTQ\)_\ HHGAO_P8Q_XTO_#2_P */^BB>&__  91?XTP
M/.?BSX'U'P5XYN_B+9W3_;9=9MKBT:/3)KV"U0:>UK,+I(CYFQQT>,$JVW(P
M378?LSZ9K5MX(UG4-=A>&\UG7[_5$+VS6I>*23Y'\ER6C#!<A6^;&,\UK?\
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ME/;M&^&!^<S9R#P/>NH_X::^$W_11?#?_@RB_P :/^&FOA-_T47PW_X,HO\
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M\=:ZJ@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN4[OM^IY/\:?"&@V=]I8@T/3(08WSLLXQGD>U>;_ /".:/\ ] JQ_P# 6/\
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M^5_A_F<WUV'9GW5YJ?WU_.CS4_OK^=?"O_"A_ '_ $+5O_W^E_\ BZ/^%#^
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M]16)M'M_D>_T445^>'U(4444 %%%% !1110 4444 %%%% !7'?\ ,A?]MO\
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M^$?^"F7_ "-/@7_KSNO_ $-*^+Z^T/\ @IE_R-/@7_KSNO\ T-*^+Z]G)_\
M<:?S_-GG9A_O,_E^2"BBBO9//(Y/N'Z5^VG@+_D1O#G_ &#K;_T4M?B7+_JC
M]#7[:> ?^1'\.?\ 8.MO_12U\7Q+\%+U?Z'OY1\4_E^IY_\ '+_C_P!)_P"N
M4G\Q7E]>G_'/_C_TG_KE)_,5YA7X=F'^\S^7Y(VQ'\67]= HHHKSSG%;HU?4
M6E_\@RR_ZXI_Z#7RZ>C5]1:7_P @RR_ZXI_Z#7T63_%/Y?J>E@MY?(@\3_\
M(MZO_P!>DO\ Z :*/$__ "+6K?\ 7I+_ .@&BOI&>Q%!X8_Y%O2/^O2+_P!
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M@^)?^PF/_12UZ1^UK_R;CX^_[!K?^A+7F_[ /_(@^)?^PF/_ $4M>D?M:_\
M)N/C[_L&M_Z$M?F&,_Y&_P#V]']#ZW#_ .XKT9^17I3J;Z4ZOTQ'R 4444 ?
MH;_P32_Y)GXK_P"PN/\ T2E?4OCK_D3M7_Z]G_E7RU_P32_Y)GXK_P"PN/\
MT2E?4OCK_D3M7_Z]G_E7Y#GO^\U_ZZ'V>$_W2/HSYMHHHK\H/)"BBB@#V?X(
M?\@"_P#^OG_V1:])KS?X(_\ ( O_ /KZ_P#95KTBON<!_NT/0]_#?PHG+#_D
M5_$'^_>_^A/726O_ !ZP_P"X/Y5S@_Y%?Q!_OWO_ *$]=':_\>L/^X/Y5WG0
MCY!_X*P_\F6^)_\ K_L/_2A:_"*OW=_X*P_\F6^)_P#K_L/_ $H6OPBIH3"B
MBBJ$%?N+_P $@_\ DSVU_P"P]??S2OPZK]Q?^"0?_)GMK_V'K[^:5+&CW/\
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MB"17E)_9%^#3* ?A[HK#T:)C_6@1_.!Y,G_/-_\ OFE\F3_GF_\ WS7]'O\
MPR!\&/\ HG.A_P#?@_XT?\,@?!C_ *)SH?\ WX/^-%P/YPO)D_YYO_WS2>3)
M_P \W_[YK^C[_AD#X,?]$YT/_OP?\:/^&0/@Q_T3K0_^_'_UZ+@>:_\ !-/4
MK.U_8I^'$<UW!%((;LE'D52/]+F[$U]/?VWIW_/_ &O_ '^7_&O+1^R-\'%
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M_P"O.Z_]#2OB^O9R?_<:?S_-GG9A_O,_E^2"BBBO9//(Y?\ 5'Z&OVT\!_\
M(C^'/^P=;?\ HI:_$N7_ %1^AK]M/ ?_ "(_AS_L'6W_ **6OB^)/@I>K_0]
M_)_BJ?+]3S_XZ?\ '_I/_7.3^8KR^O3_ (Y_\?\ I/\ URD_F*\PK\.Q_P#O
M,_E^2-L1_%E_70****\\YQ3T:OJ+2_\ D&67_7%/_0:^76Z-7U%I?_(,LO\
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M?F&,_P"1O_V]']#ZW#_[BO1GY%>E.IOI3J_3$?(!1110!^AO_!-+_DF?BO\
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MR3^0KULK:=2K)*R=OU.O":RFTB#Q/_R+6K?]>DO_ * :*/$__(M:M_UZ2_\
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M^X/Y5WG0CX(_X*/_ !L\#_%3]EOQ'X8\)^([77?$$E[:,FGV@<R,$G4OU '
M!/X5^/G_  KKQ/\ ] *]_P"_9K^G7^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\
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M%--WUOY?Y'G8G T\3/GDVNA^.'_"1Z9_S]I^1I?^$DTS_G[3\C7['?V79?\
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M<7]L?]._Q_X!^MO_  V%\&O^BB:1_P!]/_\ $T\?M?\ P;897Q_I3#V\P_\
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MZ_Y$[5_^O9_Y5^=YW*,\16E%W7_ /HL,G'"I25G9GS;4A@E2-',4@C<X5BI
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M%% !1110 4444 %%%% !1110!X%^W/\ \FT>*/\ KI:_^E$=?E97ZI_MS_\
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MISLEY+_(XIX.A4DYSC=OU/D?_AWYIG_0ZWO_ ( I_P#%T?\ #OS3/^AUO?\
MP!3_ .+KZXHK;^V<?_S\_!?Y$?V?AOY/Q?\ F?(__#OO2_\ H=;W_P  $_\
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M<HVWZ]FU^GXV]>*6&2@YQ=]OR3_7\#P.XM9[1@D\$D#$!@LJ%21V.#7Z6?\
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M;JJLU[RT.Z..Q$,++!QE^[DTVM-U^(4445T'"%<=_P R%_VV_P#;BNQKCO\
MF0O^VW_MQ0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"17\0?[][_ .A/726O_'K#_N#^5<X/^16\0?[][_Z$]=':_P#'K#_N#^5
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MLZ5^T-J6BWFHZY?:0VF121(MI&C!]Q!).[_=KR3_ (=F>&?^AUUG_P !H?\
M"OLZJ=X9DM)6MXEFG5"8T=RH9@#@$X. >!G'YUZ5+,L7AZ:ITYVBNEE_D<<\
M'0K3YI1U9\>_\.S?#/\ T.VL_P#@/#_A1_P[,\,_]#KK/_@-#_A7L_PC\3^+
MM:\;>-K35K2U^QVNIB*39J;SFR;[+"PBB4Q+N4DEB21@L1@XYK?"G4/B5<_$
M36H_%$,L>BJ5V'8@^;RD*!AO*KD<D0[P7+9*]*Y(\1XV7):4O>;6RTMWT_K7
ML>Y4X7I4O:J<H)TXQE\6_,D[*S=WK^71W/(&_P""9GAD@C_A-M9&?^G>'_"O
MKW0]*71-$T_3T<R):6Z6ZNW5@JA0?R%:5%:XC&8C%I*M*]O3]#QJ6'I4+^S5
MKA1117&=(4444 %%%% &7XG_ .1:U;_KTE_] -%'B?\ Y%O5_P#KTE_] -%2
MRHL/#'_(M:3_ ->D7_H K4KG-)DUG3=+L[1M*A=H(4B++=@9VJ!G[OM5O^T=
M8_Z \7_@8/\ XFJ)-BBL?^T=8_Z \7_@8/\ XFC^T=8_Z \7_@8/_B: -BBL
M?^T=8_Z \7_@8/\ XFC^T=8_Z \7_@8/_B: -BBL?^T=8_Z \7_@8/\ XFC^
MT=8_Z \7_@8/_B: -BN2^)_@UO'_ (%U;P^DRVS7R*@E9<A<.K=!_NUJ_P!H
MZQ_T!XO_  ,'_P 31_:.L?\ 0'B_\#!_\343A&I!PEL]#:A6GAZL*U-VE%IK
MU3NC7    Z"EK'_M'6/^@/%_X&#_ .)H_M'6/^@/%_X&#_XFK,38HK'_ +1U
MC_H#Q?\ @8/_ (FC^T=8_P"@/%_X&#_XF@#8HK'_ +1UC_H#Q?\ @8/_ (FC
M^T=8_P"@/%_X&#_XF@#8HK'_ +1UC_H#Q?\ @8/_ (FC^T=8_P"@/%_X&#_X
MF@#8HK'_ +1UC_H#Q?\ @8/_ (FC^T=8_P"@/%_X&#_XF@#8HK'_ +1UC_H#
MQ?\ @8/_ (FC^T=8_P"@/%_X&#_XF@#8HK'_ +1UC_H#Q?\ @8/_ (FC^T=8
M_P"@/%_X&#_XF@#8HK'_ +1UC_H#Q?\ @8/_ (FC^T=8_P"@/%_X&#_XF@#/
M'_(K>(/]^]_]">NCM?\ CUA_W!_*L2#3+MO#VI6\B1Q75T;A@@?<H+EB!G ]
M1VJ6&]UB**-/[(B.U0,_:Q_\30(VZ*Q_[1UC_H#Q?^!@_P#B:/[1UC_H#Q?^
M!@_^)H&;%%8_]HZQ_P! >+_P,'_Q-']HZQ_T!XO_  ,'_P 30!L45C_VCK'_
M $!XO_ P?_$T?VCK'_0'B_\  P?_ !- &Q16/_:.L?\ 0'B_\#!_\31_:.L?
M] >+_P #!_\ $T ;%%8_]HZQ_P! >+_P,'_Q-']HZQ_T!XO_  ,'_P 30!L4
M5C_VCK'_ $!XO_ P?_$T?VCK'_0'B_\  P?_ !- &Q16/_:.L?\ 0'B_\#!_
M\31_:.L?] >+_P #!_\ $T ;%%8_]HZQ_P! >+_P,'_Q-']HZQ_T!XO_  ,'
M_P 30!L45C_VCK'_ $!XO_ P?_$T?VCK'_0'B_\  P?_ !- &Q16/_:.L?\
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M16/_ &CK'_0'B_\  P?_ !-']HZQ_P! >+_P,'_Q- &Q16/_ &CK'_0'B_\
M P?_ !-']HZQ_P! >+_P,'_Q- &Q16/_ &CK'_0'B_\  P?_ !-']HZQ_P!
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MOMM*TZPUK2=9O((X[L6]PTL;P3F-51V5X258*"0QSG%(#WFBOB[X@?%;QX?
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M;VND:QXTU.\^(5QX3T^PFN;>W$,@LEG4*X4!8!@\ON<;F.6X% 'TM17R[?\
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MF&"IQ7I?A_X70:+X_C\8S:I=:AK!\.VOA^5I(XXXY4AFDD\[:B@*[-*<@84
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M3.>5P#T%%%,DV/#_ , / ?@.6ZO?!WA?2/".MS6TEK%JFF6$2S0[AU&5(."
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mtva-20251231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 C(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "L_5-5L]#T^YO]0NX+&RMHVEFN;F01
MQQHHR69B<  =2:T*^?\ ]M7]GC5OVFO@9J7@_1/$$^A:F)4NX5WE;:]=,D07
M  R8R><CHP4X.,4 >9^#_P#@J3\&->U_QA'J^M-H&@:1>PV6FZI-:W$W]IDJ
MY>0+'&WEIE/E#'+#)P.@ZH_\%-/V;<?\E(B_\%=[_P#&:^&[WP]XG\12Z]H>
ME?""YU:Q\)26@\4Q:C>Z?HW]G7$+3SI%"'#AH,, CG>3'E=QW!@R#X-_&"YT
M\FW^!^F^?+IT%L#-X@TAD79"\>TQM'GRB7$I0G=YJ@ER!MJ7)1UDRXPE/X5<
M^PM=_P""EOPPU;7;7PYX!UVPUS6;UXX(+G4DN;:T,LA"HBXB9W;)'&%7GEQ4
MNK>(_BAXBFF75?'D^E(V5:R\.V,-K&G8@22+++GW#CVQ7RX?A)\5M5U[2A-\
M$M)\-V7_  D^FZQ=:I'K^FW$T44#P>8Q"X8L1"Q_=[1ARNT]_KG4'6>^N'0Y
M5Y&8?3-?,9MF?U915*2=^UCZK)L%"LY>VIWMWN<D_A[6);B.=_&_C)ITZ,/$
M-TJ_B@<*?Q%7+2]\?Z&H_LKXE:\H!)\K4H[:^0]."98B^..@<>V*VB@ Z@T%
M 1Q7SL,\KWW/J)9;A9:.FON0_2?VF/B!X.G6/Q=X:LO%FE<#^T?#F;>[7W:W
ME<JQ[_+(OL.U>[?#OXP^$_BG;3R>&=9AO[BU*B[L&#17=H2.!+ X#QY[;@ >
MH)%?/.JHBZ=.6&<KM4>Y/'^?:O /%NGWMQ^UM\*K;1=0O- N[KP[J1U2^TN7
MR+B>S7S2(F<<XW1X!ZKNRI! (^MP&8O$P<IK8^8S'*J5*SHZ7Z'Z?#D4M?"2
M_"W3+=Q+;7VNVMQS_I-OKMY',<]2764'GOS6K;VOBG3(O*L/B-XMM8L ;)=0
M6ZZ# ^:='8?G71',Z$G8Y99#B4KII_?_ )'VQ5>ZNX+*$RW$T<$8ZO*P4#\3
M7Q7>V'B75D*ZC\0O&%VA4H5BU1K0$'K_ *@1_GU]ZQIOA5X;O)/,U'3SKDW>
M;69I+YR<YR6F9C6OUZET"&15W\4DOO\ ^ ?8K?%WP,K,C>,_#RNIP5;5( 0?
M^^ZV-&\4Z/XCB$FE:M8ZG&02'L[A)5P#@\J3WXKXFN_AMX:FA^30]-1U&%Q:
M1C\.E<G>?##PH;@SGP_86]TASYT$ BD4@]F7!%:PQ,9[(J>22BM*GX?\$_1V
MBO(/V6;J^O\ X$^&)[^ZN+Z1EG$%Q=2&21[87$H@)8DEOW0CY/)&,UZY78M3
MYN<>23CV'T444$A1110 4444 %%9>K:W::+%&]Y<+#YC;(T +/(WHJC)8XYP
M >E<AJGBW4]:>2/3&;2[$$J+F6'-Q)[JCC"#T+ D^@XSG*<8+4:5ST(#%5KV
M^M]/@::YGBMH5ZR3.$4?B>*\K?1;.[<FZ\V_G3@RW<SRN#UR"3\OX8'IBIXM
M)MX;B.=C-<S1_P"J:[N))_*_W-[-M_#%<[Q*[%<IW]OXJT>]W_9]6L9_+4NW
MEW*-M4=2<'@>]-A\7:'<2K'%K-A+*QP$2Y0DGV&:\\OC;W>I6MO+!%<R+F7,
MB!O+ & PST.<5/=2VLL31W48>/\ B26(LI_0@U/UC^Z7[,]+AU&TNI#'#=PR
M2#JB2 D?@#5NO%-+M='UB.<+8VKI#*44&!00.W;BK_VK5--EAL[;7]0@MY=W
ME(_DR[".=NZ2-F(QGJ3CZ8 M8E=4)TVG8]<HKSG2OB#>Z?/]GUF*.6-?O7EN
MI5D!Z,\?.5Z993QW50"1W\,T=U"DD;K)&X#*RG((]0:Z(SC/8B47'<GHHHJR
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M$+?]M'X*W,*2P^/[":)QN62."=E8>H(CP1[U+_PV;\&/^A[L_P#P&N/_ (W6
M=^R"?^,6/A-S_P RS8?^B$KUXD^M 'F7_#9GP8_Z'JT_\!KC_P"-T?\ #9GP
M8_Z'JT_\!KC_ .-UZ:6)[T$D]Z /,O\ ALSX,?\ 0]6G_@-<?_&Z/^&S?@Q_
MT/=G_P" UQ_\;KTTDD=302<=: /,O^&S?@Q_T/=G_P" UQ_\;H_X;,^#'_0]
M6G_@-<?_ !NNN^(/BZ/P!X"\2>)YX'O(=$TRYU)[>-MK2K#$TA4$]"0N,^]4
M?%/Q*TKP;9Z/>ZO<PV%A?"1I+BXEVB%$MWG9L '< L9)Z8 )Z"@#G_\ AL[X
M+_\ 0]V?_@-<?_&Z/^&S?@Q_T/=G_P" UQ_\;K:\1?&+P?X5N[FUU/78H;JU
ME:*>"..25XBL4<SEE120J1S1.SGY4$B%B-PK0T/XB^'?$_B'4=$TG58]0U+3
ME1KN.!79(=Z(Z@R ;,E)(V"@YPX.,'- '*_\-F_!C_H>[/\ \!KC_P"-T?\
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MH/4J*]0R#R*].G-5(W.1JPZBBBMA!1110 4444 %%%% !1110 4444 %%%%
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M]Z.W&*&( R< #UK,]"PI&!4%U=);)DG+'HHZFL9/$EQX@UQ] \):7<^*M?0
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M#[XL>--.71[3X:2^&M,TOX?:IX=FL]0M=)*K=O8&&*+3KJ.1IS'+*%+;O+7
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MJ12%MK^;1[ENRQ72 JQ_[;00J/\ KI6%;3*\8.3]*]F^.'@N3XB?"CQ)HEL
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M+PM3G6W4^4/$'B5-'BMHT@FU#4;V5;:QT^U7=-=3-]U$'YDDX  )) !->K^
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MB6;;N)&3QGWKE>(=KZ%<J,_P65TJWS--]JU"X;SKR\88>XF/WG/MV Z*  ,
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M>0@' !  1!DX10 ,GN23W'3FEHKL44E9'"VY.["BBBJ$%%%% !1110 4444
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M^)(/"=UKR:DCSB\ELX[B-Q:B,$H?,"L0PQD$!AG;Q_C/]M/Q!?\ PTGOM/\
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MW'C^"*V\726Y:^BC55*G>VS>J$JLGE["X4E0Y8+QB@#MR<UY9\"^?C+\>?\
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M;?"OB2Q\9^%]'\0:9(TNFZM9PWUJ[J59HI45T)'8[6'% &L/\YI&X%)2XR*
M CBO,_V2/^24:A_V-?B/_P!/%W7I=>:?LD?\DHU#_L:_$?\ Z>+N@#VFBBB@
M HHHH *\)\#C/[3'QH_Z]= _]$7%>[5X+X*<Q?M(?&MU1IF6ST$B-,;F(M[C
M@9(&3[D4 >H6&D6VG76HW$"L);^<7,Y))RXBCB!'H-L2#'M[UYI%^RK\)H+[
M4KN/P/IRSZDEU'=D&3$RW"NLX9=V/G$CYX_B-6_A5XN\=^(/$7BNT\7:#I^G
MV5K>[=/ETZZ\UH(S##(+>X!QF7$H;?'E"=Z\;5:2CX>_:1\.^)/CYKWPJ@M;
MN/4]*MFE74Y !:74T:0//;Q-GF2)+F!F';?[&@"+P?\ LO>!O"WC_6O&4NEV
M^K:_?:PVKVMU=0\V!-M%;K'&,X(58F*L1E?-?&,G.GI?[-/PNT6TU:UL? ^D
MVMOJHC6[BCA(5UCE$R(HS\B"4!PBX7=SBN.UG]L[P%%X@O\ 2O#][;>*38Z1
M)JLUW97\$=N@2\@M3&9)&5<EIP0V=IV, 2>*]!T[X\_#O5_%UQX7L_&>CS^(
M;9[B.73Q=*)$>#/GH0?XDP2R]0!G&.: .=\/?LV>'K?7_B7K'B<P>+[SQY+
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M.*^$/Q-TOXQ?#?0?%^D$?8]4MEE,6<M#(/EDB;W1PRGZ5V@Q7RUX 7_AF_\
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MXEMEU$ZE_;7B+4=?W&#RO)^U3&7RL;CG;G&[C/7 K%^!7/QD^//_ &'M._\
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M[']K;^T)O"$\7AM&TO6ETA+EXKJ>::QEOXXV1&\NV:$;?-CXDEC=P=RKRNX
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M*5_+CD9@"(U9_D!<J"P*CD$50N?VIOA1:VU]._C6P\NQNS83E$E<K<#S-T8
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MQ0 8S7CW[7O_ ";GXQ_W+;_TJAKV$\UX[^UX,?LY^,?]RV_]*H: /H"BBB@
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MV3SYJKYH.!\LJC&02>TXQ532-)L]!TJRTS3K>.TL+*!+:WMHAA(HT4*J*.P
M 'X5;(':@ [UY5X+'_&7?CW_ +$S0_\ TLU.O5CU%>4^"_\ D[OQY_V)FA_^
MEFIT >Y4444 %%%%( HK+N];@@N4M@X,S'&/2K,]XL,9)8$BL76@B^26FFY;
MHKE+_7W#$*_'L:R9_%$T)!29@1T!-<_UN*>QW0P-6:NCN+FW69!N[5@:O9I$
MA./I6,GCF<KAG1OJ*@OO$YO$P6'T%<=6K&;ND=E#!5Z<E?8Q];*_,":XK4G4
M9 /.:WM:U56)!(.<UR-Q<":7@]^]<;?4^RPU.22N6+< KUKM/ <ABU^UY'+
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M?^E4->Q8XKQW]KPY_9S\8_[EM_Z50T ?0%%%% !1110 4444 %%%% !1110
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M?A:B^'$ZW/[1GQGF4$+)#H+@'J,VDAKT?P/X9'A*"SL=W[V6"669!T!R@ _
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M_O\ S_\ QRC_ (8S^#'_ $(5C_W_ )__ (Y7M5% 'BO_  QG\&/^A"L?^_\
M/_\ '*/^&,_@Q_T(5C_W_G_^.5[510!XK_PQG\&/^A"L?^_\_P#\<H_X8S^#
M'_0A6/\ W_G_ /CE>U44 >*_\,9_!C_H0K'_ +_S_P#QRC_AC/X,?]"%8_\
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mtva-20251231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $E [X# 2(  A$! Q$!_\0
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MSK.E:S8ZA-)'K>HV%I?16T:VS^0=RP*=P8OL_B*[201NR"*K^T,3_/\ @O\
M(7U6C_*?,/\ PZ=TC_HHM]_X*8__ ([1_P .G=(_Z*+??^"F/_X[7U+#^T1H
M=U:![?1]8N[W[9-8M86BV\\BR16XN&RZ3&+'E$-D.>?E.&XJU=?'G18D:XMM
M*UK4M.B^S+<ZA:6BF&VDG"M'&X9PY;;(C-M5@H8;B,T?VAB?Y_P7^0?5:/\
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M]=L[]8EO-+OWMBT*E5>/ :-N2>=K#/N*/[0Q/\_X+_(/JM'^4^+/^'3ND?\
M11;[_P %,?\ \=H_X=.Z1_T46^_\%,?_ ,=K[ZHH_M#$_P _X+_(/JM'^4^!
M?^'3ND?]%%OO_!3'_P#':/\ AT[I'_11;[_P4Q__ !VOOJBC^T,3_/\ @O\
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MND?]%%OO_!3'_P#':^^J*/[0Q/\ /^"_R#ZK1_E/@7_AT[I'_11;[_P4Q_\
MQVC_ (=.Z1_T46^_\%,?_P =K[ZHH_M#$_S_ (+_ "#ZK1_E/@7_ (=.Z1_T
M46^_\%,?_P =H_X=.Z1_T46^_P#!3'_\=K[ZHH_M#$_S_@O\@^JT?Y3X%_X=
M.Z1_T46^_P#!3'_\=H_X=.Z1_P!%%OO_  4Q_P#QVOOJBC^T,3_/^"_R#ZK1
M_E/@7_AT[I'_ $46^_\ !3'_ /':/^'3ND?]%%OO_!3'_P#':^^J*/[0Q/\
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M]H8G^?\ !?Y&7U6C_*?,7_#IW2/^BBWW_@IC_P#CM'_#IW2/^BBWW_@IC_\
MCM?6MQ\:["UU".UDT#7=IO(=.EN$@A>*"[D4,('82GYAN4%ER@) W9J*Z^,U
MCJ_@76]8T".=KBU\.G7(FNH/W<>Z)VCCD ;.\&-@RCIM(S1_:&)_G_!?Y!]5
MH_RGR?\ \.G=(_Z*+??^"F/_ ..T?\.G=(_Z*+??^"F/_P".U]'Z#\:X/#7A
M5]=\2:Y>Z[8R2PP":W\-3Z>()77Y$VR'<^]BJ*5!&XJ">:Z<?&W2UU>ZLY]'
MUFTMK.]CTZ[U*>"-;6WN'ACE5&;S"QXE4%E4J&R"1QD_M#$_S_@O\@^JT?Y3
MY)_X=.Z1_P!%%OO_  4Q_P#QVC_AT[I'_11;[_P4Q_\ QVOIVR_:=\(ZA;W,
MUO%?3A$CEMTMQ#,]U&\HB5T5)6*?,R964(P# E<9Q<U3XWVLFB2?V9H^L2ZT
MT%Z[Z>L$1FLOLS>7(\N9-FT2%0-C,7S\H8 X/[0Q/\_X+_(/JM'^4^5O^'3N
MD?\ 11;[_P %,?\ \=H_X=.Z1_T46^_\%,?_ ,=KZ+T7XW:M'%H:RZ?/KK7=
M];V=X\$$5O\ 8P^G"Z))>8>823GY5&!N7&0"W3W_ ,>?#]CI\-V+35+D3V=K
M>Q0V]L'D=;BY%M&H&[[WF$9'0#G-']H8G^?\%_D'U6C_ "GR;_PZ=TC_ **+
M??\ @IC_ /CM'_#IW2/^BBWW_@IC_P#CM?66F?'KPWJ?C6'PQB>WU"6=K-6E
MDMRHNEC,C0%5E:3<%5_FV;"5(#DXSC:7\6]1M/%GB"VU#3-9OIGU,Z?I.C6<
M5H3(D<0>256\T8&#EFE=1RH49."?VAB?Y_P7^0?5:/\ *?,W_#IW2/\ HHM]
M_P""F/\ ^.T?\.G=(_Z*+??^"F/_ ..U]@^&?BYI?B_6[32],L-3EEFM/MDT
MTENL<=HN]XRLI9@0X>-EVJ&.>>G-<_9:IX[NO&'BC2++Q!I5Y#96T9CGN]),
M<=K/(^55BDV9-L0)(^7)QR 31_:&)_G_  7^0?5:/\I\O?\ #IW2/^BBWW_@
MIC_^.T?\.G=(_P"BBWW_ (*8_P#X[7TU!\3M<L_@MXM\4R7%EJ<VDI=O8:G#
M:/'!?Q1+E91%N)(SN7*L0^W<O#"I3^T#I+>)+R*%;R;3+?3UE\EM+N;>YFN'
MG6...,3*@;<6QQP#R2!1_:&)_G_!?Y!]5H_RGS!_PZ=TC_HHM]_X*8__ ([1
M_P .G=(_Z*+??^"F/_X[7U_I7Q@TK4;]=.GL-2TS51<2VTUA=Q)YD#I")OF*
M.R%60@JR,P.<<$'&-+^T5X?2SN+N/3-8FM;>QLKZ6<0Q)&BW2[H4+/*H#$9S
MSM7'S, 02?VAB?Y_P7^0?5:/\I\L_P##IW2/^BBWW_@IC_\ CM'_  Z=TC_H
MHM]_X*8__CM?4_C;XFZI!8*^C0QV6?#]UK4S7BJ\L.T*L2C:S(3N8DG+#"'&
M<YJ?2/C=8:CX?T6[M-*U?6+G5&9+**S@C5KY8XU:6XBWR*ODC=@.Q7=QM!#*
M2?VAB?Y_P7^0?5:/\I\H_P##IW2/^BBWW_@IC_\ CM'_  Z=TC_HHM]_X*8_
M_CM?4WC_ .-,'A]]0T:&UN]/UMM/FN;*>X$#(SI"92IC$AD& &^9D"$J0&)Q
MG#\9?&>_\/QZ?>M=06FC6=QI<&IWCP[C)+<'?)&O88CV=!G=*H&,<G]H8G^?
M\%_D'U6C_*?.O_#IW2/^BBWW_@IC_P#CM'_#IW2/^BBWW_@IC_\ CM?6.L?'
M'3]&MKB:3P[XAF2RM([S41#:1EM/5^4653(&WD<E4#%1RVT5C^*_BQK&F^.]
M(M["RGOM';5GTM[6RMU:XNY%L+B=PK2,JJ%=(^<@?*V3SBC^T,3_ #_@O\@^
MJT?Y3YF_X=.Z1_T46^_\%,?_ ,=H_P"'3ND?]%%OO_!3'_\ ':^IIOC:GB32
M=57PGIE[<:G::3_:@>^M@ELAVLRPR'>&WL49"%!VGD\8SZ-H>K0Z_HUAJ=ON
M^SWMO'<1[A@[74,,_@:/[0Q/\_X+_(/JM'^4^$_^'3ND?]%%OO\ P4Q__':/
M^'3ND?\ 11;[_P %,?\ \=K[ZHH_M#$_S_@O\@^JT?Y3X%_X=.Z1_P!%%OO_
M  4Q_P#QVC_AT[I'_11;[_P4Q_\ QVOOJBC^T,3_ #_@O\@^JT?Y3X%_X=.Z
M1_T46^_\%,?_ ,=H_P"'3ND?]%%OO_!3'_\ ':^^J*/[0Q/\_P""_P @^JT?
MY3X%_P"'3ND?]%%OO_!3'_\ ':/^'3ND?]%%OO\ P4Q__':^^J*/[0Q/\_X+
M_(/JM'^4^!?^'3ND?]%%OO\ P4Q__':/^'3ND?\ 11;[_P %,?\ \=K[ZHH_
MM#$_S_@O\@^JT?Y3X%_X=.Z1_P!%%OO_  4Q_P#QVC_AT[I'_11;[_P4Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5RWC?P!;^-I-*G;4]2TB]TR9YK:[TN=8I%+QM&
MP.Y6!!5CP1Z&NIHH X^W^%^EQJ[7-S?:A<R7%I<RW-S/F262V8-$6V@#JHR
M!FLS3/@9X<TF&YMX6OOL<D\$T-J;C$=MY4ZSHD8 &%\Q >23CC('%>AT4 >)
M^)_AGKFK?$R*XL[*XL=&_M.WU:>>+6,VT[Q*.3:E PE8JJ\-LP Q^88K?^'_
M ,,?(\'^*;76K3[!+XIN;N>ZLH+C>;6&;*B%9!QD*2WR\!G;&17IM% 'G#_!
M#3=3TW^SM>UK7/$U@.5MM5O%9%.PJ#\D:9(SD$YP0".165X7^!Z0^(M>O=9O
M=0N;*35X[RVL6OB]O<K'9VT*2SICF0-$^0" >"0>,>N44 >=Z;\"_#FF02V\
M<E^]KOA,%N]S\ELD4GF)&@ 'RAL<MN;  W8 %2^(/@MHFO"5TO-5TJZE>Z\R
MZTV],,KQW#!IHB<'Y"P4@8RI&5(YSW]% '!0?!?0+.VAAM9+^W,5W;WBRI=$
MOOBMA; $L#E6B&U@1SDG@\U5TSX#^'-,E:03:G<D"W2(7%XSB&."Y^TQ1H,<
M*)/J2."3QCT>B@#CK#X6:-IOC*7Q';M=13R2/.;19L6_G.NUY=H&2Q&>"Q7D
MD*#S4>N?";2-9D:YCN-0TS4OMC7T6HV%SY<\,C($<*2"-K*,%2".AZ@$=K10
M!R_A3X<Z-X,N//TR.=)#:K:,TL[2%U#NY9BW)<M(Y+'J35#6_A)I&M^%/$&@
MO<ZC;0:[<-<WUS;76R>0L5)7?@_(54(5((*Y4\$UV]% ')I\.[6;P1?>%]1U
M+4M7L;R)X))KN9!,(V&-JLB*% '3 XI_BCX<:/XON)I]06X,TEL+99(9VC:+
M;()$="/NNKJI#>W<5U-% 'G3? _17L]K:AK#:F]VUY-K'VXB\G=H_*8,X&-O
ME@)M50 !Q@\U<T_X0Z/HND7=AI5SJ.F"XM;2T,]O='S$CMX_+B + C[O!R"&
M[BNYHH \W_X4Y9V1TFPT^3R]"ATBXT6[@D=O.DAD*NK*XZ,'4]@,.<8P!4K_
M  0T**VCBL+S5M):WN7NK.6QO2CV9= LJ19!"QOC<R8*[B2 #C'H=% 'F-Q^
MSYX9NM=N=3EGU-VN&FD>W-W^[,LL/DRR$[=S,R?WF(!Y4"MF;X0^&[G0(]&F
MM9)K%;Y=19'E),DH.1O/<=L>@ [5VM% '@7CWX,ZO<7/]D>'X-0%A?64=C/J
MAU\HI120#<Q%-\AC7A"C9?A7(49KU6V^'.C6AT8QQS!M*NY[Z!O-)+331R1R
M,_\ >RLS]>G'I7444 >>2_"6WT+PQX@L_"\IL]3U.Q-DEQ>S-(D6=X#X ZKY
MC''<@#BNWT;2H-#TBRTVU!6VLX$MX@3DA$4*OZ 5<HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (KFUAO8'AN(8YX7&&CE4,K?4&JKZ!IDFK0ZJ^G6
MC:G#&88[TP(9DC/5 ^-P7D\ XJ_10!Y'^U6,_ [7O^NEK_Z4Q5ZTGW%^E>2_
MM5_\D.U[_KI:_P#I3%7K2?<7Z4 4M8UW3_#]J+G4KR&R@+!!),X4$GM]:Y^Z
M^*OAU41;+4(=5NY)$BBM+.13)(S,  -Q []S6[KWAS3?$]HMKJEG%>P*XD5)
M1T;!&1CV)KG9/A#X778]GIXTVZC=9(KJT<K+&P((*DY';N#772^KV_>WOY6M
M_F;0]G;WKW)8?BCHD,]Q;:K.-#O8'VO:W\B!^@((VLP(Y]:K^(_BYX?T3PIJ
MVNVU_:ZC!IJ++.D=RJ!$+A2S,>% SDD\<4\?"3P]<SS7&I6\FLW<K;FN;]]S
M], ?*%&./2FZE\(O#MUH.HZ996::6M\J++-;C+X5U<#YLCJM54^K<ON7O^'^
M82]E;W;W_ Y'7_VD]$MK]K?1+OP_J=N+N.T_M.ZU^*WL0S0/*09E20!ALQMQ
MDY[5VFN^.KC3++0HK+3HM6UK60/LUM!=@6W"!WD,Y3_5*"/F"$G*X7GA)/AG
M9/XU7Q&+F5)EF6;[.J((\B%XL=,]')^HI/$/PRL-1G34-(D_X1[7(KAKM-0L
MX48O(R[&$J,,2*RX!!P> 001FN(Q'VOQ'L;&33M/\2M;>'M>O&*+I[70G!.[
M:K+(H VL<;2P4DD# /%9=Q\?O <-K]HC\007L0O$L2UDCSXE9R@'RJ<C<K*6
M&0"""<BJUQ\'+G4+A)K_ ,4WUXURL2ZH&MX5^V".7S(U7 _= 'CY<G;WS\U1
MCX&VUO:Z>MIK-Y;W%A"D4$WE1L,K<>=N9< ')R"..#ZT ;5O\:/!%W!:S0>)
M;":&ZN'MH94D)1W0A7P<8P&(4M]T'C.>*V/!'B1_%GA]=1D@6V8W5U;^6K%A
MB*XDB!S@=1'GVS7%R_ NWBTW3;&QUN[LX(;$Z9>8AB<W=L7W[>1\C9S\R]B>
M.A'<^$?#,/A#0TTRWEDGB2>>8/+C=F69Y2..P+D#V H U;BXBM86EF=8XU&2
MS' %9<WBW28HG<7L+E1G:C9)^E:5U:PWL#PSQB6)A@JW0UE2>#='D1E^Q(N1
MC<I((_6MJ?LO^7E_D<=?ZS?]QRV\[_H5]-\>:9J#2!W:TV@$&X(&[Z8)I=<\
M;Z=I6AZE?PSPWCV=M)<^0LH4N$4L1G''3K19^ ])M"Q,3W&[M,V<?3&*74_
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M0<^H)4^EZ'I$'A_1K'3+4N;:S@2WC,C;F*JH49/<X% %ZBBB@ HHHH ****
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M_B32OC[<:K\=QX %BD7DQ@W#":!B'$!DD 'F[^"\0^YV;UH ]LHHHH ****
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M#& 9"![ 5MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]\+WFNZC'/-:6P!9+=0SG)QP"0._K7P=XPO;/XEW/COQY&UQ9W%O>VKVEO\
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M3Q70T5?M9\_M.OHORV'SN_-U(X$>."-)'\V15 9]NW<<<G':I***Q("BBB@
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M% !1110 4444 %%%% !1110 5\_?$?6;SQKXHLQIG@.36FL;D6O]IWEA!/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\8_:]_Y(;J?_ &$=+_\
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MN[N=92XELY@NS@^8=I !'W<<^M;UM^V_:7VH/;+X<^PV[[Q'>7%WN"?*2A9
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MHHK$ZPHHHH **** "D90P((!!X(-+10!7L-/MM*LH+.S@CM;2!!'%!$H5(U
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M)C*&*4:;YXVZM)_?:YHW>JPKXACA.KF&/8=\(*8#@J O*YY!/?M71,P1220
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M&OQDL_'N@?$W4M(DDU^RU6[L+BUMY$@CMXV11;L8F;< S85CL^=B1G%?65%
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MLBOG:P;!(.#GD<&@#R7]JO\ Y(=KW_72U_\ 2F*O6D^XOTKR7]JO_DAVO?\
M72U_]*8J]:3[B_2@!U%%% !1110 4444 <M%\/;&+Q<?$7V_5GOCD>4^H2&
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M^->*45T?V;'^8XO]8:G_ #[7WGM?]MZ=_P _]K_W^7_&C^V]._Y_[7_O\O\
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MO]KTFDX_\#T/'K\/U(2E5PU2SW7^5S)\1Z[)XGGB>6VC7RD("J-W'4GFO0?
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MIY$FI3%3[+G']*]DU34H-+LY)YY4C"@[=YQDXX KQGP/NTN^LGMU^SR3N&E
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M#I,FE&ZM_P"U&U"69)TB\^+:8 BE6?/9R!7NT?W%^E>2_M5_\D.U[_KI:_\
MI3%7K2?<7Z4 .HHHH **** "BBB@ HHHH *Y27X=6$OC#_A)3?:LNH8"[$U"
M40;!CY/+SMVY&2.F>:ZNBKC.4+\KM<PJT*5>RJ1O9W7D^Y\Z_M@_#R/6O"]K
MKVFZ/-=ZY;S+&]Q91,TGD88G?M'*C Y/2O._@--\8_"GA:[/ASPM#?Z9-<>:
M5U<&*0G8O,>Z1,KC'(!&<U]9^-%OI?"VIPZ;9?;[R:!XHX#,L0)8%<[FX&,Y
MJI\.TU2#PG8VNKZ;_9=W:HL'E"X6<,JJ 'W+QSSQ[5[%/'2AA/92BI*_7_*]
MSX3%\.TZ^=_7:=6=-N.\%;7;XFFKM;IZGQAJ?QY^(%M\6([C5KY-(N[69K*6
MU6*,I;PO)&9(\D'(S&O))/'6OO&&>.Y@2:*19(G4,KJ<A@>A!KQ/XA>"_#WB
M/XF)9WWA"\GL[K3;BUN=1M-()3[1+) T<GG*OWE59/GS\O()Y-<OX+\3:I\+
MM3O?A9XMU"ZM;>:-CH.N0/L8J?NH&(.#V'H<CN*WQ,:>,IP=*/+)+;NNZ]-[
M=F>;E-7$Y%BJ\,;5=6G4E92;>DDM$[Z+FO9-:75M-#Z7!!Z<TM<3\'X+K_A!
M["[O-5O]5N;Q!.\E_*)"IZ87 &!QTKM"Z@X) /UKP9PY)N-[V/TO#5OK%&%:
MUN9)V]1U%4]6U>RT'3IK_4;J&RLH1NDN)W"(@SC))Z<D52\.>,M#\7QS2:)J
MUGJJ0D+(UG,L@0GH#CI4\LFN9+0MUJ4:BI.2YGLKZ_<:4MC;SOOD@BD?IN9
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MXK_\E*\3?]A";_T,U^FS_=-?F3\5_P#DI7B;_L(3?^AFOJ<@_B3]#\9\3/\
M=,/_ (G^1RE%%%?:'\^A1110 4444 >V_L??\EFL_P#KUG_] K[VKX)_8^_Y
M+-9_]>L__H%?>U?!9Y_O2]%^I_3'AU_R)I?XY?E$****^?/U \^^)W_'Q8_[
MK?S%<17;_$[_ (^+'_=;^8KB*^HP?\")^99O_OM3Y?D@HHHKM/'"BBB@ HHH
MH ]SM?\ CVA_W!_*I:BM?^/:'_<'\JEKXM[G[''X4%%%%(H0\"OGSXGV^@^/
MM1F\07,NJ6<WAVPGO$M8(8C#<B"8Y6X!.+A"R@K$^%4_.,, 1]"5X;\2]"\
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M^-O#\.EDZG#(_G/,&V$#:._'%>M'$4L2^2<=7^9\I5P.)RY>VHU+QCT\OR_
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M+;WE4%<$]/F^O%?2-/&TZE*O*-7<CA[%X;&9=3J83X-5M;5;Z',?$;_D6?\
MM]LO_2J*NF%<S\1O^19_[?;+_P!*HJZ85S/^&O5_H?2OX4+11161(4444 %8
M7B_Q8OA#3ENVTS4=5+,1Y.FP"1U 4LS,69550 >2PSP!DD [M<3\5?#GB'Q5
MHMMIVB3V$=M)-_Q,(;UY8_M$&#^[5X\E<MC=QRN0,9S0!'IWQBT/5=>M-.MX
MKUH+EX[=-2:$+;?:7A\Y;<DMN#F/YON[<X7=N(%<E^UY_P D-U/_ +".E_\
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M$RBI*TE=#;>UAM(1%!$D40Z(BX _"I ,4M%#=]6-))604444AA1110 4444
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MA_Z(:O6HO]6OT'\J\E_:Z_Y-=^*W_8LZA_Z(:O6HO]6OT'\J 'T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6+XUTVXUGP?KFGVHS=75C/!$"<9=HV Y^IK:HH
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M,!:,,1Y18*&4<XW'K1^[\P]T[W_A-O#W_0<TW_P,B_\ BJ/^$V\/?]!S3?\
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MC,&,?]G:(F2.ARM@#71AZBI5HU);)W-*<E":D^AX1FC->H_\,17'_19/&_\
MX"Z3_P#(5'_#$5Q_T63QO_X"Z3_\A5]9_;6'_EE^'^9Z_P!=I]G_ %\SR[-&
M:]1_X8BN/^BR>-__  %TG_Y"H_X8BN/^BR>-_P#P%TG_ .0J/[:P_P#++\/\
MP^NT^S_KYGEV:,UZC_PQ%<?]%D\;_P#@+I/_ ,A4?\,17'_19/&__@+I/_R%
M1_;6'_EE^'^8?7:?9_U\SR[-?4/[.Q_XM[_V^2_R6O+_ /AB*X_Z+)XW_P#
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M4E7'#J2"0PZC!H ^<IM2_:HCT^^G2^\'23P7&F116_\ PB5P#.EP\2W,@/\
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MSMN/"JB*[DGLN.I (!\^0:Q^U9+I*73W'A"*Y/AMM8-I_P (G.2+X XT[/\
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M.US]GO(4GCW#!VLH(R/H:Q_B'X]TWX<>''U;4IH(U,L<$*3W"0"65V"JF]R
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MY4(Q/M%/\=?%-MIB74OAO3[?['8W>I7YGU#EX+=D!$(C\P;G#'&]OE*C/!R
M#V77-$L_$%BMK?(7@6>"Y 5ROSQ2K+&<CT=%..^,5B:/\.[+1?%FHZ_;:CJI
MGU!_,GMI;UI+=FVA1A#T  X .!DX'->::CXLUOQ#HP@UW5[;38?^$N736FT.
M\ELW%L-Q"22;@RL<+G!&:QK_ ..TWPSTC5Q;WW_"6Z3IMW(T%Y=S[Y9+6-$:
M9!/PDAC9MH=B3DX.X@T ?1]%<5X2\>W7B3Q-J>CO81P2:6TD=ZZREMC^8?)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>mtva-20251231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %& _ # 2(  A$! Q$!_\0
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M!O\ D[?QO_NV'_I#!7H8+#QQ-1PD[:7_ ".7$571AS(_1S_AMWX'?]%"T_\
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M /?B?_XW7Y"Z7X0&J^ IM4M]/U&;43K-OIL-RDD0M/WD4C>4RGY_-)0$$?*
M&SSBM'Q7\!_'O@?0[G6-;\-W%CI]K(L5Q(9(W: L<(9$5BR*Q^ZS *V1@G(R
M_P"S,.G9S?X"^MU;7Y?S/UI_X;=^!W_10M/_ ._$_P#\;H_X;=^!W_10M/\
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M'MD"@L%93NQ@'-1VOP)M=:U?P=:VFJ-IMEJ'A4^)M9U"^ D2RB26=9F1% +
M+$NU.26;&>>#^S\.MY-?=_D'UJKT2/U$_P"&W?@=_P!%"T__ +\3_P#QNC_A
MMWX'?]%"T_\ [\3_ /QNOR^T_P /_!CQ=J$7A_2-0\7:%JMS(MO::UK+VTUC
M)*2 /-AC17B1CQN\Q]N<D'&*XSPS\/WF^+VE>"]?6:S=]9BTJ^$# 21YF$;[
M201D<X)!'M366T'>[:^[_(7UNIV1^NG_  V[\#O^BA:?_P!^)_\ XW1_PV[\
M#O\ HH6G_P#?B?\ ^-U^6GQ&^!3>'/CI:^"-"NI+_2]8GMWT:_F*EIK6<C8[
M$  E?F5L #*-P*Z7XI? OPKX1\0>,+?P\OB+7M(TWPW8:W97XGM@(C<"(F2X
M!52T1\S 6,;@2N20#4_V?AM/>>NO3_(KZU5UT6A^DW_#;OP._P"BA:?_ -^)
M_P#XW1_PV[\#O^BA:?\ ]^)__C=?DI'\#/'4GA1/$?\ PCTZ:2]L;V-Y)8TE
MDMQSYRPEA(R8YW!2".<XI)?@;XZ@\+?\)%)X=N%TO[*+W<9(_.%N<8F,.[S!
M&<@[]N,$'.*O^S<-_._O1/UNK_+^9^MG_#;OP._Z*%I__?B?_P"-T?\ #;OP
M._Z*%I__ 'XG_P#C=?BS16G]DT?YG^'^1'UZIV1^TW_#;OP._P"BA:?_ -^)
M_P#XW1_PV[\#O^BA:?\ ]^)__C=?BS11_9-'^9_A_D'UZIV1^TW_  V[\#O^
MBA:?_P!^)_\ XW1_PV[\#O\ HH6G_P#?B?\ ^-U^+-%']DT?YG^'^0?7JG9'
M[3?\-N_ [_HH6G_]^)__ (W1_P -N_ [_HH6G_\ ?B?_ .-U^+-%']DT?YG^
M'^0?7JG9'[S_  U^,'@[XP6%Y>^#M=@UVULY1#/) CJ(W(R =RCM78U\+?\
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M>)(S&PX."&!Z9KO_ +,H<W+=_A_D<WUNI:]D?K)_PV[\#O\ HH6G_P#?B?\
M^-T?\-N_ [_HH6G_ /?B?_XW7X[WG@37M/O?$%I<:<\=SH )U.,NI^S 2K$<
MX//SNJ_+GKZ5U4?[./Q*FTY;V+PC?30ND<L:Q%'EECDV;7CC#%W3YU!900IR
M"00<-Y9AUO-_>A+%U7M'\S]7O^&W?@=_T4+3_P#OQ/\ _&Z/^&W?@=_T4+3_
M /OQ/_\ &Z_(_7_@KXT\,ZUHFE:CH;Q7NM2B#3Q'/%+'<2;PFQ9$<IN#$ @G
M(SSBL?2/"&I7QO+DV;/8Z;<PV]_(' \DR.44'G)R58<9Z4++,.U=3?X!]<J[
M<I^Q'_#;OP._Z*%I_P#WXG_^-T?\-N_ [_HH6G_]^)__ (W7Y@_$+]G_ %6[
M^+OC/1/ ^CF71]&O%MP;B\CB6/<H*J9)G7<QYP,DU7\,?LQ>*O$'@SQSK4ZI
MI=]X7FBMWTR\EABDED,FV56+RJ8]@^8$J0_1:C^S\+9-S?3MU*^M5KVY3]1O
M^&W?@=_T4+3_ /OQ/_\ &Z/^&W?@=_T4+3_^_$__ ,;K\F/%_P +;[3=)CU?
M3=&U.#2K72--OM1FU">!RKW2G9(@0Y\EV!V @L!C=@FL_1OA'XO\07NF6MAH
M<T\VI63:E;#>BJ;4,5,S,6 C3<I&YR!T]15?V9A[7YW^!/UNK>W+^9^N_P#P
MV[\#O^BA:?\ ]^)__C='_#;OP._Z*%I__?B?_P"-U^._C+P)KOP^U1-/U_3G
MT^YDB$\6761)8R2 Z.A*NN01E21D$=J]+G\+_"SPAX5\(3^(]+\9:IJVM:4-
M3EDTG5;6WMTS/+$$5'M7;_EEGECUH>6T$DU)N_:PUBZCT:2^\_3W_AMWX'?]
M%"T__OQ/_P#&Z/\ AMWX'?\ 10M/_P"_$_\ \;K\G="^!7C'QY:2:QX5\-7M
MQH5Q<RQ:>;JXA6:<*?N1ABAG=00#Y:GYLC Z5D^$/A+XM\=3:C'HVC2S?V<P
MCO'N)([:.W<D@([RLJAB5;"DY.#QQ1_9N'U]]Z>:%];J_P OYGZ\?\-N_ [_
M **%I_\ WXG_ /C='_#;OP._Z*%I_P#WXG_^-U^15C\'O&FH^-+SPE!X=O#X
MALT:2YLI $,$84,9'9B%5,$'>2%((P>173^/O@[<_#OX0Z+JFMZ5+I_B&\UR
MZMO-,PDBFM5MX'C,91BC#<\@W*3R",\8">6X=-+G=WZ#^MU;-\JT]3]3O^&W
M?@=_T4+3_P#OQ/\ _&Z/^&W?@=_T4+3_ /OQ/_\ &Z_)"Q^'TWB#PKX8ET;2
M=4N=;U?5)].1VEA^RW#J(RD<2\.''F#<6X.Y<=ZT+K]GKQWI>HZ+;:GHAT]-
M5O!8PSRW,&Q)L9,<C>9B-PN3L<J3@^E/^S<.MYO[T'UNKTC^9^K_ /PV[\#O
M^BA:?_WXG_\ C='_  V[\#O^BA:?_P!^)_\ XW7Y<>.OV8?%WA7XGZQX.TV*
M+77L%:=;U;BW@1H P3S),RE8<L0-KL#57PQ\(Y].NOB)IOB[2IK/5-$\,R:K
M:Q-)@++Y]LJ2!E)5U*2MC!*G/M4_V?AFKJ;?W#^M5KV<3]4?^&W?@=_T4+3_
M /OQ/_\ &Z/^&W?@=_T4+3_^_$__ ,;K\CK3X,>-+W7K718="E;5+BQ74A;F
M6-3%;,,K+*2V(5P0?WA7@CU%8_C+P+KOP_U5-.U_3WT^ZDB6>,%UD26,Y ='
M0E77((RI(R".U6LLP[=E-_>B?KE5:N/YG[$_\-N_ [_HH6G_ /?B?_XW1_PV
M[\#O^BA:?_WXG_\ C=?DZWPEU/Q"_A6P\+Z!K%WK&IZ,=5EAGDA<7"B:1/,M
MPN"$_=XVM\^Y3Q@BL/QS\,?$_P -I+%?$6E/IZWR-):S"6.:*8*<-MDC9E)4
M\$9R,C(&10LLP[=N=W^0/%U5KR_F?K]_PV[\#O\ HH6G_P#?B?\ ^-T?\-N_
M [_HH6G_ /?B?_XW7Y$W7@VTB^$FE>*8WN&U"[UR\TR2+(,0BBM[612!C.XF
M=\G.,!>!SGTOP/\  KPUK<OPB?4[C5_L_BO3-8O]3CM9XD=#9O="-82T;!=P
MMTSN#<DXQQB99=AXJ[D^O;I\O(I8JJW:R/TK_P"&W?@=_P!%"T__ +\3_P#Q
MNC_AMWX'?]%"T_\ [\3_ /QNOR1\<W/PZETN)?".C^*M/U'S@9)-<U.VN83'
M@Y 6.VC(;.WG<1@'CGC:^'_A;P,OPTU;Q9XRMO$-^(-7M]+@M]"OH+7'F0RR
MEW,L$N<>5C QUIO+**CS-R_ 2Q=1NVGXGZJ?\-N_ [_HH6G_ /?B?_XW1_PV
M[\#O^BA:?_WXG_\ C=?EW?\ PE\,^)-+TSQ1X)OM5G\,MJUMI.J6&JB/[=IS
MS'Y&+H-CHX#8;:,$8(JQ-\%O#GAW6?'>K>)-5U"T\$>&_$$^@VT=HJ2:CJ,Z
MO)LC0D!$(CCW-(1@<84YP(_L_#_S/^OD/ZU5[(_3S_AMWX'?]%"T_P#[\3__
M !NC_AMWX'?]%"T__OQ/_P#&Z_+6?P'X$^(&A:M=?#Z?7].UG2+22_N-%\0R
M0W)NK=,>8\,T21@,@)8HR<J"0?EP4_9M^$6A_&7Q3K6CZYJEQI"Q:6\ME=0N
MBH+MI8XH!+N4YC+RKD#!]Q3>78=1<G)Z>G^0+%56TDEJ?J7_ ,-N_ [_ **%
MI_\ WXG_ /C='_#;OP._Z*%I_P#WXG_^-U^7W[/'P+M?B9\7G\,>+9[W1M+L
M9Q;:D]H56>.9YUMHXU+*P!,TB Y!X!^M<_XA^&T=KX3TBZTO2-<N-2O]<N]*
MBG9HI+:Z,901Q0QH/-\W+C=D8.Y=O>G_ &=A^;EYG^ ?6JMKV1^L/_#;OP._
MZ*%I_P#WXG_^-T?\-N_ [_HH6G_]^)__ (W7Y*>)O@9XZ\(_8AJ?AZ9'O+I;
M*&*WEBN)#<-]V%DB9BKGH%8 GTJMXU^#OC#X>:?%?:_HSV=G)+Y'GQSQ3HDN
M,^6YC9MCXR=K8/'2FLMPSM:;U\T3];JK>/YGZZ?\-N_ [_HH6G_]^)__ (W7
MJO@GQOH?Q'\,67B+PWJ,>JZ+>;_L]W$K*LFQVC; 8 \,C#IVK\!*_9+_ ()^
M_P#)HO@/_M__ /2^YKCQN!IX:FIQ;>MOS.C#XB5:;BT?0U8'CGQYH/PU\,W7
MB'Q-J4>DZ-:E%FNY59E0NP1>%!/+,!T[UOU\W?\ !0[_ )-.\7?]=K'_ -*X
M:\NC!5*D8/JTCMJ2Y8.2Z&__ ,-N_ [_ **%I_\ WXG_ /C='_#;OP._Z*%I
M_P#WXG_^-U^+-%?2?V31_F?X?Y'D?7JG9'[3?\-N_ [_ **%I_\ WXG_ /C=
M'_#;OP._Z*%I_P#WXG_^-U^+-%']DT?YG^'^0?7JG9'[3?\ #;OP._Z*%I__
M 'XG_P#C='_#;OP._P"BA:?_ -^)_P#XW7XLT4?V31_F?X?Y!]>J=D?M-_PV
M[\#O^BA:?_WXG_\ C='_  V[\#O^BA:?_P!^)_\ XW7XLU<T73O[8UFPL/,\
MG[5<1P>9MW;=S!<XXSC/2C^R:*^T_P /\@^NU.R/V:_X;=^!W_10M/\ ^_$_
M_P ;H_X;=^!W_10M/_[\3_\ QNOS"UCX"^'C/XYT_P />-+O5=;\(V]S=WEI
M?:)]DBEB@E$<ICE6>3D%@0& SZYXK+^)_P $;[1?B[J7@[P3I6M^)OLMG970
MB@MVN[G$UI!,Y(B0?*'E('R], Y/)Q67X:3LI/\ JWEYFCQ55*]D?JC_ ,-N
M_ [_ **%I_\ WXG_ /C='_#;OP._Z*%I_P#WXG_^-U^.]EX \4:GXDF\.V?A
MO5[KQ!"6$FE06,KW2$?>W1!=PQWR*GL?AEXQU34[S3K+PGKEWJ%G,EM<VD&F
MS/+!*X8I&Z!<JS!'(4C)V-Z&M/[+H?SO\/\ (GZY5_E/V!_X;=^!W_10M/\
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ML=7XX_\ !0;_ ).W\;_[MA_Z0P5[64_QWZ?JCS\;_#7J?.M%%%?5GB!1110
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M9@$EFEDF1"3Y9=515/+9)&.>7^&'B>Q\-Z/X[2ZO#:7-_H9M;+:&R\WVF!P
M0.#A&.3CIUK@Z*V]FK.[O<CG['U);_'?PE'XM^'6K0736]_JWB72O$'C6\>%
M@L)M9(UV@ ?-EA<3ML'_ "T4#)%0^#_CEX4\):9\.II[N2[ETCQ=J^H7D%O$
MWFPVUQ''''.I8!21\S  YRG;BOF&BLOJT+6_KK_F7[:6Y[?\/;[PI\&/BMX=
M\7/XRLO%UK!>R++%8VEP)XXY(W3SV$T:J64N&V@DDCKWJM\1?$]K8^"-1T?3
M?&'A[68=2O8I9++1/#_V0NL>XK++(T:%6!;&U=V=S9/KXS16GLES<S>OR_R)
MYW:R05^R7_!/W_DT7P'_ -O_ /Z7W-?C;7[)?\$_?^31? ?_ &__ /I?<UY>
M;?P%Z_HSKP7\1^G^1]#5\W?\%#O^33O%W_7:Q_\ 2N&OI&OF[_@H=_R:=XN_
MZ[6/_I7#7SN%_CP]5^9ZM;^'+T9^/%%%%?>'S04444 %%%% !6MX1GCMO%>B
MS32+%%'>PN\CD!542*223T K)HH:NK#6AZ]\;/C5XB\0^,/&FDVFMPMX<NM4
MN1MTR*&*.[A$S&,N\2CS1@ @DG/6O8M<O?!WBCXO?$75$U_3=1O/[+T2/3;*
M;Q,-*TZ] LK=+@O<HZAVB9 /+#J<ENZ\?']=E<?!7XA6E@U]/X#\30V2QB8W
M,FCW"QA",AMQ3&,<YZ5R2I0223M_2_R-E.3;=K_TSZ,U'QE8WOQ(N5T[6/!U
M];7O@[3=/U&TNM;EM(+IHRADC@OFDW1R(T:\RN2RCD-7/^*/$^@^%/ OQJL/
M#/C"2>?4;SP\UN)=6%Q<OM6Z-Q#%,,&XCB+*GF*,%=N>O/S/96-SJ-[!9VEO
M+=7<\@BB@A0O)(Y. JJ.22> !3]2TV\T;4;FPU"UGL;ZUD:&>UN8S'+#(IPR
M.K %6!!!!Y%"PZ6E^WX-?Y#=5OH?4.D_%&#5OB[X=75_%<$^AMX&6PNS<Z@O
MV<RMIK*\4A+;=YD."#\V[WK?^ %[X.\,CX>WSZUH3V36[KJUYKOBIXI;61_,
M5K>.P$B*$P5^9U9#N)-?(>BZ'J7B34X--TC3[K5-1N&VPVEE"TTTA]%1023]
M!5[1/ OB3Q+JUUI>D>'M5U74[7<9[*RLI9IH=K;6WHJDK@\'(X/%3.A%KEYK
M?T_\QQJN][7.X_9=U>RT'X^>#[_4+ZTTRSAN7+W=],D,,>8G +NY"@9(')QS
M7H/B[6[^#X3Z]IOC;Q/X2U.>2XMI=$L/#=Y9SNEP)5\V5_LGRA?)WCY^Y&*\
M.UWX;>+O"UW86NM>%M:TBZU!BMG#?Z=- ]R00"(U907(+ <9ZCUJOXF\#^(_
M!4D">(?#^J:"\X+1+J=E);&0#J5#J,CZ5I*$9S4K_P!(A2<8VL?2/C+Q+I_B
MOQ-\6-'\.>+])TC5M7O--N+749M2CMK:]MHH,2P"ZW!!\[(V"P!V$=1BK&D^
M/=&\/ZAX5\/ZIXRTZ[\7V?A75=)7Q3#<?:+;3[JX<M:I]J7.X(A=#(I(3SL9
MX./EB?0]2M=)M=4FT^ZATR[=X[>]DA989F3[ZHY&&*Y&0#QFJ51]7BU:^G_
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MN/\ XBOJ?:T_YE]YXW)+L>:45Z7_ ,,R_%S_ *)EXL_\$UQ_\11_PS+\7/\
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M#\<O#>DZ7XCM[ZWNM7L+>YNM%N)#;W41N(F*995+#.,@C&1WK(\8^';[Q?\
M';7M#TV%KC4-1\17%K!&O\3O<LH_4]:U;#]G3XR:7?6][9_#GQA:W=M(LT,\
M6D7"O&ZG*LI"\$$ @U>L/@A\==*\0G7K/P-XWM=:,CR_VA%IERL^]P0[;PN<
MD,V3[FM^:"?,I*]C.TK6:9>^(/B'6M8^+^B>%OAW+<E?#,(\/Z&=,++)(1N%
MQ,"#UDD>9BW'RD9Z9JWJ.EZ1IL.@?"&SU)[MM0\0V\VO:\W%HMQS"([<G[R1
MB23,A^^>GR@$X_AGX)?';P9K*:MH/@?QQI&IHK*MY9Z9<Q2@,"& 8+GD$@_6
MM+Q)\-OVBO&%G'::YX6\?ZK;1R"9(KO3[J15< @, 5ZX)Y]ZS]U62DK+SZE>
M]JVF=M\0H]&^+FF^/-/G\$S^"Y?AYI3?V7J*W,Q3RH9UB6TFB?\ =AI/,9@4
M"L7!)+<Y\S^"?@NQ^*_ASQ9X+@LH#XP>.+5-"N=H$LKQ-MGML]2K12-(% ZP
MY[5K>(/AO^T9XKTE-+UGPS\0M4TY"K"UN[&[DCRHPIVE<' Z5C^'_@1\</">
MKV^JZ+X#\:Z5J=N28;NSTNYCEC)!!VL%R,@D?C2CRQ@XJ:\M1N[DGR_@>I0#
MX?Z+XH\5:59:%IL46D2V&@6?B75M"DU'39984=;IIEC^[+/(NX/AOE0X ZCY
M\^*OAN_\'_$?Q'HVIV-AIM]:7LB2VFELS6L1SG$19F;9@C&3D# /->@^&/A/
M^T%X+DN7T'PCX]T=KG'GFRT^ZB\W'(W87GK6+>_LY_&34KR>[N_ASXPN;J=S
M)+--I%RSNQ.2Q)7))/>JIN,)7YTUZBE>2MRG6^.[*#4O&WP*M+J%+BUN-#T>
M*6*095T:=@RD=P02*Z+QI:>'OAWX'^)^JV7A+1+S4K?XC7FB:?+?6BRI96_E
MRL%2,_*0 F%# @9SC(%>>S_ WXYW-UIMS+X%\;27&F)'%92MI=R6MD0Y18SM
M^4*>0!TJ34?@I\=]7M+RUOO!'CB[MKR^;4[B*;3+IEFNF!!G8%>7(9AN//)J
M;1T7.OO\QW>ONG6ZRVGZ-\'=!T?Q+X=\/6?B3Q-]F^S7-MHT<,^E:<KJ/M<T
MPP3++@X!/W0S'[XK7^*=AX'T>;QYX3/A?R8-'M94TZ?3/#S)=VTL9 BFFO/.
M.^-SC>S*01)\H4XQR^K^#?VF-?TN73=2T'XBW]A+$(7MKBRNW1HP  I!7H !
MQ[52U+X9_M$ZQH":)?>%_B#=Z0JJHLIK&[:+"_=&TKC ["I25TW-?>4V]N5_
M<=MXGFM/"?B[P!X=L/A)H>IZ;K.DZ6]S-<6#23ZFTT:"1HI58&$@EE!7!WJ6
M.00*7PQX TGP#?W<,]MX;U30]0\2W.FZ8;[19=5OKZ*&18V165@D2\@!LAR2
M3D@"IOB+I?QWU2XTF'PGX2^)&C:7!HEGI]S;)IUS"KS1PB.1@JY&#CKP2.HK
M@-!^&'[1'A;39]/T?PM\0-,L9W,DMO:V%W&CN1@L0%ZD#K415X_$E\QO1[/[
MCO==O8_"?PG\<^$=/T'2+C3=.\=_V4DEQIR2W A*W1\QI",F10-JOU5>*9X^
M\,Z)\.M8^+&OZ+X,TO7+O3M?M=)M;&[M#/::9;20O(T_D [22R*@+@J-WJ:X
M.T^%G[0M@-7%OX3\?0C6&+ZB$T^Z'VMCG)D^7YB=S<GU-/L/AE^T3I>OWNN6
MGA?X@6VL7PQ=7T5C=K+...';;EN@Z^E4HQ3^-??OM_D*[_E?W>IZ0-'T[XAZ
MQ\$DUWPM!HUG)H>KWK:-:PNL%Q)$]Q*FV(L&VRN@.P,,[B%P",>8?%N_\,:]
M\/+2_L]"^PZ]#JOV<7^FZ =+L9+<Q,6BD'F,K2JP0K@ [6;.<"GZM\*?VA-=
MU*QU#4?"?C^]O[%BUK<SV%VTD!+;B48KE?FYX[TSQ3\)/V@/&Y@/B#P?X\UG
MR,^4+W3KJ4)GKC*\9JH*,6GSK[_-_P"8I-M-<OX'.S>*[*R@^&&LI*MPVBDQ
M7-BD@\U3#=&;.,<!UD&#T)#>AIHUOP9JWBZ_\5Z^M[>)>ZW<W+:!;KM/D-F1
M3)+D#!=@I52&PK\KE29O^&9?BY_T3+Q9_P"":X_^(H_X9E^+G_1,O%G_ ()K
MC_XBM^:E_-^)E:?8EE\666LOXVUF34G(GTJ.QMK:YCCA=F:6/;'%$C8$:)&>
MG  &>HKR^O2_^&9?BY_T3+Q9_P"":X_^(H_X9E^+G_1,O%G_ ()KC_XBJC.G
M':2^\3C-]#S2BO2_^&9?BY_T3+Q9_P"":X_^(H_X9E^+G_1,O%G_ ()KC_XB
MK]K3_F7WD\DNQYI17I?_  S+\7/^B9>+/_!-<?\ Q%'_  S+\7/^B9>+/_!-
M<?\ Q%'M:?\ ,OO#DEV/N3_@E#_R3GQS_P!A6'_T37W37QO_ ,$TOAYXH^'G
M@/QC;>*/#VI^'KBXU**2&+4[1[=I%$6"RAP,C/&:^R*^,QS3Q$VOZT/H,.FJ
M44SB_C9_R1GQ[_V +_\ ])Y*_!NOWK^+MA<ZK\)_&ME9P275Y<Z)>PPP0J6>
M1V@<*J@<DDD  >M?B_\ \,R_%S_HF7BS_P $UQ_\17JY5.,8SYG8X<;%MQLC
MS2BO2_\ AF7XN?\ 1,O%G_@FN/\ XBC_ (9E^+G_ $3+Q9_X)KC_ .(KWO:T
M_P"9?>>;R2['FE%>E_\ #,OQ<_Z)EXL_\$UQ_P#$4?\ #,OQ<_Z)EXL_\$UQ
M_P#$4>UI_P R^\.278\THKTO_AF7XN?]$R\6?^":X_\ B*/^&9?BY_T3+Q9_
MX)KC_P"(H]K3_F7WAR2[!KEI/=? ?P4(89)C_;.I\1J6_@M?2O5=#^'ESXR\
M-_!GPYXP=K&6*XU'4KQM0W++::&GE.K2<;DC)2?8#C[P(X89Y7PU\/?VC_!N
MF#3M"\-?$'2; 2M,+:SL+N.,.P +8"XR0HY]A5"7X/\ Q^N+O5;J7P=X\ENM
M5A-M?3/I]TSW,18,4D)7+*2H.#QP*Y9-/122WZ][_P"9NKK>+/4?B?;+\9/A
MSXSFN?%OAO7_ !'H^HOK^C66B7,LKP:<P$=Q:A6B0;(U6W9<9/[MO4FOGC6=
M%N/A?J>D:GHWC#2=3U#+317'A^YE:2T9<8+%XTVD[CC&>AZ5T^C_  !^-GAZ
M]^UZ9\/_ !G877EO%YUOI5RC;'4JZY"]"I(([@FJ7_#,OQ<_Z)EXL_\ !-<?
M_$55/DI^[SJWR)ES2UY=2Y^T;/+=>)/"DTTCS32>$](=Y)&+,S&U4DDGJ2>]
M6_B4X^'?PK\+?#^WB$>JZEL\1Z[(/OEY$Q:6YP>B1$OC^]-V(-5-4_9_^->M
MR02:A\/O&=Z\$$=M$T^DW+E(D7:B#*\*H& .U2ZI\"?CCK6MOK&H> _&M[JK
MNLK7L^EW+REAC!+%<Y&!^5-."44Y+3S!J5V[/4Z#49]1^$_A_7]4\37=YJOQ
M'\6Z2]I):2[G_L^RG4!Y+EC_ ,MGC&%CZH"&;&5%=WI6F:#''X!^#-QX%N-6
MTK78;34)_$UG=31S&YNHP6NT"?NW2W#;<2!@!$_3))XO5_"_[3OB"SN[74]%
M^(]_;7:-%<17%G=NLJL,,&RO((JAI_P[_:.TGP^=#LO#?Q#M='*-']AALKM8
MMC?>7:!C![BL6E):R5_7[ON[&B;3V?W'*_"*W\/:?\7ET#Q%#:ZGH6HO<:))
M=RJ#Y!E#11749/"E'*/N[ &O5+3P!X>^$.L^$/#'BKPT=;UV.SU#7-8:+3VN
MVLM\;1V8FB4JSPQB-9W0D?ZSG(XKRV/]FGXO12*Z?#3Q:CJ058:/< @^OW*Z
M!OA3^T(_BMO$[>$_'Q\1-@-JIL+O[2<($&9-N3\H"]>@ K2;C)W4UMW_ *[_
M )$1O%?"8OQ^T&33M8T+5(X/#RZ7JVGB>RN_#EG)9PW2K(R,TEO)S'(&5E("
MJ#M!&>M7+_\ Y-0TK_L;YO\ TD6G>)/@A\=?&.H_;]<\#^-]7O=@C$]YIES(
MX4=%!*]!Z57;X!?&Q]%32&\ >-#I:3FY6S.E7/E+*5VEPNW&['&?2J4H<L4Y
M+3S$U*[:3U/3M'\+>%]&U>&^N?"^FZG!;?"F'7#9W$6(I;S*?O7VX)8D\D$$
MC(SS69\+_$:67@CQ#X[\4>"O"5YH23O;Z;9'0(?,O[]U^6*/ RL$0&YR/9<Y
M;-<B?@W\>VSGP9XZ.=/&DG_B6W7-F,8M_N_ZO@?+TXK7T/P1^TKX:T>WTG2O
M#_Q#T_3+<L8;2WL;M(HRQRVU0N!D]:Q:BU;F3^9:;O\ "_N.J\-:7X-\':#\
M.K*Z\-6VOPZ]8QWFH?\ $@>_N[UI)622*"=9E,3(%V ( 0W)SG%9;II/@7X"
MZ;K_ (?\!V'B&:?Q1J=BNKZ_IZW$L%LBPF&.6/[I=@6Z@A2KXY(K!TGX=?M&
MZ%IT^GZ=X:^(5C93L[R6]O97:(S-]XX"]3WKM+'PS\9_#?P4\/>&/#G@;XA:
M-K]EK%[>W-S:Z5<11R0RQPA%#*,DYC)((QTYJ79->\GKW]2E=K:VG;T*\_@7
M3M+\677B>'1O#F@Z:?#ECJ>I:=J^G3:A#IMS<L5"0VRL3E]F\!\A5D^AKL=(
M-AX!\9>*)=$\/:04UOX:2ZY);W&D!4$P#J5CA<L8XI-H9H\D'CH  /'M/^&/
M[1&DZ[>:U9^%OB!;:O>#;<WL=C=B689SAVVY;H.M.3X;?M%QZ_#KB^&/B"-8
MA@-M'?\ V&[\Y(B23&&VYV_,W'3DT.*EHYK[P3:VBST'1_AUX:U?_A7.J7'A
M>SO+T^"M6\02:-;Q&%-4O8)[@Q1.J89@-H^1>2L>WI7.2:X_CK]GW5_M_A33
M/#$<GBW2K=[S2++['%*IBN05*9VED!)W 9PW.>*YF?X2_M W5]IE[+X1\>R7
MFF;OL,YT^ZWVVYR[>6=N5RS,QQW)]:L^)/AO^T7XPL39:YX8^(.K69D64V]W
M8W<D>]=P5MI7&1N;G_:-597UFOO\[DW?\K^X[7XF67@?3)/B!X4/A/9%HUI,
MFG3:7X=>.ZM)8F413SW9F/F1/P'9E((D!4+Q7A>EZA:W?PCU[2C=0V]];:I:
MZFD,L@4W,6R2%P@_B=6DC.W.=K.>BFN^U+X:_M%ZSH*:)?\ ACX@WFD(JH+*
M:QNVBVK]T;2N,#L*YC_AF7XN?]$R\6?^":X_^(K2GR1C:4U]Y,N9NZC^!5\1
M^*-#\?7.FS:C/<:3%HWARTT^.-(_->\GAVQ[5(X0$,S9;@!".20#TVE^-O#-
M]\0?!3:5-=Z'X<\/WB7BVFH>4JJD6V1V+ALR32F/!) R2 H  48?_#,OQ<_Z
M)EXL_P#!-<?_ !%'_#,OQ<_Z)EXL_P#!-<?_ !%6W2:MS?B2N?L>:$Y)-%>E
M_P##,OQ<_P"B9>+/_!-<?_$4?\,R_%S_ *)EXL_\$UQ_\16WM:?\R^\SY)=C
MS2BO2_\ AF7XN?\ 1,O%G_@FN/\ XBC_ (9E^+G_ $3+Q9_X)KC_ .(H]K3_
M )E]X<DNQYI17I?_  S+\7/^B9>+/_!-<?\ Q%'_  S+\7/^B9>+/_!-<?\
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M *)EXL_\$UQ_\11[6G_,OO#DEV/-**]+_P"&9?BY_P!$R\6?^":X_P#B*/\
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M4J\94@@GJ.#@CD T1:C3<5-7Z:_UN#5Y7<7]QVFE>#/A3_PF?B70+32=(O\
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M3N_#W@+4OA[X4L+OP%I?A?QIXQO;:#2KBSU*_E:TLVD5&O)DEN&7YR2$7;R
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M5?MZ_P#/&?\ []-1]O7_ )XS_P#?IJ +5%5?MZ_\\9_^_34?;U_YXS_]^FH
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M?, 1C SD '56-[%J-I#<P%S#*H=2Z,C8/JK $?0BO-OA#_R4'XW_ /8X6_\
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MTQWKT(X5O"O$6V=M_P!+?J>'/-:,,RCES?O-7V]7O?LGT/>J***\\]P****
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MI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]12T
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M\16E:A4H-*I&URYTY4])*Q:HJKYEY_SP@_[_ #?_ !%'F7G_ #P@_P"_S?\
MQ%8&9:HJKYEY_P \(/\ O\W_ ,16;XD\0S^&="O-4GM(Y8;5/,9(YCN(SVRM
M5&+DU%;L:3;LC<HKQ3_AIS3O^@+<_P#?Y?\ "O85EO& /D0<_P#39O\ XBMJ
MV'JT+>UC:Y<Z<Z?Q*Q:HJKYEY_SP@_[_ #?_ !%'F7G_ #P@_P"_S?\ Q%<Y
MF6J*J^9>?\\(/^_S?_$4>9>?\\(/^_S?_$4 6J*\9NOVE=/M;F6!M&N"T;E"
M1,N"0<>E>GZ)K%QKFCV.HQ6T4<5W DZ*\QW ,H(!^7KS735PU:@E*I&R9K.E
M."O)6->BJOF7G_/"#_O\W_Q%'F7G_/"#_O\ -_\ $5S&1:HJKYEY_P \(/\
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M"#_O\W_Q%'F7G_/"#_O\W_Q%<ID6J*J^9>?\\(/^_P W_P 11YEY_P \(/\
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M,&Y)!' X%?<-=6,PD\')1EU5SRLJS:AFU.=2A]EV"BBBN ]L***Q?%WC#3/
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M9MI_SZP?]^Q_A1_9MI_SZP?]^Q_A5FB@"M_9MI_SZP?]^Q_A1_9MI_SZP?\
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M_DH3_P#7E+_Z$E=U^TW_ ,BUI'_7V?\ T UPO[.7_)0G_P"O*7_T)*^MP_\
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M:_L_>'K7PMXH^,^F6<U]/;0^,(=LFI7\]].=VA:2QW33N\C<DXW,<# &  *
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M>\KOO7:^7$RCIT^7@^O2M#Q9X.T;QSHTVEZY81:A92#E)!RI]5(Y4^XK,O\
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M@''3%=O:>#+;SA/J$TNI7'7,S':/PK"IAX4K.4M'V-:&/JXIRA2I6:WN]/\
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MQ8/^O=/YFO)_&'^JMO\ >;^E?68:'L\OA#LD?QEGU;ZQFV(JVM>39Y_XN_Y
M4_U7^=;'[)7_ "<9X'_Z_'_]%/6/XN_Y 4_U7^=:W[)T23_M$>"4D19$:[?*
ML,@_NGKTH?\ (LK^DO\ TD^AX9_C4?\ KXOS1]2_%S_DI&O?]?']!6[\-/\
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M./\ FU4/A'?W-@=5-M<2VY;RMQB<KG[_ %Q4GQW,4GB^TEA@2W2;3X9?+0
M9R>U5/A=_P Q/_ME_P"STJ2_V**?9'[[G$FLGG*+Z1_]*1M?%O6+^[\#WD4]
M[<31EX\I)*6!^8=B:^>;P_Z)/_N-_*O>_BG_ ,B9=_[\?_H0KP.\_P"/2?\
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MAKQ7\:-.LC<M;0^,(-IN[N6ZDYT'2&.9)69VY)ZDX& . * /8**** "BBB@
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M"%Y W#=SC^[G%=A7,>-/#:ZR+:<3"!D=8C^[W%M[JHYR.F<TJ52%2:5;[_\
M/N&)P]7#T9/"/_MWIZK56_+R(='MW\4WR:G= FQ@)6UB?G<0?OM[\5UM9^@Z
M5_8FEPV?F^=Y>[Y]NW.23TR?6J/B'Q/+H5_IEJFDW5^=0F,$<D$D2J'$;R$'
M>X/W8V.:RJ/VL[0V6WH=5!+"T5.M\3M?J[O2VE_1$GB716U&&.YM3Y>H6QWQ
M.._^R?K5'3M?L]2N+::XN#:2K&XFA>X*!74H!QD#^]73J25!(P3V/:O//$_A
M*_U#Q'/);11[)AO3Y@,X"AC^9K;#N-3W*CM;9_I^IRX]5,.U7H1YKM77Y/\
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MOG2OHO\ ;I_Y*WI'_8#A_P#2BXKYTKV\N_W2GZ'P?$?_ "-L1_B"BBBO1/G
MKZV_8$_UWCG_ ';+_P!KU\DU];?L"?Z[QS_NV7_M>O(S;_<JGR_-'UW"?_(Z
MH?\ ;W_I,CZ]K\<OC7_R67QY_P!A^_\ _2B2OV-K\<OC7_R67QY_V'[_ /\
M2B2C@O\ CUO1?F?HG&W\"CZO\CC****_5S\C"BBB@#]4/V*/^39/!O\ V^_^
MEL]>X5X?^Q1_R;)X-_[??_2V>O<*_G;-/]_Q'^.7_I3/Z0RG_D7X?_!'_P!)
M04445Y9ZH4444 %%%% !7EW[1?\ R3P?]?D7\FKU&O+OVB_^2>#_ *_(OY-7
M=@?]YI^J-Z'\6/J?/_P__P"1Z\/?]A"#_P!&+7VC7Q=\/_\ D>O#W_80@_\
M1BU]HUZV=_Q(>AV8[XHA1117S9Y@5R/Q9_Y)QK__ %[G^8KKJY'XL_\ ).-?
M_P"O<_S%=&'_ (T/5?F:4OCCZH^/:]Y;[Q^M>#5[RWWC]:^\Q7V?F?/<8_\
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M'\7/^2D:]_U\?T%;OPT_Y $__7TW_H"5A?%S_DI&O?\ 7Q_05N_#3_D 3_\
M7TW_ * E?%?\PL/1?D?U+Q'_ ,BKYQ,;XT_\@?3_ /KN?_0:\*\4_P#(*/\
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MR*JW_7Q_^DQ/B']NG_DK>D?]@.'_ -*+BOG2OH?]N.-HOBQI(:5YC_8D)W.
M#_K[CC@"OGBO;R[_ '2GZ'P?$?\ R-L1_B"BBBO1/G KZV_8$_UWCG_=LO\
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M 'K7#?M%_P#)/!_U^1?R:N[ _P"\T_5&]#^+'U/GWP$ZQ^-] =V"(M_ 2S'
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M]N5\1_ 3_DKGAW_KI)_Z*>OMROS/BC_>X?X?U9_2/AI_R*JW_7Q_^DQ/A?\
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M[\??\CAJG_74_P A7FGB[_C]A_ZY_P!37I?C[_D<-4_ZZG^0KS3Q=_Q^P_\
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MC]DK_DXSP/\ ]?C_ /HIZ[8?\BROZ2_])/J>&?XU'_KXOS1]1_%S_DI&O?\
M7Q_05N_#3_D 3_\ 7TW_ * E87Q<_P"2D:]_U\?T%;OPT_Y $_\ U]-_Z E?
M%?\ ,+#T7Y']2\1_\BKYQ,;XT_\ ('T__KN?_0:\*\4_\@H_[ZU[K\:?^0/I
M_P#UW/\ Z#7A7BG_ )!1_P!]:^AP7^Y??^9_('$7_(RGZ+\C@]7_ .07=_\
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M:-03N1ACKQG&.:[NBJ>JV4VHV$MO;ZA<:7*^-MU:+&TB<]A(CK^:F@#"^&P
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M>JW]$>/FWUK"RAC,#3YY_"UWCJTWZ/;U9[IXY_:Q\,Z1J)T/PA:W7Q \2/\
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MKC7QK^IL\\:0O9,MMY!C0N43B'?@&1SG?DYY) %=)10 4444 %%%% !1110
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M_P#D,#_KF/ZU]'_L4_\ )/\ XQ_]>NG_ /H5Q7SAXW_Y# _ZYC^M?1_[%/\
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M -LO_9Z_/:?^YQ]$?U_G'_(EGZ1_]*1?^*?_ ")EW_OQ_P#H0KP.\_X])_\
M<;^5>^?%/_D3+O\ WX__ $(5X'>?\>D_^XW\J^ARO_=I>K_)'\C<4?[_ !_P
MK\V>>GI7DDW^M?\ WC7K9Z5Y)-_K7_WC7N93]OY?J<F4?\O/E^I^A2?\FM?"
MW_KV3_T UF_#?_D8)/\ K@W\UK23_DUKX6_]>R?^@&LWX;_\C!)_UP;^:U\+
M'X*O^*7_ *4S^O8_\D]_W#7Y([CQ9_R+&K?]>LG_ *":^<J^C?%G_(L:M_UZ
MR?\ H)KYRKV\G_AS]3^5N+/X]+T?YGG=S_Q\R_[Y_G7F_B[_ )#T_P!%_P#0
M17I%S_Q\R_[Y_G7F_B[_ )#T_P!%_P#017KY7_&?I^J/#RK^-+T_5'Z+?L!?
M\F_P_P#83N?_ &6OI&OF[]@+_DW^'_L)W/\ [+7TC7Y)G7_(QK_XF?UGDG_(
MMP_^%?D4]2TJ#51;B9[E/(F2=/LUU+!EE.0&\MEWKZHV5/<&O-[;]GK1-%\3
MW.OZ%J6JZ3?R0V\42/?374$!BDN7)6*9V7YOM3C  "X^7&YL^J45XI[9CZ-X
M6LM(\,0Z"R"^L5@,$JW2A_/#9W[P1@[B6R,8Y-,\(^!_#G@#3'TWPOX?TOPW
MISRF=[32+*.UB:0@ N4C4 L0JC.,X4>E;+YVG;]['%>6?">;4WUV<3RZS*#8
M[M3&JO,T:7OG-@0B3A1LW9$?R8$?K0!ZK1110 45A^-IM8M_"VH-H%L;K5R@
M2"-60,"6 +#>54E5)8!B 2N,C-<_\#WU4_#73H]:@U:"_@FN86_MR42W;HL\
M@1G8.^<KMY)_3% '>4444 %%>7_&_P 2>(] ATIM!C<K&MQ>R!;6><7<L*H8
M;(F$AH_.9C^\.Y0(R"K;L5Z;$[21(S(8V902A.2I]* 'T444 %%>(Q2^+!^T
M9,\E]J/]@&^^S1Z<89_(^R_V8LGVC?O\C9]IRFTH9=^3OV?*/;J "BBN8^)E
ME=7_ ("UN*RN+ZVNQ;,\4FG2M'/N7Y@%9?F&2,<<X- '3T5Y5XDU WGQ,\/:
M;;7.MV5Y$(+BZN0]T++R^?W C4>5(\AR&9_N+SD-M!]5H ***Y+Q997C^+/"
M-W;7-^D,=W+'/!;RLL#HT+\RJO#8(7&[@$^M '6T5Y!\,;GQA)\9/'+>(]/U
MFUL+C3K"2T6XN(Y-/@*W%^I6 +(<,T8@9SM#$@;L 1Y]?H ***\I\:6>OV#_
M !,?2;S5FGN=!MGL'\R21+:X)NU9H$' *@1,0GS'"Y.2* /5J*\\^!IUA/!]
MW;ZQ>76I/;ZE<I;7]U%-&;BW+[HRJSN\H50VS]X[$F,D':17H= !165XIO8-
M.\-ZG=7+7BV\5N[2'3T=[C;CGRP@+%O3 SFO"Y;G59?"-G=27GBB#1[F6^F^
MS6=Q>RWUG)Y*_9(7E;]Z_(=B"3'YC!<LH!(!]$T50T!KYM"TUM45$U,VT9NE
MC^Z)=HW@>V[-7Z "BN ^,VJQ:;X:MT,>JRW5S<"&V33)[J!?,*MAIY;8>8D2
M@%CCK@  D@5SFFW3R_$;PSI<>L>(;J\T^SA;4-0NDNHK.^'V8A4$6/)+N6\U
MV/*D!<Y.T 'L5%%% !17EWC*]-Y\5= TVTO=:T^YA,-Q<7$9NOL31!V_<!%'
MDN\G(9GSL4 C#$4?!_Q#XCU?4]777-\IG O&W6D]N+&1F*_8QYC%7V(J_/&%
M#'+$9;- 'J-%%% !6;XDUE?#GAW5-6>(S)86LMTT2G!<(A8@'MG%:51SP1W4
M,D,T:RPR*4>-U#*RD8((/4$4 <;%XXO=*T'Q5=:Q!;S7>@6YNI$L2525/(\T
M*"Q.#]Y<^P.!G%8&L?%/6_#,LJZC86UPEA.B7TUE&Y38ZP,H0EOE;$DOWL@^
M4.F\8[K3O!FCZ38M9VUJRVKL6DBDGDD$N4V8?<QWKL 7:V0 !@<"H[3P'H5G
M8?8DL ]MYC2F.>1Y=S&/RR6+DD_)\H!X   Z4 6O#&MKX@T6WO \32.,2K"2
M5C<?>3GG@\5?FNHK<@.Q!//"D_RJOHVB6>@6?V6QB:*$NTAWR-(S,3R69B6)
M^IJ]0!\G^/?!'B#4O&NMW5KH]Y/;S7<CQR)"<,I8X(K!_P"%=^)_^@%??]^3
M7V3/<PVH0S2I"'<1J9&"[F)P%&>I/I4<6IV<]TUM'=P27"[MT*R N-N-V1G/
M&Y<^F1ZU[\,YJPBHJ*T]3T%C9I)61\=?\*[\3_\ 0"OO^_)H_P"%=^)_^@%?
M?]^37V4;B(7"P&5!.REQ'N&XJ" 3CKC)'/N*HZKXDTC0I88]2U6RT^2;/E)=
M7"1%\8SM#$9ZCIZU?]MUOY5^)7UZ?9'R'_PKOQ/_ - *^_[\FO=?@#IUWX:\
M,ZA!JEK/93279=4EC()78HST]0:]8!R,CI2URXG,ZF*ING**2,:N*E5CRM&5
MJ][%/I-['&6=W@=54(V22IP.E>4?V-?_ //E<?\ ?H_X5Z_JVMZ=H%K]IU._
MM=.ML[?.NYEB3/IEB!V-)I6N:;KL3RZ;J%KJ$2':SVLRRA3C."5)QP0:XZ&*
MEATU%;GSF.RVGCI1E.35NQY#_8U__P ^5Q_WZ/\ A1_8U_\ \^5Q_P!^C_A7
MME%=7]HU/Y4>9_J]0_G?X?Y'B?\ 8U__ ,^5Q_WZ/^%']C7_ /SY7'_?H_X5
M[1<7$5I;R3SRI#!$I=Y)&"JB@9))/  '>D:ZA22*-I4627/EH6&7P,G [X%'
M]HU/Y4'^KU#^=_A_D5K;4($MHE+,"$ (V-Z?2O+/VDM+O?%7@:QM-(M)]0N4
MU&.5HH8R2$$4H)Z=,L/SKV&LG4_%VA:)>)::CK6GV%TX!2"ZNHXW8'H0K$$U
MQX;$2PU:->*NXNYZ^8X"&98.I@JC:C-6NMSXD_X57XO_ .A<U#_OP:/^%5^+
M_P#H7-0_[\&ONRVN8;VVBN+>5)[>9!)'+$P9'4C(8$<$$<Y%2U]3_K1B?^?<
M?Q_S/S'_ (AGEW_/^?\ Y+_D?!W_  JOQ?\ ]"YJ'_?@T?\ "J_%_P#T+FH?
M]^#7WC44EU##-%%)*B2S$B-&8!GP,G [X'/%'^M&)_Y]Q_'_ ##_ (AGEW_/
M^?\ Y+_D?(_P:\!>(]"^)>AW^H:+>VEG#(YDFDA(508W S^)%?6?]I6_]]O^
M^&_PJ:.>.5Y%217:)MCJK E&P#@^AP0?H14E>!F&83S&JJM1)-*VGS_S/N\@
MR&AP_AI8:A-R4I<VMNR72W8^./VO_A]XE\<?$K3+[0=#OM4LX](B@>:WA)4.
M)IF*_7#*?QKPW_A1GQ _Z%'5?_ <U^ENJ:O8:):FZU&]M]/M@P7SKJ58TR>@
MRQ R:1-:TZ33!J2W]JVG%=PNQ,IB(SC._.,9XZUUT,XJT*4:48JR]3Q\=P=A
M,?B9XF=22<G?2W^1^:?_  HSX@?]"CJO_@.:/^%&?$#_ *%'5?\ P'-?IG>7
MEOI]M)<W4\=M;QC<\TSA$4>I)X%4KKQ/H]C?065SJUC;WD^WR;>6Y19)-QPN
MU2<G)Z8ZUO\ V]7_ )%^)P?ZAX+_ )^S_#_(_-G_ (49\0/^A1U7_P !S7TK
M^QEX-UWP'+XN/B#2;O21="T\C[3$5\S;YV['TW+^=?2EIXATK4+.:[M=3L[F
MTA)$L\-PCQQD=0S X&/>KX((R.17-B<WJXFDZ,HI)^O>YZ>6\)87+,5#%TZD
MFXWT=K:IKMYE;^TK?^^W_?#?X5^77Q8^ 7Q%UGXI^,=0L?!VK7-E=ZS>3P3Q
MVY*R1M.[*P]B"#7ZGUF:AXFT?2+R*TOM6L;*[F ,<%Q<I'(X)P"%)!.2".*,
MJS:KE,Y3I13YE;6_Z'N9MD]+-X0A5DURN^EOU/R9_P"&</B?_P!"/K/_ (#&
MC_AG#XG_ /0CZS_X#&OUSDNX(KB&W>:-)Y@QCB9P&<+C=M'4XR,XZ9I)KZVM
M[F"WEN(H[B?/E1.X#28&3M'4X')Q7TG^N>+_ .?4?Q_S/F?]2L'_ ,_9?A_D
M?D;_ ,,X?$__ *$?6?\ P&-'_#.'Q/\ ^A'UG_P&-?J\?''AP?:<Z_I8^RG$
M_P#IL?[KG;\_S?+SQSWK32_M9/L^VYA;[0,PX<'S1C.5]>.>*/\ 7/%_\^H_
MC_F'^I6#_P"?LOP_R/(OV3M(OO!GP \*Z-KEG/IFJ6WVKSK6XC(=-UW,ZY&.
MZLI_&O9.M+17PV(K/$UIUY*SDV_O=S[O#4%AJ$*$7=127W*P4445SG2%%%%
M'F/PDTF\\/\ G?:=-NK%9+"PM[D2(29]043?:9^,[@V8LR?Q;?:N-MOAIJFI
M:>?)L;S3;B*UT^,+*H"OJ8\T7-V<YZ PGS5^9MI YYKZ HH Y+X9MJ:^'6@U
M2T:VF@EV*SHR--E$=W(8DY\QI%ST.W( ! J?X@>"D\>Z&NF2W36D8E64NB;C
MD9P.OO7345<)RIR4XNS146XNZ/&+#]FRSL+VWN4UN=FAD60*8!@D'/K75_\
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MZUI:-XHU[4/%MQI5QI&EQ6,-K#=M>VVJR3,R2F54VH;=0>83GY^A!&>E=/\
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MGR1A2VY4SDC //3BL8_$W34-FSQ2QP3R01-.[*J0M+"TP#DGC:B@G_>%0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>mtva-20251231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $1 OH# 2(  A$! Q$!_\0
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ML]TR#<P@B9]H]3@'\Z@/7W'KUI7 93ZFL;&XU.\AM+2"2YNIF"1PQ*6=V/0
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M_P !/C#X1\ :!J&CZYI^IPO>)?/<ZC8W*A;G?:/%#"\?EL?EWR;2" &D+$'
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MM0L-GVNVCD!D@WC<F]0<KN R,]17G7[27@&3XF_#JU\/#2SK-I=:YI37UGD
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M4<>5NZ_X-PHI,^].R/6K,1*\L^.'/]B_]M?_ &2O5,CUKROXXLN-%SQ_K?\
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MD3Z3-:I_9FD2:+&CP$I-;/*\O[P9^8AW)![8%>8[D]: Z@US3P].HVYQO?\
MX/\ F=U/%UJ,5&G*UM?R_P CM+3XO^-+*WTNWC\2:@;33)H)[2U>4M%$\+!H
ML*?[I /X5V'_  T->7]GKBWNEV5E)-I-[8:=:Z1"(+:":\D0W=P^69BSHI7&
M<<CH!7CFY1WI=R^M*6&I2U<2H8VO#3G?WW #!Q2493U%(74UU'!87H*KZG_R
M#+W_ *X-_*I]ZU7U5U_LR]Z8\E_Y&L:W\.7HS2GI./J>;44F]?7]:-Z?WA^=
M?EQ]J+6IX8\07/A/Q+I&MV9Q>:9>0WD1_P!N-PZ_J*RMZ?WA^=&]/[P_.D--
MQ=T>NZG^T%JFD^,;O4?!J_V-IB>*9?%6G1W,:M/!,XVF-R#AH]N5*]QUZUC>
M(?C]X]\0W_B&X?Q)>Z?;Z]<SW5]8:?*T-J[R_P"L_=YQ@],9->=^8/[P_.C<
MOK4\J-WB*KTYCWCPG^U3JMGK_ARXU_3;*XL],N["^O)-.MQ%>:K+I\12P$[E
ML8C^494#(R3N.*\0OKR74;VYNYSF>YD>5R.[,23^IJMY@_O"E#)Z_K344MB9
MUIU$E)WL%%)N7UHWI_>'YU1B!Z'Z5ZE:?\>L7_7-?Y5Y8SK@\BO4K5U^RP_,
MOW%[^U?39)\53Y?J;4MV2^E?0?Q(^"_A>+XF:!X%\.266E7NH21Q+>/J4M].
M9GMT:-)X-@\D-(P 8$]<]!7SUYB8Y8?G7=7_ ,<O&NIWMG>W/B R7UHCI#>"
MU@6=0T1B/[P(&)V'&23CMBOHJU.K*2=-VLGWWTL_.WF=].=-)J:O>W;Y^EST
M.\_9HLK/0[BP/B3S?'2>)+/PX+$6K"U%Q/%N,1D[[3G]X./D( .0:H:A^S9'
MINJ7,,WC+3TL+33;S4;JZ-J6E@%M*L<BM"CLWS;@R'/([+SCA9?C3XREMKF&
M3Q#,PN3:L[E8]^ZV 6"0-C(= H&\$,0.2:AU;XM^)M:N;VXN=4C66]LY;"Z:
MWM((/M$,C!I _EH-Q8J"6/S<=:YHTL8MYK^ETT-G4PW\K_KOJ=IJG[.]QI;>
M, OB"'47T&*WND@L+-I)[JWFMQ<+.8MP:.(*RAV^;:2,\<UT&J_LU1WWC.ZL
MAK5AX;BO-9&AZ/:I%/<I<7?V>.4@L3F-/WB#<VXY;I@5Y</C#XK4ZBPUP^;?
MVZVEQ/Y4/G>4L(A"+)LW(/*4(0I&0.<U:LOCSXZTZXU*X@\3S+-J$@N)I"D3
M,)1'Y8EC)7]V^P;=Z;3@4W2QCU4U>W^7EZ_\ %4PJTY7:_\ GY^9T+? 9K7P
M*?$$FOV<FHQZ.VO'0C;2@M;1W7V:0&8';G=T Y(STP,S^%-/\*_$7XV:K<VV
MCQ0>%;33KS51IB[T646]HT@4_-D!G49 (XSC%>?K\2/$":<+ :S(+,:8VC^4
M0N/L;2^:T.<9P9/FSUSWIWP\\=2?#[Q9:ZU!#'?*L<]K-9R/M6XAEB:*1"1T
MRK'GMQ5NE7<)N4KRUMT_K;<E5:7-&RLKJ_\ 7S/>/A]^SKX7\<^$_AY?0?;'
MUBZ@.H:]8K-@263S3Q+-%_=\N2) WM(#7G>B_#?3_BO>K#X26;28-*L+6&\F
MEL+R[:\N2&,LI$$<GE_," #C(4'KFN0T3XK>*/#=WIESI>OSV,NF6;Z=9M&5
MS';.S,T73# L['G-<W!?RVVXP74D1;J8Y"N?K@THT*ZE)N?IY:O[]/ZT'*M1
M:BE'U\]#WV[_ &>4\*_ K7/%&J:1JEYX@M?(U"&812QV2VAN#%M8%02Y56=L
M\HK)G!S7G?QQ\*V'@[XHZSI^E0_9M+<07MI;[BWD13PQS+'D\G:),9/I7-Z?
MXTU6PTO4-*74YVTC43$+ZR,ORW"QMN ).<<YZ>O>I_B#XXE^(?C+5_$-U'%:
M/?3;EMXVRD" !4C4^BJH ^E52I5X5&ZDKK7_ -MMI\F14J47"T%9Z?K?]#"H
MJ+S8_P"\/SH\V/\ O#\Z[SFYD?LU]LN#@">7_OL_XU%!JQNTWP7IG3)7?%-O
M7(ZC(/45R?Q5L;?4OACXNLKRYU*SL[G2KF":XT:)I;R)'B92T*+RSJ&W #DD
M<5\9_!OQUXD^$F@^&4L="GMO &G>*FTZ_P#$'AWPS=6__"16[::XAGDLG0RH
MZSK'&[J K/SGJ3^)(_1C[VBUQ9;V:S34%>\A57DMEG!D16SM9E!R V#@D8.#
MCI2P:M]L\SR+[S_*D,4GE3[MCCJIP?E8=P>:_-30O&?Q=M-<M/%;W?B^R^(N
MKZ!X>ACMHO#Q>#6;I;ZX66WNV,6(@D#,V,I_>SP >N\9_$CXAZ#?>)8/"VH2
M^'-!F\>^)(K[6])L"PAN(XK<V:3&"UG8JS&0DF/,FS:7'4 'Z"?:[D\":7_O
ML_XTV74)(%+2W3Q*#@F27: ?3)-?&E_XH^(_B[Q7XV\->(?$WB?1M4?PQ$-
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M_P# &+_XFE_X0OPY_P!"]I'_ ( Q?_$UM?I2TK@D8B^"?#N/^1?TG_P!B_\
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M?^%::]*=Y?TI^VJ?S/[Q>PI?R+[D9/\ PBVB?] 73O\ P$C_ ,*7_A%=$/\
MS!M./_;I'_A6DJYI5Z4>VJ?S/[Q^PH_R+[D9G_"+Z'_T!=/_ / 2/_"E'A71
M/^@-IQ_[=(_\*TZ3//3CTH]M57VG]XO84?Y%]R,O_A%]$_Z VG?^ D?^%*/"
MNB'_ )@VG?\ @)'_ (5I 9IY.:?M:O\ ,_O#V%+^1?<C&N/!/AV\C,5QX?TJ
M>(G/ES6$3J<>Q7K53_A6W@X?\RCH!_[A5O\ _$5T*X[TX<T>UJ?S/[QJE36B
MBON.<_X5KX._Z%+0/_!5;_\ Q%'_  K?P=_T*.@?^"NW_P#B*Z,'#8I.GO25
M6I_,Q^SA_*CG?^%;^#O^A2T#_P %5O\ _$4O_"M?!W_0I:!_X*K?_P"(KHI.
M@^E%)5:G\S'[.'\J.<'PU\''_F4= _\ !5;_ /Q%(/AOX/S_ ,BCH/\ X*K?
M_P"(KH>M.Z4_:U/YF+V</Y4<X?AOX.[>$M _\%5O_P#$4X_#;P>/^92T'_P5
M6_\ \171 [J7D&E[6I_,_O'[*"^RCG/^%;^#S_S*.@#_ +A4'_Q%,?X9^#I%
M*-X0\/LA&"ITJW((_P"^*Z,]:4#%-U)_S,7LX=D<D?A!X!'_ #(OAC_P36W_
M ,11_P *=\ _]"+X8_\ !-;?_$5UO6E!)/O6=V5R170Y'_A4'@$?\R+X8_\
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MR:7[E'M:G\S^\7+'L<V/AGX./_,H>'__  50?_$4?\*T\&_]"AX?'_<*M_\
MXBNE VG^]3%7-+VU3^9_>/DCV.=/PS\'#_F4?#__ (*H/_B*3_A6G@W_ *%'
MP_\ ^"JW_P#B*Z6C'XT_:U/YG]XN6/8YO_A6?@W_ *%#P_\ ^"J#_P"(H_X5
MKX._Z%#P_P#^"JW_ /B*Z+/J*2E[:I_,_O'R1['/#X:>#O\ H4- _P#!5!_\
M11_PK7P;_P!"AX>_\%5O_P#$5TG\J:JYH]M4_F?WAR1['.?\*T\&_P#0H^'_
M /P56_\ \13_ /A67@[_ *%#P_\ ^"JW_P#B*Z*DW4_:U/YF+DCV-9?#-Z#G
M=$#_ +Q_PIW_  CM_G=YD>XC&[><X_*NIHK,HYC_ (1^_&<2)SVWG_"L+PA\
M*=.\ :2=,\-Z78:'IYFDN#;6*^6K2R-N=SQR6)Y)Y->B44; <K_PCM_@KOCV
MDYQO.,_E2CP[?!RWF)N_O;SG^5=310(Y4>'+WDEHR3U^<\_I6;?_  ZM]3\0
M:7K=U96ESK&EB5;&]DR9;82J%E"'MN  ..H%=Y10,Y9?#M\,C?&%/4;SS^E'
M_".WW'[Q.!@?.>!Z=*ZFBE8#EAX=O<8+1D8QC><8_*@^';\XS(AXQ]\]/3I7
M4T4P.4/AJ]/5HSCI\Q_PH/AB\[&+_OH_X5U=% '*?\(O>>L7_?1_PH_X1B\'
M>+_OH_X5U=%(#E!X9O!WB_[Z/^%'_"+WGK%_WT?\*ZNBF!RO_"-7?_3+_OHT
MW_A&+SUB_P"^C_A7644 <H?#-X>\7_?1_P */^$7O/6+_OH_X5U=%(#E/^$8
MO/6+_OH_X4O_  C5X.\6?]X_X5U58'CGQ)_PAW@K7_$!A^T_V5I\]\8-VWS/
M*C9]N<<9VXSBF!3_ .$8O/6+_OH_X4H\-7@[Q?\ ?1_PKPF\_;1M+;X+^$_&
M2>&FGU[5[X6-WX>^V -8&-U6Y=I-G*H'B(X&[SHNFZO1?&W[0&B^%I/$NG[+
MJQUC2;"XOXGUFPN;:SNTA*+*T4PB;S AD0'8&^\",B@#K_\ A&+SUB_[Z/\
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MPKJZ*8'*#PS>#O%_WT?\*4^&;SUB_P"^C_A7544 <G_PC%YZQ?\ ?1_PI?\
MA%[SUB_[Z/\ A75T4K <G_PC%YZQ?]]'_"E/AF\]8C_P(_X5U=%,#E!X9O1_
M%%_WT?\ "C_A&+SUB_[Z/^%=712L!R@\,W@[Q?\ ?1_PI/\ A&+SUB_[Z/\
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M(4"L6+*.#P<C%#Q'^U'J_A?7-7UNZTBP?X?Z;XBNO"T@1I/[3:YAMGE,Z_\
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M(K",G/[S&T8;G@UVC:QI@M[FX-Y:+!;,R3RF9-D3#JKG.%([@T 3_P!K6?\
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MVB0)*(6E:9 BR'&$)S][D<>]/FU.PMI?)FN;>*;#,(Y)%5L*,L<$] #D^@H
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M;=M>:=9P1P02PQ0QJ$1$( 50,  =@*O[%_NC\J-B_P!T?E0!6_M:S_Y^HO\
MOH4?VM9_\_47_?0JSL7^Z/RHV+_='Y4"*W]K6?\ S]1?]]"C^UK/_GZB_P"^
MA5G8O]T?E1L7^Z/RH K?VM9_\_47_?0H_M:S_P"?J+_OH59V+_='Y4;%_NC\
MJ *W]JV?_/S%_P!]"C^UK/\ Y^HO^^A5G8O]T?E1L7^Z/RH K?VM9_\ /U%_
MWT*/[6L_^?J+_OH59V+_ '1^5&Q?[H_*@"M_:UG_ ,_47_?0H_M:S_Y^HO\
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M_NC\J *W]K6?_/U%_P!]"C^U;/\ Y^8O^^A5G8O]T?E1L7^Z/RH K?VM9_\
M/U%_WT*/[5L_^?F+_OH59V+_ '1^5&Q?[H_*@"M_:MG_ ,_,7_?0H_M:S_Y^
MHO\ OH59V+_='Y4;%_NC\J *W]K6?_/U%_WT*/[6L_\ GZB_[Z%6=B_W1^5&
MQ?[H_*@"M_:UG_S]1?\ ?0H_M:S_ .?J+_OH59V+_='Y4;%_NC\J *W]K6?_
M #]1?]]"C^UK/_GZB_[Z%6=B_P!T?E1L7^Z/RH K?VK9_P#/S%_WT*/[6L_^
M?J+_ +Z%6=B_W1^5&Q?[H_*@"M_:UG_S]1?]]"C^UK/_ )^HO^^A5G8O]T?E
M1L7^Z/RH Y]M%\,/J+W[6&EM?2'+W1@C\QN1U;&3R!^53S0Z',%\V*P;;.+H
M;HT;$PZ2#(^^.S=:V=B_W1^5&Q?[H_*@#"L[#P[IYF:UM-.MFN)1/*88D0R2
M Y#M@#+ \Y/-/>TT"2]@O'M]/:[@9VAG,:&2-F^\5;&03WQUK:V+_='Y4;%_
MNC\J ,2:RT"Y:S:2WTZ1K)]]LSQ(Q@;^\F1\I]Q5A9-*CD#J;4.)&D# +D.W
MWFSZG/)K3V+_ '1^5&Q?[H_*@#/^U:;]J^T[[?[3L\OSL+OV9SMSUQGG%#W>
MG/<+.TL!F12J2$C<%."0#UP<#/TK0V+_ '1^5&Q?[H_*@9QR^#/"9UW6]4DM
M;2YN=9^SM>K<D2Q2O"I2-]C94,%(&0,D*N>E:4.E^'+:2RDAM=-ADLE9;5DA
M0- #U$9Q\@/?'6M_8O\ ='Y4;%_NC\J!&$+#P^)+Z06^G[[X8NV\I,W  QB0
MX^<8..<U#KVCZ#XDM+R&\-NS75I+9/<1L$G6&1<.J2#YES[$<\]:Z/8O]T?E
M1L7^Z/RH Q]#AT?PYI%EI>GO!;6%E EM;PJ_$<:*%51D]   *O\ ]JV?_/S%
M_P!]"K.Q?[H_*C8O]T?E0%AU%%% SQ7]H_X=ZWX\'@6ZT72SK9T/6GO[JQ36
M9-)EDC:SN81Y=Q&"RD/,A(!&0",UYYKOP3^('BCXP:/XDDTC1],LK-H9$N(K
MF%[F.$Z9);R6TTQ@-Q.XFD^\91&4"G:6%>J?'CXRW/PAA\.?9[*P;^V;XV1U
M36[QK/3;$B-G7SYEC<H9"I1,@#<>2.AJ:9^TKH<WQ!UKPAJNF:EI=]I<VFVK
M7GV=Y;.:XO0HCC24* ?F< $XW %AP#AB/,5_9931? .FZ7-:Z?HUA:?#^YTS
M49]/#-(-5W6DPN@%7=*P>VW[OO,44<YK:\*_#/Q5XS_9#\56NI0PV_Q"^(&F
MWFIWL$\C)%'=W4.(H26!*+'&(8\$?+LKJ_B;^U#X7\#^&M<N;%KK5]9L8-39
M;&VT^>?RWLB8Y'GV*?+A$VQ#(<#GC.#CI='^-_AR^6RMI[EH]7FU"VTB2RCA
M=F6\FM1=*HXY3RB7W_=PIYX-(#RC5/@WX[^(/C>S\;:OINF>'[VU_L:PM](A
MU,W)^RVVHK=SRRS"- 7.T!$48P3D\\<QHW[._C/2O!T&GOX4T._T32_$T&J6
MWA*^O(7DU"V6UEBDCNKI(%2<K+(DL9E0L1'AV)P1]C44#/DCPU^SGXLL_B%I
ME[+H6A:1';^)X?$8\16=YONK6Q6U$7]BQKY2L8EQY8^81F/G:&XKG+K]B_6O
M^%:RZ-:Z9H,6IW/A62ROSORMYJ"ZC%=0F1MAW?(DB"1@=N_ XK[:HH ^9#^S
MK>^)_B9::SKOAS15\)OJ5I?2^'Y76>&&./1GM/*\O8$8),R@# &!NQP!7,6/
M[/OQ*T;PY:^'H;'3+^"_TOP]:7M]+JK(;!M-O&D957RR90T3*%(*X*D'C%?8
M5% 'QQXO_9E\;>.O&'Q#N;[3?#\%IK6DZ]I<-Q$+=([K[2T;6321I )&:,Q@
MN\LDA#\H%%:%[\ ?%-U'-J2^#]!-B=:TG4V\#M>H+6Y@M].>VDMV81>7\LLB
M3*"NTF,9Q7UO10!\7R_L@:_?^';V.\T[0WU%/#TUMI$?GLZ:1=R:M/>1Q0.4
M!188I(XED4 _(0 !7M/QF^#UQ\0/B-\/M?@LM.N8M!BU02R7BJ94>:VV0&/*
MGI)@Y&-N,BO9Z* /DV^_9FU'P]X'^&=AIW@GPWXH@T/1KBRU?P[>W @MY]0G
MAMT-_O,;"5U,,BEF&_;,2O(Q679?L<:H]UI$NN6^C^(KRRU'PT)M1NV+RSV=
ME9)!>+\RD[9&!_=DX<'YJ^QJ* /FO6OV?M3G_9NC\$_V-H^K7NF>(O[6L-)N
M&7[(]M'JYN8[=69"(P;?]V!M( 8KR*HWO[-.JW>O7_B#3[/3/#_B2\\4-?1:
MO:L/M5CISZ1]D\I'"@X24Y$8PIV@]<8^HJ* /GC]E+X'ZO\ "2+47UO3FT_4
M7L++3I9(;^WFM[UH/,S.L<-M"0Q+YWREY&! 8_+D_0]%% !1110 4444 ><_
M$[XP)\,+S2VOO#VJ7ND75Q;VT^K6K0>7;//,(8U\MI!)*=[+D1JV%.ZKWBSX
MD#PWXST/PY!I=QJU[J-G?:BZ6KJ'B@ME3)"MC<SR2Q1J,CELYP#7%?'KX)ZW
M\7]2T6.SO-"TJSLIH;B/67LI&UG3I4F61GM)E<*I945>1QR3NSBM+QUX3\2/
M\7M!\2>'8XB9/#VIZ++=W #Q64SF&>UF=,AG3?"RLJG/S+R*!&-'^U!!)?R^
M'_\ A"M='CQ-0.GCPL9+3SWQ;+=F43^=Y.P0LI/SYW,%QDUT=W\>_#X^&'A[
MQKI]O>:E#XBFMK32=-B5$NKFZG;:D!WL$1@P;<68!0C'/%>6^%_V;OB#X;&@
MZTGB'PS/XST;4+N^%_+:7+Q:H]W (KJ2[S+NW_)$4V$*JQA,8QC?E_9OUK3?
MAUX5\*Z1X@L%7PA<:?JVD7%U9O\ OM0ADF>X-R%D_P!3+YN J89.3EN!0,O6
MO[7GA'^T+"SU&QU/1[AYY;34A=B'9I,Z2S1%)V60Y!>"3#Q[EV[6) 8&NLM/
MC$ES<> #<:%>Z;:>,);F&UDO65)('2)YH%DCY(,L4<C 9RI !&3QP=I^RNFH
M6FGIX@NM*O+J;5K_ %_6+N#3OWDUW.X=(("Y8QVRG:64DF3R4#<,PK.\)_ C
MQ3X2N?A]HU]>C6K.R\1S>(K^_B=_+MQ%8&WC11*[.6GFD,S8.W<TO08R ?2]
M%%% !1110 4444 %%%% !7%?$OXD0_#NSTH+IEYKFKZO>KIVFZ58%%EN9S&\
MA&Z1E1%6.*1F9B  O?H>UKS?XN_#_5_&9\+ZIX>U"RT_Q'X:U/\ M.R.HPO+
M:S;H)8)(I0C*P!29B&!R"%X/- C>^&WC^Q^)O@^P\1:=;W-K;71E1K:]0)-;
MRQR-%+$Z@D!ED1U."1QQFNJKA_A!\/Y?AEX#LM"N+Y=2OA-<WEY>)%Y2S7%Q
M/)/*RID[5WR-@$DX SS7<4#"BBB@ HHHH **** .$^'?Q6LOB-JWBBQMM+U7
M2I_#]ZMG.FK6_D/+NC619$3)(1E8$;@#["N4O_VD-/TKP]/KD_AW6+G2AXDD
M\/P75A&LT;;+A;9KF1B56./SBR#)).W(!S@7_A=X \8^&?B#XYU[Q#?:%=67
MB*XAN8X-+@FCDA:*)(%#%W((V1@G ZDXXKS^3X.>/=3^$%_X"TYM)T<6OBBY
MNH[S5HY)A=6@U 7]NZ")Q@DL(VW<_*W'2@1ZC/\ &.V?XH/X)TW1[W5+JT\L
M:E>QS010V9D3S$7;)(KRG9M9A$K;%=2>N*K_ !9^,5S\)XTOIO!FKZYI.8(G
MO].FM?EFEF$21+$\JR.Y9DP%4YW<=Z\_UK]E_4=<^+\?B^:]T*)+K4]-UN^N
M$TUCJ,-S:1)&8;:<M\L$OEKN!Y +CG=D=[J?PTU[QGJW@*\\4ZKI]Q!X=O)M
M4N[.PM7CBO+P*4M'7<Y*K$'=L$G+A#QC  ,NQ_:;\/:SJ]SI.GZ9J5UJPOH[
M*QM L>Z_W33Q/+'ASMCC-I<LYDVD+&#CYE!J?$?]J+2OAEI7CZYU+1+ZZN_"
MEY;VS6=BPE>Y2> 2PRC@$*?G4@!B#&QP16%\1_V6Y_&E[XFU>QN]+TC6-1O%
M\A8+5X81:[&\P2F%D=YGE83-)DY:"%?NJ<]9\*?AYJNE>-OB!J&O%[ZSOHM,
MTFVDOE5I+Z*UM=LEPXR0?,DFE&#_ ',]"* /1/!OBNU\;>%]+UVSBF@M-0MT
MN8X[D 2*K#(# $@'U&3BMVBB@84444 %%%% !4<LB0QM([!$4%BQZ #O4E0W
M=JE[;2P2#,<J-&P]B,&@#RSX7_M Z9\3]>ATZWT/5M(2_P!-.M:/=Z@D8CU.
MQ$BQF:/8[%/F=#M<*VUT;'/'K->%?!CX$:[X U[1+O7]?L-7M/#&A-X:T)+*
MT:&3[,TD;&6X+.P,I6"%<+@?*3WP/=:8D%%%%(84444 %%%% !1110 5Y&O[
M1&B/X^'A]=*U)M,.LMX;_P"$A_=?9/[4$1E-MMW^;T!7?LV[QMSWKURO 8/V
M<]4C\?M/)K=E)X*'BQ_&J6?V9_M_V]HROE&7=L$(=C)D+NZ+TY(![]1110 4
M444 %%%% !1110 4444 %8GB[Q5I_@?POJ_B'5I3!IFEVDM[=2!=Q6.-2S$#
MN< \5MUROQ-\#0?$OX?>(_"EQ<O:PZSI\]@]Q& 6B\Q"N\#N5SG% &)\,/B[
M%\1K_6-,N/#^J^&-:TM+>XFT_51%O,$ZLT,H:-W4A@C@C.596!''/HM>5_"7
MX;>(_#7B/7_$WB_5M.U3Q!JEK9Z?C2;9X+>*WMA)LP'9F+,TTC$DX&0!TS7J
ME !1110 4444 %%%% !17$#4KQN!<RY_WC2MJ%\GWKB9<^KD4 0_%7X>ZE\2
M/#S:39>*)_#MM,LD-ZL5C;7:7<,B[61EF1@..01WZ@CBO/KC]D_3;>2X&B>*
M-4T6)K/1XK=?*AG:"ZTPH+2YW.OS$(FUD/RMN)X.*]&_M.\_Y^9O^^C1_:EW
M_P _,O\ WT: /++W]D2&XMKHP>.];M-2U.UU*PUC44M[9I;ZVOIS/+'@Q[8R
MLC,59%R Q'/!&UI7P&73_P!HJS\< HNDZ?X;ATV&,2'=<7P+Q_:&0# 9+?\
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MV/\ EYE_[Z--_M2\[W,O_?1H [BBN(74[O\ Y^9?^^C1_:EW_P _,O\ WT:
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MM.\_Y^9O^^C1_:=Y_P _,W_?1HN@.WHKB/[4O/\ GYE_[Z-)_:EY_P _,O\
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M2UH_\(Y??\\E_P"^Q2MX>OB?]6O_ 'V*5AW,P#%(S9K4;P]?'_EDO_?0I/\
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M+_A';W_GDG_?8_QI/^$=OO\ GFO_ 'V*$AW,WH?K2_?]L5H_\([?_P#/-?\
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ME?E&>ID_9ZUF?5]55]9T^71+W7-$\0B.2U<SB>Q2UCDC)+;2CI:*5.,AFYR
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M226LKH[0L0"4+(2I()QD$@]B15^LKP[9W5AH6GV]XEI'=PV\<4R6$9CMU8*
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M1110 5Q?Q*^(\/P\LM*VZ9=Z[J^KWJZ=INE6!C66YG,;R$;I&5%58XI&9F(
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M_P"_K?XU8HH"Q7^Q+_STF_[^M_C1]B7_ )Z3?]_6_P :L44!8K_8E_YZ3?\
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MQ#=W.IR:@L=]*DQN%29V8Y95@D90<!GZ+G%?1- %?[$O_/2;_OZW^-'V)?\
MGI-_W];_ !JQ10%BO]B7_GI-_P!_6_QH^Q+_ ,])O^_K?XU8HH"Q7^Q+_P ]
M)O\ OZW^-'V)?^>DW_?UO\:L44!8K?:V_P"?:;\A_C1]K;_GVF_(?XU9HH H
M2NMQ)$[V4CO$=\;%5)0D$9'/!P2*I7ND:9J-N;>[T.&Y@,WVDQ36\;J9<_ZS
M!XW9YSUK$^)/Q.M?AXND6JZ9>Z_KFM7)M-,T?3M@FN9%1I'.YV5$144LSLP
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M"%*[<G() /9J*\G7XT^%W^&\WCB.]U631()7AG5(SY\4B-M=63VP3D''IFJ
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M=,Q6UTY+I8GN&52[X8C"A8U=R3V7U(%3>-_BKX7^'5_I%OKVK7MG%J:LT5V
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M.:K>+/V9/"VI12-_:4VCHTX:W,:Q!8F^SVMM#'\RG>JFTB(0YW$E3P:8$O\
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M)O#\&LZ?#;V,4<:2G5H-)NFLGB,^EF;]PYWDQK<72%P>1$Y4 YV@S9E^!_Q
M\1:A?1>(==N[ZSB\2V>H6JS:FQMVMH;J2161 =Z,L31(4R%8KGD_-5GP?\*/
MBL-.TM?$/BO66FMY;R6\2#6<--+]E1(7B?!/EM,&D\N3Y5/\&WY:PM2^.7CW
MQ;I6M7%AI.H6BZ5J$R0-::?-;2741TV]<)(C&3#)-%'D@_>9.%/!T_$?[2?B
MW1DU:2PTB'5S;^(6TVT@BT6[5Y((]H<2DR_+(Q+E' 8.L9;8 > #;U;X:_$#
M6_A7X#MI+EX?&.BZD]Q)<?VQ/P##<1132N2WFLAEAD>,EE(1U'! I!\+?'FM
M_ OQMX<U6[N8]4U/:=-MKC6Y;F>'9'%O!O,!@)98Y' '"B3' ^4<M9?&OXAZ
M+%'-JJI/,C36E]J4ND7(L]/*ZA-&'DMXSN<B-(QE6&?-0],D]U\-?BUX^\3^
M+-'@U[PM#I.D7ZM$\0MIQ<6TJV-O<EW=CMV,\TD84J""F"<@B@#F!\'?B7HF
M@ZZGA_6;JR_M-I;M[!]9DD:.1M6>=HXI#CRF:U<HTBD9<Y)S\U;/BOX+>*/$
M>C^%IY+^:\U_2O"VJZ:USJ%Z=YO+B.%(F<*-CD;7#.0>@/)YKDM+_:%\<6FK
M:QK>JZ6[::(8K9M/BTN\"Z?<A-198&R"9)3)%:1LZ?(?-3@$@GOOA'\7_&?C
M_P 9:YI.M:!9Z%;VEIYD22Q3+<+)B/8[!CAXWWNPQM*[0,L<D &1J/PI^(<T
M^GQIKE]=+?7FKC5#<:U,+:&UF9UM_+C0J=R1[ JC* [LC.'%?5O@CXUUOP+\
M*+**\L[2X\)R:?/=:=J<\MWON(9H2TXG#Y<B-)=H(/\ K.V!BMX!^.GCZ\G\
M!Z9J>G6VH7FI06@OW&DW-O)<,\LT=TR')2'[+Y2EU<'?N^7:"N>IT_XU^)KW
MXB?$'0[?PU->V6@:9<75B192P2W%S$<+!N+,LGFY#*RA"1R%(YH I_$[X>_%
MC6_B1]K\*^+#I_A2<1>; ]TR/$95%O<[%"G.R-5FCY'[UFZ=:Y[6_AG\9IXO
M%K0>)KYGN=72:&*#5/+2XLO.F8);G(:V=4>%2 55O+/))W&2W_:-\6R:AH%M
M::;;Z[]MTVYN[F2VT6\MHUD6WN9$"-)(6^62!(F!7DNN&!(6M_Q]\9?&7@+X
M>^"-3;1H=2\0ZOY;W=I::;<- ,A&:%3YFZ)PKD L'R48[0,X .+L?@S\7/#=
MEXD%IK,E[<:AJ$-_9^5JK6NU@W[X70C"[Q+\K,\;!QLVCY>&[GXK^ /B%XM\
M;(=)U*6#09[2*(F'59+>.W $PN8W@48F,RO$%D)S&4R-N/FR_#?QX\5ZUKFB
M6=]:V6FI>W%U%.C:/>EH)HWC5;#?NV^<5=G,Q&PA>$[UP=S\>_B;:7&D3PZ)
M=2/IFD&>?2'L;DR3E[*V<7-Q+C:R"228B-0K?N&&<D[0#L/%?[/_ (@E\"^"
MM$TP,TNG>#]0\/7*?VM+'%%<3VL*I(5.1,@>-U^8<;E./EJU9?##XIZ7\0M$
M8>)M1G\'66H2O'&NJL\RP>>'7[09.9U:/,>#N* <8X(A/QD^)VH6.G36>A:8
MR7-K KS6UG<2[YKAKU$ECRVT(GV>!V1MW^MV[NC'HM)^,NI7'P(EUJWOM/U3
MQOINCVEUJ,5Q:36\,<\J@D/']Y3C=\H(YQDHIR&!E>/OAEX]\3>-]4NHIKFZ
M\/Q:OI.J6=N^M2V\C^1(OG11*A"QQ[-[$,-S/W(QMYOQ)\,OC/X@\.7FEWE^
MUS;K%]@>*+7G@:_!%\/M!D6/,:YGM"8SDN(2IR %+/B#^T#XSU#P]>Z=HVC7
MVGZJ8$O$G72KE)H;?[/:3)(RC> 6DDN8R@9F B8=033KO]HGQI;:9J.I6^D6
M]W<HEG&)3;SK:);R7FH1"^-N6$B(Z6\. 6X\P'.!R@.B^'?@/X@VEMXYT+4M
M1N6TZQT==*T$32'R99YK=9)6Y'S)%(1$C8("AAV(K;^%GPW\<>&O$ N/$&O7
M-W8W%O=V\]J-1D>*)?\ 1A:^3'@",@+<Y*X/S+G/&.1D^-WC_5--:<QV'A^[
ML]>TZVO[)=(NKHV]E)(JO,TI*K(D@8,K(!M7KR21O_$WXT^/O!WQ)'AO1_!0
MU>QF\DV^H"*9HQ]H410;V7Y1MN0_F=-L6UN.M '(^%_@)\1?#NFZ1-I.KRZ)
MKMEI=EI)DEUB6YAE$1OQ+)(I!\Q3Y\#HK E>0,;>>P\/_"[Q[JOP-U#PMK>O
MSQZY?7'[^35+@WP:VP@E@$B.'V28DY)RHD8# P!SMA^TEXPN_P"T)F\.E;*V
M\06FG)(VD7"W$T$JR[T2 R_-,CQJ"=X 5L[,C:=OQA\4O'OASQ?XB@T?0Q?Z
M997;SL;NWGE:>!$TU/+MRF K$W,[!B&'[H\'!P <W\,O@%XS\*?%'P3KFJ0:
M7]FTC1[2RNI[28^7F*Q:W8+&09!('90"&$1C!)3?@A9OA?\ %OPWI5SK,/BG
M5=1U6"U:4VQUB6=))3%?B0)"PV$DO8;%Q@%"1@[BWHUU\5]<A_:$LO T.D//
MHDUL[W%Z]E(GDOY7F(XFWE'1B"F-BX;C)P17EVG?M3>,M1\!:]KT>C6ES);F
M%+22RTJ[DABG>2X4V\NZ12^%@B/F(=H,Z#:V1D V?A_HGQ#U?X 7-JTVO)XI
M.KI/,FJ7US:3W5J)(WEBMYIB9H$9 Z*SX.0V, @U6O/@Y\2?$^LRP:MJ5U#H
MQOK:YDW:_+,7@6\M)8DA7:/)E@BAG4RC#2,^<DG*V+7]H[QA,?,N/#T, 75=
M/MY+>#3;F:1(+B)F:-,NOF7*N &4A B\CS,C.;9_M#_%75+>_D@\):;;26QO
M9I;:6UNI)8!;Q/)]E=58?O7VJJR9P=W"<?, :-W\-OC,1HT,/B&=I[>P6 WZ
MZS(J1.C7(<2Q;<7#RH]L!*W*,A/!'S:?@_X;>*/ 'BXWES_;7B!-3M]$MYKU
M=?ED,4T._P"U-*LA(*<[L@?,#L&W-<IX@_:E\9V?B?Q?8Z7HVE26FEZ@;& S
MVTS2(B7#1273[91YL2D(K8$>QYE&2 2?3-'^(?C:]\,^-=9O=.TBP.E6D3:?
M;2)<%99S90SR.\O\40>5D&Q <)R<] #%\4? ";6_&'C74;:TL;&/6]0T*=+J
MS?[/=+%;7"R79$BKN1V"@@@Y)P<@U%\-?A]\5=$^(NDWGB?Q'=W^A6UD(=D6
MH>9$VU'39-&P!D<L4D\T#=Q@MC(//']IGQLUZ"WAA;731H\5]YMQI<XN9F>/
M+31PB7!B23"LF_.T%_,Q@'H_A7\9O$_B/Q!IUUXKB31=*O\ P_;W$>GQZ3<;
MS>&^EMW99,DA2! VQAPLBG. S$ BF^'_ ,5M$UUM8T_6;C58VOVO+C2[G6'5
M)D%].8X8RRE8D^RR1@@#!,>#D@&L23X,_%VYL8;F;QIJ*:M'9LI6#7)EMS,M
MC:K"2N,'_2DN68D?,&YR#MJ3X@>/_BCX5^*.JG3;+4-;\,2ZW!;V=I;V@S%Y
M6GK.\6\)GRKAF*B0YVO%M_BQ6C\./C#XW\8^._"T6H?8K?PY>&^ADN8-&N84
MO94@MI45#*Q:(HTEPA+95C ^.>% .<U#X._%VR?Q%'H.J3Z7IL^ISW36MOKC
MYO4EOYIQ]G&%^R,L<BA@K#><Y/>O2=/\ >.[3PKXWSXGO)?$VH6<5MI-Q=WI
M>*WV64*%]@79'(TXF9G53]X$<8%<YJ7QG^(VG>(=!MV\/:7]CU?6;VSBDFM[
MB/;!!>+ D;/N(662/?*'*[,(  W+#S^\^/7Q0TCPZFB:?874NLQZ/=7DNI:C
MHTTDL+HS2J_#;9$**4VE 0W0MTH ]'^&/PB\6:=\08?%?B.:X'E:9?6=E:W&
MM2WL]DLLT+1Q-(PQ*1ME.]MQ&Y5^;:*RM!\#?&6RM-(M;B^,\$ACM[I[C6GD
MFACCOXYFEER&$DDL DC*H0H! PH. DW[0_CA=4\5QC0]/@L-,F@ABNY+.Y9X
MX7GAC^VO$K;I(6C=Y0JE2H502WS$5/\ A:?Q)\,_"SX;:VL4NHWUVFHG5+6[
MTR9Y+J18II+:,8P\6XH ,KD\#GH0#DM/^%'QAT#3-&\.Z?<W=C=0V3Q6TIOW
MNX;8Q6B12LMR4'D"9B%CB7E""P YKN9?A1\1]6T._P!'U/4-3O8+_P ,7&GV
M\\^OO$;&Z<7/RS)'Q<%O,MU$I)91&<DG);HK;XE^+/$GPGN=9MX@-0C\16=E
M;7NG6$L4=_9F\MU>=(9=SHI1Y4.2<;&8'&#3_P!G36/&J>';&;Q_?7,ESKT4
M4^FVETGF7$3+#NN#(Z1(L:LQRL;\J/EW$\  A\%>!/B!'X;\=:;>WM[I1O[6
M,:)/<ZU)>7-G.(B-H?)41JP3!P&;Y]^[AJY:S^"OQ4\616J>.O$ G2+6;+4(
MQIVI2Q-!&3//=!'5059))A#&P(/E1+R*^HJ* / /AMX&^*>D^/=(O/$NLRW=
MA;VJ"]F&J-)#<+]DBC\@6I7:)%N%DE,PP6!QWPN#?_#GXO3>$[6SCU&]_M=+
MJ\6ZNE\32H)YG3%O>H0G[N"-LDVH&#QD''/T[10!\Z6OPF^)EEXIBUF3Q=J5
MULNEN);?^UI3;N/[2D9U$&-@7["RJ$Z;@.X#5P6B?"+XS:_X9TW5WU&YTS6X
MK FW75]5>XO(9I+:-9W5RF83*0P"9_=$9X)K[(HH ^3]<^#/Q5Q:W^EZMJIU
M"32[6UO99=?=+C9%=7$CVX*G:7*3PXFW9Q ZLV7)/5>%/A9X]@^,^@^(/$%[
M+JFF:7!(JWESJ18E9+*&+RQ;*NQ9!,DK-("-PD]L+]#44 ?*WA7]GKQQX?U&
MQOK75)M/O=-W6T-P=8FF6X1M6-P[2*V=\9MG<"-L@-V!^:M;3O@]\0->^ OC
M+PIXIUB[U'7]5"1QM=ZB7CW*(][QRK\Z1R,K'8>F<8 .*^DZ* /F[5?A!\0;
M33?%!TS6+^.0*4T.RLM9DMXANU*YF8RX*\F!K=&8-OP&"L&Y.]X9^%?B^T\.
M?$?2WU)=+U+Q#J"W<&I"\FO(522&(3I&CL&BP5E0$$'E6_A KW.B@#YTM_@]
M\1-#^ O@[PCH.N6V@>(M/EDM+N73IWCMTLYO-1FCSDF2))$D3/\ ''[UFZ9\
M-_C?-KMA>ZEXLDM[F:QN'E%G?;K.SO6^TX1HF'[V+Y[;:0I9?*.-O.?IVB@#
MY<\._"/XJ6]UX)U:\UFXFNM,EN5U."\U3?<3PR/:$11W #-LWPO+M8G.-APK
M8&O-X#^*\GPFTG2WN[F;5;;4+@W"1:]+#>7-NT<BP/)=@MAUD9)&1,(0@  ^
MY7T910!\YZE\!_$UYX$^*5M/?_;/$WB>"Q"7D=_+#Y\L%G CD$8\D/+'+C;Q
MAAGC@9-[\%/B3I<'B"Z\-ZS<:;+J]]<WD]@-7EYC:XLWC2-ND<IC2Z5I0027
M&6.05^HJ* /!?&GP\\?ZOX&\#:18ZQ>SZA C0:Q/=:F8!)&\6QFF:':TKH"2
MI4D%AEE;.1RNG_#;XR:9X;L=#TO4/[,BCTN%$N9]:>9K::/3I[=H>58L'G:&
M8/G"X'&5 KZDHH ^6?#'PS^(OA;4_#EI!<W^F6>M>(;RYU>)-2EO3:V9:*YC
M9[@@;I28#;EB22MPW)VUTGC#P!\4?$?Q6U&>TU:32O!UPUO$?L6L31O)")[1
MW*IDB*3RX[M2R!,[UY.<CZ"HH ^:_"/PG^),/Q#\'ZAXGU!]6L-&E$HN7UAW
M2.,6MS!Y9MRN))BTB.9B<X.,\8I^M^ OBK<:5J<,=Q?3W;:Q<3220>)I;;[;
M;NLXMS#A?]%6(R6Y:->'\HYW?Q?2-% 'R[K/P2^)NIZ->+J?B2\UN[EE$TUO
M'K<UM%-Y-U8RPB(* (2RQ7F2,8+KG( QJ3_"/XFM?W5Q9>)IM,)NI#;0PZE(
ML"12W.H-*SQJNUW$<UI@D$@QG&",GZ.HH ^98? GQIU/6/#UYJ&L7.F6,=[$
M;JRL-7\R2)4BLT,KDJJRHS0W1,6"/W^<$G*S>&?@QXZN=!^)\/B"Z=]7\0Z%
M_95O?/K$LQFN%:[/FJ0JFWB/GQ8C7[N&X]?I2B@#PCP'X(^(NF_$G3KW4+NY
MM?#D-NHD@EUI[I##]CBC6U,)&#*DZO(;C.7!Y)S@<;X5_9[\<^'M1L;ZUU.:
MPOM-#V\%P=8FF6X1M6^T.TBG.^,VSN!$V0&SP"0U?5-% 'SYX0\!?%/3?@]X
MFTW4M?O+CQ?<21F":XU+>/E\L3>3-@M$)@L@7/\ JR^0%Q7(I\./BYK'B1-(
MN-0U6TTTVR,US+KLSP6L$D][OM7.,W<ODM!&9<Y0JK9SR?K&B@#Y,M_@U\6=
M-\/V%KIMW):$6%M:&"'7I(YHKB.S$*7$DX4M+''*&<QDG>& P=NVMCQ+\+OC
M%#INL?V9XBGU"[U(3>8)=:GA\A_MDS0O;;2OE;8&B!4$*<$$,5&?INB@#YTU
MGX8_$M? 6KQZ9JBP^(=0U:POKV6QO#!-=Q)I]M!<*LH"^6QFB9AR,A<<;L5D
MZ[\'OBAK&O6MQ>ZO=ZMHUG=:7=P63:V]O+YL#0?:G9HPH/F@.P7.U#&V!^^^
M7ZAHH ^8M(^$GQ<N]'O[36?%VIB[EOY97N+?6&B611;70C:$K\\2&:2V+1<*
M!$/EX.Y\_P -?C%?#4R-:CAN_/\ M%K?7>H-*R2MIUQ$XC4 I'$)I(BN$5QE
MBV[:"?IJB@#YM\/?##XI#4[34+K7]0L;2VN(IK32I=>EN3"GVZ)I8[B0C_2/
MW G +[L>8H_A#"MXV\&_%WQ-X\\<2^&=3O\ 1;%)&BLKBZU-TMYXC:6W[F"#
M;B-O,\X^>#D$L,CM]-T4 ?.]C\*/B%<6%E-=^(K^2[MX-,%O#J&HF9(G34))
MKAI4&5E<0^2BN2Q.W&<Y8\S??"3XP:GX#O\ 3;O4KJX>YD2&>Q?Q)+OG/V.:
M*:=;C;E(GG>&7[/TVQL,#.T_5U% 'SOK/PS^(EC)H+Z#=1J;*TT6UDACU!K>
M%S;BX6X\XIM=HL21D!6Y(&5(R#%\6?A;\2?%?Q%N-3T+4A:VUNCRZ1>2:DZP
MV3G3YX-GV4(09#-*'\[)(4X_AQ7T;10!\VZ1\*_BB(]&G?Q3JMO-9QQLMO>:
MNTH24Z@KR++MR)U%MO4;RQY Z@$8>G_!OXM3W>CZG>:O<+J&G2R+#Y^ORW C
MG>QEADO>@#1-.8G%N>%4' &2M?5U% 'R-JOP2^+6O^!M*T?4-3O=1+RR&Z@O
M=>8"&3S;5UD9U#&>+$4^(WZ-,#@8&WL_BQX)^*OB#X@7USX<U"?3_#9TV2%/
ML&KO#+*YC&T>6YV(XE7.]0A*'[^3Q]#44 ?.?Q<^"OC#XCZ!X5NH+BQL?%>B
M>'KV$.+J5X3>S1P(T3,X9WB=%G1F8EAN5OF(KU;P%X:D\":-H^D6VE6T4+6Q
MEU&ZAFPQN\1@L5*Y?>=^6SQL48P>.VHH **** "BBB@ HHHH *0?=HHH Y[X
MB?\ )/\ Q/\ ]@RY_P#135)X$_Y$GP]_V#[?_P!%+110'0WJ*** "BBB@ HH
MHH ****!,****!A1110 5C:%_P A7Q%_U^I_Z30T44"-FO*/ '_)=_BS_N:/
M_P"D[T44#/5Z0=*** %HHHH *X'X&?\ )*- _P!R7_T:]%% D=]1110,^7_V
M>_\ DY[XR_\ 7;_VI7U!110 4444 %%%% !1110 4444 %(>E%% "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>mtva-20251231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $1 L<# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@_P#:W_Y+9?\
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M#N8RKY?)_BKMO#=LGB3X^^))-%\):'JW@[PQ:P6>NS6GA^*X:],2LL@MX57
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M'YB@<M@M0!]44444 %%%% 'PA^UQ_P ELO\ _KSMO_037C%>S?M<?\EKO_\
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MRR^9$B,SX"\IM<8-+H?@'5-0AOKRYE.@0Z<Z1R3:A%*C^8ZDHJJBE\X#'.,
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ME()R1YK#/-4['X8>#](\3:)J^D:0NCKI=Y<Z@EE9A4AFNYHC#YKC&<I&\BJ
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M (JE_P"&1+[_ *&>U_\  -O_ (JOI+TH?J?K1<5CYM/[(U]_T,]K_P" C?\
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M_BZ^@>OM1C'O1_K%F7_/S_R6/^0?ZGY+_P ^?_)I_P#R1\_?\,MW?_0QV_\
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MX<RS_GU_Y-+_ #/BK_AW?J?_ $/EE_X+I/\ XN@_\$[]3(_Y'JS_ /!=)_\
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MV4TDCF*18Y0R+&6C*.RJ0X7!.*]1^QP?\\(_^^!0*YP@QZTK$#'>NY^QV_\
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M%4?[+_Z>[K_OY_\ 6JO%%;SSS01ZA*\\./,B68%H\\C(ZC(Z9H XSXZ^#/\
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M!=YA\\;]F<;L=<9XS0%S6HK)DB@CN8[=M0F6XE!9(C. [ =2!U('M5C^R_\
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M6O ^D:GYEY/J$GVFUW;[B8*LTC'N7"*&SPVP9' H \GUS]J[Q%9^)]2T[3_
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ML,;2&*WC,DCX!.$4<L3T '6O*+;]IKP]<:=='^P_$D6OV^HKI/\ PC,FF_\
M$SDG:#[0H6,.5V^3^\+EP H.2#Q7J&N)>2Z/?+IJV[Z@T#BW6[++"9-IVARH
MW!<XSCG'2ODI/V.->,SZA)8^%KB&/6WU*#P9<W]W-I:I+9&WG=KEH_.,CN$D
MP4*KY>!UR 1]-^(?B'8^%O ,OBS5+/4K6TBM5N9+);-Y;Q<@$1^4FX[\G&!D
M ]3@9K5\*^([3QAX9TK7; 2?8=3M(;V#S%VMY<B!UR,\'!&17EN@_#_QYX7^
M#$G@B.\TC7;F#P_#IMK?:A=3QM)<,)%G\QMCD1(C)Y?WF.TAL=:[/X-^'M;\
M(?##PQH/B!; :II5A!I\ATV9Y87$2!%8,Z(V2%!((X/'/6@#MZ***!A1110
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M<74@)2(>YVG%4]:^('@KP]X@O=!O=2B36K+33K%QI\0EFG2S#B,R[$!8C<<
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M[Y;M)&>*TF5O-N \CLPWA0H5%))V@=Y^TSX+\:_&;X56$/AJPLQ:2V<][?\
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MV[[G_2&_(?X52I"*$-HO?VW??\_#?D/\*3^W;W_GX;\A_A5.EY)HO<+6+?\
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MVJ.XV+Y[0^3=(HS;7&4+>2V3MR<\4 =I]BN#_P L)/\ O@_X4OV6X_YXR_\
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M\7_? H /MUM_S\1?]]BC[=;?\_$7_?8H^PVW_/O%_P!\"C[#;?\ /O%_WP*
M#[;;_P#/>+_OL4?;K;_GXB_[[%'V&V_Y]XO^^!1]AMO^?>+_ +X% !]NMO\
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M?:X_/L)8$N[;?Y9G@:1 LT8<;=ZDC('8@D$>A?;K;_GXB_[[%'VZV_Y^(O\
MOL4?8;;_ )]XO^^!1]AMO^?>+_O@4 'VZV_Y^(O^^Q11]AMO^?>+_O@44 3T
M5P@O+GIY\I)[;S_C3C=7*?>EF7ZL10,POCE\&$^-'_",V%W)"NE6=U=R7Z29
M\QHIM/NK4&+@C>KSHXSC&W/7%>1V_P"REXRO?"^H_P!M>(]+U3Q?K7A[5=/U
M?4V$@2XO;F6S\EU&W(B2&S1".N>0.37N_P!MN<@>?*?;>?\ &C[9.!_KI/\
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M,],]Z7[9<?\ />4_\#/^- CMX=YB7>JJ^.54Y /L:DKA5N[@_P#+:4?\#/\
MC3?MUQ_S\2_]]G_&C09WE%>?S:J\&SS;TQ>8P1/,EV[F/11D\D^@J8WEP/\
MEM+_ -]G_&@#NJ*X7[?<?\]I?^^S_C5:WUY+N>ZB@U%)I;5Q'<1QW 8PL5#8
M< Y4E2&P<<'/2@1Z'17 RZF\-L9Y+MH[=5+&9I<( !DG=TQCG.:>M_.P!%S(
M5(R&#DC';'- SNZ*X7[;/_SWE_[[/^-)]MG_ .>TO_?9_P : .[HKA?MUP?^
M6\O_ 'V?\:3[;<_\]Y?^^S_C0!W=%<*+RX/_ "VE_P"^S_C2_;+G_GM+_P!]
MF@#N:R?$EM>W_A[4[;3)8(-1FMI8[:6YC\R%)2I",Z_Q*&()'<5S7VV?_GM+
M_P!]G_&D^VS]II!_P,_XT"/E;P]^RQ\0M,\!:SH\>EV5M:W9T<7VES:SY]Q?
MO:RN]P]I=>4#9*P*>4@XC(;:(B<U[C^S_I'BOX;Z?I'@;5M$(L8X+[4#?K/Y
MJ6,;70-M:/,$7[3.5>5GDP#\N3N+;CW2W=P?^6TH_P"!G_&D%[/_ ,]I?^^S
M_C1=#.+.D>/4^/?B3Q)'X5LSHDWAY-)L[EM:"/-)%+/,C,@B)C#F4+D9*X)P
M>E>9V'P2\=VW@[Q]8W/A>2[TSQ9J*3KH:^,YHK^U'V;RI)9=0\LM.KL%Q$Y8
M*H'#<J/H$WDX_P"6TO\ WV?\:07MP?\ EO(/^!G_ !HN%B]\+O#^J^$OASX7
MT/6[NWO]8T[3+>UN[JSB$4,DL<:JQ1  %7(.  .!T'2NMKA/MMP>D\H_X&?\
M:7[=<?\ /:7_ +[/^- CNJ*X7[9<9_U\H_X&?\:3[;<?\]I?^^S_ (T#.[HK
MAFO;A?\ EXE_[[/^--%]<?\ />7_ +[/^- '=U\X_M$_ ?5_BOXF$.B6EQIB
MZO9V]AJVNPZVT$1MHKAI!'+:!#Y[*'EV$,O,S!C@8/JAO;@]+B7_ +[/^-(U
MY<+_ ,MY#_P,_P"- 'G"R>/_  /\1_BIXQ_X04:E8ZC96D>DV]EJ8EGNYK8R
M1Q*T8C_=B3S@Q;)$85B<UTG[1NA^+O%_P]AT7PQH-MJU[<7UG<7 GU(6JP+!
M<PSX!*-O+>45' QG/M71_;;C_GM+_P!]G_&C[9.?^6\H_P"!G_&BZ XOQ5H_
MCW7?C1X&URU\-6MOH^F:?>6UU?'5D:2"2Z6'<5A\OY_*,)'4;\CI65\!?@#X
MK^$7Q*U[4=2\46OB#0[O1+2R25=.%O<W%TEU=SRRS'>V6S<%BQ^^93]T1C/I
M/VRX_P">\O\ WT?\:7[9<=II?^^S_C0!W5%<)]MN/^>TO_?9_P :/MMS_P ]
MYO\ OL_XTKH#NZ*X7[9/_P ]Y?\ OLT?;I^?WTO_ 'V?\:8'=45PGVVY_P">
M\W_?9_QH%W<_\]I?^^S_ (TKH!?C+X4_X33X?:AI@TJ76+C?#<6]M!J'V"99
MHIDDCDCG /ENCHKJ<8R@'>O'M&_9_P#%H^$EYX4O[T/+XO\ $YU/Q*T^H//-
M;Z<^SS;=9]JF:1T@CB9MJK^]? P!GV#[;<?\]I?^^S_C2B\N#_RVE_[[/^-.
MX%_PWK^J:IXA\3:?-H$FF:1I4L%O87TC;1?DQ!Y"D94;40LJ!N0Q#8^[7SVO
MPI^).K66LWUSX:TZPU*U\>V_C;3[)M865;U%18Y+9I!'^Z8*A*N002RC@ FO
M<_MUP.D\H_X&?\:5KRX'_+>7_OL_XT7069Y18? OQ1JGA>ST36$L[:P\1^,;
MCQ5XIM8KGSEBMS)Y\5A&2@\W=)' )&^4863 ((KZ2KA?MDX_Y;2X_P!\_P"-
M)]MN/^>TO_?9_P : .[HKA?ML_\ SWD_[[/^-(+RX_Y[RG_@9_QH [NBN$%Y
M<G_EO+_WV?\ &E6]N/\ GXEY_P!L_P"- '=45PIN[@?\MI?^^S_C1]LG_P">
M\H^CG_&@#QGQ)^S?JGBGXKWDUI:W/ACPNU_=ZO/-'K33PWE[-926XFCL]@$3
M[I=[%GQ^[^4?.2*WP1\ _$'X+ZMHMK+H,DFFW<.GZ#<V$&N3W]OOA24W&L%I
M5Q I18XUA&"Q('&!7MZWD['_ %\G_?9_QI?M5Q_SVE_[[/\ C1<#E/C?H_C'
M7_$?P_?PWX<M=7L=%UN/5KR>XU1;5AMBFB\M4*-N.)MV<_PX[UQ'C#X<?$KQ
M3KGQJ2ST'2=/M/%6E6^GZ;>WM^ERC_9_,0B2'R_D\V.5L$[MA'(:O8/MEQ_S
MWE^N\_XTHO9\_P"OD_[[/^-&P'&_LQ?#+7?AAHGB*TU2U.F:?>ZB+NPTZ?4#
MJ5W ODHDAGNRH,I9T)7.XJNU=Q  'ME<(+V?M-+_ -]G_&C[;<?\]I?^^S_C
M1= =W17"_;KC_GO+_P!]FC[;/_SWD_[^'_&@#NJ*X5KNY'_+>7_OL_XT?;)_
M^>TG_?9_QHT [JO'_P!H'P#J/B^U\/W^A:-<7_B/2[B4V5]9ZZ=*ELA+$4<^
M8$?<C# 90,]".172_;;G_GO+_P!]G_&C[;<?\]I?^^S_ (T ?/C?LF:O9?\
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MB^6NRVCPAR=SMV&3Z?\ ;9_^>TG_ 'V?\:!>SGI/)_WV?\:!'=T5PGVZX/\
MRWE/_ S2"]N/^>\O_?9_QHT&=Y17!_;KC_GXE_[[/^-% '#?&>::'X-^/9+=
MY8[A= OFC:%B'5A;O@KCG/IBOB2]\<^,OV:?V=_!LFC>1X9\0^(=+DUF)]/,
MFIQ:BT-G"Z+=27^3%,[,1Y$"Y?)P5V\_H[_8M]QBW8$=\C_&E_L74 <^2V<Y
MSN'7UZTQ'P1K_P >OB/XVL/B_HL7B*6"_C\%S:UI$7AJQC=-/*P0.T4S%1/%
M<DM(HR65@VY,%.:EC\6/%]C=7FJ>%_$$&JZOJ6E^"[#_ (2F721(TXN;F>*=
MG3A6V8V\8.5R3DU^@?\ 8VH9SY#9X/WA^'>C^QK\\>2X [;A_C0!^<_BG]JK
MXM:1J4'A-_&-AI>HV&IZKI\OB&[TNVMXKE;?44MXY[D2J4BC\HN?W0R7 ZBO
M4_VOKU(/B)X/@\6W6[X;/H5X]N]Y/=VVDW6NB2/RA?26@+JGD>8R#IOKZ'\>
M_LX>$?BAK$&I^*?"R:M?0VXL_,:ZEB66W#^8(95CD598PW.R0,,]J[M=#O40
M(ML50 +L& ,=AC.,<4 ?G%I?Q0\1>'=&M?'GAC2;GP[>6_PPM)X[27S]0%K#
M_;Y67F<%W'DEV&[)"X(X KL+W]K'Q5KWB^XCB\9Q>#OA[<^+-6M++Q@WA[[4
MOV6"TM);.V$;ISYS32G>1N8+A37W>=&U _\ +%_Q8?XTO]C:CW@8XQCYA^'?
MM0!\)7_[3'Q-/Q%UVPM=>T^TOX-3URQE\+:CHC"#1;"VM7>TU6:X5?,*.ZQL
M<DAA)A5R*Q-9_:N^)H^%W@6\LM:_LZ;4;O5K;4O%.JVEFML;JV2,P0QRK&8&
M@D9W(D"J[A"HPP)/Z#C1[_\ YXN#TSD=/SH_L6_P!Y#8&.,C'MQF@#Y6^*FO
MZOJ/CK]GVZU46XG.EZQKC):Y>V;5(M)#PE WW@I>5D!YQ7CD'Q_^.UGX?CUJ
MX\86MV(_">A^+Y+0^&(D$ANKW[-+8[AR%"9D+CY]W3 K[RUWX;6OBB]T:\U3
M25O+O1;T:CITS2%6MK@*R;U*L#G8[ @Y!!Y!K<72M14AA$X8'.=PZ^O6@#XN
M^&G[2_B/6_C]XWC\1^+K&P\$>'?[<E?1Y+>VC>XBLY=L?V=L><^V-7>1F.,A
M<<'%<%XD\6^,?AY\(?"\]QJ@\'R_%2+7_$_B#5FTO[<\EU- &LM-"X.PO"R(
M"/F^3"D5]=)^R-\.DO=2N3X$M9'U%+B.>*:XFDA"W#;K@1Q-(4B\Q@"_EA=W
M>O3X="O((TCBMO+BC4*BJ0 H'  &>,4 ? _P0\8Z#H>NZ=X8\;:J^GV/B+X0
M^'].MK&_\TQW$K0RB95&"H;:>2<>]?2'[(NI:CK'[+_PNN]7WF^DT*W#M)G<
MRJ"L9)Z\QJIS7KVM^$)/$FBZAI&I6CW&G:A;R6MS!YI42Q2+M=258$9#$9!!
MI=*\(/H.E66FZ?IZV>GV4*6UM;Q$!(HD4*J+ST 4 4N@$:MBE(Z'UJ]_8E__
M ,^[?F/\:/[#OO\ GW;\Q_C2L5<I?<]\T>7[C\ZN_P!AWW_/NWYC_&C^Q+[_
M )]V_,?XT6"Y2SMIE:/]B7W_ #[MQ[C_ !IO]B7W'^CM^8_QH0-E,=#367%7
M_P"P[[_GW;\Q_C0=#OO^?=OS'^-%A7,_K3P=U7#HE]_S[M^8_P :7^P[X_\
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MT?V'?'_EW;\Q_C185S/HK0_L.^_Y]S^8_P :*8'9T55_M.U_Y[I^=']IVO\
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M:Y74/V4/ M_;-;)K>N6MM=V2:?JT<=ZC'6(Q<R7):X=XV;>TLTK,\90G>1P
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M?-_P\_9;U_P!H&NVT,W@N_;4+>SMI=)O-,GETR_DA9FDOKJ-Y"3=297+#CY
M3OX*^A_!CP%XE^%$6D>%-VG7/AB&VOKZ\O85,*I>7%WYL=K:0[V,4$2-* &S
MD>6!_%0,T[_X_:%H_B/QOINIV&JZ7#X2TH:Q>7]Y:^7#/;@R!F@R=S@&)AG:
M 3T)KGF_:;,>C:_<2> /$<&JZ''#>7NDSRV<4D5E+&\L=R9&G\O:5BD&T,6#
MJ5([U2\;? WQ1\0_&_C>?5=9T.V\,^)/#;^&@EI;S?;H(\S-'+N9]A</,<C
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MLBGYRN!G=MP:Z#P'%XGL+S5[#6'BDT6P%M::/=3R"2]NU2!?.GN"IVDM(2
M%/RDD#<*\[\,_"OXAZ-X5^)=C<ZQX6FU#Q5>RWUM)%;7 BMY)HTBF5P9,L/+
MC!7!!W'GCB@9<\:?M3Z#X,\/^'-5?1=4OX]8T(^)&CA>"-[>P58R[?O9%$DH
M\Y (H]S-SCMGVJWF6XA25<[74,-P(.#Z@]*^5/%O[*'BOQEX4\%:7J7B'P[=
M3^']#_L2-9K2X,-C*I01:G:;90RW:I&HRQQGH0"<_4.E6S:=IMI;37DE[+#$
MD;W,I&^8@8+MCC)ZG% C0HIOF+_>'YT>8O\ >'YT#'44WS%_O#\Z-Z_WA^=
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MZ)=^.-1\ W$][!I&F>+99+AK:VE+2VT$9F;R%E*-EF$6S>58#=G'% CG+O\
M:/T:S^&?A+QQ_86N3Z9XBDMHXT@ME=K,32)&&N&W;$ 9U'#$D] :U_$OQ?7P
MCX_T3P]J7AK5X=.UF]33+37QY#6KWC1/*L6P2>;@K&XW[-H9<9[UYH_P*^(,
M?[/>@?#J'7?"WVK3KBV,E]):W'ER0V\\4\6%$F0[/'AN<8/'-='>_#3QYJGQ
MNT7QEJ&K>'+_ $73+>.&UTV6VG#V3O'MNYH2)-IED)95=P=J?+_$Q8&>WT4W
MS%_O#\Z/,7^\/SH =13?,7^\/SH\Q?[P_.@!U%-\Q?[P_.CS%_O#\Z '5X9X
M%_:CL_B1<:E;>'?".M7U]#8C4[&W\VT4WMM]H,!;<9ML+AU8^7,4;"],Y ]M
MD(DB=5E\LD$!@1D>]?-OPD_9L\4?"V[\2:A:^)='AU>^T>6P6^M+:;.J7Q<N
MFIZ@KRL'G4EON8_UCC(7:H /7OA+\3X_BKH6HZBFC7^B-8:G<:7+;WS1.6EA
M;;(4>)W5U#;ER#U1AVJ*+XLV<WQ4O_ HTC5EU"TTMM5%Y+;A+:X171&2%BV7
M8&102!MSD9R#C-\%>$-7^&$'@/P=X>AM)/".F:?,FK:E=G]_-, GEF,!OOR2
M-+*Y((Z]R*I:CX!\93?'E/&MIJ?A^/1(=&FT>*TFMYFN=KLDN]F#A21+&. !
M\I/?F@1D?\-1VZ:E?:'-X)\0VWC"*]M;*U\/2FU,]T;B&::%A(LQB0>7;S,^
M]P4V'(.17I?PW\?V/Q.\'V/B+3H+JUMKHR(UM>($FMY8Y&BEBD4$@,LD;J<$
MCC@FO"/#O[//Q#TV*WUB^\2^&+[QS9ZXNOKK)L[@KJ4[6\UM)'<J9/EC$,P2
M)8\"/RQP<DGVCX0> G^&?@.RT*YOUU*^$US>7EVD7E+-<7$\D\S*F3M7?*V
M22!C/-&@'<T4WS%_O#\Z/,7^\/SH&.HIOF+_ 'A^=% 'GU Z#Z444#8'_&AO
MZT44NHA%Z&@]!113 5.]%%%+J/H(?O&G-U%%% @7J:'^]111U 1^@H?M111U
M&,IYZ_E113$ ^]^%"_>-%%2RD"=#0G>BBFR1E/3H:**2*8X??IM%%4MR1?\
MZU)W_P ^E%% !2G^E%%)C0/]ZA.AHHHZ ']VFC^M%%,!1]^D'4T44A#A_2D3
MH:**I '84A^\:**A@+Z?6E/>BBKZ -/44J=#114L:$/]:!U-%% AW?\ *D'2
MBB@!P^_3:**0"MW^E-'4T44UL J=#2#H?K113 !T-.6BBA;@'\5-_AHHI(;%
M;[XH;K^%%%-[B =#]:<?OT44 15(/NT44 -_QI7Z"BB@ _@I#_6BBI*8Y>II
MR]/PHHJT2,?M2MU%%%); )2KU-%% "?QT444F J?>I7_ *T44NH#3T'UI#_6
MBBF]@#UIW\5%%)E(:>@IR]:**;) ]!2'O115  ZBE'W:**0")T-(W0444D-B
)^OUHHHIB/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>mtva-20251231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &F X0# 2(  A$! Q$!_\0
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M:7<E^V3_ //>3_OLUF^);RX3PWJ9%Q("+:0@B1N/E-7:S?$__(M:I_UZR_\
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MDSO*TAW%$0$+OV+D%MH&6-<!732BY03J129Y^)J>SJ-4:C<>C-3_ (2;6/\
MH*WW_@3)_C1_PD^L?]!6^_\  F3_ !K+HK;DCV.7V]7^9_>:G_"3:Q_T%;[_
M ,"9/\:!XFUC_H+7W_@3)_C6711R1[![>K_,_O.+UKQ+J_\ :]Y_Q-K[_6M_
MR\R>OUJI_P ))JW_ $%;[_P)D_QJ+6O^0M>_]=6JC7YA62]K+U?YGV5.<^2.
MO0T_^$CU?_H*WW_@3)_C1_PD>K_]!6^_\"9/\:S**QLC3GEW-'_A)-7_ .@K
M??\ @5)_C5FPU7Q!JE[;65I?ZE=7=S(L,,,5Q(6D=B J@9Y)) K%K9\&^(?^
M$3\7Z'K8@^U?V7?07GD[MOF>7('VY[9QC-)HJ,Y-I-Z'17'A#XD6FMMH\NG>
M(DU06LE[]E_>E_(C#&24#/*+M;)' P:R-,/BS6K#4;ZPEU>\L]-A$][<0RR,
MEM&2%#.<X4$D 9]:]7T3]J"U\'75L^A>$D=+5S]G&L7S3L%DN_M5P"8Q']]D
MB4 ?*%5MP;>:X[2?B?H>GKXNB_X1Q[>TU?3)=+M(M/N4A\A&F$JO,2C><Z[4
M7(VY&[U&,US=4=LE2NN6H_Q_R&GX;?%99HHO[%\2-)+;/>1JAD8O"APSK@\@
M'@XKG-2'BS1M/L;Z^FU6TM+]=]K++.ZB9?4#.<<\'OVKN?#?QJTG1=6L;J3P
M]>"/2-!&DZ-]BODCDL9VR;B\RT3*TCM),1D?)O&"2BFLKXG_ !;M_B/X>\/6
M/]A16-]ID,,4E]F,O(L=O%;JBE45@F(MY#L_S,<8'%"O?5"DJ7(W&;OV_I'$
M?\))JW_06OO_  )D_P :/^$EU?\ Z"M]_P"!4G^-9M%:V1P\\^YI_P#"2ZO_
M -!:^_\  F3_ !H_X275_P#H+7W_ ($R?XUF4460N>7<T_\ A)=7_P"@M??^
M!,G^-=WX5\0ZJVB0DZI>\EO^7F3U^M>8UW_A7_D!P_5_YFO=R9+ZR_1_H;4Y
MR;W.F_X2#5/^@K>_^!+_ .-'_"0:I_T%;W_P)?\ QJE17VG*NQT\TNY=_P"$
M@U3_ *"M[_X$O_C1_P )!JG_ $%;W_P)?_&J5%'*NP<TNY=.OZIS_P 32]_\
M"7_QKI;KPG\0;"_TRPN-/U^*\U-Q%8Q,9=URY (5>>3@@XZ\BN)89!'K7M=Q
M^T/:6]Y>WFG^&"MS=RR7LGV^^+HMTUM]F#($5"JB,R' ;<21\WR@5SUO:1M[
M.*?]:&U+DE?GDT>;Z9#XKUG4YM-L/[8O+^W61Y;>)Y"Z",$R%AG@+@Y/:M:Q
M\&_$34[/3KNST_7;JUU$[;.6-V*SG:6PISUV@G'M6W;_ !ETU_B9+XHN/#B0
MQR&>:2UTZ989GFFA*2;I65LQ[F9PN.,@9.*S?"_Q&T;05\*V=SX?DO\ 1M$G
MN+Z2T^U*K7=XY_=32$H01&JQ#800=I_O8K.3JVNH+;_/S7E]Y:]GUF_ZMY/S
M^XQ+^S\7:78/?7HU>SM$N&M&DFDD0"93ADP3G((P?0UD_P#"0:I_T%;W_P "
M7_QKOO&?QCA\8^"AH=QI$DMZEPSIJE[)%),%:XEN"Q81AO,8S%6.[:0H^3/-
M>:5M24I+]Y&S,ZC2?N2NOU+O_"0:I_T%;W_P)?\ QH_X2#5/^@K>_P#@2_\
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M,CT](-H&\O+&^'W*=KXR/P_E64&E.RDV=%53=)MP2]/Z\S,HHHKJ/-"BBB@
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MQ_T+\O\ W_3_ .+H_P"%'^./^A?E_P"_Z?\ Q=?77\-+^M/_ %JQG\D?N?\
MF+_4++?^?D_OC_\ (GR)_P */\<?]"_+_P!_T_\ BZ/^%(^./^@!+_X$1_\
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M%3G)R:6IZ<<CP\4ES2_#_(_(7_ABGXU_]"#>_P#@1!_\<H_X8I^-?_0@WO\
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M-G_0A7O_ ($0?_'*_7G/MQ1_2CZQ/LA?V)A_YG^'^1^0W_#%7QL_Z$*]_P#
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M_P#%T?\ #)?Q;_Z$N[_[_P /_P 77Z;=?PI.W-'^L6*_EC^/^8?V10[O\/\
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M:+_OD4[[1+_SZR?]]+_C1]HE_P"?63_OI?\ &@!O]EV?_/M%_P!\BC^R[/\
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M.^T2_P#/K)_WTO\ C0+0;_9=G_S[1?\ ?(H_LNS_ .?:+_OD4[[1+_SZR?\
M?2_XT?:)?^?63_OI?\: &_V79_\ /M%_WR*/[+L_^?:+_OD4[[1+_P ^LG_?
M2_XT?:)?^?63_OI?\: &_P!EV?\ S[1?]\BC^R[/_GVB_P"^13OM$O\ SZR?
M]]+_ (T?:)?^?63_ +Z7_&@!O]EV?_/M%_WR*/[+L_\ GVB_[Y%.^T2_\^LG
M_?2_XT?:)?\ GUD_[Z7_ !H ;_9=G_S[1?\ ?(H_LNS_ .?:+_OD4[[1+_SZ
MR?\ ?2_XT?:)?^?63_OI?\: .+U/Q3!I7Q/T/PE)H!:#5;"ZO(M3\Q-BM T0
M:/9][.)0=W [<]N+A^.FFK=Z/)<^&RFB:I<:Q''JD<Z,(X[#S=S&/ 8EQ!(<
M#@<9))Q7H>I>"-*UCQAI/BBZT^\?6]+BD@LYEOY4CB23&\&)9!&V[ R64GY5
M]!7.6GP,\-136,MWI]]?G3KV]O+"-[QXXK87;N\\?EHZI(A\R1<.K95MO2F,
MR_!/Q>MO'WPRU#Q7I>AZ:)[0AWT^YU$1>3%L27=/(T7[IA&V\C#+@##$'-<O
MH/[3FGWU_HMEK/@N3PW/K%O:7%K+J%U&D!24([,9655PJ.",99F^3:I(SZ%8
M?!#P?IFAWFCP^'[D:=>PO;7,,FHSR>=$R1)L=FE)90D,:*"?E5=JX!(-WQ1\
M*?"_C.<RZUX>-_*5B16>=DV+'OVHNUQM7]XX91PP/S!A2 L_#G7K;QWX5AU2
M32X]/N1<7-G<6NX/Y<L$\D#@' R-T;$''2NJ_LNS_P"?:+_OD5@>!O#">!?#
M<&CVRW5VJ2S3R7-PT?F2R2RO+([8(&2[L>!70_:)?^?63_OI?\:!#?[+L_\
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M9/\ OI?\:/M$O_/K)_WTO^- #?[+L_\ GVB_[Y%']EV?_/M%_P!\BG?:)?\
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MU O<,S7(A1$B5V+Y*A8U4KG#?-N!W-G,\/?!WP[X4\60:]I.F3V3PK=%;99
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M(GEH2K+A0</Y@# 8(V\L<D^B_8_^FTW_ 'W1]C_Z;3?]]T@+%%5OL7_3>?\
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MX+>%(%E"/N9WFSMR5CC^8;N/9-2EM=&TV[U"]O)+>TM8GGGE=L*B*I+$\=
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M:;_ON@"Q15?['_TVF_[[H^Q_]-IO^^Z +%%5OL7_ $WG_P"^Z7['_P!-IO\
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MRRM+]GG-A;&YB5F.2%D)_'=WS7K]5_L?_3:;_ONC['_TVF_[[H$6**K?8O\
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MH_MZP_Y[C_OD_P"%<;_#2G[WI0.QV/\ ;UA_SW'_ 'R?\*/[>L/^>X_[Y/\
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M_/<?]\G_  H_MZP_Y[C_ +Y/^%<=CMWH]1F@+'8_V]8?\]Q_WR?\*/[>L/\
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ME7I2T7"PG^17D\-QKLOQ;\7RZ?;>(K6UMM'DCMTOUG?3[Z].QD>#=F*-4QL
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M=*/\YH^GYT@$XIU)]>*%Z4 +2=>:6F\4 +^%)Q2D=#1VZ47"P@ZFE_G1QBE
M[4D#,SQ)%-/X<U:*WFN+:>2SF2.>TC+S1,8V =%!!9P3D 'DUX;9WOBK3OAC
MX7@OX-6B>/Q9#:M<SRSQW>H6P5C#*ZW#N\7F3B)2CL5'H%;%?0M-(!Z@$>E4
M(^3?#5O\44\&:='=Q^*Y->CUVTFB=FO4$L(6V\]&+L1&<B4,TX: DRF-5&T#
MOOB$GB?Q/\0[230)/%.BZ3)I=Y'>O';7*+'B-O+94+B-CO10J)MF+2 [L"O=
MJ1>E 'S7X2O_ (@Z?KWAFP\26NI#4O[=LHTOIYV*7%J;.831;?NMLC7>[ G]
MYRQSMKZ5I-O(.,D=#Z4M+<8A_*CMG-&:6@!/?K2TGX4'TI#-'3"?(;_>_H**
M--SY+?[W]!15W,WN='_8UE_S[I1_8UE_S[I4OVI_^?6;_P =_P :3[7)_P ^
MLW_CO^-(9'_8UE_S[I7A6O?M.^#O#X\7QSZ'?/?>'M;AT8VB;-]YYAQYT1W?
MZM=DQ)/(\D^U>]?:G_Y]9O\ QW_&O,=5_9_\":UJUUJ=WX9EEO[DW)DG^T,&
M)N'C>7'S\9,2X] 6 P';(!QFJ_M1^#]'M?%,EQI<DD^D(S6\%J'G-\5\P/C8
MA\M%* ,[ *"XYZ9]\_L:R_Y]TKRC4?V:/ 6H-<,=#U&W:Z,@N'M=1EB:9)"Q
MDB<K("8V+9*]"57T%>MF[<?\NLQ_[Y_QH C_ +&LO^?=*/[&LO\ GW2I?M3_
M //K-_X[_C1]J?\ Y]9O_'?\: (O[&LO^?=*/[&LO^?=*E^U/_SZS?\ CO\
MC1]J?_GUF_\ '?\ &@"+^QK+_GW2C^QK+_GW2I?M3_\ /K-_X[_C1]J?_GUF
M_P#'?\: (O[&LO\ GW2C^QK+_GW2I/M<G_/K-_X[_C2_:G_Y]9O_ !W_ !H
MB_L:R_Y]TH_L:R_Y]TJ7[4__ #ZS?^._XT?:G_Y]9O\ QW_&@"+^QK+_ )]T
MH_L:R_Y]TJ3[6_\ SZS?^._XT?:Y/^?6;_QW_&@!G]CV7_/NE']CV7_/NE2?
M:G_Y]9O_ !W_ !H^U/\ \^LW_CO^- $7]C67_/NE+_9%G_S[I^52?:G_ .?6
M;_QW_&D^UO\ \^LW_CO^- $?]C67_/NE']C67_/NE2_:G_Y]9O\ QW_&C[4_
M_/K-_P"._P"- $?]D6?_ #[I^5']D6?_ #[I^52?:G_Y]9O_ !W_ !H^U/\
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M\:7[4_\ SZS?^._XT >6_#/XLZ+\3-?O].M]!GT^-+<WMA<SNC+?6HG> R@
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M*^+6BZK\49?!\>A3I#]IN+"#5BZF*:[MXHY9XMF=P"I(,,>"58=AGU3[4_\
MSZS?^._XUQ.G_"_P_I?CR[\7V^EW8UBX+OM>X)@CE=%225(MVU7=8XU9P,D+
M[G(!V7]D6?\ S[I^5']D6?\ S[I^5/\ M<G_ #ZS?^._XT?:W_Y]9O\ QW_&
MD!'_ &-9?\^Z4O\ 9%G_ ,^Z?E3_ +7)_P ^LW_CO^-+]J?_ )]9O_'?\:8$
M7]C67_/NE']C67_/NE2_:G_Y]9O_ !W_ !I/M;_\^LW_ ([_ (T 1_V-9?\
M/NE']C67_/NE2_:G_P"?6;_QW_&C[4__ #ZS?^._XT 1?V-9?\^Z4?V-9?\
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MQ_\ GUG_ "7_ !I ,_L:R_Y]TH_L:R_Y]TJ7[4__ #ZS?^._XT?:G_Y]9O\
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MB;_GZG_-?\*/L3?\_4_YK_A0!X9^S\WCR3QCKC>)_P"VQ!]F;[:NK*XMQ?\
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MM?$KP[X>\8V'A>]U6[CU2\,2H%@9XHWE+B%))0A5&D,<FP,03L/MGLOL3?\
M/U/^:_X4#/$?@#XAUW5_%=_!J5OJ=F(M T]KNUU:XDEECNA-=Q[SO52K2Q1Q
MN054CY>*]XJFNG[6++/*K-C+#;D_4XIWV)O^?J?\U_PH$6J*J_8F_P"?J?\
M-?\ "C[$W_/U/^:_X4 6J*J_8F_Y^I_S7_"C[$W_ #]3_FO^% %JBJOV)O\
MGZG_ #7_  H^Q-_S]3_FO^% %JBJOV)O^?J?\U_PH^Q-_P _4_YK_A0!:HJK
M]B;_ )^I_P U_P */L3?\_4_YK_A0!:KP?\ :/;QK_:6C+X8_M]5:SN#:-H2
MN5_M+SK?R!=%1@0>69\[_DZ[N=M>W?8F_P"?J?\ -?\ "N.\>?$CP[\-I;%-
M=U2\MVN@T@\FW>811*R*\TI1"(XU:6,%VP,N* .[HJK]B;_GZG_-?\*/L3?\
M_4_YK_A0!:HJK]B;_GZG_-?\*/L3?\_4_P":_P"% %JBJOV)O^?J?\U_PH^Q
M-_S]3_FO^% %JBJOV)O^?J?\U_PH^Q-_S]3_ )K_ (4 6J*J_8F_Y^I_S7_"
MC[$W_/U/^:_X4 6J*J_8F_Y^I_S7_"C[$W_/U/\ FO\ A0!:KQG7V\2#]H_P
MP=.?6F\/BUG358@MR++F%C&^6'V<@.%&$/F[FY^0&O7/L3?\_4_YK_A1]B;_
M )^I_P U_P * /D"QU;XF3:7INKZ#+KFM:_=:?JMM/IQ%TEO8WHFU#-P7S]G
M9E?R8Q#(-P"Q[<4^^M/BM%92:CX;O_&LVE))<+:Z?J\<PO/LGV>(2R.S#?YA
MFDE$2LC.-@9!M!!^E?&_C#2/AQI<=_J=S>K'<3^3#!96S3S32%6<A8T0EB%2
M1B<<!"3TK:T:[M?$&DV6J:?J$EU8WL"7-O.A&V2-U#(PR.A!!IC/._@1KVJ:
M_>>-'O+>ZM+-;^U,-I>3M-):RO86SW$&YN?DD8YZ?,6X!R*];JFFG^7G9/*F
M26.W:,D]3TIWV)O^?J?\U_PI"+5%5?L3?\_4_P":_P"%'V)O^?J?\U_PH M4
M55^Q-_S]3_FO^%'V)O\ GZG_ #7_  H M45 ENRC'GRM[L1_A10!!_;=C_S\
MI^M']MV/_/POY&N+V]/>EZ]:FY5CL_[;L?\ GY3]:\!\<?LT:'X[\1:SK=[X
MHDAN[RYBGBCMK..&#*>8 9T3;]H;9*Z"1B& P,\5Z6O2CBF"1Y5J_P"R5X-O
MX[_R-<GM3+<6T]I#Y0:WL_+C=)(TC!!,<K2O(R[A\Q!!XQ4VH_LI^"[RTL((
MM4,0M=1N;UHVME:&5)Q$'B9!MR!Y,>QBQ(''(KT\[:/I^5,1V?\ ;=C_ ,_"
M_D:/[;L?^?A?R-<9]#2T =E_;=C_ ,_"_D:/[;LO^?A/U_PKC,?G1^E(+'9_
MVW8_\_"_D:/[;L?^?A?R-<9TI.1Q3 [3^V['_GX7\C1_;=E_S\)^O^%<8>O!
M^E'\Z .S_MNQ_P"?E/UH_MNR_P"?A/U_PKC/?M0>OO0%CL_[;L?^?A?R-']M
MV7_/PGZ_X5QOZ8HI!8[+^V[+_GX3]?\ "C^V['_GX7\C7&Y_"D;I3 [/^V['
M_GX7\C1_;=E_S\)^O^%<;2>HH [/^V[+_GX3]?\ "C^V[+_GX3]?\*XSV]**
M .S_ +;L?^?A?R-']MV/_/POY&N,Z'ZT=^M '9_VW8_\_"_D:/[;L?\ GY3]
M:XVD_B-(+'0^($TGQ-H&I:/>3YL]0MI+68(2K;'4HV#C@X8UR7PI\"V/PRLK
M]9?$$NNZA?/"9KZ>)824A@2"% B# VQQKD]R2>,X%PY'%)@>M,#M/[;L?^?A
M?R-']MV/_/RGZUQG/ _*CI2"QV?]MV7_ #\)^O\ A1_;=C_S\+^1KC/PH.,_
MUHN.QV?]MV/_ #\+^1H_MNQ_Y^4_6N,_2@#%,1V?]MV7_/PGZ_X4?VW9?\_"
M?K_A7&=N:/<T =G_ &W8_P#/POY&C^V['_GX7\C7&=N*.G>@#L_[;LO^?A/U
M_P */[;L?^?A?R-<9SU]:;4W'8[7^V['_GX7\C1_;=C_ ,_*?K7&?Q<\T-TJ
MA&%\+_A-HWPQUV\U"'7Y]30P-8V$$\:H+*U,\EP8]P&9#OE/S-S@*/<^H?VW
M9?\ /PGZ_P"%<9VYH'2E<;1V?]MV/_/POY&C^V['_GX7\C7&-TI?;TH%8[+^
MV['_ )^4_6C^V[+_ )^$_7_"N,]^M'^<4P.S_MNQ_P"?A?R-']MV7_/PGZ_X
M5QM)TX]: .S_ +;LO^?A/U_PH_MNQ_Y^4_6N,_44$4 =G_;=C_S\I^M']MV/
M_/POY&N,_&CMS0!V?]MV/_/RGZT?VW8_\_"_D:XS\>10?YT@L=G_ &W8_P#/
MRGZUY?H_PFT72/BC/XN37IY83<W.H6^E-$HC@NKB*.*>7S,;F#+&,*> 68\\
M ;@ZFE[\=*5QV.S_ +;L?^?A?R-']MV7_/PGZ_X5Q5._"F*QV?\ ;=E_S\)^
MO^%']MV/_/POY&N,XHXH"QV?]MV/_/RGZT?VW9?\_"?K_A7&'US2TP.R_MNR
M_P"?A/U_PH_MNQ_Y^%_(UQ@_2CB@#L_[;L?^?A?R-']MV7_/PGZ_X5QGXT<M
MSZ4@L=G_ &W9?\_"?K_A1_;=C_S\+^1KC:0]O2BX6.S_ +;L?^?E/UH_MNQ_
MY^%_(UQM)[]J8&)XF^%6C^)/B1:^*6UZ>VMUEL[J[TR.-2ES/:&4VS[R-R;3
M*<A?O;5Z8.?3O[;L?^?A?R-<8/SH;I0!V?\ ;=C_ ,_"_D:/[;LO^?A/U_PK
MC.0OUH_6D!V?]MV/_/POY&C^V[+_ )^$_7_"N,_2D_I3 [3^V['_ )^%_(T?
MVW8_\_"_D:XSCK1UZ=:06.S_ +;L?^?E/UH_MNR_Y^$_7_"N,_SBCJ* L=G_
M &W8_P#/POY&C^V['_GY3]:XS^E''TI@=G_;=C_S\+^1H_MNQ_Y^%_(UQG;Z
M=Z0=32"QVG]MV7_/PGZ_X5YI\5OACI/Q1OK2=O$%QI*BUFTR^2WB5_M=G+)$
M\D.6'R$M"F''(!;U!&SW_K2>U,#L_P"V[+_GX3]?\*/[;L?^?E/UKC-U!]:F
MX['9_P!MV/\ S\+^1H_MNR_Y^$_7_"N+Z&E'TZ50CL_[;LO^?A/U_P */[;L
M?^?A?R-<9CK2T@L=E_;=E_S\)^O^%']MV7_/PGZ_X5QG\J3BF!VG]MV/_/PO
MY&C^V[+_ )^$_7_"N,Z48_\ UT =G_;=E_S\)^O^%']MV/\ S\I^M<8>P_6C
M\:06.S_MNQ_Y^4_6C^V['_GX7\C7&TGUYI@-^)OA:W\?V6EFS\0/H.IZ9=F[
MM+^&!)]C-#) X*.,,#',X]C@]JWO"MIH_@_PQI&A6-R39Z9:164)E.7*1H$7
M. ,G &36'Z9XIM ':_VW9?\ /PGZ_P"%']MV/_/POY&N,^O%'7WH [/^V[+_
M )^$_7_"C^V[+_GX3]?\*XSCK1QTH [/^V['_GX7\C1_;=C_ ,_"_D:XSUH]
M>*0';)J=K*,I,I'3O17-:>?W+?[W]!15:=R=3R?]H=?%$GP=U^+P;=WUCXDF
M-M%:7>F1[[B'=<Q*[HN#]U"Q/'0&O /#WQ=_: TC4;6QU#PAJ-UJ-UXBEMKL
M7&E/+:"W7[/ 7AG5AY<98RSJ2,;2?FX(K[&Y7VI1GIGCTJ2T?*>C_'OXS:I<
M:#*? EW#!+=V=M=VDNA7,4\KM9HUQL+G8D2W)E4R,00H!7?@YS[+X^?'4^'?
M#UW<>"GEU2[U81W5K;Z#=!4@'V?S(92V#&RF2;:Z[E81<MD$-]>;CSSUZT9/
MJ<=*+A85E42,H.5R0#[=C3?\B@G%&.:+ &>M ^]S1NIM)@.XZ4?A2TG'2J$+
M2=O\*.,T<XI##_)H[48[_I1_.A@#=*.E!_.D':@0O\Z6BDXHV&'&WWI/X:4=
M31_*@!:3Z<BA>E#=* %'YTWG\J.:.:8@_BI?\YH[<4?TI##U[5Y/!JVL/\6_
M%_\ 9TFO_9++1Y!'9:E#,;*[O?E:-K4E/+5% VDALNTC<$)FO6/\YI=Q'4T7
M"Q\Y^%O$NJS+II.L>)+S2[WX?V\[SQV]S)!'J)9&9EFBB9O,*ERQ4LP&0 ",
M4S5M<\9O^SQIUOY_B.'QW!&72Z2VO!)<-YDXA&Y(B3N5%(64+UC\W&XY^C(D
M2!0D:K'&O14& .>P'2G[CCZU0CYJU75O'WA_Q1JJ:M/K=_X3NGN]UY%N@-@S
M6^6)8!OW<"2$C!5&>)F4DJ WN?P[OK[4OA]X7O-4#?VG<:5:S70<8)E:%2^1
MV.2<UOR1K-&R2 /&PPRN,@CT(/!%.Z5+8T+2;J/IZ<T=!3$!QFCI1CCZ4M+8
M>XW^*E./SIM% 6'?K1VYI/US2_YS1L M%)ZT#)H 0<YJ1%7>N[A<C/\ 6F=/
M8TM%["M<\8^"-[XRN_%.L?\ "0OK#1?96-['J<;)#!?"\G"I:D@ Q?9Q$?D)
M7[ISN)KV>DS1_.F O?-%)QQ2=_6E<=A1]>M-IS=*;1<!W?BEZ'G\J:?3TI>?
MZ9IB#],TM-YI?2@ _E2#M2]*/0_I0 =*.W%'ZT>E(8?YQ7C?A^[\8R?':]BN
M9=7.EK=7BSV\L;?V:FGBW@-D\3%=AE,QE#;6+<.&  %>R=N*!GIFF(6BBD_G
M2N,-U#=*,=<F@'- @[<4-TH_G3:!CN!1CTYIM.XZT(&-IW;BBC^M,0?RI!U-
M'?BEQB@#SSX^WNJ:9\,K^YT.YU>WU:.XMVMQHL#S32_O5W(51&.PINR1CCC(
MSSR'QF\0:Q_:GC6/2-2UJQN(?"5O=:+;Z/$[32S/<S!F$81CNRD"$[<JK=5R
M37N8..^*C"(9A)L7S "H;'S 'DC/7!Q0!XEX=\8^+$^,FLSZGI^L7/AF5,6?
MEVUTL5M;&&W,4GE%-CM)*\JG_EHFQMP"BL'6M$^(^GKJ6L>&]<\1-C7G@TW1
M-4=[DSV\*;6E9F(VQNR3D*W#*8L?,5KZ.R?7BC_.* /'?@CXDUC6/$5]!J$6
MI6Z)H6GR7%MJDK22Q77G74>_YE4J98HTDV[5XV\5[#U-((D1W=4"N^"[!0"<
M<#)[XI]*]P$;[S4<;?>FTX]!C\:+CM8/TH_#I2<T<TQ"_P!*7_\ 6112=.:
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M_P#8-C_S[C_OH_XT?V#8?\^X_,_XU-]M_P"G>?\ [X_^O2_;#_S[S?\ ?/\
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M -\?_7IWVS_IA-_WS0!7_L&Q_P"?<?\ ?1_QI?["L/\ GW'_ 'T?\:G^V?\
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M;I3$BW,ID2TA,KRF&%3]U/,E=L<]>N  .[^V_P#3O/\ ]\?_ %Z (?[!L/\
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M $PF_P"^: (/["L/^?<?]]'_ !I/[!L?^?<?]]'_ !JQ]L_Z83?]\TGVP_\
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M/_/O-_WS_P#7H @_L&Q_Y]Q_WT?\:/[!L?\ GW'_ 'T?\:G^V'_GWF_[Y_\
MKTOVS_IA-_WS0!7_ +!L?^?<?]]'_&C^P;'_ )]Q_P!]'_&I_MA_Y]YO^^?_
M *]+]L_Z83?]\T 5_P"P;'_GW'_?1_QI?["L/^?<?]]'_&IOMA_Y]YO^^?\
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M#_OV* +5%5?L]Q_S]?\ D,4?9[C_ )^O_(8H M455^SW'_/U_P"0Q1]GN/\
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M )^O_(8H^SW'_/U_Y#% %JBJOV>X_P"?K_R&*/L]Q_S]?^0Q0!:HJK]GN/\
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MO?\ 2@K^% '=?;K;_GXB_P"^Q1]MM_\ GO'_ -]BN%_&EH [G[;;_P#/>/\
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M_?8KAJ3'3]: .Z^VV_\ SWC_ .^Q1]NMO^?B+_OL5POU[T8_GUH [K[;;_\
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MV_2@ ZT'_(HZ-]*6@!/\XH[<T>AZT=O\:-@W _6D_AI?\YI: "D[<T?YXI:
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M^;^@HK0AFS_PC-EZ2?\ ?='_  C-E_TT_P"^JN_VC!ZO_P!^V_PH_M&#U?\
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M1FS_ .FG_?57?[1@]7_[]M_A1_:,'J__ '[;_"@12_X1FR])/^^Z/^$9L_\
MII_WU5W^T8/5_P#OVW^%']HP>K_]^V_PH I?\(S9?]-/^^J/^$9LO^FG_?57
M?[1@]7_[]M_A1_:,'J__ '[;_"D!2_X1FR_Z:?\ ?5'_  C-EZ2?]]U=_M&#
MU?\ []M_A1_:,'J__?MO\* *7_",V7I)_P!]T?\ ",V7I)_WW5W^T8/5_P#O
MVW^%']HP>K_]^V_PH I?\(S9?]-/^^J/^$9LO^FG_?57?[1@]7_[]M_A1_:,
M'J__ '[;_"@"E_PC-G_TT_[ZH_X1FR_Z:?\ ?57?[1@]7_[]M_A1_:,'J_\
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M2?\ ?='_  C-E_TT_P"^JN_VC!ZO_P!^V_PH_M&#U?\ []M_A2 I?\(U9_\
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MS_Z:?]]5=_M&#U?_ +]M_A1_:,'J_P#W[;_"@"E_PC-E_P!-/^^J/^$:L_\
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MQ?\ ?L_XT@N6:*K>7=?\]XO^_9_QH\NZ_P">\7_?L_XT!<LT56\NZ_Y[Q?\
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M[5#_ ,]H_P#OH5P9]<4?S]*!G>?:8?\ GJG_ 'T*^:/'O[.7B;Q7JGB1M/\
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M-)0!W_VB+_GJG_?0I/M,/_/5/^^A7!\8HP,T =[]HB_YZI_WT*/M$7_/5/\
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M:,^M+2<=_P Z-@#WI/X:4=31ZT,$>/>,_B;KFC?&32O#UK<VT-F\^FP#3)(
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M;_OH?X4?\(O:?WY?^^A_A5_^T;?_ )Z?H:3^T[;_ )ZC\C0!1_X1>T_OR_\
M?0_PH_X1>T_OR_\ ?0_PJ_\ VC;_ //3]#1_:-O_ ,]/T- %#_A%[3^_+_WT
M/\*/^$7M/[\O_?0_PJ__ &C;_P#/3]#2?VG;?\]1^1H H_\ "+VG]^7_ +Z'
M^%'_  B]I_?F_P"^A_A5[^T[;_GJ/R-']IVW_/4?D: */_"+VG]^7_OH?X4?
M\(O:?WY?^^A_A5[^T[;_ )ZC\C1_:=M_SU'Y&@"C_P (O:?WYO\ OH?X4?\
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M^T[;_GJ/R-+_ &C;_P#/3]#0!D7NB:;IMG/=75PUO;0(TLLTD@"HBC+,3C
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MH)(!']CM3<2W!C+#)D;?(?G..%48SDGU+^T[;_GJ/R- %'_A%[3^_+_WT/\
M"C_A%[3^_+_WT/\ "KW]IVW_ #U'Y&E_M&W_ .>GZ&@"A_PB]I_?E_[Z'^%'
M_"+VG]^7_OH?X5>_M.V_YZC\C1_:=M_SU'Y&@"C_ ,(O:?WY?^^A_A1_PB]I
M_?F_[Z'^%7O[3MO^>H_(T?VG;?\ /4?D: */_"+VG]^;_OH?X4?\(O:?WYO^
M^A_A5_\ M&W_ .>GZ&D_M.V_YZC\C0!1_P"$7M/[\W_?0_PH_P"$7M/[\O\
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MVW6\<(F>4J%)"A2O49RZC&33=(\9^$-?O=#M=,OKS4)M8L8]3MOL]G,ZK;2
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M#_BK-\8_!IU^71FT0?:/*CC%TMP)%,:.&#  C[^TJ0""IZC!KKUT2-2Q%M9
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M;=_\](/^^#_C0%RS15;;=_\ /2#_ +X/^-&V[_YZ0?\ ?!_QH"Y9HJMMO/\
MGI#_ -\'_&C;=_\ /2#_ +X/^- 7+-%5MMW_ ,](/^^#_C1MN_\ GI!_WP?\
M: N>(>//C%X@T#XXZ3X:LIK.*Q:XTV Z7-#NN-0CNFG$UQ&V[*K (5)PI'WM
MQ&5Q[Q7.7NIZ7;>(]/M+N_TF+79D<V=O,56Y=,?.8U+;F''.T?6MK;>?\](?
M^^#_ (T!<LT56VW?_/2#_O@_XT;;O_GI!_WP?\: N6:*K;;O_GI!_P!\'_&C
M;=_\](/^^#_C0%RS15;;=_\ /2#_ +X/^-&V[_YZ0?\ ?!_QH"Y9HJMMN_\
MGI!_WP?\:-MW_P ](/\ O@_XT!<LT56VW?\ ST@_[X/^-&V[_P">D'_?!_QH
M"Y9HJMMN_P#GI!_WP?\ &C;>?\](?^^#_C0%RS7AG[1'Q;U[X;ZAI4.D75A8
M;K&YU!4OH?,.IRQ36T:V,?S+M=Q.S97<WR# QNKVK;=_\](/^^#_ (UB^(-2
MTO3)-.&N:AI5K)+<JED+YE0O-@@"/<PR^"<!>: .CHJMMN_^>D'_ 'P?\:-M
MW_ST@_[X/^- 7+-%5MMY_P ](?\ O@_XT;;O_GI!_P!\'_&@+EFBJVV[_P">
MD'_?!_QHVW?_ #T@_P"^#_C0%RS15;;=_P#/2#_O@_XT;;O_ )Z0?]\'_&@+
MEFBJVV\_YZ0_]\'_ !HVW?\ ST@_[X/^- 7+-%5MMW_ST@_[X/\ C1MN_P#G
MI!_WP?\ &@+EFBJVV[_YZ0?]\'_&C;=_\](/^^#_ (T!<\V^/'CS4/ ^B:)]
M@U:R\/?VEJ!M)M:U&$2PV:+;3S D,RC+M"L8R?\ EIQSBNO^'NO7?BGP)X<U
MK4+=;._U'3K>\N+=00L4DD:LR@'D %B.>:?XGU#3M*T>6?Q#?:59Z4&19)=2
M*I"#N&W)=L=<8SWK3C>XGC22.:!XV (95)!!Z$'- %VBJVV[_P">D'_?!_QH
MVW?_ #T@_P"^#_C0%RS15;;=_P#/2#_O@_XT;;S_ )Z0_P#?!_QH"Y9HJMMN
M_P#GI!_WP?\ &C;=_P#/2#_O@_XT!<LT5 BW&/G>,GV0_P"-% 7)=Z_WA^=&
M]?[P_.N3\M?[J_D*!&O]U?R%.P7.K\U/[Z_G7S+XV_9W\::[K/B9] UJS\/Z
M'JFHK?RZ5;ZC*#>R%I#)(93 S6Q;=&YC42HSQ[OEKW#8G]Q?R%)Y8_NC\J+!
M<\*\0_LW?$#4K74+6/Q[/<6*SP&RMI]3F222W8/)=)--Y;#<9W1D<(?EC487
M/$FI_LT>,[C[)+#XTNY)SJ\]Y=N=8G262(B-;9A(8G DBV2?*$4,96.0:]Q\
MM?[H_(4;%_NK^0IV%<ZOS4_OK^=+O7^\/SKD]B_W5S]!2[$_N+^0I6'<ZO>O
M]X?G1O7^\/SKD]B?W1^0H\M?[H_(46"YUF]?[P_.C>O]X?G7)[%_NK^5+L3^
MXOY"BP7.J\U/[Z_G1YJ?WU_.N4V+_=7\A1Y:_P!U?R%%@N=9O7^\/SHWK_>'
MYUR?EI_< _ 4>6F<[!^5.P7.LWK_ 'A^=)YJ?WU_.N3\M/[J_E2[5]%_(4K!
M<ZS>O]X?G2>:G]]?SKE-B\_*OY"EV)_<7\A18+G5[U_O#\Z-Z_WA^=<GL7^Z
MOY"CRT_N@?A18+G6;U_O#\Z-Z_WA^=<GY2?W%_*C8G]Q?R%.P7.LWK_>'YTG
MFI_?7\ZY38O]U?R%+L3^XOY"E8+G5[U_O#\Z-Z_WA^=<IL3^XOY"D\M/[J_D
M*+!<TO%^BGQ1X3UK1X[H6DFH64UHMP!DQ&2,KNQGJ-V>M<+\"?AGJ7PWL-6;
M5WTR.[OVM1]ETAF:WC6"TBMPP+*IW/Y18C'&0,MC)ZC8O]U?R%&Q?[J_E185
MSK-Z_P!X?G1O7^\/SKD_+7^ZOY4;%_NK^0HL.YUF]?[P_.C>O]X?G7)[%_NC
M\J/*7^XOY46"YUF]?[P_.C>O]X?G7);%_NK^0I=B<Y5?R%%@N=9O7^\/SHWK
M_>'YUR?E+_<7\J/+7^Z/R%%@N=9O7^\/SHWK_>'YUR?EK_=7\A2>6G]P?E0T
M%SK=Z_WA^=)YJ?WU_.N4V+_=7\A1L7^ZOY"BPKG5^:G]]?SI=Z_WA^=<EL7^
MZOY"E\M?[@_*BP[GG_P1^"NK?#7Q-?W^IWNGSPI9-IUL]F7,EVC7D]SY]P&
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M!D@=@30!/3Z910 O4TZF44 %%/HH 91110 ^D_SBEIE #OQH_I2TR@ HHI]
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M1YMS_P \$_[^?_6HU$4O^$?3_GO)^0_PH_X1]/\ GXE_(?X5=\VY_P">"?\
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M+_A'T_Y[R?D/\*/^$?3_ )^)?R'^%7?-N?\ G@G_ '\_^M1YMS_SP3_OY_\
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M+\>=(_LW^W5TP3Z:UN]FSC31:AKC^T!<C.PR%?*V[QN^YL_BKWV@"K_:5O\
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MS\NZNR^'L>KQ> O#:>(69]>73;8:@7()-QY2^821QG=GIQZ4 ;7]I6_]YO\
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M?F:** #^S+7_ )XC\S1_9EK_ ,\1^9HHH /[,M?^>(_,T?V9:_\ /$?F:**
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4 )XC\S110 ]+*! 0L8 HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>mtva-20251231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %! AX# 2(  A$! Q$!_\0
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M $&+'_P)7_&MFBCW.S^__@!9F-_PENA_]!BQ_P# E?\ &C_A+=#_ .@Q8_\
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M_P#08L?_  )7_&MFBCW.S^__ ( 69C?\);H?_08L?_ E?\:/^$MT/_H,6/\
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MUR]J)#M:X\M>6$:Y; ') '>N[K)\0>(M.\+:>+W4[@6ULTL4 <@L3)(ZQHH
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M.+3 5BE,L9D#&1@BIM );<S*N,<YJ[%I=C;V L8K.WCLMNT6R1J(@/3:!C%
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M]AHK?P'>R*3867BW3YKQOX4C)DC1F]A+)$<^U>K5'+%'/&4D19$/57&0?PH
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M2+7);;!C%Q+=*8E.WY=V(ISQQR<<$5[Q4:PQK*T@10[XW,!R<=,F@+DE%%%
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M+K,4MS')83RK]DB261RJ!I"&8-PK;&1,+QB(<\UWTJ;L'+#GL2*DIK]!]10
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M!/\ S/LS]FOQSK?C_P -:O=:]>&[N+>]\F-@H3Y?+0] !W)KV/R5]7_[[/\
MC7@'[&W_ ")VO_\ 82_]I)7T'7Y'G%.%+'U84TDD]EIT1_0/#M6IB,JH5*LG
M*36K>K>K(_)7U?\ [[/^-'DKZO\ ]]G_ !J2BO'/HK',^/KZ?1O GB+4+.0Q
M7EIIMS<0R9SM=(F*G!]P*_,!/VV/C)L'_%7L??[%!_\ $5^GGQ2_Y)CXO_[
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M $/,G_@!;_\ QND_X;Y^.W_0\R?^ %O_ /&Z^?:*/9P[!]<Q/_/Q_>S]A_V
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M3)EWQ.HZE2* /RPE_P!=)_O-_.HZ^@G_ &+_ !HTCD:IHN"Q/,LO_P 13?\
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MT"BBBOMC\Z"OT4_X)J_\DO\ %'_8:_\ :,=?G77Z*_\ !-7_ ))=XI_[#/\
M[1CKYS/_ /<9>J_,^MX7_P"1BO1GV#1117Y>?L85YS^T;_R0#XC_ /8O7_\
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MW_DWWQ__ -@B?^5?CZ/Z5]_PY_N\_7]$?+YM_$CZ#J***^N/""OTP_X)V?\
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M&P99$895E/<$$$5$J]2:Y92;1I3PE"E+GA!)ENBBBL3K"BBB@ HHHH ****
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ML%^T[_R;[X__ .P1/_*OQ]']*^_X<_W>?K^B/E\V_B1]!U%%%?7'A!7Z8?\
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M\(^!=/\ !MQJ,EE)<2->R;V69P1$H9V$:  84-(YYR?FZUTKCI]10 ^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#BO%7P>\&>-DE&K>'K2626>.Y
MDG@!MYGE0Y1C+$5<D')Y-<[X'^ MC\-S>#PYK6IZ<E[K@U>Z4RF;SH@I7[*Q
MDW?)SDN,.<#+5ZO7SA\'=(^,3_&+Q!JWB^XFA\,C=!#9M+&Q8*N^)2?+574?
M:&7S(@F6BPV[:,@':^'/@=/I7B30[W4/&.JZ]I?AZ::?2-/O4CWP/(CQYEG
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MA4$C(1P>02.":]8CC6)%1%"JHP .@%/HH **** "BBB@ IK]!]13J:_0?44
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MI&>0RG)/[S)VOO''[S'\->ED9(Z8!IU% !1110 4444 %%%% !1110 4444
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MN2@@M;N[2*27<Q5=JL03D@@8ZGBN?L/C3X79-1DU74[7P]#:ZK=:5$^JW4<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>mtva-20251231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $R SP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK'U^_FLC%Y3;<YSQ0!L45Q
M_P#;EY_ST_2E_MN]_P">GZ4 =?17'_VY>_\ /3]*/[<O/^>GZ4 =A17'_P!N
M7G_/3]!2_P!MWO\ ST_2@#KZ*X_^W+S_ )Z?I1_;EY_SUQ^5 '845R']MWO_
M #T_2C^V[T?\M/TH Z^BN/.N7H_Y:?I1_;EY_P ]/TH ["BN/_MR\'_+3^5'
M]N7G_/3]* .PHKD!KEY_ST_05,=8NC:,_F?.' Z>QH ZFBN/_MR]_P">GZ4C
M:]=(I9YU11U9B !^- '8T5QS:_<JH9KE$3H&9@%/IS3O[<O,?ZW/X"@#KZ*X
M_P#MR\_YZ?I2_P!MWO\ STQ^ H Z^BN-7Q'/(Q6.\AE8=5C=6(^H%/&N7O\
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M\)A;?\^.I?\ @&_^% &]16#_ ,)A;?\ /CJ7_@&_^%'_  F%M_SXZE_X!O\
MX4 ;U%8/_"86W_/CJ7_@&_\ A1_PF%M_SXZE_P" ;_X4 ;U%8/\ PF%M_P ^
M.I?^ ;_X4?\ "86W_/CJ7_@&_P#A0!O45@_\)A;?\^.I?^ ;_P"%'_"86W_/
MCJ7_ (!O_A0!O45@_P#"86W_ #XZE_X!O_A1_P )A;?\^.I?^ ;_ .% &]16
M#_PF%M_SXZE_X!O_ (4?\)A;?\^.I?\ @&_^% &]16#_ ,)A;?\ /CJ7_@&_
M^%'_  F%M_SXZE_X!O\ X4 ;U%8/_"86W_/CJ7_@&_\ A1_PF%M_SXZE_P"
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MCBDN?, #K*QVMC! V<$'-<AJ'@1/'7AK7P/[0;Q5:^++F );H'_U@4*9>NU
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MZ:O^RYXWLO _B'1QK5KXSL[SQ!::@^C7T4=E%>V<5N(FA,B F(EA&P*X(\@
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M.5;YE?[4@7+RH!V&"*F669=!OFC)6=M_*_Y%+&8N27*T[J_Z'TU_P\=\#_\
M0'U7_OW1_P /'? __0'U7_OW7QE\:? $/@:ZL#::+=:?ISF6)+R:Y$RW)0X8
MC'W2.X]ZZ>'X(Z+8?!R76=5O+J#Q,DMA<30*OR6EK=.P0,.[[ '^C"J>59<H
M1FT_>=M_D3]<Q?,XZ:>1]3?\/'? _P#T!]5_[]T?\/'? _\ T!]5_P"_=?,7
M[1/P/T?X4^&["^LENHII;W[- 97WK>0>4'\X_P!PY(&VJFA?LKZCK/AZTU5O
M%NB6#3V2:B;6Y+"2*W)P9&]A4QRW+'351W2?F-XO&J;@K-H^J/\ AX[X'_Z
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M39])BZ"J0"1GT-9MKHNDV>NWFM0Z=!%J]Y$D-Q?*N)947[JL?05P/PP^(O\
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MG^G>,?C3J/[2GPYN-1\$Z[HWA VWV=[6*\1[4!H<L\O?<K>O8>M C[9HHHH
M**** "BBB@#+A_Y&6[_Z]8O_ $)ZU*RX?^1EN_\ KUB_]">M2@ KX&_X*9,J
MZSX+R0/W4_7ZK7WS7SS^TY8Z;>:KH_\ :&BZ9JVV-MG]HVB3[.>=NX'&:]#
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MO@T7PUG_ )$WPT/^X3#_ /$T?V)X:_Z$SPU_X*H?_B:7]M8-Q4'1;2_X<?\
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M79]9CV,O9L\ZUG0].\1V$EAJUA;ZE8R8+VUT@>-L'(R#[\UY-X[_ &>4\?\
MBS2WO+RRMO".GO%-'IEM8(LX,9RJ"7J(\CI7TX_AZP09,/ZFJUK8Z-?M(MM)
M#<F)MD@AEW%&]#@\'ZU#KPEN@5-]SYJ^)'P/\3_$'P%JOAA_&KQ0:CJ#7+RR
MVH<I!N#1PKSP%(ZUIWOP9OO%5MX<L?%6NG4]/T>Q>+R;>+RO/N2NQ9F'3Y%.
M5'8@&OH)]/T9+U;,R0K=LN\0&4;R/4+G.*:UGH8MI)Q+ 88R5:03#:IZ8)SP
M?:E[6'8?)+N?/GPB^!$/PT\#^(?#\^H"^?6HQ!+)''Y2+&MJMLA"_P!XHBEC
M_$Q)JE\ ?AL=+^%'ARP\4>'[:'Q)X>\^PM;NY@#21HKGRY(R>Q!!KZ/U6WT/
M0[,7FH21VML72+S)7P-[L%4?4L0/QJ2\TO2-.A,]VT5M"#@O-)L4'ZFA58+H
M+V;[GRWH?[.&HZ?J^O>))O$D47BR]MOL5G?Z;8I;QVT6_<6V#[TC=VJKK?[*
M2:WXU?4Y/$4O]BWU[::IJ=CY(,EQ=V^-C*_\*D@$BOK1-"TV5 ZQAE89#*W!
M'L:2'1=,G4O&B2)R"4?/U[T>TIVV'R2[GS1\;OV;=,^.&O:;J5_J$MFVGZ;/
M9VQ@ WPS,ZO'.K=F4K^1->)6W@+XD^&/VA-0U&#0)]9U&XU.PD76[NS633WM
M8X@DTIDW9CFQNP #R?>OOS2[;0]=LEO-.DBN[5B5$L+[E)!P1GV(-)=V^AZ?
M?6-G</'#<WKLEM&[D-*RH7(7UPJL?PI2JPD[V!0DCY^_9Q\(ZIX;\+:_J&M6
MDEAJ6OZ]>ZLUK*,/$CR$1JWOL5?SKUBNGLX= O\ 4+JQMI8I;NTP)H4<EH\]
M,UH?\(Y8_P#/+]36BQ$8JUA>S9Q!Z5L>%O\ D+#_ '3_ "KH/^$<L/\ GC^I
MIL6F6]AJ%NT,>PL&!Y]JF==3BTD-0::8MK_R,FH?]>UO_P"A2UJ5EVO_ ",F
MH?\ 7M;_ /H4M:E<9N>'?$#6=5C\>W%M!=:E!J*S6R:9'!$QA,;\2L<#:<=3
MNZ8%5?#_ (J\06GB_3[?6FOM4T_[6R6TD:,BL^]8RQ./F5<D@'L2>PKWHJ"0
M2 2.^*38O'RCCIQTH )&95RJ[CZ9Q53[5<GE;7(['>*NU'!_JEH K_:;K_GT
M_P#(@H^TW7_/I_Y$%7** *?VFZ_Y]/\ R(*\,\??MJ^ ?AMXOU+PUK2:DFJ:
M>ZI.L%MO0$J&&&SSPPKW^OR3_;#_ .3E/''_ %\Q?^B(Z]S*,%2QM:4*M[)7
MT]4>;C\1/#4U*&]_\S[._P"'AOPM]-8_\ __ *]-'_!0KX5KG":L,]<677]:
M_,^BOJ_[ P?][[_^ >'_ &IB/+[O^"?I#J?[=GP:UE[-[VPU&Y:SF%Q;^98
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M_H3UJ4 %?/O[3'_(5TC_ *YM_.OH*O%?CSX0U?Q1J>G'2[0W(AC._!QC)XH
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M#X_$G]OC0[<ZONWBZ:(DAL8W '@-CN!FD%SP/X_^--4\&?M&^&FTN2+3WO\
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M44L=_P#"GQ'+9W__ !4^@V5]'/>0Z3*4CN+FWB>4(3(0,JJ[W'<@"OK@^"O
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M*,#T%+10 A ]*;Q3FZ&N?\:>'KOQ5H4MA8ZW>^'IW((O]/V><F#T&]6'/TH
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M XY- 'T/4<'^J6GMG'RXS[TR#_4KGKB@"2BBB@ K\D_VP_\ DY3QQ_U\Q?\
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M^--7\-%X/$=OK5BZ:3.VJV5MY9MKB:XVS6S,"5;Y0#QR >: /LL&ZY^2(_\
M C2-]JX^6(?5C7C[_M/Z+I7CZX\*ZOIEWI3Q6]W<B\FDB9"EM&9)"RJQ905!
M(R.<50N_VK[+3/"6GZWJGA/5])759(4TV"\:&-KM98V<,"7PH"KDYQC(H ]N
M4W(Z+$/Q/-*HN2<[(C_P(U\MS_M3SZAXV\.ZYHFC:SK&@W6CWDUQI5H(R\4D
M+@.S$MC@9Q@G-=QJ'[6.CP*UUIWAW5]8TFWM;:[O]1M$3R[-9@-H?+ DC/('
M2@#VT?:1GY(_Q8T'[41]R+_OHUP'Q5^--K\+_#5IKCZ5<ZM93QM,7MY8HPJJ
MF_J[#)(' '4UY1\8_P!JI9O 6JCP=I6L7-T-'LM4?5+6--E@MRRF(/ELD[3D
MX!P"* 1]!Z!X;L_"UM-;:1IEGIUO-,]Q(EN"H>1CEG/N:T_])_N1?]]&O%_!
M_P >+1/%+:%>O?WUW/J-MIJ,8D6.*1K0S$@@Y*G:>3SDU/%^U#I-YJNB:=9Z
M)?SW6J37$42,\<?^ID,;8+,-QR,X'.*+ >P@7(/W(O\ OHTF+D _)%Z_>-?.
MVC?M=R6&@3W7B;PY<6E]-K=SI6GP))%&LXC+9)9GP-H R2>I&*A\:_M=6FJ_
M#JXNO"6A:SJ5_<Z#-JC2621LVGH"4!DRW)W#HN>E 'T<#=9X6(^^33]UU_<B
M_P"^C7/_  OU&YU;X<>$KV\F-Q=W6D6D\TQZR2-"I9OQ))KJ: *VZZ_N1?\
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MEC_U^3_^A5^8-?I]^P#_ ,F^6/\ U^3_ /H5?-Y__N?_ &\OU/8RK_>'Z/\
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M_P E=\/_ /8)_P#:AKY+K]6RO_<J7H?$8[_>9^OZ!1117JG"%%%% !7Z??L
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M\JL1&$QS@#[O/)Z #-:S_&+PHNNW>C2ZH(;ZV:,.LJ,JMO.%*L1AAGC(XZ4
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MC[K XZ<[3Q720Z7\4(+B.Y_MK4=0CM$L4MY4AV1S*Q(G9D/)(7KFO4?^%_\
M@<:5:Z@VK[(+FX>V57A<.KH5#[EQE0OF(23P 0:KZ?\ 'KP[K6J7=M8R2O'8
MWEQ9W;RQ,A#11ER8QC]X,#M3 \J,_P 1UTVU5+;4Y+:W5X;O457,URAFC+R1
M@\IE2PV]MIQ5C1K7XHW-PEX]QJJ6=I+ ;&&11F6(W #>;W)\LD\UZKX=^-&C
M>*M<C@TUS/IC:=)?M=X(*;'"LC*>01FM(?%[P?F0_P!NVO[L*7&[[H92PS]0
M": /(?B'KOCNX^+NMV/AB7499[)H/LL*H#:+&UHS/N]3YGE]:/!FD?$+4;CP
M]'?:SJ3Z?-=M-J$0C,;P.MK*6C9CU1IO+QC@8QWKT2W^-_A*;&I6MW =.E@D
MEGN?NS QL$VF/&XG) %9ND_M+>%=7\7QZ2EPR6EU:0W%E>&-@)6=G781CY3E
M,#/4D"A >66\OQ;A2W2*#4H=:CMX1;PB)1:^5Y!,N\=-_F\?E6YX-T?QA;>%
M?B!?V,.KQZQ?06WV2XOE'GM,%Q)M![ DXKT2+X_:+J_@71O%>CQ37&F:C?K9
M W49A9,L5+$'TP:T8/CMX*NHG>+5O,VW:V0C$;;WD)P-JXRR_P"T.* /'O$,
M?Q(\/W>KS#6KZU@TZP#VADB,HND$0+9/0/OSR:P;/5?B;?Z(DT3:^^BW%O++
M:RA!]H:]^SH80>_EF7=QTSQTKZ>\.^,=%\;KJ4&FSB^BLYC;3DQGRRPZ@$\-
M^%=!#$L<2H@"H!A0HP * /F&7PIX[U.'3]9\23:O)?VOBA6$%L^V.*V5&"L%
M'5=V,GWK/,7Q1;19)-0O]4F2ZNS'JEC;0$2P#=)AHV_ND>6,+7U@%/KDTI3(
MQDT ?-?]A^/M&^&/@FRTBSN[:_AM9A=_NU,L3$';GT-<UXN?XH^!M&U>_CU'
M6)[>(R1*\@#E8R8-A'JQ9I0#_A7USM/8U%/:QW4;1S(DL;8RCC(..1Q0!\@W
M.F_$NXN&UG3;?5)(8X9+>TN[E,W"V;39?/?=MY!ZXKK&T#XDW=Q:K'KNJW-G
M#'9+%/ GE!TDO)UFW \EEM_+&3Z!NM?2JQ[5V]J78<'FBX'ROIL'Q<GU)8KS
M4+[3VMH'6QWP;_M."PP^.-Q&.35:]\*_$":X\/S:JVLWB6EQ%=%]W*2O P<'
M'50^WCH*^L=G/7BEV8Z'% 'R=?S_ !6\/:3=:XSZA;FRB&+<1KY0C\IR[%!U
M(;;6]X"UWQ1X@^!7BVZTG5+V]\4//'Y$9/F26A98=R*QX;J[^V[':OI&2%94
M9' =&&"K#((JII6B66AV:VNGVL-E;*2PB@0(N3U.!0!\R:VGQ0TN2;3XWUN:
MV@>?^RYXP&:6?*F(2GNF-W7BN[\6:CXML?''F3VFJWEE%I$;VEOIA"QS7>#Y
MRN?RQFO;!'[YI0N!@4 ?+6D:3\1O%%AJ-IJ!U:+2OLM^T$#'YI6,8\I'8\D9
M+"L;18_B/I6@V]EY?B"'0HXV0 )_I*W8MHMBYZ^7Y_F#TXQTKZ]"8QSFEV>Y
MH ^5-)\)?$O3$UG4TNKW3M4U*^NGNAQY"@:=N27'8F=$&?J.AK&U&Y^(WQ'\
M/:;?W]IJYMM9@CU*RL;= $A9KC(CD]A$$//J:^P98%FC:-U#(PP5(R"/2DBM
MT@C2.)1'&@"JBC  '0 4 ?-%POQ%TWP]HT7D:S/K,]ZT[77F?NXE610L6P=B
MF3S6)I/A_P"(&B16.EV5WJND6AOKJ2>YE1IMLYFS']4*]NG-?6VW\*"I]: /
MG?X]:3XN\0^)-.TN"#4;O2633Y(5LEQ$\ZWT+3F4^@B4L/H>]<SHVE?%+5+N
MWLM4NKO2(OL06WB6W^28E7\Y&V\!B<8)Z<5]7;>:38<@YYH ^=4L/&OAOX >
M&8_"Z:E_;UC*(+FTN/GF8,Q1L[NRY#?A7)P>%?BGXAN[#5]8.I6^J:;#<P0O
M$H4N4 "-QVD()Q7UMLYSGF@J3GF@#Y'U+1OBA_:TFKBPNK>Y:/[-/<1Q@,ML
M;DE]N.^W!R.<9KK?'FK>+/#G@3X?V<^LZC?7%_J)@O;FP@*7$D.PE1@\C'&3
MUKZ+V'N:CELX9GB>2-'>,[D9ER5/J/2@#Y474/B_=0648L]5M-5CTJ:&YE;#
M+,3"[0R!>BN&V*>Y(-6M8\'>-?#GBC79M%75;Z_N8K-HIKIO-C?:/WAP> <U
M]2A#ZTNWU.: /DS7=;\=Z/X:M-17^V894@*ZC/-&#(L[3J&6/T&TG '%7].U
M+XC7-UH5H++6Q FIHT-[<-S)9-*JNDB_W@A8[C7U!/:QW,9CF194)!VN,CCI
M4@3&>>* /DGPKX8^(>E:3X?T;3DU>SM(XH;:^N)<-,C?;;CS@'/./+,9'L0:
MD\(>+O&7_"VM%T'Q+JU]8QV<L:*L@_X^ 6.U' ^\6 'S=J^LMG&*I2Z%I\VI
MQ:B]E;O?Q*42Y:,>8JGL&ZT ?/WC33_B3<>*=<.F/J%KI\<\\]K]E55$I"Q>
M6">XSOJK\</!/B3Q+K5O<VUMJ,TUSX>:V(MV/E"XWHWS+TS@,?PKZ7V<4NWW
MH ^6)].^*5IX@M=(&IZA8:';7$@L]0DB,K%O,4H'Q]Y=A8#/'Y5U_P :--\4
MZGKFHZ=8&_U.RU'0Y[1;6RS"+64Q.3-NZ-N(5 .H+ U[P$Q1L&: /ER#5?B5
MING1Z3H]GJTC!;:2TEGCR$@%H ZL3_%YH/!KGXW\?>%9+C4M+_M=)=<U&UT]
MOMZ@RLSQ8:4#TC8-7V&%/K44MI%.\;2HLC1MN0LN=I]1Z4 ,L(9+:S@BEE,T
MJ(JM(1RQQR?QHG_X_K7_ (%_*K(!SUJM/_Q_6O\ P+^5 BK:_P#(R:A_U[6_
M_H4M:E9=K_R,FH?]>UO_ .A2UJ4#"BBB@ J.#_5+4E1P?ZI: )**** "OR3_
M &P_^3E/''_7S%_Z(CK];*_)/]L/_DY3QQ_U\Q?^B(Z^JX=_WF?^']4>)FW\
M&/K^C/&Z***_03Y4**** "FO]QOI3J:_W&^E"W$?L=^SO_R0_P %?]@V+^5>
MB5YW^SO_ ,D/\%?]@V+^5>B5^.8C^-/U?YGZ%2^"/H@HHHKG- HHHH ****
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M3,_G ]F9G8GZTOC3]G'2?&/BZ779M70O+=/.]M-$'C*LJ@KC_@/6O</LD/\
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M)!+8^,9;*6"6X>$0PJ$A652"J#^'!.<^M>[_ &2'_GDG_?(H^R0_\\D_[Y%
M'S_H'[+]AI&G:K;R^)GN9=0MM0@>7RE&TW4$$3,/<>1N]RQK3N_@#YSW9@\7
M36H:>XN+9HHE#0/-!Y3<]_6O;?LD/_/)/^^11]DA_P">2?\ ?(H \>^%/P'T
M[X9W<\QUHZB)XKB.2-D"J1*RDXQZ;?UKD;?]D+0TNKZ2;Q+<3Q74%Q"8BJ@
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M )[)^='VZW_Y[)^=+]DA_P">2?\ ?(H^R0_\\D_[Y% "?;K?_GLGYT?;K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAA:WD.CB7%TT9D,I!X1 B#@#HH'/4UV- @HHHH **** "BBB@ HHHH _./\
MX*1?\E=\/_\ 8)_]J&ODNOK3_@I%_P E=\/_ /8)_P#:AKY+K]6RO_<J7H?$
M8[_>9^OZ!1117JG"%%%% !7Z??L _P#)OEC_ -?D_P#Z%7Y@U^GW[ /_ ";Y
M8_\ 7Y/_ .A5\WG_ /N?_;R_4]C*O]X?H_T/I*BBBOS@^M"BBB@#+A_Y&6[_
M .O6+_T)ZU*RX?\ D9;O_KUB_P#0GK4H **** "BBB@ HHHH **** "BBB@
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MFW)7W4X-);C;"@Y.!WJ2HX/]4M $E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?G'_ ,%(O^2N^'_^P3_[4-?)=?6G_!2+_DKOA_\ [!/_
M +4-?)=?JV5_[E2]#XC'?[S/U_0****]4X0HHHH *_3[]@'_ )-\L?\ K\G_
M /0J_,&OT^_8!_Y-\L?^OR?_ -"KYO/_ /<_^WE^I[&5?[P_1_H?25%%%?G!
M]:%%%% &7#_R,MW_ ->L7_H3UJ5EP_\ (RW?_7K%_P"A/6I0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!EVO_(R:A_U[6_\
MZ%+6I67:_P#(R:A_U[6__H4M:E !1110 5'!_JEJ2HX/]4M $E%%% !1110
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M*. 6X.#7T)M'H* ,=*\_'9O+'4O9.%M;[G7A< L-/G4KZ6%HHHKYX]4****
M,N'_ )&6[_Z]8O\ T)ZU*RX?^1EN_P#KUB_]">M2@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M &7:_P#(R:A_U[6__H4M:E9=K_R,FH?]>UO_ .A2UJ4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '#0_#01
M?&B?Q]]N8F70QH_V+;P,3"7?G\,8KN:** "BBB@ HHHH **** ,N'_D9;O\
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M;?X4 2T5%]I3T?\ []M_A1]I3T?_ +]M_A0!+147VE/1_P#OVW^%'VE/1_\
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M *]8O_0GK4K+MPS^(+F4(XC-M&H9D(!(9\C)'N/SK4H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>mtva-20251231x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %+ S<# 2(  A$! Q$!_\0
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M876SU#S)=DFR/9ECM&3N(VY!H ^O_P#A*;G_ )YQ?D?\:AD\;^4;C?):K]F
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MUFT2>.0-)9HK>2R+MVACA'W[L$$B@#Z@_P"$HN?^><?ZT'Q3<_\ /.+\C6,
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M_=6O@:\NY=+Q/:+]HBOQ&L\:R!9%#(,J6 ;:U*PSZA^T1#I;CW^<THN(B?\
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M:Y7Q%\,O!GBW6X-9UCPQ9:AJD 01W,Q8L AW*" <'!Y&0:Z'! %.SE<5-P+
MN8NAMQR>?G-+YT/_ #[CZ[S54J1VHQ0!;\^'./LXZ\_.:EOO)M;N2$0;@C8R
M7/\ GO5%1SGJ,U;UC_D*7'^]_04P(_M$(Z6P_P"^C2BXB/)MQ_WV:K9H )-
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MX@58BL+LIX59&6.,MU6,#U-?81LKL_\ +[_Y#_\ KTC65WQ_I@X_Z9C_ !H
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M7T?#_P#OT?1GDYG_ +L_D?*-%%%?J!\>%&**4G- "4444 >Z_L3?\G%>'O\
MKG/_ .@5^IHZFORR_8F_Y.*\/?\ 7.?_ - K]31U-?FW$?\ O<?\*_-GUF5?
MP7Z_HA:***^5/:"BBB@ HHHH *^&_P#@I3Q)X*_[;_TK[DKX:_X*5??\%C_K
MO_2O=R/_ '^G\_R9YN8_[M+Y?F?$(X%+GB@#-)7ZL?%A2[:2EW4 &*2ES24
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MX]^ /^PS!_Z%7Z_5^>\3?QZ?I^I]-D_\*7K^B"BBBOCCWPHHHH R!_R-;?\
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M%_WV* )Z*@^VV_\ SWB_[[%'VZV_Y^(O^^Q0!/14'VVW_P"?B+_OL4?;;?\
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MS0!N2?ZMOH:2+_5)]!1)_JV^AHB_U2?04 /HHHH&%?G5_P %'/\ DL7A[_L
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M:DXX)53]*V='^%.D:%HVKV%K/?EM4"BYO)+C?<,JH$50Y' 50 !CIGUKGO\
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M!!PGRYX)OV7@SXEV-S927T.J7]JKPP7BZ?JD45]<0QRWNS]\9$SA7M2V7!8
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M#&*['XI>%_BQ"^A2>!)_W-O81-<VKWBQHUQ#R(L,<;90Q4D?W!DBO;OL4/\
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M '\H^QQ?\_<__?RBS'=%_ HP!VJA]CB_Y^Y_^_E'V.+_ )^Y_P#OY19A=%_
MQC%&!5#['%_S]S_]_*/L<7_/W/\ ]_*+,+HOX%&!Z50^QQ?\_<__ '\H^QQ?
M\_<__?RBS"Z+^*-H]*H?8XO^?N?_ +^4?8XO^?N?_OY19A=%_ ]*,#TJA]CB
M_P"?N?\ [^4?8XO^?N?_ +^46871?P/2C%4/L<7_ #]S_P#?RC['%_S]S_\
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M#21?ZI/H*!#Z***!A7YU?\%'/^2P^'?^P!'_ .E$]?HK7YU?\%'/^2Q>'?\
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M110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110
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M-S'_ '67R_,^(:*#UHK]6/C S1110(,T44K=#0,]#_9R_P"2]_#_ /[#-O\
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M HHHH **** "BBB@ HHHH *^&O\ @I5]_P %_P#;?^E?<M?#?_!2G_6>"O\
MMO\ TKW<C_W^G\_R9YN8_P"[2^7YGQ!1117ZL?%A1110 4'I1B@]* /1OV<?
M^2]> /\ L,P?^A5^OM?D#^SC_P EZ\ ?]AFW_P#0J_7ZOSWB;^/3]/U/J,H_
MA2]?T04445\<>\%%%% &0/\ D:V_Z\Q_Z&:*!_R-3?\ 7F/_ $,T4 :]%%%
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M0M#-YC&1-V$.X G.>.E9W_"_OBGH_P %/!_C*]U*SU/4_&E]'I]I9Z=I)(L
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MX1\)>'O#)\6:P8=<U'1H-5FM+"QGNWCC9%+3.D*.8H]V0&; X//!K6U7X_\
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M**TSX7UK/_(&U'_P$D_^)H_X1;6_^@-J/_@))_\ $U^I\T>Y\;ROL9E%:?\
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MYJGXU_9W^(['XD:9X0UOPY;Z)X[L8X;N?51-]HL9EMQ"YC1499%< #EEVY)
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MM:OI+^)[_P"(%EXQU5+42BUAM[> P1VL#%0SLJ;?G94W$G.,4.]PCRK4[/\
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M1Q1QR, I95 ) Z#Z"L;P/X$TCX=^'+30]$M_LNG6P 2($D XY//3/7CBNAH
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M84444 )6):V>IZ<UPD*VTD4DS2J7)!Y.<5MXI: ,OS-7_P">-I_WTU'F:O\
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MQM/^^FHSJW_/&U_[Z:M6B@#*W:MG_4VO_?;4;M6Q_J;3_OIJU:*0&46U8_\
M+"T_[Z:C=JV<^3:?]]-6K13 RMVK?\\;7_OIJ VK Y\FU_[[:M6B@#*W:M_S
MQM/^^FHW:O\ \\;7_OIJU:* ,O?JY.?)M/\ OIJ/,U?_ )XVG_?35J44 9?F
M:O\ \\;3_OIJ/,U?_GC:?]]-6I10!E^9J_\ SQM/^^FH\S5_^>-I_P!]-6I1
>0!D65E>-JTEY=>4H, B5(B3_ !$YY^M%:]% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>mtva-20251231x10k022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !; X<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]&?C7\2X_
M@U\)O%GC>6PDU2/0=/EOS9)+Y9FV+G:&(.W/K@X]*\I_9'_;)TS]J+P9XDU>
MZT)_!=_X>DC-_875T)U2"2+SHIP^U?E90YY'\'O6[^V[%)/^R-\6(XT:21O#
MUR B*2Q^3T%?F[X^T/QS\)_"?PNO/ NG7+-\:OAQIO@V^6-&#0WB""/S, 9#
M&%@HSV9_2@1]Q?LH_MY6O[4GQ*\3>&+;P9<>'K+3+#^T[/4KB^67[9;><(E<
MQ[%V9SNZFO<_!WQX^'7Q$\17F@>%_'.@:]K=GGSK#3M1BFF4#J=JDD@=R.E?
MG?K/PBUOP7\8_P!HWP'X M;EKW3OA'I^EZ?]CC*/<;(K99 F.KR 2<#DLQ[U
MS/[*&G>%O%GC[X&O#\5M.7Q=X55C!X-TOP*]AJ <0,9K2YO%PKAMA'F2$Y+$
MXRQH _2S2_VCOA;KOC3_ (1+3OB%X:OO$I<Q#3(-4A>9I,X* !N6_P!D<T_Q
M1^T-\,/!,EU%K_Q!\.:7+:W8L+B*[U2%'BN"H;RV4MD-M(.#VK\C/$GQ C^(
MR_#Z_LM(\)^#]<L?'UJ9?!OACPG);:AI"+<%?-NK\]2[$'8?O%@1C:0/<?\
MA4'ACQQX]_;RUGQ#X5MM8U/2[:5]*NKRV,C6SFVN)-T.?NL7BB.Y>?E Z$B@
M#]-Y]:@&B2ZK;NMY:K;FYC>%PRRIMW J1D$$=#7R-^SO^W!\0_VB+O1-3TSX
M$7EGX#O[U[6X\3MXA@>.T1"0\AC,:LVTCD#\*[W]CIKJ7]ASX?\ VKS7N/\
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MG=\>O&/PI\7W/P<\=^$/"KQ? +2_'5T_BGR=">"QGNC!;".Z:W"_-$%4KDH
M2C#!)YQHO#WPW^+/BW]IGQ'H]W=^"/V?-9T?2],;Q!I>DRI:G45GMV$T5LJ
MLBNK;R%&%<DD;LT ?I-X-^.'P^^(>@:EKGAOQKH>M:1II(OKZTOXWBM  3F5
M@<(, G+8XYI_P[^-'@/XN"\/@KQAHWBC[&VVX72KV.=HCVW!22 >Q[U^5NO^
M(O&_Q)_9-^,GAK0-.T;Q-I/AS4-&$OC7P=H;6*^(=/0L722(*GFF']VQP,8W
M=1\Q]M_8LL_"7C+]IBQ\7Z'\7M*\4ZQ:>&I;.?0_#_@A]!B%MO3:+@KB,NC,
MN!RWR@ X44 ?H[1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0/C[
M_P %!]/^ /[0^G?#?4O!MS?:4\-E<:AXBCOE1;**XF\L.8MAW*I*Y^89S^?0
M?ME_MM6/[)4.@0)X8D\8ZQJL<]T;&"]%M]FM8MN^9VV/P2P &.2#SQ7S]^T#
M\'6^.'[<GQ9\'O;.[:M\)_+LYVC.U+I+F*2 ANG^L1?PS7S_ &R>+?CO^S+\
M;/BWXUL+B._\.^%M*\":3%+$Q.89[=KN49Y#,P4MC_GHPSQ0(_5/4/VA/ WA
M;P!X8\5>,?$FE>#;37K*"\MHM7O8XB?,C5]BY(WE0XR0*T_$WQQ^'W@SPM8>
M)=<\;:#I?A^_&ZSU*YU&)8+H8S^Z;=A_^ YK\R/C*NI^#OCQ\,?$/BWQ'9>"
M/"5S\--.LM)U[7O"_P#;UA#*(D\^W,)!$<C$L2V,X8#HU6O[:\/_  9^#OP<
MT#3-5\+^+_!^KZUK,L/Q)\8^$)YK'0@60-#;V3DD;V4A6. <\< D,9^E]G\:
M/ 5_X.MO%D'C30I?#-Q,EM%JZZC#]E>9F"K'YF[&\D@;<YIW@WXR>!?B-J^J
M:5X7\7Z-X@U+2VQ>VFFWL<\EOSCY@I) SQGUXK\?+G3[FY_8K^-%HL<L]D_Q
M2M);<6^FO8QO&XSYD=L>848;2$_A! K[#T/X7>'?A)_P4H^'>G^"_#EMX:TB
MY^'LPN8--A,<4K*\@!?'!;")DGD[03DTA'T1\7_VD4^$WQI^$_@ Z ^IMX\N
MKBV%^+H1BR\H*=Q38=^=_3*XK$\;?M7'PM^T'KGPIA\-F6[L/!UQXJCU:2Z_
M=NT8;$)B"YP2O+!OPKP__@H/\/H?BA^TS^S1X:NY=3M-/U&]U&"XN](E:&XA
M4K"=R2@'8>.OUKS/3O@98_ S]N/Q?X>T.\\0:UIS?"W4+C[9KMVUY,9'# J)
M"HX&T87USZT ?57[*?[9OASXV?#7P3<^+?$?AC0OB#XA69D\.VUZJ2-MGDC3
M9$[EP6" @$DGM4/[8W[;UG^RA>^';"+PG<>,M0U*&>_NK:UN_(-E9Q%5:=OD
M;(+/@=!\IYK\S?"[> _$'[,?PK^'_A7P;>0?M W'BF"]%VNDR1W,L)F<K.+D
MCYH=GE  ' *$X&"3],:QH7Q4_:@_:+^.OB?P-X9\,:[X8CL9/AU'+XLN9X52
MW S.]ML4Y8R9?=VRM,#[B^*7[0VD?#CX2Z=XZLM(U?Q=#J\<3:3IVAVQFGNV
MEB,L>>T:;%+,[<*!ZX!H_LQ?M%VO[1'P+T_XEW&F+X5M+A[H2V]Q>+*END,C
MH6:4JHQA"Q) Q7RS^R]^TEIGPP_8GU[PU\3[J?1M8\%W]WX*E!M)YF,C)*;=
M<(A.,*Z ]/W8R1FO#?AEXP?QM_P2M\7_  T\'RWUSXZT1'O]6TB"RF$OV%]0
MWN5;9M?,>20I)VYR*0'ZD?#[XS>!/BNU\O@WQ?HWB=[%MERFEWT=PT)Y^\%)
M(!YP>AKMZ^2?V+/B7\"_'US%!\*O"JZ=KVG>'+2WU74(-&-FB*"!]FEDP/,E
M#AFZ-G!.ZOK:@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%=PM%-&LL3##(X!!^H-)!;Q6T*PPQ)%"HPL:* H'L!7&?\*1\#_]"Y:_F_\
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M^0#;_P#?4G_Q5'_"J?"'_0!MO^^G_P#BJ0'M=%>*_P#"JO"'_0!M_P#OI_\
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M/_ W_P#BJ /:Z*\4/PI\(#C^P;?_ +Z?_P"*I/\ A5?A#_H V_\ WU)_\52
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M'A75]#UG5'C:6.TAEE225%Y9HP^-X'<KG% 'UE17BG_"JO".,_V!;X_WI/\
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MS)C>F<]LJ<BNB_X55X1_Z %O_P!]O_\ %4 >UT5XG_PJKPC_ - *V_[[D_\
MBJ7_ (55X0_Z -OC_>?_ .*H ]KHKQ/_ (57X1_Z -K_ -]R?_%4O_"JO"/_
M $ ;?_OI_P#XJD![717DWPKT"P\.>/?%5IIELMG;-8:?*8HV9EW%[H$X)/.
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M7_A)]5_Z$?Q/_P" ]O\ _'Z0'0<G%''-<_\ \)/JHZ>!O$Y_[=[?_P"/T?\
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MQGX5?\^WB3_P7+_\<KKC@\3-*4:<FGY,P=>C%M.:OZH^I:*^6O\ AXS\*O\
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MUR&YOTN[G-<]_P )+JO_ $(_B?\ \![?_P"/4?\ "2ZK_P!"/XG_ / >W_\
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MWD>U9L826-7+*_S#Y",\]*])T[XD:-XPN/'>A6E[=3W_ (J\?6&HZ4K9C,D
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MD/CK]GOQOK?PX_:4TJRTB"74/&OB&"_T5/M42_:84CM 69B<(089.&P>/<4
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M_P"@QJG_ )"_^(KUZBE_:.,_Y^R^]A]4P_\ S[7W(\A_X9GT+_H,:I_Y"_\
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M?^"VR_\ C5=Q10!P_P#PA/BK_HH>I?\ @MLO_C5'_"$^*O\ HH>I?^"VR_\
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MSXI:]<>)VOHOB7XDEF@$4]K)]CL(+3#'2+><C:\L"R;YMN-TCN<D*, 'M_\
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M+<(5211A6'S^@'!R*4?&W3)+O4)KC5M"O([[:9K>>X0H64 !AAN#@>M?2O\
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M_P!![3?_  ,C_P :/^$T\/\ _0>TW_P,C_QKZY_LNR_Y](/^_2_X4?V79?\
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M_BJR/%'CCP?XD\.W^F1?$/3]%ENHC&NH:9JUNEQ ?[\98L P]P17;?V38_\
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M*ZCF* QQ@%MI.!FO5*K06-M;2!HK>*)L$91 #V]*LT"N%%%% PHHHH ****
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M_A1_9-C_ ,^5O_WZ7_"@# _X6IX*_P"APT'_ ,&<'_Q5'_"U/!7_ $.&@_\
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'/Y44Q7/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>mtva-20251231x10k023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !4 =P# 2(  A$! Q$!_\0
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M"OQJU#Q%J7ASXFZIX4\4>$-+TEQ\,[FW^TQ2PVL<,UK=I*&_=,58\<?-U/.
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MD*-Q5BSE08V^:BPCV_\ X6_'_P!"EXG_ / */_XY2?\ "WD_Z%'Q1_X!Q_\
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MEQZB2 +1KCH)-Q"=-H8[2V>*]-QCKUH&'_"W4_Z%#Q/_ . 4?_QRD_X6\O\
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MX@AU?4[Z]CO[19)_/,?V=08I'C<DH^0,!=PS7T\8Y#DE&YZG%+_PHSP5_P!
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M .QJ\#F6&HTN6K55_GV7]?B]63BL)5J3O3AH>=T5Z)_PS[XS_P">&G?^!?\
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M*UX&CEN+^X4%"SN$:0J!''G!).:^@YDUFXBCCE^%VF2Q1VILD1KVW(6 XS$
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MT_Y^X/\ OZ/\:/[1M/\ GZ@_[^C_ !H GJAXA_Y%_5/^O67_ - -6/[0M/\
MGZ@_[^#_ !JAXAU"U.@:F!=0$FUE_P"6J_W#[T ?=WA/_D5M&_Z\X?\ T 5K
M5S7A7Q!I:>%]'5M2LP19PY!N$_N#WK5_X2'2O^@G9_\ @0G^- &A16?_ ,)#
MI7_03L__  (3_&C_ (2'2O\ H)V?_@0G^- &A16?_P )#I7_ $$[/_P(3_&C
M_A(=*_Z"=G_X$)_C0!H5\E?!/XO>(-6^*ZZ;XY^)NJ:;JUSJVJ6MGX*U+PO'
M8VUS%%+*L @O#"#*PB6.3"R%CSQC-?4O_"0Z5_T$[/\ \"$_QKPJ7X6Z]XN\
M;^%]2\>?$[1M>T/PMJG]LZ;I^G:8EE+/=".1(GN)3,X(C65\+&JAC@GIB@#5
M_:]\7^// 'P3\0^)? FI:9I%QI-E-?7-W?VIN90J+E4AC.$W,W!9\@#HI/3O
M?%&L7B?"'5M5BF,.H#0Y;I)HN"DHMRP9?3#<BO+_ (I_##Q-\4?@YJ'@:Z^+
MFE)+JANH-1U2;187>6UE9C'"D:3HJ-&I5=_S;MN2,FNZTC2I3\+)O"OB#QCI
MFK:E-8S6$FJV=NEJFUE9%(A\U\%5('W^2,\9H ^=[7]JK6;O]C_6M>\,27E]
MKGACP197-[XSNDCFM/[6:WB,D W_ .NE3<SR'!520I.3BMCX3?'WQ6?%?C/3
M]/\ $*_'3P[I6B6FI1ZSI]M::>;>]DF9'LWG4I;L!$/.+9!100<G%26O[(>B
M:-\./$7@;1OB+%IOA[Q%X:M](U*S%O&\3:A#''$=2B3S1Y;R)'B2,'#':<Y&
M3ZC\:/AIHOQ3^%1\&V6OZ;HHBN;2\BS''+:3O!*DHBN( RB2)RF'3(R#F@#3
M^!7QQM?C9INN.NF-H^JZ'?\ ]G:A8_;(;R-9#&DJO'/"2DB,DBG(P0000"*]
M1KQ#X!?"K3O@PWBZXG\3:+>W7B74(]1EM]+L8M.M+1E@2'RX8D=OD^0')^;G
MDD\UZ_\ \)#I7_03L_\ P(3_ !H T**S_P#A(=*_Z"=G_P"!"?XT?\)#I7_0
M3L__  (3_&@#0HK/_P"$ATK_ *"=G_X$)_C1_P )#I7_ $$[/_P(3_&@#0KA
MI/\ DMUO_P!B])_Z4I74_P#"0Z5_T$[/_P "$_QKB)-=TS_A=5O)_:-IL_X1
M^1=WGKC/VF/WH ]'HK/_ .$ATK_H)V?_ ($)_C1_PD.E?]!.S_\  A/\: -"
MBL__ (2'2O\ H)V?_@0G^-'_  D.E?\ 03L__ A/\: -"BL__A(=*_Z"=G_X
M$)_C1_PD.E?]!.S_ / A/\: -"ODGXX?M#3V/QLUSP<?'.H_#SP_X8TFVO[^
M_P!(T!M3N)Y9R[!I&,$J0V\21J6) +&3K@''U-_PD.E?]!.S_P# A/\ &O _
MBA\%K[Q/XS\4:]X/^).G>%%\7Z1%HGB"WN;*.\\V.,2JD\!,J[)52:1/F#+C
M!QE>0#2_::\<WGAC]G#_ (230?$C0N;G1G37+:18Q+!)?6RO)N'RA'C=LD<8
M8]JX?XU?M,:C?_#KPGXA\+ZM<?#KPYK/C6TT-/%FJVUNRW.G/%,SWD4<P94B
M9D&QI "RC<  PKTKQU\(?#'B[X&Z;\,;3Q#;6&CV$>F00S3-'<,8;.:%U1U+
M -N6$*3_ +1.#TKD8?V;-$M=,T+P_'XZAD\(^'_%\/BC1](NHDF^Q0(DH;3Q
M(9/FAWS,4)&47"_, " #%^%_[27C4?#SQ#J5QIT?Q,M-/\0W&EZ9XJCN+31+
M74K-(XV%P[3.L>?,=X@8@5<QD@  FO>_A!\3]-^,WPWT'QEH\4]M8ZK"95@N
M@!)&RNR.C;202'5AD$@XR*\\^.OPAT_XM:QX*U.Q\1Z!:2>&7N0FGZS8QZC8
M3)/&D9<P&1!YD87,;9(!)&,&NE^ _@C1_@?\*= \$1^);76$TI95%ZWEP&7?
M,\O^K5B%QOQ@<<=NE CU.BL__A(=*_Z"=G_X$)_C1_PD.E?]!.S_ / A/\:!
MFA16?_PD.E?]!.S_ / A/\:/^$ATK_H)V?\ X$)_C0!H45G_ /"0Z5_T$[/_
M ,"$_P :/^$ATK_H)V?_ ($)_C0!9O?^/.?_ *YM_*N<^%/_ "3#PC_V";7_
M -%+6G>^(M*-G.!J=GGRV_Y>$]/K67\*6!^&'A$@@@Z1:8(.?^6*TF!H:SX-
MT#Q'/'<:MH>FZI.B^6LMY:1S,JYSM!8$@9).*I?\*M\&?]"CH7_@L@_^)HHI
M@'_"K?!G_0HZ%_X+(/\ XFC_ (5;X,_Z%'0O_!9!_P#$T44 '_"K?!G_ $*.
MA?\ @L@_^)H_X5;X,_Z%'0O_  60?_$T44 '_"K?!G_0HZ%_X+(/_B:/^%6^
M#/\ H4="_P#!9!_\3110 ?\ "K?!G_0HZ%_X+(/_ (FC_A5O@S_H4="_\%D'
M_P 3110 ?\*M\&?]"CH7_@L@_P#B:/\ A5O@S_H4="_\%D'_ ,3110 ?\*M\
M&?\ 0HZ%_P""R#_XFC_A5O@S_H4="_\ !9!_\3110 ?\*M\&?]"CH7_@L@_^
M)H_X5;X,_P"A1T+_ ,%D'_Q-%% !_P *M\&?]"CH7_@L@_\ B:/^%6^#/^A1
MT+_P60?_ !-%% !_PJWP9_T*.A?^"R#_ .)I#\+/!>/^11T+'3_D&0__ !-%
M%  /AIX/ Q_PB>A_^"V'_P")H_X5KX0_Z%30_P#P6P__ !-%% @_X5KX0_Z%
M30__  6P_P#Q-'_"M?"'_0J:'_X+8?\ XFBB@ _X5KX0_P"A4T/_ ,%L/_Q-
M'_"M?"'_ $*FA_\ @MA_^)HHH /^%:^$/^A4T/\ \%L/_P 31_PK7PA_T*FA
M_P#@MA_^)HHH /\ A6OA#_H5-#_\%L/_ ,31_P *U\(?]"IH?_@MA_\ B:**
M #_A6OA#_H5-#_\ !;#_ /$T?\*U\(?]"IH?_@MA_P#B:** #_A6OA#_ *%3
M0_\ P6P__$T?\*U\(?\ 0J:'_P""V'_XFBB@ _X5KX0_Z%30_P#P6P__ !-'
M_"M?"'_0J:'_ ."V'_XFBB@ _P"%:^$/^A4T/_P6P_\ Q-'_  K7PA_T*FA_
M^"V'_P")HHH /^%:^$/^A4T/_P %L/\ \32?\*T\'YS_ ,(GH><8S_9L/_Q-
M%% "_P#"M?"'_0J:'_X+8?\ XFC_ (5KX0_Z%30__!;#_P#$T44 '_"M?"'_
M $*FA_\ @MA_^)H_X5KX0_Z%30__  6P_P#Q-%% !_PK7PA_T*FA_P#@MA_^
M)H_X5KX0_P"A4T/_ ,%L/_Q-%% !_P *U\(?]"IH?_@MA_\ B:/^%:^$/^A4
MT/\ \%L/_P 3110 ?\*U\(?]"IH?_@MA_P#B:/\ A6OA#_H5-#_\%L/_ ,31
M10 ?\*U\(?\ 0J:'_P""V'_XFC_A6OA#_H5-#_\ !;#_ /$T44 '_"M?"'_0
MJ:'_ ."V'_XFC_A6OA#_ *%30_\ P6P__$T44 '_  K7PA_T*FA_^"V'_P")
MH_X5KX0_Z%30_P#P6P__ !-%% !_PK7PA_T*FA_^"V'_ .)H_P"%:^$/^A4T
M/_P6P_\ Q-%%  ?AKX//7PGH?_@MA_\ B:Z.WMXK.".""-(((E"1Q1J%5% P
+  .@ [444#1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>mtva-20251231x10k024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231x10k024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '' V$# 2(  A$! Q$!_\0
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MX./:K- &:N@:>EM# -/M1!"_F11"!0J-ZJ,8!]Q7C'[;(V_LZZS_ -A'2O\
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MW48'02;7'\J7[+K<3?+>VTZ^DL17/Y4>UFOB@_P_S#V<7\,U^/\ D;!8#J:
M0PR*\^^)>L^(M(\&ZG/!I<-Y*(\ 6\C949 +8ZG'7BM/X3ZI?ZQX#TRYU*S:
MRNF4@HQ.6 /#<\\]:YH8Z$\5]5Y7?EYM4^]NQTRP,XX7ZUS*W-R[KM?O?\#K
MZ***](\X***0G% 'YY?M':7XA;XO:[=VG@*'X?HD[2CQ5H6H6\>HZG&I/[YX
MY)XHB&P0?-20U]Z^#KM;WPAH=PLSW"RV,$@ED*%G!C4[B4^4D]?EX].*^,/V
ML[S0O'WC*_T[5I])\-2PV;Z?N\1>$YKZ>;)?Y[:=,@C#9 Z@U]&?LP76NR_!
M[1X-?N)[V:T L[:ZGTXV+36\:JD;&$DD<#J<9]!0!ZY144EQ% H,CK&I(4%C
M@9]*B.J68:X7[5#NMQNF7>,QC&<MZ<>M &?XMU*+2O#&J74[%(HK:1G8#.!M
M/:OSR\*^&O$6N6=EX7T2QFE@L&DDCM;-CL5G<N6W'IDGN:_0[69K:[\.WDI,
M=S:O;NV<AD=2N<YZ$8K\L-"_::\2?"[7M5G\-F&5YYCN:=<C:&/&/PQ7GU*%
M2K6]HG>,8O1)WO?==-OF>?CLLK9Y3I991?*IRO.5TERI:+57UDUY:(]PT;XE
M?$3X4S1V=P]W]@1B);+48O-CD&?FPS#/XYQ7T3H?C;P!\4O"FC:IK.G6T!-R
M]M!:L&S%-\I(^4#J"I]*\C^#W[<'A'XQ0?\ ".^.K"UT#5)8G7[3.%>U(VC)
MRWW2>>/:O3/&?[.&F:]IGAB'2':."Q<EY;4J@>-B&W>[<<-Z5GR4L1%II379
MJ_X,\MY-Q!PC5E&E4E-6]U-M=4O=DGM:^WW'KB2W'AHJLC/=:4,8DY:2 >A_
MO+[]16['=PRQI(DBLC\JP/!KG+;4[C0(H[75HPULJA$OHP2I'3YQ_"??I7G/
MQ2L?$%EXJ\./X9E@6QFE#>4TP"%\Y/!/W2/3O66*Q$\OI>TA%SC=*RW5W;3R
M_K8^VP4*>95/9SFH2LVV]%HKZ^?GU/;0X8X!S3JQ+3Q%;B18KQ7L+CILG&%)
M]FZ&MGS!C/7Z5ZL*D*BO%G#.G*F[20ZBJ]O?VUW(Z0SQRNGWE1P2OUQTJQ5I
MIZHAIK1A1113$%%%% !1110 4444 %%%% !3#R<&GUB>(KW5;2)#I=C'?.20
MZR3>6%'J.#FDW97&H\SLC64 5(.17QW\!_C#\<O%'Q4U73/$OA]CHD2SF'S[
M8VR9#X7$A'/'YU]=6TTPL$DN81%-LW/&C;MIQR >]84:T:RO%6/0QV!J8"HJ
M<Y)Z7T=R9@H.3UZ4AC&<;!_GK7R/^R3XQU_6?BIKD&KZQ<ZA:WVEO?Q1O<^=
M@B[=<SI_R[R[651&."%)[4C?'SXGFUN-66YTH68M=2U%+,6+%_+M-1^RB+=G
MJZG=GMBN@\X^A?"WP9\*^#?%5[XATVRF&J7.\&6XNY9EA5VW.L2NQ"!CR0H%
M=U7SC\'_ ([^(?&OQ3L]&U"]TR2TOK.\NFTR"(K<Z<T4WEJDASR2!GD#K7T=
M0 4444 %%%% !1110 4444 %%%% !1110 4444 -D&Y"*^2OAW^T=K_BSXW2
MZ%J&J^'M(5=6N-/_ +&_X1[4/MKQQLRJ1=D>3E@ V>G:OJK6M5M]#TF[U"[<
MQVMK$TLC*I8A0,G ')_"O@'X:ZV-5_:;LX[8W*ZO+K<US+XK?5+]OMUHV62S
M-HRB-0%*KSA1MR#DT ?H.@^;WQ4E,3&XTXG% "U\[_M\13/^S5KTD+%5BN;5
MI-IYVF95X'?E@?PKZ&W"OGK]O*9A^SAK42H'26[M%?.> )E<=/\ :5:UI45B
M:D:+^TTC2G7EA9*O#>.O?8_-GPWKWB31@EQI.K7]H]KAE,%PR%>PQS7N/PR_
M;'^(_P /-9LW\47=_KGA\MMF@NXP9' '1)&'!Z9YKS'PEHNNZHYDT2)HY(XP
MDCPL$![X.>.?2NJ\.^*H["Z&G^-M*DU:UBF'E)<0I((<L/,.'4C[N>F.:^IE
MF^';="I03IK16W26BL>5*A5G)UO:/G>K\V][GW9\/_VG/AI\1O$VG:%82[/$
M=^A;[(]FQ*ML+,IEV[3@ \YKT+4/A[9?:GOM)N)M!U!CEIK A4<YS\\9RK_B
M*^?_  )\(/A%K/Q@&H>&I=;MM<2V&H1RV-ZL5O$CKM!55&1_N]/7BO>6;Q;X
M7P&*>*[!><J%@O5'/4<1R<>FP^QKY_%4<)4DOJS=K;2[^3.^C5KT_B?W=O-'
MR=\.OB!\4;']JW7+3Q'::I?^&XI)TF:WTLE#$ 1'(% )"G&>,U];:7!I'B"%
MM0\,:HD#9^<VC!DW>DD1Z'V(!KS#P/\ M+> ?%WQ@N?"ECX?NK#Q,9)89KRX
MLHXR60?,&?.[MC%>M:WX!TG6KP7X273]4 PNHZ?(8;@#T+#[X]F!'M7DRP-?
M!^Y66KUUWL^S/4Q>+PF8RC*--0Y4E[JTNMVUI]]SE/BOK*:7\/=9'BS36NM-
M6+FXT]N&;<-O!^9"6QS\P]:H? 62UU+X<6-]X:FEMHR[K/9WI\P&4?>R0!@G
MCIQ]:Y_]H[Q/XE^&?P8\2WNH06?BK2UA2'SV58IT#R*F9(RK(_+#D8[?*.M8
M?['GB:Q^(_PCM+NS9= UFTG>V9+9D'FA0"&>, *P.X\XSQUKQYT82QJJ->]R
MVOL]]KD*AFU&@ZU.:EA+V<=WS]]NW>Q]"0>(XX&2'4H6TZ5CA6D.8G/^R_3\
M#@^U;(<&N7DUFXT]6@UZS1K9OE:[@7? 1_MJ>5_'(]ZGM],\B$3Z%>A(6&1;
MN?,@/^[W3\./:O3C.I%V^)?<_NV?RMZ,Y8RHUM$^5]GM_FOQ]3HMP-+6'!XB
M%O(L.I0-82DX#L<Q-]'_ *'!JW/KUK!>VUJ?,:2X!,92,LI Z_,.*V5>FU>X
MW1J)VL:-%%%;F(4444 %%%% !5358[N6PE2PGBM[LCY))XS(BGW4,"?SJW37
M.%S1MJ!\C>,? W[05S\=[;4--U.1O"2W$)=X+I8[?8!\V8#+N(]L\U]4:+!J
M<%IMU2ZM[NYR3YEM 85V]AM+-S[YJX67/^U3PV#BNS$8N6(C&,HI<JMHK7]3
M*%-0;:;U/F_Q)H'Q*N_VI?"VO76@I=^%;.[FM;.YMM2;9;6K6KB226+R\;V<
MC!+8PJ*,$DUE^/-!^)NO_%/4S::SXLTO06U:*SB736,< LS;,SR*=IY\P*-W
M8G'>OI"7Q7HT.O1Z,^IVL>KR1^:EBTJB9D]0O6M/@YYKC-#X4T'XG^/['XA>
M!M*\1Z[XF@\1SZUIMD^GIM^Q2630%I1<KU6<L"Q! ;&"/EYK[M3..3GWK&?P
M9X?F\2)XA;0]-;7XT\I-5:TC-TJ8QM$N-V,=LULH,9H&/HHHH *S?$.H2Z5H
M>HWMO"+B>VMI)HX3QYC*I(7\2,5I5S/Q&U^W\-^#]4N[B]DT\&%H8[J.)I#%
M(P*HVU02<$@].U 'SW^S)^T%K7Q5\9FUU36/#RO-9R7$FBV'AZ_M+JW8,!M>
M>8>6VW.#CKU%?4VS(YKX/_8YU$WWQF6"UAN-(N+:PN%U>[?5;Z\'B&7>FV<Q
MS*$B*'<<\-\^ ,5]YK]V@#Y(^*?PKU^#Q/\ $6ZT_1-7U31;Z[T:[FBCD>=K
MR)'<W,<2ELM@;<HO7L*\[\)_"SQY9Z]H?V[PSK7G37^G3Z#<&,[=(LX[YY+B
M.9LXA)A.-AY;<!R1BOOIE)[XI"AXQP: /DKXZZ/\1+'XA_!ZX\2>(M$U/P^W
MQ M!:V5CI;V]Q&3%<%-TAE8-A<@_*,GFNV\$_$+7]<^,7B&R\1V4MAH6D&1X
M9;H>7#!SA69R #N'(Y[U/^U+QK7P1SU_X6'I_P#Z(N:A_:UL'TKX-^([KP[=
M)I>M7<D2/<I<")I!NY4L3W':N2O3G-Q<7L]NY@\)/%XBC%5.2*EKV:\_S-WX
MB_M4> /AGX@TG2-5U/S9=24.DUKB6)$+8#$@\CK]W-?&2_MH_%M6\:2V5NS^
M6PDMI&M7D6V7SD7A6R,%6/4'J.U<)?)IVE7?@G_A.GU37]6WJS2V6J1R(EOY
MO[I(_E;##T)]J[8_&GX@Z1!\0I?$WAR;5-'U$A)[>^2:*-)2T:QMG<<$(%P
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MNZ4@\@L<M@^M 'FO[37@;4?&'A_PQ+I-K>WE]I_B"RN/*M)64"(2?O&=00&
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M/QM_;GC?3K>U\67_ (MM6TAQY]SX$DTMX8U9?+\Z\?[QY.%7=G!/:OL]>%%
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M=/\ !_Y&\:E2'PNQFGX::='-YEG?:G8$=!;WKX'X-F@>$=<LV8VGBRZ/HEY
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M)"_-P<?9/A*YFO?"NC7%PLJ7$ME#)(L\'D2!B@)#1@G8<]5R<'CM0!K4444
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M/0=GZV/8W\!MI3?:O#%^^CN<-]D;]Y:2'_</W?\ @./I2+X]FT1C#XIL'TO
M(^W0YEM6]]PY7\?SJ;PYXIG@U"/0/$$266LA#]GE3/D7R+U:(GHP_BC/(Z\C
MFNFO;%-2L[BUD_U<J,C' /!&*\N=%TG[KM^7]>AUQKJ>E57\^OW_ .=SR?X=
M>)/ GCKQ#KEIH>KZ/?W[R?:B=*)6>,?=R6P.]=^NH7V@$+J2F\LQPM]$OS(/
M]M1_,5XE\+_V24_9_P#$^I^*O">L7&LWUVC)-IVHJB)*A;<51U VMZ$Y'KZC
MW3PYXLL/%-K*UN7BN;=O+NK*Y79-;OC[KH>GL>AZ@D5STI3M:HK2*Q>"PM"5
M\!-N'=K6[WNM-+[?F37.G6FM10W<,@67&8KJ!L''U[CVJ&/5[G2'V:HFZ'H+
MR(?+_P #';Z]*CGT*6PG>ZT=UMY2<O;/GR9?7C^$^X_(U8TW7H;^9K.XB:SO
M@,O:S8R1ZJ>C+[BG*G[W-!V?X/U_JYSPQ%DJ=9:?UL_T_ L:OK2Z9I;7T<1N
MXUP<1L.0>X-7X9#+$K,NQB 2I.<'TKRWXPZ?KVB^%I9?"D;GS) +FV #!4Z[
MD4]#G&<=C78^#==N;W2K2WUA!:ZZ(5-Q;L-ISCDKV(^E<5+&-XN6&J)JR3_N
MMN^SZOR]3TZF#2PD<33DG=M?WE:VZZ+S]#I:*0-NS2UZYY04444 %%%% !32
MN:=5._U.+3E5I4F8,<#R87D_/:#BIE)15Y.PU%R=DB<Q$C&<5)CC%>:>$OCI
MIGBSQ-J>CQZ;?0&S+;9?*:0N%;!RBJ2O/K7H\,ZSQ+(H8!AD!U*G\CR*Y,+C
M,/C(\^'GS+;[CKQ6#KX*7)B(.+T?WF9JGAC1=969-0TJRODE97E6YMTD#LO"
MDY!R0#@9Z5;DTRTGC@CDM87C@_U2M&"(^,?+Z<<<=J\%M/B5\1(?'7C/PA>W
MV@PZE:Z,FK6-]?6<MK9P RE9=K%B9XHD*EGRN'(!P#D:7@WXYZE:_!C7?&VN
MPG7K/3[R6+3[VPMQ:_VO; J(YT1VPH9F90<X8*&'!%=IQG=^/_@SX:^(ND0Z
M=J%JUI#$RLC6(6)N 0%/RD$8)X(X[5T?A7POI_@SP[IVB:5#]GT[3X5M[>+.
M=J*, 9KQ.3]K7^RY)H]:\$:CI;+/-8Q 7T$WG7D;1CR5VGH?-3YSQR?2O2OA
M5\37^)-EK!N=%GT#4-)U!]-N[.>=)MLBJK$JZ<$884 =S1110 4444 %%%%
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MR16]^Q7X>U:SU[Q+J%UX2_X12PCT?2]+ 6UN;<7MS#Y_G3,L\:-O.]=Q (Y
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M$']D7W_7%S_XZ:\<_8N_Y-M\)?6[_P#2J:O9=8_Y!%]_UP?_ -!->-_L7_\
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M:+\(QIBZE:ZAJ-UJ'G/#::9"LLHBAC\R:4AF4;47D\Y)( !)H ]!KPC]MO\
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M6%0#.?>GUW'DA1129'K0,6BF%B.<9%/H **** "BBB@ HHHH **** "BBB@
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MD(V!2>!SQ7CFE^,_$,TMA#J'B#7XO#EW-:'Q==%I5:PN&>YWQHVW*+\L&0O
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M2P'0K$2HX!-?3- '@G_#"/P'_P"B=V7_ (%W/_QVD;]A'X$?]$[LO_ NY_\
MCM>^4UNU 'SKKW["/P3DT34$T_X>V27S6\@@87=R,2;3M_Y:^N*Q?A?^P7\*
M;7X?>'X?%G@"SG\1I:(M_(U[<,6E_B.5DP?PJ#XOOXJT[QS\2[9/%VHZ=I<V
MAZ?<6MT\#M!8%KF19%3RQG[JC)ZC.:\UM?B!XFOGLBMYK-C/:^5'X=6WEF>'
M59_MRI,Y++ED,63AL8&30![X/V$?@/C_ ))Y9'_M[N?_ ([1_P ,(_ ?_HG=
ME_X%W/\ \=KW:V+F!#(,/@9 ]:EH \$_X81^ _\ T3NR_P# NY_^.TT_L)?
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M[+_P+N?_ ([1_P ,(_ ?_HG=E_X%W/\ \=KWNB@#P0_L(? ?_HG=E_X%W/\
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M?P1X@BT#X?V<6NOIUPM@XO+@%;@Q-Y1R9<??V]>*^EI"0I(&2.U?#GBSQ_\
M$VY\=^.EURUUS0-%EETE91$,16-@;MDE:-UR=S)@LPY )Z8H ]%^'/[!OPCM
MO 'AN'Q/X!LYO$4>G6ZZC(UY<$M<"-?,.1+@_-GI72C]A'X#_P#1.[+_ ,"[
MG_X[7SY8>-O&KW6FDZQKLE];FS7P=$_F;=3A;6[B*9IAM^<_8U@R6QA#N[U]
M^IG'/- '@W_#"/P'_P"B=V7_ (%W/_QVC_AA'X#_ /1.[+_P+N?_ ([7O=%
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MO[ TS_GPM_\ OV*/[ TS_GPM_P#OV*7UY?RA]2?\Q[3_ ,)!I?\ T$K3_O\
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MS'M/_"0:7_T$K3_O^O\ C1_PD&E_]!*T_P# A?\ &O%?[ TW_GPMO^_8I?\
MA']-_P"?"W_[]BCZ\OY0^I/^8]H_X2'2_P#H)6G_ ($+_C2_\)!I?_02M/\
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MKR_E#ZD_YCVG_A(-+_Z"5I_W_7_&C_A(-+_Z"5I_W_7_ !KQ;^P-,_Y\+?\
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MF/\ WW_[Z/\ C3O$-24:;<@ "SG ' _=-_A3O[.N_P#GUG_[]M4!D<#[[?\
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M_P#??_OH_P"-'NA[Q/\ V==_\^L__?MJ/[.N_P#GUG_[]M4'F/\ WW_[Z/\
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M==_\^L__ '[:C^SKO_GUG_[]M4'FO_??_OH_XT>8_P#??_OH_P"-'NA[Q/\
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M^_;4?V==_P#/K/\ ]^VJ 2N?XW_[Z/\ C1YK_P!]O^^C_C1[H>\3_P!G7?\
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MOJ<'(]:R_'_[ NN_$#Q_J_B*^\;VDXO]:M=:5KFTDDN+=H]FZWC8MM6'*DJ
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M8Z#!ZUQGC/X17.C^$_@Q\,K34S-XSLXFTZ^FT^VD,+Z5+N^U.S8VJG"XR<Y
MP*VY:<MC+FJ1W/I"V\6ZMXU^%B>(/"UBEOJNHV8GT^WU0[54L?E9\=L?-CZ5
MY_X4\3>.=&^(NN^#IM<M/&UW;^'SJ9D:W%LME?%ML5L[+D;7Y89Y 4FO5/$^
MF:Q;^"KW3_![V5AJ\=J+?3I+U6,$) "J6"@G  _E7F'P@^'WQ(^'NB:I8W<7
MA%[RYMYISJD4UU+<WFH,/DEN2X&4SG(7H  !6<>6S-)7NAGA+Q%XY\-_%KP[
MX6\0^([7Q1<:OILU_JEI;V@B&DLJ@JRL#_JV<E &Y.,U[D.IKP[X'?#GXD>
MM6N)_$Y\*ZI-JDK7&KZY;2W+:A=28.P .H147@!!@*.G->X@8^M34M?0=.]M
M1:***Q-0HHHH *\=^+6M^*[CXI^"O"?ASQ /#L.J6MY<7%R+59V8Q!2H ;ZU
M[%7E'Q4\!^,=6^(/A/Q9X/ET,W.CV]U;R6^N-,J.)0!D&($Y&*TIVOJ1.]M#
M)\/?%?Q!X0U+QAX<\6V[^)M7T&&UNK6?1;;$E_#<$K&/+SA6#*0QSC'-6K;]
MI72D@O\ ^U-#U#1KW3-2L;#4+:9D?[,EV<0SEU)#(2,''((KGO$/[/OB[Q3X
M?\2ZCJ7B'3YO&NMW%D\R0)+!I_V6V;*V65/F>6P+;FSDD].U<ZWP:@^&_@SX
MKZIXT71='TCQ+IUG:Q6'AN">9+26(2JFT%=\CL[H0V!SG@ 5T6IOU_X8PO-'
MOV@>/;/Q%XQ\2>'[2"8OH)ACNKIL>69)%W;%]PN"?J*X'PGXO\<G]H'4/#?B
M.?3UTB31#J-G962$F$"X,8+R'EB0,GL*TOV:O!FJ^$?A3ILOB(N_BC5\ZGJL
MDJX<S2 85AV*H%&.W-;7_" WA^-@\9_:(/L T+^ROL_/F^9YYDW=,8P<=:R]
MV+:-?>:3.ZHHHK U"BBB@ H/2B@\B@#QCXK:WXMO?C-X)\'>&_$2^'+;4]*U
M*_N;@6BSL[0/ J* W0?O&J'0/BYX@\)7GBWP[XKLI/$NN:$+::VFT2VPVH03
MY"$H3A&5E(8YQWK2^*/@'QIJ/Q0\)>-/!TFA-<:/IU]I\UMKC3*CBX:$AE,0
M)X\H\'UKD_$7[/'BOQ'HFN:GJ&OZ??>,]9O;6XNX526WTU[6 G99?*3((SN)
M+=23TKJ7(TD[?TSG?-=M?UH=1IW[1^E3Q :AHVH:3>1:O!HU[;3%'^R23+F)
MV9204;@9'<UVWA?Q[9>+?$_BK2+*"8CP]<Q65Q=M_JI)VC$C(GJ4#*#[M7SW
MJ7PA3X7_  P^*-UXK;2M,A\1+"]A8^&[:>06]U&G[A$!4LS&15P<#WQ7LG[/
M?@R_\$_"S2H-;)?Q)J)?5-8D889[R<[Y,_3(3Z)2G&"3<1QE-NS.'\=^)_B+
MX&U:RUJ]UZP;^T-<33]/\)06P?[3:LX7?YGWO,"9<]A4GQ;\2?$3P*U]XF_X
M2"PM+9-2@L]'\,);B4ZDC.JE6?[PD(+'C@!:;9?#;XK0?%S4?%]ZW@[65>4P
M:<UY)=!].LMW*1(%VB1ARS=SQG%&M?#;XJWOQ?N?%Q/@[6+.V_=:+:ZG)=+_
M &?$?O,%1=IE;N_/H*M<MU>Q+YK.USWN%BR*S#:Y )7T/I4E,BW^6GF;?,VC
M=MZ9QSBGUQG2%%%% !1110!YK^T?XRU;X?\ P3\4^(-"G2UU>RAB-O,Z!PC-
M/&A.T]>&-<Y=ZYXX^$?BWPO#XB\06_BWPYKU\NEM)]C%O<6D[J3&PVG#*2N"
M.O(KK_CS\/\ 4/BE\(_$GA;2KFWM-0U&*-8)KO=Y2LDR2?-MR<?)VKF/^%;^
M/?'WB31=1\>:IH=GI^B3->66F^'8YF\RZV%4EEDE.<)N)"J.O4UT0Y>77S_0
MQES<VGD6;?\ :#MSXDM]*N_"NLZ:E\T\6G7-TJ+]LDB4L4"9W+N"G:6'-:>D
M?'#1->3P%]AM[F>7Q@9OLT( W6R1(6E:7T"D!3[D5Y/X*_9F\4>'?&GA36=3
MD\-NGA^_FO+C5X#<2:AJ:LKC,A?A"-P^4$CBK_[./@V"]^)_CGQ;8S3W/A*W
MN9M/\-B:W>%425_.O&C#@$KYI"AL<A*N4:=FT0I3NDSJ_C_XQ\<>"[OP_>Z'
M<:?9>'FU*RM+MI8S)<7#33B-D4=$4*<YZG->T, &('3-<#\8_A_>_$?PYING
MV-S!;26VK6>H,T^=I2&9791@=2 <5WS'+$CI6#:<4;)-28E%%%9EA1110 5Y
MM^T+XLU?P5\+-1U30KI;+4Q/;P13O&) GF2JA.T\'@UZ37 ?'+P'J?Q)^&]_
MH6CSVMMJ4DL,\,E[N\G='(KX;;S@XQQ5PMS*Y,[\KL<C#XC\:_"_QMX3T_Q/
MKT'BO0/$L[V,=R+,6]Q9W(B:5.%)#*P1AZ@XJY8?M%P7&M6^G7GA/6]):_AN
M9=+:\5%:],*%V39G=&Q121N'-01?"_QWXW\2:3JWCG5]&L8=#CG;2[#PY%*0
MMU)$8A<R22G)**QVJ !GFN'^''[-/B3P?XQ\$ZUK!\-)%X8-P;S4;$W,M]JX
M>W>,RS-)]ULL&*#(Y.#T%;V@U[VYA>:>FQZYHWQKT7Q#)X(BT^"XN)/%=L]W
M;JH&;>)%RYD],-\OUJM\5(_&+WLMUI_BFR\%^%-.L'NKK5)H5FE:49.&#<+&
M  3W.<5Y[^R_X*C/B[QIXKM9Y[KPS]KELO#1N+=H0EL[^;.45@#M,I(!P,@5
MT?QT^&_C_P"(GB+0TTB;P]=>$+'%Q<Z+K#SH+VY!RAE\H'=&O!"$X)ZTN6,9
MV7XE)R<+D.B:]\1OB3\./!.LKJ=GX'MKK2Y+_6M1: /*KJ<1!(WX1'7,A)Z
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M[@L"KYS&ZA0!][H>3Q5KDIV/JD=??T->;_M$^/+SX=_"#7=6TMMFKR+'96+
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M*C;$4L<N<]>V)\0O&WBSX:_%GPQ87/Q.OM3\::UKD48\,"S6#1ETUW.1YCH
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M<EHVQY!D0PID]1O<MC_9%>?6_A_QCHG[1GA[PKH'Q.\4>(H=/M)-5\00ZS+
M]LD3 K;PG9$I#.^6Z_=7WKOO&&@:AX;_ &G_  ?XMMK::XTO5M)N- OI(T+"
M"3<LT#-CHI*LI/N*Z3X5?">[\ )XKU6]U&'5?%?B*^EO;G4#&511C;!$!UV(
MH QGGF@#QZ*X^(OPY^+_ ,-M+OOB%<^,?%GB:[FEU_PPD4?]G66F*CE[J$!0
M\*QR>4BLQ_>,Q7DYQW'QT\0>(=9^(_@'X<:!KUSX63Q +N\OM7L50W*6]N@/
MEQ%@0K,S*-V#QFN>^#_P*^+7PY\<:EKVJ^*/".OW&N7PGUK5)=-N/[0G@!.R
M"-_,V1HB\(@7:.3@DDUO^*?@GX^UY?#GB2/Q?I0^(GAZ^NY+*_DTYA936<Q*
MFVEB#;ON;?F4YRH- 'EM[\5?&O@SP_JK:AXANM6G^'WC*UTN]OG"H=2TZXVK
MF=% !=/,4Y&.5SWK['AD$T*2*<JRA@?8U\F>.O@AKND^ X?"US>/XC\5^//%
M5MJ&O:E:6QAMHHHW623:,G8BK&J+DY.:^LH(E@@CB7[J*%'T H&>/_M9^,];
M\"_ [7M2\.O?0ZP7AMX9=,MS/<Q^9*J%HT .6 )QQ7G_ ,%[N+Q_'XI\*+\1
M?B9IGB>.&&62T\56D5E?VD1/RS0*8L%'P1GGTX->]?$KPQK/BWPC=Z?X?\0S
M>%]8+));:E#&)-C*P8!D/WD;&&'!P3S7F'ASX+>/FU_Q!XT\2>*='N/'5SHY
MT?2GTNQDBLK!,EO,*LQ=V+'<<G Q@4 <)\,[#XCZM\0/B7;>$OB3J6MZ)HL,
M6AVM]XK2.YB_M,R*UU,BQ+'D0QG8%)PSDY. :]!_9 \4^(/%GPAGG\3:S-X@
MU:UUS5-/;4)T5'E2"[DC0E5  ^51P*[[X1?#&S^$?P\TGPO8R&X^R1DSW;CY
M[F=B6EE;_:=V9C]:XKX;?!?Q5\+_  WIVCZ3XFL5@_X26^UC4C)9EC<6MQ/+
M+Y"$M\CC>OS<]#0(\A^*OC3Q7\,/B9H$5Q\3[V[\9:SKD,=GX5CLQ#HQTYY,
M%7D=-HD"9.XR;BV %.<5[+^U'XUUGPA\,(+/P[=-8>(_$NK6/AO3[R/K;2W<
MRQM*/0HGF,#V(%<EXM_9\^)?C>"Z\*:WX_TS4_ %SJ*WSR76F%M76-91*MNL
MF[RP 0 'V[@*Z/\ :J\*:EJ/PGL-3T"TEU'5/!^L:=XDMK%!N>Y6TF5Y(QZL
M8O,P.YQ0!R7C/Q#X^\"_M'_#VRN_$Z2^"]02^@BT6WA^>2.WLB_FW$S99Y"X
M/ P  .I)KB+7XA_$&R\":#\;9_&-W-9:IKJ6TOA0QQFP33Y+DP(% 7>)1PV[
M=R>,8KZ \7_#/_A8GQ#^'/C**]2"QT$7<KVLL3;[A+FW,8';:1NR<UYM9?LK
M>*8GT[PE<^,;.;X5:=K']LVVFK9L-1)$IE2V:4ML\I7.<A<XXI@7/!GB'XA6
M7[6=UH'B;Q+;ZAH=]X8EU6TTFPMA%!:;;Q8T^8Y9WVYRQ/?@8%<U^TI\9-4C
M^,MA\.].U;Q5I=O#H?\ ;=Q%X(TT7FJ7;-*T:*,J1'$@1F8G&<J!UQ7LFN?"
M?4KSXRMX]T[5;>TF3PM-H-O#+"7V3-/YJ3'D94$#*]ZY#6_@G\18M<\.^-]"
M\7:*OQ$@T-="UJ?4=-=K#4(M_F!T1'#1LLA8C!((8@TAG#^'?BSK]CHGP@\5
M/XQ;Q3I=_K$OA_4Y5MFM?,5]PB,\!QLN(V7:W YSQ7T1XA_Y'KPF.^V[_P#0
M%KY^O?@=J'AQ_AAX"BNKC6W;Q%-XL\0:P8/+A:1<N=H'"Y=@%7).!7T#XA.?
M'7A3Z7?_ * M '6;Q[T4W8?:B@6IQ>KW"P?$FW+YP=*D' )_Y;)6I_:$7H__
M 'P:SM1&/B5#S_S"9/\ T<E;.:Y*E^;0ZJ=N4K?;HO1_^^#3C?Q?[?\ WP?\
M*L%B*3=[5EJ7H5C>Q$8(<CT,9_PIOVF#/W"#Z^4>W3M5OGTH!XS3U#0I1R6D
M  BA6,#. D&.OX?7\ZD6]B08 =0!@ 1D8_2K.^C<31J&A7^WQDY^?/\ N&@W
M\7'W_3_5FK&<49S1J&A7-]$#QYG_ 'P:0WT1YP__ 'P?\*L\#M1GVHU#0K?;
M8O1_^^#0+Z(?W_\ O@U:Z49_&C4-"'3]0A34)&^<@Q@?</J:U!JL&/\ EI_W
M[/\ A533>=2E_P"N2_S-:XK>FI<NYC4MS%3^U8/^FG_?L_X4?VK!_P!-/^_9
M_P *MXHQ6MI=S/W>Q4_M6#_II_W[/^%']JP?]-/^_9_PKC/BO\8+#X51:/ V
MDZIXCUS6KEK32]%T:$27-U(J&1S\S*J(B*69V8 #Z@4OPT^,>D?$KP_J>I1V
ME[H-QI$[VNJZ;K"+%<6$J*&99 &(QM(8,"00<@T6EW"\>QV!U*'.?G_[]FG?
MVK!_TT_[]G_"O/\ X(?'[PY\?M/UR_\ #4-]'9Z5J#Z>TM[$(Q.5&?,CP3E"
M#P3C-<[X_P#VJ-(\#>(=?L8O"GB;Q#IOAH(WB#6M(M$DM=,W(),-N=6D*H0[
MB-6VJ03Z46EW"\>Q[%_:L'_33_OV?\*/[5@_Z:?]^S_A3].O[;5M/M;ZSF6X
MM+F)9H9D.5=& *L/8@@U8Q1:7</=[%+^T8"?^6G_ '[/^%._M6#_ *:?]^S_
M (5;Q1BBTNX>[V*G]JP?]-/^_9_PH_M6#_II_P!^S_A5O%&*+2[A[O8J?VK!
M_P!-/^_9_P */[5@_P"FG_?L_P"%6\48HM+N'N]BI_:L'_33_OV?\*#JD!'_
M "T_[]G_  J>ZN8K*VEN)G$<,2EW=C@*H&23[ 5XIX)_:NT/QGK^A6C^%_$N
MAZ-XCD:/0-?U2T2.SU-@I8!<.7CWJI9/,5=P&?:BTNX7CV/8EU*!?^>G_?LT
M[^U8/^FG_?L_X5YYXW_:$\,>!OBCX2\ 70NKOQ#XB=EACM$#);*%)#S$D; V
MT@=SBO35;=VQ^-%I=PO'L5?[5@_Z:?\ ?L_X4C:G 1_RT_[]G_"KF*,46EW#
MW>Q3&J0#/^L_[]G_  JMJ&I0NL.-_$J'[A]:U<54U(?)!_UV3^=3)2MN5&U]
M@&JP>DG_ '[-']JP?]-/^_9_PJW1BJM+N3IV*G]JP?\ 33_OV?\ "C^U8/\
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M'_33_OV?\*/[5@_Z:?\ ?L_X5;Q1BBTNX>[V*G]JP?\ 33_OV?\ "C^U8/\
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M%MS:JNFWUV-P$:-OWJ&*,$9E 8C -.TNX7CV/:!JD &/WG_?LTO]JP?]-/\
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M_?LTX:I !_RT_P"_9_PJWBC%%I=PNNQ4_M6#_II_W[/^%']JP?\ 33_OV?\
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MO[O;@]JA^+&@'P1K7Q:\$:!?:IIWAM=3\'7,$$-Y*S6[W-TR7!C<DLH<1KD
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MH&8(2%ZXQZBF_#SXR>#_ (K)>?\ ",:U%J4EIC[1!L>.6,-]TE' ;!QP<8H
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MP<XQ3]-^-G@W6;;PY<V&MP7=KX@F>WT^>($I+*HRT9./E;@\'!XH&=U12 Y
M-+0 4444 %%<3JWQE\(Z#<^)X=0UF"S7PU%#)JLTN1';>:"T:%N[D ':.?F7
MU%5O#'QX\"^+_#VJZWIGB*TDTW2EW7\LVZ$VHQG+JX!7(Z<<T =\>AKQ+]J+
MXZK\$/"EA+8Z<U_XBU>8V6G,UN\D%JQ'SSS,H)5$!R0.6X KLOA[\</!/Q5N
M;RV\,:]!J5U:JLDMOL>.0(V=KA74$J<<,.*9\1?C?X(^%-[9VGBG7H-,O+R-
MI8;?8\DK1@X:0J@)"#/+'B@#YKB\,:KXS^!=MHOPQ9O'0U+63=>,[V_F.ESZ
MBS8>54,B_*C$*F .$&!78?L7KXJM-?\ BQ;Z]X.B\+6;>(I)84BNQ,JML53$
MF%&54*N''!S[5['XF^.7@7PAX=TO7-3\1VD>F:JH:PFAW3&Z!&<QJ@);CK@<
M5T7@[QGHGCSP_:ZWX?U&'5=+N,^7<6YR#C@@YY!!X(/- C>HK@_B'\<O!/PJ
MNK2U\4:[#IMY=HTL-ML>64QJ0&D*("0@S]XC'6G^)/C;X)\)>%-/\2:EXAM(
MM&U$*;*XB)E^T[AD>6J LW'H*!G<TAK@M'^.7@OQ GAV33=<@O8/$$LEOI\T
M0.R26-=SQDD?*X /RM@\&N\!S0!2T_\ X_+[_>7^57ZH:?\ \?E]_O+_ "J_
M6<-BY;A136;%<3JWQI\':$?$9U#6X+.+PZ8EU*:4$) \@RB9[L1@[1D\CUK0
M@[9E!ZU\9_'GXW^'O'GQ+O/AAK$]YX<\ :7<1OXAN4T^9I=<E#!A9PE5.V'(
M4R2=6^Z."37T_P" /BKX6^*FGW-YX7UB'4X[9_*G159)(7ZX=& 93CU%2^'?
MB+X9\6>)?$'A_2-7M]0UCP^\<>J6D!):T>0$HKGIDA6XSV- CY!_:G\+?$S6
MY/'WB9/!%KX@\-QZ&-/\/3Q:HL;64$BJTTHM]I9I7.%XQA5QW-?7WPKN-2N?
MAQX;DU?3UTO4OL$(FM%E$HC(0#&X 9JYXN\9:+X#T&YUKQ!J4&DZ9;C,MQ<-
MA1DX ]22>@')K"\&_&SP5XZT/4M6T77[6YL=,!-\\NZ%K8 ;LR*X!48YR10!
MW=%>7:!^TQ\.O%5CKEUI'B*+4!HUF^H7<,<4@E^S*#F5$9073CJN1^=>BZ/J
M]GK^DV6IZ?<)=V%Y"EQ;W$1RLD; ,K#V((- RY1110 4444 %%)G&:\WN?VB
M_AY8^'K77+WQ/9V.F7E[)I]I/<,5^U3)(8V$8ZN-P(W 8H Z/XA>+M.\ ^"]
M8\0ZK;SW5AIMNT\L-M"9I9,=%5!U).*^6O@S\2Y/BAK_ (L\;VCIJ'Q<O-#G
M@\/>'+J":"RTJV7YD@>5E 9WD,;2-[ +@"OH;QW\?O 'PSUB'2_$OB.VTV^D
MC$IA97<QQG@.^U3L7W; KN;&]@U&T@NK66.XMIT$D4L;!E=2,@@CJ"#0(^&O
MA/X0^)/@#X_?":RUGP$D-R+/6)]7ULZPER][<7#0-<W4A5 %;(^6//W<*#\M
M?>-<KXX^)/ACX:VMA=^)]9MM(AOKI+*V:X8CS9G/RHH'))K'\=_'WP'\,]8A
MTOQ+XBMM,OI4$ODLKN8XR<!WV@[%SW; H ]"HKFM(^(>A:YXHNO#]G?)+JEO
M:0WYB'1X)<[)$/1E)4C(Z&NEH&(>U<GXB_Y'GPG]+O\ ] 2NL/:N3\1?\CSX
M3^EW_P"@)0(ZKR_>BGT4!8XO4O\ DI,/_8)D_P#1R5K5BZO<1P?$F R.$!TF
M3&3_ --4K4^W6W_/9?SKDJ-<QTTTW$GS25#]NMO^>R_G2?;[;_GLOYUGS+N:
M68^6UAN'B:6))&B;?&SJ"4/J/0UYIXD^!EKXC\;2>(Y-3:*5M6T[5?(\A6 ^
MR1,@CW$]&W9SVQ7I'VZW_P">R_G2_;K?_GJGYU2DELQ.+?0^<])_8ZDTC6?#
M]U%XREFM]%FM[B"&XL0Q1XYI)=J?. BMY@R,$DCJ <5ZA\&OA"OP@T_5+*#5
MY=4M]1N3?2>="JL+E\F9@5_A8\A?X>@KO/MUMT\Y2/<T?;K;.?.7\Z'._4.3
MR.8T#X9:3X;\5>)-;M?,;^WKB*]N+*4!H4N47:9D&,AF 7)SV[5TLFF64\KR
M26D$DC[-[/&"6V'*9/?!/'I3S?6Y_P"6R_G2"^MQ_P MD_.ES)]1\K['.P?#
MO3T^)%QXUEFFN=4:P73H(Y"/+MHMVYM@QD%CC)SV%=2>M0_;[<_\MD/XTAO[
M;O,OYTN9=PY7V)P<4N<U!]NMO^>R?G1]OML']\GYT<R[AROL6],_Y"<O_7(?
MS-:XZ5@:?J%NFHRDS+@Q@9S[FM0:K:#_ );I^==%.2Y=S"I%\VQ;-?+GAA/#
M&J?$']HJ_P#B!):_V-;W%K:WO]HL%A2PCMU==V?X<DGW-?3']JVF?]>GYUYM
M??";PYJ/Q&\0>([J6UOM.\0:;%8:MHM[;+-;W31-F.0AN,@'!!!S@>E:\T>Y
MGROL>.?#_P 7IXT\5Z_\:K'2XVM]*\-W&F^$O!^F,C:IJ%KO25KB:)22K2M%
M$L<>/E4Y/+&O*?@YXDN;/]I_P+J6K^$_&,/CG7],U*?5[K5]"FMHVGD\ORT0
MMDBVA4!-W8<XRU?9WA/X4_#7P)JO]J>'/"'AO0-3,9B^V:9IL-O+L.,KO10<
M' S]*Z6>UT*YU:WU26"TEU.WC:&&]>-3-&C8W*KXR <#('7%'-'N'*^QYAJ/
MB/Q%8>%_$UW\:M'\(Z=X"@M]T\MA=W-]E-X'[V-H%&W[N2,X[\#-?/GC6]U1
M?CG>RV&N:+XPO=8\!ZY!X43PH%B?28PD<BFX168R>81$B2;@-RD!><C[<N;O
M3KVWEM[AH9X)4*212@,KJ1@@@\$$<8KFO!OP]\ ?#N>\F\+>&]"\.S7AS<2:
M78Q6[2\YPQ11D9[=*.:/<.5]CXU^#VIR^&M,_9[N1XP\/^-$U>6UM1X9AL+<
M-I;>1\\L#)^]62(@B0N3D[LX/%?0/[+>+'7/BWI5LQ.E67BVX%HH/RKO17<#
M_@1->B:7\._ OAS7]0\0:'X=T'2?$5Z&\[5;73XDG=FZEG4!CD\GGGO5;X2>
M!-,^%7A=]+AU(:A=7%W-?WE](H1KB>5BS,1S@=@,G@4<T>X<K['HE%4_[6M/
M^>Z?G1_:UI_SW3\Z.:/<?*^Q<HJG_:UI_P ]T_.C^UK3_GNGYT<T>X<K[%L]
M*^=/B,+J^_:O\-V\1+36O@_4;C3T/3[2SA=P]P !7T =6M,']^GYUPGC+P'I
M_B?QUX2\60:K_9VJZ!)*NY$W"YMY5P\+\C@D*P/J*.:/<7*^Q\1_#G5K_P +
M?![X:ZY=>*]"\1WK^)K+3YOA[)IT#2O</>!'*''G"[C):8N3CY#D8K[.FUOQ
MW:ZKKC>,]%\+V_P\ABN&>ZL[VYN+QH #MWP&$+ROW@&/?&:WK?X>> +7QC)X
MLA\-:%#XGDSOUA+&);ILC!)E"[LD<$YR174-J%DZE6F1E/!!/!HYH]PY7V/C
M'Q3K%E>_&/X4W_AKQ!X;U[PA=FXA\+Z1X<C2WNK&1K8[9Y2"QDC7&"I";21G
MFN:L-6\.W?[,7P@T31KJS'Q 7QKID26BNIO8[^.^W7C.@.\8C$Q8GC:>>#7V
M1X;^&OP\\':[=:UH/A?0=&U>ZSY]]86$4,TF>3EU4'GOZU+:> O FG>+YO%=
MIX=T2W\3S@K+K$=E&MVX/!S*%W<]^>:.:/<.5]CS?X%XLOVBOV@-.M_DL1?Z
M3>^4O"K<2V7[T@>K!(R?K7OM>=?"[P)IWPYD\47CZH-4U?Q%J\VK7U[(@0DL
M D42C)PD<:(B\]B>]=S_ &M:?\]T_.CFCW'ROL7*IZE]V#_KLG\Z/[5M3_RW
M3\ZJZAJ5LZPXF0XF0\'WJ92C;<<8N^QJBEJG_:MH/^6Z?G1_:UI_SW3\ZKFC
MW)Y7V/#OC2/M_P"TO\!M-NCNT[S]7OA&Q^5KF*T_='Z@/(1]*\_\5W'@SXG>
M/D^''A&31='\-Z-KB:KXDUDSQ1M-?!_,%K!DY>0O@NPX7[O4U[O\3_ FG?$2
MZ\+7ZZH-,U7PYJL6J65VB!^0"DD;#()5XV93@]P>U5Y/@?\ "2?56U27P%X3
MDU-IOM)O&T>W,IESNW[MF=V><]<T<T>X<K['QI^USXSU'Q/J7BK5O%'@;QK#
M:Z%J.G:?X;(T*5[!$%_;M-=^=]WS)L;$QVVC.6K['/B+XG:GKVE7&B^'= C\
M'74-M-))K%[<6^J1*Z@R*UN(2H=<D;2_4<XKM]7MM"\0:>;'4[>SU&R+(YMK
MJ-9(RRL&4[2",A@"/0@$=*N_VE9\?OTX]Z.:/<.5]CXP_:-UOPQJGA6:^\'^
M(_"W_"*:;X@C;7O#4%N+;5+Z_2X7>D<C?,)"V#CR_FQPV#FN4U<ZH-5_:#UF
M_P#'^D^#7L+J2\30M:L+>4W]L;56B2X\[YFB<?NU6/'.<$GBOLZY^&OP[O/%
MR^*KCPMH$WB52&&KR:?$;H$# /F;=V<=\YI_B;X>> /&FLV6KZ_X:T+6M4LL
M?9KS4+&*:6+!R-K,I(P>1Z&CFCW#E?8\+\+ZH;G]H/X%:K:Z:NB7>O?#V\34
MM*A7:MK GV26%"O4!))&49]2*^JZ\WT[P'I\'QDU7X@W6JB[O)M*AT:PMMFU
M+*W5S)+@Y^9I)"I)XP$4=J[S^UK3_GNGYT<T>X<K[%RBJ?\ :UI_SW3\Z/[6
MM/\ GNGYT<T>X^5]BY2'I53^UK3_ )[I^=']K6G_ #W3\Z.:/<.5]CY:^'=S
MX,3PU^T+XA^)+V?]B0>.[LZC+J)!3RK1+;[*A!^]@*FU1R2V #G%5O"?BO5)
M+?Q]\:K#1?M_B.^TA++0?!>C%+B]BLU;=%)<QQDGS79@Q7^!<+R<UZ_;?!GP
MJ?%OCF_U 6.L:!XO:UN=0\/ZC:)-;?:X%">> V02ZK#D%>L0.:Z'P?\ #;X=
M_#V]FO/"_A;P_P"';N9/+EGTK3X;9W7.=I**"1GG%'-'N+E?8^.?V<=:FT3]
MI=H(_"_BM/%FJ^%7FO[WQ#HLUFL]\TTCF25CDI#G"*V#TP!7TKJOBG4].\":
M_>?'G3/"&D>$(VME\RQN;B_@+&90IG62%=JB3RB&Y ZD@"O4?L^A_P!L_P!K
M>19_VIY/V?[;Y:^=Y><[-^,[<DG&<5+J#:3JUA<6-\MM>65Q&8IK:X4/'(A&
M"K*1@@CC!HYH]PY7V/@_XDW.O6_C/XK)_;.D>,M?U+P-<-IEUX701Q:?:)*K
M>5<1(6)9]P*R;^0K  5U?PLU&3P]\0O@O;CQAH/Q#@UNQEV6%M86RR:*JVZG
MSH'B^98_^6;!R<GOFOJ;P9X#\"?#JVNK?PMX>T7P[#=-NG33+..W$I_VMJC/
M4]:J:3\.?!/A"35[WPGH6A>&=;U&-Q)J5AIT4<A<@X9MH!8 \XSS1S1[AROL
M<#^QBQ@^&WB+386+Z7IGBO6+/3V[&W6[D*@>P)8#Z5[[7!?"/P9I'PD\ :5X
M7L;W[5%9(QDNI>'N)G8O+*P[%G9FQ[UV/]K6G_/=/SHYH]PY7V+$_P#J7_W3
M_*H=+_Y!]O\ [@_E44VJVIB<"=,X/?VJ+3M3M4L8 9T!"#O[5'-'FW+L^78U
M*\=_; OKG3OV:O'\UK*\$ITXQETZA'=4?_QUFKU;^UK3_GNGYUC^,-,T7QOX
M8U70-4=)M/U.UDM)T]4=2IQ[\U?-'N3ROL>&?%'QIX3^%%GX6LM TK1M0^*.
ML:)'I6B6]]*D4=O9J-S3W#M_J[:,DD]W;"*"3QP'CW2[GX=_"GX:_"?2=*\4
M>,_!+PR3^(/$'A73&OEND61I'MU\HX02RLV>?E0$<U[SI?P,\!W?AC0=.\8Z
M/H7CG4M(LH["/5=9TR&:9XD^Z"7#$>X!QDD]Z[SP[I/AOPCHT&D:'8V&CZ5
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M.5]BV>U<IXA_Y'CPG]+O_P! 2N@_M6T/_+=/SKF=;NXKCQSX4$4BOA;O[O\
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M .+O_P! 6K'PX\7)X]\!^'?$<054U6P@O-B]%+H&(_ DBH/$7_(\^$_I=_\
MH"4Q'5[!13=Y]:*!:''ZC_R4J'_L$R?^CDK9/2L+5IU@^)$!<D Z3( 0"?\
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M7_[X;_"C^U(?5_\ OAO\*.>/<.678NT52_M2'U?_ +X;_"C^U(?5_P#OAO\
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M.IR_]<A_,UL  CI61IG_ "$I/^N0_F:UQTK:E\)C4^(,#T%-; SQ3ZBFR58
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ME1@=YA1B$ '#,6'.* /LKX<^-[#XF>!= \6:9'/%IVM6,-_;Q72!94210P#
M$@'!YP:Z3 ]!7B7[%K:V/V8OAW!KVC'0[JUT:UMX[=IA(SQ+$@61@ -A;NAY
M7H:]NH&)@>@JGJ0&V#C_ );)_.KM4]2^[!_UV3^=3+8J.Y;P#VHP/04"EJB1
MC*.M>->//VG=&\%^*-5T2S\+^)O%DNBPK<:U<^'[%9X=-C8$CS"SJ6;:"VU
MQP,XKV5S^5?%/QSU1_ /Q/\ 'L.C>)]:\'7'B2TC:ZT]M!^WIJ\GEF-6LI5/
MR2=$8,#C(.*!'UE!\0/#]QX#'C,:G"GAK["=2.H,<(MN$WESWX4'BO.O O[4
M6C>,_$>G:5=^%O%'A2/5[66]T>_U[3Q#!J,,:[W*%78HVSYPL@4E1G':O+M5
M\&7[_L6W_P &M.N_.^(T/A!9_P"RRP>X W9 /8EBI4 ]3Q7(^ =;4_$#PNWP
MKU7QCXINI])O7\7V'B2>YDMG(MCY/FK+\L,YGVH%CP-I88Q3 ]V\'_M:>&_&
M&OZ'9KX>\2:5H_B"=[;1/$.HV*I8ZE(N>$(<LN[:2I=5W8J.']KWPO/X@MX!
MH/B-?#,^JC1(_%S62C3'O"_EJF[?Y@4O\H<IMR>O>OEKX26:V6L_"9=$UCQ'
MXE\6V&I-+J'@C5+5X]-T3>&\XP@J/)\HDA"S."#P.:S[>S<0V:Q:CXBD^(<7
MC)-17X7M9N-&5_M0W$)MRJJA:42[RNX [: /TL ! X%+@>@IL63&F1@X&1Z4
M^D,3 ]!1@>@I:* $P/048'H*6B@#S;XV?'?PS\!?#2ZOXA6_NWE$C6VGZ5:-
M<W5P(TWRE5' 5$RS,Q50!R>F<3Q?^TIIGAJ[\+66G^%?$OBS4?$6FG5K:ST.
MVADDBMP$.Z3?*@7_ %BC@GO6W^TC9O>?L_?$B*" S7#^'-02-(TW,S&W?@ <
MY)KYQ\>Z%\/;6X^'VH_$&?QIH4X\&V]I;:AH]S/;6FX)&6B+0?.)@0" W!QT
M- 'UQX8\2-KWABWUF[TF_P! ,D1EDL=414N( .H<*S 'CL37F7PT_:53XJ3Z
M?)I/P[\:0:+?1R2V^N7=I;I9R(JL0V1,6P^W"_+R2.G6L+X%^,+_ %#X-:?X
M9\97]_<^*M1TV^FLK2Z(&IW5@I9(I&!Q^\*LHRV.2,UXK\)DT'P_XX^%.G?"
M'4_'7]J1W8M?%&B^(KFXDM[?3$@D$GVB-_W4<J.(A&8\9Y R#0(][M_VJ8;?
MQ3X=T/7/AOXX\-2Z[>?8;2YU6SMEA,FTL<E)V8 !22<< 4:3^USX:U/7[& >
M'_$EOX<U'43I-CXJGL5&FW%UDJ$#!RX!92%9D"DCK5#P19ZA\4OB_P"+OB+<
MV3MIOAR.?P_X7M+A2HFD _TJYP>SL!&#T(5L=:^6_"EB8I/!<5GJOB'4?',7
MBQ;R[^&US92+H]B6F;S'5-N4$:DR+(7*YZ#FF!^DZ<GD9I^!Z"FQDD#(P<=*
M?2&1S >2_'\)_E4&F '3[?\ W!_*IY_]2_\ NG^50Z7_ ,@^W_W!_*H^T5]D
MLX'H*CE8)SBI:CE;:I/&,<Y]*LD\-T3]K;PSKGB72K%= \1VGA_5]3.C:9XK
MN;$+IMY>995C5MQ<!V0JK,@#'C/-&O\ [6GASP]XAU*VE\.^)KCP[I>HC2=1
M\50Z>/[-M;K(4J6+B1@K, S*A4'O7D^G_&OPK\</CCHD.LW=SHWA3PUK"+H&
M@O8RI)JFI@E([R8[<)$C,?+3/+?.W851_:?\?Z;\1YKS1H+SQ9IGB_0]2%O:
M^")K)GL-==)5:)Y JY>)Q@AA( !U'% CZM^(WQ(TCX7^$YO$.K+=W%JC)%%;
MZ? 9[BXD<A4CC0?>9B<#H/4US_PN^.5A\2M;U;0+C0-:\)>)M,BBN9](UZW2
M*8V\FX1S(4=U9258<'((((%1>)/CAI/AGPGJ=\]M>:K=:+)!:ZU9Z''Y\VG/
M(H)8KU(3.3C)QVKYM\ 7'BF?QG\6-3^$&H7OQ!O=1\/P?8O$GBN/RGMK\2LJ
M6B2LJHT21NTNT*,,,$G- 'T5I_[2?A?7OBAXN\!:-;:EK.O>&+#[=>"RA1H9
M&#*K01.6 :52Z@C@ G!.<BLGP_\ M0V^J^/] \(ZG\/?&GAC4M;\S[+)JUG;
MK$0BY9F\N=V"CUQC)KPS]GOP[XT^&_[26EZ5>^ &T?3[;P6T%[?R:M'=-*6O
M/.ENY) /WDLDI)9>OS9Z 5[1\#=-O/B+\0O$_P 5M8M98(IV;1_#]O<H5:&Q
MB8AY0#T,K@G/< 4 >]@# XI<#T% Z4M Q,#T%&!Z"EHH 3 ]!6!XV\8Z7\/_
M  KJ?B'6)7CTW3X3-,T,32/@= JKRQ)(  [FN@KG/'GBL^"/">HZ[_9E[K(L
M8_-:STZ,23NH/.Q21D@9./:@1YOX1_:B\/ZWJ.I6.OZ'X@\"7%II;ZXJ^)+1
M8A<6"??F0QN_W>,H<,,CBNB^"WQQT+XZ:7K=_H5GJMA!I.I-ILT>L69M96<1
MQRAPA.X*RRJ1N //(%>!?!K5;/Q7^U,NO^%]9UOQQI5]HLZ:G=^(+=E_L/\
M>*T5O;OM10');='M)^0$M79_!'Q%8?#S7_C9?^(IO[(L[WXB/#;27*E1,\MK
M:)&$S][<W QWSZ4 =1J_[3$%KX\UOPMH_@#QAXIN-%GBM[Z]TBT@>WADD4,
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M8NBM8RI+K&IJVV.ZF(7"0QLQ,:?Q-\[< "OL]3D"@ P/048'H*6B@8F!Z"C
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MV+_=7\J3:O\ =7\JRU--"+[9;_\ /:/_ +ZH^V6__/9/^^JFVC^ZOY"DPO\
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M;IY[2R."#U;]VN . GO3O#'QV\$>+=<\9Z7INJ1RR>$,?VO.R8AA&UF)#]&
M"MDCT-9'P^_:8\$_$GQ+9:)IRZG9W>H0/<Z9)J>G/;1:C&@!9H&8?. I#=C@
MYI^\/W3T'2K'0M"DO7TZWM+%KV8W%R;>-4,TI !=L=6( Y-,BTOP]#>:G=)9
MV(N=3 6]E\I=UR NT"0X^8!>.>U<]\3OC'X:^$HTZ/5UO+R_U!F6TT[2[1KF
MZF"C+,L:\[0.IZ5@WO[3'@^#PSHVOV%AKFOZ=J@?RGTC2I+AHF0X9)5'*,#P
M0>XH]X/=-O1/AEX+\"Z3K4'@C1=#\(WFI1.)+G3K".+<Y!"E@H&X*3D+G'7'
M6KGPG\':/\*/ .C>%;"\^T0Z?$5>YD(#SRLQ:25O=G9F_&N"L?VN?!>JZ$FK
M6&A^*=0MOMUSILJ6NB22207$&SS$D4?=QY@'/<$=C7=_"3XM>'OC1X?NM8\/
MQ7:6MK>26,R7]J8)$F3&]2I],BCWA>Z=C_:EI_S\)_WU2'5+3_GX3_OJK'E)
M_P \U_*@Q)_<7\J7O![IEV6HVRWEX3,@!9<'=UXJ[_:EI_S\)_WU4-E&IO+W
M*J1N7M[5=\I/^>:_E4QYK%RY;D']J6G_ #\)_P!]5PGCSP'8>,/%W@_Q+;:J
MNG:OX=NGECE5=XG@D4K+"W/1AC\0*]"\I/\ GFOY4>4G_/-?RJ_>(]TX"V^%
M/PWLO%[>*X/"GAZ+Q(Q+-JJ:?$+C<>K;PN=Q]>M1_!_P'8_"KPS>Z<=6&J7N
MH:I>:M>7SKL,TT\K2,<9.-H*J/917H?E)_SS7\J/*3_GFOY4>\/W3$L++0=*
M^W?8K>SM?M\QN+KR8U3SY& 4N^!\Q( &3Z51M_"OA*TCTF.#2M-A32I&EL$2
M! +5VR&:,8^4G)Y'J:ZGRD_YYK^5'E)_SS7\J/>#W3SKQSX"L/'WC;P/K%_J
MH_LSPO>2ZG'I@7*W%X8C%!*S9X$0>4@=V8'M7>C5+0#_ (^$_P"^JL>4G_/-
M?RH\I/\ GFOY4>\+W2#^U+3_ )^$_P"^J/[4M/\ GX3_ +ZJ?RD_YYK^5+Y:
M?W%_*E[P>Z5O[4M/^?A/^^J7^U+3_GX3_OJI_*3^XOY4>4G_ #S7\J/>'[I2
MGO;"YADBEECDC=2K(W(*G@@CTKRSPA\"?!VD?"RP^'_B*#3O&/AW3)Y#I\&K
M6B2^1 9&:*,[LY,:ML##&0!P*]?*1@$E$P.2<5X[X6_:G^'_ (O\46.C6,FH
M*NHW+VFG:I<:>\=C?3*2"D,Q&&/RMCUP<4_>#W33USX3^']4U[P%<V4UKH^C
M^$+B6YM=(LH%CA9VCV+@+@*%R3C'>NVU6TT37GLCJ,%I>_8KE;NV^T('\F90
M0LBYZ,-QP1R,FO-K#]I_PCJ_BZ;P_IVE>(M0FAOSILE[:Z1(]HDRG# RCC )
MY/:NP^*7Q1T#X/\ AJ'6M?2Y>VGO(;""&QMS/--/*VV-$0<DDT>\'NF+KOP)
M^$OBC6;K5]8\"^%]3U6Z?S9[RZTR&265\ ;F8KDG ')]*-?^!7PF\4W_ -LU
MCP-X8U.[\M8O/NM,AD?8HPJY*YP!P!VJO8_M%>$I_!6L^*M0L]8\/Z3I3HDQ
MU?37MY)&;A5C0\N22  .Y J+PY^TOX$U[2?$5_/+>Z"= MQ=:A:ZU9/;3Q0M
M]V38>JL>!COQ1[P>Z7= ^%NB:%\43XOCN[>.&TT:/0])TNWA6*&PMP^^0+C@
MEV"=A@(!7HW]J6G_ #\)_P!]5YW\,?CWX3^*NLW6DZ9#J.G:K!;K>?8=8L'M
M99;=C@31AOO)GC(_&O2_*3_GFOY4>\+W2O\ VI:?\_"?]]5S.MW45QXZ\*>7
M('PMWG!_V%KKO*3^XOY5ROB!0OCGPI@ <7?0?["4+F#0ZBBEQ15F9R&I?\E)
MA_[!,G_HY*C\8>-=!^'N@RZSXEU6VT72HW2-[R\<K&K,<*,XZDU)J7_)28?^
MP3)_Z.2OFK]K6ZN/B+X^\-?#FS\,ZEXPTVUMIM7UJPTLQ[U#(T5MNWLJX#,6
M'.<J*YY*\CIB[1/I34?&&B:1?Z'87FI06]YKDK0Z9"QYNG6,R,J>N$!;Z4LO
MBS1[?Q/%X=EU*!-<EM'U!+%FQ(;=6"M+Z;0S &OC?PQ\0I]0TW]GB^\6"32+
MWPEXHO?#^N/?$ VEP+.6*$3-D@%_DP<XRPYK=_:$OYO&'Q=\91^$+D:E?Z=\
M,;Z&=]/?S#"\MU&R)N7H[(KD#KWI<NH^;0]Y\-_M)_"[Q=XQ/A71O'.CZAKN
M]HDM(IC^]=?O+&Y 21ASD*2>*]*)ZU\])XG^#-[\'?AW87)TZ^TGS+!-%TZP
MYGBNP%V[$CPRLK9W'ZYS7I/@_P"-'A_QOXDET;3OMJ3^7)+;7%Q;,D-XD3A)
M&A<_?"L0#CU%2UV&GW.[I,XKF-1^).@:+J^IV&JW\.DFP\D-/>NL<<AE5G"H
M2>2%4YJOX=^*>A^*/'.K^%]+E:[O-*MX;FYN(\&%1(,HH.>3CGIWZU-F5=#O
M$/Q8\(^$M2O['5];M[&?3[>"YNS(&VP1S2^5$78#"EW. O4_2NIN+F&SA,L\
ML<42]6D8 <GUKX?^+Z/JWP[_ &E;V:9H]4;Q=IE@DYP7B@CFM!" #V&XD#ID
MUW[_  RNKCXN>+OA'-XPU_5O"VN^#(-7<:]<+J,EO<B]:)FA,JD(&4?=QA6P
MR@$"KY41S,^E=!\1Z7XJTR'4-(OH=0LY@626%L@C)&<=>JGKZ52\8>.O#_P_
MT^VO_$>K6VC65U=16,-Q=,55YY#B.//J3_*OD[4/@3??L\>"?A]X.T+QEJVG
MMX@\5P0:A?Z=*(KAHRLFY/.VAW!&W[^=ISC%<I\7?"MWXCTOQ%\*-6\1:OKF
MB0?$+2;&RN]7NFN;RWCN+9VQYI^9MCMN7/I344',S[>\9^.= ^'>A2:WXFU:
MVT328Y(X6N[ML*'D8(B\=RQ  %/T'QAI'B>]U>RTZ]%Q>:1<"UOK<JRO!(5#
M*""!D%2"".#V-?GY\:?'FL_'?X51>'M866*[^&EE]I\5AL@2:TES]CMD/U59
MKCZ,E?57A,BR_; \7V]M\L%[X3L;J[1>AF69D5C[E21GT%)QL@4KGN^F#&I2
M?]<A_,UKCI61IG_(2E]?*'\S6N.E:4OA(J?$+1116QF%)2U%/YBQ2&)0\@4E
M5)P"<<#- $F1ZBEKS[P)KGQ$U/6KR'Q9X3TG0]+12;>YL=7:[DD.> R&)=O'
M/4UZ .E "T444 %%%% !1110 A. :^>?B]86ME^T?\&9(8(H'GNM2EF=4"[V
M\A>6/<_6OH8]#6+'K6C7_B*?2H[FVN-9L8EGDM@098$?@,1U4'% 'R);_&?X
M<?&[XOZ'X;M/%7ASPUX \'Z['/9Z<;N*&[UW6(W/E^7%D,L$<C9'&9']AS[-
M^T!^T)X"^%'@R/Q)J%UI6LZA;ZDVFZ5!]IB.-2 *F)I"<1% 6WEB-H!KT33(
M_!NI:_?6>GP:/<:QI;HUU%!%$9K5V^9"V!E2<9'TK"\)_#;PE\'OAY+IUX\$
MVDVUS=:I=W^L",EIII7EEED)&,Y<C/H!0(\4^&WC_P  ^!?AEK7B_7/&6E^*
MM3US6$GUW7M""7MEI5Y(I6$G&1'%&, .WU/6O))TTCQ5IWQ^2]\:7/Q TAK+
M2=2F^(.@V(NGM9H)]\5MY,7[J98-BRL(_P"!GW<XK[@EU[P9X<T&WO'N]&T[
M1M2*+%*3'%#<E^% [-G/'UJ#6?'O@7X9?8=,U'6-%\-?:>;>T>6. /D]0O'!
MSUH ^8OA#XD\0_&/]J'PAK\OC/PWXUM?#NA7HO;CP? XT^W6X$:Q!YF=MTTA
M4MY>1L$><<U]HKU-8&BZEX<L-8F\/Z7)86M^(!J#V%J%1C&[$"7:O4$@C=70
M9S0,6J>I?=@_Z[)_.KE4]2^[!_UV3^=3+8J.Y;%+2"EJB0HHHH *3-+7GGB7
M7OB/:^-X;/1O".D:CX79HO,U.XUAH9U!_P!81#Y1SM[?-S[4 >AT4B_=%+0
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MC0!J45E_\)3HO_07L/\ P)3_ !H_X2G1?^@O8?\ @2G^- &I167_ ,)3HO\
MT%[#_P "4_QH_P"$IT7_ *"]A_X$I_C0!I2'",1R0#7Q-X<^+%Y\.?@/X[\5
M6UO<W'BGQ+XUU*P%S%;/.;4B8P(\@0$[8XXP1_\ 7K['/BG1<'_B;V'_ ($I
M_C7F_P ,?"6E?#C6O&@C\0Z5<Z!K>JG6+6S,R;[6:11YX)+<AF4,/0DT"/C7
MX<Q^&=5^&O[0G@SP]K[VCS75G>-J.L136T=SA8?-\Z1E&T2N"ISSA_2N[T[Q
M9J'AK]HKP)K:?#NW\#66F^$M9FU:PTF2.>XOK6**)XW9(1@QB7:(R?F9G8#I
M7U:OACX>JOB)#%HCQ^(6#:I&\D3+=G:$^<$X/R@"LOX<?#3X7_"62]E\+6^D
M:;/>*$GG%TKR,@^ZFYF)"#LHX'I0!\>?"3XD:3X@_:N^'_C#7+F^;Q;XEM=1
M6[MI;"X5+"-E46MHFY!PBYW,.-S,3VKZ8_9:)TS6_BSX>@8G2])\53K:)VC6
M1%D91[!F/YUZ-J&F>#;WQ%8>(6ET=]=TZ&:&RNWG3,2R !@,'H<#-<_\%/"^
ME?"[P[?P7OB+3=1UG5-0GU/4+R.=%6261LX +9P!@#/I0,]7HK+_ .$IT7_H
M+V'_ ($I_C1_PE.B_P#07L/_  )3_&@#0G_U+_[I_E4.E_\ (/M_]P?RJE-X
MIT4Q./[7L,X/_+RGI]:ATWQ/HRV$ .K6((0<&Y3T^M1]HK[)NT5E_P#"4Z+_
M -!>P_\  E/\:/\ A*=%_P"@O8?^!*?XU9)J45E_\)3HO_07L/\ P)3_ !H_
MX2G1?^@O8?\ @2G^- &I167_ ,)3HO\ T%[#_P "4_QH_P"$IT7_ *"]A_X$
MI_C0!J45E_\ "4Z+_P!!>P_\"4_QH_X2G1?^@O8?^!*?XT :E%9?_"4Z+_T%
M[#_P)3_&C_A*=%_Z"]A_X$I_C0!J45E_\)3HO_07L/\ P)3_ !H_X2G1?^@O
M8?\ @2G^- &I7CW[6VJW6B_LZ>.+BRD:&=[+R?-0X*+(ZHQ_[Y8UZ;_PE.B_
M]!>P_P# E/\ &N;^(ECX9^(_@;7/#.H:O8K::I:26SL+E,KN'##YNQP?PH \
M9^.6E:+I7PM\)>#?#^@Z1<>,_%<,&A:1<2V,4KVL/E#S[G)4G;%%N8?[16NR
M^)GPPT_PQ^RMK7@30=1B\-:=8: UA;WDK[(X46/&YV'(!Y+'W)K:\#^&/#^C
MVWAG4=?U31]6\7Z-IG]EKJZ3*I\OC=M!;Y=VU<_2JJ^$]-O_ (M^)?%.L>)-
M-U'1M0T2WT2UT=KA3%'&KR23M(I;:Q<N@SCHN*!'S/I>N:GH7Q<^$=W:_#VP
M\$Q:9IUU]M&D3Q3RZC:);99D6(?-%E059N22*Y;PI\4]&\5_M1_"WQSK<^HI
MXGUJ]U&W:QEL+A5T^U:)$M;==R $Y)9B.[$GBOL?X=_"OX5?"J_NKWPO9Z/I
M=U<KY;S+<JS*G78I9CM3_9&!71:EIW@K5]>T?6KN72)M3T@RM8W!GCW0&10K
M[>>X _*F!X)X2^&?AOP;^U]XQT72M.2"RU#X=PSWGFL9&N99-1N=[R,V2Q(X
MY[ "N^_8PU&XOOV>_#T,\C3#3YKO3H96.2\,-S)'&<_[J@?A75^*-(\/WMUK
M>OZ-J&C6?C.]T=M(AU6XF5MD89GC5@&Y4.[-CWI_PDT7PY\*/ASX?\)VFMV4
M\.EVJPM.UR@,LGWI)"-W&YRS8]Z0'H=(:S/^$IT7_H+V'_@2G^-!\4Z+_P!!
M>P_\"4_QH&2Z?_Q^7W^\O\JOUSUCXFT=;R])U:Q ++@_:4YX^M7?^$IT7_H+
MV'_@2G^-9PV+EN:E%9?_  E.B_\ 07L/_ E/\:/^$IT7_H+V'_@2G^-:$&I1
M67_PE.B_]!>P_P# E/\ &C_A*=%_Z"]A_P"!*?XT :E%9?\ PE.B_P#07L/_
M  )3_&C_ (2G1?\ H+V'_@2G^- &I167_P )3HO_ $%[#_P)3_&C_A*=%_Z"
M]A_X$I_C0!J45E_\)3HO_07L/_ E/\:/^$IT7_H+V'_@2G^- &I167_PE.B_
M]!>P_P# E/\ &C_A*=%_Z"]A_P"!*?XT >*?%]CJ_P"U'\#M%N>=-ACUG6!&
MWW)+F*"..(X]4$\C#T/->+?$7PA:?"'XD?&B/P59O9W9^&POBZ2,TTUPUW.6
MD9SDECZ^@]J^COB;X7T[QEXK\!>)M,\1Z98:SX5U0W*/+.C+/:2QF*Z@.&X+
M(00>S(M=+)IO@J7Q+>>(7ETE]8O+%=-GN6N$+26ZL6$9Y^[EB?QH$?*/PHT2
M?X?^-?@E/J^G^%+ZWU^U:/3'T& P7=B3;AV:20'_ $A&'#%NC5]"?%_0-!U_
MQ'8FVL- UWXDVFGRR:+I?B&4^286D032!.>@&-P&1P.E9MA\#_AAX.BUV^\'
M0:'H?B*^LI[6VOQ<*WV5I%(!C!;Y%W$$A<=*9#\$?ASK7PY\)^&?%UQIOB2Y
MT&U6&/5);P)<;]H$C+('WC<>HSSWH ^5=!66_P# GP]\(:;965[XWL_B)JK/
MI5^Z_P!A?:8O,EN(D[&!5E'EJ!G<.G!JIX@?7-.TKQ1X6GL=*L-8O/']@NL6
M-N^-&ACDC)A QCY"5!=3C) !ZU]G7_PD^$FI>!K+PA-I>@_\(_9/YUM:QS(G
MDR=Y%8,&#G)RV<G)YJ72?A7\*-$\%7WA2UT_0ET&^.ZZM))D?SV_ONQ8EF_V
MB<B@#YX_X16&QOOCEX#\3:?X?GU2Y\$_;Y-8\.V_V6$Q;)A&LT(.U)49=RMU
M(P>U?3G[/WB"]\5_ SX=ZUJ3,^HZAX>L+JX=^KR/;HS,?J23^-<#K_P0\%:=
M\*/%7@WP#?:-X3F\2Q"SOM2,XEF,#X28[B^YF\HNJY. 2*]:\/WWAOPUHNGZ
M18:CI]O8:?;QVMM$+I,)&BA54<]@ * .D/:N3\1?\CSX3^EW_P"@)6P?%.B_
M]!>P_P# E/\ &N<U75[#4O'?A5;2]M[IE6[+""57(^1>N#0!W%%)D44#*%]H
M>GZHZ/>V%M>,@(4SPJ^T>V15%_#7AN,X;2-*4^C6T8/\JWJ^:OVB/A]H>J?%
M[X6RW$=P&UC59+6^6*\EC6>-8&*J55@.#Z4"/>QX1T ]-$TT_P#;I'_A2_\
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M\P33?_ 2/_XFOCK1/C3XTU7Q/;+;7MC9ZYJ3:;IMQJ/V<N"K2W*.XC+8!_=
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MB@!/^$-T#_H!Z;_X"1__ !-'_"&Z!_T ]-_\!(__ (FMFB@9C?\ "&Z!_P!
M/3?_  $C_P#B:/\ A#=!_P"@'IO_ ("1_P#Q-;-% &-_PAN@_P#0#TW_ ,!(
M_P#XFC_A#=!_Z >F_P#@)'_A6S10!C#P;H/_ $ ]-_\  2/_  H_X0W0?^@'
MIO\ X"1__$ULT4 8W_"&Z#_T ]-_\!(__B:/^$-T'_H!Z;_X"1__ !-;-% &
M-_PAN@_] /3?_ 2/_P")H_X0W0?^@'IO_@)'_P#$ULT4 8W_  AN@_\ 0#TW
M_P !(_\ XFC_ (0W0/\ H!Z;_P" D?\ \36S10!C?\(;H'_0#TW_ ,!(_P#X
MFC_A#=!_Z >F_P#@)'_\36S10!C?\(9H'_0#TW_P$C_^)H_X0W0?^@'IO_@)
M'_\ $ULT4 8W_"&Z!_T ]-_\!(__ (FC_A#=!_Z >F_^ D?_ ,36S10!C?\
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MZ;_X"1__ !-'_"&Z!_T ]-_\!(__ (FMFB@#&_X0W0?^@'IO_@)'_P#$T?\
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2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>mtva-20251231xex10d3g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231xex10d3g001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'0 !  $% 0$!              <!! 4&" (#"?_$ %,0  $#! (! P," P0(
M! $"%P$" P0 !081!Q(A"!,Q%")!%5$C,F$60G&!%R0S4G*1L<$8-&*A"8(E
M)D-3T? V1&.2M-+4&45F<W:$HN&DPL3_Q  8 0$! 0$!
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MH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H+&VCR]_Q?\
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M\7_:KVK.W_#G_&?^E7E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MU7U I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E!0'9JM4 T:K0*P>87J7CU@G7"WV>5D$UAOLU;(2VT.R%$@!(4
MXI*$_.R2KP 3Y/@YROFMOLK=!^<>>>F?D.!Q[QGG>/V/*;KR]:KZ[>Y=GE3(
MOTC;[KON3-?QNJ$K4$!)25$I0 0/%2=DC&;7'UC8;R<WQ9EB,<MF-R+9*3J$
MI\/N*64A*1)\I^X>=_Y5V8$H)_.Z]=$_MO\ QI9*F5PQZK[ERMZ@N!.1<1@<
M27VWN2Y=N:L33JXRI#R6GVWWW7M/%+:?LZH ))_/]-JQ6R(P'+K!=./.#K[C
MU]N#;%GNDR:S'CPF(:GVENO.!#RE+4@(7UU^5DG8\5UW[8'QO_G5"@>?P:<&
MUQ!SGZ8LFR?GS*[9CK'TN#\KV1M&3W%;0<:@R8:D%MQ*3X]Q8ZI3\:+CB_E/
MG</15A6<X1QF_?\ DRV2TY5"A-V"-"0CO(,&$IP-E"=^2ZI:B/CL$MGXU76
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ME I2E!Y"?/Q7JE*!2E*"FMTUJJTH%*4H%*4H%*4H%*4H%4U\U6E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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M0\]CDGLA#DAYD(VR)1;[$:VE*@DD=5"IA]0+L.U^JCTX&)!D-6RPO7ER<N)
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ME*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4%E;M=7-?[U7M6=M'\-?\
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M^=>K]RSB.,WU%ENN36JW79:4*3"DRD(=/=:4(^TG?W*6D ?)WXI;AW;A5"H
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MF-KZ,I!*EZ"MZ&CYJ;/*MNI6KQ>2,;F8_$O:+];F[5*Z!J6])0A!4H I1LD
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MLD4VYB-$%Q;QYWZ@LM]4K"-S"$+6A)3V\Z[; \5+]?-QQ+8)40D#\F@A+).
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M>:7' LWY5B\77JX7V[2L%1=H$!^<]< [<0M9]QD.J5I?LE*^B= ^#UKM<L)
M!\^/ZU\EQT%0)V1^PI)),Q=KD3CO,<*R#U'\67#%,EN>0Q)6+W:.Y(N$J3((
M?[PCI0=W[;I"5=TC6NH\#0K/\L/8Y']51DY3?9.-VC^P7MIN3-R>MZ4NF>I0
M3[S:D_=U2I0220>OP=5TC;[C#ND!N=!E,S(CR.[<AAP.-K3^Z5 D$?UKZVV=
M O442H,EF;'*E(]Z.X'$E23I0[ D;!!']"/Z5.)V3NX;MO+>:LV+BN'R7ETS
M"K/=[%<E&_S678QFS!)4B']0II;19=^E]IT)4I(4MP[!*?MVC&;0G)N<;U:;
MER7>TWRY89;$VRZ1Y+MN7->!EH7(;B]AL)*4N% ^W:B3X578XC( (^X[^?-?
M-]#;+94L@(2-DK/@?UJY#:X.Q_E',?UVRPI[V0N3KG"D89):5<Y09AY*P>H>
M0>VU(<93[Q)^T:!\**JVB_YQ>+;R_F&$W3EAS!)5C;M1QARZ1793ES8]E#DE
M\)#S:9:W'"XRIM25] $] DG==A1%1[@RV^RXAUM?W(<;4%)/]01X_P Z^WT+
M*W$J*-J0=I/['6C_ .U,AM<A83RA=\LY3R!B]\HLXEDMFRIZ(<2?A+6MRV@=
M64(;]U*5I<2KW??]M2DD>5=!JM-P+E60C&>)LLG\N2;G>[AGERL<Y$FZ,B+*
M@B;,: 5'1U;_ -FEA:5@;3[B-$)*0.ZY<6)&[S7@VVIM!"GUZ!0CY/W'X%5,
M!E]/9: L_N0*S)(<H']8W)4*T<;-83&R*W63)LWDMV.$Y.D):#3+JP)#YV0>
MJ6NXV/[RDCYKGOTX97;_ $K^JWD;BS);_C=OL.0LM7^#]%($>';Y0!#L?3BU
M%!4GSI2MZ;3K^:N^OT^.\OLXRAQ0^"I()'_.O+]A@2W%*?A,.%7R5M@D_P")
M(\UI-L<+^BGG'C[!+?S=<,@S6QVN,]FTZ8TN3.;!=8.M+0G?98_8I!W^*U[D
M_F3'.3_6#P%DMIS1O"(\S%I\DW&2N*'H >9<6TAU#P6A"EI4-!0^%@BOT!=P
MRPO ^Y9X*_\ BCH/_:OD[A&/25]W;';G%Z">RXC:CH#0&R/@  #]@*F&W.SF
M7%HV)\OXUR#PG+SEOD2[W*),GS,BB>TXF.R]))BH6IK2 M"CV"$ )'3X&ZXM
M;S&_V:V\;<A9%B[STWAJYM8EF\MP_P .9'$L"( C7WJ9Z!1/^\ID_D:_7:UX
MS:K$IQ5NML2 IW7<QF$ME6OC>@-_)^?WJVD878)<:=%?LT!Z+.=]Z6PY%0I$
MAS:3W<!'WJVE)V=G[1^PID7=<0^L2VOXG_\ #JS=S(W68F6Y1)A7>:R\XD..
M2WKG&=4RD?WO9:"6_']UG>J^7K,RJT7#&_388.40(2U9%!?1.;D,N!AM+(27
M_N)24I4""3]NQH_M7=-YQFU9 VVW=+;$N3;9[(3+80Z$G\D!0-8Z3QEB,Q#"
M)&,6=Y#">C2'(#2@VG9/5(*? V2=?N=_-7@US5S9BEWPOTZ\YW7*\Z9R:/?K
M<3:I<E+4<M-?2(;#(" &SM86H!(^[MOYW6@<6YQ:<!X7XMRO).6X%UQ*S6?M
M.P]*(I=<4J,4,M(;;^]U:7"/L7\?S>"FNX[CB5FO-L;ML^U0YMN;Z](DB.A;
M2>OA.D$:&OQX\5A4<-X&V\EY&&6!+B5!25"V,;!!V"/L^0='_*ID_P"A+?30
MO69/CP?2QR:Y)?1&2NR2&TEQ83M93H)'GR2?P*@[@'TWR.48'!G)-\SEJXV/
M#K,TJR8[ MR&_IWU--A?O2?=5[I"FTG00G74#]]]EW[%K3E$$0[U;(=WAA06
M(\YA#S?8;TKJH$;&SYKQ:L2LEAM;MMMMH@V^W+[%<.+&0TRKM_-M"0$^?SX\
MU1^36</7Z9A/J4?M]S;EX,G/PK)[/!0W]>_ +R"7V'E%70)6&]Z01K9V!L5-
M6=.XQC'J:]+68V^6U)X::M;EKM%Q4X5QXSY8>0W[BC_(LJ<CJ)7H_P ,_E'C
MN:T<2X19$RA;,0L5N3+9,>0(EM8;]YL_*%]4#LD_L?!KV>*\.&/2,?3B]G18
M9"_<>MB(#28SBO![*;">I.P#LC?@4LE'(OJ-5_;?UU\ 6K$5>_?\?^KG7Z1$
M5OZ."2T4I=4/"0I*9">I/GW0-?<-Z#C7'-ZYVYQ]7F&XQFUMQB->IEHC39;E
MO%P6_']F2EQ+0]YL)4-:)\_S?@^:[YPOC/%..X;L7%L>MN/,/*"W6[;%0P'"
M-Z*NH&];/S^]>+)Q3AF,7 W&S8I9;1<.JD?5P+>RP[U5KL.R4@Z.J#B3G7!8
MO%?,7H]PC'\A:MSEA3=X;-QN+:'BW_!B ..-]D#[M*T-@;^/BIHLV31K'<L[
MQO)<MMV99K.M]PN4.9 82@QK:F-'3[2TI4H,#W0=(*CW*2OY)U-V0<1X1EEP
M7/O6(V.[SUI"%2I]N9?=*0- =E))T/Q5HSP/QS#CRV8^"XZPQ,;#4EIJULI2
M\@+2L)6 G2@%(2K1_*0?Q3DWZ?EEQ8R7^'/2Q_I(NC8X=DW>XK0N$T&';?<D
MSI!:3)=/8J:6?/V^WH%6]]4D]>__ !,85OLOHTRV/#:9A"3<8CZ4-!*?==7,
M2XM6A_,H[4H_D^3Y^:Z0;X2P%NR2;*C"["BSR'TR78";<R&%NI&DK*.NBH#P
M#\^:^E\X3P/)K9:[==\0LMR@6IM34"-*@MN-Q$*Z]DMI(T@'JG8&OY1^U7\"
M+?6% MC?I:Y7O#+++4N?CA8=EH "W4([>TDJ'SI3J^H_=9_>N<?4XXH^@;@]
M+3[;+KD['^BW0%)V&5:)&QL?&_(_Q%=PS.%\%N&'Q<4DXE9W\:BK+C%I7#;,
M9I1*B2EO6@=K6? _O']ZQDSTW<87"UP+;)P#'G[? +AB17+<TIM@N$*<Z)(T
M.Q )U\ZI,\HC>4XYAW(O7EG,+5D$6]M1H6,1X=M7&>9E%N:F8IMI+CJD]F'!
MV=V!UV/&AN#^+Y><<%WOA>$J_P!AY>XCO%P3 Q2[+B"/=;:EYIQ*%(.MD):6
MXDD[/7L#T\ =<V'TZ<8XS=V+G:L$L$"X1^WM28UO;0XWV24JTH#?D*4/\":^
MV&>GOC?CV[INN-879[)<D!:6Y4.*E#C87_/T.OM[?G6MUG\U4)?_ !/WT_\
M@OS/QO<BW_\ XXS4_7'DO&L1N&+6.ZW1N-=\@=$6V0PE2W)#@:4X=!(.DA*"
M2HZ2/'GR*^F><1X;R>F&C+<;MV1IA]_ITW&.EX-=^O?KL>-]4[_P%:O%]+7$
MULF"7#X]Q^-)#;C0=:@H2L(<0I"T@@;TI*BD_N#3-$#_ /P]LAM^.\"9_=[G
M);M]MB9A=G9$AY75MM">FU$_BM;]+^5P,J]=7+MXN4KZBX7:T1)F-N/MJ;4_
M:UA"DJ:2L!21[98V- [[;\A5='J](/"RD>VOC+&NF]A(MZ -_O\ %;'E' G'
MN:M6=%YQ.W3#9FTLVYWVNCL1L  (;6G2DIT-:!U3#5UB,S#W\DRQO'50%7MN
M8T+\J$G2_J?81T]XCP5^U[?]0- ZJ'E<[90GU%8UB9?MKUHN-^GV:3#B1U."
M(AFVO2F291*09"BSM324D(2M(40K1,VX!Q7B?%MI=MF)V&'88+SI?=9AM]0X
MX?E:C\J4?W.S6+7P#QV[>EW=>(6M=S7/-T,I3.U_5$$%T'\*(.C^_P"=U1(%
M*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H+.VI :7_Q&KRK.VG^$K_B
M-7E I2E I2E I2E I2E I2E I2E I2E!S=ZEL'5R9E$&V6UY+&5V7'YEZL+R
M5?>B8W,@K;( \Z)9]L_@I=4*C2%FD?E/U">G/DA++MO9R47@08<HZ=:BMVQ8
M (_]3JWE#]P4;^0!UX_Q_C,K($WY['[8]?4E)3<W(;9DIT-#3G7L-#Q\U;W'
MB[$+Q<(TZ?B]FFS8H2F/(DV]EQQD).TA*BDD:/D:^#4HY3MWJ%RI')[,96<0
M)MJG6C)GE//,,-VIF3!?9;CE@A D*0V7%MN+<)#BT+Z#0%>[)RYRRJR7:SN/
M2E9\Q-M&[--EVU*9;#[,A:C;IR6?867A'6M*7FP4>VI)([)(ZB8XBPB)*1)8
MQ*R,R$/NR4NHM[04'74E+J]]?YEI)"C^1\U1/$.%)L[EH3BUH3:UN(>5$3";
M#9<1_(O6OYD_@_(_&JF+KCKD?U-9I8^&#D%FS&0+O;L>F71463:8K<YV3&G+
MCN?7H4DM-,I4W[ ]DA;JU=D: \2ZYR+?\[Y3Y5L;'(#6 PL)=MQ82(D5],B.
M['0^Y)?+R3MM14MH>VI'7VR2=G0F6?PQ@MU5'5-Q*S2E1XBK>T7H+:O;C*WV
M:3M/A!VH$#]S^]4G\,8)=)=HE3,0LLJ39VTM6]UZ TI45"?Y4MDI^T#7@#P/
MQ5DPUR?<LBR_ IG,V7XYDK<*);^1K?'D6A5O;<1.;D&WQG$N.*^])"7]I*.I
M!3Y[ ^-GY<YLS3"L1]2,N-DK469@;L2397'HC!_AO0&7PRL%.EI4XXM(/\WV
M@;V*GZ3P/QY,9GLOX=9W6I\A,N4A4-!2^\DDI<6-?<H$D@GS7J^\%X!D]R-P
MNV'V:Y33$$ R)4-MQ98T4^WV(WUT2-?L2/BI9+W1$63\MYEC?/2K9<%2H^$J
MNT>WPI5MCQYK#[JX27%1)201(COEU04VORV4J;&O)K6^*.7N3>4^,K/GPO5E
M@66^VBXOEM"FUNPY*$+6PAA!;VM;?MK2ZEQ2M]>P"=%-=%P>),0M5^3>(.-V
MZ)<D^V4OQXZ6R"AKVD$   %+?V _(3X'BK;'^#< Q7(;C>[/B-GMMVN)694N
M-#0A;I5X7O0_O#P?W_-7IBZYBPF]<AW"V^FB.>09:%Y'!ERY3CD)EQ2E)MA6
MCOL;<T5+^?R=GR$ZDCC3ES,+OS$YC^4^Y;(DL7)5K0Q'9D6^Y,L/@(<CRFE%
M2'$(\.-.C9421H#1E!/I_P"/$6FVVQ.)VY,&V.J>A,I:T(ZE-^VHH/RG:/LT
M#KKX^/%96R\7XKC=Y>N=LLD6%/=4ZM3[2-'LZH+=(_"2M0!5K6R!O=,-09SY
M=;G:.:[)<K--:A72#@V12H[S[/O(2MM4-8*D=AL?:1\C_M6M63DSES)9WT=M
MR^TP CCJ!D[:I5C2^I<I:5>Y[A2X@'NM!.TA(2DZ""1VKHG+>$L)SF\)NU_Q
MZ)<[BF,J&)+_ &*PPK^9L$$?:K0V/SH;W6/M_IUXZMA486+0HBE0Q;B6>Z=Q
MAO3/\W\@V=)^/)JHB3CSEWD7)KUQHF?=;*8?(6,S+M'9:M:TFTR&41UI\^_M
M]!$@[!Z':/!\^-3X<Y5Y'Y*O_"<^;E;$>/>,&?O]RB(M:5ID/!Z.%^$K2 2E
M6DZ&D>?"M^.AAZ=N.@;/K&([9L["XMN+3KJ#$:4?N0WI0ZI/@$#Y  ^ ->K3
MZ?./[";#^F8XU _04+:MOTS[S?TS:U)4IL:6-H*D(/0[2"/ H(.Q7U+9Y/X?
M8YAE62VR\)DV6?=W84=Y*'HQ;251FFR"HK)*%(<[ :/D: ZG*17\BN/J"X*N
M][O,"YHN.-WR6EJ#$+*&5K1 40A96HK1I0 V-^"=GM]LM8[Z<^.L3N=PGVK%
M(41ZX*=4^VGN62IU)2ZI#146VRM*E!10D=@3O>ZML2],G&N#W2T7"R8RB#+L
MY=_3G!*?7]('0 XEL*<(2@Z'V =1KP!4Q=1]S].GV_U"\:3;0_&8N$7$<M>8
M7+94ZT%I_2U#LA*D$CQKPH?]CH\;U0YO&Q3!+G,_2%&='Q];T1$=;K\Y,]U#
M3[RBTH)AH0I:0V' ?<*5@>!71^9\'8?G]]CWJ]VY^7<V(CT%J2W<)+!0P[H.
MM@-.) "PE/;QYZIW\"M1;]'?$S,&3#3C#B(TAJ*RXA%VFC28R^\;J0]M!;)^
MU2=$#[=]?%,34+R<URSBB)ZC,YL#]JE0L?R=5PDV>=&6%3&T0HA=2F0EP>VK
MKOJ2VKR!OP=CWSGG=[RG'N8++<OHC:;9*PZ7;$,1BT\A$FXMK4'B2KLL=$CQ
MH#7@#=3]</31QU<IDZ3(Q];AGRFYLV.+A*3&F/("0A3S =#;O4(0 %I('4>*
MM<A]+7'667&^S[I:;@_+OJX[EQ4F^W!L2%,+]Q@E*'P![:AM(  !^*HA[,.5
M^1S=LCM-ONEFM4F+R-:L?3*:MCBNT1YB.\.W\9)*O(2OS]R24CIX(WA?)W(,
M;/[Y@STS'C>XZ[8NTO\ Z3(0W.BR._ON=?J24ED,2"1V.PA'Y7XVA7I;XZ";
MJ3:[DIRZ7"/=93[E_N"W53&->T^E:GRI"TA*1V202  =CQ7UL>#JG<O?V@FX
M\Y:H^,VURS6F?*F"0]<$/J:<=<V%J4$H]L)'NZ65*=.M>2%[S7RC+X\A8Q!M
MD9A^]9+>F+)#<FE0CL*<"E*=<ZZ*NJ$*T@$%2B "-UJUPY&SNP9EA^#3S8'\
MAR5^XR&+O&8?3&9@1$-*4M4=2]EY2GVT= [H;*MD)T9)Y$XVQSE;&UV')K=^
MH6Y3K;Z4)>6RXTZ@]D.-N-J2M"TGR%)(-8)GT^X6Q"@M(BW$S(,E4V-='+M*
M<G-O*1[:E?4+<*R"C[2DDI( '70 J7D[(CR#U)YE DN6&'9K*_D5KS:%BER>
M<D.ML.MR6FWV7FDA*RGNTL!22I1;(.NQ^+"^>H_DS$K1GTZ?9,5EHP*\Q(-U
M,>1)0;@P^F.XE4<*!#2DMR$D]BL*(/\ */)F&=Z;\#G6N)!=@3T(C77]<#S%
MVE,ONS][$EUU#@4XL?CL2 /   U5M?/3+@V01,NCSH]V=8RR4U-O#8O<Q(E.
MMI2ALG3OVA*6VP$IT-(2->!2<'=&V9<[<HV?)^7V[-8L9N5KP%,288TB0^A^
M=%<C?4+"5@=4.!(5Y((\ :_)N<E]5%TMEZQE^+8HC%@O#]F;8:G229TUJ>$[
M?;2@D,H94XA!]P?Q%!83UZA2O&+\0-Y9R_S#$R2UY"UB]Z%JC-*?D.H8NS$>
M+[;B7%I5V([[!V4E8)WV3XK?<F]+& Y=>[K<YD:YLR;BNWO.B#='XS;;D( 1
ME-H0L!!0 1X\>2=;.ZHC0>H_D$L7*_O6:P0[):,Z3B$VV)=>>DNMK>98#R'_
M +4I*5.A74H/8;&TZ\[G:N8,OG\@W[$#;+.W=K9?(L%*2X\ ]!=BJD_5C]OM
M2M'7X[MK'8[&LC-]+.(OV.XVE4R_I@S[VG(9"$79P%4Y*TK#N_G^="%=?C:$
M^/%7F&8JF]\P9'FDJP3+1(C0FK!&=EN)W.0TZZM4CJE1!3_$ 0HZ5HK\ &@]
M\S<FWWC"Z8>N/;X#V.W>YHM4^Y2W' ;>ZZ%".M24@A2%N^VUO8T7 ?Z'2N->
M?\PY(BV=B'9[ F_+N=UM]UMYG/!,/Z)025I<#:NP65L?W? ?2=*T14T<A\?V
M7E##+OB]_9<D6FY-!I]#:RA8TH*2I*AY2I*DI4#^" :P&/\ !.+8=?\ *+SC
M[$BSW/(8\:-+D1W]EI+#0:;+04%!"N@3V.CV*$D[(%!!7%G-&:Y9)X9M]FL.
M,VFQ9'C,NZS;<AQ;#+8;>8;*&TI:5H(2Z>J1KL2=E.@#8\#<CWSC'$<0MK6,
M6_\ L;>,XN]@3*9F>W(8==N4TM*0P&^I;!3U(*@KY('@=IFQOTQ8YAG]DOT6
MZWZ"O&(TB# <^M2ZKZ5Y3:EL+*T*VGLTD@C2AY';1U5(?I@QV+9++:47O(!#
MLU[7D,-)E-$IFK=6ZIQ1+7W#W''5=3L?Q%#6M 3!L?*_(,_!(-L5;[:Q*5-D
M%AV?<)!CP8" @GW7W E1^Y75M*4C:EK2/'DC%X)FD;GCT_V[*)]G9BQ,BLZI
M#MLD*$AM(6@@H)*0%#Q^0-C\#=9_D+BRU\C2\<D3YMRAO6*?^H13 ?#86Y[:
MV]+!2>PZK5KX()V"" :\\:\16?BS &,/L\FXO6=A"VF!.DEYQIM6]-I5K^5(
M\#\_DDDDFCGWT_<MW[ >*.#+-<L<@?H>2VQBUP;A&N2U.1Y8C*<92^V61I#G
M7KV05="/(4#NMXQOU+W&^VCC&YKQ2+&CYE>9=D>"+LIQ<%YE<E(4D&.D/(4(
MI.]HUV_/R=EQ+TVXYB+V(>W<KS=(.((4BP6ZXR4+9@*4V6E+'5"5NJZ*6 75
M+Z]CUZ^-8Z-Z5L8@7*TOM7K(FXEFO+M\M=O1< (\-]U3JG4H3TV4*4\X=+*M
M;TD@>*".KUZK$9CQ[R;UPZU788[9Y4BXX]<[DIN4V6W2@LRH[C (2MO;B5H[
MH4 4]AM*CD;WZE\PMHSJ)8\$MSZ,*QZV7UU<V[?3IE,R&GUE#*&VUE.A&6E/
M8C^4[_&]VO/I?L&0V>5 N-]OLH.VQ^RMRW'&%2683S@6ZP'2R2H*ZH2%+[*2
ME/VD$J)JWZ9;6IG*TKRG(G5Y-9XMBGN.&(%&+'#B6DIU' 2H)>>!5K9]PGY2
MDISC6L)=O5*XY>+K QC#+CDZ[1;[?/N+<4/%Y/U:/<;9:2VRXE;B6OO(6MM.
MB %?.KB)ZGV9_)61XG&L0D/X^F6N7&^OZ73JRR'6W6X:VD^ZV\=I0IMQ6CU[
M!.SUOH7IAMMFR%%[L^79-9;B_;H]INKD-]A/ZJPPDH8]T%HI0XA)ZAQH(7K\
M[\UE9WI\M-XOK5RGWF[2E0W)[UM2MY/N6]4QE;+_ ++W7W GJXLI25$))!\]
M4];B:\\!<[QN=[+/NL"/ ;M[!92S)MUS^L"U+22MMQ!;;6RZV1I25H_(()%8
M^Z>HC]-Y8LV(R,;>CP;K=G++%N4B4&GG7D1U/+=;CE/93 *"W[NQ]V] CS6W
MX#Q5$P>]7J^+N$F\7V]-16)URDH:;6^F.E:6BI+:4@J <7M6MG>O@ #2KGZ7
MH%RY!?S$Y5?&KFN]M7QL($<I:6AA3 9!4T5%H-K6E*23U[*(TH[IE1'F?\D#
MF&+P[E5OQY"<>?SR(U;KL_,'OK;2XX@N^R$_:APM$I^XG022!O0QW-W(J.9,
M)P3);9CH_LTG/+?'M]Z>F /J]N>&5N!CKX;6MM21]Q)&E=0#NI'L_I-@8] M
MMHM68Y# QBTWI-]M5D;^E4S!?#JG2A"UL*6IONXO2%*(';^@U\VO2/;H%C_L
M];<RR"V8JS>47V!9&A%6U!D)D?4D-K6RI9072I712B!V-3I%G(]6$BRRL]F7
M;!+C Q3#)4F)<;S];'6KW6VF5--I8"NRE/*="4]=@;3V(*B$W=W]5T/%[)=;
MAD6-3+$S!>M[2ILA3GT(^J4I(4N06@$AM22ESP0.R-$A7C*N^F2TW2Q<@6.^
M7JX7FSYN\N3<XKB&FBEU26TA;2T("DE(:;ULGRG=92!PU?&K$Q!G\DY#=I49
MQLLS);44#VT=MMNMH:2ET+2LI45[)T""#Y+/M=:M>?5;%LCF)P7["VF^Y#"=
MG1+>Y=V$MR0V^&RW&D?[)]PI/N)3V3M)3\%6JE#D_DFW<6XD]?9[,B7_ !V8
M<:%$ +LJ0\XEIII&R!M2E)\D@ ;).@:CN9Z3;#)P/^QB+I*:Q=Z/(8E6I3#*
MF'"]*<DEUI)3IA:5O.!*D:TGJ-'JG4C\D\<VSE#%'K'=%OQVR^Q*8DQE!+L:
M0RZEUEU!((VE:$G1!!&P002*LX1IM\YQDV>7DN/S,>=@9; L"[]"AB2AUF<T
MGLE71T]0%(6$A05U\*!&QO6'](V-L2.+K+F4RPKM>47^U1'+E<'Y(>>N)]L+
M#Z^JB 25J.M CX^-"MEF<'MW6^7C(+G?I<W(I]G58F)Y8;2F#&42IP-- =>R
MU$$J5O\ E2!H @[1Q7@:N,L"L^+INC]XCVJ.B)&DR6T-N%I"0E 5U !( ^=#
M=3,77/.(RX_&?+T:;G^'WRQS;Q<+F+?ELO)5S(#BMOO)0Y%2\6XX,=)Z$HUI
M&CI7BO&%\UP\V]45BF+RVW_H]QQR7^G6=JXM$-$RF4M]DA7E]Q*2OJ?*4E*0
M-I43,UNX9DS+O8)>5Y=<<O38GWI4)F9&CL)4ZXVML+>#3:0X4H=6E(T!]VR"
MH A<.!L?7R5%S""EJU3XMG>M3#<6$SU:4XXE8D)VD_Q$]=#QKSY!^*U^41!Z
M:?\ Z <YM>/YEA60XEG5XM#C[$ZZ9.Y=XUR+7MJE!* ^XVRXDJ0KJ$C[3]IU
ML5N.87V=R#ZG8''3TN1"Q:TX^;_/C17E,JN3RWPTRA:T$*]MO2EE(("B0%;'
M@[OCW$LEC*K-D>39+,RR[V>(]$@//QV8R&O>ZAYTH:2 IQ80D;\ #?5(V:NL
MQXHAY%FUGR^#,?LN46R,[";GQTI6E^,X05L/-J&EI[)"D_!21L$;(-5A,@_L
MWP!#OF7+?N:X<\Q(:+.W(6^E<LNEIH1VUJTA;JGDI5HA.D))UHFL!R'ZJ+=Q
M5:LI<R;&KG%N]CL_ZZFVL*;?,N+W]M2VUI/4=%Z2OMY ((!%9K+>#7.0HMU:
MR7*I\U+JHC]N3%8;81;'XSWO-O-I&^ZRL(WW[ I3UT 3O"<B^E]GE>+DCF0Y
M/*>N5WLBL>1,CQ6VTPH:UA;P:;\@K<4$[6HG74  #8K-B+A/J7C6"]9?#S7&
MYN&1L?L@R'ZJ1):DA^%V*%'31/5P+3KIL[)\&KNX>H)S&[-.NN483?L=A)1$
M^@4ZJ.\JX/25AMJ,A+;BBA[NI(*5]0-DE74$U9YAZ:HO(M^OT_*,@D7*#>\;
M.,S;>U%0RDL%7?W$K!)2OW"5 ^0/ UXW7N;Z?+QE&'IQ_*^0;C?FX:HKMMEH
M@1X[L:1'=0ZU(40#[CFVP#OJD@J!3L[J9]KKSFWJ9M_'=LRK^T&.72+>[#9A
M?C:6BV\J9$[%"EMN)44_8L:6#HIWO2A5S$]0<>]2K79$XE?6K]>OJ7(5LD!N
M.MV&RELKEE96 AL^\A*=D+*CH)\'6-S_ -,[W)1R*7><K<_6[M8U8ZB8Q;TH
M:APUJ*W?;:*SMQ:B#V4HZZ@ "KR]<#WBXY+B.4P<S-KRZP17[:9K=K0N/-AN
ME!+3C"E^""VDA25@@[\$'5,^S5MZ,)LF7PR5RS/[MWZ\,H1=)*GY#:$7!]*6
MUK4M9/4 )'W$:'@ZK4?5/RE,P?,L<RF#=9<:UX-<8KM[@-,.*9EQIG\!Y3B@
M"G^"VXAP _'<JU]HJ6^(.*Y7$V'W"R_KJ[TN3<9EP;DR(:6BVN0^MY22E*ON
M 4L_D; UXK'3>&)=\XZS?&+U?8]S=RI4@R9JK:6^J74]"DH#I[=6PA"3L:#:
M?GSNV:C*91S''Q;D?'L+58KG-GWZ/)D0)3"V$QW?82E3J.RW4GN I)UKR"2-
MA*B-0N7JQQVU6ZU/3+/<XMPN5M=O3-L?=BH?^A; _CE7O=/O)TA 45J(/@ $
MC[WKTZ.9;QEAV,7S*9,J[8Q(8<C9!&C!A]QM""RXVH=U:]UA;C:E _W]Z\5?
M9GPE<KCR;;,YQ#*1B-XCVW]'F1W;:F;%EQ>_N(26_<;*%(5O2DJ^#H@TD76J
MWOUD6*/$R6?8<5R+*+9CMMAWBY3([#<9#<20A;B7$B0MM3G5#9.D@DZ('D5O
M<CGNSQKGD=O;M-VF2;+9V+\L,(9 DPW>VEM=W4^1T7M*^A^PZ!V-Z;?_ $VW
MN_N\DK>SAM:\WLT2S2''K,DN1T,)=3W'1Y*5*4)#N_M \I_;SZO'ISOLBYB=
M;<V9MTJ9BZ<7NRE64/"2VCN6GF@7Q[*D^XO8/<*W_=(IB:R>3>KS!,;MMNEN
MN27OJK*C(7&$EEMV/"6/L6H..)[+5]VFV^RST5XUK<R6>Z1;Y:XEQ@O)D0I;
M27V'D?RN-J 4E0_H00?\ZY^QCTS9)@5[L5WQCD%$&X1[%$QZ[?7V1,EFXL1B
MHQUI0'T%EQ <6-]E [\@U(/'<W.D9OE\._NLS<5C)B)LTU4/Z:0XYT4)*5@$
MA8"@@A8"0>Q &ANJ),I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E!9V
MS?LKW_O'57E6=M)]I7C7W'_.KR@4I2@4I2@4I2@4I2@4I2@4I2@4I2@Y?]0=
MSO6(9Q)O&4XU>LKXME6MN.9>.R%B3C[Z5++SZX[:DK=#B5-_Q$[+?LG0'8[V
M[&N=8#29=@M#$S*4V;%HE]C7?ZIH_JT50*/<"B1IPEM:CV !/[;K:+CQ[?SG
M%UR"T9B[;XUSB,QI%KDP$266UM!82\R2I)0O3GW ]DJTGQ6C*]+;5AD6O^QV
M42\5B1L;&+RF!#:E&3%02IM04OPVX%+7L@$$*_E'C4Z36OW/U#6I606_+8&%
M76=-=X_DY+$E+N2&DN14J9<5'#/<H[[4"7%)! 2 DJ!(&;@^J@6O%<.-^QR2
MQE5_M*KJW;FY,<(4PAMI2GN_<I0E:W4H0E1[$_( !(L+9Z2I,!BS0G\W>EVV
MVXE)P]+*K8VEQV,\@ K*PO06"A!'VZTD@@D[J]3Z;<@M]PP:]VO/D6S*<6M)
ML/UR;,ER-.@%+8#3L<N[[!384%I6""H^->*F<X:E2V<IV&Y<81\]<?7;<>=M
MXN2W;@TIE;#77L?<01M*A\$:WL>-^*Y-R;U'9-BDKU Y([>HZ;G;\2M$RR6<
M/-O-V]UUR>GJ "0MQ.FENGR-^-=0*[$BXRW)QE-GOSZ,C;=;]J4Y/CM]9.SY
M"FPD(U_37_,^:A^?Z-L"N&69[<'K1:FK;E5DC6808=K:87 "$R4NNM.I^%.I
MD@'24_[( E0.@Z?LU%'J+Y%O/IGNS]FQ:Z3M7S&=AV:^N4N/.%PB1$2TEPJ^
MY29I*A\$MI)^*EW%;D[@WJ8=P""]+>QZX8JB](CS);DDQY+4HL*4E;BE*TX@
MI*AL[4C?@DD_;(?3:WR%&N_]MK\;Y<)=D18XLR)$^E,- =2\7@GW%A3RG6VE
ME7@?PD@) W5KGF!YKC,#*LZLEWB7KE%^V1K3:%ILR_I4-(?]Q3/L>^=>ZI1[
M.*6$HTE6@$D%D]&VME]4/*-SXDXAN-ZL2&7;_(EP[5;OJAMEN1*D-L(<<'Y2
MCW"HC\]=>-U>1^'%0XMK>9R_)OUR));D/W1ZY.+$S2P74.QR?8Z. *3I*$]-
M@IT164Y(XW@\R\:W#%,G;4S'N3+7O*A.$+8?0I+J'&U'X*'$)4DG\I&Q6,7B
M7(;\.W0',ZMS;,=]M<N='L11+EM(6%% )D%MLK (4H((THZ2GY%I&$MGJ>Q>
MZW*3';@7CZ46Z7=8$U$3W47./&=]I]3"6U*</59  4D=@0I.P0:P^/\ K#Q_
M(&L;2QBF6F1DMM-RLC(M@_\ G()2A3K;1[ !2 X"2OJG0)"B-;P<'TR9=!SU
M&6N\@0IMY7#ND!^1*L;BRZS*=2XU_P#=7V^R$(1U3U24I\!)*E'(XGZ;LDQ5
M7$I3F%LD(X^MTFWM)-B<09J764LA:C]6>A2E*#H;V0?@'P[*P62\SC,<TX!S
M'$G+_)M=ZNEY@2;"TL1URBQ F!33S#CB6PXT^P1V4H =3Y/BMQF^KK"H=GM\
MQ<6^?5R;Z<=<M1M;IEQ)H\J:>2GLD'KI20">X(Z=O.M?QOTS91B\/!G&LMM,
MN?B>07>_L*59W&FI/Z@)/N,K3]0HI"?K'.JP?[J=I/G?QE^F+)#(C71K*+4J
M_P C+V<QNKKMM=]EQYEOVF([*?>!2VEL=2I1*E$;\;T%WPC,XUZBL.;R'/+S
M..4VOZ*'9'),&]174 +E^\B,U%C:*@XM0TL)!!5KS]I-83%N9TXSS7S3,R>7
MD%KQ^U6W'GF[3>/XQBOR79C76.AHK2KW5)82 A2MJ\;!WKY9_P"E[*\_RO+<
M@5E=JM<^YKLDNV+9MSC@A2K8X\MHK!=TXA?U#J5#[2!H@_OIGJ XYRRP6S,<
M@OE_QV3=<V&/6*' 9M[\=AF=%FN/1U_4*>4&QMPJ#BTD!24?:?Y5S*LL3T[Z
MHL'AO7:'<)$^UWFU2FX,RSR8+GU*)+GM^TRDI"FUJ6'6U)Z+4"E7;>@2-WP+
MDBR<BP;@_:'UJ<MTURW3HSJ>KL:0@_<VH D;\@@I)!!!!-<E.<3W;D>_Y)C\
MJ%&L')L.YVW,W+W*GHO<&:ZT%1VH\IMMF.&DAI!0E(0/M^\=B"*F9$KD#CZX
MX5;8=FQB:B]7-3=X@66$]';A1@VGLZV[Y2HI.U$N]>VTH0"?E)=-E7GJ:GYU
M:,=LC_'ER>CY$Y/6AN![;"V9H;BR))96'&U*'?Z?V^R%)*?<)\D"H\YU]1%S
MF<08+D7'=T=M1R69:WG)K<=IYR-$>F1X[C?5U*D)62^4[*3KVEZ'@D33R+8<
MEO=\PVX6)BUO(LEP<GO(N$IUDN=HK\<(24-KU_Y@JV?]T#7G=0YEOI/N[6)7
MVPXA<+:B)<\HBW]E%U6XA$!AF4B8(K00E6PI]4@[V.H=^%:JB5W^;<1Q/*H>
M(3[S-EW=,F-;'I!A+=0W*?;*V&WW6VPVAQQ*2H)\?S#X"D[^B_45@K*ISC]U
M?CP(D>9)7<G(3PB+1%<]N3T=Z]5%"_M*1Y/X!J*.1. ^1,WSIV_Q[AC=O8BW
MBT7FW0-O]/<CH2)"7^B$>ZI2@>KJNQ"&T("6]J-&?3%>8UYRJX06[#;1?(ER
M8N$)"Y#UMO;C[B3'=DPE (:6A *5J;)*RLDU,IJ77^>L1C1W%27KE'EHG"VI
MMCMJD_6O2"U[P0TP&RMS^%M>T @)"B2-'7P>]16 IQ[';W&NK]RBY#"7<;6U
M;;=)E2)49 25NAAMM3@2D*3LJ2-$@?/BHFM/IVR_%X=MAX_)MMNM+5[3+:M,
MNXR)CEJA&*&W6(<QQ'NI#CH[%("3T*FPI(5L8SC3TZ\C\0M<?72UR\=NEXQR
MP.XM+M\IUYEB7$]Y+C+Z'@VM3;H4%%22@@I4$[VGLIEAL9<^I*W8OS7?)MYR
MN>[@4G$H-[M\(6IUQ4<K==2ZZEIICW^O5 4HN ]"3OJ"!4RQ^:\/E7-NWQ;B
M_,F/6E-\93$M\EY,B$>NG6E(;*7/YT_:@E7GXJ-)O%/($O/LJR-]&.35WG$T
M8^.DI]@!X%Q9<ZEI>D=G2G78G2 ?E75./Q;A?/,)G\8W6#^@RKE8,9=Q>Y,2
M)3WM)1W:4W*:4&P7#_!VIHA/E6@OQV.N4V1)!]1W'QQ^U7QN^+DVRYP$72._
M%M\E[_5%+"$OK2ALJ:;*E =EA(\']CK+3>:L-MN3.8^_>$IN3<QFWN@1W2RU
M)=1W:9<>"/;0XI)!"5*!/9(UM0!YIM_I.S&'QQ@%B+EIAY3C./HM$'*K/<),
M:3;WDN;[E/7K)84C79EQ.@I)U_-L;A8> ,AQODW+7';'BN38W?K_ /VBCW6Z
MEP3K8ZKH5H]GHI+VE(_AJ]Q'7>SOXJ95V-@?]8N",V:=<@+F6X]^18&TBVR=
MNNJ=#?<'VM:&G#KR=(_=214AP>:\0D7Z#9471WZ^:\F.RVJ#(2D.J8]]+2UE
ML);<+6EA"R%$$>-G50E(X*SF'B%RLL6-:9)B9V,M@/+N"V_K&53/J%,J'M'V
ME)!(WM0) \>?&>/#&3O\WC.8L>/B\F1/B2+C)MUV>?:N41$-+*X\F(M ;6ZE
M:=(>2$D(ZD^4!)25&Y\I9W<;9R/QU@UKEFVOY0[.>?G-H0MUB-$8#B_;2M*D
M]E+<93M0.DJ.AOR-+Q',^1>2X-XL-HO=NM%RQV^7&SW3(9%O$DN^RILQBB,%
MH2%.(=VM6RD%DZ [CKO?)O'D^^YS@6:V=MB3<\6=F(,-YWVA)C2F?:=0%Z/5
M25)96-CS[9&QO=1K,XJSW'+%.M]KL]IR!O*KO.O63M.WERWE1>6/;BM.)8</
MMAL!*U?:5=3KJ%:%&''J&Y"D>E2!R$U$LHNIF*CRKCU6(\AA-Q3%;D,,D[(>
M00M/90"1Y'8%-;WZK<VR;CGCJ9?K%E<'%W8;+BF??@"6J;).BTT0KPAH +*U
M_('W$I"3NPY+P3/^0_3_ '/&$X[8+1?)4N,F-;8EP48D.*P^RXA/NEI/<Z94
M/"$@=Q^!YD/*+IFJU*9MN)VRX1Y$ ]ER[H4!N0?!:<1[)[-ZU]P.SHCKYW2_
M'%19G?J'7BUTQ>+=<GM6,VJ\8VNYQLB;C*EPKA/!3N.RK8&@#[@3OLL+ 21U
M.YNP3([C<>/K->LEA)L-S>@-2KA"4K[8CA;"G$DG_=._\-5S]B_I@E<?6W%[
M)*M5OY)QRUXJ+"8%T<#2&9 <4XMU"%)6GJ[V2@G^9(;1K8V*E/!N)YV.>GF+
MQ[*N7U$YNQN6I4Q*U*""MM2!U*ON*4!02"?.DC=2(C0\W9-"R'B3);U=HUEQ
M#,IUQ==MCL9(,6 BW//Q"MT_<5J+2'%: \N=!L)V9LMO,V%7/%+=DD'(H4NQ
MW)TL0I;"^XD. J!0A('8J!0K:0-CJ=_%0G:;->^2F> ,BMMCC/P<1>D?K,63
M)2VY%DI@O05LI04G:FWB3\CPCQ\BM:C<$\A6W]&O"<9M4]^U9;=[P<?7=O:1
M)BSTJ2%(?2C['6MDZ(T>R@" :9Z$_7SU(<8XY @S;EF]GAQ)L54YAYR0.JF
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MELD0BX6W9DHNP9OL#:G@&RXC24J4VIS93\D%UV&]>8$5AAQ^6RRV^H(96MP
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M(ZX$E"7'&VU)3_.C>S]O8=M;K>0=IW\UQWD5^FX]%SCE?BK*8=^QI,M4G),
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M*]Z 4MCWTH*A_,5#^96CU)DF9XSBDX?K=T@6V2S"?F^Y+6E):C(*/=<)/\J
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M?'D>:=1RU>P^F^RXW<,#EP[Q?!_8J*[!M#3LIM3:6' D+;6/;!6"E"$[)WI
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MM&4%)<2I!6%I6-]BG6O-31<[S<XV3V.$RU _392)'U+K\HMR$K2$%L,M]2'
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MFGFG%-NH6VL @I6DCXU^1L:-;&6AYUO>OWJ#E&9Q!D,+E[.I<SC2+F6+Y?\
MIDR$M^Z,QFK2[%CM-F/(;[$J0%LI<0IE#@!*O'G9L.2N%^0,[@^HBTP;";<,
MPEVZ=9ILN:PIB2(C$-M;#J4.%: ]],M.R/Y7/.B*Z[6E*1X\'^M:=R)R9:.-
MG+$F[M32B\7%FV1W(L53J$/.*"4>XL>&P20-D^?QNM#G+DKC?).1>*[RW$X6
M58LBO%PL;TMJ3>H,EYU$.>T^X%+]WH4):2ZA'W=E%P@H0/G;8V"W*1ZDX.3N
M<8N,8T,<3:_>6JW$,2S,$@N%M+Q5I()VH G:21OP3.^/9 UD1G*;AS(GTDMR
M&H3(ZFO<4C6UHW_,@[\*'@^:S28Z=D>='\5.I,UQ7QKP#F$'C<X'?,(5%R6T
ML7>);L_5>6W(RS*;D)^J;92XIQ+K@="5I4VGR5J[?OL."8GR-)R;@1V[<9/X
M^SA429;;F\FZ076@'(:&$NM!#Q46RI'8CJ%>1]OC8ZT<;"$;&S_2M&N/*]E@
MYQ'Q1+-RG7-;J&'W(5O>>C1'%-^XA+SR4E+94C1&SX!!.MC<[*U;EC'\@<YG
MXKR>UV"7?K99V[M'GIAO,-N,&0TR&E$.N(!3MM0.B2/'BHHN'#&;/<!W7BA%
MD=%\EY"[,;RTOL_3);7=/K$S2>_N>\A&DA'796@>>GW#KGV4C5 TD$Z.C6A$
M?J'MM\N-DQQS'L8>R*Z1;W&>;>:<;[6P?<%2TM.N(0ZI(40E*R4A2@K1Z:/.
M<3ASD%7$^/V9.,WZRY99UY*U$NK,B!)CN?53O?;8E1U*+;L>0@I"E%*>A9^
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M78*GF'@]^RP+E+L[EQM:?H+C'6['>B/^V"TX-=5#JK6P=;&P14H",@#\U["
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MO,:]6F\W!8:8FQS%;:+0=4>H6RM!1T)!TI) .S72:8Z$#0!U\>:JIE*OG?\
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MO\S4P<.XUR9$Y"@^FO+;QFXGY/<<F+EVMKLUM#<9_P"EE!37TYU[/M**6QH
MGL._8D&NB.=<=LF:99AMG1ET[!^0E-S9F,W> I)<'MA@26RTO['DE+C14VH'
M83L:U4I)P3'6YKTU-CMR9;SR9#CXB-]U.@$!PJULJ )T3Y%?2_8A9<HBMQ[Q
M:H5V8:7[B&IT=#R4J_W@% Z/]:L'(LK(<TS>]\5V?(\D79[G!S>Z627=\9]I
MF-=2S;I"T24H<;<"5=@4%'D)7[@\D#K?6GF>_JY_QFQ_V]^MMUQNUZM,KHEA
M,!OV8O=AIH*2'''6U!!6X2$J6XI [  #J:=@]@O5J8MEQLD"?;6"E34.5%;<
M9;*?Y2E"@0"-^-#Q5N>,<1]QY9QFSE;K_P!4XHP&MK>T1[A^WRK2B.WSHG]Z
M<+N.4>*LOS!;O"&0W7/[I>G\CR*]6:YQGU-)ARF6C/\ :*6DH'5251VRD@D_
MW=E.A6%G\DR^4^*^/\LOF8*8O#W(D5B;CO:.AJ&&[BMM$92.G<*0A"%=]]E$
MJ.RD@#L)KB/"8PC>SB-C:,9PNL%%M9!:62"5)^W[3M*?(\^!^U>YW%^)S[A+
MN$G%[-(G2E)6_)=M[*G'E @@K44[400-$_L*<>T<FPLZSN;?H%J1GMQ0Q*Y6
MN6.2GDL1R^[#1$[LMI/3JWU+?]U(V5$G?G>7M7)N4XLU)L$S+)TNV0^17;!(
MO,A+3UQ1;_IP\A"1T/<^XI*%+"2I+:E*\=04]%1N$\!9?2\W@^-MO(6' XBT
MQPH+'PH'I\C]ZCWEKTWVS(KEC3EEQ?''+)$G+FWFR*CIA&YKZ%+#GOMH*@II
M2UJZGPON02*8,OZ=+KG%[Q&XS\VG/24.W"0U:OJX"(<E<)MY:6GW4I"?+B.I
MUT1X&]?<*@>X3,QQ;%_57DUISF?$NEMN;SC 5$BJ0TI$&*I"O]EV[!O38^[0
M !ZD^:Z,X8XRF<?G(3(6(D*YRT28ED:G/2V;<D-)0I*''?)*U K( 2D$^ ?)
M.P2.&\%DJF%W#; HS%=I1-K8/OGMVVY]OW'>SYWY\_-40SB=USQ_EN'@UZSN
M:N(]8%Y$F<Q;XC3TE3CB&OIFR6U#VV/*MD%:O=1V) ^[3\;Y3Y$Y!NG%$5&7
MJM+5POV16.9/A6]DBYHALR?9EH"P4C_9^4@%'<$ZUH5TVYQ7B3EHB6O^S-J%
MNB*6N-$3#;#;)5_.4) TGML[UK>SOYKZ2^,\5GO6QZ3C=J>>MB0B"M<-LF(D
M?W6O'V#^B=5),'+N+<C\G1;'C%_N6=.7=#.>N8E-@N6F(RBX1A*=8#RU);"D
MN@)2H>V4I\>4FI*]:<EN+P4M3ZPVV,BQ\J6K0  O$0D_Y ;J2'N#^/Y,%$)[
M#;&Y#0\9*8YM[7MAT@ N!/778Z'W?/BLQEN 8[GD%$/([-!OD1M?N(8N$=#R
M$JUK?50(WJJ(+]=,F,[P5*MT0A>;3Y\-O%F6B/JE7(26E-J9_/V@%2C\= H*
M\'565CY1Y"SG/LT-EN-HM]JQ7*FK/)MD^0VVCZ1*4AQ;FV2YW=*RMLI6D?:D
M$'SN>+'QCBF/7%-RM>/6R%<$MAI,QB*A+R4 :ZA8&PG^@.JMYG$F'73+4Y/+
MQBU2<A0E*1<W(C:I'@:3]Y&_'X\^/Q4')4'D;(\'P')D6"],V=;M^S"8A+$=
MN1-DOQWBXVEM#B2VEE.U+=<61K2$@[6*SN:<P\EV^%9Y<?)V8"LQPM%SQW5N
M96TB]-,MO.Q"%)*EAU"B4 G8TL#>O'1(]/\ QREV.XG#+,%L+><:W$00A3H2
M'2 1K[PE/;]]#>ZR\#BW%+9:;':XM@@1[=8WA(MD5N.D-PW % +;&OM5]ZO(
M\_<:62]QS_:N:\CRGCJY9Y8\LCMV%%NM;*3>(C:6HTEXMJE+);;[N.(;<0$M
M :4ZKKX\ 8-/-7)5QP0+@WZ/'N4;DD8JJ5<;4VE]Z&76^A6VE02A8"R% )V1
MX^Q7W#I:7Q'AL_#WL3>QNW.8T^^9+EL]A(84Z7O?*RD?GW?OW_O>:PZ_3GQL
MXJ0HX9:07Y*9CO2.$]WT@!+AU_> 'S\_\S3)X74,JY'Y>FYIEV#6*Z6F[Y%A
M=JMKKTZ3':A,W21(2IU3CC9*U-L]$^V/;)(45$DZ KJ"VW2+,:6EF2R^XR0E
MU++@7[:B K1U\>% ^?P16I7S@O ,GNMNN5WQ.UW*X6]@1HTF3'2MQ#7_ -3[
M'RI/_I.QYK8[)AEDQJ;=9=JMD:W2;K($J<Y&;"#(="$H[KU\GJE(W^PJHS54
M)U5:4"E*4"E*4"E*4"E*4%-?%4(\UZI0*4I04U5:4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H+.V_[-7_$?^U7E65L\
MLD_^H_\ :KV@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@53\BJTH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H*
M$;J@&MUZI0*4I0>0D@_->J4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H
M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H
M+*V$^RK?^\:O:LK9Y9/_ !&KV@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4JBCU&Z)/8;H*TI2@4I2@4I2@4
MI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4
MI2@4I2@LK7_L#_Q'_M5[5E;/]BK_ (C5[0*4I0*4I0*4I0*4I0*4I0*4I0*5
MY<*@!UT?/G?[544%:4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0
M*4I0*4I04^*)4%#8.Q^]/FB4A(T!H?M05I2E!0G55JA&ZK0:3RIS)B7"V-_K
M^97-=FLP6&U3/I'WVVU$Z'<M(5T!) !5H$D#YK#\?>I'COE#(I6/XYD29-]C
M,B0[;),.1#D!H_"PV^VA2D^1Y (\U$?_ ,34%/HCY%*5%)!MOGX__647_E4.
M\.P'[CZ]82N3)S4;*[/BK"L,%L9^GAW2&N.M+RU J6HNH#C@Z%6OM41X2-S+
M>=PV.I&/5]Q9*N-P@1[[/DSK<I*)D9BPW!;L92M]0XD,$IWU5K?SHUL4;U"<
M?2>-GL__ +3Q&<086XT[=)"5LH0M"RVI!2M(5V"P4]=;)^ :Y'XKMV<WKU->
MK9G!LAMEBN2)-L 3<+8J677%1I :Z*#S?M$$'[BE?\P.O&CK?J<R&R.W?T_1
MQ)C.8A:LO7$R]YA.HR;Q_JBUEU6NJU'O))4-C95L['B26^5V>G8N/>JKC3)[
M^BQP[S.:N[D)RX,PY]DGPW'V$)[+6T'F$>YI/G2-G^E6:/6%Q,_:)%SC90J5
M"C36+<\XS;Y*NDAU75#>O;V5;!VD;( )(K:LED8BWFN'M7SZ#^U#K\D6 OI!
MD>[].HR/9/R/X05V^!K6SLBN;O0'9+=?;#R)*G0VI3UMY!NDB*MU(467=>WW
M3^QZ+6G?X"J9O:IPEZ7ZT^'(+5R6YEP)MNA,:3;I1<8)_E"T^UM))&AO6S\5
M)&8<F8S@4JQ1[_=&[:]?)R+;;DN(4KZB2H$I;'4'6PD^3H?U\BN5/3KC]NRO
MU/\ J\LUVA-S[5-FV:/(C/I^QU!9E[!K3?7)CV5\YWS)CBELERF^,8C4F+/B
M3$-"/<UEJ4^HMJ(+JD14(2 -]5.G\@@W,\G#M#DGFG"N((\*1F5_CX_'FJ4B
M.]+2H-K4G6T]@" ?N'@Z)\ZWHZV.-DUMEV--Y1*2BV*9^H^H>!;2&];['MH@
M:!^=5PAZP>6(O,OH)PO-XZ4J3=[K;5NI:&PV^''&WD#_ (7$K3_E73OJ3NF)
M3>,[SAF4Y3&Q1.56^;!CRY!(T41UNNK_ &TAM"EJV0-#6P5"I;%RM@P'U!\?
M<GWUZS8UD;-RNC4<3/I?9=:4M@G0=1W2GW&R?A:=@_O4C5Q+PQDW)/&O._'>
M!<M8_8;^_/M<ZW8QG-C64N%EAAMYYIUK]E(:;\D#SUT3M6NUVU%2=D:\U9,1
M[I2E4*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I
M0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I065L_P!B1_ZC5[5E;/\ 9*_'
MW&KV@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@H1O54(.Z]4H(@YRX!8YSC6^%<[R
MJ+:XO92H"[9#F-.K.M+(D-+T1KQK0J/IOHICW!&/(D9<M]./ BT^YCUK[005
M!1#1$8%.U#?C\UT_JJ'YJ9#ER3_^CZQM,F1(%X8,B0=NN_V;M@4YYV>Q#&SL
M[^?WK88/I!5;,&DX9$R]+&)2%J6]91C5L,9Q1())1['SX'G^@KI7J/ZUY4WK
M>JOW5EL<LXUZ'X.)W07*VY8^W<$QEPFY3UJBONLL+3U4TVIQ*BVDI)'5&AHU
MF<"])+W%(GC$,Q5CXG@"4(%A@-A[6]=A[>M^?FNCP@#\4" *G3\<S%ZOE[<R
M8?Z-6N/,@<OV,Y2FRWAWM[DN+8H25N;!!*ST^[Y/SOYKZVKTB+L4*_P[;F!A
M1[]YNB&K-&3]6=[VOKHDG\G8)  .ZZ44WV%4#('YI))X3?E[<C*_^'[8/T5%
MH3=(7Z4V[[Z('Z(V(Z7-_P X;#@2%?U W7W_ / C;UW8W-R]V^7-,9Z$7IMD
M]]7L.H+;C8*G_ 4@D'Q^376800=[JH;%:_3+G;BOTGN<5Y1;[M;LDCR$1&_I
M4-RK>\^XW&)'=EAQZ4Y["5:&P@ ?:/!U70[:2 0?WW7L) JH&JBJTI2@4I2@
M4I2@4KR#YKU0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0
M*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I06=M\L_\ RC5Y5E:Q_ /_ !'_ +5>
MT"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E>5J*4[%1+F'-=VQGE^V8&SC4>
M4_>;3*N-GFOW(L(FNQRCWHVO:5U6$K2K>R-'?X.@ERE<Y8%ZMI.?X9(R:'BC
M+%OM]G?N5U0]<R';>^VZ^T(BT^SM3I5'7L#^7^NT]MJQ;F^^WKEI.!W'$6K5
M,;L;-\ER/U,.AA#BBCV@D-CLM+@*3YUKSO\ %9ZHN)CI406;F^\7WD3D/$HN
M+-?48>Q$>7)7<](E?4H4XT /:VC[$*)WO1T//S5AA/J!OV=<38UG\#".UNOC
M,>2S"%T29*6G5 ;Z^V I24DJ*0=GJ0*=4,3=2H'R?U,7'&LKS^R_V(D7%6&V
MQB]3'(MP:[/0W?>*5MI4!M8##A*"1^-$[K*95ZBXUEQ[CV^VNRR+W:\UEPX4
M!Q+R6%-N24=FRXE7P- [(^/ZU=$R4K3+'F=ZG98NRW+&W+<T(1EBX-RD/L=@
ML)]I6@"E>E=AL:(!_:L*QS?!=YVF\9+ANLSFK0FZ1YRC_#DD+T\RD:_F;2ME
M1\_#OP-#:742;2HMR'FIZ'.S"'8,<DY/*Q/V1<XT20VV]V<92^$-(4=K5[:T
M* /4*[:!)! DYE9<;"B-$TT?2E1FGF*0KF=?'8QQ\RDVU-W_ %'ZIKV3%+OM
M=NN^W;OXZZ^/.ZDA"RI._BFCZ4JFQ5G=)DB'"D/1HJISZ&RIN,A:4J=4!X2"
MK0&_C9.J;!>TJ$>-?4[%Y%NG'L1.-7"V(S2T3KM#??>94EH1'6VW6EA*B>W\
M9L[ Z^?DZ-365ZIL'NE?-:RD;K1<"Y53G.59M8?TF3:YF+3VH$@R7&UAXN,(
M?0XCHI6DEMU!T=$;\@4V4;]2J$ZKR5&FP>Z5H?+G*C?$>,L7V7:I=S@+GQ(#
MRH:FP6#(?;CMK4%J!*?<=0"$@GSO6MD9#*<]1C5VLUL3:[A=)EU4Z&D0&DK#
M:6T!2EN*4I(2G:DI!)\E0'YIHVRE19C'J!L^7P[=-MMIO#EOFW5RS)F*C(#3
M<AMUQIP+TLD .-+3VUHD#1.Q4H)65#=-D'NE>"K55"MTV#U2K>3+;B,./.NH
M;:;25+6LA*4I'DDD_ KZM+*T[/[_ (JCW2O!5K\UY6\EM)4I:4I V2?&JFP?
M6E?-IT/)"DJ"DD;!3Y!KWH_O316E442!XK3Y')MNC<G1L&<C36[K)MSES9?4
MR/IW&FUH0L!>_P"8%Q/C7YJC<:5AW+^6LEBVCZ":X)$9R1]<VSN*WU4D=%KW
MX6>VP->0E7[5E]']ZFBM*\(6' """D_!%>Z:%*U#E#DZS\1X?)R:^)F+MD9Q
MMMTPHJGUI[K"$DI3\)V1LGP-UMC2BM.R-51[I5-^*;W4ET5JF_.J$ZKR0"K?
MYH/1.J [KP5:^:Q5^R6/CJK>)#4ET3I;<)HQHZWNKB]]2OJ#T1X.U'P/&S31
MF H$Z%5J@2 =BL3D63V_%81F7.2F-'[H:22"I2UK5U2A*0"5*)(  !-49>E:
MSB'(5FSARY-6J2\M^VO"/,CRHCT5UAPI"P%(=0E0VE0(.M$'YK9$G8J:/5*5
MK'('(=DXQL#M\R*4N%:FEH;<?;C.O]2I75.TMI4H#9 WK0_)%-&STJFZH3YJ
MCU2M2M7)EAO.=7C#HLXKR*TQVI4N&8SJ0AIS80L.*2$+!((^U1((T=5\KERU
MB]IRAS&Y5V2W?6XPEK@I9<6X&2>H<TE)VGMXW^_B@W*E8;&,KMN86\S[3+1,
MB!UQ@N)24Z<;64+200""%)(T169J:%*4JA2M/D<L8K$R].*O7R,WD:DAQ-M(
M5[JD$#[@->4^1Y'@;K;D*[IW0>J4I0*4K'WJ]1,>MLJXW"0W$@16E//R'#I+
M:$C94?Z"@R%*P^*95;,VL$"^62<U<K1/9#\66QLH=;/PH;_!K,4"E>5JZBM>
MM7(%@O>57;&X-WB2K]:4-NSK>VO;L9#F_;*T_C>CK_"@V.E*4"E*4"E*4"E*
M4"E*4"E*4"E*4"E*4"E*4%E;/]@?^(_]JO:LK9_L#_Q'_M5[0*4I0*4I0*4I
M0*4I0*4I0*4I0*4I0*5@LYS6S\<XG<LDR":BW6:W->]*E.)*@VC8&]#R?)'Q
M68:>2ZVE0(4%>01\&@^M07ZL\1NMQPVSYCC,)V?EV#W-F^6Z-'3V<DH!]N5'
M3KSMR.MT ?DA-3GNOFXE*C]U!R%Q[Q9F=EY4N-IN-L4WAV<R6LSNBD(2$P);
M2R78!Z_/=?T1)_(;?^>Q(V*;A2<K]8%ZN%TLM^39#BS%O8N;")L6.N2B0MU:
M/>;* =(4D[)ZDG0)/BNFDLI!_<'\5Z+"2=_G]ZG"ZY5XYMO]@N9>>)8L63,6
M.YQ+4BVRG;;<)1EK8CNMO!MQ2%K5U<<2!^XV4[2":P?!5@AX!Z>^,#><?S9K
M+L3M[4AVS1K5<7?>DI8<:+!24%GR7#H[T"$G8U75F7Y18\%L3]YO]TBV:UL%
M(=ES'@TVDDZ V?R20-?FM;/->"#!6\R;RJUNXJM?1-T9D!QI2R?Y04[VK_TC
MR-5>.R.7N1N+LEY?Y2Y8$"%>K'=+EC%E;M<EV+*;MDN;$=DN2(CQ*4M.M*[H
M;/N?:H.$I.P:V+DJ_3.5L,X9=5A&38_+A93;9MVLR+3,:5;&6D+#O5QML#HD
MJ 2I!\C6M:('4.(Y19LZQZWWVP7*-=[--;]V-.AK"VG4[UM)_P 01_31KXYA
MFF/<?VM5QR.\0;%;00CZJX2$LM[/PG:B-GQ\?/S4M@C"TY)9N/\ *IZ[9;,M
MNL.[I^LFOR(-PD)B!EL(2E"G6RI2G%%.D ^/N)T/F+<_QVZ6BT\5\MP(^07+
M*K7>S,DV9$-]U28\TEJX-):]KLGHE84.VMAA/7?VBNEG^2<6CV2W7C];A.6R
MX_\ D9+#H=3)^TG^'UWWT 2=;T =_!KY7WE3#<:L4&]WG*+1;K/< DQ9LJ:V
MVU(! (*%$Z4-'\4EG?3GTY^Y:L5DSW*\GOMIA97@_)5GCMBQ9-9H<D*O+2H[
M;C:5M]/:?2'5+:+3NRGH3M(4:G+CKE*'>;L[AET<<9SNT6N%,N\;Z5QMA2G6
MDE2V'2.CJ LE)*%'J?!T:N,MY<PK X=MEY'E-IL\6Y$"(]+EH2B1_+HH.]*'
MW)\_'W#]ZV"V8Y:6+M/O<6,V+C<4MI?F)45+=0@?8G9^$CL2 /&U$_))JB"G
MLACP?6+<+T\Q<&[/'PP6M<XV]_V3*$[W"TE?32CU\[&QK\U&OJ9SZ?R;&F1\
M>LV8$BU7=BU 0Y<>.I]EMI0E!"$)<4Z5GVV@XI*0$+<_("NU_80D'0UNO!C(
M)WYK-S5CB.[6Z'R%E>:2\@1D5PMTKCZ$Y$:F-3VV47$!WL6FR $N^&%:UO9[
M?)563Q'*Y[U^X]3R(UDKV(R,)CL0G&HDY0_5DKZR_J4LI]Q+W5*0@N#7\Q2=
MFNL\GO\ 9L,L<N\WJX1[3:XR0I^9,>#;38) !4HG0\D#S^]7MN?BW:#'G1W$
MR(TAM+C3R#M+B% %*A_0@@U<B/S]PEW);7C/!T;&+;<H^66C"<JA,HN$!]OV
M)[RX9C(<+B  I9:<UV\$H-2C;9#\>Z<5JL$O)66%VZ5_;J1,5+2IM@Q%;<>4
MYY1)3*">G3[OY_[GD=<ML-$_&R/BO2HS9V.OC]J9!P!QT_=\;X"XSOTR9F,U
M$^7;8_(39<F.2HC#:'NB4L?SMI+BV@Z64]EI3M142HJG+TR&WQ^6.;OTMJX(
MM<V[V^9 =FL2$A]K]-CH6IM3R02D.I<2!LZUH:3JNBDQF^I_._!-5^G1K0'B
MF*XRR'/KK$]2UN>:N&1.P8F8*M]QE.HDHCHC.6]T(CHCH06_92[[6GE?<MPD
M@  &M7QJ0Y:K)@N3O7K*9N3,<D2(TF;-D35N+M*I3R5%QG^0-%HLG?37W C6
M_'>P81Y2-_\ .O)C[^?^5,B.">2<G7D/'N:1LP7??](]OSJ"]^F);EEE%N;N
M\8LJ:0@>TI@14^X2-[6"22H"N['+O$A6UV>^Z$1&T>\MY0T$HU\D?-5N,R)9
M(+TV=):AQ6$E;LB0L(;;2/)*E'0 '[FO-END#(;;&N-NELSX,A <8E1G MMQ
M)_O)4/!']1XI@YI],F13VO3AE[>.,*D95#NF03(<!YI2%*6[.E.Q24K ^U8Z
MD?@@_-0G?<VO$KTS9+D-IY5R096<24B=:$6Z0S*3<@H*5[JW2OV7"M2VPEM+
M?=*@4C201^@%_O5JQ>UNW&\7"+:X#1'N2ISZ66D;.AM:B -G7Y^:^%UR6S6*
MT*NETNL*WV[[29LJ0EIGS_+]ZB!Y_'G\TX\G/AR?EN7VSC?*N4_T#.+U"MTC
M#H=U^M0X]=W6I(><2MR.AY1 <4TMKPDA([(41H5H%[Y.N[>(\AVMC+[YCJ8.
M8V!=MAMW%R6Z+?($(R4"4ZV7%M[7)<VE6OL7HJ0D[_0=<="@=[\UY,5*DZ(V
MG]B:9!P7R7*99PKU0XI8\@O$NUP8,"XVR/\ JDB4XTM;6Y71U:U.*;[A)4GL
M0.Q&@#H].9;>9>-\ Y)=..)+V3W*););]I>?F+GN2'QW*?XCA47-*V -GX J
M5U,)U^?^=6=QN$&SMH7-ELQ&E'25/N! )_;9(W5XDTFVY'"N59_+/ISS3(\:
MYLN%QE.8XQJ,Q">$F/.0XGN5NOK=+3K@64*:2&S]O9 '4FK_ )4NS,"7SSC-
M@S&[S[?*P1JZL-F\/2EB6"^7%,K*E%/=KVBM""$]3_*!79KN5V&/'D2'+U ;
M88;+KSJI2 EM ^5J).D@?N?%99EM+K?9)VD_D'P:S+\;V6[.[BN^YZW R?%,
M5:Y1?QS!I^-ONVW(Y,QZ6W+NJEA);,IMYO2F4$%#17U/8_:2D:O?[6WF[\TW
M& URG<;I)MV*6^X0+9$+5N;N=Q072J/[)3V2'O;2I;9)6/= V$@"NS/IT#]_
M/@_UJB8B-G6]?XU<1PCC/,V8N<,7;,\:Y+5E^;L8Q(<N&)&TNJD1[B%)*G5M
MK=4EA3(]T!H-H2Z GQL;.^8!E>'7OU-8#+QC.'LPBS,2N30D29ZI)4\EZ*I1
M';^1:D@J4V-=>H^U._/5+,B.N<J&'FS+0V'2UW!6$$D!74^0-@C?Y*3^U70C
MH2 - :^-51R7ZBN43AW,[D&+R(,>>3@MWDMPURX_2/+;+*V5AI8T7%)*]=^W
M@;2!YK6\/S]R/DW&4>)R?<+J_F6 W"5/87=VY"_K6&XI9<9000TYMR0G03]W
MM*V"I*C7;/TR0 !O7Y&ZI]*-[\[_ '!H.)N',[F,8-P1:F\ZE_V8R""Z[?[K
M]8RI466B,RJ/;P\$[8#JENJVHA:BSU"OOJ>/3QF=XRIW.XDBX.7_ !RSWQ<*
MQWYP))GQ_:;6L=D@!SV75.,^Y_>]O9).S4M_I<<-K9+2%,KV%(4 4JW\['YW
M7GWV&Y'TR7$)>Z]PT%#MU^-Z^=5,' G)=W;8X:]2"[KGLB7<1E+T1NV7.3&T
M$(>A!M8;2E"_"$]1I03U3\#YJ0<DYFNG'64<M6F1RRU*@P;)9[O#N-P9BONP
M%R)*VGPRAI"0OLGVO;2L%*5.-[/4DGKD62"'7G?I6?=>Z^ZOVQV7U_EV=>=?
MC?Q7SD8Y;93;C;T".\VX.JT+:20H?L1KR/ \?T%4</\ ^E6]9Q"MUKE9[.@_
MI?*,6VJ<3)@NR&X:VO>8#ZPTIM?5Q"NJM%*NI_GZ@CH3U#<CW+C7B.W7BSWD
M,QGKA;X<O)EMM2!"ANN(2[,*>OMJ\$>>O0%P*(T"*EI[&K5-CO,R+=%?9>(+
MK;K*5I<(T$E0(\Z &M_M5ZN"TZTII2 II0*5(5Y"@?D$?FI)@Y1SSEZ9@MTQ
M2T6GE)O(;)?<A<B3L@GR(:$VE AJ>:B&2RP4)+SB1I:T*4 HI!&TD65TR[.+
MEE?%>-)YF@1I%W8O34N\65B*\EUQ@@L. .)]M:PE70_9T*D*(2#KKU8,5M#=
MH5:A;8J;6K>X(93[/SV_DUKY\_'S7S?PRP3%MKD6> ^MM(0A3L9M12D? !(\
M ?C]JEDO==<FC.KYADKGB^S>2U6]=JR&/!;:N<6,\VTTMJ$$J;;0T%J=T][;
M:>P05*25@[).-L_/63W2TV)J1FZB_$Y5:QZ6AQ4,/R+:H]D(?+*0GP4J3V;Z
MA0202?.^P9F&V"X293TNS0)+LI"6WW'HK:U.I204I62/N (! .]:%?*5Q]C$
M]Y;C^/6MYQ9[*6Y";*E'JE.R2G?\J$C_  2!^!5XGE/TY+LO*&:MV2S99<N2
M'9;[/(SV./VY,:*S!?A&6MC10$E84$A*@KOX_P R3/?J%M=@R+&;':;QDDG#
M[A+O# LE\B*2ER%<4H=<:4._VGLE"T=5#2N_7Y(K=O\ 1OBI;#:L;M*F@LN!
M!@M:[: [:Z_.@/\ E65N^/VW((+L&Z0(URA.>%QI;*76U?XI4"#3]CC?D+,>
M28EJNV(WS)(4:^VC)L:CO99CT1J/^J1Y<DZ;>97W#3K8;25)"BDI6C^ZL@YO
M-^=<CPCEFSV89U%G6^-DULLMP8^GBI93&?C%;BI3JDI5]03_ ! &-(0CH%[[
M#?3YP7'UV!RR&Q6U5F</WVXPVS'5Y"O+>NI\@'X^0/VJU7QCB9==<_LS9_<>
M]GW%_0-=E^UKVMGKL]-#K_NZ&M4X77++_)?(;5BR#*)7(*PJP\DMXVFW-6^,
MU"E0U2H\=2%A25.;ZNJ4%!S8(/S^+3F/E"=G_&_.+4_*V<?&-WD6AK'"VQM4
M=*V"EQY2TEPE[LI22A20 1H*T375+G$6#R&G6G,0L2VG5^XXA5L9*5K\_<H=
M?)\GR?W/[U>7'C;%KQ<%SIV/6F;.6R8ZI,B"TXX6B""CL4[ZZ)&MZT:9/9KG
M.7SU?H_J#Q^SC*X+MAF9-*LLFWQV&?HVV46YV0VGZA8#JI 4A"EE!+:?<2C^
M;8K6H_,_)F+<1Y9GMTS.'<X\3)7L<2TNSMH8A W5$7ZU:@LJZMMJ5_#^/C:O
MDUU4>+\/+KSBL6LQ=D/(D/*-O9VXXC80M7V^5)!(!/D;/[FJ6GBW#K$U-9MN
M*62WL36O8E-Q;>TT'V_/V+"4CLGR?!V*<>T0MQBY[?J[SA!R89+O$;4MMY08
M2M*3(D$C^$E*3O85O7PH?/BOM=&[G*];4K]*GQ8+XX^3M<J*J0G7ZB?[H6C7
MG^IJ:;!QMBF+R6WK/C5IM3S39:0Y"@M,J2@DDI!2D:!))('S^:^Z< QE.2*R
M!&/VM-^/DW1,)H2C]O7_ &O7M_+X^?CQ\4@A:QY!F4+D#$.-9EVCVF=_9E=Z
MNMXBQFW%W26EU#2TM!8*4Z*BXLD$GNGX'SHL;FSDC.(_'\.SWZWV=^XY9>,8
MDW3],$AF>F,Q)4U+;2I0 2"UY0#I2T$=@GP>J;YAUDRIEIN\VN'=4,DJ;3,8
M2[T)&B4]@=$C8.OD$BL9=.*,,OZ(2+GBEEGI@->S$$FWM.".C_=1M/VC^@U3
M!RUEO*7+N)6SFJX_VZM<QWCVX6UMII=A0VQ.0Y"AONI7_$*FPKZA0^U6PKSO
M6DB9^-\ORQCF_,<&R2\Q,@BP[1!N\.4S!$1QHO+?;<:*0I04G;22DD[&]'9\
MUNDOAG!IGUXD8=8GA/4%R^]N9/U!!V"Y]OW$$_)J_MG&6*6:_+OD#'+9#O*F
M@P9[$5"'RV $A!6!OKI(&OC0JB)KU) ];^-)[:2,&F$C_P#G6P*]\H<[RV^8
M\3XZQ27#$RY)N"ILEWKW2[':86(S7?["YJ0E:AY(2G6MJVF3IO$6&W&^/WF3
MC-L=O#XZNSU1D>\X/V*];(\#QO\ %6DW@O +E8Q99>'621:!*5-$-R"VIL/J
M^70->%'\J'DT'/G('J"Y#PJR0EW"9C;5\@Q[8J=!M"53VY+CUQ3%DJ<6>HC-
M@$!L=BM;A6!L-*!V"]<]Y5C7+=Q@7B"MG&FI,]-M5"C)E,79#$!;_L)?0OM'
ME)6TX2AU "D@A).@3+UQX%X[NY4)F$V.0%0TP-+@-^(Z22EH>/"02= ?&SJL
MG:^+<1L%X_4[=CUO@SP>P?CQTH4D^V&]C0\'H G8\Z&OBLY%U%GI\Y,S[D&-
MB>27E5BD8QD=G5,"HCR4NLRB0I+;*027$!!4E78@I+>_R0,S>>0[YDO.=\X^
MLURA8^+/88]U,B5&]]V8M]QU">J>R=-M^UM6O)+B?*?SNN(\.X1@-WFW3',5
MM%DN$PJ+\B#$0TM>SM7D#QLZ) ^="OIF'$6&<AW&WW#)<9ME\G6_L(LB;&0X
MMH*^0"1O1_;XK2.+\#YSR7B?TI\;N661;6&H&&0+DW%<95+?FDO(0X'-%*8S
M24G0<4?O6X$I!*2DRQE?+N5X#R#SED+UT:N>-879($]JP"&4J="X\E82'O</
M0^X 5*Z'8 &AK=2S_P"&?BQ4=J.K!+$IAJ(J AHPT=4L*45%L#7QV4H_XDUG
M6>'<*C787-K&X#<X1$0"ZEH#M'2A2$MJ'PI(2XM([;\+5^YJ"",CYTY#X]P)
MR_WUO'94.Z,VMJUW$.I2TU)DR6V7'%I0L]XZ$O(6E78$D!)/W@C8.-8EU@>K
M3D!%UN+-S6<5M!;>:B?3D)]^9L*'8[/;>CX\'6B1LR-:/3WQM8+#=+);\)LL
M6TW1OV9L-$1'MOHV5=% C^79WKXWY^:N\/X0P/C^Y_J..8M;;-/^G$4R8C(2
MX6@20@J^2!LZW\4D76\4I2JA2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*"RMG^
MQ5_Q&KPD#YJSMG^P_P#E&KM:.P_F*?ZB@]4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@B+F6TKY%<8P:/'A36)<1Z5=&)A4&TLE):9"NH)!+BU*3_5A1_%0CCW,&5X
MIZ1[5-_5&X>6X5?8&+7U#["'$+"+DQ"<*NP^T*CNI>"@1KQ^QKJN/@&-0\@=
MOS%AMK-[=!#ER;B-ID+!^07 .QWYWYJPC<0X5#B72*QBEF9C75LM3V6H#242
MT>3IT!.E^3^:9! .;\\Y3B-\YJ@P[S"N+>-+Q\PW'([>[>B<^M$DK2DCW2TV
M.Z4GR= >=ZK%7;F7DZQ/W.;^IQ)>)0,OM=DA7:;9_8>NL:4N.EY>^P2 VMYU
MKNE"0I2$D$@D"1>:/3?9[_A+%IQ/%,>CMF5%%QAF,B*J9 :<[JC-OH05,J*@
M%!0\@[T03NJ8'Z?V(=URB/=+4&\'N\*/%.*W.YO7=IUUM:E%\A\J2UX*$A"#
MH]0HZ( ID66M5O',F>0KORE9[*]$R.;8<BM=O@,L)88E*COQ6WWVVO<6&G7T
M KZI402$$:*M;P]DY$S+D3..$4VW-5Q6KG&R$W!$FQAAUUZ&\VUU>84L%*TA
MQ2" >H6"I.P1KH)O@OCUEJ2VUAME93(]H.EN"VA2_:Z^UL@;^SHGK^VAJKV9
MQ'AUPC6B/(QRW.LVA;B[>E<=/^K*7_M"C]NW][_>_.ZDF)M4SIW'[4FV7J\Q
MS*E6U]3EM:;07'ER%-J1U:;'E2RDK \>!V/@;-19Q3Q;<+'8\V>1<K98.1,C
MN[][6TAAN:FQN/(2AM*6^R0M892"I6P%*4H_<G^:6\YXMQ+DR'&B97C]OR&+
M&67&6;BPEY+:B-$I!'@Z_-8"#Z<N,[3%9C0<*L\%EF0930B1DLE#I0$%:2G1
M!*1U/]/%4:9Z.;@[&XJ?QUZ#"B-8K=YU@:DVT+3&G)8=(,A <4I0*E*7VVI7
MW)5Y_ D/D!=CM<^U9!,MZKG?H*7V;1&:/\=QQU([H:23U[*" "L_R)[;*4E1
MK7\KX%L.3Y'QQ.8C0[3%PF8Y-M[4*,6W$E2 D-MK2L!#9_OI*%=P /MT2<_G
M_"F"<N& O,L5MN2&!W$7]18#OL=^O?KOXWT3O_A'[4'-O$&$2>.>>>/;!.>B
MK+=CR&<XQ!7VCQ+C)G1Y$B,C7@!MIUA(\#8^[7W$5D>"685KXKE7AJQMY)DE
MPN=_MV/0'5DB3"-TD+ZCMM+;)4LE:R "D('W:0FI[MG!. V/'HMAMF*VZW6B
M(^N3'B1&O:2RZM)2M:.NBE2@2"0?()'YJTROTX<99P[ <OV$V>YKM\9,.)[\
M<'V&4G:6T ?RI!_ H=^Z'IWIZE67TDQL LU_LLJ1;[,JVW2YSHRG&I;+*UN/
M10I#B"R@N=T%7;:$[\=AXFWA/.5<A<1X=D[EL%E5=K7'EFW@$B/V0/L&P#K]
MOZ:JQ@^G/C6WPF(4/#[=&A-13#^G904-+8+BG2TM /5:>[BU:4"-J5^YJCG#
M\1'-L/D!AQ$-V)9E6<1H_N#WVRM*D^X"OIU;TKH$H!_B*VH^  CSG7GS).,<
MD<8A-VQ$"$_9TB*\VN1(N")D]$5U9+:M14->X.JG ?=5L#X.]6Y%YUY+LJ>9
M+I!>Q^WP..;G#;%O<BNR57&.[&CR%)+_ '1[2NK_ ,A"M'Q\)[*G/+_3WQ_G
MEUNESOV-1[A/N;$>/+D+=<2IU#"BMC^50TI"B2E0TH;.C7PF^F_CJXQ;Y%D8
MVT[&OBVUW-HR'@F66TA*/< 7YTE*4@?LD#X %,-Q%/,7(]\SJQ<^XS95VV!$
MPRT_22OKH[CSLQU^#]2HCJXCVT);<2E)TKLH*/PG2I+MN13<1].UKO%KM[=U
MGV_'(ST>'(EMQ6W"&$?SO.$)0D?)43X .M^!5W??3;QUDUT7<;IC;4J:Y!%M
M>?\ J'DJD1P-);>*5CW0 3HK[$;\$5L%TXHQ6]<=OX)-M27\4?A_0.6Y3S@2
MIC6NG<*[Z_KVW_6F?9OT@>W>I?*)-GS/Z:TLY'*QZ_P;<9]EMS_\2'(A,RUR
M40EN>ZY[8=Z]4K)4D>X/MV*EKB_D9_.^)8651U0[])=:D%(M*5L-R5M.K;Z)
M2_I32R6^JD.$=%$I)^W=6[?IDXW;G39K=A=:FS'XTIZ4U<Y:'B\PCHTZ%AWL
MEP( 25@A2@ %$ZK<H.!6*UXH]C46 EJR.MO-.1?<6>X>*E.]E$]B5E:R5$[)
M43O=3/L_3F-_U69D,-Y-FQ[3C\V[XYC$7(8GT[SR8J5.*?2ZPIW[DR/:+)TX
MWU0L['VCS6RJY?Y7>SN;B$>S8G^HN8XC);?*<D2?;0U[I;4PZGJ"I95UTI)0
M!YV%>*VUCT?<41+=(@MXX^F+(M:;*^@W><2[#224LK47MJ V0"22$DIWU.JV
M!' .&-W<W5,.Y&X_IGZ/]2;W.[_1_P#U+_;>!OSOYWYWOS3IAM15 ]4N19^U
MBL/",6;F7NZ8FG*I$>2\A2&TK4$-1T]G6=]EA0+@)Z  E!WXIE7._)B[GG$&
MW8]8\9D8QBT3)%LW:2J<XZI:'UN1C[)2E&BPI'<*4/ .E=M)WY'I0XR:@XS$
M:L,J*G'&7(UJ?BWF<S(C,K.U,AY#P<4V3_<4HI'X J_E^G/ 79EYDFUSFG+Q
M;6[/.$>\S64.Q$;ZLA"'@E*1M7\H!/=>S]RMLBRV-6L7.-WY*R&+CN,VZV1I
M?]EH&1SU7=2W6_\ 7$J]F,A*=$C['.SOD)&OL434+>FOF[)87". 89A&+)R.
M[VC!8-YE(??2V'BZ5I8C([*2$E7M+)=/8(\#J=BNCG/3+QXIW'Y";1-C2K#"
M_3(,F/>)K3XB;\,..I>"WFQ^$N%0'P-"L9$](7&%L_0!;K).MKEBBJ@09$&]
MSF'DQE*[%A3B7@I;>_(2HD)W]NJ9/:2HPYWY0NO)7#W.=IMUEA1+?C-I,.>U
M=7N\AZ0Y#3(<;2$ I;]D.( 4>X6I)UI.EG8_5+':=]"F<!Y <0G$NXV-Z*6D
ME*AOX(.B/SX'[5O&1^E?C?);I=9\RRRF';M";MUR:@767$8FL-MAMM+S33J4
M+*4 )!()UXWX&MON_%>-Y!QO(P2X1'I>+OPA;W(CTMU:UL  ="Z5%P^!K95O
M^M,^Q&.2\U9QBV7W7$G,8M-RR%VPOWZQHASG?;E^PXE+T9S;6T+TM'10!"BK
MX&M5LG#O*5SY40FY,Q[;_9QZV0IC,N+(<4XMY]H.%HI* !U24'?8[[CXUYNU
M\>V3BJ-=\LMEIO>37I$-+"&US7)TQ3"%=DQV"^YI([$J(V"HC[BK0K[\*\>_
MZ../[9:F8+5L<<=?FS(B5ESVW7G5.EL+V=A'?H-> E  \ 4R&UIG(GJ#NF!<
MCVRP+L$95ND7:!:_J)$[4F2F2"#(9:2A6FFUE*"5E/906!KKLV7KF0@^FN_$
MLH=ZW2R%*%Z'8_J\,:V?C>R//[ULF7>F/!,TRB\WZYQ[JJYW:3"F/N1KQ)82
MAZ(D)8<;2A8"%!(UL?NH_))KX^HCB"]<OXY$Q^VS[=$M'NHD3(\T2@77&G&W
M&"%,.M^$K1VTK8VE/[5J<<P:=R]>[KB^)\CY7*XSM#JL9L =MB9SZ?9G(>+G
MU;;A0A04$AED^V4^=CRGML96)SCFUQY8R#$;7A$*X6ZQ0;5<'Y:+J&W7&)2)
M)*FVR@A2^T?JEO8'\Q4L; JWSKBGE?D7 YN)7R_8D]:IS)C2E,19[+S[1&E)
M4XF0#HCY_>L!8/3ER+CV072\(O\ 8)TFZ0&;9.3+7<%MR8S2'4--K27_ #U#
M[I!^=JWO=+U7NS+\9V65U]6N07[B7,;YC]HM<.\6==I;5#DSG6I4)<M\-+;D
M1W8Z5H6V2-**2A845))ZD'J2P3)[UG8=N\6-!N!!]Z/#D*D--G9\)<4VV5#7
MG?0?D?BN9)7IKSFXXM=K'<+GC%R;N<2'!>G2A.,I+,5PNQD)<#O_ -+62H*(
M*B?YBJMY=Q#FQS&E6=&1XLV5)ZJN(:F?5J^[9/?OH$[(\ :'QK0K//\ UG^U
MV>T>W^_RL>]2>$<F)@SX^-9"_)Q"=-==:^F]I1!@.) <*QV?:<'W(3X?'G[?
M.R\A^IG*L&R/E!B-@<2[6K!8,"YONKO(C.OQGP^5.)'M+'8!DZ0=;ZG:O(%8
MC)_3_P G9=Q= P"X7'%7L?AE@HU]8V^?8<2XP/<2>PZ*;001H_:-D^=XV^>F
MOD[(GLR<G7O'7U9=!8MMY/ORT>^PR%!M*0$_9H+<!*=$]U;ISZ_O/]KL]MPN
MWJJ=P:7E2<VQ0V&):,;_ +4Q7H5R3-7+B^Z&O;4D-H#;O=2!H%8/;^:OGDOJ
M:R/$\/R*]S>,YR7+6+>IHB0XW&?,EX-*3[C[#)"FE%'8)0H$*!!_FZZO>O35
MR'DEWD3[[)QB^-RK&K'9,.7+F(8?A$>6U!"$G?8!?8$$*\@_BK-STP<ER\&=
MQ2?>X%SMBT,M]YM]FNNH:9<2ZVTDJ8("0M"%=NO<]0"HI&JG_=Y_M99?+?9W
MJ:F8(YR>UFV.,P%X=%MLUD6B>90GHGN.M1V@5MM]'/=:Z'?V_>#L"HVSG/KS
MQ7S_ )MG<C"+>N[6_C4SG(=MN25?6AN:D;<>4TV04)!'D*^U(ZD^!66OGIOY
M#RJ?E\C(&\<OK.56Z/:[I$E7>2AIQIA2E,*3[<5*D+0M:U!23O:MG>AK'73T
MO<DWZ+,:NEVBW"1,LSE@DRI&2/K=>A+4%%M1,$CP=_< %>222=$3;Z_O/]KQ
M[2(?41FCF4S<9:XP+EZ_147^"G]>90W)B]_;7W/MDM.!?4! "P>VRL $U1OU
M;P+] QQW%L;GWZ?>,;&3JA@K2J/'5I+:"4-.$N+7V2!H)^TDJ (WKS'"O+L7
M*VLB:NEG%V:LOZ"A\W;P(W;M_+^FZ*^^E[U\C6NOBM;MGI<Y#QH8B_C[ELLE
MXQ> ;/$NL/(W0\];RK8C/)5;RVXE)_E*D%0/G9/FIS?_ +/]G'M(.1>IS(H4
MO+F;+QM)E?V<Q^)D4C]:NB+>IQAU#RU(2@-NJ2XD,+'50&U _ T3E<>YUOV8
M<O6&R6K&VSC=PQB-D"Y3TT)=2B0M("NO0[+8"AU!^[MO8T-Z+-X-Y/DW#)Y:
M$6QLY!9F;#+1_:1QS45OOU"5NVU:RH^Z]M2B2?=/[)ZW^%<0\F8GEN*71EBU
M,(M5J9Q^2XB_EU4F TZ%MI6A5N2"I(V-H*"1\G>S6Y+.\1(/,?*F1X%G'&MA
ML>/,7LY1<941TO30QU#,%^0$@E*M$^UOL?PDC^]XQ3OJ;ALX7)SK]!D'CV/<
M%0%WOZA/N]$R3%7)#&NWLI>!!/;MU!7UU6^\B\61\^N>*W7]6G6:[8U-=G09
MD$-**%NQW([@*7$+2H%MY8\CP='\5JDGTS8[*Q]_%G)MP."OW(W5W& M BK=
M+_U"D=^ON>T7C[A;[:)V/Y24U<U-QK/KUA,N^E7.9:V_]:A,,O1WPHI4ROZA
ML;2H>1X41_@=5+V19'CW#^!72[S4HM6/6.*Y*=3'1L-M)!4K21^3Y\?N:P_,
M_$3'-F$2\4GWJ?:+3-T):;>AKN^@+2L)[+0KJ.R0?MT3OS6+S/@=CDAUEC+,
MAN-[LB(\J.Y9BEEB.][[*F5+66T!94E"UA/W:'8G6ZF7P;(PMK]2#TV#+<DX
M1?6)26(C\2.RU[J9!?<]OVU.@!#:VR05]CH)/8%6C6'<]86/,8=;;U+@(@N3
M+S+L6I-P:1#3*CA9(,L#VPESJ.BCH$J_!%9"3Z99%PX[<P^Y<C9/=+<E,=F,
M[*,8J989=;<#2PED!X*]M*%%WL2G8^%*W<VSTU(L35R9AY==S$G7.5<78<QJ
M/(CK$A'5YI;9;TM)5I8[;ZE( TG8++X-CQ>_5!!MLJ9$AXS=KO/MMJAW:Z0H
M?5;L5,D$MLH"20Z[U2M6DG6DC[ON3O?^1>3+7QKACN0W!N1(9]UB.Q&C(_C2
M'WW$-LM)!(\J6XD;5H ;)T =1S;O2K;,2OD"YX9E5^PY;=JC66X-05,/)N,>
M.DI8+@>;6$N)"E .(ZD;U\>*WWD_BBU<LX!(Q:ZO2X\92F'69D9XIDQGF7$N
M,O(6=GNE:$JV=[\@[!.YGV:@BS9@[A7J7Y2O\_%)\66K&[*I=OMS@FN37G)3
M[+91U.AY*4%1Z@!)4?M&ZVB^^J>2O$8UQL&*/S[F<O:Q)^(9C!0V][B>ZDN=
M^JPI!(20?!/W> :^]X]*LO(AD3]QY,R.5=;[:HMHEST1X3)+3$@O)TE#*0 K
MLM"A\*2M6_QK[,>E2+%@76+'R^ZM?59%$R>+_JT8)ARV0D'JE+8"D+ZC:%>$
M@ )UKS>E=7KOJ>MC.23K2W8+K,5:Y\2VW1V&D/&+)?#9*$I1LNI:]UOW%)\)
MV?GJ=1UZ@.18G)^!VF\6BPRW[-;\UMT.)?S)0VCW6KFW'?6EOL%J;*O=:V0=
MGSK7W5)=N]/*['G%\R"S9O?;0QD#K4J^6N,F/[,V0AM*"\E2FBIA2PD=O;*=
M_/@Z(P,_TD-_I%RL%LSR^VC%)5Y;OT>R-,176H<E,M,M0;<<:*_;4\DJZ$Z!
M4?QL%E79X77K@==@>FO);A&=D1ID1^ ME^(ZMMU!5.80KJ4D'RE2A\_!KQ/R
MG$N.[WDV47"R7S&;9B=J:ENR'BXINX"4XZCVT-=E!:T*CM@$^=O > 3O>>:.
M)SS/@,G$9%[DVB#+=8=D2(K#:W' TZAU(^X$#[FT[T-G1J_Y'XM@<L\:77#<
MC?=D1;G'2S(E1OX+O=*@M+J-;ZJ"TI4/VU590'S)RDWF_P#8\LX]>(%ZL.9V
M8B.ISVVY*)'N:2AT*#3GEM25)4?M4D'X*2=\OWJLM>*8]GTF[XQ>85[PL17+
MG9]-N+]B1V]B0AQ"E)6TKHL$C:DE!!2"-5<W+T]WS(<=M<'(.2[W>;A;+C$N
M,2Y.0XK2FUQ^Y1MM#82LJ*@5*4#OJ .NR:M,C]+B,LLF=-7/*Y:KWFB8K%VN
M;,1M)$:,%>Q'9;\I;2DK6HJ\DE:B?QK,ES[-\-DLW.;ETRF+CLG"[]:;M-AS
M9T./.^G07T1G4-J^'3U*O<0I/;0(/SX-:[*]76-M<=0<NCV*]S(3]KDWF2PR
MTV%PHC#I:<6XI2PC?<*"4I4I2M$@:&ZSV3\-7?(<AQ/)6,SE6K);$Q,AN7"-
M 86F7'DE!6DM.=DH4DLME*@#Y!V"#4;3/1)^H8-9<0?Y!N<BP6RW7& F._ 8
M62J4LJ]X>  XV2H!1!.E'123NITWV;/3?;UZDX,'/U8E;,1R3(KA]!%N*'+=
M%3[:V'U=4N!2UI'5/CLHZT?'X)&<X\YOB<D.V,VZP71F)=;>NXIE2"P$QVTN
M%L(=0ETK0LJ! '7^ZK_=5K6\>X7NV"YFWFEPSH36XED9M4QMVU-MI7&8)<*N
MR5[2=[.]'0\>?DW_ *;\4MD#'[YD-ID.R;/D=TDW&V)=3U]J&MY;B G?GJMQ
MQYT;\@/ 'S5Q=8;U)XR_)QF^W^?FE]Q^!;+>$VF%CKZV'E3U*(0I02"7EJ66
MFT-_'\QUM7B-N0HF6KLF+73DNUYS,BVS%&';])PJYIAMQIA6KZE;C;;R%O$)
M2DZ:"]#L0-5,_(W$N6Y=F\;(+-R&K'&83'M1(*K*Q,0PXK8<=2IP@]E A).O
M"1H?S*W\'N)<ZE6A5H?Y3F2+=*MJ8$U3MG8,A3FU>Z^RZ"/;4M*M=5!:4]4]
M0G1VS>+#<[)1LETA7VRP+A:WQ)MTMAN1&?3O3C2D@H4-^=$$'S^]<]^JC&\J
MA8]?,HMN=WVU7YGV(^(6:Q+"$NS"!_#=:((D%Q94"%?:AM&_&E$R%@-HRO&>
M3+O9F5(1Q?;K3#B6F,Y%#;L>0A"4E#;O8J?1T *EJ THA(V4J(QN7\.9]?N0
MI>3VCDYFR-EH1X,)['69?T3>AWZ+4Z/*U DJULC0.PD5I$3Y3E^27_'.=,J>
MGO0;W@7L1[.B+(<2PP^Q"9DOJZ)(#B7'7%I/;>T)2/%7W,2<X58[)G5@S:\Q
MLOO-QM_]F\0@.)-O<CK4V767VRG^)_!]YUQU1'31"?Y4[WJZ>FMRY0LDMSV3
MK>MF6QX3>3-O0^SUP<890PXZVX' &2\TTA*QU5\;3HDFJ7_A'D>X9-?+Q9N5
M8=C-P0J-%']ET/NVZ-U 2TRLR !HCMOK]RO)\!($Z9.QMK5\KO(Q_GBY7',)
M/(-KQS]:@1;7<(DDHQ\DQXW1#J$DJTN0IQ!44A)40":Z@9_D_P ZB+(^(,ES
M67(@9%FS5PP]=S9N"+8Q9TL2NC+B76HZY(=(4@.-H)(;2LA.BK1-2\V-)\?&
MZD@]TI2M!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*"QM/A@_\1J^JRMG^P/\
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M?DI00I0'\H^=5[A<LX=<84N9&R2W2(T4M!UQJ0E03[A(:^#_ 'R"$_[Q^-U
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MHD@=C7.&><46W&/2KS&+VBW3<DEHNF1W"%'(4Q;I;[*E(;0/_0WTTL@%1VL
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M>F7[*'\>DQG+FDM)5'<>"@VZ&]+2Y[!*5]1H?C9J=53'0]NQZWV1MU-NM\2
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M*0E+B2 IQ'57C78$53TE9;=<]].>"Y!?+DY>+K/@>](GNH2E3ZO<6.Q"0 /
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M6$1W'O<@R F*F0KHP9"NFF.ZO"?=*-_BL+=/5=QM:[G)A.9 IXQ;FW9Y<F+
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M/GR:KFG/&&KP:[W")G\*PHB_2J7=$LA]3 >6"R0TH'N'0E:4D [\D>160O\
MZC^.,7NC]ON&7V]J3'EMP)/3LZB-(<*0A#RT I:V5 ;60-G6]^*:+6S^G#'K
M4S"C?77:9;(JX;PMTR6'65NQ D17#M/9);"&Q]A2%=$]POSNRQWTQXMB$>ZV
M^U3;]%L$XR%IL2+LZF#&6^%AY3* =IV7%J *BE*CV"00#6ZSN4\8M.4QL:E7
MV QD$I:4-6Y;P#JE%)4E.O@*4E*E $[(!U4$9#ZH+:UE^?7=S/8-HQC )269
MEIC16I+ET2&&RZ/<5I3:O>=#2>O@%!V#OPT3GA/&4'"[K<[JF7,NMWN3,>-*
MN5P6A3[K4<+#*%=$I!Z^XYYUV)6=DUAN7L>N^?3+'B,:$IO'Y,EJ=>;HM2>J
M68[J74QT)WV*W5H0DG6DH[G>]"LG)YKPF%;8=P?R>V-PI:7%,/*? 2M+:NCB
M_P"B$J\%1\ _)%>7^9\*8RQ6-N95:47X.,,?IYDI]WW'@X66];_F4&G"$_.D
M[T-C;JA(^& XEE%EY#SN[7:^29N/75V*JU6N2\ET0BVA:7EH(2"A#FV_X9*M
M%!._N(JVY*]/.'<JY"F\7^$[(E?I,JS.(0\4MO1WTD'NGX4I&U]#_=+BCY\:
MS69\MXCQX_':R?([;8EOM./MIFR$MDMH3M2R"?"1_O'0WH?)%7(Y,QC]<9LP
MO]O5=7B@-Q$R$E:E+1[B$Z!^5(^X#Y*?(\4W%QJ-T]/UIFX[A=DC7B\6^'BD
MMN?!4P\TMUV0C?5UY;K2^YVM9/P%%9)WXUAKOZ6+5>8^1L2,HR)+5^O,:_S4
M-.1!N6PMM;12?IMA(++'V_!]H;WV4%87 >>$\CYMDMXBY_8+;B>,7*7!FV4L
MMNN/L-I#:92I/NCV@7B2/L(*0$_)W4HR^;,(@08LR5E=HC193[D5IQZ6A 4Z
MVDJ<1Y/@I2"5;^!\_(J=4\TRWLUNR^G6!BMWN4RQ9-D5FAW&:JYR;7%E-"*N
M:H?>^ 6BI/90"RV%!M2AY01L&UQOTR6;%HG'<2'D%],3 UNJLS+RXRNH<9<8
M4EPA@%8]IUQ ^#]V]]M$;C$YEPN==8MNC979WYTKV?8C-S&RX[[R5*:"1O[B
MI*%* 'R!O\BKRU\CXW?S._3K];9Q@M^Z^6)2%!I'W#NH@^$[2H=OC[3Y\'3J
M^-\F5B>1>*6N0[IC-PD7JXVQS'IPN41$'V>JGPE2 I?N-K)'5:QH$#[B?G1%
MK@O"L'#,@3?#<IU[NC-M%H8F7%3?O)B!SN&UK0A*G3L)'9940$^/*E;UO%>:
M7\J]1<O%+9?;/>L7.-"[-I@H"GF'_J$-]5N!9"DJ2KL/M'A0^?FMTG<RXA:>
M0XV$R;] 8R.3'^I1!=DH2YU*TH0GJ3LJ65;2D>2$J/CQO2-8S'TU63/,FR.[
MWFZW.0F]Q(D-V&VIIM# BO%^,XTI*.Z5MNDK"NQV?!!'BOI?_39CN=/W>1FC
MTG+9-QM#EB4Y,*60S#<5V<0VEI*0E2U!*BOR=H3K0&JWJR9_C>1W1VWVR_VV
MX3FPHKC192''$]3U4>H)/@^#^Q\'S5YD>6V7#H!G7V[0K-!"@@R9\A+#?8_
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ME"DZ!!VH*"O[I&JFB+,=],%WQZR<<6UO-6GF\,N\F[-+-GT91>]X*;4/?^T
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MP%:2?3'E^4\+S<6?Q"T8OEL6P,65N]F_/SH\U#+S+OL)9(_AL/>R0L'13[A
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M,O Y^..VY4NU**9*E(,=!'U 2IM.B$JWXUO0\;[,2P@[\:._FJJ0E.AYT/\
M.F0Y<3XKPED*9]TF7SB26XM[CB%CW^L/6Q]3EP90MI24_P"LGK]O0!?@$)_%
M:GE46Y0(N-XIE6/SHTR7QNBP33,@JO"+,Z' A3Z&H/OK[** H;* OHWI8*%
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MP:TWT]Y_=\SSWF2#.O<V]VNR7^-%MAGP$PW8S+D".^MHM^VVK[7'7$@K!40
M23O9U2_\%YE<_P"S62VBRX3BN5XY=F;FU:[8EP1+@ P\P\E]\-)4GLAXEO\
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M2T K5I(*AYI+J-,@^E/!6'X[\UN\WIQFVR+.D7:^S):%0W@ MA:%N%*DZ2-
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MC<9S8;4X2A3@7H I)!)T!V44#7]*\% W^?']:NI=]N-8_I^S#'L X=D6O#(
MN^%.C]7L<:YMPUW<F&8PDHE-Z_B-E2E)[D;!4-C8-92]<)WS^T^'/6OBZ/'Q
MV%:<@BSK<J[LR5=[@IEP!1>5]Q[MN+4-E(+O@GS76@2/CYKV&TZ^!2G/MR)A
MG#^<61C@-A_#0G^QUCN%KN[C%R8:TJ1'2T/;6A7?14V%%2?([@_(-8OC3AWD
M>Q2+FY>,#C,0;E@R;$BV1Y\4LPGFEO*;CA)42M.G$:6M:B=*4I0)ZUV;[2/V
M_P#>A;!^?/\ G4X7F.4+)Q1EEKQG@!Y[ VW)F$K>8N]L:EQ"I:56QV*'$++@
M0I/N*22.W;0/@U:\0<)Y#AXBVW,..G<FN%CN5SGQ\D.1[C3Q*4^5K$13N@ZM
MM[VU(6@(/D]OC77(;'C^OXJH92/@:'X%5$"^D3BV3Q7Q9;K3=<-8QC(8[ CS
M);;D=U4T)<<4WMQM2E$("] *UH>!XK4+EPMG$CE#()=E;EV.TW&7=7779\B+
M,AMK?@N--3(9W]3'>+BF@XV?L([Z_NZZK2@=M_FJ^TG]OZ5-GE7"MP].>1Y3
MZ>K_ (T>*W;%F[6'.8W$ERLH$R-)*>JD)CMEY2$H4M/<%Q+103H;WNNO;&D/
M8?\ Q,859FEMN[L3@C%0!*B4$-K4U]^]_P ^ON\GYK:BRD_C_P#O50PGR?/G
M^M6U(XPXHX.R_$[+Q/*EX*8AQ&Z75^YV1#\'<SZE3WTTMLH=]M:F X1U6I)'
MNJ*?*1OY\@\%Y=D=ORF:<$>G1KYG%LR"!CC<N$%VJ.P(Z9;BUK>0@+D]'5%#
M:E#:R%'9)KM,LIUYW^WS3VTG\'_G3AKES"SQ8O$N;;5DEDXJ_P#H?3B0@1XL
M%-O0Y;IB91>ZE*GDI2KJOPMM1&_&]5I?"?!F2<>S?3S*5QD_9[CCMMFP,HN#
M,FWE:2['2VCNM,@K?3W2E7CL4@#0!\5VE[*/\_WJOLI))\^:=T:_@-ZO60XU
M!GY#CR\6O#R5E^TN2VY2HY"U)3MULE"MI"5>/CMKY%;)7A+24J[?G]Z]T"E*
M4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4%K;O_*H
M_P _^M756MN_\JC_ #_ZU=4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"
ME*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E1SZ
M@><;%Z=>+KEF^0H>?@PW&64QHW7WGUN.! 2@*(!(V5?/PDUELAY3QS%N/W\W
MN=U8BXNU%3.5<3M2"RH H4-#9[=@  -DD#YH-PI7/+/J\;3CEJRV9Q[E4# [
MF^RU'R)YN.4I2ZL(;=<CATO-MJ4H:44:T0?@C=WE/JTM^*<D7G!W,,R:YWVU
MP3=7&K<W%=[PPHI]] ]\$@D?RZ[_ +I%35Q/=*@M7J^PJ1P?_I8M2+C?,1;7
MTEKA,MI?AD*"%>ZVXM)\*4D:3V/W)(V#NKB-ZGX:X6/7&9A666RS7Y^)'AW6
M3%C*C[DD!@KZ/J4A*BI(V4C6Q^2!34392H(A>K&VW+/,EPV%A673LBQPM?J<
M./$C*]@.I"VE=OJ-$*20H:)\'^A%6&4>M;$L.PM>477'LJBVQBZOV28E=N;#
MT.6V$GHZDNC78+VDC8.C\?FCH:E1OG'/>)8!Q(KDBYW+MBWT[$EJ1&;+BWDO
M%(;"$>"22M/C\>2=:-:1>O65BV/8KBF17"P9/&M>4.):M:U6Y*E/N+_V:-!S
MP5CRG?R*"?Z5#0]2]M;O\2R2\3R^W76:Q(?A1I=G*3*#*>[B6R%$%8200G8)
M_']+CA/U08)Z@&KNG$KDX[-M+@:FP)T=4:2R22 2VKSK8(W^X(J:)<U5:@F1
MZN\7:F/0FK)E,B>S=D65<)%D>#YDEM3JDH2?Y^K:?<5UWI*@?S6/'K=P1_\
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M9O><\?7-#,J#;GD..W"W,/E2'6@-]T(2H':=[]@>23H_I%>N$+9>[G)G+O\
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MN?*B=?TJ!8'!5VGX%:>:^%)K#/*UFF7-,V&RXE;-\CB>_MAY.^ON>V!UWHJ
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M-4\T%=4U5%'0V*HVX'.W50)2='7X/[&J*A/]*KH4\_O5#L?F@J1N@&JK2H/
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M$I3U2.H.AJL%%]*&!08V*1V$WYMC%75/V5*LBG+^B66U-DH[.G^XI2='8 )
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M;;0LH(!< !'8@C6QG^/>0(UMX'Q?*\KNJ&&C8H<VX7&40D=U,ME2E:_)4KX
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M$?XBOSGX-3<<=X[>M>9VZ]1[B]@C2<=NMM8FQ505M1W&W8;K;?EN2'?(</\
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MKB+TZFZY-SQPA;L2:F8'=[7C+5WRERYSRMO)HCB4=5,,I4M"S_M-E750]P;
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ME! 4H"D6RSNZ KR7 #K\U!T7U66--WS:/<++>[=!QFX(MBIRX*EHDOJ#75M
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MVOJ.GM]E%*NOW>>O_J3OZXOZI,(R9.7/B>];X6-S5PY,J;#?9;64%M!4DJ0
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M1%CZCL%.%F0N/W:2O6E ;.CH$>#75N/<G8GELIN/9LDM-TD.MEY#$2:VXXI
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M)2J-,>2-(3(<2D%;>QO1'Y/]:A#(_3OR=>\9Y6M,VT6V^.YG<;-<1*GW9"E
MQ6X:'0ZD,)1L_2KUT 2/<2D#0W7: '7_ #H1LTV2J@R\89EB.7\.S>W8U%,:
M+9+A;9ML1/0TN.Z\^PZE05UZK!]M9)&O)&_R:AO%?3QR5BLO"+S)QBTWW]$D
M9"S+LJKT6>S-QN*IC;[#H1H+0%!"TD#L$^#^W:33J'EK0E044'JH [*3H'1_
MR(/^=:)G/+2,3R)FQV['KME5U]EN5+C6=#2E0HZW/;0ZY[CB-@J"]!'96D+.
M@!NK:B%+CZ=,AC9)9IF+V&%A#T-JVLH_1KE[MN5&9DE;D65%=1U<"$%1:<2D
M*"UGXZI-2GSMB^1WMG%'\7L\6?<X%W:?5,>?0AVWM%"T./,)<!;4YU44#L%=
M0LJ ) J5^PZ=@= 5Y)1H**@!^^ZFP<10?3?R)'XKQ6PBRNV?*+)"NT"->K1?
M6E!)>D^ZA$AET>W(BN@CLA22L=/Y1V(KH;U#8+D&?\"7K'+2TQ.R!YN(M#0<
M##;KC4AEU:0I7A.PVK6_'D;K9<7Y/M^3\BY=AC,2?%NF-,PGY2Y+:4M/-R@\
M6E-*"CV'\!P'8&B*W!]9:;6L)4OH.W1/E1_PH.>W\!ON0^HZW9M=>.F#9Q84
MVMQV3(B/.,O_ %*74NE.R5=$I V/(/QOYK2,.XDY,L4/BNP2,3C*AX7E<VX2
M+G^K-:F1GC,Z.MM@%0.I"=I7H[&@"/N'5>,7G^TEB@7)4&7;#+92Z85P:#4A
MG8WT<3LZ4/@C?SNLFM*4:^?']:L'*WIRX5R3 9&.6?+,&:FW+%YLYZ+FOZ\5
M,R4R"Z5/HBA14EUP.]5H4@)\J4%? JY]6O%N;\AR9<#$<79F?7XM/MCU[7.9
M2L+<(*(H;=.D(44A2G$)*E$(25( W4QP.7;?<\Y5C4"U7B<&778[]Y8A%5N9
M?;0%K94]OPL @?&NQZ[V% 7?)/)]JXO@6Z=>&)SL6?<(]M0N''+@;<><#;9<
M/PE)4I(V?W \GQ4WZ5S-<^(,UN,/FYV-QI]#*S3&+=;8B$SH/9R6TT^VZ75!
MW0\O(/;\^V?SK>>BX%R'CN:7^Z+P1>20,JQ&WV8 W.*VY8WH[3R'&7 MS2VG
M2Z%]F^WE/E)\:GSC;DNU<G(OB[8Q.C&T7)VU2FY\<L+#S825:2?.M*3HD#_I
M6Z!I(/Y-$1MZ;\=O&(\'8/8K_;C:KQ:[4Q"DQ5/-O%"VTA)^YM2DG>M^":DR
MO(0 =_FO54*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I06UO/\ JK>OCS_U
MJYJTM@ZPVQ_C_P!:NZ!2E*!2E*!2E*!2E*!2E*!2E*!2E*#GW'...1>-^1\]
M<L=OL5_QW+KLW>$3KC.6P_;7"VVVZA;0;5[Z1[84C2T:\).AY&LK]-V8*X.3
MPV# 1:!>3+&4B22\(WZE]?V#'7?U&_X?;MK?W[_NUU12@YH@<5YC;[WS?<%8
MK:WUYH\'K<K]01V1J U#ZN'V]IV4N+V-^%$?)-:F. ,[MEKX9N4;%[-+FX/!
MDVFYV)=S+"+@V]'8;^J9?2C[7$%@Z"D^4K4-C>Z["(!IK=+R3AR]9N(<RXWY
M#MN5XWAF/R+9+L+MFF8RQ<BPBVGZIR0A;#JFB' Y[A]T=4_=M0V/%;;@V#Y?
MC'.F1Y+.L< VO(['9H*W+?. 1 >AF87$!"DI4I!^I0$D ?!V!\5.FJH4 U,7
M7*7JFXAY Y(N.11L6L<#Z"?9HK2IWUK;+TU]F4'4QWBM"E);2D**0G04MPE9
MT *L<QX9SF^L>H-43$(;#G(-JA1H+:+BSHO(CK:<+IT/[R][\D@'_/KDM)_K
M3J*O#//MRC(X[Y)L^8Y]<(^)Q[Y SK%X-M"';JTTY9I$>,ZRIE?8$.-++O<%
MO>E;V#O=2AA6,WZP^FFU8]/L(=R"+8$VURU-26EI4XEKVO#BE!!!T#Y/_O4O
M=!H?/_.GMC7Y_P *<$UQIQ)POFV$W6)-N''J&W6^.F,8D.,S82ER)C2C\D+\
MI*.J03^  ? JO%G$_(G&$O%+I<,#;RJ.K"HV*S[2;C%#D!YA9)4DN+]M;+P/
MW *W]J=I.J[)6VE8T?BGMI!)_)J:;?..76N*<ML$/EZ&O!XU^_MTPT888G,"
M/#'T*8XAO%PMJ#3*TJ*"VA6TK\)2=U8X;P'<['S)CLS),+;RRW0,/A8_*R&5
M]&Y]3-:<2HRE-N.>XH!"0D**2L:\#5=8AI WKQOYKX38#<V(\PIQUI+J"CNR
MLH6G8UM*AY!_K39X6ZX3X#XFE\@<.<%*LV&HL+U@O2KN_E0<BHU';>D!;38;
M67E%[LE!2I"4@;V3H;W-?".<#@S_ $:-V%?]IADIN0S;ZI@,Z_4_J_KM^Y[Y
M>]G[.G3^;[=]-FND^,.*['Q'BD?&\?5-%GC*66&)DI<@M!2BI0"EDJUV43Y)
M^:VWV4_M5O/-)L<6HX6N$6R<U2W.#E7&[7BZOW"Q1Y$Z Q]0TXB.DLEUF5W:
M"EH6M:-A*T]DDGL0<;)X6SF1BV>1+C@LBX./9M9LCC!8MZ?JXR#$$@-M(=*$
M+2&G=H)&QX"G"23W&64?U'^%"V#^335Y<;W?B*=<>5<\7D7%MZR#%<G8MB[(
M+5>D0$6U,5E ,1]+<IOV0A]!>2M';9<.MD:JRSWCO-YF&\@XM(XZG9)?Y>71
M[]"R5AV$6I45,YAY "W7D+0XTPVID)(  3\]3NNTTL) 'R=?'FJAE ^!K_"G
M'IFZA+U66&\YYPBNS67'IUXGS+M9Y*X+"V@M#+-RC27NRE.!(TVTL>%'9T!\
M[J$N0^'<JEL<Y6[!L(EV:WWP8_)A06 S CW1,5P&<PDI7II3K7V;4!VT021N
MNVTM@'S\53Z= ._S17&'(?&$2^<?*<L/%.619MRR*RW1^//>0XZ?IGF_>6&P
M^I+/5A'38ZES8\'6ZLKGPFU'Y-RR%.XRR&?Q_?+9;F\99Q];,5-I]H*6]&<2
M7$*BE3ZO=#@(!*OG[17;I93^*\ICHUH_^U./2ZX/S3BZYWG)L[>1QQ>5P+AR
M#8[]$2B$"R]%9C16ICG4*\[6R\=*&U]@0#VJ=> ,:=Q7EKF5+&-2L=QVZ72%
M,M)^B$>,\A$!AEXMI3_*?=;<)V 5 ]O@U/WL(UKS_P Z!D>?)\_UJ<>$<9<K
M\:O7>_>H!F;QO/R*XY*Y"3BL]F$EP./HMD=KNF3_ /<WM/)V5K4@'J=%1V*R
MUSX2<A<K8U;;E:(%];S6PQ8N3W!R.VH"7;%MNE\@C9+X<6V2/R$D_ KK3Z9"
M/*1K?@UK-NP1B!G5VRAVXW"?*G--QV(LIX*CP&PE(6EA  Z^XI"%+V3LI'P!
MJF",_5G@ ROB:W0XN/&^MVZ^6F4J#'B^\M,=N6T72AH E02UWVE(WK8 J&^0
M>-[/E.5<M=L O$BT.X3!A8ZRFQ2T-&6V)9"6VPWI+B%/1R"0"G:OC2]=MK0%
MC1'YW7R]EM"M@:-4<,WO&KED-U@+DX]FJ)DKC)JS7*ZP+1)1*3/#C+BT]W$!
M*EI2VM6C]J]%&RI0!GGTN6"\XWBU_@WB)% 3=E.1KM$M:[4FZ-J9:V^8*_\
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M&9$5C,XMOG67)K>_.5 E+N,J4AUM3+KNTI92O0?+"1I*4!([;7T3-?I/CWR
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MZ.QL$:/GSYJ9!PSFEQB,\@\]2[!R9+LZ['A-AE1I\*Z-+>DO-"X*;+KBNQ6
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MP1)B4HDQQ#;]MX).TA:=:4 ?@&DK!,<FL^U(L=N>:[!?1R(VI/8)"0=$?/4
M;_8 4XGDWZ0AZ?\ /\;M.2<C0Y=YAQY=XY#N$. RIT=I+P8;64) ^3U0L_\
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MQ5>PKP4$T""*"(^7>0K!Q_/+;$BRM9U>H7TD)-WEH8;#*%+/N/*4?#*%N*)
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M5)0WI#@ 2D+5U  "=G6JMK/Z;^/<?.-?IUB<B)QH."SH:N,KK""TE"PVGW=
M%)*?\#JF2>5VWP\<!\EW3E#!7;C>X42#>(5TG6F8W;UJ4PMR,^MHK;[?<$JZ
M;T=D;^:CE'J7OS?$\3EMZV6\83*NS<+](2VZ+BB,N;]$E_W"KHISN4K+(;'V
MG7;L/,UX!Q=C?&4"9!QN"NW19DE<QYLR77NSRSM:]N+405'R=?).S6-1P1A#
M=V1-39!]DTW)$0R7C#1*)*B^F-W]D.%2BKL$;[$JWL[JHC7BQS(;UZFN:6[@
MFV.6:!)M3+2%)<<>1J&EUDH4=)3_ +5:E>"05>%?FLJK,LPN7J5RC$D.VO\
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M:W'N(^H][/I\!W'L/N%QQ^X3IUOC7=*G>@5'+B/>=_@E*&5NM*;"@M1!ZDI
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MM.@$DE.U?RC=;3'YZPJ5?F;2B\A+TAR6S'DN1W$Q7W(J2J2AM\I]M2FPE94
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MR*%/D-?IP:\!PR0KW]E *@D_?\@5K? UOBXQR'P7*@6VZ09URPN;$R9UR)+
M=EI^D^F3(4M.NX4B6$E1&@"!H%.V5-GEV7D5Y8Q^S3;E)"U,1F5.J2VDJ6H
M;TD#R2?@ ?-:UPQRI;^9.,,?S*WL.1(]VC^Z8KAVN.XE10ZTKP/N0XA:#X^4
MFL'R;DL>[Y)CF$B7,A.7*6F1*E1&%*]IMD>ZA/<MJ;25NAH:5\I[U!>,V:1C
MDCU"<404W*:S)0]?<=D^PXU[DB3'6MYEMQ"4H"VY+84 "-^ZG0^:O([&6^D
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M@4I2@4I2@4I2@4I2@4I2@MH'_E&_\#_UJYJUMJN\-HC_ '?^]75 I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E!;P/,1G_AJXJWMX(AM _.JN*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*"VMX"8C0&_P"6KFK:"-1&?^&KF@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4KX%\AU".JB%;\
MI'@?XFOL#N@K2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*"V@'<1D_^FKFK: 0J(T1X
M^WXJYH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*H:;W05I2E I2E I2
ME I2E I2E!0T%5I0*4I0*4I0*4I0*4I0*4I0*4I0*4I06UO_ /)M>->/BKFK
M:!_Y5O\ P/\ UJYH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H
M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H
M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H
M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H+:!YB-'^E7-6
MT %,1H']JN:!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2O#JRA.Q447WU)8SC'-EEXNN[,^W
M9!>F??MTEUIOZ22.JCU"PLD*VVM.E)&U)\;V-A+5*BI?J'L+G,,_C.!!N=WR
MBW0/U&:F&TV&8[90%)2I;CB?O5V0  #Y<3L@;(U+'_618,GPY[++?B.7/XVS
M(<BNW!$!A26UMN^TX"E+Y60E6]D)/@$^0":#H*E0 [ZP[%%N^-VV1B66-R\D
MDRHUF0+>@B>8Y/N*;_B ]>H[@J V%#6ZS=V]4V'8SQ18^0;^N99++=IK<!IF
M8QTD-NK>4UIQ&_M *%*5L_:$D^=5-$R4J+>0?4#9>-,VQC%[O;+NJX9(_P#2
MVMV-'0MA]X>5-]RL=5 >=* V/C=8++_5EBV!6G,+K?;9?X%JQ.6S"NTTV\*:
M9<=Z>WU*5GN"'6C]N]>XG>M^&B;Z5!69>KS%./V+Y+O]IR.WVVR&(BX3U6M2
MV([LA#:FFE*23I?\5L$:\%8_<52Z^K_$+#+<BW.V9';Y"+HS9BR]:'/<,IUI
MMUI'4$D=TNIZGX.E?M3<7$[4K1<+Y=M6:Y/.Q]J#=[7=H<5N:N-=K<Y%*F5J
M4A*T%8TH=DD'7QX_>MZJH4K0>0.;L1XPN5CM^17EJ'<+U*;AP8:&UNNNK6KJ
MD]4@E*=^.ZM)_K6=?SBRQ[BS 7>+>F:](,1N.9*/<4\$*7[?7>^W5*CKYT*F
MKC8:5'&?\\XMQCDUBL%^=N+=TOG<6YF%:)4OZE21M2$%EM6U >2GY T:R6#\
MM6#D&==X-J7.1<+0II,Z)<;9)A.L^ZDJ;/5]M!4" 3M.QXJHW6E?-UY+0!4H
M)V=#?Y-5"]U-@]TKSO\ K6!R3.+1B<^RP[I+^FD7F6(,%'M+7[SQ2I?3:4D)
M^U"CM6AX^:;!L%*I38IL%:4I5"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*
M4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4%K;1J&U_@?^
MM756T#_RC7^%7- I2E I2E I2E I2E I2O)40K6MT'JE*4"E*4"E*\E1[ZUX
MU\T'JE*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E>5'0JHH!.J [H:"@K2
ME*#RLA(&ZXF]8G#V1\P9GD#^/6"\-WNPV.!/QV]ML)#)N,:4Z\II"BK>U-O=
M1L:[?X$'MI20H>:^*HR"3H?B@XNXCPS*L!]32K]D&+WJ9]5B2Q=;W&A%4=VZ
M./F8\A)"MJ2D:900/[B$_@5'?">&Y'QEQC:9T[CCD.5GECR.?>(5F1[_ .GR
MR][Z&O<!=++8ZO!2EA'8$'YK]%%-(4 %#8_:J>P ?^]4YCEKU#1[U.]2? ES
MA8S>[I:,;F7"5=I]OM[C[+"9$8--:4D?<>P.P-]1HGYJT]2O'DKU#Y?=\5GL
MWBU8W8\?DJ8G?H;TEF=.?T%>VH)T2TVA(!1M1+ZNOE)UUC],DD?)/]:\JC^3
M_0:']*@X>NF+YSS5Z&[2Q<K!><?Y<PE,>?!:GPG$/+EPUCH4=@ Y[K*2#K>E
M*\_'G,>I_CS)9/H-R+%(EDN%[S[)UQ[A)@6V(Y(<7,<GM2Y 44I\);2%)!5H
M:;2D>="NR@R!K9)JPODI=KMTJ2S!D7%3+?<1(G3W7=?A(4I*=_XD5.PYP]>+
M4_/O2O<[)CEBO=[NE[>@JB08EL?+H0U*9>674]-M:0A7A?4[\5B_6G]3G..<
M6NV>TY'.93DT6[2#;+5*$F+%;WW<4D-]FUCNG25 *)WH'1U+V#>H+&,[FXU%
M9C72U+R:$NXV15QC!*+@RD!2NBD*4$J2DA1;64JT=Z^=2BVAL^/SX_/]*=Q
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;@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>mtva-20251231xex10d3g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20251231xex10d3g002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M<)^-&SBTQX\ MH2V$?M![0V-)2>J1\:_AXI8Z/D3V(C1=?<#+0(25N$) )(
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M9[B>P<BLRQ)2D ^#WZIWL>=:\5'/,_J*;X?EO^[CTNXV^"F(N=-4ZF.V@29
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M4N+&_-:Q'X9ND'DSCZ:WQ+:X^-V.T7"WNQH<R,^TRJ3(9<;"0Z4J<#80LJ)
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MQQ'=T#2>4<T_7RNWD_\ /$JP5'*2"H"J%U(_.H[_ ,%M_ '7E3+P/_3-K/\
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M._4,I2.!>1B?RQVX?^3N5MF'C6*68#X$-GQK7^@*U'U'+Z>G_D<[U_WO3_\
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MP']SOL=0?G?C=>LKE+$F\@CV1600D7>1[8;AET!PEQ"EMIU^2E)2HI2?) \
MUQWF')L>\YO;,QMEN:@W.U-PX[UJF-RPQ?FT*[A,A7TX#:HZE>XRKJK[E'MX
M(ZX-BO\ C3?(.5*R6&[DEJNN2,Y+$NPNUTAHC*'M%MM^,AL)4ICVP$*2%!82
M >HI<^XE:=$<R>H)C$+UC5KQV^6:5<Y&1Q+/<+<^E3CW1U:0L(4E8"%H2=D$
M*.E#P*]_U(<D7KB'BJXYA9&[?)7;7(X>BW!IQ0>2Z^VSH*0M/0@N!6R% ZUH
M;V./K?FR;/QYC>$2%VJY2<?S%%^5?U2U(%R;5.=DK<Z+:[-NE+NE)/CQX/D
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MEUB6W_(J_K&LN@4I2@4I2@4I2@4I2@4I2@4I2@4I2@5$OJPW_BX<D: .[)(
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M@5HR'DFUJNN+>HJ?D5L2Z63)A6FTNMA8 )3V3'^=$'^VMM1Q=R"CP>8KLO\
MG9+=_P"P:]_AS&YN,X';&;LGK?907/N>SL_5/K+KHW^82I90/X)2!X%;N=;J
M5$ERBIWC'D$H'7ENX]MC]ZR0-?/\&JC+TV<?\@SN"\,DP>4Y,",[;T+;BJL<
M1U+0V?'8@*/]IKJ%S77S45>E?:?3Q@(UY_"V]_P\FM5'"7,]U/\ !QR@/W>7
M 3_M8U&/]RA5!@'*R"-<K0%:^>^*MG?^Z0*EJJ$;IB$0/EEPR[CYN&O)N;<;
MLB9KI9C*N&.(9]Y825%*=RO)T/[OU%7Y%<<NQ63:V+SS7B]H>NB_:@MS<>;;
M,E?CPV#,';Y'Q^H_6HU]8F&9%#RNRYGBRX.02E1OPR?B5P" )3(3(6E33QW[
M*B%.I((*5GKO]SS=R[C-FY ]+-NRG#\6LD6QLVB)=WK3=FE,NJ@Q3]0B"VXG
M_(Z4".PW\$:^XD7Z"4+BSR#8Y,2+<>8\7@RI:O;C,R\92TMY7CPA*IH*CY'@
M5Z?]%N6&T=E<G8\G0*BI>(+ T/D_Y\*YIY:O.49VODN\XC8D7VR7S#K8G(X,
MT(1,M*5LK>0(A60E]89>4X6U= %="%$GJ.K)\#%N2^)X:KF\XYB,V'&G._5N
M% >C)"7@'RKSU(2.X/[P[ ^"=OJ->L\3DF_0TR[3ROB-TAE10)$;%5/-DCP1
MV1<-;%9,.S\IW%4@1>3<2DEAPLNAO$75%M8 )2K_ +H^#I0.C^1'ZU$EDAKX
MAG<F9Y8;*YC=ES"3;[?9+9 M;SR(_LMN(=NCD9E*BD+[[" D%26&NVBY]OK>
MB3*;/)M_(]GMDBYRELY?<I0>N4&2TMQI1; 6M;K:05D@DI_>&_*0*STKU)0&
M,<NG6N0,55_/$'Q_]4:O3C_+Z#YS+#W1^AQF2G?_ *WFI.UYJM6,(YRYOM/*
MS/'+_P!=D&'RF/Q&VCJU9932BHSV CS]6KP%=2?'D CQO=;P;=S,DGK><%6/
MU-JFI_YOJ36?Z@=?X,GM_'XK:?\ Z91JD1)V":I<\HL5%YFUXGX*3_\ "4T?
M^OJM3$YI(\S,#/\ \:31_P"O:E8@4&A3''\ESRA^1<N6X*VDRI^ -*<6&T)<
M1,;*U$@ #:_)VI(_M'ZU>J;R^U*;94O BXZ#T;4Y,0I>OG0\[U7/'K+L$_&.
M08^6W['4YUQ_,$)N5'BK*+G8VV)#1=<CC8*TN=AOVREQ)5O>@*\[FVSJQS!^
M<<BE,S)ZKM#M$S <E2AR0H!+##41AIT]E-NIDGL.Y!<+Q5]VUZSTQ[F?R9=,
M_B/,274-&+@A602E!G3$*4!\D#V2?SJ]<[F9!&[7@O\ $_B<P:_]9ZASU5XO
M"PZ]XERM<L33<&,?NL.YWV_Q;@6YT9 ZQTM1VRD[8[+"W$ IV.V@5*41T;R#
MB\/,,1F6Z?;?QR,H>XJV*?++<LI/9+;BO]0D#8/@CY!&P9T1[F?RMS[IJZ;C
MS(0%)M6#J!&Q_P!TYFB/_D:JB[<PC6[-@QV=;%WF?]E_A7//$?*=HX"XQR/C
MV5]-@V56O)7K<IB=+2];H"I:/K4.L+.@6$1W.R6]!2E )(!5X]'T[G'>7_3!
M+LC0C\E3K7>;R\_9)ESZMS"[=9WTYEKT=H4C]H-@_N@A)(2*O1'N9_*]2=?Q
MOF$$]<:PE9_]3TL?]#J@R3F%L]589ASGZE.324C_ ,AK5?1C<&6.#(.+AB=&
MN>(S)-@N4:X.AUQJ0TZ2I*5@D*;TM/3SX3U!T0:A+#.19%JY"Q)R_-R[="3E
M-T2.1VW'7K??F29(3#/C[""I+8]P!L&,2VHGJ J([?RF[IE.2\P*(3_0C$'#
M\_;E,E/_ $"KSD_+Z4^./,56?X9>\/[[?4"\;^H#'\Z]5UDN*LWMCT2[8U(9
MMMF:G-K3&4J4R&FR ?,AQ*>ZA\C83\(V>RFCM/GYW5@F)A%R<IY> ';C?&=[
M_+,'?_9?5#EG+Q)/^#;&C_+,7/\ L%2H1N@&JU<(Y>PC*.4D<U<EN,<?V&3,
M5'M(?CKRE2$M::>Z:7]%]^P3OP-: \_-2<G,.6NNU\96+M^B<M)_OABOGQX"
M.>^6?T]FS:__ !#M2O4G(BHYERLVC[N,;2=?ZN5@_P#115J,\Y163VXQMB2/
MG_OI3_V:I3?'9HCYKA+([A<<7]7CT+D*7>L?1<9\9W'\LMTY:XBF2[($>(XV
M-H8[[+!2M&ED*5OL0JLUYK$QPZ95GG*"/GC"W'^ RA&__H%%9]R>D^>+H6OU
M_I.W_P"P*TR_\1VFT\B89;[9=,A5>9]P>N\Z4]D4]:!%84'' &"][0"W'6&N
MO4 )6K0\>-^Y>P?';]"_'\GN]YMEJL<*0\\FUW>3 1T/5:W%^PM!64I;.@=Z
M['QLTJ2XX80Y%Y-2H]N*&PD#Y1DL<_WH%7GDCD9/[W$LA1_])9!#/]Y%:+9N
M'(/^!_'[EG.0Y5;&[/ EW*:TSD$QIQH/+#Y0ZXEWNX64)#8VH_!_,UH-_P @
MO'#.,<0Q<C3E%\L-QC727>K;:[B_(N[;SGMO1]]5A]YIA"W&E=%>#[:B#XJ9
M[?[_  OO9.PY0Y!*M?X(+DO^*+Y;]?\ .Z*?X4<_2K1X?NP_]7=N_P#8U>#Q
M;RNFQ^E.%R!?[NC(T0;1(N,B=&<#I>0VIPA!6 -N )#:E:\K2HUKW">;75Y,
MA_-9=S7R=?+*;Y'MBMB"F(0%)8@MA12KVE*;0X5@.E2MG["G6HJ)V^[&?<-_
M_P *>?$@#A^[D_\ J:MO_L>G^%'/C\\.7K^R\VS_ +14?>EG(FH]]./9$O/;
M?G)LT>4[!S:6IY$EO[0Z]&(4I'AS04G84GLD:%=+^/UJE3[A%:^4\[2/_=-W
M]7\$WBU_]JK5\2RB^9+ZFHRKUB$_$5-8A)"&I\N+(4[N:QY!8=<  ^/.OGQ4
M^=0*BJ3H^J: G_X#))_];F*S EFE*5I2E*4"E*4"E*4"E*4"E*4"E*4"E*4"
ME*4&);C^Q/\ 6/\ PK+K$MP_8G^L:RZ!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M40>K1+B_3GR"&D!;AM3G5)5U!.QH$_E_.I?J*O5&COP#G(/D&VK\?VIH+$Y9
MS$/GC?%__%S)W_V75<K+N8/RXUQD[_\ @R=_]E]2KK55H(A7FG,+77?%^-E)
M.CUS-?\ Q@4.<\MI5H\76/1/CKEY/]\,5++X'M^?BN4L'8AX1SA;I6:X;E-L
MR"^WFZ,VK)Y60.R;9(6M<A;37TB)*FV"8VDH[M)V4^-*\U)$M-YORMH;XPM6
M_P#9RM)_Z**^G]->4_)'&=MW^@RA'_9ZE,I!U0) J5/*W'#F/U(9GR/)X#Y#
M:F\<0X45=CEI=DHR-MTMI]I6U!(9!5K]-BI$3G_): H?X*0L@_\ @\BCD?\
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MC7)F918\;$)&3S[_ &>]<@C';+E;Z4-2Y-M;8+\H!Q  4I*VGF$O  G14#L
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M0'&U)4E322%)4/S!!!\09D#/ISL/$J\ZG<8V=R*%OQUVUFRMN2D/L.EI]I0
MZCVUI(*BH)UH@G8W[_(W&'#6!RX]M@\*0\LN[C*Y?X;8K2PIQF.@Z+JRLH2
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MQ^36]Q/53"@Y#&LF1XI=K)=[A8%Y';8;2VI3DV.VGLZV@(5H/('DH)\CX)J
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M9"O9"MZ_/XJ!(?'-XPC/<'R"-QSD5]P=ANZI-DE/1)$VVSICK:S++)=#:4.
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M6>P((6/N"=D:YHS^3F"L&9QC'V,SCVQZ]2P]=7E0FH_U!:C(2L,A2UN ;4=
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M6RH_!\Z[?VU(.J%((J*A5?"N4/\ (SV9R<PMR[D[CR\?+35C6AL)4Z70Z/\
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MW0E124^_W'V^>NMCYK1,']/.4\>9=?OP]W$;KC\Z[O7V+*N=N6;G%==5[CC
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ME-%7N)'<>VI.B"0 =>#XJ:3G./HS-C$E76.WDC\54YNV]_VRF$D)4X$_ZH)
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M3J6FFTC\U*.@!_$U2SW"%?[7%N-OE-S(,EM+K$AA84AQ!&PI)'@@C\Q2H+E
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MGS,(&8-VS(\8A2VKEB:\FML;'777Y2BV4)7&4E:0%K47$]2G0'D'>MUIO'_
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MA*DJUH]02#Y (\P]GO-_,M@YYY#XUAW2SBY)L9R+"4N6K?XBA'W.QG/V@VL
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M!\^:>\-_!J(?3CEESRK![DN\_B*+C"N\J&\Q<93,LL*24GVVY+0"7VT]M!9
M5XTH!237/>,^I"\S.0)D!'(\=^)<,;O$IF8^F+],F=%DE*51FO"TH2GNGJXK
MLM+?<@ @EU%.X@^DD#R-_&Q6IY1RE9\1S#%,;G-3C.R9]V-!=9BJ4P%MM+=4
M''/A)*4*T/DZ^*Y4XQY.R2T7#AJ[N9O/R^;F&'7&=<+%,EL>W(EQV8ZV4L)2
MD>VLJ6X@D;[:.]D;KR,9Y48S^^>FC)KMR6Q=KS<;S*>N=G6J*RU$D*MTM/MA
MI*0XUT6?: 6H]B1O:B#2RG9>6YO%QJ;C]O+#LJ?>YX@Q6&M ^$*<<<))_=0V
MA:C^9T /)%; TZE*=?F?-1/CSJLZY@R3(4I,FV8HRJQ6Q*#U#DM80Y-6#^>N
MK#(/Y%#OZU#EAYNS=?%?&O("\A7<[_DU_9MTW"_I(Z&D!UY;;T5OJV'DN1D@
MK4I:U;]I?8 *&EHZ^0\EPZ%?2N=/33>,VS+*\UN5[SXWBTVC(KI9V[0BW1VT
M.(;4T&7?<3M:>H"@$@Z/8D[(KHNK$V%*4JA2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*#%MO\ FB?YG^^LJL6V_P":)_F?[ZRJ!2E*!2E*!2E*!2E*!2E*
M!2E*!2E*#Y>\C_A5OOH[ >=GX%<2VV]S)?J2QY]UG*)%K?OE[M%WN4YB6/JT
M+8U';+2&PVRPA24I:4"2KHI9*225>9Q%?K@ZYZ9(=T3E7]([09UIRU3\.X!*
M3^'RD(1(44]%[?\ ;4E>SKPK8!W4*AU+R;S'&X_M]@N$:VJO\&Y7UBQ./Q)*
M$B*ZX_[!4K?[W5P%)"?((-2,U(;2@>=?V5^>5IQ^U63T]6>S,HO-NR'_  @
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M<;MB+F&2[C,NDV<Q)19+DE24Q"T\I/1"GRI0]G^ ( VG68N>S51R[0#C9!2
M:J74!/7S_"N#8W)ESQ;"N&)$CE%^X8QEJP<@O\V</I[=(;MS19@^^P4KC!QT
MJ43W"BI&E*^\[S\TY3RS&+-8R.0V\XBPK8J5*DV"5^'7):1<5H;E1VEI+-P
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M;);7I/U^.R6XMP;DQ'6.CBVPZD)[I'<%"DGLG8((T36TE;8WYUJN(>4<IS+
MK]ZI,UQ7)V[(YC$FUW$PS :D)G*1:8Q4TZIP$I0I/@= E0*M]B!JMUY6YVR/
M$^:XMLB9)%:M,?);19Y-M88:+;<>4R5K,EUQ(6'SLK0EDD);0E2_WQ4F^%=.
M0;1 M<F7(B1(\9Z8Y[TAQEH)4\OJ$]ED#:CH ;/Y 5G^X@C>_%<MX3F?(5YY
M+R/C:Y9G(1D-EO"92YC5MBA+UC<CE;#B1[?7NIW]DH_DI*M?E5_!O,V;\I2+
M-DSEULL>P2+Y<;9<;(^^VAZ*&W'FH[3:?;]SWPII"E!2B%)6H@  &F=Y3$[.
MH0D C7Q^E6[2LG6S4 \O\JY4SS5CW'.,2XMGE7&Q2[JW)D>V%2GDK#;;3?N)
M4D]/N<6 "HCKHI&R=2SWE?D+#58_-G9;96K5>[<PW-FVZ*F3&L$KW6VU2UJZ
M[<BK45H!5UZJUL]=J3+E759&R-[U52E)&R ?YBN8[IR_G5TY)Y QJP7*U,N8
M)^$%Y5V4VPW.;?:0_(?=/7:$%M:D)+>@E;9)V"!7I\<<@YERX9^1Q\QMN*6V
M!DDVR/X_)MB'UI;9=,="5O*6E27UJ2EU)\ITXE/17S3/"5#H;24)!V-?PKZ)
M6@C]*Y7Q+G?,KSCW"=PEW.W&1E>07"R7..F&$A895,"5MCMM"D_3(!'GR3\>
M*U+!N;<^Q;B/%Y-PR&+>+IF&:W&P1)DR&EE%O"+G/2M15WZK+@9"&TGJ$; ^
MX#S1VFZ^VTPIQ>^B1LD?I^M>!@N>X_R58U7?')Z+G;0^[&+Z$+0 ZVLH<3I0
M!V% C^RH.B<M9\WR3B7&=]DV>SWVZ"ZSG+HP ^IZ+&+18;2UL)2^I+X4L;4
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M:#S!;!0A?0@*2M>CK8'G4H0?5"7\3Q;,I6,.0<*R::U"MUR7,!?!?44177F
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MM_PK7I/H_P"'I>--8XY@=L58675/MVOLZ(R'%:[+#87U!.OG7YG]32H'/_\
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M@FIT]IC[RMQ#8, ]4N:<AVBQ7>U8_895HR&]Q;39W4RGT+FI+'O37@DH/5+
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MFUDY<Y P.V<<6F\S<0L_X\X^K)EQQ*BE*5 )289"7.JO@JUL?)K>_37>YO\
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MU^9%:7Q59LO]*7JKPB;F<-F!;^4(CMLO,UBX&4V]=TDO!Y8]M :4MQP("1L
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M-_%>\M ^3Y\?'ZUQFYR)EG%V0\YY;9&K0]9K?FMO3.BSDN*>EH?C0&%!M:2
MT4!P*!(7V^-(UYWGDCU$Y=A=FYWDQ6K*^[QVS%FQ??BN]933L4OEIP![84-A
M(6/'C?4_E2G2(2DG77K5Z4!)^*Y_O/J"O6/\W1\6N<1JSV!Z<U#AS9,%YYJY
MA40.K2W);44-/I=)2&74 K2G:5$J2*UW%?4=R1G/&+/(%KQ*WMXU<K'<+JQ)
M>>;*;>64*5'#A3(*W^_125A+;9;5H?<-FEK3IUSJ1X '\:M]KNKL!XKE*)R=
MRTFV>GMA%VQYZ?ERW52WGHKW5Y";0])3[@"][[(*CUUM01K0V*WS".?KS?\
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M9C16@/)^P'LZK1)\A.M 6\J>GGD+DC)G[JG(+#&CQYUHN5M@+9?]MEZ,I*I
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MW5MI!"4%6_( 4= _&Z>0Y;X.XQ<X:]0V!8'DUT-UCX]Q^6<7ER!U;>E?4?\
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M)*"E"DD?! K9,2X6P_!HEXB6:S)CQ;PXMZ>P](=D-R5K&EJ4EU2@2H?)_/\
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MU'D@>1^8K0N+.*LHXYY7R2>[;(LG')MAM-ABSU7#O*0BWMR0'%M^V!MTOIV
MKQH[W46<#<67OES@STZ?5P&+)9L7A,W0W1B9WDOGZ9;3;;*0D%O96%+*C\(Z
M@*WV"IY,.K;9R[A]ZN[%L@W^')FR'78["$+^U]QL$N(;5^ZM20E6PDDC1W\5
MY,/U%<:7"3-8CYM9778;+LF0$RT_LVFEAMQ>_@I2LA)(\=O'R#4,VO@++O\
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M\GVSU(W7--RSYCG3.\=Q5Z Y;5X_ELD7:"XX'MF(TMV,K:?'5PEM>C\:(\D
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M8?:20102]BF97S(4XM+DV>!;H%WMKDV0/Q$NOL.?LU--H3[20X"A2BI6T]2
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MDF26S$+',O-YFM6ZUPVR[(E/JZH:0/E2C^0K69/-^"0Q,^HRFW,F$T'Y25O
M*8;()"UCY2"$JT3X/4_I6V7:V1+Q",6;&;EQRM#A:=2%)*D*"TD@_HI(/\Q4
M X)!9N/JRY]ARF4R(K^/XRTXTYY"T*3<@H']0=D5)$UV3,[/E$FXL6N7]6[;
MG$,R4I;4GHI;:74@$@!6T+2=C8\Z^00/AC_(6.Y+D=]L5LNK,R[V(M)N41&^
M\4N!1;"MC_2"%:U^E<JYUR-R&)F6XY#RB);6[7R'9+%$7'M0TW">8BR WKW
M3HK^XE1[ * Z Z'RS#E*\\-<K\IS(Z(MVR6XIPZQ,276PRQ[[YFI4\I)7I(
M*R$E>BK0*AO=-AVC\_ %5Z#_ %14.8A>.6)TJ+'O#=DM;4:]*2Z[+"52+A;2
MR5)Z-M.*2T\'-I\D@I03H;U4Q,K+B.QU_90564I3M0\?E6BIYTXZ6^ZR,VL(
M=:=##B57%H='#\(5M7A1T= _I6].@%&CY%<;7O';OF?)GJMQBS6&)?95Z;LU
MO")LE+,=GW+6E/NN>"2$E15I*2=I'Z[%'8B0AX ]=_Q-5,= ._C^%<Q8QEW)
M6 \AQ^,HB[#/L&)XS:YDN[3R\9,A@%34A02D>'#[2NB=J&D^5$JT+\)]17*F
M:87"S:W<:BYX]=K)+ND1IF7'0IAQ*0J*SV^H4M_W1M*B&FRA2=:(.ZEK3HF_
MY#:<<:B.7:;'M[<N2B(PJ2Z$!QY>^C:=GRHZ.A7PO>88_B;\!J[W>';';@\(
M\1N6^EM4APD (0"=J.R/ _45S@/4K?\ (<7M%QMSEDN;2LTM]BF"1;I$.9#;
M>+9(<B/*)9?2I2D^5%)24K22#6M<A\DY!S5QQQ[F4=BUQ,5FY] ;B1"TM4Y#
M3-P4PEXN]NO9:FU$MA ZI5HJ)!!64[.'7\@-5=U!W^5<[85Z@\TY#NC5QQ[#
M/Q+$7+S/L_O)6&W&DQU.-"4MQ2]=2^TI!:#?9*5!796NI\3COU)Y_DSO%%YO
M-EL,+'\WN,^U.08KKKDN$XRF2IMSW3I#@/TY24]!K85L[T)8ZB2OL=#\JNZ?
M-0KZ:\]S?D-G*+AD[=H1!CWN? C)@/.*<;+#Y:Z:4A(Z (WVWLE7P/BIMK2/
MFEOH-"K@D[\_%74H+"BG4C^1^:OI06I&A5U*4"E*4"E*4"O'N>+6R[7NV7:5
M;X\BXVSW?HI;B 78_N)ZN=#K8[  ']="O8JA&Z7,;"M*4H%*4H%*4H%*4H%*
M5:3YH-:3@F-HR4Y)^!P$W]?@W,1D"01U*-=]=B.I(^35]SQ2R7N7*D3;5$EO
MR82K>^Z\R%*<C*.U,J.O*"?/4^/X5!OJ1A7;COCV[Y+;\IO2+S<LGL[25MS7
M&V8T9^X1(RV6V@KH![)4"HCMV45;!UKWLY;MW'.;XVJXW#)[JC(;Y#BVN,W*
M=,>#(2AT$NN=_N;6E9/MJ!!*!KX\,]BFS'T^\:%AR,,'L7T[L9,1QOZ!L)<9
M2HK2@C7W)"B3H_G7J#A7"7I,I]6,V]3LJ*(+[BFON=8  #2C^:/ ^T^*Y\SO
MF^7RGQ0+]!MF0XLY;,S@P&'RXN.W);%X3$<0KHO]H2D+[(4- G\];J7V/4]@
MSN:M8PU<RN4[=%V1N6 DL+G(05J8 [=^V@H=NO0J!2%%6@9$R/6N7IXX[NT*
MS19F%V23'LR5HMS;D5)$5*B2I*/'VI))V/CS6UV3![)CUVN=TMEG@VZX7)+"
M)DF*REM<A+*"AD+('D(2>J0?@>*MP/,8^>XO;;]#BS8<2<U[K;-RBKC2$#9&
MEMK 4D^/@BMCJC36N-,8B9JYEK-FC-Y*\W[#ES (>6W_ *A._*?/Q\#9(K7[
M]@L7!59#E^#X7!NF;W'VDO)7,^C,[2PG;KQ"AIM"E* T?CJ-;W6K^JZZW;%+
M%B%TL]_N%D<>R>W6R2(KJ4MO1GW@EU*@I)\]?@C1_C6BXOZB&N.<KY7E7[*I
M64\6V/\ #/PV_>TF06)C_=+T(/-( >2DAI7<G]GWZJ5Y\2Y*X3=:.%,;C\4V
MW ;C:XMRLD9AE*F%(*&U.(6'/<2 =H/N[6-'8.O/BL)7INXV"9B4X=;&TRY3
M,V0&D%'NOM !IU6CY6D)&C\[&][\UCRO4S@\*UMSGIUP;0J/*F*CJM$M+[<:
M.OH\^MHMA:6P1X40 H?N]J]0<Y8I)OK=IB3WI\A3S3"GH4)YZ.VX['$EI"W4
M)*4E;)2L;/GLD?*@"M:E&_-_I]B7Z*T[C>--R';K>(<G(5Q9A8GOL,DE"V'5
MK" ZA81HD@A(4$D'5;=P[AN3X[D>0.7"7>4XNZQ&1;;=?[DB?*9=27??7[B5
M**4*"F@$%:O*"?MWH^=@/-F'RL(L2X.07JZB^RKJW;3+B//W*1]/+=0^0TEL
MJ2VTH%*>R1U2&P?)T=>]-_,\5GB:U2,DR&Y7RY72^7F+;ER8CKT^6VQ,?2![
M#;?<=&T)[?8 GQO6Z7!28+)Q3C6-9A>LJMMN5&OUY#:;A+^J>49 0--]DJ64
M_:"0/'@$@5X7^+I@"[?E$!['6ID')UAV\19LAZ0W-7]NEK2M9'8=4Z( (ZC6
MM5YLGU3\?(<M[,&[R+W+N%L5>(D.SVZ1,?<BI4E)7[;:"I/W'6E $=5; ZFO
MA.]4^%Q9''ZHLB9=(&;,O2[=+A6^2\/8;:*RLI0VI7ST3U(!&R3\4N!L,'@#
M"+=9#:6;(%1"\S([ORWWGTN,DEE27UN%U)02>NE#6R!X)K'NOI_P>[VV7 FV
M9R0U+F,W"4XJ?)]Z1(9(++CKWN>XX4%*>O91Z]1JI+<6I*01\[J!N'LMR3U"
MXS.S=C)96,8[<),J/8H=LBQEN?3LO+8$EU;[3A4M:FUJ"0$@)*0=D[JI"1\9
MXQQ[%<LOF2VV&^S>;R&TSY;DV0][X;'5O:%K*1U&P" - _SKYO\ $>-/<A(S
MA4*2<H1&,1,W\1DZ#.^WM^U[GM]-^>O76_.M^:B7/<RR[C[D3ABQ7K.TQ8]^
M1<F+W,:B16675QHON-N(]QM1;*EZV.Q'G0U67EG-[_'6%\B9G&R-G.+3;78-
MJM41*&D];DZI""V764 +0I4F-YT2GJY^E29G>C?NV6=Z6N.+E/RJ<Y9)2).4
M@IO)CWF<RB>"-:<0AX)/CQ\?!-9+/IDP-IJ]A$"Z)_&;:S:)Y_I!<-R(C78-
M-$E_8"0MP#1!TM8WI1!P<UMG(V*<=SKY S(7K)[9%5-7;Y-LCH@3%-I[+92$
MH#K84 I*5%U122DD*T0=RX\Y,M>>\867.&7!"M%SMR+EVDK ##91V5V4?'V^
M=GP/&Z7S!3SK-P)B5AR2PWV'$GMW2QP#:[>ZY>9KJ&8I !:+:WBA0/5&^P)/
M1/G[1J1FT]$ZV3_.HR5ZC^.&\>NE\=R^WQK9;'6F9;\DJ;]M;J0MH=5 *5W2
MH*3H'L/(WYUGXOSIA>7.9$BWWY@JQY*'+J)33D7Z5"TJ4AQ1=2C;:@A1"QM)
MZGSXI:TWY+B5#8^/UJXD5 F*\MOY3ZE?P6TY1^)XN]BQN@MGT:&PT]]0VA+@
M<* XI*D*)&SU\G5??/,TR^W^HW#<,MU]8AV6_P!GN5Q=2J AQUA<4QDI"5$^
M4K]]1.QXZC]:J)R*@D_%7!78;%03'Y8R/CSEVV8/GDN!.M>0PY4NQY%%9^F/
M>*@.2(\ALJ4D$-GNEP$ A*OMV#K.QOU%X#8,(L4R^\GV:Y)FQGY3=WD=(B93
M3;Q;4Z$#PA 44H!^%'6B2:E\B::5JIY,QK^DZ<>3?8"KTI?MB$'AW*_;]P(_
M3MT^[K\Z\ZU7A3_4+QY;5W5+^969*K7&<F3$"2DJ;9;5U6O0/D!7VG6_N\?/
MBEB1Z5'MAYUPO(<6M5_C9%;Q!N2?^3]GTE2EAL+6WH$_<A*@5 ?'YUZ-WY;Q
M"QP[5*GY/:8<:ZMK=@OO2T);DH0TIU:T*WHI#:%*)^ !\^12X6I;C2L2WW!F
MYQF)45]N3$?;#K3S2@I+B5 %*DD>""/.ZRZJ%*4H%*4H%*4H%*4H%*4H%*4H
M%*4H%*4H%*4H%*4H%*4H/A#_ ,W:_JC^ZOO7PA^([6_GJ/[J^] I2E I2E I
M2E I2E I2E I2E I2E!8Z@N(*1\G]:TNS\.8E8,LDY/;;%%AW^5_G%Q;[>Z]
MH$ +._N "E:!^.WBMWI01N]Z>\!D"Z]\7A=[I):FS'!V"WGVU!3;I4#OND@:
M4-$ :WJOC/\ 3EQ[=6;PU-Q.WS&[RPW&N*9 4X)3;9VV%[4=]"-I/RG\B*DZ
ME-A'MJX(PBS)M0C8W$*[5+3.A/R"M]YE]*"A+GN+45E02HI&R= ZJ0$)*0=U
M=2K8L<25(T/FM,QOB+&L1RN]9):8#T:]7E257"4J=(=^I*0$I*D+64_:D:'C
MP/ T*W:E0:+_ (&\93G;^9HB24Y*^VAEV8+C)ZK;3VZH4W[GME [*/7KK9WJ
MM=M/I9XVL%MN-NM^.JCVR>EY#MO_ !&6J*V'>P<]EDNE#!5W7LM!)^XU+E*(
MB:\>F?![[$;8FV^X2.LYNY*?_'9Z'W)+:4(:=<=2^%N*0EM 3V4>NO&MFL)7
MI+XU4MY*;)+88<N2;P(<:]3F8S<P+[^\VRA\(;5VVHE(&R3OYJ9JIKSNBHJM
M'IQPJPY%<[Q;(<ZWOW*2N=*BQ+M+:B+DJ^7Q'2X&TN;\]@D'?W?(!'SMWIBP
M:T0\7BPXET9CXU-<N-K;_'9Q$=]PJ[K\O'MONOPK8^]0UHFI9UNJTV2FF8)Q
M79N.[A=Y%F,UAJYRGIKL1R8XY'0\ZONZI#9)"2I6U'^9UH'5;G2E%*4I0*4I
M0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*I_?5:4"E*4$6\\</W'F/%8UBBY"WC\
M5$Z+/=68/U*W%QY#4AH ^X@)'=I._!)'Z5\N1.)K_GRL*<&3P[>_CUT:NSJQ
M:E.)EO-@@ )]\%M.EJ\;4?(\^-&5Z4'.5P]+N2KP&7B,/.8#-K5DAR*,X]85
M./-J_$/KO:61*2%CW-)[ )/7?C9V/;XPX)RKBRZ7.);<Z8=PZ9='[JBT/68*
ME1EO.%UYIN27B/;4XI:M%LJ 40%;^ZIQUNJ'QNJ-?P2R7RP8O;H.1WY&37EA
MOK*NJ(288DKV3V]E*E!'@@:!/Q_&MBI2H(HYYXEO?+-HQZ%:[S LXM=YBWE:
MID)<CW5,+"T('5Q'4'R"?/\ #5?3G?BV]<N<6S<4@W*!:Y,\L?42Y,=;R$!M
MU#IZ("DGRI 'D_!_.I2(W5:#GO,> \IOO)EJSV%<\:_%E6K\'NULN]J7,A/-
MATN-O,;6E;:T%2M@^%;UL:\_.3Z;KJ]RA$S%F99XEVA2(KS5UMK#D&3(8:BA
MI<*0ALEMUE;@[!2^Q;2KJD?:DUT.0#0) JF7)V%^EW/^.[EBU]M&28^[>[.[
M>6'V)45_Z67$N$Y4U0V%=FW&G5D C86D#>JQFO27F=L<P^[,WC%;S><;N=\D
M"#=+8Z8$Z+<Y"7G$+VI:FW&U(04J2%>!H[^3UST _*J]='=/1$!0.'\ML/)N
M.9/":QE$2U6*9:C A(=A->X^\EX%"$H6$I2IM*?G:MJ7X/VGP,)]/.:X79>&
M@B58IMQP)F?"=:,AYMF4U(:#:7$J]HD*3K904Z/Y*%=.!.AJFJBHUXBRW)\R
M9R/^D5JB04P+N_$M\R$MSVIT=/4I< < 4""5(4==2I"BG8T:\#CGC/*>#,?F
MXOBK-JR#'$2I$NTLW"8Y"=@!YU3RHZBEIP.-I6XX4J'4@$)T==JF9#*6SL;_
M +:OU00'>>+N1;YR#Q7E,YW'Y\O$VY[D\HEO1_JGI4<LE+20RH(0CQHJ)*OS
M (W63R'PE>^88&2XY>V+5C>+W>+[RW;5)5)F.7-*XZF):NS*$CVOIT:2">VA
MV\>*G/55J;&Z(<DQWDW+\#EXO(58K3<)\9<*5D<1]QQ+:%#JMUF,IL'NI.])
M4YI).^R@-'T;GQ0U8>"I. XK M[[,6S&V6Z)>078R^K?5 ?_ #4DG15X_6I-
MI5'%MT]-'*5QQGDN!(%EN$O,6+*LR9=V<6MI^)U]WMJ.$Z)1M/0)2D*2D)TG
M9VKE3T]YQRQ<N56BFUV&'EF/VVWQ)29BGULR8;[CZ0XW[8[-K+O0Z5^ZD^#V
M\=3Z\_-*MH@7#<1Y*N/-EGS7)\>L%HC(QUVS2VK?>7)2TN%Y+H6D*CH!22".
MN]@>23\5=R+@V=3O4=A&:V:R6Z?C]@M5QMSZ7KG[$ATRS'5V0GVR/L,<#14-
M]B?&O,\:U5:BH&/&.8YARU:.1,IB6^&C$XLMO',<@2RZI<B0W[;S[\@H2 2V
M.B4!)"0M1V:BSC;T_P">X[.X?7?<+LLY&'Q+W$F*_%&W?<^M=0I"FPIKR$H"
MPH'7[QUO==F535!R5BOI]RBQ7[)+%=<6M5[MTW()5]MN:*NA;D0R^LJ[&,4D
M^^UV*4*2='0V0/GT<*XRY$;X-<XQNV)6.&Y;,:E6&/D#=R"TRR6BVT6FPWW:
M2O[2L*(ZD:^_P:ZB]H>/GQ0I%2BW,^$\>YMC.8XEFDK&527(F)(QF3:E3XY?
MB.-%M8?:5V]M27%)*5#L".J#Y&P-,@^G3++'*XL=G8C RAFRY%>L@N<-$ACV
M8C4YF4E$-D/$%:4+?;6=Z22E1 ^!7974;_\ KTZC^)_MJ[)+Y0HC<)EIIEI#
M#+: A#;:0E*$CX  ^ *R:IKS5:*4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4
MI2@4I2@4I2@^$3_(-?U!_<*^]?")_FS/]45]Z!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*"A.J [H1N@&J"M*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%4UYJM*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*"E5I2@4I2@4I2@4I2@4I2@4I2@4I2@4
MI2@4I2@4I2@4I2@4I2@4I2@^,0[8:_J#^X5]JQX?^;M?U!_<*R*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!5BR=>/FKZ4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*IYW_"@K2E*!2E*!2E*!2J$Z'SJ@.Q\[
MH*TI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@H1L5:VDI[;.]G8\?%7TH%*
M4H/A#&H[7]0?W"OO7QB>8[7]4?W"OM0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
M4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*536JK0*4I0*4I0*4I0*4
MI0*4I0*4I0*4I0*4I04UNFM56E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E!\(AVPU_4']PK[UCPO\V:_J#^X5D4"E*4"E*4"E*4"E*4"E*4"
ME*4"E*4"E*4"E*4"E*4"E*L45;&O[:"^E*4"E*4"E*4"E*4"E*4"E*4"E*4"
ME*4"E*4"E*4"E*4"E*4%"=4!W0C?S0#7Q05I2E I2E I2E I2J$;H*TI2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@M6DJ T=>:J*K2@4I2@4I2@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@QX?^;M?U!_<*R*^,
M4:CM?U1_<*^U I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M JAJM*!2E*!2E*!2E*!2E*!2E*!2E*!2E*"@^*K2E I2J=AVU^=!6E*4"E*4
M"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4'QB#
M4=O^J/[A7VKXQ#N.W_5']PK[4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*
M4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*
M4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*
M4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4'QB
M#4=O^J/[A7VKX0SN.U_4']PK[T"E*4"E*4"E*4"E*4"E*M*M&@NI2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E!8XDK3H5AP&)R'9?U;S#K2G=QPTV4*0WU'VK)4>RNW
M;R->"/'CSGTH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H/C$&H[?]
M4?W"OM7QC?Y%K^H/[A7VH%*4H%*4H%*4H%*4H%4U\U6E I2E I2E I2E I2E
M I2E I2E!0?%5I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@
M^,;_ "+?]4?W"OM7RC^&F_ZH_N%?6@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@^,?PTV/]D?W"OM7R8_R;?]4?W"OK0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
M4I04\U6E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*#Y,?Y-O^J/[A7UKXQ_+39_V1_<*^U I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E!\H_EIO^J/[A7UKXQO\BU_5']PK[4"E*4"E*4"E*4"E*4"E*4"E*4"
ME*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"
ME*4"E*4"E6I5V)'Z5=0*4I0*4I0*4I0*53=5H%*4H%*4H%*4H%*4H%*4H%*4
MH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4
MH%*4H%*4H%*4H%*4H/C&_P BW_5']PK[5\(AW':_J#^X5]Z!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*"GS5:M&RH'?C]*NH%*4H%*4H%*4H%
M*4H%*4H%*4H%*4H%*4H+5K#8V?BK4O)42!^0W_[7^ZCZ0IHI(V#X(K\Y>*>7
M\I].W)V2V*X.S,@LN>/7-6%1YLE;_LW*)<'X?T86HJ5U4 P22= :/YF@_1GZ
MA&C5JI#>_DC^8U7Y>W*??;;_ .B_^:\D>R6]S\PLV8+BM7PW"0EX>W.BLDI2
M%Z0"EU[:4@#[OCP-=&6[B"+G&8W:Q7:VY1QI;DPHK,=E>3N2C>@\ZX[(;!]]
MP!2&X:1MLAQ*7EGQ]I$W'6Z7D[^350^@DC9W_*N)>/N,HV=^HOG_ !!Z_9##
MM>*3L8D69+=YEN?2!<<2GD=5N$.)<6@A07VT%'6O%8^=^HJ\8UZR\<NGUTU7
M&JIKF$RVC%?3$$E2$K3)#Q3[2B)!4R0%=DAA1\A7A$4.X0ZD_!-$OHU\[_E7
M#/)=VG\(^H/+[)-E7JYVG/\ 'BO$8SUXEA$>Z)4EMR,V0YM/=:VW-_*00$D#
M8K8,AQ.?@?J7X$PB+D^02H,NRW55P=?N\I?UTF,REQIYU!=TK]HM2NO[I!ZD
M$  9B):N'8Z9*%IV"=?RJOOH_([/Z5Q1<^-EX9ZDN*N.&<KRZ39+AC=P?N3J
M\DFI<E264CH_X>T@[/;JG2/R((KQY+60X5ZA[E@ID9SG=JL^"19_TEHR)V&X
M[+0L-J?5VE-Z[I0!U05>5$]2=D[B)9=X)<2HZ'FKZA[C#)HW'7!4"^Y/?[C/
MBM,?7RI4_P!V;+BID+]U$=SJ%.++0>0ULI[$(!('FO4PGU&8%R-?TV3';VY-
MN9;4Z&'+=*8^U/R>SC20/R_.@DI#J7/CXJ[8WJN/,DY6Y!PGU,Y[;6;DK)V(
M&%_B]ML@84Q$0\J4E"!U3V4I03O:RKR2?W$_$G<#\OY=R/?KNC(K6+)$1:X,
MN)$<M[C+JEN%U+Q*RXI) +:?M&_"@>Q'DI$XAU!_6KT*"QM)V*X0OO*.0V/G
M7U#VN3<\\O=CPYJTRK9!Q^2V$Q?J81>>2ZM22KJ5D%/VKZI2KQH5-4_GA_@:
M9C6!9?'O>37F3;R(&2%AAMN^RTZVPD!>FWSV'VJZ@^2#JLYX7U=#$;JM<RY!
MZTV,,S?/+1D6(7&V6[$X5L=D2D/L/.N2)JE!AD-I<\E2NB 4D@'N5%*0"<^7
MZS;)%@6=:L5R15QN60#&T0414?YR=%)#JEI0I"DGLE:20=$'J15LIT75BG4I
M(!V*YP>]<F&LXW:K@Y;[BQ<9]RN%I%IE+CL.M286C(;+BW0T3I2.H2L]BL:W
MHZK(]3MDQO..29=XO-Z3:\?@64?@3UJ;06Y$U3H9#"@?<=6\2A)2O24=?R'8
MB=4(Z1I4!Y+ZP,=P]F\,7>QWR)?;1<8%MG65$=#[S*YOF,ONVM3:D+';R%'R
MDIUO0K>>(^9K9R[#OBH4*=:I]DN3MIN-ON+:$NQY"-$I)0M:5>"#M*B*MK20
MZ4I50I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E!\8IW';_ *H_N%?:OC%&F6Q_LC^X5]J!
M2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E4._P J"M*4H%*4H/G(;+K12/D_QJ+K+Z:./L>%G$.RR"JSSI5S
MM[DFZ2WUQ9,AM;;[J%..J(*PXLD? 4>X 4 H2K5"-T$&+]&G%1P2]88<?G+Q
MB]3!<+A;UY!<BF3("NW=1,CMY4 H@$ E()!(!K8['P#A^/Y;:LF8C7:5>K6T
MZS"D7*_3YPCI<3U<ZH??6@$I\;UO52?U'F@2$[U^=!%V+>GW$<+S')LILS%S
MB7W)4H3=I:[W->,OHDI02E;JDA2$J(00 4CXU7C7GTHX!D/'2<$N46Z2L8$]
M=S^B7>)78OJ<4ZH^[[GN:+BUKUVUV434U% -6%K[MB@T:Z\.X[?9^&3[G&>N
M<W$I*I=KD3)"W76W5-*:*UK427#U5O[B?N2D_(KS,GX0Q[*>4L?S^:]=$Y'8
M6ELP%,3UMLM(6-.)]L'J>XT%;^0D5)J4JZ^?FH/]14/65\6.I<FZDY"8<F-$
ME.-"6P8<EPMJ2E:4J^YM)&_S%![=_P"!,=RCE:T\BRIUX1DUJ:,>&MBX+2RR
MTH:<0&OW>J]?=^IW6+=O3=8KSR5/SQ%[R.VY+-BI@NR(%S4TD1TD*#24:(">
MP!_7?YU&HY4R?TW\>7NXY39+I<+6+C<)MJB7.Z-+EQ+:WT4AE;I4LNNG;JVT
M;)"$D+4GKXW;)_4]%Q?,95G5CTJ5$BW)RU.RT26T.)=;A?6N+]E>C[09['OO
MR4^ 003)U4L0D'C3C6U\58\NTVMV;):>EOS7Y-PE*DR'WG5E2UK<5Y423K^
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+2E I2E I2E!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>mtva-20251231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 3:11:51 PM-->
<!--Modified on: 3/25/2026 3:11:51 PM-->
<xsd:schema targetNamespace="http://metaviatx.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mtva="http://metaviatx.com/20251231" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://metaviatx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>99940201 - Disclosure - Prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>99940301 - Disclosure - Property and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>99940401 - Disclosure - Current liabilities - Accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails">
        <link:definition>99940602 - Disclosure - Commitments and Contingencies - Operating Lease - Lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" id="DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails">
        <link:definition>99940801 - Disclosure - Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" id="DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails">
        <link:definition>99940901 - Disclosure - Income taxes - Loss before income taxes and Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails">
        <link:definition>99940902 - Disclosure - Income taxes - Reconciliation of income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>99940903 - Disclosure - Income taxes - Significant components of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" id="DisclosureFairValueMeasurementsRecurringBasisDetails">
        <link:definition>99941101 - Disclosure - Fair value measurements - Recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>995200300 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>995200305 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies" id="DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilities" id="DisclosureCurrentLiabilities">
        <link:definition>995210401 - Disclosure - Current liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureRelatedParty" id="DisclosureRelatedParty">
        <link:definition>995210501 - Disclosure - Related party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCommitmentAndContingencies" id="DisclosureCommitmentAndContingencies">
        <link:definition>995210601 - Disclosure - Commitment and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995210701 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995210901 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock" id="DisclosureLossPerShareOfCommonStock">
        <link:definition>995211001 - Disclosure - Loss per share of common stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995211101 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211201 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables" id="DisclosureCurrentLiabilitiesTables">
        <link:definition>99930403 - Disclosure - Current liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>99930603 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>99930703 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables" id="DisclosureLossPerShareOfCommonStockTables">
        <link:definition>99931003 - Disclosure - Loss per share of common stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99931103 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" id="DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails">
        <link:definition>99940403 - Disclosure - Current liabilities - Warrant liabilities - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureRelatedPartyDetails" id="DisclosureRelatedPartyDetails">
        <link:definition>99940501 - Disclosure - Related party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeasesDetails">
        <link:definition>99940601 - Disclosure - Commitments and contingencies - Operating Leases - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails" id="DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails">
        <link:definition>99940603 - Disclosure - Commitments and Contingencies - Contingent payments and license agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" id="DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails">
        <link:definition>99940604 - Disclosure - Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails" id="DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>99940701 - Disclosure - Stockholders' equity - Common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" id="DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails">
        <link:definition>99940702 - Disclosure - Stockholders' equity - Private placement and At the market offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" id="DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails">
        <link:definition>99940703 - Disclosure - Stockholders' equity - Securities purchase agreements and Placement agent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails" id="DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>99940704 - Disclosure - Stockholders' equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" id="DisclosureStockholdersEquityWarrantsNarrativeDetails">
        <link:definition>99940705 - Disclosure - Stockholders' equity - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" id="DisclosureStockholdersEquityStockBasedCompensationDetails">
        <link:definition>99940706 - Disclosure - Stockholders' equity - Stock-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" id="DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails">
        <link:definition>99940707 - Disclosure - Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" id="DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails">
        <link:definition>99940708 - Disclosure - Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails" id="DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails">
        <link:definition>99940710 - Disclosure - Stockholders' equity - Stock-based compensation - Stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails" id="DisclosureStockholdersEquityStockAssumptionsDetails">
        <link:definition>99940711 - Disclosure - Stockholders' equity - Stock - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>99940904 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" id="DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails">
        <link:definition>99941002 - Disclosure - Loss per share of common stock - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" id="DisclosureFairValueMeasurementsNarrativeDetails">
        <link:definition>99941102 - Disclosure - Fair value measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941201 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995210201 - Disclosure - Prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>995210301 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes" id="DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes">
        <link:definition>995210801 - Disclosure - Significant segment expenses and loss before income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>99930203 - Disclosure - Prepaid expenses and other current assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>99930303 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables" id="DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables">
        <link:definition>99930803 - Disclosure - Significant segment expenses and loss before income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99930903 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails" id="DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails">
        <link:definition>99940402 - Disclosure - Current liabilities -Warrant liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails" id="DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>99940709 - Disclosure - Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails" id="DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails">
        <link:definition>99941001 - Disclosure - Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20251231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://metaviatx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd" />
  <xsd:element name="MaximumAggregateOfferingPrice" id="mtva_MaximumAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentageOfSalesAgentCommission" id="mtva_PercentageOfSalesAgentCommission" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AggregateOfferingPrice" id="mtva_AggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuanceCostAtMarketOfferingAgreement" id="mtva_StockIssuanceCostAtMarketOfferingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LicenseAgreementMember" id="mtva_LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanEmployeeEligibilityAge" id="mtva_DefinedContributionPlanEmployeeEligibilityAge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanEmployeeContributionDeferredPercentage" id="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeCompensationVestingPercentageOnContribution" id="mtva_EmployeeCompensationVestingPercentageOnContribution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanEmployerMatchingContributionVestingPercentage" id="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockVotingRightsPerShare" id="mtva_CommonStockVotingRightsPerShare" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" id="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" id="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPlan2019Member" id="mtva_StockPlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DongStMember" id="mtva_DongStMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentCostPolicyPolicyTextBlock" id="mtva_PatentCostPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsLeaseLiability" id="mtva_DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxLiabilitiesRouAsset" id="mtva_DeferredTaxLiabilitiesRouAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsIssued" id="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonesAccrued" id="mtva_MilestonesAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="SecuritiesPurchaseAgreementMember" id="mtva_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Da1726Member" id="mtva_Da1726Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Da1241Member" id="mtva_Da1241Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForFailToCureBreachMayTerminateAgreement" id="mtva_PeriodForFailToCureBreachMayTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CurePeriodForPetitionForBankruptcy" id="mtva_CurePeriodForPetitionForBankruptcy" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CurePeriodForBreachingParty" id="mtva_CurePeriodForBreachingParty" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassUnitsMember" id="mtva_ClassUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassBUnitsMember" id="mtva_ClassBUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesWarrantMember" id="mtva_SeriesWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBWarrantMember" id="mtva_SeriesBWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfCommonStockIssuedPerUnit" id="mtva_NumberOfCommonStockIssuedPerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueCommonStockAndWarrants" id="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesCommonStockAndWarrants" id="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TwoThousandTwentyOnePlanMember" id="mtva_TwoThousandTwentyOnePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="November2022SeriesAndSeriesBWarrantsMember" id="mtva_November2022SeriesAndSeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantLiabilitiesPolicyPolicyTextBlock" id="mtva_WarrantLiabilitiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPlan2022Member" id="mtva_StockPlan2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForTerminationNotice" id="mtva_PeriodForTerminationNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharedServicesAgreementMember" id="mtva_SharedServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewCorporateHeadquartersLeaseMember" id="mtva_NewCorporateHeadquartersLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidExpenseAndOtherCurrentAssetsTextBlock" id="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" id="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" id="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfCommonStockOutstanding" id="mtva_PercentageOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AccruedLiabilitiesClinicalTrialCurrent" id="mtva_AccruedLiabilitiesClinicalTrialCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedExpensesAndOtherLiabilitiesCurrent" id="mtva_AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PreFundedWarrantsMember" id="mtva_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdPercentageForBeneficialOwnership" id="mtva_ThresholdPercentageForBeneficialOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" id="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PipeCommonWarrantsMember" id="mtva_PipeCommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" id="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfPlacementAgentFee" id="mtva_PercentageOfPlacementAgentFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PlacementAgentFeesNonAccountableExpensesAndClearingCosts" id="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PlacementAgentWarrantsMember" id="mtva_PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" id="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PremiumOfOfferingPriceForExercisePricePercentage" id="mtva_PremiumOfOfferingPriceForExercisePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockAndWarrantsIssuanceCosts" id="mtva_StockAndWarrantsIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PlacementAgentContingentWarrantsMember" id="mtva_PlacementAgentContingentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="June2024OfferingMember" id="mtva_June2024OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfSecuritiesPurchaseAgreementsEntered" id="mtva_NumberOfSecuritiesPurchaseAgreementsEntered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WeightedAverageFairValuePerShareOfWarrants" id="mtva_WeightedAverageFairValuePerShareOfWarrants" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPlan20192022AndInducementPlanMember" id="mtva_StockPlan20192022AndInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" id="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CurrentLiabilitiesTextBlock" id="mtva_CurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FairValueOfWarrantsIssuedToPlacementAgent" id="mtva_FairValueOfWarrantsIssuedToPlacementAgent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" id="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SingleReportableSegmentMember" id="mtva_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LaborAndRelatedExpenseResearchAndDevelopment" id="mtva_LaborAndRelatedExpenseResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsultingFeeResearchAndDevelopment" id="mtva_ConsultingFeeResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LegalAndProfessionalFees" id="mtva_LegalAndProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsultingFeeGeneralAndAdministrative" id="mtva_ConsultingFeeGeneralAndAdministrative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LaborAndRelatedExpenseGeneralAndAdministrative" id="mtva_LaborAndRelatedExpenseGeneralAndAdministrative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockAndWarrants" id="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" id="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" id="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" id="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" id="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfGeographicLocation" id="mtva_NumberOfGeographicLocation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceOfStockAndPrefundedWarrants" id="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentsForPlacementAgentFees" id="mtva_PaymentsForPlacementAgentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyExtendedPaymentLiability" id="mtva_RelatedPartyExtendedPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" id="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyAccruedInterestPayable" id="mtva_RelatedPartyAccruedInterestPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyClinicalTrialAccruedLiability" id="mtva_RelatedPartyClinicalTrialAccruedLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" id="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="June2024PreFundedWarrantExercisePrice0.011Member" id="mtva_June2024PreFundedWarrantExercisePrice0.011Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice33000.00Member" id="mtva_WarrantsExercisePrice33000.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice15919.20Member" id="mtva_WarrantsExercisePrice15919.20Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice9900.00Member" id="mtva_WarrantsExercisePrice9900.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="November2022SeriesBWarrantExercisePrice0.00Member" id="mtva_November2022SeriesBWarrantExercisePrice0.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="June2024PlacementAgentWarrantExercisePrice54.0375Member" id="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="June2024SeriesBWarrantExercisePrice43.23Member" id="mtva_June2024SeriesBWarrantExercisePrice43.23Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="June2024SeriesaWarrantExercisePrice43.23Member" id="mtva_June2024SeriesaWarrantExercisePrice43.23Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" id="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingAgreementMember" id="mtva_AtMarketOfferingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DongSocioHoldingCoLtdMember" id="mtva_DongSocioHoldingCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" id="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" id="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PublicOffering2026Member" id="mtva_PublicOffering2026Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantLiabilitiesFairValueDisclosure" id="mtva_WarrantLiabilitiesFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SeriesCWarrantMember" id="mtva_SeriesCWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesDWarrantMember" id="mtva_SeriesDWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonCashLeaseCreditCharge" id="mtva_NonCashLeaseCreditCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" id="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" id="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfWarrantsIssuedPerUnit" id="mtva_NumberOfWarrantsIssuedPerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DeferredTaxAssetsUnrealizedBuiltInLoss" id="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfOwnershipChangesOfOver50" id="mtva_NumberOfOwnershipChangesOfOver50" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="AtMarketOfferingMember" id="mtva_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>36
<FILENAME>mtva-20251231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 3:11:51 PM-->
<!--Modified on: 3/25/2026 3:11:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://metaviatx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <calculationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_639100483092715964" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639100483092715964" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100483092715964" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_639100483092715964" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100483092715964" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_639100483092715964" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639100483092715964" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639100483092715964" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_639100483092715964" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639100483092715964" xlink:to="us-gaap_LiabilitiesCurrent_639100483092715964" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100483092715964" xlink:to="us-gaap_AccountsPayableCurrent_639100483092715964" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedLiabilitiesClinicalTrialCurrent" xlink:label="mtva_AccruedLiabilitiesClinicalTrialCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100483092715964" xlink:to="mtva_AccruedLiabilitiesClinicalTrialCurrent_639100483092715964" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100483092715964" xlink:to="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_639100483092715964" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100483092715964" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_639100483092715964" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100483092715964" xlink:to="us-gaap_OtherLiabilitiesCurrent_639100483092715964" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_639100483092715964" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639100483092715964" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_639100483092715964" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483092715964" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_639100483092715964" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_639100483092715964" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100483092715964" xlink:to="us-gaap_AdditionalPaidInCapital_639100483092715964" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100483092715964" xlink:to="us-gaap_PreferredStockValue_639100483092715964" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100483092715964" xlink:to="us-gaap_CommonStockValue_639100483092715964" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639100483092715964" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_639100483092715964" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639100483092715964" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639100483092872212" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483092872212" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_639100483092872212" xlink:to="us-gaap_InterestIncomeExpenseNet_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_639100483092872212" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639100483092872212" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483092872212" xlink:to="us-gaap_OperatingIncomeLoss_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_639100483092872212" xlink:to="us-gaap_OperatingExpenses_639100483092872212" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639100483092872212" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_639100483092872212" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639100483092872212" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_NetIncomeLoss_639100483092872212" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_ShareBasedCompensation_639100483092872212" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NonCashLeaseCreditCharge" xlink:label="mtva_NonCashLeaseCreditCharge_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="mtva_NonCashLeaseCreditCharge_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_Depreciation_639100483092872212" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639100483092872212" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100483092872212" order="6" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639100483092872212" order="7" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483092872212" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100483092872212" order="8" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100483092872212" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100483092872212" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639100483092872212" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_639100483092872212" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" xlink:to="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483092872212" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483092872212" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100483092872212" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Prepaid expenses and other current assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts_639100483092872212" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639100483092872212" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Current liabilities - Accrued expenses and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639100483092872212" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Commitments and Contingencies - Operating Lease - Lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483092872212" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LegalAndProfessionalFees" xlink:label="mtva_LegalAndProfessionalFees_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_1" xlink:to="mtva_LegalAndProfessionalFees_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeGeneralAndAdministrative" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_1" xlink:to="mtva_ConsultingFeeGeneralAndAdministrative_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseGeneralAndAdministrative" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_1" xlink:to="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense_1" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_639100483092872212" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_1" xlink:to="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_1" xlink:to="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_1" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseResearchAndDevelopment" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_1" xlink:to="mtva_LaborAndRelatedExpenseResearchAndDevelopment_639100483092872212" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeResearchAndDevelopment" xlink:label="mtva_ConsultingFeeResearchAndDevelopment_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_1" xlink:to="mtva_ConsultingFeeResearchAndDevelopment_639100483092872212" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Income taxes - Loss before income taxes and Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_639100483092872212" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Income taxes - Reconciliation of income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100483092872212" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100483092872212" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Income taxes - Significant components of deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_639100483092872212" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_639100483092872212" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxLiabilitiesRouAsset" xlink:label="mtva_DeferredTaxLiabilitiesRouAsset_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_639100483092872212" xlink:to="mtva_DeferredTaxLiabilitiesRouAsset_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsGross_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsUnrealizedBuiltInLoss" xlink:label="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639100483092872212" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsOther_639100483092872212" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_639100483092872212" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsLeaseLiability" xlink:label="mtva_DeferredTaxAssetsLeaseLiability_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="mtva_DeferredTaxAssetsLeaseLiability_639100483092872212" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100483092872212" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_639100483092872212" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100483092872212" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_639100483092872212" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639100483092872212" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Fair value measurements - Recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639100483092872212" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantLiabilitiesFairValueDisclosure" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure_639100483092872212" />
    <calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="mtva_WarrantLiabilitiesFairValueDisclosure_639100483092872212" order="1" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>37
<FILENAME>mtva-20251231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 3:11:51 PM-->
<!--Modified on: 3/25/2026 3:11:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureRelatedPartyDetails" roleURI="http://metaviatx.com/role/DisclosureRelatedPartyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityWarrantsNarrativeDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockAssumptionsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurementsNarrativeDetails" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://metaviatx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://metaviatx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_FairValueAdjustmentOfWarrants_2" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:title="us-gaap_RelatedPartyMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" xlink:title="srt_AffiliatedEntityMember" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyMember" xlink:to="srt_AffiliatedEntityMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyMember To srt_AffiliatedEntityMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_3" xlink:title="us-gaap_RelatedPartyDomain_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_1" xlink:title="us-gaap_RelatedPartyMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyDomain_3" xlink:to="us-gaap_RelatedPartyMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_RelatedPartyDomain_3 To us-gaap_RelatedPartyMember_1" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_10" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_10" />
    <link:loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongStMember" xlink:label="mtva_DongStMember_2" xlink:title="nrbo_DongStMember_2" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_10" xlink:to="mtva_DongStMember_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:srt_RepurchaseAgreementCounterpartyNameDomain_10 To nrbo_DongStMember_2" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://metaviatx.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AircraftTypeAxis" xlink:label="AircraftTypeAxis" xlink:title="AircraftTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AircraftTypeMember" xlink:label="AircraftTypeMember" xlink:title="AircraftTypeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AircraftTypeAxis" xlink:to="AircraftTypeMember" xlink:title="definition: AircraftTypeAxis to AircraftTypeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationDocumentAxis" xlink:label="DocumentInformationDocumentAxis" xlink:title="DocumentInformationDocumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentDomain" xlink:label="DocumentDomain" xlink:title="DocumentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DocumentInformationDocumentAxis" xlink:to="DocumentDomain" xlink:title="definition: DocumentInformationDocumentAxis to DocumentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedAndNonrelatedPartyStatusAxis" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusAxis_1" xlink:title="us-gaap_RelatedAndNonrelatedPartyStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedAndNonrelatedPartyStatusDomain" xlink:label="us-gaap_RelatedAndNonrelatedPartyStatusDomain_1" xlink:title="us-gaap_RelatedAndNonrelatedPartyStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedAndNonrelatedPartyStatusAxis_1" xlink:to="us-gaap_RelatedAndNonrelatedPartyStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedAndNonrelatedPartyStatusAxis_1 To us-gaap_RelatedAndNonrelatedPartyStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingAgreementMember" xlink:label="mtva_AtMarketOfferingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mtva_AtMarketOfferingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NonCashLeaseCreditCharge" xlink:label="mtva_NonCashLeaseCreditCharge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mtva_NonCashLeaseCreditCharge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="mtva_FairValueOfWarrantsIssuedToPlacementAgent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="mtva_FairValueOfWarrantsIssuedToPlacementAgent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfGeographicLocation" xlink:label="mtva_NumberOfGeographicLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_NumberOfGeographicLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - Current liabilities - Warrant liabilities - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesAndSeriesBWarrantsMember" xlink:label="mtva_November2022SeriesAndSeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_November2022SeriesAndSeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureRelatedPartyDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Related party (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LicenseAgreementMember" xlink:label="mtva_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mtva_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_Da1726Member" xlink:label="mtva_Da1726Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="mtva_LicenseAgreementMember" xlink:to="mtva_Da1726Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_Da1241Member" xlink:label="mtva_Da1241Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="mtva_LicenseAgreementMember" xlink:to="mtva_Da1241Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SharedServicesAgreementMember" xlink:label="mtva_SharedServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mtva_SharedServicesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongStMember" xlink:label="mtva_DongStMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mtva_DongStMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongSocioHoldingCoLtdMember" xlink:label="mtva_DongSocioHoldingCoLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mtva_DongSocioHoldingCoLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="mtva_PeriodForFailToCureBreachMayTerminateAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_PeriodForFailToCureBreachMayTerminateAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurePeriodForBreachingParty" xlink:label="mtva_CurePeriodForBreachingParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_CurePeriodForBreachingParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PeriodForTerminationNotice" xlink:label="mtva_PeriodForTerminationNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_PeriodForTerminationNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurePeriodForPetitionForBankruptcy" xlink:label="mtva_CurePeriodForPetitionForBankruptcy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_CurePeriodForPetitionForBankruptcy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_MilestonesAccrued" xlink:label="mtva_MilestonesAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_MilestonesAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfCommonStockOutstanding" xlink:label="mtva_PercentageOfCommonStockOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_PercentageOfCommonStockOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiability" xlink:label="mtva_RelatedPartyExtendedPaymentLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_RelatedPartyExtendedPaymentLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyAccruedInterestPayable" xlink:label="mtva_RelatedPartyAccruedInterestPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_RelatedPartyAccruedInterestPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyClinicalTrialAccruedLiability" xlink:label="mtva_RelatedPartyClinicalTrialAccruedLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mtva_RelatedPartyClinicalTrialAccruedLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Commitments and contingencies - Operating Leases - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NewCorporateHeadquartersLeaseMember" xlink:label="mtva_NewCorporateHeadquartersLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mtva_NewCorporateHeadquartersLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="mtva_DefinedContributionPlanEmployeeEligibilityAge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mtva_DefinedContributionPlanEmployeeEligibilityAge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:label="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:label="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EmployeeCompensationVestingPercentageOnContribution" xlink:label="mtva_EmployeeCompensationVestingPercentageOnContribution" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="mtva_EmployeeCompensationVestingPercentageOnContribution" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Stockholders' equity - Private placement and At the market offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingAgreementMember" xlink:label="mtva_AtMarketOfferingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mtva_AtMarketOfferingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice33000.00Member" xlink:label="mtva_WarrantsExercisePrice33000.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_WarrantsExercisePrice33000.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice15919.20Member" xlink:label="mtva_WarrantsExercisePrice15919.20Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_WarrantsExercisePrice15919.20Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice9900.00Member" xlink:label="mtva_WarrantsExercisePrice9900.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_WarrantsExercisePrice9900.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" xlink:label="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PaymentsForPlacementAgentFees" xlink:label="mtva_PaymentsForPlacementAgentFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PaymentsForPlacementAgentFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_MaximumAggregateOfferingPrice" xlink:label="mtva_MaximumAggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_MaximumAggregateOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfSalesAgentCommission" xlink:label="mtva_PercentageOfSalesAgentCommission" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PercentageOfSalesAgentCommission" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AggregateOfferingPrice" xlink:label="mtva_AggregateOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_AggregateOfferingPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - Stockholders' equity - Securities purchase agreements and Placement agent (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SecuritiesPurchaseAgreementMember" xlink:label="mtva_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mtva_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesWarrantMember" xlink:label="mtva_SeriesWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_SeriesWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesBWarrantMember" xlink:label="mtva_SeriesBWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_SeriesBWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PipeCommonWarrantsMember" xlink:label="mtva_PipeCommonWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PipeCommonWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentWarrantsMember" xlink:label="mtva_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentContingentWarrantsMember" xlink:label="mtva_PlacementAgentContingentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PlacementAgentContingentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024OfferingMember" xlink:label="mtva_June2024OfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mtva_June2024OfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfSecuritiesPurchaseAgreementsEntered" xlink:label="mtva_NumberOfSecuritiesPurchaseAgreementsEntered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_NumberOfSecuritiesPurchaseAgreementsEntered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PaymentsForPlacementAgentFees" xlink:label="mtva_PaymentsForPlacementAgentFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PaymentsForPlacementAgentFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPercentageForBeneficialOwnership" xlink:label="mtva_ThresholdPercentageForBeneficialOwnership" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_ThresholdPercentageForBeneficialOwnership" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" xlink:label="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfPlacementAgentFee" xlink:label="mtva_PercentageOfPlacementAgentFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PercentageOfPlacementAgentFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" xlink:label="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" xlink:label="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PremiumOfOfferingPriceForExercisePricePercentage" xlink:label="mtva_PremiumOfOfferingPriceForExercisePricePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_PremiumOfOfferingPriceForExercisePricePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WeightedAverageFairValuePerShareOfWarrants" xlink:label="mtva_WeightedAverageFairValuePerShareOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="mtva_WeightedAverageFairValuePerShareOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="99940704 - Disclosure - Stockholders' equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice33000.00Member" xlink:label="mtva_WarrantsExercisePrice33000.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_WarrantsExercisePrice33000.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice15919.20Member" xlink:label="mtva_WarrantsExercisePrice15919.20Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_WarrantsExercisePrice15919.20Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice9900.00Member" xlink:label="mtva_WarrantsExercisePrice9900.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_WarrantsExercisePrice9900.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesaWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesaWarrantExercisePrice43.23Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024SeriesaWarrantExercisePrice43.23Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xlink:type="extended" xlink:title="99940705 - Disclosure - Stockholders' equity - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" xlink:type="extended" xlink:title="99940706 - Disclosure - Stockholders' equity - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" xlink:type="extended" xlink:title="99940707 - Disclosure - Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2022Member" xlink:label="mtva_StockPlan2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mtva_StockPlan2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2019Member" xlink:label="mtva_StockPlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="mtva_StockPlan2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" xlink:type="extended" xlink:title="99940708 - Disclosure - Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_TwoThousandTwentyOnePlanMember" xlink:label="mtva_TwoThousandTwentyOnePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="mtva_TwoThousandTwentyOnePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2022Member" xlink:label="mtva_StockPlan2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="mtva_StockPlan2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan20192022AndInducementPlanMember" xlink:label="mtva_StockPlan20192022AndInducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="mtva_StockPlan20192022AndInducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails" xlink:type="extended" xlink:title="99940711 - Disclosure - Stockholders' equity - Stock - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentWarrantsMember" xlink:label="mtva_PlacementAgentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PlacementAgentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentContingentWarrantsMember" xlink:label="mtva_PlacementAgentContingentWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PlacementAgentContingentWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024OfferingMember" xlink:label="mtva_June2024OfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mtva_June2024OfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SingleReportableSegmentMember" xlink:label="mtva_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="mtva_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseResearchAndDevelopment" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mtva_LaborAndRelatedExpenseResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeResearchAndDevelopment" xlink:label="mtva_ConsultingFeeResearchAndDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="mtva_ConsultingFeeResearchAndDevelopment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LegalAndProfessionalFees" xlink:label="mtva_LegalAndProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mtva_LegalAndProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeGeneralAndAdministrative" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mtva_ConsultingFeeGeneralAndAdministrative" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseGeneralAndAdministrative" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mtva_LaborAndRelatedExpenseGeneralAndAdministrative" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Income taxes - Loss before income taxes and Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DomesticCountryMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalTaxJurisdictionOtherMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DomesticCountryMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxExaminationDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfOwnershipChangesOfOver50" xlink:label="mtva_NumberOfOwnershipChangesOfOver50" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="mtva_NumberOfOwnershipChangesOfOver50" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" xlink:label="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" xlink:label="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Loss per share of common stock - Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Fair value measurements - Recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantLiabilitiesFairValueDisclosure" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="mtva_WarrantLiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Fair value measurements - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://metaviatx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesCWarrantMember" xlink:label="mtva_SeriesCWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_SeriesCWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesDWarrantMember" xlink:label="mtva_SeriesDWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="mtva_SeriesDWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PublicOffering2026Member" xlink:label="mtva_PublicOffering2026Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mtva_PublicOffering2026Member" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingMember" xlink:label="mtva_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="mtva_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassUnitsMember" xlink:label="mtva_ClassUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mtva_ClassUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassBUnitsMember" xlink:label="mtva_ClassBUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mtva_ClassBUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfCommonStockIssuedPerUnit" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mtva_NumberOfCommonStockIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfWarrantsIssuedPerUnit" xlink:label="mtva_NumberOfWarrantsIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mtva_NumberOfWarrantsIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>38
<FILENAME>mtva-20251231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 3:11:51 PM-->
<!--Modified on: 3/25/2026 3:11:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedLiabilitiesClinicalTrialCurrent" xlink:label="mtva_AccruedLiabilitiesClinicalTrialCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_AccruedLiabilitiesClinicalTrialCurrent" xlink:to="mtva_AccruedLiabilitiesClinicalTrialCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_AccruedLiabilitiesClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_AccruedLiabilitiesClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Clinical Trial, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_AccruedLiabilitiesClinicalTrialCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued expenses and liabilities classified as other, due within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses And Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As of ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">As of beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current, Related Party [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, short-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, long-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 6)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2025 and 2024; 2,308,294 and 785,194 shares issued and outstanding as of December 31, 2025 and 2024, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock, basic (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock, diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares of common stock outstanding:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares of common stock, basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares of common stock, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares of common stock, diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares of common stock, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:to="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of common stock and warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Common Stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:to="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock and warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Common Stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of placement agent warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock from exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under an at the market offering agreement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock for vested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock for vested restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockAndWarrantsIssuanceCosts" xlink:label="mtva_StockAndWarrantsIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockAndWarrantsIssuanceCosts" xlink:to="mtva_StockAndWarrantsIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockAndWarrantsIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of issuance costs related to stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockAndWarrantsIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock And Warrants Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_StockAndWarrantsIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and warrants issuance costs</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuanceCostAtMarketOfferingAgreement" xlink:label="mtva_StockIssuanceCostAtMarketOfferingAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockIssuanceCostAtMarketOfferingAgreement" xlink:to="mtva_StockIssuanceCostAtMarketOfferingAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockIssuanceCostAtMarketOfferingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of issuance costs related to at the market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockIssuanceCostAtMarketOfferingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Cost, At The Market Offering Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_StockIssuanceCostAtMarketOfferingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private placement offering</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingAgreementMember" xlink:label="mtva_AtMarketOfferingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_AtMarketOfferingAgreementMember" xlink:to="mtva_AtMarketOfferingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_AtMarketOfferingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to at-the market offering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_AtMarketOfferingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_AtMarketOfferingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NonCashLeaseCreditCharge" xlink:label="mtva_NonCashLeaseCreditCharge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NonCashLeaseCreditCharge" xlink:to="mtva_NonCashLeaseCreditCharge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NonCashLeaseCreditCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash lease (credit) charge.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NonCashLeaseCreditCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Lease (Credit) Charge</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NonCashLeaseCreditCharge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease (credit) charge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of issuance costs in connection with the sale of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock under an at the market offering agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment, Tax Withholding, Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental non-cash investing and financing transactions:</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="mtva_FairValueOfWarrantsIssuedToPlacementAgent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_FairValueOfWarrantsIssuedToPlacementAgent" xlink:to="mtva_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of fair value of warrants issued to placement agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants issued to placement agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants issued to placement agent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business, basis of presentation, new accounting standards and summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business, basis of presentation, new accounting standards and summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:label="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:to="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for prepaid expense and other current assets at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurrentLiabilitiesTextBlock" xlink:label="mtva_CurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_CurrentLiabilitiesTextBlock" xlink:to="mtva_CurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_CurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for current liabilities at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_CurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_CurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant segment expenses and loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant segment expenses and loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New accounting standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimates and assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:label="mtva_WarrantLiabilitiesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:to="mtva_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for determining the warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PatentCostPolicyPolicyTextBlock" xlink:label="mtva_PatentCostPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PatentCostPolicyPolicyTextBlock" xlink:to="mtva_PatentCostPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PatentCostPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PatentCostPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Cost Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PatentCostPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs Capitalized Prepaid And Other Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding awards issued pursuant to our stock-based award plans and inducement plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of restricted stock units ("RSUs") and related transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of the status of outstanding and exercisable options and related transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in the Black Scholes option-pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant segment expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of computation of basic and diluted loss per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding securities which were not included in the calculation of diluted earnings per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value measurements on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business, basis of presentation, new accounting standards and summary of significant accounting policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split, ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reportable segments</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfGeographicLocation" xlink:label="mtva_NumberOfGeographicLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NumberOfGeographicLocation" xlink:to="mtva_NumberOfGeographicLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NumberOfGeographicLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of geographic location reported by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NumberOfGeographicLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Geographic Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NumberOfGeographicLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of geographic location in the United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred equity offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee related costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional service fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesAndSeriesBWarrantsMember" xlink:label="mtva_November2022SeriesAndSeriesBWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_November2022SeriesAndSeriesBWarrantsMember" xlink:to="mtva_November2022SeriesAndSeriesBWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_November2022SeriesAndSeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to series A and series B warrants issued in November 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_November2022SeriesAndSeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series A and B</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_November2022SeriesAndSeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series A and B</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LicenseAgreementMember" xlink:label="mtva_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_LicenseAgreementMember" xlink:to="mtva_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exclusive worldwide license to certain patent rights to make, use, sell, offer for sale and import product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 License Agreements</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_Da1726Member" xlink:label="mtva_Da1726Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_Da1726Member" xlink:to="mtva_Da1726Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_Da1726Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The License Agreement covers the rights to DA-1726 for treatment of obesity and NASH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_Da1726Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1726 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_Da1726Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1726</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_Da1241Member" xlink:label="mtva_Da1241Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_Da1241Member" xlink:to="mtva_Da1241Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_Da1241Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The License Agreement covers the rights to DA-1241 for treatment of NASH .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_Da1241Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1241 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_Da1241Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1241</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SharedServicesAgreementMember" xlink:label="mtva_SharedServicesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SharedServicesAgreementMember" xlink:to="mtva_SharedServicesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SharedServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Shared Services Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SharedServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shared Services Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_SharedServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shared Services Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongStMember" xlink:label="mtva_DongStMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DongStMember" xlink:to="mtva_DongStMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DongStMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Dong-A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DongStMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DongStMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongSocioHoldingCoLtdMember" xlink:label="mtva_DongSocioHoldingCoLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DongSocioHoldingCoLtdMember" xlink:to="mtva_DongSocioHoldingCoLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DongSocioHoldingCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Dong-A Socio Holdings Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DongSocioHoldingCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong A Socio Holding Co Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DongSocioHoldingCoLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong A Socio Holding Co Ltd</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:to="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Developmental And Regulatory Milestone To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Developmental and regulatory milestone payment eligible to be received</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="mtva_PeriodForFailToCureBreachMayTerminateAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PeriodForFailToCureBreachMayTerminateAgreement" xlink:to="mtva_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for failing to cure the beach, the agreement may get terminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Fail to Cure the Breach, May Terminate Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for failing to cure the beach, the agreement may get terminated</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurePeriodForBreachingParty" xlink:label="mtva_CurePeriodForBreachingParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_CurePeriodForBreachingParty" xlink:to="mtva_CurePeriodForBreachingParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_CurePeriodForBreachingParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cure period for beaching party if cannot be cured within the 60-day period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_CurePeriodForBreachingParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Period for Breaching Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_CurePeriodForBreachingParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure period for beaching party if cannot be cured within the 60-day period</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PeriodForTerminationNotice" xlink:label="mtva_PeriodForTerminationNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PeriodForTerminationNotice" xlink:to="mtva_PeriodForTerminationNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PeriodForTerminationNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for petition for termination notice for the other party's material breach that is not cured.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PeriodForTerminationNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Termination Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PeriodForTerminationNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for termination notice when material breach not cured</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurePeriodForPetitionForBankruptcy" xlink:label="mtva_CurePeriodForPetitionForBankruptcy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_CurePeriodForPetitionForBankruptcy" xlink:to="mtva_CurePeriodForPetitionForBankruptcy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_CurePeriodForPetitionForBankruptcy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cure period for petition for bankruptcy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_CurePeriodForPetitionForBankruptcy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Period for Petition for Bankruptcy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_CurePeriodForPetitionForBankruptcy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure period for petition for bankruptcy</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_MilestonesAccrued" xlink:label="mtva_MilestonesAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_MilestonesAccrued" xlink:to="mtva_MilestonesAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_MilestonesAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to milestones accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_MilestonesAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_MilestonesAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestones accrued</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfCommonStockOutstanding" xlink:label="mtva_PercentageOfCommonStockOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PercentageOfCommonStockOutstanding" xlink:to="mtva_PercentageOfCommonStockOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Percentage of common stock outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current, Related Party, Name [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiability" xlink:label="mtva_RelatedPartyExtendedPaymentLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_RelatedPartyExtendedPaymentLiability" xlink:to="mtva_RelatedPartyExtendedPaymentLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_RelatedPartyExtendedPaymentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable to related party under extended payment terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_RelatedPartyExtendedPaymentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Extended Payment Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_RelatedPartyExtendedPaymentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended terms payable</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" xlink:to="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable to related party under extended payment terms due in six months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Extended Payment Liability, Payable In Six Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended terms amount to be paid on March 31, 2026</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" xlink:to="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable to related party under extended payment terms due in next twelve months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Extended Payment Liability, Payable In Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended terms amount to be paid on September 30, 2026</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyAccruedInterestPayable" xlink:label="mtva_RelatedPartyAccruedInterestPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_RelatedPartyAccruedInterestPayable" xlink:to="mtva_RelatedPartyAccruedInterestPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_RelatedPartyAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest payable to related party under extended payment terms.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_RelatedPartyAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Accrued Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_RelatedPartyAccruedInterestPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended terms, Accrued interest payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed interest rate</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyClinicalTrialAccruedLiability" xlink:label="mtva_RelatedPartyClinicalTrialAccruedLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_RelatedPartyClinicalTrialAccruedLiability" xlink:to="mtva_RelatedPartyClinicalTrialAccruedLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_RelatedPartyClinicalTrialAccruedLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liability payable to related party for clinical trial services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_RelatedPartyClinicalTrialAccruedLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party, Clinical Trial Accrued Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_RelatedPartyClinicalTrialAccruedLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable in clinical trial accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NewCorporateHeadquartersLeaseMember" xlink:label="mtva_NewCorporateHeadquartersLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NewCorporateHeadquartersLeaseMember" xlink:to="mtva_NewCorporateHeadquartersLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NewCorporateHeadquartersLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to New Corporate Headquarters Lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NewCorporateHeadquartersLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Corporate Headquarters Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cash payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity of the lease liability was as follows (in thousands):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less effect of discounting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain Contingency, Unrecorded Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent assets recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="mtva_DefinedContributionPlanEmployeeEligibilityAge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DefinedContributionPlanEmployeeEligibilityAge" xlink:to="mtva_DefinedContributionPlanEmployeeEligibilityAge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee eligibility age criteria under defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employee Eligibility Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age of employee to cover under the plan</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:label="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:to="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employee contributions may be deferred to a defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employee Contribution Deferred, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation deferred percentage</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:label="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:to="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer matches vesting period</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EmployeeCompensationVestingPercentageOnContribution" xlink:label="mtva_EmployeeCompensationVestingPercentageOnContribution" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_EmployeeCompensationVestingPercentageOnContribution" xlink:to="mtva_EmployeeCompensationVestingPercentageOnContribution_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_EmployeeCompensationVestingPercentageOnContribution_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employee contribution vested on contribution made by employee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_EmployeeCompensationVestingPercentageOnContribution_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Compensation Vesting Percentage on Contribution</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_EmployeeCompensationVestingPercentageOnContribution_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employee contribution vested on their contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of discretionary matching contributions on employee deferrals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CommonStockVotingRightsPerShare" xlink:label="mtva_CommonStockVotingRightsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_CommonStockVotingRightsPerShare" xlink:to="mtva_CommonStockVotingRightsPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the voting rights per share for common stock of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Voting Rights Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, vote per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockAbstract" xlink:to="us-gaap_DividendsCommonStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock, Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfCommonStockIssuedPerUnit" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NumberOfCommonStockIssuedPerUnit" xlink:to="mtva_NumberOfCommonStockIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of common stock per units issued under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Common Stock Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock per unit</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PreFundedWarrantsMember" xlink:to="mtva_PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded Warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice33000.00Member" xlink:label="mtva_WarrantsExercisePrice33000.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_WarrantsExercisePrice33000.00Member" xlink:to="mtva_WarrantsExercisePrice33000.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_WarrantsExercisePrice33000.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price $33,000.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_WarrantsExercisePrice33000.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 33,000.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_WarrantsExercisePrice33000.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 33,000.00</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice15919.20Member" xlink:label="mtva_WarrantsExercisePrice15919.20Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_WarrantsExercisePrice15919.20Member" xlink:to="mtva_WarrantsExercisePrice15919.20Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_WarrantsExercisePrice15919.20Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price $15,919.20.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_WarrantsExercisePrice15919.20Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 15,919.20 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_WarrantsExercisePrice15919.20Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 15,919.20</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice9900.00Member" xlink:label="mtva_WarrantsExercisePrice9900.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_WarrantsExercisePrice9900.00Member" xlink:to="mtva_WarrantsExercisePrice9900.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_WarrantsExercisePrice9900.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price $9,900.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_WarrantsExercisePrice9900.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 9,900.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_WarrantsExercisePrice9900.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 9,900.00</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to November 2022 Series B warrants with exercise price of $ 0.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series B Warrant Exercise Price 0.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series B Warrant Exercise Price 0.00</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series B</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xlink:to="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants issued through placement agents in June 2024 with exercise price $ 54.0375.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Placement Agent, Warrant Exercise Price 54.0375 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Placement Agent, Warrant Exercise Price 54.0375</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants issued as series B in June 2024 with exercise price $ 43.23.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Series B, Warrant Exercise Price 43.23 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Series B, Warrant Exercise Price 43.23</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants issued through pre-funded warrants scheme in June 2024 with exercise price $ 0.011.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Pre-Funded, Warrant Exercise Price 0.011 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Pre-Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Pre-Funded, Warrant Exercise Price 0.011</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" xlink:label="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" xlink:to="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net cash inflow from issuance of stock and pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Stock And Prefunded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PaymentsForPlacementAgentFees" xlink:label="mtva_PaymentsForPlacementAgentFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PaymentsForPlacementAgentFees" xlink:to="mtva_PaymentsForPlacementAgentFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PaymentsForPlacementAgentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow made during the period for placement agent fees in connection with the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PaymentsForPlacementAgentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments For Placement Agent Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PaymentsForPlacementAgentFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash fee payment to the placement agent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original issue price, per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering shares (Per share)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of pre-funded warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_MaximumAggregateOfferingPrice" xlink:label="mtva_MaximumAggregateOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_MaximumAggregateOfferingPrice" xlink:to="mtva_MaximumAggregateOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum aggregate offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_MaximumAggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfSalesAgentCommission" xlink:label="mtva_PercentageOfSalesAgentCommission" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PercentageOfSalesAgentCommission" xlink:to="mtva_PercentageOfSalesAgentCommission_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PercentageOfSalesAgentCommission_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of sales agent commission.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PercentageOfSalesAgentCommission_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Sales Agent Commission</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PercentageOfSalesAgentCommission_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of sales agent commission</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate net proceeds</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AggregateOfferingPrice" xlink:label="mtva_AggregateOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_AggregateOfferingPrice" xlink:to="mtva_AggregateOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_AggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of common stock that the company is still authorized to issue or remaining available for issue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_AggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_AggregateOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024OfferingMember" xlink:label="mtva_June2024OfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_June2024OfferingMember" xlink:to="mtva_June2024OfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_June2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to June 2024 offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_June2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_June2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SecuritiesPurchaseAgreementMember" xlink:label="mtva_SecuritiesPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SecuritiesPurchaseAgreementMember" xlink:to="mtva_SecuritiesPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Securities Purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesWarrantMember" xlink:label="mtva_SeriesWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SeriesWarrantMember" xlink:to="mtva_SeriesWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SeriesWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SeriesWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A warrant</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesBWarrantMember" xlink:label="mtva_SeriesBWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SeriesBWarrantMember" xlink:to="mtva_SeriesBWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SeriesBWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series B Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SeriesBWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_SeriesBWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PipeCommonWarrantsMember" xlink:label="mtva_PipeCommonWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PipeCommonWarrantsMember" xlink:to="mtva_PipeCommonWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PipeCommonWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to PIPE common warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PipeCommonWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PIPE Common Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PipeCommonWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PIPE common warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentWarrantsMember" xlink:label="mtva_PlacementAgentWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PlacementAgentWarrantsMember" xlink:to="mtva_PlacementAgentWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PlacementAgentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement agent warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentContingentWarrantsMember" xlink:label="mtva_PlacementAgentContingentWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PlacementAgentContingentWarrantsMember" xlink:to="mtva_PlacementAgentContingentWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PlacementAgentContingentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Placement Agent Contingent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PlacementAgentContingentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Contingent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PlacementAgentContingentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Contingent Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_PlacementAgentContingentWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement agent contingent warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfSecuritiesPurchaseAgreementsEntered" xlink:label="mtva_NumberOfSecuritiesPurchaseAgreementsEntered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NumberOfSecuritiesPurchaseAgreementsEntered" xlink:to="mtva_NumberOfSecuritiesPurchaseAgreementsEntered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NumberOfSecuritiesPurchaseAgreementsEntered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of securities purchase agreements entered during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NumberOfSecuritiesPurchaseAgreementsEntered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Securities Purchase Agreements Entered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NumberOfSecuritiesPurchaseAgreementsEntered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of common stock issuable for Issued and outstanding warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xlink:to="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold period following the public announcement of the Company receiving positive Phase 1 multiple ascending dose ("MAD") data for expiry of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period Following the Public Announcement of Receiving Positive Phase 1 Multiple Ascending Dose Data For Expiry of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period following the public announcement of receiving positive phase 1 multiple ascending dose data for expiry of warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPercentageForBeneficialOwnership" xlink:label="mtva_ThresholdPercentageForBeneficialOwnership" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ThresholdPercentageForBeneficialOwnership" xlink:to="mtva_ThresholdPercentageForBeneficialOwnership_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ThresholdPercentageForBeneficialOwnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold percentage for beneficial ownership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ThresholdPercentageForBeneficialOwnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage For Beneficial Ownership</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ThresholdPercentageForBeneficialOwnership_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of outstanding common stock</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" xlink:label="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" xlink:to="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The effective period for changing beneficial ownership limitation from receipt of written notice from holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Period For Changing Beneficial Ownership Limitation From Receipt of Written Notice From Holder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days written notice</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfPlacementAgentFee" xlink:label="mtva_PercentageOfPlacementAgentFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PercentageOfPlacementAgentFee" xlink:to="mtva_PercentageOfPlacementAgentFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PercentageOfPlacementAgentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of placement agent gee on gross proceeds of offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PercentageOfPlacementAgentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Placement Agent Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PercentageOfPlacementAgentFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of placement agent fee</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" xlink:label="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" xlink:to="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of non-accountable expenses and clearing costs as placement agent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agent Fees, Non-accountable Expenses And Clearing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-accountable expenses and clearing costs</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" xlink:label="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" xlink:to="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of shares exercisable through warrants as a percent on total shares and warrants sold in the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Shares and Warrants Sold in Offering, Maximum Shares exercisable Through Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock sold</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PremiumOfOfferingPriceForExercisePricePercentage" xlink:label="mtva_PremiumOfOfferingPriceForExercisePricePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PremiumOfOfferingPriceForExercisePricePercentage" xlink:to="mtva_PremiumOfOfferingPriceForExercisePricePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PremiumOfOfferingPriceForExercisePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The premium of offering price for warrants exercise price in percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PremiumOfOfferingPriceForExercisePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium of Offering Price For Exercise Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PremiumOfOfferingPriceForExercisePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium of offering price per share (as a percent)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WeightedAverageFairValuePerShareOfWarrants" xlink:label="mtva_WeightedAverageFairValuePerShareOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_WeightedAverageFairValuePerShareOfWarrants" xlink:to="mtva_WeightedAverageFairValuePerShareOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_WeightedAverageFairValuePerShareOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value per share of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_WeightedAverageFairValuePerShareOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Fair Value Per Share of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_WeightedAverageFairValuePerShareOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash issuance cost</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesaWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesaWarrantExercisePrice43.23Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_June2024SeriesaWarrantExercisePrice43.23Member" xlink:to="mtva_June2024SeriesaWarrantExercisePrice43.23Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_June2024SeriesaWarrantExercisePrice43.23Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants issued as series A in June 2024 with exercise price $ 43.23.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_June2024SeriesaWarrantExercisePrice43.23Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 SeriesA , Warrant Exercise Price 43.23 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_June2024SeriesaWarrantExercisePrice43.23Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">June 2024 Series A , Warrant Exercise Price 43.23</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded Warrants were exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xlink:to="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised for the securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Securities Called By Each Warrant Or Right, Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-Funded warrants issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2019Member" xlink:label="mtva_StockPlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockPlan2019Member" xlink:to="mtva_StockPlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2019 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_StockPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2022Member" xlink:label="mtva_StockPlan2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockPlan2022Member" xlink:to="mtva_StockPlan2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2022 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Plan 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_StockPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares added (in shares)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period over which the shares reserved for further issuance under share based compensation will increase annually.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Period Number of shares reserved for further issuance Increase Annually</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of automatic increase in shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the common shares outstanding (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_TwoThousandTwentyOnePlanMember" xlink:label="mtva_TwoThousandTwentyOnePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_TwoThousandTwentyOnePlanMember" xlink:to="mtva_TwoThousandTwentyOnePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_TwoThousandTwentyOnePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2021 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_TwoThousandTwentyOnePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Inducement Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_TwoThousandTwentyOnePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan20192022AndInducementPlanMember" xlink:label="mtva_StockPlan20192022AndInducementPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_StockPlan20192022AndInducementPlanMember" xlink:to="mtva_StockPlan20192022AndInducementPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_StockPlan20192022AndInducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Stock Plans 2019, 2022 And Inducement Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_StockPlan20192022AndInducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Plan 2019, 2022 And Inducement Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mtva_StockPlan20192022AndInducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based award plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of Common Stock Issuable for Options, Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining shares of common stock available for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation - Weighted average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's, Number Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's, Number Vested and Released (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's, Number Forfeited/Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Ending balance (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Opening balance (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Granted (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Vested and released (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU's Fair value, Forfeited/cancelled (per share)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Aggregate Fair Value, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Aggregate Fair Value, beginning balance</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Aggregate Fair Value, Vested and released</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of Common Stock Issuable for RSUs, Vested and Deferred Release (in shares)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share or unit weighted-average fair value of vested award under share-based payment arrangement. Excludes share and unit options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average Grant Date Fair Value Price , Vested and Deferred Release (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Vested and Deferred Release</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options, Additional Disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Outstanding (per shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (years), Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of Common Stock Issuable for Options, Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price, Exercisable (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term (years), Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable, Intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SingleReportableSegmentMember" xlink:label="mtva_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SingleReportableSegmentMember" xlink:to="mtva_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to a single reportable segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant segment expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" xlink:to="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred in the first clinical trial program associated with research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, First Clinical Trial Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct expenses - Vanoglipel (DA-1241) credits (costs)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" xlink:to="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred in the second clinical trial program associated with research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Second Clinical Trial Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct expenses - DA-1726 costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Direct expenses - Other R&amp;D costs</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseResearchAndDevelopment" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_LaborAndRelatedExpenseResearchAndDevelopment" xlink:to="mtva_LaborAndRelatedExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense provided in the period for labor and related services incurred in Research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor And Related Expense, Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indirect expenses - employee compensation and benefits costs</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeResearchAndDevelopment" xlink:label="mtva_ConsultingFeeResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ConsultingFeeResearchAndDevelopment" xlink:to="mtva_ConsultingFeeResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ConsultingFeeResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense provided in the period for consultancy services incurred in Research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ConsultingFeeResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Fee, Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ConsultingFeeResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indirect expenses - consulting expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LegalAndProfessionalFees" xlink:label="mtva_LegalAndProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_LegalAndProfessionalFees" xlink:to="mtva_LegalAndProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_LegalAndProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense provided in the period for legal costs and professional costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_LegalAndProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal And Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_LegalAndProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and professional fees</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeGeneralAndAdministrative" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ConsultingFeeGeneralAndAdministrative" xlink:to="mtva_ConsultingFeeGeneralAndAdministrative_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense provided in the period for consultancy services incurred in General and administrative.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting Fee, General And Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting expenses</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseGeneralAndAdministrative" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_LaborAndRelatedExpenseGeneralAndAdministrative" xlink:to="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense provided in the period for labor and related services incurred in General and administrative.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor And Related Expense, General And Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation and benefits costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" xlink:to="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a reduction (credit) to research and development expense recognized in connection with the close-out of a clinical trial with a clinical research organization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development, Expense Reversal On Close Out Of First Clinical Trial Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Close-out of a clinical trial</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:to="us-gaap_StateAndLocalTaxJurisdictionOtherMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Tax Jurisdiction, Other [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before Income taxes:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (benefit) expense:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred income tax (benefit) expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes at U.S. federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in valuation allowances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nontaxable and nondeductible items</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" xlink:to="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value of warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Fair Value Of Warrant Liabilities, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax (as a Percent):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes at U.S. federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in valuation allowances (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nontaxable and nondeductible items (as a percent)</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" xlink:to="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value of warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Fair Value Of Warrant Liabilities, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant components of deferred tax assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred income tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal and state net operating loss ("NOL") carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Acquired Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired intangibles</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsUnrealizedBuiltInLoss" xlink:label="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss" xlink:to="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on an ownership change and holds assets whose fair market value (FMV) is less than their tax basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Unrealized Built-in Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net unrealized built-in loss (NUBIL) - 382</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsLeaseLiability" xlink:label="mtva_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DeferredTaxAssetsLeaseLiability" xlink:to="mtva_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total gross deferred income tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxLiabilitiesRouAsset" xlink:label="mtva_DeferredTaxLiabilitiesRouAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_DeferredTaxLiabilitiesRouAsset" xlink:to="mtva_DeferredTaxLiabilitiesRouAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_DeferredTaxLiabilitiesRouAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_DeferredTaxLiabilitiesRouAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, ROU Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mtva_DeferredTaxLiabilitiesRouAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ROU asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred income tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Paid, by Individual Jurisdiction [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Paid, by Individual Jurisdiction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry Forward Research Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payments for income taxes</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfOwnershipChangesOfOver50" xlink:label="mtva_NumberOfOwnershipChangesOfOver50" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NumberOfOwnershipChangesOfOver50" xlink:to="mtva_NumberOfOwnershipChangesOfOver50_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NumberOfOwnershipChangesOfOver50_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of ownership changes over 50% defined by Section 382 of the Internal Revenue Code of 1986.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NumberOfOwnershipChangesOfOver50_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Ownership Changes of over 50%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NumberOfOwnershipChangesOfOver50_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ownership change of over 50% since 2022</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" xlink:label="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" xlink:to="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net operating loss carryforwards expired unutilized and written off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforwards, Expired Unutilized, Write Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NOL carryforward amount</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" xlink:label="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" xlink:to="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research tax credit carryforwards expired unutilized and written off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforwards, Expired Unutilized, Write Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit carryforward amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantLiabilitiesFairValueDisclosure" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_WarrantLiabilitiesFairValueDisclosure" xlink:to="mtva_WarrantLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial and nonfinancial obligations for warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities at fair value</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" xlink:to="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants into which each share may be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Called by Each Share of Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesCWarrantMember" xlink:label="mtva_SeriesCWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SeriesCWarrantMember" xlink:to="mtva_SeriesCWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SeriesCWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to series C warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SeriesCWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_SeriesCWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesDWarrantMember" xlink:label="mtva_SeriesDWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_SeriesDWarrantMember" xlink:to="mtva_SeriesDWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_SeriesDWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to series D warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_SeriesDWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series D Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_SeriesDWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series D warrants</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PublicOffering2026Member" xlink:label="mtva_PublicOffering2026Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_PublicOffering2026Member" xlink:to="mtva_PublicOffering2026Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_PublicOffering2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The underwritten 2026 public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_PublicOffering2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering 2026 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_PublicOffering2026Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 public offering</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingMember" xlink:label="mtva_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_AtMarketOfferingMember" xlink:to="mtva_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassUnitsMember" xlink:label="mtva_ClassUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ClassUnitsMember" xlink:to="mtva_ClassUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ClassUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Class A Units, each consisting of one share of Class A Common Stock and one Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ClassUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ClassUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A units</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassBUnitsMember" xlink:label="mtva_ClassBUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_ClassBUnitsMember" xlink:to="mtva_ClassBUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_ClassBUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Class B Units, each Class B Unit consisting of one share of Series B Convertible Preferred Stock, convertible into one share of common stock, one Series A Warrant and one Series B Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_ClassBUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_ClassBUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfWarrantsIssuedPerUnit" xlink:label="mtva_NumberOfWarrantsIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mtva_NumberOfWarrantsIssuedPerUnit" xlink:to="mtva_NumberOfWarrantsIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mtva_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants per units issued under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mtva_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mtva_NumberOfWarrantsIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>39
<FILENAME>mtva-20251231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.2.0.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/25/2026 3:11:51 PM-->
<!--Modified on: 3/25/2026 3:11:51 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://metaviatx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://metaviatx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies" roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilities" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureRelatedParty" roleURI="http://metaviatx.com/role/DisclosureRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentAndContingencies" roleURI="http://metaviatx.com/role/DisclosureCommitmentAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquity" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes" roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxes" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureLossPerShareOfCommonStock" roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurements" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSubsequentEvents" roleURI="http://metaviatx.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilitiesTables" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityTables" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables" roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesTables" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureLossPerShareOfCommonStockTables" roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" roleURI="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureRelatedPartyDetails" roleURI="http://metaviatx.com/role/DisclosureRelatedPartyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" roleURI="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityWarrantsNarrativeDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureStockholdersEquityStockAssumptionsDetails" roleURI="http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" roleURI="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://metaviatx.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails" roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" roleURI="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureFairValueMeasurementsNarrativeDetails" roleURI="http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="mtva-20251231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://metaviatx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://metaviatx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639100483093501749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639100483093501749" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_639100483093501749" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639100483093501749" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639100483093501749" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639100483093501749" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639100483093501749" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639100483093501749" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639100483093501749" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639100483093501749" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639100483093501749" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639100483093501749" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639100483093501749" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639100483093501749" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639100483093501749" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639100483093501749" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_639100483093501749" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_639100483093501749" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_639100483093501749" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_639100483093501749" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_639100483093501749" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_639100483093501749" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639100483093501749" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_639100483093501749" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_639100483093501749" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_639100483093501749" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_639100483093501749" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_639100483093501749" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_639100483093501749" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_639100483093501749" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_639100483093501749" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639100483093501749" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_639100483093501749" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_639100483093501749" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_639100483093501749" order="36" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639100483093501749" order="37" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100483093501749" xlink:to="us-gaap_AssetsCurrentAbstract_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100483093501749" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100483093501749" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_639100483093501749" xlink:to="us-gaap_AssetsCurrent_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100483093501749" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100483093501749" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100483093501749" xlink:to="us-gaap_OtherAssetsNoncurrent_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_639100483093501749" xlink:to="us-gaap_Assets_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_AccountsPayableCurrent_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedLiabilitiesClinicalTrialCurrent" xlink:label="mtva_AccruedLiabilitiesClinicalTrialCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="mtva_AccruedLiabilitiesClinicalTrialCurrent_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_OtherLiabilitiesCurrent_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639100483093501749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639100483093501749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_LiabilitiesCurrent_639100483093501749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_639100483093501749" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483093501749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_Liabilities_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_CommitmentsAndContingencies_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_StockholdersEquityAbstract_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_PreferredStockValue_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_CommonStockValue_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_AdditionalPaidInCapital_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_StockholdersEquity_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_639100483093501749" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_639100483093501749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_639100483093501749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_639100483093501749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100483093501749" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100483093501749" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100483093501749" xlink:to="us-gaap_OperatingExpenses_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_639100483093501749" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_639100483093501749" xlink:to="us-gaap_InterestIncomeExpenseNet_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639100483093501749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_639100483093501749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_639100483093501749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_639100483093501749" xlink:to="us-gaap_EarningsPerShareBasic_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_639100483093501749" xlink:to="us-gaap_EarningsPerShareDiluted_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639100483093501749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639100483093501749" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_639100483093501749" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_639100483093501749" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100483093501749" xlink:to="us-gaap_StatementEquityComponentsAxis_639100483093501749" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100483093501749" xlink:to="us-gaap_CommonStockMember_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100483093501749" xlink:to="us-gaap_AdditionalPaidInCapitalMember_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100483093501749" xlink:to="us-gaap_RetainedEarningsMember_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_639100483093501749" xlink:to="us-gaap_EquityComponentDomain_639100483093501749" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100483093501749" xlink:to="us-gaap_StatementLineItems_639100483093501749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_StockholdersEquity_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_CommonStockSharesIssued_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants_639100483093501749" xlink:to="mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_639100483093501749" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_639100483093501749" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_639100483093501749" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_639100483093501749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_639100483093501749" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_639100483093501749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_639100483093501749" xlink:to="us-gaap_NetIncomeLoss_639100483093501749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6391004830935017491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_StockholdersEquity_6391004830935017491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_6391004830935017491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_CommonStockSharesIssued_6391004830935017491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockAndWarrantsIssuanceCosts" xlink:label="mtva_StockAndWarrantsIssuanceCosts_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="mtva_StockAndWarrantsIssuanceCosts_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockIssuanceCostAtMarketOfferingAgreement" xlink:label="mtva_StockIssuanceCostAtMarketOfferingAgreement_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="mtva_StockIssuanceCostAtMarketOfferingAgreement_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_639100483093501749" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100483093501749" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100483093501749" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093501749" xlink:to="us-gaap_PrivatePlacementMember_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingAgreementMember" xlink:label="mtva_AtMarketOfferingAgreementMember_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093501749" xlink:to="mtva_AtMarketOfferingAgreementMember_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_639100483093501749" xlink:to="us-gaap_StatementLineItems_639100483093501749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_NetIncomeLoss_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" xlink:to="us-gaap_ShareBasedCompensation_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NonCashLeaseCreditCharge" xlink:label="mtva_NonCashLeaseCreditCharge_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" xlink:to="mtva_NonCashLeaseCreditCharge_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" xlink:to="us-gaap_Depreciation_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_639100483093501749" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100483093501749" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100483093501749" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_639100483093501749" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="mtva_ProceedsFromIssuanceOfCommonStockAndWarrants_639100483093501749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100483093501749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483093501749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_639100483093501749" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_639100483093501749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_639100483093501749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639100483093501749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_639100483093501749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6391004830935017491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6391004830935017491" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_639100483093501749" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_639100483093658725" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_FairValueOfWarrantsIssuedToPlacementAgent" xlink:label="mtva_FairValueOfWarrantsIssuedToPlacementAgent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_639100483093658725" xlink:to="mtva_FairValueOfWarrantsIssuedToPlacementAgent_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_639100483093658725" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="995210201 - Disclosure - Prepaid expenses and other current assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock" xlink:label="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="995210301 - Disclosure - Property and equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilities" xlink:type="extended" xlink:title="995210401 - Disclosure - Current liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurrentLiabilitiesTextBlock" xlink:label="mtva_CurrentLiabilitiesTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="mtva_CurrentLiabilitiesTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureRelatedParty" xlink:type="extended" xlink:title="995210501 - Disclosure - Related party" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentAndContingencies" xlink:type="extended" xlink:title="995210601 - Disclosure - Commitment and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="995210701 - Disclosure - Stockholders' equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes" xlink:type="extended" xlink:title="995210801 - Disclosure - Significant segment expenses and loss before income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995210901 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock" xlink:type="extended" xlink:title="995211001 - Disclosure - Loss per share of common stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995211101 - Disclosure - Fair value measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211201 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_639100483093658725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:label="mtva_WarrantLiabilitiesPolicyPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mtva_WarrantLiabilitiesPolicyPolicyTextBlock_639100483093658725" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_639100483093658725" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_639100483093658725" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_639100483093658725" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_639100483093658725" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PatentCostPolicyPolicyTextBlock" xlink:label="mtva_PatentCostPolicyPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mtva_PatentCostPolicyPolicyTextBlock_639100483093658725" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_639100483093658725" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_639100483093658725" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_639100483093658725" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_639100483093658725" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_639100483093658725" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_639100483093658725" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Prepaid expenses and other current assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_1" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Property and equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Current liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_6" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_6" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="99930603 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Stockholders' equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_639100483093658725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Significant segment expenses and loss before income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Income taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Loss per share of common stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Fair value measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093658725" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093658725" xlink:to="srt_RangeAxis_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100483093658725" xlink:to="srt_RangeMember_639100483093658725" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100483093658725" xlink:to="srt_MinimumMember_639100483093658725" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100483093658725" xlink:to="srt_MaximumMember_639100483093658725" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093658725" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_CommonStockSharesAuthorized_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_NetIncomeLoss_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_639100483093658725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_NumberOfReportableSegments_639100483093658725" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfGeographicLocation" xlink:label="mtva_NumberOfGeographicLocation_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="mtva_NumberOfGeographicLocation_639100483093658725" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093658725" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_639100483093658725" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Prepaid expenses and other current assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2" xlink:to="us-gaap_PrepaidInsurance_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2" xlink:to="us-gaap_DepositsAssetsCurrent_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2" xlink:to="us-gaap_DeferredOfferingCosts_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Property and equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_Depreciation_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Current liabilities - Accrued expenses and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="mtva_AccruedExpensesAndOtherLiabilitiesCurrent_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - Current liabilities -Warrant liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_4" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_4" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_639100483093658725" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_6391004830936587251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_4" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_6391004830936587251" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - Current liabilities - Warrant liabilities - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_5" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100483093658725" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483093658725" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesAndSeriesBWarrantsMember" xlink:label="mtva_November2022SeriesAndSeriesBWarrantsMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093658725" xlink:to="mtva_November2022SeriesAndSeriesBWarrantsMember_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100483093658725" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093658725" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093658725" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093658725" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureRelatedPartyDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Related party (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100483093658725" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100483093658725" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100483093658725" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100483093658725" xlink:to="us-gaap_RelatedPartyDomain_639100483093658725" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639100483093658725" xlink:to="us-gaap_RelatedPartyMember_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100483093658725" xlink:to="us-gaap_RelatedPartyTransactionAxis_639100483093658725" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_639100483093658725" xlink:to="us-gaap_RelatedPartyTransactionDomain_639100483093658725" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LicenseAgreementMember" xlink:label="mtva_LicenseAgreementMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639100483093658725" xlink:to="mtva_LicenseAgreementMember_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_Da1726Member" xlink:label="mtva_Da1726Member_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mtva_LicenseAgreementMember_639100483093658725" xlink:to="mtva_Da1726Member_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_Da1241Member" xlink:label="mtva_Da1241Member_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mtva_LicenseAgreementMember_639100483093658725" xlink:to="mtva_Da1241Member_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SharedServicesAgreementMember" xlink:label="mtva_SharedServicesAgreementMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_639100483093658725" xlink:to="mtva_SharedServicesAgreementMember_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100483093658725" xlink:to="srt_CounterpartyNameAxis_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_639100483093658725" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongStMember" xlink:label="mtva_DongStMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639100483093658725" xlink:to="mtva_DongStMember_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DongSocioHoldingCoLtdMember" xlink:label="mtva_DongSocioHoldingCoLtdMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_639100483093658725" xlink:to="mtva_DongSocioHoldingCoLtdMember_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_639100483093658725" xlink:to="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="mtva_PeriodForFailToCureBreachMayTerminateAgreement_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_PeriodForFailToCureBreachMayTerminateAgreement_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurePeriodForBreachingParty" xlink:label="mtva_CurePeriodForBreachingParty_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_CurePeriodForBreachingParty_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PeriodForTerminationNotice" xlink:label="mtva_PeriodForTerminationNotice_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_PeriodForTerminationNotice_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CurePeriodForPetitionForBankruptcy" xlink:label="mtva_CurePeriodForPetitionForBankruptcy_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_CurePeriodForPetitionForBankruptcy_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_MilestonesAccrued" xlink:label="mtva_MilestonesAccrued_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_MilestonesAccrued_639100483093658725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfCommonStockOutstanding" xlink:label="mtva_PercentageOfCommonStockOutstanding_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_PercentageOfCommonStockOutstanding_639100483093658725" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639100483093658725" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="us-gaap_OtherLiabilitiesCurrent_639100483093658725" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent_639100483093658725" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration" xlink:label="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent_639100483093658725" xlink:to="us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiability" xlink:label="mtva_RelatedPartyExtendedPaymentLiability_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_RelatedPartyExtendedPaymentLiability_639100483093658725" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths_639100483093658725" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths" xlink:label="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths_639100483093658725" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyAccruedInterestPayable" xlink:label="mtva_RelatedPartyAccruedInterestPayable_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_RelatedPartyAccruedInterestPayable_639100483093658725" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="us-gaap_RelatedPartyTransactionRate_639100483093658725" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_RelatedPartyClinicalTrialAccruedLiability" xlink:label="mtva_RelatedPartyClinicalTrialAccruedLiability_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_639100483093658725" xlink:to="mtva_RelatedPartyClinicalTrialAccruedLiability_639100483093658725" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Commitments and contingencies - Operating Leases - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_639100483093658725" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639100483093658725" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639100483093658725" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_639100483093658725" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100483093658725" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NewCorporateHeadquartersLeaseMember" xlink:label="mtva_NewCorporateHeadquartersLeaseMember_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_639100483093658725" xlink:to="mtva_NewCorporateHeadquartersLeaseMember_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_639100483093658725" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" xlink:to="us-gaap_OperatingLeaseExpense_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" xlink:to="us-gaap_OperatingLeasePayments_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - Commitments and Contingencies - Operating Lease - Lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_639100483093658725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_639100483093658725" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_639100483093658725" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639100483093658725" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_639100483093658725" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_OperatingLeaseLiability_639100483093658725" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_639100483093658725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_639100483093658725" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_639100483093658725" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_639100483093813977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails" xlink:type="extended" xlink:title="99940603 - Disclosure - Commitments and Contingencies - Contingent payments and license agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligation_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_GainContingencyUnrecordedAmount_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="99940604 - Disclosure - Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100483093813977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100483093813977" xlink:to="srt_RangeAxis_639100483093813977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100483093813977" xlink:to="srt_RangeMember_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100483093813977" xlink:to="srt_MaximumMember_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_639100483093813977" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="mtva_DefinedContributionPlanEmployeeEligibilityAge_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" xlink:to="mtva_DefinedContributionPlanEmployeeEligibilityAge_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:label="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" xlink:to="mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:label="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" xlink:to="mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EmployeeCompensationVestingPercentageOnContribution" xlink:label="mtva_EmployeeCompensationVestingPercentageOnContribution_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" xlink:to="mtva_EmployeeCompensationVestingPercentageOnContribution_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_639100483093813977" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Stockholders' equity - Common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_CommonStockVotingRightsPerShare" xlink:label="mtva_CommonStockVotingRightsPerShare_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_639100483093813977" xlink:to="mtva_CommonStockVotingRightsPerShare_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_DividendsCommonStockAbstract_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsCommonStockAbstract_639100483093813977" xlink:to="us-gaap_DividendsCommonStockCash_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfCommonStockIssuedPerUnit" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="mtva_NumberOfCommonStockIssuedPerUnit_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Stockholders' equity - Private placement and At the market offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_9" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_639100483093813977" xlink:to="us-gaap_RelatedPartyDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_639100483093813977" xlink:to="us-gaap_RelatedPartyMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" xlink:to="us-gaap_PrivatePlacementMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingAgreementMember" xlink:label="mtva_AtMarketOfferingAgreementMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" xlink:to="mtva_AtMarketOfferingAgreementMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PreFundedWarrantsMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice33000.00Member" xlink:label="mtva_WarrantsExercisePrice33000.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_WarrantsExercisePrice33000.00Member_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice15919.20Member" xlink:label="mtva_WarrantsExercisePrice15919.20Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_WarrantsExercisePrice15919.20Member_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice9900.00Member" xlink:label="mtva_WarrantsExercisePrice9900.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_WarrantsExercisePrice9900.00Member_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member_639100483093813977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member_639100483093813977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants" xlink:label="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PaymentsForPlacementAgentFees" xlink:label="mtva_PaymentsForPlacementAgentFees_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PaymentsForPlacementAgentFees_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_SharesIssuedPricePerShare_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_MaximumAggregateOfferingPrice" xlink:label="mtva_MaximumAggregateOfferingPrice_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_MaximumAggregateOfferingPrice_639100483093813977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfSalesAgentCommission" xlink:label="mtva_PercentageOfSalesAgentCommission_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PercentageOfSalesAgentCommission_639100483093813977" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100483093813977" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AggregateOfferingPrice" xlink:label="mtva_AggregateOfferingPrice_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_AggregateOfferingPrice_639100483093813977" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - Stockholders' equity - Securities purchase agreements and Placement agent (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_2" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024OfferingMember" xlink:label="mtva_June2024OfferingMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" xlink:to="mtva_June2024OfferingMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" xlink:to="us-gaap_PrivatePlacementMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_TypeOfArrangementAxis_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_639100483093813977" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SecuritiesPurchaseAgreementMember" xlink:label="mtva_SecuritiesPurchaseAgreementMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_639100483093813977" xlink:to="mtva_SecuritiesPurchaseAgreementMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PreFundedWarrantsMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesWarrantMember" xlink:label="mtva_SeriesWarrantMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_SeriesWarrantMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesBWarrantMember" xlink:label="mtva_SeriesBWarrantMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_SeriesBWarrantMember_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PipeCommonWarrantsMember" xlink:label="mtva_PipeCommonWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PipeCommonWarrantsMember_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentWarrantsMember" xlink:label="mtva_PlacementAgentWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PlacementAgentWarrantsMember_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentContingentWarrantsMember" xlink:label="mtva_PlacementAgentContingentWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PlacementAgentContingentWarrantsMember_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639100483093813977" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfSecuritiesPurchaseAgreementsEntered" xlink:label="mtva_NumberOfSecuritiesPurchaseAgreementsEntered_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_NumberOfSecuritiesPurchaseAgreementsEntered_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PaymentsForPlacementAgentFees" xlink:label="mtva_PaymentsForPlacementAgentFees_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PaymentsForPlacementAgentFees_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_SharesIssuedPricePerShare_639100483093813977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100483093813977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_639100483093813977" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPercentageForBeneficialOwnership" xlink:label="mtva_ThresholdPercentageForBeneficialOwnership_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_ThresholdPercentageForBeneficialOwnership_639100483093813977" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder" xlink:label="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder_639100483093813977" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfPlacementAgentFee" xlink:label="mtva_PercentageOfPlacementAgentFee_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PercentageOfPlacementAgentFee_639100483093813977" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts" xlink:label="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts_639100483093813977" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants" xlink:label="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants_639100483093813977" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PremiumOfOfferingPriceForExercisePricePercentage" xlink:label="mtva_PremiumOfOfferingPriceForExercisePricePercentage_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_PremiumOfOfferingPriceForExercisePricePercentage_639100483093813977" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WeightedAverageFairValuePerShareOfWarrants" xlink:label="mtva_WeightedAverageFairValuePerShareOfWarrants_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="mtva_WeightedAverageFairValuePerShareOfWarrants_639100483093813977" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_639100483093813977" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_639100483093813977" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="99940704 - Disclosure - Stockholders' equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice33000.00Member" xlink:label="mtva_WarrantsExercisePrice33000.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_WarrantsExercisePrice33000.00Member_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice15919.20Member" xlink:label="mtva_WarrantsExercisePrice15919.20Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_WarrantsExercisePrice15919.20Member_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantsExercisePrice9900.00Member" xlink:label="mtva_WarrantsExercisePrice9900.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_WarrantsExercisePrice9900.00Member_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member" xlink:label="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesaWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesaWarrantExercisePrice43.23Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024SeriesaWarrantExercisePrice43.23Member_639100483093813977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member_639100483093813977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xlink:type="extended" xlink:title="99940705 - Disclosure - Stockholders' equity - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024PreFundedWarrantExercisePrice0.011Member" xlink:label="mtva_June2024PreFundedWarrantExercisePrice0.011Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024PreFundedWarrantExercisePrice0.011Member_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024SeriesBWarrantExercisePrice43.23Member" xlink:label="mtva_June2024SeriesBWarrantExercisePrice43.23Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_June2024SeriesBWarrantExercisePrice43.23Member_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" xlink:to="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants" xlink:label="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_639100483093813977" xlink:to="mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails" xlink:type="extended" xlink:title="99940706 - Disclosure - Stockholders' equity - Stock-based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_IncomeStatementLocationAxis_639100483093813977" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_639100483093813977" xlink:to="us-gaap_IncomeStatementLocationDomain_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639100483093813977" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_639100483093813977" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_639100483093813977" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails" xlink:type="extended" xlink:title="99940707 - Disclosure - Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_PlanNameAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639100483093813977" xlink:to="us-gaap_PlanNameDomain_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2019Member" xlink:label="mtva_StockPlan2019Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100483093813977" xlink:to="mtva_StockPlan2019Member_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2022Member" xlink:label="mtva_StockPlan2022Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100483093813977" xlink:to="mtva_StockPlan2022Member_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_AwardTypeAxis_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" xlink:to="us-gaap_EmployeeStockOptionMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="srt_RangeAxis_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100483093813977" xlink:to="srt_RangeMember_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100483093813977" xlink:to="srt_MaximumMember_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails" xlink:type="extended" xlink:title="99940708 - Disclosure - Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_5" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_AwardTypeAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" xlink:to="us-gaap_EmployeeStockOptionMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639100483093813977" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_PlanNameAxis_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_639100483093813977" xlink:to="us-gaap_PlanNameDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan2022Member" xlink:label="mtva_StockPlan2022Member_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100483093813977" xlink:to="mtva_StockPlan2022Member_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_TwoThousandTwentyOnePlanMember" xlink:label="mtva_TwoThousandTwentyOnePlanMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100483093813977" xlink:to="mtva_TwoThousandTwentyOnePlanMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_StockPlan20192022AndInducementPlanMember" xlink:label="mtva_StockPlan20192022AndInducementPlanMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_639100483093813977" xlink:to="mtva_StockPlan20192022AndInducementPlanMember_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940709 - Disclosure - Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6391004830938139771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6391004830938139771" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639100483093813977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_639100483093813977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_639100483093813977" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6391004830938139771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6391004830938139771" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_639100483093813977" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding_639100483093813977" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_6391004830938139771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance_6391004830938139771" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_639100483093813977" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue_639100483093813977" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_6" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_639100483093813977" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="99940710 - Disclosure - Stockholders' equity - Stock-based compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_7" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_639100483093813977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_639100483093813977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_639100483093813977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_639100483093813977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails" xlink:type="extended" xlink:title="99940711 - Disclosure - Stockholders' equity - Stock - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_8" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483093813977" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentWarrantsMember" xlink:label="mtva_PlacementAgentWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PlacementAgentWarrantsMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PlacementAgentContingentWarrantsMember" xlink:label="mtva_PlacementAgentContingentWarrantsMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483093813977" xlink:to="mtva_PlacementAgentContingentWarrantsMember_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100483093813977" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_June2024OfferingMember" xlink:label="mtva_June2024OfferingMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483093813977" xlink:to="mtva_June2024OfferingMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_639100483093813977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_639100483093813977" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_639100483093813977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639100483093813977" xlink:to="us-gaap_StatementBusinessSegmentsAxis_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_639100483093813977" xlink:to="us-gaap_SegmentDomain_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SingleReportableSegmentMember" xlink:label="mtva_SingleReportableSegmentMember_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_639100483093813977" xlink:to="mtva_SingleReportableSegmentMember_639100483093813977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_639100483093813977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_639100483093813977" xlink:to="us-gaap_SegmentReportingInformationLineItems_639100483093813977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_639100483093813977" xlink:to="us-gaap_OperatingExpensesAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100483093970228" xlink:to="us-gaap_NumberOfReportableSegments_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100483093970228" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" xlink:to="mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" xlink:to="mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseResearchAndDevelopment" xlink:label="mtva_LaborAndRelatedExpenseResearchAndDevelopment_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" xlink:to="mtva_LaborAndRelatedExpenseResearchAndDevelopment_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeResearchAndDevelopment" xlink:label="mtva_ConsultingFeeResearchAndDevelopment_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" xlink:to="mtva_ConsultingFeeResearchAndDevelopment_639100483093970228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract_639100483093970228" xlink:to="us-gaap_ResearchAndDevelopmentExpense_639100483093970228" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_639100483093970228" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LegalAndProfessionalFees" xlink:label="mtva_LegalAndProfessionalFees_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="mtva_LegalAndProfessionalFees_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ConsultingFeeGeneralAndAdministrative" xlink:label="mtva_ConsultingFeeGeneralAndAdministrative_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="mtva_ConsultingFeeGeneralAndAdministrative_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_LaborAndRelatedExpenseGeneralAndAdministrative" xlink:label="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="mtva_LaborAndRelatedExpenseGeneralAndAdministrative_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="us-gaap_GeneralAndAdministrativeExpense_639100483093970228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="us-gaap_OperatingExpenses_639100483093970228" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="us-gaap_OperatingIncomeLoss_639100483093970228" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_639100483093970228" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483093970228" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram" xlink:label="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract_639100483093970228" xlink:to="mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram_639100483093970228" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Income taxes - Loss before income taxes and Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639100483093970228" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639100483093970228" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" xlink:to="us-gaap_DomesticCountryMember_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DomesticCountryMember_639100483093970228" xlink:to="country_US_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalTaxJurisdictionOtherMember" xlink:label="us-gaap_StateAndLocalTaxJurisdictionOtherMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalJurisdictionMember_639100483093970228" xlink:to="us-gaap_StateAndLocalTaxJurisdictionOtherMember_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_639100483093970228" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639100483093970228" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_639100483093970228" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_639100483093970228" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_639100483093970228" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Income taxes - Reconciliation of income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_639100483093970228" xlink:to="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxExpenseBenefit_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100483093970228" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100483093970228" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100483093970228" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent" xlink:label="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_639100483093970228" xlink:to="mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract_639100483093970228" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_639100483093970228" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Income taxes - Significant components of deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_639100483093970228" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsUnrealizedBuiltInLoss" xlink:label="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="mtva_DeferredTaxAssetsUnrealizedBuiltInLoss_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsLeaseLiability" xlink:label="mtva_DeferredTaxAssetsLeaseLiability_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="mtva_DeferredTaxAssetsLeaseLiability_639100483093970228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_639100483093970228" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsOther_639100483093970228" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_639100483093970228" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsGross_639100483093970228" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639100483093970228" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsNet_639100483093970228" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_639100483093970228" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_DeferredTaxLiabilitiesRouAsset" xlink:label="mtva_DeferredTaxLiabilitiesRouAsset_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639100483093970228" xlink:to="mtva_DeferredTaxLiabilitiesRouAsset_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639100483093970228" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Income taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639100483093970228" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639100483093970228" xlink:to="srt_RangeAxis_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_639100483093970228" xlink:to="srt_RangeMember_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_639100483093970228" xlink:to="srt_MaximumMember_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639100483093970228" xlink:to="us-gaap_IncomeTaxAuthorityAxis_639100483093970228" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_639100483093970228" xlink:to="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" xlink:to="us-gaap_DomesticCountryMember_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DomesticCountryMember_639100483093970228" xlink:to="country_US_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_639100483093970228" xlink:to="us-gaap_StateAndLocalJurisdictionMember_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_639100483093970228" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_639100483093970228" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_639100483093970228" xlink:to="us-gaap_OperatingLossCarryforwards_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_639100483093970228" xlink:to="us-gaap_TaxCreditCarryforwardAmount_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_639100483093970228" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="us-gaap_UnrecognizedTaxBenefits_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxExaminationDescription_639100483093970228" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="us-gaap_IncomeTaxesPaidNet_639100483093970228" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfOwnershipChangesOfOver50" xlink:label="mtva_NumberOfOwnershipChangesOfOver50_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="mtva_NumberOfOwnershipChangesOfOver50_639100483093970228" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff" xlink:label="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff_639100483093970228" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff" xlink:label="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_639100483093970228" xlink:to="mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff_639100483093970228" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss_639100483093970228" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100483093970228" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639100483093970228" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic_639100483094126087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_639100483094126087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Loss per share of common stock - Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100483094126087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100483094126087" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639100483094126087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_639100483094126087" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_639100483094126087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639100483094126087" xlink:to="us-gaap_EmployeeStockOptionMember_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639100483094126087" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_639100483094126087" xlink:to="us-gaap_WarrantMember_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_639100483094126087" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_639100483094126087" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Fair value measurements - Recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_639100483094126087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_639100483094126087" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_639100483094126087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_639100483094126087" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_639100483094126087" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_639100483094126087" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100483094126087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100483094126087" xlink:to="us-gaap_FairValueInputsLevel1Member_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_639100483094126087" xlink:to="us-gaap_FairValueInputsLevel2Member_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639100483094126087" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_639100483094126087" xlink:to="us-gaap_AssetsFairValueDisclosure_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_WarrantLiabilitiesFairValueDisclosure" xlink:label="mtva_WarrantLiabilitiesFairValueDisclosure_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100483094126087" xlink:to="mtva_WarrantLiabilitiesFairValueDisclosure_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_639100483094126087" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Fair value measurements - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_November2022SeriesBWarrantExercisePrice0.00Member" xlink:label="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" xlink:to="mtva_November2022SeriesBWarrantExercisePrice0.00Member_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_639100483094126087" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock" xlink:label="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" xlink:to="mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" xlink:to="us-gaap_ProceedsFromWarrantExercises_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://metaviatx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_639100483094126087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PreFundedWarrantsMember" xlink:label="mtva_PreFundedWarrantsMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" xlink:to="mtva_PreFundedWarrantsMember_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesCWarrantMember" xlink:label="mtva_SeriesCWarrantMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" xlink:to="mtva_SeriesCWarrantMember_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_SeriesDWarrantMember" xlink:label="mtva_SeriesDWarrantMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_639100483094126087" xlink:to="mtva_SeriesDWarrantMember_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100483094126087" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_639100483094126087" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_PublicOffering2026Member" xlink:label="mtva_PublicOffering2026Member_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483094126087" xlink:to="mtva_PublicOffering2026Member_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_AtMarketOfferingMember" xlink:label="mtva_AtMarketOfferingMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_639100483094126087" xlink:to="mtva_AtMarketOfferingMember_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100483094126087" xlink:to="us-gaap_SubsequentEventTypeAxis_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_639100483094126087" xlink:to="us-gaap_SubsequentEventTypeDomain_639100483094126087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_639100483094126087" xlink:to="us-gaap_SubsequentEventMember_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100483094126087" xlink:to="us-gaap_StatementClassOfStockAxis_639100483094126087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_639100483094126087" xlink:to="us-gaap_ClassOfStockDomain_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassUnitsMember" xlink:label="mtva_ClassUnitsMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639100483094126087" xlink:to="mtva_ClassUnitsMember_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassBUnitsMember" xlink:label="mtva_ClassBUnitsMember_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_639100483094126087" xlink:to="mtva_ClassBUnitsMember_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_639100483094126087" xlink:to="us-gaap_SubsequentEventLineItems_639100483094126087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_639100483094126087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_639100483094126087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_639100483094126087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfCommonStockIssuedPerUnit" xlink:label="mtva_NumberOfCommonStockIssuedPerUnit_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="mtva_NumberOfCommonStockIssuedPerUnit_639100483094126087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_NumberOfWarrantsIssuedPerUnit" xlink:label="mtva_NumberOfWarrantsIssuedPerUnit_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="mtva_NumberOfWarrantsIssuedPerUnit_639100483094126087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="us-gaap_SharesIssuedPricePerShare_639100483094126087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_639100483094126087" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_639100483094126087" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="mtva-20251231.xsd#mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised" xlink:label="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_639100483094126087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_639100483094126087" xlink:to="mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised_639100483094126087" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 20, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">METAVIA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">545 Concord Avenue, Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MTVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,090,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,278<span></span>
</td>
<td class="nump">$ 16,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,875<span></span>
</td>
<td class="nump">16,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,123<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">3,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_AccruedLiabilitiesClinicalTrialCurrent', window );">Clinical trial accrued liabilities</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">1,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Warrant liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">$ 3,312<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party [Extensible Enumeration]</a></td>
<td class="text">Related Party [Member]<span></span>
</td>
<td class="text">Related Party [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, short-term</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,648<span></span>
</td>
<td class="nump">8,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, long-term</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,790<span></span>
</td>
<td class="nump">8,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2025 and 2024; 2,308,294 and 785,194 shares issued and outstanding as of December 31, 2025 and 2024, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">154,161<span></span>
</td>
<td class="nump">143,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(148,830)<span></span>
</td>
<td class="num">(135,857)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">5,333<span></span>
</td>
<td class="nump">7,931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 11,123<span></span>
</td>
<td class="nump">$ 16,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_AccruedLiabilitiesClinicalTrialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_AccruedLiabilitiesClinicalTrialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates status and type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481679/480-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,308,294<span></span>
</td>
<td class="nump">785,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,308,294<span></span>
</td>
<td class="nump">785,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 6,802<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,906<span></span>
</td>
<td class="nump">7,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,708<span></span>
</td>
<td class="nump">28,809<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,708)<span></span>
</td>
<td class="num">(28,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liabilities</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">510<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(12,973)<span></span>
</td>
<td class="num">(27,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,973)<span></span>
</td>
<td class="num">$ (27,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share of common stock, basic (in dollars per share)</a></td>
<td class="num">$ (7.35)<span></span>
</td>
<td class="num">$ (39.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (7.35)<span></span>
</td>
<td class="num">$ (39.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares of common stock outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock, basic (in shares)</a></td>
<td class="nump">1,766,026<span></span>
</td>
<td class="nump">705,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock, diluted (in shares)</a></td>
<td class="nump">1,766,026<span></span>
</td>
<td class="nump">705,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2023</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 124,949<span></span>
</td>
<td class="num">$ (108,265)<span></span>
</td>
<td class="nump">$ 16,685<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">446,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs (in shares)</a></td>
<td class="nump">300,717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of stock from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of stock from exercise of warrants (in shares)</a></td>
<td class="nump">31,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes (in shares)</a></td>
<td class="nump">6,552,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,592)<span></span>
</td>
<td class="num">(27,592)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2024</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">143,787<span></span>
</td>
<td class="num">(135,857)<span></span>
</td>
<td class="nump">$ 7,931<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">785,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants', window );">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs (in shares)</a></td>
<td class="nump">861,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of stock from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of stock from exercise of warrants (in shares)</a></td>
<td class="nump">548,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under an at the market offering agreement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares)</a></td>
<td class="nump">106,788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of stock for vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of stock for vested restricted stock units (in shares)</a></td>
<td class="nump">5,902,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,973)<span></span>
</td>
<td class="num">(12,973)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2025</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 154,161<span></span>
</td>
<td class="num">$ (148,830)<span></span>
</td>
<td class="nump">$ 5,333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Dec. 31, 2025</a></td>
<td class="nump">2,308,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Consolidated Statements of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_StockAndWarrantsIssuanceCosts', window );">Stock and warrants issuance costs</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 1,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_StockIssuanceCostAtMarketOfferingAgreement', window );">Net of issuance costs</a></td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_StockAndWarrantsIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance costs related to stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_StockAndWarrantsIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_StockIssuanceCostAtMarketOfferingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance costs related to at the market offering agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_StockIssuanceCostAtMarketOfferingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,973)<span></span>
</td>
<td class="num">$ (27,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NonCashLeaseCreditCharge', window );">Non-cash lease (credit) charge</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liabilities</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(542)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,819)<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">431<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,701)<span></span>
</td>
<td class="num">(24,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering</a></td>
<td class="nump">9,996<span></span>
</td>
<td class="nump">19,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,964<span></span>
</td>
<td class="nump">18,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(5,739)<span></span>
</td>
<td class="num">(6,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,017<span></span>
</td>
<td class="nump">22,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">16,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_FairValueOfWarrantsIssuedToPlacementAgent', window );">Fair value of warrants issued to placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs in connection with the sale of common stock</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">$ (1,651)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingAgreementMember', window );">At the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs in connection with the sale of common stock</a></td>
<td class="num">(351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock under an at the market offering agreement</a></td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_FairValueOfWarrantsIssuedToPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of warrants issued to placement agent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_FairValueOfWarrantsIssuedToPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NonCashLeaseCreditCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash lease (credit) charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NonCashLeaseCreditCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business, basis of presentation, new accounting standards and summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1. </b></span><b style="font-weight:bold;">Business, basis of presentation, new accounting standards and summary of significant accounting policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">MetaVia&#160;Inc. (the &#8220;Company&#8221;), a Delaware corporation, and its subsidiaries are referred to collectively in these notes to the financial statements of the Company as &#8220;MetaVia,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us.&#8221; <span style="letter-spacing:0.2pt;">We are a clinical-stage biotechnology company focused primarily on </span>developing novel pharmaceuticals to treat <span style="letter-spacing:0.2pt;">cardiometabolic diseases. </span><span style="letter-spacing:0.2pt;">We have two programs, vanoglipel (DA-1241) and DA-1726, focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;) and obesity. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;letter-spacing:0.2pt;">While we focus our financial resources and management&#8217;s attention on the development of vanoglipel (DA-1241) and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases which we are not planning to advance development on and have, or continue to consider for, out-licensing and divestiture opportunities. In July 2024, we entered into an exclusive out-license agreement with MThera Pharma Co., LTD. (&#8220;MThera&#8221;) to provide MThera with the rights to one of our legacy therapeutic program, NB-01, for the treatment of painful diabetic neuropathy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">Our operations consisted principally of performing research and development (&#8220;R&amp;D&#8221;) activities, which include preclinical development and clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Common stock reverse stock split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In December 2025, we completed a <span style="-sec-ix-hidden:Hidden_8EGw4Ym3A0uwPDR1wgoCVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-eleven reverse stock split of our common stock (the &#8220;Reverse Stock Split&#8221;). As a result, every eleven shares of our issued and outstanding common stock were combined, converted and changed into one share of our common stock. Any fraction of a share of our common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of our common stock as reported on Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;) on the last trading day before the Reverse Stock Split. The Reverse Stock Split was approved by our stockholders at the annual meeting of stockholders in June 2025. At the annual meeting, the stockholders approved a proposal to amend our certificate of incorporation to affect a reverse split of our outstanding common stock at a ratio in the range of <span style="-sec-ix-hidden:Hidden_o4iplQlu0UKYhhkCeUIVBg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-five to <span style="-sec-ix-hidden:Hidden_3jKcbu2it0anJWRaB5fFmg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-thirty to be determined at the discretion of our Board of Directors (&#8220;Board&#8221;). In November 2025, our Board approved the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Reverse Stock Split did not impact the number of authorized shares of common stock, which remains at 100,000,000 shares. For the Reverse Stock Split, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of our common stock, the number of shares issuable upon vesting of restricted stock units (&#8220;RSUs&#8221;) and the number of shares reserved for issuance pursuant to our equity incentive compensation plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the accompanying consolidated financial statements and these notes to the consolidated financial statements, the number of shares of common stock and per share data have been adjusted to give effect to the Reverse Stock Split for all periods presented. Additionally, since the common stock par value was unchanged, the amounts for common stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">As reflected in the consolidated financial statements, we had&#160;</span><span style="color:#212529;background:#ffffff;">$10.3</span><span style="color:#212529;background:#ffffff;">&#160;million in cash as of December 31, 2025. We have experienced net losses and negative cash flows from operating activities since our inception and had an accumulated deficit of&#160;</span><span style="color:#212529;background:#ffffff;">$148.8</span><span style="color:#212529;background:#ffffff;">&#160;million as of December 31, 2025. We have incurred a net loss of&#160;</span><span style="color:#212529;background:#ffffff;">$13.0</span><span style="color:#212529;background:#ffffff;">&#160;million and net cash used in operating activities of </span><span style="color:#212529;background:#ffffff;">$15.7</span><span style="color:#212529;background:#ffffff;">&#160;million for 2025. Due in large part to ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="color:#212529;background:#ffffff;">We plan to continue to fund our operations through equity offerings, debt financing, the exercise of existing warrants, or other sources, potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all, or that the warrants issued in previously consummated offerings will be exercised. To the extent that we can raise additional funds by issuing equity securities or in the event our existing warrants are exercised, our stockholders may experience significant dilution. Any debt financing, if available, </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, we may slow down or stop our ongoing and planned clinical trials until such time as additional capital is raised and this may have a material adverse effect on the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The determination as to whether we can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;</span>Our consolidated financial statements&#160;<span style="background:#ffffff;">have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of our liabilities in the normal course of business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).<span style="background:#ffffff;"> Our fiscal year-end is December 31st for each year presented. </span>All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">New accounting standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;background:#ffffff;">Adoption of new accounting standards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">In December 2023, the</span>&#160;<span style="background:#ffffff;">Financial Accounting Standards Board</span>&#160;(&#8220;FASB&#8221;)<span style="color:#212529;background:#ffffff;"> issued</span><span style="color:#212529;">&#160;</span>Accounting Standards Update (&#8220;ASU&#8221;) <span style="color:#212529;">2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve the transparency of income tax disclosures by amending the required rate reconciliation disclosures as well as requiring disclosure of income taxes paid disaggregated by jurisdiction. As amended, the rate reconciliation disclosure will be required to be presented in both percentages and reporting currency amounts, with consistent categories and greater disaggregation of information. This ASU also includes amendments intended to improve the effectiveness of income tax disclosures and eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. This ASU is&#160;</span><span style="color:#212529;background:#ffffff;">effective for annual periods beginning after December 15, 2024. We adopted ASU 2023-09 in 2025, </span>and applied the new disclosure requirements retrospectively. Accordingly, prior period disclosures have been adjusted to reflect the new disclosure requirements, <span style="color:#212529;background:#ffffff;">see Note 9. Income taxes for additional information. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;background:#ffffff;">Accounting standards issued but not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">In November 2024, the FASB issued&#160;ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the consolidated financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to the consolidated financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting period beginning after December 15, 2027. Early adoption is permitted. We continue to evaluate the impact of adopting this ASU to our notes to the consolidated financial statements and processes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">D.</b></span><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We maintain cash and cash equivalents at a financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Property&#160;and equipment, net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Property and equipment are recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from <span style="-sec-ix-hidden:Hidden_zDOjGvv570SVRG19o1qIjg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to five years. Tangible assets acquired for R&amp;D activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">F.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We assess our contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. We have recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to our&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, we recognize lease payments as an expense on a straight-line basis over the remaining lease term.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">G.</b></span><b style="font-weight:bold;">Warrant liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Warrants are accounted for as liabilities at their fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities is recognized as a fair value change in warrant liabilities in the consolidated statements of operations and as an operating item in the statement of cash flows. Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">H.</b></span><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. <span style="background:#ffffff;">The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.</span><span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">I.</b></span><b style="font-weight:bold;">Segment reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We manage and operate as one reportable segment, which is principally the business of development of pharmaceutical products, with one geographic location in the U.S. We do not operate separate lines of business with respect to each pharmaceutical product being studied. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our chief executive officer. The CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. The measure of performance used by the CODM to assess segment performance is reported on the consolidated statements of operations as loss from operations and net loss. Since the Company only has&#160;one&#160;reportable segment, our CODM does not need to decide on how to allocate resources between segments. The measure of segment assets is reported on the consolidated balance sheets as total assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">J.</b></span><b style="font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">R&amp;D expenditures for pre-clinical and clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the United States Food and Drug Administration, are charged to R&amp;D expense as incurred. These expenses consist of costs incurred in performing development activities, including salaries and benefits, equity-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Expenses incurred for certain R&amp;D activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for R&amp;D activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected as clinical trial accrued liabilities in the accompanying consolidated financial statements. Advance payments, if any, for goods or services to be received in the future for R&amp;D activities are deferred and capitalized as prepaid expenses and other current assets in the accompanying consolidated balance sheets. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">K.</b></span><b style="font-weight:bold;">General and administrative expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with R&amp;D activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">L.</b></span><b style="font-weight:bold;">Patent costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">M.</b></span><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Compensation costs related to equity instruments granted are recognized at the grant date fair value, which is amortized as compensation expense on a straight-line basis over the requisite service period (generally, the vesting period) for both graded and cliff vesting awards. We have elected to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">N.</b></span><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for under the asset and liability method.&#160;Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Regular assessments are made on the likelihood that our deferred tax assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of available positive and negative evidence, giving weight based on the evidence&#8217;s relative objectivity. Sources of positive evidence include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years, and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected in future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that, if unfavorably resolved, would adversely affect future profit levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The remaining carrying value of our deferred tax assets, after recording the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably. To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our policy is to recognize both interest and penalties related to uncertain tax positions as part of the income tax provision.&#160;A significant judgment is required in evaluating our tax positions, and in determining our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions are likely to be challenged and we may ultimately not prevail in defending those positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">O.</b></span><b style="font-weight:bold;">Foreign currency translation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Certain transactions are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">P.</b></span><b style="font-weight:bold;">Loss per share of common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Basic earnings or loss per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the weighted average number of shares of common stock. Diluted earnings per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the sum of the weighted average number of shares of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive securities had been issued. Potentially dilutive securities include convertible preferred stock, outstanding stock options, non-vested RSUs and outstanding warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share of common stock by application of the treasury stock method, except if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities. For additional information, see Note 10. Loss per share of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q.</b></span><b style="font-weight:bold;">Concentrations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Financial instruments that potentially subject us to concentration of credit risk consist of cash. As of December 31, 2025, our cash is held by one financial institution in the U.S., and we believe that the financial institution is financially sound. Accordingly, minimal credit risk exists with the financial institution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Supplier Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In 2022, we entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A ST&#8221;), a related party, which requires Dong-A ST to be the sole manufacturer for the production of vanoglipel (DA-1241) and DA-1726. If any issues arise in the manufacturing and we are unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete the development of vanoglipel (DA-1241) or DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">R.</b></span><b style="font-weight:bold;">Loss contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In determining whether an accrual for a loss contingency is required, we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range, that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely), no accrual is recognized. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock', window );">Prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2. </b></span><b style="font-weight:bold;">Prepaid expenses and other current assets</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Prepaid expenses and other current assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Deferred equity offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 55</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expense and other current assets at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3. </b></span><b style="font-weight:bold;">Property and equipment, net </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Property and equipment, net consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (73)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (54)</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">We recorded depreciation expense of $19 thousand and $20 thousand for 2025 and 2024, respectively, which was included in general and administrative operating expenses in the accompanying consolidated statements of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_CurrentLiabilitiesTextBlock', window );">Current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4. </b></span><b style="font-weight:bold;">Current liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Accrued expenses and other current liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Employee related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 713</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 55</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 785</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><i style="font-style:italic;">Warrant liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">Changes to our warrant liabilities are summarized as follows (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 658</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_VOralR6i3ki9t2Jyaw8bcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gain from change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (297)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_W8CSMwv8-EWiuCXptape3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gain from change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (225)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">Our warrant liabilities relate to the 2022 Series B warrants issued in November 2022. These warrants are considered to be derivative instruments; accordingly, we recorded their estimated fair value as warrant liabilities. We estimated the fair value of these warrants using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby eight warrants can be exercised for one share of common stock for no additional consideration, which results in the warrant exercise price to be zero.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_CurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for current liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_CurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">.</b></span><b style="font-weight:bold;">Related party</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">License agreement with Dong-A ST for </b><b style="font-weight:bold;">vanoglipel</b><b style="font-weight:bold;letter-spacing:-0.2pt;background:#ffffff;"> (DA-1241) and DA-1726</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We entered into a license agreement with Dong-A ST pursuant to which we received an exclusive global license (except for the territory of the Republic of Korea) for two proprietary compounds for specified indications (the &#8220;2022 License Agreement&#8221;) upon meeting certain financing milestones. The 2022 License Agreement covers the rights to vanoglipel (DA-1241) for treatment of MASH and DA-1726 for treatment of obesity and MASH. The 2022 License Agreement also provides that we may develop vanoglipel (DA-1241) for the treatment of&#160;<span style="letter-spacing:0.2pt;">type 2 diabetes mellitus</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">In connection with the 2022 License Agreement, we entered into a shared services agreement with Dong-A ST (the &#8220;Shared Services Agreement&#8221;), relating to vanoglipel (DA-1241) and DA-1726, pursuant to which Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel (DA-1241) and DA-1726 under the terms provided in the Shared Services Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Under the terms of the 2022 License Agreement, Dong-A ST will be eligible to receive (i) regulatory milestone payments of up to $178.0 million for DA-1726 and $138.0 million for vanoglipel (DA-1241), dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by us from the commercial sale of products covering vanoglipel (DA-1241) or DA-1726. The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A ST or MetaVia may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60 days of notice of such breach; provided that if the breach cannot be cured within the 60-day period and the breaching party started to remedy the breach, if such breach is not cured within 90 days of receipt of written notice, or (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a 30-day cure period in the case of a petition for bankruptcy).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025, there were no potential milestones under the 2022 License Agreement<span style="background:#ffffff;"> that were </span>yet considered probable; therefore, <span style="background:#ffffff;">no</span><span style="background:#ffffff;">&#160;liabilities were recorded.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">As of December 31, 2025, Dong-A ST and Dong-A Socio Holdings Co. Ltd. (&#8220;Dong-A Holdings&#8221;),&#160;an affiliate company of Dong-A ST, owns approximately </span><span style="background:#ffffff;">39%</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">37%</span><span style="background:#ffffff;">, respectively, of our outstanding common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Shared services agreement with Dong-A ST</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In conjunction with the 2022 License Agreement, we entered into the Shared Services Agreement with Dong-A ST, relating to vanoglipel (DA-1241) and DA-1726. The Shared Services Agreement provides that Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel (DA-1241) and DA-1726 under the terms provided in the Shared Services Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="font-size:10pt;">Either party may terminate the Shared Services Agreement for the other party&#8217;s material breach that is not cured within&#160;</span><span style="font-size:10pt;">30 days</span><span style="font-size:10pt;">&#160;of notice. Dong-A ST may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by us which is not cured within&#160;</span><span style="font-size:10pt;">30 days</span><span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="background:#ffffff;">We incurred R&amp;D expenses of </span><span style="background:#ffffff;">$3.4</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$4.9</span><span style="background:#ffffff;"> million for 2025 and 2024, respectively, under the Shared Services Agreement, which are included in operating expenses: research and development in the accompanying consolidated statement of operations</span>. The aggregate payable to <span style="background:#ffffff;">Dong-A ST</span><span style="background:#ffffff;"> was </span><span style="background:#ffffff;">$3.3</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$1.5</span><span style="background:#ffffff;"> million as of December 31, 2025 and 2024, respectively, under the Shared Services Agreement, which is included in </span><span style="color:#212529;background:#ffffff;">related party payable</span><span style="background:#ffffff;"> in the accompanying consolidated balance sheets. Of the total amount payable to Dong-A ST as of December 31, 2025, (i)&#160;</span><span style="background:#ffffff;">$2.0</span><span style="background:#ffffff;">&#160;million is payable in accordance with an invoice with extended terms in which&#160;</span><span style="background:#ffffff;">$650</span><span style="background:#ffffff;">&#160;thousand will be paid on March 31, 2026 and June 30, 2026 and&#160;</span><span style="background:#ffffff;">$716</span><span style="background:#ffffff;">&#160;thousand will be paid on September 30, 2026, (ii)&#160;</span><span style="background:#ffffff;">$29</span><span style="background:#ffffff;">&#160;thousand is payable in accrued interest based on a fixed interest rate of&#160;</span><span style="background:#ffffff;">4.6%</span><span style="background:#ffffff;">&#160;per annum, and (iii)&#160;</span><span style="background:#ffffff;">$1.3</span><span style="background:#ffffff;">&#160;million is payable in clinical trial accrued liabilities.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6</b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">. </b></span><b style="font-weight:bold;">Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Operating lease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"><span style="font-size:10pt;">In August 2023, we entered into a non-cancelable operating lease for our corporate headquarters in Cambridge, Massachusetts. The initial lease term is for&#160;</span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;">&#160;with an option, which was exercised in November 2025, to renew for an additional&#160;</span><span style="font-size:10pt;">two-year</span><span style="font-size:10pt;">&#160;term. The lease commenced in September 2023 and expires in August 2028. We recorded lease rental expenses and made lease cash payments of </span><span style="font-size:10pt;">$0.1</span><span style="font-size:10pt;"> million for 2025 and 2024. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Operating</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Lease</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 94</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 64</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 250</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less effect of discounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (40)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">  Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 210</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 68</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 142</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">As of December 31, 2025 and 2024, our lease liability, which represents the net present value of future lease payments, was calculated utilizing a discount rate of 11%, which corresponds to our estimated incremental borrowing rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Contingent payments and license agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;">We have certain contractual contingent payments under various merger or license agreements executed between 2019 and 2020 for our </span><span style="letter-spacing:0.2pt;">legacy therapeutic programs. </span>Since we have discontinued the clinical development of our legacy therapeutic programs, we believe any <span style="letter-spacing:0.2pt;">contractual payments to be paid by us or to be received by us under these agreements are</span> remote. Therefore, a<span style="background:#ffffff;">s of December 31, 2025, </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;">&#160;liabilities or </span><span style="-sec-ix-hidden:Hidden_wKCHieRLFUC2maYfjLnuGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">assets</span></span><span style="background:#ffffff;"> were recorded in the accompanying consolidated financial statements for our legacy therapeutic programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Legal proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">From time to time, we may be involved in various claims and legal proceedings arising out of our ordinary course of business. We are not currently a party to any claims or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business and consolidated financial statements. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">Purchase commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies, and testing, manufacturing, and other services and products for operating purposes. These contracts provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. There are no minimum purchase requirements under these contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Employment agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Employee benefit plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;background:#ffffff;">We adopted a 401(k) defined contribution plan in November 2018, which became effective in January 2019, for all employees over age&#160;</span><span style="font-size:10pt;background:#ffffff;">21</span><span style="font-size:10pt;background:#ffffff;">. Employees can defer up to </span><span style="font-size:10pt;background:#ffffff;">90%</span><span style="font-size:10pt;background:#ffffff;"> of their compensation through payroll withholdings into the plan subject to federal law limits. Discretionary employer matches vest over a </span><span style="font-size:10pt;background:#ffffff;">six-year</span><span style="font-size:10pt;background:#ffffff;"> period beginning on the second anniversary of an employee&#8217;s date of hire. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are </span><span style="font-size:10pt;background:#ffffff;">100%</span><span style="font-size:10pt;background:#ffffff;"> vested upon contribution. </span><span style="font-size:10pt;background:#ffffff;">No</span><span style="font-size:10pt;background:#ffffff;"> matching contributions were made for 2025 and 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></span><b style="font-weight:bold;">S</b><b style="font-weight:bold;">tockholders&#8217; equity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;">The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock when outstanding. The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. Common stockholders are entitled to receive dividends at the sole discretion of our Board. There have been no dividends declared on common stock to date as of December 31, 2025. In the event of any liquidation, dissolution, or winding-up of MetaVia, the holders of common stock shall be entitled to share in the remaining assets of MetaVia available for distribution post preferential distributions made to any holders of our preferred stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="color:#212529;font-weight:bold;">2025 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Private placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In May 2025, we closed on a private placement offering with Dong-A ST and Dong-A Holdings, and received net proceeds of $9.1&#160;million, net of placement agent cash fees of $0.4&#160;million and related offering expenses of $0.5&#160;million. The private placement offering was comprised of (i)&#160;861,758&#160;shares of our common stock for a purchase price of $7.81&#160;per share, and (ii)&#160;418,651&#160;pre-funded warrants to purchase up to an equivalent number of shares of our common stock for a purchase price of $7.799&#160;per pre-funded warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Each pre-funded warrant had an exercise price of $0.011&#160;per share, and was exercisable beginning on June 30, 2025, which was the effective date of receiving stockholder approval for the issuance of the shares of common stock underlying the pre-funded warrants. Thereafter, on the same date, all pre-funded warrants were exercised for an equivalent number of shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">At the market offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">In November 2025, we entered into an At The Market Offering Agreement (the &#8220;ATM Sales Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as sales agent and/or principal (&#8220;Ladenburg&#8221;), pursuant to which we may offer and sell, from time to time through or to Ladenburg, shares of our common stock having an aggregate offering price of up to $2.3 million (the &#8220;ATM Program&#8221;). The offer and sale of the shares of common stock pursuant to the ATM Program is made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-278646) filed with the SEC on April 12, 2024, and declared effective by the SEC on April 23, 2024, as supplemented by a prospectus supplement to be filed with the SEC on November 6, 2025 pursuant to Rule 424(b) under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;">Pursuant to the ATM Sales Agreement, Ladenburg may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act. We are not obligated to make any sales of the Shares under the ATM Sales Agreement. The offering of Shares pursuant to the ATM Sales Agreement will terminate upon the termination of the ATM Sales Agreement by Ladenburg or us, as permitted therein. We are obligated to pay Ladenburg an aggregate sales agent commission of 3.0% of the gross sales price of the Shares sold pursuant to the ATM Sales Agreement. We will also reimburse Ladenburg for certain specified expenses in connection with entering into the ATM Sales Agreement, which contains customary representations and warranties and conditions to the placements of the Shares pursuant thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;">In November 2025, we sold 106,788 shares of common stock under the ATM Program and received net proceeds of $0.9 million, net of sales agent commission and related offering expenses. As of December 31, 2025, we have $1.1 million remaining under the ATM Program in which we may offer and sell shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;padding-top:8pt;background:#ffffff;margin:0pt;"><b style="color:#212529;font-weight:bold;">2024 Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Securities purchase agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">In June 2024, we entered into and closed on&#160;</span><span style="color:#212529;">two</span><span style="color:#212529;">&#160;securities purchase agreements (the &#8220;Offering&#8221;)&#160;</span><span style="color:#212529;">with an institutional investor and Dong-A ST, and&#160;</span><span style="color:#212529;">received aggregate gross proceeds of </span><span style="color:#212529;">$20.0</span><span style="color:#212529;">&#160;million, of which </span><span style="color:#212529;">$10.0</span><span style="color:#212529;">&#160;million was received from Dong-A ST. The </span>net proceeds received was $18.3&#160;million, net of placement agent cash fees of $0.7&#160;million and related offering expenses of $1.0&#160;million. <span style="color:#212529;">The Offering was comprised of (i)&#160;</span><span style="color:#212529;">300,707</span><span style="color:#212529;">&#160;shares of common stock at a purchase price of </span><span style="color:#212529;">$43.23</span><span style="color:#212529;">&#160;per share, (ii) pre-funded warrants to purchase up to&#160;</span><span style="color:#212529;">161,924</span><span style="color:#212529;">&#160;shares of common&#160;stock at a purchase price of </span><span style="color:#212529;">$43.219</span><span style="color:#212529;">&#160;per warrant, (iii) Series A warrants to purchase&#160;</span><span style="color:#212529;">462,640</span><span style="color:#212529;">&#160;shares of common stock, and (iv) Series B warrants to purchase up to&#160;</span><span style="color:#212529;">693,962</span><span style="color:#212529;">&#160;shares of </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">common stock. Collec</span><span style="color:#212529;">tively, the Series A and Series B warrants are referred to as &#8220;PIPE Common Warrants.&#8221; Of the total shares of common stock issued in the Offering,&#160;</span><span style="color:#212529;">69,396</span><span style="color:#212529;">&#160;shares were sold to an institutional investor. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">The pre-funded warrants have an exercise price of </span><span style="color:#212529;">$0.011</span><span style="color:#212529;">&#160;per share and are immediately exercisable and </span>are considered to be perpetual warrants without any expiration date.&#160;In the second quarter of 2025,&#160;all of the&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.<span style="color:#212529;"> The PIPE Common Warrants have an exercise price of </span><span style="color:#212529;">$43.23</span><span style="color:#212529;">&#160;per share and are exercisable as of September 18, 2024, which is the effective date of the stockholder approval received at the Special Meeting of Stockholders for the issuance of the shares upon exercise of the warrants. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">The Series A warrants </span>were exercisable at any time from September 18, 2024 and expired unexercised in June 2025. The <span style="color:#212529;">Series B warrants </span>were exercisable at any time from September 18, 2024<span style="color:#212529;"> and </span>expire on the earlier of September 18, 2029 and the&#160;six month&#160;anniversary following the date on which we publicly announce receiving positive Phase 1, Part 3 data for DA-1726.<span style="color:#212529;"> Based on the terms of the PIPE Common Warrants, we have concluded that the accounting classification of the PIPE Common Warrants is to be stockholders&#8217; equity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;font-size:10pt;">Under the terms of the pre-funded warrants and the PIPE Common Warrants issued to the institutional investor, we may not affect the exercise of any such pre-funded warrants or PIPE Common Warrants, and the holder will not be entitled to exercise any portion of any pre-funded warrants or PIPE Common Warrants, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group together with the holder or any of the holder&#8217;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#8217;s or any of the holder&#8217;s affiliates) would exceed&#160;</span><span style="color:#212529;font-size:10pt;">9.99%</span><span style="color:#212529;font-size:10pt;"> (in the case of the pre-funded warrants) or&#160;</span><span style="color:#212529;font-size:10pt;">4.99%</span><span style="color:#212529;font-size:10pt;"> (in the case of the PIPE Common Warrants) of the number of shares of our outstanding common stock immediately after giving effect to the exercise (the &#8220;Beneficial Ownership Limitation&#8221;), as such percentage ownership is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the SEC. A holder of the pre-funded warrants or PIPE Common Warrants that were issued to the institutional investor may increase or decrease the Beneficial Ownership Limitation to a higher or lower percentage (not to exceed&#160;</span><span style="color:#212529;font-size:10pt;">9.99%</span><span style="color:#212529;font-size:10pt;">), effective&#160;</span><span style="color:#212529;font-size:10pt;">61&#160;days</span><span style="color:#212529;font-size:10pt;"> after written notice to us. Any such increase or decrease will apply only to that holder and not to any other holder of the pre-funded Warrants or PIPE Common Warrants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"><i style="color:#212529;font-style:italic;">Placement agent</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">We paid the placement agent a cash fee equal to&#160;</span><span style="color:#212529;">7.0%</span><span style="color:#212529;">&#160;of the gross proceeds of the Offering received from a certain institutional investor and&#160;</span><span style="color:#212529;">$0.1</span><span style="color:#212529;">&#160;million for non-accountable expenses and clearing costs. In addition, we issued warrants to the placement agent&#8217;s designees (&#8220;Placement Agent Warrants&#8221;) to purchase up to&#160;</span><span style="color:#212529;">11,564</span><span style="color:#212529;">&#160;shares of common stock (which represents&#160;</span><span style="color:#212529;">5%</span><span style="color:#212529;">&#160;of the sum of the shares of common stock and pre-funded&#160;Warrants sold to the institutional investor in the Offering) at an exercise price of&#160;</span><span style="color:#212529;">$54.0375</span><span style="color:#212529;">&#160;per share (which represents a premium of&#160;</span><span style="color:#212529;">125%</span><span style="color:#212529;">&#160;of the offering price per share of common stock in the Offering). The Placement Agent Warrants are exercisable at any time from September 18, 2024 and expire in July 2026. The grant date fair value of the Placement Agent Warrants was&#160;</span><span style="color:#212529;">$0.3</span><span style="color:#212529;">&#160;million, which represents a non-cash issuance cost. The weighted average grant date fair value per share of these Placement Agent Warrants was&#160;</span><span style="color:#212529;">$30.03</span><span style="color:#212529;">, which was determined using the Black-Scholes option pricing model. Based on the terms of the Placement Agreement Warrants, we have concluded that the accounting classification of the Placement Agent Warrants is stockholders&#8217; equity in the accompanying consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">Upon the exercise for cash of any PIPE Common Warrants issued to a certain institutional investor, we shall pay the placement agent (i) a cash fee of&#160;</span><span style="color:#212529;">7.0%</span><span style="color:#212529;"> of the aggregate gross exercise price paid in cash with respect thereto and (ii) a non-cash fee in the form of additional warrants to purchase the number of shares of common stock equal to&#160;</span><span style="color:#212529;">5.0%</span><span style="color:#212529;"> of the aggregate number of such shares of common stock underlying such warrants. The cash fee payable to the placement agent for any PIPE Common Warrants exercised by the institutional investor is accounted for as a contingent commitment and will be recorded as an offset to any gross proceeds received from any future exercises of PIPE Common Warrants by the institutional investor. The non-cash fee payable to the placement agent for any PIPE Common Warrants exercised by the institutional investor is accounted for as contingent warrants (&#8220;Placement Agent Contingent Warrants&#8221;) to purchase up to&#160;</span><span style="color:#212529;">28,915</span><span style="color:#212529;">&#160;shares of common stock, which is subject to performance criteria of the institutional investor regarding any exercise for cash of any PIPE Common Warrants with an assumed grant date of the Offering closing date, and an exercise price of </span><span style="color:#212529;">$54.0375</span><span style="color:#212529;">&#160;per share. The weighted average grant date fair value per share of these Placement Agent Contingent Warrants was </span><span style="color:#212529;">$37.73</span><span style="color:#212529;">, which was determined using the Black-Scholes option pricing model. Based on the terms of the placement agent engagement letter, we have concluded that the accounting classification of the Placement Agent Contingent Warrants is to be stockholders&#8217; equity. On each balance sheet reporting date, we will need to assess whether it is probable for us to issue warrants to the placement agent based on whether it is probable for any PIPE Common Warrants to be exercised by the institutional investor. As of December 31, 2025 and 2024, </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">we determined that the issuance of additional warrants to the placement agent is not yet probable; accordingly, the Placement Agent Contingent Warrants had no impact on the consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Warrants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following warrants were outstanding as of December 31, 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of Common Stock Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Outstanding Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Expiration</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrant Issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Date</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 2020 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">33,000.00 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 942</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">15,919.20 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 2021 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,399</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">9,900.00 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 2022 Series B <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,176</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2027</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Placement Agent<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,564</p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,564</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">54.0375 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Pre-Funded <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.011 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">No expiration date</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Series A <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 462,641</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">43.23 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Series B <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 693,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 693,962</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">43.23 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">September 2029 (latest date)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 722,644</p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,316,698</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="margin-top:4pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants expired unexercised in April 2025.</span><span style="display:inline-block;width:4.57pt;"></span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">T</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hese warrants have a cashless exercise provision whereby&#160;the warrants can be exercised for common stock for&#160;</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;additional consideration, which renders the </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$264</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;per warrant exercise price to be&#160;</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expire in July 2026. </span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable immediately and are considered to be perpetual warrants without any expiration date. In the second quarter of 2025,&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">130,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock. Additionally, in the third quarter of 2024, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31,924</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expired unexercised in June 2025.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expire on the earlier of September 18, 2029 and the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary following the date on which we publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.</span></td><td style="width:36pt;"></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense was included in general and administrative <span style="color:#212529;">and research and development as follows&#160;</span><span style="color:#212529;background:#ffffff;">(in thousands)</span><span style="color:#212529;">:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 366</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 172</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 538</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Stock-based award plans</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In December 2019, in connection with a merger, we adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;). Additionally, we adopted the 2021 Inducement Plan in November 2021 and the Amended and Restated 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;) in December 2022. The 2019 Plan, 2021 Inducement Plan and 2022 Plan provide for the grant of stock options, restricted stock, RSUs and other equity awards of our common stock to employees, officers, consultants, and directors. Stock options granted under any of these plans expire within a period of not more than </span><span style="font-size:10pt;">ten years</span><span style="font-size:10pt;"> from the date of grant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">With the adoption of the 2022 Plan, no additional shares may be added to or granted from the 2019 Plan, and any shares related to forfeited awards are carryover to the 2022 Plan. In June 2024, in connection with the 2024 Annual Meeting of Stockholders, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">our stockholders approved an amendment (the &#8220;Amendment&#8221;) to our 2022 Plan. Pursuant to the terms and conditions of the Amendment, the 2022 Plan was amended to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">automatically increase on January 1st of each year for a period of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> commencing on January 1, 2025 and ending on (and including) January 1, 2032, the aggregate number of shares of common stock that may be issued pursuant to Awards (as defined i</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">n the 2022 Plan) to an amount equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the Fully Diluted Shares (as defined in the 2022 Plan) as of the last day of the preceding calendar year, provided, however that the Board may act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of shares of common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of Incentive Stock Options (as defined in the 2022 Plan) to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million shares of the common stock plus the amount of any increase in the number of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shares that may be available for issuance pursuant to the annual increase described above, but in no event more than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million shares of the common stock issued as incentive stock options.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table summarizes the outstanding awards issued pursuant to our stock-based award plans and inducement grants as of December 31, 2025 and the remaining shares of common stock available for future issuance:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining shares of</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">common stock available</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Plan Name</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for future issuance</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2022 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 167,471</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2021 Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 378</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 167,849</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;">For outstanding awards granted under the 2019 Plan and 2022 Plan as of December 31, 2025, unrecognized stock-based compensation costs totaled $0.2 million. The unrecognized stock-based costs are expected to be recognized as an expense over a weighted average period of 1.1 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><i style="font-size:10pt;font-style:italic;">RSUs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table summarizes the status of our RSUs and related transactions for the period presented (in thousands, except share and per share amounts)</span>: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vested and Deferred Release</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Grant Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Aggregate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Grant Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Aggregate</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Intrinsic</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,855)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 51.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (6,693)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Stock options</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The following table summarizes the status of our outstanding and exercisable options and related transactions for the period presented (</span><span style="color:#212529;background:#ffffff;">in thousands, except share and per share amounts):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:37.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercisable</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contractual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contractual</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Term (years)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,149.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The aggregate intrinsic value of our outstanding and exercisable options was zero as of December 31, 2025 and 2024, and January 1, 2024.<i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="color:#212529;font-style:italic;">Grant date fair value of RSUs, stock options and warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">We estimated the grant date fair value of RSUs granted to employees, consultants, and directors based on <span style="background:#ffffff;">the closing sales price of our common stock as reported on Nasdaq on the date of grant. </span>We estimated the grant date fair value of stock options and warrants granted to employees, consultants, and directors using the Black-Scholes option pricing model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The following table sets forth the fair value per share of Placement Agent Warrants granted in 2024 and the assumptions used in the Black-Scholes option-pricing model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placement Agent</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contingent</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Warrants</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Granted in</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Granted in</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2024</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average fair value </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected stock price volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">140.0</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">127.0</p></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.63</p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.31</p></td><td style="vertical-align:bottom;width:4.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant segment expenses and loss before income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Significant segment expenses and loss before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Significant segment expenses and loss before income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></span><b style="font-weight:bold;">Significant segment expenses and loss before income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;letter-spacing:0.2pt;">The following table sets forth the significant segment expenses for our </span><span style="color:#212529;letter-spacing:0.2pt;">one</span><span style="color:#212529;letter-spacing:0.2pt;"> reportable segment (in thousands) that are regularly provided to our CODM: </span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Direct expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Vanoglipel (DA-1241) credits (costs) <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,959</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">DA-1726 costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,397</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other R&amp;D costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 303</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Indirect expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,606</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 288</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,553</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Legal and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,864</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,512</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,659</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,221</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,256</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,809</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,708)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (28,809)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,217</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,973)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (27,592)</p></td></tr></table><div style="margin-top:4pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes a credit of </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$1.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> million recorded in 2025 </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">in connection with the close-out of the clinical trial with the</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">clinical research organization.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes clinical, non-clinical and preclinical services or other R&amp;D expenses that are not attributable to a single product candidate.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.35pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes all other general and administrative expenses, such as insurance, software license fees, non-income state taxes, lease rental expenses, etc.</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> </span></td><td style="width:36pt;"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></span><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our loss before income taxes is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,973)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (27,592)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,973)</p></td><td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (27,592)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The components of our income tax provision are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income tax (benefit) expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,683)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5,809)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 270</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,592)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred income tax (benefit) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,413)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (8,401)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,683</p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,809</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (270)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,592</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our effective tax rate for 2025 and 2024 was zero percent. A reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate is as follows (in thousands, except for percentages):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income taxes at U.S. federal statutory rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5,794)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">State income tax, net of federal benefit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Changes in valuation allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (20.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (21.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nontaxable and nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective tax rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The significant components of our deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. federal and state net operating loss ("NOL") carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,959</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired intangibles </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net unrealized built-in loss (NUBIL) - 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 458</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,516</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 118</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">R&amp;D credit carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,114</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (18,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (16,077)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (36)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (37)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred income tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The realization of our deferred income tax assets is primarily dependent upon future taxable income, if any, and such income is uncertain in both amount and timing. We have had significant pre-tax losses since our inception, and we have not yet generated revenues and face significant challenges to becoming profitable. Accordingly, we have recorded a valuation allowance of $18.5 million and $16.1 million as of December 31, 2025 and 2024, respectively. U.S. federal deferred income tax assets will continue to require a valuation allowance until we can demonstrate their realizability through sustained profitability or another source of income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">As of December 31, 2025 and 2024, our U.S. federal NOL carryforwards were $33.0 million and $18.5 million, respectively. We had less than $0.1 million of U.S. federal R&amp;D credit carryforwards as of December 31, 2025 and 2024. Our U.S. federal NOL were incurred after December 31, 2017 and therefore, will not expire. As of December 31, 2025 and 2024, we had state NOL carryforwards of $12.1 million and $17.4 million, respectively. The state NOL carryforwards will begin to expire in 2042, if not utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Our ability to utilize our NOL and R&amp;D credit carryforwards have been and may be substantially limited due to the ownership changes that have occurred or that could occur in the future, as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change,&#8221; as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. We completed a Section 382 study for 2025 and it was determined that we experienced one ownership change of over 50% since 2022, which was the year of the last 50% or greater ownership change. The 2025 ownership change occurred on May 8, 2025, and going forward, the utilization of loss carryforwards and tax credits generated before May 8, 2025 will be </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">subject to an annual limitation. As a result of the ownership changes and limitations, $100.8 million and $68.6 million of federal and state NOL carryforwards, respectively, will expire unutilized and have been written off. Additionally, $1.2 million of federal R&amp;D credit carryforwards will expire unutilized and have been written off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We recognize interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December 31, 2025 and 2024, and as such, no interest or penalties were recorded to income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We have analyzed our filing positions in all significant U.S. federal, state, and local jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, we are no longer subject to U.S. federal, state, and local tax examinations by tax authorities for years before 2022, although carryforward attributes that were generated prior to 2022 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">For 2025 and 2024, we had no cash payments for income taxes, net of refunds received, in any U.S. federal, state, or foreign jurisdiction.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share of common stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per share of common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></span><b style="font-weight:bold;">Loss per share of common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table sets forth the computation of basic and diluted loss per share of common stock <span style="color:#212529;background:#ffffff;">(in thousands, except share and per share amounts):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:60.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:middle;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (12,973)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (27,592)</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Weighted average shares of common stock, basic</p></td><td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">1,766,026</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">705,193</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Effect of dilutive securities</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Weighted average shares of common stock, diluted</p></td><td style="vertical-align:middle;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">1,766,026</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">705,193</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Loss per share of common stock, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (39.13)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:8pt 0pt 0pt 0pt;"><span style="color:#212529;">For each of the periods presented in the above table, our basic weighted average shares of common stock include any outstanding (i) November 2022 Series B warrants, (ii) June 2024 Pre-Funded Warrants and (iii) vested RSUs in which their release was deferred in accordance with the respective award agreement during the respective period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="color:#212529;">Since we reported a net loss for 2025 and 2024, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per share of common stock and our basic and diluted weighted average shares of common stock are the same for 2025 and 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">The following table sets forth the outstanding securities as of the periods presented which were not included in the calculation of diluted earnings per share of common stock for 2025 and 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,728</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 706,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,170,522</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></span><b style="font-weight:bold;">Fair value measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Fair value is a market-based measurement, not an entity specific measurement and is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three-level hierarchy:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Level&#160;1:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Unadjusted quoted prices for identical assets or liabilities in active markets;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Level&#160;2:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;">Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability; and </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt -0.7pt 8pt 36pt;">Level&#160;3: Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table sets forth our financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy&#160;</span><span style="color:#212529;background:#ffffff;">(in thousands)</span><span style="color:#212529;">:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:35.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:33.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December&#160;31,&#160;2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;3</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Bank money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"><span style="background:#ffffff;">The bank money market funds </span>are carried at cost, which approximates market fair value. We estimated the fair value of our warrant liabilities using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby eight warrants can be exercised for one share of common stock for no additional consideration, which results in the warrant exercise price to be zero. Accordingly, our warrant liabilities were considered to be Level 2 of the fair value hierarchy.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12. </b></span><b style="font-weight:bold;">Subsequent events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><i style="font-style:italic;">2026 public offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">In January 2026, we closed on an underwritten public offering, pursuant to which we issued and sold, (i) 1,006,870 Class A Units, with each Class A Unit consisting of (A) one share of common stock, (B) 1.5 Series C Common Warrants to purchase 1.5 shares of common stock, and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of common stock, at a price of $3.10 per Class A Unit, and (ii) 1,998,704 Class B Units, with each Class B Unit consisting of (A) one pre-funded warrant to purchase one share of common stock, (B) 1.5 Series C Common Warrants to purchase 1.5 shares of common stock, and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of common stock, at a purchase price of $3.099 per Class B Unit. Each pre-funded warrant has an exercise price of $0.001 per share and is immediately exercisable and will expire when exercised in full. Each Series&#160;C Common Warrant and Series D Common Warrant has an exercise price of $3.10 <span style="-sec-ix-hidden:Hidden_oXMhiHp3dkGLoMt6wJhXIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">per</span></span> whole share of common stock, subject to certain adjustments, are immediately exercisable, and will expire on January&#160;16, 2031 and January 16, 2028, respectively. Under the Series&#160;C Common Warrant and the Series D Common Warrant, we&#160;may not affect the exercise of any such warrants, and a holder will not be entitled to exercise any portion of any such warrants, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) to exceed the beneficial ownership limitation contained therein. We received gross proceeds of $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;">The Series&#160;D Common Warrants are callable at our option following the release of a positive data readout for our Phase 1b Part&#160;III clinical trial for DA-1726 via a widely disseminated press release, subject to satisfaction of certain conditions. The Series&#160;C and Series&#160;D Common Warrants are fixed priced and do not contain any variable pricing features or alternative exercise provisions. Subsequently, 1,630,964 pre-funded warrants have been exercised for an equivalent number of shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><i style="color:#212529;font-style:italic;">At the market offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;">In March 2026, we sold 216,625 shares of common stock under the ATM Program and received net proceeds of $0.3 million, net of sales agent commission and related offering expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (12,973)<span></span>
</td>
<td class="num">$ (27,592)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Risk management</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We recognize the importance of assessing, identifying, and managing risks associated with cybersecurity threats. These risks include, among other things, operational risks; intellectual property theft; fraud; extortion; harm to employees, violation of privacy or security laws and other litigation and legal risk; and reputational risks. We are committed to maintaining robust governance and oversight of these risks and to implementing mechanisms, controls, technologies, and processes designed to help us assess, identify, and manage these risks. While we have not, as of the date of this Annual Report, experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations, there can be no guarantee that we will not experience such an incident in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We aim to incorporate industry best practices throughout our cybersecurity program. Our cybersecurity strategy focuses on implementing effective and efficient controls, technologies, and other processes to assess, identify, and manage material cybersecurity risks. Our cybersecurity program is designed to be aligned with applicable industry standards. We work with a third-party provider to monitor threats and potential cybersecurity breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">We have processes in place to assess, identify, manage, and address material cybersecurity threats and incidents. These include, among other things: ongoing security awareness training for employees; mechanisms to detect and monitor unusual network activity; and containment and incident response tools. We monitor issues that are internally discovered or reported by our third-party monitoring service that may affect our information services and have processes to assess those issues for potential cybersecurity impact or risk. We impose security requirements upon our suppliers and CROs, including maintaining an effective security management program; abiding by information handling and asset management requirements; and notifying us in the event of any known or suspected cyber incident.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We recognize the importance of assessing, identifying, and managing risks associated with cybersecurity threats. These risks include, among other things, operational risks; intellectual property theft; fraud; extortion; harm to employees, violation of privacy or security laws and other litigation and legal risk; and reputational risks. We are committed to maintaining robust governance and oversight of these risks and to implementing mechanisms, controls, technologies, and processes designed to help us assess, identify, and manage these risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Our Board has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to Company priorities, resource allocations, and oversight structures. The Board is assisted by the audit committee, which reviews our cybersecurity program with management and reports to the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">The audit committee is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The audit committee is composed of Board members with diverse expertise including risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Our Chief Executive Officer, Chief Financial Officer and corporate controller have operational experience in assessing and managing cybersecurity risk. Our Chief Executive Officer plays a pivotal role in informing the audit committee on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">cybersecurity risks. They provide comprehensive briefings to the audit committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current cybersecurity landscape and emerging threats;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Status of ongoing cybersecurity initiatives and strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Incident reports and learnings from any cybersecurity events; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with regulatory requirements and industry standards.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In addition to our scheduled meetings, the audit committee and Chief Executive Officer maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#8217;s oversight is proactive and responsive. The audit committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into the broader strategic objectives of MetaVia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The audit committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">Our Board has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to Company priorities, resource allocations, and oversight structures. The Board is assisted by the audit committee, which reviews our cybersecurity program with management and reports to the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">The audit committee is central to the Board&#8217;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The audit committee is composed of Board members with diverse expertise including risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Our Chief Executive Officer, Chief Financial Officer and corporate controller have operational experience in assessing and managing cybersecurity risk. Our Chief Executive Officer plays a pivotal role in informing the audit committee on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;">cybersecurity risks. They provide comprehensive briefings to the audit committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current cybersecurity landscape and emerging threats;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Status of ongoing cybersecurity initiatives and strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Incident reports and learnings from any cybersecurity events; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with regulatory requirements and industry standards.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;">In addition to our scheduled meetings, the audit committee and Chief Executive Officer maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#8217;s oversight is proactive and responsive. The audit committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into the broader strategic objectives of MetaVia. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Chief Executive Officer, Chief Financial Officer and corporate controller<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our Chief Executive Officer, Chief Financial Officer and corporate controller have operational experience in assessing and managing cybersecurity risk.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A.</b></span><b style="font-weight:bold;">Basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).<span style="background:#ffffff;"> Our fiscal year-end is December 31st for each year presented. </span>All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">B.</b></span><b style="font-weight:bold;">New accounting standards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;background:#ffffff;">Adoption of new accounting standards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">In December 2023, the</span>&#160;<span style="background:#ffffff;">Financial Accounting Standards Board</span>&#160;(&#8220;FASB&#8221;)<span style="color:#212529;background:#ffffff;"> issued</span><span style="color:#212529;">&#160;</span>Accounting Standards Update (&#8220;ASU&#8221;) <span style="color:#212529;">2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve the transparency of income tax disclosures by amending the required rate reconciliation disclosures as well as requiring disclosure of income taxes paid disaggregated by jurisdiction. As amended, the rate reconciliation disclosure will be required to be presented in both percentages and reporting currency amounts, with consistent categories and greater disaggregation of information. This ASU also includes amendments intended to improve the effectiveness of income tax disclosures and eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. This ASU is&#160;</span><span style="color:#212529;background:#ffffff;">effective for annual periods beginning after December 15, 2024. We adopted ASU 2023-09 in 2025, </span>and applied the new disclosure requirements retrospectively. Accordingly, prior period disclosures have been adjusted to reflect the new disclosure requirements, <span style="color:#212529;background:#ffffff;">see Note 9. Income taxes for additional information. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;background:#ffffff;">Accounting standards issued but not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">In November 2024, the FASB issued&#160;ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the consolidated financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to the consolidated financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting period beginning after December 15, 2027. Early adoption is permitted. We continue to evaluate the impact of adopting this ASU to our notes to the consolidated financial statements and processes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;background:#ffffff;">Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Estimates and assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">C.</b></span><b style="font-weight:bold;">Estimates and assumptions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">D.</b></span><b style="font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We maintain cash and cash equivalents at a financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">E.</b></span><b style="font-weight:bold;">Property&#160;and equipment, net</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Property and equipment are recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from <span style="-sec-ix-hidden:Hidden_zDOjGvv570SVRG19o1qIjg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to five years. Tangible assets acquired for R&amp;D activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">F.</b></span><b style="font-weight:bold;">Leases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We assess our contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. We have recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to our&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, we recognize lease payments as an expense on a straight-line basis over the remaining lease term.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_WarrantLiabilitiesPolicyPolicyTextBlock', window );">Warrant liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">G.</b></span><b style="font-weight:bold;">Warrant liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Warrants are accounted for as liabilities at their fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities is recognized as a fair value change in warrant liabilities in the consolidated statements of operations and as an operating item in the statement of cash flows. Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">H.</b></span><b style="font-weight:bold;">Fair value of financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. <span style="background:#ffffff;">The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.</span><span style="background:#ffffff;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">I.</b></span><b style="font-weight:bold;">Segment reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">We manage and operate as one reportable segment, which is principally the business of development of pharmaceutical products, with one geographic location in the U.S. We do not operate separate lines of business with respect to each pharmaceutical product being studied. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our chief executive officer. The CODM manages the Company&#8217;s operations on a consolidated basis for the purpose of allocating resources. The measure of performance used by the CODM to assess segment performance is reported on the consolidated statements of operations as loss from operations and net loss. Since the Company only has&#160;one&#160;reportable segment, our CODM does not need to decide on how to allocate resources between segments. The measure of segment assets is reported on the consolidated balance sheets as total assets. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">J.</b></span><b style="font-weight:bold;">Research and development costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">R&amp;D expenditures for pre-clinical and clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the United States Food and Drug Administration, are charged to R&amp;D expense as incurred. These expenses consist of costs incurred in performing development activities, including salaries and benefits, equity-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Expenses incurred for certain R&amp;D activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for R&amp;D activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected as clinical trial accrued liabilities in the accompanying consolidated financial statements. Advance payments, if any, for goods or services to be received in the future for R&amp;D activities are deferred and capitalized as prepaid expenses and other current assets in the accompanying consolidated balance sheets. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">K.</b></span><b style="font-weight:bold;">General and administrative expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with R&amp;D activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PatentCostPolicyPolicyTextBlock', window );">Patent costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">L.</b></span><b style="font-weight:bold;">Patent costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">M.</b></span><b style="font-weight:bold;">Stock-based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Compensation costs related to equity instruments granted are recognized at the grant date fair value, which is amortized as compensation expense on a straight-line basis over the requisite service period (generally, the vesting period) for both graded and cliff vesting awards. We have elected to account for forfeitures as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">N.</b></span><b style="font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Income taxes are accounted for under the asset and liability method.&#160;Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Regular assessments are made on the likelihood that our deferred tax assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of available positive and negative evidence, giving weight based on the evidence&#8217;s relative objectivity. Sources of positive evidence include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years, and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected in future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that, if unfavorably resolved, would adversely affect future profit levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The remaining carrying value of our deferred tax assets, after recording the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably. To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our policy is to recognize both interest and penalties related to uncertain tax positions as part of the income tax provision.&#160;A significant judgment is required in evaluating our tax positions, and in determining our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions are likely to be challenged and we may ultimately not prevail in defending those positions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">O.</b></span><b style="font-weight:bold;">Foreign currency translation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Certain transactions are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share of common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">P.</b></span><b style="font-weight:bold;">Loss per share of common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Basic earnings or loss per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the weighted average number of shares of common stock. Diluted earnings per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the sum of the weighted average number of shares of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive securities had been issued. Potentially dilutive securities include convertible preferred stock, outstanding stock options, non-vested RSUs and outstanding warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share of common stock by application of the treasury stock method, except if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities. For additional information, see Note 10. Loss per share of common stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Q.</b></span><b style="font-weight:bold;">Concentrations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Financial instruments that potentially subject us to concentration of credit risk consist of cash. As of December 31, 2025, our cash is held by one financial institution in the U.S., and we believe that the financial institution is financially sound. Accordingly, minimal credit risk exists with the financial institution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span><i style="font-style:italic;">Supplier Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In 2022, we entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A ST&#8221;), a related party, which requires Dong-A ST to be the sole manufacturer for the production of vanoglipel (DA-1241) and DA-1726. If any issues arise in the manufacturing and we are unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete the development of vanoglipel (DA-1241) or DA-1726.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Loss contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">R.</b></span><b style="font-weight:bold;">Loss contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">In determining whether an accrual for a loss contingency is required, we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range, that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be accrued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely), no accrual is recognized. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PatentCostPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PatentCostPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_WarrantLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_WarrantLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Prepaid expenses and other current assets consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Deferred equity offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Other prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 55</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Property and equipment, net consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (73)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (54)</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 34</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Accrued expenses and other current liabilities consist of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Employee related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 713</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 149</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 55</p></td></tr><tr style=""><td style="vertical-align:bottom;width:56.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 785</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock', window );">Schedule of warrant liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">Changes to our warrant liabilities are summarized as follows (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 658</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_VOralR6i3ki9t2Jyaw8bcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gain from change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (297)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_W8CSMwv8-EWiuCXptape3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gain from change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (225)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:76.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and terms of the financial instruments and the rights and obligations embodied in those instruments, information about settlement alternatives, if any, in the contract and identification of the entity that controls the settlement alternatives including: a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, "the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable. g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments are disclosed separately from the amount of retained earnings or accumulated deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2025 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Operating</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Lease</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 94</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 64</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 250</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Less effect of discounting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (40)</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">  Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 210</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Short-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 68</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 142</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of outstanding warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of Common Stock Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Outstanding Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Expiration</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrant Issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Date</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 2020 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">33,000.00 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 942</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">15,919.20 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 2021 <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,399</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">9,900.00 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 2022 Series B <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,176</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.00 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2027</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Placement Agent<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,564</p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,564</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">54.0375 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Pre-Funded <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">0.011 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">No expiration date</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Series A <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 462,641</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">43.23 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2025</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">June 2024 Series B <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 693,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 693,962</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">43.23 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">September 2029 (latest date)</p></td></tr><tr style=""><td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 722,644</p></td><td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,316,698</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="margin-top:4pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants expired unexercised in April 2025.</span><span style="display:inline-block;width:4.57pt;"></span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">T</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hese warrants have a cashless exercise provision whereby&#160;the warrants can be exercised for common stock for&#160;</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;additional consideration, which renders the </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$264</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;per warrant exercise price to be&#160;</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expire in July 2026. </span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable immediately and are considered to be perpetual warrants without any expiration date. In the second quarter of 2025,&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">130,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock. Additionally, in the third quarter of 2024, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31,924</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expired unexercised in June 2025.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These warrants are exercisable at any time from September 18, 2024 and expire on the earlier of September 18, 2029 and the </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">six months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> anniversary following the date on which we publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.</span></td><td style="width:36pt;"></td></tr></table><div style="margin-top:8pt;"></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Stock-based compensation expense was included in general and administrative <span style="color:#212529;">and research and development as follows&#160;</span><span style="color:#212529;background:#ffffff;">(in thousands)</span><span style="color:#212529;">:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 366</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 172</p></td></tr><tr style=""><td style="vertical-align:middle;width:56.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 538</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of outstanding awards issued pursuant to our stock-based award plans and inducement plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining shares of</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">common stock available</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Plan Name</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:26.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for future issuance</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2019 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2022 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 167,471</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2021 Inducement Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 378</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,693</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 167,849</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock units ("RSUs") and related transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table summarizes the status of our RSUs and related transactions for the period presented (in thousands, except share and per share amounts)</span>: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Vested and Deferred Release</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Grant Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Aggregate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Grant Date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Aggregate</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Intrinsic</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Value</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 20</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 50.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,855)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 284</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 51.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 22,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (6,693)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 53.58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,142)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:25.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the status of outstanding and exercisable options and related transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="background:#ffffff;">The following table summarizes the status of our outstanding and exercisable options and related transactions for the period presented (</span><span style="color:#212529;background:#ffffff;">in thousands, except share and per share amounts):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:37.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercisable</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Shares of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Weighted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Average</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Remaining</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contractual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Issuable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Exercise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contractual</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">for Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Term (years)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,149.85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.6</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.5</p></td></tr><tr style=""><td style="vertical-align:bottom;width:24.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,240.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.6</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black Scholes option-pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Placement Agent</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Contingent</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Warrants</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Granted in</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Granted in</p></td></tr><tr style=""><td style="vertical-align:middle;width:44.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">June 2024</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average fair value </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected stock price volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">140.0</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">127.0</p></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected term (years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:44.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk-free interest rate </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.63</p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.31</p></td><td style="vertical-align:bottom;width:4.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant segment expenses and loss before income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Significant segment expenses and loss before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of significant segment expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;letter-spacing:0.2pt;">The following table sets forth the significant segment expenses for our </span><span style="color:#212529;letter-spacing:0.2pt;">one</span><span style="color:#212529;letter-spacing:0.2pt;"> reportable segment (in thousands) that are regularly provided to our CODM: </span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Direct expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Vanoglipel (DA-1241) credits (costs) <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,959</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">DA-1726 costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,397</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other R&amp;D costs<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> (2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 107</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 303</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Indirect expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,606</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 288</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,553</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Legal and professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,864</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Consulting expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 823</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,512</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Employee compensation and benefits costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,659</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other expenses <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,221</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,256</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,809</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,708)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (28,809)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 735</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,217</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,973)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (27,592)</p></td></tr></table><div style="margin-top:4pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes a credit of </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$1.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> million recorded in 2025 </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">in connection with the close-out of the clinical trial with the</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">clinical research organization.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes clinical, non-clinical and preclinical services or other R&amp;D expenses that are not attributable to a single product candidate.</span></td><td style="width:36pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.35pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">Includes all other general and administrative expenses, such as insurance, software license fees, non-income state taxes, lease rental expenses, etc.</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> </span></td><td style="width:36pt;"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">Our loss before income taxes is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,973)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (27,592)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,973)</p></td><td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:middle;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (27,592)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The components of our income tax provision are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income tax (benefit) expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,683)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5,809)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 270</p></td><td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,592)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred income tax (benefit) expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,413)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (8,401)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,683</p></td><td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,809</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (270)</p></td><td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,592</p></td></tr><tr style=""><td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate</a></td>
<td class="text">A reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate is as follows (in thousands, except for percentages):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income taxes at U.S. federal statutory rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5,794)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">State income tax, net of federal benefit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Changes in valuation allowances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (20.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (21.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nontaxable and nondeductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:52.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective tax rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;">The significant components of our deferred tax assets and liabilities are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred income tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">U.S. federal and state net operating loss ("NOL") carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,959</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired intangibles </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,000</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net unrealized built-in loss (NUBIL) - 382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 515</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 458</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized R&amp;D expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,516</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 118</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">R&amp;D credit carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total gross deferred income tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 18,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,114</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (18,491)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (16,077)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred tax assets, net of valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 37</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (36)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Gross deferred income tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (58)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (37)</p></td></tr><tr style=""><td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred income tax assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share of common stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted loss per share of common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;">The following table sets forth the computation of basic and diluted loss per share of common stock <span style="color:#212529;background:#ffffff;">(in thousands, except share and per share amounts):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;white-space:nowrap;width:60.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">Year Ended December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:middle;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (12,973)</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (27,592)</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Weighted average shares of common stock, basic</p></td><td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">1,766,026</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">705,193</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Effect of dilutive securities</p></td><td style="vertical-align:middle;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:middle;width:60.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Weighted average shares of common stock, diluted</p></td><td style="vertical-align:middle;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">1,766,026</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;">705,193</p></td></tr><tr style=""><td style="vertical-align:bottom;width:60.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Loss per share of common stock, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7.35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (39.13)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding securities which were not included in the calculation of diluted earnings per share of common stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December 31,</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,213</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,728</p></td></tr><tr style=""><td style="vertical-align:bottom;width:61.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 706,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,170,522</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value measurements on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#212529;">The following table sets forth our financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy&#160;</span><span style="color:#212529;background:#ffffff;">(in thousands)</span><span style="color:#212529;">:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:35.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December&#160;31,&#160;2025</p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:33.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">As of December&#160;31,&#160;2024</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Description</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Level&#160;3</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Bank money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,519</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr style=""><td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment </div>
<div>location </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, ratio</a></td>
<td class="nump">0.091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 10,278<span></span>
</td>
<td class="nump">$ 16,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">148,830<span></span>
</td>
<td class="nump">135,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">12,973<span></span>
</td>
<td class="nump">27,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">$ 15,701<span></span>
</td>
<td class="nump">$ 24,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfGeographicLocation', window );">Number of geographic location in the United States | location</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, ratio</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Business, basis of presentation, new accounting standards and summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, ratio</a></td>
<td class="nump">0.033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NumberOfGeographicLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of geographic location reported by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NumberOfGeographicLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred equity offering costs</a></td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 597<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Office equipment</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current liabilities - Accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related costs</a></td>
<td class="nump">$ 829<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional service fees</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current liabilities -Warrant liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">As of beginning balance</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Gain from change in fair value of warrant liabilities</a></td>
<td class="num">$ (225)<span></span>
</td>
<td class="num">$ (297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">As of ending balance</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481679/480-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current liabilities - Warrant liabilities - Additional information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesAndSeriesBWarrantsMember', window );">November 2022 Series A and B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants per unit</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesAndSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesAndSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,802<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,312<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Related party<span></span>
</td>
<td class="text">Related party<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mtva_LicenseAgreementMember', window );">2022 License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PeriodForFailToCureBreachMayTerminateAgreement', window );">Period for failing to cure the beach, the agreement may get terminated</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_CurePeriodForBreachingParty', window );">Cure period for beaching party if cannot be cured within the 60-day period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PeriodForTerminationNotice', window );">Period for termination notice when material breach not cured</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_CurePeriodForPetitionForBankruptcy', window );">Cure period for petition for bankruptcy</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_MilestonesAccrued', window );">Amount of milestones accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mtva_Da1726Member', window );">DA-1726</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mtva_Da1241Member', window );">DA-1241</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mtva_SharedServicesAgreementMember', window );">Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PeriodForFailToCureBreachMayTerminateAgreement', window );">Period for failing to cure the beach, the agreement may get terminated</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration', window );">Other Liability, Current, Related Party [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Related party<span></span>
</td>
<td class="text">Related party<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration', window );">Other Liability, Current, Related Party, Name [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dong-A<span></span>
</td>
<td class="text">Dong-A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_RelatedPartyExtendedPaymentLiability', window );">Extended terms payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths', window );">Extended terms amount to be paid on March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths', window );">Extended terms amount to be paid on September 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_RelatedPartyAccruedInterestPayable', window );">Extended terms, Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_RelatedPartyClinicalTrialAccruedLiability', window );">Amount payable in clinical trial accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Dong A Socio Holding Co Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_CurePeriodForBreachingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cure period for beaching party if cannot be cured within the 60-day period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_CurePeriodForBreachingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_CurePeriodForPetitionForBankruptcy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cure period for petition for bankruptcy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_CurePeriodForPetitionForBankruptcy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_MilestonesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to milestones accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_MilestonesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Percentage of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PeriodForFailToCureBreachMayTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for failing to cure the beach, the agreement may get terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PeriodForFailToCureBreachMayTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PeriodForTerminationNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for petition for termination notice for the other party's material breach that is not cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PeriodForTerminationNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_RelatedPartyAccruedInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest payable to related party under extended payment terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_RelatedPartyAccruedInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_RelatedPartyClinicalTrialAccruedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liability payable to related party for clinical trial services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_RelatedPartyClinicalTrialAccruedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_RelatedPartyExtendedPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related party under extended payment terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_RelatedPartyExtendedPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related party under extended payment terms due in next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related party under extended payment terms due in six months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates name of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates status and type of related party for liability classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mtva_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mtva_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mtva_Da1726Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mtva_Da1726Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mtva_Da1241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mtva_Da1241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mtva_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mtva_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mtva_DongStMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mtva_DongStMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mtva_DongSocioHoldingCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mtva_DongSocioHoldingCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies - Operating Leases - (Details) - New Corporate Headquarters Lease - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mtva_NewCorporateHeadquartersLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mtva_NewCorporateHeadquartersLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease - Lease liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of the lease liability was as follows (in thousands):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less effect of discounting</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term portion</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent payments and license agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent liabilities recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Contingent assets recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Employment agreements and Employee benefit plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DefinedContributionPlanEmployeeEligibilityAge', window );">Minimum age of employee to cover under the plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage', window );">Employer matches vesting period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_EmployeeCompensationVestingPercentageOnContribution', window );">Percentage of employee contribution vested on their contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Amount of discretionary matching contributions on employee deferrals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage', window );">Employee compensation deferred percentage</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employee contributions may be deferred to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DefinedContributionPlanEmployeeEligibilityAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee eligibility age criteria under defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DefinedContributionPlanEmployeeEligibilityAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_EmployeeCompensationVestingPercentageOnContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employee contribution vested on contribution made by employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_EmployeeCompensationVestingPercentageOnContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Common stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Vote / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_CommonStockVotingRightsPerShare', window );">Common stock, vote per share | Vote / shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockAbstract', window );"><strong>Dividends Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_CommonStockVotingRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the voting rights per share for common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_CommonStockVotingRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Private placement and At the market offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2026</div></th>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice33000.00Member', window );">Warrants Exercise Price 33,000.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice15919.20Member', window );">Warrants Exercise Price 15,919.20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,919.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice9900.00Member', window );">Warrants Exercise Price 9,900.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member', window );">November 2022 Series B Warrant Exercise Price 0.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member', window );">June 2024 Placement Agent, Warrant Exercise Price 54.0375</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member', window );">June 2024 Series B, Warrant Exercise Price 43.23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member', window );">June 2024 Pre-Funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingAgreementMember', window );">At the market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares)</a></td>
<td class="nump">106,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PercentageOfSalesAgentCommission', window );">Percentage of sales agent commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate net proceeds</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants', window );">Issuance of common stock and pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PaymentsForPlacementAgentFees', window );">Cash fee payment to the placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">861,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related party | Private Placement | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Number of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock that the company is still authorized to issue or remaining available for issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PaymentsForPlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow made during the period for placement agent fees in connection with the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PaymentsForPlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PercentageOfSalesAgentCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sales agent commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PercentageOfSalesAgentCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow from issuance of stock and pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice33000.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice33000.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice15919.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice15919.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice9900.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice9900.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Securities purchase agreements and Placement agent (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>security </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfSecuritiesPurchaseAgreementsEntered', window );">Number of Securities | security</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Aggregate net proceeds | $</a></td>
<td class="nump">18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PaymentsForPlacementAgentFees', window );">Cash fee payment to the placement agent | $</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares) | shares</a></td>
<td class="nump">300,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share) | $ / shares</a></td>
<td class="nump">$ 43.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PercentageOfPlacementAgentFee', window );">Percentage of placement agent fee</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts', window );">Non-accountable expenses and clearing costs | $</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants', window );">Percentage of common stock sold</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share) | $ / shares</a></td>
<td class="nump">$ 43.219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable for Issued and outstanding warrants | shares</a></td>
<td class="nump">161,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ThresholdPercentageForBeneficialOwnership', window );">Maximum percentage of outstanding common stock</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder', window );">Number of days written notice</a></td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | Series A warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable for Issued and outstanding warrants | shares</a></td>
<td class="nump">462,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable for Issued and outstanding warrants | shares</a></td>
<td class="nump">693,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | PIPE common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares) | shares</a></td>
<td class="nump">69,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 43.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ThresholdPercentageForBeneficialOwnership', window );">Maximum percentage of outstanding common stock</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable for Issued and outstanding warrants | shares</a></td>
<td class="nump">11,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 54.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_PremiumOfOfferingPriceForExercisePricePercentage', window );">Premium of offering price per share (as a percent)</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_WeightedAverageFairValuePerShareOfWarrants', window );">Weighted average fair value of warrants | $ / shares</a></td>
<td class="nump">$ 30.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Non-cash issuance cost | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | Placement Agent Contingent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares of common stock issuable for Issued and outstanding warrants | shares</a></td>
<td class="nump">28,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 54.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_WeightedAverageFairValuePerShareOfWarrants', window );">Weighted average fair value of warrants | $ / shares</a></td>
<td class="nump">$ 37.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember', window );">June 2024 Offering | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective period for changing beneficial ownership limitation from receipt of written notice from holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NumberOfSecuritiesPurchaseAgreementsEntered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities purchase agreements entered during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NumberOfSecuritiesPurchaseAgreementsEntered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PaymentsForPlacementAgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow made during the period for placement agent fees in connection with the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PaymentsForPlacementAgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PercentageOfPlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of placement agent gee on gross proceeds of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PercentageOfPlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares exercisable through warrants as a percent on total shares and warrants sold in the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-accountable expenses and clearing costs as placement agent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_PremiumOfOfferingPriceForExercisePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The premium of offering price for warrants exercise price in percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_PremiumOfOfferingPriceForExercisePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ThresholdPercentageForBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold percentage for beneficial ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ThresholdPercentageForBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_WeightedAverageFairValuePerShareOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value per share of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_WeightedAverageFairValuePerShareOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PipeCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PipeCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mtva_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mtva_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">722,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice33000.00Member', window );">Warrants Exercise Price 33,000.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice15919.20Member', window );">Warrants Exercise Price 15,919.20</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 15,919.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice9900.00Member', window );">Warrants Exercise Price 9,900.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member', window );">November 2022 Series B Warrant Exercise Price 0.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">16,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member', window );">June 2024 Placement Agent, Warrant Exercise Price 54.0375</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">11,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 54.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member', window );">June 2024 Pre-Funded, Warrant Exercise Price 0.011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesaWarrantExercisePrice43.23Member', window );">June 2024 Series A , Warrant Exercise Price 43.23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 43.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member', window );">June 2024 Series B, Warrant Exercise Price 43.23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">693,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 43.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice33000.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice33000.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice15919.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice15919.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice9900.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_WarrantsExercisePrice9900.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesaWarrantExercisePrice43.23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesaWarrantExercisePrice43.23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Warrants - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-Funded Warrants were exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,644<span></span>
</td>
<td class="nump">1,316,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member', window );">November 2022 Series B Warrant Exercise Price 0.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-Funded Warrants were exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,176<span></span>
</td>
<td class="nump">16,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member', window );">June 2024 Pre-Funded, Warrant Exercise Price 0.011</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-Funded Warrants were exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised', window );">Pre-Funded warrants issued</a></td>
<td class="nump">31,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member', window );">June 2024 Series B, Warrant Exercise Price 43.23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-Funded Warrants were exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,962<span></span>
</td>
<td class="nump">693,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants', window );">Threshold period following the public announcement of receiving positive phase 1 multiple ascending dose data for expiry of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised for the securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold period following the public announcement of the Company receiving positive Phase 1 multiple ascending dose ("MAD") data for expiry of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024PreFundedWarrantExercisePrice0.011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_June2024SeriesBWarrantExercisePrice43.23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock-based compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtva_StockPlan2019Member', window );">2019 Plan | Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtva_StockPlan2022Member', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares added (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually', window );">Period of automatic increase in shares reserved</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of the common shares outstanding (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtva_StockPlan2022Member', window );">2022 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period over which the shares reserved for further issuance under share based compensation will increase annually.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mtva_StockPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mtva_StockPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mtva_StockPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mtva_StockPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of Common Stock Issuable for Options, Outstanding (in shares)</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs</a></td>
<td class="nump">29,295<span></span>
</td>
<td class="nump">15,912<span></span>
</td>
<td class="nump">12,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares of common stock available for future issuance</a></td>
<td class="nump">167,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtva_StockPlan2022Member', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares of common stock available for future issuance</a></td>
<td class="nump">167,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtva_TwoThousandTwentyOnePlanMember', window );">2021 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining shares of common stock available for future issuance</a></td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mtva_StockPlan20192022AndInducementPlanMember', window );">Stock-based award plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation cost</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation - Weighted average period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of Common Stock Issuable for Options, Outstanding (in shares)</a></td>
<td class="nump">6,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of Common Stock Issuable for Options, Outstanding (in shares)</a></td>
<td class="nump">6,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs</a></td>
<td class="nump">29,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | 2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs</a></td>
<td class="nump">29,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mtva_StockPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mtva_StockPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mtva_TwoThousandTwentyOnePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mtva_TwoThousandTwentyOnePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mtva_StockPlan20192022AndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mtva_StockPlan20192022AndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSU's Fair value, Beginning balance (in shares)</a></td>
<td class="nump">15,912<span></span>
</td>
<td class="nump">12,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's, Number Granted (in shares)</a></td>
<td class="nump">22,218<span></span>
</td>
<td class="nump">10,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSU's, Number Vested and Released (in shares)</a></td>
<td class="num">(6,693)<span></span>
</td>
<td class="num">(7,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSU's, Number Forfeited/Cancelled (in shares)</a></td>
<td class="num">(2,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSU's Fair value, Ending balance (in shares)</a></td>
<td class="nump">29,295<span></span>
</td>
<td class="nump">15,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSU's Fair value, Opening balance (per share)</a></td>
<td class="nump">$ 51.46<span></span>
</td>
<td class="nump">$ 50.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSU's Fair value, Granted (per share)</a></td>
<td class="nump">7.05<span></span>
</td>
<td class="nump">50.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSU's Fair value, Vested and released (per share)</a></td>
<td class="nump">53.58<span></span>
</td>
<td class="nump">47.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSU's Fair value, Forfeited/cancelled (per share)</a></td>
<td class="nump">30.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSU's Fair value, Ending balance (per share)</a></td>
<td class="nump">$ 18.86<span></span>
</td>
<td class="nump">$ 51.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance', window );">Outstanding, Aggregate Fair Value, beginning balance</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding', window );">Outstanding, Aggregate Fair Value, Vested and released</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance', window );">Outstanding, Aggregate Fair Value, ending balance</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber', window );">Shares of Common Stock Issuable for RSUs, Vested and Deferred Release (in shares)</a></td>
<td class="nump">3,082<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue', window );">Average Grant Date Fair Value Price , Vested and Deferred Release (per share)</a></td>
<td class="nump">$ 43.85<span></span>
</td>
<td class="nump">$ 46.9<span></span>
</td>
<td class="nump">$ 44.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Vested and Deferred Release</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock-based compensation - Stock options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares of Common Stock Issuable for Options, Outstanding (in shares)</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding (per shares)</a></td>
<td class="nump">$ 4,240.22<span></span>
</td>
<td class="nump">$ 4,240.22<span></span>
</td>
<td class="nump">$ 4,240.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares of Common Stock Issuable for Options, Exercisable (in shares)</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable (per share)</a></td>
<td class="nump">$ 4,240.22<span></span>
</td>
<td class="nump">$ 4,240.22<span></span>
</td>
<td class="nump">$ 4,149.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Exercisable</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable, Intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Stock - Assumptions (Details) - June 2024 Offering<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentWarrantsMember', window );">Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="nump">$ 30.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">140.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.63%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentContingentWarrantsMember', window );">Placement agent contingent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value</a></td>
<td class="nump">$ 37.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">127.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.31%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mtva_June2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentContingentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PlacementAgentContingentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">$ 6,802<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">6,906<span></span>
</td>
<td class="nump">7,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,708<span></span>
</td>
<td class="nump">28,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,708)<span></span>
</td>
<td class="num">(28,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(12,973)<span></span>
</td>
<td class="num">(27,592)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mtva_SingleReportableSegmentMember', window );">Single reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram', window );">Direct expenses - Vanoglipel (DA-1241) credits (costs)</a></td>
<td class="num">(845)<span></span>
</td>
<td class="nump">9,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram', window );">Direct expenses - DA-1726 costs</a></td>
<td class="nump">5,468<span></span>
</td>
<td class="nump">9,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Direct expenses - Other R&amp;D costs</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_LaborAndRelatedExpenseResearchAndDevelopment', window );">Indirect expenses - employee compensation and benefits costs</a></td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ConsultingFeeResearchAndDevelopment', window );">Indirect expenses - consulting expenses</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development</a></td>
<td class="nump">6,802<span></span>
</td>
<td class="nump">21,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_LegalAndProfessionalFees', window );">Legal and professional fees</a></td>
<td class="nump">3,338<span></span>
</td>
<td class="nump">2,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ConsultingFeeGeneralAndAdministrative', window );">Consulting expenses</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_LaborAndRelatedExpenseGeneralAndAdministrative', window );">Employee compensation and benefits costs</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other expenses</a></td>
<td class="nump">948<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">6,906<span></span>
</td>
<td class="nump">7,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,708<span></span>
</td>
<td class="nump">28,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,708)<span></span>
</td>
<td class="num">(28,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(12,973)<span></span>
</td>
<td class="num">$ (27,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram', window );">Close-out of a clinical trial</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ConsultingFeeGeneralAndAdministrative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for consultancy services incurred in General and administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ConsultingFeeGeneralAndAdministrative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ConsultingFeeResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for consultancy services incurred in Research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ConsultingFeeResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_LaborAndRelatedExpenseGeneralAndAdministrative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for labor and related services incurred in General and administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_LaborAndRelatedExpenseGeneralAndAdministrative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_LaborAndRelatedExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for labor and related services incurred in Research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_LaborAndRelatedExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_LegalAndProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs and professional costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_LegalAndProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred in the first clinical trial program associated with research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents a reduction (credit) to research and development expense recognized in connection with the close-out of a clinical trial with a clinical research organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred in the second clinical trial program associated with research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mtva_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mtva_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Loss before income taxes and Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before Income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (12,973)<span></span>
</td>
<td class="num">$ (27,592)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(12,973)<span></span>
</td>
<td class="num">(27,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(2,683)<span></span>
</td>
<td class="num">(5,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">270<span></span>
</td>
<td class="num">(2,592)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax (benefit) expense</a></td>
<td class="num">(2,413)<span></span>
</td>
<td class="num">(8,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">2,683<span></span>
</td>
<td class="nump">5,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">$ (270)<span></span>
</td>
<td class="nump">$ 2,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Reconciliation of income tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income taxes at U.S. federal statutory rate</a></td>
<td class="num">$ (2,724)<span></span>
</td>
<td class="num">$ (5,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="nump">2,683<span></span>
</td>
<td class="nump">5,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract', window );"><strong>Nontaxable and nondeductible items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax (as a Percent):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes at U.S. federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances (as a percent)</a></td>
<td class="num">(20.70%)<span></span>
</td>
<td class="num">(21.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract', window );"><strong>Nontaxable and nondeductible items (as a percent)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent', window );">Change in fair value of warrant liabilities (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other (as a percent)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income taxes - Significant components of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Gross deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">U.S. federal and state net operating loss ("NOL") carryforwards</a></td>
<td class="nump">$ 7,661<span></span>
</td>
<td class="nump">$ 4,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">2,890<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DeferredTaxAssetsUnrealizedBuiltInLoss', window );">Net unrealized built-in loss (NUBIL) - 382</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D expenses</a></td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">7,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred income tax assets</a></td>
<td class="nump">18,549<span></span>
</td>
<td class="nump">16,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(18,491)<span></span>
</td>
<td class="num">(16,077)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Gross deferred tax assets, net of valuation allowance</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Gross deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_DeferredTaxLiabilitiesRouAsset', window );">ROU asset</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred income tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DeferredTaxAssetsUnrealizedBuiltInLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on an ownership change and holds assets whose fair market value (FMV) is less than their tax basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DeferredTaxAssetsUnrealizedBuiltInLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_DeferredTaxLiabilitiesRouAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_DeferredTaxLiabilitiesRouAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 18,491<span></span>
</td>
<td class="nump">$ 16,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income Tax Examination, Description</a></td>
<td class="text">We have analyzed our filing positions in all significant U.S. federal, state, and local jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, we are no longer subject to U.S. federal, state, and local tax examinations by tax authorities for years before 2022, although carryforward attributes that were generated prior to 2022 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash payments for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfOwnershipChangesOfOver50', window );">Number of ownership change of over 50% since 2022 | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff', window );">NOL carryforward amount</a></td>
<td class="nump">100,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff', window );">R&amp;D credit carryforward amount</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff', window );">NOL carryforward amount</a></td>
<td class="nump">68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforwards expired unutilized and written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NumberOfOwnershipChangesOfOver50">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of ownership changes over 50% defined by Section 382 of the Internal Revenue Code of 1986.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NumberOfOwnershipChangesOfOver50</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research tax credit carryforwards expired unutilized and written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,973)<span></span>
</td>
<td class="num">$ (27,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock, basic (in shares)</a></td>
<td class="nump">1,766,026<span></span>
</td>
<td class="nump">705,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock, diluted (in shares)</a></td>
<td class="nump">1,766,026<span></span>
</td>
<td class="nump">705,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share of common stock, basic (in dollars per share)</a></td>
<td class="num">$ (7.35)<span></span>
</td>
<td class="num">$ (39.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (7.35)<span></span>
</td>
<td class="num">$ (39.13)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share of common stock - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares)</a></td>
<td class="nump">420<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares)</a></td>
<td class="nump">26,213<span></span>
</td>
<td class="nump">14,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Loss per share of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares)</a></td>
<td class="nump">706,468<span></span>
</td>
<td class="nump">1,170,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Recurring basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Bank money market funds</a></td>
<td class="nump">$ 8,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">8,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Bank money market funds</a></td>
<td class="nump">8,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">8,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_WarrantLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_WarrantLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations for warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_WarrantLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member', window );">November 2022 Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value of financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock', window );">Exercised warrants</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants into which each share may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_November2022SeriesBWarrantExercisePrice0.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - Subsequent Event - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_PublicOffering2026Member', window );">2026 public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_PublicOffering2026Member', window );">2026 public offering | Class A units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfCommonStockIssuedPerUnit', window );">Number of common stock per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_PublicOffering2026Member', window );">2026 public offering | Class B units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,998,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">216,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember', window );">Pre-Funded Warrants | 2026 public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised', window );">Pre-Funded warrants issued</a></td>
<td class="nump">1,630,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember', window );">Pre-Funded Warrants | 2026 public offering | Class B units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants issued per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesCWarrantMember', window );">Series C warrants | 2026 public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesCWarrantMember', window );">Series C warrants | 2026 public offering | Class A units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants issued per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesCWarrantMember', window );">Series C warrants | 2026 public offering | Class B units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants issued per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesDWarrantMember', window );">Series D warrants | 2026 public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesDWarrantMember', window );">Series D warrants | 2026 public offering | Class A units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants issued per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesDWarrantMember', window );">Series D warrants | 2026 public offering | Class B units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mtva_NumberOfWarrantsIssuedPerUnit', window );">Number of warrants issued per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised for the securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NumberOfCommonStockIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common stock per units issued under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NumberOfCommonStockIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mtva_NumberOfWarrantsIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants per units issued under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mtva_NumberOfWarrantsIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mtva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_PublicOffering2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mtva_PublicOffering2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mtva_ClassUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mtva_ClassUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mtva_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mtva_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mtva_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesCWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesCWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesDWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mtva_SeriesDWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>57</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200305 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995200400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Business, basis of presentation, new accounting standards and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid expenses and other current assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Current liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCurrentLiabilities</Role>
      <ShortName>Current liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Related party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureRelatedParty</Role>
      <ShortName>Related party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Commitment and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCommitmentAndContingencies</Role>
      <ShortName>Commitment and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Significant segment expenses and loss before income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes</Role>
      <ShortName>Significant segment expenses and loss before income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Loss per share of common stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock</Role>
      <ShortName>Loss per share of common stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Prepaid expenses and other current assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid expenses and other current assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Current liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables</Role>
      <ShortName>Current liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Significant segment expenses and loss before income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables</Role>
      <ShortName>Significant segment expenses and loss before income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Loss per share of common stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables</Role>
      <ShortName>Loss per share of common stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Property and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Current liabilities - Accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Current liabilities - Accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940402 - Disclosure - Current liabilities -Warrant liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails</Role>
      <ShortName>Current liabilities -Warrant liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940403 - Disclosure - Current liabilities - Warrant liabilities - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Current liabilities - Warrant liabilities - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Related party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureRelatedPartyDetails</Role>
      <ShortName>Related party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureRelatedParty</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Commitments and contingencies - Operating Leases - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails</Role>
      <ShortName>Commitments and contingencies - Operating Leases - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - Commitments and Contingencies - Operating Lease - Lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease - Lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940603 - Disclosure - Commitments and Contingencies - Contingent payments and license agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Contingent payments and license agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940604 - Disclosure - Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails</Role>
      <ShortName>Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Stockholders' equity - Common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' equity - Common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - Stockholders' equity - Private placement and At the market offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails</Role>
      <ShortName>Stockholders' equity - Private placement and At the market offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940703 - Disclosure - Stockholders' equity - Securities purchase agreements and Placement agent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails</Role>
      <ShortName>Stockholders' equity - Securities purchase agreements and Placement agent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940704 - Disclosure - Stockholders' equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940705 - Disclosure - Stockholders' equity - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails</Role>
      <ShortName>Stockholders' equity - Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940706 - Disclosure - Stockholders' equity - Stock-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails</Role>
      <ShortName>Stockholders' equity - Stock-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940707 - Disclosure - Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails</Role>
      <ShortName>Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940708 - Disclosure - Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails</Role>
      <ShortName>Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940709 - Disclosure - Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940710 - Disclosure - Stockholders' equity - Stock-based compensation - Stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stockholders' equity - Stock-based compensation - Stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940711 - Disclosure - Stockholders' equity - Stock - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails</Role>
      <ShortName>Stockholders' equity - Stock - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails</Role>
      <ShortName>Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Income taxes - Loss before income taxes and Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails</Role>
      <ShortName>Income taxes - Loss before income taxes and Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Income taxes - Reconciliation of income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails</Role>
      <ShortName>Income taxes - Reconciliation of income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Income taxes - Significant components of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income taxes - Significant components of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails</Role>
      <ShortName>Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Loss per share of common stock - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails</Role>
      <ShortName>Loss per share of common stock - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Fair value measurements - Recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails</Role>
      <ShortName>Fair value measurements - Recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Fair value measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mtva-20251231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metaviatx.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mtva-20251231.xsd</File>
    <File>mtva-20251231_cal.xml</File>
    <File>mtva-20251231_def.xml</File>
    <File>mtva-20251231_lab.xml</File>
    <File>mtva-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mtva-20251231x10k.htm">mtva-20251231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mtva-20251231x10k001.jpg</File>
    <File>mtva-20251231x10k002.jpg</File>
    <File>mtva-20251231x10k003.jpg</File>
    <File>mtva-20251231x10k004.jpg</File>
    <File>mtva-20251231x10k005.jpg</File>
    <File>mtva-20251231x10k006.jpg</File>
    <File>mtva-20251231x10k007.jpg</File>
    <File>mtva-20251231x10k008.jpg</File>
    <File>mtva-20251231x10k009.jpg</File>
    <File>mtva-20251231x10k010.jpg</File>
    <File>mtva-20251231x10k011.jpg</File>
    <File>mtva-20251231x10k012.jpg</File>
    <File>mtva-20251231x10k013.jpg</File>
    <File>mtva-20251231x10k014.jpg</File>
    <File>mtva-20251231x10k015.jpg</File>
    <File>mtva-20251231x10k016.jpg</File>
    <File>mtva-20251231x10k017.jpg</File>
    <File>mtva-20251231x10k018.jpg</File>
    <File>mtva-20251231x10k019.jpg</File>
    <File>mtva-20251231x10k020.jpg</File>
    <File>mtva-20251231x10k021.jpg</File>
    <File>mtva-20251231x10k022.jpg</File>
    <File>mtva-20251231x10k023.jpg</File>
    <File>mtva-20251231x10k024.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="530">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mtva-20251231x10k.htm": {
   "nsprefix": "mtva",
   "nsuri": "http://metaviatx.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "mtva-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mtva-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mtva-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mtva-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mtva-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mtva-20251231x10k.htm"
     ]
    }
   },
   "keyStandard": 275,
   "keyCustom": 73,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 19,
   "memberCustom": 36,
   "hidden": {
    "total": 22,
    "http://fasb.org/us-gaap/2025": 18,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 147,
   "entityCount": 1,
   "segmentCount": 57,
   "elementCount": 626,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 530,
    "http://xbrl.sec.gov/dei/2025": 37,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5
   },
   "report": {
    "R1": {
     "role": "http://metaviatx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://metaviatx.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:InterestIncomeExpenseNet",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "995200300 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "995200305 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:StockAndWarrantsIssuanceCosts",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:StockAndWarrantsIssuanceCosts",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies",
     "shortName": "Business, basis of presentation, new accounting standards and summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995210201 - Disclosure - Prepaid expenses and other current assets",
     "shortName": "Prepaid expenses and other current assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet",
     "longName": "995210301 - Disclosure - Property and equipment, net",
     "shortName": "Property and equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://metaviatx.com/role/DisclosureCurrentLiabilities",
     "longName": "995210401 - Disclosure - Current liabilities",
     "shortName": "Current liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:CurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:CurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://metaviatx.com/role/DisclosureRelatedParty",
     "longName": "995210501 - Disclosure - Related party",
     "shortName": "Related party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://metaviatx.com/role/DisclosureCommitmentAndContingencies",
     "longName": "995210601 - Disclosure - Commitment and contingencies",
     "shortName": "Commitment and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquity",
     "longName": "995210701 - Disclosure - Stockholders' equity",
     "shortName": "Stockholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes",
     "longName": "995210801 - Disclosure - Significant segment expenses and loss before income taxes",
     "shortName": "Significant segment expenses and loss before income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://metaviatx.com/role/DisclosureIncomeTaxes",
     "longName": "995210901 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock",
     "longName": "995211001 - Disclosure - Loss per share of common stock",
     "shortName": "Loss per share of common stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://metaviatx.com/role/DisclosureFairValueMeasurements",
     "longName": "995211101 - Disclosure - Fair value measurements",
     "shortName": "Fair value measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://metaviatx.com/role/DisclosureSubsequentEvents",
     "longName": "995211201 - Disclosure - Subsequent events",
     "shortName": "Subsequent events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)",
     "shortName": "Business, basis of presentation, new accounting standards and summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "99930203 - Disclosure - Prepaid expenses and other current assets (Tables)",
     "shortName": "Prepaid expenses and other current assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "99930303 - Disclosure - Property and equipment, net (Tables)",
     "shortName": "Property and equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables",
     "longName": "99930403 - Disclosure - Current liabilities (Tables)",
     "shortName": "Current liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "mtva:CurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "mtva:CurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "99930603 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityTables",
     "longName": "99930703 - Disclosure - Stockholders' equity (Tables)",
     "shortName": "Stockholders' equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables",
     "longName": "99930803 - Disclosure - Significant segment expenses and loss before income taxes (Tables)",
     "shortName": "Significant segment expenses and loss before income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://metaviatx.com/role/DisclosureIncomeTaxesTables",
     "longName": "99930903 - Disclosure - Income taxes (Tables)",
     "shortName": "Income taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables",
     "longName": "99931003 - Disclosure - Loss per share of common stock (Tables)",
     "shortName": "Loss per share of common stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://metaviatx.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99931103 - Disclosure - Fair value measurements (Tables)",
     "shortName": "Fair value measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940101 - Disclosure - Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)",
     "shortName": "Business, basis of presentation, new accounting standards and summary of significant accounting policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:NumberOfGeographicLocation",
      "unitRef": "Unit_Standard_location_PUM6ABDH9EqMpz0Yzt6Sgw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "99940201 - Disclosure - Prepaid expenses and other current assets (Details)",
     "shortName": "Prepaid expenses and other current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "longName": "99940301 - Disclosure - Property and equipment, net (Details)",
     "shortName": "Property and equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "99940401 - Disclosure - Current liabilities - Accrued expenses and other current liabilities (Details)",
     "shortName": "Current liabilities - Accrued expenses and other current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "mtva:CurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "mtva:CurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails",
     "longName": "99940402 - Disclosure - Current liabilities -Warrant liabilities (Details)",
     "shortName": "Current liabilities -Warrant liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w",
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw",
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
       "mtva:CurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
     "longName": "99940403 - Disclosure - Current liabilities - Warrant liabilities - Additional information (Details)",
     "shortName": "Current liabilities - Warrant liabilities - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "mtva:CurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
     "longName": "99940501 - Disclosure - Related party (Details)",
     "shortName": "Related party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A",
      "name": "mtva:PeriodForFailToCureBreachMayTerminateAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
     "longName": "99940601 - Disclosure - Commitments and contingencies - Operating Leases - (Details)",
     "shortName": "Commitments and contingencies - Operating Leases - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails",
     "longName": "99940602 - Disclosure - Commitments and Contingencies - Operating Lease - Lease liabilities (Details)",
     "shortName": "Commitments and Contingencies - Operating Lease - Lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails",
     "longName": "99940603 - Disclosure - Commitments and Contingencies - Contingent payments and license agreements (Details)",
     "shortName": "Commitments and Contingencies - Contingent payments and license agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails",
     "longName": "99940604 - Disclosure - Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)",
     "shortName": "Commitments and Contingencies - Employment agreements and Employee benefit plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg",
      "name": "mtva:DefinedContributionPlanEmployeeEligibilityAge",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg",
      "name": "mtva:DefinedContributionPlanEmployeeEligibilityAge",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails",
     "longName": "99940701 - Disclosure - Stockholders' equity - Common stock (Details)",
     "shortName": "Stockholders' equity - Common stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:CommonStockVotingRightsPerShare",
      "unitRef": "Unit_Divide_Vote_shares_ETjCJisZMkuUls7w3gpdKA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "mtva:CommonStockVotingRightsPerShare",
      "unitRef": "Unit_Divide_Vote_shares_ETjCJisZMkuUls7w3gpdKA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
     "longName": "99940702 - Disclosure - Stockholders' equity - Private placement and At the market offering (Details)",
     "shortName": "Stockholders' equity - Private placement and At the market offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_h23ZVALXkUePo8zvVv2roQ",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
     "longName": "99940703 - Disclosure - Stockholders' equity - Securities purchase agreements and Placement agent (Details)",
     "shortName": "Stockholders' equity - Securities purchase agreements and Placement agent (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA",
      "name": "mtva:NumberOfSecuritiesPurchaseAgreementsEntered",
      "unitRef": "Unit_Standard_security_7HQ_97jGkEaCEOxlJP1q6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA",
      "name": "mtva:NumberOfSecuritiesPurchaseAgreementsEntered",
      "unitRef": "Unit_Standard_security_7HQ_97jGkEaCEOxlJP1q6A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
     "longName": "99940704 - Disclosure - Stockholders' equity - Warrants (Details)",
     "shortName": "Stockholders' equity - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_YGrezCPF50-XvUz2iIIe3A",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
     "longName": "99940705 - Disclosure - Stockholders' equity - Warrants - Narrative (Details)",
     "shortName": "Stockholders' equity - Warrants - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_nrhpLK0mj0K9W2Dt9Ye5iQ",
      "name": "mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
     "longName": "99940706 - Disclosure - Stockholders' equity - Stock-based compensation (Details)",
     "shortName": "Stockholders' equity - Stock-based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails",
     "longName": "99940707 - Disclosure - Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)",
     "shortName": "Stockholders' equity - Stock-based compensation - Stock-based award plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2019Member_gmTdCJ8ork6VP-4xURIA1A",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2019Member_gmTdCJ8ork6VP-4xURIA1A",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
     "longName": "99940708 - Disclosure - Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)",
     "shortName": "Stockholders' equity - Stock-based compensation - Award plans and inducement grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails",
     "longName": "99940709 - Disclosure - Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details)",
     "shortName": "Stockholders' equity - Stock-based compensation - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails",
     "longName": "99940710 - Disclosure - Stockholders' equity - Stock-based compensation - Stock options (Details)",
     "shortName": "Stockholders' equity - Stock-based compensation - Stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
     "longName": "99940711 - Disclosure - Stockholders' equity - Stock - Assumptions (Details)",
     "shortName": "Stockholders' equity - Stock - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
     "longName": "99940801 - Disclosure - Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)",
     "shortName": "Significant segment expenses and loss before income taxes - Schedule of significant segment expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ",
      "name": "mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails",
     "longName": "99940901 - Disclosure - Income taxes - Loss before income taxes and Components (Details)",
     "shortName": "Income taxes - Loss before income taxes and Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails",
     "longName": "99940902 - Disclosure - Income taxes - Reconciliation of income tax (Details)",
     "shortName": "Income taxes - Reconciliation of income tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "99940903 - Disclosure - Income taxes - Significant components of deferred tax assets and liabilities (Details)",
     "shortName": "Income taxes - Significant components of deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
     "longName": "99940904 - Disclosure - Income taxes (Details)",
     "shortName": "Income taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails",
     "longName": "99941001 - Disclosure - Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details)",
     "shortName": "Loss per share of common stock - Computation of basic and diluted loss per share of common stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R62": {
     "role": "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails",
     "longName": "99941002 - Disclosure - Loss per share of common stock - Antidilutive Securities (Details)",
     "shortName": "Loss per share of common stock - Antidilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kgPNiqIU3EqTQ0FXBCZBtQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kgPNiqIU3EqTQ0FXBCZBtQ",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
     "longName": "99941101 - Disclosure - Fair value measurements - Recurring basis (Details)",
     "shortName": "Fair value measurements - Recurring basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
     "longName": "99941102 - Disclosure - Fair value measurements - Narrative (Details)",
     "shortName": "Fair value measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA",
      "name": "mtva:ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock",
      "unitRef": "Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://metaviatx.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941201 - Disclosure - Subsequent events (Details)",
     "shortName": "Subsequent events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_0R6iYR8SXEKx11Ao953ZHw",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_0R6iYR8SXEKx11Ao953ZHw",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20251231x10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r683"
     ]
    },
    "mtva_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses and liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued Expenses And Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_AccruedLiabilitiesClinicalTrialCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "AccruedLiabilitiesClinicalTrialCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to clinical costs.",
        "label": "Accrued Liabilities, Clinical Trial, Current",
        "terseLabel": "Clinical trial accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "mtva_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional service fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r92",
      "r487"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r683",
      "r965"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r835",
      "r836",
      "r837",
      "r838",
      "r909",
      "r968"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "verboseLabel": "Issuance of placement agent warrants",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r21",
      "r54"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_AggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "AggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock that the company is still authorized to issue or remaining available for issue.",
        "label": "Aggregate Offering Price",
        "verboseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r740",
      "r773"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r733",
      "r743",
      "r776"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r768",
      "r777",
      "r781",
      "r789"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r319",
      "r328"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Outstanding securities not included in the calculation of diluted earnings per share of common stock (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Loss per share of common stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r70",
      "r94",
      "r111",
      "r112",
      "r113",
      "r151",
      "r163",
      "r188",
      "r192",
      "r201",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r378",
      "r380",
      "r425",
      "r472",
      "r473",
      "r478",
      "r564",
      "r644",
      "r645",
      "r655",
      "r683",
      "r686",
      "r687",
      "r698",
      "r854",
      "r855",
      "r924"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r98",
      "r111",
      "r112",
      "r113",
      "r201",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r378",
      "r380",
      "r425",
      "r683",
      "r854",
      "r855",
      "r924"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r674"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_AtMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "AtMarketOfferingAgreementMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to at-the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "At the market offering"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r726"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r726"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r726"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "netLabel": "Cash",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r90",
      "r623"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Bank money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r910",
      "r911"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r46",
      "r110"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r46"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental non-cash investing and financing transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ClassBUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ClassBUnitsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Class B Units, each Class B Unit consisting of one share of Series B Convertible Preferred Stock, convertible into one share of common stock, one Series A Warrant and one Series B Warrant.",
        "label": "Class B Units [Member]",
        "terseLabel": "Class B units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r95",
      "r96",
      "r97",
      "r111",
      "r113",
      "r140",
      "r141",
      "r143",
      "r145",
      "r153",
      "r154",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r241",
      "r242",
      "r244",
      "r245",
      "r247",
      "r250",
      "r253",
      "r254",
      "r257",
      "r260",
      "r266",
      "r425",
      "r520",
      "r521",
      "r522",
      "r523",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r552",
      "r572",
      "r594",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r811",
      "r829",
      "r830",
      "r839"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price",
        "verboseLabel": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r116",
      "r267"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrant liabilities",
        "verboseLabel": "Warrants",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants per unit",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Shares of common stock issuable for Issued and outstanding warrants",
        "verboseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "mtva_ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants into which each share may be converted.",
        "label": "Class of Warrant or Right, Number of Warrants Called by Each Share of Stock",
        "terseLabel": "Exercised warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Warrants Issued",
        "label": "Number of Warrants Issued",
        "verboseLabel": "Number of pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Pre-Funded Warrants were exercised",
        "verboseLabel": "Number of Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised for the securities.",
        "label": "Class Of Warrant Or Right Securities Called By Each Warrant Or Right, Number Of Warrants Exercised",
        "terseLabel": "Pre-Funded warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "mtva_ClassUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ClassUnitsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Class A Units, each consisting of one share of Class A Common Stock and one Warrant [Member]",
        "label": "Class A Units [Member]",
        "terseLabel": "Class A units"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "verboseLabel": "License Agreements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r63",
      "r480",
      "r551"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r221",
      "r222",
      "r617",
      "r850",
      "r852"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Loss contingencies",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r618"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "verboseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r689",
      "r690",
      "r692",
      "r693",
      "r694",
      "r695",
      "r835",
      "r836",
      "r838",
      "r909",
      "r964",
      "r968"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r552"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r552",
      "r570",
      "r968",
      "r969"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2025 and 2024; 2,308,294 and 785,194 shares issued and outstanding as of December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r242",
      "r249",
      "r482",
      "r683"
     ]
    },
    "mtva_CommonStockVotingRightsPerShare": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "CommonStockVotingRightsPerShare",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the voting rights per share for common stock of the entity.",
        "label": "Common Stock Voting Rights Per Share",
        "terseLabel": "Common stock, vote per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Gross deferred income tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "verboseLabel": "Significant components of deferred tax assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "verboseLabel": "Gross deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r424"
     ]
    },
    "mtva_ConsultingFeeGeneralAndAdministrative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ConsultingFeeGeneralAndAdministrative",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for consultancy services incurred in General and administrative.",
        "label": "Consulting Fee, General And Administrative",
        "terseLabel": "Consulting expenses"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ConsultingFeeResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ConsultingFeeResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for consultancy services incurred in Research and development.",
        "label": "Consulting Fee, Research And Development",
        "terseLabel": "Indirect expenses - consulting expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Contingent liabilities recorded",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r834",
      "r933"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r119",
      "r120",
      "r236",
      "r255",
      "r456",
      "r466",
      "r477",
      "r625",
      "r626",
      "r627",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_CurePeriodForBreachingParty": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "CurePeriodForBreachingParty",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cure period for beaching party if cannot be cured within the 60-day period.",
        "label": "Cure Period for Breaching Party",
        "terseLabel": "Cure period for beaching party if cannot be cured within the 60-day period"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_CurePeriodForPetitionForBankruptcy": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "CurePeriodForPetitionForBankruptcy",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cure period for petition for bankruptcy.",
        "label": "Cure Period for Petition for Bankruptcy",
        "terseLabel": "Cure period for petition for bankruptcy"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_CurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "CurrentLiabilitiesTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for current liabilities at the end of the reporting period.",
        "label": "Current liabilities [Text Block]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r804"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r797"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r799"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r803"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r798"
     ]
    },
    "mtva_Da1241Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "Da1241Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The License Agreement covers the rights to DA-1241 for treatment of NASH .",
        "label": "DA-1241 [Member]",
        "terseLabel": "DA-1241"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_Da1726Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "Da1726Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The License Agreement covers the rights to DA-1726 for treatment of obesity and NASH.",
        "label": "DA-1726 [Member]",
        "terseLabel": "DA-1726"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs Capitalized Prepaid And Other Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r832",
      "r901",
      "r902"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income tax (benefit) expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r77",
      "r827",
      "r832"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred income tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r62",
      "r351"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "verboseLabel": "Deferred equity offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r832",
      "r901",
      "r902"
     ]
    },
    "mtva_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs",
        "terseLabel": "Capitalized R&amp;D expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Acquired Intangibles",
        "verboseLabel": "Acquired intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred income tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "mtva_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred income tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Gross deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "U.S. federal and state net operating loss (\"NOL\") carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]",
        "verboseLabel": "Operating loss carryforwards:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "R&amp;D credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "mtva_DeferredTaxAssetsUnrealizedBuiltInLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DeferredTaxAssetsUnrealizedBuiltInLoss",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on an ownership change and holds assets whose fair market value (FMV) is less than their tax basis.",
        "label": "Deferred Tax Assets, Unrealized Built-in Loss",
        "terseLabel": "Net unrealized built-in loss (NUBIL) - 382"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "verboseLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "mtva_DeferredTaxLiabilitiesRouAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DeferredTaxLiabilitiesRouAsset",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets",
        "label": "Deferred Tax Liabilities, ROU Asset",
        "negatedLabel": "ROU asset"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_DefinedContributionPlanEmployeeContributionDeferredPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DefinedContributionPlanEmployeeContributionDeferredPercentage",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employee contributions may be deferred to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employee Contribution Deferred, Percentage",
        "terseLabel": "Employee compensation deferred percentage"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_DefinedContributionPlanEmployeeEligibilityAge": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DefinedContributionPlanEmployeeEligibilityAge",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee eligibility age criteria under defined contribution plan.",
        "label": "Defined Contribution Plan, Employee Eligibility Age",
        "terseLabel": "Minimum age of employee to cover under the plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Amount of discretionary matching contributions on employee deferrals",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_DefinedContributionPlanEmployerMatchingContributionVestingPercentage": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DefinedContributionPlanEmployerMatchingContributionVestingPercentage",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Vesting Percentage",
        "terseLabel": "Employer matches vesting period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Current",
        "terseLabel": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18",
      "r106",
      "r628",
      "r629",
      "r631",
      "r633"
     ]
    },
    "us-gaap_DividendsCommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock [Abstract]",
        "terseLabel": "Dividends Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Dividends declared",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r726"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r726",
      "r769"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic",
        "verboseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "mtva_DongSocioHoldingCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DongSocioHoldingCoLtdMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Dong-A Socio Holdings Co., Ltd.",
        "label": "Dong A Socio Holding Co Ltd [Member]",
        "terseLabel": "Dong A Socio Holding Co Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_DongStMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "DongStMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Dong-A.",
        "label": "Dong-A [Member]",
        "terseLabel": "Dong-A"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per share of common stock, basic (in dollars per share)",
        "verboseLabel": "Loss per share of common stock, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r105",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r138",
      "r140",
      "r143",
      "r144",
      "r145",
      "r150",
      "r239",
      "r318",
      "r371",
      "r376",
      "r399",
      "r400",
      "r471",
      "r492",
      "r635"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average shares of common stock outstanding:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per share of common stock, diluted (in dollars per share)",
        "verboseLabel": "Loss per share of common stock, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r105",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r140",
      "r143",
      "r144",
      "r145",
      "r150",
      "r239",
      "r318",
      "r371",
      "r376",
      "r399",
      "r400",
      "r471",
      "r492",
      "r635"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share of common stock",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r147"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per share of common stock",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r146",
      "r148",
      "r149"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r666"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation of income tax (as a Percent):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Income taxes at U.S. federal statutory rate (as a percent)",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r115",
      "r338",
      "r362",
      "r666"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowances (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r666",
      "r827",
      "r833",
      "r893"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "terseLabel": "Income taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r666"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent [Abstract]",
        "terseLabel": "Nontaxable and nondeductible items (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value of warrant liabilities.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Fair Value Of Warrant Liabilities, Amount",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible change in fair value of warrant liabilities.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Fair Value Of Warrant Liabilities, Percent",
        "terseLabel": "Change in fair value of warrant liabilities (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other (as a percent)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r827",
      "r833",
      "r893",
      "r894"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r666"
     ]
    },
    "mtva_EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective period for changing beneficial ownership limitation from receipt of written notice from holder.",
        "label": "Effective Period For Changing Beneficial Ownership Limitation From Receipt of Written Notice From Holder",
        "terseLabel": "Number of days written notice"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_EmployeeCompensationVestingPercentageOnContribution": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "EmployeeCompensationVestingPercentageOnContribution",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employee contribution vested on contribution made by employee.",
        "label": "Employee Compensation Vesting Percentage on Contribution",
        "terseLabel": "Percentage of employee contribution vested on their contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "mtva_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Employee related costs",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized share-based compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation - Weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r80",
      "r81",
      "r82",
      "r102",
      "r103",
      "r104",
      "r121",
      "r122",
      "r123",
      "r125",
      "r132",
      "r134",
      "r136",
      "r152",
      "r202",
      "r203",
      "r214",
      "r238",
      "r268",
      "r318",
      "r360",
      "r361",
      "r368",
      "r369",
      "r370",
      "r372",
      "r375",
      "r376",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r449",
      "r491",
      "r509",
      "r510",
      "r511",
      "r529",
      "r594"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r730",
      "r740",
      "r773"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r727",
      "r737",
      "r770"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Gain from change in fair value of warrant liabilities",
        "terseLabel": "Gain from change in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r413",
      "r674"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r413",
      "r674"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r415",
      "r420",
      "r461",
      "r462",
      "r463",
      "r622",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r674",
      "r676",
      "r680"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r674",
      "r913",
      "r916"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r408",
      "r410",
      "r411",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r469",
      "r674",
      "r677"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r270",
      "r275",
      "r277",
      "r403",
      "r413",
      "r420",
      "r461",
      "r622",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r674",
      "r680"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r270",
      "r275",
      "r277",
      "r279",
      "r403",
      "r404",
      "r413",
      "r420",
      "r462",
      "r622",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r674",
      "r680"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements on a recurring basis",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r406",
      "r674",
      "r913",
      "r916"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Gain from change in fair value of warrant liabilities",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r414"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r412",
      "r413",
      "r415",
      "r420",
      "r461",
      "r462",
      "r463",
      "r622",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r674",
      "r676",
      "r680"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recurring",
        "terseLabel": "Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r916"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "mtva_FairValueOfWarrantsIssuedToPlacementAgent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "FairValueOfWarrantsIssuedToPlacementAgent",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fair value of warrants issued to placement agent",
        "label": "Fair value of warrants issued to placement agent",
        "terseLabel": "Fair value of warrants issued to placement agent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r414"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r777"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r777"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainContingencyUnrecordedAmount",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesContingentPaymentsAndLicenseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Contingent assets recorded",
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "Total general and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r574"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r703",
      "r726"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r114",
      "r337"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails",
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r65",
      "r69",
      "r472",
      "r474",
      "r489",
      "r630",
      "r632",
      "r634",
      "r638",
      "r644",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Loss before Income taxes:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r382",
      "r383",
      "r384",
      "r385",
      "r407",
      "r409",
      "r414",
      "r426",
      "r427",
      "r428",
      "r506",
      "r508",
      "r579",
      "r621",
      "r622",
      "r667",
      "r668",
      "r672",
      "r673",
      "r675",
      "r680",
      "r903",
      "r904",
      "r935"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r382",
      "r383",
      "r384",
      "r385",
      "r407",
      "r409",
      "r414",
      "r426",
      "r427",
      "r428",
      "r506",
      "r508",
      "r579",
      "r621",
      "r622",
      "r667",
      "r668",
      "r672",
      "r673",
      "r675",
      "r680",
      "r903",
      "r904",
      "r935"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r338",
      "r339",
      "r346",
      "r357",
      "r666",
      "r898"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r338",
      "r339",
      "r346",
      "r357",
      "r666",
      "r898"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r115",
      "r332",
      "r338",
      "r342",
      "r343",
      "r344",
      "r348",
      "r355",
      "r363",
      "r365",
      "r366",
      "r367",
      "r476",
      "r515",
      "r525",
      "r666"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Description",
        "terseLabel": "Income Tax Examination, Description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Effective tax rate",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r78",
      "r111",
      "r135",
      "r136",
      "r151",
      "r171",
      "r192",
      "r336",
      "r338",
      "r364",
      "r493",
      "r630",
      "r632",
      "r634",
      "r666"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Income tax (benefit) expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation of income tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "terseLabel": "Income taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r357"
     ]
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "documentation": "Disclosure of information about income tax paid by jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r357"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r334",
      "r335",
      "r348",
      "r349",
      "r354",
      "r359",
      "r519"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowances",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r666",
      "r893"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income taxes at U.S. federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r666"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount [Abstract]",
        "terseLabel": "Nontaxable and nondeductible items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r893",
      "r894"
     ]
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxUncertaintiesAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]",
        "verboseLabel": "Income tax:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash payments for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r109",
      "r356",
      "r357"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Change in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r768",
      "r777",
      "r781",
      "r789"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r793"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r793"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r793"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net",
        "verboseLabel": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r632",
      "r843"
     ]
    },
    "mtva_June2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "June2024OfferingMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to June 2024 offering.",
        "label": "June 2024 Offering [Member]",
        "terseLabel": "June 2024 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_June2024PlacementAgentWarrantExercisePrice54.0375Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "June2024PlacementAgentWarrantExercisePrice54.0375Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants issued through placement agents in June 2024 with exercise price $ 54.0375.",
        "label": "June 2024 Placement Agent, Warrant Exercise Price 54.0375 [Member]",
        "terseLabel": "June 2024 Placement Agent, Warrant Exercise Price 54.0375"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_June2024PreFundedWarrantExercisePrice0.011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "June2024PreFundedWarrantExercisePrice0.011Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants issued through pre-funded warrants scheme in June 2024 with exercise price $ 0.011.",
        "label": "June 2024 Pre-Funded, Warrant Exercise Price 0.011 [Member]",
        "terseLabel": "June 2024 Pre-Funded",
        "verboseLabel": "June 2024 Pre-Funded, Warrant Exercise Price 0.011"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_June2024SeriesBWarrantExercisePrice43.23Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "June2024SeriesBWarrantExercisePrice43.23Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants issued as series B in June 2024 with exercise price $ 43.23.",
        "label": "June 2024 Series B, Warrant Exercise Price 43.23 [Member]",
        "terseLabel": "June 2024 Series B, Warrant Exercise Price 43.23"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_June2024SeriesaWarrantExercisePrice43.23Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "June2024SeriesaWarrantExercisePrice43.23Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants issued as series A in June 2024 with exercise price $ 43.23.",
        "label": "June 2024 SeriesA , Warrant Exercise Price 43.23 [Member]",
        "terseLabel": "June 2024 Series A , Warrant Exercise Price 43.23"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_LaborAndRelatedExpenseGeneralAndAdministrative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "LaborAndRelatedExpenseGeneralAndAdministrative",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for labor and related services incurred in General and administrative.",
        "label": "Labor And Related Expense, General And Administrative",
        "terseLabel": "Employee compensation and benefits costs"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_LaborAndRelatedExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "LaborAndRelatedExpenseResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for labor and related services incurred in Research and development.",
        "label": "Labor And Related Expense, Research And Development",
        "terseLabel": "Indirect expenses - employee compensation and benefits costs"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_LegalAndProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "LegalAndProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs and professional costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal And Professional Fees",
        "terseLabel": "Legal and professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r448"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r448"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r828",
      "r834",
      "r933"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r828",
      "r834",
      "r933"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r828",
      "r834",
      "r933"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r828",
      "r834",
      "r933"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less effect of discounting",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r33",
      "r111",
      "r112",
      "r113",
      "r201",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r379",
      "r380",
      "r381",
      "r425",
      "r550",
      "r637",
      "r655",
      "r698",
      "r854",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r64",
      "r484",
      "r683",
      "r686",
      "r687",
      "r827",
      "r831",
      "r847",
      "r918"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r89",
      "r111",
      "r112",
      "r113",
      "r201",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r379",
      "r380",
      "r381",
      "r425",
      "r683",
      "r854",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r910"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.",
        "label": "License Agreement, Developmental And Regulatory Milestone To Be Received",
        "terseLabel": "Developmental and regulatory milestone payment eligible to be received"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive worldwide license to certain patent rights to make, use, sell, offer for sale and import product.",
        "label": "2022 License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_MaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "MaximumAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r223",
      "r224",
      "r225",
      "r226",
      "r281",
      "r311",
      "r312",
      "r313",
      "r329",
      "r406",
      "r467",
      "r505",
      "r507",
      "r514",
      "r542",
      "r543",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r650",
      "r656",
      "r662",
      "r667",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r684",
      "r856",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "mtva_MilestonesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "MilestonesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to milestones accrued.",
        "label": "Milestones Accrued",
        "terseLabel": "Amount of milestones accrued"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r223",
      "r224",
      "r225",
      "r226",
      "r281",
      "r311",
      "r312",
      "r313",
      "r329",
      "r406",
      "r467",
      "r505",
      "r507",
      "r514",
      "r542",
      "r543",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r650",
      "r656",
      "r662",
      "r667",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r684",
      "r856",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by (used in) investing activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r48",
      "r66",
      "r82",
      "r87",
      "r99",
      "r100",
      "r104",
      "r111",
      "r112",
      "r113",
      "r118",
      "r124",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r142",
      "r201",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r239",
      "r243",
      "r246",
      "r251",
      "r318",
      "r371",
      "r376",
      "r400",
      "r425",
      "r490",
      "r571",
      "r592",
      "r593",
      "r630",
      "r632",
      "r634",
      "r696",
      "r854"
     ]
    },
    "mtva_NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carryforwards expired unutilized and written off.",
        "label": "Net Operating Loss Carryforwards, Expired Unutilized, Write Off",
        "terseLabel": "NOL carryforward amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_NewCorporateHeadquartersLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NewCorporateHeadquartersLeaseMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to New Corporate Headquarters Lease.",
        "label": "New Corporate Headquarters Lease"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_NonCashLeaseCreditCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NonCashLeaseCreditCharge",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash lease (credit) charge.",
        "label": "Non Cash Lease (Credit) Charge",
        "terseLabel": "Non-cash lease (credit) charge"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r734",
      "r744",
      "r768",
      "r777"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "mtva_November2022SeriesAndSeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "November2022SeriesAndSeriesBWarrantsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series A and series B warrants issued in November 2022.",
        "label": "November 2022 Series A and B",
        "verboseLabel": "November 2022 Series A and B"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_November2022SeriesBWarrantExercisePrice0.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "November2022SeriesBWarrantExercisePrice0.00Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to November 2022 Series B warrants with exercise price of $ 0.00.",
        "label": "November 2022 Series B Warrant Exercise Price 0.00 [Member]",
        "terseLabel": "November 2022 Series B Warrant Exercise Price 0.00",
        "verboseLabel": "November 2022 Series B"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_NumberOfCommonStockIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NumberOfCommonStockIssuedPerUnit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common stock per units issued under the arrangement.",
        "label": "Number Of Common Stock Issued Per Unit",
        "terseLabel": "Number of common stock per unit"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_NumberOfGeographicLocation": {
     "xbrltype": "integerItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NumberOfGeographicLocation",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of geographic location reported by the entity.",
        "label": "Number of Geographic Location",
        "terseLabel": "Number of geographic location in the United States"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_NumberOfOwnershipChangesOfOver50": {
     "xbrltype": "integerItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NumberOfOwnershipChangesOfOver50",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of ownership changes over 50% defined by Section 382 of the Internal Revenue Code of 1986.",
        "label": "Number of Ownership Changes of over 50%",
        "terseLabel": "Number of ownership change of over 50% since 2022"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r649",
      "r842"
     ]
    },
    "mtva_NumberOfSecuritiesPurchaseAgreementsEntered": {
     "xbrltype": "integerItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NumberOfSecuritiesPurchaseAgreementsEntered",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities purchase agreements entered during the period.",
        "label": "Number of Securities Purchase Agreements Entered",
        "terseLabel": "Number of Securities"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_NumberOfWarrantsIssuedPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "NumberOfWarrantsIssuedPerUnit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants per units issued under the arrangement.",
        "label": "Number Of Warrants Issued Per Unit",
        "terseLabel": "Number of warrants issued per unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r630",
      "r634",
      "r638",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Rental expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturity of the lease liability was as follows (in thousands):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short-term portion",
        "verboseLabel": "Lease liability, short-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseLeaseLiabilitiesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liability, Noncurrent",
        "terseLabel": "Long-term portion",
        "verboseLabel": "Lease liability, long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating lease cash payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "NOL carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business, basis of presentation, new accounting standards and summary of significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business, basis of presentation, new accounting standards and summary of significant accounting policies",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r83",
      "r84",
      "r85",
      "r516",
      "r517"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "mtva_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r967"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current",
        "terseLabel": "Related party payable",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r683"
     ]
    },
    "us-gaap_OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liability, Current, Related Party, Name [Extensible Enumeration]",
        "documentation": "Indicates name of related party for liability classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liability, Current, Related Party [Extensible Enumeration]",
        "documentation": "Indicates status and type of related party for liability classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses",
        "terseLabel": "Total other income",
        "totalLabel": "Total other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r671"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r848"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Direct expenses - Other R&amp;D costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r732",
      "r742",
      "r775"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r745",
      "r778"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r735",
      "r745",
      "r778"
     ]
    },
    "mtva_PatentCostPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PatentCostPolicyPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Cost Policy [Policy Text Block]",
        "terseLabel": "Patent costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "mtva_PaymentsForPlacementAgentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PaymentsForPlacementAgentFees",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow made during the period for placement agent fees in connection with the offering.",
        "label": "Payments For Placement Agent Fees",
        "terseLabel": "Cash fee payment to the placement agent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of issuance costs in connection with the sale of common stock",
        "verboseLabel": "Offering expenses",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payment of employee withholding taxes related to shares withheld from issuance for vested restricted stock units",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "mtva_PercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PercentageOfCommonStockOutstanding",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Percentage of common stock outstanding.",
        "label": "Percentage of common stock outstanding",
        "terseLabel": "Percentage of common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PercentageOfPlacementAgentFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PercentageOfPlacementAgentFee",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of placement agent gee on gross proceeds of offering.",
        "label": "Percentage of Placement Agent Fee",
        "terseLabel": "Percentage of placement agent fee"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PercentageOfSalesAgentCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PercentageOfSalesAgentCommission",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sales agent commission.",
        "label": "Percentage Of Sales Agent Commission",
        "terseLabel": "Percentage of sales agent commission"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares exercisable through warrants as a percent on total shares and warrants sold in the offering.",
        "label": "Percentage of Shares and Warrants Sold in Offering, Maximum Shares exercisable Through Warrants",
        "terseLabel": "Percentage of common stock sold"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PeriodForFailToCureBreachMayTerminateAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PeriodForFailToCureBreachMayTerminateAgreement",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for failing to cure the beach, the agreement may get terminated.",
        "label": "Period for Fail to Cure the Breach, May Terminate Agreement",
        "terseLabel": "Period for failing to cure the beach, the agreement may get terminated"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PeriodForTerminationNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PeriodForTerminationNotice",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for petition for termination notice for the other party's material breach that is not cured.",
        "label": "Period for Termination Notice",
        "terseLabel": "Period for termination notice when material breach not cured"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PipeCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PipeCommonWarrantsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to PIPE common warrants.",
        "label": "PIPE Common Warrants [Member]",
        "terseLabel": "PIPE common warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PlacementAgentContingentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PlacementAgentContingentWarrantsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Placement Agent Contingent Warrants.",
        "label": "Placement Agent Contingent Warrants [Member]",
        "terseLabel": "Placement Agent Contingent Warrants",
        "verboseLabel": "Placement agent contingent warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PlacementAgentFeesNonAccountableExpensesAndClearingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PlacementAgentFeesNonAccountableExpensesAndClearingCosts",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-accountable expenses and clearing costs as placement agent fees.",
        "label": "Placement Agent Fees, Non-accountable Expenses And Clearing Costs",
        "terseLabel": "Non-accountable expenses and clearing costs"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Placement Agent Warrants.",
        "label": "Placement Agent Warrants [Member]",
        "terseLabel": "Placement agent warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "mtva_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to pre-funded warrants.",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r253"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r552"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r253"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r552",
      "r570",
      "r968",
      "r969"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r242",
      "r248",
      "r481",
      "r683"
     ]
    },
    "mtva_PremiumOfOfferingPriceForExercisePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PremiumOfOfferingPriceForExercisePricePercentage",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The premium of offering price for warrants exercise price in percentage.",
        "label": "Premium of Offering Price For Exercise Price, Percentage",
        "terseLabel": "Premium of offering price per share (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PrepaidExpenseAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PrepaidExpenseAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expense and other current assets at the end of the reporting period.",
        "label": "Prepaid Expense And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r651",
      "r848"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "verboseLabel": "Private placement offering",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityCommonStockDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Proceeds from the issuance of common stock under an at the market offering agreement",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "mtva_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from the issuance of common stock and warrants under the securities purchase agreements from a private placement offering"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ProceedsFromIssuanceOfStockAndPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ProceedsFromIssuanceOfStockAndPrefundedWarrants",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow from issuance of stock and pre-funded warrants.",
        "label": "Proceeds From Issuance Of Stock And Prefunded Warrants",
        "terseLabel": "Issuance of common stock and pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Aggregate net proceeds",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r520"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesAdditionalInformationDetails",
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsNarrativeDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "verboseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Office equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r91",
      "r488"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r447",
      "r475",
      "r488",
      "r683"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and equipment, net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r74",
      "r75",
      "r486"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r447"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "mtva_PublicOffering2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "PublicOffering2026Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The underwritten 2026 public offering.",
        "label": "Public Offering 2026 [Member]",
        "terseLabel": "2026 public offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r223",
      "r224",
      "r225",
      "r226",
      "r269",
      "r281",
      "r311",
      "r312",
      "r313",
      "r317",
      "r329",
      "r406",
      "r464",
      "r465",
      "r467",
      "r505",
      "r507",
      "r514",
      "r542",
      "r543",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r650",
      "r656",
      "r662",
      "r667",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r684",
      "r690",
      "r851",
      "r856",
      "r913",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r223",
      "r224",
      "r225",
      "r226",
      "r269",
      "r281",
      "r311",
      "r312",
      "r313",
      "r317",
      "r329",
      "r406",
      "r464",
      "r465",
      "r467",
      "r505",
      "r507",
      "r514",
      "r542",
      "r543",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r619",
      "r620",
      "r650",
      "r656",
      "r662",
      "r667",
      "r669",
      "r670",
      "r676",
      "r677",
      "r678",
      "r679",
      "r684",
      "r690",
      "r851",
      "r856",
      "r913",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r727",
      "r737",
      "r770"
     ]
    },
    "mtva_RelatedPartyAccruedInterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "RelatedPartyAccruedInterestPayable",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest payable to related party under extended payment terms.",
        "label": "Related Party, Accrued Interest Payable",
        "terseLabel": "Extended terms, Accrued interest payable"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_RelatedPartyClinicalTrialAccruedLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "RelatedPartyClinicalTrialAccruedLiability",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liability payable to related party for clinical trial services.",
        "label": "Related Party, Clinical Trial Accrued Liability",
        "terseLabel": "Amount payable in clinical trial accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r200",
      "r276",
      "r280",
      "r453",
      "r454",
      "r479",
      "r485",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r569",
      "r601",
      "r966"
     ]
    },
    "mtva_RelatedPartyExtendedPaymentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "RelatedPartyExtendedPaymentLiability",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related party under extended payment terms.",
        "label": "Related Party, Extended Payment Liability",
        "terseLabel": "Extended terms payable"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related party under extended payment terms due in next twelve months.",
        "label": "Related Party, Extended Payment Liability, Payable In Next Twelve Months",
        "terseLabel": "Extended terms amount to be paid on September 30, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_RelatedPartyExtendedPaymentLiabilityPayableInSixMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "RelatedPartyExtendedPaymentLiabilityPayableInSixMonths",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related party under extended payment terms due in six months.",
        "label": "Related Party, Extended Payment Liability, Payable In Six Months",
        "terseLabel": "Extended terms amount to be paid on March 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r453",
      "r454",
      "r455",
      "r456",
      "r479",
      "r485",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r569",
      "r601"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r453",
      "r454",
      "r923"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r923"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related party",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r200",
      "r453",
      "r454",
      "r456",
      "r575",
      "r576",
      "r579"
     ]
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Rate",
        "terseLabel": "Fixed interest rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r200",
      "r276",
      "r280",
      "r453",
      "r454",
      "r479",
      "r485",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r569",
      "r601",
      "r923",
      "r966"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r454",
      "r457",
      "r526",
      "r527",
      "r528",
      "r577",
      "r578",
      "r579",
      "r598",
      "r600"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r119",
      "r120",
      "r236",
      "r255",
      "r456",
      "r466",
      "r477",
      "r625",
      "r626",
      "r627",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r905",
      "r906",
      "r907",
      "r908"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails",
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r621",
      "r630",
      "r631",
      "r644",
      "r932"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ResearchAndDevelopmentExpenseFirstClinicalTrialProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseFirstClinicalTrialProgram",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred in the first clinical trial program associated with research and development.",
        "label": "Research and Development Expense, First Clinical Trial Program",
        "terseLabel": "Direct expenses - Vanoglipel (DA-1241) credits (costs)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "mtva_ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a reduction (credit) to research and development expense recognized in connection with the close-out of a clinical trial with a clinical research organization.",
        "label": "Research And Development, Expense Reversal On Close Out Of First Clinical Trial Program",
        "terseLabel": "Close-out of a clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ResearchAndDevelopmentExpenseSecondClinicalTrialProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseSecondClinicalTrialProgram",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred in the second clinical trial program associated with research and development.",
        "label": "Research and Development Expense, Second Clinical Trial Program",
        "terseLabel": "Direct expenses - DA-1726 costs"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research tax credit carryforwards expired unutilized and written off.",
        "label": "Research Tax Credit Carryforwards, Expired Unutilized, Write Off",
        "terseLabel": "R&amp;D credit carryforward amount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r728",
      "r738",
      "r771"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r729",
      "r739",
      "r772"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r736",
      "r746",
      "r779"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes (in shares)",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r890"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Issuance of stock for vested restricted stock units, net of shares withheld for withholding taxes",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r890"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r54",
      "r483",
      "r512",
      "r513",
      "r524",
      "r553",
      "r683"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r121",
      "r122",
      "r123",
      "r125",
      "r132",
      "r134",
      "r136",
      "r202",
      "r203",
      "r214",
      "r238",
      "r318",
      "r360",
      "r361",
      "r368",
      "r369",
      "r370",
      "r372",
      "r375",
      "r376",
      "r387",
      "r389",
      "r390",
      "r392",
      "r398",
      "r437",
      "r438",
      "r509",
      "r511",
      "r529",
      "r968"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r682"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Gross proceeds",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accrued expenses and other current liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding securities which were not included in the calculation of diluted earnings per share of common stock",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsAndEmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of basic and diluted loss per share of common stock",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r666",
      "r893"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of loss before income taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r832"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r118",
      "r453",
      "r454",
      "r456",
      "r575",
      "r576",
      "r579"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of significant segment expenses",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r17"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of outstanding awards issued pursuant to our stock-based award plans and inducement plan",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "verboseLabel": "Schedule of restricted stock units (\"RSUs\") and related transactions",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "verboseLabel": "Schedule of the status of outstanding and exercisable options and related transactions",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r56"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in the Black Scholes option-pricing model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of outstanding warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "mtva_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Securities Purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities purchase agreement",
        "verboseLabel": "Dong-A"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70",
      "r151",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r199",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r219",
      "r220",
      "r373",
      "r374",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r641",
      "r644",
      "r645",
      "r652",
      "r685",
      "r934",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant segment expenses and loss before income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Significant segment expenses and loss before income taxes",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r151",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r175",
      "r177",
      "r178",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r199",
      "r639",
      "r642",
      "r643",
      "r644",
      "r646",
      "r648",
      "r649"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Significant segment expenses",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r195",
      "r198",
      "r640",
      "r641",
      "r647"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and administrative expenses",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "mtva_SeriesBWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SeriesBWarrantMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series B Warrant.",
        "label": "Series B Warrant",
        "terseLabel": "Series B warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_SeriesCWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SeriesCWarrantMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series C warrant.",
        "label": "Series C Warrant [Member]",
        "terseLabel": "Series C warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_SeriesDWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SeriesDWarrantMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series D warrant.",
        "label": "Series D Warrant [Member]",
        "terseLabel": "Series D warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_SeriesWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SeriesWarrantMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A Warrant.",
        "label": "Series A warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation.",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Fair Value, Vested and released"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Fair Value, Outstanding Balance",
        "periodEndLabel": "Outstanding, Aggregate Fair Value, ending balance",
        "periodStartLabel": "Outstanding, Aggregate Fair Value, beginning balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSU's, Number Forfeited/Cancelled (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSU's Fair value, Forfeited/cancelled (per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSU's, Number Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSU's Fair value, Granted (per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSU's Fair value, Ending balance (in shares)",
        "periodStartLabel": "RSU's Fair value, Beginning balance (in shares)",
        "verboseLabel": "RSUs",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSU's Fair value, Ending balance (per share)",
        "periodStartLabel": "RSU's Fair value, Opening balance (per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSU's, Number Vested and Released (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSU's Fair value, Vested and released (per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Number",
        "terseLabel": "Shares of Common Stock Issuable for RSUs, Vested and Deferred Release (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average Grant Date Fair Value Price , Vested and Deferred Release (per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of shares added (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Remaining shares of common stock available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Stock Options, Additional Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Shares of Common Stock Issuable for Options, Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable (per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "verboseLabel": "Shares of Common Stock Issuable for Options, Outstanding (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Outstanding (per shares)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of the common shares outstanding (as a percent)",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "mtva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which the shares reserved for further issuance under share based compensation will increase annually.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Period Number of shares reserved for further issuance Increase Annually",
        "terseLabel": "Period of automatic increase in shares reserved"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r289",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value, Vested and Deferred Release",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options Exercisable, Intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "mtva_SharedServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SharedServicesAgreementMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Shared Services Agreement.",
        "label": "Shared Services Agreement",
        "terseLabel": "Shared Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Original issue price, per share",
        "verboseLabel": "Offering shares (Per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block]",
        "terseLabel": "Schedule of warrant liabilities",
        "documentation": "Tabular disclosure of the nature and terms of the financial instruments and the rights and obligations embodied in those instruments, information about settlement alternatives, if any, in the contract and identification of the entity that controls the settlement alternatives including: a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, \"the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share\") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable. g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments are disclosed separately from the amount of retained earnings or accumulated deficit)."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r858",
      "r860"
     ]
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureCurrentLiabilitiesWarrantLiabilitiesDetails",
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current",
        "periodEndLabel": "As of ending balance",
        "periodStartLabel": "As of beginning balance",
        "terseLabel": "Warrant liabilities",
        "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r859"
     ]
    },
    "mtva_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to a single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_StateAndLocalTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalTaxJurisdictionOtherMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Tax Jurisdiction, Other [Member]",
        "terseLabel": "State",
        "documentation": "Designated state and local jurisdiction entitled to levy and collect income tax in country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r897"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSignificantSegmentExpensesAndLossBeforeIncomeTaxesScheduleOfSignificantSegmentExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70",
      "r86",
      "r151",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r199",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r219",
      "r220",
      "r373",
      "r374",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r641",
      "r644",
      "r645",
      "r652",
      "r685",
      "r934",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r95",
      "r96",
      "r97",
      "r111",
      "r113",
      "r140",
      "r141",
      "r143",
      "r145",
      "r153",
      "r154",
      "r201",
      "r227",
      "r229",
      "r230",
      "r231",
      "r234",
      "r235",
      "r241",
      "r242",
      "r244",
      "r245",
      "r247",
      "r250",
      "r253",
      "r254",
      "r257",
      "r260",
      "r266",
      "r425",
      "r520",
      "r521",
      "r522",
      "r523",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r552",
      "r572",
      "r594",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r811",
      "r829",
      "r830",
      "r839"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r38",
      "r39",
      "r80",
      "r81",
      "r82",
      "r102",
      "r103",
      "r104",
      "r121",
      "r122",
      "r123",
      "r125",
      "r132",
      "r134",
      "r136",
      "r152",
      "r202",
      "r203",
      "r214",
      "r238",
      "r268",
      "r318",
      "r360",
      "r361",
      "r368",
      "r369",
      "r370",
      "r372",
      "r375",
      "r376",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r449",
      "r491",
      "r509",
      "r510",
      "r511",
      "r529",
      "r594"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r152",
      "r241",
      "r242",
      "r244",
      "r247",
      "r438",
      "r468",
      "r518",
      "r530",
      "r541",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r574",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r632",
      "r634",
      "r691",
      "r966"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r152",
      "r200",
      "r241",
      "r242",
      "r244",
      "r247",
      "r438",
      "r468",
      "r518",
      "r530",
      "r541",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r574",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r632",
      "r634",
      "r691",
      "r966"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r731",
      "r741",
      "r774"
     ]
    },
    "mtva_StockAndWarrantsIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockAndWarrantsIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance costs related to stock and warrants.",
        "label": "Stock And Warrants Issuance Costs",
        "terseLabel": "Stock and warrants issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888"
     ]
    },
    "mtva_StockIssuanceCostAtMarketOfferingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockIssuanceCostAtMarketOfferingAgreement",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance costs related to at the market offering agreement.",
        "label": "Stock Issuance Cost, At The Market Offering Agreement",
        "terseLabel": "Net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_StockIssuedDuringPeriodSharesCommonStockAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockAndWarrants",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock and warrants issued during the period.",
        "label": "Stock Issued During Period, Shares, Common Stock and warrants",
        "verboseLabel": "Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock under an at the market offering agreement, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r54",
      "r520",
      "r594",
      "r608"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of stock for vested restricted stock units (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r54"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of stock from exercise of warrants (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r54",
      "r295"
     ]
    },
    "mtva_StockIssuedDuringPeriodValueCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockIssuedDuringPeriodValueCommonStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock and warrants issued during the period.",
        "label": "Stock Issued During Period, Value, Common Stock and warrants",
        "verboseLabel": "Issuance of common stock and warrants under the securities purchase agreements from a private placement offering, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock under an at the market offering agreement, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r35",
      "r54",
      "r529",
      "r594",
      "r608",
      "r697"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of stock for vested restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r54"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of stock from exercise of warrants",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r38",
      "r39",
      "r54"
     ]
    },
    "mtva_StockPlan20192022AndInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockPlan20192022AndInducementPlanMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Stock Plans 2019, 2022 And Inducement Plan.",
        "label": "Stock Plan 2019, 2022 And Inducement Plan [Member]",
        "verboseLabel": "Stock-based award plans"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_StockPlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockPlan2019Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2019 stock plan.",
        "label": "2019 Plan",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_StockPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "StockPlan2022Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationStockBasedAwardPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2022 plan.",
        "label": "Stock Plan 2022 [Member]",
        "terseLabel": "2022 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r49",
      "r554",
      "r570",
      "r595",
      "r596",
      "r683",
      "r698",
      "r827",
      "r830",
      "r831",
      "r847",
      "r918",
      "r968"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://metaviatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r252",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r268",
      "r386",
      "r397",
      "r597",
      "r599",
      "r612"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r459"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r460"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockAssumptionsDetails",
      "http://metaviatx.com/role/DisclosureSubsequentEventsDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Business, basis of presentation, new accounting standards and summary of significant accounting policies",
        "verboseLabel": "Stockholders' equity",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carry Forward Research Credit",
        "terseLabel": "R&amp;D credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "mtva_ThresholdPercentageForBeneficialOwnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ThresholdPercentageForBeneficialOwnership",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold percentage for beneficial ownership.",
        "label": "Threshold Percentage For Beneficial Ownership",
        "terseLabel": "Maximum percentage of outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold period following the public announcement of the Company receiving positive Phase 1 multiple ascending dose (\"MAD\") data for expiry of warrants.",
        "label": "Threshold Period Following the Public Announcement of Receiving Positive Phase 1 Multiple Ascending Dose Data For Expiry of Warrants",
        "terseLabel": "Threshold period following the public announcement of receiving positive phase 1 multiple ascending dose data for expiry of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "mtva_TwoThousandTwentyOnePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "TwoThousandTwentyOnePlanMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityStockBasedCompensationAwardPlansAndInducementGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2021 stock plan.",
        "label": "2021 Inducement Plan",
        "terseLabel": "2021 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails",
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. federal"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r347",
      "r665"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "verboseLabel": "Interest or penalties",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r665"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Estimates and assumptions",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r155",
      "r156",
      "r157",
      "r158",
      "r472",
      "r474",
      "r636"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureIncomeTaxesLossBeforeIncomeTaxesAndComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "mtva_WarrantLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "WarrantLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://metaviatx.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations for warrant liabilities.",
        "label": "Warrant Liabilities, Fair Value Disclosure",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_WarrantLiabilitiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "WarrantLiabilitiesPolicyPolicyTextBlock",
     "presentation": [
      "http://metaviatx.com/role/DisclosureBusinessBasisOfPresentationNewAccountingStandardsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the warrant liabilities.",
        "label": "Warrant Liabilities, Policy [Policy Text Block]",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "verboseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r689",
      "r692",
      "r693",
      "r694",
      "r695"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_WarrantsExercisePrice15919.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "WarrantsExercisePrice15919.20Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price $15,919.20.",
        "label": "Warrants Exercise Price 15,919.20 [Member]",
        "terseLabel": "Warrants Exercise Price 15,919.20"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_WarrantsExercisePrice33000.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "WarrantsExercisePrice33000.00Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price $33,000.00.",
        "label": "Warrants Exercise Price 33,000.00 [Member]",
        "terseLabel": "Warrants Exercise Price 33,000.00"
       }
      }
     },
     "auth_ref": []
    },
    "mtva_WarrantsExercisePrice9900.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "WarrantsExercisePrice9900.00Member",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquityPrivatePlacementAndAtMarketOfferingDetails",
      "http://metaviatx.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price $9,900.00.",
        "label": "Warrants Exercise Price 9,900.00 [Member]",
        "terseLabel": "Warrants Exercise Price 9,900.00"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Non-cash issuance cost",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r911",
      "r915"
     ]
    },
    "mtva_WeightedAverageFairValuePerShareOfWarrants": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://metaviatx.com/20251231",
     "localname": "WeightedAverageFairValuePerShareOfWarrants",
     "presentation": [
      "http://metaviatx.com/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndPlacementAgentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value per share of warrants.",
        "label": "Weighted Average Fair Value Per Share of Warrants",
        "terseLabel": "Weighted average fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares of common stock, diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r145"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://metaviatx.com/role/DisclosureLossPerShareOfCommonStockComputationOfBasicAndDilutedLossPerShareOfCommonStockDetails",
      "http://metaviatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares of common stock, basic (in shares)",
        "verboseLabel": "Weighted average shares of common stock, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481679/480-10-45-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001104659-26-034911-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-034911-xbrl.zip
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M^<<,F+&Y)20OU0=BA&@*$P/,,BT)V42V#_XM$?-*]FBH?L8691<[K%1HITK
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M8/J;'_JI80K_J/2*F/GRD)?WRRCMR.SY,6NJ*#@IE9RD1GARQU4BX@'5G-H
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M.\)XKT4# )9JW8Z'2IS8@A%PY&_.CYUM (C%7'_RMV$$>/EG]U;W,S]8-P[
M$[33_& -N&^?.2701<B+KBE&EJE-J4.SN?D-"';UX9K]EFJ^]:;;\0'.J,_G
MJBPK)R?] D=2]XRZ"ES+OH.(S: #DJI.&Z4I>]IZ %;H/<I7CQ^FD#/3DA^W
MEPY=914 D^LPHFU"!R35S,1DKQ,\X^I)Z6M,K-(1VC<'(.;2OR&W9PL<33'G
MSLZ+<A#'6?O3!AM&P)$_(YG]CWD37IT@5>?\3"7[0)><U1]*)=-#;G4?]M6[
M&R1L -!_+-ESY(]T=%S-YTBZL1N:" !6R? :RH$9\YWH91]J!L)Z#: UT)2
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M+/ C6Y>=RC3"NAD VX06VF(-$\XVL?$"SS2ABD[\?YF_.E2N 2#B;"\_)2)
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M7^;0X(T97;Q 5VFT>($9&NV(V5OOOQ!-OD)^0FY"TLQMRDJVM;QRW&6UK(W
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MT^KW$3EIH M;_E6)[H=K9Y]/E5PK?1_1\6/)M1+1/7"-)RAZV>NWD<& UE0
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M*@+P9[:6L!H9G$V=B-I'%*(WNG2F1%M(KU(+0+951Z*KP((CMRJ1ZO"NI"R
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M)0 Y;RV5<#L]&Z"$MY_?E\3>D8XO'!)[#XF]A\3> 1)[T^R5K"/53"(H!B#
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M-[*9*#OXK+QFV; N $^TD2:6168(;531/:((46XL*9&7Z!4%>,VPF0C.J"8
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M&V2^3I%/+XKR?XV@NH(!XPJRH(8%I6;S9PHR<EQ&C3IIS: BC,E&JZL5.1G
MZO$5K-E\3O<CX4+_VE6])(!YQER7&H];U='LIR/U$-L\Q#:'C&VF!Q1NLI.Z
MOR&VJD#>]!419X'XQTLG1M>.3_[I!(ETCSLT%0 69,#\^VTY"<?;VAKZ%DW)
M[\1N0&4IH__$ 6TFH  ?*>ZNU=>FYT.D=!?N 5/3%SW<%QNXSXBL9 & /CO\
MON.D/3$-F"YV-?0>_>B/:X+0#5WM$!3%0QE,<;_?;>1T -Z-$WGR%Z$_]UVZ
MQ'A*%\C9+>3L1.PMCJ)S-,<$I>]X/#OO*"HMW*5UK:-5/YTTHU5%ZY-L[3Y!
M6?O\9"PM&4U>.'D3G],WB1F!K&Y&XP3/)Y&JG7V*<Z6T/Z(U)LPS>!-2Y"NN
MAE3WTH^&$2WSE@8VC/D[,>=)1 =C%&7$1"H'H[H.Q!B6K2 K=D@-=]QY+25%
M[3VLE@'B*#31NXH4JBCZ.!5!%2- J8XP7<AZ5!R%4%> X"44J4=Q_$%-/P3%
M%HU8K>?/J.IXOCT+9!+OG;DUVS\_W8R:>8>AVBZ*7M@[<JXL-591'H+OJZ6P
M%:C@;*KR3-F&!9&-3%4% -92JWIE":FPP!&1\FT_S<@RK M@E%D)SA!6WU<?
M*LFX]DD47]!&Z!XJ>":^$SP0O"!._=ZWG5H",.*LU'.[;FD+>%21/B$ZZWJ=
MR%35%(#1V(-058CA&%M^?DF)0[:&,:@(("IB+5@;?'T/SEOG!1/:]R,*V'.
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MX8;M,/&U/9R09T_3L3\D1@ODY:C@A1@SHX%]^$ZS6R,X02W+O[%/_\ 5(Q>
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M>L6?#O5RDE7A !,DV(0Q :AM&OJ6KP!8M7;!#%%N59G/JQ6JO04G5SRV?U?
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MIHTHR07BY,4_@,6S-5M >SQ6;70>1 !Z9 ^UA>*#L;,9OC5TT'?]CH=B 8*
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M>4;4>S4(1;SDTS$FEL!E7:E3\I\L#_UE'(BR+ .3.%VJ<X&F459KAB@MDG.
MJG&*F8@^4=;LGHF Y,)NA1ALPE54( *'6^XM&-%[WL)^H>,B<95=Z)0^B>D)
M\L)&Q"ZB<O<QCO$JS ?BE@[%N6"6MK6:\6HPN3E@E;Y2)J*LXBZA%A&@J**/
MW@@9WL+#*+>6\VN6JQ"*WO1\##-')>2DDS>K%:;KC!5\WW@YOA$GK$.6@@Z$
M*BV2<\$J?7NU'+4;3&\.:#5"*R,'Y@KV,E11"5!=!(C[ HY-E]8-=(_S)XQC
M&;@HHNWH\K^75_L'[%[<EW>W[] *!^P=D>KCE!J>IK$'ERMP^3M1PK2=6S L
MBH$0H_."'R2%U;_Q/I3:7"!0RTK-Z#>(U!R 3T\A$X%;UN"A6"=J[-"@ WYK
MWIW!@L)@%'N\RF"N[\U7(\%>"=1C+V.3ZM,PHO@[-"L;2&TN:*1EI99<; BI
M.:"1GD)&,K"&"L.,.W_ND?.'-U=T9S">594W-^Y+6P7"5A&X@L52Z9,X#YF<
M))6[Q3Z]_TO0\^S9CW8!#LY)Y)Y4ZAU:>4 1(7.,YH)OIFW;4I3($)<YH*)Q
M78T4.9*$0I54J! +4?] )W64.$19>) *TMKR2;>L,O;3.O37Z D3.\9)3B>]
MW/;B\(;O1?XN*JU?(#,N?@50Z'SNA2D]](*E;/H3]FC9E^ JOJ%*IT1J.L+U
M7L#5I04;8T=9J/9*C0XAN$@Y3AWM^DN$*SMN)M4^H3%9<*;5.4K>+)<$<P[-
MC<%D/%M1XSU2$="&,^;EJ^A[?W1)3UB-9I5N)K6[^XR, E[Z<I7RJ@F?<+Y.
M@HOX$6<YQK=>65OA^.6P<=&,_=QM(XY9%K"A:PI[UA)#@_3A MTD6FJ'<TF?
MEC\1=5&X/*C@M$!4I+**"CO2UM2M:"\ <A\5]4,^2W,IW,F_JE G__C;#;W+
MNWP.LSV#[W\',[@:-:!14?L"GCLWBZ?KAXP2^DIIV?6;3WASC],VW<IO@?M.
M78N:]_"O /O/GH C/>@TV7AA;,V'/H5QN-EM6KUH_WNX?M2H2>%)M2]A^E*S
MB+K>)*A9<R/ON=N-]KX'[$9-FI1N)'\)U(T:1=1V(T[-[>1'2B@OPQA?Y'BS
MGRHI=X+I>,-T;IYR-/6 YZ(#Y1X_+=A/_K]2)HAQ<;3&.ZWFQ[N,T,JR!5^V
M$._C9#C.Q86>&#_1.OBT\"M;QZ4+NJQ"#MTVRW:;#9L4U:^X2.VW],6QPTU^
M:T<@)O:;6IE-S.:%3L"OL5XF^_1V&X7Y24+FJBD]!WM#?];W;=8:3@8X0&K:
MI0:9 VD !E%=3<R$1ZT*+4=7QG:!*L:(<78#M+:M<X,I/2S*X&3<%&F#_E8@
MY/..9H"TYB.]'4D7M,2-R+;<J;,#;%CHUU4&@/;6<$-=069=M^6D>>'3@GAQ
MYW>28;XW<JTHFU;*9LW*JH3I)G_T6.R]__#Q/8L_^DFIP2\X>4B][3KT+T41
MUCV5^UO#C#Q%+6G8]31U&W-!XK,W:S1^&X.^^% 21U%1B)C[)WU+X84=HR!"
MDB'LW10!V00\]I2OB*."NE74<?LSBT,RM&0?*T;HY6X.4+>^V/@EPZM==!FN
MVK:0U7K"A#$-[96>*JVZP4TIA@BOZ_N=CY4N$.>$*"M8SY0:-,%9EH<;=F]K
MQ[6-#K6U%.'LF>2+.-NE]'&>5IL<-(,>N\UZU0.UW@9R5+9(JA^"_'7LDJ*C
M2#.L5ILZ5D+IE.1F&:VQR^X_G?"G0ULT;VL+.Z@Z-90CJ[$AW/#J%E?7&0NJ
MX@;A @G"3D)M6A7=A!N_<WBU(O\-XP?V;$FK]LUMH8=;AX;U<&MH"#G<NL35
M]T5Q![4@RQ_H<;0E-;&.?!.*3!^%JGZ#JE:B\(J^DRW&<5$(IGODZ^P .Q[[
M=96#LKTUW,A4D%G7=1EI5.2=@KC;,7%R;;="6Y=%(%MGL[^D2=8V7O9V@AVH
M:CHKK=FP'G #5E'NB59J&!-8:S1F]":C-GT;$!=4703NTO=WFQU['8"DV2GV
M>1DA\G>$6?'M.%AN:(G;O[//6RW28D&#Y&&#@6D[RK!ABC9<@#&NH6Y(2H(@
M69(%*F5A\"1+0V"K#F"+.H(9A:Z?N#%C_$!E[ (O,#:EC\_38WRE80-)'!>8
M5[Q=>L-?19'N@'9/*E3ZP48I9<UE^.GM!!=7U$77WF(1'(Z*)W8D'I/..Q16
M!^QI7SXPY&R%@*!=NL,!0;$5@1L"+%YTCOL"NK<3[&A6TWDOD^CH 3>.%>4>
M,>I3\DBFCR@#MRL'$VM=TS83#Y6OL)L%!+:4(116'I![.\&.7S6=#U;[6GO
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M&2]:QL$-?J"OP23IRZ<PPEF>Q/@N.::E%7'XB(,F7!M/$F90F[17ZZ&2@?2
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MLUPHW6>SUEXSP>5NK1O!M[G+C!"V1P%M&.5D"1IRNG-;')C(+'O86%BI8%,
MHEOHFTCW.KY5RN^["* +[3?DPY85YNX>, %O@+8*-]AI<[@[ "I"&[^WOD"4
M/J0+ZT;T/0^?Y3A-#W4TE':<D.:A[T5W]/RHP ?EC8F^SC!C4L\&C;E(9\\9
MI21J>HS-3**"8GMJ0@\"^D(8E+,SS9FHJNDN,YG6.GL)2L$,,6[ED UD!V-B
M1ZFO!)!Y_9XO>'N>%&*=%R!&YRZ7.,LPOL1$Z%.<^6FXI4'6]=!N=P^8.#E
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M"5.[!<CL&D=P0S([1/DM4&DWB24!"0?O6-@UR:<P#C>[#1+O;^/"#'E"7(.
MNW 7>J&&>H<UL)0_)TUQFN*@>BI<PVZ]!.<+IFJV4@77;FKS!EM%W72#J?Z6
M?1E+,L9F:..]T/>P L&>1IHW$SB>V'PJ\%S[KI!A@2HIP 'VQ$8[J[QL0ZN.
M\**CI7=MVPPS&72GG[S<7X?Q@_S]KSBC:Y)C$%R9[FR!?)CE%/%<C>BL87V@
MBB/0/4P"]+0._35+B 3 IW74?@JCB +\(Q& !&!/NKV@KW+\Z3K^K_A3?'H7
M_Y7\Y_9/B%</7K#G6_"S1_C@!6GU_K]^_/3^X^F?4%HO-TS^F:24V<KCAP$3
M,N=_P5Y**(3E"YX+MG:0KT/2%!.(\%XLOP$#XE?L'V125$A2:[1 0AC @XTE
M&Y:&VE!V.&.^3BVS92%B;J2IQM!J;#M0YRJ6M6TRFAX9P./("+N4PX8&#>"C
MQ!B-)DSYBY& _%7[>.,%&-V_E)WL@K$+8TE9O)2K'L(J-97,V#[,PG<E,NZ'
M]<S#Q5Y>SW!$2T&EF'[JI2]RH\Y#/*.)PD1NLS:3=^C&482[)V=(KRE3Q9H,
M]98.CQ@Y-IQX=U#<2JK,LRGRZOJ*&+%5B79\X<*+G-R6I \;)/%MGOB_?][1
MQT^N5K=K+Z7UJM)?O6B'EW%P18"7&3!*LAWYJJ?6VTB2L)',A+WJ)PWTZ<%%
M,2-:C7FK@\07X[Y G#\-3"X!O9.=(B8$6QQ@8B!)#M<5Y,#8SMR<5E+IUX0F
ME#?APSK/2/;'-&O*1ON[P,2)(?J6\]*>]L#GH*K2ZU<8KZW\/3(>*&5,Z/(+
MRB@;_NXS=]^,RE(4120=P_S%[DQS:I/(88HX!\19T"DE1SK[,TA+6F<<V(D?
MX.KG=S(3#!_# ,=!)BG>DQOU=(&):4/TK<W1.MK#S5V4I-:>7Q7$%Z@6PXYS
M#CLZ"XB"$JHG7K8>8 _1?'XA*NO9%YZT[;Q"LR:QX; D_R+4P42D6551@/V(
MC)P&]ZZ*^8HD\T66[=CACR]QN#\HJO:!&7*#-*[>%N[I #S75Q9?NZ8(R=CC
M<LI>R^>W[&AF2'+<D+&4SFEZU1EZRZ\)3VT/L7QQM:KG"YP)2_8I&_NYOBW%
MVYS '&A=I_B<>E+P&_.B/&M_#;V]*6"(ZM&O1*:6=L !J4]J0XL.[:^;DV9'
M*R8!>A(BV(6@J2Q Z!YQPJB@C+YRVG8G*;:U- <M!<6S9YSZ88:OT]#''S_^
M\,,/[W[XH1UFU+H!AIP!>I?PH] '.!0-T< 0+!6(@Y["?(VP8$PPB7!&__3Q
MXX(SMPM(-NQ0(E+!!#$NJ%39(52!T']B$'O_XT_O?WKW82B('72;&X@UZ]T-
M8O4^<P2Q%@VL@-C['Q><.0 0,VR'MB N588&8K;UGQC$?OI))Q';[S4W"&O4
MNAO!:EWF"&#-"EC!KY\6/T')P<Q:H2UZ"X6A@9==[0TNJB>/3&3Z@,PM3D.<
M'0OF-?6ZD4R'"&!@T[9)M0X_E )PV-/7QP *MJ^.%6(A*A?B@J'C;LA,5NB?
MD'W(M&_!%N,(KOO(XAA3YV >R]6>0-G%W(#SG[L8DT__?!UY/MM26]+"FDU*
M_?CG=S]\_.<?VX<=?5* !Y^1]BF'($TZP >BL5J93LK%7G&^3I/=PYI>0.=B
MT?(_?.Q"5&0:3']NSN"1$-3N<.3*CI4Q2LZ(L5ZT(:_@[W!LFIVMS(-UQ]#S
MYX_O/GSLQVAE"C. YF'6.$!DM>XS >*!RDR$OUZ&LB*#4X!<)ID;P+5DK\H"
M10;7"AJ,+0!X!6J9"3+?O<,&^YG\^_<**:\ZC1D ZE"+'":YB@1F JJ#U9DZ
MK3T\A80R?TU2$A6T90([2F]M&5+*U<HC/ZVXPA@#0%RGUG&QF@)"\6ZW,'GR
M-/$Q#K)S@K?T\*Q'L/AJQ2_?Q &19U4[\=9DK^$D  \VFO:03K .Z@]\J-'5
M9M3)>YPCW\O6=$4_2IX0_7'84$.9TX5Y?@B;WIL'<.[5KGT*?H@R1 5'>C*?
M'\DG3%')M>TPJ963LG;M<B&Y1^VH?HN7&,1/\<K\>9+65W[.,6Y&RYX.D+%1
M1=<*";M:0\<])=G'U^EA.)?L<@9TK#!=L$O9MN4:BZJ.K*; WHHQ6A$Q:%)-
M?K$8^Z+^:<[+HR:K%:8T+"/AI!8KJ"-"?G^=$U$.#B!N4H7I-4OZ*Z,M9T/W
ML<5C +(C.'E9CA6"$1>M:$K:4D)%I3U,L%/6M/9<6UMCN%>9^T76=5].6=P0
M7(B9BYNJ(-,K>Y6&#V'L17P]A"]H+%JK@DP]A;6@KQA@N'H9>G-=J/K68+FF
MR,NRJY7($*]25K:AN/!9Y(U<NR9T'M8=)@SIVJ$JZ:3>%W@^IJ.)]M!+>='D
MK%B (2D'XR?7<2N/7G*F=@L[632&58W[%N;<*#[I]/&3]TS?@5H^/*3XP<MQ
M@:T,L9MLT-<!,)0IZ5J"5V=KX'"E)ON813*OG$)N."\R'Q#,R@D@ST3L3@.G
MU5Q01R5Y5.8BC(']6: =?=M^6X/+6%5U]=6M%^&,365I80V2U+8MDO3W 8Q&
MJAI7ZUD]'8!CDK+XVFLTM3KZ&64A5JO\DHGE-2F+*M,E>*8R7Y.JF#A8F8+P
M2[M8F6K<=4BI":Y69W_LPORE9:ZLU!$FE@W775ZTZN\%=_5J@.RCM]M6M>TV
M,B&D;*CS<T:.EG@L6*#*M.BV[%8P-)=WJ$]\YCCC49SJS'*.,U'**^V-R?NX
M^=K+V08(?6[3BU]0F)%OZ)-_WBY?)VGX=_ZD*U^")0&:XHVX >@]>B$1/.+5
MN5D#NVG(5):R. GJ6YF97,6IYCW%6:]"[OXSM0<M >-/MW8'YV/KS8#C3X_0
MD]?<JP[MN=EPGTC_2JT25=P?09U<1Q>SE3M"^VJUK*K&+I_#_1-#?6UA8H^2
MAO(TI+$AW)E'M[C:R[J$*LU[)+KL^-KG)#Z2:@NC._)GYOG\#:^OE/5^9%IQ
M7TG,;!D'G^E38^4GLHR-0ZH^%=@NKVD5.1@&DH ;)KJ*:&>+$C^%R#E-Z Q!
M)W9:<LE;[._2, ]Q=DW,N"8R+4GZREBWIY4JG6"Z_#"=RV2SMP?PO%-=_LE3
MT$H45,B"O$(8N]GH]%9I4K;DX3!'M:KY]N!G=C';GU[ETR1^.%J:A&9ZB5<<
M$>D"XZ9FH.&W52\)< _:@(?8=HDGK10F[GHOB\-.MC'4O-JE1N+HDNF0.E:,
MJ8-VX(.J6;.]J#J>7UBUB&PCKHY=QI5AO?=5<I%X3*G6!#?EPBWF+_4T/P)3
M.\+0WA8P</1I6!TE:FD('$!ZQ9X41*XOKL^*34%'MWVGTI^I)M[6*L]9.WSG
M9E(]]WY"@P#35'FM"V2ZVT,&&@5-*[#I: P=<%1$GWR99?^^Z6]NP&=*6[2I
MZ!*$[.C+SRU.#48G24S?(M> I8Z>LP&H/NU;H*JMVZQ JU<)Z_!5200"R28S
MD(+>8.#-I1%<K"!;U[XXGEYJ;Q[QBXN(':OCV5E,O*+YQO*P[H"Q7\,.!R]3
M*_0%/@KH:#*J:E9Y7S7KVB[*$.9,#PO-N'FTVH9]JKN\G9N(&1(,W;UD[<H:
M+@X0==[FKD0[\:((!\<OQ= @&K:=E!M/%2:T&K::?.!H)$FX!Y!,*39I)0D)
MDK@@Z/ZE2E"+'G8+7$$QH"@CM'\9A!6#+"YT7(C:[G% "ZEE.?F#CFLM^=W4
MV2T4RY4.1%^'+T:ZK-&<YC+@._)MMDZBX)HE%.=)%"5/]#+([CX*_64<)[N8
MY^-7JQOLX_"1?IEDQ!2/^)J*^/[3+LK#;827F8_9#WE*#'WJY=YYDIX];\/T
MI:KTT320VA<!YG#A\O<HLWG+_('/"%Q98\RL(B]DKHI1"JGYQ(&)3K"WDIVB
M"_WJ1-S32PM-T%:H@I@NZ#W:"&V05ZB# J(/>O/=I^7I=V]10!1C$(^9:I2R
MFWV_^?URQ:_&!4;GM5^-BXV6>[]:*3FZWO^E"NE1*3ZB\B.J "O)>5;^0NYJ
M#L_W5QH26PWQM.V)IXXXFF;L%\4AB-&.<8Q7H1]ZT=533'Z]=;CM^^GZ.L]D
MO%6R0>-(V=ES1F.<FA[&1J>B(@EU]/N2(4H*CNZ&C*D-(8%]802*R14S5')S
MB\K3&J(HEK6M5:>1YX33S'K.5BM:@OL1%^-.>K(F&A"&#5I>AIN0AP\MVL&&
MH2T9CWXCT\$<QY^3//0Q_>:OQ&+-V\/3L@.,KA;L7.+QA+R ([@-S<=@/B[D
MD\OC^T+$1N!'42DEK^.3<CE9'L0E13$3E7^]9L+:'2X@6[V4K9I-I*@0KW&4
M096$_*&2F\KB0DK$Q>1?<T'MCTV0K5XM$ ?>2[;GJ-/4?3QXQJ!QY[ZG ^ !
M1$G7QG*/!ZV!@[B:[&-@N)YD[3]/\H#)QS%Z2),L*XN&L6S,S=LDDYJC7@VQ
MX7$2MQ4@IU:XX6F:J4Y1TI=5/B?QTO=IC3"Z W3VO,5QAFEY@9,(>]2U3I*L
MY9DZ?5J006VDA5K.7JH3@@Z%8]4R4Z4[IJ4H*JYT*8ZQ9?N6OF!,)J@9+5V1
M-;[WY/*0ID6[-;WNM."E/"3[%>S9BW>% (A)X/HLIT5;[5NEPZLF*A7.=I2)
M7L6J^"W)?B_BLEX77Y+AK<0[IE30._YB<.>CHE-P@8SCDUFUN8"Y$1;0L7\Z
MA<>,"L6+#=*137XP U=\RT>URY>TR:C@%6DW3:[S)"=S;M&3QGOUYC9=# YC
MEX\!PC-\/6F]K<Q6GI2Y%68K)%N@8D7Y]O#G$>*Y?&(5NHUK1[:H3YI\M!IO
MPMWF:E4K-\LV::4GNBMQ&NTWG ;DX4/3(M*[U<,(0(=^775&+8IPIO)"!Z]7
MS!:I2WS&Q8/N_+LPEE93;#]?;=E*UY6%ZD6KQ2D2^:7[A;2AZ>(%:W>FV7.>
M\B5)]$9. @P^MO@;IJ=.<;!\Q"G=H/7"]%<OVI5/1G:?N1S4&S"&#K="B9[J
M78'CIH8B8Q#S2;!#'N>'5H0A>J0<);=W=O#/HC4*5DCP0I098MRJAW/='K!S
M88T&OQAW?&WTM:5"Q\])?HOS/,(TD[Z(Z8/=I45.P\R/DFS7^B;V8"(P87.<
M3>0[2,,HP+URI*G'Z&L>A!^J&-*<DK)<R"A2L75RE\BR9>C2J$]H\\M"]-4F
MN@QJ_N$07C#-$]K5DL,_?WSWX6/_@R+*%&!BP AK'#Q HM8=> JEJ8RA.B#E
M+#,4]^(RE!4U0 DJ5$]?/(7Y>G\J^D^(2>;F(1-+]JHLP!DNT:*\GUF?@')C
M 'C^Q)%E4)]I7*9?RSC@5R7)>"*-&\O[+$\]/^\9A/I[PP1;32LT95H]7>&G
M6*H*C,RM4!1Z]V'45";!;N)D25\XM2"NJJ/[+:91Z 8[CE7U[BW7(/6!&[G*
MDD]0<$%B Z>4@DG=KU-\=+Z+ RQM:3[A%)<YWB1E;71+(9C4O#HJ/0+"6J9Y
MC<(?UF\X\_QUO4U1ZZ$0J<B?&FM_3<(%)O)-;-5R2FF>!?!IYX0*CP_,@[U/
M?F^'3EBK<F5VIYT [<6'KZMJ^+H2PU=#D:#C%T1%.VA:EA:JR&3EY,U!93.
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MD*,F]HB[V8*Z2*D8??2&<,C>3GJF1N'8PL2J$Q7-K2/?/25WZV27D:3J[HD
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M;WC0'K0G#D.B;WRHGW[+]+J812,QCJ,GP?.HJ+VUJDW%1:+PCUFXN]_,?AX
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M5O^F4O9@HY&M!#I]&O?:"X/CEXLX"!_#8.=%_[E+PRP(?3JYO*/3MA:;#2(
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M*9M5.2J?A.5A@7&N,4N)LUV&\^_H);6-N\/;+" (YV'J;_V X#Y@\GZ6Q>S
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M/_#,YFY;0\_U__P+^9\G_+T)IM"/_O(6N7][]QS'+W_Y^/'U]?7#ZZ</0;C
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MTRCB/?Q$AQR&V !OVO&:Z!MX^;X0;-^B6)@^RBA#D)1S]<:UGES/C<4!W33
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MXJ3N-B&0H!ZZWT._&>I[M[WFD[OVL>0LWZ;O$M5FT+8$01XW;0<<!)IE%[W
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MKI&X(M5KRS<:VION2.\GVTE,W.TL]NOR]*7O;>C<LZ)H-L\EDE=-9N6\HW>
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M<O5;I&K*UA%YW_R.>Z^4(K!LMC:<BL#46;%:/@!VQVF68R?+E0PKS+K;43A
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MBNY2IH)%C&!5ZEEC@;?>P5':S\7/,[[.T& SQ*'6@5,:K@/*DU_D/EAL*G=
MQ-\1&H Z"'.+C([DFW5$"0&'KY.1H.E >B_'5J_.-K=D\1"_) D_FUIT(=W/
M9O.9O?&P^=7[^C_XV"CTL2'B.WC9X#N@9T71;)Z?L;/PGF1J8#R#4MM#$?I0
MYD$QQHRY/&0CI<PG4$8/:+ 1$R,G#&1>-/4#@9;D,5BESR[XEY,'%.+5<I93
M<_F&0MN-T%WHVNCHP]%1XX.6W""CP '7BY9"^@V(SCL\<XWL'.OMF4N/K494
M@:)L@HW+O\A;E?\U.K<\#SEGZTO+?LZ3O*2AE4T;8J<!3<0DKW%0$_?,,@W=
MA8&-D!.14*.=<X:V:;*Z[#/>I/EC6I;#QC57T5ZV2R__-3H6N0"TC75 H4K&
M]90_49=Q\R%YBE)O]_AR16R.PN;,DWK8X';,"4H'A6^\W&4#Q7!);]9S%K3J
M/)BYS!J:0MD!VKA>R4C&2\?!&MAGC@->J1P,>P?#GJ&&O;L0727D>"P4!KKY
MCM)T%#+E-]*)4#ET1 )%IIEM\9R5YHC:SC!I<I,X=.@ 4Y07G**\,%^4'"1J
M\)CO7T%V'=<*UP^65QBL& H7M3TT!'10N,1H5+2:!U&X2O21C&ZS^2/&>V2E
MQ9.9>E=[1XAXX!=J RCD* :HA25/GFO/YOCKKK_ OW]EJ&&4MN"$*R><775,
MA%J@^M@T_F&%?Z*XH((NV^:69DI6@-:AE3/E)B_\J9;SO*$U.!AT.\UY*52D
MS@USEM?I9!_AM/;09<\2()?XX>=WV)DT,VZ_L>T(9"@4G<]/Y-#G<G?98\&D
M;NWY';;U1D9K#QT#(GNX$(V*2G8-:0+/*L!R6+Y+#<')6TAH5(-W&X7P;ECI
MQ-/T]G3M>[<--.%Q,G]'S^:B:N@=FB6U,QZQG9DIMU:R3+L:W;2X]=*:0Y.Y
MNLL1FT1%U1";718_]Z]GX25R'44)<BX28A2X0W@R>3'86_2:_D17NG@Z P<*
M6]I-6I@TT69YNQX\$]4"2[F3H3&%-YA^Y]M*#X7G^2Z31##'/^H^H*\C-X 5
M"Z=%VN5$EBH#9]L[WMB),MBD ;?U,00<\K0JLCYHS02S&[G"+?7&#B:*G)]0
MK5IQ[ZI-ILSE5).3MZ@11%.$:>T- 84<G3DFO@+9_E7ZB9P'?N1BZE+9W2,;
MN:MT?93>9=M]1C@&,0T_W8G/0?7-D(VFA2$SOSNB*F/L&:#::<_Q]!T$GD3"
MH.LZ.8FX9<?F%K=)ITF[4?\50\#6)W=R.)YJA6.'Z,#T6Q&R/RR"U4=D.]GG
MKK.EA]>:0R(N":&++"G9NXI<J9&!7SY__K(;%Y@/.LE'G>P,RQL8F).LBKB[
MP'-M+' 2F,Q/W+<VXHIA)Y;O3-*@9X?DR>J!3GN=TWF^?B*H21&]OG>C/W]8
MOI7Q>^H[#S'>6=%B74]UV$;]ER]'N]17/C4AWYIL/Y:RH/C<I/(]$5[\]6.V
MP^5_^[?_#U!+ P04    " "T17I<Y5SRG_0T! !G>B8 %0   &UT=F$M,C R
M-3$R,S%X,3!K+FAT;>R]Z7+B2M8H^O\\A6[U^4[O'6$H2<RNO>L$@\"8T0R>
M;MQ0)%(",D("#8#\]#<'"<1H;(,1+CJZJPT24N;*-8___-_94&4FT# 57?OW
MOUR8_2\#-4F7%:WW[W_3S6RQ^-__^_M__?/_A$*,\IAIE!E9E^PAU"Q&,B"P
MH,Q,%:M_S;3TT0AH3 4:AJ*J3,90Y!YT?\)Q83[,AF-,*.0^*@-,]$M=N_;N
M"'.+BUGWP?ARY"<?^\FS?)R)7'/<=23)U"N+.^F/RTK' (;C[>(:/8T-IZ+1
M9#C*QUAN]?8F-":*!)E;O<,4<]<,Z_XGM.$?[S_T&7T+P0K!2S.O;3/4 V#T
M[X^^98VN?_[L K,3UHW>3_<"7G/LAWNSJFB#^9W3Z30\ZQ@JN9MGV<A/?+F#
M .+=+NFV9AG._!?D;A-*X9X^^>E>7'J^Y,A;;G;DI1MGIK*TCFG$6P7W\[%2
M;DI]. 0A13,MH$GS]>!'RM;R&]R?Q7[2B]ZMRLP*H9<OO<1;C**AC4)\!#\M
M VAF5S>&P$('AA[$Q4)L,A3AO.>8AK4.6O3ETFZ&U@3,[QI""TP48,W"DCXD
MMW'\XGG*;!O\N8AO8=[M!NQN/:_X3W35#QIEQ]&N@E*&RN:30A>6]J:8>I3G
M$KL>3>]P?[#I6+E4*O5SAI'6>RJ4MB *NK",*&LHN_1,?'6!4Q] *80GF[>V
M"TEX/L3R(2Z^A)?*1KR,4[Q4?OS^IP^!_/L?C!Z,I&L6XES__K#@S/I) 8-_
M'()C6YG\^\.]'K*<$?SQ\_<_EF*I\'=%:*7OBVFF6,V&Q1R4X+ ##2;"73$8
M8O_\I'?]\Y.^J*/+SN]_9&7"F):CPG]_#('14[20I8^N(^S(^H66]!-=7KI'
M5LR1"IQK3=<@OD&97>.G08/^J<@RU,B?Z(8JXKZ&(M'-S*P&1M6T*=:Z(L>+
M$4[$BQ)OIZ^-=CS=OV?'U<2-JE>5&>Q/?S :&*+7N3SJNF;UH5%60$=1%<O)
MVH:!=M^ *N:^=6!83@L!0I@AF)A*1X6"AE]-3N,'HR!,NB$+$V\RW8[Q6IS(
M[5JSFGNJ6R6IG>C]^+V+-?['_YH* >D_/Y<VZ.TW;P )OY*Q-87NMHW^$)L(
MGV1@R&*[F1/5>MPHB9G$8%"(/61 H5J;:.4>PA/S6E-4=-Z&C5#O !#+ZL.A
M8F'Q9Z8U.8L>B.0DDI<*-)=  A[Z=WD8N2^Q\=3XR>K;1@*&>OCHES?UI9N,
MBN6;AZ?$5'YM" H2CS%>JMST0Q_>9/2QEA7*HY8J.).7VL/D3KA_:4^W;W(3
MYN9LBE B)[H'T=+]Q_*0'$E&I-]AV6Q=B*<+<JLZ$'K>BA'7O!;0\A#RHM4:
M0"UJ,IR5H$/7V9+$5SU2RA:G\HU0F\F1D-I(QZW[M,B+W(_?2*YS\4B23R:V
MH-YQ%IQS%:B\8DI ?8+ R*-OS/F2HTH.C!\K"9FU)1A+/AB=YWXL+4;QDBG'
M.=EBZ^@-NKR\W/OZPZ25X+MLVY[P68XWFK&&="?&\'+S3^]8[!JVNO@H+G$D
M+!0H6J5GBBEB'4!L]H$!95>O,],] T*\9LI6Q.'=S4OL.3^Y;X?:W1S(\*/2
ML]0[$B],2I5B2AX.3&$<';="F4+4Z9>GA^*%>_'^ X%MDM!R3KI<[PNELMF(
M5O/B?2&2/A+8N/ICO) RU(8 QK7V--N*]3+*5X(M:-B6Q6H^-$;X[RKZZ=L@
M9*-."/)RM\:6FH895[/M3ME:@'"S?OR?G*[UFM9W0[KW0Z^F&B60:#>R@ZR5
MG]C]GIR,I=)? [U]Y?*!:*TK-HNM)^W98)W7;,-,-NN9J'TP6@N4NE9'IAHT
M,+Y9NC2X!RI^K@\4C>>!T(JU[OKL@YA[>C4;6NB&2Y^)FO;6YAP@::-\[Z$@
MA*;C>NDI=U^8->\^OKF1;4#1ZG%/O6JM7&UG<YG:[&;@%)L@_>,@6H<,)64(
M5&1/1E;W2K;8UU5D$B'):B/TK^H6)-\V1X@:D)+J>G\:^-7<LDP6"M/HTS"2
M9NUI/=?@ICT]>X\0G@VS*>[DT# -2VP I& 3'HD_511-&=I#ER5F[T>W0V<X
MB[/Q;%<VTOKSJ-=.^Z'%'11:>E09J7>JS;9+3_W^( O;Q?M,#T.+#R*LP,P'
M*^L6IKA>_-9N@Z<*?&WT*L!")WTTS(J\E*2.S2L6"[3;AP;(Q+KY(8$5&XF\
MQPQ:XV]O8<7DE4O76*V1:D.M41[+['VBUMC (O011!R[K@+-0K8<WN (B]NV
M";NV6E:ZRRSC-5=[*4PFL03;O&\4N)3.C8LO:#_UR'L4^=53C"Z=8E2\CYAM
MJ1\2V4&V'E-?G/RXWW3N5M>>!XI!F%H#2DC4(1,T TS%;&MZQT3: T 2KJB-
M;/1*]&X)B43RSKEX+ !%*^NFB9#0(AI&K5O4D/#V"<BR8EI+V[^O(1.R$5<B
M R5E\;<.F"8[4OH-R3A?9UI^L4V+ONH!&$CYL<POL]5."+6'9+99F4Z2(>%!
ML;./(PN,8.084/N,]/V0,K%@&Z$UOH$AM7"-.&W-0! U9"BGAUCY7(+0M)2]
M46"CG&]G^2%XZKZ4-;N )#'[3H::4R:*#,D^3:Q&FZ)M9+7[QT&&9PLWK7N8
M:4K@#J]\PW;=W<;GJGI6!:8Y!WK-:"B]ON53U!'HH9EU+[MLQ_MMTT;H-+;1
MJ0D3] ]6/,DOMUS?\&M%5H#A-($*:UW";1=OKML=59%J7:3=(.CB-;N_?U7B
MTK 4L11VK,N-VKC6&6;$)<6!7_-E;=JD,(.&I)BPCI ++M#.O6JNR,/'2E^Y
M&47D0:&L5ZSX]+;_6$3H'0ES6\_O.+Z8-*(2F3AC5-"C:ZRBI8M%*02SB9)^
MQS9K[6K]?E!X+*$;?G<12. :+?U<]B@3)1)A,#1__X/=^M<F\=BC)3/$S7^-
MG>'__C"5X4C%[GOR79\$2/!AA3Q;*#PS9>PS_[GR3/+1U&V#?"+QDFL7+&0'
M;X'%PQG*AEI@EK:MOFX@7K6,<)AA(0E7UB6@HKMN;4,Q986<"K&;7!324I&;
M3N7NWA@\L*%Q\_5YE.IB6+DK@\29Z'U"Q(8^=Q5H, 0J<&-<*ULL+?L25W_L
M/<Z$/7QZ]*.,7C9#"H:DN-3!R,H0LUA=6V#OYDW_^+U07O;:]3\_-[[QM[?4
M^<)^;H+"B#C]YINPD F80Z\EOL@0RZ'_SI\SOS8'I[RXE>-#$6[Q"GK%^^R]
MY.<2AAP!8=SX*6*B8M6:F5-=KQ@#R!I*H^](T;%^=VZXX&[HNMW\UL>\JD0>
MF"\XVL1@$5N3A'B1:Y>C;#I5J*7/#1>"PA>B^R-,-" (X^,+]Y7*>,3687HP
MO.>>8*I>,^X2%[X0C&-><Y:]Y1/HMT=.L=3HI=CQH]D!R<*XQ"4"1]EHW=?S
M7?SXC3\N;>.09TB3,:P-Q^)=^3SUQ0GUK=D<<[O2U<M7-'_R+39US$#8&]5X
M[:G_^MR8#IS<T]3(39QI;!!897$K;'_\QMN\7@7N5I3:_XV;3\4GAS8=RV'>
MN_$\W9UN.]"C,<+X_HR0W'H,>?<)BLL$A^1RK^59)<(7(VWEAI6?G\ULYY8[
M;Y++7&CNV]%<W*=CQL4(NZQBON%9JRLCB'.L=,WS/+V/>&YM#>+W><#V,@_X
M;F(T:6I%UHZ7AAS4^2+,!4[1V>F8\^/3%B ='Y,W@_>82G1\;R4:W1IAC^]#
M^6!,,F"HMDFG]F_C6_M+#A0Z/8,C/9:9=/(CW9ID-5<[:, :L<F1KI%T7;^"
MUH 64#0H"\#0$!OSA(R<&N<-@9_DV+A8B]L<IV<RW>!K6)NVNE!Z-N_U2$9S
M[%!&\R</."W+"B9YH-:!(A>U+!@I%E#=<^:F-[>MBE[1A'&MU9A,"O%.8APX
M@G[G.>_<\ID==_0P]-R5IZ%8\?Z1%6 H<?M4R^NO=]G R>(@T_/!G&"?/.#=
M].QD8D:'[[8EUI8Z?< FN5*%O=!S<(X[<AAZCHZ,V7 P'C196[WKW6;+-[;A
M7.3S.PXX$I #WDW/TR;KU/J%-AP,U5 R'HDZ%7,6V"A3@.GYP,<=6]/&WG+G
M&#!O:S*4MWASMI1$F!G'?V6%-:QFV^_A&_+NJ!O*!/VZK@+)7UK1[CQ6Z_EI
M(SH8AO(9>9 PA/8LL'SE3??09J!_WCNT_VGYN=MZ<<1GU['#2[7([MUTT$?3
M@MG84:DL(&32"VF55FXP--BQU)X,6RT95K3 DLD%6[\$6]==_!]ST0NSTEVA
MZDA\.YM3QU;$D;N57G!MM9,[RI>T]B7?]^$R%2)+CM*(F'E*I++U]//S@$_<
MAJ;CYZ?76N+H=M9[_9&1_?V1D:/[(]-38,AK 6)A.%)U!]):FMH(PWR%2>.R
M%%R>Z4LZQ_?BKW&W#R^!I_!D6K-2Z[7-/X^=G'3+Q0IL8#GR$BP6W&\K,#[/
M>_U0="ES QC/S#GV<>2:)-JO%4%,VNV2\SS(A6 O-RL&UJXZ&+H$_1C7:;TU
MU5M]W3:!)K>F:)U.3</:@7>.E9MHY#5EAB;"4!>XIQ=9:#U*@27[#42X>W]G
M=Y!O!1#?Q]2G,>&A9(L#J=T4-#V%]&Z1G0;.F_GA<..%>;\'&;KUF]?4"-8G
M[5#,2(6>)N;@=1A8EOT]CFS?,IJWG%^>.9?NH7\.FL_4F-TE\IF$]CIH:B.A
MGBEFI7HC<"QB;X?5#D =U?X^14Y3$!-@/H30\PK?PZ+V<[]25=)RK,%FI^IM
M+9X=Y?M"8'6;]Z'V-I!=D#P 65Y'M=BYE.=#';;D[&U2-P;Q^WHH.FLWBFDN
M<&ZNXRMW0?,%> ?TK4CBG8Z#!C0M0Y$LMVT2R<UO--L?,F(RLT:V^9JV'P5E
MJ&4;^=ZD>B<&5D/9@HT[ 7(Q<(Z 9!&.3S[$N:=;%M9*S]F85;EKI0-K[AP4
M;0)RG/O63IVD!(IMQ)6G1K+Y*)1F')?64['(\TU@N<JE'BD(]4@1'QY'OA:/
MTU8%& -HK5KOZ5FU_?PD5]JPFNS;L5%2G]8#:^($%8LW _>8.!S9'X<C7]JW
MX9.=9>UJ>@+KH<=G-EYP'@93>R"'7@*+CSLVZRE1NW9[- 0)0F./;8Z=3R+(
MC6Y$,D),J[$E)^9H!;M>KBJ!,UJ#CB"!L  _V#PS8$?]E>6+@8@@5AO=VV0K
MVHD+MA@J9N3BB]X;G,6Q?$&GEJ %?JKZA.P+V_"T563&O76INR*"O4=T$Z *
MO5#+:,.7QBC*W0O)AWK@3G=?G_>^VP][^_]6''>!0RX2\02).#=-DO\X$J4U
M>1F<7L"E4 C5G,)3YZ8-)\-6/&(]F7(NL/K;^]%GV\:/AC=\B-L7;\BMA^T[
ML.1X\? F_E&;<U672PW,)^FY%FNPXT[%>8VTQ:K&!=;#]EXC\*MTN?C^&!(_
M.(;L[K#RL;"K]VMLWM>Z:4QF/1JX]'4]EFQ#L1 =UFU#Z@,3KN+6S(G4JIWF
MH]96VM'GVNUM\VX:W.Z !XZ9[OW>C2#V+).W8'Q,\S5PO58^7;'2>!'2KZ$D
MN&''A9NB>3>\9>^=P"I6@:@4"9 "]5&DV$L.WHJE)%<WX7,;YE+MVT+S*5HN
M!59I"JH<# *";/.*?IAK#%./MXE>HWXK*%8C:2><3KL0NG"-0'M"OWAF74!Q
M(4"NSR]M(O*>3N?^AM_N(8];NF/H<OJ9K75*B;+#L>7F36#]V^_J<+Z^V^]V
MR+[NY*-\5GIZL36U#>_NG@=3:_PZL0/+N+^V._E7=+;>IJIMG;65<>8!=^KT
M@M.L;HQT]%AX X$\MA$G@X99AL@2\ESAL.R\#C*MAM <5.Z?&\_:Y"416(Z\
MQ]8]O]?;>_\CU;B#(D\N\YHK5@HUMOWP')LH^4SJ)A3<!*+S0)X@![X_U6XJ
M!(NR$'V,# ;CNZZ@UU_D7NDNN.ZLH+2;.AO.\BGDN!^/QS":-F[9A\J-)$04
M776*@>4DP42.TQF*R;6^90<5,V(;:KE"=QAGQ[6BK#Q'[I12-+"<([!B9JF3
M&9L\<CWN(1$ VB^WT9Y\=R^,E6+2:?5?,OQ#8+G#.2# \5O-'A0!^D[M3M?+
MY0D+6D^S\<QL*6+^@@!G9;7N+NC#P7\$JJ(FV]2KZF_0(<7-V$#L%-AF,_V<
M>!&'16,:7/[_1F7<CIU^*[WQ8ZT:=F,"J JA?OR^8K;YT6LIDB[>:4XJN-Z*
M8&!" !O*TWDK!!CNR3[8SZ&IU;A)M\?/RL@HQ;F0! +K--[3 %C;YID=ZWN-
MN_5C-5KL0P^T>J"=?7E,/CR]=&YO6X$5W $[UJ#T#U\_UC)[4Y**4;G"ECJY
M&_.5M5NU2&#Y<,".]<!MI+V<M;T3JKU,K-7.QBOIU!SG65_<=-:\-36'591:
MAC.-Y# ;W'C>6PFQ^^T^/-_^T5CV@;J,;F79;V"!E_R[M.]4BEWDT0\=M9A.
MW'"RH(1 )0YC]YU>-K!$_M:Y;]WO41+GOS24^Y&3CD18WU$_%0SXFJWG8VSH
M<=)^Y95B$4;.EL2W;_C//&LNEL+&AGO6=>NI.!H6JO<#OMP?O2J#Q*P>7-G]
MH;,F&P[SW_RLWUT8E9DD^9$9J]0&<347-4M:J>'4SY;*3UH8%20\\#2:'4"(
M1OB(BP2EZE/])=(7X*"4'<>5H@!BX/9LD6"OO8>]S?\9& #>P "VE:[.U.CK
M0YNO1)7V@YA[=8*;\O,^#-BR]S\& _:UZ=J9S(WXS+5>V:88?2S<*4Y!'@76
M+W,F-EUPL&!3"]@E8,2B;"01<Y$ACG[S4%?JI4%SRJ7'C>3#?>3E_)%A#R"$
M%U X#YQX]PAXRA;=JRO5B1^K;8PUQ(?8X+:0&H381C==8N^JV<;9BH\-\-F*
M"7N_]/3]8X\QS^93&)@Y) JF$WD]U+A3RH.:7"FW&H5"I) Z6QUV$X N.+A3
M,JXUGML+!W/;<?#KFR\VC$FER?/.;%![:<X&;"%]/SY?H;L)P(?!X2 VR_N*
MEH\^ZEGIXG@BZLD&B7I>E;@T+$4LA1WK<J,VKG6&&?',E9#LA7J^(_6\-;7W
M- 3T/*B+L^8D.FD_# $;CVLRF 2WN<C)AO1>:.@H-/3N)G!O1ZNSJMPJ/S;:
M":%P^\07HXERV9'/%J%/%JT^?H;@YZ/5?3[R?)\N/P[:L*XG7R?W$][0O]=1
M?TFT.IAGO1RMGCKW1>DN6=3:)7L0N==GM;O<S=DJ>J>+5I_\K-\7I8P]5H>V
MGAXWA()4X,UH$51>X-F2>""BE '#@+>BE,-;.1*_MS*O SO]PBEQS7QP<M\$
M TX4I0P,!NP;I8S=) HWN4P%"'S;FMT,VG)$RIX]#IP\\S0H6/"^**5Z.^K?
MZ_%;E1U7$[?3MBU7&N<;=PI6E/+ ./'NE/2W?"1;.G&9&<=_9:71P.*"^[2F
MFGYZ-)_9"5M[>1%!H9[(UL_71#R:SV-_8/M;':Q"^VB8>MIHYA''$&>@D^GU
M8%T20E,^E1ZG:]*C?;[H^<W'$ <HPOXEDX3K+ZS8>4HV=$%YF.9"94NIC]BS
MC;G_.9.$CQB%/\ 4AC<RUG5C=C=M]SB.10I*/*55^[E2[&R#Y$')6%^9LA $
M/-@ZC:.J"6U5*M0M=MQ^C$BS69M7N]\( [YB&L<1CYYUC;_CL8 IR*;S3Q&I
M*]C/3BY]6W/:^OE6GP:(!;#'=0+D@6+< ]6&&6?^YPV"+3"DOE.&$Z@NF6OS
M>XK:R+9,<@.WHKCX'EF!P+0-(L'S!HF_2L[FY_GN-!MX'H1/IV'E:*06M2U.
M4!PYELA(/3'Q'%C<V@^B"YML!T@_K]CL<18;5K+C,(+NV=BWSU$:K4M65-M2
M)G Q?T282:J-;/6\H0]Q_P';(@^K=;W>@'5HD&;B&6?S Y:0>SD3:Z*TK';\
MI6\(MF$7]3IW=]/O!=8Q=D3X+!!NOTRJ#V#6R;LJ!0D-=P^?AZV7=OJYV,@,
M^&Q%98=C5C3E/QLMOVR4_05-?6@J#$>J[D!(8%X;^285#'KUJC(NMB/"N'7'
MYA\SV>>,%5B/VY>@Z%9@?6OTW-;3^.N%^7.]55+D;"DN9$UQ/(8S3BC<!58E
M_4;"/ A]UT^)AKN%^?BE7;WE<[(D-/.J7'C47F&F$%@WS#<6YG\ZFFX7YLZS
MWNE ^;XQX!4;BD9*9D/!;37X385Y$-!SFZY))P3-FP'B@4[SV64^+@BQ/R6-
M5H/])3KIVRS,1NC\O&;4[7@W]B@D1P/AH:>J]Z_*K=$-!59KW+'K)5[VUK:_
MM?[W&90I0 T:0$6@2\M#15.05 "8*)>1)C&^*<>[9:LG-"OJ8S4WKCW?\H'E
M3GLAS5X;_]9HLTT0'HK3I-+I=-E0;T>L\]";JI%.9CR9!-88"#RG"8)P^@S*
M[,=IN/X3:);Y\FP0XFS5D/+WL99QWDAS6DYS4K39/9T^"(E!>J:DZV9!+["%
M82XR:YGWM69PY_M>$H.VX?B7SZL_9NB8/W;HN"3J-Y6R.5;;#VIGDGQI];EH
M.K!8?XC0,7\)'1\Q1^) 6'D_SI1+]\]B^R'?&#Z$'M*EV[-(:/@C$2%Z5APO
MT:P4.WJ,&PH.&XG$<YU&[(4+K-OCPO$^@.C';V!Y<*Q48"_^<",;^J 6X09L
M)112AN <Y/"?@0C[.MH.6CQ^5\@E\P"T2H/0?78,<XT7O<8&%B>"6SQ^<G_;
M1^MA]NBX]'X[URH*555[J3?9!Y">)F:WZ0=]%MA\II-V3/JN%2_OQT1E!.E8
MJ8.B8K?[F,[&-,D4AEJK,>8?9AGQ);"JV)NHN 5(%US\G$S=;[A;6I85_#2@
MUH$B%[4L&"D64%U,RX=R13X!'NX&=K]?Z-_K7#T3W%9+>PYZV[GE;R5 ]XT^
M' 158A7!>4WW&VQMFKEYJ&=G@^>;"ZJ<7<3A(%QE?61DJ*]WD]-V7QHX0E*L
M)3KYN/026-=4$$9&?C/NL8X2CZ'1;-#LIO3!.-DJE](WE4;:.'>.\74H$60N
ML7/&-^_Y*IU^]R$;NKW/#6QEG,]-4H^"4 VL2;5[G#?_EK?P'#G VN#@IJ2(
M=S>O298=2N6!5KRO<<^/1W>MO$_1/O!\W0W8O:5#C@_9<8XF+NR>*!(TTST#
M$L[A%>PEM)R3+M?[0JEL-J+5O'A?".ZTS1V;]:A@UVZ#'I,Y1J;%08W]VG0Z
M@C#>>A":CS7A!3KCB1'<2/.?WA;HY%D5<WQ.B6YG!H3/J;4.'9]D83<Q,(VQ
MCTZR7:M7[E[MS,M+50@L4@:(A2WA!Q]B4WOB![GU*%DWIF$AW=Q&=Q@C#*!E
MM2VG:[WFZM"!P[3C2P&9K]8%9R+ RO/+Y#;Y9"0[@=/^$'BN-X''11P_?#[/
MOP+>>N]8>M4>**A+BGZCHTUIO:Q>MN2C8*28?50[D[@S9K-ULYV'L*L."X%3
MS/;!R,W@NB#H.V5HS&?EQO8U ]Z)=&]KAW.CVE FZ-=S%<I]0(?-/P[*'64V
M>)@UBY-0/?E49 /K1CDR!AU"59P;_!OA?4P#/[:W@8]N/:"!?]AY>IZCS'W(
MBIE#OB75LAL(X.L'(8WY8;:GFIT^6RMDVKW[SHO"6X'30O8UKXXTAV_;B;IO
M73W2PU#G9>[2R6>7?9K.,\$A]-=NN5#(M,:-=BTYKN:&<MIX*5X(_?V$GKE0
M^G>E]&TS/L]*HM=>A+HSZL]Z;9A*%=2D"E*]^\!9<>\C](//!KU(] N=G[M$
MORE,U73I)M<2QM-*LSY^C+_F1Q="OTCT"Z7ODP5_7L1>%$/V0X^K.6P-<@V]
M^5B>I#J!C3B=+OW^0N_G3N][9B1\+)M@\FK HEIZ=-A01\T\AMI\RI("*S,O
M\?RMW/^\;++Z5,N-;T5V-H"=_JT8$3E^J@66>U^LHW/GH5M3]VB_H1:8I6VK
MKQO*2GR.G'Q:DW$?(O76-A135B1?D\G"[+:=G+6L 1N/3J1(1K$&7'!3]S9O
MUH=4NW<;]##M>P]9PD%SPQ';33$J#ZI2LEFX99OJ[.E.*PU /1E89_"V<W0W
M=-UNGNU1O9F'5E8DW.-K-0$MF10B3=.6*H-X]D6;U!X2\*4>6$)\.P%M\S;/
MY%BYM7FO;^@)::L"C &T/,&R>KH/PY?\@"^\C@:AR>OL&3I)36T$-J7A+2'Z
MQFZ/=\B''/7U@132'. 2<PTPS]YUH3Y26BS/<95\']S9J?@9$ZQ_<T<ZP96<
MS].<(!_UQG U9[<W51ZH):'VU.H;3>-9F&0#J\/O=8+SS07]! ]4I7"4QAB\
MG(TX(BQ%!@I7,FNW4,M++X'5I?[@QA@G]V6\55!Z'S';4C\DLH-L/::^./EQ
MO^D<7>Q_ '*GKKOD4@1R%'#H@]UJ)J=L\O9YD*T)<G_V*E4[QT^E?R?@N-3>
M@*.W?@'@<.9Y V@]Z@/#GRI@I@SMH<O;TJ#"RZ\]J],NM)5J#BHW3@@&3A'%
M&>'S7?SXC3\N;>-83.2T)_K) J<MAN50>BYVH\GT8. \SE[AZWTZ/8N=L9YZ
M?,/RY"5-[VY=D;%-18.FV:2[-'WI$4CPJK !1[IA@8X*W3L\+W8D7['9=*D^
M4)3'3M$IJWWV#+KA;-JNEW2P:[]'0Y*S:&;Q423)BLU)5;^]TX6X.;1+K<?&
M\SC OHO (LE)U:R(Z(;;$))$#IYY<9H07+9SWZK+9H,M-1(=3GI]>2B_!-9\
M/ZF9]J=&XI;H#UF'D3WIC]QZ4/I+^)ATZKUN#L^27L61I9ZI"&L]QY9F]$?E
M$CM\84NI!SYGI9Y@3 DLQ]ZW7^SNW8?GVS\F T_L[V$XL"JXNW+SDPP\((6?
M@ET0#5,8L.V:U.EU%24J5N6SQ=NC<?1+Q6D *T[?W0*\JD_(KK'AN*,5-L)=
MSY!_'3D#H_4@"SQOM/MY6'VM.8$UY-^BCGVW'_;V?R:AXPU6^N="QZ5\OQUJ
M<F.VS=>2=X)R*][)?&"98F!#QT<ZY-OI:Z,=3_?OV7$U<:/J564&^P'K'W>\
M<2_EFX>GQ%1^;0A*-)J,\5+EIG_\46GOV_T11C^PF]UR=WPL\IQ(3?7!,-)-
MI/.1^#UW<W0&_7X9R;&GG7L0$]5BZK;1[R?*@B-$JF75J,A-.PCAG26J.6BK
M_0C:.76Z5)[C7%&J&A8+HH^.7+_7N[U($(*"RWFKD1#_!;W='Y(CR8CT.RR;
MK0OQ=$%N50="$##A)/Y=6U,HV' N-O;<:C(P9-'$S=Q,L54W7L&KF=<'(;%C
MW7+V<R/$+F UI%-U?KMK)+_QWN-=\S[C%[WQTG8S)ZKUN%$2,XG!H!![R(!"
MM3;1RNMO5$P]RG.):_23][\PITS0T8CWN@6]C0JME^RM8CY7!G9;-1/32&\D
MEQ:,5":_\#^M:@\APC/=6%T9T3GPHW>M:^W7^,L<U/2AHFUZZ+X 7GK$S^6U
M[W\.(_18T>IQ3[UJK5QM9W.9VNQFX!2;(+WEZ/$O/G'PJCNR5JRW*_%T)G>3
M$L:5T2O[]&K%F[WIVDL)C+T??>*]B@6'HL(I*3:2&]8&(-+-SN)VXZ5A;GDG
M_L$GWF?BR5.(_L7$S9V82KP4!@+("K69>EOGQO%UX))W>C_Z,)YCLG+1W#:R
MVOWC(,.SA9O6/<PT)7#GTQW?@>9[$F"P$=W5[<6GD#E[&CT9&<'ILN+-746=
M-<5UIN,>!_G-[M/XJ<RNT0YTVY"@23_V(9")($#+_/T/^H<Q+4=%\F0(9J&I
M(EO]:XYE_^?7",BXY5Q(A5WK.AJ.)A9?&=B@];[333)5 ;U&)8.<?_U8>:K1
M4[20I8^N$V%^9/U"T KU(7D"SX:Y&/K*]U;TXY'WTRZ2$*$N&"JJ<_W?%C*X
M3*8*ITQ#'P+MOU?T&_3_)I(KW?_^(G>;RBM$#T+/5!4->N_APESJ%UW(-;K&
MX/_%Z?_C%P*F;\#NOS_^T](E]-$< 6UI">3O:TTWAD"EKYG2Y[I?_?C=PJ$T
M1N\R>,@PCKC]\Q,_!0$9H/^--@!;4B$PKCNZU?^U"O<U@/H@%N7HDC\-H^@F
M$'GGBP\+OPC+YQ!0E9YV+4'<H_!71S<0\M ;PNCH&%-7%9GY#TO^XX,Q6F27
M[!P0=!>[G13/Q6%<[*:2G!B5HT $;+<KIEB00-I*E(_&DC\HO#Z]M]0REG%\
MF-VXF:75_M-9>JU[PAU=E='%=K78$G),LY5N"<U_?G;HH09PH4TAVVX46T6A
MR:2K.49XS-ZDJP6!R=8JE6*S6:Q5C[;ZY*<7_P#,/D(_2]>NF%R6X=E8-'6X
MY1*N\%EHSS>^8?EYQ T8LE[$935=(R)'D1A7T6U@%O-!FX#1 -;X9:A<YW3)
M'KK!S!^$MJK ,,1G/C^\,_/EC)"UBZ.^4'NPN-K=N]:/;.,2!??2^K\(6UYL
M$YDHSCO0Y2_L3F-J&OP;K_K__(>+L[^66$XW F(R@BQ,L;(8[<2 F&0!8CX@
MQD<D*2%WXA&7Y=!?M"011I00?W]3U0?CIWAUV&IVC7@OC4]K]<[6\$'/U6_[
MSX,'I?34?AEW*DH_+?+S.TEZA;=\EV]*NJJ"D0FOO3_\^(DDTB\7.E@D2%24
M+,MA#)9E*<RNR4_+\-[J83J%I25[WT^@82D24%W0(REDZ4/W*<G_\1^!^R[O
M.'P"S/=L'3VOJ^K3Z[XB(TMS_CDT-<#HNF- , A-$0#>U!7H0NB+O5M!!XD8
MVX(KFZ0"U?W7DO?=78H+IU)GNL.?EN$_W,.<Z,'9ZGYB8)E#=K$>9?W[0YE9
MUUUE!N609=B(NQV'<Z8US08J38'ZX9&S>*-6['ZQ,6)+W7Q[F$AUC2C$A,]N
MT@@].#5A3X=,N\@TG2'B2JO\[@?B2JE$-/YKK@YNX*R'Q-[C<.FEHTM7J^UT
MF6D(]5JCQ=3;C68[76TQK1J#=(\64C 8+L+4&@P7^TO^FZGEF=:-P/C4DKE*
MDLZV\&4N%8DNX!!,''\;*C[I$ZCSW$R=G]!P&*L/F:YBHATQ#C)A&(C#_)O4
M'C]1R\""H2%Z8!^38T@&3@C_. 2U8Q%YG3@;!>J"].E)3MP0AG#Z&AWPL[BC
M1>Z:[?'#="='VK#XPZ\[:QL&6G:>0/8)P69]Z:IJCSJSVGVK78H5<G6^'L\V
M*M-W'6 .2C1\B;VT&S2]_9]TQ>"-;547%\3\D^A!7VYN1%TS/[HP\W?IDK7&
MW-!PM<=XM).,Q+I(>XQ%XF(T!1-B,AF5Q4Y7BB63$M]AD]U5G3#?;#7%?K*'
MM,?G!Z?.@N=7^+!1>^3,)E>OB[5.>YA^D)64'FGD)Q?M\:(]7K3' VB/7:":
M1U,?2=H9@?V*"MF=.&RU_R)P+*]T6V*OE!;LA^EA5,CH=U(A6XUTM5DDNN+^
M:N1%A0SL>>Z4K)[.:,W)AJ&!8*9KZ$-OTYU=#R'L0(:23DD8RT'=N/9\SJM7
ML5?[&B>?&OBOM<O4F4_<UG.@[__O&ROU'FCIWW1C<RWI" K>.V6!I^&QVS2\
M7>HKGNRKF#A_#QDS2-'2;*(6']U[*Y"TBSQZ996\T:?>=RHUF!P^AP +\S<=
MO5F;PI;3>]>N6%R6FTBRJ8UZ^7I<RR]DZ.FZ,N88_O:W1?NJPJX,>XQI2/_^
MP/'.$(8PQT>X&<<.T$;#+R,$6: BP5] :E1?D7YX*Y85<Z0"YUK12(2KH^K2
MX)<_@$99)\]%PS$<?OSQ\U!;CB]OF?V -G,,?&O GF)B!FSA^6(^G),GB;X:
M:R9N69NO]FO<.)>/A-)O</2*T$K?%]-,L9H-?UF\X&U0KF#/7\(,2!8!!0[,
M+D#  ),Q1U#"^5 RHVB,8IF,U <&>MS??@LP!B6)3R6!F))B0(QV4A$12*PD
M)N68'&,3L6A7CJW:=;7;&?O2=,95H11[23[H#Y%FF4V++-$!E^[42G$@&["5
M9&O1CE,SXG9LE+Q#%N#:G=;S;<'IO;[PPKAC&3>*63)@;XKNY%?O9.&HUBUQ
MS2)KEVM=I6JE1KHT%2/KS\Q.E2?)LD<3MO22$KI0ZJ:,]E2,KM\YDX:#E[8F
MRT*H6^4KJAD7!AU\I_?V,[54HZEPBCL/6^X@M+0C'P*] VMHOD2%=UO&7#@>
M/0]@?G"#T60X&CG3'7[4(GJ31()F_H=,*.$,50N.#'V"6?_A';54HN(NGL;(
M5;U)W7V6]N_,ZC*<>P1*.5,HEJ142X"]9U#G2RE3J7A!I?=X;54P!3BQ<9>W
M]3"$&EA#]TT"/#@RQ@.BO;7 K.@F<--$4[_I@+!LD$V,9H[0N6T_L%F8B@T5
M6TE@+./?A6711(B/)%.I9'0/KWX@N<E'$I+^(L3+Z :C(QEH,"^^SLE8;U3\
MA$YN,WI 4U[)Y[\OU'?:PRLVFHPP'*FZ@XYNF4B8JA[^^QRP]ITR,++N]C@^
M"TK+R%0Q3??_RDB5Y'Q6Y'TOT6XD9#G6=CJM6#_TE$H\;; B=S&?6#2&<V<1
MK<E,>@(U&UXQ35M!E,ES[/&,S$/H'T>$=Q;]63-:^E3S07MX!\I1*2'GV'BW
MW!\E"YPDQM^7Z9<%PXZAR+W-&L5[@L"[X_Y?IX^Y "/,O&;4T=L0X_9[.J(Z
MU^K.IK,6"T$I6I;5^_CT_GU0JP#3!%+?-J&%$[PONEAPF.)7$V9=1UBM/BNC
M)74?%&T[7I]DD@-8S5NYV8!OM"9WN/SQ?5Y<GHLD_R@=S(4JUK=&!B)<9014
M!LZ@9&-+&'V-A#HT+]K6B8\)X3N#$7Y5K3I5!&B#*K0_E?UU]%@/EMYI X(%
MCR"2J/T0D\?Q3BS'.D*M,<N7[EM*['UI7,E8XI.2^^_CA[K(()IZ7]?60UW&
M77PH=_5.I_UPD]'[]_F7V$W_?0IC@N5#J3A[1-WP0R2R"#/\G_\D>2[QRV0L
MJ,(1!H,;9+S"-J5J8W)F $(/!':/I(Z;[KDA)<X?$MP8-2/[531L6?D]\$GZ
M<S=<N"NPV*1%HPHT*2LT"("@ 67Z>60;IDW Y8^;HU]AY*,?./ZOSM_T3R0@
ML*<Z+5G7_EBE&["1.QS+15-1,1'IIL1H@@5B,I7LBDF6C78@+\4[2"5<#</<
M)B?#J=J];8^UEVZ.'3WTY6'/==$MW>E8HT&=;3V]M$N309X%[=JPW^BY;I:E
M.X?-XH.52E9$-BNQ5LX:Z+;U>(?NC*[>*3A%D8^/FJFV,[N;5.JM=JX'>R(_
MO_-,@RN19#A^)HERQPZN$)*+S$G.KQ#L'8FP]-%"I>%/"-=U8.)*T'7L^9H2
MWLAF1K;"PFG]L0\C)HJI=!0526</'OA8DCP;64J ^-#QQ,.I4Z; [GL^'PR"
M\6'V3$*F'XWRL>%XXDQW^%&;\$U>?9I"83]%'S%/KJ58M')? %*?(9W[EIC
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M%]*=5$3!Y.L.B;Y;\Q'92"A!S<1CN-UR*EI-E=.1PI-FFBW$P<-73-F2T;^
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M[ IUX[B4.'#J")#=_)%%4PEB8., &ZX['<Y+)#L.,T27E1'.DG=+0! V$2?
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M;P9U45*^1$GY&2#]A/9&I'ULG"O<E5S'LTXIUZ:,G(XW1#)FI"NXY$C'N<.
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M_?6^L,,1?5Y_T7X(K<:?GK]_K;5XI]RVZ$O(ZY<-Y8H7'4W@.JN9>8_>YF>
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ME^[5GAYLG8"KD&EJ G;O2V(NX!XGWLQ*8=J=>N)-S("R##3!.]/VDFQBK:L
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ML1L,>R8,Z^X8AOW?'!3-B]8O"F.+4U?U>\D0]/V 3 ,QLT]G\ (,4Y^'WB!
M"^XT36,_%.4/F'SOE3H=@(X)=I_J'!WU6Y=K<&TW?#7]1_#56(R:%.1+5KU_
M#N-"Z3Z-O.D";-6G=>)TW?9FGL&'QI?LB,R9-C&N,2+SA&4&*T_WB'ZWWSFD
M[NOD![3#*(D;?0ZF8&!U>/$^Z:(*872]/K %MI<:A4F*M]:BU.NE!RCRC8Z-
M>(:YX0Z:?#CUH25.ARE^-HQSY)X#^"W\E=W&+3#_,G:9H>^A*'T(V)=&P3%'
M'"!<(^.HRU_9%KP\1V: \9JIA',QKDQ)A:D?4"HCO#$MA_&T2\-1,?J*;D,
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M//$I'6(E/.W5U_ZP,+_ANS3'O@ B?>LWQ9URI!)>GL0Y!"&W#4\#"H.Q$9&
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MC&"S4 WKN R%%PB^DM=R"A"AJ*?QK358M.2?HE3G8.TM\&/Y)R8+P]7FF/K
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M-08_KK?:G>!85ICVNMD^NC[))PDR8CKD2FNP[BUTCGB0>9Q!9IW!$942E#Y
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M7HACFHR=8H.?_P4IXWMJ/O7A<J<9M1@/9+<_Q\$$%6Q U0OXWRGVRE)O9P/
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M'5U!?OK"J#F..H-%8J:E<W;-R<*OJCM\@0I0EH3 EJU]UNV%5C/O>*5.9^-
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MB7"&*^#- &N,D'/-9(X\300<@]IA!4[1%J:!L)J3,=LNG8(RR^4H=DE7@(T
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MYE6NJ&@D_UG@D4$J: ;-$U!I+.!J>\](>G3\TAK$)JZ'NHC=,4,HMW\(.WF
M-0 %SFA<KIY1.C,$@?6E=-ZTHUCK&8%&]\7I#B?J[.3T; IK=$F^9UYFS"J%
MY4 G"+8$%=?.TVZ7-[%3X4640)+>MK!,R^PFJ=ZQV^6"/W%<)8J70H8Y4 1G
MD1S"B.>*X%L%-<][T(;>0[)QSY>!^\[E,ZPWFNERD1(-Y_2B<%Y/DL=G R2
ME1&'\;U#"8[_\R5UK:,Z84!538*+L^BWI9^T#RM\&L I:+%TNDF$VC(J:*I?
MG "T(:PB95O"M\,2K:NB].U[_H=B,*50H.HB+,-U> 6,H/;] BZ$2R!?U-MK
M"9K$-B.#*2@+]W;'-X9K>/P+=;11,WI.Z0%GZC4DD.]7G9[VV(8OY_6)8RN'
M;5N2%&0QRWL(%GMDV.5931_O:Y-IP/3$->G0LC=A>R )V6:+A5H/K=;K*)A-
MD&M.)"-QA#Z6 I07&1\H0J($?R%&N?*,-L]63]B\9^\*(_EHVGS=Q$4=L5F,
M6R\Y!T3IKV"4RKS>F^;G02$UQF!1GS0ID.LEJP9 \(1\L+"/F]&@3WL#M/PX
MG=Q01=( E\EY\2</;HU/IOGV 1V^Q65&TT2WJ)WV!%+H/0F["L$KB(T1K,M1
MN)".2*_Q(FN@#^2+JM9X2;,V H!FQP105V%ZDUJ1?9(+,"\EFN7)FRU/4<S>
M<MFQJ:)[TW<-2#]&/N_U#\AYZ&5L[-4$R\VF4RE'O&4B!=?8Y&7/.*)<,YU1
M7@>V-^B?F'72YYJ75YGKK]4$L,MHFJ@Z'3I@=7KO7:\"ENGEVKV?<MH5G\Z9
MK\PPF8B[/*;;;GN:II?"8))(ZRX Z7-I-TYX[U57S[@"C?5-*0+8S"<:R=(U
M0C*Z$1?D^NK%UQ,;HSP/)8%_QO8O0SSR4BM;29UK?]PDEU]RTQU+A(UCP,@V
M24$]\RT\NSR%<$Y*QFWY$CGZ:L-?%]U2CAS1R&@4)(*_W*+7N_!UXS>>_0*0
MQ3HX8C"7>L5;,LQQK"R+=[CV"%^.O*1KII&?IIW-%LB\E^2!HN<<)H!*T5QD
M*@3#4]0U8@D6B0X7XD6X;=E>KB#VN:26__<:%]]5#+EXG\=& IWAC&0?4Q,;
M&C2[4OH$\5 :$EH"^1GA]\/[UV.=I&IC6,7FTG :2\0H!*R5'FJ?-I;+X;9=
M1LEMZVB6F/EMT88)GYWJ4)Y6<QJ6$HN]]KLTN')O@HU!.^]/4B1[A?_QZ/2Q
M-2Y;$,\- ?'73;MF@%Q*L,HD8,^U+DN_"IM$H]"Q+7,%5_Q-1JJU2 ZT=/ )
M+55K2V#\, ]?X@:;E84*^V)07@RZ9Z?C1Y'<$SDR>@TYYA(OV8Y+0'(2HT$&
MG1ZZ&0NF@6,3)%=$[S=(]M8NO!#O8X0+9>[B.[:^1L=[N.\'PV;Q]FH!R^Z/
M/'FZ:+A<;BS>@-<PQQ&&&1B8#E3@^REJ=<#D9<>]R]Z0\>L5EU7-70O61* B
M2W)[[R*,23'\VGQ1U;W2ZDBKB[2:\)5JIBAQK75Z/=JY4HC7E.PC^27K^^"W
M2C^1#8S69,[ H=ZD[<N$5\E0/O78&DV*Q(J @2_EV%:ED-13K6W.CB50T00)
MBR0AUD$>LRN, I3^S^'QUB)RZ;).G@?,L0XL>.H$ I+D$<^6_=K\R!E(#W2>
M56LAF.$6!B$=I+HQ%^B3U^\_8)U2G@1)"$7CQG&EQ7#VPA^<,\H$\TGAY/1,
M$?=6R!YK&6+(V'M]V%#>M[R)-+GGEWET51"+!,^V:34+FQ+01%>S6(D#S^7X
MWB(L))^G36>U?= OCJ+'_>KNN /=O;#BS@^8&^74:/*6X_WPWQ'\&*[P6E3L
MS4@B5U4IW(/VN$Q*-@^&A>GY'AM<9VS4TG48G$;^);KLF ]^,6(6HMVOF'8>
MKXV2SD-7JIK-PA34:C*M7OX[>"_1$S.V3H">$?2-EL93]TI8M2U'$8OHY-.G
MP9?CMYS!EM:]E:98@-\HI]L:AR:,<9)<(QGQ&,YS#O^<IZ:>4SCGR281@*V]
M1'FQUJH8'+%+E9B)7@.U=]_6G>ALJEUS\8WN3U#R&7AZ?ZG7N*61#FX^*_UN
M$I.Y42'_G(9=!%8*+Y(^0C>;#Y?QZFF'C]7]:R)H'G.EXD[>Y6MED@E=Y#<:
MYIR=G$Q/3DXHG1OBN2[3WC7JP?,3\? =9>*1@EGL\>OWMNF5H0M DV^VS9X7
MBN8".,)<FCOHR-59"!C*;)5SR@O*+7T"@B)-UY.X!"_8;$GY);;M8%MT],:_
M;'D35@6:06)F0ZVEX2;(N!T7DB\XC"[QX"R"DA1;:4%N_\286>WE+8$G:N[G
M<Y<A0XQSQ&!)Z'* .'P\Q.'[ \3A ''X(T(<!@P\F3:B7"(/E4N7HMPD[G-Z
M75 2G0B7MQA$T!O ("\ER<&"0D?@O(VRQ"X2T)Y.U]/--:#,2#ZG\5\B^.QX
M\BS&4"._@2O!TSCJQ>J;A$@*B L"/@L4DS[T['";Q-QG_!=>$%(ES=>4-%<4
M>!^BK;2AQ/$LX+>8_NAHE+7 /GQ9C@L6;IW=W-(;R4_:;B1D]O(R@OPH-/;]
M7VBXRPFHMW5ZB7LPG22?B.E@]Z"1KX7;G?CY\<T>]@6ZCUOV$=&!9;]/9MB7
M+?OR6F)57G_IQ[O)BFNF/5*HQ7[WL'\&#_@5!6;PEUY$V,P^*5%$MS@.];6^
MYN<A.@H[VZM'O'K]_#SR>5+C;\7(%M?<0?\LM,N$SY?FO83]>6LEJ\]<QIFP
MK%A1I&Z]-E3Q8C'1_)J@1S:!I 1F1*%*AC>O&B.<2#$J^#6B$=SRJ!3#O:/!
M,(4I<$RQZ):)!@*?'CY@*=X*BY6P:,\I>ZU=T%1-H)P5RAI))BJ#1(*D)'M=
MD.'3\TW">&C\]L2#1J0=$B>XZ0O7<E9;AC.?Z*7@FO.VU*OYO3,B7>EGEB(J
M[L!NP]\35M]!NC"REFQ<66$ZP;:,%AAFB'4UPD43[67I,=3Q5:HE=$;0<B#2
MN[(_-@S[Z@>@(%-5"-X93Z^*Y3S<!\F)_>&5TWNQNB"L-; NV($HY/\N/?<F
MV\T=T!M_Q1V)[B"UF9?ROX[D*J)MMHCM4E$* 'MGE;?'\._TW^BDN<O3,\CX
MFND8PX?#'_:I83I-UAED7[4%;(>YTXRSR7=^KMUK=D,6\FOQX]Z=X7+UY*8&
MDJ(T9"K!1OI[.<(N8^Q(G!DR;N&&F#IQFHG^6HS@]6 8:;;RBB!^1;9J ;+@
M8[3J1(<JDD9C$_#53@5C*J,9+B MVK.,310RM26A]?"G!%6%L'_VYW!\A@O^
MC?0!OE):W'.ZX7 5[M,U?VYJ0]R+DI$3Y[A;$A+AN&]V3,\,S)M7B7V9$8.G
M@43,8@MDC#*L85)#FNXTJX8S(5YYL0)<C2I(PLM@;'#D%SCJ$4]S<8P>MHIQ
M=<@@ART\X&&)A[K)\W?-@&?3V([EW#W^>J)H=7<^G6<SBISJP7J)1T<U6]@X
M@+\XHFGX'1%%#GRGHIEUTN.M1!C1WHP3M!&;<7@Q]E'-":Z0J/-7[Y8Q,K.1
M%#E@#-:J3MNX_&(#ZMKD*A]]C-# JKF,NX[]$J#/B:Y &:$<I(K) >8IJ*"G
MD,7"89YR"1IG]%7*:G8%$V4/A#:B!76576*IQ](E)8B+(NF@)TZ&]PU '5K<
MFE*;'OM70V!);O1B^J:FB9U^>@TZRG?79^LE(<(UL;&7)UK5VIE=H>X2-A&A
MS@6+1K+378DEO"RIA=+#"2,5G'!^V^E/V^22Q@*\76,6)PE&*O74!?/7H6:U
M<(/59X 2N^&3;^5F^V$>*X)Y/%W 2-YF_8^^A)YQ#AWE1:31] B^I2/8#SR_
M&)'$-Z+:,'935-'3#"__2$5%YX[TR-?G'?&7P._A"_GR+#?IY[R5M281O=F>
M 4^9,#,]:#?Y!5'"Q[9TK650?NUGI09]41JH)DSD)SZ>1I+UXJ?(?_"B[^Q&
M(A)+T@VYP:?,,3I@)9WJD2M4UM$KAGA6QHS@\UOD*9@."#:9I]T3=Q"^ [F'
M["T2CQ@ UU7XTJ7.Q)::OVG<D2TU*P]XO'MTF<>3=.N_UT,$6#@/R[D1$$:W
MIE6]J40CK$@ZT)1&0KLIA&,P. P)D3Z[)EUI>",G :;?HQN.*,Q[74U)8&XA
M3"]>-<88]W!Q3-"2@;$?D]9Z6!R2-($CT='B@B]4ZVNN5\QM+^)\#4\"@>PR
MGU_FKBVAM;8FY9[@[A]-U:0]$-1?GD"5I LB'C+& 7JW@W<F8T54!H_^2=\G
M12P4O?([DR@(?4-XHY?D"11,6L,BCR&BS5OJ=$C4'FD3^B0M@EE%>;6TE3>.
M)(Z2MHN.I+HTDU/.FXAX4BK0*$4)3+NR2<IQIFCV1Z*8>XU.N[#@:J?)3#?'
MX>O)T7'Q(+?Z.3K;BWR6)9J*!35F?3N=H"B"WS3OAZB,*&9;2IM6'*<-#-LR
M_ CCAROIK,NQ.6;\^JLF1;^%>QBD7&W?,JC23O"#*[K1&?I"*?V*R*,NL;_9
M KAX,T)%ER*PD$6_3=U!S/*\NX3W>79R=I*DIBGP0(UW*4TJ12OA!$<BZ!2B
MM@3O2JFS3@)#<#G,C=^^@63>V=BN^1_MA+P"@E"90B:OW6;9<[<##A2!.CS%
MG0I\LWJ9:=+V:$63PO\\A,J-9;P<LA1Z71F5WY2$N"B[E  V =V9YS*NL)R<
M0Y\!ZPDH<Q4NW,].\=@ZST3Y6-T=I[CKY,_5V*L">FJ12'I4]#_ WPB"L-PU
MS,4PG&[M"#UDTG@69U=OIG^ON?+=W#2*??;?8/@&$Z1<@+AV;O79K!C XP#/
M^&AXQJ.3 SSC ,_X(\(SS(;'3-9&XP3+&@GOJ88Q7!)36P[C6((.6\O>J9EF
M[WT3+Q7K8&>;RI'==BY/5PR$(4PBASS7(J(685,V^69O>F\=(<>44[7NRJT3
M0F! 69@N])ISC.+NNR]$Q0II3FVV1_7AJT7M.6X3KY-RTL081E3S5K09WN-\
MH888KRR#;9O1N"A4ICO),41PZ\$H\6W<%L<I)SEC,=QEG)#RZKYS ^(QA_?,
MU(^I<J\-:QHICJ52'AS V!1&HN_,H 8/]FEZ+Z=;4M+[4V.EBI>Q5/JI+X[C
M\683EGXU"%P9$(J_HTK6+JV0*]E>QN6;Q@GU#R1^EIQ1%D5,3F>_V2R1\4LR
M(>*)U76D"Z%:<? 3M"4-X1V],>'MYQ!(G1_RFR0NT?2,.^\F%>XSI+2UAUNZ
M=Q#<.KL*QC+5LZ@=OH(4C5&X^!TTKQ1K3RET,7 %2HKR8V'A,R?HK4M!-%[M
M1A4R&(K%22Q>!+>7Z:',-1J<TZK7(^6ZO4?3ZY8T0(X^>GFN5!0MIA1:T[5Q
MCJ/?5H S[XN=>WO5-=+ P1DK*TW9)D9Q07DQ1PYB(:J*KM$J<S2>Q!G!A1WU
MZ,-.SI;+YA8&S32&9[.WC5)3,O5&JDFM)*[6$'\9%9Q&S 7NM^/)W]$1Q+*I
MP=G=B,S*-9J7B5F558KLT5QSCKY_M&/GSVG#P.(&E[E8DYG0?EJ,4 B:9JS9
M2@\:/4O2";=%>'/+$DU[I3A,H5&L8A*V6!3"O(S<B:]*@99D>\*&Q+B!1Q2<
MDA[-V'$B>0GW6*+L?6)2L_;,Y *Q*"G,@<RMPP4([ZPD[(XGO[0LH:0,DZ3I
M2FNK8NNV1C[W06PSPLT[#%?_0F=21!PE-" W'F'!,ELW^5_T/Y[<AU.LD1LB
M&.>OXQL<D(70K.K:ORR*W_/YV"%WWJO&'^Q9MW7XO[E.RJ=+OO)_^*1)]0)%
M&EX8_I.;JZ+-CX(;/H/O?E-G:Y^OD5A&!OKG__C^FV^_?_*?7[5S/Z[T0\/
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MKB'>'_E2SR G%S(SD?_UXL4+CA*9Y4/>1)*;,LX8>GP86-Q8!H/U_,QTN3[
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M1\0B_'J;P1D/A3EL8Q(TU/T6->!S>E_GIDK*R<KW\%?-+WI)R;>STQ/FG7Y
M5(0,,T1*&768->$8\]+7)U5>#VGSNB?Q6C36<R/DV/)C3I@BI=VFZXRO_.9=
M_#QNG(<2G6?S*M&+1/P:?G?;5'>Z?<&0T]D_1E-%<+MK\AS<*G*9-,R@YT72
M%8C\IZ8),DL7\0*-%%\*8A/.9ZUI*1*C[C_1?03QVEE$8?(-$]-:ZZI@'XR*
MOSTYOGBU 6"^B((H2*_-NE6GC?OA385]G$6)#6SKJFN<4J3Z/RJCPM&D"[6S
MBX;35PO3!6;Y(NB0<J;K.I%?X<]D",_8HR*O+5S1LV)M.]4OXU4AJ4)]P$7P
MJQ9%2VDYXESU<-2I;5XN+3L:+_<:3?N1(QB=++]% 9P2^X+X0:=?RRG03FC]
M(MP ^&_S9//L2U+@1YHF8!,CQ<I4@6FKEY,P.XW* 4@6[KUB8672US#??-V8
M'&PB*JC,(S]R3+K$_;HKSS-Y( AKR<R2XUNDJ!(4!%2P@0FQD\24::+10"@8
MV9%#,#[8N*@[L]5]L6Z)><O>\LGD_JUY^OSWHAE99;D>WF.4D4/(^JDV\*#Y
M[$_JHGE'65EO@AZZ$[\M:?8@EGL2P:G:EYR:<%$MPT'-F;49H[ZIC,-ZUWH]
MY*P<1G%K6D[??9(6V+8_?<Y@QP >_D^N]K[D@_;:';17]N+WJ<C[]E:K(&F
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MTG*EVPBYX(8REMXGO<[JH@K1H>IF.4GD\"[)LVLPG%E&6:1>AO6Z6G82**Y
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M7270"XT '&^CU2'F-F$\"R[=C0$ID.@>PR_H<,)GU@#U!O]7P#67P(LA@E1
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ME0_U:AOLM7:Y\N0D\TSF>1D'LI;E:H.H[O+**8>,TA&PV[Q)[F.RL4ML;#-
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MB>[@FR"C<H]VJ9"RNR^849%(-VI,$7D?GHR!*T%$U.AY#ZD+FS=D..84G,R
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MFG_B(-U0)XDKPN6[SN7M:IM=6C U(;*VAH:["IFC60X8P+?+LF_S:;;J9#]
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MP353014/S9(]*:\RV+=6 TFYM##*:X=GUF$78WZM'AK3X[%I13HPBA069H_
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MFJN=*[ YC9@4".BUQRYU7*NAUUVEJ)3M(),B7T#3-36S_3=AB#M7E\VLX7E
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M/W 3U>*5H>ZS5$ T40\I<G>.A:]B%,LJW^?:39/Y:YA^4>PH\U@;6$YZB>T
MDS:!X> &$0]-M)G,7Y\5B?#"W[U\'HV"3[0SA 'OH*KD13.G#'9$&IUIQIM[
M-^W9"N*+7-WJE&HB=0X]JG/H]ZES*'4._1;5."[D?1$)9T2+],WJ_8*(7:[D
M-'QDJ-&6*[O#AG<3XH>[!B>LDE17A4D%S/<:@7 \2F/7=TY%')DS'#NH6[B]
MH?NP=[TVDH)W6U8H)FSHT:':YAVS24O\$ @%+%G&TM.@1&/J<7$FZKA'Z)T.
MMA8'I4^6KN6%VA0DIP<E3P2Z\4MW: 242@7'IK(>C]?:DI>#1QIVL2ZG8BOE
M'B3(.'2=:OK">R)^Y>E7SW"=++[C;]&?GCQ#04>1AR:4K%Y#=+\2DB]EB^:.
M' U&/-\ NG8P%V3_^]9YS[3KAX*<VY&OFEG_L@ _G4OK,\P3L#'U0S<*S$>*
MQNB9ST6IC S?#VT7HG)&N5YW*C^9^W69^YB^+$?JDVX@D4/'_ C:U; >A/*L
M@P.AX^T4.3 IX$13[5&X*INA6M(CJ)@C79JS;J].#5[\9FM81H*: B5DI*M%
M1)@YN@L]+WG;8J:(ZV_Z^3V\8$+OI15R4;&+C%QEQI5Q*/0BC:PR5( ?,DJE
M"B<NK0ZGN>RV:0-/YGG9!E[6<4O>OCH$D6#$&>R&'5AEUT]0"6#'?\^[(O_G
MXD6^QS!M\8K;?G[\\<7B"W&N^1OB5O\N;9[).B_;/,.6N=J6X #(Z4].0]2L
M2)]27U?F?=^9H[]I?=>"^MZ1TQTRO?!NL*TV!(Y1  X[)+L=9HD]'%9=^*CU
M6+Z)(M92C,E'SKYZ]1 6N')/EYI)+J<5DU;,^0!N'S$2(R<XW]1</#*\C)J"
M3WR,AHD2IC4K,RW<!]G^XR\F7R/9YF-R(],$A\WLF4V==L8[-[<MCOL<1YD/
M^PON0Q#711QK5&ZBFC,V[5**AE"/,-)[:O)G#WV4G$E;<3+WBYP7@QI7\G>Q
M++5:[8)7K"[6FA$"P_HTH;?!M9BMN'*D;3+!ZS)!V\T;4+;8,@@>[U!%.R6U
M:B7C2L9UZ7%N@A[$BT%<U-:&ETE@+$0>A(2[5>F8%,P*VQZC!4OVF.SQ[%36
M2C#8Y+V-6_=93+GN\PV5G8NRHZ[_+&XN"'T)8V+Q4>3>E;U3@SX@P%%U6"+<
M%OR7@-B2)2=+OB@I:X*@<UC2DE^8#.RRT,3$(Q8D7K3#)NU6R9C.-Z92"O&B
M.[A"%1'U_V9R,^[#'O57,$&/O14L7$SX1/G3&J&W C<;B1EC8+P6I!CJRE<>
M!3 CTBV2L@',-Q):IM!'/],_4MVKSMNVN8?;P9LLVR8OLHFP,O@#>;E+"R4M
ME$L")@;#""H,8QQJ;P4;?N\.5B7NB&)0.N23N9UO;D.-P.55N:?-5=K-)#Z/
M0.'H#8@<XSQ>,.URR>PN@P36-1SB*X.=B[J??/T]_E[K-CFQLT;MGIGJCM&7
MLJB+57FH,(PWNE1<R1ES5Q/+-;?1W;FN9W:T9-G)LB^*FC $YYY!(A 7_[.'
M:7*]-# FJTI6==%^F7%R4MM^]TC,4]XY#8*Z$AX@;UEP-[.9H9T#HX.A8!D/
MIHE46>_8A]P,<)3#)II,,YGF^;34H_XMW.G^.<!QZI#184J7+G"VDU]9GVOH
MR5*3I9YMJ?MAJ8D?1E$*44'K]JS-L8190:D*\465185TN C-6>B^"3^L14Q=
MC1KY!78*+,(,4='F]WD5W8G27J3^?,#6P:%5\H2\.G3))4C6_#C8!NLZ$Z8>
MR58"X8WNE7XW/6%AB3/B49P1?TB<$8DS(JG-INW^?VZ[W[C:H6Z&LGQEQE.)
M)3;D4/!B&IU*$/W6I3-2#20MK<<L+4I!2Y>BYY:E2EQYA\J\!2VP%2PT:<O%
M<G'@K?,N?2:R>QS)!@J5)7*@K<L5H1N+$N(*CVRT*6OZLN>/T6C$(M<*M^Q3
MN)",_")Z\<" ,\?OD\PIF=.CF@96= HS=Q2V42EK(\RH\IK6 B*+%*6%KRFE
M/9+AG6]XF#H8R'E$1W<CV;PV;C#@4(H;]U 3!M4VT=NE2/:Z[>VK9&]796^]
M9Q8(C?XLI=8<<I3 VN<'T5"#OR99@61\G[+L2T$N26AWS&0A/(@[85,^Q8/X
MV:L*1!3)A*L0QDY*:H1$2";\,MRF$[X(X[,LFQ&G<T2<'<CGA7@]D#L76#)'
M"ALAQ,1+B^\<53R)7HE^VZQ[5S-!YE K<HY"QP[/H*8ECK/>*9H.I<IRE6-?
MXY1+;,=<DOY!;Q??(+Q8WYL]*^'W5\))DG!WFUQ5Y)GEW-0%CK)Z9H*HJHR'
M)J)]LP](W)EXX7W>]9FM8JVJ'#6RF57>',Y(&VK&1FG!87!4/2O,R1IV.1:%
MQWEH"GHDX1%%[J&XV.%?*I=+!/'9\%PB-= ?]O35\&"D+QZ>)CO)ZTKDVC3V
M.>8"D/><TU,!/A$ :STUBC6U2&X*D[G2Q]X+07V[&W6/A?$V9<50'?=9O-MK
MH8V]G(OW-<*@[IM%A5"H;I3H0"-&B"G,<-E&^1"?-\2E@VH&RM: V'ULKX/%
MQ=WQ.*)*AQ8N?6U\N]' 22WHZ>^?K)]^-7N\OUF\>K?XJ6W^'_CI<UH2KZB<
M_/2K#/[OZ9]8IO[8N&:+ERAS\'SQ]AT9I/ZK697-XF_P';"X;O&BN<T6/_:%
M#M7B(YY12;WD3GH/9??"?1JW*%C2N!W*TL77\@^*2A<0/98Z;X]]ELK!6FS)
M!\!C_.:KVR<T 2O6B&KN:S";)W_^-QJ8)U__6T;TPQRS(N%SL_[$3_#5[5_H
M 18?>UW&T-XUO%]07'.[>!X$LLVL?_2,'AM%8TW>CM 7(3\6EJK[ )X92H3C
M4O[D _GDC_00GWJ&X.V^XBOKWO/)G_RK_^XGKP;.$_-I"9[[BGFS/_F;?/UI
MC/GH,FW:/7;_NRD]SR?8ILPFZ0F#(KD4!YLI,1)LT:JU+A J6H&0 'W%O$%<
M.J89(.S87=V9$WG31.I,$D_LB_Y :'=P-][03K)XOFD=8T*7KK]'MRT^0X;H
M5-D*Y1UM0T26!"=RB:UVBWK8+5%KBQW+4/%@/!6*):FB#9+9$-8/V^\=L>=+
MX#UU6=F10G\A>&OA<23^(<48K+@+*;9RE2DXAD26&G!]J9[BGTP/KV_P(SVR
M?&0!&RY[G%6%XD+_A[TW;VX;._9 _W^? N7DICQ5$(>+5CN9*HV\1!-OL3PS
M-_?5*Q4('$H8@P 'BV3FT[_>S@(2)"59"V0CMVYB221P3I_N/KW^ND2[!>S$
M:5Q*GTQ@/H++KM_#O&R5HGXDBDTU>#XLEQYI&=Z 7HG]2CTYJ9[EB8^_E'X%
MH@.!4_F\2S0;9SEYC2@W&@)6 _!/@HLL7VLMZ2%19',5M8N9/8T,89BQ& 66
M!>* ,/YTAB:\R]_C2L_:@U:]\16V:A8TD G_U[X/MEFP #9.4C 'LYJ#@7C.
M?"W[9!JJ1)Y;W=2<6.TIZ"1BX/O&5O=F29#JD9,)PEC7L,EP/2("9E8/N)($
M2(8N@T*9,-LA1O-=&/?4HE-KN&R- BPZB!P1+$C4/;0X@8VVP+P':Q%.TF[(
M>,Z(/LR#9UB(F%JA):<E",^;!X"0S^?ZRG3808UNEAT=(7:E8(GT8VLHA &U
MECELJR>PZ3GR&5&.:S/-'\4;1 /2*1@P-'7F3A"H?A4IZEVKTH(.C5Q0VQ'$
M+V#F7R-M,NQ,X6!;Y<VSBEOBP'M#+Z1*-<JY@-+AN&@UC2N>&C<G<AANKG,R
M#\-C?Q;3QV3HJS+X+0Y8Z29<80J&ZY0T[37<_(6!4^455(I ]]3#"9NGA(P5
MGV8L LE^G:[BQF@(/#@@_N"4^R55T@I1,)]D/ )BLU5Y\=9XP8[3LF0,LW("
M;]:X.Z",TK. F3?PJ'&<1JV5.; (X=>"GI(: JM1G&XTS?5<.Q-R?[R$@R0@
MELQ-E,;8),"V.;=OXD5K%)G[NNMNA!#%[6;,DV0<(W_>:G]=0K3RJL@*M?J*
ML."Z3 NF"JF#Z"(F)'2]*24W'M_I"6$VXK1(^:D^1T\F5TIXSBAE0R#!&S"@
M5-2% ]0&@]JH<% :[V#%>DF;U#%:FG!ERBJ=JX[AB-DTJ9-:_J2M%*!PQA,G
M2T]-9TDVY_L<]*-3OX7?2+-T2SZAZE\'2<"ICAB<2RW=I3@%]T&FTSF;$Z@N
MS+?)[.4/T@R^D$[]!XU(Z"R;IS#BPBNM%2=8.N9-\FS*O ,+]5><E*]9O8"K
MKHEEJ8532IQ7_!DEFX[)_#U.=1Q.AV!5KSE"8KD_*3)W%DKMTC!J/]8G*B.E
M&-8991;E3ZY5&^V#%_DT8],X["P!JQ^N32^\."\"V+7<GGAIU;1[C:46-V-F
M"@9./1Y* .Z-V,9IDO4IV$DATKSF\, ]D!;:*<-=Z\,"OOVCBL[87N*[4EIS
MC4(PJLRGU ;N&R=PD'S7GLNW''PA2Q#>E>:4"1V7;X*N?OU&]>L[7?UZ5[_^
M3<X\O'9RX@/>RX7;QVC=<? XL%W1B[*P8C.,+'*:?OT"-GZ)1@+\#ZE7&KB,
M,>ZZ<R&VO!N^&"L)=%.&IT&W^=X4G'70PGC?8J2#R[KGUE,J2[C?RT*[\[6,
M"MVXH*E"Q4!&X((R-AR7DI:.<]NV<%7#86QR<2F@0VXNAT3B HW> &>6&^QN
MZV!R=,^O'Y*I*S<.9MW[I/M]*6D%GREBY 0*K3 *E1,-<*\T8WTLG15?=F9^
MU H'4G)CY"R1J\JSL#6I^,(E>X5&'W*FEGPU6KKCE-'KQCQ;6I=*!2;#*O$&
M?.7JX MEY7,UGI,[#%:-#GY<TQO5+J/UW.-"SX&,45/A,B2@8EY1#Z(X7>RE
M"J9Z(*-#&CRH25XQY$>-%< ^=:5HLP11T&%)@O"[(/GD!92+8CO)5HMF4SRH
MYQU.,19F\&[!=%O>5#=@LJL;:KK?S9POFMH1@&!.8O 06;;8SD9MP''<Q&5
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M6OTS'ENI\<$QD &R%9!ECS)0)<A68MU'P11M3F,LTNLNXAQ$OL#(JU-^R<%
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MPD!AARRO(?[&*0$7<L#$1(T(2]\#AXH#)18X<E+EI)#<\V;AFTY5CM9*_-_
M98R&V?4FQTZ'HZ+V6!.O>'=XA?J"A%'3N[;'?I)D6>3#S8^?5%]F&/PFW(@,
M%%J4*1Z!5I[_68'/ZQNHS$L5R%B.5 >I,+"*#.S,^)AEEQ0E!]ZDYJQE%:.G
M5YH+0NLJGE<YQ3D?6F,4S![Z!V)+RVU5(<YJE6I5.:DPBE<AHN1_F;WA3D8^
M(! $MSU:TBY2B* !89SHFO2/<^>9Z>RV2"EL8P7 UC%ZS1A^9%Y;@IW1X)T<
MK_Z3$&@*_49K*CMW+<=[9:Y+SWLCZL6F>MBTLWM;B-9I%1"Q_/N.+F&\)"<
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M,?VE/PSE#RU@[AM%#B4H;[TSBH@&N0 JS8(YJ1B=T<PP1JQ(KW%VDZLTPJ#
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MA:BHLJF"*Q#3$\BV6#_L3%*\VN:(2\O+3*,6%LU[X,'SL+BIH+6^/3SY)Q?
MC54!=FA]@N/#]_DV%"%=O\^W:^J]I:;>%?SW6Y!F9TD\ V%X^N)P:S#<'OQ
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M*5!4OU3 "%P_=MCT'7^1\LZ+ [*_LH))'TP5L280!*\>S%^44E&OA]T( &'
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MZ5ZZ! 5B^VXNP>_SQFN#7W1[XOPX9??6[[(VD^%;YNVVD>$Q2\7^K5]FCV'
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MYF:BS0<N&444ZC1^&/Q3I!A.O5$ +[RH&Q_!&G@'"H#6L@8L"7=8&%5&+NE
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MD?37_P/?(US4_,(_9FXL+WH>Z[H9]:2,)ZEXJ/+2LI->=#O%LI%1([YNSXO
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M4'7T1($KR$P]@N>M[H/CNHG=7$U@1F(:Z$IV"Q:G>E6, &B#OB98X .*D3Y
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M(/6!/9R/6LFW&=PJQF/9XI01+*Y9-L+B@$\4^.X2]9"\B@,IZVF,Y&=%3 $
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M:[^"GC/?'->-W^%!K@RT\2!  M=5,K:JC(V7@4D*&N'3?V\W,+XS7XD%I4S
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M5!GZ[@B^O!)V',!*8(96'-WY 4R#SX$3CYF=9/%7[$0SQ 13X844ES= &WA
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M"+KQ1)R.0,[0*EI?Q@'X9 #"3A.T<:3!/%K?TI\K_,>P0;:L1 96^-CQ8(8
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M8BR]6&1@^'N52[ML%FER#4DJXM! !N,>R,O 85DVZ >ZH<%L5 FGVFU26%J
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M-RQRBR#%)XV'U-HJ5EM+7&*Z&F7<.11]HZL_UM2R\88>!12S2;&Y-S!NGC<
M22"/WE'P?3("7TRR;%M,84[\ PRZI!FS[JQ&8R%Y8A<CG?#WZ-X)\29->@5/
MW0'!3\>P]C&X))R7G%U_&F+$P"M>&G)&CH4)"F^22U!#2L!+XHTC9<DD$=8>
ML:[=J?!F35!^ [/3^-Z\&8FQV;9NS$8'="-L+6 P<3.];<H+%"60A^OD]A:>
M>Q '1^!8>&2_T4%)TJ1U45"7QA,$(N_R*+Y^N..P=/9'=\QH*C$Z@P\("L2A
M0AZ($Y#NL+D("Y!K+;[6DCD46 LKX,-YK% W3D-:(K(:+Y%^A2NN:5?:D#=
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MJO?#MT9=* [L-T7=LTO(V>YVOR A&<V ?KX&K?L@24BPQ(&%VH&HAZ,S/QM
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M)RK?CH9;]&Q>;B?"N;K<;R_0T!U$X?5E,9^N#S21!XNPI*3RE<D,#]V%E/+
MJB;Z1E1K3Q0NJV8+L4D'48O=71<S&LL3_C[*T!U^Q*FE1E+@TW4T='=K-5M>
MW$5-/=L.CZ/#Y"0\,*TPOJZV,[1\&QD(51JDZ-0P6;Q=9N+)7 '?F]W9+[4]
MKUE"4IZ+S0+3G=ZO!XTTQ#\X='<&Y4Y<9^3\.DR'R^&R8>2K[;*);XCL#&V%
M+1[:]<LHS1<B.;$>JU5F&LX6WYG!HFI9\VA2FX]E>CJOS\8+OG6?0$-W9R#
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ML9Z(.A[JV<Q]+S%>T71G$"TO.=U ^EGX\2>RFZ%-*HF0'""2 T1T,\D!(CE
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M@D>2"U\S>M:Q\?/WBCIN-[QP&KE$>];5IE:19\**_)E[15NO\.X2>5ED^_+
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M-Y'_WK(79]!4M^_7A844'<P==ECQD0AO)MU5\GDB3.;-TB!1S&PVA4I:&*9
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M:I/^C%]'Y['T=CIHV=OT9C,!G@-&GLQ5G/^>?0:9O"*S[@DDW@)D%\C@(']
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M# AXBPE3$(W9P$O']$)GQ^@S5BQ:*-X#67+E25,%#Y4#AR'GI*V\MUD=[-3
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MOV$^8/,Q_B=1>1S\$9Q]D1^C/__A["46%A8(D=[F$C(LXOM0-%&3B.*@8&7
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M)GL [P"4&)8G6.(D65;B&*_RAZBNQ:WI)+7&\"DX+L4?KD4Z3M@'>'^XW9\
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M1KKM8W&M0R-% /E VM,FV[TF E5BZ$15A;VJ#DT$S=%;D;<2[AM-GY0!X;6
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M",U:8.S 9"J8<JGSKPT[WM8G)5/,S5,B>.1:Y;=T."RDSF=5>*\+AAU?,SO
MEBOQYTMG#[<]QB(?KW#1@VWJAGA$%R$_A<3?'+"L0%2"H_@PW@'GBZP5*\P'
MA*, Z(=[LO/9 *0Y2]@AQ60?IK8QXOS)NDZ(C'R7!PH^:&6 ]T^$@WO >MI3
M:*F8*&AF!0^A$XZW0@V>K[%60"^#]29SQL.XNPX#%/#4ULC5M_8&V$/0)9@
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M7PZ "NTA%:K <:=("SKTL$$M.>!%NP>S2R(+<*RNQ!I60BXX,%2K5 Y9(4@
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M6F.]9D['5=$8%R>3#)6-&*TIM#D^DSNU[Z'B(0FA#8)<#OO$)6AO6&1F%4;
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M4=(P+.OFT'IX TXT?A^V/ EMG(0RP(*)H1NNXA$$(<]CO+IY"UQ'K'POD+D
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M!.(;V'8J.0.)_V 2_TV\.B,^;RG>?2?;CF!@*^R6OTIFKT+C5LJ'[\[]!C7
MI+0KG)[TX<GOK>9:&0V^ \O;!!&YVK7NN\-_X;7_9E31NO9]!Z(WZ ,U=KB
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M*,O!O^&EH %%@Y4,SM(XIKS,JXQD^5JXA2 +F@Z1 OC@%0_FK[]P/9")X%(
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M K;MEWJ]+3M+=T8F$%9 V\;CKXUVN;K_V'^-L,^;[X>T%TLX;F?6^QPP/G*
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MN"G).*./3+#R[.WKAJ!$#2JK8;W\J$?+-+6JS$PKV_?D1+M)+IN;E19T;#C
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M1V.C<12;C%@F&<-8(L;SS-E^L=D&6Y>J\05=%X:U9)QIT_$ZI.BS_8YT,]7
M)UH98S+-^";*)!;<,@7UW[.'UF6VB:_Q[ICFV[5PLM6N#,9XRHOX^Z.ZVJVF
MY2Z]VK!X1Z@NJ')\"E:> 0$;U'N5B3@TJ<PBQ2Y7<A17HO"9YZ^/,QNSWAWD
M2M@VG157Q019;^AHZ=G[QY/P/++1JA%ZU8_KM=VFF>$KGHP2+^T&4:*PS(C$
M?%6,+W>1#::EO!AE&$MV6YNR HAE:0Y6&5&?5 M-*ZOU>&4LQ@T9@RMN,6(6
MJ4:Y.JYN2/C,\S/1$SV_3F<W0SI<V*FS953.CL=PH^=G4KHJ)R92D05&3"-F
M7:[E>3J.ED9/ETZK<8KOU71#7.3*[3C1IBHRT_3BO]RV7,BG.GQ2W(Y*J5V_
MB6WBK:D7_\7P>$/)& V!KK<Z4KRLF9M-+&6E&1ROW*2SNW17*' 4.#[6[@ZP
M!F[ E>?'E^/+P20Q8*(4+ZU(WJA4UE@7;O3\^$LF:Y2G5&^'+7KA7'K)UK?1
M*'KJV?%[,ZF_P$?TE%J5-#*M;P>%:<<$ N"<^+MF*MI7)FV*WT6$GJ$4XG0I
M986C3@"UBL03PFBJ841^G&ENQ"IMCE.6-_EXY:[>3E;*9)03B?0F'.-6J<PF
M \7/^?%G;7,3T_1*!RM/<LMAH[>>#G"XT?/CEQ8UIE"HF[S8[A"5Z"9-BJD.
M>NK9\?4",<U+22Q+&^6H*,4G:[I8,+VDFE;6V[W:9C>@!7&WZ#*%:B.B3+UD
M57V;:M9,.;/!>O4%C:O1\++9AU+M[/BT$)O54[EBC:XG<\5.+S*/UW6X\OQ,
M:CT1U5.D,A3SO*Y,=*62II)HZ=F9^B6LV)[)$D<MR"XW7"^*9&9\+BO!RNJV
MG*AR--W MI+!KYN#^K#3F(X2YRL'15+(UL51%ABUL>BXJ"4B2\H<)<]7KKAD
M:5UH]&IBK#.K\.OB@M@!UL,Q#Y"J70KGMI&Y&![V\^V9N:858@JG4YTMY9/F
MJ%[7=CUL-1J4J?@J.V/"*>AM.%M*]/GN7-+"=;%'UR<%:IR?EK@F'%U^MK02
MC6#I8I+C,8'"6A&VQ6,E%DTY/T,JVY3X)(['Z_1JG"T6=_%FA+<&HI]A=3S?
M39KM<B4C M/;**TR67671ALX1VLF3O5FJ=QB2!,-)AV7B7F;R%IK';R>V--.
MZ]%M?5(RQ=P\)>:YSEKEMW0X+*1&<"EI^6F0JIK2WUH=^9+@VT6NK).>I=#G
MJ[D\#"%F"1W,R.,=8J#S&_FAW6[ME//IWJT-?2F&ZG9X- Q5,Z!?VO:% /UZ
M8?F>X108P7(.VPZT_?.>CMTFJ%TJ8_O?=>7/>_N*/O0\92N"=)4^Z^A0IVW6
MX?;>VVO]__Y7,A9/_NNS?NNP!^R"08>3MK"]KLK#%M* BTL,X&=U&\(U%!_A
M&7:&_-76[ I7J.%Z?=,_YX>]L"'ZA[VNEM_?\;U:'E>87*H"?L\I:LY086"H
MJ$'69?FB#4K+)2EM77[8_&:7JJSU#4?%EB9>[N#; =&[1V-T].<[@Q"W[HP.
M0VB\S"+WK8L(47 O:O7V1SWHX;>_X9]62VCPR3_'JTG"DHC,=*KR4Q@D\1JQ
M<ARQFS&ZX^<6 !Z!Y%RZ1''*<E?_!H*5XR= SH&7WVO2C'PL[=$M@NX<<''I
M,#C)2/ CGT]+ M#E1_H4'TQK]4J-SF33]4U!W!;;3.J^D1SB75DMGQ$IT'W&
M3/GZQ#4M#.W9CJ_N(SEAPB5"QDM]GICCTZE8Y^KFJM!7V,9L"NM9SD(Y_W,O
M&G TE)P!KY:L 'L"<B%+;AXST1DQ,WOU1F+ ]<,Q3N0[M(2##Q#_0ZA *D+R
MZ\D)['-/H9EB\BB0!+D9_B:MP+P0R-< )'"6KK*/,O&3"0PDK0]A5!2S,E!A
M)XHE[:]$\ LG>6#_Y/V7\$Y$OT(WI"E($HJ5A># =;"5MR3/OU"P'<UD\/=X
MG$!MN[/:=J#*HQMN8<F,3]]TB#6<X=/@MX<T'2M!I6XGJ+S.Q?Z_?]X]FO+#
M5\ZD4=@EEWQC38>C:C(\6&OB;G&<21G[FCOG6('U2!F(N>Z91*:LYPTAHV!M
M9L,WAN(JWA>;X)[QS<B]$'BZ!%%\H'1(AD?4OI0,S>(42SVRQ?R>B6S2/7#-
MO0YCG\'-G<R:$20D_^$=(]C6Q1FWGMY6'*^QJC"&GHBQLN:?0F-#A^>4E1"X
M'&6OY+!OR*.79JU=QL-FE.J5C9'(TFU*5I+J:#K"3-/W/%P4LZ;4GN96-$.Q
MX^Z YJ1L"XZ9]6H3Y%\FMJ\I:PB0?1L=)6T^OZQ 73"[R@<3D%Z=#P1375V3
MPBR-T%B AX&76])-.5@03FJ5Q]V^]UF>9TV'+'MZGS\[M8?P(82X&^0>C'%K
M%MF"$63XUA>TC6,9-C%T0^7WHNQH\-'7#=QZ@?>@,2#H6Y37<CY-*R%L*Z7Z
M-)L3^5&&RL5W^DZJIVXT3>O+JPJ^T]2IMRJ$(O'G8*2!/T<:/">C 6;\B)GD
M,Q$+,.-'S 0\XUO,8,]Q,D"-+U$3,,V=,./TGWFQ2T;LF<2#,:'WP-D[N@A]
M5L7^GFT7WI(JW_/4;ZF&W_/4/Q/7;ZHTW_38WQ+9G[Z*[U-@U#IW.7ZH$UYP
MA_T<4O?I'?8&I:- 5(#3X*X*D/V@=Y5W*.R&UY7O6@D?@0,5)\!@^]7HW-_G
MO==%YCNHO,$F=DY90!6WO0I]!Y:W-/TV'=#$C6],WX'E#9KPR"*YY77J@^%7
M1\??=UFZ'E_XX(A^F^IFWZ+^ALQYAUC4"H;X-R"-+[A*_0V:@#;N01O.E>IO
MT%Q &]_,B[JO2WE<]XK?2/W^#M.K-4R_1B'035K?[HL/9OF!IF_*G1U-#%?;
M+%O"HWGLU>ZC-ZL^L"UU5\&J58]PVG04]L^J2"NQ),7:E*!%%JK!U)3MMFDU
M[XD]Q9+D+69$!.QY5]_W8_%G:]_H&W$=?*W6:M,?XM'TII5I[U)&GQ(6<J:5
MFZYKS9%Y%QZU^JL797 X _6(K,/F%)T9(]O<6U/D-3@ZS[W(NY-(+VN6J91
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M.P:BK9>D(*)+J[**+NJ2(FH1N/ YWFIB1Q#*$<1/CPL0UM 9L.O.ZT^LN3=
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M/QP*Z]JHN%2S4U;-R>V%!=8\AL$IHJ;4E\2]IJ[M**/U2_>,>7;/]HWH7=A
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M%9U+D\/VN(_7],5RD(REF^7Q&$+4UX32;TC4PJ3$RSL>U('C00F=F,U+$TS
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M'_@ME&_4<M=H*ZT2'*UHVN!Q]^'G)71MIQ2H\N[>Z- OO$%AFK@V7.=QI*R
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M[ECF@;JNR;&! .;Q=(Z%N//Q4TJ?,/T"=ZKN0\?@(Q?RB -'@*^!VL#1X S
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MSC2;F4Y:3=M6,E&LE.KM_E*(HWQM\H%F+G;T+FB2'R+ >1$@<).]R[3LSP/
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M%KE-!55.?V73-XSSA>@6.'2[.=+=FCW[NTBWUA<6/K& Q-$%@B]3.)O,U=B
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M8@L2@EIK#?L7*%FM2DPK5\1;VJK?@"NU6&?&GU"&FHDP%B)C&:+SP36!)W6
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M 8R0?[8-\:0)]YKVZGUT]]A&IPC@PHR;]&?MK![AN[324Y&/;RK25=D6.HI
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M$=#6%1DWCOL#FR@$PD6+ 8$9 S,&9@S,&+=0O_WJZF) .E1AQ@@$'#!C8,;
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MS[S,AN8RK8DR)S1EIMCHM@.)*D E[FA35G24#V/*H@SP*!%CTP#'_-R+S?^
MD/SM_(77[EVN(O+()J/TFHG6$UM>4U3*2,8B_<)ADD/L<WK9R^LS^XD(30_@
M0$UK W*S7-CNA!VS[P*7F057Y)H),M3-=RM,2$NNZ,;=8S(<\<LZ()LTE.<
M#CG#A+0!]!Q'1%<ENVA4^(>D6*+A0"L2L@TD2,6"Z4CNW]L@52@99-V2+1B!
M?+F@6R\9<)LY"$.&/Y-0UCX2.GY+V<T6TS17Z[!1!H$Q1^0\,C3-6&U3NTQ9
MDP5/P@#Q8"E0O!&28 O@*T$R'-O-^ '/UY&E1 V)NF#:[HN+Q2(A@MW!9$K"
M-B$3PM'95(B*TPRQ5 0PZPH0 >!T@ !+GBDZRD(#JC1@.^_E!U+= N1BC3S6
M@Z+#D_* I=P4%X":X_UG]M2AMR R4M;HW>#D=2..)0.)3$]&()FX%, V(-3@
M, BED2S8#I)C)B%HMFR"'4 8^3/;P,I>N!3F;5SP$C>R)TPB?X9!4,\,.^VZ
M9#7)<C,^I,3G:;<R??-:Y4TGU4D8^#T.4-5^.\]NJ[%))U6S#!F+Z/%J:\.7
MR[K.1.:Y?-T->V8BY'V2.7'GZ[<C+:"S+^%9=F .0%:">OS"49;@O4"9>.]L
M#5\[\>%$=NM1G_)3N1"BH1GFPS]IBH[1R5^G,B-2KD+D): &)S>"W,^-J,+<
MJI?,")C.<#T1<%$>3ME5A(DM%V\-J-2ZQO=[4I67:XF)$YLGC%7]6L$878JM
M5Y;139YE^N.G4K'3BTUB@#%IH- S](<]A:X6@:@OU:X2==,8F\(,G1X[)5)'
M2='?H$+>(LK/K$!R^GOZ8Y9Y3M2$_'*DRLM*>]5RBFPH-X;.F[?T1QW)%:!^
M:+ 1PQA*VQ<ET4.WAG07OZZXRZ8\?[V$0YE$)]X0I_N6^RM%,;8*)WSBHV5#
M)&7Y^%_P8R>L@<YFPIH9DU_;M$)4,>+H%70\'(D=%GR@F3 3>TDL),E_PV7O
M37TP7TB4->W76YT_MC/\-J03[PA_$5"#;&Y!3T=]PC_W2N$*ROTZY &4CNZ!
M=._G/_:!\'*$AKQST2LFL@?X+4!WJ88AF,'YD @GZ']O/T'U/PX_LHWY0\0M
M1C*60T.@X*LA802V]B L#47RP)J@ >:V[64>2 AA;ZU#0]J ?R;V3'O\?U!+
M P04    " "T17I<6T#:1V C    )0  &    &UT=F$M,C R-3$R,S%X,3!K
M,# Q+FIP9[UW>314\1OW92PAV27;2$0)*?LV40B5W62=2K)EBZRSA*R)4HC*
MA(0LD^S[3MGWL60=96<&,6;&S#O]SKO\\Y[S+N<][W/O<\X]Y][[_3Z?[[-]
M'MHD;0'@-C$T-@08& & @7X!M!G@.@!B9/QWTX6)?C.?8&9F8F)F9V5E.7&2
M_>1)#G8.#LY3O-R<IWA.<7!P"W+S\/$+" B<Y#HM),@OQ,LOP/]O$080_1\F
M9C9F9C9^3@Y._O]CH;4 /"< 2X92$(,DP,C# .)AH'4 8+J=S S_$>"_"@,C
MW486UA-L[!ST#RJY 48&$(B1"?3/:OI;!/T]P,3#S'M628^%S^(^JZ0__Y6(
MU]DGSNF7M0I8#N.EKCYX$LG&+GA:Z(RP]'D9V0L7E554U=0U-*_?,# TNFEL
M8F5M8PN]:V?O\M#UD9N[AV= X-.@X)#0L*CGT3&Q<?$)*6_>IJ:EO\O(S,G]
MG/<EOZ#PZ_?RBLJJZIK:NK;VCLZN[A\_>T9&Q\8GL)-3TXM+N.7??U96U]8)
MNWO[?P\.B4>D?[@8 !##?Y/_*2X>.BY&)B80$^L_7 R,P?\^X&%B/JO$PJMG
MP7K?GT_R2L0)?OW7V66M;.>N6N(%'CP99A>44EZ4)OR#]A]D_WO (O^OD/UW
M8/\#US1P$L1 =QZ(!X  QU8Y";( 74'QA-@NV(D0K@Y[9&RIYX9K(8S9/5>I
MGMGVP=>!%NY/KPR-M];Z@\:/R&073Y8-7%(VMX^WO'PVR15$ S;_'G"U^(JA
MXYK9]^7M[6Y5]YZ>PIQI(F1"4N-I0#A#\X)^(_P.LT6[%09<V3QH#<]R^*C]
MR"6^9<SX"21HUC(H^&AR7UCVLPQ()L)9[V_DL#-S"7)<-9YPW0P_$)M_OB3_
M9[#8A\,V1Y]@O\\=0"N[F1665?0>&E%:1[2?=#UMJ_H':O3Z6?^WT ]?N]ET
M?1\=.6&\CG307]EE<VJY'&5S$H#_U[J / ]_@@]NDRM1G>F8?F]WNX#WP8WH
MWV=9F6?<U<UO@GNS2\O;J>=&*#9Y[87NAP>DU,3V)V;>$D\A<3M;SE?)CG .
M&A!=NP#;XE25GY,>MOA3R:Y1DUS4_E>]AYR(XL%$Z(I1; G0-F_'N9!@Z\S6
M0R1IO,G==2LV$8^X.A8DV=BGRBA4)SJ6YU$R.DE\W O!O'5I3#O_<;5WT0L%
MD7$;O1.[\5%@#]**G@EN=U:_[-$D=P/?]6W2XJJJ]WE?-X@?60V\)4RR/8.K
MC9>.G[C[RP=Z_951@<KOB6PK+@7[A.ZQ!0+Q<1NZHOVV,5)NW">YWW?ZG+4W
M#.>6*..2DM[O2S1D<J$!US /CF/@H0<Z ?;XEQTO?SL;'6R8F_5(W;KTC,O6
M,G_M#"8+>79]#4,D=V1^<%.:\X1>_0*I&RD#9^?#-0GP.09"UXNE$]>5OM7:
M.?$O-"#$ K;S8G&P3S;MX8_!91NNOC9E1 4^)=(7W[^]:P,[JS/-"X-CZT?0
M@W?'V4QM&ZW4,[4] >*Y")Z-R;98&J /B2UQ1P[#*N"V0=Z+S6S.; H^DBP;
MEM5(2<,S4V? '7K+21FX+/1YOC>.9Q3,PA^4<0PC,?LZI]1Q4F^_%U<Y6Z70
M@!$KRGQO[<;\]^YHHWBDPEVS2\ZN5>DB\[IA+.!+J+@@*QK @*G?6 %/5K?E
M]+9E3C1+W)<__E&5?"Y902G%:/Q#,I$9(>:LBX#-N+@*5 32 $@'61=H09A*
MY6LHAA4%(),-B%+4^P;\T$%P;C2_Q37F?QJP"]?'-T!?NM/#)F7MH9*R?*B0
MWU'7+S>-0:&2WOB)Z3D[]'97WN#02>Q>1.F&FN9*G JG_9(^-CW=TLE8 J>P
M?1?=-Z1<BKH9"(VA=L'$8K= >#X] G-?FU/0,*K\J?\SKND<X'3+@J]E<C=8
M5PM::RZ1D["'F>;#,2>W)$=1I0AYV]W>NI/'*:P_^7Y5]YZ$!T3^#EB]$F[.
M:AI*X&@C(<:JL,[G1DJV)1^D&,@O>_YH+Y#X$.6PL/SPB=Q1'5:E:)[7RSZF
MI-!192(7Y2\]WK?]9,1DTVZ2G&*,6?5=5*V F^(QK76UWMWFPX]+>\-V(D0@
M)2#/;J@!_S]3_E.)@)S:G;@LB5H\NIT&\'FE>8G,KF4ZC6_*79;FZ.;3C $B
M#:W=F* KZ,U1&L!\CH@FQ.+RGVN+E'CH"D69CF_W\?UT==.\]?7<HR/3.RVB
M!>N<H,K!D6G9G CF_WK2W+-.K2X@,_\K>NPN@2F7;41Q*9Y:8I:#UE OK0*?
MU%-"[1)PA+\UQ6ZQ'B84XF4Y[ M]6KG)R2&^\;J=R\_/J ;SJMD-QNM$D26V
MAR_>MFLH\,W3A/>BWSJ>U;5*/)"YJ!,<Y5QUFK$L\.+8\T:BE\\&Z9CK=7_Y
ME*LZ14&\$C)K"V\X)+H.JWAG9<XWNVQIRN8TO-F(3)#]Q)Y.*DE+XYYS:O4$
M:]T:89I-JNF_[?V4<Y--I:%06['GIPB+U;YDDQQQL=2)XD&<]UILO-"75E7.
MJ?JK\%)$.7GMIE@$J\S(9:_-9"YWVZ8S0\7*[_EYINWT7QE^"K)(1 >,H:V<
MJQ09O[WU,'ER^ ?CTTLZ-GO]<V_*3:C/YJ(U#0@PWBV<7TIWD'O<&!ZL<$2(
MAV.4X'UNCT*[1SYC7E6B(L&\V[JJO<4W'KK/6))OA-74B%CR'HFZJ;,';78_
M?B*W,=U[.CH_QCQP_<*>7'V@YG?X*%^&25W'_3RC%%O'>8]@>\6V#2<1>EUN
MP*TQTA'_1YLA*._D9S0 _YR83N73$9[WB2_J06)%77Y7UVF_V<3\/- 0?0A=
M%7 AMK=E!B?!E0K=-2LD$;I4OI.%\V.7]R6>Z6U>*]T4EU[T+"RI(XF+!Z1=
M5VGK>3%B>K=ID)+51PG$V!*-R*8AHXML#EX<N(+5V5,989TX"QIP:]!:^P W
M)ORG21Y^=:R)-V3# O_G<UXB5]T<3L@ASNS7*X21Q>1R4*EFTU%7EF365X+;
MPN7"^-ZB)L-%]7K(KF:XCJ5( Q!D?#Q1E-H56"*BX^D OX1N-$/FU(W59P4D
MN]2-/MKS?B:3NE1B*QA;T*G=7 ^/$9+XRU*/9O: S#A?&"U)B$WNYY+08<?T
MZ9$BDKL:[9]:YO61P ();<8X 2%$5<D>#8A$[.$G>MH7Y]L1(./Z^NJJE.GA
M6ZW+H,.2O6:J=E?)/,42?YQ2-?.EUI_"G:U!,0.7A.AI:&AGFE"6[@J-O2^T
MO%VUC;IC->!Y?[6=*S8R\4&*4Z!);]GZ(0T0D72^5(%%'>3[U5!8/.<CFB36
MFV2QMRLF_#EN1V?>C&"!W$H)'33KJL&PP'4;"#=>*&=4CK8>?3F7=F QO^&,
MS5VM"N-,F9[2/QL?ABL"6X9G+G44JPC5^;W\?20^X+QWTG'<L[Q"R\Z+!H &
MMQ4M# 1P:%M^"P/ #RW>8$+E))XE@)Q>5O7GKZIAE41QAR] ;\&'$W)X4)LN
MSS@\H+2;OD$*S-.R77MXIH-#.U+6&<K.:E6EVK(#JP97SS5HZY EX88ULY5?
M*F+ZC0)6' UX0/B (^@*F,*[T[Y6@IRPMQE5V-DL43C /W1CZEY&;;GH>3V@
M 10^,*Z;<G$^R:4M,Y%J&XT#THR";^Y (6Z^WIV9D*+2,.@F BE&_=4,>G3\
MD0:X(PP"W\UUZX\[>@DK?W-E.OM>7CBK2X,!Q'HV2/POJ9<L0_&-/8@@GEF<
M%\C@7L^"3?Z]^2998?LRTX<@SMT:\219ONVP8R0]SUKOZNHD\X6L&!-A>;]B
MOPT!3>.J2NW.-YNEW,JF1-P2]RZ(V38;457@5J-(=HH\ ?Q21?_+O$F%AZ6@
M=Q.\^W>"!,*I!X.#T>D5(U5L U;9O'7!]7[A;>F^NHGL\_DE<P\CTQ8;?DZ*
MBO+J&FS5O@W\=#J@M\%L81;:NI;[T7Y\2\1F%#>VE7)-SROT3"1DN(I7)P[S
M2W'2K>-)2/[!+:)'Z(7>]B^(V#?HM#FC"!1A,AHN0*^V7O@^^].=]#V-/1Y7
M38?@.X($UX3:+K;[JW*',TA2'S25TB/5CHBA\H*G[HR:0<+UQW>4J1_?E;30
MNVHBDI]S/1GCGM-\!;7P"56=5NZQ]-)T,;W]I47%3#B+*JFK\A$Q8P4<=N(#
M^-79([O8_AINI:A7;TL1&SC4-,=B=7LH=7 ))K(:IH/U"G^_.F&U?VME_VO3
MJ>,\7<$0ZK[=JKC.T%.Y"76'NYC</8?5Y\L)E!BB$IF5XD0\RC?"3*T->]CK
M+'BXC%?6]CUX8C9G\WN2#_WN@OC?7 **RC9.0"V>BE6M(B'RX_;K[_9AU82E
MNFPCC"Q=[I5>$TUA $[=!GV'/(XXR< J<<A?>61&9D#.9J[$-L#R*!K$B*_]
M7XDHJU3OP*T[!_I[=G>Z3R1M/ADNTPK]:6F$WS^^^^GVW=V=)%T=_&QSVR#8
M8W=C.C"X_4;S\QF5$3;0\<>NV=J!@.EF$=0#'7VLR?%7JNCLW"\##R_!3_U2
MH^K6>LL_?\I$P$RH8\UX,TC<G#3Q!4%F2:<J.T<A5J5S[EN9L=^2K[3U#T-5
MER &G I!K0T=,XVF>RHN3":JPD,BUFK\S^5KA[=L+[>:PCL8K[5EC?%703XU
MRG7KBF%]!4?O8)7)Y"_,SU4/9;>OK?N=\GK2K-/L8C;)M\2U>4P8O4-(CO/=
M=WAY96[D#ZOIA=GE62E7*/!):+ 1\1?CE:8K-/27T\6ZUE1'M6W.M.A]_"E!
M]=>F5\'W&)1Y[>OJ8KKFC+>E;YY-] F5NO<U=^R-LUD)%0MA:= IT$D][$@^
MU1WX0=L+F61.$N6+VO3:#3CX?EP.=Z+7ZZ\[=[[7U8YJ<XIVR7$*_DI5XZCQ
M3O'3)9<!T=J*P,G(.ROM9L3S],$E+E,J[/.!K?CIJ@RF5U\J-9+L^!.39[^6
M*U).L+/ZK&R"HYK.AK@L"23/P)66.-5@%30@:_KIR)U<@J5'-8R'(N?R5*6R
M.VZ_1N%L@.AKXV#A[Y?5+^II<QLJP1)T+Q!-"=4'9PF(Y+CER+WV[>_/8Z&C
MOWFG'9_I[2Y?-$E]#"HCX?(%<$@( ='= 18CONE4\^OV#2Y9AVI^&.K\&+=G
M,G*E-)RQ@QWTEIHX/'$#:GGF[D.>H82CJP<=>*E,V\8O(2.M]BJU<KY/)44?
M9["X^!::&U& ,.R8.!\->.U@2 ,PLJA]!CL:P$,YP]K!Q>Q9QT\$>SZ/^WQ.
MUS'WK6_K,\I5YRR'%Z2L\RK.,Q"C8\<C9^D>VZ=I-FV8Y*5D8MH\<BXQ%Q_5
M'4\ +U)32P2M@@A'4,]<$3=G<%)+EE$Y^^8&;F=*JRM8G)/P)W^AT5KE^US]
MQ<X+$IU/Q?4< YG?<B.&#1!1-AF+NOGQ;\_A&Z&YU&+7MJGR@2MU3[^B>'4W
MR7OR.QNY1]%^,!$*4E<4KCGV]^;R%$KR.'/P"WR%"12%=>]%M7@U8EZB/!4%
M9^'ZQ(_Y1(@Q#;AIRNK@^A+R.V_L.<M*/LB3+#9N9ROP@*"4V"10M&\(MWNO
MG2OWT036@:[E\.U7*!IV(KV?+\,\$U[:L2*D+OFPO==2]<D;O-*\K+\R6[3>
MTXI7?+[5P+'(*:=?^4=.]H8KX7"^J'JI ]U5772IFY_P+L-F[?N^@]@'C;?%
MZ9?RGI-M&QJ6_Z*">G]*OIXH%B1O&AXP!'\(9=%K5A]0PN8Y85ZI0(YT;M!=
ML(K:3_7:("F],XBVS@Q>24C/(W%(#TB_-^7/.P5SL;0^;#P*.X)]LPG?,L2:
M5GN]Z(TKN6>1EN+&GDM0B25P==N"3\%EPDL]695::I(D_$9OAEB++U.ORU3"
M,W)" KK!E9 XF3'%G=M)T4SO?DWMGJ4!#Y2I,L!?2+RH;8TVZ\39B^.N/^]H
M-0^+UF*Y:<"CB1@.#N.)#C,;YKST4-T7I"$2HDF-R.:C_6:I41'ICZXHG1]4
M+ZV^/?ZX\H5K35E]S"[+FM0I,;,EN3:)XQ<4J32'\^-/C17*J+5V E>IVZ.4
MC0B"3-N.,+(?VXQ/"8%9(<RNOXRHO?V9L^F-T0>!Y9?M^55>)?>^J<=NXL?1
MD#NN#ZD(+O'0.42ZT<:9+#9-F,=HZF^!V=*J#=\&4I^7?6@3^?2,-Q7[L<GH
MG=K*F2[-\6EBU.).0@ZA><L@;^-;QSW3C3>*;[NEN:9^N ["N0V]MDA+?9<5
M0;)Z]=7\\V\VPS]H91534SV'7N:RU7SYN)UR6R<5@Z 398PLJ;T=X@6.,":@
M6OK#\_6YXBN>>Q3W)+G=P;"1<.=^N=1B^D\;QD^)F6A^$+@?R96'',*VH*M6
M6J(6%>E'U^:?ZX"[.>[:N>^N'KF\5[]*03\:+,#D]RA]P*SO(='+2)?.*8@V
MJL*]!-JY-DRI0CK']NSC^.(ZHH4,[X!<(I$5TR2C+K 8'%1,[9N&13ZN ('C
M):JKXGJ\QVTOO,I_K^[_4[&R<6#;:^WBV%M1:Y?P1GC#8/_EFC ;G,78U^R>
M4LP!^B%\PRWH ,JF[,9L9F9/<EAP2ICK#R[REA:43E+=2ENF2C <8?ML#F M
M\Z?,7/%DHX@'+OY/T.ZNW;=G(82ARCS[N8'$W%_=S)%W/WA?3",JT  #XGJ0
M9][DQ4CC!0;GCPO)T8]@"F0[_<)VZ>QUQ,SHFIV]3.R#4=7^\U*UHC&;:#-"
MZ>!M@LUX%B]L/XX&3$,N4[R6"2HKTKTWCV,56BV?I]ZR;'8=_1-$Z'K55=:5
MS6,H8'V/8?7".#I_(RWS%:.&:O,A.,I>8*]$>7.P(3%7.J213N@_FUL8\#,0
M\BD"X5"$VH%3=;71=%ULG+S\!U3(B3_IX _7J )[& H/N>W+X5)^$L4PU$G+
M,*$%X7.>"]TS27TZAVI]0#%5%@<371?W???#BXHVCJ"03MX;<:@+GXM0>"/4
MJ5[?A>0XTAYH><Y3M4K6GV+>L3V?US8$O3X-6<A!,T 6 RF,36.7Y!MV>(@.
MR$+7"M[=&Z>/)<\FU;_R =4;YC;"Z;64J9*XCQ2GP&KQXOF!+L/:=QEGBI."
M#)#/CD+$&%X_B:V55)J$;K2>$5(A^I)=*2(-QQD0#Y'QH;XZG_?^5[PR.?N8
MHAC3+PF8N8@F]&@M7-BY)A^HFT!G0.5P.'4$JPR+%K89N#=ZL![6G491[CL1
M>;[[T#Q=@@8,WM IFJ !"ZDT * !BTQ$:"B!RZIZJCBD8+-\]C#WF^$1,LLE
M<F[11>5HBSXP4R6/OT$\M+3D[RR9?C3JL(]R7L<6*"VWG#KZ& X4L!?\G98[
MC#(8WJ3HY$ZNV</9O.Z[, 5-X TOEW4E"%AS70/X0<-W*;MTRSI7)9U BTD5
M!2"] ,2C;58I3?UUKM%>W[Z)? K/!LPT.1;,77'-*,.MR&&.)VM4WQRUIE':
M2V7_N5@] 7E4HF7Y\DG@1^1TJ,B(6H)[,E6;@(V@DUGQOUW5Q'0"JR'GKM,:
MMU/JH-7)&08:\&-E[Y,F.&^>AV)(/44,77J)E#B9:9O^%/[I4$E_ +(O3$5J
M<Q:M[L%O#?_U%5$9IR8\E:H?;RAK\GI'Z=]-,KM$25PAEL.&(!VH4\8XKM@F
MV:$'$J9?UX)M91V^N$:_<J.2,"OT\YMX^:F3 +TQH@VO3M-D/4B96J<!;O[\
M!S]@+E4WU65#M<%U!J!XT@OZ_,'L2-1P\>:L;'J!:?5E/X%+D%,?M[C68@Y:
M -0[;Z(6BM$GXB36G"4E#LB74!2GNU%4-E.\_OJ)/['FA%O??F2/W!A;O-AC
MJ,?Z<]F*OO/H/#-D9:\3151Z00,2A^2Y>M%)39)X3#SR,C'="2]=3/*-P6Q3
MI]R\E$WY'-+-!R*@T19G$9\"G2K)M7BUKM,P;N3)D-,=6"(969)C-_=K2TC<
MJZV8>/#K-CQ\<8<H4[WY<VF09WV:Y36.T\U\HJ*PX46OD$J!\%W8F5:8C&[N
M^HDMF$\(1VL8JAW-M.HL.)+Y:%392[98/G,QZJ;+2_W2)8!IX8F?+$L?^B5J
MU[ AE ;<XZ !QS(IS8*0^Y C+50,^H#']YA/&CE*H9]/B@IND S :,":=BJQ
MC,Q& W[.4)1IP+<7J-4,6>')XQG,:WK@%B!5:_"QFR7A;M[G.DC40J^\JUV=
M=_JT-Z]H\3!8:L6<:T3XP\[1(\-"6P#RHMG5:Z8W9 XZI.+@9).F]*9\)2)Y
MB*T7?%]/+@"73)1&M6XI+LETS4([,CL;@M.H_!6F[]VES7L/"N\6^^AM5$@E
MZ@A=V()A_AZ!Z$F+(;;GP;6(V**0@+LUINK:-H_2#D9[6JVV+)3<A]Z,^H72
M4\K+?0>&&>/<OD?<:156ZT"SKL\)$9@S8:NDC_4.O_071*.&8W,OM(/&N$^L
MP09A'3 VM6=("2*ZG4MM&FPPKE QD2XT=S\U=S9I:B:3&@WWQSF!%['/*\UX
MO;"O)STT'W/Z:X^(WF/XP&49QO#K];\E? 6KD^D<,[=CBR>BLL1RPU*)[V.,
MA_WMYIA-<W7TT,IS&K!L.]R\T0,^!FQ+7$/,J ;>(M2&;!HPQ.PYI$<8W#);
M%$$S4(Q&X6Z?HWS2!\I#7R>>V,Z52 F'M[/^BL$4-C OD7W%0R F6&^_<PW/
MM20T=N=S\Q=:DMN^ZUX-84.>HVB/*T>;8R.TR?KAMS+DCG:;#546867-R9DC
M9"N\ZQZ_PNW9G&811_^+"#^&;K(\S )"-.^UILZ*@8FH!60BY6LRQ>67V44M
M\RZYTIZ<6?@.#7BCT#V$YM/VYFH?9/*LVZRWV\K1O>$3DF+5IKC4@3R#R: !
M#S%,@TO-(I[.RF/M=])NS3E^3SRJMGQ8_O#O138(E*68.JFK_<:><.K]0J-V
M19&G;?C;Y)2]F@Z/9/-\"![B20(O*D:X$ ,6Q.0,;& 5W>",P U*@)H" A\B
MWF(%PZ/38%OT8CF"6J#FI%,>.IKG-IX4/M),IF22<7^"^"T,X&6DLEV6?!H@
M4X#^>\Q%32E!H& 2GJC=,/IT#!NBQ_)%+/;OOEUS>PR=Q/E#U!=VDJ_00SH!
MG;V;OU54\LNL,,3E6AQ:-G?V.Q?N29#,[U@:T%2TN@,B6F);J'PC^Z8W;!(&
MF U=P0A2_;'==Y3P4??!^+""Q%B#$J:#*X5GZTPW7MU[[>AW\TXF2:N%*E=)
M:'Z^W^_3/[[4$.T4*;H)AZ\BQK]#V$-ZZ;3M?JTN.(Q:30-BSYW_30/L]B#>
M%%,K^A-S977JD>\?GS%HT+=Y^WYO?^%^IA\N*6IGH):7]<2?6U>*=78$O3+6
M'B@S$$X/=GGVZ8DQYB.T*7:-MQ*MVMT!.=6@ HZB 9[A3L)B<P99>=K^OAJZ
ML+3?5W<J$L@)36 B8NEF XQLX^#%S3N!#?NPJW_WWCM*-=MKZJK (3-"%]&_
MY1&P\P.S$81T6CS\3BI5G(2+3SLVI;UL!G(2Y'X/CK5]AT,7$5I=32)C@3KV
M# 'Y\_KW,Z^NAO&LZK6REC%6%GQY_Z+NO$7B$DXZ<+!WYR6J')S0Q+W^I*8R
M'3ID-_BZT,'P9K<Z+\.A@UA=&)^SKF2 3'I9]8J(_P RE7RM1XC[FL1?EMI%
M_$9;Y.%65+O]M;K9^@%!)=_!TJ"_AYB\O(\F2I5W9P\ARIUX&XVQ/^TVOU^L
MCF^M[ARA/\!8(&X?O;HS2RJW\]WD8YXEBOW.,,EX1A40"_V+J=XOD9PQJKKK
M/20+,$XN8XOH;ICF.@IZ027RH]SLZ1VY G;84JIMZ'IQQ^9A>"CJE%4O;MMD
M-[PJM$1@#38U@=[;.GV,EZ7VTP='M'OS3H0CVLXIV6V=E^K2'W%1CY4I4+*J
M8IY_UFY1FC[1)!]C&B#"&S2@W!NR,JU(7C!7GKFF)SC\$/7MHJOS%5M_Y1C>
M/+60@0Y"39JRWXF3#*WY%@;^X@7_:-.1'CT0X 3%&>05XE4]U@OYJX\V<>5F
M6H7@M^PH85( E<TNYZ/B@6W2<NEPH5=P^C72@M$IU.XI"#O)MP/- 1?#B5V#
M;<P)#%>^7X@\&X!RX1]A8GI5GV'<\A,W5Z4,YO) "HXLCBI[:V)-1K,ON524
M1S^(OV(J>O$9B[',NKO8?EFV\SFR!;4'*7I<2('D3'H%5PL[3;SQVYN!V7]R
MLWG*>!-_4\B[ %D@-U/PR6@ ]1V[:;KH.^5K/_$7H6A5AU71,6&J/'WZ]44A
MR9-VJ7YF<UKT+N(''7YK<0VL@6J]7J%1N3-) Y:8S&4RY!MLJT/V[VYG!T,B
M62#12'I[:I5O,)]FW8+=?\#56[*FEL9) Q@L_" ._K R4E:&6XG'H:!P=+%:
M%53IW9>JFFN$'\_O%5U8B%KU>C_4Q!,";B-]UDQ+7CCF,AV[/Y@:[);?R5_X
MRGHQ5>\,4W+VI^"1;B=8!AAOGCQI!D5W3*=WT+,PTPLV/<_G7[PF6)0AF7XF
M/ Y+3/UF]VR9U^QZ]UHC/V,0A O)19V#".F"ULR)05CS6*N18H*H/;(69#*Q
MKC[Y\E4/L !ZI772E@9TP(@7W+I0<9D/IVWR?B?';&V?[GTTO#7E<T*;6^S=
M:_0]KFS,^+PP=0!]LDGR5V_ DB*3.REUK+_.-*:*[5+L^,?+QJ3,O$6S*=]%
MQ4@%7H1(B[!TQ6KKB+$\Y8^MV(DK/JV?@HU66#?%R*=#NKOGN971<5GGG:ZW
MSXF,EC(O6VDUJ-DG?D*GWKG.)*/UOD8J6(7T^R8  D687GM?V_F_;/!RA[;;
M(QQDNY+2^Z8O/%[GIEVPOE+W.O*S^*>H1.B%7(HH'AQ;J84P,L4_BLJ'S52M
M^I0$KKJD7$UTO:N@UZHCR[09I'+=>6@3;I:]KJF;[U,=YI/M*YW77W\\)?GT
MXCKRTVOHZB>CQ<,M&%DTI/S G?#\L$KUT#X]*N]]WVCE^Z=2;5?N2GU&=#L^
MW4E,^$4,IV?"9>+@@CPOIX+#EE:'GQXX772ZL2S%C_56W??M[D*FK#_-;IAB
M[THMC1)%^:7ZRHR33UHU68WY$P5<M;D1G*'B161Q^.F)2H;P8/R&H=>S@'>Y
M[NG4(T,.DKD-&?UV&MO)E=1<G9RP3P-.GGDTYCUM;HC.OW'O6U26:_J;MK^]
M?$GCBRA>N#@-X-*5#,EO^^XH/Y8I7O3TB_+Z9:G+?<-IH*J@%0)FU;25RHB?
M;S_6*8:K9$^Z!R5>U[95W> .&)6/2-/]\UV%*Q+&]=2!_'YC'D0,V][]8YL9
M'E_QP^GWZ_A+?9U/C*52S!R'3FMRT;WQHR07A7T+(0$E]H_]/RM]]B^X<4W
MQA  ?>)?9V,GUN/^Q ;C@W%.Z2^4WTXQ;\Y/<Q]8R4*:$G%E V;EV&D5=!$1
M=0L[HCRV3W;2<Y'Z5!O]D-W,\:&_\Q?82U(J]()<YY?,[>34)>TWY  V8>N5
MGY:\EHGU*C0 1*AVP=& J?;V=!0_57$^I-I6/##HROLCA[*:)_!*\78FLK?
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M 5+>X7F>LWO6<W;/[G[>WW\[,)"9N>_K^E[EOLK,A#9$FP0XKVOI:@%T] !
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M=4TCKJFYI;6M_4M/;U__P.#0\ A^:GIF=FY^87&)N/YK8W-KF[2SNR\7'<!
M][?MG\IU&)2+GI&1@9%Y7RXZ>M_] 8<9F4Z</\"E8<1LY\$M*A=ZD.?*T^RR
MSX?$Y&\1>.\][F;A$U? 2Q#W1?M#LO^>8&'_*\G^3;!_EVL$8&.@ XW'<!B
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M>>#+5F5]FRAVT@.J4(R"JNJ:FI[/^NUIBOT!%;9'RH*4X_T(Q[4H_XDP+QK
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M,@)6&SO3$V0IL-I@@>)?_40L^!(GJ#S&YL5&VIC"'ZI_#;P\! Y<F\:2I?)
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M(_VD<Q'M.>''HM-D(:?/^[A-9#C.+ J\#O$/":[<%9_X(!NIQZ50JZZJ\LZ
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M5Q.FPV-W>161>Q3(_G.UK?VW&-50X]BOJF\#4";=MM((W"<5)1IP):^,!B#
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M')F]V,;6.1CHJ3.@O-Y-\.5:\O<AN:ZZ\\]\J$F76_&L3A>?_,Y<"??<.D^
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M>A)E"LE"AB)O]\_5$TO&&N+SEOU';>]8C<1?:WC:T,54[*'.5LZ_<WJ&@^<
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M%2AD-(_J/CV9I^"O9,D2@%@\8^I2R"(7J)E+ME'N>ERS78JY-VI268F$^GV
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M)9*4 SYO@:YJ-*[ZMS[I)]*4Q=6##T-V<]:4P*/M. 3.F>@ V P[8K2!3C+
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MI._\Z&3"']L!_T"Y<?8/7&P3?^GCN9\]3/U/#__3P__M/5QBQ /*.)-B _&
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MNX@G/,<,XZ9GV)D;Q#HCY_+<GTO?ZTKWSJW[PM;?<TG_D^7.5M]X@RP+O98
MZYT;R20EG7P4^>4(WOZ@O_\W06<MZ&>VV7_Y9_])D5!G=3?N:\,QCF"D<[AB
MN[7*DKK,N%&FFADXEKXYR!L9BA$72"@G-0*X <MA4<C.0BW-SV@_G%"MN&SL
M4RE*D%4NUOO:)YEJ#8W?(>P:]15;J/K8]5"V73.MB4]:T'E7=R'VE&/++%P
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M#C#0FP$(Z"<+PV\?X/</ R/HXQ[6O?O8V,$;RO<#C Q,3(S,3+M>@U>#P.L
M\P$6GB,G+^SA-;[)>M2#[]3#Q#=[Q2\6-_";]. E3M^Z'[J/34!02%A$4DI:
MYIBLDK**ZIFS:IJ7M+1U=/4NFUXS,X=?M["TNWW'WL'1R=GS@9>WCZ^??]BC
M\(C(J.B8I*?/DE-2G[](>YOY+NM]=DYN7DEI67E%Y<>JZL:FYI;6ML_M7WK[
M^@<&A[X/8W&34],_9V;GYA<(:^L;F\0MTO;.+BX&@(GAC\^_BNL B(N1F9F)
MF747%P.CS^X-!YA9CIS<PW/!F/6F!^_14P_W\EU,?%/<L$_\M F>_];]'C8!
M"26<)&$7VF_(_CE@H?\E9'\#]G=<6("#B0%,'M,!  90#Y&R"2Y:)*UWPPLB
MV!]E@G"(0\)2S^JY"H'9Q%:^H31DTUT2$\W/&4/B@)'R6J@U=&#Z GZ<&IY
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M_-\R8_[[%X;"I[CNF#@W&$YTP,^4#BB8^"-K;$'L+ ?P\"BH(5DM4*:D5\E
MT[2VHCH\.[1W^*=O2/&=<\D7Q#/.KB*")HRT_0=YNK)E^Q?O*WI4UN]<W^'(
MCG#Z>3DO'J[P(&6P/&%VA,87V:RXPQ-X@0Z$MF-V0>D&7@1]DVZ&D(Z_W(W'
MG/B-C<P;&V@[ZMU\$%GJ6#><+(9:+\6':7X+5B4Y-/7-69HG3[%SBOCX21:'
M=N%N^=S!?H6[G3K?Z@P1(,&G#!/$RPP/.-(4!Y/Z/"H%*WQX_*Q"."OE6KV+
M@N[);:7^IKX@E;==_X51/)D.Z&*6LMP0CDM(#7"6O-,X@OSV=)*;(F#P^PS3
MG!2D[M,X#!+AV^,4 ^0%4=8L\,^%5@'. Y3^ZFVD71_-.W"9#C#3OGDI<M+:
M:?O[REW8TU5HTO7K\D63CM/68U>TS4+$#X>1AF:ZE^_@$UJQ0\MR!*F=ID;+
MT9_)K>5*B=87LK_,'WWR4;;AGLY'] AP\H)1 #SZ49?THQ:S%AFIV2#%\M&N
MG>\R@YDB\O.\VT2PBHX0V&F/4/N1$R7N-*F">=3>>BE';'PA->$15,\IP$6V
MDYG@U)??NG"_@&MLK[@R"/2#O_$'?W@9J2B_IQ?AUT!-, BJ"!:FYA,C:'U/
MC0^0IA&?0U4_"FP=&=84 -)K<='0K:*CBQ/=S0$C+XH4H**39[-?8/4DGUY-
M?_']59*>K9[$JZ$-UM^T7M.)D>2.> 3?G+M6DM,QF3-, >TU/B&%@VN%810,
M;P&VF[RVJ>33E,.$UJ?D2Y33=77XB"HG!_=).6'[#%>-:[K?KKPKY?D(^*=1
MZ[ZK'[OX$)ML>RS?G"?L7;GYCR//&GE,9OR!>2UY?@)K+9^Q%O _-JX)OBM\
M-<VS5_MPPAMT&LP!B7T+.Z#/&@&]>>_)0E9MOH'>YVM59S_I+$&^;<!LZZY]
M&) S3;[L3*G),)<[U32QV-LTY.VEZ-"[@ U<?;.QR6=LG9WWKQJ"1P8/0<H^
M4E,#&3))48X\I,>NAM<C=6.ZA ?%ZR\EAKF)#YPD#;&_#OXAF";8C.#RA4UB
MFFQ<<.G=T=("U>99?L=]!#R_ZC*>/@I)CC[LN2##M% M-\.-'2&.%5.?0R]D
MSO7XVFZUI/;-KRV*Q'F;/%(1."9[22HPK.G<?MCH%OJ=$N?]CN8=@?0"IU+Y
M+E2.59N7ZRDQB?C^4Q]V0CD!Q-M:*^(KZKM,ZBO*$96B>KY!J*F:9:?O?'9+
ME#PNUFTKS7[;*'"**<GOT^2[/J2C4[G[\% 3BG=C=:]S]>A@E9V3ERN.>OQX
M)<?ZE+/;&:,]]Z]/ #),PX[HY\%[@K'N!.FI8#0^M:6>I9_",F4E)YZCX^IW
MRO#@-YQ5Q-5(E[ YOQ6YTY-MR]N9%'7JZS+%"'_WB!7*^53+NI3(G$6CRSQC
M7XBXB,/MD--Y^Y=8KZ8[,BV*R,T@L:7$WEBBH^^4&.L@Y6)H@*.",I\QRS-Y
ME55YYL*M'^'2SF&/I^&]Q7HSK0EQ;L!D"$2+SXCAM\&_#EDN)5NY($LZ*T,%
M+^#C;!4Q!/G1EI(1O0??GJTEBOYLK- ;W3%B[7L&[[;<6H[%+2L2-<.FTLO1
MV$*WC;GWY;VUXQGZ[4*7Y'T8^O63);ABKLIR?Q\GYF&H61J'?-'-&N+X)3&N
M&CRQ7..IEW.E]AU#69EI;WO9CZU$9F3I>8BV,4(L^"NRLG]<C'8"\Z@<MA><
M9:??+1 %+;/#RU4_*F +:P45V7G"M0>/JMYE#)X*,%L]&#PL=A)#VII,"$>Q
M:XAA?6O,\64G]?/T\YP[[#Y61XPP)DOBA6[OT/@8-@OYU]WC,<YU[I\P AI,
M)'%3_"-O'\R!(\GE_&GKBEGZ!QT[A1H3I80_2XMGN9*>$I]^_$8'7,99*4()
M6A$!!C[G7UH$62TS0Z]$W-46;]VK86B]]9K;YVV,#/#'>"?-5Q;?1^!C(!!!
M8L,BB_=^F6MK@0DOCPAPFG[X7$]LGXZL[BSV-01O:K@'M9WLA2)O0TA#LVTQ
MJ1IR0[ E<2\ZD)E1.N"R/&@6[N1$0K$?'^%[.1#4-O<9W%%>^"J!W7E^ =BG
M@J>MKV 3631.V+KL(FQK#49 =X5;]S]TQI3<JT.-W5A_94G67]&9>PW*I?B>
M >4*"Y!_$]/@@JW+N4!^B0U8)INCB%<%2\G#L5V$V&7%*LB;*1J;P01(>T[5
M%X,MMC@=$+D'*DKRA8**T+\KPD ;^P8\#<G2[,/4&4-UL.4[14[<$8!-O-/@
M!M4O0K9^(*>N0O#&JWLAVRG*2/(*:*T[W#(1#L(H.0%Z^=46^1CA%/29R@+>
MA=F+^N.N+/ 4]?=3=/=/2_\B)SIP^R8LF;K43N!2#\K:$M\ D U:M1+(&8L!
M.K#Z\1>TM\$\L/7C"^.[MA$,LOTQ9;NV4%]HQ%NDA!.[QLA+R(9+4%#,<@#S
MA]2;>E[8NKSS+RFFO)EW9IED\7T4]*J]8;0G/S'U1T)=)(5/KM&!=J?.BD9.
MH#CI4/@@C9'@*7SWU&5BP#(1#*(V[S9B["N"SQ[153\=- &;>)W!!RI>P/P>
M"B-%-A#5)N(W5(^2G;4LD=])AC^1 :<"S5Z@*T"909@[N"NCME.5$;\B43D;
MGD#I2$-3M\!":6(K/UH(^25R,M B3;%B]Y'R%Y@[FAVRG>IEN"N2S3TRWCA+
MNS-J2B-?)GF8OS/KA"W=E5[#U#VO5^B$C^P^5,9!*K/#NRD=V&PJ\1F.[$NR
M!O-:EPL6EA--F<!6J)MO^.M)O+UAW.D[Q"$:8T(EZ_(H+@S,,3&;#@1E*5)4
M'2)@<XA^,/1ENR^2/.<P_OUQ_U?DT,'Q[5V9"B2N!GH2W"1INS*_7D 8QB7L
M"&["R,NPUGJIO[]1,/6W-PJZ_Z(9]F<=0\W]__"0W//70_*!C]1JZ$GEVL1X
M)E.69SGG^C[N#+4DJ6S9+^G!"E5B5IINS.$4EY*+?/U2/&,[JS3*);;=720J
MR^F ^ (=&.XF%KAPEY <6BOO+)-B^N O2DP_Z"5X?(?-+B)NBA?D%,4)7[]]
MXBPS?-HK2)!\EM:O*L:D,G:0 .VU\?4Y(K_R4EXRM3)?9WD@P.,3OO1X=L;F
MAT7;? KF,[E>=+)2/Y7UN?[HL-[&6FHJZFJUZY86OVTC;?Q:2<1*K^^*J_UY
M0B?O'KCIMU"U@1A29YG#4O3[HM 8F=<W_[8T\QFQ-J/P9B0%R$3JP^R(P9EE
M^4"GFQXR%>%9=^)O/2^]>4$]/YKZEB;51O8@9>)\'FH(D3RM:DK[ @U=BYS'
M)/H?M+NZ%AR./!+B!$A&W;\'JV;UIS+U%VV0WI65UR<!6_>?+T\^C_N"$_YL
MY/\DKVV.\\Z(;U,CD5AITI#O5#PR4A*=<?:;K(!K?A*WYZ=-)8;MEO>^+E/<
MR]($U:G*9FX.7]4+ [4G)Y^A&@3<)V.C"^_$7@V_F/)PSYDGSYX\I6@^CJA9
M'=XS-06+I0/VW^M%YS1DPG!TX+'&P<6G<_[A787OV%NJ2FUHN@930JSW(PZ]
M%:NEMKM.=G.UR"<7B!1EE-CF)&%E9J]\%7K"%N+7SLSA=;B_R?;;\N'^E=8W
M=GPJ5\UWD&<9&R<8+T7"C@%AW85 8"K9P9<VA>M>"L\CB;:EU=*D""#]5I+K
MT%5\4'AD4+1J(%6BX$:!M1J7QRM>L/H;(-CU\R13\MZYZN2,V(+%M-FPC728
M]L=>0<,TJ8"AN$<V+<$3,B.O' #_1(33F//.P4IBBBK<V]#O7DWA1(J6XN'#
MKW*@KT+\_2&74S3?6=EHOJ\JBYF<M[R^?#W'Z:*=)\O"Q17KC&$^ANT^\F%?
MC#X!F0"],Q5 M5\UI[X+]'QOHY,=O>$2I31ZR.1'K4K.2LT]:$[326C4)^%V
M^6D,;S!7X'W2A?<4[F]>D'V^]V?6(&(Z^3IY5K:&GAJY>9\7.I7!U9JM&,O.
M<4.&*2NXMBE[>.2S1,R8S \DSVMF4[0E5D8DH#!4AN%93=PCX';EA S3^A"-
M+8%@TF=&TGI#.?>QO"ZUS=C9TKXXP"7[>Z=RR6$]:&=2> -# E/12<2]0$D2
MZDT@ J^%BH:J;9DX>9YNC/>[2UQSTRPO><QP,*&U^@#U19[5A4#SL4GA'I&S
MSQD/68G>,RS2UBB7>NIWT\]=FOC@0SO':3VFJ+V-NG%F_5-OF/=K 39_[)SH
M)S#7[GT+- G2+%G!V@EK-I;I<'.*5WZC J^4V'#@Q)UWAV_"&:J@]UP6=V28
MUH9PF"7"U&>84PTD9 AK-D0YYKZ7U(@\A!W7Y]WF;;33J2@?W;I^/"&TOO!(
MBQ;N8_T17W:B"4BD#D&:1#X3=!X'2R$<JWT%[N_9;UW@(MG&%$4I3_39Z.!R
MV=2( 2AH4C:>FQA"8L\*%"7T$S-XA^[2^'^,#%M>)YUJ721?##C+]JY#86G[
M86B%+C!CKM[I!:EP18?2)'Q3FU7O48Z1(M]2+,L>*48&6N "+,1%HM<&"L?@
MFI6./_A6&?J/ 7B6X&<FMT)@)S5D*9R$\99QX>"V:NF60CFSP56-)B1KC,*R
MY25'S^+,]>Q840EL;E7)OAL#PR1]HG5O,!-8K#K!AU0?4F %%W#:^,+I(9\A
MN*!@HF2'?*/K:5TKIT^&J>H[GH@W2G];/GX;NJ,@D]?5=F3"][7HTP%^VRHZ
M<%,433VX^2H_C9P*ML^ACHLB*6BD;[U:<;R;VYU71_I>)7,M?:<#%B/*UY$-
M)\L3P?[[9R2-'0%.7OA801M;TA8=8*7IS'IVG(ROT20@9@*-\DUDA[!-M'U/
M"Q*V,Y9@>'!R4>Z#>^R+-) TO%AI WE1-QUHD\64?4!UDV!K)_S,E>E !Z8%
M^8)PJU!7H+X'@K]"O8W\NFD'>@2V_U//P+6"N7>0E=*M B,I(&EG#<GZ^RAT
M -R-Q 6?3:$H-13X-DI(=B;+#%VJ0^&%7X>L0T&O)T" I)]GD TJR@]!QUL2
M:.PHT'%3BQ3>[5VWM16E06^ZT;N6\\ ]#W$[@20U]@$VXPN2GH8 .D#XLLMZ
MW%V8: X!$(H@C X<S*9F/Z(A&^A 8FR[)RL=4,#PTQS:V*IRS5R6C$$W<:";
M740821%T$]SPKZI;([\NWP&U;.T"03KA8"@\<OK6&K0%Q/R;Y<E=RS<22-(J
M1; 9[Y(_+/N",@\6IF@.5HH400QH.8_6!YJ%3="!SRW39\'M,A41 Z*:9@&9
M1WT=:*KS.O+K/&@JA)L.M/2U47@QYI!U-0OD!%@QA =(YQMT8'9V5[QA6AAD
MIZFP..37[0,@/T 7@4'K!F\^._S[S3]!X_X+332'<XH4 $E30!'?<]."@[DI
M<2AN^P2:->WDKN5DZVLQ']&%H/"4&2AL 4;\-^G==)$'="A=YD@2 &;?!K9\
M!4*A4"#;0O6'.E&4*F0@:/FD>9992] MV 0*FP,61BM8% !85['9W-]9KT'6
MS^RJ8_^KY_@QD!YI0,8AZQI&9F#,%QK(C,Z9- =V&(4!]#,#=B/("/EUW &,
M@B(8A0&D\\0?LBWX+C";/YO(8$R_Q-0_PY]$F'%_EP9-J0[_80J#;[#,IG(2
MD23&7;\AV(^P[6VP1D\&*K[";-^CD4!'UPKY-^&4$^8@6](,0M$ ,#>".G\]
M)Q;]BE<T'3 K3=C&_^<EPZCF7;#97]Z6P0<0?_'LWW"4>],*Y/HH[M6$;91L
M#\*TD\RZ<*]Y#2)H\23/"G(SN(FZLWUGR*YDAT>N*$+VL12M%5Z9.SU54F!O
MU;%9'5@[5)&[7-^YQ5/W<@*R-)M+L:[7)Z^J7L4W&Y)'7I_8$EI(=%B3_Q:0
M-DY-1]JSHZ-,K19IDC'Z,([<T4-57]J#'C=5MRWX9X0-UO_L*UNTD6IE/R?G
MN^QZXWQB$T_X->-O@!H\^H5]7OS<-Y]4^ B->SJHDA-?4/SJ8^W]<HW$147;
MCO6-,4PD!99-LM(J[7V0?ZVD;UG\@"9S$+_.^F;[=%K/VQA2Q(_T8?(#.R$M
M;=G=M]QT7_]#"\;43CM%8KI&J(P.5$M),G"]HY)>,']JW"J^^Z;\0%X!_/SM
MH''YH;.+,IN='DF!^PD556XI/HJ9CB*!)HY?*ZH#&WU3]/4_9Z5<UQR)C[&+
M"X_?"NUL%VK?48@!MD?,J:DKQS<7]>O8B*K%?7WZ2:(V%SUCJU[WK[@K<(S8
M;5\@:T\?"REZ[?K]A)LSDK6</,X=:-?[M*E:9(148J>2SN[,VC'F:E=YZ@HT
M(1GL?Z>\[[/:NHP[ON8&7DY<K<PCH9I$GD8]>!\R+RA2$!VLP#_6\/R=Q[&0
M,Z.-*5PA^2K7$KLB'VOL]VVR)3W/.%LR>/QH3:_B\=:GV4J75DNUCLZ+N>7T
M[9L5O9A(SMD'/1@0Q,>PIM.D& DYH,S._-2LLJ8Z7:1WRJ2\'^UV_"A8;#H?
MXYH^9IY(.6MYUJ9?Z;Z ]<%L]?343W0@2F#-<M2:E*M8?B:XA=U&?1IW.UQI
MJ+**Y82VK3>/C[3C+4U ;NZR#--,[&I(\-G^@O?E];6E_<M)\B*>_(.Y*@[5
MI2D#[ZZ/WMHCE'[DU<U'D0$1+!=NVI;BT1?J>Y6Y#]F,8M7CZ[,GA=T*)H+K
M349&/B$.A;5S/%;79!JK6?A[._W?/!C95TEK*%I5Y9HR86MID2RG4:RD(4-(
M+]6Y6?.UM/>.D-/VYR3CX2!!C&D;ZU)P69U<183">[%7.,.K+BY;&0JJQYIF
MA&+,"&P+Z4O5*LN8K IA/CUFO8..Q:TALGEQ .MY%HT8N2ABQ>X[@W\=AP.\
M[26N+&8T/ETJI /JXQOY?$8LR))*RA:R-^'7H<#X/#_MR_CZ*!VXK/'[L5@+
M@)/ED-T^5)E?!]D6/@;$[RHR_[^J_TE518A)= NG-([U$:HY;;*#FLK_=;^A
MA%Q5)L\9 ]+">6D)L-> Z[Q=-!<[VNNJK'YJ192JL:*<QO[2A_M@E+;FL4-:
M"(EG?H5O#A+N3]>_P]QQWUZA UF0WX_7W[XNP0Q;T0(P\SJ_#N8RK]GHP+^X
M+42.FHR9K:$]"_KMD'PK!D 307:7L;IC_/O1#"S^_Z-T@2*,,;,4ERDZP$DY
MTYO93S$NN@XNRDE1/+/&'Z_;.>V5D#GN=\;$8\DY,K1>T5=Z$EK2@D,*.&(I
M/9S= NE!![LR^_->325V EX;\--3L.AZ7M*#0?9)Y('Y-"9$U>-^9U4][HPF
M8?:/<5/W9Q?DWH/VOA!48\K<6>;Z%K#$7(=,IR<<[3Y!:DT\_G>>/WPZ;Z%6
MV8)@G;/E+B.8OYET5>AH\@D][9[7_2#:70%_V?7^O?L,;;TA:M5RW91CY/.!
MJH2N*O=,7V2;"%=IOO6>DQ86B+;C):XFG>&LT@#O!K_;R!0\Q!T*LIJ]+9BX
M#6&*)J:#]C7!.#I;D3KZL+1FI!#P+H.?G4)$T01('G?XQV,"-=_[!F/MY0ZF
M)?>>EQ#/L6EVR)FW]&>-4NKF=R165\3G6#E7W^EU#UWK,DLY!C_SI22)^W!"
M8XB2S-L8X-?X0+&90G&16*_0>@A25=ES*F>Q"LJBSQ[NVV"):B?R,51I>69P
MD!)P[E$5]VU\$<UJ#E'RD^=N/S6HT6N$:&.OPD02<%O-&':*68_4 $6RT,JE
M^C;\E$5=9ZZD^>W6C6DN;9W9\X?4^8S/L_!_#;Q$>HES?U0O1ALE1%2YX*CB
M7?K(\K&3U]8A*VA@[1Y2W(;#Y]Z5+[FRYT[MX]O#G*S.I2[#Z/RG=?&=&RKJ
M]5Y:GR!ETY \9TQ\CIS-0XY?Q$@%ZGDI4B34*E<1-)@;+ ZD[>8%J36I-/]V
M.A"4MC/P9!2!I4'PAE_&#UJ4;[I30'Y<#D-H#'#_KBCG=T40RQ7$]K(TE>@L
M_3=IV ?8_.HN:>WQ*$6N@^SY*9*8O03#O@%K$^1F06R&Y4W@!#>E[?"39H8\
MD=U.L-52H[IIS#K6D+S40P7[$$,D-TDJ/PZT^ASYR_;M^B'0=@)MAR^H"+*]
M"*%NR!'2T5*@RE[DN/T;EW;,;!EJ:SCK-VG8KG3L"$C*(=NJ=, YN/L/(1FR
M-6Q]$$:>@T].V1J 7KRC _7=I'Y%/U4*\2F-#)O2)[/3,H(A> ,X?R78C\#6
MW$FLRX98D/)F]-"!\5L)%1= ,9#PU[<$RZA/C__F]#_(ZQ %J5 *;.*E@HP[
M#6S6IL?QW".(OPM![H;1 G3 ,,10+@4,__*:#HB$K_Z.Q8'BA+Q)!_JZP9XO
M;U(;I-C=--!1@-I O@U9Q\+(2\;$S[#9,N36=W13:AV*%@ VGT$H0HXET7U[
M59%*1+:F$B&_N9!6=,2=9A,,PW/_Z/Y7'9!W 4W/EF%^\R!Z%:3Y&6L@QET7
M;B%_>=#MOMN404BL"^[+6YZ\M$X1DIYQ K: Q+&/#M@F$U27,&1+%QBP:=:'
MOE*-#G.3&-5 U<B[Z<WH>G[;DOM&%G/Y]+,Z10O;6Z.8>?)H_FEXKB83V[5#
M^^IOCW:Q?1\>+,ION%]6$#Q'DFO%*C8;<EJXT""86)/>5=Y TV;/31.U"-90
M[L.#R\$JM"Y46784'7! \[R,976A,LXW]"OY0;;N$]=YR24,%)LVUCB[S4@<
MH@7)%6B'3ZZ,@BH'5GHG!99<\DT9N^)Y,)9R'&;[MMY*^&&& -RR#;.-,@MK
M;>(7=548G_96,M;RBWS[GWFX%Z@.]MX.E8\7)] A1]*4TX2AGMF9K8M5%E<\
M&?>N[)W\N#H"3N!0#2;2^$1"+$UP;@<92CO<.<5NM;<0"F/$4NL'NB3A$5 Y
MCF43C\]/PEX-?8>5*2[-XV!8NX9!6U&"7S]/8Q=-_;)@GT)]M^S7J(5L;VXA
M[ZE#'O/6[HUTX#L"Y]ZX*HSUK18UL&K.D"[Y7-I/T<]M1TJB:R]\R/,CC]Q7
M=V3"N8^H3BHVC3^F V6*+?&0ENJUZ]])TDT\<[9"A@IZ @:NK_2/5QEYE#]M
M/TO<0.<%,P9C/RS 2@Q#H$Y!KUW&C@^ K?]-YR>.*MHSCD435Y229*"L9CK=
M5"7^%00KTH&;)9#G6[GZ:<WBE"VRH0G*O+9VX)6-M:&'@FKI66-J3]NF5#K>
M@>B#3_WD,B[8B5.NKPAKWGGI/.1M^F,[!=\U4NEW[.&'0]_;H+*/^QEPL K[
MASC$8TCQ;%2]A'.]<'V865^M:H!'EN6BOH3)]7/)+%C.$694C:AUZ#6QO>U%
MBT0+O'L$Q8LL$"C5%PA_ZY1&2ZH_^"&]T"O@^LIACN+;9RT8A(6AQ$ZOW=A6
MX0RQYMT&982KF6BLI85$3VR0J(E*<5?)T@])FW>P'T+=5U"6G207,H2DB8,W
M*?*1!#4' XVIL9/LQ@ZG;9Q;+0K?KF'5*Y8K#P06Z3#U]89HV%/C- Z1$%.P
M93,"[Y1A)%0YB^3Y2>/@. [);C4O8(S5\I3JK13TC3]O+]L9 9V\ 0N!\Q-0
M$_"FU3C,(0T(Y02)"7>.DY_"G\O>S>?;IQN5-ZR=I?NPR,]IYK/TC/V-3YY;
M^1N".'@#C)TB3+*RF^#FL#)P>&VI*2%7?<O!\\BME5X.GNGBLU,5)Q\B-!PA
M>/W5<%N!B.MER/V^ZU=B+*##/'W-!OM]:(01H?8ML#<BE=1+DU+!VN4@O72"
M-,E+3W[-X/VVE-E;AN!98&<)?\;-9Z)W)GX@1<<A,62*"0E]F/ !<W,U5NP0
MJ8&L,:^&CH!*ND^X:O2NS#0:[/FJ.+QL;\&N]],5X+=_4GFA0T3C1' SAC-8
MB90WTHRMM6Q].2FT-&3XTJ3'2T]>JJ;2^.'!EOL';WA]TJ"P;2J&C[,'GL0[
M-(CX/*J%9.EDSIFS75+I26J3^/GB1?3QKWJ2T1)/SQ^RV=T2=T=P,"FV28V[
MC9LDJUV.<X\V:BJ<$Q/!OU*U%?OF=:2ZU^G5Q5Z]GY 4S1>2$V'I8;#[F//Y
MK?5G:>T(+HRCNJG!(-0@>W3$-]; 4+;/NF=5K(LHT7X.VDSN2-+EX#KE$9<&
M;-M=Q[M'TMB0#48TP7D$^\:(#6-?LPCG,$$J_AT#?V4*C[>>F.2VT<R9;N!^
MGL?3ISA4Z5:LAC+E!#6!$D 0_%1_YML#&)>O0W-JY:DYN*6EM7[.R23))WIR
MLS>:9,P,WDVL?T;WH$(A)3I-J!"U%EHEKE-M9;4Y=?ZG]6)UY^*8;3N$U>$Y
M'?#R/2@C_*G+P_8V;.(YBEFCC>6EQ>+R'6)*56TY#?OB5O_US[<9<8(,%4]#
MSIN&,$CS,4PA!&%ND*B,8X2MAU#)B9'AVGT"V1,CBOS.ELF1D8^KO&]7Q=O<
M>,RS]T#1!'OBJXQ,H7,G@GLA92DU9.D?+N8:PFG<8DXT&=J7FO[6J$N]\Q=4
MJ?6BQTYPH$Z%?FQCGO#>.3U)!Y8<\'U3\L3HG 5S0:Q4<::E LHNE^2]N>1V
MM!Q1L\<T-.S#X2EIH4[C6FI4_:'1P!,E>+51W[2QUC[3H%OJ%P]Y>P2Z9<#D
MT]]+3/-/N9UL/=\)!*82'(CQ!(%R\GX7_XTQY9Y@<9<4L9.E?6.N5HW>^';'
M;*<3/RP,1+5+\O<<"9UF:OBL_&;2G8-RN1\SD7MRQ)$.'+#K5;#'OUT06$N7
M.F9RZ/3RP>]+XAR^[F/4E:#\^1>P&PF/.O'!6[@OUQ<\'+$1N6*E0;[*K"Z+
M'65G>?1.,QJ^!YCZ6-/F@N6"/R.YZQ4I6M^@'@5:>1:^J=KA\G9UO5["\I:^
M_%L%)LM@I8R>"+YU^CQ$T7>$.$C8:A#EQBHVU,L/O.V'!KVVO4C;6^4B8Q>0
M;S6TSSVJY^+G6S^*[G-=G?",(<?B;-#1=VFB)'M%H04F,X+E_#>DLTW!L?U)
MTZ]/W=S/ IP\?(,K>1W6EC L9T0:(M^E*! ZN\*<!,,"%6\K*,L;K_!U!'D<
M1$N68YZ^2M;!^AP(%8Z\B;CQF 60_V-^B#^@:,GO_@<$:_LF8R;?#M"!12+8
M!FB7WZZ!&TS"V!;=)P]9I.I@[JB6/M$J78,.$@NR\1DU=."\JR8=8$!0Y#8=
MNU0L45\?/]H>KZ9-'1E[XUWHC4^I1LZPYR GY.A ^$4:SQ!FCCV'#OQVJN&[
MI1(OO/NC];A(__"T"M%&M2TJ@S*$PO*4(BN(CZ@#=1N A(-!@@ZP61-6O+1!
MOIG\?&6 O?QN9=@F'=AA=(:1]DF3KLE/4)&T$/\$&J,>C:]JZL="O##1_G3Y
MI<Z887=6WS#P4NKN)7YVWW/-D W&?@R>QQ"?.YO@6:3D,/S\ZP![W5U,6" (
MX[R\_N_VHFN%)R$[#,Z(WPRLMU4-B)@LW2J]IK!9-L9!X*8"7C *,^BG%!X1
MA9EC OGIQ$$43C]#O2NG-]7N0-H;[TY73&CM)>3,']>,54-K=79_EFP(LK+I
M/R ]JQ%Z#-H'[PW\T\7HV@.3L-W?VI)8I4DFO[GZ\WN3_?O!]*WPS72%X2)%
MI9>+NGPA=S*&>[3][VO+G4I>+2XL? WO&?_P,[*YBG;\@L>$ZHGYG"_5_:DW
M7DJ%00M"O )O%VG<""K-\"&Z4%.AFN2+BU_LUI70[".Z+"M%[4]8?2=9(Y[0
M-',W8/D8KF!14@#.,-P5JHXKU%"'&518L]C::J^LC%HDF!CXOGBLPO=V7M(/
M]HGX0>CL0%+>:!+E:D:,##I>X^/?&Y__>*PEQ-6?(;"&UVJ^MIP[\;+JI<&@
MLE()$PVV(E_XK,%9=Y:K-V4*-<KM/W&8-)1[78=-<U)T^49L/)=+H<DD=O@N
M)3;V^YNJO5%O<'=/QR?=SA'F?**WV1UE>ZH7JHHFN0TN7L0,E;^([QQ#":2[
M)>D+)@OQ?%188&U7^<&H-QK":?&M%CF!YIE7&1H4*7JI_#YK6HU5-E[\2M8D
M1WP$UR<>_@A?Z#U'INZ-;B'?H68$?SDARQ9#.5KM_;98O;/?2)2YQ%7V6)BV
MMI1??9]L1HV*.W,HBQ^QF! YR4$'N*'0'2FT1E5A4'ZSD<VH4T7%YW5J?#;Y
M]-W;MX$\[1'!F1O:^[HUU@5;8.P=A8[^*JE0M6QBW5>BOE1&3ZV1'G_5BY0K
M8J=";@#^CW_TN!-.-U;4GQT(E!"R0,RG(+""O'I['W\_S':;\6IXCYB !T5.
M5HP"^-EC".>:TY**:K*<'SZ(5U<J/+IZK>Q1>9FG39G)F.W>EV</7/HFZ_Y9
M\W0*\S$6(HQ_4]W0M/=!]E"YO+BV:G5XW6J40F\OW.]FQ*#NX9AKF@)#@CP5
MDR]+F;+O#N4XT0&>>C'L]7/#I$C-F*[)A>O?6SR$=% _3S%UCU$G'6!CP@O'
ME%'1MOO["KSD]%U&54T_]D6O;]0$Y#]X("?;NLVCEK?L8ST=Q\-JP@"L&XA/
M#GZ .O!7Y.8Y\^AB\;V'^XZ_KKBDTF)TP4NV>COI>$-<UN2-_0?MIL_6D95\
MZ4 +39%'.M;AXZG.U_-J[T[:ZNQ-''OPK/.XO839 0$S8]$[/8F5!T\-O1X+
MO(;7JJC*PFI49K?GCB/TLBSW?DZ,_R)>VE1U@>V\^8(.U&NRG,(]F<]]T->Y
MP[H/E[37 1[7I,:2)*CC.!T=(G''1OCJ/N&#1GNH?RR1_\0XL'V #G@@9:%@
MMS&;1C.3Y&/[G+!$0'8K4W+(4,1Z)U(V*8;QW_Q*Z?>O8+M?-2,=8FE^V3]U
MAL'-,\-I^]HS(P'QWR]K= M2U@V_O'L;4@SY_;(QT1<SFQ8,FN2(7>I!=H-K
M6+T6Q!Y4(4U=D[64850LU:(#T*>T;;Z@-,7M:=36YUS'U]POD1.O3[2B2J6C
MV-[FDLU2#R/[&N&MB)+4I: \BE?_F\'R\I>7\5#N%PK B#P!LM8%N4"=7?YV
M>X.J1'J![],BE>)V7R'8K[T^;^C!V?Q!W'4]L)*+#[62M"<H_TW?@PX#4</*
MXN+*F-ZN46:/"VSAEXP_ 5RA=99GYF_B5Y)AT77DNWY>'XS146;2)59\%'F<
MC72#)6=&[-OKFN_G4Z+$([ LV#S6=0VJ@0O8:+E6K'0;2"0_,=;BB_C/M%P>
M8\HD[WKY(26#6YR6JSK]#W)6;D6X&$4>4WM]3Y/Q-+F\8=GZ$;)4,6)I5:GI
M9D#.]^L60='U;7ROHV^7/]:=3'P>/U+Q9;AA.L2_1PLPF% <;M/$BZ'OY#;E
MC(^-8D>I']2;B@[1FH_3[G(AO1FD:SPM,LY04Y4,>1RKFZZ/60^3DB@+]U5R
ME>)H-^LB=&_K7)EH*YX". YJ0F#R?$8L-MS$.WI* 2.N=O TE=J8E<;;I?=G
M]$7#> W8VP\?7^H^X'XZ@H'XF,^<5D@^0_*$/WZ0,K/)W.=\NJ*-Z64[+L.X
MK_1\2(!]C QC5SI>_&IOX,6TSHK\H$/]EFW$9N-CQFQG8QS?G7_^B:N2QTT\
MZ9YG8MI\O;"OBB&#KTJW;L9/=X44J]C\Z![O_$[HFN$QX^_NB1_43VKQ,?3W
M:/$!QO_S@X$^_+\ 4$L#!!0    ( +1%>EP//JD^'CT  -9'   8    ;71V
M82TR,#(U,3(S,7@Q,&LP,#0N:G!GQ;QW0%/=MB^Z:((@ M)K$%!0FG2D!42:
MB @J50B*2 >1%B 01.D=!!24WI02I4J7WD0Z2"=!>DL00H"0O+CWO?OL;W_[
MO;/W.??<M\CX8\VUUL@<<XSY&[\QYPK$'\1%@/&6MIXV0$8. &2D/X X V@"
M%.3DOS^D@Y+TH:*AHJ*DI**EICY#<X[VW#DZ6CHZ^O,7&.G/,YVGHV-D8V1B
M9F%E93W'P,[!QL)Q@865Y;<2,@K2,Y149ZFHSK+0T]&S_-L'\2O 1$-F2-9#
M028 D#.143"1$3L $*F?5&1_.8#_=9"1D_IXAIKF+"T=Z89J1H"<C(*"G)+B
M=Z])5P-)UP%*)JH+%Z4TSC ;/:(6\&"1?I&80R-XXW,KJ_$P6DCF\?.0L[1L
M[!R<7)<N"XM<N2HK)Z^@>%U)\Z:6MHZNWJU[]Q^8F)J96]@^L7MJ[^#HY.GE
M[>,+]?-_^2HT+#PB,BHI^75*:MJ;M^FY>?D%A47%'SY65%95U]1^J:MO:^_H
M[.KNZ>T;&1T;GYC\,36-1"W]7%Y975O?P.S]VC_ 'N*.CG_;1090D/WOXY_:
MQ42RBYR2DH*2^K==9.2^OV]@HJ2Z*'7F@H81]2,/9@'I%S0L-Q)S/K>>%90Q
M1K,^?CY,RR8DB[R$^6W:7RS[UPP+^2]9]C?#_L.N:> <!1G)>11, !@XO9<;
M)0+\01JW8 %H#_ %)O<"1P)(4 ^A?E'MB8AX\W =->8EGT?<8M2NB[O@F%C9
M3HY0IXKSU0O7?#[U$+S(5%F,U*E^"VL__C8N#;GP2HUF'&:.*M-6E=$:?20]
M()/U]I/B3>O2[2&1G^D(%!&(L@"_Y*/9>=3<]'8;=#=)E,Y3IM7IS8)*L)=1
MPC7I[G<4+X//MT5%C6R(;IJYV23H4_94:&\.OXX) 5,8#Y%IL=S]JSS/8E03
M@;HC0VL2)2.\.;8R3,;*JC(X_'L]/%5*6!RBQ_86DW^0&YA.!HDY9/)-YH]*
MV#9YN LQSD,TW2RF!U;Y;U0T0\7,_2F"^RP=^(>H[?^F^;>8CLG165WN0F&Q
M*Z+*RM!I\W+A9XE=4=+?OD$!LB2#9UP*W8.TN#SD3O22*A7">P!DT11 +^>R
M300"?07TQ>R=ZAZ>:Q>TBSC2=J 87OOHKYU]7)Y!-3,UN[Y[]>>,]=5(V]4\
MJJ><Q\RF?^>#NH"6R"">2EQD$8[S0"2CD[WFGI/4^IJOTDQ73YG@TD[(D[LR
MD^^\9*&>W9]P66:-E54C<EK5-:D.YXMD=6LJ])BWO.^U>!R]X)PF:\T^3U*9
M3?XW6=Y'D'1/J@24XN3;C:-V.[CD2A7\0TN%?:>23#PXGBN>@]4H^R]1?_G@
M91BAQ![1:(D"T3M.]OJ6K)$S;'/8_K2LZK.0M3W=SA/RH?0?HM;YPW#]<Z'N
M!K.IT>#:#MM:>/$:R,#+B[@*(F T5K:U5<'B[&_W/=F1HK.W=>8JIZ!;#O*J
MH@_UIB']3*\S<D[B;$*WF,]GP3QO$QHRU@(M@,7HK^+7O<V)U&NT1XMVIUNE
MOI&SL@BD):BJS6KS:3[#5G1E6OM+S=]G.D4I3U)@#)%C@TME.AWWUHZ_UY[F
M(45D7=54Q3-.SQ/.NCW143;S<UMPXGXJZ.2G(R8MLR_.0I:!_"*Y#5,NT/S8
M5\N5[_/YTNR'0VN;8&6&QU-R!5HL@-%?A6P%7,7PRAYC^LJK9>M4S$FIH+PE
M]WM,8EBJ"/.#JM3G#'=S!&9_;&6V?28(;"HT7\6]=$=:;HM:5J%37F'3?-E]
MTK4ZOXX+GZ_HINV+,%8T2CD7XV>[A\^64AOX#T-_BZ:O_9D<UTM-8U*S,SWR
MC<;%=H_6-!8G!YL9T==&FAG7V*S%T5:$S_1%47(94ZXVCBHS9LO-+0Y%>X+7
MWYM?UJC,O$3_LJ8Y(C=843*$ZVEM/AX<QNMM'_:TN2G]^\1ZK:'SXT/CIOP+
M/%GO^1U>Q[RSY53LW77(#:85^:NHU';R,=5G8,/1U!%B^]]^S*QSC2D<8KH
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M4?H-/IEG^1.Z+_VJV(G3,M4,D2[->;$8K"VZ]E>004.F2PBJ*@J$T^Z]N.8
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M$R+[X;,.\!!P$IBU&]XT3DJ[+?(D?_OKT)A.@RKA^"1>$*'>D CD939+(JK
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MK.TK1$!](11RN&K\NZJN) *T][K!^^+61&!!$.] \M>5I:QC-@1\-Y$@=XS
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MCS.+D\)KZE.G;]SXVDZ%?'S])-^>FA\(]-6"K6,7IB<)P0M41 #M2BIK]^1
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M6?;#B6.KV,[EV5Y71W=N ]D1^?%8%KLWF5\! UAO/F&DA0YO+:%V;2V3;^(
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M6N+15/UWG>G)KATCIA\LWFP[M?;#D<%'DC/C^!]7T^PX]_$JE($I/,"RB\J
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M%1=]%1>Y\]-['3ZK9]\Q?&.DO=+@\ Q-G#XVI,/$L-5AS0)Z'9/XA*E3E$5
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MI.U;:=XCR*?ZLBTKR-2==\:Z+8V@N@0I.]V4YOY9-(HQ'#-K4.H&!'Z(]WJ
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MIRGZ_AG?@)H(:045# O,<]W'#7;XK;KL^E[>QT['MZ_?7KEP2R/M@?.S[]P
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M32CECF_L ,W6GZ3G.$I^W)M?:&$KCB0PLZ:8WAN>D@_S'XU;?G<Q%<NVL;F
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MKMB_$&=H5DV@(ET(NZ?4L<O:P2%92#/(%7TVLNO+14LV?7;K8G)&DZA AQ.
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MY2=JB7\^%/?_QP=Z,O%?4$L#!!0    ( +1%>EPD#L@^]ZP  '3R   8
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MA]_Y'F7AO,^FCDD<%KJ^"P<-#SQKY(WFDIX"XNLZO"7(UF*#U0I?A_EGJ]7
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M2!]%;,#UZ\%W#61X&F$"RE/S.=]_2%4C,[!E&K;1 [Y2__/M+SA9]0=.KDM
M7]F /R$GP=: 2M&?(4BO?\)0VG+:U[3:^B'%_3K@YK;"YEY'+D(B&Z8"37(O
M#*$=(?>K?/=^WD4*TD_Z'F,CNKTDO$9^OCX*49<D9%;07[?.H.O T-\<8;H*
MI>?I6P/HD1 :H";K! FG6(DMRAUPVG['SQ UGPUU^7 5G#B)).[*]P ,;<,;
M512PXYO(35>R$-_E?N5QP46D<TS'FG34"WD[+^]FZ63@&]D!-U-OO:-?J'3
MY20-N'O5[EU%J<_UP)2'6O0L_0).-6]J'AF^?;@\>#5YR'O0=%H]MDU3#?8
MQ4_)FL8="FDHU&EIJ#T0<:7753!V/D[C,*<6_\&/K;PP:?84=ZNM>F?$!4P
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M,_^S_U93)WCT'$Y/>C.K'JP>.Z-G+KP)Q=0<"O+_)LW"OT=#$>: 1RX"K0]
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MVU<;LF>X=[DB[=[[G5HPP#UD'3_:6XVE74&T6^*0)^-==13F4^T%JA,7WG[
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M5 JEWYO0JP C :;/=H2O;0L?+^[<Q8J#K99!6PPX0<8+_HFE0H]S:!F!,">
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M/OXYA\HI<6" 'PUR,)P7I06URU:%:3?M1B\SQC 'D> K>X96,$^>/^T<?L?
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M,0+C6@C&]<,7,]:0G%S])+UB^\-Y^%6*)*GW6\I_TAMF?] ;$IVVQG\Q)"]
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MB+?X*NS+HXK)15]/O8ALHE+<I:\U _DUL6CNO$*J2#M2IP7L7J^H*E%=/?F
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MM/[C>Q1OXGDFH7#.]<4^1EM93L_PQV5>LAUK=)'Q)%'RQ255%08,)W.!Y+S
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M3Q3^KJ58]V_]O_7_UO]G]/=&]T-4P9^/)*'&Z;S)2W[)>?J6K8UZ;1Z.Z3=
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M#$.,0_!YK-VMN0SL&)YS^M)Y5-K EI>=.BNQ? 1>[;O?)K'#ZH)JAD3Q[E,
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M!2$1"?C=%']#!G%4@)V?Z01,6OIA=/)<K8(Z2VX^PZ#)AXH36DK *%9I(WM
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M2C#2/-O02I.LP,^NOGZ%\"<54D^G_Q=02P,$%     @ M$5Z7(>"PU'$BP
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M ",ED3&Q%0G1%8"8D8B$D8C0!8 N["0C^ML!_/T@(KZPD9R"DHJ:YN(#M9<
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MPD'EEA$[]?EP9VSGRV6K&YT^WLY<"ZJ^&:EWOHMU3%,\>1R[X(O1!-W\=Y%
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MHQHU.0\"O_E.X5M_79!DW@77I>-O368?[2GAPWB=[@FR&&O_M9F+HDISO$<
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M!*#B5>"AZ-;-8/[<*%&.BWJ)^G#Z&.W>D!:Z4FA*Y458O\9I<K7Z2Y:R<NG
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M1LMBY>Z/2N[BKGW1=I-?_1:CR[<DJ47!+]6]-UNC*H24%/B:Q5LU[$DC6K/
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M$?/M8]VU]4XU!K4_)LV?3Q\]E/S?YF(JSOWZ_R$7H[&UZ'Y.K;+/P%M8N4(
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M&*>$W(;55.>.;<\I0^\ N)U/ &."+=*+[_38G*S^;DO7@IS]V;5H$P-XU*P
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M*]+Z*3,C6),8%KED^H)>9:OM.]@.PV=6!3L*S= I-[J2*6K1\UIX.H$C1E4
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M)-'1#%@,NFY(U;R;1KS:;SM3 9NW*&>I@%E^(.DY_,\-ZPU4SW!1 4R7$%3
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MIM#Z(;K^+R($C17#9X>0WUEM_K,0P>\AOM^*(\&2L[ M\YF_P6\KY6>48U2
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M.1>86FIZV7B>'CC:H5LGI'$HX<W.D5,W2ORYNL>YPAJ-$40O7:1.J87:*2K
MH9U;2-6.L2=G[LCKG-?,FCPXU2^)=3 Z6!$:]/>PYM(?PI[O[RP=%*+^V53*
MO)%ZK7HVY@8B87ZDE 810!%H5NN>09($P:;7C;G3$52!4.TK*CBR\F!!P6:_
M:LO83YT*.$J/GZZYB,#X^S],AC&WNHA7QKR[Y'+=;]5U==42 /O6Z>M]R\:"
M=<L)/IGL2*HRV="WZ>X76AC<Z^#X0>^YJ[AK 2/2#P.9FJ6A(.RDG'#;WK#Y
MJ^H6GI4QWNO9])DB+?R^,:)-B,_Z8ZZWB(&>A$-5,Z&CG#7/%JO7+W0DK1+&
MZN6[WY@^M4R]"ERV18_.X.L"I*"NT;!9W-)M>BD'W@B:.XXA==5+CMW,M$*U
M]\N,]0H3*]UG*\#6+PNMF>3&I9SQ=_8X(W:70!."JBA3=2SD!+2F;8,NA,OG
M@2T0?Q:6ZZD 7 'CBSL.F4CPF$[TS+1"STS"]Y</[:'?*2&YCGII3_1"UI6Y
MY_ 5SXTY2%,9DUO*SR(ZATB03.@+EN5^9_WA"M1RC4%?QO[WY/$R>BXN1U&!
MWD+1]UD1EWX#(Z*?*%>)S'N[RR0KS(MSA$?PC2XNBG4F1<34:PW>X34W(E*Z
M,)IPHK";(N"IW_O6))L7_S2)))>\H7D)C^NN!K+ZR;@4CPF4P;S<GN@/',E>
M$PP Y8D6(Y@(3<'=K3">FNC-,#.23$$MW*H\'!H.UPD6J,.M47;.].<O<8Y7
M13?]R"ET<U$X<3[A.F/.4W67\&QN\U*)EQ;>*H6[B$XGF]#B2]8)D!C%W6UG
M--Z'2^0@VG/S_Q]1':-0)Y>#L [[O=%$]R6NIQ86-U&3NF<C1.[:I0VH*NM+
M[SLS%$^T.KK2#3Q_II0 E)S808KQ)@G57%)OBAC&#/L['F*FO]Y_F8S9XKCU
MY_BMW-_CMZ^+/8GM-)C,^/R&.KNA""GV-W<.^<6=>R*Y:/BXF(BFM'/!]B1Q
M<8A)&D ^=B9R'<2"(#GN(3_K=^>*Z^:/EV7Z'SD]93$FUE\Y93G_Z95/\V W
M\(9UYISK*Q^K4+B?<J;#7F=IR_!*"17@^:B&R[UCW4*PLN$D8[;D9*;>\W35
M7(7!_ LG/'57OA5Y7#8.2N7L%]]?]M;E6#Q808ZI&Y]9.79N6'V9JRAHQSOY
M+%9(*F#_T#/+.+8"JYPMA(23AU-;(\?M)XL153R8)05CCF20&O+^P.XY.,VE
M.R/(!^@B%78?^8\#WQ,V/0-N)%,!2!,:2059?*(")FEH*CC@AH'5W[,RAL/_
M*% !)_J\XOW%)!HK RDW."%;K:!-5K (72(AH:O&(03"/#;NQ/MIO'?;UWGQ
M\ZFZ&4XUA6*..25LHRITVO60GTM*!X2#[0Z^;MCOO/A[AS)>7PWHDUSOL]IF
M8(]@H>AJ&V%Y +8Y[)= M&E]Q<L5 _N0ZPG<"N'LLMP>@LK=I0"_?7P#F$#_
M"D9#0RQ0&[60$P$7@"Q\*XH:S:]OX?AT@I]/M1P7@KS9X<9^@#W25;3"UW1)
M\#KL3+.F:-/?1EGOK<_=B_AIDB''-*\%)MM\'A \+6]5NV#2G+>.#B Q$;M\
ML2^*2K3HA M7'0Z7Y7)\KXZJOM;NZA8;FBYX.9"R8$?Q_$P"Q1 >5P5*XWNO
MCI35U-\TL)A?XG+K_NG\L0QR4$@W\%LAW<-  >8)^.XB%WD?1#+F>P*:SX'L
M+%,!!&-E]J-ALI.P 2WDVA@5@"V8<*,"E,_3WH8]%1!1N/!>[$;U',6'9H0#
M!J@ #HU_7D1?_=!#IAK@QE>)_6T8L>B7:Q3YB#"<<JFE M)C83,55$"GP:^7
M,!I2-6U#*VD_P,3?KR\K?9#/MU^P[')TXCAI/_1+3[SXAN)]C*8P!TN8GWJN
MPT#^-YQY68KM>%5+>67(5H(*^MKA6UHE,XJG3K0,Z"6LNZX0\!N="FL1E%-+
M"K .%_V;J#4EM^S%ZGKCIH3&6#.K"CV37;/A"JVZ%HU=_^)KVVGD>,I5*!70
M0>%LQN='>Y;>V!108+KI7-QO)VY(!1@%G2IXR0%W244P)C$_X7HZV>+"W0_P
M1]CE1<M.6HQ?J*JDB^6_^QC20A=H4OW/'A>+MNZ)0MW;ZC42=[B\7.T<.1HL
M(9/^65C=@F.V272^;GWWGRB-_@"8Q)W(O5F&_YA^7/(T"T79LJP.G]&6?D&#
M-S_$0W1JRMQ*A@%(Y'2W2N-XFKK8T%JU<">3IUC;$M]OL2U+?% H]X[SI<>[
M<DJ%3ETB6\;^,OSKQ_AM?>3@A HGL1"[<D+QU@[00;\G%G++P HGV9EK;U U
MCYAW#_]!!!?EQ:^CULLW!O'TW50 \Q7I@; ]X;"SUC>=>;T25Y;-#E$\^9&G
M D!$1SHG&+.';L 4_9<]E<RJ;S[!CR@)F[KLE*9^DOG=I$\S>SJWR#I)1$\[
M( W';19G)$Q?(><$G"=V=U0X"W?LY<76Z^+-%M%,[)Q%/F?O/OW&?:1:>UYF
M)W2YGP"Z1ZS")^F.>EYWF3"),!-;G6+CFY;M(M%U88)BKG\1#29D+%^8'6 C
M5KM8#]P;WA1U+HS:4?!/;V=]^&S:S$[%5(G0PS-[J--Q"?;1!1EL![]'!&/Y
M!NAP;N>+!;50XU9S%-]S7[25]4&W=\IK2RKX;K(7^L99>7M8ZXV3MI0LSP E
MVTP*38KG(Q?]O::$LS91>,U!Q7\JP[U?A18\8&Z_ D3XR3<%:1 [,872QX2$
MK 51[/WY ZCXF+M[-,KN 6YT,*>D8/VE!#2UFFN&2Q[QZ$0Z'@F;":,8;\C@
MJYYNNUOCQDJ--FGN>>^D?++QZOLMB_QLB'#!_HJ\4Z+1^%28?77R-?YR:=L0
M^H+]D3GK4TT-1.$Y&;QUOGM#.V]*9;(X:4DKXJ9WC4WZ=?)36!BZ 2Q.8&@9
M!;(J2;KG0)@:NA:>L/OA/ZG@"K<I9ODAI=PT+_K28O>Y<W^ Z(V'(I],"O7G
M8J;]4>NPH.&%ZG^EYPA)HO)<PWZXJQ(?%CY)S-?<U9$C-=\@216N=5W;W9L;
M<;X\;'?SR6DJ(-2*=TLFVT1F-A](M!_Y[[3<E.];D$LW:3.20LZ@7([^IZ5H
M)ZS!/8 A*J>&&PVPOEM?*P5DS\E,X;+K.^H8X@H8SF@M7&;A\]/&K[5G')DD
M-G0HO$8U*CZ.[15?C- ^+!95]*KHTA.S88\U58$S_[1&;J#3K^I0.PK K;=M
MP&UE7"/.4NX_P0E_G0#^%1I@:V'1P/7;?@8T]J)O)>\ZA]J"O.L/IS"2@=_]
MV%46<G)I6 &,F_^>;X5/)YGYW1R\YNCJ/F_="MR[94=J[$%*;;0'>.9F^MVL
MQM.&O$IG/^U,EW$OJ]D-ARQ9_TXOSL<?227S/Y;<8B,PI5?F4:NS==7O2E?/
MO=9A[WEJXS88]&U8[Z<V8Y3.-?[XR7C+^/:NG(G$?E-<R/E[V#=>>E1 (*Q#
MCK"4//7C,XBP^I659?4TVX>G&>?]WL\R)Z@>A!FN^\ +RM[FLL==3TU-&]M3
M^Y41W?MCR!#)"V,#06)Z:#A,'1@'Y$+^!CS:=@Z 1WQ9#98*("7 >*F ;P_7
MJ  -Y6?&^VG V?:A $W,UL$R@N#=, TU9J+,,.D6P1@90=)V*?@6&>D1JEM1
MN4MT&9P0TM-@N7EW;KRNKM0^T""W)F[RCE3P8'3[L#UB-([/,7\@GJY98=D0
MEN PQW5!I8A&E$B2E]T-/+Y.#ZQ.;(@YC8]0&IY60*::)B-B6QC.1,2^N@&W
M.P0[9'RI[9+?FH@@UW<7NHQ/[RANQK9Q6I%ULC_J]@3^YY1VR?_E4.6?OEOT
MY[+W1I;S854?3.G(",]6T K:R-HJER0_U&CL6S8#*?GI7F0IO/I3Y"H?7:#J
MNUQ_0G;[-B_*<77C@Z9DTZ>SDH5?E)^I;AUN*)B/L3/1YFAGC#KU3-FYW;7Y
MT!)LXDYUS6LFR0Q1L5?O6-T'HY[YXQI0%&:HKWY=36V4U;M,3\^+F/+:4YIT
MB\:V-W\JM4&B,MA<5RAGG9/UTC L1$TEX2*(::5"<.=G.:/<#XP=\D?9/RBQ
MM2@[N[8A*[N2"ONP#"O>#P8K144%.%>')I623C>1CAFPJA]I" H^^2(^J/,1
M47#;&C\RVC"G:]]%X4!YNN@8$&1^9MI+?W[$Y/3CCD62(JQI/=:,"CA%886N
MPSB(,\;XEI<,+K<W;L6)E);%C?]T=G:PT\X.,8P2_\Y(2'C,3 ?0<-)EN5--
M),_J(!D@T*#]IS?ROTV))WRRM-#AZ  S17]XRW,K>.)I6_#UE=1[$/S@]&$7
M9@$SF2YH;KWOD<J8+\\;Y8XWI$M4')%:O7L#) $(&@RRELPDT1.VTU2*2YN"
M*Y.CSEQ$-6H^>%" DX#N.#,5MPI)32G$";7'\9<-?J,+3!XB(-KTPU3DT)4P
M/B<?\;#FC^DK]"&5:8]T3HR.FV:I/VJ.8MHX%BHLZ&@RSG+XA2+\-.7KM,!0
M%9).U\6+B89I2=I,^_[5QR\FNXDCDZJE@]GK'GYI?5,&=NSAEAER E72OZA<
M8= 828%8I"@_L%KF_#3N')YO^D7HO,A@[7'HXX)QJ+P2.)XF;,=)+K.B:W2X
M<8G@RI2)?@47IS6#KU1 M9T8[T;OB<AW[3P7R--F82>U'A^*-23J8UC@ 5S$
MF(&N;5Z3=UAEY[N1!G#CP3FD[-"$S,AL/:3B4X_:9=;RCX>4-7SNT@^F\Q*N
M)&%73@Z8#JUE#GOT]71\L%(=,V.G E)/>=-'C") 1(%919HS +*X5*:96'C+
MF)65(583!U1N/=-7_#S4^9JY<Z:2GW%.G@>A^IX9W$4%,)% !-;*8^AEW;5M
MSN)C50_VT?J75_EWG_GE/.F::^W9XACYB\"JW]P^%-K733E!3O<#^\^Z2%UJ
M^;K&G%W,='?,TM'@^$?AH)-W8I@#[H+SS0D94<C3 2!(P"<5EFI4I8ZR1*>*
MR/JF:2;*DR\E[>;<YQ#AZOJ0)9E[@3UFR?IR48Q/A-!H$'\ GUR7Q"L5";PJ
MDM<,O3FV21O$MXTSPCZSLI^CYE#GZUF.+="WI;,.2:O)C5OHEH<,?&&H@25&
MI)3'1ZU\N:8*OT).]M,N\[M/9,G!J2A^_)H?;VPB^H"IJJWDZ953ZE*6T3^-
M[9[V[YA&(8Z87*S9E[2&@@Q3K(CJ6)Y&OL+K4Q?C):46T2J=S,\IV8L0M2&K
M>Y+&3]';KIKU/OE+Z:$RCV7$U.M&B^TKK*.=X.G2H/'G&ZU[;Q2X.@=8=&>G
MU&.^;4$#D_3J=IBOU6P!;^^D7;M7.?KX7..'NI#M4;LI_NU5H>CN@K.SPPJK
M@7G$;-T4W9$2ERW1$R%GII?.G9>;U1!MK=(?0UH377UER_&^'1\=Q+2]_10+
M)5/T,PI;!D1\O:@ *-CJP]M2I*=$2B39AHA02R26R%(!C?!>[0!M"LOP6O-5
MXN$-JQAT1S._BF:DA\W/<9JI[//@K]3%I;MM=?O,$!T)AU%8S9#SPZ4M-77Z
M4U;C\1L3GU76,QZO,WF'AB"=3#VBS2582 :#\WCF>JC%N_5Q_]8M;5^6,LU]
M8_NNT:]^5PEBL--*TD=7 P/8G1,3/_,(L.B\$HS:H2$-=F>OT$(1,1E/1_]0
MFE5^OJ^XN;%U=7MS3BXL:PU878]8L_! 6^,&=YPNA\07F^.27:HS;:0FS28U
MA"+LE*32MP(:-9*?VU<F.RWL7J.<A,P>]]/?%X<BK?R=+5 9-\N]X_KTD [B
MKEZ]IU?JHQAO%T<5*)^0"2> MUGU(S,8_(YB^B2XG4\(I/2*SX?)]!MB-XQB
M1N^Q?%=5$WN<=R_RO+J\\:Z6S%9-1..E;.*\:M-@%5EV@J971GUUY8U1VNS%
MKY]^@@J>Y46]/+YR7^NA ;]!P3UU[I/T@).JWLCE%7R9:Q#PN <+P[1__+[A
MN-3.^C=]-VFVR?(IH2+[1[!44@?;"^V6PY64?['(\Z4GGN9_^#JZV=X??MZY
M\;\#/J<53JZJ<!-OMULVCB)D:I]<0$G[RUIIZ#B8=J&//N6@F_OQ?:L,6.IS
M,9"0;1J!U8&QZKLA%E!F.OF]SG4VGM%MZU%<0>L19*/31?4NAJ1EBC5,.N!!
MB,<;5/&NE1^I^<X ,1<3K=B>M"<S'<\_Z)C<E<*9S=2X[@U_8G$NWHO &%,U
MCIMAD&ZBQTSR1CAPU2=F>12L"3?5#+]F\/+\<@<(+>B9SW6CB!"F8['^.G*\
M8G-W/G[5>)<[$=FH7 >I$ZU6"<A)Z);)I.]D MX9<@7>P8]](#"MOO4H7,W*
M(+-W!6R^%//?/D-V?FG046NDK9A?UK#7D)\UX^^;-@2U4X@>[W?,FXY,G%BI
M3HL)Z@0R>"!8H(=%OU4R3.RO+?>4Y2-##76KUQ6"$H/6'I]I$NVB-]A": +9
M-IT%V.Y2>O%C*$^RCBZOU4C; "7Z!Z%N5.QI/]Q:M!^]QE+J>7_._/)M1  2
MO[:Y>;W\6?8E]:_54R!,8M/.%DBK\@_IH:+D7\)*Z!\L6/LER;&C[ 9:V>N:
MOZ$U."_LF_4!6)-Q)ETEV@'#A8>V&J9LU&J^HN^%\*7)X@Q8IW6 R8'5:O"W
M C-?RILE6*D !INN1O@NHQ4A8\]AI"?\YH?[JH*O6S:H !QB4O#$  MWZX3Z
M+C#\T].0\X:%?,7(SWLU<]7Y!<24%B3;[.B-6EWZKJOF#@]F :T\AGDB>)75
M%F;Z4MN +\V7(ELR6&0NO&LTR)IR-B=QBA8[['D\*[FEV?'8[HB]>UQ?]+?N
M4BB-1TD3T9V]N67E6(L&3.[M^/%5VUU;2)VP_KO0G109N5#*=>A\.V],N7\>
M-/GGZ!HX9:#9]75X#HV4O!5]006LB'OK2!1O@6^LKZ;O.;I*B*XTI]N7;%P&
MFIL&]U> J^MG!G)7FC^1Q?S-\)J8"SNO*&)+ 8+#/RL))@UN95/F,G,#[(]&
M61O[GCWLN6C&=Y+CQDFY]"U"4J2T,^TU9QBC$!R&J^-+]]X9=[P0F*)C#-IB
MGQ+NW"L+QMH1.&+RE9MK*Z2QQ-=?=^&O.Q)QJ>G^."GM]@;)^V;A8NZ3Z$=<
M)TR"'>\5RHCF5%>C-ZJJ%JD EN[(+H,.@VB%IS\J7'W77-.FJI#Y^0M>RUP'
M&3LJ8%G\;_FY5-C]]HQ > P,Z_+W'-[N$V<*V8)TARQWF0IPRZ9P[![]YYI#
M.K_'TJP-EE[_EQ)GU]TCIC11^K7&V9&F[1NP?Y8X_S[[5^3T29&_RH)'6_BY
MX),"JZQ\M4?6'KW<DKD^%2MN^_I!C.;EXZ6.!H7FEI59$^N2Q29I'/V&VA+*
M+'99S7HC,&>7Q]!T;8]]OFN9FN<8CGR:?EP^O\8Y\$D_[ZHR#BV-&%=KV6N:
M2LN1VSF\M/CU@D;E:Z:5EB-S6XB;U>#(; YAAIGJZBWY2X^@YOV=>J-KN606
MXZQF6[Q^D)\:006'U2O(8&TTRUHR]XJH$@#I18SNZJ;5JU=V\!Z[6?*^YFRZ
M)C\8- >$*PS$J+#X25=5$=0S7BH98XN]$5<\[>MCIN75LV27N00=$MU.!Y)'
M87?0;WSRT1[@)#\0D8!Q92-)XQ$1GBY>MP=GS*M[8O:VY0^EJ9C%REV=JEJ7
M'W U;R=HU,TI2HR#6I+]N[)=7#!,ZIY'0_4KI^UJ)2=$O>/+YT) ER7X;>/T
M /350Q!9Z#L_"XQ^N I7"(A_B7<FVM/?M;\6OU(AL6W7'/GS:FSZ^;HH(5_5
M-VG]%]T:4CEAW#*NO &#TPS^<L8ZKH#)-,.NZ>/?>89_A%R8>C:S.?!945!@
M6]'C@2I0>\A:/!>7+@D9=ZR,=J(,*2E+A):MEDCW ;X=NO)>/?G1XR=OBEE?
MR!;,VL8Y <=YY[O8G,\PH91D7+&AJ/S$57\]5P;NA[6'SA\6DNK?KV1<2?=6
MO"I"-[& >.NGB+6 1R0/!)&XLHCMG<G/X^JMLPN=O-#7-)D_HD]-74".Y3Y]
MJ\;7,P9XQJ$0T[36!@M7R$6WI,R<PKF2BXL6U QJ:E,.@ZJJ4C^^=P\,OE+^
M\NG5$TH/7RB'1.S.:)&S2"ZEE@NCB4BF<Q937NJ4&52<E>=A_X3GKAOPA'70
MFN XX/$:C^"QRLJU<9 A(;CL-84);YO\X_,>N_599,C\70O(Q\YS=EK&U7+O
M1+F_M^R"&5*C!ND;#"R3VF9X,\*!S(W*V"!'<KJGA72];.[.VQJ6A@8Z^3VP
MA>IOGV#\T\:=+H)/A,_I7K2Z9H5RJ;(XH7G52H/'QY-GP;];9G8O?WD-BPC1
MP.(P&DBD3M)%&#UN9=[L3GY15_?J=[<OH&E$SD+9)^[Z6M^N*P3?_"*8Q(CS
MSV?@MJ^(DH2<^E+>74J*-Y#-3YF<\YW("BN&PKJ:>4<\%/63L2C=;W8..;B/
MPO),?)[T\@+NHTT@#/U*!@8182T:VHY6L)H)]61HK^XMLS5[F%:>%APB6T?W
M0E.EZ=I P(P*>Q.:Q(+IVQ=AI +&=M9^'EWBF.N>[[Z]:S\+#*IR@<P)!QTV
MG=04:"YT=1-#\, /RS%^&Q .1-?(;-]MG=T0XR?$P\7&?56*$0.E5,!LQ@4Q
M:XDKG>WT7/T,I:/5_M(K7WO(!EG-:E3 RR _/6(&?J--Y0P5\$I8&UI9MY4F
M\T0&Y_+8[/-%YRH#^Q_!D[TBF SY0S$W.MV 551 -TO,-,_79F!9"B;,PWEW
MV'DO+SQK2>Z:U41N5/2%KWWNIX_G5#G<47U/GN,\2Q=!9%ME:<3]4KMA030N
M=0ZX0'3'D,$=$GDZQ1#S"Y_7'7JES#^XU=UQOGH:<*^P_87ZO5^K/<3_C?3T
MB[^JXC<1CFQ4!$;Z72MT0-W&JWN?",Z]PWG7-VITBL,@/NI-=OU% T,]B4=^
M^U0 HW<FS:3"#*F 9IO?/A(/EP;M<7N"]K$@/.)] <)H'\Q'!8" &(KF.W)2
M$!60X4R@ J[-SQ!M^EDH07M)Y W@P:?K&3TS88.MA53 #,TI!_L?50>.U\[L
M$FGN8IUEN1%(VH? =S-4J(#V,PZP3> P<NTM%= 6N']FX7X0&5E .TWR7YP6
M?K2I?F*B\]1UUH*[_D\O^X@@A+9D#^Q[J@NZ3?\HQ++?W0LC?OHG]I&$V$='
MPC5%MCAMT0'E11!&%\I >=7/0 4<'8(19,:&+"YO)4W ?"6WI9$)_MT\M-XZ
MMT V+SI B%<BJ8#P; H[^@5RX<X@$F]%<V5L5FGLY";7>9@OUX=<4O&JYK]S
M@J_/S!?*]IFVI'5$'8\"?:@'@F&,#-=$E7KTW>PDI6B9"(GYI#(R;OZL*L@J
M=^F=JK!]8_SZE[G-OW_ +43M/_D:@B6H0R)RKK7Y7) JRN]Z$;3"0E:_2-\N
MS_NVRPI'-8]V[)O3%N?NVI;3?ZTA/; I=G)PJ137$^<RCAN]<90TVO;C@2+V
M>X>9EUML5 2A+JD31D\1R6"#QDT8$?##?O+U;L-*RMFIY"+1=T):R4<>K;>7
M9*K%UUQVCQH\OJT(#!MGSL9O*;D(+$"8FD*W8^L]S^8<DHL#%YREBT4K@4&S
M+)$H*,HLHFVC=7PM)'&];U]3OVXX2XUCI/D'_]NQQD(5SXMR[??G1QNQ[2V\
MZP&?1?&IB^A8:#JNK:+GBA]R4[Y,()RS7_9YN)R*) J0_K*0Q(C?F/#3'EHE
MR6'@K%#].Y%J<1+L3$^N9^E,K SMGCUQ8L/.\.)%XSGGP'0W5: >6G"V0=$;
M92%U@ZUFNPHM]CZC:;,LU*C<_W;_>YVZY;>O_7 /,[N5C\VJWQU2NIK,5/*Z
MW=];XIUHOU"\5**]39SVN,@WBW3_0DK_&<:11MV+Y6)@K8]]\SHV[)GW8ROB
M8Z->^!_B6+JZF/CZ*.MXZYG)HV/<W'M&S1U4P,8.Z"<2H_DM@Q(P3T*31+/*
MSE?9)FC7N$1=PBP:N* BP),$+W*Z#,YW@$,MST]GQ,.?OL,GK2O7.W_,U.*$
M<;[@9]-5'C-4X O-VS-X]/(6QI69&%W%51EJ6!&D7354N:*P/B44T38MT/%J
MDMELK.;:&;VC+I:DNWCU1,3%!+<Y,N_,O1C(N66[$?%$NWCY;W?36BLF>$K[
M[0W*\3\BIY?&QQVKG9:BW;VEW31XWEY^^1EP) ZP)<SQQ8,?%MQ\"&K17H%S
M5 Y.+\^=7GKFE.@3D&G#'KOX4:OHHNFS?*>&LW[/90:AH2VGH$'=*J<)TDG/
MU.1"FT?/UZ@??;2!9:W6-ZAD)%@!_]'_RV\V)L:GS<WZBW;EO-2;!^AZN;VK
MH_O+M7I;OL_E KR%@Y#V,ZQ0N4Z?O I7PIFEV24T%?!X.&Y>HRK.HG)@+_'M
M2^Q5Y.473[/SKY<*[E\A@:H) R%*.KE$+]VO%X>$DA^X.CZ*B._YU&Q1OFPC
M^"QV$OTL76Q0B, &]5<R?K2W'E6=6/,ZY;UDZB[,-_]Z]^TFF:G2LDQG&]F2
M<TT-TZ/;7W5X>V5;&)8-I29N')G+\W[/.-;(<&2&K53)]DD.URE'J<7S:(=O
MQC]C#'=QKVWH""4#83 63PC[4KU>Z7OHQYVVY*[TCUT78CCJJM,OR:YJWW_(
M$78YU^)LX4"I)Y/,QR7'_.H"]>58Z<7'MC=$S[_F:9N[<,/NR.81N'D<7C/?
MO,_=O4#;U?4D5YRC (?@72FS<&X L[;T\753I+W@^S$'=Z)]9\VX7$3E:(-C
MU5AI5KWSA@=6)T/A8EO:U\L?Y_B>QV3+?(/","II&&0P&Y1S=!6S<K&BMCIQ
M[['TFM#^YPJYAY_7%7W<8Q(0)<0D-?S/!,["8F@R^@[JT67!IL:&$&[(TT\K
MS]M28S18I*><.Q7H0S9QSF2+3LYDN^@AXY<_U]>Y'[Z)C:U* 7Q_=M4[V^ M
M+["U3Y<-C&]^G_QF7248TX7_[M!3F\ 2OX]:F*GC9[XN@TV_0C0K(UVBM'_
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MEQM(]BUG1%5<?V9Z=>->*DK^D.;'C>V4*1:[@KYN""5K*D;_ %!+ P04
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MDWW" 5W^.(!LJB#\'>S?ZD!PIG$<L,GH@ /"=K",Y>K U:\>D4(<\/W6, [
MF\4(_?F9)L4,I,-_KC+" :2-5T-0K1##D("153I'L*LKECPT-7+,$!4U^DZT
MAK$H6</C^IO[8^T]&]XD+*/.!/5_V4<9E _!@/)Z<6SM?=T-<B(L)&;"I!AO
M>]]TWL!',GXV&J-_66WP LNW!&'O7B*8Z>"#).G'.D[93KSE#\@/XV&:[\M]
MZQ1&K#H* ;A0?^ZZ$$OKP8T--P&CJ3KA-H+(WM/F[QTW(-P#\RV;3?,:G2L7
MYM7^(&KP'?-)6\6GEAP1=@[\88\2-75 CN#Y!:W+(NJ7QIQL7E0_7:XQC#!.
M#PVOW[_XM!(% *8D*@4)JJ=C?SD'O\]62/9*B['?071B&,&G\*QV:0^/DE;=
MK>IT]30Z=;5#(D*G9\IN6Z[ ?U"RTGI',,I@SS30#C6T <^-5L(K1[><=JF>
MIZTU#-WC+-"N$XM^V/Q(JUF><W/*Z?-?3^IC;@[TLB;:&ZZGVY=Y,O]C2P&J
M8;[!DZ, D/AH U2_PL'B7R]@8UZE_0C+I!<VPDUH&'^X:5]"0C&YQW*=YW+I
MV%ZF-.V)*89W'G2)7]F)Y(3U)/U)#Q"O 8-Y'*"#MLM'DSP>EQ+.95^ ?-/R
M.]C=ZG/OOV^I:ER4;B?$'A0A;HR1OBS"/%VM87>9OU&.-.CO8*AM65YW/4^Y
M$T%9]DV6^[8_CYA-D2%)XU]C,AT*(MG;J8*T;5/#QR)"A5",Q0G#"WJ^)4,W
M[OOOZ@P\\XY,"CJM">.NYXJZN OQ/#*:\/ \;MU3@'U:WLK(N^;Q:T!#:R5"
M,G*;E,<V3)G\7Y>-YK\";1#*<P3_S\A=C519_^.NPY?  7^J8X#]"9NP<1SQ
MOV_,6\*Y%"[X\\92%7?N<H3"0U32ZHRL88.5R_O<:ZHTSLN'I+4XH/K:E4+B
MFA\=PWX3FL-F":^:JUOE4808Z#=,^;^2:FV*6V.Z9F[RB )OD5OI;+WHWPBF
M#O;%9Q+[60\'Y&N:;M)F_,56LGAC2/S7:OCVG^@I[#]KX3]M"QTA K'_<:::
MO1*Y&0K0PLA!"]3[<VAFI87MP(@+0X1,*C262Y;&.^%W56Y,AVC2()8(B0-B
M[1K=I*8KG[9;!CX9N,Y+/*^UDOS>J"R!^B]1( ]>Y3;$09@1?&CZGE#2F=#K
MZ.KY14\O$:FZ6A&C,#Y?#UM]5FV6KI]MOQ E:.T+RZO6#/4U++'UG/=Z.X20
MQ?5-"DDQ)_B$0V4LV57ABSKOP]3X$IT)YO^#:GIACJ % IW+HA,/-[VF[Z)*
MH.<E"X,^=(@UQZ-"QUM]3S5DL@NQ1.:YQ""/*KY5@P'V7/RM);;6>K/^R<$/
MVG[5*94B80%$7RCD=_J!$/*_G.AW(P22H+\>#98'.VUJPX[^ODP)%;]2YF-4
M=:V;%^,T)CWC&MF"QD6H.Z-B&%51BFFU\+P2&+$HW,W%-N6_YXF2NA3M8<I!
MK.N_+#SA/P9\#'0(S?YRRFO2'"X[-["C7O26&%Z4%0Z@GKA;VA=#EB5[14TN
M5DZ7;0$C 9U,., ]A!P^&XZA160S:S2CHG,1<ZRWH]XCF F)?FO="G7/;@VF
MC0/.P'\]NYU Z&2.)"HF_KB*V0C-CL !E'-+NFO#%6 ^4H_H:S]_#<BM4+7O
M)$SB ,]%NSZ+QF8'>&<DUPV45)#>S_1 9C:K)9\*81I9C_B]40F\0J/<A["_
M)+$L[-ARO7[LA9H+6_T,6\CIJPH79OP%HXD&(GS+0/F%+]M4,YPO;ZEQF%8;
M\OW/"_^*HBC^?V(;"+'^&XE4RR*H$DKG+B-W3YEJ/8]D/:(TO)LX*\8KHM#9
MLU?$TYA[(2(83.GI;_$G8\?\_$^7#]34&0SQ_B%@:5CW/1SP:P:CC@/ ,KGG
M\FY;%@B5.Y@;XQTR$+:#GB!,T^NM#&--_B0[WD%1HT@*NDJ%1$C>_5SBSE^O
M(>S8+AG0N0$GM&(5',V-S,5^SQ&?#26&&H(IH6J?R)E?2@6_M->R?O-"T-N8
M55O]R_QJ )4&W/H]"*G?&1-PH=1)!YDSD9 IFV' 2XSD,C5PW5$1#AWH($)7
M(7H1ST7]DZ@@">-VF3C@7NLAUS/ ZC//VD?@I_A[BO7P'&[D!B+CY8DR:'4Y
M#..?OVF(7M!!CER.+#47+*C3VU#S1].S#+#6\;Z&;*NQ,AXUO6A[[(^D[@[E
M1.E]D$U;]2)T#3)RX!0UV7ZD<5YV..IVK @?V\U?,8CFHD7)A!<-A@BC4V9T
M]70?M[W7#;[M&5]$LA U<,I'/IN:.3B# VS!,4O7T<$K!\0V>I4=:7#SDLP!
M]18UR=\U[3,:A\A'.5U4$6$J?I<)4 85[M!IW?RT!2D;PH;,)YJ\YL;SIB18
MPE^F];!NU=#K;MAK:-VB.6?9H\U5\+3M9/6)$$MA-YZ)(UY+]:Z/VB;I@4US
M"90,>9J*RC)$9Q'.#B/(]Y2EYIX<F>X6") 23RV\A@6T[6.$O1"FO6+44&MD
MR$9TF]$3:<I;&Y1-WJ8)@XM^3X<^GF!?Q 'H3D1&;S#LQPZ"I"?$";[>7*DG
MTUPNFEV^-1L8[3=5^.WI^]('V9?1>+<T%+N1EBL&,<RG.ZB!-X+31$W1=)2V
M7[)F1(_VHVJ%86R.&K\-W*FFC[E[83]:NSJI,-9/$29MLU"#<I<X^@?8Y8Z+
M^P$\(<LB=\-(=_6]IX#GU1N]( (E$-S@58< .LE)^0(="6[4M2Q;?Z?74K [
MT$]^!:/=["Q/\VJA=FM5UE1W.E;$U&MSD4I;FGN>^A""[@P'>SGOC"\@N,/J
M07--^BBJ3S.FH:1)&DVF804&'+6_70MH8J+=$UJ5U8.BFPO,(%E:;1,-NEI>
MQSM?XF69)DM^I5$3TKAM"'6N9"^3KD[/;.7/K$U.>,DY?W)]X-X]IO=Y,0G-
MY*W*I7P!=F.#Q=.?/IM2X6BH3G,**=>?OYW@]$N-@%7DA?O3A9Z87PEM25:S
M$]S$;<*HX?NH1Y,8+51C.(*3=/Y3OUOQW'.)VQ<9;O1K-2P4XCF(IE!>[!@7
M(SJC#,UV8'AA'8.Y/HN_^J!QTEXKWYC"3,,XYA>7#D L5V.<Y[1>L_MJ)3>>
MZR;R+,$![;TZHMACX>.6,NCK\=RVKO[3'K><;4)X?7CXELV["_I^+^FF@:1H
MMB$&E)*I;W4-0E<QE:==XGDRLW'OFE @[:!BK)ST'#5:4+/W\>?/F2*^ S)+
MT"K)XHX/R>6._#F$-N@:0[3'A02$#VX:WH #R#>99@T7=L:5%**.)P]:WYFS
MROO<(:7X 3RATY>7PFM%:L)S<I$Q\+68J.-VBQVKNH;GYEY>]J9IKYIMKQDE
M2L8=[,2BU9"E&FCA%4NQ:YN2-E8NZ4E\@P*8 FWMP-MS3SXHI"8*-^;AQPG]
M'\EOP0%)+IT_04,E9=6=JS->9]2'>:12_VJ'?0@"82)N=^Y$P#9YJPV)KL%^
MR;OA )O#*](UFC[/E\7$B,!VEL"79 J=JJ^-U!DHA KB@'\5I-A")U;OX2#H
M9'3ARK@NJ)X]]5Y=8>X=NP#FKCI)JTJ*6Z8XSGV%)9A6XJL:]F?**'MAGC.D
MFI*06"V3PD+U**"&P  M*-O[ULYL%2684*C.\LCZJ2K!=SQF'4*?3KH.MEX4
MWVD"BJL<&8B(P?#F,KA[I(BXZ7Z.?A3WV/H#U>7GI^%<IFY)+6X@.+B?FE$L
M+E04JH!^5; IMFII0&5M/8S@9)OG3UF#)K]Y5T@0<"^?<(^/A4]NL %J?)F@
M1(XRL*B;=?P\?0RB4?-,'WP\(8IY5W+?L&+=0<L6&(#(K<HQ%B.;3O61LCUZ
M['TR07?!BTL[IV,NL(IM9A6/G\D?><H\\O!2#/0_"\HQ4& .T-Z(UIJP#GID
M8-+>O2(5/B2VN4!K_%GH]\0!)I &1#^$8;8R]$L'N0K!9;D294D+8MV+4.3X
M][9]MM)D[C,.ZIZ.=U,XX.ER3%!GSQY)5R"]FUZ1<U/*TORHZ&LKSU3%Z:SA
M[H<YX9IJ(X$!N74X(-I=15P-Q;MX4##+,ZF1QMGRK=/![.X>BU[S%\XS0Y(L
M[#*,5AH'Q,#PF]!!A]82JX^G\B8=.Z/BVMOTJ[\]CKFE/])\+-A^Y1R!HIER
M:S'+%&UVR+.^EOKS!FPQ8_9E^\B1'E,-._!M03*>ZRTK0= J(7XH'!V%/%-#
ME\*%#R@AZ?W2G#=0=[_2T[%JK9F;^522$M+:**]0_XCI4B%&.;ZK&0ZN@62&
M\." ONH%ZXZCE=KNH=_.##Z?5Y6HY+Z, !#NR X"M"OL:OGT!]&/?0A)TJF/
M 3<]#>JYYV-Q32M@P$+I2Z]3B;+P FPE/[TE:G:WNR;DA2*_J<DGZZM%G,-K
M]/Z"^ >,[(12<B4@O CJ/*,BV"U] 4EZ5*NG LEY?'$GP>2.3/7/R(OB#>^#
M_D"+D@R7:I<SA=!\+\:UA"D/BM.C//MDTEYA@BF:9VIYU->13HEMM$78H?,;
M[65C#K*156V*9%9]C^T3(GH85WY G&Z3N2L;,!XQ[V4@.$D&<JE#B;9AU'R1
M#\8/I-_IIU<XG#KGAVSB'0;$X_'PK_B.6<TV:., PGVTYHV/GB\4?@9Y9XTJ
MW-K6.U7:D%M(^($#PF<+H;J7F1ANU-WA[AG9X< 2<X@QW%-JP>.6>A1#]3<^
M_*JT'BIBE7J\2&12#YBKWHM58*P/Q($.!".7DWD;<K+L?@TYR/U8:"M>\4W.
M_*UY:HL,[$]BV%EF^(7V6,T&]<C4NAT*_#)M%'[FY#/AX2# [DFLN0HN2CL<
M6<;0#\/[U\MA90EN_:=URU;:OA(6KK%LS(ZW(;1^&TFN /SJ1!X,IF:'.J$]
M$#RB4%M/A^;I-B,W'WOF9A'6BRZ/6_:.'#!Z)T+3"1R KT*_E4NL1, =(Y7@
M>F13;_G.Z<+AN(+_1?-7JQH6ELJ:*.XZL7 L!3K88@*JZ.+';G:/\S0_$)3E
M+Y'&0_GK"5[S9X+RL1M-'110CN]8(LA-)1'X[X-JJ>//*2LJA7?2K4<U-%8^
MB ]R&/)U%,0)L5PQ$O"O8DJ.4JS.P@$>H%.+_3^9;Q]G-A[GX8 OY/HXH.8/
M&Y/6@C'WWRH8^AB,U '&8<Q]%#^6&JG24+6@SC'+)#,BH2D30*?($5!=\!F4
M"#[44K+$ 4_.JBMO\SVDU:>SD!= OY<[3RE^46%,-:*A%U0TL*FBV#:-I1%\
M9;-$V.$AHWL@$/C<,LUL[Z1[P4IZ>3#!4>Q%!P?*8JOQQMG#*?7WKU.PC]S:
M9WV.WF,BJWQRV-%Z(F?=0B?P5<I0T@6=](T+!>'D4^@MV?W3U?WW/L*9LZ>P
M7A&(\)A<S(75[Q<!UD=.QS75A1DKBR89[1=+UIF?ZNN/YKAS$)+N/5*/BB&A
M\&&__0/J8 _9H.>YIF;H4HWI@Y*ZVNG*ZH.G"*WKV=:3VWF_3*^A!A%7U$-^
M/"+EDOYZ6Z'].)ZO,2M J=ZJ]>GSU;BC)+8M%:;OH7P8\:RN'2?*O?X?YL0Y
MJV>-.$#L&WHGN9/_\/F83DT%)-44Y36HIVLYCI$4>^6WAR\S:1M],YG6.IQB
M3J44MF5EYMZ84DXV9N;3+"VL^>BGL>>I:6BPU3'JW72@3@F;B$:-DFTQ^9C&
MF_<I#0OQ@>,[3G7*!UTV$HVHIHCCD5#EY$%_(.7Q&.W'BU4DSVS.7.CWQ@Y>
M=$T1VDXU3OCRQNHW[1/FGQ+;\3]>U7*+\6,91T-'6M)F(BO1J5U!B_&9[N]D
M3V<D:=^NPCJY-"F['R8?F&"T"\T@P:=Q:-_2K<;O/^;N/;V32$IS*U%@3_O)
MQV/OQYNCLF<.0F[%S98&(WN>D<]S)&G#>Q WOZH?]4@S-G0JO++8S:E:M)GY
M<3KBU)=I&K.B[:^G,VN0@#9I3K.C")&OD&&+JJYPSI Q%;=>Z+QYFXK5$L6X
M$C22GEP3.IDQ$RJ2N.3&'B+ KA]Q<:FO/Z%%$K_Q#=->T8:6I8Z\G3];I<2L
M]&F^-VC9)<GWK5W&A/)/C\&S8-NV(;2045[I<WEI5H_]>1O8]%),7=2W;5MO
MXU+GLILZPDMG"TDVEJX=0<*2W*O+ U7WX ,U*[D4:,^)24.45]S)_;K&Z&/Q
M:!:&)(5 TGM/U5@X#T.$OX;RAOX(O86L282"17/SM^C1PCT*:XFQY0*].M+D
M&;F*1;'A/_)U<E@X4&@+%/PY;*5@F3)EE\"#.]K3YKNL'OKS3\U.Q@EH"%H
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M!$UA $1GTJ#C<VSNL#9[2&^9 )_$%[,HP<3/K*/"$\YYU(R7Z:%4KB#2-KP
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M[+GS<SV)3\D_W;BN;0*LLA*'B8Z;F6!ED7NS+P6^/YFMGVOX_ FLEW@HT_R
MRI?%HY<+4;.MT)^8?.K5N*3FZ.EH"2$\_/#\4V/ P#L^7PX.H5_?>4\8-8VF
M=H_?IKOME'GPNC )I#S'OQGXY$->ZG0L0/5K>OMOX8E_""/C+"9H! O'/A91
M]\<!7'6PS[ T0.U/9^C#?_,MPH3T<,#U8?#Y608.N)M8,WVM\U\2MV:3T'O^
M22^YV4DBJC!Z%1"P[D?DRO2W^=L]K"7-*?"")%\:GY=\=G7Y(J.J_?B:3>,V
M#Y&I_5A>=-8%R,5B*M#DM.-6^V1QK)A]C!_O%GF?@)!"N=_/1R'"R>@GYZ/)
MJ ]@JJV..S-*'L5F6YY*>OX?ANK4/,KV#6[R/"FT2UY/?TG'&+!!PD!Q3A=7
M_,%U9EXZR]JZ59WL-?DMR9-30SW-(K=TA9/<^4I/HC[V.7) C8**E"=,[31/
M(X%A<6=;:*FC(*PY!<L\<0/%;W,]5:\AQ$?8L3[)4/QF-H_(YP'N,JNCI(?J
M-=%2V2";SEF1^AUGZ1 UOL3]WWSXYC-W[I*XVT>1$"@+6P:=Q\G6E.6)>B.A
M?$B'FOCE_H\0.[VDOFI=F9+&;8';&N1.%WW^GD6!U4-9[2'J[+-3ALR<ZK+_
M:*80YWERPN %-E*U<J\5Z#/@B..293<WLZ<)-F%L"E=2M(,3(ZLZ7CF01,\S
M-RE8W"WX.? K7>_MP#6[W"JO ["1QE5KHJ'YD*C&5#LO!R=\2PO+@8^]A&X-
M?.K K;)= ,![[&= [=+!'@WQ&V:YS9N#T"VW:XKG>6YO.R%/4&ZK?:/^K*:L
M\&HX^*ME)?_H<-!([TH_"5=J(D^L##'MF==H+=\*2L-FNP7#BEN'[;RE=,;<
MO[6:%_)#BQ*OG59Y_%.A2W\HE$&%)U6O,<23/>!*H<[=[Z[_H5!6,JU195\K
M;"L2W+4DA%*RX9N&WBP&[W@S\IX&.SC9=OHU<<MSOG+BK&C\Y[,+_EN5U9[
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MD@S:K1"]NPF>O\8/^W%>R=;?.1=7LI6_6*^B-I0]R!=__EVR'^8*(\LV]B*
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M $'U6R/L2RJ61#642;:7"+B0(D >8%!EA+J:4];,^D9DRO>N25!8I?%_^R_
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M8Z4^%93R3/\IXH<PP4C")/UW8>('SEGB?$G@%YE%0MD"<)Q'PW@$K@!_%XW
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MBEBWP3[7Y5>L5+W&W7W3?<@#1"'09FH >JNL(G')MJ8JW3CG&6L*+#4M2B$
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M9L;9V081U=[BQO<Z]L:2-_B*HI:HGFSRJX@-:JS$.)!4B^J7P,<Z[V=/-4'
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M7]J@?YA*4E?-A3!4 Y+PW!($_C +G.*'A02I+AGO'!4AYV'O2+A@VBWD=_0
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M/ML<UX)^>U$^ K3O.Q9B3L('3/SXX-X2U_,^#;SM&<*:)DYP%RA 4FX-AD0
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M2W_;\OH%G!K=_)%LU?M39:A)H(@V1NL4>Z^[Q1%F?RL$QHUX[\?][9-?VX*
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MW>[<?O;S@;;B-"K0VF),!3Z,0=L35A\@>[7_O(B]O1]6J5?>9Z.\K0]=/%9
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M7<0(18_E#Q0/MPI4 4?8 K(?NA#Z^C;LAR8<9S"$LH)&[Z78@+HM+LP O%6
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MK0')6JYP47<,ZTXY%H3]'*4ZZ2:S&*T4 G-2$Q5;XR'FG25_1Q-1\X$#053
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M'YQ>O*@Q;-QG,"?F)[B[@&,CQ:3TD'V@GQH3T*F_I>?&/V$BY8T&_SUP6X+
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MC'_F ^\#,P@4AG=IGT[Y/RI4+-R4U#_S_ @(KW#,H^[_ ERYO^*F8=K4$'E
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M)UIUX"H5+_,B3MV/B/:5RJU>HG?=O.'W0:WHW/[J"#R ;N&1I:^UMGAE_$7
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M:.#M5:* 0US-QZAW1:3;G>=\&FN<.$O(*PP/+5YQ):2NX0$T6.ZU0Q;<.![
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ME</IN:# '=%?Q"DA2ASGO:O!@U1*E%"1YJF3+!K7S:U>^+O)<)@TG>#*!Y4
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M@*O97^4_$P93_H2A_RYFNXKP;)G6AAFEDPBO9S^IS/EDL0FS6R,+7^5EQ=W
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M??GU"^*K4=?9$F9T8UADNHDEUDN?W?31O8+283(!'R:" [C8^_I1LA>SWO+
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M<,4$DA:6??J*1(+'?L(2WZ44O/_LZSP]!?FM21T2@6_V%S],W"]\-[)V$;:
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M5(=9IP(A-K9N6GMX'Y)Q4QVXLRY,$K=Z#O,6WYD)ZKJP8>WJ\@/O9LI'48?
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M@GS^US)51[P->09(5?#@,N%&<(MG2$7=T:CNYNZIOK"M5RHR:D3MXZ&6KCP
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M<]NGP:PMQX;YIH';%K!ID#=$RZ%?&_Y*L$^J>8 :^7^<_?SGVXY(\<IN'M9
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M1U5!A:&/+9&J%Z4:WF_'('=>?7Q6NF+%>!6H/: 5[VSO\,BLSN<2\<4U\L.
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M<4L)RSV<ORY,\O%6F>"I&F:(+#"*@?HM)2K(_+8;5(/MOX4A(A!)=:W&NM2
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M'CXU'K838,?)28CWYP7\X\*[@I/Q*M$U8A)2W TU5, 5/'S\*P3X?TB-FPW
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M&61^+?C"N%'J<?) J4K2-L<Z9MWFEYF9F='(*I^*E:[D"L-6ESW*:VDR:"E
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M7?0)G>0; L8QIM^%:9'!=26X#KRW<67H_+P:-\$%J]E9JH*<;D.%^]B5@["
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MMNG@WC6@,8((K.2&/4XIY:<<7H'\8 :B75R,2 \AJO_MM"=^S@ZO#[$L,'R
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METY*;#0_SK[?7DDSDEM%V+TW)!;3I"YZX>[<B,FGT!J.LFXVMI(J1<CKXS6
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M+#_]1UCHB62PTR</DS20+>7U;:L7Z'#VFB,\9(@W%9UA00-TK5U_06R;(O.
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MZ5('SSRV>/4FW"L"KU. 3#!I3+,H=#ETR\ARN=34*;M=B\_LX<4!E<4OO<\
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M_]>X=1D2:&[BKH"I<S96W71&9G",0PN\=/M6HX^C?W^L\KK#,OI,4]! 7$U
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MU+*D]O9K&9LAL6F(^Z!?J_EZF?". D0Q;4*L0)#%//-/;F7N5B\;QLU]C10
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M5=? T51P=R]'G,*_<Y'0NQ\!!NMM/:DDO!WY5.AV^=E"A7$[^HKON SG':8
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M>%:9"BQ85^S _VQ&ZP[0P8RVUXL$#"_=(\@)#;E;E#\RS['Q#B!S#S2N87>
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MOW)9+D>.UD(,!N>IS-7;',V5Q^P,T8\T8,SKX9?72UP/8JVVM?;=DB,]2N'
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M(A+PA[NOH64M0E;N=M*/=M*-D-';P;ZG12R#?=5DD,*CG%>\B$Y7X@,4F/R
M  ;>81?ODP/X<>WZ<2")3,FGW0ZNK5 @J_5,\;=SVT&JCOQ'6^G:IZ"&D_C/
M2_+F\N]^\)CIV':22'-^0R6?]'G[AYR#F!^N.EYKECL4]C(N7\>"("6Y2QQ$
MFV<FE "(WQV@=J=/?03*;/;3UB-=9CM_E7GNO&^N/L]_>V7O5*J]O1<;9GQ$
MGQ*8):EOAI2"5<9V<*/,U!= /72R4#BQG$G#W!9BUKM:L8C#XTR!3=WW >OJ
MBU^*07A?FO>=SV,H,,Z,[P X]>U4 IC@X-Y;HJJJUFF(NEA[$=B#46<TJ:]!
M!U3K^UTK6:U1M4R-Q=R<Z7=L9^U"C+3,Q@H>W"_#UM*UO!L>HV/4B?AF@A.^
M9+I84$TZ.DRQS!)AG%BOEJ#PU<6O[%N =.>Z9V_4"58VW?[5UX=["ZL\"]_G
MU]0;XM084]^K]B0#<./;VH]5Z+\&:(HSO_XW!\UWO_XO4$L#!!0    ( +1%
M>EPGX:?$&[(  (O0   8    ;71V82TR,#(U,3(S,7@Q,&LP,3(N:G!GU+L%
M5%S!EC;:> CN#@D>-(([(7CP0.,D 8)TL& --#02W"%  @D0W+UQ=PENP>F&
MX-*-=M!'[IU[[\R=>7/_-VO-O]:K[KU6U^I]JFJ?KVKO;U>=<_OS=A5 JJ:D
MJ@3 P 0 ,.X^@-L%@ ( "Q/SS_>N8-]]<>[AX&!CX]S'P\.]1WB?D)#@/@$!
M$3$Y*1$Q&3$! 2DU*1D%)145%2$)#2TU)2TY)17EGT8PL.ZNP<;!Q\'!IR0B
M(*+\_UQNVP%D]S!$L RQ,%@!F&086&08M]T EKMQXF#\I0#^K6!@WHT1%^\>
M_GV".P48*0 3 PL+$QOKSZCO_O6]^Q^ 389#_O")/"Z%SAL\5A?*IP'QW^^Q
M/:_LH-(=1[(_>_LA$/\^-0TM'3T')Q?W(QXA81%1,7$)A1>*2LHJJFIZK_0-
M@(9&QI96UN]L;.WL7=W</3S!7MY!'X-#0L/"(Q(2/R4EIWS^DIJ5G9.;EU]0
M6%1570.KK:MO:.SLZN[I[>L?&)R8G)J>F?TY-P]'K*W_VMC<VMY!'1V?G)Z=
MHW]?_+$+ X"%\;?R7]I%=F<7)C8V%C;>'[LP,#W_*)!AXSQ\@DLNKX/WQH6"
M]6G /<KG\=\K._#9GNDBJ=Y^&+]/S2X$YT#],>TOEOV?&1;X/[+L[X;]PZYY
M "$6QAUX6&0 6< U)W(SZ(0.(IT[P!F>UQP+(GL',AQXJVVUR9@Z?@OXR-NU
M<H(Y*8LDE[WA+ %;WBB6<MVTL-X"QG#LM7%9KAZ:,]\",JF_W +\XV\!*"%H
M)Q7\\ +#+@.-SW(+H##Y]']5R50V[$H'84%ZI5R/C TI+ZUY-5DR<72NG?Y3
M<[VAD_6AV/8 9]45< U*AR9I/TLQODKUK?W.7(?S-64L>ES+=OA8O0Z-S]0$
MS"=LS5EDS6G(!?'NVE0O'#4M*'07INGD%6GTFL:U_+(> A_4;6\D-'K8Y/W3
M")3_>8C"'6@L!'$IBLMLVKU4QO MTCH Y./S2NX<6%4PX'K=L^[ I/$,?MYM
M089.ZVWEKI@6*M_K+RE9;:B99'_P(^V<;./Q&A=6+#Q7JK5&_'<IF'V^M>AL
M<M;,6Z!L+3_MS<ZEC,E\MKW O"3GX=;>_O1!$DSR%H!^WBQ]"Y#C?W8+P&"[
M!2!L_PG(9A]X2L\H*3JC^\P#:!R2X2=0ZLC5,KGO\,,I1\KF?E1/S%5&RFD1
ME/"&:S?]:<.$WQP*2[&VK:&^._7!9,H^8<3FKZ6VP/X&/,9WC3:?@/FC/V:;
M0 ?G;=;KI][O#]_%2$#D@XOWIB@@^[G(T@:? <&:&J!/7EFJ=-T-:3D)=(S@
MY2V@7>5NG*FR\/O(\VM S>@5=NPM(+R<$9V$4N_QUL@K=<]4QZ4POQFHCBZ=
M/L<.<FN0/N94KITW<UTSKW1?L\ VVDKHN$XJ4+;FS/Y<]W7Q26?A?B>,VYHV
MO$?5>%BT=08XJY52J/_LBD-\D%QS.[?VW&/23!>VDO1ESP(9#/:Y\3>VN<%4
MO@5TW\WR>\#0MBV</.@J._1*PRN]>"V6=HN%XL27YVA7/6%!O]4V:_Q[>-3X
M/&1E&]>R]S EJ:^B9*$\LI4S4K]AUD"=!:W(?R4G1)'_FVN?L.'^NV-19T^6
MIHBP7^ZY-M0PH/%5:>VYUM"/!ALP6/R1DFK/W%9-E49=V8#0Y6[E[LI_/QI'
M'7/Y$\[_NPL-CP,$(LH/.NU_$/XP@/Y45VR*IV#Q"B!QO\EAM8T$5L.^9?R&
M ^^J47G[9A_(<L2+#KJ^7+G&W\V&W0)B#:&++(,!;&S_ NG206ZZT'^RE>4_
MWHJ97Y08_U=4IIU8=FDD2 )@^VK]14OS1NI"1@S^UKK*+#JFT$ _X9\@TFT#
M[Z\TM9YU]#8+P=/#Y4DX_2]PW\6F!R5.QD\T/8+SZN?LRIMQ.4F7>4V[H+VI
M9IA+2CG+RFO+5KXLW@+^E8<81DLB-KZMJ>^"?,Q$]6$Q1YSU-8V-M=VB]R3B
MVK\RH]_3R_"!9W60+>FQ;[*4\6=@Q2<5L(1U"DK% $XE)B2>&C5Q7>TK]E*N
ME8OMTNYC0HFNYE?6PU0+93/J,SM+!XU,7/\)\S9D"!CZEQN T7=W V:I'+BZ
M60A%JN9;KD/J<O/2^'M:OS-B+AO::*LHA9$S@4= 0VZCT<O<S"QCI_HHC\@R
M>V#B\P2T/0&?:?1PB&DQ^3W&(][:9*!!R]*CGER'\EGS>8=RX1(OV/$\+9#*
MF#S2TP/2Q)ER#&JL$WSFES_V+R8]^##\AA7\1<IZ35(22F/;RE(S#LEVPLVV
M+YD\"'N"48<U&X.Q:YZ+'.VAD1%",H>7F9M$FJ3MNO#%!;1+1<5:1L66NLZV
M3W5-1-L)3=;Y%>VZ-7HTS 4/<R-VATBP)X'+\T=#27L+QN=JUQ*I+/]R ;KL
MT4+_E9+<_X[*C.Q<UBT@V/,,RB$SVC9T5'O5!+FR9/Z\QIPT#V2Z!3REN:Z]
M!2Q$ *;_R<7'_G,, 'V( '3]_U*)!#$:708A@C_Q>H/M:9PT_4-$)'[03TM$
M:3ZW)=1X= R.#L@$S?293)5(R6>I8K7\&%N(M'-@4E(:(QG)SR_U4"!XI'M6
MINIDM5RVL* U,KOE!7LR'@Q]G?U(&%13$_O,SL+DQ(?+82E^YE\&\U\2)&$R
M'.#CKGW$/N[YR]KJY'<BQH1G#<=90-[CT7HJRT PHG&)I><"MM)+L$)B^AE1
M&:D0<KFWBCGP3!76ZC)E,/V8(O]'0Z*+YK:T?JE[78:&U(BW>*G$(/EZ@IZ=
M8DW)09H&")8\,NI G/\O/&B9"4+_%A#%ET=NFY+Z+C1KP7C U:MHAW<#'JK2
MZ4A+NPY[?_44Q;\9)86?M2L17/?S4-"AN^H%+I[>,<G;Q\HS%<GT.IG%2T)+
M==-.;4M'NXT2WZ,^H@0)!J<26HN5:EI:3QN!,[/50O_4;?8_#VLQJX%$[G\$
M=<H-Z2C)'97\2UMB?]I:R/)_? OXEQW^9Z4<)QRPC]W=#^HODS>^?^G0(_46
MX-+Z"6- '80S&WC"X)6E^MK5JI2AP/K-I]6@*1^#C/\$KR)T_17R_/+,XH(<
MJ/^_M*+_EU2 T1"#Z2LGN(:)1H8FBNJCA%]Q84>^O(- *MWJ<CZ?!71X,/VQ
MQ*P! S%*6/JK5>)QV]:7CNB>$BI!!^X&CI;2_/12YL3_/DS.INW("*"T@J_,
M\K=H+K[59FT^;YVR3I=\0NJEG<$7/-".14>W4=]"LS8:?BA#L;*L>;;9\^YH
MF4&753M$/$ZEM+J5C/VJ>"Q$SSSGU>JDYI*%P82/0UY^$E"F<RPMW^"IKIJQ
MD>^GG)GHXKGMI<7ST7_)8E7]>,'9>EJAR/PPH6&\2R?5A+.CBZ,Y^H>L:[1#
M L\FZ4IO 9A7^BC.<KB#[RV@>A5ED)]O;S%W-BMA<U!ZT,&HIBKVR@+QX(2R
MR%I_N^L+[/QW_<&$2=E:=L8;T*MU-1,+T,J2'BSQP]P9[*1E5/-?SO$,-#_B
MFT(OE$3HVD0_X9'@AM>+$/;Y-KZ2>BQDV5'SX%3N\Y)"+7!MZ]I\%S"&)XIW
M$FV5:!YM^G^R>KJW_V<K(_>N[6=W'?RE<>*[QFNW,@EE_]6]K>/.)%;O-B<9
M>XN\*63WYLQ@# ?Q\O+GO ZJ6 V*X2[-H+@%]-<5WP)F<]HN,+(2Z4D(H?VP
MG#]UBPM J=H0LN\JTEOYVEOQ;H'=G\I[D!7!#?BK'&6$L]QE:"PQ)[$ -.>*
MUEW/$3>#9KJ[.M-!,%APZN-8:/)'.J9O_OK]C.3@3 (_;B1UF]-:,LKI8WG)
MPY:&&FK/&>]4\1!WO<\_GWXHD3"0J4,F=LMP(#5JTTIV7>PO/J7^,(X>;R#D
MGWDP9_O67,74&>.:%Z\72MG*"1% VZVU*'?3&\2Z%MJZ+&CD@0R*=BW]JOH+
M.N "9DS/^I>"XN2+GX'/$<1!\'*JW;IE#B1SFU/VUFS*KEV6R0C'TSX*(9_P
M;_[/AX)Z?>^5J]%>('_!RAF,YBPTDJYBF?/T0@KWQ<OMEG<.EL\.%LQN/'UJ
M/>@]NW97B" ::>9CZ[6A\E.KKZ9J-@;?OF)AK_1_\I61K,\[?0%^C4!?]LP/
M+2DS)</>X'PUUY%Y;TV6]/GL,#[(7'\U(]9/H&'V"I\XOQ#-VWUVPQ7/FJB%
M'/AL3\V0:?>R+,\((UH$/K 0%6&&=98VE3DCG/;MO=WD=J7Q#I WYR<;P;Z$
M.J@'%H(_8)E2+]#DI_\[%A #XHHJ.74RUV?XS9GZ>ZM5J7*H E6EKLC%7I[E
M(+2_?K#4U/1--+"5%!VI,GWUM/%3XTL#&8:Z^I!E'P "<?Y#HZVE_[?RAZ<?
M0!5H'>3O*_S5)J:G%[R\W]3F?KE*/>I88GO<19:.];91%D^D=IEVTJ([P\;,
M!6[0K*[8K?IH/>OH XVD:[I+^FD/NO@L' G]*%R\2[ MS!6KD2SFSJ\TJY$.
MXI=><9Q.=]<M4+$^[(5_-4@ZOH_^N"9IM. @TG2U?F 9/.C\4_71I.:V<'%K
MM*+??3+UR29K>62&]MV<@G;,?%@T477/!^'I3UG]KOUAEF-#T,=U_IFNCVH$
M[70&F1;"KB*"@B07T#%,*N0FD6)!V%$NYR%K?5K>NU=X*)\;"JT(<VEDQIGU
M<(X?0_*][,:$>46C(*62]6JB;(Y6;9FCZ*X@T]XVU*0Q\B -98Z_]_[7;/,S
M7P>'G(7,URFJX/A(Z:OU1+8*A_K+?-I2R]2W;[_JC1_FIT$+HXZD*'_1J0F@
MQNTO.7ZSV^W*$DO9(#3>S0R]FJ[9+2=9L-\NZH&P6K>]4EJ, P!,L7H/ZDLN
M,X+H3^9;>E/KDGGA!-%NH-&NZQ(1!5J7<X]D%A]AFI ;B5T_]DD9R@ZBI$\2
MY^%.!P[N/A[$EC 3X3CS][^K[L53"B#\T",@A4X+)J=F>91@3ZI2-OPRE@3M
MJ30^^2K05^EIBB?OAEKLHUA9=FBCI )1-U$?(."%J]0+JFRKTCFGE2G7@<<P
MAD^_TYP\.9?:DF\!0^L^TE3'HYU.L7[LZ$C$,*57.EG#I+!A^H89C5;;2'%.
MNW8SN4;#V:#*/).._/.UH" +!6""3X<BI3;&OPF>@.RZ 0KO\KSM@F)6&70+
M8*ZX!=3+)KD&W2@ZD4+;?&X!WZ7=/-I0NR270;^UV=7OKGG\=V_2'-E["R"%
M (LA:G>8X[5'YB[84Z=^V/$NJRSN8Q\W[F.K4J1_$96[_K9LL0(#V/  *+CF
M%,E"?L-R)3O%,7/20CYI43NSY]9D9G@H8;U'0\[J=6..8J5<5. 5U>]GU\:K
M J\I9G0O$\_4--G$B!\Z<-1%YUYF5L7AGY7QR]#NV)6 .??,C'L;.6-%OLD.
M6CR54@M(4ND24'ZP%H& 6*+T$#3^,O3HIAZ@]WD Y(5;L<KR,A'SLDN5P1=2
M.M5OK1JY];3BAT ( RJEAPOQ+A(>K:>+#(TJA:F;%-Z,KYXE#E<\+JJPF\Z)
M>__!X]'@U<]=,[=*?=N^!!(-*)4-FMD7@L/XXCI7L>P;--ET""4 QEOMK8.W
MT<SM/(-:;YT]5N0#QMM6O:30$:C'^>Z4(.7^V^>DM-1SU2"#.O$^V'[#@=>@
MNB56&];8G&J21)[)1L@4.RC?T>.5'W0+L+N&ZH[#\,N^3\!\E0[58<T3^T(]
MUB+GYWH#V,9NOUT;.A0]9!]A6$DZ8Y3GNGT^?#C)3Z.3RALM_T:Q/I7R$<-
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MF>?MF"]KL\EKOX@/.=O?>P\#3G*9$#0E+7U^^[5L]GUV0 R^+H;PV#']A,,
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MSG6Y]P/O,LI'&\].T<4 2B=%4+"MN^.Q+#!N/?G]B\.O1IK*O1@E.GW+='Q
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MGG3 *#*EY_-IR$QILW+V$IA7=SQ!O)QU.C>J_2%D+TF *LJQ[1%>G#SM T_
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M&,><A4C.6X!N\Y2 H]03.U?IV>YZX;I4_?!4#6&#QZ8)'UZ]:548-1<O(<C
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M<1>SKQMHP[4BME'EOMZOO=),2!9NDRI*Q4Y9?@@%4D))EGYFM/="K-O&%S;
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M53U##9^(VDK>'C<D1:8,;&Z3+%>QQ$<Z%DQF.5%T:Y(/NXDM?BJZ\IRG<.1
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M++85FHD70$/'((J^6 KUNATKA[&%>(Y+VB*S9_P&8OX(+> T-,YE ]5(@^*
M&(;]H!R-MQRR\5>FG5G\!=0X.7H*11$J1M!XF7\4D_WT2!>6./P/P0^BTL?9
M,#'<,!L&<>_L"\!A*Y05FMP"(BEH^JCTHL"8 /4W1!*1@ZB-6VJ%VEO\XF*>
M8O+5#,4,/(";#@,F%!<F)SK_EPBA*^LGA.#+J_%/N0Q^\GK^F<O .VX60IA2
MDG6X9;@S:X/)6_R+@';TPDD_!VB D EM?> .J;4!3M+T #M(\:9!9EYRD?\.
M?_ZC]EC<#?7U.[7X#3_XZ7Q#?H S0]5W0^KM.:15]*RB&9!B;"RF,L JJ&^O
M9;UQ,QQP!7\(S.Q!4B[@WP1TX1:<U-6A&QR "3U4W#!R!%J4SCH4=1P<'*H0
MI@E PD8WRJ#4^-V%5L8J.H07U[:S84]LAW ,[B@67\R27"1NY!PG8K*'#8OQ
M*_CO[P,TD]BP<CQ8BK -8L/N1*6H.R:'R2P$-G+2%:BA!T.8=R'#,PT]P.MF
ME/A%X#YB8?57Y#0D/C9FE##&2RY&OAH<@#/WOOSPBY[?_;N>;X[Z)ZM@.7Y2
M7>,?%#W.$QC,1"[88"$1Q/R@5KO>!D%KYOU6DSDY)M\V\.PR'JS&$YIE2%,X
M%V#P,;!@6XA;EL""]A?JHMQ8'Y C!*8NN(0#H\XPB9BV^;XUH#X;5H.>ATSJ
M! 7S180E&(+LWPU*TR1'%U'#&(-.Z*FC+GI5H5X1<J29CYN<&1N^L6&'46A%
M.@^##VC<#&F=#Q$MBP*+%IH@!(F=Y;XNN1;YZ32"(:T02PBP\[_]_ZNL?U%9
M'C]4UEZ,?9+?*>170(7E3EIA/NJU9?E AOM5&/,AL@MGR4FGOFOY!;16<X")
M75CIAU@1%+*5+O8+M:'^C=JH_]^IS0@C9!)5F 0ML6A$-7IY2R%G$:(>NOI7
M4S!]!K"_^*Q0]^,R6/!7GY0YS2*IT+-&T U8KD]I80OT)40D"L*YG$CC?<CG
MF(.8:A<V[+MRQ/,R+P.6T/Q@5,<%2A7]M5*A:N6;P.(T,!!UL*@?:?8KU7DD
M34V#ZM=;5X[]?^9@^O,M8D8[_J#0GW'VD'VU4H1DU1>8.%FA5-ZT_ Q:]@+#
M* 97$1@D@]D(+NHQ]1:U!3A^,QT:XGG*J]0W9F:L^/I*Z2O)8?NV^U<S.#,2
M.(1B;(R"=/@DH@##3(B*PLV($.A\^ 2P$KFP@QH'?K1FP[1D?71F(66X9WAX
MGK$>JK^ %GP$U&;#EBF YO1M-FQ.I@T=;?5LRCE5!7=6IX$C1HC7.)*^'&U/
M (1R/Q1#3V(?Z@)U&CPUBP(KT#23)M1_?3MR;)[1#$R_7O8R6#E-/S+6NS<9
MMU?U,<<CU -N !I6LV$@%EC6PNABE#ET:P<W&T:'8&6/<<4N[/@J<!:N2:@&
M-DD?^&E;2/?7\$[@;^&=)MZM48__KI P_02J#)SYPODAI!E!",*>V8[;D/[Z
M4'+8_B !QB..#X4->ZH&:=X/2RN+9Y@JF&\HJA2"^6(6PPK!X.(OYJ1 &N86
MG*;,AO$!%9!^3VG''76@^"[CH/L"R A&%]1Y-9G%8)PVL65%%W@(GJ99=/:6
M4EBFAEH"2]*/!>APCFKB^5TUT<BH5Y#>@-17W^_JZT@-<@ZU# F:^0$VS(N&
M;%VA0U.FJ)[_O_' J"Q?";L<"G/5Q=P'!G,\E_&XW.SGA2N'SU77= 5EGA,:
M;BP>7XV=^WK <<F<.T&F.-97+[17^%I 9/B&*_ZA4B;/T#V"@QU[N8AS8=5M
MR=8L.U[FH+<\T (-'&OO]P(Y#B%N@B)+@@VKWN$'6>-DM]=002"H /SEV@(^
MSMWX%/3&L19U1QK9,%4"2,-,,$#A-8/UK&V)<)")@)CICZLLZ I8FBB6@![O
MVHZOF;/ -70(;[/GV@L;G!IUHB]&44K*MJ$, ,=)PB(;!OT(B&,Z-.G,1)!<
M3JPA+H>_\N ]!!80<04K,PS2="6:6]8= :?JZ+<[)UP,WN;B%,3W0$K*U<=&
M9]12R$>^IC-"J.S8<>'.=^D:S13U&K"O S<.XD$V3([:QBI* UI8&!:((F/J
MD51M"H:V\&@!HM 5<J#?$#-C$N@LU_E.H"4;P*Y4)H:$M$864N9I;!@D/;@F
M:")^Z24$FG@KCH!^KYD0;0]R@]0*6@BW'_E[)3O^)W6,(7J:EF]1KPZUW =%
M(?V]SMZ3'O'QC$W)BXVVNTP,7R).K'-!%LY7&H3@MF"Y==Y3'3Z6!D2\2S0>
MV.9R*TBI#AXS35B-#3AZ64]@R7S:%_5Z2J7MHG\!Q,@+_JM94M\,&?!XROF#
M#619U "J &)!%3/K@_K$AJU9D6$XGX-&PT QF+AAG>6!1#8,N8Q;H0%U.!YL
ML^"*'4,5U9_R^WWPWV^3_M?;L$:L6*2M7'#2$2H74=;!@N24D#X5YW+V1FFB
MKO>&)"WA*@HL0*#3[SPK#N2?2!(25+):U^XXOMCF*>78\3*R8.$H9EE'4=;;
MN2AZ^GW.'19&SX+._>^M02KG@2 )4D(/U)1!*G)8A[D7%\*&4?9-XE:JV# 1
M$JY@$I!A(C^/T&>.'YEMF:TX#@*SP/P"&Q:!Z//Q9+)A$(4E0#9'A!H%\J,@
MK4+GIQ 8@YSO2<D@ E+X:6^A7W Q[4 \YRFS88?^7I4Y9\^1! ]!Y<Y_A-86
MMST>+[&NW:9L-_K+X4)7\1Q"MPF.8_=]+XZ]U]!W-SD^O'MO^L&T@YP\<[X_
M\LR]SS;DY)F;_Y%GSL2,X[+]8S/>[](_;8!U(4GG$30A56'(A..1=#'W!?<
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M1I+EFH5,0/X*Q$C -<P9,ZU43$\;C01QTFA7=2+K+C"B099C!=5#Q(V"[NT
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MLNH020N[6NBFS@0'Q!N6].EYM].6B+9OV,1[:T&(M%%,?SE/@DIZ8W\YO3*
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MPVC1P]$J"26(@72!Q=, !NYYBO@4 )W1 XHJ@5.O22EW\9M6FN5N-.*1.+U
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M_[K:_YSP_Y*Q9Y"!,3;IZL[PE;V&H80^E:/O\:-O?K!XVHT.A*L(LK@E]35
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MG6P?+;,:+;O=#$8CCL*-3E/M[(F>QZ*VT+H<73K3%H#!!*CY=05+V5BGOUB
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MWN8F;CZ#"4!FEAMP.+(UKT7"G7?-/-37Z: 8U<5241V9-V90 ^X>O) VU,C
MM$5G@D8:4]L_?W[]N$M*E1A)(I*,8%_P"R+Q+"QBYTP-B5N)JY#"7ZTW'/0F
M9SXQ\D>8&_!QO0M8NM8T^J;+::)?'[-P==M>8\W#A_L%13RTW]F.K,[L\%/#
MD98'K?'GSQ3FW5*RW72&B_GU89**GW[U1+%6?OG7>Q#_OTV/?5N*1M\G:,L
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M3(P/GXN)9$3D2<RHR,NZ")WI*@Y'82'W.W)O^GO(RXM#2:3[_$5"8;;@L&
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M 8$H8<%%/L.;[#RI8=98_M(WQ/(._V*H"%(]WD6#!R0Z>BPQ-^H(H@J#1Q2
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M HMA3_"0@RN3[IS4[_42*Q*W@IU?&^H(=4Z?Y(<Z0[MO&-D_@)_YBDGG4;+
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M D 62I+O?80X<P8D>11]F]M.#]8Y\C+\6B+;T76Y=S3WSO/<<3?:N$X5IU/
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M3G >NN>&*T;_W#8,\PSXU(TCRGZY7:GZ*D/C^7Q( E;Z$>=METUW)1M,.(:
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M@U:B9CB$8S\=Q?T5D+SXI>DSFM\MMR_CB$H\BE#'S1&DU$-S!KH-U38<DXV
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MSA94MLD#:<8A]A'<TE'.IQC\G[()=^A=LHPCR07?:42V8V8Y(E$'0A/?1&1
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M2ZGKR5R7;J/%=][\@V":XY]O1MOS%]"JGZ;?DJ^\5>+U>;OF.^R4\N)I,4[
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M',5R=$Y_5U@M%")6%!:BLR#0,29;E3<?Z4_7(@L +P#$'!;6I^U 6#.K)OG
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MA.63F3#^4B*7SO62X,(]$N&P8*O5[80)E;JDYB;\3OY\B$)$<L&ZO<< C[.
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M51G9MO\%PH;WGXMGO(2Y <[AM_F=AJ$- R._ARUS*Q*K))XA!MK!^O:!?H(
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M/VQHR,<Z6-!2?Y2R"0^<,?T1L"5YIZ6-T\P/,(TUW:FS^5T.YHJ13<P3*PT
MH0>'WUX%)I/YNT%V,2#:/F_';VUZ?'3$QL&C*VQ)@I,6XXGX$2IMP"%;?8:/
MZ/(#X69RY/AGOFO19G0JNG791C]Y&V$%8];=@?5,5/593*&>%\BOX0 2'TMQ
M)J3C3'-<9VGSL&BSO)GETF24/9]8"H-BW9X)_9#!!YO[']$<M^ UDD+6,&/M
M*&0VN5A";D&]L/BP/\@N_J:"H-:>E_DJSL=5E<W4YILX1?TH_5A.=128J$5/
M-G*3H9]%B&+$=I[:!WL*.B9)C;R^_%6XN7OD4CYP91+9_^*G$^]NH %+-F$$
MUB]9P3XC?=Q,$YC6,SGPE%4+Y>_I0#GNWA=6K(?NORF&&*HFY!GL>.& .QOO
MQ4YOMB.A*FJ*TG',LO1Q[W?V.Z[GE9,7(@3&L225?$'$SCXPQ(+K$-L%GY<E
MRW+C::/GP1P"DT0UE;X<:T@;WV316].([/[SV<W_SB!;TQ2SU!3?C5)(2,TW
M50>652T+?Y,;)U0)%^Y,A^9WD@6(3#PAB^*=0ES_HJ\"K)4^TI._U0BYPYYI
MW<LN??C9K5^5:NL5O=%:;7 7<>#^T* #!W;>:.PI7I'L2!)6ASJK'-_GU4^6
M/JOP*9-B&";$=_<$IS; "E>G7H$XI*DT#Q7Q68K9-]090GX!B+:(K?:@AJM
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M($-D-WJP.M'2/E%*&D<@;!VM-,D<.MGH )<#_ZK^_[2L(<"5^4#K48)%].%
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MZ>V_\FHAVOD_4%[O:_WM^S17\;O3T(S3I]/)VZWTUC3SO@ D[K+CEO:0\R,
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MG"'VI!FTP:6K;PT!>JWU\RJ$EH[MJ7T$NKYM:,!;;6>-_H!-IM6)^5:^*6'
MGV6N9(<FY*9EZV\]/F*[$*?:$Z/QQ]9D:>$LY5A->)@3VPJ_=UC&IMWYY;WA
M1%E"($$C'?6[)IXA]!RNC,?7X.7 T\+V]O9SW/X;N ?GAF"TV'/'^7(IC?J_
MQ !Q'<2E-C 9=U78)(3K>OSH9Z:. !PZ>&3B85XV/@+B#%&01X#)2-8C()N\
MQ9KF0N&<^"P145>V,N^.,2KKOY8S60,5&WA81 L/T17AHD:]24\Z,- ZG$7B
MG77!<(A4D7R5B200+QX%T<E<L\+G$HA4LUFO]M'] R(?BIK&#%[*6YPSG2UV
M-B7.[=;4%I'CV8K#*4UG5+A\J&J&6I6&8X."_AL<[H@HCSVMC1AS*9=ONYUO
M?V\2'.BS\3:<JZ::YQKT:D4]3*4+5IP4=%+<BZW+O3[3#D5 XE^6TWVK538.
M,.PTXO.=2U9PSS]H6R#._6'-G^B,M?$FE7WJ&;A\X^*\[*Z5()WYN9?]E;7W
M+-%L2?  RT!PUT38(Z N&;Q2EFY1>/=DYASAO"8>O/(%Y,Z&Z"ZQ_Y0KY+ "
M\:1RYV]C(]]86TZSRE[>#V5KMN>)6(MP]%Z,(F]9%B2TG!X/R,$)^AHMQ6I+
M+]]<>I1>("T9DD[+GKO?FZ JS^:1^^M##I\\DUCN\Q,=F%F+D'T(;3=#%XF)
M:B';7QG4.I+B1"FV-+_7JZ_5.JZMVJ61Y?<=X0REBE\]8U>&3&YO@G1K+$XM
M33I"YM55?"2(U_B56LGO2S-C0J*H+&3,!RF?[(V>ZEXEHYHNYZ:VXGIU10L_
M:P3UQ;P+J#\RC5;. YE7W]=8R#\"""VOC]BZ66%H.+9E>U._8H\AR3"%_-$J
MD_HP[VLGNJ2#FI_=<D89?I@/;ZW]L,[]7EF_WL/1+:V]'+;'R(RLE9WO9R5Y
MDXXE> 7-@5EP1-TD=F/Q^J%D,[Y4)2S(3CP+N)*Z0H\),DT/R#-D82T*5DLU
M6&^\7Q*S$%/N(?TRXE*H'AZHDX]HU+0'Y3>ZB2XDCQ3F_?'_V4^WWK!"<B=]
MLO(CL&'VPLN'&T%VVGQXASJ(0#\P8GF8A%%CAKROF+RC65=USEY<:#22M*O7
MM%W$6,P\/R^S87]>QFS-I"-6ZR;J?1#BX,&+/55$S]2SO Y,,:AN0:PH1G L
M*'22%T3ZBNV[Z1+_;H2,5_^\*Y&@#"3 B0OHW3 "NG]?T%/&MRK_$B284QM)
MA:_RZ8>4=_ MG>5";Q!OFEX7*%ETP<K9JMY_7SM,BI,+^GSSV[FH*,L>'#]4
MLZI/<WU&EDM"+=C7MX73,-_T>:Q*9[O!5TU8&CAF36YMC?DZSVU-Y$O*EA>]
MVTRM5LN5,#,3<4"A\5C$Q.QP1G'@VUTK*_QW/\0D)WRY=5&2ETE(DL3\+Y<W
M+4.Z-B'T*IHJ:R(CJ5'*5,"#-F<C&M]Q\>?GL,#&[;2-)B"\J:DIS9R=OBJ)
M?00_R2T:C09$>3-S48> 6?D4BE:BG _YCIME/!Q!]0P#\J\ETD:XT(YG6N.(
M?KGW?2T)C)PN?=!U%7\_4%5OIAVA]$*P.'OQ.A/B\QZ^S**<WCOU6^NO/ <\
M JR4B;T54 %XH25Z>T66EZ>RN@LD,L\D>NE'3Z$%_6U0"J*@HL",JJ*&JVLE
M^Z"1\F.B0!@;HKBVY($2&[W%6Z/0VWJJAF;!>N!R?V*81*DQ3CK2UR>;@_=W
MG\<M2EQ)2-WHU8.H^^1?<")S32$5D73%B[0H#+SEL2)[\D:+F:OUS[&F[VMW
MX<^H<-=U**6BY;+U@;2>941$JWR%Q=,?#KUTGN?0K(YO":_Q(#[J"0E[SJ>'
M.^()KJ$%_H,I$47J=O*:59LS^[/ST-ZC6_:1FQ65X.':/^_!PJ"W?:-YROJ)
MG:$YY+2]VQQ_=BK@Z9X<U@? ;:#D_'"[B_BW#DWW,(+B*\N_^JGKX-_JNK1*
MFS\:IC\NVRLTPT[EVHG2S*HJ?V$]V9<RKP@8U2,EVC30?P 0GVM?3R["%^6>
M.BG;:7?3ENF*1% 5U,H0F_P5R>(+T =9MY9'@ &;WWD^\T7N;?@YE/Z^^!&P
M&0Q<N9B8?03(FT!UE>MA\@#7_UOKJ#ENU;W%&Y"C/UXK>,$5WN;]X3!"?-$:
MTHB(+?GA:QH5_[=FX%]PD/D.Z](WWP0E8H;<$?F^WM8;9@J7L]:1EAL1K1?Q
MJV;93[.0F+B3L:Y=J$VQ*M9C"7W*7\[:1^IB\X%6)-UG;X:<+R//ZL#8U-36
MW"2SL+8NT#0$?<H6G7)SMD2!HO^C2JI'C@]L]4J,FZQSE"!ID"M+=;)H(#9V
M5F.93:<;,CV:T2R*Y%X+JD+Z]VI43&WJ'']#>PIQR4%$K7WZS6 IK"1D"[5
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M?]%#)?,'/>+ E>NWC1GWOUQ@]P)P%<S*_R:'H#+*C2PCXI8<UPPDXA=(_(=
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MV>:U7F*=,7GK(;'F[ARIJ-=LF?N,/4,GR.*VC6,;^#.J5W7<F](T=GF^U*Z
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M@Y+$)63I:P^Y^6\.RCB2WW>1KTQ9<\-.\X)*7L?7B06EFP85O5Z<J+UZ! 3
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MJAH48^Y7'5Y01^3Q@Z!NX&D(\JIA*16'6N%R$ D-KH8%879>-5[^L8#N:]T
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MS.3/KA89M)E2+K"#!/?2=H /4QA8/ORD4'1CMOX8&ZGIHBN_%Q:K+4MTEE/
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MA]0\V?T8H%FX: MAA9,L*@@CWSWN\C6_>4,%[-!.8'.;7Q[D2N3+^87MYSW
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MP)US[4Z*%$/#&I>CUDBOZN(!Z=#++74%JBR7;H>DR,?4\&!\\A[6._G5+BM
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M>&9&9^ %WN33(2Q1R%8K>98'/4GJ;RRO8EZ0OA)=##N-GCS1#CLZ9R0]R&B
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M\8J\[TW_)TOU*.CXY\O)6N23%08TX/-.-AH0D@2":8"^.ZX?7Q/9@A'4E&@
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M@*)0V#CJ02,O2GLN>S__1.4FT%FM#=R%Z-CT/3JRX!_A32IYML/.NJ8;#'P
MK__I*/%HFS.JHR;RFRN(>*,U-)Q31U=&I'GUA;WGUJ=3S,P%8L27Z& *]+O*
M9Q6%W ,A(^60XK68/Q;6;8)NSDHP>(P^$ =^1'ME><E[!N1! SXZ9H/&(:
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M_.)MS1&5"3%W+-V,S S8KG2*86W91\J -P(-:+[7@F1VWZY%.2/2=V\4CT^
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MADV ]7J@N%ZP-'/G1WD*_-16S7''O=-D,3KO44# "%''C?90B9&A.$)6/#,
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M)K:8_"_!PU.%P7R=7.N*Q#BVQJ9?R?@[:R6FEGY.*4G4N)V*UXWP 8.I  !
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MSN=0OB?.^<2#$VCH1\SJA<\=Z>=YS]Y.M__NF[0R,E*]U>H/\B'Q2X&AF<J
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M?*WO] @Z7Y\G?E0A#=)G,1#'HY\(&M+U'C+P5I\:2%&P+.3S^(1JA'JAK7#
MW&\WC/Q:$4M.U=1(;X[P1FP>C1'WFZ.N,NNP3;2=F&_TH*_4)^CJ73,E \RK
M@*"G]67<43I 4-90^NP(5ATI,[,,7U_+H=341%/T-'<*OJ4X1:1.&<D0.'JV
M< _8NQ[.1^GV1-)6<BX,:7 GP=O"\-:4&\JA%R.R!#4;W912O@GO?2A!WR^C
M!82)\U'V>9L_K\<B\ &=X53,W.H$G@P_)8"Q@W.='AV)<5!,?!">!@6/,!6C
MIATWA-';"@O1_J<G'2&'#E_\ \7B-J7QWO"[HW#%TL0U%O17C73Z=**3;-E
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M2'-'5(&(5O<5,9<;G=B[Q"\DW(KE[?1Z8T@>\=?NP:0W&1B9F%EX[_+=N_]
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M\F[E]_,J'. 2!<0!6&'=&?SSV/X\S"CR>MWHQ8EVWU4A#A"VA&;' 93)='"
M5EH< -7PCYU:&>SS+N_&'P,[,2&[4S+<IYE85I]5GRLZ02 6<[VL9^M_V 5C
MDAN_EP$<P@&HCJA@^GOQ\^"_$Y3WMVUV4;8-.:$<]%6HF6YA8H@+5OU+^;17
MIIPT0M.6[$&OP#8K'<\M)J)'/-39/<D#7[L?KO^U.4O/I,NTZNXAYN%AV^'%
M/5/H%3H'!X@=PP$H&I$RV"B&ZT]!?#C FM=Y+ (<SH$WB6%%#-MUU& ?C*TC
MI[K<1N:OAA@?GKTKH#YW4V<3=4[+@FOO?2_?-_($O6UAJT>?^<+WE70GG3'$
M#@4UK4)?6(OFN]]5TZHHS/VHMXNE&HQ)XN?<P\AENOOY02VTY"N-*H":?Z"-
M06ZD=Z]R"QIV52\W/X>6Y@N>G6\(R]X_8&!U[?I&**+Y@XGG?CM]/\88&9OS
M3O[VFP;Z]\G##O:O9\\$6)0:>#R2 .S&I\5Q9N')%<D8V::F?DC#-XO\H"8<
MH-,%0XD#Y(86X0 KD3@ >HD3N="*W[KUQ0$'.$- L5*@A ;0>Z+BU?O5FH%
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MXHWHUKQ$)=1.) YUP!,W+^/#\S;NJ.+K:X,?^>NKJ&[.N;K P+.B#,;I'1Q
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M_5G?T7P]%YQ=4'(32'2G7XQ?6;1OZ]Z9&_^#_O+YAVTOJ<ACI+UA;1I723A
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M7V.9B1,HAY(#(K^^%E50(O7\31!WN6._DZUZ4T]U(TBP]F#THHM<_NFCW\?
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MDF^ L7]9/FC]=9.,!=H9<4AF,6NZ:\DP715=JA UUPDMTL)?3'C")6E#V"=
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M+.P0PXGB[/)[6&3UJG#%U+(O:=[!:=B1>L2-VM9V+E@T.4&$2G)+G@FM<ZD
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M,JJU#G3*P0-LY#&HC$NN%G&VB2XMV*[2ELCV=]UG".S?_Y<$6VZ-KF&4AG5
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MO^,43^22;ZBOUUV=:%LW4_E^]L4;/$;3,C%).UF^?-;92N62[;E]5RV[W>?
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MU_K1DC4EZ; <1MWK\J6Z8D(^+=\C>A]D=G81K$WY(7#4IS9(YWO#X!J CP-
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M[B%!%9B4CP5<F5!(58HPH58_/]@8?.;@]Z*T@]AU'ZT#0CBT9.[U"\KZ[MK
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MPC3L1<M%']A]$;KBV>="\LGLE3ETM0D.P<9+V5<\1N8^-ILI^UTTUWN^F2H
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MGH&5=Z\A)I+-REY9<Q%XMP]GEJXZ7%DT+HX/>997@M,*L7_F;:K19243[9O
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MY]EW/4B=<V'3V^IFTXWX#4>4]PF*A^MMC8J+L_<SW0,,[@''3R^JQIL2G2[
M2!C8[?EM$/?DQH#DYO;@A:2T67+VI2G\71BY+%E_N'F=T^?S]M$MMM0_6]A
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MFINRX6X7DLEU5?#S9N"6S]*_X0C_0^X0'=AF>NJ$0J)9U6T490/_!/T_X7#
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M0=R(63%UE4VN_&EB3&[5C&KF*$KQAIE5H&378>\=W!16/H3@QMR^E4?I_'O
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M14Z./TG6;-S21E/$L<<S^B0"'E[7]P9.87^\E3!\3U[F1E;!4:J>/_/)(I$
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MU;K-M[ XGLP"A-,WM3$ZPWW#E^70#QG])7:O)D=KI#'-!2F36-X!O=G=Z:(
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M0_, )J4EK22[ND($F%?1U(7.@S5QDL\,:DR,):9MN)FJ>87WABD8ISH3D?>
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M\XZ3[GMPB@"-,,&EU^OI/22)+N3P'G9*M]\@+I;@VSUD@8"3_-QU_%>X*/%
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MV,0Q.&[(-*Z^&C?E&V$?]5^N$;V.\<AC0&PO;2>[,;6XL@8^("&X 7_@F3_
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M@)(8C_+:!3X>"^ :)1X^)1ZV$P#$V4F ]^<"_'WA7</92$A$?.,F"6Y"]2W
M-3Q\_&O7\7];C;OKC[L/N$Y)</L^OQSA':U71"PN5 +O/W\E9GU2_H-:>P3!
M)OC:-?#&31I:.GJ&!P_9'W%P"@F+B(J)2\@_55!44E91U7FAJZ=O8&AD86EE
M_<;&UL[-W</3"^SM$_0A."3T8UAX;%Q\0F)2<DIJ=DYN7GY!8=&WBLJJZIK:
MNOJ&]H[.KNZ>WK[^T;'QB<FIZ1G8TO+*ZMKZQN;6-O+PZ/CD] QU?O';+SP
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M6$ZT6IA;M5I#-O[[^12E%<T6)'E&@=V%9XJ+-Y5$=#:;2.+/!:EV84+UUOW
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MZ<1T.!/%G,=7 ='4N)T%23V"WY#TR=;7Z#<LEX_X*GZ[T1HTC.Z7 & !=2^
M: 5^##U*0N$1_!;B\CX=IWNQ*S$6T,*5(VTKVR6J#1GLVEV:8?J,DEO$=4X"
M?"$@A+KCW\Y[M8&.65"X1O7ZY ):P:/95H[M<M++RE7!71R(>L&,!SSZZVX-
M[BX04="$ARL$_UE WVC^T:S"=#WK]"IDZ3F8"//!G!2RF#J+\Q"7P,&@11R4
M L#_SA;P+S*P:*9]U<?<PQ)  ;X.&8Q8RD+?,88@J2#MV0B**^),.BS@!P\.
M"$I3KX73KH?#%FHI,3,]Y7V0]JR_[@]?O2]M185K_C8.5T=H.X"HAS6_@2O#
MIX*))_N*G8H+(GS;I-$D2^^Q@+?VSAB64KX./D( $9J%F9GD%Z3SVT(,VK5!
M@\AA5-"Z5./Y3. '7Z9-U)M%'&$%0D.16,#+0M!O!7J_/TKT51Z732C.H-^@
MQ2%RK8?T:XK0PP<,.)F#OWCP=0F'\1^<<$Y4(&QQ;;;2'YF_Z&3=EW<9_Q=T
MKCWE0S$A >2@HT=@"(X<S__X785POKK)# 2>W?PCD(=OBSGAUQ=JKM9<AX#/
M6:<W-#M 1!3G\7X@+"#P;\LR?UOV+RUY.<"HWW3*@O,:G(JW_@_3<_ZB_7-<
M?<+<+,6-AF]6;G-P^/Y)]$.E\F&*D$SRWQ*RN/#_YA,04>K'B(,Z-+3U+T[J
MJZ"+OM7GS+[ O#D+9?-EVD!S:1)B ;]R_NL];ED],_+_Z/UC6';NO"9L'&/-
MJWPJG-0A^F7#':>A"=*.2V_B/8R7]^=]5L;:])7#LOSPP9QD7-$/0+^YS2Y=
MFX4HX2/VXQAKPLO-$.SP,0T)+4C)K1.9Y%HK5F-U\I)R-<A469W*UE)L<VU%
M1"\LEJ%.X]*=Q8;75*4D_9AJD]-:FYLVSO5U%*Z):RT-P%5L^J0#W(:W#'%&
MD9>>@&[9^LQ/).3]+,\+T^L^?9;B^.$;S?/0FD6 V#:!5_QSP41S\@72*&2P
MM.+1\)82FK5V+@ I1@<47_1QQUFJAY_(?+>YFT11D3]J@PY=*'.W56SP([AG
M05I: J?RL;C\4O'81([8UA$0\07U^J@\ G,!6C(UI<+KA[3S>>_07AU#VF-0
MBGQ$X-8#'#03(\KDS\'6"*\_\Y30+&>9Y9 %)317<78R$Q3-J@\Y'L!<""W@
M)'[_<51+#$K?4 '@&MHA&MID?C;R5QUO.OE'R[LUT!+=WR_5<'&>6#R@@<!Q
MMW1?@C<ZLQ"A8"YS)%[H'FC&R.^LFVS6;YA3Q+^^AWXV<CD9!^)_9%6EA,&2
MN+W7'XB WFBZJG+D:2%!:7:K+.5GF4T<!$<MA+9,XQO0S>NMP=33OQ%]C"8\
MD.!-*Q[Q<[R4M6FAB>ML"!@HOFNA\KVN->PDC23-7K+J0W;_R#,6Y\?W/^--
M,QY<$WB$#\5A_OIHDN]R$U<P)#&4Q<,75G]4EKU10UTM:=X&PR%$6UY>[&:&
M9;O9OA'THZ-JC2XI7PS[K[^1E:?6#C!3,$1IKD09&XT(^8.Z$#Q)D?L.C,_K
MJ@)';9:5/S3BP3MLG/17YS,7+5(!\SAEUD=LZW]INX\86CKX@T5],478Q?Q!
M%Q\-6 [-S9.E.LHR?CRS-H[;YVQ"8PVZ%[_Y)?#1X+&EN\IN::&Y4.5%X'Q-
M1A@X2:UR%-KTP(>'=U^HL;NQ(DED2WR&E47DV/!:0\*Y\L[0-8F<I;0.^%_Z
MV-&LM'\#VR;L##LP^^40 )2>^K!KV8RTSB(L<K9SM@Q4Z\I<5;J;E\S_/7:)
M-9:#3<^*SDEL"^8G>I5=YN>\O$ Q.[?YW #EU554V+>TLPDU4@M3B'\/W*.D
M&U<T=6/9LVZC<[+Y/HS#_8/9/V$%(B)-+_X&\AZ28D_)^\N.1$8_RM19ZKY5
MV1S8P$0!O "[8\=O++3 S6RVP)%!>N]@OBYD-IKSK#T&YBC#L>/CE$2>864A
MJ2:Q,'R5LRX+(-I=G@GG2%F[G^9$.!'6M]WXX=T)"*58A@5L)?T.:0J.>%T;
M)7_1\RO"K4<4<LN/]O1*%<ZH;C9Y<:3>&C@==UO3V86-I]9+TOCEJ\Q!KL8O
M2EPXL:&-9UTG<Y#V3_])"1RI2=>(0O[.%ZHL1*29SU_^E%6$ U;_Q=G??&_^
M1^WV9MY+7"Y&_ , \%]R9>$O72'_?9V#H8P8-OB3C9-:LDP%.*A"4=E_<DWK
M?RPIMY3VXW]B6H)+UB(<I:3H_A@9VD'[3W9N;W[Y5W[+(;K^IEU#PR/\!!Q0
M=@>8%,B"XB?4ZX/_3ZG@]WX_^$]^TS<!N_XC%/?OI.'[=[UX)P[Z;Y70^C<&
M.X^^D.OZ"8);_UH&=U9,^]OAB1%9IB^(H<6_C(I'V1UA4H HRM^&%WXA-\;E
M9.N?B;B]2MB[A_^/IJ+L3[@@_:/XT1][B)+_7D[A'0XLY[_!@K0+_EWQ&AHX
MWO=3D,+)D;]E.#1#G/^I9KJX:O8O,/+^35X/=^WO3%G_"?-?8B $ZV]%SWZ'
M]1A"]4^0Z/Y;!$N('DD)_E.^<O\=+X]X'?SX?P\\0DPLWOW'$C-IY,#*KCE!
MD\XB(TDS&]P6P](<"S]Z3GN-O^!)B]%YEV?&0,,+LMZVOCW9Z&F4->+L[Z+-
M*OHW",-"PS"]4=SF-Q7E]S"5>J\[;:F1H(XA([!YL#;NQE/MCKL-]U]K33^4
M PFTR@KJF&#&,F]71R_HUK5< D.[@H<FIF"EO-H7, -GEBHP'(]9<<8*UH:>
MZ::*K 9XY72(!OV/FF_R(HNF&L@T P[ G='U2J6 B,\0RYU$6'4\PL20)8<>
MO[N-;MHOE#TFQ=_>O">+T=V<$,TV+@6ATE[8FD1%T^7K5=I:VW821UKI\D.3
M9;D[@L_KZ7H%O?Z3$U2_N?@7B'51DBN?G-^;L:#>N\@$?9-)</80&29?4/%R
M.F!8>\V-S.%*A.6I1KX1%H)0>URQ+P.#FWB6*<@[[,D+LH<*-4M^@$DA-N_O
MV^9$DYO<$T#\E#LF*KTFR?K?)/U71OU8OH)ZY#F3R+LM-AK[9C'](!C^@#=!
MGZB;:!E)TLXR^$#[:?SN[;>>5]L)K8[$58YZ8YI(HM#;W6KVLU&21K'P\SR#
MAR&V+-8US,\%"Z>C9V#]E=V/#98_,6_].S'^%4>%F&YI#4,9ICDS@VGC&50V
M9N-94S@)5$9=9E&!;1)9R3?0ZL =RX>HIQ-;O:26)%UK76)H//F' %Z_S59L
M2/WSCPWP!P-X_10G<#D)5FO'T%>5UR/UPWGS T?5M>8=>7("[P@=*=]9]WMT
MLY"XSZ47,$EVMD=OL<CX.0?U<]+0PU^<I[7VA(^B[<@V5:ON4U[CLT-J#W*1
M= +7+ZO($.G:3F@PS+FSKBJTOG6\RE1'N5$TU1.:^XREH?I3#NN>M9YV661_
M;[_N^ZTVUM#FJP0_T6]P==ZO4%32<[63*E,[QHA>F+3-K++EA_F ';;(O:N9
M2&I=[<>/KK5 +XU0YFI(ZOTHVE IXR*X\;R9P5,'H>](N(G1D0L5MR7]HRP9
M#:IWL@]:C&KM+W7!DL^G'+AY'*H;T]3JA3:CR^^&7I UFG?'&H99\B0(>!<V
M<< &\2WN90Q WLDPU$SQ5%NE/;]\P9!8].U;U4#M4.N3N$"1JU\4_9(^J4M^
M')=LAC8!_'7U]5/5*E+\MKP1#]-R%-REBJ(S')G>-D_SHP<K%,M$!(*JO? C
M 3<SF:\JFB1S4:+MHC(" O*E=C4<A698P)M.J8A'9FNE*PD=+<LEO>!(2;](
MU46]J- ]_Z\=2SWC'@ND.SX/5E/7OV;/;(T12\U.5J>^B%6>R7O17F+H/_BX
MQV;^A\0II (:[-[82C&WU9 (?>62._TP^:&\HZ#);.Z!!'>F U\@E"T9W"YR
M-\3G%2QKMW(I2B'HKK%1B(%P6K-3UYFQ*O>#!EXGBS"K]^-=K,J#>K(HJ<#'
MC_#Q>[*J6Q((PZQ$ W>AU5ME.DH-_G(.$3.&\A I^UMUCOV]!_2NA.1CM9YX
M]-.HHDM94Q1K-_P^(B$KY("7UP%]UVO9P".HNI0R^[:C"NW]FD19 ?$^?#K)
MX SG4W/$>GU11.TD6MZN4J% J=#8<*Z+R2C.H.72EEV+%DX'^/ H]W\1]QY0
M36U=N&@0$)0FO8-TE"9(40A%Z2)25'I3:H" BC0I 93>04! FG3I)70('9'>
M)?2 (#VAAA9>\)SC\?SO_/>]=^]][S'&'F./;/:<W_SF-^=:*VOL;,!5I/"0
MV\I\?.CB'*5JL?&<K8YK @/71&!QS%<+O2W[E7ZM-@ZF HJO7Y^\G7B!\&5B
M"3TQ=;-PDQ%0-AIQ3I$PT"VKPO345JAPU<6O78[G#O3T!5;I+=O7YVLQ.K3,
MKZ.G%H\@OBZLY)YD9O#&N(W!M])]#</<:5<2>E(1;L\O*^NI@'M8-/!6 $EI
M[:85!.\:[O?P)TA^I(V&6(LUCCI25I)84I6V?RU7^M*1F?KTQ5K+V]?,=@5U
M:(=A-QX-Y&9"\'X?6^&D@?1C#1OVNN=9'V_M/%1@FB^))V#.HU].TMA49F+8
MCTC(7RTHTC\'M')(A&QYJB_DXQT[*3+*+-!9D?A1TJ\Q^:_V.3-,;+(NA+.;
M@ZDCRCZO/;*GF7HTLHF70 MVIZI0*/-KME#&*^X(\2=T_URGBTTO";TH>K/8
MV9>806SKK2NC,1_) _B:<KPC<*-_D3]&A4'D@]5>\V<&R$9".FCHBFZ'MT""
M7H0'8RC8RNZ'P=98T;-XPG>0VLG*#F!><P8Q7>R *([R0LFF8?9ZZE6U,^_Q
MK0DC*6X&3QI+SM2[^W<+P>.\D^5&0-OB6D8UZT8O A-\@HVR[%5O$;2NL[D3
MY[&R'ZS2VF646V36I.\%0N5MJ2:]MDZ,4;72%=\>AD,X@/=3R*^#CZQ3AB&T
MTYMB?._*<@R<1/NK![UE*'ZT15@&!]#B\H!8K2FE&ROBZ:&_IQ"*M:-T#?XH
M$]%#8OY$S4-J@'+&Q,2$W8Z,PD \)25^8ZVLC3)'18!%Z4HZV=.$ S%DQ3G
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M$H'2^3_*9Z8!*/V'R_2;5J^_6*LCR\OS!WH;0O#,E4\T[W&=-K&> ][Q&;,
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M;D\S]R4<!1@HF&" :>K]4EU*)L$6*GT-8*9T^3)!_QT6/_]!H4[E^!II)=0
M'>9),_H^:P2,YE0CXX>X@40HFY]401I5*(3Z'- JQ0BQFUQ%\H]7$^$"@BS
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MZ+QOJB(#VU#KK]S,M5&7/W*I%'.-9%?+.PRP*[(L\ <9.GTAZ/GXZA$^S3F
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MZ:O.ER&Z4)_UD__<$-!-AEG',(<E$M5_VEOR\3C[MS>K/T?#.B0AOJ="!>A
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M(F?1(><\+D7+^%FU9&X*A6:)GL;G0>51;?%'JG?3^;UT_[TKZ9N0#CIXWEX
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MB@/1M^Q(J@+2,+)>++(\988C  [F4]1L8>S0&$'38?ZDKI#Y1W#!,#F.0?!
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MF?B/$DA:10'^.Y5P9J&0%R[N9O@K)UKVJRF$1E_JO&YWM@HGQ8'S%-?<3+"
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MUK>!W<K;$W8>C7,^3I$25WA"9P1\3M;!$5% <(E@=#0E*9M5SLV[/MP^\4R
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MNN;%VLH ';&E]T<KC4GL>\7ZU>G\,8[+6\ *!6./D-GSEXD61[4.\>$/0",
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MKR]5_9*B<%'+F"#U63-#?L\'6/B6J2RF(F-XL!S7L5E/.\'D&>C1DMLH30_
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MJ^]OH8E11X_:X/'=4$IA 8A$\\FZ *:\S&.FXZ>\9#WW9@G+CZ5PU)J3WOZ
MJT#K.6'BKK0X:?P8ST>I2^(#&&"X]?$&X8.7TAIHFI4*NM^S4_7FQ5(YKE!W
M>_O#XH]EXZS);WL9G93==;1K.QY%O\4P&5]X>V4VW_;S=J)NY,33[\HU9L%G
M7<X*=G)")#5KEY&FL[S,):8F4$Y%ICAHQ1.$4P%POF5%4ZT$4GGE!9+:IM.;
MV$X]-.2QB_PL1<DJB_EQJ4'7T_PQP"H;B7E-?<O5.!=8HS@C>-B.@!6.#!4%
M2AGZ]2FN,GT8%WT8O+ E0LNH#WE7 K9-'G2%0*EF6F\&W\8_D?X1VV ;G!D6
M>=RM>/PK0G+)22-D:T%[=JF@P]5?+F%DXR%R4S9U)D@7\#4:(S9I8%NA]J+[
MAJ%;KT4.\2(])^F!XD6*9R+=Q@(]*QM\4Q&W5=>Y)&#;Z"Q"B*,ETB)R5C75
MTH265*6FU 9S).7< QW0R&<E00T4A9QS!SM5/E,C3=@T65$[K6V+W3U(UNDI
MQ:XPN<8]UOCB"_'T+U KT;1[L,#V[5M3ED6,7U>(KC=N:FFZL7@8AW<GU=*W
M13YWIE;U$$^=/;)WS9])\3";Z.B>UCZU[04X>^0\O.8Q7V5ZWJVU<X%7:"M
MA/!OWQA]C%M"523F'?J,O6CI)T)JG5'/KZ,.WKWCZ,C]5VF8(4B2$JGI8@\'
MXD>3Z-<!+(>696R!8#71$+7*/X(ZDVNWOKR'7V G6/K)\Q;8+_3&9BUW<U=6
MLILD)1LV:+*M$P5<+C7,$\TQ:_IU'V^K% *\/=*NI-'*?79=QXL2Y)I.DIDB
MBX..L_*O!.DO7?J&^:Q.N87V-SI2/?7V61ZV<=D'NA:/X\>HVD[DF2V&AFW3
M$:.GU2).+%-<2O 7%EBW6H=X,8?= ^>17?1%2<609PS##E(+KS-TTWFKBD\=
MMY+IV..'Y>\CQ4-RF//U.D[LH_U P#4>382^45SWA$H)3U(-S#M90I3VE:4Y
M28WJE63'2[J3SXQ11X)5K&VG<FGY*4.N#)?VQ/U,2K_E^\I_<(PWD 0'$$PC
M=BHE/#V;FI*W!^ IN!,@@1H01X^>XCMS =%V\X4P.MIA:T$%:P7L_G6@$YE@
M1=^5FTERV.%KBA$>P^L=L<L$>!ZCC.409O2I:8;DHMY)#TP]H6V\5M*CTZ/S
M,=VN,][WWY+O@[/-BV_'S(A_>\0CT%!V8>',[XN+(@JM,/;,YIOY6$/*W@M<
MI];OI0<=UG< 3+!FP8A$1B3GY$B@!>2,OQ0_8M/PO=X2VW+);GG)I2[K"F'F
MGZ?Z\.:H ^!S=M4O4<G/<!?QL*"+9!\4J=P<F)'/JV/')BS ;E:/N-(VG=(^
M,=;!^F$^V4_<*AX]:C%YR36U4!YA_4+?IMMOJ""37!;SPP<DSF2PO4%>5,7Y
MSX#Y<R<IA7K[4[DLI/SBNL=RTSA=KF7Z7VC&1[B'>>F&[&IDA9^8WV,_3.3@
MX&BT]0'P?CTV>>G*.4A9RO'LBO.-L[H41F?_\Q!BDO>/>@&4VKI;S6%X'&J<
M+R!@6WY2@D:\[TQC&!(8[_^%[:R"NE+EDDA\HD_&IQL U+!BC+MH/'SBO=X0
MNIDT^S@!*%[35<*D)H$A2:6'.%_>J2&<&/(02%4F.FGT@/]86;DH!GE2M547
MP/+D_LURX[/'6"L^](":?R%@]5O;PKJPT]<,#E9-:]4[W_BK[<R6W__^7+ '
M*J*?H!5O\."[LV@B^HU>ROG<UCLGN=>I9L.)P\X+#("#Q]O.2KT \#_@@9AA
MZ-'C299/.<1G9H2:(O KH]+8]V"REFK6^ +K+[151.BT*PFONAYY-M3DMJ>4
MWBTCRH)]]G;6+HR$4V]6ZQ/KX\?<[C#IP3N WORO0M^Y7F&BO5O^8\NMM-5
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MIL/\65N1X/]=*_/_<L.YF_]_ %!+ P04    " "T17I<2<4.*/ZP  #-P@
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M'N"V]<@UWN>@@:QR6!D*T@-W=,& 7<YDL]NT!G*TMX=+LG<40Y+"J/,KRM
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ML^GDEC4R>3?&5)O,JK[^DT&1>P:*5[@O2PX-Z!1<1 -&>YTQ3L=8V#W^Z\[
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M\LLA"JO_Q#M(*H+_XT^EME#>W9=C&.SK]R*/(W\4XHM?R3/0!=+LT7J9WX+
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MBDX!F2+0^6L)5;IGH> \&?NY"CBU@A_!<Y_XN:D.Z'=&?,*$+/8'D"W,&EO
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M7K?Z6,M%5Z-APEHUR4*&_T7ZLKA!;6HLS3O"=BYW2*EP-)!>C@\5#B+O7[3
MNY+^RY6[+S^]$(O 4!%)V[Q;?'%E?KH,OK(H?+RA]QM\^G>Z:)_V^E, G3@E
MP:",<NGJ=XV)\B])-U(G4"2&LE]!URLI2A6_Y=.VTS?:+0E?6/,F#;0K^P9+
M%2:"\7NZ^9!UC73=2KWU;LF1AE#"/3]VA$3M8!IZM,UX<L![[ 7#8E7.XFKK
M75^=_2#\FI+(A3N*=*> W\'-)_A#@J9I7-#9F9C=P/MX<[(@\.T0M2D7^,J<
M\/'"'8(_F[K L8<_%H1/XP(7?YP8^>^"6UM U[/7D?#M*K4_OOX^4_3/DG.4
M,#!TN,OJ<"IO<V)^%_UC9W(8]KC[QP&=_](P^'\\K_[LF%C(_]-] ?_)/GK+
M3>?'QZ;EKC27[X5=2E)? Z@0<B5_ V23_5EEJ5(8((I6B$$3]EKRUJ/GGMNB
MN5L84&"%J ;3%UJ1)C $U#<LL?.2T%)HSPVK^\=J6-EQ,?]956DW>L'NO&XW
MH02/*]T;/CK]#MRUVI<=4NW4[O)2:+Y:HI^!\'2;478!*97+[$N6/[=4OQN0
MKU$6$%7C5!/05UT0D9$1J7XF31PLAQ=%NWDJRA _GD[[( Z'XB9GE/1XAM+,
M@VC2O'2N'=Q8V-6EHPP?SF 2LT-_EE#Z?#XO__.#?7&W:U3;S/H6 C[052%(
MOUQZY9?^90/'AQ'51TM&!8"<O--D*B($)];UG_!K /N5FW-((^[IA=R=45R(
M19NC3W+D*-(I"MZ*%U939'@>@#=!..IU.,P,]OS:K" \I96JZW9(7[M!^S =
MP=HIX/_&V"@H%%H 25.M_+37>7[N=2"1C]$D==& @$Y.8KB:T@7QG']C!?B+
MB'_V^4U$O;_F_5&M63P-0-30>>M_52OO[.#M[;/#.@%_LN"_F%<ACX;UN!$%
MR*,O,2LT/IJ8=&,U^ =MTB]@Y*$EG$('H^&@#V.^96C:QT12R07PQ ECJ LQ
M\XM#R8N;^L<J8!>A+18,1_TH9\(=W]Q_5+E:A4SSC&0/B$BDB)9"/V#%3UYN
MMS%:SJXQ&R<(Y'W2>=%D:USUK2_!76&DNJ[[VVX"HOQBN.Z-C9Y#J17Z=4LZ
M3!C2BAF3T)7.%N5Q93D'N:H_KZ_H^KZR[QB5\_)6D(V[9A(!D1TG7:8")@XI
M'$ZU6@V)7^.GW.1OV"B[ ZZ-$RA__Q9@*&5>_36>SM9VA"0#HWOP**+3BC$B
MSJK;^S#( I<3E./,(+O:/:&6Z.FS3"MVT^[0_H[+U"OLJV/X[U@9LYT"J%NX
MLJ@747Q-42T&@GES,=PP:P;NZ:1AV#VWESJC/M1#-W50*UW"I)":'LNS_ZWJ
M>WX9AAQF7S-"=WB_>TAQQXV_+J'O\T4-_1OND&R*YC^Y^R<8_T6I(?PS[S^J
M#,F?U/U7EOZC>%0(82)0DP9H6!>(!!,^W9T>]+H0$[CL/79M+."@<3?7OI#8
M2MX[E(5*P2"T?W:T&<B,R5+$!"*GX]S,']>-E1UPBKRS]?%QCXR,)).M$7E;
M3)1TZUQ#20*"I/T&Y@XFS$4\YK4,G]#]%@G$^?%JAV&W!&FA1)MKYQJ'@$RL
ML?'VA-&C\(=Q3DHCMM65F-P#O$A$#(?+R;Y1*52M7C72%G#CE-P&^=]4MXY5
MO^3O[4K6,&F';SLBV#A0NB%[%>2K0>*C8E-BQTXE]G'A3ZN*AMD$YVV&3@%B
MCQZJ<B>D:\S&:^P)DAB,!FAEFSAY\[.F>^VW^+AKHNEF:;,?6%\^)Y+/2G5A
MVUP[JS<KHBDA=!NK;0<]F+T^K(_KG3W_M$R\&SE%<]GZ<YN1#<?YJ7S6+ZR>
MM\@Q3"C$(9(Q7.AQH%;7@0*G0SGYP+S*/1>>3!^N0?'.VM&7MM[2 AZQ]P
MPK&@?S.K)4W_)+>%I !B&* A6%\A%$WCW=@,&Q'Z F8(>?]/FJS-!Z'8LI0
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MHO=[ UC7UUIFF?$!^@\-USH3G!=E:9YM::7D1"U\/P7$]Y\"IFV.;8FJTZI
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MH7+TO;LU-7XGEIH#@BCGC;Q9:D7NXI:OS50 6C<* %%@KT=!1956Q03;NY_
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M[++.JN]OT2_0\<K#;GZ;V.^[0MRK!S]N'TOH>E-=\88BO.#;DT I>>.TKZ>
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M"QY>JPI_T@=K+#%7\B%VGUJ)_!G0+GU)?E3L!>,]B0OUSN[R#,DL)]F[,=?
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MM6L&1C4._B$P;B( HGS@]'!?>98Q*_A5Q.TPD@27NW+[%\18@F+-$]#3K7O
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M(X.03U%U\@*-KJ+%X8EM6K@%\'3L?P!02P,$%     @ M$5Z7&#I9V"#NP
M.0<! !@   !M='9A+3(P,C4Q,C,Q>#$P:S Q."YJ<&?LNP545&O[-KX1!"5$
M0CI4D YID!@5*1$0$&GF""@,2'>.H(!T20C**(V42.=(=Y=T2\/0 PPS_\%C
MG?.>]U?K_ZWU^];ZML!R[_W$?5_7=5_/LV?MP7S!3 ,7[\HKR0,X9P  !_L/
MP(P!L@#NF3.G/]@##_MS]MS9LWAX9PD)"/#/$1,2$Q,1$A&17""_2'*![ (1
MT46JBV04E)<N72(FI::AHJ0AI[Q$>3H(#BZV#][9\V?/GJ<D(2*A_&\?F,\
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M.(WZL^\FI\>5+K=HM6T]DY@(\1A81WAO'O,Y!ZL7PC2#S,[CV2\\"?V#@C'
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MJ<V(3QKLC0NI8-TOJ)^U-.\M6K*)=3,2+%7B;C&)%%RY*?!"O/ZB$M.@S6Q
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MR>V(/&9%Z4M+43M"U[]BY\J_=2R(,B_NYQ-&5G%[QFI3*$@-K3K@#T7BXMG
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M"Z-%.$H _!<X+$)#IJ>/G=+7Q;LNR+SR,C;TF1]@'HV;A+>@_+!:X$0.8[5
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M;$8UGD3+'L)FT I?M5&"-HUPK(=B-TXHT.D"UPH]K77E2NQB@,5OR^G(,DQ
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M#_N<W!2&VDV_ KFAOKZJK&AL[SXLMD4U!:Y"6*=9S9C0K6H3%MS9[IX_M.C
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M(IM.^FNR:(\_W>5[YV#A?Z,??:QN)J''&W&_<5'S4[7?&?W/';#O1Z'VG$U
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M7"]E<.%=-&IXTLQ8+;:4,K>M1HP^P*T.[I>J0TE#ERKIMQ&&'_JIU@6*,+Y
M3ESGWD8H]2,Y@IMG9.9D#V[9<02MK<#"4W:MFU&>%*N"3?:IWVQOG^W^]5H
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M764L5#D4GKJ:R^_MR#\W!84G<[DW2 BZJ_5L#)66=%H_7*\&Z:PR!5IA/HA
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M?HOZI23MS)%ERG'="&\GGUT[>JERF#Z'[^L_X'L:>1>6>T"0WV HNH,>($2
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M7(/7Y5J%[TM ;S1E4WFQ8DV#VPB+&$;B 2HW:1C7+?!0HAQI^!P\>FTUUCN
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M*$M#H>+-1A0K(10>9$UIJ7M/?387VB_!Z)7*%7YB(Y/=XWC[T<P<P3C?HR>
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MSSKRO]<:OB3#Z=.93@QH,K>[_A]02P,$%     @ M$5Z7*V^G6Y!30  WUH
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MC%=<:X_QQ>M!<B8^B7E^Y$_5?M7L_YIB?O];FOVIV#_TF@0H"?!PBT= !X"
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MYQ 1GD\2+H):IH*UW#Q!]H35=>@PWB(_=4%C6J,08G"*:BFF5Z3-8RV" 6
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M[02KXU)4N=['TO"GM8I[3.=*H[L(Y_Q'UKO*PZ(VSP,'<9$TM/-%B7"!F#)
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MWH@7BK\\^9P)4/L\7?L'<O]/9(._&33_?:#:_ =0;?]O6/&?7=T?5;XXE4H
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M!#2>3-@U-WBFG/.:!RNR5AMJY:V8.4FB9L49W9]7E$;L(<2#B+C($S';W[$
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M<YJK%(OUAD'?+V.!B++J!>Y.(<HA)_&,9&\;!D;JG^KWTY;2A5NI[=,L!;%
M:.+)G][R%R7/*E\JJ(C^I"3I<W_R<B1U%05;O1HB[DKG>"]Q4WQ?\^3/0=*B
M[$.1V?S4BU6;^_'4@O;[AT-.]KY+L<WW5V&,C@RF^W5G-S83G,4_GVS4+G"J
MWP&U4LT1VCEY0ZFA-F9MM! G[K!B7*$Q& KU=>IIFHM(9YI2=9L:^=+;]\LY
MX*V?49DJHD\]7C2FL+U],4X]YL']<E5T#4^3WV_B)#1)/5(SHOVKF<Y$S<C^
M]6.P#D1I_89]K)N:9);YAYLGV^:$&")$_75Z5L]4,G.S=D"A',SO_JJ8AFS6
MHHW[,*5/'Q.LR%\:<=G5&5<LF6;#ECUA)R5U,^&H.J*X[\WQ6,4=%!G<6.24
MM?^$U28)39^U<7%3_FT+H\)$$#) J@\CCI@,KX.W@'N\QG:I^PJA-N YAQE;
M2.@;L])W75+];]5/2P\IT"]0*:LM8AWIFIEU#KD0[[+2OF^6\R8":9+O9I\0
MA%G%OX/EU(R$RG!$EL%>M8TYK3,F]MR&U1-UFQPA5.^4:]T\%;]FA*M$P<\J
M9 *371S?A*[@A]K(P:.@A^4G[1>9+O$<-/[VF8PUB*D"BG"8:[[)@J8+6_K0
M64/FAEJ!-!<AWET[@J79QJSP+-I ;E37RI-YC:)!4$B&;I;V5__0%W4T2:UV
MGYM<W\2KR$YMQN% :8%T@^U_U\@*,:JDCY'QE:7/R_W.=Y/% GD#7WK5$]N>
MG2S(+I]%Y:.^H,*GM=5J#!7+1 >/*GJEZ(>EV#?I\);;:)W1ZG!H;"8(*1$.
M<]9*AD?R5-5D3CR*2[?(HYA+4C\=$BY;38B:2G2L?=]K:LV8R8ZX] DY\*Y@
M:J&4NMD^\O,[GOEE(EAY!TQYLO_:[P(F?N47);(_-;;^)6'Q:5D]WQEQ^A!2
MI -&A6K<U:J?]/#S^UQ]2D+&T-<OPVEU*,)&11?N?U&.-D,E?Q\JA?A*UKS*
M=V#P#8]YG6XQE/4)"VR??9!E@)ZQNZF6WX2I(,"1Z,<E_O*HJ"*?9)T8O<D3
MLI(6>=ARS  M;VSEU[P<-H&Q@T!6!R-;U$"A65;M?,>[MX_PUD/YNY<0U-'$
M8V5S/L)30Q(2X<-T%GJ&Z0C\AV(_.H10KL]5>Z$DIQI9X6D,Y]ZB/&%M-<UW
M"6O3!&0M\\<B"(9\CKN^MN,M2?PQ01N@\ER76XRDR.LN)2O6=DS3_JP>PRN/
MZB["V?X\6OYR>Z5E21U% A>BTF@=+Q,G>UK=DO#SLW&X+*B19$L>^)9Q%HC(
MV"HI@+[N%@SM](JSE?8B8+;*]%G>++LCY]:U2M4-I4?K<""BS!3*X/)2.E75
M#4=EOU7=:;MA7.LS[WF6R(EDC-C@6."V8R Y(E_*5^.)<)F'"]W28_%^X]+$
MA;BOE^[]L&+G0$I[1O;[%=-8H#(G1J_"P-@Z[$R8[I5;]O+R6S$M$#%:8:K-
M3D:B.**_OG:N5ZYASF/PQ&J@Z*U" )*XERHRDW"\9HC_7+=N^G1 Y<MEP$)9
M=JS9=9&7T:M';^A7>5K\B#LL]'M]T\(.C/HD]<P<I\Z=;KL-LO0>]Z"%==5)
M_3S+2_11X'P(GW^=KT5SY]FBK,DY36J<V \_IX$.>DAG*WXUPC*!_7/^W 6#
MO<8-!^];VN9)[HJ,JJ:SB#YTP !F\[04"_R+/I=I4[5/3<=RM0O7ZU &UDBR
MBIAB@?Z!;]#IFC9,F)"CH04,'9L><>UGA@6V]*8*'I#RY@;]W6$!WTRW4S?\
M!B/+7A$2< W3/)8GTC2&,5^7--\%Q;<RFVU5F,Y;*'M^G\W??9-?J0).6_VQ
MB](A+M<NGIG3<+H]K=-S?V .7RZ(64LLC UU4F* 3(V!B[#Y)'0OTDV@-0HM
MHM <98]S'?H@3E\-I6/KG!+@+@O" 3<,$#SQ"IRF6PJ<S9.YTY[:-'\<I$"S
MO@]_9#)MUM/RA\<[QU5H.-&X#2KN!< ,:BB>C:O72C'6/315O$FD_H5_[819
MXHBC:TBC;U',JFAA"+9]2>9XCG]+:#TX_8_IP>.TB\Z+SQT\TF70>,B*!?CL
M^>C]YKI)%XF2 )5ALX1[HT5-?Y)OMWTD,@["ZY7.IBI^(\%JH3?C+'CPNC&X
M49TL7!\5'6,^+2@GD6^QD_YUPLLTH-36Y(#[D=J$)]=TC^6MEFE_/KB?P."U
M5,\''_Y=@Y;Z^LS.CM6V9F^#!]6I@[_L67WP7/N9=XVAC ?H@&+T@XEFT$J&
M"\..3'PQW-."G4UA=%W=3NRA2PT=DXE<&R^UG]WMWPP*5W69LM\XTWEN*=^+
M4+6,O=DO86EAV4N7LM92]S2JVWF(/RC>EV_S??]*JPL*7(I:W%PUMR1J;FNP
M8%2LM7 T"69*(H$_#1GJTZWH+F(/AGQ%]2"*NF6P0$^<7Z>79%I$ER47C4_<
M82[%>H^G$S-8X.V61>A32I0XWNE/BRZN0_SG<>(O&6,?"&:?].^KI7T8<+_?
M^+/0I]TVEEU17@Q,K2'230:FG/&9PHP8C\V9M_C4&+^N2G6 J^4=P7^YHJ\T
M0F;8<_-0,4B.%8[W7,I) ?K&-?6:_+QZ:IH9X"HESF=!""5K/DYIIHV@BK/-
MLZ&TLY$S[5DKS-@5:+9U*"OKYT)=H+R4JZ&>SYKWTT23\0B#E\^N P167"@Z
MRE''&A$]+,XE94N6<S[X5S\GLE54G51DS^[13KMS\N&YN=WP3>C@A!:AS9$%
MM25$->PE)7_^[%#/:Y-G6;N<O.2ZP.S4^Z-;E/&LYEV:(=G;E?/*[B4S78(W
M+5\XI+D!HFX"AL,'K%=JSDYK)B\_$R;V%]W]&!LBL!K'JYJ#(NM=O#&%%B@#
M^S^I#WBRMN-0*/=#"^RNLNLZ?O#2JMRGQSA\M1=*X4&A,B5@ 3498WPZ9DVM
M=M^*KMQKV.CEO%>L#6,F+\&>J< J^*:%_S,D.-SI[J0P6MGAMJ3I_%8Q6>?>
MZ*,K)NF+JH1&DH%R=PW<*6 P(4[&, .V8W0F6>Q9T'ZN^*'8]?[WK IU)DXB
M=>.'KTG89'$!LU\:@72.N7W<>5E0ZM;!&Z[\3G%VS9IOQ-\+EMEFBRM!,D4Q
MPK3=IJGEPOMOUA+T*UK'"^+YA/W;"4I+O6H?*,YT$$OT.[(3:K/Y0, $5X^;
M#2 K@Y_PS;*AI\%//OON*^;=;;**)@RP<UVY9AB#PS/T:N/5UM68F(D'.:][
M%#;'DKLM14;1W(+0&MA*E51564UEPT7!AQ,#@C+_@!*IR).L,$LQQ/I&O)/G
M(^>]V26#^K DC3+%A3M/2M6ICLA#9$C/8%&M]*U3@7SHNRWVPAL,ZH'GHITD
M\3P,[<7.74)]\O;,!W1&O8WA!:M@2A]M^$;!BFP6@Z7#;/E7=^[*68];&EX2
MMT"C[WOS>(.LO9@))**^S:-ML[H:)Z?RWJTP><:P"G'N.3BP.HEPA6K](=AP
M^K2PK<CA-FII@)#P?VP#7;40,8+,>%RQZ:@6:@8DC9#$J=]-6&2-@AED/U:F
MT\'#=2)ST)'H A:8+@5?TDX5V'1A 4ZAI6O?'BR0(^_XM\C_V,U'HH*D7+%
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MV%D1=>.X-&L'X3*3IQ-7[4WM>K  F?(*!^7<"/=7KCB6C.#UUA?+2'"<Q&7
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M.>0].UGY-+E])N9]P^1V#%5"=];<JE*=3.O^RG8N5WBO%.!#$;]L^\$< 4K
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M-^-QMY-)&1H4)D9<(AL(%YIV=^V1H>ON@RCYQ$V*S^5&HF6=BVG<N%952MD
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M_=W'B6PW"D^E2 "NN1#'A#E' "8#F]1+BJ _L\QV]#RA!. )_"3/;K'NQ$B
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M-VW\3TS]XU]OK#QG8?@5 N @/((1*3D(^D4 %%;Y>3.:)2&(?^^MR8^ H0F
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MU;-M9OGJRX@:L!TM^)%N.$.*/?UC"6T<=X'/;&O]C#HF G4^(<W [K*=G[I
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M=& )8M2P9?$("[,,O49+UD<9-WVP7V+_>T?*$U<(0*HJ ? ,!=#; 5"2O>U
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M5_0B(K#SG2/07QGR!,#/GP!TG:9=-K<%[VEQ$H 6XL.%48S9%!/H\! +W8'
MCJ&7<7#B%V\C#04V2[!OQ=,)@.(E$(X.3-2F<=*L#PE 1@@EG@I$ #@RC\U)
M"  42HF7/X&'X#4[8(EH(3'\@I? YL ?6ZK,H>Z;R/N"466<*_AT2@(0I752
MX4, X'#BB#CQ ^T$@ ?9_.UHX$]W]<E8AWD&%*.O*!0D^[W12WQ4J.^+AM]]
MEZGW4?UU:KA^1%S!5W7+"<Q##?GK1&3U3/_4'^ T5.RPZY]%IHW!_QS!YET4
M3P!J'^U!N-CQNU"S[T2@M__@PF^>C'^ZM]\]TZS9_ 1\*-$+/L+!B3NK)'F
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M^* )==RMAMH6N8D6*:8.TS(T1WS^VL&D2=&T]MR/ K%OYSYULEDX3<4H'_5
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MW+;)>>-;KSW*-9U7Y]NNZYT99F:DH_O\?-<]=P<" .C_M(]Q3= 3Y%!#X^%
M^4*;H>QND3D3_YFO2-=#<V_^3]N[9O)9K0X%VX=+HS<=K:[;TI<FO$\*E:EZ
MXL\(=-H38O$_F,F>&B6UQSZC%;/[0]0Z+MEBX\6EE+NZP7>T[R%TF)VXKTQ
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M2O,P2\]&\Z,X+?FUY;O:0#1M^@))*9\-/+?>6+Q.3[H6O.ZJV]3G&#*<TB'
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M7;9Q.CJ;\*+K?\ D1%9,VN;;:\C-.PVUW;/O/E#8K?2XYL=WI==R8T(AAT_
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MO<BDFX^A96I;:FTD6I%6AY]V[=)%I!GFV^3/F[<XRT[NR+Y<2B80.\/O*=<
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M"7ZDS;;.W1$NF__A5*/N[G8*6)N,&Y%Q^0U<LTW[&:0-IZ/UFU@F#WJ0NQV
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M?<&V7- VD/R!3FCC+#??V+[@M%"JWD<'NROF->_"WJP)-0JV:V%NC>*"\_!
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M?)7U :-D8N+* .I.YC8J][5-I$LC!6D+8V.J:*V( U53V'4.3>(,!ZD]2<1
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MQX)W8X'&ON&':(C"3WJLGL)WU9-/Z8*]0S?#RA^]?L#PF$Q5;5F189'D>':
M<1D:)'JEK.!2/>ITN_[[]R,Z&N/-'=(W-8JF"P#\6<AO L!?9KF$'1!^&7&C
MER$_-5K) P/ &K*9LMW?'L.B$31E](5-%8?FF:LQO533PR31.AFK;W?*96WR
M0%[IGRKLI7.E#;<^B.C(LKS\U-Z[?[(]8 /IT/&^0ISK80"$8H=GL'4S;Z*T
ML$VUSW?SW)Y?ZFEXDK\_,:Q =W]\G&(0/&!$6$H2VP?U\&0T9I!KHTU$5'7/
MP*+8X0MA7 'N2%'B<_:6"=NZ6M.\6:8&\Q<B/2N9'[='6T*1"7 ,@ )5!%GF
M;$8C486G8C+XLCJIS7KP0,-1=SF[+DO&J@DGT1+ATP4^D'Z ^7L#\7.[ /9.
M I_I1R]U[AW,)[3@KW DKZ DD<;%X#PJQEDYD&:&V4.%.Q7/OL*V]@CWV\L>
M80#ODX^DYO"7>!G3G$$_S!C?1]NG?%'W]T<1Y/P8WV,9Y<)']#U"7$-Q(WQK
MKJJ0C9MZQH%:-6-[--\=32ARUT[1)_8+H-5N5F*.87=R E"<R2+RI4N-*ON3
M3R0$9A0BZ/)@6[VMFA^"864WD6VH&_A==2%2[*R:<E&/V_?O>!ZV19#3UX:M
MJC;53TRIU-L R<I""6Z6^U-2N>!FGW^>34VOV;PE&""69M4F;12*9IIR;%;"
MJ[!MO3UNTQAKA,1WXV-W62>XO685&'[!A:8R[QR!K7$#J2S+$#&],5;R[4/4
MG;*L<)@17"*B6:[D*OUB='2L*WG&<L#5DQW&\G'-(L6=[7/,O?NAT4M3*G#6
MI<V09BNX^?)@UHH<K8"@XQWO67+)M&$UCC(.1;<>RK&?M-MCNV<2]YOU]\!S
MM.XVU^_+4JCE\[Q D,Y1WG/]]% OR% 7P/R.QIOAE R<5BDP$N[N"H%_7,
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MA0_,19\)V*FO@O?ABD:,WP?)U-MQ2WPE_>C!DMO$>1A !Y?U/3H=J6=TO;3
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M#DX-*0LKA]4/+V'=+LS@S?96[N%G(QO#ATXU4:J,,K["]AR7!H*F0+!3)F^
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M@:=@K,G<B4,Z8P"FC1.BYA&AG(W5\?POM.I7\!VI";*U$1\#VG[^:)?DH.X
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MZ0"S:_Y*[%Q>O 2H89$$]=3(&NO?6SA/?')4:(QW\+_]B3Q8=O_[$L+/OO^
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M>VNPW:@QD-TGQ$\/^%+J_:X X$44VTH#]JPFM5*[KW4J9\2]TJ#',_?0GI)
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MQQ1^D)$%?FM<.W8@N._>=%BN>*=&9O119;E[CS%)))D7I8G9S7URK,%)"M:
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M%1D4N'NT<!<MIZ S?N&8@=0_N:+04Z%%P%I_K?Q8_^,:><BWR<63#85C$16
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MH<G1=5@?3+GDOYN*B-3%+U*XR+_0NWF1>T'DB @)J_IAD(T!&&4H*7[&VG7
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M?HL>6WGT>[CDV'8J!CZ!&+@",/ORGC_"2^9!K!Y>3D=UL2#"W32J=)_V:W%
MJ85M?C.@=8M7V=CAD;M^MB FR&S7 N>4'TIFS.F]Z'LWXMJ*AL;*,]Z4Y-E7
MQ3$,*[<_:<DI%R9.=>[-F!TTJE+;-X26_;1WKQTQ<U" A"^8:G*).?'>[&ER
M8_7GM?U)_VY3K[J<^N('6LA//) ?AO(07R/V@IUD+Z7$YF(70RX%\.T'RB\[
MO=*O )W*!E-@<U$Q&11/H'IM,%MF0WEGW0'Y:U7[*P#Y>HO J"\;_F@%KE<Y
M.=OI]8K*>(-"<X8^CZ_5;=3L6.6+BYV*^7L?7>4!]U^]PA7">AJYZ7/^=!3:
MO ?TJ988=I+7]:;>RF!@8WH ]WW1^.D A+_#2A;8MJ!=)=.;CO&%67<O7TE'
M47%Y?*C!2[@ R4WJ6/"R0,MMB#<:T9W)H;G4S*B.C8D+JHIH4K;_N2Y#/>N)
M+)DS_EJI\3V>S/LENYKB2Z=94J%,4,SS$62ONVB6S&C@V'->5CJ*G(P@NK4R
MKCI_<W6E3[,*GE$2O^[W;V9\/2[SE^:;5.%T\%"E3%./W.DWF!"^ E15@>[\
MEI%4)SGW*GKPFEP&SAO$Z1&4 -ZFO(EOU,7M=C2R^VG5@)45SG1M0R?]7]Z:
MUN@@(702[\GE$XK5JY!5$L#HDO1X:4TJR1<;@V'V+DR-O]+?A?\"Q-=_DB#@
M3#=1N3O6G2<U7F!"_B2F8WP8),O1* D[F3WRQ"?*^E\!WHD%?E9#.8([;YS!
MIR)MQAP[HXAY'J52:$AFCDR!ND$$$--N$),2)VJ8&.\!#.JF HN#3Q?#B[<G
MS(S:.?GX4C6V^CN"^?,@V6D/_TR<_JJY3VFA>_80JH90HG5>:N:'C\W..&0(
MX<A;@F%)<RJN[D_7>:K2)&1K>#H*N*PCEZ&>:.<("PK$]5RK(+H:7J_DHLGU
M5\96C5.>MFLQS/UNK:>Q&KCI!R'L><KZZXN3#^4WW%2]=HL07N96]8H?W;I@
M REHV_F@Z@KP:.Y#BX?J/2 ;NL4F"*/:Y2,$][#@GH"J92\@[2S$XN"R#'KV
M-JPO(G*-!KK.A^?K%AX >(+,,X_X\B,N%2]'%%ZOO;3U0XG((-\L49<OU1L,
M0=9T1;VW#/EJ5>(-:>Z_41-8IAX90WSQ[>/@:L)I;B&PLR];WWG75RG:)&CP
MIDP'$-)X)="QG2&*)BU6'(U#KD%\^,H5X"7_6?Z) 6,[YPGMR\L&V?V2F=:)
MWLOUR]<A6,W+)Q-7@-*8\TV6]'\AASS7Y-#9[Q_D\/!?R*%&-5U/_ N: <"Q
M=#L$A.YJC83:N'W7S!\F"#;CE$\'GJ8:R,Q]_R/+T+?ZDXYL-^=?F",OUY-Y
M$CKURP*5P #*'Y'WF?[N.NL_Z,LXJ'I!0K5(.=,B)A;=M+S7'>Z:64DG/W\4
M()::D4ZL#,ZK')':%'D,7A-^$[KWX69ESD-%C%SOYMRE6_9_'#[^=Z/'(L[I
M\B]L_T,\I1[\M_8$>#I,Y'=-LRQV-"^O ,#5$\G! ;_YW+WSX7"@R?T?K08J
MPG_K5-PW'.E8_J? F>!_")SU7.K\;P)G*O\B<+;POPF<.?Q3X$QZ[?H[VE(N
M[$]A3XW]IC(+<DH7PK[2Z1FU2.!B8[!G'<B4\',U*.Q=1+[ZJOF"5G$_C35Y
MYWW^ G8BPKG,3AA16635G0ONLX$S]BV1FRW/0F61<!(PQ:NSR'U=SB-C+$7B
M4AD5Q';+ W&D<#1<"_3SYCT6JV05%V+OKR5D4GJ-.=.!REUV54_26F2 31O#
MJJNT7!OK[S5:OQ@8Z>06$[8TXA2GRZ-<*%8&8II,\CO%0I,O&2>*JRE)\;&*
MJ_7UTSJ^?PBZG]^F<DGBX6&;F&?X$G&@.B.)6@A"#=/8Q1LMFB$AL=W*BJ^2
M]TZU\^I"F%/5%&D^R6;X/!!4)CG2PGNCIJ67*VHFCC<9T&/:RQ.YGHZH^<;^
M@-X!G6\?ZM:$G)]?Y/AR;#(B#!A@@^.@1S8RWVOV[#T^*@]0^Q5[?QBEK"+:
M_>.D%"M?RM/&6:T;UR46YDN!$TV7;@U9G733>K^S59VNLO?"(^5BLBF AV*+
M]F[W'XLPF/+HV2H0?"8"N8U +90O+598S*W#2CJN$;F912_?[$ .G9]2>ELI
ML3RZW*ULN@R5$LY\.>]8]"QQ!F[K0C5YC]25^V%\$UQ5*>#A29P2Y=,#)A5I
MR+U5./)=/4<S[3HL"3^VS6>4(\(WA6XQ&&P,(#*5)V3J11= /(X"\7[H5MI9
M.Q;#<(-5O49/JRH1L)3[<1S#LZB;6X$"D?[:U)5L-[Q9E$>]N]-[.LHHS,"^
M]R9SJA.W6[A_Q3V?  W*)="1T1&<\Z\ZJ;OTG\E!1*07;VU2S5H@%R$6H^_?
MLRP<:<$?UW<\)>CTM\9.@M"[V[0_SN_B6H.4% MF%N8XJ8:%'95+T@<6;=5C
MOCZ@?G+6RT7^/9!@^)$A5/U,ZUP6FU$OFE@(2=PZ?E%E_VG3]@/61.KK=.5
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M)NH/J.9'F :'_]-(\-C]_+Z0@>&@NQ<I*KR;_/"&EOQ\.$4)IBAU^_)NH9D
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M!HLHGT3,=E3PFRL5]A;U+=@L&E<513E67CC[YFQU/!;^Q9UIE[SC&1[P$@_
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M@ =8YKQR ID;PX,2PU &A>R)OD(6@$1_%F%B:EJ,3/[4 ;Z7N#R/KNB-OQ]
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M#(SNR$KHXMS9 O=G?!W6)>,B8"_ /A;ARWT&K/PSW(0L?EW4'[UY^;?[$X-
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MN836S77E5@]NZ_ZSC>%#W0]JYW[*(5;7'E<?\8AF(MM8H02#='T!7P<SS?=
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M+[AJ9UR*$2N[_*U&J/HKH&QX Y1=8:A)S7@A*^#_QJEV@W!(!FCI!TD J?_
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M)D0>:0G>TL?0,!ZR:1"L,#.O$3BCV% ?^"OB56=,R=DES,^6119%3B&CLH8
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MC9'.KUJQM'[Z_IV_R!E,(6?$[]CD_[;JKR35/[;JV%9.RE7#XZL6;H.+_ZQ
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MJ-L'TJ5?09BE<!A_EMZAGO9<NJY.->X0VK(\/;&:<%KGT2%+S:.%S[_"^0%
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M@UH;+2P;RD:?]TP:K?*,X/28W[0W1;YG?':7<0XMCRXW)204KR%882;G,]W
MH;N-4F:[$]'Z'8:KX84J32)7G4MHG/;L=%XPGC^1>6GRE=-RH%3WD=HO?X$U
MF\.[@27%2X?<I8=0TPN/HQM^%KZ)3!02SAZHW62%J>&J@QITI,/DI5]5UZF5
M2QWMCYA;?7Q)G('3Z&UM;%;S;VHV[6KL9JL^K9TAZ'C\5\'BDTQ1QQ3M\2T:
M"S_$'U-SX3/CWM"9@=B.WY*B\J^'_26/Z5F<*#:./&*8%N]#QAT_N_K:R9$,
M;)U$TY/\YBFHUGL"H_!_O"_&Y9#6'+[\MC %&;Y[+P=R$:<=_I9/[%<4#P%T
MD0SD#B?/LG&L.LRR,1="I=L2+JUX%HK=DMQ#G56/>Q_8?&! _\%(Z?82''-N
M&+[\#QVTZO7GVTGB9 #]6Z6\V7#G(S;:KXT?NW5L:</?ENY>Q*O]783^S,!!
M]OZ8[&D4L\!,B!1\-@5O7Q>\D#@:)G6V+E1C,.FQ[V!!NM8]Y_G3*FV!>VGY
M7_BORT$<I,-W#6,)F<2[E"8[SY<BJ2SM0BE:3+_EVMB(/"1P:^5:U:(KW"[+
MM/-:4B]62/?-7>^S 6I.1YDD,6B05E#[P6(0' MM4)\-'7!6N*Y'-$A*<2XY
M%&/&:>0]/,J_5>R5M&I6E2;I@9+&+T55;(:+G"&(\X8I*#>H8Z5YS!ROG2\^
M[^;JA/DU-&G-,)-ORE+1'Y1!4R@Q7CES FK7+G(FP7I$C<EJ->7;IS"1@VV=
M\B2=4R^H>=XM40=FW)@UYE<] _?"]TJ'\_ISXL6VQY;%_QC\J1E<=I0*FWX\
M\ MA?RX25L@+7.C;CY81! O!Z&9.55!$Q809(6NTY5K5>^3$VC6_J>$RR_#S
M@8_;;,['*>'FW[#Z6XX&08/FQ-L@@E#>CFDF@2=+$<AGJG<S^(>(]V8E.-HK
M1@+T7"\;O&<P:TF@HOI:I 9M]]V,EG=6P:K%I]A%H+@=#T@992>-9@P^5<49
M-IV6771)_'3K2W.[)>ZKYFRCP,PM"I^U"CMI#GR@_UKVZ7-EB)C8_)LB)2-O
M\8+-6W8Q_FT^[6E)9(!K)UJI9;PSQ+U;FF^JL4(@^L,KY;,R+9'.K4*Z?.JU
MOB>N7D7F^KI9AKSW/)"P%F0+O7:48#VIL/"]NKQ*7\T3D$>&H^Q43"Y[*Q?-
M4%1'&KR=!0N'3_XI.Y9=-[7G1FHW*9K::HPB7T#_4"[YOQO3)=(%EW_VJO0W
M7:>3CC&XZT+!H-[?O4#ROS>>'U@05!0]HXO7/PJ2WSSB]]"T@\D./7=!G8$6
MZNSX:=SR&*R8_;3*$+&A- 5K=?HD6BU>R=7TBVEO$#=O+7N$5!7]H*<RWEHX
M[C B+7M!DB]^T?@RU6Q<"K;296RBN0X=IOH$XT)/R#-/[E#CTPT'Z8\49]V2
M'@'M9O&+/@L:%0Q5]1?>7P\N'8>:['W%/2C/ESN/R%//M9J4O?B4/6<HJHVJ
M2YD^8G%7.@+!0F2?VP3!-"A[$88DZF/AI\[-^SQ/D^^2?%BF=-W:S)(XH05E
MZO$CT1F/\,3GP(/'OZX2I]R_6_3_BOK#X=K@7M(4Q$+EY<Y5Z1!XN1\Z%L4.
M@:;X.5J 3DWF_!SGB1>E<3SI6#@H-'?=-# &VR"FZ!I#JMQ]GGIX%RK1Y'^9
MX.641;"Y[J2#*XE2U$%VN;K1MGAG'\G$ S?3DFQ#Z,%W3&()W5B1Y-P>+)*5
M +G=CR1*^_JJ)IFG+\:S?GCS9>)5<4F(%=K==;PQ[;JE1EKC1ZN,PKT')CY^
M(YX^TTL(<Z[[HMWG/+*WX;C]84AF)IYS=C%HEK*WUD+'/V;(QIKM"M_494I@
M^1PQKOC'9(MLD\I#?$* =VER*YR>Q /M:\JX@J=+Q()Y6E "@ZA1-ZGLO&;A
MVO<U$:>^ML5O-JVT*[7[H%N[T'9ZHLT'\)B/J)&=R)7=)U'+"5F3\D6Q8C+*
M1F 45+G4I0U^JD)8>L^W7_4DIB@TU1#=Z =I*^>[8]L#,)QF]M_*GY^+"EPS
MRS/_R''79-%QKRJY<3J]:OM)Y6V.YU\G&S>13Y!^1RQD "#R$?SPTDW68@A-
MO$A#QB4<*<PCM0-5'G%=^4VM_=MY- TWLVM&S;KQ,_^3!/@-@G,F(;)=%SLQ
MI6%9YG>3 78UK[C?8>_7(Z%D6:7]L%ZZ*Q*%+AS$2U4$7N?9*?K.Z@RAE+TS
M'LBX3#W5@YPOEL62%TY?OCU&I2W<Z]VG-PL:![=Z7@.WIKL8X*N*/E:_WO$:
M]&"C4W>6T"ZZ8O19]I.:-8-$/#$Z>U"AYUI-HA?M>63YW;WR->?47Y)2/=EW
M0R+N*E5[.(\B-/?7;!>0-%"P(9X,1,JC65=DPJ5W3[;I(.J"".FQ3PR3Q#_1
M-4Z8'26K*JI=(="W^(A'24F[0S@=MAQ!X^4MA=].=6VU-#Q&];T%6>\NS#"1
M+K.%^(N->AABUB0?>3BI1/)4U&3<@H7E/*M.PK_YZDE\3_/":3*V<R8X!1&-
MXIBVM&=?&5$#?1\_F1-QM90NU35DRT#[S-%/U\]L]0D;KA&K[7W< HAZ_:0^
MI^O/2#XJIJULS"JAJ.&-ZKJ!M9W&/FG"("[V!D[I->PJ5IA#SZ?-<=1$$9E%
M2)E6=K'=NJO:STDX.1<W\KF!^_ :48,0GCVV6D<?:KVOU\#!]WQ\\<* !O_X
M5Z8KO\I8>0N:.S6LD.NT>&D-?&Q @]+'+BR"8)IQY7-CAAGLCOQ>Q83]V(3S
M-M"W+3P9<PERDO@$-QV'@01>@^T/=DH'JVJZYJ\Q?*J]'YS+_-'3K5J5S=RP
M(#Q&1%+BZZ;[WG!I7Y9YC,&'-?FIQ*0>;_$I#U\1;VQ? $H-IQ3R<W?*JS79
MW!_A\:*JJ/'MEP2E*;.S]+ G-4T/Y>(>J.H<JA+V6T2$4*,>>@(7W-=8LO#Q
MI&GMRJ<='*;#W1+$UGE1U1VDSB!*S'[Z2@U^.MC!UX.BE",:_![EK]P>B^H"
M:L R<371GTPVW3LK?7C7=3_H%$,UL,;3,8_Z=Z:4VMBM'*NJS85&I LG>>WG
M[#=$M#FY:1!Q!J>\;%/ZUA+GC+A6Q5+],J8W$:DF&Y$'E1=OW@MZWEVW308D
M#N2P!Q>R&@>[&3=(5/ N+X(K&;!EB27%F&,DZ@G49.#<!*;S*$H1?*#@%"M(
M6C,A2F\I43IT 9&B;? 3^ZP((O1P%LE(F,!7=X"826>@U+<'B:).KIAH+\CG
M[](*$VM-@GZ43CV>X=[BY4Q9*UQ# +5;K <R!>Q8HH)5BB"JSPKJ,\"4:O%2
M" R:PX%T+M50S[IW^,D6K']D-?Y+,=_FO9HH SH**4H1-4?5)-<R3A!,\J"N
M&PT*']4+5D=)Y[?'E5)FN_9\39/.&Q4_$'\:%TXML97AU/OHZ%.#!9YU#C/I
MSRIR$E='2&[9<AIEFXNLC;/-4,FI\K5/4;1J4]O>X$I94;!2PGJU0J)%SE/R
M*(0DW(TM@@O97W-7$GCLDU/!L7(ML?!+88)<C<GKXAI9+0M:-KZSM>LJ&-8\
M''IV\Q61N@C&^HG0[6J756&T.NWWJIU[?J!+K!]4\0;?7KLE9HGS.7&!>O7H
M9*7A!]-T2[.NXDAWI9M-GZKEG 6)93.*/6,=&ZXC#6RM( &4F -8!'9Q5I_?
M@J!D6(V73#_JCVTIM[S>&^7<\NE0Y\V;Y<.&3QC;7X1V)R(3KKH-_(H,L*CQ
M0UFW=8+:6KJU:V(?C K>'Z^Z]V'&Y411@;?!QE90;)TH38RKM=WL9K#:Q6$R
M8(]@@'9K$6ZCZ7B:-Q;PUMDB><Z7G,+%G*M^:#_O[!5Q.JG:Q>VY/FL70>/'
MA->8BPU"L?9\G"!DWX_OW3;=3M8KJRY/6?0=#;OX./SL@\LSUS ^&5,LKB3A
MHS(U3FCY_?[+[FCV;K?SU2^2'FS#[2PORUA]/B/Y],T'4[MSI@QI(7-YHDHD
M4=CU$:+&X4V8"%XO.DLOB^"AD)D_R6]\APX[KHQM24B:_-JZL#+=X \:6^O
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M.OF'/#'ITWZ[@!LY2%FXEEJ'GHNCX\JLX3%KMUU==HCJY98_>5$#C7TM2+\
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ML;F'2TSF@XF8Z*NL1>*[Y]%;O;O5$@W((3BEM0I<PI(<[@D4^H*#DLW@G&:
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MR]KFEM:V]HXW;]_U]0]\_#3X>6B8.#4]\V5V;GYAD;SZ?6U]XP=E<VN7%QW
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M_$4'/W&OO _\3/\Y+$X(\[PXS4]Q"E^MQCQCL &IV%+DH/MZ>C;[2RIJVK8
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ML=18K)\\#4BTFZ0!VPQ#4%*___0T$@<G5:_WQ\'+;OC0@.I!B\]6<PW+-*"
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MOQT\7H4G[NMKF)>'BK1 -E"-+L, ^M2LGX/O.0\UA?3\5*B&"0D_0P.>/B&
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MR;)LH#RV$6A^K="!8O53F5H)K'5O$4?L&;GLLL&[<$]?K5.R1>3&;.A'R;/
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M24U8?47$_6*P?SHI,J"8KA>:T*FTX".PPC>#.F,ZDI#7<H8<[[RK+G5],/P
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M():!EIEJ#=/(?-TD/W'^O-S+,]K)0]KCTBB?^?SSV#E7'T&:W3RKX[E/ZG>
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M>QB.Y.48PKCYZ,7[0%9'JF-8O)LWN?%YXU15Y:&$JYAE;5M3QHEA<]Y:OVB
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M&A0DH-BI(6W#*DXIS:\#$T)2MBSUYGPB642*__Y5K@<K_]0J=@Q,0K5S((-
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M-?5J#D_J8+CX#F#K7XV'8*-LN$KL/T!;W(=)<UTE;@2#=L!Z+I76B1#*J#N
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M3(#;I[X5:1Q\ZB9K/N3@GZ>9Y-)"=B9T-C$Z7EG8-($W#Y?L.#_-KH]_B#Q
M9($% N^3+3^\&P-[=U3:,+*LRGLZM[C(:,W8KP^?X<J0&E?/<C7-YMS;]"?1
M6JZ"J-#6T'S;:K4.?:#]F*714Z[]0!O]^7,$0-/K2%-V_:!(K 0P%,M0LM;O
M?*:GJ3R)-&)9^;+'+:9+F"BPN#'^"UYD> <+>AKZ2#ZF-8-R,TN2M:_R>U@1
MERD$T058#TL"[$+MK0F X-E6((;7&(I_6U=RU*T19(K2#M]R8M5QEIGJ6F%A
ME6Q5^\K,'MG6[(>>1D;LM\(OXFDWA[UF.V2V#*"TCO1V/K%K1P.[(?,O5<[1
M](91^[">&"@BO^;E>)6:C HY9Z2-WY\L/Q/JH%9Q^;DO4LOQGNF'>T<>.!U!
M-F.RUX[S3=>I% 9S';R8[/TRK>-0ZW7!$CDJ##&.#>75YW@SW_VC;%YF(=8<
MMD@?R?-++O<R7]R<#9FE%B< 0OS/-2/Q.<YGONAMNV%4<<%78'%O575=QEFZ
MBV7G0>VIH'GP*X%&^3R35F?Z,VG:%;L4>\!&M,?CLQNJ/N/F*H#'U4>C\K R
M>(,OXDN:X;ZKB8YM9DA'>F8(+\G<+D+UB$TX0K( ZFBW8*(93L]<N9GJJ3?<
M^3*R/UJ=9J*+PDT5I*"^]_5F:166@5O,2THI^EN;XTP;61CBZW!W95<M@NOY
M9D28-U?,6+,4KEP *^6.TKR?;#@BA!7QMIR?=[?BEGK>)H&(G%6M;KDB^2SZ
MSIO(Y..9N".:]E)^/,-QH%RXQ($AM'S;PZ[TN)CIL^DMOP$(/ #@)M%K#Z7#
M\F=I%G?ZEDP@>C([V:="*MLE>RY?IHQ O+WD,ZX'EL:JHTF*-A4$46,UF8CU
M#7?M+=E"7P]G 3-M*P^;J*N7W%Q>QL"&7LA_Z.TX 8=!@$+%6>:=^7;#K<()
M+B1.NHI6CPY):=4>\W<0 (^=*4Q,((S(L<:$A-P=VYT,+W-(>Z699AB/?43[
MD>?X+H0<(@%D<N"D&7&2< 2;)/6WC_,OG_*4CGML;25;#9!F7DZJ@3ZV5>C'
MB'F)BG%]MC2)W0?N*@A9L2BL%$BQ(?(CW3-#KJM>7M)US--19%&X@IQ."'8;
MJVB.A/B^[MKPZ*&+K%]KC[/PN6"ZD[S 3P"<FU7.1D?HB#_GJ/9I/EV$#Q:Z
M:012W5XWJV-A+NJG7;^Q<2*XG#+(O2E^-X.;W8;=OZKH6O-9Q^\^9TORBS/0
MU=T=XTD!.>]KC9YR[^6)*:)>S+SXR+(X//;!"];JLG%,N^$A)9CC,+99SG&+
M@31N<_E3$W<DJ,W'G5ENO!=<8? &?QDKB Y>2-7K=/8NL.4UGE()62\Y+UQ[
MXWGJ'<J747U^T+R-^/KI6 -]@PO?$!I2W&752B5A'A?I>7I87-6T#)[;ZL.Z
MXF"':';\RT4^[B8S+K,:5J=*\L\9%52?@)UTGL"M-#6H\;>1@T*SQQ<X.E2J
M4WNNI):R0;T-G],,98QC92T79$D<H$SOTW?4R&G8/*R<TC'C$HXE&YP4M1'#
M'=1.![FRE\84,6FA-SGDI=P..[T]GPV9>!( 8F7# >X[@K[0A._L\"XX&Q@B
M@;1,GN1I?K7P,) R__19I<UJQ7;F%M"-+K_"1B1N)W61 #B[[O->G57V;;SM
MS%V!P13WSP<@#3"[EY,PJY>3)AU#\6>-A^/;@'*7KZI\ELA>.U2G4&Q/WK</
MO%Z6I"UHYE;S69T^Y3QO!2NWP<5APZ2;B??$G!CUS6#ZJ3A0_RWWAA%Q3J'7
M]I+*>/,+4%]F8GNCIK,#NCY1!7]UQ!!_5M\0D77YJ\.5[@ZN?D:?-V1M2"3#
M5\L87-?NP>:]QH'&NJF5-CVKY]X69,0/E_&9<7F:<\<)3G">\=7CM")[O9*J
MP>/U?3,%L*?>4TE?71:1J;)MB>WHXBHLU++.B3[F_1(!X [/R+<()@#F^>J_
M[(M2,+Q1:594Y\J;?[B]L-U;/-TDKW$D:K R]!F?IYAWB=78WF]P)M6,YZ;>
M.9LFA1! GG.VD=&W?A=G.U(FNI1> 9<SWC28V\^AK)7W1>?V9!ZGJMQ]G%G,
M\*A.6K;:FYL *.]O1S1)&0WON&WV%LKK([9$.Q6RGBVP.8MK+MW27.'MS;]J
M %@DYPK9R$#KI4>2:\_[EM9L^,AM47;GS_8]0S.W!5D+T#LR ^8,+%7N1PJA
M5HD]X?PLDQ=4K[*Z)J17MS[:X7TI]^RE$&])IQC;9\\A56M*S)]:"YI)L9<3
MYLD##]EDFQX>AJOIP6-T&NJ>+[$ 20"?=I8 6?&/'8;61?K^_9UD_IA?H/4.
M<]H!K(?O<$4E!]/&OEK@#BC"P,3] <KQZS"G^AT5>/1E3Y46$?)/W7=#,)[=
M>/[7+<T4XW+*[B3?$.OQSZ<;119=W^A.L!QV0I(SO92-D;,A"HP./EW%GJ#7
MC<J%U;EIS#4--='R8O=A;E$?8V]SIX'>1TM191_3#T169&UX%?"%2%^#W;$)
M\Q\QIQ^%:,[ASAX\&=D1?GJ(8/G"ZA9!HGJ5K?<#+%%Q->V,M]IVE@/JKA>-
ML;<PEI@Y*)B.<N-5:JM@F-MYB&*DU.YD@P<H*-=A<\RLK9'K:$H19.-G@V^3
M,<"G"*Z1?"NFMM#6ROK^8)0JOX,"- G\G/OG_0I(Y09#C'E/4?2YXB\C8XVS
M"_QLQ.RF&KF.I=Y%0*==!L='6-?L;O"2) XVFO @QN^,7]8"&7(=^ZKO.;W
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M\ /LC1C-A/G2-[#;KTS,&"I#E2W/=)]\FMO3Z]4G &R%3AVG4R>]MR1=@:D
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MF-.. *!38%['7Q]B=!N62)7=CN]U!R;PAB]^.E]W\REG8BD(%R8*KX"^42(
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MSN6"(P%02* 4+' ^UF+IW!%H8D9S'6HC3(&K_/RIX%F\H\C5OO>UL28V<@1
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MY45--L\E$Q,1TI<C-GNE=KA$+-L"/"B-*J%]YA)R)6"^E__*JR[YB\MY8DM
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M1S^7C7&NUS1JXU(]B>,X<<B?K<["R.SB_7[(<GR('?\J!<<=0+L2OD!W?Q[
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M4HSXA)#17"O7V[J_ZM*.F:K@]O+G]+UT(I(W:3_BD=<5JO"G3\)HRYY4)>T
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MS X[)98?Z33>:@@K:^5L?M89E'FO!D--FVC%ZGKKN!\ECCF-!V:XZ/7C"2T
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M1<P?52N[_KML2^]9!(89Q7N"F(&5 EC0YC>>(8:-W8_JIQ0J#1)4:8W]*#]
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MTYT4Z&7W!6 #=#:.*V$7/E<XO #L4'W74B^!OWU/.BXI=U8B**-3H\9$D$E
M(G.JZZZ<\6KKV$N,'Q;H2+:9*7-HC\%-53739$KVFDF'>NL&XCS36TS^PK;A
M^=UQ41 KUD)O1$Q9M?KLV92:ZO@D^Y/W?OL&@QPK^'(R'**%*0P]IS/"&O<_
M&*MV>H2,K\Q5+K!-/1K+UYJ;+9H?GY<)+*V-3=+P=KSQ6H.-&.K1E!T1>#6
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M[,V%1JJWO1X&BS:U/&$J-VR;OW3K.<S;62JWW?,W /\:L<3[MFBUX16FA L
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M.K"&ZR#PEP%*EC8TJ[I>K]+DG$9,K^O<Z9U+8?IVRM*96DRAS:G_Y^/_@L)
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M>X@AFMO)W +^7P&O5.C1WB$>&=D165=&?\KQFV#>!W)ZM'@8*^1].N)\81L
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M"3,XI:K.&KI5!:1(9P5+/J:CB^>@T;1/]+MIL:T\*?:LYR0<P[U0FN5YKUH
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MOQHHM0+(\73_[=] ?[H!N3\OTCT-WWW_]W?Z_YN3=/:(ZY4N"ARO "#2*T"
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M5X#X?\G@GO]"GV3_M,'_A5YN-H6Z0_DLKM66V\Y?$Y7ZMR(JP&7_88O_]@O
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MFQ)NU$YG:U'$G8+WNG_L&=4[?^X'[PJF5ZS!/]7(OGYQIJ>C-#!<VVB_DDZ
M6@R_5XMV-9U[/&:=*&VZNU/^]>?+=XV^ HH O2,@HR,[3]/DK^KM4?>WV2_(
MS+8]BLMNA"OS<@2_UP\A63Z1^/U[/Z\G;;@'&JX#]C<V>=6 =;0]@=-%]-(X
M:WB>R-J #$Q*%6*3CXW">BLORN4LW5P/VOQ1LBQ%U181MI\2C,^3N>Q'=-TK
M"?DS]G+)G72ATW?^O=WL$TM+WG^MR''41-W-ZQ2DU3%C"N<65 %]K%!_]?R
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M5],F*2ZWP;_)4ZER^FB0>6VW6_"5S5N7XI^VM^ET(ARF2P$K=X/DK+M>!@X
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M^XM-%O3U;WOLR>@N97=#N^OZ!U!+ P04    " "T17I<.YNMY_,#  #%"P
M&    &UT=F$M,C R-3$R,S%X97@R,V0Q+FAT;=56X7*C-A!^E6TR=TEF#$9@
M, :?9Y+T,M=I?9=)G/:W !G4 XD1LAWWZ;L"'#MIFIN;I-/6,P9IM?JT^VEW
MV>D/EO51%%2D+(-/B_DOD,ET53&A(56,:I1NN"Y@(>N:"I@SI7A9PH7B6<X
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MO=F_=HLH+'1TO<N+038C1.]#A3.X4>H#FP1P7V)PN[)/WP*Z!$;)P"ZJD'*
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MGPF 201L)'VC<%80&<?(L0WP9RJ31*$ ?('/\BB"W>1#7ZS;F^UF-IHN8$,
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M4$L! A0#%     @ M$5Z7"&_J0?L%0  @?(  !$              ( !
M &UT=F$M,C R-3$R,S$N>'-D4$L! A0#%     @ M$5Z7,)A8NO9#P  /^D
M !4              ( !&Q8  &UT=F$M,C R-3$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( +1%>ESU#\QXMS<  &1[ P 5              "  2<F  !M='9A
M+3(P,C4Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "T17I<CPK;WW&   "Y7 @
M%0              @ $17@  ;71V82TR,#(U,3(S,5]L86(N>&UL4$L! A0#
M%     @ M$5Z7" O X7 40  "#X& !4              ( !M=X  &UT=F$M
M,C R-3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( +1%>ESE7/*?]#0$ &=Z)@ 5
M              "  :@P 0!M='9A+3(P,C4Q,C,Q>#$P:RYH=&U02P$"% ,4
M    " "T17I<6T#:1V C    )0  &               @ '/904 ;71V82TR
M,#(U,3(S,7@Q,&LP,#$N:G!G4$L! A0#%     @ M$5Z7 )V%7O%?0  RJ0
M !@              ( !98D% &UT=F$M,C R-3$R,S%X,3!K,# R+FIP9U!+
M 0(4 Q0    ( +1%>EQ:_:D!##X  &%-   8              "  6 '!@!M
M='9A+3(P,C4Q,C,Q>#$P:S P,RYJ<&=02P$"% ,4    " "T17I<#SZI/AX]
M  #61P  &               @ &B108 ;71V82TR,#(U,3(S,7@Q,&LP,#0N
M:G!G4$L! A0#%     @ M$5Z7,X>*OUL90  ;H$  !@              ( !
M]H(& &UT=F$M,C R-3$R,S%X,3!K,# U+FIP9U!+ 0(4 Q0    ( +1%>EPD
M#L@^]ZP  '3R   8              "  9CH!@!M='9A+3(P,C4Q,C,Q>#$P
M:S P-BYJ<&=02P$"% ,4    " "T17I<AX+#4<2+  #SG@  &
M    @ '%E0< ;71V82TR,#(U,3(S,7@Q,&LP,#<N:G!G4$L! A0#%     @
MM$5Z7$ZL5"DCC   TIX  !@              ( !OR$( &UT=F$M,C R-3$R
M,S%X,3!K,# X+FIP9U!+ 0(4 Q0    ( +1%>EQT?I9VR&T  &]]   8
M          "  1BN" !M='9A+3(P,C4Q,C,Q>#$P:S P.2YJ<&=02P$"% ,4
M    " "T17I<6B<FS$:"  !PG@  &               @ $6' D ;71V82TR
M,#(U,3(S,7@Q,&LP,3 N:G!G4$L! A0#%     @ M$5Z7$6/'J)^N0  6.T
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M:S Q-2YJ<&=02P$"% ,4    " "T17I<G$HUM%/%  #AU@  &
M    @ '@B@T ;71V82TR,#(U,3(S,7@Q,&LP,38N:G!G4$L! A0#%     @
MM$5Z7$G%#BC^L   S<(  !@              ( !:5 . &UT=F$M,C R-3$R
M,S%X,3!K,#$W+FIP9U!+ 0(4 Q0    ( +1%>EQ@Z6=@@[L  #D' 0 8
M          "  9T!#P!M='9A+3(P,C4Q,C,Q>#$P:S Q."YJ<&=02P$"% ,4
M    " "T17I<K;Z=;D%-  #?6@  &               @ %6O0\ ;71V82TR
M,#(U,3(S,7@Q,&LP,3DN:G!G4$L! A0#%     @ M$5Z7)E_'LM*?P  %)0
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M:S R-"YJ<&=02P$"% ,4    " "T17I<"<2(T#0"  "U!P  &
M    @ '$.!, ;71V82TR,#(U,3(S,7AE>#$P9#,N:'1M4$L! A0#%     @
MM$5Z7#N;K>?S P  Q0L  !@              ( !+CL3 &UT=F$M,C R-3$R
M,S%X97@R,V0Q+FAT;5!+ 0(4 Q0    ( +1%>ES/B2N39PL  %25   8
M          "  5<_$P!M='9A+3(P,C4Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4
M    " "T17I<RA\A>DL+  !TDP  &               @ 'T2A, ;71V82TR
M,#(U,3(S,7AE>#,Q9#(N:'1M4$L! A0#%     @ M$5Z7 ;EL97H!0  N2
M !@              ( !=583 &UT=F$M,C R-3$R,S%X97@S,F0Q+FAT;5!+
M 0(4 Q0    ( +1%>EP7Y+PFX 4  +X@   8              "  9-<$P!M
M='9A+3(P,C4Q,C,Q>&5X,S)D,BYH=&U02P$"% ,4    " "T17I<VD]"QYX<
M  #_J@  %P              @ &I8A, ;71V82TR,#(U,3(S,7AE>#1D-RYH
8=&U02P4&     "4 )0 '"@  ?'\3

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>mtva-20251231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mtva="http://metaviatx.com/20251231"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mtva-20251231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_n93HbMQVrkW0-qSzZp9fag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_NtxswooMrke0riRhyc4qoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_ynvr0hrecE6I1UL40A9GOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_VMMqp0PeAkmV1Ye9POrQ7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_hUpyIKRg90qXsba8GqK17A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_N6OYhzZRwkyDYwrDvyw5kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_DzLxM32I3UiH0dZZsCbJ1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_m2f7pvSnI0u6Km1eo2IeDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PipeCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_CVpJmymx606CfdrAoZpgUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_tJe91g6JuUaYMezRgMatVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d9qFrE2vD06_O6u11oBBfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1wHJTMoMnEqOTRvvG6b7qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fdw-5IVX0Ee-7JYOFozQCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yB5rb2fUc0ucbha081KM0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4prxmkqkS0ulQgJCLHuryg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wS0yOhGUekml-8634yMsxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_UbXNPFwR4km-FBdk7rEUxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_g-nMTDkmr0qcUvmTTdeMng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ExKQGNyc2UCDlqt3ydfMgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_BY79CPAZZk27J-wqZYzO7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_hGYstxKTzU2ZqyDcJ15G0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_v7UzME_8uUKyZkD-egDxIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_TwoThousandTwentyOnePlanMember_MH43z9s-vEmoE1YjdETXcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:TwoThousandTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_w5EWKu_kcUSEno9r_g_0ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_fPHz9pePvU-5r9-YvskzmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentContingentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2019Member_gmTdCJ8ork6VP-4xURIA1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_BxRCSzAuXEimnCRFgvNQ_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_3128W61YJ0eOKZC5tMQTAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_0R6iYR8SXEKx11Ao953ZHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2026_To_3_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingMember_RAxNUZYdMUeN8hu5p8owPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_uNAveP-XZ06GyWkwukd-jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_Hor3BE5nO0Ky5ynGuPLNiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_vz1AO0nR9UenRLqd0V7ORw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_NRfJ8T4b6Eu_-IBdIjogkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_vvalEg-TrUejRp41VE8WPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_GG-OyGYbHUevmT63tYsdDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-01</startDate>
            <endDate>2026-11-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_us-gaap_TypeOfArrangementAxis_mtva_SecuritiesPurchaseAgreementMember_xy3ONbSXnUiU4ZOJJSQw7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mtva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RjEAz-8aH0qGHIsQmJ0Vyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_J_K81PseZUeD9UJGSY4LKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_m9XJ7gRPJEitR8u7ybUG-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_qToyrodAZ0ObK7Ly10LSHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_pFCcYjunlUeQQZkwtqzvuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_NeLyzkBTRESkMVZRZnvj7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_DBzDIMGO0UWZ5viFB9H-Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-eIdE4X3kkqQfEoPjdgKQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Vqqqe4ArJ0WMHcE3iolyIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_eujJ4gdQVEqiI8yThjB2Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_hyOQooLLv0aTYxqxsTi_Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mtva:NewCorporateHeadquartersLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_Mc6s5k_bG0SSAZ7j_mIrwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan20192022AndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_aNE-h6VMsU2pzK3AIQny9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan20192022AndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WuZ-wtRHAUqZiprK61-caA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rT0WgaTgaUCjX8WYjbJJTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_e1wxSJsny0iiOB1sr8mCHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_mylIA7H1dEi-aM6e5VbgCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice9900.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_YGrezCPF50-XvUz2iIIe3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice33000.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_PtYIpmGNVk2Lhpzik7xP3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice15919.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_Bv82ps5MOk6lD4sKnKRyPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_KNYPj3hEekKCq6iIEa5aJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesBWarrantExercisePrice43.23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_0TANxl4zWU2M4iUW_Dzy7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesaWarrantExercisePrice43.23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_UBBH_Z1Tz0S_4XGQiyGdpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_6202WPiPKkSw1AqR8WV3jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PlacementAgentWarrantExercisePrice54.0375Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_5R_W5kJG9k-0RfAK0QNCRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesBWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_A7Fo-RQiLkOdMLTRGG3G9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_RrvMS22yxkOjSxk0GAVqjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesDWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zi6cmK3ti0qodROqObmB_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesCWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_ZkP_xSv4vUWma066ndav7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_CldTLXRU7EGJY2I47LLydQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice9900.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_h23ZVALXkUePo8zvVv2roQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice33000.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_wyVIcQ8InUKuk3VoxOQDHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:WarrantsExercisePrice15919.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_5XNmuoAqREGcG2s4IaMjeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesBWarrantExercisePrice43.23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_mJd36VtBzkuAj1i6nsWyDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesaWarrantExercisePrice43.23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_5H7GHDBMaE2UtxHkUd3cCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_lJphVo6Jl0qN7JwUudMRRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PlacementAgentWarrantExercisePrice54.0375Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SlAYXsZ0v0Ojj_aGP7CPdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Pj0_bY8RoEiWwD-LtiPp0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentContingentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_orxQwUg110-1269nNhDK5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_waCAFY3cfEuZyDAJOyUoHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0d43O4ut1Eiyd57Bcg_7ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_viTtU6jhrEuruIoP1QHhgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_eTjUAZIRBk2CMl0mq0_sdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kgPNiqIU3EqTQ0FXBCZBtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ZPTKidCK6ECs_qqex1EGQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qjUNJ2DdcESFldGXnzeBGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_yZobbedVRk2iue_r9d0-Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U6f5XE8pkEWgllVziJrf-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_7qHL6fLtgESMlXNDqOZJ2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9AAALrlJp0yWgwl3bBqvvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1hYaSL2Lxk-1ulrcFV5TrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_oBKoosGoG0GmD3xTsVOS-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentContingentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K_oHMLsqlUWlbv8jTh14Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7SMIbo51mEy0336DbR5j1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ieg6WHdrokO31k0M--imaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_QGD8FaaTKk-VCqeDRjoO0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024SeriesBWarrantExercisePrice43.23Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ffXAC5ncsEmnTRq2WxB_jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PipeCommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mtva:StockPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Owwpee6TWESXOEjeyqvrAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_H5aw50Xy8UOPMQzuBjjNEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongStMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9ad2NPEyvEeMZjvJ8Yr8bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mtva:DongStMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongSocioHoldingCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__CXlbv6yq0CPsUFeeflmGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mtva:DongSocioHoldingCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesDWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesDWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_OjEPyphxgUe99Gl8la9gVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesCWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_HGwlAKHDTEqwMSPqX6zFpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:SeriesCWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_I_-uWg1Oy0Oe1RoSXLv9bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PwnDqJ_0xkebhJ_3_12wnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mtva:ClassUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_GxJU8xTtk064vc3Bitk13A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_88E3SsucMk6CjnvOW7ejPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_WmjFk2Gzpk-vzxZey8nlRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1726Member_F0QfeopiT0211MFhaQu96A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:Da1726Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1241Member_SxJHN2alKEOYThrSrZEvCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:Da1241Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_2dC3y_eK3ki1KsOJenFcjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:June2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_31_2019_srt_RangeAxis_srt_MaximumMember_AaM2dzgtbUGUiNDeiHy-eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mtva:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mtva:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mtva:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PCbVTPdsR0KR7b1czjWLjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:PublicOffering2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_nrhpLK0mj0K9W2Dt9Ye5iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:June2024PreFundedWarrantExercisePrice0.011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2025_To_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EuG_rsEk0UOcbgfii4_NdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mtva:November2022SeriesBWarrantExercisePrice0.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_KFhU-S1q0U2O8QEiJ_Qd2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mtva:AtMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_lI9JRhh7LEyE3NLlrMdSug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2026_MZ61IcNrt0a4XydPVofg3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2026-03-20</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_Vote_shares_ETjCJisZMkuUls7w3gpdKA">
        <divide>
            <unitNumerator>
                <measure>mtva:Vote</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_location_PUM6ABDH9EqMpz0Yzt6Sgw">
        <measure>mtva:location</measure>
    </unit>
    <unit id="Unit_Standard_item_i1i903DmOka3fCx6uRjRsw">
        <measure>mtva:item</measure>
    </unit>
    <unit id="Unit_Standard_security_7HQ_97jGkEaCEOxlJP1q6A">
        <measure>mtva:security</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g">
        <measure>mtva:segment</measure>
    </unit>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      id="Hidden_HBfbrzIvdUOSNDYPtKcU7g">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      id="Hidden_aWhQFe3VK069qYthur7e-g"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      id="Hidden_4XOCELpTlEyvjOWvQEVjUw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_zo3KCIwdHEOxd3-lRA6tVA_2_1">0001638287</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_4iDaqXM7d0uce58WrbZh5A_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_VPWvT72f0Uuv2C12rS5RcQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg"
      id="Hidden_8cMI9dmksEq4qT-BG4yhLw">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      id="Hidden_1PX6G9rlREaqOUwCT5gBiw">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg"
      id="Hidden_04y-e2dfO0KSrs6lCUbLtw">http://metaviatx.com/20251231#DongStMember</us-gaap:OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration>
    <us-gaap:OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      id="Hidden_OlrKa7URCkCtFvuhgd859A">http://metaviatx.com/20251231#DongStMember</us-gaap:OtherLiabilityCurrentRelatedPartyCounterpartyNameExtensibleEnumeration>
    <us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      id="Hidden_f_SITYnZr0yzCRs8SPB4uw">http://fasb.org/us-gaap/2025#RelatedPartyMember</us-gaap:OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      id="Hidden_RZkET5TQh0W_DYzsRn-H1A"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      id="Hidden_yacnpFgWGE-wqPKYDVGxSQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="3"
      id="Hidden_8EGw4Ym3A0uwPDR1wgoCVw"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.091</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MinimumMember_CVpJmymx606CfdrAoZpgUA"
      decimals="1"
      id="Hidden_o4iplQlu0UKYhhkCeUIVBg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_tJe91g6JuUaYMezRgMatVw"
      decimals="3"
      id="Hidden_3jKcbu2it0anJWRaB5fFmg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.033</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MinimumMember_vz1AO0nR9UenRLqd0V7ORw"
      id="Hidden_zDOjGvv570SVRG19o1qIjg">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      id="Hidden_VOralR6i3ki9t2Jyaw8bcA">http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Hidden_W8CSMwv8-EWiuCXptape3A">http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Hidden_wKCHieRLFUC2maYfjLnuGQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zi6cmK3ti0qodROqObmB_g"
      decimals="2"
      id="Hidden_oXMhiHp3dkGLoMt6wJhXIA"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">3.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_Ic-eC7KoQ0SOUNPVkGXKag">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_Z2FmQsFLBECuIphEOWt1OQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc__HlMuhIRp0KfFUm79fr4eA_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_y6rEmewz4k2x6yn3QSUqWw">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_llupbxOVTUK5GDP2P6CRMw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_fvy0NhjE102ifT_gKAEuWw_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_bMOe8mZ-a0eFHboSOweTyg">001-37809</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_dv7hl5S7J0u2NhO1qDF3-A">METAVIA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_KDsEIKc9TEegZaP2K9siMA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_kC7pxyEbJUW0Ce95miui7A_1_2">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_Vg7UR7dd5UybT5h-Y97Y-A">545 Concord Avenue, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_mQaL4c7dD06fLhp8G1c_6Q">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_4o1TfxwxT0eaK4LdlV6wVQ">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_aIuu6PvB8keNFtDxk2RTvQ_3_2">02138</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_UW5dq6b5D0yEORxFKVTi5w">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_rQ6mdfobbUWHBohVFj5HhA">702-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_dwBFcYNJyUKBwXeEP_W-qw_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_dEtpjhcVjkyMYv5qUgrtdA_2_2">MTVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_u2D8s_5vekOHEWZ9JBxGzg">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_5GmRfF2T4UuacdVTHTXe4w">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_QTalRdA-OEyVeFIOuDuuPg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_By85bIV8-E6KFt7iSQofkg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_rtDdaDJqG0-s-gOzKng_bA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_9U7CxDhuqUq1ZDWUMGKVPA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_waZ5dt-BlkmWmiuU7tTDuA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_uSTykthic06c6_rfMo3uFQ">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_RBv3KIinC0axcv6szOWvbg">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_Bua0hKR0y0mczvI_mqD19w">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_ukZtz0-S-E2SoaRtMCveYw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2025_lI9JRhh7LEyE3NLlrMdSug"
      decimals="-5"
      id="Narr_466U2PL9Bkei-qjS36xL3A"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_20_2026_MZ61IcNrt0a4XydPVofg3Q"
      decimals="INF"
      id="Narr_iOQBqJrVu06vT_38AapCeA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">5090936</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_hjPP7Rv1zkWBsTxptJb0gA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Risk management&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We recognize the importance of assessing, identifying, and managing risks associated with cybersecurity threats. These risks include, among other things, operational risks; intellectual property theft; fraud; extortion; harm to employees, violation of privacy or security laws and other litigation and legal risk; and reputational risks. We are committed to maintaining robust governance and oversight of these risks and to implementing mechanisms, controls, technologies, and processes designed to help us assess, identify, and manage these risks. While we have not, as of the date of this Annual Report, experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations, there can be no guarantee that we will not experience such an incident in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We aim to incorporate industry best practices throughout our cybersecurity program. Our cybersecurity strategy focuses on implementing effective and efficient controls, technologies, and other processes to assess, identify, and manage material cybersecurity risks. Our cybersecurity program is designed to be aligned with applicable industry standards. We work with a third-party provider to monitor threats and potential cybersecurity breaches.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We have processes in place to assess, identify, manage, and address material cybersecurity threats and incidents. These include, among other things: ongoing security awareness training for employees; mechanisms to detect and monitor unusual network activity; and containment and incident response tools. We monitor issues that are internally discovered or reported by our third-party monitoring service that may affect our information services and have processes to assess those issues for potential cybersecurity impact or risk. We impose security requirements upon our suppliers and CROs, including maintaining an effective security management program; abiding by information handling and asset management requirements; and notifying us in the event of any known or suspected cyber incident.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_cjncE07pGUGDv_HrlyALjg">We recognize the importance of assessing, identifying, and managing risks associated with cybersecurity threats. These risks include, among other things, operational risks; intellectual property theft; fraud; extortion; harm to employees, violation of privacy or security laws and other litigation and legal risk; and reputational risks. We are committed to maintaining robust governance and oversight of these risks and to implementing mechanisms, controls, technologies, and processes designed to help us assess, identify, and manage these risks.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_67r1kivvkEa5OM4mg5Vf_w">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_n_4TA8NdgUOHlw2CcRXwMQ">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_Nf00S4jlcEub_ZplXeIvJQ">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_56Ofq76ZCUqZwX6TP-4itw">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_-xFRZbhKsk6F5_ikMGeuCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Governance&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Our Board has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to Company priorities, resource allocations, and oversight structures. The Board is assisted by the audit committee, which reviews our cybersecurity program with management and reports to the Board. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The audit committee is central to the Board&#x2019;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The audit committee is composed of Board members with diverse expertise including risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;Our Chief Executive Officer, Chief Financial Officer and corporate controller have operational experience in assessing and managing cybersecurity risk. Our Chief Executive Officer plays a pivotal role in informing the audit committee on &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;cybersecurity risks. They provide comprehensive briefings to the audit committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In addition to our scheduled meetings, the audit committee and Chief Executive Officer maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#x2019;s oversight is proactive and responsive. The audit committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into the broader strategic objectives of MetaVia. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_qgyXAbr950mC1hOCTl7UIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Our Board has ultimate oversight of cybersecurity risk, which it manages as part of our enterprise risk management program. That program is utilized in making decisions with respect to Company priorities, resource allocations, and oversight structures. The Board is assisted by the audit committee, which reviews our cybersecurity program with management and reports to the Board. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The audit committee is central to the Board&#x2019;s oversight of cybersecurity risks and bears the primary responsibility for this domain. The audit committee is composed of Board members with diverse expertise including risk management, technology, and finance, equipping them to oversee cybersecurity risks effectively.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_At2LzhHgw0muDG3xjgmCyw">The audit committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_RHwe12homk2v3lruVoxG8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;Our Chief Executive Officer, Chief Financial Officer and corporate controller have operational experience in assessing and managing cybersecurity risk. Our Chief Executive Officer plays a pivotal role in informing the audit committee on &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;cybersecurity risks. They provide comprehensive briefings to the audit committee on a regular basis, with a minimum frequency of once per year. These briefings encompass a broad range of topics, including:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Current cybersecurity landscape and emerging threats;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Status of ongoing cybersecurity initiatives and strategies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Incident reports and learnings from any cybersecurity events; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Compliance with regulatory requirements and industry standards.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In addition to our scheduled meetings, the audit committee and Chief Executive Officer maintain an ongoing dialogue regarding emerging or potential cybersecurity risks. Together, they receive updates on any significant developments in the cybersecurity domain, ensuring the Board&#x2019;s oversight is proactive and responsive. The audit committee actively participates in strategic decisions related to cybersecurity, offering guidance and approval for major initiatives. This involvement ensures that cybersecurity considerations are integrated into the broader strategic objectives of MetaVia. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary. Furthermore, significant cybersecurity matters, and strategic risk management decisions are escalated to the Board, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_437FtPUV_kmu3Q5Km_4PAw">Our Chief Executive Officer, Chief Financial Officer and corporate controller have operational experience in assessing and managing cybersecurity risk.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_m-_6x3psmkyasVVJ9PB_FA">Chief Executive Officer, Chief Financial Officer and corporate controller</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_lMKqAi0Ho068139nJ5RsdQ">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_dqU5NYcWRkumfJ6kOa7gtA">Our Chief Financial Officer is informed by our third-party monitoring service of any cybersecurity incidents, who will then escalate the incident to our Chief Executive Officer, if necessary.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_oitQHDQz802lEB3Qkfsk9w">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA"
      id="Narr_SGH1Z6y0_keDCHtA4fFzqw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA"
      id="Narr_1w2Me-CPfEqZduWeDeVKSQ">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA"
      id="Narr_x3YHVWX9-EibiJnLorv3Gw">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2025_To_12_31_2025_Q253Z79wokm3f7AF36V1HA"
      id="Narr_xr1Oy9dcxkaMTl0kGurgPQ">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_7lsHq2GGZUKiIkAYP6Q-9g">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_IwwTOihZrUGl_SchNjxHvA">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_5rwyb3PM7k6u8vYIrfirxA">Boston Massachusetts</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr__9vPvvMBhUi8Wjw2uRYxIQ">243</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_nwKMfHdgnkCM59Umdf7scA_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">10278000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_NxBBAjRuvk6dfSYngfodEg_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16017000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Mav3pGXxl0miZgHhe8zwBA_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">597000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_dF1A5BsqJU231E22SoGMDg_6_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">55000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_wXyKYb54xkOKWGPI3WKunw_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">10875000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_2Qr7vSJESUq_R2XHGPQf6A_7_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16072000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_jLgJMnBSVEmczfb2cFfl1w_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">17000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_qCijoPXF4EiY_hqHwULMvA_8_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">34000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_EXuynwVihkipo8zzefhBUg_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">210000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_K7Yl__PlUU2qS0d7BnB-Zw_9_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">133000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Ajy6tW_Mk0Gq1k4Ts4G7iw_10_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">21000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_yLPXPfiPtkWtSGAAvuqO2g_10_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">21000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_uA-Jk3TC6kKwpaobs_YGfA_11_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">11123000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_gC2cLLXlkUG97-TeeJUQhw_11_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16260000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_mGQMEytW-EiY-wLH_ehvug_14_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1060000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_k5-BGuMugUCBDV4Zr8kZOw_14_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3879000</us-gaap:AccountsPayableCurrent>
    <mtva:AccruedLiabilitiesClinicalTrialCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_HzvEG_LOtUaDMLnQKJt0bQ_15_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">79000</mtva:AccruedLiabilitiesClinicalTrialCurrent>
    <mtva:AccruedLiabilitiesClinicalTrialCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_1WK4sCsJiUWhmaThUrb_uw_15_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1696000</mtva:AccruedLiabilitiesClinicalTrialCurrent>
    <mtva:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Qab1VdD0PUCmxZX1ABqrSA_16_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">993000</mtva:AccruedExpensesAndOtherLiabilitiesCurrent>
    <mtva:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_gX5pPXK_YUCdxlrE0bBuGg_16_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">785000</mtva:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_z2frcdPUQkWMjKU-fm-cPg_17_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">136000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_F6gRQrMxV0aQV6QJJrdEgw_17_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">361000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_bVIHllOxP0WVRbL9pfcLyw_18_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3312000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_ivUuDOUsE0Cn0O83fC8LeA_18_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1472000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_1Fsyxd3UOk6of4xpY7NgWA_19_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">68000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_AFMhy9_yjUuW9VYtPjQkNQ_19_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">78000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_ZcWqKjTB3024zYsrPwmFbA_20_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5648000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_D9MxSonDE0620Cl0h95Bzg_20_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8271000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_RVHaO-4VtkuA2mtK-fv4SA_21_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">142000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_LuFy0zyz7EG2IXErt9b6mQ_21_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">58000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_qxiNZJhH7EONgwWQE3TMLg_22_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5790000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_RLHqvw2OZkSIosMWIUjA8Q_22_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8329000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_l4Pp8gyCMUmtkCN6VI3zRQ"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_dz_6CcFZVkCb0LeDUD01Mg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_Lv7-QfvbK0uPvEypHDZQBA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_dUgm6wkH3Eyjj66KkbqG4w"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_JXs2yaO0F0mg6uYszBlsKQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_0iIYdtnw10mGBFOoPhj9IQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_dThWxl5FFUiLPUU1-3VCaA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_Zlv8r10yW0OxgSjyhvmmGw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_M9AibZJMZkGNnPEsv78MTA"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_YfwL9zkV3EeP_jregAuZXg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_MvR6JN8d5ky4ZrHRWuEQEA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_Rpf77MeP8U2fF-WaZt4_EA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_dLuT3i2icU-NryId3ZgZWw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">2308294</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_9XoDNMvBzEeGOl27KsUoBw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">2308294</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_ZFx55uqcBECeeFbl1v3vfg"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">785194</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Narr_kebsGtkiMEKMHMKy-kJLjQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">785194</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_EJIMDje4n0e6Ta_3voK3Lw_26_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_MUFrnPN-D06GG9QcXdeVBQ_26_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_IDH_Rd1p20y1g8IpgsGQ6w_27_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">154161000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc__dZZT6QFQ0WgG7_ujxcRuA_27_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">143787000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_CF9z_H3zo0G3LBneTcnx_Q_28_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-148830000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_URM2BDXs60ewne9haTvG0Q_28_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-135857000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_XtffdNRSqEOZajza1t6y9w_29_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_XvaBUNBZt0ScDNCiATFmGQ_29_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7931000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_8r5HgWhJjEaR2GGlrk5VEg_30_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">11123000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_1WucLgu3FUeLZs_uicAjOg_30_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16260000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_RSaqH1g-uEuDFMcM6iRH9A_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6802000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_77ZwWVQsC0Wc6rwGRHwyuQ_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">21553000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_DwhKxR3SMU-NT0VINzeMoA_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6906000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_iGT4XQH8pkSMrzjCXCX_Sg_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7256000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_ZQGziAuQa0GB7y1SyTFF-A_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">13708000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_DZlw6zMHpEGi7zLBYt04XQ_6_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">28809000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_sl3ZoRr--0mdrzq8pVU7uQ_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-13708000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_pfPMp-YKMUmJIPHRZpI_qg_7_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-28809000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_1XTF-qmDbk61JLH427br1g_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-225000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_gmWFABmkd0WvChpbNWzFAA_9_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-297000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_hTO1cFBou0-7sXt7IhRfgQ_10_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">510000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_rMn3Zxu0jkG5z5PFpQxBkQ_10_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">920000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_uYKdX3Vxl0KmBzQL_70AZA_11_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">735000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_8vhnBu0O5EWnyy6rpDYCnA_11_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1217000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_RqRbPKN-cUSiZ-85DeRJ1g_12_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_w86cJyIbVEqBJXui19MKjw_12_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_CZ1hfqqHT0eaucBxhAykcA_13_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_LpphFcyFKUm9t3Y2nnCUKw_13_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_oLnfJueySU-JUV5bd8DK3g_14_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_2KmeyEYbYUyZO31WxAzL2w_14_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_sqIRN93zqUuCY2RvW2iZFA_15_3"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-7.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_sqIRN93zqUuCY2RvW2iZFA_15_3_2"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-7.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Tc_qhZCwEMbr0mRRlftle-WsQ_15_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-39.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Tc_qhZCwEMbr0mRRlftle-WsQ_15_6_2"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-39.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="0"
      id="Tc_vXHOx7K29EKF7xai2KgnmQ_16_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1766026</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="0"
      id="Tc_vXHOx7K29EKF7xai2KgnmQ_16_3_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1766026</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="0"
      id="Tc_MG6adgwKFEmFu55csFLtAg_16_6"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">705193</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="0"
      id="Tc_MG6adgwKFEmFu55csFLtAg_16_6_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">705193</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g"
      decimals="-3"
      id="Tc_ngsj666n7Uq56dR3Pl4n0Q_4_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">446000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_L0HKcI4dM0KbDHsz0uTO3g"
      decimals="-3"
      id="Tc_D1XDa5iZSkaUl23ClFAkNA_4_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_wS0yOhGUekml-8634yMsxQ"
      decimals="-3"
      id="Tc_p-pPooLQV0eavrjdX7YqHw_4_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">124949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4prxmkqkS0ulQgJCLHuryg"
      decimals="-3"
      id="Tc_C6q5EoUx6Ui1HSzLI8ztkQ_4_10"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-108265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="-3"
      id="Tc_LRmdGexm3US-hQTSxxzf7g_4_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16685000</us-gaap:StockholdersEquity>
    <mtva:StockAndWarrantsIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Narr_9q4SyGdp9EmDxDjzBGDpNg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1960000</mtva:StockAndWarrantsIssuanceCosts>
    <mtva:StockIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ"
      decimals="-3"
      id="Tc_7VjtZqE05kCJWjiUeeKYDQ_5_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">300717000</mtva:StockIssuedDuringPeriodSharesCommonStockAndWarrants>
    <mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ"
      decimals="-3"
      id="Tc_dxkQlnauAE6ZJWQeNdMWdQ_5_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18038000</mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants>
    <mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_XLMEUmGSdUS-DBvdaEsm3g_5_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18038000</mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ"
      decimals="-3"
      id="Tc_XIdy2AkBjk6-aGeD7bR94A_6_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_EFBtSxt45UeReZB9JA-xYA_6_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">309000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ"
      decimals="-3"
      id="Tc_jW4X7hRVyUO4Ocp5ENIEOw_7_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">31925000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ"
      decimals="-3"
      id="Tc_hJD2G8yJGUKwm1icXZNCiw_7_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_e28yap288E2fFOSZHwcEJA_7_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_X-pxkSf9okq8TLKAHMRArQ"
      decimals="-3"
      id="Tc_WKOTzhQSD0eNdVi2fLPqtA_8_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">6552000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ"
      decimals="-3"
      id="Tc_dkhlGFYbAky00Wg5Mx3lnA_8_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-48000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_ras103tzok2o0AuwuL-GkA_8_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-48000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F5MEyzAhR0OwBHWPCxkZHQ"
      decimals="-3"
      id="Tc_vZV7KC_4g0e6Lc-TUrwcsA_9_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">538000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_YQXMTxXpc0Kq59UGnzGNjA_9_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">538000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Vqqqe4ArJ0WMHcE3iolyIw"
      decimals="-3"
      id="Tc__n_xs-ZDBEaXsNVdWFvqWg_10_10"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_JJBwLDSPWkaytTgfR0fZBQ_10_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rT0WgaTgaUCjX8WYjbJJTw"
      decimals="-3"
      id="Tc_GCISPq3QpkOP_G0StyPHHA_11_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">785194000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rT0WgaTgaUCjX8WYjbJJTw"
      decimals="-3"
      id="Tc_otNcr_MQr0qTBUDGw4_5EA_11_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yB5rb2fUc0ucbha081KM0w"
      decimals="-3"
      id="Tc_TtdmAvx_zU2MFqNA3szTgA_11_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">143787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fdw-5IVX0Ee-7JYOFozQCA"
      decimals="-3"
      id="Tc_hhQZP74YekGpTueAfH1sMg_11_10"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-135857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_xAyPVOSZjU-UMuuMNImnFg_11_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7931000</us-gaap:StockholdersEquity>
    <mtva:StockAndWarrantsIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Narr_2udofOYuwEeJz2hkCY2DXA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">887000</mtva:StockAndWarrantsIssuanceCosts>
    <mtva:StockIssuedDuringPeriodSharesCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA"
      decimals="-3"
      id="Tc_Jr2d3xKB1E67GeDQXaAWnA_12_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">861759000</mtva:StockIssuedDuringPeriodSharesCommonStockAndWarrants>
    <mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA"
      decimals="-3"
      id="Tc_UJfr0xKwMUuhBVThiw3aRw_12_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants>
    <mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ"
      decimals="-3"
      id="Tc_tO-C7Y-aw0KQdQx2O4MjvA_12_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9108000</mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants>
    <mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_t2tL4XyJ_UGEHFoCfDf0sw_12_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9109000</mtva:StockIssuedDuringPeriodValueCommonStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA"
      decimals="-3"
      id="Tc_4bQRBqlS2kapfXsjG4MinA_13_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">548651000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ"
      decimals="-3"
      id="Tc_AXrTqqMUfECyT7aTwWJn1Q_13_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_l96_DME7DU-IpeMg9w1vjg_13_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <mtva:StockIssuanceCostAtMarketOfferingAgreement
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Narr_Tt7yqV6yMkq54kw-m_JQuw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">351000</mtva:StockIssuanceCostAtMarketOfferingAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA"
      decimals="-3"
      id="Tc_nZqOrKlcuEWafwizqj0QwQ_14_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">106788000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ"
      decimals="-3"
      id="Tc_UjXTAyc-V0ORGQuw26DUAg_14_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">861000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc__AVHSq4G7EqAdHSxaMbq-g_14_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">861000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-hof8wUhckyE8_O7bF6cjA"
      decimals="-3"
      id="Tc_Abj3aaW540eWCSbB0mDpUw_15_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">5902000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ"
      decimals="-3"
      id="Tc_0ZIc6ryZF0GDKaAGgf4FSg_15_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_W6uApr-Wx0egQ1Q9Y8jgNA_15_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_F-DI27aWQkuhhGhVo1PBoQ"
      decimals="-3"
      id="Tc_TCiX7L6qR0G1KnAkBFfrxQ_16_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_O5c6m47DIkeLD0NpCRvJqA_16_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">411000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-eIdE4X3kkqQfEoPjdgKQQ"
      decimals="-3"
      id="Tc_P8_AqpiXWkejjEpfYNd32A_17_10"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_KM7XUpMNrUiDNQjN7SzdkA_17_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WuZ-wtRHAUqZiprK61-caA"
      decimals="-3"
      id="Tc_WMMNth4xGEuAHbkV_J87jg_18_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">2308294000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WuZ-wtRHAUqZiprK61-caA"
      decimals="-3"
      id="Tc_4SU1byqoVUelpjnLQnG2ew_18_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1wHJTMoMnEqOTRvvG6b7qw"
      decimals="-3"
      id="Tc_b-cNY6wWak-n0Jpq92y9-Q_18_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">154161000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d9qFrE2vD06_O6u11oBBfg"
      decimals="-3"
      id="Tc_LiG2OHktOUydmTZpWi9uwA_18_10"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-148830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_E-776yTjlEucwnW4GAg8ZA_18_13"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5333000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_ybB3BGIJf06tpZyLk0vjyA_4_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_4-SpmduImk2iv41rwgrbfg_4_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_JgSv5zgAgkOFW4E8xxDH7A_6_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">411000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_QrOQ5ixe60eJTdMvK3K5hQ_6_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">538000</us-gaap:ShareBasedCompensation>
    <mtva:NonCashLeaseCreditCharge
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_vlTP3sgYO0izqr8rrpkMLQ_7_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-3000</mtva:NonCashLeaseCreditCharge>
    <mtva:NonCashLeaseCreditCharge
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_ASKp-MwllUOGnhp8WYAh6A_7_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">4000</mtva:NonCashLeaseCreditCharge>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_h1zBqECJXEqp-fq1s4uedQ_8_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">19000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_VsUS7Bqq9kydZHNAsGf5zw_8_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">20000</us-gaap:Depreciation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_JUd4VwMnMkODogB9eG2BRQ_9_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-225000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_TwPHqIqngEiNYs1AVl2Yaw_9_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-297000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_WjUZS1SgGEenR8ZJ7-z6Yg_11_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">542000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_iapRxwDbV0mJ5dzVghhOUg_11_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-20000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_3oZN9WKQZECg0Um_DX3utw_12_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2819000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_P6TGv8V-n0aWiScj_rGIiA_12_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3058000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_fBL8PZQNPEOtjPuKYWURAQ_13_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">431000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_vV-olSnR-UiFAEq8sntgfA_13_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-461000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_HS4UrSrf6ke8gm_v7JY1eg_14_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-15701000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_K2mtE7nSbUeG2heJ08cb2g_14_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-24710000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_cE7Db4uLxESK10LOaUpkuA_16_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_5hnAelWY7Ui4Ct9M66BJyg_16_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_yXR0jJ7ASUWTUtrqR7Emeg_17_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_xek2EgKbl0WIO9HICir7QA_17_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <mtva:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_h-pEcIfcHkmFa9D7IkICLQ_19_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9996000</mtva:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <mtva:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_hRhTNABM1UqRfD8nPxNCSg_19_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">19998000</mtva:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RjEAz-8aH0qGHIsQmJ0Vyw"
      decimals="-3"
      id="Tc_Mygo1PcH9ke4ij4C8k30YA_20_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">887000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_m9XJ7gRPJEitR8u7ybUG-w"
      decimals="-3"
      id="Tc_m6pnIIJ8REOxcYl3jRmuhw_20_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1651000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_J_K81PseZUeD9UJGSY4LKg"
      decimals="-3"
      id="Tc_OWWX__4qUEOK1qyUj7JvCg_21_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1212000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_J_K81PseZUeD9UJGSY4LKg"
      decimals="-3"
      id="Tc_Y1e6Lg3UNUKVyOmleo8ZJw_22_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">351000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_UZaegN36Gkm6N2UPwFHWLw_23_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_MfbTCvCj7EeOcEU3R1nOLQ_23_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_vZmcxe7SWEuvkRSrjNlgwA_24_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">12000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_ksv80UEnXk6ZZ0_htrTinw_24_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">48000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_LWPR3NESlk62InYd9kYI7w_25_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9964000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_T8KgUj0w1k27yhWPuy7xxg_25_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18300000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_-LOf-oFrMUeYPegjsAqRrw_26_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-5739000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_awNBlM1yBEyfsdsPSF7xGw_26_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-6418000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_mth9HEhN2kaOr_HtF7hMQQ_27_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="-3"
      id="Tc_p6BGbHzMikGjugACnlLEcQ_27_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">22435000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_CX-3zot4EkWQAUTu1qvi9g_28_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">10278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_rFThqKngD0mnYqExeahaBA_28_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mtva:FairValueOfWarrantsIssuedToPlacementAgent
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_qN-brSMSikKwMRku6a0HmQ_31_5"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">309000</mtva:FairValueOfWarrantsIssuedToPlacementAgent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_gNlwzEdjek2jbEi0Y_3zSQ_32_2"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">152000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_Wp5OK9utLEeaYTcs8OZzLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;1. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Business, basis of presentation, new accounting standards and summary of significant accounting policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;MetaVia&#160;Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, and its subsidiaries are referred to collectively in these notes to the financial statements of the Company as &#x201c;MetaVia,&#x201d; &#x201c;we,&#x201d; &#x201c;our&#x201d; and &#x201c;us.&#x201d; &lt;span style="letter-spacing:0.2pt;"&gt;We are a clinical-stage biotechnology company focused primarily on &lt;/span&gt;developing novel pharmaceuticals to treat &lt;span style="letter-spacing:0.2pt;"&gt;cardiometabolic diseases. &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;We have two programs, vanoglipel (DA-1241) and DA-1726, focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (&#x201c;MASH&#x201d;) and obesity. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt;While we focus our financial resources and management&#x2019;s attention on the development of vanoglipel (DA-1241) and DA-1726, we also have four legacy therapeutic programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases which we are not planning to advance development on and have, or continue to consider for, out-licensing and divestiture opportunities. In July 2024, we entered into an exclusive out-license agreement with MThera Pharma Co., LTD. (&#x201c;MThera&#x201d;) to provide MThera with the rights to one of our legacy therapeutic program, NB-01, for the treatment of painful diabetic neuropathy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;Our operations consisted principally of performing research and development (&#x201c;R&amp;amp;D&#x201d;) activities, which include preclinical development and clinical trials, and raising capital. Our activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common stock reverse stock split&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In December 2025, we completed a &lt;span style="-sec-ix-hidden:Hidden_8EGw4Ym3A0uwPDR1wgoCVw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-eleven reverse stock split of our common stock (the &#x201c;Reverse Stock Split&#x201d;). As a result, every eleven shares of our issued and outstanding common stock were combined, converted and changed into one share of our common stock. Any fraction of a share of our common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of our common stock as reported on Nasdaq Capital Market LLC (&#x201c;Nasdaq&#x201d;) on the last trading day before the Reverse Stock Split. The Reverse Stock Split was approved by our stockholders at the annual meeting of stockholders in June 2025. At the annual meeting, the stockholders approved a proposal to amend our certificate of incorporation to affect a reverse split of our outstanding common stock at a ratio in the range of &lt;span style="-sec-ix-hidden:Hidden_o4iplQlu0UKYhhkCeUIVBg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-five to &lt;span style="-sec-ix-hidden:Hidden_3jKcbu2it0anJWRaB5fFmg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-thirty to be determined at the discretion of our Board of Directors (&#x201c;Board&#x201d;). In November 2025, our Board approved the Reverse Stock Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The Reverse Stock Split did not impact the number of authorized shares of common stock, which remains at 100,000,000 shares. For the Reverse Stock Split, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of our common stock, the number of shares issuable upon vesting of restricted stock units (&#x201c;RSUs&#x201d;) and the number of shares reserved for issuance pursuant to our equity incentive compensation plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In the accompanying consolidated financial statements and these notes to the consolidated financial statements, the number of shares of common stock and per share data have been adjusted to give effect to the Reverse Stock Split for all periods presented. Additionally, since the common stock par value was unchanged, the amounts for common stock and additional paid-in capital have been adjusted to give effect to the Reverse Stock Split for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Going concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;As reflected in the consolidated financial statements, we had&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$10.3&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million in cash as of December 31, 2025. We have experienced net losses and negative cash flows from operating activities since our inception and had an accumulated deficit of&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$148.8&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million as of December 31, 2025. We have incurred a net loss of&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$13.0&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million and net cash used in operating activities of &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;$15.7&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;&#160;million for 2025. Due in large part to ongoing clinical trials, we expect to continue to incur net losses and negative cash flows from operating activities for the foreseeable future. These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;We plan to continue to fund our operations through equity offerings, debt financing, the exercise of existing warrants, or other sources, potentially including collaborations, out-licensing and other similar arrangements. However, there can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all, or that the warrants issued in previously consummated offerings will be exercised. To the extent that we can raise additional funds by issuing equity securities or in the event our existing warrants are exercised, our stockholders may experience significant dilution. Any debt financing, if available, &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;may involve restrictive covenants that impact our ability to conduct our business. If we are unable to raise additional capital, we may slow down or stop our ongoing and planned clinical trials until such time as additional capital is raised and this may have a material adverse effect on the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The determination as to whether we can continue as a going concern contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;&lt;/span&gt;Our consolidated financial statements&#160;&lt;span style="background:#ffffff;"&gt;have been prepared assuming that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of our assets and the satisfaction of our liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;span style="background:#ffffff;"&gt; Our fiscal year-end is December 31st for each year presented. &lt;/span&gt;All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;New accounting standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Adoption of new accounting standards&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In December 2023, the&lt;/span&gt;&#160;&lt;span style="background:#ffffff;"&gt;Financial Accounting Standards Board&lt;/span&gt;&#160;(&#x201c;FASB&#x201d;)&lt;span style="color:#212529;background:#ffffff;"&gt; issued&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;&lt;/span&gt;Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;span style="color:#212529;"&gt;2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve the transparency of income tax disclosures by amending the required rate reconciliation disclosures as well as requiring disclosure of income taxes paid disaggregated by jurisdiction. As amended, the rate reconciliation disclosure will be required to be presented in both percentages and reporting currency amounts, with consistent categories and greater disaggregation of information. This ASU also includes amendments intended to improve the effectiveness of income tax disclosures and eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. This ASU is&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;effective for annual periods beginning after December 15, 2024. We adopted ASU 2023-09 in 2025, &lt;/span&gt;and applied the new disclosure requirements retrospectively. Accordingly, prior period disclosures have been adjusted to reflect the new disclosure requirements, &lt;span style="color:#212529;background:#ffffff;"&gt;see Note 9. Income taxes for additional information. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Accounting standards issued but not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;In November 2024, the FASB issued&#160;ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the consolidated financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to the consolidated financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting period beginning after December 15, 2027. Early adoption is permitted. We continue to evaluate the impact of adopting this ASU to our notes to the consolidated financial statements and processes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Estimates and assumptions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We maintain cash and cash equivalents at a financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Property&#160;and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Property and equipment are recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from &lt;span style="-sec-ix-hidden:Hidden_zDOjGvv570SVRG19o1qIjg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&#160;to five years. Tangible assets acquired for R&amp;amp;D activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We assess our contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. We have recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to our&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, we recognize lease payments as an expense on a straight-line basis over the remaining lease term.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Warrant liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Warrants are accounted for as liabilities at their fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities is recognized as a fair value change in warrant liabilities in the consolidated statements of operations and as an operating item in the statement of cash flows. Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. &lt;span style="background:#ffffff;"&gt;The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We manage and operate as one reportable segment, which is principally the business of development of pharmaceutical products, with one geographic location in the U.S. We do not operate separate lines of business with respect to each pharmaceutical product being studied. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our chief executive officer. The CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. The measure of performance used by the CODM to assess segment performance is reported on the consolidated statements of operations as loss from operations and net loss. Since the Company only has&#160;one&#160;reportable segment, our CODM does not need to decide on how to allocate resources between segments. The measure of segment assets is reported on the consolidated balance sheets as total assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;R&amp;amp;D expenditures for pre-clinical and clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the United States Food and Drug Administration, are charged to R&amp;amp;D expense as incurred. These expenses consist of costs incurred in performing development activities, including salaries and benefits, equity-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Expenses incurred for certain R&amp;amp;D activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for R&amp;amp;D activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected as clinical trial accrued liabilities in the accompanying consolidated financial statements. Advance payments, if any, for goods or services to be received in the future for R&amp;amp;D activities are deferred and capitalized as prepaid expenses and other current assets in the accompanying consolidated balance sheets. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;K.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;General and administrative expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with R&amp;amp;D activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;L.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Patent costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;M.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Compensation costs related to equity instruments granted are recognized at the grant date fair value, which is amortized as compensation expense on a straight-line basis over the requisite service period (generally, the vesting period) for both graded and cliff vesting awards. We have elected to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;N.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method.&#160;Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Regular assessments are made on the likelihood that our deferred tax assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of available positive and negative evidence, giving weight based on the evidence&#x2019;s relative objectivity. Sources of positive evidence include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years, and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected in future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that, if unfavorably resolved, would adversely affect future profit levels.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The remaining carrying value of our deferred tax assets, after recording the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably. To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our policy is to recognize both interest and penalties related to uncertain tax positions as part of the income tax provision.&#160;A significant judgment is required in evaluating our tax positions, and in determining our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions are likely to be challenged and we may ultimately not prevail in defending those positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;O.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Foreign currency translation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Certain transactions are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;P.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Loss per share of common stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Basic earnings or loss per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the weighted average number of shares of common stock. Diluted earnings per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the sum of the weighted average number of shares of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive securities had been issued. Potentially dilutive securities include convertible preferred stock, outstanding stock options, non-vested RSUs and outstanding warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share of common stock by application of the treasury stock method, except if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities. For additional information, see Note 10. Loss per share of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Q.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Concentrations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Financial instruments that potentially subject us to concentration of credit risk consist of cash. As of December 31, 2025, our cash is held by one financial institution in the U.S., and we believe that the financial institution is financially sound. Accordingly, minimal credit risk exists with the financial institution. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Supplier Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In 2022, we entered into an exclusive license agreement (the &#x201c;2022 License Agreement&#x201d;) with Dong-A ST Co., Ltd. (&#x201c;Dong-A ST&#x201d;), a related party, which requires Dong-A ST to be the sole manufacturer for the production of vanoglipel (DA-1241) and DA-1726. If any issues arise in the manufacturing and we are unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete the development of vanoglipel (DA-1241) or DA-1726.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;R.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Loss contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In determining whether an accrual for a loss contingency is required, we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range, that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be accrued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely), no accrual is recognized. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_sjacPYcP-k2E-s0nbbmITw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-5"
      id="Narr_-GUtkhYWIEmDI9TL5bnnfg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">10300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-5"
      id="Narr_SKFBRUjHnEiO2onhs71iLw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-148800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-5"
      id="Narr_0JBcK2osK0aGULmsAELjVg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-13000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-5"
      id="Narr_0DS6G7R5y0G4keuXPzQytQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-15700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_yIhAM8zTQkW1ITfLVcs5Dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;span style="background:#ffffff;"&gt; Our fiscal year-end is December 31st for each year presented. &lt;/span&gt;All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_XHhuEbM02k6OaEgzMz8DQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;New accounting standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Adoption of new accounting standards&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;In December 2023, the&lt;/span&gt;&#160;&lt;span style="background:#ffffff;"&gt;Financial Accounting Standards Board&lt;/span&gt;&#160;(&#x201c;FASB&#x201d;)&lt;span style="color:#212529;background:#ffffff;"&gt; issued&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;&lt;/span&gt;Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;span style="color:#212529;"&gt;2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures to improve the transparency of income tax disclosures by amending the required rate reconciliation disclosures as well as requiring disclosure of income taxes paid disaggregated by jurisdiction. As amended, the rate reconciliation disclosure will be required to be presented in both percentages and reporting currency amounts, with consistent categories and greater disaggregation of information. This ASU also includes amendments intended to improve the effectiveness of income tax disclosures and eliminate certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. This ASU is&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;effective for annual periods beginning after December 15, 2024. We adopted ASU 2023-09 in 2025, &lt;/span&gt;and applied the new disclosure requirements retrospectively. Accordingly, prior period disclosures have been adjusted to reflect the new disclosure requirements, &lt;span style="color:#212529;background:#ffffff;"&gt;see Note 9. Income taxes for additional information. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Accounting standards issued but not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;In November 2024, the FASB issued&#160;ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the consolidated financial statements at interim and annual reporting periods. The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to the consolidated financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. In January 2025, the FASB issued ASU 2025-01, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting period beginning after December 15, 2027. Early adoption is permitted. We continue to evaluate the impact of adopting this ASU to our notes to the consolidated financial statements and processes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;Other recently issued accounting standards not yet adopted by us are not expected, upon adoption, to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_Z36PNNdx_0qNEcfQEIIWNQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Estimates and assumptions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in our consolidated financial statements relate to clinical trial costs and accruals, classification of warrants as derivative liability or equity, and the fair value of stock-based compensation and warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_7iD2znEzCUixNxL-At-GRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We maintain cash and cash equivalents at a financial institution that at times may exceed the Federal Deposit Insurance Corporation insured limits of $0.25 million per bank. To date, we have not experienced any losses related to these funds. Our cash equivalents consist principally of bank money market accounts and these securities are carried at cost, which approximates market value. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_33zJL9LY2EWyH92xpFadjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Property&#160;and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Property and equipment are recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from &lt;span style="-sec-ix-hidden:Hidden_zDOjGvv570SVRG19o1qIjg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&#160;to five years. Tangible assets acquired for R&amp;amp;D activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_NRfJ8T4b6Eu_-IBdIjogkw"
      id="Narr_lDPj4xnuuUi_dlzdhF7aKA">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_4xCuHQD2-EKJ6cv2uHU8cg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We assess our contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. We have recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to our&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, we recognize lease payments as an expense on a straight-line basis over the remaining lease term.&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <mtva:WarrantLiabilitiesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_vzc-xHh_WEu5_2OlBOw3Xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Warrant liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Warrants are accounted for as liabilities at their fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities is recognized as a fair value change in warrant liabilities in the consolidated statements of operations and as an operating item in the statement of cash flows. Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations. &lt;/p&gt;</mtva:WarrantLiabilitiesPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_H4h8RU8w306TyliZ2LClwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. &lt;span style="background:#ffffff;"&gt;The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_c2RfVQQ3MkuMcghw3H_Mdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Segment reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We manage and operate as one reportable segment, which is principally the business of development of pharmaceutical products, with one geographic location in the U.S. We do not operate separate lines of business with respect to each pharmaceutical product being studied. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our chief executive officer. The CODM manages the Company&#x2019;s operations on a consolidated basis for the purpose of allocating resources. The measure of performance used by the CODM to assess segment performance is reported on the consolidated statements of operations as loss from operations and net loss. Since the Company only has&#160;one&#160;reportable segment, our CODM does not need to decide on how to allocate resources between segments. The measure of segment assets is reported on the consolidated balance sheets as total assets. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Narr_91M_AP6Q2kOZTIYpj49-fQ"
      unitRef="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g">1</us-gaap:NumberOfReportableSegments>
    <mtva:NumberOfGeographicLocation
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Narr_AbS5ZoXJAU2AkMSQRXRyCg"
      unitRef="Unit_Standard_location_PUM6ABDH9EqMpz0Yzt6Sgw">1</mtva:NumberOfGeographicLocation>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Narr_pwm5DyNCfkWPrEDEuoO6tg"
      unitRef="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_vCtNhG5yAUOBQVEpy0EdKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;R&amp;amp;D expenditures for pre-clinical and clinical development, including upfront licensing fees and milestone payments associated with products that have not yet been approved by the United States Food and Drug Administration, are charged to R&amp;amp;D expense as incurred. These expenses consist of costs incurred in performing development activities, including salaries and benefits, equity-based compensation expense, preclinical expenses, clinical trial and related clinical manufacturing expenses, contract services and other outside expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Expenses incurred for certain R&amp;amp;D activities, including expenses associated with particular activities performed by contract research organizations, investigative sites in connection with clinical trials and contract manufacturing organizations, are &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;recognized based on an evaluation of the progress or completion of specific tasks using either time-based measures or data such as information provided to us by our vendors on actual activities completed or costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of expense recognition. Expenses for R&amp;amp;D activities incurred that have yet to be invoiced by the vendors that perform the related activities are reflected as clinical trial accrued liabilities in the accompanying consolidated financial statements. Advance payments, if any, for goods or services to be received in the future for R&amp;amp;D activities are deferred and capitalized as prepaid expenses and other current assets in the accompanying consolidated balance sheets. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_6-lE8_YPkUmTpLSUFD3LqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;K.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;General and administrative expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with R&amp;amp;D activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <mtva:PatentCostPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_AkxpN7TfzUmGr3ue6dj3oQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;L.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Patent costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.&lt;/p&gt;</mtva:PatentCostPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_SfcWxPiWEkWvZB5r7iRjPQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;M.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Compensation costs related to equity instruments granted are recognized at the grant date fair value, which is amortized as compensation expense on a straight-line basis over the requisite service period (generally, the vesting period) for both graded and cliff vesting awards. We have elected to account for forfeitures as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_SpMm6ZENU06fJ-sUVOY_Sw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;N.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method.&#160;Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and income tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in income tax rates is recorded as a component of the income tax provision in the period that includes the enactment date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Regular assessments are made on the likelihood that our deferred tax assets will be recovered from our future taxable income. Our evaluation is based on estimates, assumptions, and includes an analysis of available positive and negative evidence, giving weight based on the evidence&#x2019;s relative objectivity. Sources of positive evidence include estimates of future taxable income, future reversal of existing taxable temporary differences, taxable income in carryback years, and available tax planning strategies. Sources of negative evidence include current and cumulative losses in recent years, losses expected in future years, any history of operating losses or tax credit carryforwards expiring unused, and unsettled circumstances that, if unfavorably resolved, would adversely affect future profit levels.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The remaining carrying value of our deferred tax assets, after recording the valuation allowance on our deferred tax assets, is based on our present belief that it is more likely than not that we will be able to generate sufficient future taxable income to utilize such deferred tax assets. The amount of the remaining deferred tax assets considered recoverable could be adjusted if our estimates of future taxable income during the carryforward period change favorably or unfavorably. To the extent we believe that it is more likely than not that some or all the remaining deferred tax assets will not be realized, we establish a valuation allowance against those deferred tax assets, resulting in additional income tax expense in the period such determination is made. To the extent a valuation allowance currently exists, we will continue to monitor all positive and negative evidence until we believe it is more likely than not that it is no longer necessary, resulting in an income tax benefit in the period such determination is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our policy is to recognize both interest and penalties related to uncertain tax positions as part of the income tax provision.&#160;A significant judgment is required in evaluating our tax positions, and in determining our provisions for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We establish reserves when, despite our belief that the income tax return positions are fully supportable, certain positions are likely to be challenged and we may ultimately not prevail in defending those positions.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_1-1M_hCKpkGRjvniwmVRlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;O.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Foreign currency translation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Certain transactions are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_8ldNbMYmXkOTt15J74_J5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;P.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Loss per share of common stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Basic earnings or loss per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the weighted average number of shares of common stock. Diluted earnings per share of common stock is computed by dividing net income or loss available to stockholders of common stock by the sum of the weighted average number of shares of common stock and the number of additional shares of common stock that would have been outstanding if our outstanding potentially dilutive securities had been issued. Potentially dilutive securities include convertible preferred stock, outstanding stock options, non-vested RSUs and outstanding warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share of common stock by application of the treasury stock method, except if its impact is anti-dilutive. Under the treasury stock method, an increase in the fair market value of our common stock can result in a greater dilutive effect from potentially dilutive securities. For additional information, see Note 10. Loss per share of common stock.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_-TmJv0wwakCMY3O4rnMWbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Q.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Concentrations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Financial instruments that potentially subject us to concentration of credit risk consist of cash. As of December 31, 2025, our cash is held by one financial institution in the U.S., and we believe that the financial institution is financially sound. Accordingly, minimal credit risk exists with the financial institution. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Supplier Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In 2022, we entered into an exclusive license agreement (the &#x201c;2022 License Agreement&#x201d;) with Dong-A ST Co., Ltd. (&#x201c;Dong-A ST&#x201d;), a related party, which requires Dong-A ST to be the sole manufacturer for the production of vanoglipel (DA-1241) and DA-1726. If any issues arise in the manufacturing and we are unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete the development of vanoglipel (DA-1241) or DA-1726.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_yXbvhNye0UmuvmCJnePt8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;R.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Loss contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;In determining whether an accrual for a loss contingency is required, we first assess the likelihood of occurrence of the future event or events that will confirm the loss. When a loss is probable (the future event or events are likely to occur) and the amount of the loss can be reasonably estimated, the estimated loss is accrued. If the reasonable estimate of the loss is a range and an amount within the range appears to be a better estimate than any other amount within the range, that amount should be accrued. However, if no amount within the range is a better estimate, the minimum amount in the range should be accrued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;When a loss is reasonably possible (the chance of the future event or events occurring is more than remote but less than likely), no accrual is recognized. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_ARfeCe10nU6oWtA2FVes6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Prepaid expenses and other current assets&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Deferred equity offering costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</mtva:PrepaidExpenseAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_gNUgKDKZtk-FxxQXDhriXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Deferred equity offering costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Other prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_HdwC_WcjQE-8Fvl4e-_bRg_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_GJWuP7wiRkCARgMPq4B0bA_3_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Za741FJ_HkiQzDgMVV8scg_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">32000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_n-2cQcx200OBrAka5yw6wA_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_ogP4mvZapU25213hbxfrBQ_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">511000</us-gaap:DeferredOfferingCosts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_JMH0td9A2UKdAPaR5nxj0A_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">47000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_mJj0mKxdnkqwZJuhN71f_Q_6_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">34000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_SCpDBp9EvkOMPamWXcw16Q_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">597000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_5KtX7F-gVEGCRaOwN5qoqw_7_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">55000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_PWRKFS7yxU6hUiptMUYdvw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Property and equipment, net &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (73)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;We recorded depreciation expense of $19 thousand and $20 thousand for 2025 and 2024, respectively, which was included in general and administrative operating expenses in the accompanying consolidated statements of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_OiLptOCobkykxunUpgewZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (73)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (54)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_sz9glBx46kKXETTsz5EoAg_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">90000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_85dZqCPnjEaYZ4xVvfqvFw_3_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">88000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_IwamY-sDG0uNnqA8yURd5g_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">73000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_iDdQ_xcG50G_tDBiPXiw-Q_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">54000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_lGQuEuBIiUWE7AALxq6fUQ_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">17000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_xHvHu0-tTUiRFr7u-F8tGw_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">34000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Narr_PpeMgF1hqkSux_UwdpP6jQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">19000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Narr__yoKruYtD0uDXvpaZYASpQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">20000</us-gaap:Depreciation>
    <mtva:CurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_Jr9Wu_FhJ0mrakawNh1R3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Accrued expenses and other current liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Employee related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 785&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrant liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;Changes to our warrant liabilities are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VOralR6i3ki9t2Jyaw8bcA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Gain from change in fair value of warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (297)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_W8CSMwv8-EWiuCXptape3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Gain from change in fair value of warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (225)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;Our warrant liabilities relate to the 2022 Series B warrants issued in November 2022. These warrants are considered to be derivative instruments; accordingly, we recorded their estimated fair value as warrant liabilities. We estimated the fair value of these warrants using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby eight warrants can be exercised for one share of common stock for no additional consideration, which results in the warrant exercise price to be zero.&lt;/p&gt;</mtva:CurrentLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_yH6mRNl1NEOQGeHHcMHo2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Employee related costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 149&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:56.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 785&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_AT8nD7X950G8BzEACFZh0g_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">829000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_z1c8__TxCEKIrox3B08E8g_3_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">713000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_gLTT5uTR1EioesULEjcYpg_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">15000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_ImxB0ATupk2Fiz7ILoCNMg_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">17000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_pWKWh3cxYUKJ9KZjq83wUQ_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">149000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_CU9v3LXKYkeIEyRgaRuY3g_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">55000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <mtva:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_f-8hLSb0z0qERliY4HFi3w_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">993000</mtva:AccruedExpensesAndOtherLiabilitiesCurrent>
    <mtva:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_bfSJ4_R1xUugoBIDE4Hx5g_6_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">785000</mtva:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_N74r6oCNt0utbjek1ZHqXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;Changes to our warrant liabilities are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VOralR6i3ki9t2Jyaw8bcA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Gain from change in fair value of warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (297)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_W8CSMwv8-EWiuCXptape3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Gain from change in fair value of warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (225)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:76.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="-3"
      id="Tc_oZ2bPylSU0moVYW2zamVgA_2_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">658000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_AB9deOn6Gkitl1khKYTroA_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_nnGAXZ-nU0-hsSIqw411lA_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">361000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_oXhh9QoGJ06KoqLsMacv5g_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-225000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_RfUehSAMhE-yfb0J-NG-xw_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">136000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw"
      decimals="INF"
      id="Narr_5JUPmWBTaUaA1SH0VbF-BA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">8</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_GG-OyGYbHUevmT63tYsdDg"
      decimals="-3"
      id="Narr_CPue0qjI9EyKCGeZkw5ndA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesAndSeriesBWarrantsMember_NnEUlcGPt0qUX3cxxU2lfw"
      decimals="0"
      id="Narr_Pm8jpU390US1n5cJZv4yWw"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_m5Kr-gwjxUac9XKlSyRUUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5&lt;/b&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Related party&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;License agreement with Dong-A ST for &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;vanoglipel&lt;/b&gt;&lt;b style="font-weight:bold;letter-spacing:-0.2pt;background:#ffffff;"&gt; (DA-1241) and DA-1726&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We entered into a license agreement with Dong-A ST pursuant to which we received an exclusive global license (except for the territory of the Republic of Korea) for two proprietary compounds for specified indications (the &#x201c;2022 License Agreement&#x201d;) upon meeting certain financing milestones. The 2022 License Agreement covers the rights to vanoglipel (DA-1241) for treatment of MASH and DA-1726 for treatment of obesity and MASH. The 2022 License Agreement also provides that we may develop vanoglipel (DA-1241) for the treatment of&#160;&lt;span style="letter-spacing:0.2pt;"&gt;type 2 diabetes mellitus&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;In connection with the 2022 License Agreement, we entered into a shared services agreement with Dong-A ST (the &#x201c;Shared Services Agreement&#x201d;), relating to vanoglipel (DA-1241) and DA-1726, pursuant to which Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel (DA-1241) and DA-1726 under the terms provided in the Shared Services Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Under the terms of the 2022 License Agreement, Dong-A ST will be eligible to receive (i) regulatory milestone payments of up to $178.0 million for DA-1726 and $138.0 million for vanoglipel (DA-1241), dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by us from the commercial sale of products covering vanoglipel (DA-1241) or DA-1726. The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A ST or MetaVia may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60 days of notice of such breach; provided that if the breach cannot be cured within the 60-day period and the breaching party started to remedy the breach, if such breach is not cured within 90 days of receipt of written notice, or (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a 30-day cure period in the case of a petition for bankruptcy).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;As of December 31, 2025, there were no potential milestones under the 2022 License Agreement&lt;span style="background:#ffffff;"&gt; that were &lt;/span&gt;yet considered probable; therefore, &lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;liabilities were recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December 31, 2025, Dong-A ST and Dong-A Socio Holdings Co. Ltd. (&#x201c;Dong-A Holdings&#x201d;),&#160;an affiliate company of Dong-A ST, owns approximately &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;39%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;37%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, respectively, of our outstanding common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shared services agreement with Dong-A ST&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In conjunction with the 2022 License Agreement, we entered into the Shared Services Agreement with Dong-A ST, relating to vanoglipel (DA-1241) and DA-1726. The Shared Services Agreement provides that Dong-A ST may provide technical support, preclinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A ST will manufacture all of our clinical requirements of vanoglipel (DA-1241) and DA-1726 under the terms provided in the Shared Services Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Either party may terminate the Shared Services Agreement for the other party&#x2019;s material breach that is not cured within&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;of notice. Dong-A ST may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by us which is not cured within&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We incurred R&amp;amp;D expenses of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$3.4&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$4.9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million for 2025 and 2024, respectively, under the Shared Services Agreement, which are included in operating expenses: research and development in the accompanying consolidated statement of operations&lt;/span&gt;. The aggregate payable to &lt;span style="background:#ffffff;"&gt;Dong-A ST&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$3.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million as of December 31, 2025 and 2024, respectively, under the Shared Services Agreement, which is included in &lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;related party payable&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the accompanying consolidated balance sheets. Of the total amount payable to Dong-A ST as of December 31, 2025, (i)&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million is payable in accordance with an invoice with extended terms in which&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$650&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;thousand will be paid on March 31, 2026 and June 30, 2026 and&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$716&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;thousand will be paid on September 30, 2026, (ii)&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$29&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;thousand is payable in accrued interest based on a fixed interest rate of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;4.6%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;per annum, and (iii)&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million is payable in clinical trial accrued liabilities.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <mtva:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived
      contextRef="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1726Member_F0QfeopiT0211MFhaQu96A"
      decimals="-5"
      id="Narr_fnK2zV0ErUauXnf1Kpfqlw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">178000000</mtva:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived>
    <mtva:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived
      contextRef="As_Of_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_Da1241Member_SxJHN2alKEOYThrSrZEvCw"
      decimals="-5"
      id="Narr_UE--tdxS9Eqw5T-lMeRyMw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">138000000</mtva:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived>
    <mtva:PeriodForFailToCureBreachMayTerminateAgreement
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A"
      id="Narr_qYrbDbAGZkKSLdoGYsLbIw">P60D</mtva:PeriodForFailToCureBreachMayTerminateAgreement>
    <mtva:CurePeriodForBreachingParty
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A"
      id="Narr_M4apPvEAwUSL5goiTfKKlg">P60D</mtva:CurePeriodForBreachingParty>
    <mtva:PeriodForTerminationNotice
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A"
      id="Narr_X5UH0W3_0UO0YfKIkvIW6g">P90D</mtva:PeriodForTerminationNotice>
    <mtva:CurePeriodForPetitionForBankruptcy
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_mcZIf48AkkyXxzezVAAx5A"
      id="Narr_GWzlaVha3ESmuYwfUBWTpA">P30D</mtva:CurePeriodForPetitionForBankruptcy>
    <mtva:MilestonesAccrued
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_LicenseAgreementMember_88E3SsucMk6CjnvOW7ejPA"
      decimals="-5"
      id="Narr_yR0T9WMyj0ONFCzsx8iApg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</mtva:MilestonesAccrued>
    <mtva:PercentageOfCommonStockOutstanding
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongStMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_9ad2NPEyvEeMZjvJ8Yr8bg"
      decimals="2"
      id="Narr_4czs7M2IZkmQD3P6kaOVXA"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.39</mtva:PercentageOfCommonStockOutstanding>
    <mtva:PercentageOfCommonStockOutstanding
      contextRef="As_Of_12_31_2025_srt_CounterpartyNameAxis_mtva_DongSocioHoldingCoLtdMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember__CXlbv6yq0CPsUFeeflmGA"
      decimals="2"
      id="Narr_GW0gkcFozU-01TesEtzs5w"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.37</mtva:PercentageOfCommonStockOutstanding>
    <mtva:PeriodForFailToCureBreachMayTerminateAgreement
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_H5aw50Xy8UOPMQzuBjjNEw"
      id="Narr_PoTz9ArO70qnokzUOCVjfg">P30D</mtva:PeriodForFailToCureBreachMayTerminateAgreement>
    <mtva:PeriodForFailToCureBreachMayTerminateAgreement
      contextRef="Duration_9_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_H5aw50Xy8UOPMQzuBjjNEw"
      id="Narr_We8xgnFaL0y8rzK1ZRAVrg">P30D</mtva:PeriodForFailToCureBreachMayTerminateAgreement>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_Hor3BE5nO0Ky5ynGuPLNiA"
      decimals="-5"
      id="Narr_O7kEMHJJzUqQVmw-eCCNEg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_uNAveP-XZ06GyWkwukd-jg"
      decimals="-5"
      id="Narr_IfpMelcF-U6V2q-xOe8Thg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">4900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      decimals="-5"
      id="Narr_ijSpHdvY9EeDuNgww9C1Jg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_mQHj5ZFvVU-UfDaB2pKZcg"
      decimals="-5"
      id="Narr_LoTBTmyOiUmq8mWhqf-jlw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1500000</us-gaap:OtherLiabilitiesCurrent>
    <mtva:RelatedPartyExtendedPaymentLiability
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      decimals="-5"
      id="Narr_TX3vj0vg4Ueu8-rRRQAZzQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2000000</mtva:RelatedPartyExtendedPaymentLiability>
    <mtva:RelatedPartyExtendedPaymentLiabilityPayableInSixMonths
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      decimals="-3"
      id="Narr_q4Cd07Unr0aBvdGvk_4Tdw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">650000</mtva:RelatedPartyExtendedPaymentLiabilityPayableInSixMonths>
    <mtva:RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      decimals="-3"
      id="Narr_14WD4Zo0qk665cS260xa4Q"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">716000</mtva:RelatedPartyExtendedPaymentLiabilityPayableInNextTwelveMonths>
    <mtva:RelatedPartyAccruedInterestPayable
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      decimals="-3"
      id="Narr_cdKjiBh3k0KHtPNA740ZwA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">29000</mtva:RelatedPartyAccruedInterestPayable>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_Hor3BE5nO0Ky5ynGuPLNiA"
      decimals="3"
      id="Narr_NGhUw8KhfkuDEzO0Oxo7Ng"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.046</us-gaap:RelatedPartyTransactionRate>
    <mtva:RelatedPartyClinicalTrialAccruedLiability
      contextRef="As_Of_12_31_2025_us-gaap_RelatedPartyTransactionAxis_mtva_SharedServicesAgreementMember_v7nDyALPhEKLsR4NF_VG3A"
      decimals="-5"
      id="Narr_j7-OnoSMT0iWDPGeTZzWxw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1300000</mtva:RelatedPartyClinicalTrialAccruedLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_iYe_778hB0yP7kBd-QUUpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;6&lt;/b&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating lease&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In August 2023, we entered into a non-cancelable operating lease for our corporate headquarters in Cambridge, Massachusetts. The initial lease term is for&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;three years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;with an option, which was exercised in November 2025, to renew for an additional&#160;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;two-year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;term. The lease commenced in September 2023 and expires in August 2028. We recorded lease rental expenses and made lease cash payments of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$0.1&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million for 2025 and 2024. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2025 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Operating&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less effect of discounting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (40)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Short-term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Long-term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;As of December 31, 2025 and 2024, our lease liability, which represents the net present value of future lease payments, was calculated utilizing a discount rate of 11%, which corresponds to our estimated incremental borrowing rate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent payments and license agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="letter-spacing:0.2pt;"&gt;We have certain contractual contingent payments under various merger or license agreements executed between 2019 and 2020 for our &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;legacy therapeutic programs. &lt;/span&gt;Since we have discontinued the clinical development of our legacy therapeutic programs, we believe any &lt;span style="letter-spacing:0.2pt;"&gt;contractual payments to be paid by us or to be received by us under these agreements are&lt;/span&gt; remote. Therefore, a&lt;span style="background:#ffffff;"&gt;s of December 31, 2025, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;liabilities or &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_wKCHieRLFUC2maYfjLnuGQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;assets&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; were recorded in the accompanying consolidated financial statements for our legacy therapeutic programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Legal proceedings&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;From time to time, we may be involved in various claims and legal proceedings arising out of our ordinary course of business. We are not currently a party to any claims or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business and consolidated financial statements. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Purchase commitments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies, and testing, manufacturing, and other services and products for operating purposes. These contracts provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. There are no minimum purchase requirements under these contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;Employment agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"&gt;We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee benefit plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;We adopted a 401(k) defined contribution plan in November 2018, which became effective in January 2019, for all employees over age&#160;&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;21&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;. Employees can defer up to &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;90%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; of their compensation through payroll withholdings into the plan subject to federal law limits. Discretionary employer matches vest over a &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;six-year&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; period beginning on the second anniversary of an employee&#x2019;s date of hire. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;100%&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; vested upon contribution. &lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt;No&lt;/span&gt;&lt;span style="font-size:10pt;background:#ffffff;"&gt; matching contributions were made for 2025 and 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q"
      id="Narr_5m5x1hDwJUSw-MwbZwWdpQ">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_8_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember__UenDGfm60qOIdiZ3QiK4Q"
      id="Narr_C7AFsxAbE0SrylNm15swdQ">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_DBzDIMGO0UWZ5viFB9H-Hw"
      decimals="-5"
      id="Narr_jFGU-5v3YEeeT3vucLpaAg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_NeLyzkBTRESkMVZRZnvj7g"
      decimals="-5"
      id="Narr_9yYh_Kzodkm9nyVpO3xhsA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_DBzDIMGO0UWZ5viFB9H-Hw"
      decimals="-5"
      id="Narr_IfIYlR2W5U-sf8IaQshrgg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_NeLyzkBTRESkMVZRZnvj7g"
      decimals="-5"
      id="Narr_IdmyvdE91E6F8tz2OudfTA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_YFmtnYE-wkevLFfUSqTrhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2025 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Operating&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Lease&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less effect of discounting&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (40)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Short-term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Long-term portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_R171cp4eMEGf2yZ0hHCjpQ_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">92000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_tdVFkw6gn0yYQRZlT_scfQ_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">94000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_NRFCOdpgpUKaaXaYKR09NQ_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">64000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_-9sfFGkEfkS3IGcoZqGS7Q_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">250000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_RFlLrxyka0WtFAK1FjQtwg_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">40000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_4k4qEeftZEu_YHA3cUDscg_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">210000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_3Btod2l5pkCD1rWosBw_ww_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">68000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_PiSJTs1myEm91dghVECZeA_10_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">142000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_hyOQooLLv0aTYxqxsTi_Fw"
      decimals="2"
      id="Narr_dp8--xAWSUeIYbLwqy9New"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.11</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mtva_NewCorporateHeadquartersLeaseMember_eujJ4gdQVEqiI8yThjB2Ww"
      decimals="2"
      id="Narr_eRwWylDNmkmI_ZWw_yoQdw"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.11</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:ContractualObligation
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Narr_cfAO8Huhjk-YSdm0XDZuLw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:ContractualObligation>
    <mtva:DefinedContributionPlanEmployeeEligibilityAge
      contextRef="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg"
      id="Narr_RVNqvAhtL0m4gW8BW2vJsw">P21Y</mtva:DefinedContributionPlanEmployeeEligibilityAge>
    <mtva:DefinedContributionPlanEmployeeContributionDeferredPercentage
      contextRef="Duration_1_1_2019_To_1_31_2019_srt_RangeAxis_srt_MaximumMember_AaM2dzgtbUGUiNDeiHy-eQ"
      decimals="2"
      id="Narr_rzQe7El220y5923fOMP43Q"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.90</mtva:DefinedContributionPlanEmployeeContributionDeferredPercentage>
    <mtva:DefinedContributionPlanEmployerMatchingContributionVestingPercentage
      contextRef="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg"
      id="Narr_UOBlGVkcTU-gOtnRHgyv7w">P6Y</mtva:DefinedContributionPlanEmployerMatchingContributionVestingPercentage>
    <mtva:EmployeeCompensationVestingPercentageOnContribution
      contextRef="Duration_1_1_2019_To_1_31_2019_uTS8w08JZkCOEdhxzcNbbg"
      decimals="2"
      id="Narr_2L07GgwzsUGNo_yOu3ilkA"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">1</mtva:EmployeeCompensationVestingPercentageOnContribution>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="0"
      id="Narr_YXaYJtstS0aQEh4kulVFvQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="0"
      id="Narr_8EDgZHAkuEyLPMg5GzTEtg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_yOfJwkFjAkGdTvreyU--iA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;S&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;tockholders&#x2019; equity &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:0pt;"&gt;The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock when outstanding. The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. Common stockholders are entitled to receive dividends at the sole discretion of our Board. There have been no dividends declared on common stock to date as of December 31, 2025. In the event of any liquidation, dissolution, or winding-up of MetaVia, the holders of common stock shall be entitled to share in the remaining assets of MetaVia available for distribution post preferential distributions made to any holders of our preferred stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="color:#212529;font-weight:bold;"&gt;2025 Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="color:#212529;font-style:italic;"&gt;Private placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In May 2025, we closed on a private placement offering with Dong-A ST and Dong-A Holdings, and received net proceeds of $9.1&#160;million, net of placement agent cash fees of $0.4&#160;million and related offering expenses of $0.5&#160;million. The private placement offering was comprised of (i)&#160;861,758&#160;shares of our common stock for a purchase price of $7.81&#160;per share, and (ii)&#160;418,651&#160;pre-funded warrants to purchase up to an equivalent number of shares of our common stock for a purchase price of $7.799&#160;per pre-funded warrant.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Each pre-funded warrant had an exercise price of $0.011&#160;per share, and was exercisable beginning on June 30, 2025, which was the effective date of receiving stockholder approval for the issuance of the shares of common stock underlying the pre-funded warrants. Thereafter, on the same date, all pre-funded warrants were exercised for an equivalent number of shares of our common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="color:#212529;font-style:italic;"&gt;At the market offering&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;In November 2025, we entered into an At The Market Offering Agreement (the &#x201c;ATM Sales Agreement&#x201d;) with Ladenburg Thalmann &amp;amp; Co. Inc., as sales agent and/or principal (&#x201c;Ladenburg&#x201d;), pursuant to which we may offer and sell, from time to time through or to Ladenburg, shares of our common stock having an aggregate offering price of up to $2.3 million (the &#x201c;ATM Program&#x201d;). The offer and sale of the shares of common stock pursuant to the ATM Program is made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-278646) filed with the SEC on April 12, 2024, and declared effective by the SEC on April 23, 2024, as supplemented by a prospectus supplement to be filed with the SEC on November 6, 2025 pursuant to Rule 424(b) under the Securities Act.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Pursuant to the ATM Sales Agreement, Ladenburg may sell the Shares by any method permitted by law deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) of the Securities Act. We are not obligated to make any sales of the Shares under the ATM Sales Agreement. The offering of Shares pursuant to the ATM Sales Agreement will terminate upon the termination of the ATM Sales Agreement by Ladenburg or us, as permitted therein. We are obligated to pay Ladenburg an aggregate sales agent commission of 3.0% of the gross sales price of the Shares sold pursuant to the ATM Sales Agreement. We will also reimburse Ladenburg for certain specified expenses in connection with entering into the ATM Sales Agreement, which contains customary representations and warranties and conditions to the placements of the Shares pursuant thereto.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In November 2025, we sold 106,788 shares of common stock under the ATM Program and received net proceeds of $0.9 million, net of sales agent commission and related offering expenses. As of December 31, 2025, we have $1.1 million remaining under the ATM Program in which we may offer and sell shares of our common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;padding-top:8pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="color:#212529;font-weight:bold;"&gt;2024 Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="color:#212529;font-style:italic;"&gt;Securities purchase agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;In June 2024, we entered into and closed on&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;two&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;securities purchase agreements (the &#x201c;Offering&#x201d;)&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;with an institutional investor and Dong-A ST, and&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;received aggregate gross proceeds of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$20.0&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million, of which &lt;/span&gt;&lt;span style="color:#212529;"&gt;$10.0&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million was received from Dong-A ST. The &lt;/span&gt;net proceeds received was $18.3&#160;million, net of placement agent cash fees of $0.7&#160;million and related offering expenses of $1.0&#160;million. &lt;span style="color:#212529;"&gt;The Offering was comprised of (i)&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;300,707&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of common stock at a purchase price of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$43.23&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;per share, (ii) pre-funded warrants to purchase up to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;161,924&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of common&#160;stock at a purchase price of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$43.219&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;per warrant, (iii) Series A warrants to purchase&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;462,640&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of common stock, and (iv) Series B warrants to purchase up to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;693,962&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;common stock. Collec&lt;/span&gt;&lt;span style="color:#212529;"&gt;tively, the Series A and Series B warrants are referred to as &#x201c;PIPE Common Warrants.&#x201d; Of the total shares of common stock issued in the Offering,&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;69,396&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares were sold to an institutional investor. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;The pre-funded warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$0.011&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;per share and are immediately exercisable and &lt;/span&gt;are considered to be perpetual warrants without any expiration date.&#160;In the second quarter of 2025,&#160;all of the&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.&lt;span style="color:#212529;"&gt; The PIPE Common Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$43.23&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;per share and are exercisable as of September 18, 2024, which is the effective date of the stockholder approval received at the Special Meeting of Stockholders for the issuance of the shares upon exercise of the warrants. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;The Series A warrants &lt;/span&gt;were exercisable at any time from September 18, 2024 and expired unexercised in June 2025. The &lt;span style="color:#212529;"&gt;Series B warrants &lt;/span&gt;were exercisable at any time from September 18, 2024&lt;span style="color:#212529;"&gt; and &lt;/span&gt;expire on the earlier of September 18, 2029 and the&#160;six month&#160;anniversary following the date on which we publicly announce receiving positive Phase 1, Part 3 data for DA-1726.&lt;span style="color:#212529;"&gt; Based on the terms of the PIPE Common Warrants, we have concluded that the accounting classification of the PIPE Common Warrants is to be stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;Under the terms of the pre-funded warrants and the PIPE Common Warrants issued to the institutional investor, we may not affect the exercise of any such pre-funded warrants or PIPE Common Warrants, and the holder will not be entitled to exercise any portion of any pre-funded warrants or PIPE Common Warrants, if, upon giving effect to such exercise, the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates, other persons acting or who could be deemed to be acting as a group together with the holder or any of the holder&#x2019;s affiliates, and any other persons whose beneficial ownership of common stock would or could be aggregated with the holder&#x2019;s or any of the holder&#x2019;s affiliates) would exceed&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;9.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt; (in the case of the pre-funded warrants) or&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;4.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt; (in the case of the PIPE Common Warrants) of the number of shares of our outstanding common stock immediately after giving effect to the exercise (the &#x201c;Beneficial Ownership Limitation&#x201d;), as such percentage ownership is calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the SEC. A holder of the pre-funded warrants or PIPE Common Warrants that were issued to the institutional investor may increase or decrease the Beneficial Ownership Limitation to a higher or lower percentage (not to exceed&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;9.99%&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;), effective&#160;&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt;61&#160;days&lt;/span&gt;&lt;span style="color:#212529;font-size:10pt;"&gt; after written notice to us. Any such increase or decrease will apply only to that holder and not to any other holder of the pre-funded Warrants or PIPE Common Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt;"&gt;&lt;i style="color:#212529;font-style:italic;"&gt;Placement agent&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;We paid the placement agent a cash fee equal to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;7.0%&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;of the gross proceeds of the Offering received from a certain institutional investor and&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$0.1&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million for non-accountable expenses and clearing costs. In addition, we issued warrants to the placement agent&#x2019;s designees (&#x201c;Placement Agent Warrants&#x201d;) to purchase up to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;11,564&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of common stock (which represents&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;5%&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;of the sum of the shares of common stock and pre-funded&#160;Warrants sold to the institutional investor in the Offering) at an exercise price of&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$54.0375&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;per share (which represents a premium of&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;125%&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;of the offering price per share of common stock in the Offering). The Placement Agent Warrants are exercisable at any time from September 18, 2024 and expire in July 2026. The grant date fair value of the Placement Agent Warrants was&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$0.3&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million, which represents a non-cash issuance cost. The weighted average grant date fair value per share of these Placement Agent Warrants was&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;$30.03&lt;/span&gt;&lt;span style="color:#212529;"&gt;, which was determined using the Black-Scholes option pricing model. Based on the terms of the Placement Agreement Warrants, we have concluded that the accounting classification of the Placement Agent Warrants is stockholders&#x2019; equity in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;Upon the exercise for cash of any PIPE Common Warrants issued to a certain institutional investor, we shall pay the placement agent (i) a cash fee of&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;7.0%&lt;/span&gt;&lt;span style="color:#212529;"&gt; of the aggregate gross exercise price paid in cash with respect thereto and (ii) a non-cash fee in the form of additional warrants to purchase the number of shares of common stock equal to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;5.0%&lt;/span&gt;&lt;span style="color:#212529;"&gt; of the aggregate number of such shares of common stock underlying such warrants. The cash fee payable to the placement agent for any PIPE Common Warrants exercised by the institutional investor is accounted for as a contingent commitment and will be recorded as an offset to any gross proceeds received from any future exercises of PIPE Common Warrants by the institutional investor. The non-cash fee payable to the placement agent for any PIPE Common Warrants exercised by the institutional investor is accounted for as contingent warrants (&#x201c;Placement Agent Contingent Warrants&#x201d;) to purchase up to&#160;&lt;/span&gt;&lt;span style="color:#212529;"&gt;28,915&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;shares of common stock, which is subject to performance criteria of the institutional investor regarding any exercise for cash of any PIPE Common Warrants with an assumed grant date of the Offering closing date, and an exercise price of &lt;/span&gt;&lt;span style="color:#212529;"&gt;$54.0375&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;per share. The weighted average grant date fair value per share of these Placement Agent Contingent Warrants was &lt;/span&gt;&lt;span style="color:#212529;"&gt;$37.73&lt;/span&gt;&lt;span style="color:#212529;"&gt;, which was determined using the Black-Scholes option pricing model. Based on the terms of the placement agent engagement letter, we have concluded that the accounting classification of the Placement Agent Contingent Warrants is to be stockholders&#x2019; equity. On each balance sheet reporting date, we will need to assess whether it is probable for us to issue warrants to the placement agent based on whether it is probable for any PIPE Common Warrants to be exercised by the institutional investor. As of December 31, 2025 and 2024, &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;we determined that the issuance of additional warrants to the placement agent is not yet probable; accordingly, the Placement Agent Contingent Warrants had no impact on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The following warrants were outstanding as of December 31, 2025 and 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of Common Stock Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for Outstanding Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Expiration&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrant Issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;April 2020 &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;33,000.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;January 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;15,919.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;October 2021 &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;9,900.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;November 2022 Series B &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;December 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Placement Agent&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; (3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;54.0375 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Pre-Funded &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.011 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;No expiration date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Series A &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(5)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 462,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;43.23 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;June 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Series B &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(6)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 693,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 693,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;43.23 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;September 2029 (latest date)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 722,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,316,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants expired unexercised in April 2025.&lt;/span&gt;&lt;span style="display:inline-block;width:4.57pt;"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;T&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;hese warrants have a cashless exercise provision whereby&#160;the warrants can be exercised for common stock for&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;additional consideration, which renders the &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$264&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;per warrant exercise price to be&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;zero&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. &lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable at any time from September 18, 2024 and expire in July 2026. &lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(4)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable immediately and are considered to be perpetual warrants without any expiration date. In the second quarter of 2025,&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;130,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock. Additionally, in the third quarter of 2024, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31,924&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(5)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable at any time from September 18, 2024 and expired unexercised in June 2025.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(6)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable at any time from September 18, 2024 and expire on the earlier of September 18, 2029 and the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; anniversary following the date on which we publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Stock-based compensation expense was included in general and administrative &lt;span style="color:#212529;"&gt;and research and development as follows&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#212529;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Stock-based award plans&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In December 2019, in connection with a merger, we adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;). Additionally, we adopted the 2021 Inducement Plan in November 2021 and the Amended and Restated 2022 Equity Incentive Plan (the &#x201c;2022 Plan&#x201d;) in December 2022. The 2019 Plan, 2021 Inducement Plan and 2022 Plan provide for the grant of stock options, restricted stock, RSUs and other equity awards of our common stock to employees, officers, consultants, and directors. Stock options granted under any of these plans expire within a period of not more than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;ten years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from the date of grant. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;With the adoption of the 2022 Plan, no additional shares may be added to or granted from the 2019 Plan, and any shares related to forfeited awards are carryover to the 2022 Plan. In June 2024, in connection with the 2024 Annual Meeting of Stockholders, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;our stockholders approved an amendment (the &#x201c;Amendment&#x201d;) to our 2022 Plan. Pursuant to the terms and conditions of the Amendment, the 2022 Plan was amended to:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;automatically increase on January 1st of each year for a period of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eight years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; commencing on January 1, 2025 and ending on (and including) January 1, 2032, the aggregate number of shares of common stock that may be issued pursuant to Awards (as defined i&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;n the 2022 Plan) to an amount equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of the Fully Diluted Shares (as defined in the 2022 Plan) as of the last day of the preceding calendar year, provided, however that the Board may act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of shares of common stock; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;increase the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of Incentive Stock Options (as defined in the 2022 Plan) to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million shares of the common stock plus the amount of any increase in the number of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;shares that may be available for issuance pursuant to the annual increase described above, but in no event more than &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million shares of the common stock issued as incentive stock options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The following table summarizes the outstanding awards issued pursuant to our stock-based award plans and inducement grants as of December 31, 2025 and the remaining shares of common stock available for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Remaining shares of&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;common stock available&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Plan Name&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for future issuance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2019 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2022 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,693&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 167,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2021 Inducement Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 378&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,693&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 167,849&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;For outstanding awards granted under the 2019 Plan and 2022 Plan as of December 31, 2025, unrecognized stock-based compensation costs totaled $0.2 million. The unrecognized stock-based costs are expected to be recognized as an expense over a weighted average period of 1.1 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:8pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-size:10pt;font-style:italic;"&gt;RSUs&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The following table summarizes the status of our RSUs and related transactions for the period presented (in thousands, except share and per share amounts)&lt;/span&gt;: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Vested and Deferred Release&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Fair&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 50.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 50.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and released&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,855)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 51.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and released&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (6,693)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 18.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 43.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Stock options&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the status of our outstanding and exercisable options and related transactions for the period presented (&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:37.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,149.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The aggregate intrinsic value of our outstanding and exercisable options was zero as of December 31, 2025 and 2024, and January 1, 2024.&lt;i style="font-style:italic;"&gt; &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;/span&gt;&lt;i style="color:#212529;font-style:italic;"&gt;Grant date fair value of RSUs, stock options and warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;We estimated the grant date fair value of RSUs granted to employees, consultants, and directors based on &lt;span style="background:#ffffff;"&gt;the closing sales price of our common stock as reported on Nasdaq on the date of grant. &lt;/span&gt;We estimated the grant date fair value of stock options and warrants granted to employees, consultants, and directors using the Black-Scholes option pricing model. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The following table sets forth the fair value per share of Placement Agent Warrants granted in 2024 and the assumptions used in the Black-Scholes option-pricing model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Contingent&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Granted in&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Granted in&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;June 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;June 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted average fair value &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected stock price volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;140.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;127.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk-free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mtva:CommonStockVotingRightsPerShare
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Narr_9OEbb1sco0C72jPi_U1aYg"
      unitRef="Unit_Divide_Vote_shares_ETjCJisZMkuUls7w3gpdKA">1</mtva:CommonStockVotingRightsPerShare>
    <us-gaap:DividendsCommonStockCash
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="0"
      id="Narr_e8ZsuSa-kES7swEDjIHSGg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:DividendsCommonStockCash>
    <mtva:ProceedsFromIssuanceOfStockAndPrefundedWarrants
      contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q"
      decimals="-5"
      id="Narr_9gAgdbjBFE-0BXwnhRi7dw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9100000</mtva:ProceedsFromIssuanceOfStockAndPrefundedWarrants>
    <mtva:PaymentsForPlacementAgentFees
      contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q"
      decimals="-5"
      id="Narr_4ASI11rtKEOLUFMxseQoTA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">400000</mtva:PaymentsForPlacementAgentFees>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q"
      decimals="-5"
      id="Narr__Gk0X5xUFES_xM1KEpShZw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_b0FXkLbixkWxSIv-P8YI0Q"
      decimals="INF"
      id="Narr_wnYn01gZwkuVXR2tkTICZw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">861758</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2025_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_g-nMTDkmr0qcUvmTTdeMng"
      decimals="2"
      id="Narr_YFtyoxW15E6CFBG4MBwE5g"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">7.81</us-gaap:SharesIssuedPricePerShare>
    <mtva:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_5_1_2025_To_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_EuG_rsEk0UOcbgfii4_NdQ"
      decimals="INF"
      id="Narr__C0Rbf1yLEiPCLXrbls5Sw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">418651</mtva:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_UbXNPFwR4km-FBdk7rEUxg"
      decimals="3"
      id="Narr_tkFyyJdJokm6FoE15EPDqg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">7.799</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_SlAYXsZ0v0Ojj_aGP7CPdQ"
      decimals="3"
      id="Narr_3qx26sz80EiDmRUJk8EM6Q"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.011</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mtva:MaximumAggregateOfferingPrice
      contextRef="As_Of_11_30_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_WmjFk2Gzpk-vzxZey8nlRQ"
      decimals="-5"
      id="Narr_IVxqrKrtRUqSc8lmc9QHVg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2300000</mtva:MaximumAggregateOfferingPrice>
    <mtva:PercentageOfSalesAgentCommission
      contextRef="As_Of_11_30_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_WmjFk2Gzpk-vzxZey8nlRQ"
      decimals="3"
      id="Narr_UElZ-0GONUSDC3tVE3u1uw"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.03</mtva:PercentageOfSalesAgentCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q"
      decimals="INF"
      id="Narr_tsRUNXWZPEGfDNhRZemC5w"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">106788</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_11_1_2026_To_11_30_2026_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_9ksYcZO5R0qbMyz3U_Nn1Q"
      decimals="-5"
      id="Narr_aqF2nNXCCkaYBcbWg_ubGw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <mtva:AggregateOfferingPrice
      contextRef="As_Of_12_31_2025_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingAgreementMember_KFhU-S1q0U2O8QEiJ_Qd2Q"
      decimals="-5"
      id="Narr_vdFmDrj_QkSaANYa380Jyw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1100000</mtva:AggregateOfferingPrice>
    <mtva:NumberOfSecuritiesPurchaseAgreementsEntered
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="INF"
      id="Narr_QKLtXQEm10qRFzjIdgXSoA"
      unitRef="Unit_Standard_security_7HQ_97jGkEaCEOxlJP1q6A">2</mtva:NumberOfSecuritiesPurchaseAgreementsEntered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="-5"
      id="Narr_XGG-TXLTCE6irySFyVooBA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_us-gaap_TypeOfArrangementAxis_mtva_SecuritiesPurchaseAgreementMember_xy3ONbSXnUiU4ZOJJSQw7Q"
      decimals="-5"
      id="Narr_JSQ5p1Au2kemQROv4ydxHg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="-5"
      id="Narr_nWm-0apYuUqLdzwLg9iW4w"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <mtva:PaymentsForPlacementAgentFees
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="-5"
      id="Narr_XVE00dMkekeo_rxDG30HwA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">700000</mtva:PaymentsForPlacementAgentFees>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="-5"
      id="Narr_TYx9uSrGb0OzgDAw8wi68w"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="INF"
      id="Narr_LI4XOpgH4UWr_CcK618ewQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">300707</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ExKQGNyc2UCDlqt3ydfMgA"
      decimals="2"
      id="Narr_YwNBgD7n8EiXK_KbEVwNXg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">43.23</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg"
      decimals="INF"
      id="Narr_XsQA2v8F9EmA-rSv4Z8zuw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">161924</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg"
      decimals="3"
      id="Narr_B4d24TGsU06ooiONIt817g"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">43.219</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_5R_W5kJG9k-0RfAK0QNCRg"
      decimals="INF"
      id="Narr_Z4CCYnDiU0OUR6aVHbhaDg"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">462640</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesBWarrantMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_A7Fo-RQiLkOdMLTRGG3G9A"
      decimals="INF"
      id="Narr_oQWiYiEp_U-3QG1HPRrFMw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">693962</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_m2f7pvSnI0u6Km1eo2IeDA"
      decimals="INF"
      id="Narr_wN9-AbGwB0a-NxnVcvE-7A"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">69396</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg"
      decimals="3"
      id="Narr_Apz5-CsLqE66VJhI9Exrlw"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.011</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ffXAC5ncsEmnTRq2WxB_jQ"
      decimals="2"
      id="Narr_6DY12ZzxH0eowCRt91rOxQ"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">43.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mtva:ThresholdPercentageForBeneficialOwnership
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg"
      decimals="4"
      id="Narr_iKRzkA49RkGt1ayJ8-R3ug"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.0999</mtva:ThresholdPercentageForBeneficialOwnership>
    <mtva:ThresholdPercentageForBeneficialOwnership
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PipeCommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ffXAC5ncsEmnTRq2WxB_jQ"
      decimals="4"
      id="Narr_5WvCWznwck-al7ysHcMblg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.0499</mtva:ThresholdPercentageForBeneficialOwnership>
    <mtva:ThresholdPercentageForBeneficialOwnership
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_tIENlnjPS0WaAw7xJAWoxg"
      decimals="4"
      id="Narr_l2MUpM4nR0W44LKu4o0pyw"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.0999</mtva:ThresholdPercentageForBeneficialOwnership>
    <mtva:EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_2dC3y_eK3ki1KsOJenFcjg"
      id="Narr_24JHYo2fjU2S2tN8OV0GSw">P61D</mtva:EffectivePeriodForChangingBeneficialOwnershipLimitationFromReceiptOfWrittenNoticeFromHolder>
    <mtva:PercentageOfPlacementAgentFee
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="3"
      id="Narr_Y1aOzlZnvkGf04TXh_7sIQ"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.07</mtva:PercentageOfPlacementAgentFee>
    <mtva:PlacementAgentFeesNonAccountableExpensesAndClearingCosts
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="-5"
      id="Narr_ZOkuYIoBeEqmXx2GGCG6iw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</mtva:PlacementAgentFeesNonAccountableExpensesAndClearingCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ"
      decimals="INF"
      id="Narr_UWwXt0LFQUGszw5aFILSWg"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">11564</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <mtva:PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="2"
      id="Narr_M22hAD_um0S12rslnJ8nVg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.05</mtva:PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ"
      decimals="4"
      id="Narr_pVBUh4UCvUWaR2wRlPETNg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">54.0375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mtva:PremiumOfOfferingPriceForExercisePricePercentage
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Owwpee6TWESXOEjeyqvrAw"
      decimals="2"
      id="Narr_GajzAu84AU-tovqERLFEZg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">1.25</mtva:PremiumOfOfferingPriceForExercisePricePercentage>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_BeyBggePcE-w29AqAOcXuQ"
      decimals="-5"
      id="Narr_JRbtNwgbMkubIffCED4uRg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">300000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <mtva:WeightedAverageFairValuePerShareOfWarrants
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Owwpee6TWESXOEjeyqvrAw"
      decimals="2"
      id="Narr_QqTPNEmZa02wL-cGnEIGpg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">30.03</mtva:WeightedAverageFairValuePerShareOfWarrants>
    <mtva:PercentageOfPlacementAgentFee
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="3"
      id="Narr_jJ8RaZLtM0CWIu6zUipbwA"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.07</mtva:PercentageOfPlacementAgentFee>
    <mtva:PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_vzreIlKXy0-blBX-U29tcA"
      decimals="3"
      id="Narr__ZnZFbInY0u7wYMi4dbJOQ"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.05</mtva:PercentageOfSharesAndWarrantsSoldInOfferingMaximumSharesExercisableThroughWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Pj0_bY8RoEiWwD-LtiPp0A"
      decimals="INF"
      id="Narr_7Uggju1H3kqx0kLuyWd1_Q"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">28915</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_Pj0_bY8RoEiWwD-LtiPp0A"
      decimals="4"
      id="Narr_8p1cC49bg0GxFAQqldtBNg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">54.0375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mtva:WeightedAverageFairValuePerShareOfWarrants
      contextRef="Duration_6_1_2024_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_oBKoosGoG0GmD3xTsVOS-w"
      decimals="2"
      id="Narr_nRw4ituWC02RUKMe-7YtJA"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">37.73</mtva:WeightedAverageFairValuePerShareOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_iRwSIDeWIU6-jO8KxYZk5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of Common Stock Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for Outstanding Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Expiration&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrant Issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;April 2020 &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;33,000.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;January 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;15,919.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;October 2021 &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;9,900.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;November 2022 Series B &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;December 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Placement Agent&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; (3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 11,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;54.0375 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Pre-Funded &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(4)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;0.011 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;No expiration date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Series A &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(5)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 462,641&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;43.23 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;June 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;June 2024 Series B &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(6)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 693,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 693,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;43.23 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:25.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;September 2029 (latest date)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:28.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 722,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,316,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants expired unexercised in April 2025.&lt;/span&gt;&lt;span style="display:inline-block;width:4.57pt;"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;T&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;hese warrants have a cashless exercise provision whereby&#160;the warrants can be exercised for common stock for&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;additional consideration, which renders the &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$264&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;per warrant exercise price to be&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;zero&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. &lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable at any time from September 18, 2024 and expire in July 2026. &lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(4)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable immediately and are considered to be perpetual warrants without any expiration date. In the second quarter of 2025,&#160;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;130,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock. Additionally, in the third quarter of 2024, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;31,924&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;pre-funded warrants were exercised for an equivalent number of shares of our common stock.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(5)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable at any time from September 18, 2024 and expired unexercised in June 2025.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:27pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(6)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;These warrants are exercisable at any time from September 18, 2024 and expire on the earlier of September 18, 2029 and the &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;six months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; anniversary following the date on which we publicly announce the receiving of positive Phase 1, Part 3 data readout for DA-1726.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:8pt;"&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_YGrezCPF50-XvUz2iIIe3A"
      decimals="INF"
      id="Tc__6UCso7Hs0upP_kAGJfCAQ_5_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">14</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice3300000Member_h23ZVALXkUePo8zvVv2roQ"
      decimals="2"
      id="Tc_2RGdiUMyCk6UxMDRTUAI0w_5_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">33000</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_wyVIcQ8InUKuk3VoxOQDHg"
      decimals="INF"
      id="Tc_oiJjbR7yTk2PYZ8NOoXi9g_6_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">942</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_PtYIpmGNVk2Lhpzik7xP3g"
      decimals="INF"
      id="Tc__jYwjMVEhUuLzPIV4dwVXw_6_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">942</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice1591920Member_wyVIcQ8InUKuk3VoxOQDHg"
      decimals="2"
      id="Tc_8eVQMufNtEGsF5utXYocPA_6_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">15919.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_mylIA7H1dEi-aM6e5VbgCg"
      decimals="INF"
      id="Tc_dXtbXuqAZE2qRFr3evCzAQ_7_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1399</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_WarrantsExercisePrice990000Member_CldTLXRU7EGJY2I47LLydQ"
      decimals="2"
      id="Tc_U6tSg15Sr0SEHr1zkchmew_7_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">9900</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA"
      decimals="INF"
      id="Tc_P2PYXQtICka2t-8vSHUfrA_8_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">16176</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_Bv82ps5MOk6lD4sKnKRyPA"
      decimals="INF"
      id="Tc_J7IsQ8CKVUSriKTluwUA6g_8_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">16176</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA"
      decimals="2"
      id="Tc_Z-hHgsnYS0GGw_lNgdOT-Q_8_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_lJphVo6Jl0qN7JwUudMRRg"
      decimals="INF"
      id="Tc_HPjcDq5xw0K5qk4As0Uz4Q_9_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">11564</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_6202WPiPKkSw1AqR8WV3jw"
      decimals="INF"
      id="Tc_gWtJ1XNPwkaNl-kdl0MICQ_9_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">11564</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PlacementAgentWarrantExercisePrice540375Member_lJphVo6Jl0qN7JwUudMRRg"
      decimals="4"
      id="Tc_1Sur5rg8ZEGlddaXU6nZWw_9_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">54.0375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_UBBH_Z1Tz0S_4XGQiyGdpw"
      decimals="INF"
      id="Tc_sS0UDqGWzEmVLl_a-fi4rw_10_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">130000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_5H7GHDBMaE2UtxHkUd3cCQ"
      decimals="3"
      id="Tc_eBU5bwuqWUy4C90sskSSHQ_10_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.011</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_0TANxl4zWU2M4iUW_Dzy7g"
      decimals="INF"
      id="Tc_i0LyqIFn1E2nETOQFp_PjQ_11_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">462641</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesaWarrantExercisePrice4323Member_mJd36VtBzkuAj1i6nsWyDQ"
      decimals="2"
      id="Tc_Q2rUUolfyUGl808Ez8VKtA_11_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">43.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_5XNmuoAqREGcG2s4IaMjeQ"
      decimals="INF"
      id="Tc_hBDZssLNYUyNkyd5U38Zug_12_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">693962</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_KNYPj3hEekKCq6iIEa5aJA"
      decimals="INF"
      id="Tc_bGRAZtnpaUumefeT4KPrMg_12_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">693962</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_5XNmuoAqREGcG2s4IaMjeQ"
      decimals="2"
      id="Tc_EYWsAHago0mgEEW4Mm-I9A_12_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">43.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Tc_Mlp1gj5kJE2pVxl-jy10Ig_13_1"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">722644</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Tc_NDHlvQzLFUqvB2yVL-YJ5w_13_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1316698</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_vvalEg-TrUejRp41VE8WPw"
      decimals="0"
      id="Narr_aW1gUfZAlEyY8jtoEtbsSw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_waCAFY3cfEuZyDAJOyUoHA"
      decimals="0"
      id="Narr_c86q4lSMZUWMgLqbPbMYjw"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">264</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_orxQwUg110-1269nNhDK5w"
      decimals="0"
      id="Narr_I6xw34AGg0miQteYY0BFVg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_e1wxSJsny0iiOB1sr8mCHA"
      decimals="INF"
      id="Narr_m5OO97UkAEmJ-Po4o9Vo7w"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">130000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024PreFundedWarrantExercisePrice0011Member_nrhpLK0mj0K9W2Dt9Ye5iQ"
      decimals="INF"
      id="Narr_yrZcbrrVkUqJUJkpO5rLtw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">31924</mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised>
    <mtva:ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_June2024SeriesBWarrantExercisePrice4323Member_QGD8FaaTKk-VCqeDRjoO0w"
      id="Narr_CIWpvX1rNEmBAQO0Yu8N4w">P6M</mtva:ThresholdPeriodFollowingPublicAnnouncementOfReceivingPositivePhase1MultipleAscendingDoseDataForExpiryOfWarrants>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_zOf13awCrUSmwnJ5izt-ww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Stock-based compensation expense was included in general and administrative &lt;span style="color:#212529;"&gt;and research and development as follows&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#212529;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 172&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:56.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 411&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 538&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_7qHL6fLtgESMlXNDqOZJ2w"
      decimals="-3"
      id="Tc_BNJgHxVouUySqp7vpGnm4A_3_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1hYaSL2Lxk-1ulrcFV5TrA"
      decimals="-3"
      id="Tc_2-u-Ut5rd0mLaMS4STG1qg_3_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U6f5XE8pkEWgllVziJrf-Q"
      decimals="-3"
      id="Tc_yft7mZUF0UuHGorGLZDieA_4_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">106000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9AAALrlJp0yWgwl3bBqvvA"
      decimals="-3"
      id="Tc_m0L3j3TMH0yXJWWychBT_w_4_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_V8n0HcPbhEW4EysAB-8qUQ_5_4"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">411000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_YO2lcn88Tku2dqnR9QVUrg_5_7"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2019Member_gmTdCJ8ork6VP-4xURIA1A"
      id="Narr_LS5zrXslwEu58p-lLRWN5Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg"
      decimals="INF"
      id="Narr_WheZv6ekHUqp74VTHk60Zw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg"
      id="Narr_GxzALvtxdE6pw1KT1yY2Ww">P8Y</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_yhfWC-JVDkuiqFDv9XEENg"
      decimals="2"
      id="Narr_bptj8j1ggkOdOwqHXocPhg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_fPHz9pePvU-5r9-YvskzmQ"
      decimals="-6"
      id="Narr_8CKtGuiCo0SaxePZkq7XkQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_w5EWKu_kcUSEno9r_g_0ww"
      decimals="-6"
      id="Narr_IkDwlSgFqUaEcbVYUdlDRw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_8iyLJOgDFke_CEF7ztzlOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Remaining shares of&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;common stock available&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Plan Name&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:26.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for future issuance&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2019 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2022 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,693&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 167,471&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2021 Inducement Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 378&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:47.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,693&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 167,849&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_hGYstxKTzU2ZqyDcJ15G0g"
      decimals="INF"
      id="Tc_dLlqkJl6SEis4mruaNoyyQ_5_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">6693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_BxRCSzAuXEimnCRFgvNQ_w"
      decimals="INF"
      id="Tc_f4WDwKEAiE-CiTjOR18sbQ_5_4"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">29295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan2022Member_fPHz9pePvU-5r9-YvskzmQ"
      decimals="INF"
      id="Tc_9UbFIe_2_EaFl3MogUHDMg_5_6"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">167471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_TwoThousandTwentyOnePlanMember_MH43z9s-vEmoE1YjdETXcg"
      decimals="INF"
      id="Tc_pYp_sNYIok2pU99-aLBpvA_6_6"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_v7UzME_8uUKyZkD-egDxIQ"
      decimals="INF"
      id="Tc_sPqL5jhMOEeL228TriQckA_7_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">6693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_3128W61YJ0eOKZC5tMQTAQ"
      decimals="INF"
      id="Tc_N2aJCpxHJEOo_0UKG5nWQg_7_4"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">29295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Tc_V8H3B9tvJUatjjXtAV7WOA_7_6"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">167849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_aNE-h6VMsU2pzK3AIQny9g"
      decimals="-5"
      id="Narr_pz8zhF8N2UKRKdZWGi0DEw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_PlanNameAxis_mtva_StockPlan20192022AndInducementPlanMember_Mc6s5k_bG0SSAZ7j_mIrwQ"
      id="Narr_keCO0FiOSUOM0Tx352MKVw">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_K1o6QGN74EOPZ_qiHweoZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The following table summarizes the status of our RSUs and related transactions for the period presented (in thousands, except share and per share amounts)&lt;/span&gt;: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Vested and Deferred Release&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Grant Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Fair&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 50.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 44.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 50.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and released&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,855)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 284&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 51.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 22,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and released&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (6,693)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 53.58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,142)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30.04&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:25.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 29,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 18.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 43.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="INF"
      id="Tc_ZDQqGsRISUiWCgfaDh1AhA_6_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">12849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="2"
      id="Tc_GVUq89SD1kib4cfH-1Dd5w_6_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">50.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="-3"
      id="Tc_7xNasLXYgkmsX3IjHdD3GA_6_8"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">523000</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="INF"
      id="Tc_q9H0Uy0NsUatst6JYUSWbQ_6_10"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">497</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="2"
      id="Tc_FiZKrSJNZkSBLBgu-iZ46Q_6_13"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">44.19</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="-3"
      id="Tc_0Bn4uHW-f0CCpGP_h0qurQ_6_16"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">20000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="INF"
      id="Tc___GKh__XtUeY958Eir7CkA_7_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">10918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Tc_1swAPaflPEmznJOoy052fw_7_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">50.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="INF"
      id="Tc_8OikCtoockqubBzR4HJshQ_8_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">7855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Tc_Gq6bMFhxCEmWEL1EOBYHFg_8_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">47.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_KNw91BHQVkmVTBRJj-_ScQ_8_8"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">284000</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Tc__Hd_FnGicUan5ExvhckZ9Q_9_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">15912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="2"
      id="Tc_F2xdH_5YBkiRNrIvAEyf5w_9_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">51.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_Y5X50EvtXkGa17_KVbjzvw_9_8"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">355000</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Tc_IsBoRJeiS0-drroSgKZYfg_9_10"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1184</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="2"
      id="Tc_c69EfIQbV0e3_RnufL2mRg_9_13"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">46.9</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_iwXQwTZof0mNMbO5qiqZpQ_9_16"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">26000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Tc_i96CxDU7AkufaDkrQpFcvA_10_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">22218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_szkIGhNijkm4YngiYjUDmg_10_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">7.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Tc_wqDmuMMHekmuh5-0OfDkkg_11_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">6693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_IDqqhFo8vEyDnk6gjr5fIA_11_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">53.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_wmxlTRIyxUe3d2-GxnPTIw_11_8"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">70000</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Tc_PZ_60SYQvE2heVE8GTcAaQ_12_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">2142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_nhIWyJUxGUykIrPB3NTsuw_12_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">30.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Tc_h1EpaziwJ0uJ91CIPMO8QA_13_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">29295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="2"
      id="Tc_MICUTEgWdEuukWQSBELGDg_13_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">18.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_5UFgjPPzXEiz9Tvcdqj7Kw_13_8"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">247000</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateFairValueOutstandingBalance>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Tc_-swsZmxzBEmYAa5dlbr3kw_13_10"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">3082</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="2"
      id="Tc_AngwFLSrHEC8RMVMHgM5Ag_13_13"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">43.85</mtva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_phdDK7r47EO4S5ChPFgNlw_13_16"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">26000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_TKKr_QJSoE6qLqwss4l1Gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the status of our outstanding and exercisable options and related transactions for the period presented (&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:36.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:37.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercisable&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Common&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Issuable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;for Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,149.85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:24.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,240.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="INF"
      id="Tc_QcL6GkLVHk2fdLfeiuukqQ_7_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="2"
      id="Tc_0M6nQgA_8k-JvXKOgZ2c5Q_7_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">4240.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_BY79CPAZZk27J-wqZYzO7w"
      id="Tc_Gtr4BHY3s0Oq5nbp6pLjig_7_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="INF"
      id="Tc_JmRV3DykD0Sxs89dNMN1tA_7_9"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">408</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="2"
      id="Tc_MN6aKowe8U-ulWSIUZLKqA_7_12"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">4149.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_BY79CPAZZk27J-wqZYzO7w"
      id="Tc_o_45NMxpn0adTYb4mmHYRg_7_14">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Tc_B2Nodj2iTUeVHcOKJLkRVA_8_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="2"
      id="Tc_inEC2bTgY0OnvwZ93CRLgg_8_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">4240.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      id="Tc_EosatiHxTUuZnUiddyeAtA_8_7">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="INF"
      id="Tc_DsFkQOeZ6EKH15jNgKXuSw_8_9"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="2"
      id="Tc_rLqnmzcNHEGItFGM26tPqw_8_12"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">4240.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      id="Tc_o2swNSt0TkGu4EbXmdrufA_8_14">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Tc_y3vBSDGTQky6T8eXKLJZ6Q_9_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="2"
      id="Tc_Gu8t0kSGq0qRFLlqCL-VqA_9_5"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">4240.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_zylc2RUf5k6UjEeWDzA9AQ_9_7">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Tc_93T3V8SWX0mNDFPcU1UFjA_9_9"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="2"
      id="Tc_2Xx3JLIYSECv-uIZ4EZJMg_9_12"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">4240.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tc_Y24k1hsq3E-m-QIGOkkGeg_9_14">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2023_Sci_QHz800mcLknIVO1ZXw"
      decimals="-3"
      id="Narr_TjTu3Xn8X0qsgpAwd6wrCg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Narr_U0o2I5rEZkSNSAg4JADT9A"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Narr_J9xMbPiMYEqA3FhGkkspug"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_tHjxjNsdXUaG4r6cDZoeEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:51.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Contingent&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Granted in&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Granted in&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:44.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;June 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;June 2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Weighted average fair value &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected stock price volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;140.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;127.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;5.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:44.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk-free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;4.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw"
      decimals="2"
      id="Tc_PWleMhOS-E6wShqBoEtk3g_6_3"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">30.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg"
      decimals="2"
      id="Tc_sKC-hDcUvUeiFx_EjLBkDw_6_7"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">37.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw"
      decimals="3"
      id="Tc_wRjWTWaxxUKRmmRAeOHdeQ_7_3"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg"
      decimals="3"
      id="Tc_lXg2UpTO9kuGXJYkc8pMGA_7_7"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw"
      id="Tc_twQWHWCZgECIDvgIX1Wlow_8_3">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg"
      id="Tc_SsPDtUbBIEqkU9gmgPUBYw_8_7">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_RxQ7FB7nzkSnpEPBICcPRw"
      decimals="4"
      id="Tc_8mH0RPsrKkW_GEITdkVicg_10_3"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.0463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_PlacementAgentContingentWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_June2024OfferingMember_ZhMNiAd5R0CwlJO6CpFhEg"
      decimals="4"
      id="Tc_I0lXVXCg-0O29KFap2IkRQ_10_7"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_A32EAp2B9U-k0SKeovmiww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Significant segment expenses and loss before income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt;The following table sets forth the significant segment expenses for our &lt;/span&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt;one&lt;/span&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt; reportable segment (in thousands) that are regularly provided to our CODM: &lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Direct expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Vanoglipel (DA-1241) credits (costs) &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (845)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"&gt;DA-1726 costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Other R&amp;amp;D costs&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; (2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Indirect expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"&gt;Employee compensation and benefits costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"&gt;Consulting expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Legal and professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Consulting expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Employee compensation and benefits costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,708)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (28,809)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes a credit of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; million recorded in 2025 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;in connection with the close-out of the clinical trial with the&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;clinical research organization.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes clinical, non-clinical and preclinical services or other R&amp;amp;D expenses that are not attributable to a single product candidate.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45.35pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes all other general and administrative expenses, such as insurance, software license fees, non-income state taxes, lease rental expenses, etc.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_F71nPkZs7UmZVp4rREt5HA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt;The following table sets forth the significant segment expenses for our &lt;/span&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt;one&lt;/span&gt;&lt;span style="color:#212529;letter-spacing:0.2pt;"&gt; reportable segment (in thousands) that are regularly provided to our CODM: &lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Direct expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Vanoglipel (DA-1241) credits (costs) &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (845)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"&gt;DA-1726 costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Other R&amp;amp;D costs&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt; (2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Indirect expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"&gt;Employee compensation and benefits costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,653&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,606&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"&gt;Consulting expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Legal and professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Consulting expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 823&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Employee compensation and benefits costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Other expenses &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total general and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 28,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,708)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (28,809)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total other income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 735&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes a credit of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; million recorded in 2025 &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;in connection with the close-out of the clinical trial with the&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;clinical research organization.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes clinical, non-clinical and preclinical services or other R&amp;amp;D expenses that are not attributable to a single product candidate.&lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:4pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:45.35pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt;Includes all other general and administrative expenses, such as insurance, software license fees, non-income state taxes, lease rental expenses, etc.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="INF"
      id="Narr_vnRde_-5UU2hJ00RaXK1ow"
      unitRef="Unit_Standard_segment_Y-sxYpYrBEyf0_HQMlxS_g">1</us-gaap:NumberOfReportableSegments>
    <mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_6aObyGwtFkyxT-nJscdKlw_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-845000</mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram>
    <mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_7K_iHL1iQUSJR8yJe0YpvQ_6_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9959000</mtva:ResearchAndDevelopmentExpenseFirstClinicalTrialProgram>
    <mtva:ResearchAndDevelopmentExpenseSecondClinicalTrialProgram
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_j1_1EtSiR0qpfyKwPDSbQg_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5468000</mtva:ResearchAndDevelopmentExpenseSecondClinicalTrialProgram>
    <mtva:ResearchAndDevelopmentExpenseSecondClinicalTrialProgram
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_NKaCycz4bEWsoAmg80ZZAQ_7_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9397000</mtva:ResearchAndDevelopmentExpenseSecondClinicalTrialProgram>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_iUSdVORlq0OroDLZD6Y2Og_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">107000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_NTMBTxBPE0CpyQSJZS0Drw_8_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">303000</us-gaap:OtherResearchAndDevelopmentExpense>
    <mtva:LaborAndRelatedExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_49XcaDWLaEGieUu6AmajVg_10_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1653000</mtva:LaborAndRelatedExpenseResearchAndDevelopment>
    <mtva:LaborAndRelatedExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_f44ZE5MnrUGBB3OLoCIFog_10_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1606000</mtva:LaborAndRelatedExpenseResearchAndDevelopment>
    <mtva:ConsultingFeeResearchAndDevelopment
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_YvgmapzFHEWpoSQWZ-O2KA_11_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">419000</mtva:ConsultingFeeResearchAndDevelopment>
    <mtva:ConsultingFeeResearchAndDevelopment
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_Wkr7HAkrw0GbtZ-_gxoDyg_11_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">288000</mtva:ConsultingFeeResearchAndDevelopment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_go6lX10Uh0yDtxXfHXEoyw_12_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6802000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_KEPMvSzX1EmM_kSArEha3Q_12_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">21553000</us-gaap:ResearchAndDevelopmentExpense>
    <mtva:LegalAndProfessionalFees
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_TxK3A9Ydw0OeNpCXoA1vew_14_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3338000</mtva:LegalAndProfessionalFees>
    <mtva:LegalAndProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_AnaZGDHNuEqiCJVtbMkQiw_14_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2864000</mtva:LegalAndProfessionalFees>
    <mtva:ConsultingFeeGeneralAndAdministrative
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_UnaASSrCkU-jDRiXFCthFw_15_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">823000</mtva:ConsultingFeeGeneralAndAdministrative>
    <mtva:ConsultingFeeGeneralAndAdministrative
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_yG_eFnxHgEeABC3q5nJG8Q_15_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1512000</mtva:ConsultingFeeGeneralAndAdministrative>
    <mtva:LaborAndRelatedExpenseGeneralAndAdministrative
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_4bVcrab82UWL-lgX8ZFOFQ_16_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1797000</mtva:LaborAndRelatedExpenseGeneralAndAdministrative>
    <mtva:LaborAndRelatedExpenseGeneralAndAdministrative
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_aBLnnMxT5kmLrmxXo88NAA_16_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1659000</mtva:LaborAndRelatedExpenseGeneralAndAdministrative>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_cpxKrsVL00qoVefKeCYPdA_17_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">948000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_5Wqasac64E2wd8-LjHMQCw_17_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1221000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_SO948mnW-EyoCe1D64tnCw_18_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">6906000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_aKIMjiAMJEqVbrlwEOdPiw_18_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7256000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_MMA83WEPN0iqAA4dvStEWA_19_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">13708000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_sLbohdsnd0ys-YuAOdpXhg_19_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">28809000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_NJIZ_oanREKGwkgMspcTDA_20_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-13708000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_gnpvGiT0tE6d5X17-H9j0w_20_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-28809000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_dP-97CvVC06gXuPtMEJqKw_21_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">735000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_60ZjPLmW0E-zyRpO3zBXyw_21_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1217000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-3"
      id="Tc_I6i9CIa4T02amMIfMWZpdw_22_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_C_SvNoJQoE6smuKTXRZqRQ"
      decimals="-3"
      id="Tc_JesIar9_DkaSTsnnmmBXCw_22_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <mtva:ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_StatementBusinessSegmentsAxis_mtva_SingleReportableSegmentMember_P3FMu0AKPkiiXbIyLlh0oQ"
      decimals="-5"
      id="Narr_kikZxq7Am0WVRHAFcHg5ag"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1200000</mtva:ResearchAndDevelopmentExpenseReversalOnCloseOutOfFirstClinicalTrialProgram>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_FNvYXOoovUKnjlpyjThDnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our loss before income taxes is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss before income taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The components of our income tax provision are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Income tax (benefit) expense:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,683)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (5,809)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 270&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred income tax (benefit) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,413)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (8,401)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our effective tax rate for 2025 and 2024 was zero percent. A reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate is as follows (in thousands, except for percentages):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Income taxes at U.S. federal statutory rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,724)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (5,794)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;State income tax, net of federal benefit &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Changes in valuation allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (20.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (21.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Nontaxable and nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (62)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Effective tax rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The significant components of our deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred income tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. federal and state net operating loss ("NOL") carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Acquired intangibles &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net unrealized built-in loss (NUBIL) - 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;R&amp;amp;D credit carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 18,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (18,491)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (16,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (58)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (36)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (58)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred income tax assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The realization of our deferred income tax assets is primarily dependent upon future taxable income, if any, and such income is uncertain in both amount and timing. We have had significant pre-tax losses since our inception, and we have not yet generated revenues and face significant challenges to becoming profitable. Accordingly, we have recorded a valuation allowance of $18.5 million and $16.1 million as of December 31, 2025 and 2024, respectively. U.S. federal deferred income tax assets will continue to require a valuation allowance until we can demonstrate their realizability through sustained profitability or another source of income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;As of December 31, 2025 and 2024, our U.S. federal NOL carryforwards were $33.0 million and $18.5 million, respectively. We had less than $0.1 million of U.S. federal R&amp;amp;D credit carryforwards as of December 31, 2025 and 2024. Our U.S. federal NOL were incurred after December 31, 2017 and therefore, will not expire. As of December 31, 2025 and 2024, we had state NOL carryforwards of $12.1 million and $17.4 million, respectively. The state NOL carryforwards will begin to expire in 2042, if not utilized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Our ability to utilize our NOL and R&amp;amp;D credit carryforwards have been and may be substantially limited due to the ownership changes that have occurred or that could occur in the future, as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state provisions. These ownership changes may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an &#x201c;ownership change,&#x201d; as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. We completed a Section 382 study for 2025 and it was determined that we experienced one ownership change of over 50% since 2022, which was the year of the last 50% or greater ownership change. The 2025 ownership change occurred on May 8, 2025, and going forward, the utilization of loss carryforwards and tax credits generated before May 8, 2025 will be &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;subject to an annual limitation. As a result of the ownership changes and limitations, $100.8 million and $68.6 million of federal and state NOL carryforwards, respectively, will expire unutilized and have been written off. Additionally, $1.2 million of federal R&amp;amp;D credit carryforwards will expire unutilized and have been written off.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;We recognize interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December 31, 2025 and 2024, and as such, no interest or penalties were recorded to income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;We have analyzed our filing positions in all significant U.S. federal, state, and local jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, we are no longer subject to U.S. federal, state, and local tax examinations by tax authorities for years before 2022, although carryforward attributes that were generated prior to 2022 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;For 2025 and 2024, we had no cash payments for income taxes, net of refunds received, in any U.S. federal, state, or foreign jurisdiction.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_PTWyi32skkWIsztGZzv31A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Our loss before income taxes is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss before income taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_c_W3aazixUmlg7-_0r5uOg_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_vAxJWgdUekyOd3Z_eq5CGA_3_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_8d-Nos0RmkOz0_Pneei5lA_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_9zfkzIZiTUCvGpZGQVTEjg_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_AoQCvxSUp0mjE_KLfdQz4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The components of our income tax provision are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Income tax (benefit) expense:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,683)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (5,809)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 270&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred income tax (benefit) expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,413)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (8,401)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,592&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:64.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_pZP8RRDVCkCsr97JMKPTYw_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2683000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_ZTZ4MIaKiE-e2S5rZRkSmw_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-5809000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_MXthECkjtUSAkfWIuFXBlg_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">270000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_J0Yjs1AhWEysYdX_kun0yQ_6_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2592000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_G8UlVcjzG0-ZAFklXwKsrQ_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2413000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_9qYvAJi-F0CMAOxuz77qOQ_7_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-8401000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_NtxswooMrke0riRhyc4qoQ"
      decimals="-3"
      id="Tc_mxtWnn8-20mFVVZzLHPT6Q_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2683000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_VMMqp0PeAkmV1Ye9POrQ7Q"
      decimals="-3"
      id="Tc_OFBPMUjyn0KuUFOfs-1KHw_8_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-5809000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_n93HbMQVrkW0-qSzZp9fag"
      decimals="-3"
      id="Tc_mGDtGStZa0eZVZTY-vGzMA_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">270000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalTaxJurisdictionOtherMember_ynvr0hrecE6I1UL40A9GOA"
      decimals="-3"
      id="Tc_Rgb_JVVw9kiYt-KRr1OY9g_9_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2592000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Narr_ldzweiKsa0KEdZwYy3DlVg"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Narr_L7uZQiLrXEu461KEql7Pqw"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Group_LOYe-rtx3kmRNl-a719d9w">A reconciliation between income tax computed at the statutory U.S. federal statutory rate and the consolidated effective tax rate is as follows (in thousands, except for percentages):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Income taxes at U.S. federal statutory rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,724)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (5,794)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;State income tax, net of federal benefit &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Changes in valuation allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (20.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (21.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Nontaxable and nondeductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (62)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 0.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:52.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Effective tax rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_2fM26tOJHUe7loakmvbLyA_3_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-2724000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="3"
      id="Tc_p1JYKbGITk23K2fCOv38GQ_3_5"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_kcFwIpc3Z0a4FuYI2l0VAQ_3_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-5794000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="3"
      id="Tc_1rBOR_hOK0654DwgK6PrMQ_3_11"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_jqpOH4xOV0WDkfWopWzrhA_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2683000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="3"
      id="Tc_ITiRH1HLU0mR2BJ6mXTS-w_5_5"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">-0.207</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_TwTBSV5BZ0me13s-Ynttdw_5_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">5809000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="3"
      id="Tc_Ru8jaJ5ApkaLWA10HQ-Egw_5_11"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">-0.211</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_Zgyo82RNIUa1AdL0lcOofw_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-47000</mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount>
    <mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="3"
      id="Tc_4h-nL5T88U-4lPuFmsZpfw_7_5"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.004</mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent>
    <mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_8xoLvRDHDEuYDKFexpHD9Q_7_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-62000</mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesAmount>
    <mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="3"
      id="Tc_SDepet6-GUGlHUSBs17_Ig_7_11"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0.003</mtva:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrantLiabilitiesPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_YouGkKkjbkmojPyj7P6M2w_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">88000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="3"
      id="Tc_u769VhVCVUC8kfJLcVjpTA_8_5"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_enWbz3qk6Uy9UJ3PPmrQNQ_8_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">47000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="3"
      id="Tc_HOtPq9UrkUWhMj09LeJoGw_8_11"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_C-dzxIpl1U6oT6YRgjgRPg_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="3"
      id="Tc_thLnp91ClU6QvDoPrlqUSw_9_5"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_L0MQBt6QIUOwFg4D4e0TJg_9_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="3"
      id="Tc_xkRhnLO7cECGXfyeWzw7zg_9_11"
      unitRef="Unit_Standard_pure_tg1YgNOLNUCDBOxHkyISaA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_q-Vf_KJd70qWPPlnqnUfag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;The significant components of our deferred tax assets and liabilities are as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred income tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;U.S. federal and state net operating loss ("NOL") carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Acquired intangibles &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,890&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net unrealized built-in loss (NUBIL) - 382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized R&amp;amp;D expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7,516&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;R&amp;amp;D credit carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 18,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (18,491)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (16,077)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (58)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (36)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Gross deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (58)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:65.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred income tax assets, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_egh37u_4eUifzkx588TWFQ_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7661000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_XtCD4DWNA0uN1xaH-cF81A_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">4959000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_7rkP82L9v02Yr8wHvh9QoQ_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">2890000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_75_LVwMoDkmF7iZ-9ww0gw_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">3000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <mtva:DeferredTaxAssetsUnrealizedBuiltInLoss
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_-pVVPW6CvEaG1ZzZrQ_enQ_6_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">84000</mtva:DeferredTaxAssetsUnrealizedBuiltInLoss>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_p4RKVbE7pUemdaI2X1Us4g_7_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">515000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_UvcZrD8uBEuAr8xVGb43qw_7_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">458000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <mtva:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_HveKb5HEcE2igZDI3FIF2w_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">58000</mtva:DeferredTaxAssetsLeaseLiability>
    <mtva:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_B86TV_uSzUej3aEHf-AB8A_8_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">37000</mtva:DeferredTaxAssetsLeaseLiability>
    <mtva:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Z2zRv-GXME2Nib8y12rgvw_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7265000</mtva:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <mtva:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_uxKwb6VdH0OcWKXaG1_wBw_9_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">7516000</mtva:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Bmi23W-vcUCjWOtmyXR0wg_10_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">52000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_8fR710u1lky19kxzpswoQQ_10_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">118000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_rDhBq8TFFEaU2WFTqwDNtQ_11_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">24000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_JZFDuEqrZEGdSiB6n9Oyzg_11_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">26000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_Iq4NVegL8k29yO_GNKq8yQ_12_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18549000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_Iyr4QzlJEEOQQrvIto0l-w_12_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16114000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_eZXSJVpZDUarHRGnbxZkhw_13_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18491000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_0M5IQgeqPE-fPfN41faQmw_13_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16077000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_dEWpS_I49EqsyBLRnLq0MA_14_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">58000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_B4nkngU6Hk2DHeRGgjhGJA_14_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">37000</us-gaap:DeferredTaxAssetsNet>
    <mtva:DeferredTaxLiabilitiesRouAsset
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_c1szzZDbbUyVa0s87pk6MQ_16_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">58000</mtva:DeferredTaxLiabilitiesRouAsset>
    <mtva:DeferredTaxLiabilitiesRouAsset
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_D88Bepx39kWTe_EmD6htBw_16_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">36000</mtva:DeferredTaxLiabilitiesRouAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_5Bkw0c0Lx0ubWpBaeMR9Tg_17_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_M3Or_95ajESs0BEWcpXoFg_18_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">58000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_METVlHSD8Uaoz4i3bC8KQg_18_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">37000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Tc_f-qh88iWOEisYOygHUVjHg_19_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Tc_KtWEnKkwUkK6M1PoYnhvKg_19_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-5"
      id="Narr_bvBiOj9W-USks05lHjonjQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-5"
      id="Narr_lVZqyJkq1UqonGQyaJzx-Q"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">16100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g"
      decimals="-5"
      id="Narr_6zn-kRdrl02p1w4xtZXVzQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">33000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_country_US_pFCcYjunlUeQQZkwtqzvuw"
      decimals="-5"
      id="Narr_D6qw5Gv9WU-JAug3EdZO-A"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">18500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_hUpyIKRg90qXsba8GqK17A"
      decimals="-5"
      id="Narr_9OohKjOchUaE1r7n4RFWhg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2025_srt_RangeAxis_srt_MaximumMember_NRfJ8T4b6Eu_-IBdIjogkw"
      decimals="-5"
      id="Narr_vWTBRbYCy0amSR-mQntGpg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_GxJU8xTtk064vc3Bitk13A"
      decimals="-5"
      id="Narr_arbQikBCskqNJ9gzHjk_FA"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_qToyrodAZ0ObK7Ly10LSHA"
      decimals="-5"
      id="Narr_BGVwPBX1e0a-wShQRq8LZw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">17400000</us-gaap:OperatingLossCarryforwards>
    <mtva:NumberOfOwnershipChangesOfOver50
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="INF"
      id="Narr_z1I_7mbF8U6gEItbtP7_hA"
      unitRef="Unit_Standard_item_i1i903DmOka3fCx6uRjRsw">1</mtva:NumberOfOwnershipChangesOfOver50>
    <mtva:NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g"
      decimals="-5"
      id="Narr_fy9zgEndYEykq3qOOSDyvg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">100800000</mtva:NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff>
    <mtva:NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_GxJU8xTtk064vc3Bitk13A"
      decimals="-5"
      id="Narr_sHsya9BFK0Ob0NPZWDDFfw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">68600000</mtva:NetOperatingLossCarryforwardsExpiredUnutilizedWriteOff>
    <mtva:ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff
      contextRef="As_Of_12_31_2025_us-gaap_IncomeTaxAuthorityAxis_country_US_4dkNc8SGJ0SlxYQnKkaP8g"
      decimals="-5"
      id="Narr__GPnGwF1hEu-ZedmuwVjow"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">1200000</mtva:ResearchTaxCreditCarryforwardsExpiredUnutilizedWriteOff>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_LHWY7wdzREi44852cMHh-w"
      decimals="-3"
      id="Narr_TeP_S8C42ECfFpy8ABxVew"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2025_JwzRU6AhV0qN7HloNixehw"
      decimals="-3"
      id="Narr_LAfa9QcDzEWHSxsdhMTnJw"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Narr_vfwXbosRjEykFz9OPU34og"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Narr_xnvMYT0z7kmD2qMIpYfccQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Narr_EQrAfed_i0-QAr25Y8iQug">We have analyzed our filing positions in all significant U.S. federal, state, and local jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, we are no longer subject to U.S. federal, state, and local tax examinations by tax authorities for years before 2022, although carryforward attributes that were generated prior to 2022 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Narr_fweFx9qQGkS03qDtlC9DEQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Narr_f1l6paO0ukO7XfSSPjfFwQ"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_63d1yx7-okKhhofz6n16Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Loss per share of common stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The following table sets forth the computation of basic and diluted loss per share of common stock &lt;span style="color:#212529;background:#ffffff;"&gt;(in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of common stock, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;1,766,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;705,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Effect of dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of common stock, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;1,766,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;705,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Loss per share of common stock, basic and diluted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7.35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (39.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:8pt 0pt 0pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;For each of the periods presented in the above table, our basic weighted average shares of common stock include any outstanding (i) November 2022 Series B warrants, (ii) June 2024 Pre-Funded Warrants and (iii) vested RSUs in which their release was deferred in accordance with the respective award agreement during the respective period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;Since we reported a net loss for 2025 and 2024, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per share of common stock and our basic and diluted weighted average shares of common stock are the same for 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;The following table sets forth the outstanding securities as of the periods presented which were not included in the calculation of diluted earnings per share of common stock for 2025 and 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 706,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,170,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_x0Bc7-R_nUepOo75fQdcrQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;The following table sets forth the computation of basic and diluted loss per share of common stock &lt;span style="color:#212529;background:#ffffff;"&gt;(in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:85%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (12,973)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (27,592)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of common stock, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;1,766,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;705,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Effect of dilutive securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:middle;width:60.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Weighted average shares of common stock, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;1,766,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt;705,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:60.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Loss per share of common stock, basic and diluted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7.35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (39.13)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="-3"
      id="Tc_e1R2--Jf2kq7f6csw1INyw_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-12973000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="-3"
      id="Tc_xc0uN8Sfv0ersAGDQg2bcA_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">-27592000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="0"
      id="Tc_ptIPYegB8EegXPtcbI-Z8Q_6_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1766026</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="0"
      id="Tc_Gv5BeH3bNUK7FrqBp6JQDg_6_6"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">705193</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="0"
      id="Tc_IVqvihXhy0qhHhaX9UAeRQ_8_3"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1766026</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="0"
      id="Tc_iNF5JB0TwE-tiyTY_GVbFQ_8_6"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">705193</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_HwY-3oPY_Uyl3k6L0wd0cQ_9_3"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-7.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      decimals="2"
      id="Tc_HwY-3oPY_Uyl3k6L0wd0cQ_9_3_2"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-7.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Tc_WQUvIiOpVkmvMKsx-dcOeQ_9_6"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-39.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_V3sUch-_0kCP5ljyFqhSyQ"
      decimals="2"
      id="Tc_WQUvIiOpVkmvMKsx-dcOeQ_9_6_2"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">-39.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_e9iNl9JpHkW9A4FcSUzBPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26,213&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14,728&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:61.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 706,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,170,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kgPNiqIU3EqTQ0FXBCZBtQ"
      decimals="0"
      id="Tc_vaKwFS-L4ECYpW7wBw_jdQ_3_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_yZobbedVRk2iue_r9d0-Tw"
      decimals="0"
      id="Tc_GZmUSBR0N0qIOhrLqnCH8A_3_4"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">420</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_eTjUAZIRBk2CMl0mq0_sdg"
      decimals="0"
      id="Tc_TCI-jNz0MEiu69M9OkXMXw_4_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">26213</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qjUNJ2DdcESFldGXnzeBGw"
      decimals="0"
      id="Tc_6grSF64dLk-oekTHUXMgkw_4_4"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">14728</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_viTtU6jhrEuruIoP1QHhgg"
      decimals="0"
      id="Tc_Vhc40kNMgkSISIKC42DnRg_5_2"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">706468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_ZPTKidCK6ECs_qqex1EGQA"
      decimals="0"
      id="Tc_D2gfjVWHvkWME93Axq1sjg_5_4"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1170522</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_pL56Wug0OkODVVQvdSP8KQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;Fair value is a market-based measurement, not an entity specific measurement and is defined as &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three-level hierarchy:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"&gt;Level&#160;1:&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"&gt;Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"&gt;Level&#160;2:&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:8pt;margin-top:0pt;text-align:justify;"&gt;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt -0.7pt 8pt 36pt;"&gt;Level&#160;3: Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The following table sets forth our financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#212529;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:35.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:33.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Bank money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total assets at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total liabilities at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The bank money market funds &lt;/span&gt;are carried at cost, which approximates market fair value. We estimated the fair value of our warrant liabilities using the trading market price of our common stock due to a cashless exercise provision of these warrants whereby eight warrants can be exercised for one share of common stock for no additional consideration, which results in the warrant exercise price to be zero. Accordingly, our warrant liabilities were considered to be Level 2 of the fair value hierarchy.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_QTaT0oTJrE-26dplpaoowA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;The following table sets forth our financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy&#160;&lt;/span&gt;&lt;span style="color:#212529;background:#ffffff;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#212529;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:35.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December&#160;31,&#160;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:33.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;As of December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Description&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#x200b;&#160;&#x200b;&#160;&#x200b;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;Level&#160;3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Bank money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total assets at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,519&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style=""&gt;&lt;td style="vertical-align:bottom;width:26.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total liabilities at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA"
      decimals="-3"
      id="Tc_CirOSrYFhUubOMQ7x_Dp4Q_4_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8519000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0d43O4ut1Eiyd57Bcg_7ZA"
      decimals="-3"
      id="Tc_dGfhCCUXFkuro5Wlha99uw_4_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8519000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA"
      decimals="-3"
      id="Tc_tJR0T3GFu0C0YDbDOHivig_5_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8519000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0d43O4ut1Eiyd57Bcg_7ZA"
      decimals="-3"
      id="Tc_yYIOEevoaUurGzhDcTL8Jg_5_6"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">8519000</us-gaap:AssetsFairValueDisclosure>
    <mtva:WarrantLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA"
      decimals="-3"
      id="Tc_MzXMo9aWpU2SRiV560iUsw_8_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">136000</mtva:WarrantLiabilitiesFairValueDisclosure>
    <mtva:WarrantLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K_oHMLsqlUWlbv8jTh14Aw"
      decimals="-3"
      id="Tc_Y6byeNasmUOzMfMEbpSSkw_8_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">136000</mtva:WarrantLiabilitiesFairValueDisclosure>
    <mtva:WarrantLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ieg6WHdrokO31k0M--imaw"
      decimals="-3"
      id="Tc_EISOEQuIE0eMeGh4BEWJHQ_8_15"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">361000</mtva:WarrantLiabilitiesFairValueDisclosure>
    <mtva:WarrantLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7SMIbo51mEy0336DbR5j1Q"
      decimals="-3"
      id="Tc_ioJ3hTy5-ESfEv9POgXrFg_8_21"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">361000</mtva:WarrantLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KVqBLKVZ_UWFRmW-WAKJZA"
      decimals="-3"
      id="Tc_G9O-_3h84UisTHnavln19A_9_3"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">136000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2025_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_K_oHMLsqlUWlbv8jTh14Aw"
      decimals="-3"
      id="Tc_wW2zRVt1IEuKlD5f43GeEw_9_9"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">136000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ieg6WHdrokO31k0M--imaw"
      decimals="-3"
      id="Tc_VsZflq0S406xuslEiY3aQQ_9_15"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">361000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7SMIbo51mEy0336DbR5j1Q"
      decimals="-3"
      id="Tc_d7erSAkTKE-AluHZixbk-g_9_21"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">361000</us-gaap:LiabilitiesFairValueDisclosure>
    <mtva:ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA"
      decimals="INF"
      id="Narr_eTXy3A1EskigG3Ta4GynWw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">8</mtva:ClassOfWarrantOrRightNumberOfWarrantsCalledByEachShareOfStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_vvalEg-TrUejRp41VE8WPw"
      decimals="-3"
      id="Narr_XT2YDoFUZECYTxtv--Kc7g"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2025_us-gaap_ClassOfWarrantOrRightAxis_mtva_November2022SeriesBWarrantExercisePrice000Member_mzpykrTWdE22rUhFeNzOyA"
      decimals="0"
      id="Narr_r7s6Ae3Eokm5iTwCgZDr7A"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_12_31_2025_W8pcr3hb00CPE6AGdTNkEg"
      id="Tb_sNOY7TXMtEy22U6CdzIZ4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;12. &lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Subsequent events &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;2026 public offering&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 8pt 0pt;"&gt;In January 2026, we closed on an underwritten public offering, pursuant to which we issued and sold, (i) 1,006,870 Class A Units, with each Class A Unit consisting of (A) one share of common stock, (B) 1.5 Series C Common Warrants to purchase 1.5 shares of common stock, and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of common stock, at a price of $3.10 per Class A Unit, and (ii) 1,998,704 Class B Units, with each Class B Unit consisting of (A) one pre-funded warrant to purchase one share of common stock, (B) 1.5 Series C Common Warrants to purchase 1.5 shares of common stock, and (C) 1.5 Series D Common Warrants to purchase 1.5 shares of common stock, at a purchase price of $3.099 per Class B Unit. Each pre-funded warrant has an exercise price of $0.001 per share and is immediately exercisable and will expire when exercised in full. Each Series&#160;C Common Warrant and Series D Common Warrant has an exercise price of $3.10 &lt;span style="-sec-ix-hidden:Hidden_oXMhiHp3dkGLoMt6wJhXIA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;per&lt;/span&gt;&lt;/span&gt; whole share of common stock, subject to certain adjustments, are immediately exercisable, and will expire on January&#160;16, 2031 and January 16, 2028, respectively. Under the Series&#160;C Common Warrant and the Series D Common Warrant, we&#160;may not affect the exercise of any such warrants, and a holder will not be entitled to exercise any portion of any such warrants, which, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by the holder (together with its affiliates) to exceed the beneficial ownership limitation contained therein. We received gross proceeds of $9.3 million, prior to deducting underwriting discounts and commissions and offering expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;The Series&#160;D Common Warrants are callable at our option following the release of a positive data readout for our Phase 1b Part&#160;III clinical trial for DA-1726 via a widely disseminated press release, subject to satisfaction of certain conditions. The Series&#160;C and Series&#160;D Common Warrants are fixed priced and do not contain any variable pricing features or alternative exercise provisions. Subsequently, 1,630,964 pre-funded warrants have been exercised for an equivalent number of shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;background:#ffffff;margin:0pt 0pt 8pt 0pt;"&gt;&lt;i style="color:#212529;font-style:italic;"&gt;At the market offering&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:8pt 0pt 0pt 0pt;"&gt;In March 2026, we sold 216,625 shares of common stock under the ATM Program and received net proceeds of $0.3 million, net of sales agent commission and related offering expenses.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_N6OYhzZRwkyDYwrDvyw5kg"
      decimals="INF"
      id="Narr_O8X6Cae_3UKfSvn85M2I_g"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1006870</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mtva:NumberOfCommonStockIssuedPerUnit
      contextRef="As_Of_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PwnDqJ_0xkebhJ_3_12wnw"
      decimals="INF"
      id="Narr_rgUca9Pbu0ymJqTLQxHTcQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1</mtva:NumberOfCommonStockIssuedPerUnit>
    <mtva:NumberOfWarrantsIssuedPerUnit
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_OjEPyphxgUe99Gl8la9gVA"
      decimals="INF"
      id="Narr_IAVylbQrykOYDcpoAPt0Ww"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</mtva:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_OjEPyphxgUe99Gl8la9gVA"
      decimals="INF"
      id="Narr_9EPugOhc6Ua3UCAq6NYWSw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <mtva:NumberOfWarrantsIssuedPerUnit
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg"
      decimals="INF"
      id="Narr_dgtOcprWaEyEASffHjyseA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</mtva:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg"
      decimals="INF"
      id="Narr_Ey1n12vDl0Wm_4-qgoW7Lw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_q2mCglsbh0OGBUgVbji2tg"
      decimals="2"
      id="Narr_Rsuf-J-0jkyFxSc8o3L7-A"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">3.1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_DzLxM32I3UiH0dZZsCbJ1g"
      decimals="INF"
      id="Narr_ermnyb4GPkGAw5sFbVmUCw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1998704</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mtva:NumberOfWarrantsIssuedPerUnit
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_I_-uWg1Oy0Oe1RoSXLv9bw"
      decimals="INF"
      id="Narr__HgBFtqEiEuyTNMNuAXCBw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1</mtva:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_I_-uWg1Oy0Oe1RoSXLv9bw"
      decimals="INF"
      id="Narr_eDxD06NVgEuGyn2Cl7DdEQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <mtva:NumberOfWarrantsIssuedPerUnit
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_HGwlAKHDTEqwMSPqX6zFpA"
      decimals="INF"
      id="Narr_AgJJrbd6W06C7gjBCQPJQQ"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</mtva:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesCWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_HGwlAKHDTEqwMSPqX6zFpA"
      decimals="INF"
      id="Narr_Kq06cEGL00OLp0lTXNe8PA"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <mtva:NumberOfWarrantsIssuedPerUnit
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg"
      decimals="INF"
      id="Narr_XYdGUc6sgEKTJeSPRGDy3A"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</mtva:NumberOfWarrantsIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg"
      decimals="INF"
      id="Narr_-Vgc2U6spU2Vhgu7WfYJRw"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_StatementClassOfStockAxis_mtva_ClassBUnitsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_zfLGGBTqRUO8qNDmdArjIg"
      decimals="3"
      id="Narr_WKNaLAIU7EmX_VSqVOloNg"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">3.099</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_ZkP_xSv4vUWma066ndav7Q"
      decimals="INF"
      id="Narr_jnHbOR9QJE-c8NnWfFgduw"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_SeriesDWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_RrvMS22yxkOjSxk0GAVqjw"
      decimals="2"
      id="Narr_9Tbi0Vxp50Wmi1d001597A"
      unitRef="Unit_Divide_USD_shares_urCnVXkB20GHTVeBScaQhw">3.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_1_1_2026_To_1_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_0R6iYR8SXEKx11Ao953ZHw"
      decimals="-5"
      id="Narr__e6qOIOR80-WGWL6-l9w2Q"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">9300000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_3_1_2026_To_3_31_2026_us-gaap_ClassOfWarrantOrRightAxis_mtva_PreFundedWarrantsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_PublicOffering2026Member_PCbVTPdsR0KR7b1czjWLjw"
      decimals="INF"
      id="Narr_C053n7MSyUKKnn63pFGP_g"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">1630964</mtva:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_1_2026_To_3_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingMember_RAxNUZYdMUeN8hu5p8owPg"
      decimals="INF"
      id="Narr_W1EPLv4yGE6ZgXJIVY5h5g"
      unitRef="Unit_Standard_shares_TPrzazsFok-_btJ1uZR-0g">216625</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_3_1_2026_To_3_31_2026_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mtva_AtMarketOfferingMember_RAxNUZYdMUeN8hu5p8owPg"
      decimals="-5"
      id="Narr_D6z8NaGvfkevLTwSuIE-Fg"
      unitRef="Unit_Standard_USD_lP6rK_B7kkG5WBaGNOvnLg">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
